Four,O
decades,O
ago,O
in,O
1985,O
",",O
alleles,O
of,O
apolipoprotein,O
E,O
(,O
ApoE,O
),O
ε2,O
/,O
ε3,O
/,O
ε4,O
became,O
famous,O
for,O
explaining,O
16,O
%,O
of,O
genetic,O
variance,O
in,O
low,O
-,O
density,O
lipoprotein,O
cholesterol,O
in,O
the,O
benchmark,O
study,O
of,O
Sing,O
and,O
Davignon,O
(,O
1,O
):,O
total,O
blood,O
cholesterol,O
",",O
low,O
-,O
density,O
lipoprotein,O
cholesterol,O
",",O
and,O
apolipoprotein,O
B,O
were,O
elevated,O
by,O
ApoE,O
ε4,O
(,O
ApoE4,O
),O
allele,O
and,O
lowered,O
by,O
ApoE,O
ε2,O
(,O
ApoE2,O
),O
.,O
Preexisting,O
morbidities,O
increase,O
risk,O
of,O
COVID-19,O
infections,O
and,O
mortality,O
:,O
for,O
young,O
adults,O
:,O
diabetes,O
and,O
obesity,O
;,O
for,O
older,O
people,O
:,O
diabetes,O
and,O
dementia,O
(,O
"14,15",O
),O
.,O
COVID-19,O
also,O
damages,O
the,O
cardiovascular,O
system,O
with,O
atrial,O
fibrillation,O
",",O
ventricular,O
arrhythmia,O
",",O
and,O
disseminated,O
coagulation,O
(,O
16,O
),O
.,O
These,O
morbidities,O
are,O
also,O
associated,O
with,O
variants,O
in,O
the,O
ApoE,O
gene,O
cluster,O
that,O
we,O
hypothesize,O
are,O
relevant,O
to,O
COVID-19,O
.,O
ApoE4,O
homozygotes,O
have,O
2.2,O
-,O
fold,O
higher,O
risk,O
for,O
COVID-19,O
positivity,O
and,O
4.3,O
-,O
fold,O
more,O
case,O
-,O
fatality,O
after,O
COVID-19,O
than,O
ApoE3,O
homozygotes,O
(,O
"17,18",O
),O
.,O
Heterozygosity,O
(,O
ε3,O
/,O
ε4,O
),O
was,O
modestly,O
associated,O
with,O
COVID-19,O
below,O
linear,O
dose,O
dependence,O
.,O
Strong,O
associations,O
for,O
ε4,O
/,O
ε4,O
with,O
COVID-19,O
were,O
not,O
diminished,O
by,O
excluding,O
dementia,O
",",O
hypertension,O
",",O
coronary,O
heart,O
disease,O
(,O
CHD,O
),O
",",O
or,O
type,O
II,O
diabetes,O
.,O
Based,O
on,O
these,O
associations,O
",",O
Kuo,O
et,O
al,O
.,O
hypothesize,O
that,O
ApoE4,O
has,O
recessive,O
effects,O
on,O
COVID-19,O
outcomes,O
and,O
suggest,O
that,O
these,O
effects,O
are,O
independent,O
of,O
these,O
common,O
age,O
-,O
related,O
diseases,O
.,O
We,O
discuss,O
how,O
ApoE,O
allele,O
pleiotropies,O
can,O
mediate,O
COVID-19,O
infectivity,O
and,O
survival,O
.,O
We,O
hypothesize,O
that,O
ApoE4,O
associations,O
with,O
COVID-19,O
extend,O
to,O
the,O
ApoE,O
gene,O
complex,O
with,O
balancing,O
detrimental,O
and,O
protective,O
effects,O
in,O
haplotypes,O
",",O
and,O
multiple,O
gene,O
-,O
by,O
-,O
gene,O
transcriptional,O
interactions,O
(,O
28,O
),O
.,O
This,O
approach,O
could,O
identify,O
protective,O
genes,O
for,O
COVID-19,O
.,O
ApoE2,O
also,O
merits,O
consideration,O
in,O
COVID-19,O
",",O
given,O
its,O
benefit,O
to,O
CVD,O
and,O
AD,O
.,O
Several,O
ApoE,O
cluster,O
genes,O
may,O
interact,O
with,O
COVID-19,O
",",O
for,O
example,O
",",O
NECTIN2,O
(,O
herpes,O
receptor,O
HHV1,O
),O
and,O
ApoC1,O
which,O
",",O
like,O
ApoE,O
",",O
is,O
in,O
the,O
HCV,O
envelope,O
(,O
42,O
),O
.,O
ApoE,O
cluster,O
haplotypes,O
associate,O
with,O
the,O
same,O
morbidities,O
from,O
CVD,O
and,O
obesity,O
(,O
"43,44",O
),O
that,O
increase,O
vulnerability,O
to,O
COVID-19,O
.,O
The,O
outbreak,O
of,O
COVID-2019,O
initiated,O
at,O
Wuhan,O
",",O
China,O
has,O
become,O
a,O
global,O
threat,O
by,O
rapid,O
transmission,O
and,O
severe,O
fatalities,O
.,O
Recent,O
studies,O
have,O
uncovered,O
whole,O
genome,O
sequence,O
of,O
SARS,O
-,O
CoV-2,O
(,O
causing,O
COVID-2019,O
),O
.,O
We,O
also,O
performed,O
functional,O
overrepresentation,O
analysis,O
of,O
interacting,O
proteins,O
to,O
understand,O
their,O
role,O
in,O
COVID-2019,O
severity,O
.,O
As,O
per,O
the,O
results,O
",",O
Prevotella,O
proteins,O
",",O
but,O
not,O
viral,O
proteins,O
are,O
involved,O
in,O
multiple,O
interactions,O
with,O
NF,O
-,O
kB,O
",",O
which,O
is,O
involved,O
in,O
increasing,O
clinical,O
severity,O
of,O
COVID-2019,O
.,O
Prevotella,O
may,O
have,O
role,O
in,O
COVID-2019,O
outbreak,O
and,O
should,O
be,O
given,O
importance,O
for,O
understanding,O
disease,O
mechanisms,O
and,O
improving,O
treatment,O
outcomes,O
.,O
The,O
rapid,O
spread,O
of,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
has,O
dramatically,O
impacted,O
oncologic,O
care,O
.,O
Two,O
observational,O
studies,O
suggest,O
that,O
infection,O
rates,O
of,O
COVID-19,O
may,O
be,O
significantly,O
higher,O
in,O
cancer,O
patients,O
than,O
in,O
the,O
general,O
population,O
(,O
Liang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Yu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Further,O
analyses,O
suggest,O
that,O
cancer,O
patients,O
may,O
also,O
be,O
at,O
increased,O
risk,O
of,O
severe,O
complications,O
from,O
COVID-19,O
",",O
including,O
hospitalization,O
",",O
respiratory,O
failure,O
",",O
and,O
death,O
(,O
Dai,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Liang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Multiple,O
factors,O
are,O
likely,O
contributing,O
to,O
the,O
increased,O
prevalence,O
and,O
severity,O
of,O
COVID-19,O
infection,O
seen,O
in,O
cancer,O
patients,O
.,O
Compared,O
to,O
the,O
general,O
population,O
",",O
cancer,O
patients,O
tend,O
to,O
be,O
older,O
",",O
are,O
more,O
often,O
smokers,O
",",O
and,O
have,O
more,O
comorbid,O
medical,O
conditions,O
",",O
all,O
of,O
which,O
are,O
reported,O
risk,O
factors,O
for,O
severe,O
COVID-19,O
infection,O
(,O
Jordan,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Of,O
major,O
concern,O
to,O
medical,O
oncologists,O
in,O
particular,O
are,O
antineoplastic,O
therapies,O
",",O
which,O
have,O
a,O
variety,O
of,O
effects,O
that,O
can,O
theoretically,O
be,O
deleterious,O
in,O
the,O
context,O
of,O
COVID-19,O
.,O
Lymphosuppression,O
and,O
myelosuppression,O
directly,O
caused,O
by,O
cancer,O
itself,O
as,O
well,O
as,O
cytotoxic,O
treatments,O
pose,O
an,O
increased,O
risk,O
of,O
respiratory,O
viral,O
infections,O
(,O
Vento,O
et,O
 ,O
al,O
.,O
",",O
2008,O
),O
;,O
some,O
cytotoxic,O
agents,O
also,O
cause,O
pulmonary,O
toxicity,O
that,O
may,O
prove,O
harmful,O
in,O
the,O
context,O
of,O
severe,O
COVID-19,O
.,O
Some,O
monoclonal,O
antibodies,O
(,O
for,O
example,O
",",O
anti,O
-,O
CD38,O
antibodies,O
such,O
as,O
daratumumab,O
and,O
isatuximab,O
),O
result,O
specifically,O
in,O
NK,O
-,O
cell,O
depletion,O
and,O
increase,O
risk,O
of,O
lower,O
respiratory,O
viral,O
infection,O
",",O
although,O
it,O
is,O
unclear,O
whether,O
this,O
applies,O
to,O
COVID-19,O
(,O
Nahi,O
et,O
 ,O
al,O
.,O
",",O
2019,O
),O
.,O
Early,O
reports,O
have,O
demonstrated,O
a,O
hyperactive,O
",",O
proinflammatory,O
T,O
 ,O
cell,O
phenotype,O
in,O
severe,O
cases,O
of,O
COVID-19,O
(,O
Xu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Some,O
clinicians,O
have,O
accordingly,O
hypothesized,O
that,O
immune,O
checkpoint,O
inhibitors,O
may,O
promote,O
a,O
more,O
severe,O
COVID-19,O
phenotype,O
and,O
are,O
using,O
these,O
drugs,O
with,O
some,O
hesitation,O
",",O
although,O
the,O
subject,O
is,O
controversial,O
(,O
Bersanelli,O
2020,O
),O
.,O
Finally,O
",",O
a,O
significant,O
proportion,O
of,O
cancer,O
patients,O
take,O
corticosteroids,O
for,O
prophylaxis,O
",",O
treatment,O
",",O
and,O
symptom,O
control,O
related,O
to,O
cancer,O
",",O
which,O
might,O
be,O
detrimental,O
in,O
the,O
management,O
of,O
acute,O
respiratory,O
distress,O
syndrome,O
due,O
to,O
COVID-19,O
(,O
Russell,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Prospective,O
clinical,O
trials,O
of,O
investigational,O
antineoplastic,O
therapy,O
",",O
which,O
drive,O
many,O
advancements,O
in,O
medical,O
oncology,O
",",O
are,O
now,O
faced,O
with,O
additional,O
logistical,O
and,O
practical,O
barriers,O
in,O
the,O
COVID-19,O
era,O
.,O
In,O
addition,O
",",O
despite,O
COVID-19,O
-,O
related,O
trials,O
accruing,O
at,O
record,O
pace,O
",",O
no,O
randomized,O
data,O
are,O
yet,O
available,O
to,O
guide,O
practice,O
.,O
Notably,O
",",O
some,O
antineoplastic,O
treatments,O
may,O
be,O
helpful,O
in,O
mitigating,O
the,O
harmful,O
immune,O
response,O
associated,O
with,O
severe,O
COVID-19,O
and,O
are,O
under,O
active,O
investigation,O
as,O
repurposed,O
therapies,O
for,O
COVID-19,O
(,O
Table,O
1,O
),O
.,O
Given,O
the,O
above,O
",",O
it,O
is,O
imperative,O
that,O
real,O
-,O
world,O
evidence,O
about,O
the,O
effects,O
of,O
COVID-19,O
on,O
cancer,O
patients,O
is,O
collected,O
and,O
disseminated,O
rapidly,O
to,O
inform,O
clinical,O
decisions,O
.,O
The,O
CCC19,S-Repository
 ,O
is,O
a,O
multicenter,O
registry,O
that,O
was,O
created,O
to,O
help,O
bridge,O
the,O
knowledge,O
gap,O
in,O
cancer,O
care,O
caused,O
by,O
the,O
COVID-19,O
pandemic,O
.,O
Participating,O
sites,O
are,O
asked,O
to,O
obtain,O
necessary,O
institutional,O
IRB,O
approval,O
and,O
data,O
transfer,O
and,O
to,O
make,O
the,O
best,O
possible,O
effort,O
to,O
report,O
data,O
on,O
cases,O
of,O
COVID-19,O
in,O
cancer,O
patients,O
that,O
are,O
treated,O
in,O
both,O
the,O
inpatient,O
and,O
outpatient,O
settings,O
",",O
to,O
ensure,O
data,O
are,O
collected,O
on,O
patients,O
with,O
both,O
mild,O
and,O
severe,O
disease,O
.,O
Of,O
note,O
",",O
a,O
large,O
global,O
analysis,O
is,O
planned,O
",",O
subsequently,O
fusing,O
RedCAP,S-Repository
 ,O
databases,O
with,O
the,O
European,B-Repository
Society,I-Repository
for,I-Repository
Medical,I-Repository
Oncology,I-Repository
COVID-19,I-Repository
and,I-Repository
Cancer,I-Repository
Registry,I-Repository
(ESMO-CoCARE),E-Repository
 ,O
project,O
.,O
National,O
and,O
international,O
consortia,O
will,O
play,O
a,O
key,O
role,O
in,O
understanding,O
the,O
effects,O
of,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
on,O
cancer,O
patients,O
.,O
The,O
COVID-19,B-Repository
and,I-Repository
Cancer,I-Repository
Consortium,I-Repository
(CCC19),E-Repository
 ,O
aims,O
to,O
collect,O
and,O
analyze,O
observational,O
data,O
at,O
scale,O
to,O
inform,O
clinical,O
practice,O
in,O
real,O
-,O
time,O
.,O
National,O
and,O
international,O
consortia,O
will,O
play,O
a,O
key,O
role,O
in,O
understanding,O
the,O
effects,O
of,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
on,O
cancer,O
patients,O
.,O
The,O
COVID-19,B-Repository
and,I-Repository
Cancer,I-Repository
Consortium,I-Repository
(CCC19),E-Repository
 ,O
aims,O
to,O
collect,O
and,O
analyze,O
observational,O
data,O
at,O
scale,O
to,O
inform,O
clinical,O
practice,O
in,O
real,O
-,O
time,O
.,O
According,O
to,O
the,O
Johns,O
Hopkins,O
University,O
Coronavirus,O
Resource,O
Center,O
and,O
the,O
Daily,O
Technical,O
Statement,O
on,O
New,O
Coronavirus,O
Cases,O
Worldwide,O
(,O
COVID-19,O
),O
issued,O
by,O
the,O
Secretary,O
of,O
Health,O
of,O
Mexico,O
",",O
as,O
of,O
March,O
20,O
",",O
2020,O
",",O
"234,072",O
confirmed,O
cases,O
have,O
been,O
reported,O
worldwide,O
with,O
9840,O
deaths,O
.,O
At,O
the,O
time,O
of,O
this,O
writing,O
",",O
768,O
complete,O
genomic,O
sequences,O
of,O
SARS,O
Cov-2,O
have,O
been,O
obtained,O
and,O
deposited,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
",",O
and,O
10,O
clades,O
have,O
been,O
defined,O
from,O
phylogenetic,O
studies,O
carried,O
out,O
with,O
these,O
sequences,O
(,O
A1,O
",",O
A1a,O
",",O
A2,O
",",O
A2a,O
",",O
A3,O
",",O
A5,O
",",O
B,O
",",O
B1,O
",",O
B2,O
and,O
B4,O
),O
[,O
5,O
],O
.,O
A,O
diagnostic,O
test,O
for,O
COVID-19,O
was,O
first,O
conducted,O
at,O
the,O
Instituto,O
Nacional,O
de,O
Enfermedades,O
Respiratorias,O
",",O
Mexico,O
City,O
",",O
on,O
February,O
27,O
",",O
2020,O
.,O
The,O
complete,O
genome,O
sequence,O
was,O
assembled,O
using,O
CLC,O
Genomics,O
Workbench,O
20,O
(,O
QIAGEN,O
),O
and,O
SPAdes,O
[,O
9,O
],O
and,O
mapped,O
against,O
the,O
reference,O
sequence,O
Wuhan,O
-,O
Hu-1,O
(,O
GenBank,S-Repository
 ,O
accession,O
number,O
NC_045512.2,S-AccessionNumber
),O
.,O
The,O
sequence,O
was,O
deposited,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
[,O
5,O
],O
under,O
accession,O
ID,O
EPI_ISL_412972,S-AccessionNumber
.,O
A,O
database,O
was,O
constructed,O
including,O
178,O
genomic,O
sequences,O
available,O
on,O
the,O
GISAID,S-Dataset
 ,O
platform,O
",",O
obtained,O
from,O
December,O
31,O
",",O
2019,O
to,O
March,O
05,O
",",O
2020,O
",",O
reported,O
in,O
22,O
countries,O
.,O
A,O
second,O
database,O
of,O
768,O
sequences,O
deposited,O
until,O
March,O
20,O
",",O
2020,O
",",O
was,O
used,O
to,O
construct,O
a,O
phylogenetic,O
tree,O
.,O
This,O
finding,O
correlates,O
with,O
the,O
transmission,O
events,O
reported,O
by,O
GISAID,S-Dataset
 ,O
[,O
5,O
],O
",",O
which,O
suggest,O
that,O
this,O
strain,O
was,O
first,O
introduced,O
into,O
Belgium,O
",",O
then,O
England,O
",",O
and,O
finally,O
",",O
Italy,O
",",O
where,O
the,O
Mexican,O
patient,O
had,O
been,O
traveling,O
.,O
Very,O
recently,O
",",O
the,O
outbreak,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
due,O
to,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
has,O
posed,O
significant,O
threats,O
to,O
international,O
health,O
[,O
4–9,O
],O
.,O
The,O
outbreak,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
due,O
to,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
has,O
posed,O
significant,O
threats,O
to,O
international,O
health,O
.,O
One,O
week,O
later,O
",",O
on,O
January,O
7,O
",",O
2020,O
",",O
Chinese,O
health,O
authorities,O
confirmed,O
that,O
they,O
had,O
identified,O
a,O
novel,O
coronavirus,O
(,O
COVID-19,O
),O
.,O
The,O
Chinese,O
Center,O
for,O
Disease,O
Control,O
and,O
Prevention,O
issued,O
an,O
epidemic,O
update,O
and,O
risk,O
assessment,O
of,O
COVID-19,O
in,O
late,O
January,O
.,O
Zhou,O
et,O
 ,O
al,O
showed,O
that,O
COVID-19,O
shares,O
79.5,O
%,O
 ,O
sequence,O
identity,O
with,O
SARS,O
-,O
CoV.,O
It,O
was,O
also,O
confirmed,O
that,O
COVID-19,O
uses,O
the,O
same,O
cell,O
entry,O
receptor,O
",",O
angiotensin,O
-,O
converting,O
enzyme,O
2,O
",",O
as,O
SARS,O
-,O
CoV,O
",",O
which,O
is,O
highly,O
expressed,O
in,O
airway,O
epithelial,O
cells,O
.,O
Zhu,O
et,O
 ,O
al,O
also,O
identified,O
and,O
characterized,O
COVID-19,O
.,O
COVID-19,O
seems,O
to,O
be,O
the,O
seventh,O
member,O
of,O
the,O
family,O
of,O
coronaviruses,O
that,O
infect,O
humans,O
.,O
Notably,O
",",O
COVID-19,O
grew,O
more,O
readily,O
in,O
primary,O
human,O
airway,O
epithelial,O
cells,O
than,O
in,O
standard,O
tissue,O
culture,O
cells,O
",",O
unlike,O
SARS,O
-,O
CoV,O
or,O
MERS,O
-,O
CoV,O
",",O
suggesting,O
the,O
potential,O
for,O
increased,O
infectivity,O
.,O
Homology,O
modeling,O
revealed,O
that,O
COVID-19,O
had,O
some,O
amino,O
acid,O
variations,O
at,O
key,O
residues,O
benchmarked,O
with,O
SARS,O
-,O
CoV.,O
A,O
familial,O
cluster,O
of,O
pneumonia,O
due,O
to,O
COVID-19,O
has,O
been,O
reported,O
.,O
The,O
basic,O
reproductive,O
number,O
of,O
COVID-19,O
was,O
estimated,O
to,O
be,O
2.2,O
",",O
lower,O
than,O
that,O
of,O
SARS,O
-,O
CoV,O
(,O
around,O
3,O
),O
.,O
",",O
 ,O
However,O
",",O
host,O
virus,O
interactions,O
may,O
hasten,O
the,O
birth,O
of,O
potential,O
super,O
spreaders,O
",",O
leading,O
to,O
major,O
outbreaks,O
.,O
The,O
first,O
reported,O
patient,O
with,O
COVID-19,O
infection,O
in,O
the,O
United,O
States,O
was,O
administered,O
remdesivir,O
.,O
Two,O
randomized,O
controlled,O
trials,O
have,O
been,O
registered,O
to,O
evaluate,O
the,O
safety,O
and,O
efficacy,O
of,O
remdesivir,O
in,O
mild,O
/,O
moderate,O
or,O
severe,O
patients,O
with,O
COVID-19,O
viral,O
pneumonia,O
.,O
",",O
 ,O
Kirchdoerfer,O
and,O
Ward,O
noticed,O
that,O
nonstructural,O
proteins,O
(,O
nsp)12,O
polymerase,O
may,O
be,O
a,O
template,O
for,O
the,O
design,O
of,O
novel,O
antiviral,O
therapeutic,O
agents,O
to,O
interrupt,O
the,O
assembly,O
of,O
the,O
SARS,O
-,O
CoV,O
core,O
RNA,O
-,O
synthesis,O
machinery,O
.,O
COVID-19,O
has,O
full,O
-,O
length,O
genome,O
sequences,O
with,O
>,O
75,O
%,O
 ,O
nucleotide,O
identity,O
with,O
that,O
of,O
SARS,O
-,O
CoV,O
",",O
which,O
allows,O
the,O
molecular,O
structure,O
information,O
to,O
be,O
used,O
as,O
a,O
model,O
for,O
coronavirus,O
antiviral,O
design,O
.,O
It,O
is,O
of,O
great,O
significance,O
to,O
share,O
what,O
is,O
known,O
of,O
COVID-19,O
genome,O
sequences,O
",",O
the,O
epidemiology,O
",",O
and,O
clinical,O
features,O
of,O
the,O
illness,O
.,O
Hopefully,O
",",O
the,O
early,O
suggestion,O
that,O
COVID-19,O
infection,O
is,O
of,O
lower,O
lethality,O
than,O
SARS,O
holds,O
true,O
.,O
The,O
goal,O
is,O
to,O
break,O
the,O
transmission,O
chain,O
of,O
COVID-19,O
.,O
Each,O
week,O
a,O
sequence,O
data,O
cutoff,O
is,O
applied,O
across,O
the,O
consortium,O
to,O
give,O
a,O
defined,O
dataset,O
for,O
weekly,O
analysis,O
to,O
report,O
to,O
SAGE,O
",",O
initially,O
focusing,O
on,O
:,O
(,O
1,O
),O
local,O
transmission,O
versus,O
imported,O
cases,O
",",O
(,O
2,O
),O
rates,O
of,O
epidemic,O
"growth,5",O
",",O
6,O
(,O
3,O
),O
reconstructing,O
spatial,O
movement,O
",",O
(,O
4,O
),O
chains,O
of,O
transmission,O
",",O
(,O
5,O
),O
observed,O
genetic,O
changes,O
",",O
and,O
(,O
6,O
),O
identification,O
of,O
genomic,O
changes,O
potentially,O
affecting,O
common,O
diagnostic,O
tests,O
or,O
direct,O
(,O
eg,O
",",O
chemotherapeutics,O
),O
or,O
indirect,O
therapies,O
.,O
The,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
declared,O
the,O
outbreak,O
of,O
a,O
coronavirus,O
disease,O
of,O
2019,O
(,O
COVID-19,O
),O
as,O
public,O
health,O
emergency,O
of,O
international,O
concern,O
and,O
put,O
in,O
place,O
a,O
series,O
of,O
temporary,O
recommendations,O
on,O
January,O
30,O
.,O
The,O
current,O
outbreak,O
of,O
COVID-19,O
has,O
nearly,O
3,O
million,O
confirmed,O
cases,O
worldwide,O
with,O
more,O
than,O
"200,000",O
deaths,O
",",O
as,O
of,O
April,O
27,O
",",O
2020,O
",",O
according,O
to,O
the,O
WHO,O
.,O
Many,O
researches,O
are,O
now,O
underway,O
to,O
develop,O
effective,O
interventions,O
for,O
controlling,O
and,O
preventing,O
the,O
COVID-19,O
pandemic,O
",",O
including,O
therapeutic,O
drugs,O
such,O
as,O
inhibitors,O
of,O
the,O
RNA,O
-,O
dependent,O
RNA,O
polymerase,O
or,O
the,O
viral,O
protease,O
",",O
and,O
blockers,O
of,O
virus,O
-,O
cell,O
membrane,O
fusion,O
as,O
well,O
as,O
vaccines,O
",",O
and,O
large,O
scale,O
clinical,O
trials,O
have,O
just,O
begun,O
[,O
6,O
",",O
7,O
],O
.,O
Full,O
-,O
length,O
viral,O
nucleotide,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
(,O
accession,O
number,O
MN908947,S-AccessionNumber
 ,O
and,O
MN996527,S-AccessionNumber
-,O
MN996531,S-AccessionNumber
),O
[,O
1,O
",",O
2,O
],O
",",O
SARS,O
-,O
CoV,O
(,O
accession,O
number,O
AY274119,S-AccessionNumber
",",O
AY278488,S-AccessionNumber
 ,O
and,O
AY390556,S-AccessionNumber
),O
",",O
bat,O
-,O
derived,O
SARS,O
-,O
like,O
coronavirus,O
(,O
bat,O
-,O
SL,O
-,O
CoV,O
),O
RaTG13,O
(,O
accession,O
number,O
MN996532,S-AccessionNumber
),O
",",O
and,O
MERS,O
-,O
CoV,O
(,O
accession,O
number,O
JX869059,S-AccessionNumber
),O
were,O
downloaded,O
from,O
the,O
NCBI,S-Creator
 ,O
GenBank,S-Repository
.,O
Epitope,O
prediction,O
was,O
carried,O
out,O
using,O
the,O
predicted,O
proteins,O
",",O
including,O
S,O
",",O
E,O
",",O
N,O
",",O
M,O
",",O
and,O
ORFs,O
(,O
corresponding,O
to,O
accession,O
numbers,O
QHD43415,S-AccessionNumber
-,O
QHD43423,S-AccessionNumber
",",O
QHI42199,S-AccessionNumber
),O
of,O
the,O
reference,O
SARS,O
-,O
CoV-2_Wuhan,O
-,O
Hu-1,O
(,O
accession,O
number,O
MN908947,S-AccessionNumber
),O
.,O
We,O
first,O
aligned,O
each,O
of,O
these,O
SARS,O
-,O
CoV-2,O
sequences,O
to,O
the,O
reference,O
sequence,O
SARS,O
-,O
CoV-2_Wuhan,O
-,O
Hu-1,O
(,O
accession,O
number,O
MN908947,S-AccessionNumber
),O
using,O
BLAT,O
software,O
[,O
14,O
],O
.,O
After,O
the,O
alignment,O
",",O
we,O
extracted,O
nucleotide,O
sequences,O
corresponding,O
to,O
individual,O
proteins,O
of,O
SARS,O
-,O
CoV-2,O
",",O
translated,O
them,O
to,O
amino,O
acid,O
sequences,O
",",O
and,O
then,O
compared,O
them,O
to,O
reference,O
amino,O
acid,O
sequences,O
of,O
SARS,O
-,O
CoV-2_Wuhan,O
-,O
Hu-1,O
(,O
accession,O
numbers,O
QHD43415,S-AccessionNumber
-,O
QHD43423,S-AccessionNumber
",",O
QHI42199,S-AccessionNumber
),O
.,O
Genome,O
sequences,O
of,O
SARS,O
-,O
CoV-2_WIV02,O
(,O
accession,O
number,O
MN996527,S-AccessionNumber
),O
",",O
SARS,O
-,O
CoV_GZ02,O
(,O
AY390556,S-AccessionNumber
),O
",",O
and,O
Bat,O
-,O
CoV_RaTG13,O
(,O
MN996532,S-AccessionNumber
),O
were,O
compared,O
with,O
SARS,O
-,O
CoV-2_Wuhan,O
-,O
Hu-1,O
(,O
MN908947,S-AccessionNumber
),O
156,O
amino,O
acid,O
mutations,O
",",O
which,O
were,O
observed,O
at,O
more,O
than,O
0.5,O
%,O
frequencies,O
in,O
at,O
least,O
one,O
region,O
",",O
were,O
plotted,O
To,O
control,O
the,O
current,O
COVID-19,O
pandemic,O
and,O
prevent,O
the,O
second,O
pandemic,O
in,O
the,O
near,O
future,O
",",O
the,O
development,O
of,O
new,O
drugs,O
and,O
vaccines,O
",",O
and,O
the,O
establishment,O
of,O
tools,O
investigating,O
the,O
immune,O
responses,O
in,O
patients,O
or,O
silently,O
-,O
infected,O
individuals,O
are,O
urgent,O
issues,O
.,O
In,O
addition,O
",",O
several,O
reports,O
have,O
suggested,O
that,O
a,O
subset,O
of,O
patients,O
with,O
severe,O
COVID-19,O
might,O
have,O
a,O
cytokine,O
release,O
syndrome,O
[,O
19,O
",",O
20,O
],O
.,O
These,O
HLA,O
-,O
oligomers,O
might,O
be,O
useful,O
to,O
predict,O
and,O
monitor,O
acute,O
T,O
-,O
cell,O
responses,O
in,O
COVID-19,O
patients,O
who,O
cause,O
these,O
life,O
-,O
threatning,O
symptoms,O
.,O
To,O
control,O
and,O
prevent,O
the,O
current,O
COVID-19,O
pandemic,O
",",O
the,O
development,O
of,O
novel,O
vaccines,O
is,O
an,O
emergent,O
issue,O
.,O
An,O
outbreak,O
of,O
novel,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
spread,O
from,O
China,O
worldwide,O
since,O
December,O
2019,O
(,O
Zhu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Therefore,O
",",O
most,O
COVID-19,O
patients,O
require,O
hospitalization,O
or,O
isolated,O
observation,O
",",O
but,O
large,O
numbers,O
of,O
patients,O
could,O
overwhelm,O
healthcare,O
systems,O
globally,O
.,O
It,O
is,O
important,O
for,O
us,O
to,O
avoid,O
an,O
increasing,O
number,O
of,O
COVID-19,O
-,O
related,O
deaths,O
by,O
early,O
detection,O
of,O
the,O
high,O
-,O
risk,O
group,O
.,O
The,O
inclusion,O
criteria,O
were,O
mild,O
/,O
moderate,O
symptoms,O
of,O
COVID-19,O
when,O
hospitalized,O
",",O
serum,O
collection,O
on,O
the,O
first,O
day,O
of,O
hospitalization,O
",",O
and,O
serial,O
serum,O
collection,O
during,O
hospitalization,O
.,O
For,O
a,O
screening,O
experiment,O
",",O
a,O
total,O
of,O
28,O
patients,O
with,O
COVID-19,O
who,O
were,O
eligible,O
based,O
on,O
the,O
study,O
’s,O
criteria,O
participated,O
.,O
To,O
confirm,O
the,O
discrimination,O
ability,O
of,O
the,O
predictive,O
markers,O
between,O
the,O
COVID-19,O
severe,O
population,O
and,O
other,O
diseases,O
",",O
114,O
patients,O
with,O
several,O
common,O
diseases,O
",",O
who,O
were,O
negative,O
for,O
SARS,O
-,O
CoV-2,O
RNA,O
(,O
Supplemental,O
Information,O
and,O
Supplemental,O
Table,O
3,O
),O
",",O
were,O
enrolled,O
.,O
However,O
",",O
IP-10,O
",",O
CXCL9,O
",",O
and,O
CCL17,O
levels,O
were,O
specifically,O
associated,O
with,O
the,O
COVID-19,O
severe,O
/,O
critical,O
group,O
.,O
Laboratory,O
data,O
showing,O
significant,O
associations,O
with,O
the,O
development,O
of,O
severe,O
/,O
critical,O
symptoms,O
(,O
Supplemental,O
Table,O
1,O
),O
were,O
compared,O
between,O
COVID-19,O
and,O
common,O
diseases,O
(,O
Supplemental,O
Fig,O
.,O
2,O
),O
.,O
The,O
ranges,O
of,O
all,O
laboratory,O
data,O
except,O
for,O
CRP,O
overlapped,O
between,O
COVID-19,O
and,O
common,O
diseases,O
.,O
To,O
validate,O
the,O
predictive,O
power,O
of,O
CCL17,O
",",O
independent,O
samples,O
from,O
COVID-19,O
patients,O
were,O
added,O
",",O
and,O
CCL17,O
levels,O
at,O
an,O
early,O
phase,O
of,O
hospitalization,O
were,O
determined,O
.,O
Approximately,O
80,O
%,O
of,O
COVID-19,O
patients,O
have,O
mild,O
or,O
moderate,O
disease,O
and,O
recover,O
within,O
a,O
few,O
weeks,O
",",O
but,O
as,O
previously,O
reported,O
",",O
the,O
remaining,O
COVID-19,O
patients,O
develop,O
severe,O
or,O
critical,O
symptoms,O
(,O
Guan,O
et,O
al,O
.,O
",",O
2020,O
",",O
Wu,O
and,O
McGoogan,O
",",O
2020,O
),O
.,O
ALB,O
",",O
LDH,O
",",O
CRP,O
",",O
and,O
neutrophil,O
counts,O
were,O
associated,O
with,O
the,O
development,O
of,O
severe,O
pneumonia,O
(,O
Gong,O
et,O
al,O
.,O
",",O
2020,O
",",O
Mo,O
et,O
al,O
.,O
",",O
2020,O
",",O
Wang,O
et,O
al,O
.,O
",",O
2020a,O
",",O
Zhang,O
et,O
al,O
.,O
",",O
2020a,O
),O
",",O
and,O
COVID-19,O
patients,O
with,O
hypertension,O
were,O
also,O
significantly,O
more,O
likely,O
to,O
develop,O
severe,O
disease,O
(,O
Wu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
COVID-19,O
",",O
the,O
CCL17,O
expression,O
range,O
was,O
very,O
narrow,O
in,O
the,O
severe,O
/,O
critical,O
group,O
.,O
This,O
feature,O
might,O
explain,O
why,O
many,O
more,O
children,O
with,O
COVID-19,O
have,O
mild,O
symptoms,O
than,O
adult,O
patients,O
.,O
Dysfunction,O
of,O
Treg,O
cells,O
in,O
the,O
lung,O
could,O
induce,O
severe,O
/,O
critical,O
pneumonia,O
in,O
COVID-19,O
patients,O
.,O
The,O
mechanism,O
of,O
CCL17,O
suppression,O
in,O
COVID-19,O
is,O
unknown,O
.,O
High,O
expression,O
of,O
IP-10,O
was,O
associated,O
with,O
severe,O
disease,O
in,O
COVID-19,O
(,O
Ma,O
et,O
al,O
.,O
",",O
2020,O
",",O
Runfeng,O
et,O
al,O
.,O
",",O
2020,O
",",O
Xiong,O
et,O
al,O
.,O
",",O
2020,O
",",O
Yang,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Interestingly,O
",",O
there,O
were,O
no,O
associations,O
for,O
both,O
IFN,O
-,O
λ1,O
and,O
2,O
in,O
COVID-19,O
",",O
and,O
IFN,O
-,O
λ1,O
or,O
2,O
genes,O
were,O
not,O
associated,O
with,O
response,O
to,O
interferon,O
-,O
α,O
(,O
IFN,O
-,O
α,O
),O
treatment,O
for,O
CHC,O
(,O
Ge,O
et,O
al,O
.,O
",",O
2009,O
),O
.,O
Therefore,O
",",O
clinical,O
trials,O
of,O
IFN,O
-,O
α,O
treatment,O
for,O
COVID-19,O
that,O
classified,O
patients,O
by,O
SNP,O
type,O
showed,O
that,O
it,O
could,O
provide,O
good,O
results,O
(,O
Li,O
and,O
De,O
Clercq,O
",",O
2020,O
",",O
Wang,O
et,O
al,O
.,O
",",O
2020b,O
),O
.,O
The,O
present,O
data,O
showed,O
for,O
the,O
first,O
time,O
that,O
IFN,O
-,O
λ3,O
itself,O
is,O
a,O
key,O
molecule,O
for,O
the,O
development,O
of,O
severe,O
pneumonia,O
",",O
and,O
the,O
natural,O
course,O
of,O
IFN,O
-,O
λ3,O
in,O
COVID-19,O
patients,O
was,O
shown,O
using,O
serial,O
serum,O
samples,O
.,O
The,O
association,O
of,O
IL-6,O
with,O
COVID-19,O
has,O
been,O
previously,O
reported,O
(,O
Chen,O
et,O
al,O
.,O
",",O
2020a,O
",",O
Gao,O
et,O
al,O
.,O
",",O
2020,O
",",O
Zhang,O
et,O
al,O
.,O
",",O
2020c,O
),O
.,O
The,O
present,O
data,O
suggest,O
that,O
COVID-19,O
patients,O
with,O
RA,O
have,O
high,O
levels,O
of,O
IL-6,O
without,O
severe,O
/,O
critical,O
symptoms,O
.,O
These,O
data,O
suggest,O
that,O
the,O
SNP,O
type,O
of,O
individuals,O
should,O
be,O
considered,O
to,O
understand,O
the,O
profiles,O
of,O
predictive,O
markers,O
",",O
in,O
addition,O
to,O
COVID-19,O
outcomes,O
.,O
However,O
",",O
Yang,O
et,O
al,O
.,O
reported,O
that,O
CXCL9,O
levels,O
were,O
elevated,O
during,O
disease,O
progression,O
of,O
COVID-19,O
",",O
but,O
they,O
were,O
not,O
useful,O
as,O
predictive,O
markers,O
(,O
Yang,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Highlights,O
    ,O
•,O
 ,O
CCL17,O
",",O
IFN-,O
l,O
3,O
",",O
IL-6,O
",",O
IP-10,O
",",O
and,O
CXCL9,O
were,O
predictor,O
for,O
COVID-19,O
prognosis,O
.,O
The,O
downregulation,O
of,O
CCL17,O
could,O
be,O
unique,O
in,O
COVID-19,O
.,O
COVID-19,O
",",O
a,O
novel,O
coronavirus,O
-,O
related,O
illness,O
",",O
has,O
spread,O
worldwide,O
.,O
Therefore,O
",",O
almost,O
all,O
COVID-19,O
patients,O
require,O
hospitalization,O
",",O
which,O
can,O
reduce,O
limited,O
medical,O
resources,O
in,O
addition,O
to,O
overwhelming,O
medical,O
facilities,O
.,O
To,O
identify,O
predictive,O
markers,O
for,O
the,O
development,O
of,O
severe,O
pneumonia,O
",",O
a,O
comprehensive,O
analysis,O
of,O
serum,O
chemokines,O
and,O
cytokines,O
was,O
conducted,O
using,O
serial,O
serum,O
samples,O
from,O
COVID-19,O
patients,O
.,O
Low,O
expression,O
of,O
CCL17,O
was,O
specifically,O
observed,O
in,O
pre,O
-,O
severe,O
COVID-19,O
patients,O
compared,O
with,O
other,O
common,O
diseases,O
",",O
and,O
the,O
predictive,O
ability,O
of,O
CCL17,O
was,O
confirmed,O
in,O
validation,O
samples,O
of,O
COVID-19,O
.,O
We,O
successfully,O
typed,O
a,O
total,O
of,O
77,O
HRV,O
strains,O
representing,O
all,O
three,O
HRV,O
species,O
(,O
GenBank,S-Repository
 ,O
accession,O
numbers,O
MH824434,S-AccessionNumber
‐,O
MH824510,S-AccessionNumber
),O
",",O
whereas,O
16,O
HRV,O
strains,O
could,O
not,O
be,O
typed,O
.,O
I,O
am,O
an,O
instructor,O
at,O
Mount,O
Sinai,O
",",O
meaning,O
I,O
am,O
still,O
an,O
early,O
-,O
career,O
researcher,O
",",O
and,O
COVID-19,O
has,O
negatively,O
affected,O
my,O
career,O
development,O
",",O
my,O
research,O
work,O
and,O
our,O
hospital,O
.,O
The,O
outbreak,O
of,O
COVID-19,O
has,O
stalled,O
both,O
the,O
basic,O
",",O
clinical,O
and,O
non,O
-,O
COVID,O
medical,O
research,O
.,O
This,O
Editorial,O
describes,O
an,O
early,O
-,O
career,O
researcher,O
's,O
experience,O
and,O
highlights,O
how,O
after,O
efficiently,O
contributing,O
to,O
‘,O
flattening,O
the,O
curve,O
’,O
of,O
COVID-19,O
infections,O
",",O
the,O
research,O
community,O
has,O
an,O
opportunity,O
for,O
growth,O
and,O
re,O
-,O
structuring,O
.,O
The,O
COVID-19,O
outbreak,O
has,O
created,O
a,O
global,O
health,O
crisis,O
that,O
is,O
profoundly,O
affecting,O
early,O
-,O
career,O
scientists,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
caused,O
by,O
a,O
novel,O
coronavirus,O
named,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
has,O
spread,O
worldwide,O
as,O
a,O
severe,O
pandemic,O
(,O
Callaway,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Currently,O
",",O
no,O
validated,O
therapeutics,O
against,O
virus,O
-,O
target,O
interactions,O
are,O
available,O
for,O
COVID-19,O
.,O
Convalescent,O
patients,O
’,O
plasma,O
",",O
which,O
contains,O
neutralizing,O
antibodies,O
produced,O
by,O
the,O
adaptive,O
immune,O
response,O
",",O
has,O
led,O
to,O
a,O
clear,O
clinical,O
improvement,O
of,O
both,O
mild,O
and,O
severe,O
COVID-19,O
patients,O
when,O
used,O
as,O
a,O
therapeutic,O
modality,O
(,O
Chen,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Shen,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Cao,O
",",O
2020,O
),O
.,O
Here,O
",",O
we,O
report,O
the,O
rapid,O
and,O
efficient,O
identification,O
of,O
SARS,O
-,O
CoV-2,O
-,O
neutralizing,O
antibodies,O
achieved,O
by,O
high,O
-,O
throughput,O
single,O
-,O
cell,O
RNA,O
and,O
VDJ,O
sequencing,O
of,O
antigen,O
-,O
binding,O
B,O
cells,O
from,O
convalescent,O
COVID-19,O
patients,O
.,O
Overall,O
",",O
we,O
showed,O
that,O
high,O
-,O
throughput,O
single,O
-,O
cell,O
sequencing,O
could,O
lead,O
to,O
the,O
identification,O
of,O
highly,O
potent,O
neutralizing,O
mAbs,O
that,O
have,O
strong,O
therapeutic,O
and,O
prophylactic,O
efficacy,O
",",O
which,O
could,O
greatly,O
assist,O
in,O
the,O
intervention,O
of,O
prevailing,O
and,O
emerging,O
infectious,O
diseases,O
",",O
such,O
as,O
COVID-19,O
.,O
To,O
exploit,O
this,O
hypothesis,O
",",O
we,O
first,O
collected,O
peripheral,O
blood,O
mononuclear,O
cells,O
(,O
PBMCs,O
),O
and,O
isolated,O
the,O
B,O
cells,O
from,O
12,O
COVID-19,O
convalescent,O
patients,O
from,O
Beijing,O
Youan,O
Hospital,O
(,O
Table,O
S1,O
),O
.,O
To,O
evaluate,O
their,O
neutralization,O
potential,O
against,O
the,O
authentic,O
virus,O
",",O
we,O
performed,O
the,O
plaque,O
reduction,O
neutralization,O
test,O
(,O
PRNT,O
),O
using,O
authentic,O
SARS,O
-,O
CoV-2,O
isolated,O
from,O
COVID-19,O
patients,O
.,O
We,O
compared,O
every,O
IgG1,O
-,O
presenting,O
clonotype,O
’s,O
predicted,O
structure,O
based,O
on,O
CDR3H,O
using,O
FREAD,O
to,O
the,O
available,O
SARS,O
-,O
CoV,O
-,O
neutralizing,O
mAbs,O
’,O
crystal,O
structure,O
in,O
the,O
PDB,O
database,O
as,O
well,O
as,O
the,O
structure,O
of,O
BD-23,O
.,O
However,O
",",O
a,O
total,O
of,O
12,O
IgG1,O
clonotypes,O
showed,O
high,O
structure,O
similarity,O
with,O
PDB,S-Repository
 ,O
ID,O
2dd8,S-AccessionNumber
 ,O
and,O
2ghw,S-AccessionNumber
 ,O
(,O
Table,O
S2,O
;,O
Figure,O
 ,O
5C,O
),O
",",O
which,O
corresponds,O
to,O
previously,O
isolated,O
SARS,O
-,O
CoV,O
-,O
neutralizing,O
mAbs,O
m396,O
and,O
80R,O
",",O
respectively,O
(,O
Prabakaran,O
et,O
al,O
.,O
",",O
2006,O
",",O
Hwang,O
et,O
 ,O
al,O
.,O
",",O
2006,O
),O
.,O
A,O
total,O
of,O
64,O
confirmed,O
COVID-19,O
patients,O
discharged,O
from,O
Beijing,O
Youan,O
Hospital,O
",",O
China,O
",",O
from,O
February,O
01,O
to,O
February,O
28,O
",",O
2020,O
",",O
were,O
enrolled,O
in,O
this,O
study,O
(,O
Table,O
S1,O
),O
.,O
Patients,O
13,O
-,O
64,O
",",O
as,O
well,O
as,O
8,O
patents,O
from,O
ID,O
1,O
-,O
12,O
",",O
enrolled,O
in,O
the,O
study,O
corresponding,O
to,O
sequence,O
batch,O
1,O
-,O
6,O
(,O
Table,O
S1,O
),O
.,O
Discharged,O
COVID-19,O
patients,O
were,O
isolated,O
and,O
observed,O
continually,O
for,O
28,O
 ,O
days,O
.,O
All,O
COVID-19,O
patients,O
were,O
confirmed,O
infected,O
according,O
to,O
positive,O
respiratory,O
RT,O
-,O
PCR,O
tests,O
.,O
The,O
SARS,O
-,O
CoV-2,O
pseudovirus,O
is,O
a,O
gift,O
from,O
the,O
Division,O
of,O
HIV,O
/,O
AIDS,O
and,O
Sex,O
-,O
transmitted,O
Virus,O
Vaccines,O
",",O
National,O
Institutes,O
for,O
Food,O
and,O
Drug,O
Control,O
(,O
NIFDC,O
),O
.,O
The,O
S,O
trimer,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6VSB,S-AccessionNumber
),O
was,O
used,O
as,O
a,O
reference,O
for,O
the,O
3D,O
classifications,O
.,O
This,O
BD23,O
-,O
Fab,O
model,O
and,O
the,O
S,O
trimer,O
structure,O
(,O
PDB,O
ID,O
:,O
6VSB,O
),O
were,O
docked,O
into,O
the,O
cryo,O
-,O
EM,O
density,O
using,O
UCSF,O
Chimera,O
.,O
Various,O
concentrations,O
of,O
mAbs,O
(,O
3,O
-,O
fold,O
serial,O
dilution,O
using,O
DMEM,O
",",O
50,O
 ,O
μL,O
aliquots,O
),O
were,O
mixed,O
with,O
the,O
same,O
volume,O
of,O
SARS,O
-,O
CoV-2,O
pseudovirus,O
with,O
a,O
TCID50,O
of,O
1.3,O
 ,O
×,O
104,O
in,O
a,O
96,O
well,O
-,O
plate,O
.,O
Cell,O
types,O
were,O
identified,O
using,O
SingleR,O
(,O
Aran,O
et,O
al,O
.,O
",",O
2019,O
),O
against,O
a,O
human,O
immune,O
reference,O
dataset,O
(,O
Monaco,O
et,O
al,O
.,O
",",O
2019,O
),O
.,O
The,O
COVID-19,O
pandemic,O
urgently,O
needs,O
therapeutic,O
and,O
prophylactic,O
interventions,O
.,O
Graphical,O
Abstract,O
     ,O
Neutralizing,O
antibodies,O
",",O
which,O
could,O
effectively,O
block,O
virus,O
entry,O
into,O
host,O
cells,O
",",O
are,O
urgently,O
needed,O
for,O
intervention,O
against,O
COVID-19,O
.,O
Coronaviruses,O
were,O
detected,O
in,O
three,O
individuals,O
by,O
mapping,O
clean,O
reads,O
without,O
ribosomes,O
and,O
host,O
sequences,O
to,O
an,O
in,O
-,O
house,O
virus,O
reference,O
dataset,O
separated,O
from,O
the,O
GenBank,S-Repository
 ,O
non,O
-,O
redundant,O
nucleotide,O
database,O
using,O
the,O
Burrows,O
-,O
Wheeler,O
Aligner,O
(,O
BWA,O
),O
ver,O
0.7.17,O
[,O
10,O
",",O
23,O
],O
.,O
After,O
gap,O
filling,O
",",O
the,O
whole,O
genome,O
sequence,O
of,O
pangolin,O
-,O
CoV-2020,O
was,O
submitted,O
to,O
GenBank,S-Repository
 ,O
databases,O
(,O
accession,O
no,O
.,O
MT121216,S-AccessionNumber
),O
.,O
We,O
downloaded,O
44,O
full,O
-,O
length,O
genome,O
sequences,O
of,O
coronaviruses,O
isolated,O
from,O
different,O
hosts,O
from,O
the,O
public,O
database,O
(,O
S5,O
Table,O
),O
",",O
with,O
the,O
data,O
kindly,O
shared,O
by,O
the,O
submitters,O
.,O
The,O
outbreak,O
of,O
a,O
novel,O
corona,O
Virus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
in,O
the,O
city,O
of,O
Wuhan,O
",",O
China,O
has,O
resulted,O
in,O
more,O
than,O
1.7,O
million,O
laboratory,O
confirmed,O
cases,O
all,O
over,O
the,O
world,O
.,O
Age,O
-,O
wise,O
and,O
gender,O
-,O
wise,O
distribution,O
of,O
COVID-19,O
in,O
Faisalabad,O
is,O
shown,O
in,O
Table,O
1,O
.,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
or,O
COVID-2019,O
is,O
a,O
new,O
global,O
health,O
challenge,O
which,O
causes,O
severe,O
respiratory,O
complications,O
.,O
This,O
retrospective,O
study,O
is,O
the,O
first,O
report,O
of,O
epidemiological,O
trends,O
of,O
COVID-19,O
in,O
Faisalabad,O
",",O
Pakistan,O
.,O
RNA,O
was,O
extracted,O
using,O
QIAsymphony,O
DSP,O
Virus,O
/,O
Pathogen,O
Midi,O
Kit,O
and,O
real,O
-,O
time,O
PCR,O
was,O
performed,O
to,O
quantify,O
COVID-19,O
.,O
Our,O
finding,O
showed,O
that,O
overall,O
prevalence,O
of,O
COVID-19,O
in,O
Faisalabad,O
on,O
April,O
4th,O
was,O
17.18,O
%,O
(,O
22,O
of,O
128,O
),O
.,O
Patients,O
belonging,O
to,O
age,O
group,O
37–47,O
 ,O
years,O
were,O
found,O
to,O
be,O
most,O
(,O
45.5,O
%,O
),O
infected,O
with,O
COVID-19,O
.,O
Highlights,O
    ,O
•,O
 ,O
SARS,O
-,O
CoV-2,O
or,O
COVID-2019,O
is,O
global,O
health,O
challenge,O
.,O
This,O
retrospective,O
study,O
is,O
the,O
first,O
report,O
of,O
epidemiological,O
trends,O
of,O
COVID-19,O
in,O
Faisalabad,O
",",O
Pakistan,O
.,O
   ,O
•,O
Our,O
finding,O
showed,O
that,O
overall,O
prevalence,O
of,O
COVID-19,O
in,O
Faisalabad,O
on,O
April,O
4th,O
was,O
17.18,O
%,O
(,O
22,O
of,O
128,O
),O
.,O
Arizona,O
’s,O
first,O
confirmed,O
case,O
of,O
COVID-19,O
",",O
the,O
disease,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
",",O
was,O
detected,O
in,O
late,O
January,O
2020,O
in,O
a,O
student,O
attending,O
Arizona,O
State,O
University,O
who,O
had,O
traveled,O
to,O
China,O
(,O
5,O
),O
.,O
In,O
order,O
to,O
assist,O
with,O
both,O
local,O
and,O
global,O
efforts,O
to,O
track,O
the,O
spread,O
and,O
evolution,O
of,O
this,O
virus,O
",",O
we,O
began,O
intensive,O
sequencing,O
of,O
viral,O
genomes,O
from,O
across,O
Arizona,O
and,O
deposition,O
of,O
these,O
sequences,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
",",O
which,O
makes,O
them,O
accessible,O
to,O
the,O
research,O
community,O
for,O
downstream,O
analyses,O
",",O
notably,O
including,O
real,O
-,O
time,O
pathogen,O
tracking,O
through,O
Nextstrain,S-Repository
 ,O
(,O
12,O
),O
.,O
First,O
",",O
did,O
the,O
initial,O
case,O
of,O
COVID-19,O
in,O
Arizona,O
lead,O
to,O
cryptic,O
community,O
transmission,O
that,O
helped,O
to,O
fuel,O
the,O
ongoing,O
epidemic,O
?,O
This,O
data,O
set,O
includes,O
at,O
least,O
one,O
genome,O
from,O
11,O
of,O
the,O
15,O
Arizona,O
counties,O
(,O
see,O
Table,O
 ,O
S3,O
in,O
the,O
supplemental,O
material,O
),O
.,O
The,O
first,O
case,O
of,O
COVID-19,O
in,O
Arizona,O
(,O
AZ1,O
),O
was,O
documented,O
in,O
late,O
January,O
2020,O
",",O
and,O
contact,O
tracing,O
suggested,O
that,O
this,O
initial,O
case,O
did,O
not,O
result,O
in,O
additional,O
symptomatic,O
infections,O
within,O
the,O
state,O
(,O
5,O
),O
.,O
The,O
genomes,O
used,O
in,O
this,O
analysis,O
were,O
selected,O
using,O
a,O
novel,O
bioinformatics,O
pipeline,O
(,O
see,O
Materials,O
and,O
Methods,O
),O
",",O
which,O
subsampled,O
genomes,O
uploaded,O
to,O
GISAID,S-Dataset
 ,O
to,O
reduce,O
the,O
size,O
of,O
the,O
data,O
set,O
while,O
representing,O
the,O
temporal,O
",",O
spatial,O
",",O
and,O
genetic,O
diversity,O
of,O
the,O
full,O
data,O
set,O
.,O
A,O
reduced,O
version,O
of,O
this,O
data,O
set,O
",",O
including,O
376,O
genomes,O
with,O
complete,O
date,O
information,O
",",O
was,O
used,O
in,O
the,O
Bayesian,O
analysis,O
.,O
1,O
.,O
Sequence,O
database,O
representation,O
through,O
time,O
for,O
each,O
of,O
the,O
six,O
major,O
named,O
lineages,O
or,O
sublineages,O
observed,O
in,O
Arizona,O
.,O
Lineages,O
were,O
assigned,O
using,O
Pangolin,O
(,O
37,O
),O
for,O
all,O
sequences,O
uploaded,O
to,O
GISAID,S-Dataset
 ,O
as,O
of,O
16,O
April,O
2020,O
.,O
For,O
this,O
analysis,O
",",O
we,O
considered,O
the,O
full,O
collection,O
of,O
SARS,O
-,O
CoV-2,O
genomes,O
available,O
on,O
GISAID,S-Dataset
 ,O
(,O
as,O
of,O
16,O
April,O
2020,O
),O
.,O
The,O
second,O
case,O
of,O
COVID-19,O
in,O
Arizona,O
was,O
reported,O
on,O
3,O
March,O
from,O
a,O
traveler,O
who,O
returned,O
from,O
France,O
on,O
27,O
February,O
(,O
40,O
),O
.,O
Based,O
on,O
our,O
phylogenetic,O
analysis,O
",",O
it,O
is,O
clear,O
that,O
the,O
ongoing,O
COVID-19,O
outbreak,O
in,O
Arizona,O
has,O
been,O
fueled,O
by,O
multiple,O
distinct,O
introductions,O
of,O
SARS,O
-,O
CoV-2,O
to,O
the,O
state,O
.,O
Sequences,O
included,O
in,O
the,O
analyses,O
presented,O
here,O
were,O
derived,O
from,O
GISAID,S-Dataset
 ,O
(,O
accessed,O
on,O
16,O
April,O
2020,O
),O
",",O
NCBI,B-Repository
GenBank,E-Repository
",",O
and,O
sequences,O
generated,O
by,O
our,O
teams,O
at,O
Northern,O
Arizona,O
University,O
and,O
TGen,O
North,O
(,O
n,O
 ,O
=,O
 ,O
75,O
),O
",",O
Arizona,O
State,O
University,O
(,O
n,O
 ,O
=,O
 ,O
3,O
),O
",",O
and,O
University,O
of,O
Arizona,O
(,O
n,O
 ,O
=,O
 ,O
1,O
),O
(,O
collectively,O
referred,O
to,O
as,O
the,O
“,O
Arizona,O
sequences,O
”,O
),O
.,O
To,O
support,O
efficient,O
Bayesian,O
phylogenetic,O
analysis,O
of,O
this,O
large,O
number,O
of,O
sequences,O
",",O
we,O
developed,O
genome,O
-,O
sampler,O
(,O
36,O
),O
",",O
a,O
novel,O
protocol,O
and,O
software,O
for,O
sampling,O
sequences,O
from,O
GISAID,S-Dataset
 ,O
across,O
time,O
of,O
sequence,O
acquisition,O
",",O
geographic,O
source,O
of,O
sequence,O
",",O
and,O
SARS,O
-,O
CoV-2,O
diversity,O
.,O
As,O
the,O
COVID-19,O
pandemic,O
swept,O
across,O
the,O
United,O
States,O
",",O
there,O
was,O
great,O
differential,O
impact,O
on,O
local,O
and,O
regional,O
communities,O
.,O
The,O
novel,O
coronavirus,O
SARS‐CoV‐2,O
leads,O
to,O
coronavirus,O
disease,O
2019,O
(,O
synonym,O
:,O
COVID‐19,O
),O
.,O
Numerous,O
researcher,O
groups,O
have,O
been,O
focusing,O
on,O
the,O
COVID‐19,O
pandemic,O
in,O
recent,O
days,O
.,O
Cancer,O
patients,O
are,O
at,O
a,O
risk,O
for,O
the,O
development,O
of,O
several,O
infections,O
",",O
including,O
the,O
prevalent,O
COVID‐19,O
pandemic,O
in,O
recent,O
days,O
.,O
Lung,O
tumors,O
may,O
block,O
normal,O
mucus,O
drainage,O
",",O
which,O
can,O
lead,O
to,O
infection,O
",",O
and,O
further,O
",",O
other,O
types,O
of,O
entrance,O
molecules,O
that,O
have,O
been,O
changed,O
by,O
cancer,O
can,O
be,O
more,O
prone,O
to,O
COVID‐19,O
infection,O
.,O
In,O
this,O
way,O
",",O
we,O
first,O
designed,O
our,O
in,O
silico,O
analyses,O
regarding,O
COVID‐19‐related,O
genes,O
(,O
ACE2,O
",",O
TMPRSS2,O
",",O
CD147,O
/,O
BSG,O
",",O
and,O
FURIN,O
/,O
PCSK3,O
),O
expression,O
",",O
as,O
well,O
as,O
mutation,O
analyses,O
",",O
for,O
revealing,O
the,O
susceptibility,O
of,O
COVID‐19,O
in,O
lung,O
cancer,O
subtypes,O
(,O
lung,O
squamous,O
carcinoma,O
[,O
LUSC,O
],O
and,O
lung,O
adenocarcinoma,O
[,O
LUAD,O
],O
),O
.,O
The,O
lung,O
cancer,O
data,O
set,O
was,O
obtained,O
from,O
The,B-Repository
Cancer,I-Repository
Genome,I-Repository
Atlas,I-Repository
(TCGA),E-Repository
 ,O
database,O
.,O
The,O
cBio,B-Repository
Cancer,I-Repository
Genomics,I-Repository
Portal,E-Repository
 ,O
(,O
http://cbioportal.org,S-URL
),O
is,O
an,O
open,O
accessed,O
platform,O
containing,O
TCGA,S-Repository
 ,O
data,O
set,O
;,O
it,O
is,O
a,O
collaboration,O
between,O
the,O
National,B-Creator
Cancer,I-Creator
Institute,I-Creator
(NCI),E-Creator
 ,O
and,O
the,O
National,B-Creator
Human,I-Creator
Genome,I-Creator
Research,I-Creator
Institute,I-Creator
(NHGRI),E-Creator
",",O
is,O
the,O
large‐scale,O
cancer,O
genomics,O
projects,O
that,O
allow,O
interactive,O
research,O
of,O
multiple,O
cancer,O
genomic,O
data,O
sets,O
",",O
and,O
provides,O
access,O
to,O
the,O
data,O
of,O
more,O
than,O
5000,O
tumor,O
samples,O
from,O
various,O
cancer,O
studies,O
.,O
The,O
selected,O
TCGA,S-Repository
 ,O
data,O
set,O
comprised,O
the,O
genome,O
sequencing,O
data,O
of,O
1097,O
LUAD,O
and,O
LUSC,O
patients,O
.,O
Finally,O
",",O
the,O
score,O
given,O
by,O
the,O
COSMIC,S-Repository
  ,O
(,O
https://cancer.sanger.ac.uk/cosmic,S-URL
),O
database,O
was,O
used,O
to,O
predict,O
and,O
verify,O
the,O
pathogenic,O
effect,O
of,O
detected,O
mutations,O
.,O
GEPIA,O
offers,O
customizable,O
features,O
such,O
as,O
differentially,O
expressed,O
tumor,O
/,O
normal,O
analysis,O
from,O
the,O
TCGA,S-Repository
 ,O
and,O
the,O
Genotype‐Tissue,O
Expression,O
 ,O
databases,O
.,O
Since,O
the,O
first,O
case,O
detected,O
in,O
December,O
2019,O
",",O
a,O
new,O
coronavirus,O
causing,O
COVID‐19,O
disease,O
has,O
led,O
to,O
more,O
than,O
3,O
 ,O
500,O
 ,O
000,O
infections,O
worldwide,O
and,O
about,O
245,O
 ,O
000,O
deaths,O
.,O
Cancer,O
patients,O
may,O
be,O
at,O
a,O
higher,O
risk,O
of,O
being,O
more,O
susceptible,O
to,O
COVID‐19,O
infectious,O
diseases,O
.,O
First,O
of,O
all,O
",",O
mutation,O
profiles,O
of,O
target,O
genes,O
",",O
including,O
ACE2,O
",",O
TMPRSS2,O
",",O
CD147,O
/,O
BSG,O
",",O
and,O
FURIN,O
/,O
PCSK3,O
from,O
the,O
genome,O
sequencing,O
results,O
of,O
the,O
LUAD,O
and,O
LUSC,O
patient,O
",",O
which,O
are,O
accessible,O
in,O
TGCA,S-Repository
 ,O
data,O
sets,O
",",O
were,O
analyzed,O
extensively,O
.,O
Ulrich,O
et,O
al,O
 ,O
reported,O
that,O
inhibition,O
of,O
CD147,O
/,O
BSG,O
may,O
have,O
beneficial,O
effects,O
in,O
the,O
prevention,O
of,O
diabetic,O
complications,O
",",O
involving,O
severe,O
acute,O
respiratory,O
syndrome,O
triggers,O
by,O
COVID‐19,O
.,O
Therefore,O
",",O
assessment,O
of,O
the,O
TMPRSS2,O
gene,O
downregulated,O
expression,O
only,O
may,O
be,O
useful,O
for,O
predicting,O
prognosis,O
and,O
susceptibility,O
to,O
COVID‐19,O
in,O
these,O
patient,O
groups,O
.,O
The,O
challenge,O
for,O
today,O
is,O
building,O
the,O
assessment,O
of,O
genomic,O
susceptibility,O
to,O
COVID‐19,O
in,O
lung,O
cancer,O
",",O
requiring,O
detailed,O
experimental,O
laboratory,O
studies,O
",",O
in,O
addition,O
to,O
in,O
silico,O
analyses,O
",",O
as,O
a,O
way,O
of,O
assessing,O
the,O
mechanism,O
of,O
novel,O
virus,O
invasion,O
that,O
can,O
be,O
used,O
in,O
the,O
development,O
of,O
effective,O
SARS‐CoV‐2,O
therapy,O
.,O
The,O
increased,O
expression,O
of,O
ACE2,O
and,O
CD147,O
/,O
BSG,O
and,O
decreased,O
expression,O
of,O
TMPRSS2,O
in,O
tumor,O
tissues,O
results,O
in,O
more,O
susceptible,O
to,O
SARS‐CoV‐2,O
infection,O
in,O
COVID‐19,O
patients,O
with,O
lung,O
cancer,O
subtypes,O
.,O
The,O
downregulated,O
expression,O
of,O
TMPRSS2,O
may,O
useful,O
for,O
predicting,O
prognosis,O
and,O
susceptibility,O
to,O
COVID‐19,O
in,O
LUAD,O
cancer,O
patients,O
.,O
The,O
impact,O
of,O
genetic,O
variations,O
in,O
lung,O
cancer,O
patients,O
need,O
to,O
be,O
assessed,O
in,O
order,O
to,O
effectively,O
reveal,O
potential,O
invasion,O
genes,O
for,O
SARS‐CoV‐2,O
in,O
COVID‐19,O
susceptibility,O
.,O
On,O
11,O
February,O
2020,O
",",O
the,O
International,O
Committee,O
on,O
Taxonomy,O
of,O
Viruses,O
officially,O
renamed,O
the,O
novel,O
coronavirus,O
(,O
ie,O
",",O
previously,O
2019‐nCoV,O
),O
responsible,O
for,O
the,O
current,O
outbreak,O
of,O
COVID‐19,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS‐CoV‐2,O
),O
.,O
The,O
virus,O
",",O
which,O
emerged,O
in,O
December,O
2019,O
in,O
the,O
Chinese,O
city,O
of,O
Wuhan,O
",",O
causes,O
a,O
respiratory,O
illness,O
called,O
COVID‐19,O
",",O
which,O
can,O
spread,O
from,O
person,O
to,O
person,O
.,O
",",O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
officials,O
outlined,O
their,O
top,O
research,O
priorities,O
for,O
controlling,O
the,O
outbreak,O
of,O
the,O
coronavirus‐associated,O
disease,O
known,O
as,O
COVID‐19,O
and,O
highlighted,O
the,O
importance,O
of,O
developing,O
candidate,O
therapeutics,O
and,O
easy‐to‐apply,O
diagnostics,O
for,O
identifying,O
active,O
",",O
asymptomatic,O
",",O
and,O
resolved,O
infections,O
.,O
The,O
discovery,O
of,O
a,O
virus,O
closely,O
related,O
to,O
the,O
newly,O
emerged,O
SARS‐CoV‐2,O
in,O
a,O
data,O
set,O
from,O
pangolins,O
sampled,O
more,O
than,O
a,O
year,O
ago,O
illustrates,O
that,O
the,O
sampling,O
of,O
other,O
mammals,O
handled,O
or,O
consumed,O
by,O
humans,O
could,O
uncover,O
even,O
more,O
closely,O
related,O
viruses,O
.,O
As,O
of,O
9,O
February,O
2020,O
",",O
73,O
genomes,O
of,O
SARS‐CoV‐2,O
strains,O
obtained,O
from,O
humans,O
have,O
been,O
released,O
on,O
GISAID,S-Dataset
 ,O
(,O
http://gisaid.org/,S-URL
),O
.,O
The,O
final,O
data,O
set,O
(,O
“,O
dataset_70,O
”,O
),O
included,O
70,O
genomes,O
of,O
SARS‐CoV‐2,O
strains,O
from,O
Australia,O
(,O
n,O
 ,O
=,O
 ,O
4,O
),O
",",O
Belgium,O
(,O
n,O
 ,O
=,O
 ,O
1,O
),O
",",O
China,O
(,O
n,O
 ,O
=,O
 ,O
40,O
),O
",",O
Finland,O
(,O
n,O
 ,O
=,O
 ,O
1,O
),O
",",O
France,O
(,O
n,O
 ,O
=,O
 ,O
4,O
),O
",",O
Germany,O
(,O
n,O
 ,O
=,O
 ,O
1,O
),O
",",O
Japan,O
(,O
n,O
 ,O
=,O
 ,O
1,O
),O
",",O
Korea,O
(,O
n,O
 ,O
=,O
 ,O
1,O
),O
",",O
Singapore,O
(,O
n,O
 ,O
=,O
 ,O
3,O
),O
",",O
Thailand,O
(,O
n,O
 ,O
=,O
 ,O
2,O
),O
",",O
UK,O
(,O
n,O
 ,O
=,O
 ,O
2,O
),O
",",O
and,O
USA,O
(,O
n,O
 ,O
=,O
 ,O
10,O
),O
with,O
sampling,O
dates,O
between,O
24,O
December,O
2019,O
and,O
3,O
February,O
2020,O
.,O
To,O
investigate,O
the,O
potential,O
intermediate,O
hosts,O
of,O
SARS‐CoV‐2,O
(,O
between,O
originating,O
animal,O
and,O
human,O
hosts,O
),O
",",O
two,O
samples,O
(,O
SRR10168377,O
and,O
SRR10168378,O
),O
obtained,O
from,O
previously,O
reported,O
Malayan,O
pangolin,O
(,O
Manis,O
javanica,O
),O
viral,O
metagenomic,O
sequencing,O
data,O
(,O
Bio,O
Project,O
PRJNA573298,S-AccessionNumber
),O
were,O
downloaded,O
from,O
the,O
NCBI,B-Repository
SRA,E-Repository
 ,O
public,O
database,O
.,O
We,O
defined,O
another,O
data,O
set,O
(,O
“,O
dataset_6,O
”,O
),O
composed,O
of,O
six,O
genome,O
sequences,O
of,O
coronavirus,O
strains,O
.,O
The,O
two,O
data,O
sets,O
(,O
“,O
dataset_70,O
”,O
and,O
“,O
dataset_6,O
”,O
),O
were,O
aligned,O
using,O
MAFFT,O
v7.222,O
 ,O
and,O
then,O
manually,O
curated,O
using,O
BioEdit,O
v7.2.5,O
.,O
To,O
assess,O
the,O
recombination,O
of,O
“,O
dataset_70,O
",",O
”,O
we,O
employed,O
the,O
pairwise,O
homoplasy,O
index,O
(,O
PHI,O
),O
to,O
measure,O
the,O
similarity,O
between,O
closely,O
linked,O
sites,O
using,O
SplitsTree,O
v4.15.1,O
.,O
The,O
best‐fit,O
nucleotide,O
substitution,O
models,O
for,O
the,O
two,O
data,O
sets,O
were,O
identified,O
according,O
to,O
the,O
Bayesian,O
information,O
criterion,O
(,O
BIC,O
),O
method,O
with,O
3,O
(,O
24,O
candidate,O
models,O
),O
or,O
11,O
(,O
88,O
candidate,O
models,O
),O
substitution,O
schemes,O
in,O
jModelTest,O
v2.1.10,O
.,O
To,O
evaluate,O
the,O
phylogenetic,O
signals,O
of,O
“,O
dataset_70,O
”,O
and,O
“,O
dataset_6,O
",",O
”,O
we,O
performed,O
likelihood‐mapping,O
analysis,O
 ,O
using,O
TREE‐PUZZLE,O
v5.3,O
",",O
 ,O
with,O
25,O
 ,O
000,O
to,O
175,O
 ,O
000,O
randomly,O
chosen,O
quartets,O
for,O
the,O
two,O
data,O
sets,O
.,O
For,O
“,O
dataset_70,O
",",O
”,O
split,O
network,O
analysis,O
was,O
performed,O
using,O
Kishino‐Yano‐85,O
distance,O
transformation,O
with,O
the,O
NeighborNet,O
method,O
",",O
which,O
can,O
be,O
loosely,O
thought,O
of,O
as,O
a,O
“,O
hybrid,O
”,O
between,O
the,O
neighbor‐joining,O
(,O
NJ,O
),O
and,O
split,O
decomposition,O
methods,O
",",O
implemented,O
in,O
TREE‐PUZZLE,O
v5.3,O
.,O
For,O
“,O
dataset_70,O
",",O
”,O
NJ,O
 ,O
phylogenetic,O
trees,O
were,O
constructed,O
using,O
the,O
Kimura,O
2‐parameter,O
method,O
 ,O
implemented,O
in,O
MEGA,O
v7.0.26,O
.,O
For,O
“,O
dataset_6,O
",",O
”,O
NJ,O
 ,O
phylogenetic,O
trees,O
were,O
constructed,O
using,O
the,O
Maximum,O
Composite,O
likelihood,O
(,O
MCL,O
),O
method,O
",",O
 ,O
and,O
rate,O
variation,O
among,O
sites,O
was,O
modeled,O
with,O
a,O
gamma,O
distribution,O
(,O
shape,O
parameter,O
 ,O
=,O
 ,O
4,O
),O
in,O
MEGA,O
v7.0.26,O
.,O
For,O
“,O
dataset_70,O
",",O
”,O
maximum‐likelihood,O
(,O
ML,O
),O
phylogenies,O
were,O
reconstructed,O
using,O
the,O
Hasegawa‐Kishino‐Yano,O
(,O
HKY,O
),O
 ,O
nucleotide,O
substitution,O
model,O
in,O
PhyML,O
v3.1,O
.,O
For,O
“,O
dataset_6,O
",",O
”,O
ML,O
phylogenies,O
were,O
reconstructed,O
using,O
the,O
general,O
time,O
reversible,O
 ,O
nucleotide,O
substitution,O
model,O
with,O
gamma‐distributed,O
rate,O
variation,O
among,O
sites,O
(,O
GTR,O
 ,O
+,O
 ,O
G,O
),O
model,O
in,O
PhyML,O
v3.1,O
.,O
For,O
all,O
NJ,O
and,O
ML,O
phylogenies,O
of,O
the,O
two,O
data,O
sets,O
",",O
bootstrap,O
support,O
values,O
were,O
calculated,O
with,O
1,O
 ,O
000,O
replicates,O
 ,O
and,O
trees,O
were,O
midpoint,O
rooted,O
.,O
For,O
“,O
dataset_70,O
",",O
”,O
regression,O
analyses,O
were,O
used,O
to,O
determine,O
the,O
correlations,O
among,O
sampling,O
dates,O
and,O
root‐to‐tip,O
genetic,O
divergences,O
of,O
the,O
respective,O
ML,O
phylogenies,O
with,O
TempEst,O
v1.5,O
.,O
We,O
also,O
estimated,O
the,O
evolutionary,O
rate,O
and,O
time,O
to,O
the,O
most,O
recent,O
common,O
ancestor,O
(,O
TMRCA,O
),O
for,O
“,O
dataset_70,O
”,O
using,O
ML,O
dating,O
in,O
the,O
TreeTime,O
package,O
.,O
We,O
used,O
two,O
schemes,O
to,O
set,O
the,O
time‐scale,O
prior,O
for,O
each,O
data,O
set,O
:,O
that,O
is,O
",",O
constrained,O
evolutionary,O
rate,O
method,O
with,O
a,O
log‐normal,O
prior,O
(,O
mean,O
 ,O
=,O
 ,O
1.0,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
;,O
95,O
%,O
Bayesian,O
credible,O
interval,O
[,O
BCI,O
],O
:,O
1.854,O
 ,O
×,O
 ,O
10−4,O
to,O
4,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
),O
placed,O
on,O
the,O
evolutionary,O
rate,O
parameter,O
",",O
as,O
per,O
previous,O
studies,O
",",O
",",O
 ,O
",",O
  ,O
and,O
the,O
tip‐dating,O
method,O
",",O
for,O
which,O
the,O
overall,O
estimated,O
evolutionary,O
rate,O
was,O
given,O
an,O
uninformative,O
continuous‐time,O
Markov,O
chain,O
(,O
CTMC,O
),O
reference,O
prior,O
.,O
The,O
HIV,O
TRAnsmission,O
Cluster,O
Engine,O
(,O
HIV‐TRACE,O
;,O
www.hivtrace.org,O
),O
 ,O
was,O
employed,O
to,O
infer,O
transmission,O
network,O
clusters,O
for,O
SARS‐CoV‐2,O
“,O
dataset_70,O
.,O
”,O
We,O
divided,O
“,O
dataset_6,O
”,O
into,O
four,O
clades,O
(,O
ie,O
",",O
Clade,O
A,O
",",O
Clade,O
B,O
",",O
Clade,O
C,O
",",O
and,O
Clade,O
D,O
),O
",",O
with,O
Clade,O
A,O
designated,O
as,O
the,O
query,O
group,O
.,O
For,O
“,O
dataset_70,O
”,O
and,O
“,O
dataset_6,O
",",O
”,O
HKY,O
and,O
GTR,O
 ,O
+,O
G,O
were,O
the,O
models,O
of,O
best‐fit,O
",",O
respectively,O
",",O
across,O
the,O
two,O
different,O
substitution,O
schemes,O
(,O
ie,O
",",O
24,O
and,O
88,O
candidate,O
models,O
),O
according,O
to,O
the,O
BIC,O
method,O
",",O
and,O
were,O
thus,O
used,O
in,O
subsequent,O
likelihood‐mapping,O
and,O
phylogenetic,O
analyses,O
for,O
the,O
two,O
data,O
sets,O
.,O
The,O
PHI,O
tests,O
of,O
“,O
dataset_70,O
”,O
did,O
not,O
find,O
statistically,O
significant,O
evidence,O
of,O
recombination,O
(,O
P,O
 ,O
=,O
 ,O
1.0,O
),O
.,O
Likelihood‐mapping,O
analysis,O
of,O
“,O
dataset_70,O
”,O
revealed,O
that,O
69.7,O
%,O
of,O
the,O
quartets,O
were,O
distributed,O
in,O
the,O
center,O
of,O
the,O
triangle,O
",",O
indicating,O
a,O
strong,O
star‐like,O
topology,O
signal,O
reflecting,O
a,O
novel,O
virus,O
",",O
which,O
may,O
be,O
due,O
to,O
exponential,O
epidemic,O
spread,O
(,O
Figure,O
 ,O
1A,O
),O
.,O
Likewise,O
",",O
25.9,O
%,O
of,O
the,O
quartets,O
from,O
“,O
dataset_6,O
”,O
were,O
distributed,O
in,O
the,O
center,O
of,O
the,O
triangle,O
",",O
indicating,O
a,O
strong,O
phylogenetic,O
signal,O
(,O
Figure,O
 ,O
1B,O
),O
.,O
The,O
split,O
network,O
generated,O
for,O
“,O
dataset_70,O
”,O
using,O
the,O
NeighborNet,O
method,O
was,O
highly,O
unresolved,O
",",O
and,O
the,O
phylogenetic,O
relationship,O
of,O
“,O
dataset_70,O
”,O
was,O
probably,O
best,O
represented,O
by,O
a,O
network,O
rather,O
than,O
a,O
tree,O
(,O
Figure,O
 ,O
1C,O
),O
.,O
Both,O
the,O
NJ,O
and,O
ML,O
phylogenetic,O
analyses,O
of,O
SARS‐CoV‐2,O
“,O
dataset_70,O
”,O
also,O
showed,O
star‐like,O
topologies,O
",",O
in,O
accordance,O
with,O
the,O
likelihood‐mapping,O
results,O
(,O
Figures,O
 ,O
2,O
and,O
S1,O
),O
.,O
The,O
ML,O
phylogenetic,O
tree,O
showed,O
greater,O
star‐like,O
topology,O
than,O
the,O
NJ,O
phylogenetic,O
tree,O
",",O
indicating,O
that,O
the,O
ML,O
method,O
was,O
more,O
reasonable,O
for,O
“,O
dataset_70,O
.,O
”,O
Root‐to‐tip,O
regression,O
analyses,O
between,O
genetic,O
divergence,O
and,O
sampling,O
date,O
using,O
the,O
best‐fitting,O
root,O
showed,O
that,O
“,O
dataset_70,O
”,O
had,O
a,O
minor,O
strong,O
positive,O
temporal,O
signal,O
(,O
R,O
ML,O
dating,O
analyses,O
between,O
genetic,O
divergence,O
and,O
sampling,O
date,O
also,O
showed,O
that,O
“,O
dataset_70,O
”,O
had,O
a,O
minor,O
strong,O
positive,O
temporal,O
signal,O
(,O
R,O
Based,O
on,O
Bayesian,O
time‐scaled,O
phylogenetic,O
analysis,O
using,O
the,O
constrained,O
evolutionary,O
rate,O
method,O
with,O
a,O
log‐normal,O
prior,O
(,O
mean,O
 ,O
=,O
 ,O
1.0,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
;,O
95,O
%,O
BCI,O
:,O
1.854,O
 ,O
×,O
 ,O
10−4,O
to,O
4,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
),O
placed,O
on,O
the,O
evolutionary,O
rate,O
parameter,O
",",O
the,O
estimated,O
TMRCA,O
dates,O
and,O
evolutionary,O
rates,O
for,O
SARS‐CoV‐2,O
from,O
“,O
dataset_70,O
”,O
ranged,O
from,O
21,O
May,O
2019,O
to,O
13,O
October,O
2019,O
(,O
95,O
%,O
BCI,O
:,O
27,O
and,O
30,O
January,O
2020,O
),O
and,O
from,O
1.57,O
 ,O
×,O
 ,O
10−4,O
to,O
1.06,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
(,O
95,O
%,O
BCI,O
:,O
1.08,O
 ,O
×,O
 ,O
10−4,O
to,O
3.10,O
 ,O
×,O
 ,O
10−3,O
),O
",",O
respectively,O
(,O
Table,O
 ,O
1,O
),O
.,O
Furthermore,O
",",O
based,O
on,O
Bayesian,O
time‐scaled,O
phylogenetic,O
analysis,O
using,O
the,O
tip‐dating,O
method,O
",",O
the,O
estimated,O
TMRCA,O
dates,O
and,O
evolutionary,O
rates,O
from,O
“,O
dataset_70,O
”,O
ranged,O
from,O
22,O
to,O
24,O
November,O
2019,O
(,O
95,O
%,O
BCI,O
:,O
23,O
October,O
2019,O
and,O
16,O
December,O
2019,O
),O
and,O
from,O
1.19,O
 ,O
×,O
 ,O
10−3,O
to,O
1.31,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
(,O
95,O
%,O
BCI,O
:,O
6.22,O
 ,O
×,O
 ,O
10−4,O
to,O
1.96,O
 ,O
×,O
 ,O
10−3,O
),O
",",O
respectively,O
(,O
Table,O
 ,O
1,O
),O
.,O
Thus,O
",",O
the,O
estimated,O
TMRCA,O
dates,O
and,O
evolutionary,O
rates,O
for,O
SARS‐CoV‐2,O
from,O
“,O
dataset_70,O
”,O
were,O
consistent,O
among,O
the,O
different,O
clock,O
models,O
(,O
strict,O
and,O
relaxed,O
),O
but,O
were,O
distinct,O
among,O
the,O
different,O
dating,O
methods,O
(,O
constrained‐dating,O
and,O
tip‐dating,O
),O
.,O
The,O
estimated,O
TMRCA,O
dates,O
and,O
evolutionary,O
rates,O
for,O
SARS‐CoV‐2,O
from,O
“,O
dataset_70,O
”,O
using,O
the,O
tip‐dating,O
method,O
exhibited,O
much,O
narrower,O
95,O
%,O
BCIs,O
than,O
the,O
constrained‐dating,O
method,O
.,O
In,O
addition,O
",",O
the,O
estimated,O
TMRCA,O
dates,O
and,O
evolutionary,O
rates,O
for,O
SARS‐CoV‐2,O
from,O
“,O
dataset_70,O
”,O
were,O
consistent,O
between,O
the,O
different,O
coalescent,O
tree,O
models,O
(,O
ie,O
",",O
constant,O
and,O
exponential,O
),O
when,O
using,O
the,O
tip‐dating,O
method,O
but,O
were,O
distinct,O
when,O
using,O
the,O
constrained‐dating,O
method,O
.,O
For,O
each,O
data,O
set,O
",",O
we,O
employed,O
the,O
HKY,O
nucleotide,O
substitution,O
model,O
",",O
as,O
well,O
as,O
a,O
constant,O
size,O
coalescent,O
tree,O
prior,O
and,O
strict,O
molecular,O
clock,O
model,O
to,O
estimate,O
the,O
TMRCA,O
.,O
Based,O
on,O
this,O
",",O
we,O
identified,O
one,O
large,O
transmission,O
cluster,O
that,O
included,O
66,O
of,O
70,O
(,O
94.29,O
%,O
),O
genomes,O
",",O
thus,O
suggesting,O
low,O
genetic,O
divergence,O
for,O
“,O
dataset_70,O
”,O
(,O
Figure,O
S3,O
),O
.,O
Based,O
on,O
this,O
",",O
we,O
identified,O
6,O
transmission,O
clusters,O
that,O
included,O
37,O
of,O
70,O
(,O
52.86,O
%,O
),O
genomes,O
for,O
“,O
dataset_70,O
”,O
(,O
Figure,O
 ,O
5,O
),O
.,O
On,O
the,O
basis,O
of,O
“,O
dataset_70,O
",",O
”,O
our,O
likelihood‐mapping,O
analysis,O
confirmed,O
additional,O
tree‐like,O
signals,O
over,O
time,O
compared,O
with,O
our,O
previous,O
results,O
.,O
",",O
",",O
  ,O
Split,O
network,O
analysis,O
for,O
SARS‐CoV‐2,O
“,O
dataset_70,O
”,O
using,O
the,O
NeighborNet,O
method,O
was,O
highly,O
unresolved,O
",",O
indicating,O
an,O
explosive,O
",",O
star‐like,O
evolution,O
of,O
SARS‐CoV‐2,O
",",O
and,O
recent,O
and,O
rapid,O
human‐to‐human,O
transmission,O
(,O
Figure,O
 ,O
1C,O
),O
.,O
These,O
results,O
are,O
consistent,O
with,O
the,O
ML,O
phylogenetic,O
analyses,O
",",O
which,O
showed,O
polytomy,O
topology,O
from,O
“,O
dataset_70,O
”,O
(,O
Figure,O
 ,O
2,O
),O
.,O
Therefore,O
",",O
we,O
concluded,O
that,O
the,O
human,O
SARS‐CoV‐2,O
virus,O
",",O
which,O
is,O
responsible,O
for,O
the,O
current,O
outbreak,O
of,O
COVID‐19,O
",",O
did,O
not,O
come,O
directly,O
from,O
pangolins,O
.,O
To,O
explore,O
the,O
potential,O
intermediate,O
animal,O
host,O
of,O
the,O
SARS‐CoV‐2,O
virus,O
",",O
we,O
reanalyzed,O
virome,O
data,O
sets,O
from,O
pangolins,O
and,O
representative,O
SARS‐related,O
coronaviruses,O
isolates,O
from,O
bats,O
",",O
with,O
particular,O
attention,O
paid,O
to,O
the,O
spike,O
glycoprotein,O
gene,O
.,O
Therefore,O
",",O
we,O
concluded,O
that,O
the,O
human,O
SARS‐CoV‐2,O
virus,O
",",O
which,O
is,O
responsible,O
for,O
the,O
recent,O
outbreak,O
of,O
COVID‐19,O
",",O
did,O
not,O
come,O
directly,O
from,O
pangolins,O
.,O
First,O
case,O
of,O
COVID-19,O
was,O
reported,O
in,O
December,O
2019,O
in,O
Wuhan,O
(,O
China,O
),O
and,O
since,O
then,O
it,O
has,O
spread,O
worldwide,O
becoming,O
a,O
pandemic,O
",",O
with,O
maximum,O
death,O
cases,O
in,O
Italy,O
",",O
although,O
initially,O
",",O
the,O
maximum,O
mortality,O
was,O
reported,O
from,O
China,O
[,O
1,O
],O
.,O
According,O
to,O
a,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
report,O
",",O
as,O
of,O
2,O
April,O
2020,O
",",O
there,O
were,O
confirmed,O
823626,O
COVID-19,O
cases,O
and,O
40598,O
deaths,O
",",O
that,O
included,O
cases,O
which,O
were,O
both,O
locally,O
transmitted,O
or,O
imported,O
[,O
2,O
],O
.,O
From,O
India,O
",",O
there,O
were,O
only,O
two,O
full,O
genome,O
sequences,O
submitted,O
from,O
the,O
state,O
of,O
Kerala,O
(,O
GenBank,S-Repository
 ,O
accession,O
numbers,O
MT012098,S-AccessionNumber
 ,O
{,O
(,O
isolate,O
SARS,O
-,O
CoV-2,O
/,O
human,O
/,O
IND/29/2020,O
or,O
isolate,O
29,O
),O
and,O
MT050493,S-AccessionNumber
 ,O
(,O
isolate,O
SARS,O
-,O
CoV-2,O
/,O
human,O
/,O
IND/166/2020,O
or,O
isolate,O
166,O
),O
},O
.,O
Structure,O
of,O
the,O
spike,O
glycoprotein,O
was,O
retrieved,O
from,O
the,O
protein,O
data,O
bank,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6VXX,S-AccessionNumber
),O
(,O
Figure,O
5,O
),O
.,O
Abstract,O
 ,O
Since,O
2002,O
",",O
β,O
coronaviruses,O
(,O
CoVs,O
),O
have,O
caused,O
three,O
zoonotic,O
outbreaks,O
",",O
SARS,O
-,O
CoV,O
in,O
2002,O
",",O
MERS,O
-,O
CoV,O
in,O
2012,O
",",O
and,O
the,O
recent,O
outbreak,O
of,O
SARS,O
-,O
CoV-2,O
late,O
in,O
2019,O
(,O
also,O
named,O
as,O
COVID-19,O
or,O
novel,O
coronavirus,O
2019,O
or,O
nCoV2019,O
),O
.,O
As,O
the,O
nCoV2019,O
takes,O
its,O
course,O
throughout,O
the,O
world,O
",",O
more,O
and,O
more,O
sequence,O
analyses,O
are,O
being,O
done,O
and,O
genome,O
sequences,O
are,O
being,O
deposited,O
in,O
various,O
databases,O
.,O
We,O
are,O
seeing,O
that,O
even,O
in,O
epidemics,O
from,O
an,O
infectious,O
agent,O
like,O
COVID-19,O
",",O
there,O
are,O
differing,O
clinical,O
phenotypes,O
that,O
lead,O
to,O
MODS,O
",",O
requiring,O
changes,O
in,O
therapeutic,O
course,O
(,O
14,O
",",O
15,O
),O
.,O
Using,O
only,O
the,O
first,O
of,O
the,O
paired,O
-,O
end,O
reads,O
",",O
we,O
performed,O
bacterial,O
and,O
viral,O
read,O
mapping,O
with,O
kraken2,O
-,O
2.0.7,O
-,O
beta,O
(,O
61,O
),O
used,O
against,O
the,O
full,O
transcriptome,O
database,O
of,O
the,O
tool,O
downloaded,O
on,O
June,O
24,O
",",O
2019,O
.,O
Samples,O
were,O
normalized,O
to,O
every,O
million,O
mapped,O
reads,O
to,O
human,O
and,O
clustered,O
based,O
on,O
patient,O
ID,O
.,O
Using,O
GTEx,S-Dataset
 ,O
(,O
28,O
),O
tissue,O
annotated,O
expression,O
data,O
sets,O
",",O
we,O
filtered,O
for,O
genes,O
that,O
are,O
unique,O
to,O
each,O
tissue,O
/,O
organ,O
.,O
All,O
sex,O
-,O
specific,O
organs,O
were,O
removed,O
from,O
the,O
database,O
to,O
begin,O
.,O
While,O
reads,O
align,O
to,O
some,O
of,O
these,O
transcriptomes,O
",",O
reads,O
may,O
belong,O
to,O
closely,O
related,O
species,O
not,O
within,O
our,O
transcriptome,O
database,O
.,O
This,O
is,O
further,O
exemplified,O
by,O
viral,O
outbreaks,O
",",O
such,O
as,O
COVID-19,O
",",O
that,O
show,O
selectivity,O
in,O
age-,O
and,O
sex,O
-,O
related,O
vulnerability,O
and,O
inflammatory,O
phenotypes,O
leading,O
to,O
differences,O
in,O
presentation,O
",",O
severity,O
",",O
and,O
management,O
(,O
14,O
",",O
17,O
),O
.,O
The,O
entire,O
world,O
is,O
facing,O
a,O
devastating,O
crisis,O
in,O
the,O
growing,O
pandemic,O
associated,O
with,O
the,O
coronavirus,O
disease,O
—,O
COVID-19,O
—,O
and,O
Italy,O
is,O
paying,O
dearly,O
for,O
this,O
pandemic,O
both,O
in,O
terms,O
of,O
public,O
health,O
and,O
economics,O
.,O
Since,O
Feb,O
21,O
",",O
2020,O
",",O
when,O
the,O
first,O
Italian,O
COVID-19,O
patient,O
was,O
confirmed,O
",",O
the,O
National,O
Healthcare,O
Service,O
",",O
based,O
on,O
the,O
Beveridge,O
model,O
offering,O
universal,O
and,O
equal,O
health,O
care,O
to,O
all,O
citizens,O
",",O
has,O
faced,O
increasing,O
pressure,O
",",O
with,O
"110,574",O
total,O
cases,O
of,O
COVID-19,O
and,O
"13,155",O
deaths,O
as,O
of,O
April,O
1,O
",",O
2020,O
[,O
1,O
],O
.,O
Herein,O
",",O
we,O
report,O
changes,O
regarding,O
the,O
execution,O
of,O
the,O
germline,O
BRCA,O
(,O
gBRCA,O
),O
testing,O
",",O
during,O
the,O
COVID-19,O
outbreak,O
in,O
March,O
2020,O
",",O
in,O
a,O
referral,O
center,O
for,O
the,O
gBRCA,O
testing,O
[,O
2–5,O
],O
.,O
With,O
the,O
implementation,O
of,O
the,O
behavioural,O
restrictions,O
by,O
the,O
Italian,O
Government,O
(,O
March,O
2020,O
),O
during,O
the,O
COVID-19,O
pandemic,O
",",O
a,O
substantial,O
reduction,O
in,O
gBRCA,O
testing,O
(,O
about,O
60,O
%,O
),O
compared,O
to,O
the,O
first,O
2,O
 ,O
months,O
of,O
the,O
current,O
year,O
was,O
registered,O
",",O
but,O
the,O
requests,O
have,O
not,O
been,O
reset,O
.,O
Even,O
in,O
the,O
presence,O
of,O
a,O
serious,O
ongoing,O
emergency,O
",",O
such,O
as,O
the,O
COVID-19,O
pandemic,O
",",O
it,O
is,O
evident,O
that,O
cancer,O
patients,O
must,O
continue,O
to,O
take,O
advantage,O
of,O
gBRCA,O
testing,O
to,O
target,O
therapy,O
.,O
The,O
first,O
person,O
-,O
to,O
-,O
person,O
transmission,O
of,O
the,O
2019,O
-,O
novel,O
coronavirus,O
in,O
Italy,O
on,O
21,O
February,O
2020,O
led,O
to,O
an,O
infection,O
chain,O
that,O
represents,O
one,O
of,O
the,O
largest,O
known,O
COVID-19,O
outbreaks,O
outside,O
Asia,O
.,O
An,O
outbreak,O
of,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
occurred,O
in,O
Wuhan,O
",",O
China,O
in,O
December,O
2019,O
and,O
has,O
spread,O
rapidly,O
across,O
the,O
globe,O
.,O
Several,O
studies,O
have,O
provided,O
evidence,O
that,O
coagulation,O
dysfunction,O
is,O
a,O
major,O
cause,O
of,O
death,O
in,O
severe,O
COVID-19,O
patients,O
[,O
1,O
],O
",",O
[,O
2,O
],O
",",O
[,O
3,O
],O
",",O
[,O
4,O
],O
.,O
Awareness,O
regarding,O
thrombotic,O
complications,O
in,O
COVID-19,O
patients,O
is,O
extremely,O
important,O
for,O
deciding,O
the,O
appropriate,O
course,O
of,O
treatment,O
.,O
A,O
large,O
number,O
of,O
COVID-19,O
infected,O
patients,O
have,O
been,O
reported,O
to,O
have,O
other,O
chronic,O
diseases,O
such,O
as,O
cardiovascular,O
disease,O
",",O
malignancy,O
",",O
respiratory,O
diseases,O
and,O
kidney,O
and,O
liver,O
abnormalities,O
.,O
Presence,O
of,O
such,O
comorbidities,O
results,O
in,O
increased,O
severity,O
of,O
COVID-19,O
infection,O
.,O
Increasing,O
viral,O
load,O
during,O
COVID-19,O
infection,O
progression,O
leads,O
to,O
cascade,O
of,O
events,O
like,O
inflammation,O
and,O
sepsis,O
releasing,O
inflammatory,O
cytokines,O
which,O
in,O
turn,O
leads,O
to,O
increase,O
in,O
circulating,O
thrombin,O
levels,O
.,O
Various,O
recent,O
reports,O
have,O
shown,O
increasing,O
concerns,O
of,O
hypercoagulability,O
in,O
COVID-19,O
patients,O
[,O
14,O
],O
",",O
[,O
15,O
],O
.,O
Higher,O
incidences,O
of,O
thrombotic,O
complications,O
have,O
been,O
observed,O
in,O
COVID-19,O
patients,O
admitted,O
in,O
Intensive,O
Care,O
Unit,O
(,O
ICU,O
),O
.,O
Reports,O
have,O
also,O
shown,O
that,O
coagulopathy,O
in,O
COVID-19,O
infection,O
results,O
in,O
higher,O
D,O
-,O
dimer,O
levels,O
and,O
subsequently,O
high,O
mortality,O
rates,O
[,O
14,O
],O
and,O
this,O
mortality,O
is,O
reduced,O
by,O
the,O
use,O
of,O
anticoagulation,O
therapy,O
with,O
heparin,O
[,O
15,O
],O
.,O
Thus,O
",",O
abnormal,O
coagulation,O
parameters,O
",",O
especially,O
increased,O
D,O
-,O
dimer,O
and,O
FDP,O
levels,O
are,O
associated,O
with,O
deaths,O
in,O
COVID-19,O
patients,O
.,O
This,O
study,O
was,O
conducted,O
on,O
449,O
severe,O
COVID-19,O
patients,O
and,O
99,O
of,O
them,O
received,O
low,O
molecular,O
weight,O
heparin,O
(,O
LMWH,O
),O
treatment,O
for,O
7,O
 ,O
days,O
or,O
longer,O
.,O
They,O
further,O
reported,O
that,O
among,O
patients,O
had,O
higher,O
mortality,O
rates,O
and,O
raised,O
D,O
-,O
dimer,O
levels,O
in,O
absence,O
of,O
heparin,O
treatment,O
and,O
LMWH,O
treatment,O
was,O
associated,O
with,O
better,O
prognosis,O
in,O
severe,O
COVID-19,O
patients,O
[,O
15,O
],O
.,O
Researchers,O
further,O
stated,O
that,O
VTE,O
incidence,O
in,O
severe,O
NCP,O
patients,O
was,O
the,O
prime,O
cause,O
of,O
their,O
poor,O
prognosis,O
and,O
significant,O
increase,O
in,O
the,O
D,O
-,O
dimer,O
levels,O
could,O
be,O
a,O
good,O
parameter,O
for,O
identifying,O
high,O
VTE,O
risk,O
amongst,O
COVID-19,O
patients,O
.,O
Furthermore,O
",",O
the,O
abnormality,O
in,O
coagulation,O
in,O
COVID-19,O
differs,O
from,O
what,O
is,O
typically,O
found,O
in,O
other,O
infectious,O
diseases,O
.,O
In,O
the,O
non,O
-,O
survivors,O
of,O
COVID-19,O
there,O
was,O
a,O
marked,O
decrease,O
in,O
fibrinogen,O
levels,O
and,O
elevation,O
in,O
FDP,O
.,O
Most,O
recent,O
reports,O
demonstrate,O
that,O
D,O
dimer,O
levels,O
are,O
significantly,O
increased,O
in,O
COVID-19,O
non,O
-,O
survivors,O
and,O
thus,O
its,O
prognosis,O
can,O
be,O
predicted,O
based,O
on,O
this,O
parameter,O
[,O
1,O
],O
",",O
[,O
4,O
],O
",",O
[,O
18,O
],O
.,O
Asakura,O
et,O
al,O
.,O
suggested,O
combination,O
therapy,O
of,O
heparin,O
and,O
Nafamostat,O
against,O
COVID-19,O
infection,O
[,O
22,O
],O
.,O
Other,O
recent,O
reports,O
also,O
suggest,O
thromboprophylaxis,O
for,O
all,O
hospitalized,O
COVID-19,O
patients,O
[,O
23,O
],O
.,O
During,O
these,O
unforeseen,O
conditions,O
with,O
worldwide,O
pandemic,O
of,O
coronavirus,O
",",O
it,O
is,O
extremely,O
important,O
to,O
consider,O
risk,O
of,O
thrombotic,O
complications,O
while,O
treating,O
an,O
infected,O
COVID-19,O
patient,O
.,O
Highlights,O
    ,O
•,O
 ,O
Coagulation,O
parameters,O
such,O
should,O
be,O
checked,O
at,O
the,O
time,O
of,O
admission,O
of,O
COVID-19,O
patient,O
.,O
Background,O
 ,O
Recent,O
reports,O
on,O
outbreak,O
of,O
SARS,O
-,O
CoV-2,O
coronavirus,O
(,O
COVID-19,O
),O
have,O
shown,O
its,O
association,O
with,O
abnormal,O
blood,O
clots,O
.,O
Spread,O
of,O
COVID-19,O
has,O
been,O
associated,O
with,O
disseminated,O
intravascular,O
coagulation,O
(,O
DIC,O
),O
and,O
subsequent,O
coagulopathy,O
.,O
Initially,O
coagulopathy,O
in,O
COVID-19,O
patients,O
result,O
in,O
significant,O
elevation,O
of,O
D,O
-,O
dimer,O
",",O
fibrin,O
/,O
fibrinogen,O
degradation,O
products,O
(,O
FDP,O
),O
",",O
and,O
abnormalities,O
in,O
coagulatory,O
parameters,O
",",O
which,O
resulting,O
in,O
formation,O
of,O
thrombus,O
and,O
eventually,O
death,O
.,O
Methodology,O
 ,O
Present,O
report,O
intends,O
to,O
summarize,O
the,O
information,O
of,O
the,O
research,O
reports,O
available,O
so,O
far,O
on,O
the,O
complications,O
of,O
formation,O
of,O
unusal,O
blood,O
clots,O
(,O
thrombosis,O
),O
during,O
COVID-19,O
infection,O
and,O
its,O
therapeutic,O
strategies,O
.,O
Extensive,O
web,O
search,O
was,O
done,O
for,O
various,O
reports,O
associating,O
COVID-19,O
infection,O
with,O
increased,O
coagulopathy,O
and,O
abnormal,O
coagulatory,O
parameters,O
such,O
as,O
PT,O
",",O
PTT,O
",",O
and,O
platelet,O
counts,O
;,O
along,O
with,O
increased,O
D,O
-,O
dimer,O
and,O
fibrinogen,O
levels,O
.,O
Results,O
and,O
conclusion,O
 ,O
Findings,O
of,O
these,O
research,O
reports,O
were,O
summarized,O
to,O
recommend,O
cautions,O
for,O
clinicians,O
while,O
treating,O
COVID-19,O
patient,O
.,O
COVID-19,O
",",O
caused,O
by,O
a,O
positive,O
sense,O
single,O
strand,O
RNA,O
virus,O
(,O
a,O
member,O
of,O
the,O
coronavirus,O
family,O
),O
called,O
SARS,O
-,O
CoV-2,O
[,O
1,O
],O
",",O
[,O
2,O
],O
does,O
not,O
",",O
as,O
of,O
now,O
",",O
have,O
any,O
treatment,O
and,O
a,O
majority,O
of,O
its,O
aspects,O
are,O
yet,O
unknown,O
[,O
3,O
],O
.,O
As,O
is,O
the,O
case,O
with,O
many,O
viral,O
diseases,O
there,O
is,O
no,O
vaccine,O
for,O
COVID-19,O
.,O
With,O
the,O
number,O
of,O
cases,O
crossing,O
six,O
million,O
(,O
and,O
more,O
than,O
three,O
hundred,O
and,O
seventy,O
thousand,O
deaths,O
),O
worldwide,O
",",O
there,O
is,O
a,O
dire,O
need,O
of,O
a,O
vaccine,O
(,O
and,O
repurposing,O
of,O
drugs,O
),O
for,O
SARS,O
-,O
CoV-2,O
disease,O
(,O
COVID-19,O
),O
.,O
As,O
testing,O
for,O
SARS,O
-,O
CoV-2,O
was,O
limited,O
to,O
hospitalised,O
patients,O
across,O
much,O
of,O
Europe,O
there,O
is,O
limited,O
data,O
on,O
the,O
self,O
-,O
reported,O
clinical,O
characteristics,O
and,O
outcomes,O
of,O
patients,O
in,O
the,O
community,O
with,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
Anonymised,O
record,O
linkage,O
was,O
conducted,O
between,O
routinely,O
collected,O
healthcare,O
datasets,O
in,O
order,O
to,O
ascertain,O
clinical,O
characteristics,O
and,O
outcomes,O
of,O
those,O
who,O
tested,O
positive,O
.,O
Hospitalisations,O
were,O
recorded,O
using,O
the,O
new,O
ICD,O
code,O
for,O
COVID-19,O
:,O
U07.1,O
[,O
5,O
],O
As,O
testing,O
for,O
SARS,O
-,O
CoV-2,O
was,O
limited,O
to,O
hospitalised,O
patients,O
across,O
much,O
of,O
Europe,O
there,O
is,O
limited,O
data,O
on,O
the,O
self,O
-,O
reported,O
clinical,O
characteristics,O
and,O
outcomes,O
of,O
patients,O
in,O
the,O
community,O
with,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
Anonymised,O
record,O
linkage,O
was,O
conducted,O
between,O
routinely,O
collected,O
healthcare,O
datasets,O
in,O
order,O
to,O
ascertain,O
clinical,O
characteristics,O
and,O
outcomes,O
of,O
those,O
who,O
tested,O
positive,O
.,O
This,O
new,O
strain,O
was,O
first,O
described,O
in,O
January,O
2020,O
as,O
a,O
cause,O
of,O
a,O
novel,O
severe,O
respiratory,O
illness,O
now,O
known,O
as,O
COVID-19,O
.,O
RNA,O
was,O
detected,O
in,O
54,O
%,O
of,O
those,O
who,O
reported,O
symptoms,O
compatible,O
with,O
COVID-19,O
",",O
but,O
in,O
only,O
4,O
%,O
who,O
were,O
asymptomatic,O
.,O
Among,O
these,O
",",O
115,O
SARS,O
-,O
CoV-2,O
isolates,O
were,O
obtained,O
from,O
humans,O
",",O
4,O
SARS,O
-,O
CoV-2,O
isolates,O
were,O
collected,O
from,O
the,O
environment,O
",",O
and,O
8,O
SARSr,O
-,O
CoVs,O
from,O
pangolin,O
were,O
downloaded,O
from,O
GISAID,S-Dataset
.,O
The,O
consensus,O
sequence,O
of,O
HKU,O
-,O
SZ-002a,O
(,O
accession,O
number,O
MN938384,S-AccessionNumber
),O
and,O
HKU,O
-,O
SZ-005b,O
(,O
accession,O
number,O
MN975262,S-AccessionNumber
),O
have,O
been,O
deposited,O
into,O
GenBank,S-Repository
.,O
Raw,O
reads,O
",",O
after,O
excluding,O
human,O
reads,O
",",O
have,O
been,O
deposited,O
into,O
BioProject,S-Repository
 ,O
(,O
accession,O
number,O
PRJNA601630,S-AccessionNumber
),O
.,O
Two,O
complete,O
virus,O
genomes,O
(,O
HKU,O
-,O
SZ-002a,O
and,O
HKU,O
-,O
SZ-005b,O
),O
were,O
sequenced,O
using,O
Nanopore,O
technology,O
and,O
showed,O
a,O
novel,O
coronavirus,O
that,O
is,O
most,O
closely,O
related,O
to,O
those,O
of,O
the,O
bat,O
SARS,O
-,O
like,O
coronavirus,O
bat,O
-,O
SL,O
-,O
CoVZXC21,O
(,O
NCBI,S-Repository
 ,O
accession,O
number,O
MG772934,S-AccessionNumber
),O
and,O
bat,O
-,O
SL,O
-,O
CoVZC45,O
(,O
NCBI,S-Repository
 ,O
accession,O
number,O
MG772933,S-AccessionNumber
),O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
was,O
first,O
reported,O
from,O
China,O
in,O
December,O
",",O
2019,O
.,O
Although,O
Middle,O
East,O
respiratory,O
syndrome,O
coronavirus,O
(,O
MERS,O
-,O
CoV,O
),O
and,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
(,O
SARS,O
-,O
CoV,O
),O
infections,O
have,O
a,O
higher,O
mortality,O
rate,O
than,O
does,O
COVID-19,O
",",O
SARS,O
-,O
CoV-2,O
spreads,O
much,O
more,O
rapidly,O
than,O
MERS,O
-,O
CoV,O
and,O
SARS,O
-,O
CoV.,O
We,O
have,O
reported,O
use,O
of,O
posterior,O
oropharyngeal,O
(,O
deep,O
throat,O
),O
saliva,O
for,O
diagnosis,O
and,O
viral,O
load,O
monitoring,O
in,O
a,O
cohort,O
of,O
12,O
patients,O
with,O
COVID-19,O
.,O
Here,O
",",O
we,O
report,O
use,O
of,O
self,O
-,O
collected,O
posterior,O
oropharyngeal,O
saliva,O
samples,O
from,O
patients,O
with,O
COVID-19,O
",",O
which,O
avoids,O
close,O
contact,O
between,O
health,O
-,O
care,O
workers,O
and,O
patients,O
",",O
for,O
viral,O
load,O
monitoring,O
.,O
If,O
patients,O
were,O
intubated,O
",",O
we,O
obtained,O
endotracheal,O
aspirate,O
instead,O
of,O
posterior,O
oropharynx,O
saliva.6,O
",",O
9,O
",",O
10,O
",",O
11,O
Our,O
initial,O
experience,O
showed,O
that,O
such,O
saliva,O
samples,O
are,O
promising,O
in,O
viral,O
load,O
monitoring,O
in,O
patients,O
with,O
COVID-19,O
.,O
Ten,O
patients,O
had,O
severe,O
COVID-19,O
",",O
of,O
whom,O
all,O
required,O
oxygen,O
supplementation,O
",",O
and,O
13,O
patients,O
had,O
mild,O
disease,O
.,O
Chronic,O
comorbidities,O
were,O
more,O
common,O
among,O
patients,O
with,O
severe,O
COVID-19,O
(,O
seven,O
[,O
70,O
%,O
],O
patients,O
with,O
severe,O
disease,O
had,O
chronic,O
comorbidities,O
vs,O
four,O
[,O
31,O
%,O
],O
with,O
mild,O
disease,O
),O
",",O
although,O
this,O
difference,O
was,O
not,O
significant,O
(,O
table,O
),O
.,O
A,O
high,O
viral,O
load,O
on,O
presentation,O
of,O
COVID-19,O
was,O
recorded,O
in,O
our,O
cohort,O
",",O
even,O
for,O
patients,O
who,O
were,O
hospitalised,O
shortly,O
after,O
symptom,O
onset,O
.,O
Currently,O
",",O
no,O
standard,O
treatment,O
is,O
available,O
for,O
COVID-19,O
.,O
Background,O
 ,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
causes,O
severe,O
community,O
and,O
nosocomial,O
outbreaks,O
.,O
We,O
aimed,O
to,O
ascertain,O
the,O
serial,O
respiratory,O
viral,O
load,O
of,O
SARS,O
-,O
CoV-2,O
in,O
posterior,O
oropharyngeal,O
(,O
deep,O
throat,O
),O
saliva,O
samples,O
from,O
patients,O
with,O
COVID-19,O
",",O
and,O
serum,O
antibody,O
responses,O
.,O
We,O
included,O
patients,O
with,O
laboratory,O
-,O
confirmed,O
COVID-19,O
.,O
Unlike,O
severe,O
acute,O
respiratory,O
syndrome,O
",",O
patients,O
with,O
COVID-19,O
had,O
the,O
highest,O
viral,O
load,O
near,O
presentation,O
",",O
which,O
could,O
account,O
for,O
the,O
fast,O
-,O
spreading,O
nature,O
of,O
this,O
epidemic,O
.,O
The,O
fifth,O
",",O
isolated,O
from,O
a,O
pangolin,O
",",O
Pan_SL,O
-,O
CoV_GD,O
/,O
P1L,O
",",O
had,O
been,O
deposited,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
as,O
Pangolin,O
.,O
Outbreaks,O
due,O
to,O
members,O
of,O
the,O
coronavirus,O
family,O
have,O
been,O
especially,O
prominent,O
in,O
terms,O
of,O
transmission,O
and,O
mortality,O
",",O
beginning,O
with,O
the,O
emergence,O
of,O
SARS,O
-,O
CoV,O
in,O
2002–2003,O
[,O
"1,2",O
],O
",",O
followed,O
by,O
middle,O
east,O
respiratory,O
syndrome,O
coronavirus,O
(,O
MERS,O
-,O
CoV,O
),O
in,O
2012,O
[,O
3,O
],O
and,O
SARS,O
-,O
CoV-2,O
(,O
COVID-19,O
),O
in,O
late,O
2019,O
[,O
4,O
],O
.,O
The,O
door,O
of,O
development,O
for,O
peptide,O
-,O
based,O
therapeutics,O
was,O
widely,O
opened,O
by,O
introducing,O
peptides,O
with,O
varying,O
sequence,O
length,O
",",O
side,O
-,O
chain,O
reactivity,O
and,O
degree,O
of,O
modification,O
 ,O
and,O
incorporation,O
of,O
unnatural,O
components,O
.,O
In,O
the,O
immediate,O
future,O
",",O
repurposed,O
drugs,O
and,O
vaccines,O
will,O
be,O
the,O
first,O
line,O
of,O
defense,O
against,O
COVID-19,O
[,O
53,O
],O
",",O
however,O
drug,O
resistance,O
and,O
other,O
issues,O
with,O
vaccines,O
(,O
use,O
in,O
immunocompromised,O
or,O
immune,O
deficient,O
individuals,O
),O
should,O
allow,O
room,O
for,O
development,O
of,O
therapeutics,O
targeting,O
other,O
pathways,O
.,O
During,O
a,O
disease,O
outbreak,O
/,O
pandemic,O
situation,O
such,O
as,O
COVID-19,O
",",O
researchers,O
are,O
in,O
a,O
prime,O
position,O
to,O
identify,O
and,O
develop,O
peptide,O
-,O
based,O
therapies,O
",",O
which,O
could,O
be,O
more,O
rapidly,O
and,O
cost,O
-,O
effectively,O
advanced,O
into,O
a,O
clinical,O
setting,O
.,O
Furthermore,O
",",O
we,O
discuss,O
the,O
advantages,O
of,O
peptidomimetics,O
and,O
other,O
potential,O
targets,O
that,O
have,O
been,O
studied,O
using,O
peptide,O
-,O
based,O
therapeutics,O
for,O
COVID-19,O
.,O
Abstract,O
 ,O
Reverse,O
transcription,O
(,O
RT)-PCR,O
",",O
the,O
principal,O
diagnostic,O
method,O
applied,O
in,O
the,O
world,O
-,O
wide,O
struggle,O
against,O
COVID-19,O
",",O
is,O
capable,O
of,O
detecting,O
a,O
single,O
molecule,O
of,O
a,O
viral,O
genome,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
clinical,O
data,O
has,O
so,O
far,O
shown,O
that,O
the,O
mortality,O
rate,O
for,O
men,O
is,O
higher,O
than,O
for,O
women,O
.,O
An,O
initial,O
report,O
released,O
by,O
the,O
Centers,O
for,O
Disease,O
Control,O
and,O
Prevention,O
(,O
CDC,O
),O
on,O
population‐based,O
surveillance,O
sampled,O
across,O
14,O
states,O
",",O
representing,O
10,O
%,O
of,O
the,O
US,O
population,O
",",O
has,O
indicated,O
that,O
age,O
and,O
comorbidities,O
are,O
associated,O
with,O
increased,O
hospitalization,O
rates,O
of,O
patients,O
with,O
COVID‐19,O
.,O
Based,O
on,O
data,O
from,O
literature,O
",",O
we,O
propose,O
a,O
novel,O
mechanism,O
of,O
the,O
observed,O
sex,O
differences,O
in,O
clinical,O
outcomes,O
in,O
patients,O
and,O
identify,O
a,O
role,O
for,O
the,O
transmembrane,O
protease,O
serine,O
2,O
(,O
TMPRSS2,O
),O
as,O
a,O
contributing,O
factor,O
to,O
the,O
more,O
severe,O
outcomes,O
noted,O
for,O
COVID‐19,O
.,O
While,O
ACE2,O
is,O
the,O
main,O
receptor,O
for,O
the,O
spike,O
protein,O
for,O
both,O
viruses,O
",",O
its,O
expression,O
and,O
gene,O
polymorphisms,O
did,O
not,O
influence,O
sex‐specific,O
effects,O
or,O
outcomes,O
for,O
SARS,O
 ,O
or,O
COVID‐19,O
(,O
based,O
on,O
2,O
recent,O
preprint,O
studies,O
published,O
on,O
medRxiv,O
 ,O
that,O
have,O
yet,O
to,O
be,O
peer‐reviewed,O
at,O
the,O
time,O
of,O
writing,O
),O
.,O
Indeed,O
",",O
the,O
clinical,O
manifestations,O
of,O
COVID‐19,O
include,O
not,O
only,O
complications,O
from,O
acute,O
myocardial,O
injury,O
",",O
elevated,O
liver,O
enzymes,O
",",O
and,O
acute,O
kidney,O
injury,O
in,O
patients,O
presenting,O
to,O
hospitals,O
",",O
but,O
also,O
gastrointestinal,O
symptoms,O
in,O
community,O
patients,O
experiencing,O
milder,O
forms,O
of,O
the,O
disease,O
.,O
The,O
study,O
proposed,O
that,O
TMPRSS2,O
could,O
possibly,O
be,O
a,O
candidate,O
gene,O
that,O
contributes,O
to,O
the,O
COVID‐19,O
epidemiologic,O
data,O
seen,O
in,O
the,O
Italian,O
population,O
",",O
with,O
higher,O
death,O
rates,O
and,O
differences,O
in,O
severity,O
among,O
sexes,O
compared,O
to,O
East,O
Asians,O
.,O
We,O
may,O
never,O
know,O
the,O
true,O
incidence,O
rates,O
for,O
COVID‐19,O
;,O
however,O
",",O
looking,O
at,O
current,O
data,O
",",O
Europe,O
and,O
the,O
United,O
States,O
have,O
overtaken,O
China,O
and,O
eastern,O
Asia,O
as,O
the,O
epicenters,O
of,O
the,O
pandemic,O
.,O
Clinically,O
",",O
increases,O
in,O
IL‐6,O
have,O
been,O
linked,O
to,O
severe,O
COVID‐19,O
cases,O
 ,O
and,O
have,O
been,O
discussed,O
as,O
a,O
potential,O
biomarker,O
.,O
Cytokine,O
release,O
syndrome,O
(,O
CRS,O
),O
has,O
been,O
noted,O
in,O
some,O
severe,O
patients,O
of,O
COVID‐19,O
.,O
Furthermore,O
",",O
autopsy,O
findings,O
from,O
COVID‐19,O
patients,O
revealed,O
that,O
tissues,O
that,O
had,O
been,O
destroyed,O
by,O
SARS‐CoV‐2,O
exhibited,O
characteristics,O
of,O
the,O
so‐called,O
primary,O
cytokine,O
storm,O
(,O
induced,O
by,O
viral,O
infection,O
and,O
mainly,O
produced,O
by,O
alveolar,O
macrophages,O
",",O
epithelial,O
cells,O
",",O
and,O
endothelial,O
cells,O
),O
",",O
rather,O
than,O
those,O
observed,O
in,O
secondary,O
cytokine,O
storm,O
(,O
induced,O
by,O
different,O
subsets,O
of,O
activated,O
T,O
lymphocytes,O
in,O
late‐stage,O
viral,O
infections,O
or,O
a,O
complication,O
of,O
T‐cell,O
–,O
engaging,O
therapies,O
),O
.,O
Since,O
SARS‐CoV‐2,O
shares,O
similar,O
mechanisms,O
of,O
viral,O
entry,O
with,O
SARS‐CoV,O
",",O
this,O
transgenic,O
model,O
could,O
potentially,O
be,O
used,O
to,O
study,O
novel,O
therapeutics,O
for,O
COVID‐19,O
.,O
In,O
summary,O
",",O
no,O
in,O
vivo,O
preclinical,O
data,O
for,O
SARS‐CoV‐2,O
are,O
available,O
to,O
justify,O
any,O
of,O
the,O
treatment,O
regimens,O
for,O
combination,O
trials,O
currently,O
under,O
investigation,O
for,O
COVID‐19,O
",",O
as,O
an,O
in,O
vivo,O
mouse,O
model,O
for,O
SARS‐CoV‐2,O
is,O
not,O
yet,O
available,O
",",O
and,O
it,O
would,O
require,O
too,O
much,O
time,O
to,O
test,O
each,O
proposed,O
drug,O
combination,O
in,O
primate,O
models,O
of,O
human,O
disease,O
or,O
use,O
existing,O
models,O
for,O
MERS‐CoV,O
and,O
SARS‐CoV,O
pathogenesis,O
.,O
There,O
is,O
no,O
doubt,O
that,O
antivirals,O
and,O
supportive,O
treatments,O
are,O
key,O
areas,O
to,O
focus,O
on,O
in,O
treating,O
patients,O
with,O
COVID‐19,O
.,O
Our,O
proposed,O
treatment,O
combination,O
is,O
based,O
on,O
existing,O
data,O
from,O
in,O
vitro,O
/,O
in,O
vivo,O
studies,O
that,O
have,O
been,O
conducted,O
for,O
SARS‐CoV,O
and,O
MERS‐CoV,O
for,O
each,O
individual,O
agent,O
as,O
well,O
as,O
clinical,O
features,O
of,O
COVID‐19,O
since,O
current,O
in,O
vivo,O
animal,O
models,O
are,O
not,O
available,O
for,O
SARS‐CoV‐2,O
.,O
Both,O
are,O
being,O
investigated,O
in,O
Japan,O
and,O
other,O
countries,O
for,O
their,O
ability,O
to,O
block,O
SARS‐CoV‐2,O
entry,O
",",O
with,O
Japan,O
initiating,O
a,O
clinical,O
trial,O
for,O
nafamostat,O
(,O
which,O
is,O
also,O
a,O
short‐acting,O
anticoagulant,O
),O
for,O
COVID‐19,O
–,O
positive,O
patients,O
.,O
Direct,O
inhibition,O
of,O
TMPRSS2,O
using,O
protease,O
inhibitors,O
(,O
nafamostat,O
),O
or,O
indirectly,O
by,O
downregulating,O
TMPRSS2,O
expression,O
with,O
androgen,O
pathway,O
inhibitors,O
",",O
as,O
with,O
all,O
potential,O
novel,O
treatments,O
for,O
COVID‐19,O
",",O
are,O
promising,O
hypotheses,O
",",O
and,O
it,O
remains,O
to,O
be,O
determined,O
whether,O
this,O
approach,O
can,O
mediate,O
the,O
sex‐specific,O
outcomes,O
and,O
severity,O
of,O
outcomes,O
in,O
patients,O
.,O
Another,O
drug,O
under,O
investigation,O
for,O
COVID‐19,O
is,O
remdesivir,O
",",O
an,O
RNA‐dependent,O
RNA,O
polymerase,O
inhibitor,O
with,O
antiviral,O
activity,O
",",O
which,O
has,O
been,O
shown,O
to,O
act,O
on,O
viral,O
replication,O
after,O
entry,O
in,O
SARS‐CoV‐2,O
.,O
While,O
remdesivir,O
is,O
not,O
US,O
Food,O
and,O
Drug,O
Administration,O
approved,O
for,O
any,O
indications,O
",",O
the,O
WHO,O
considered,O
it,O
as,O
a,O
promising,O
drug,O
candidate,O
to,O
treat,O
COVID‐19,O
based,O
on,O
its,O
broad‐spectrum,O
activity,O
",",O
in,O
vitro,O
/,O
in,O
vivo,O
data,O
for,O
coronaviruses,O
(,O
SARS‐CoV‐2,O
",",O
SARS‐CoV,O
",",O
and,O
MERS‐CoV,O
),O
",",O
and,O
clinical,O
safety,O
data,O
from,O
Ebola,O
virus,O
disease,O
trials,O
.,O
Initial,O
results,O
of,O
the,O
compassionate,O
use,O
of,O
remdesivir,O
in,O
patients,O
with,O
COVID‐19,O
have,O
shown,O
some,O
encouraging,O
results,O
.,O
Additionally,O
",",O
there,O
are,O
clinical,O
trials,O
using,O
the,O
antimalarial,O
drugs,O
hydroxychloroquine,O
(,O
HCQ,O
),O
and,O
chloroquine,O
to,O
treat,O
COVID‐19,O
patients,O
.,O
The,O
clinical,O
data,O
for,O
HCQ,O
from,O
early,O
trials,O
for,O
COVID‐19,O
have,O
been,O
mixed,O
",",O
with,O
some,O
studies,O
showing,O
encouraging,O
results,O
and,O
others,O
demonstrating,O
lack,O
of,O
efficacy,O
.,O
",",O
 ,O
",",O
Potential,O
inhibitors,O
of,O
cytokine,O
storm,O
have,O
shown,O
some,O
clinical,O
benefit,O
in,O
COVID‐19,O
patients,O
and,O
include,O
agents,O
that,O
target,O
cytokine,O
release,O
such,O
the,O
anti,O
–,O
IL‐6,O
antibody,O
tocilizumab,O
",",O
the,O
anti‐human,O
granulocyte,O
macrophage,O
colony‐stimulating,O
factor,O
monoclonal,O
antibody,O
lenzilumab,O
",",O
or,O
the,O
Janus,O
kinase,O
1/2,O
inhibitor,O
ruxolitinib,O
(,O
with,O
phase,O
III,O
trials,O
initiated,O
or,O
being,O
planned,O
for,O
COVID‐19,O
),O
.,O
Sanders,O
et,O
al,O
 ,O
provide,O
a,O
comprehensive,O
review,O
of,O
the,O
recent,O
clinical,O
experience,O
for,O
remdesivir,O
",",O
HCQ,O
",",O
and,O
other,O
therapeutics,O
",",O
including,O
inhibitors,O
of,O
CRS,O
that,O
are,O
currently,O
under,O
investigation,O
as,O
potential,O
COVID‐19,O
treatments,O
.,O
Since,O
high,O
levels,O
of,O
inflammatory,O
markers,O
such,O
as,O
IL‐6,O
have,O
been,O
reported,O
in,O
patients,O
experiencing,O
COVID‐19,O
complications,O
",",O
we,O
suggest,O
using,O
this,O
potential,O
clinical,O
biomarker,O
or,O
any,O
of,O
the,O
above,O
laboratory,O
markers,O
as,O
a,O
guide,O
to,O
monitor,O
patients,O
on,O
drug,O
therapy,O
.,O
COVID‐19,O
treatment,O
will,O
involve,O
a,O
polypharmacy,O
approach,O
;,O
we,O
therefore,O
expect,O
a,O
multitude,O
of,O
adverse,O
effects,O
from,O
these,O
drug,O
combinations,O
.,O
There,O
are,O
also,O
many,O
factors,O
that,O
can,O
explain,O
the,O
difference,O
in,O
outcomes,O
in,O
men,O
and,O
women,O
afflicted,O
with,O
COVID‐19,O
",",O
and,O
TMPRSS2,O
emerges,O
as,O
an,O
interesting,O
candidate,O
.,O
Moreover,O
",",O
genotyping,O
studies,O
performed,O
on,O
clinical,O
specimens,O
collected,O
from,O
patients,O
on,O
COVID‐19,O
trials,O
are,O
warranted,O
to,O
further,O
evaluate,O
known,O
SNPs,O
and,O
to,O
find,O
additional,O
functional,O
polymorphisms,O
in,O
the,O
TMPRSS2,O
gene,O
.,O
On,O
a,O
broader,O
scope,O
",",O
multiple,O
institutions,O
have,O
initiated,O
genomic,O
investigations,O
in,O
a,O
project,O
called,O
the,O
COVID,B-Repository
Host,I-Repository
Genetics,I-Repository
Initiative,E-Repository
.,O
SNPs,O
that,O
are,O
confirmed,O
to,O
be,O
predictive,O
biomarkers,O
can,O
be,O
incorporated,O
in,O
the,O
CDC,O
's,O
current,O
list,O
of,O
clinical,O
biomarkers,O
for,O
disease,O
severity,O
as,O
discussed,O
above,O
.,O
The,O
ongoing,O
pandemic,O
of,O
COVID-19,O
has,O
infected,O
over,O
20,O
million,O
people,O
globally,O
",",O
of,O
which,O
over,O
"750,000",O
have,O
died,O
(,O
as,O
of,O
13,O
August,O
2020,O
),O
[,O
1,O
],O
.,O
COVID-19,O
is,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
a,O
novel,O
coronavirus,O
",",O
which,O
emerged,O
in,O
December,O
2019,O
[,O
2,O
],O
.,O
For,O
COVID-19,O
",",O
the,O
rapid,O
development,O
of,O
diagnostic,O
polymerase,O
chain,O
reaction,O
(,O
PCR,O
),O
was,O
facilitated,O
by,O
the,O
availability,O
of,O
genome,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
isolates,O
[,O
"4,5",O
],O
.,O
The,O
primary,O
objective,O
of,O
this,O
analysis,O
is,O
to,O
compare,O
genome,O
sequencing,O
results,O
from,O
direct,O
amplification,O
of,O
the,O
SARS,O
-,O
CoV-2,O
genome,O
(,O
i.e.,O
",",O
the,O
Liverpool,O
or,O
ARTIC,O
PCR,O
protocols,O
),O
[,O
7,O
],O
with,O
bait,O
capture,O
enrichment,O
from,O
COVID-19,O
patient,O
swabs,O
with,O
markedly,O
different,O
viral,O
RNA,O
concentrations,O
.,O
To,O
confirm,O
the,O
epidemiological,O
origin,O
of,O
both,O
isolates,O
",",O
the,O
best,O
genome,O
sequence,O
of,O
each,O
was,O
included,O
in,O
a,O
uniform,O
manifold,O
approximation,O
and,O
projection,O
(,O
UMAP,O
),O
involving,O
the,O
aligned,O
genomes,O
of,O
8074,O
SARS,O
-,O
CoV-2,O
isolates,O
(,O
obtained,O
from,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
"Data,",I-Dataset
GISAID,E-Dataset
",",O
https://www.gisaid.org,S-URL
),O
labelled,O
by,O
country,O
of,O
origin,O
[,O
28,O
],O
.,O
FASTQ,O
sequences,O
and,O
assembly,O
FASTA,O
have,O
been,O
deposited,O
in,O
NCBI,S-Repository
 ,O
Bioproject,O
PRJNA636446,S-AccessionNumber
",",O
with,O
assembly,O
FASTA,O
sequences,O
additionally,O
submitted,O
to,O
GISAID,S-Dataset
 ,O
(,O
Wuhan,O
-,O
derived,O
:,O
EPI_ISL_413015,S-AccessionNumber
 ,O
as,O
submitted,O
previously,O
",",O
Iran,O
-,O
derived,O
:,O
EPI_ISL_450747,S-AccessionNumber
),O
.,O
There,O
is,O
very,O
little,O
variation,O
among,O
available,O
SARS,O
-,O
CoV-2,O
genome,O
sequences,O
",",O
as,O
summarized,O
at,O
GISAID,S-Dataset
 ,O
(,O
www.gisaid.org,S-URL
),O
and,O
exemplified,O
by,O
our,O
own,O
detection,O
of,O
only,O
6,O
SNPs,O
between,O
the,O
original,O
Wuhan,O
genome,O
and,O
our,O
Iran,O
-,O
derived,O
sample,O
.,O
Cross,O
-,O
referencing,O
with,O
GISAID,S-Dataset
 ,O
metadata,O
revealed,O
that,O
within,O
this,O
small,O
cluster,O
",",O
isolates,O
from,O
Australia,O
(,O
2,O
isolates,O
),O
",",O
India,O
(,O
4,O
isolates,O
),O
",",O
and,O
Pakistan,O
(,O
1,O
isolate,O
),O
also,O
had,O
travel,O
history,O
associated,O
with,O
the,O
outbreak,O
in,O
Iran,O
.,O
Unfortunately,O
",",O
GISAID,S-Dataset
 ,O
did,O
not,O
contain,O
sequences,O
from,O
Iran,O
",",O
but,O
phylogenetic,O
analysis,O
confirmed,O
these,O
UMAP,O
results,O
",",O
placing,O
our,O
Iran,O
-,O
derived,O
sample,O
and,O
the,O
nearby,O
UMAP,O
samples,O
in,O
a,O
well,O
supported,O
clade,O
(,O
Figure,O
S1,O
),O
.,O
However,O
",",O
our,O
work,O
did,O
detect,O
mismatches,O
for,O
currently,O
used,O
diagnostics,O
PCR,O
primers,O
",",O
specifically,O
in,O
primers,O
designed,O
by,O
the,O
CDC,O
and,O
the,O
Japanese,O
NID,O
.,O
The,O
foundation,O
of,O
COVID-19,O
diagnostic,O
testing,O
has,O
included,O
direct,O
detection,O
of,O
viral,O
genomes,O
through,O
nucleic,O
acid,O
amplification,O
methods,O
.,O
Reports,O
of,O
false,O
negative,O
results,O
from,O
real,O
time,O
PCR,O
testing,O
indicate,O
that,O
even,O
the,O
high,O
analytical,O
sensitivity,O
of,O
RT,O
-,O
PCR,O
may,O
be,O
challenged,O
by,O
the,O
pathology,O
of,O
COVID-19,O
[,O
"6,7",O
],O
.,O
Eluted,O
RNA,O
(,O
5,O
μl,O
for,O
the,O
CDC,O
2019,O
-,O
nCoV,O
Real,O
-,O
Time,O
RT,O
-,O
PCR,O
Diagnostic,O
Panel,O
(,O
111,O
specimens,O
),O
",",O
10,O
μl,O
for,O
the,O
Taqpath,O
COVID-19,O
(,O
EUA,O
),O
Multiplex,O
assay,O
(,O
Thermo,O
Scientific,O
",",O
Waltham,O
",",O
MA,O
),O
(,O
5,O
specimens,O
),O
was,O
subjected,O
to,O
real,O
time,O
PCR,O
either,O
by,O
the,O
CDC,O
EUA,O
Real,O
Time,O
PCR,O
for,O
SARS,O
-,O
CoV-2,O
",",O
or,O
the,O
Taqpath,O
COVID-19,O
Multiplex,O
assay,O
.,O
Comparison,O
of,O
the,O
Taqpath,O
COVID-19,O
Multiplex,O
relative,O
to,O
the,O
CDC,O
2019,O
-,O
nCoV,O
Real,O
-,O
Time,O
RT,O
-,O
PCR,O
Diagnostic,O
Panel,O
showed,O
100,O
%,O
sensitivity,O
and,O
specificity,O
relative,O
to,O
one,O
another,O
",",O
with,O
100,O
%,O
concordance,O
through,O
20,O
specimens,O
.,O
As,O
shown,O
in,O
Table,O
1,O
",",O
the,O
Taqpath,O
COVID-19,O
Multiplex,O
assay,O
demonstrated,O
detection,O
capability,O
of,O
5/5,O
(,O
100,O
%,O
),O
samples,O
at,O
5.5,O
×,O
10e5,O
copies,O
per,O
milliliter,O
and,O
at,O
least,O
one,O
SARS,O
-,O
CoV-2,O
gene,O
in,O
5/5,O
(,O
100,O
%,O
),O
of,O
samples,O
at,O
a,O
concentration,O
of,O
5.5,O
×,O
10e4,O
copies,O
per,O
milliliter,O
.,O
This,O
ability,O
to,O
perform,O
high,O
-,O
throughput,O
testing,O
",",O
on,O
a,O
sensitive,O
molecular,O
detection,O
platform,O
has,O
potential,O
to,O
make,O
a,O
significant,O
contribution,O
to,O
the,O
COVID-19,O
pandemic,O
",",O
where,O
such,O
high,O
demands,O
exist,O
for,O
testing,O
.,O
After,O
two,O
months,O
of,O
relative,O
quiescence,O
",",O
a,O
large,O
COVID-19,O
outbreak,O
occurred,O
in,O
Hong,O
Kong,O
in,O
July,O
2020,O
after,O
gradual,O
relaxation,O
of,O
social,O
distancing,O
policy,O
.,O
Therefore,O
",",O
treatment,O
of,O
COVID-19,O
should,O
be,O
based,O
on,O
the,O
staging,O
of,O
patients,O
",",O
and,O
the,O
window,O
of,O
opportunity,O
may,O
lie,O
between,O
the,O
first,O
and,O
the,O
second,O
phases,O
",",O
when,O
clinical,O
deterioration,O
is,O
observed,O
with,O
evidence,O
of,O
abrupt,O
inflammation,O
and,O
hypercoagulable,O
status,O
.,O
Coronavirus,O
disease-19,O
(,O
COVID-19,O
),O
outbreak,O
is,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus-2,O
(,O
SARS,O
-,O
CoV-2,O
),O
at,O
present,O
has,O
jolted,O
the,O
entire,O
human,O
race,O
.,O
COVID-19,O
pandemic,O
has,O
affected,O
natives,O
in,O
more,O
than,O
200,O
countries,O
and,O
territories,O
located,O
in,O
different,O
geographical,O
locations,O
and,O
climatic,O
conditions,O
.,O
According,O
to,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
",",O
nearly,O
3.8,O
million,O
individuals,O
have,O
already,O
been,O
infected,O
globally,O
and,O
more,O
than,O
260,O
thousands,O
have,O
died,O
till,O
date,O
(,O
WHO,O
COVID-19,O
Situation,O
Report-109,O
",",O
08/5/2020,O
),O
.,O
Recent,O
trend,O
indicates,O
much,O
lower,O
overall,O
case,O
fatality,O
rate,O
(,O
CFR,O
),O
in,O
COVID-19,O
pandemic,O
(,O
4.58,O
%,O
),O
compared,O
to,O
outbreak,O
of,O
SARS,O
(,O
11,O
%,O
),O
and,O
Middle,O
East,O
respiratory,O
syndrome,O
(,O
MERS,O
),O
(,O
35,O
%,O
),O
(,O
Peeri,O
et,O
al,O
.,O
2020,O
),O
.,O
The,O
incidence,O
and,O
CFR,O
varies,O
drastically,O
in,O
different,O
populations,O
",",O
where,O
the,O
present,O
global,O
CFR,O
(,O
6.9,O
%,O
),O
is,O
significantly,O
lower,O
than,O
Europe,O
(,O
9.2,O
%,O
),O
and,O
considerably,O
higher,O
than,O
Africa,O
(,O
3.4,O
%,O
),O
",",O
East,O
Mediterranean,O
and,O
Southeast,O
Asia,O
(,O
3.6,O
%,O
),O
",",O
Western,O
Pacific,O
(,O
4.1,O
%,O
),O
and,O
America,O
(,O
5.5,O
%,O
),O
(,O
WHO,O
COVID-19,O
Situation,O
Report-109,O
",",O
08/5/2020,O
),O
.,O
Genotypes,O
of,O
these,O
variants,O
in,O
26,O
populations,O
from,O
five,O
major,O
global,O
regions,O
were,O
obtained,O
from,O
1000,B-Repository
Genomes,E-Repository
 ,O
database,O
(,O
https://www.internationalgenome.org,S-URL
),O
and,O
used,O
for,O
comparative,O
analysis,O
.,O
GTEx,S-Dataset
 ,O
database,O
was,O
used,O
to,O
evaluate,O
the,O
eQTL,O
(,O
Aguet,O
et,O
al,O
.,O
2019,O
),O
.,O
At,O
present,O
",",O
more,O
than,O
200,O
countries,O
and,O
territories,O
are,O
directly,O
affected,O
by,O
the,O
coronavirus,O
disease-19,O
(,O
COVID-19,O
),O
pandemic,O
.,O
In,O
late,O
December,O
2019,O
",",O
an,O
outbreak,O
of,O
a,O
novel,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
originated,O
in,O
Wuhan,O
",",O
China,O
.,O
The,O
Diamond,O
Princess,O
(,O
DP,O
),O
cruise,O
ship,O
was,O
put,O
under,O
quarantine,O
soon,O
after,O
its,O
return,O
to,O
Yokohama,O
",",O
Japan,O
on,O
February,O
3,O
",",O
2020,O
",",O
after,O
visiting,O
Kagoshima,O
",",O
Hong,O
Kong,O
",",O
Vietnam,O
",",O
Taiwan,O
",",O
and,O
Okinawa,O
",",O
because,O
an,O
80,O
-,O
y,O
-,O
old,O
passenger,O
who,O
disembarked,O
in,O
Hong,O
Kong,O
was,O
confirmed,O
as,O
a,O
COVID-19,O
case,O
on,O
February,O
1,O
after,O
the,O
ship,O
had,O
departed,O
from,O
Hong,O
Kong,O
on,O
January,O
25,O
.,O
The,O
Japanese,O
government,O
asked,O
about,O
"3,600",O
passengers,O
and,O
crew,O
members,O
to,O
stay,O
on,O
board,O
in,O
Yokohama,O
during,O
the,O
14,O
-,O
d,O
isolation,O
period,O
through,O
February,O
19,O
to,O
prevent,O
the,O
further,O
spread,O
of,O
COVID-19,O
cases,O
.,O
A,O
field,O
epidemiological,O
study,O
about,O
the,O
DP,O
COVID-19,O
cases,O
has,O
been,O
published,O
(,O
3,O
),O
.,O
As,O
of,O
March,O
8,O
",",O
697,O
COVID-19,O
cases,O
had,O
been,O
identified,O
among,O
the,O
"3,711",O
persons,O
on,O
the,O
DP,O
and,O
7,O
people,O
had,O
died,O
(,O
4,O
),O
.,O
The,O
73,O
genome,O
sequences,O
(,O
including,O
3,O
sequences,O
of,O
DP,O
isolates,O
deposited,O
in,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
[GISAID],E-Dataset
),O
were,O
compared,O
with,O
the,O
Wuhan,O
-,O
Hu-1,O
(,O
isolated,O
on,O
December,O
26,O
",",O
2019,O
in,O
China,O
),O
genome,O
sequence,O
as,O
a,O
reference,O
.,O
A,O
number,O
of,O
nucleotide,O
variations,O
have,O
been,O
identified,O
;,O
specifically,O
",",O
52,O
SNVs,O
among,O
DP,O
isolates,O
(,O
n,O
=,O
73,O
),O
and,O
449,O
SNVs,O
among,O
all,O
tested,O
isolates,O
",",O
including,O
entries,O
from,O
GISAID,S-Dataset
 ,O
(,O
n,O
=,O
412,O
),O
",",O
(,O
Dataset,O
S3,O
),O
(,O
Fig,O
.,O
1,O
),O
.,O
Maximum,O
-,O
likelihood,O
(,O
ML,O
),O
phylogenetic,O
analysis,O
including,O
other,O
SARS,O
-,O
CoV-2,O
genome,O
sequences,O
that,O
are,O
publicly,O
available,O
on,O
GISAID,S-Dataset
 ,O
and,O
haplotype,O
networks,O
from,O
genomic,O
SNVs,O
(,O
HN,O
-,O
GSNVs,O
),O
were,O
used,O
to,O
map,O
the,O
genotypes,O
of,O
the,O
SARS,O
-,O
CoV-2,O
isolates,O
that,O
disseminated,O
in,O
the,O
DP,O
cruise,O
ship,O
after,O
isolation,O
of,O
the,O
passengers,O
on,O
February,O
5,O
",",O
2020,O
(,O
Fig,O
.,O
2,O
),O
.,O
We,O
did,O
not,O
find,O
any,O
area,O
-,O
specific,O
events,O
of,O
COVID-19,O
spread,O
in,O
the,O
DP,O
because,O
all,O
COVID-19,O
patients,O
were,O
widely,O
distributed,O
in,O
all,O
18,O
decks,O
across,O
the,O
ship,O
.,O
The,O
highest,O
incidence,O
of,O
COVID-19,O
onset,O
was,O
observed,O
on,O
February,O
7,O
",",O
2020,O
;,O
the,O
epidemic,O
curve,O
in,O
the,O
latter,O
half,O
of,O
the,O
epidemic,O
was,O
dominated,O
by,O
crew,O
members,O
whose,O
work,O
was,O
not,O
strictly,O
controlled,O
to,O
maintain,O
service,O
on,O
the,O
ship,O
(,O
7,O
),O
.,O
Zhang,O
et,O
al,O
.,O
(,O
9,O
),O
also,O
estimated,O
that,O
the,O
reproduction,O
number,O
(,O
R0,O
),O
for,O
COVID-19,O
cases,O
was,O
2.28,O
(,O
95,O
%,O
confidence,O
interval,O
:,O
2.06,O
to,O
2.52,O
),O
during,O
the,O
early,O
stage,O
",",O
and,O
estimated,O
that,O
the,O
outbreak,O
size,O
on,O
the,O
DP,O
cruise,O
ship,O
might,O
have,O
been,O
greater,O
",",O
if,O
the,O
strict,O
infection,O
management,O
and,O
quarantine,O
had,O
not,O
been,O
conducted,O
.,O
The,O
personal,O
data,O
related,O
to,O
the,O
clinical,O
information,O
were,O
anonymized,O
",",O
and,O
our,O
procedure,O
is,O
not,O
to,O
request,O
written,O
consent,O
for,O
all,O
patients,O
suffering,O
from,O
COVID-19,O
.,O
However,O
",",O
the,O
virus,O
content,O
in,O
pharyngeal,O
swabs,O
is,O
not,O
abundant,O
at,O
the,O
early,O
onset,O
of,O
COVID-19,O
",",O
which,O
might,O
lead,O
to,O
difficulties,O
in,O
achieving,O
WGS,O
.,O
The,O
obtained,O
NGS,O
reads,O
were,O
mapped,O
to,O
the,O
SARS,O
-,O
CoV-2,O
Wuhan,O
-,O
Hu-1,O
reference,O
genome,O
sequence,O
(,O
29.9,O
kb,O
single,O
-,O
strand,O
RNA,O
;,O
GenBank,S-Repository
 ,O
ID,O
:,O
MN908947,S-AccessionNumber
),O
",",O
resulting,O
in,O
a,O
specimen,O
-,O
specific,O
SARS,O
-,O
CoV-2,O
genome,O
sequence,O
fully,O
mapped,O
with,O
a,O
read,O
depth,O
of,O
at,O
least,O
≥100×,O
from,O
the,O
99-,O
to,O
"29,796",O
-,O
nt,O
region,O
of,O
Wuhan,O
-,O
Hu-1,O
genome,O
sequence,O
(,O
see,O
details,O
in,O
Dataset,O
S2,O
),O
.,O
The,O
nearly,O
full,O
-,O
length,O
genome,O
sequence,O
(,O
≥29,O
kb,O
),O
of,O
SARS,O
-,O
CoV-2,O
isolates,O
until,O
February,O
19,O
",",O
2020,O
were,O
retrieved,O
from,O
the,O
GISAID,B-Dataset
EpiCoV,E-Dataset
 ,O
database,O
on,O
May,O
14,O
",",O
2020,O
",",O
followed,O
by,O
multiple,O
alignment,O
using,O
MAFFT,O
v7.222,O
(,O
17,O
),O
.,O
The,O
poorly,O
aligned,O
regions,O
in,O
5′,O
and,O
3′,O
ends,O
were,O
trimmed,O
;,O
we,O
determined,O
that,O
the,O
core,O
regions,O
were,O
from,O
the,O
99-,O
to,O
"29,794",O
-,O
nt,O
position,O
by,O
comparison,O
against,O
the,O
Wuhan,O
-,O
Hu-1,O
genome,O
sequences,O
(,O
GISAID,S-Dataset
 ,O
ID,O
",",O
EPI_ISL_402125,S-AccessionNumber
;,O
GenBank,S-Repository
 ,O
ID,O
",",O
MN908947.3,S-AccessionNumber
),O
.,O
Gap,O
-,O
containing,O
sequences,O
in,O
the,O
core,O
region,O
were,O
excluded,O
;,O
sequences,O
of,O
243,O
isolates,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
were,O
used,O
in,O
subsequent,O
analyses,O
.,O
The,O
genome,O
sequences,O
of,O
the,O
DP,O
isolates,O
were,O
aligned,O
using,O
MAFFT,O
with,O
sequences,O
retrieved,O
from,O
the,O
database,O
",",O
followed,O
by,O
extraction,O
of,O
SNV,O
and,O
deletion,O
sites,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
caused,O
by,O
SARS,O
-,O
CoV-2,O
",",O
started,O
in,O
November,O
2019,O
in,O
Wuhan,O
(,O
China,O
),O
",",O
and,O
from,O
there,O
it,O
was,O
transmitted,O
and,O
rapidly,O
dispersed,O
all,O
over,O
the,O
world,O
(,O
Jin,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
March,O
2020,O
",",O
the,O
WHO,O
declared,O
COVID-19,O
to,O
be,O
a,O
pandemic,O
.,O
The,O
spread,O
of,O
emerging,O
infectious,O
diseases,O
such,O
as,O
COVID-19,O
has,O
a,O
link,O
to,O
unsustainable,O
use,O
of,O
the,O
environment,O
.,O
A,O
relationship,O
between,O
pollutants,O
and,O
viral,O
diseases,O
(,O
such,O
as,O
COVID-19,O
),O
was,O
recently,O
reported,O
(,O
Tsatsakis,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
This,O
is,O
an,O
important,O
finding,O
",",O
because,O
pollutants,O
can,O
depress,O
the,O
immune,O
system,O
of,O
animals,O
and,O
thus,O
might,O
increase,O
the,O
impacts,O
of,O
pathogens,O
",",O
such,O
as,O
the,O
current,O
global,O
coronary,O
disease,O
(,O
COVID-19,O
),O
.,O
The,O
main,O
effects,O
of,O
COVID-19,O
on,O
human,O
health,O
are,O
related,O
to,O
respiratory,O
problems,O
(,O
Xu,O
et,O
al,O
.,O
",",O
2020b,O
),O
.,O
This,O
fine,O
particulate,O
matter,O
can,O
obstruct,O
the,O
airways,O
",",O
exacerbating,O
the,O
effects,O
of,O
COVID-19,O
.,O
Some,O
research,O
has,O
correlated,O
fine,O
particulate,O
matter,O
(,O
PM2.5,O
",",O
PM10,O
),O
with,O
confirmed,O
cases,O
of,O
deaths,O
due,O
to,O
COVID-19,O
(,O
Table,O
1,O
),O
.,O
They,O
found,O
a,O
strong,O
relationship,O
between,O
PM2.5,O
and,O
death,O
risk,O
from,O
COVID-19,O
.,O
The,O
study,O
conducted,O
by,O
Saha,O
et,O
al,O
.,O
(,O
2020,O
),O
also,O
reported,O
that,O
areas,O
with,O
better,O
air,O
quality,O
showed,O
a,O
larger,O
number,O
of,O
COVID-19,O
recoveries,O
.,O
Concerns,O
have,O
been,O
raised,O
regarding,O
an,O
association,O
of,O
indoor,O
air,O
pollution,O
with,O
susceptibility,O
to,O
COVID-19,O
",",O
mainly,O
in,O
geographical,O
areas,O
where,O
wood,O
or,O
coal,O
is,O
still,O
used,O
for,O
cooking,O
and,O
heating,O
(,O
Mbandi,O
",",O
2020,O
;,O
Sharma,O
and,O
Hossain,O
",",O
2020,O
),O
.,O
All,O
available,O
research,O
so,O
far,O
show,O
a,O
positive,O
correlation,O
between,O
air,O
pollution,O
(,O
PM2.5,O
),O
and,O
COVID-19,O
.,O
The,O
evidence,O
indicates,O
that,O
particulate,O
matter,O
appears,O
to,O
play,O
a,O
key,O
role,O
in,O
the,O
incidence,O
and,O
severity,O
of,O
cases,O
of,O
COVID-19,O
",",O
because,O
it,O
acts,O
as,O
a,O
carrier,O
of,O
viruses,O
",",O
influences,O
lung,O
obstruction,O
",",O
and,O
produces,O
immunological,O
effects,O
by,O
chemicals,O
associated,O
with,O
it,O
.,O
The,O
underlying,O
question,O
here,O
is,O
whether,O
multiple,O
pollutants,O
carried,O
simultaneously,O
on,O
particulate,O
matter,O
act,O
in,O
an,O
additive,O
",",O
synergistic,O
way,O
to,O
increase,O
the,O
severity,O
of,O
COVID-19,O
-,O
like,O
diseases,O
.,O
The,O
relationships,O
between,O
confirmed,O
cases,O
or,O
deaths,O
by,O
COVID-19,O
and,O
environmental,O
factors,O
has,O
been,O
studied,O
in,O
Europe,O
",",O
Middle,O
East,O
",",O
and,O
Asia,O
(,O
mainly,O
China,O
",",O
Table,O
2,O
),O
.,O
Temperature,O
appears,O
to,O
be,O
the,O
environmental,O
factor,O
most,O
related,O
to,O
COVID-19,O
spreading,O
.,O
A,O
study,O
performed,O
in,O
several,O
locations,O
of,O
China,O
found,O
that,O
environmental,O
factors,O
by,O
themselves,O
could,O
not,O
explain,O
variations,O
in,O
those,O
cases,O
of,O
confirmed,O
COVID-19,O
(,O
Poirier,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Interestingly,O
",",O
environmental,O
variables,O
have,O
been,O
found,O
to,O
be,O
crucial,O
just,O
in,O
the,O
initial,O
phase,O
of,O
the,O
COVID-19,O
infection,O
",",O
during,O
which,O
time,O
the,O
dynamics,O
of,O
transmission,O
are,O
more,O
affected,O
by,O
airborne,O
viral,O
infectivity,O
rather,O
than,O
human,O
-,O
to,O
-,O
human,O
transmission,O
(,O
Coccia,O
",",O
2020,O
),O
.,O
Although,O
SARS,O
-,O
CoV-2,O
RNA,O
has,O
been,O
detected,O
in,O
the,O
air,O
(,O
Liu,O
et,O
al,O
.,O
",",O
2020c,O
),O
",",O
the,O
way,O
environmental,O
factors,O
may,O
affect,O
COVID-19,O
transmission,O
is,O
not,O
well,O
established,O
.,O
It,O
is,O
necessary,O
to,O
assess,O
whether,O
environmental,O
factors,O
really,O
have,O
a,O
cause,O
-,O
and,O
-,O
effect,O
relationship,O
for,O
infection,O
cases,O
or,O
deaths,O
by,O
COVID-19,O
.,O
There,O
is,O
evidence,O
for,O
an,O
indirect,O
effect,O
(,O
negative,O
/,O
positive,O
),O
of,O
COVID-19,O
on,O
environmental,O
outcomes,O
",",O
mainly,O
related,O
to,O
preventive,O
confinement,O
measures,O
on,O
the,O
population,O
imposed,O
worldwide,O
by,O
various,O
authorities,O
(,O
Fig,O
.,O
1,O
",",O
Braga,O
et,O
al,O
.,O
",",O
2020,O
",",O
Corlett,O
et,O
al,O
.,O
",",O
2020,O
",",O
Saadat,O
et,O
al,O
.,O
",",O
2020,O
",",O
Zambrano,O
-,O
Monserrate,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
worldwide,O
COVID-19,O
pandemic,O
has,O
caused,O
various,O
positive,O
impacts,O
on,O
the,O
environment,O
and,O
the,O
climate,O
(,O
Sarkodie,O
and,O
Owusu,O
",",O
2020a,O
),O
.,O
In,O
USA,O
",",O
NO2,O
declined,O
around,O
25,O
%,O
during,O
the,O
COVID-19,O
pandemic,O
as,O
compared,O
to,O
2017–2019,O
levels,O
(,O
Berman,O
and,O
Ebisu,O
",",O
2020,O
),O
.,O
Prior,O
to,O
the,O
COVID-19,O
pandemic,O
",",O
greenhouse,O
gases,O
raised,O
average,O
global,O
temperatures,O
",",O
causing,O
melting,O
of,O
glaciers,O
and,O
rising,O
sea,O
levels,O
.,O
The,O
use,O
of,O
wood,O
for,O
heating,O
",",O
along,O
with,O
other,O
commonly,O
used,O
fossil,O
fuel,O
",",O
probably,O
increases,O
outdoor,O
and/or,O
indoor,O
air,O
pollution,O
",",O
which,O
is,O
worrisome,O
considering,O
that,O
air,O
pollution,O
is,O
associated,O
with,O
COVID-19,O
(,O
Setti,O
et,O
al,O
.,O
",",O
2020,O
;,O
Wu,O
et,O
al,O
.,O
",",O
2020b,O
),O
.,O
Hospital,O
wastewater,O
usually,O
contains,O
high,O
levels,O
of,O
drugs,O
",",O
and,O
one,O
would,O
expect,O
that,O
their,O
concentrations,O
and,O
diversity,O
has,O
increased,O
during,O
the,O
COVID-19,O
pandemic,O
due,O
to,O
a,O
higher,O
demand,O
by,O
patients,O
(,O
Escher,O
et,O
al,O
.,O
",",O
2011,O
;,O
Jelic,O
et,O
al,O
.,O
",",O
2011,O
;,O
Ort,O
et,O
al,O
.,O
",",O
2010,O
),O
.,O
Hydroxychloroquine,O
and,O
chloroquine,O
are,O
some,O
of,O
the,O
drugs,O
that,O
have,O
been,O
used,O
to,O
treat,O
COVID-19,O
(,O
Liu,O
et,O
al,O
.,O
",",O
2020a,O
),O
.,O
As,O
of,O
July,O
2020,O
",",O
there,O
are,O
more,O
than,O
15,O
million,O
confirmed,O
COVID-19,O
cases,O
around,O
the,O
world,O
",",O
and,O
an,O
unknown,O
number,O
of,O
negative,O
cases,O
(,O
Dong,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
On,O
the,O
contrary,O
",",O
plastics,O
and,O
drugs,O
in,O
wastewater,O
produced,O
during,O
this,O
pandemic,O
by,O
COVID-19,O
will,O
persist,O
longer,O
",",O
particularly,O
those,O
are,O
not,O
biodegradable,O
.,O
There,O
are,O
key,O
lessons,O
that,O
can,O
be,O
learned,O
from,O
COVID-19,O
",",O
which,O
relate,O
to,O
the,O
need,O
to,O
be,O
prepared,O
and,O
environmentally,O
responsible,O
.,O
It,O
is,O
necessary,O
to,O
establish,O
preventive,O
epidemiological,O
models,O
(,O
e.g.,O
",",O
monitoring,O
of,O
domestic,O
wastewater,O
),O
to,O
detect,O
the,O
occurrence,O
of,O
COVID-19,O
in,O
advance,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
has,O
become,O
a,O
global,O
pandemic,O
.,O
This,O
article,O
aims,O
to,O
deal,O
with,O
a,O
possible,O
association,O
between,O
COVID-19,O
and,O
environmental,O
factors,O
and,O
provide,O
some,O
recommendations,O
for,O
adequately,O
controlling,O
future,O
epidemic,O
threats,O
.,O
Pollutants,O
and,O
viruses,O
(,O
such,O
as,O
COVID-19,O
),O
produce,O
negative,O
immunological,O
responses,O
and,O
share,O
similar,O
mechanisms,O
of,O
action,O
.,O
Significant,O
associations,O
between,O
air,O
pollution,O
and,O
COVID-19,O
have,O
been,O
reported,O
.,O
Particulate,O
matter,O
(,O
PM2.5,O
",",O
PM10,O
),O
can,O
obstruct,O
the,O
airway,O
",",O
exacerbating,O
cases,O
of,O
COVID-19,O
.,O
Too,O
little,O
is,O
known,O
about,O
the,O
current,O
pandemic,O
to,O
evaluate,O
whether,O
there,O
is,O
an,O
association,O
between,O
environment,O
and,O
positive,O
COVID-19,O
cases,O
.,O
•,O
 ,O
Climatic,O
factors,O
are,O
not,O
well,O
established,O
as,O
factors,O
influencing,O
COVID-19,O
pandemic,O
dissemination,O
.,O
Alternatively,O
",",O
with,O
prolonged,O
waiting,O
times,O
until,O
results,O
are,O
available,O
",",O
viral,O
replication,O
may,O
be,O
measured,O
by,O
determining,O
the,O
RNA,O
or,O
infectious,O
titers,O
of,O
progeny,O
virus,O
released,O
from,O
infected,O
cells,O
by,O
RT,O
-,O
qPCR,O
(,O
Chu,O
et,O
al,O
.,O
",",O
2020,O
;,O
Liu,O
et,O
al,O
.,O
",",O
2020a,O
;,O
Yao,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
or,O
tissue,O
culture,O
infectious,O
dose,O
50,O
(,O
TCID50,O
),O
endpoint,O
titrations,O
(,O
Chin,O
et,O
al,O
.,O
",",O
2020,O
;,O
Manenti,O
et,O
al,O
.,O
",",O
2020,O
),O
and,O
plaque,O
assays,O
(,O
Keil,O
et,O
al,O
.,O
",",O
2020,O
;,O
Ma,O
et,O
al,O
.,O
",",O
2020,O
;,O
Runfeng,O
et,O
al,O
.,O
",",O
2020,O
;,O
Xia,O
et,O
al,O
.,O
",",O
2020a,O
),O
",",O
respectively,O
.,O
It,O
can,O
be,O
used,O
to,O
measure,O
the,O
TCID50,O
",",O
to,O
screen,O
for,O
antivirals,O
",",O
and,O
to,O
determine,O
antiviral,O
potencies,O
of,O
drugs,O
(,O
as,O
inhibitory,O
concentration,O
50,O
),O
",",O
neutralizing,O
sera,O
or,O
antibodies,O
in,O
a,O
timely,O
and,O
cost,O
-,O
effective,O
manner,O
",",O
within,O
only,O
two,O
days,O
.,O
Two,O
SARS,O
-,O
CoV-2,O
permissive,O
cell,O
lines,O
",",O
Vero,O
E6,O
(,O
African,O
green,O
monkey,O
epithelial,O
kidney,O
cells,O
),O
and,O
Caco-2,O
(,O
heterogeneous,O
human,O
epithelial,O
colorectal,O
adenocarcinoma,O
cells,O
),O
",",O
were,O
seeded,O
in,O
96,O
well,O
plates,O
and,O
inoculated,O
with,O
increasing,O
multiplicities,O
of,O
infection,O
(,O
MOIs,O
),O
of,O
a,O
SARS,O
-,O
CoV-2,O
isolate,O
from,O
France,O
(,O
BetaCoV,O
/,O
France,O
/,O
IDF0372/2020,O
),O
.,O
The,O
antibody,O
-,O
targeted,O
S2,O
domain,O
is,O
generally,O
conserved,O
between,O
SARS,O
-,O
CoV-2,O
strains,O
(,O
Ng,O
et,O
al,O
.,O
",",O
2014,O
;,O
Walls,O
et,O
al,O
.,O
",",O
2020,O
),O
(,O
www.nextstrain.org,S-URL
 ,O
(,O
Hadfield,B-Creator
et,I-Creator
"al.,",I-Creator
2018,E-Creator
),O
),O
which,O
allows,O
detection,O
of,O
the,O
S,O
protein,O
of,O
the,O
France,O
/,O
IDF0372/2020,O
as,O
well,O
as,O
the,O
Netherlands/01,O
isolate,O
and,O
two,O
isolates,O
from,O
Ulm,O
",",O
Southern,O
Germany,O
(,O
Fig,O
.,O
S1,O
),O
.,O
We,O
were,O
wondering,O
whether,O
this,O
high,O
sensitivity,O
and,O
ease,O
of,O
quantitation,O
may,O
also,O
allow,O
to,O
determine,O
the,O
TCID50,O
of,O
virus,O
stocks,O
",",O
that,O
is,O
usually,O
done,O
on,O
Vero,O
E6,O
cells,O
by,O
manually,O
counting,O
infected,O
wells,O
using,O
a,O
microscope,O
.,O
The,O
subsequent,O
calculation,O
of,O
TCID50,O
/,O
ml,O
by,O
Reed,O
and,O
Muench,O
revealed,O
exactly,O
the,O
same,O
viral,O
titer,O
for,O
the,O
in,O
-,O
cell,O
ELISA,O
(,O
Fig,O
.,O
4b,O
),O
as,O
for,O
microscopic,O
evaluation,O
(,O
Fig,O
.,O
4a,O
),O
showing,O
that,O
the,O
established,O
ELISA,O
is,O
suitable,O
for,O
determination,O
of,O
viral,O
titers,O
.,O
As,O
shown,O
in,O
Fig,O
.,O
6,O
",",O
the,O
two,O
control,O
sera,O
",",O
that,O
were,O
obtained,O
before,O
the,O
COVID-19,O
outbreak,O
or,O
shown,O
to,O
contain,O
no,O
SARS,O
-,O
CoV-2,O
immunoglobulins,O
",",O
did,O
not,O
affect,O
infection,O
.,O
In,O
contrast,O
",",O
both,O
COVID-19,O
sera,O
neutralized,O
SARS,O
-,O
CoV-2,O
infection,O
(,O
Fig,O
.,O
6,O
),O
.,O
These,O
titers,O
corresponded,O
well,O
to,O
the,O
presence,O
of,O
immunoglobulins,O
which,O
suggests,O
that,O
the,O
here,O
established,O
method,O
can,O
be,O
used,O
to,O
detect,O
and,O
quantify,O
the,O
neutralizing,O
capacities,O
of,O
sera,O
from,O
COVID-19,O
patients,O
.,O
Additionally,O
",",O
the,O
assay,O
can,O
be,O
applied,O
to,O
detect,O
and,O
quantify,O
titers,O
of,O
neutralizing,O
sera,O
of,O
COVID-19,O
patients,O
",",O
all,O
within,O
only,O
2,O
days,O
.,O
We,O
found,O
that,O
the,O
in,O
-,O
cell,O
ELISA,O
allows,O
to,O
i,O
),O
discriminate,O
infected,O
from,O
uninfected,O
wells,O
",",O
and,O
ii,O
),O
even,O
after,O
infection,O
with,O
very,O
low,O
MOIs,O
(,O
as,O
low,O
as,O
0.000005,O
",",O
which,O
corresponds,O
to,O
one,O
virion,O
per,O
three,O
wells,O
),O
at,O
4,O
days,O
post,O
infection,O
(,O
Fig,O
.,O
4,O
),O
",",O
representing,O
an,O
alternative,O
for,O
non,O
-,O
biased,O
determining,O
the,O
TCID50,O
without,O
the,O
need,O
of,O
counting,O
infected,O
wells,O
or,O
plaques,O
.,O
The,O
development,O
of,O
efficient,O
drugs,O
and,O
vaccines,O
against,O
COVID-19,O
requires,O
detailed,O
knowledge,O
about,O
SARS,O
-,O
CoV-2,O
biology,O
.,O
Utilization,O
of,O
the,O
in,O
-,O
cell,O
ELISA,O
allows,O
to,O
e.g.,O
determine,O
TCID,O
50,O
of,O
virus,O
stocks,O
",",O
antiviral,O
efficiencies,O
(,O
IC,O
50,O
values,O
),O
of,O
drugs,O
or,O
neutralizing,O
activity,O
of,O
sera,O
.,O
The,O
SARS‐CoV‐2,O
ssRNA,O
virus,O
was,O
initially,O
detected,O
in,O
December,O
2019,O
within,O
China,O
's,O
Hubei,O
province,O
and,O
its,O
associated,O
COVID‐19,O
pandemic,O
is,O
currently,O
ongoing,O
",",O
with,O
a,O
global,O
toll,O
of,O
over,O
5,O
million,O
infections,O
and,O
333,O
thousand,O
deaths,O
so,O
far,O
(,O
WHO,O
coronavirus,O
disease,O
[,O
COVID‐19,O
],O
situation,O
report‐124,O
",",O
published,O
on,O
23,O
May,O
2020,O
),O
.,O
Despite,O
having,O
such,O
climate,O
conditions,O
",",O
COVID‐19,O
cases,O
are,O
increasing,O
at,O
an,O
alarming,O
rate,O
in,O
relatively,O
hot,O
and,O
humid,O
subtropical,O
South‐East,O
Asian,O
countries,O
.,O
As,O
of,O
22,O
May,O
",",O
a,O
total,O
of,O
"182,278",O
cases,O
of,O
SARS‐CoV‐2‐infected,O
cases,O
were,O
identified,O
in,O
South‐East,O
Asia,O
",",O
with,O
a,O
death,O
toll,O
of,O
over,O
"5,500",O
(,O
WHO,O
coronavirus,O
disease,O
[,O
COVID‐19,O
],O
situation,O
report‐124,O
",",O
published,O
on,O
23,O
May,O
2020,O
),O
.,O
In,O
addition,O
",",O
GISAID,S-Dataset
 ,O
differentiated,O
COVID‐19,O
into,O
three,O
major,O
clades,O
:,O
Clade,O
S,O
(,O
prevalent,O
in,O
North,O
America,O
),O
",",O
Clade,O
V,O
(,O
prevalent,O
in,O
Asia,O
and,O
Europe,O
),O
and,O
Clade,O
G,O
(,O
prevalent,O
in,O
Europe,O
),O
",",O
having,O
NS,O
mutations,O
with,O
aa,O
substitutions,O
at,O
NS8_L84S,O
",",O
NS3_G251V,O
and,O
S_D614,O
G,O
",",O
respectively,O
(,O
Fuertes,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Finally,O
",",O
based,O
on,O
genomic,O
data,O
available,O
from,O
the,O
GISAID,S-Dataset
",",O
Nextstrain,S-Repository
's,O
SARS‐CoV‐2,O
global,O
genomic,O
epidemiology,O
analysis,O
shows,O
10,O
major,O
clades,O
for,O
this,O
virus,O
.,O
The,O
number,O
and,O
ratio,O
of,O
sequence,O
by,O
country,O
were,O
determined,O
based,O
on,O
the,O
available,O
number,O
of,O
sequences,O
and,O
the,O
total,O
number,O
of,O
COVID‐19,O
cases,O
up,O
to,O
23,O
May,O
2020,O
.,O
Accession,O
ID,O
",",O
collection,O
dates,O
and,O
locations,O
of,O
this,O
subset,O
are,O
provided,O
in,O
Supporting,O
Information,O
S1,O
.,O
Non‐synonymous,O
mutations,O
with,O
their,O
specific,O
mutation,O
sites,O
in,O
the,O
60,O
genomes,O
were,O
determined,O
using,O
‘,O
CoVsurver,O
enabled,O
by,O
GISAID,S-Dataset
’,O
in,O
GISAID’s,B-Dataset
EpiCoV,E-Dataset
 ,O
database,O
.,O
Group,O
1,O
consists,O
of,O
11,O
sequences,O
",",O
including,O
the,O
reference,O
sequence,O
hCoV19,O
/,O
Wuhan,O
/,O
WIV04/2019,O
(,O
Accession,O
:,O
EPI_ISL_402124,S-AccessionNumber
),O
.,O
A,O
geographic,O
heat,O
map,O
(,O
Figure,O
 ,O
5,O
),O
revealed,O
that,O
most,O
of,O
the,O
78,O
NS,O
mutations,O
found,O
from,O
60,O
sequences,O
were,O
also,O
common,O
in,O
Europe,O
and,O
North,O
America,O
(,O
according,O
to,O
global,O
mutation,O
statistics,O
database,O
;,O
Supporting,O
Information,O
S3,O
),O
.,O
This,O
mutation,O
was,O
later,O
reported,O
as,O
C,O
type,O
by,O
another,O
group,O
(,O
Forster,O
",",O
Forster,O
",",O
Renfrew,O
",",O
&,O
Forster,O
",",O
2020,O
),O
and,O
was,O
clustered,O
as,O
S,O
clade,O
by,O
GISAID,S-Dataset
 ,O
(,O
Fuertes,B-Creator
et,I-Creator
"al.,",I-Creator
2020,E-Creator
),O
.,O
Most,O
of,O
the,O
S,O
protein,O
mutations,O
identified,O
in,O
this,O
region,O
(,O
Supporting,O
Information,O
S2,O
),O
were,O
also,O
observed,O
in,O
Europe,O
and,O
North,O
America,O
according,O
to,O
the,O
GISAID,S-Dataset
 ,O
global,O
mutation,O
database,O
.,O
This,O
specific,O
aa,O
substitution,O
was,O
identified,O
on,O
55,O
occasions,O
according,O
to,O
the,O
global,O
database,O
.,O
The,O
SARS‐CoV‐2,O
coronavirus,O
is,O
responsible,O
for,O
the,O
current,O
COVID‐19,O
pandemic,O
",",O
with,O
an,O
ongoing,O
toll,O
of,O
over,O
5,O
million,O
infections,O
and,O
333,O
thousand,O
deaths,O
worldwide,O
within,O
the,O
first,O
5,O
 ,O
months,O
.,O
The,O
incidence,O
rate,O
of,O
COVID‐19,O
is,O
increasing,O
at,O
an,O
alarming,O
pace,O
within,O
subtropical,O
South‐East,O
Asian,O
nations,O
with,O
high,O
temperatures,O
and,O
humidity,O
.,O
To,O
understand,O
this,O
spread,O
",",O
we,O
analysed,O
444,O
genome,O
sequences,O
of,O
SARS‐CoV‐2,O
available,O
on,O
the,O
GISAID,S-Dataset
 ,O
platform,O
from,O
six,O
South‐East,O
Asian,O
countries,O
.,O
Coronavirus,O
Diseases,O
(,O
COVID-19,O
),O
comprises,O
symptoms,O
reported,O
by,O
patients,O
infected,O
by,O
SARS,O
-,O
CoV-2,O
",",O
ranging,O
from,O
mild,O
to,O
severe,O
",",O
and,O
some,O
cases,O
result,O
in,O
death,O
.,O
We,O
analyzed,O
"17,928",O
genomic,O
sequences,O
obtained,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
(,O
updated,O
on,O
07/24/2020,O
),O
derived,O
from,O
patients,O
infected,O
by,O
SARS,O
-,O
CoV-2,O
from,O
different,O
areas,O
around,O
the,O
world,O
.,O
SARS,O
-,O
CoV-2,O
reference,O
genome,O
(,O
RefSeq,S-Repository
:,O
NC_045512.2,S-AccessionNumber
),O
was,O
obtained,O
from,O
the,O
GenBank,S-Repository
 ,O
database,O
.,O
Furthermore,O
",",O
the,O
dataset,O
available,O
did,O
not,O
allow,O
us,O
to,O
determine,O
whether,O
this,O
deletion,O
happened,O
as,O
a,O
series,O
of,O
independent,O
events,O
in,O
different,O
temporal,O
moments,O
and,O
geographical,O
areas,O
",",O
as,O
if,O
the,O
virus,O
has,O
an,O
intrisecally,O
fragile,O
site,O
",",O
or,O
it,O
emerged,O
from,O
a,O
single,O
transforming,O
event,O
originating,O
from,O
a,O
unique,O
cluster,O
.,O
Understanding,O
the,O
different,O
steps,O
that,O
characterize,O
the,O
pathogenicity,O
of,O
this,O
virus,O
",",O
as,O
well,O
as,O
the,O
spreading,O
and,O
changes,O
of,O
these,O
pathogenic,O
determinants,O
among,O
the,O
population,O
",",O
may,O
help,O
determining,O
proper,O
strategies,O
of,O
containment,O
of,O
SARS,O
-,O
CoV-2,O
spread,O
and,O
identify,O
better,O
drugs,O
for,O
treatment,O
of,O
COVID-19,O
.,O
A,O
total,O
of,O
"17,928",O
genome,O
sequences,O
were,O
obtained,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
(,O
December,O
2019,O
to,O
July,O
2020,O
),O
from,O
patients,O
infected,O
by,O
SARS,O
-,O
CoV-2,O
from,O
different,O
areas,O
around,O
the,O
world,O
.,O
The,O
rapid,O
advance,O
of,O
the,O
coronavirus,O
COVID-19,O
pandemic,O
has,O
significantly,O
increased,O
mortality,O
but,O
also,O
has,O
demonstrated,O
considerable,O
potential,O
to,O
negatively,O
impact,O
mental,O
health,O
",",O
including,O
in,O
the,O
young,O
[,O
"1,2",O
],O
.,O
Perhaps,O
no,O
group,O
of,O
individuals,O
with,O
mental,O
illness,O
is,O
as,O
directly,O
affected,O
by,O
the,O
worsening,O
outbreak,O
of,O
COVID-19,O
as,O
people,O
living,O
with,O
obsessive,O
-,O
compulsive,O
disorder,O
(,O
OCD,O
),O
.,O
For,O
others,O
",",O
COVID-19,O
is,O
likely,O
to,O
cast,O
a,O
long,O
shadow,O
",",O
as,O
people,O
of,O
all,O
ages,O
with,O
OCD,O
are,O
known,O
to,O
be,O
particularly,O
inflexible,O
at,O
‘,O
unlearning,O
’,O
danger,O
responses,O
when,O
they,O
become,O
obsolete,O
[,O
"6,7",O
],O
and,O
thereby,O
conditioned,O
to,O
prolonged,O
virus,O
-,O
induced,O
distress,O
and,O
anxiety,O
.,O
Confirm,O
the,O
diagnosis,O
of,O
OCD,O
",",O
paying,O
particular,O
attention,O
to,O
other,O
obsessive,O
-,O
compulsive,O
and,O
related,O
disorders,O
(,O
OCRDs,O
),O
including,O
hypochondriasis,O
(,O
recently,O
endorsed,O
as,O
an,O
OCRD,O
in,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
ICD-11,O
),O
[,O
8,O
],O
",",O
as,O
these,O
disorders,O
are,O
likely,O
to,O
be,O
most,O
affected,O
by,O
COVID-19,O
.,O
It,O
is,O
also,O
important,O
not,O
to,O
assume,O
that,O
every,O
patient,O
with,O
contamination,O
fears,O
related,O
to,O
germs,O
and,O
illness,O
will,O
necessarily,O
be,O
excessively,O
concerned,O
about,O
COVID-19,O
.,O
In,O
particular,O
",",O
note,O
WHO,O
ICD-11,O
guidelines,O
regarding,O
mental,O
health,O
and,O
psychosocial,O
considerations,O
during,O
the,O
COVID-19,O
outbreak,O
[,O
1,O
],O
.,O
Additional,O
COVID,O
-,O
related,O
factors,O
found,O
anecdotally,O
to,O
potentially,O
increase,O
suicidal,O
risk,O
include,O
a,O
recent,O
increase,O
in,O
OCD,O
severity,O
",",O
experiencing,O
a,O
family,O
member,O
found,O
positive,O
for,O
COVID-19,O
or,O
finding,O
the,O
effects,O
of,O
quarantine,O
or,O
isolation,O
distressing,O
.,O
Review,O
medication,O
status,O
as,O
a,O
priority,O
:,O
Based,O
on,O
the,O
risks,O
associated,O
with,O
exposure,O
and,O
response,O
prevention,O
(,O
ERP,O
),O
in,O
the,O
pandemic,O
(,O
see,O
below,O
),O
",",O
and,O
uncertainty,O
as,O
to,O
which,O
of,O
the,O
two,O
evidence,O
-,O
based,O
treatments,O
",",O
pharmacotherapy,O
or,O
cognitive,O
behaviour,O
therapy,O
(,O
CBT,O
),O
",",O
represents,O
the,O
most,O
efficacious,O
first,O
line,O
treatment,O
modality,O
[,O
11,O
],O
",",O
pharmacotherapy,O
should,O
be,O
the,O
first,O
option,O
for,O
adults,O
and,O
children,O
with,O
OCD,O
with,O
contamination,O
",",O
washing,O
or,O
cleaning,O
symptoms,O
during,O
the,O
COVID-19,O
pandemic,O
.,O
This,O
case,O
-,O
control,O
study,O
examines,O
the,O
association,O
between,O
receipt,O
of,O
the,O
bradykinin,O
2,O
(,O
B2,O
),O
receptor,O
antagonist,O
icatibant,O
and,O
improved,O
oxygenation,O
in,O
patients,O
with,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
This,O
emerging,O
virus,O
was,O
later,O
identified,O
as,O
coronavirus,O
called,O
SARS,O
-,O
CoV-2,O
responsible,O
on,O
Coronavirus,O
Disease,O
19,O
(,O
COVID-19,O
),O
[,O
"1,2",O
],O
.,O
Despite,O
the,O
fact,O
that,O
COVID-19,O
has,O
a,O
death,O
rate,O
of,O
2.8,O
%,O
as,O
of,O
April,O
",",O
the,O
"8,844,171",O
confirmed,O
cases,O
with,O
"465,460",O
confirmed,O
deaths,O
in,O
a,O
few,O
months,O
(,O
December,O
8,O
",",O
2019,O
to,O
June,O
22,O
",",O
2020,O
),O
are,O
terrifying,O
.,O
The,O
complete,O
genomes,O
were,O
downloaded,O
from,O
the,O
NCBI,S-Repository
 ,O
database,O
.,O
Our,O
genomic,O
database,O
contains,O
in,O
totally,O
22,O
species,O
(,O
Table,O
1,O
),O
.,O
Fig,O
.,O
1.b,O
shows,O
an,O
example,O
of,O
the,O
CGR,O
-,O
centroid,O
plot,O
of,O
each,O
sub,O
-,O
region,O
and,O
the,O
center,O
of,O
CGR,O
(,O
X,O
),O
for,O
COVID,O
19,O
after,O
being,O
partitioned,O
into,O
sub,O
-,O
regions,O
of,O
size,O
2,O
 ,O
×,O
 ,O
2,O
.,O
Nucleotide,O
sequences,O
are,O
converted,O
into,O
a,O
numerical,O
sequence,O
(,O
1D,O
signals,O
),O
before,O
processing,O
from,O
our,O
database,O
extracted,O
from,O
NCBI,S-Repository
 ,O
platform,O
.,O
The,O
used,O
methods,O
are,O
an,O
alignment,O
free,O
method,O
",",O
requesting,O
only,O
a,O
sequence,O
database,O
and,O
a,O
bioinformatics,O
and,O
signal,O
processing,O
knowledges,O
[,O
[,O
16,O
],O
",",O
[,O
17,O
],O
",",O
[,O
18,O
],O
],O
.,O
Prior,O
scientists,O
searched,O
the,O
evolutionary,O
history,O
of,O
the,O
Wuhan,O
COVID-19,O
virus,O
[,O
1,O
],O
",",O
[,O
2,O
],O
",",O
[,O
3,O
],O
",",O
[,O
4,O
],O
",",O
[,O
5,O
],O
",",O
[,O
6,O
],O
",",O
[,O
7,O
],O
",",O
[,O
8,O
],O
",",O
[,O
9,O
],O
",",O
[,O
10,O
],O
",",O
[,O
11,O
],O
",",O
[,O
12,O
],O
",",O
[,O
13,O
],O
",",O
[,O
14,O
],O
",",O
[,O
"15],34,35",O
],O
.,O
Nevertheless,O
",",O
it,O
was,O
not,O
clear,O
",",O
till,O
now,O
",",O
if,O
the,O
COVID-19,O
arose,O
from,O
a,O
recombination,O
event,O
or,O
no,O
between,O
those,O
viruses,O
[,O
12,O
],O
.,O
Others,O
scientists,O
suggested,O
possible,O
genesis,O
of,O
COVID-19,O
virus,O
through,O
recombination,O
between,O
Bat,O
[,O
"10,11",O
],O
and,O
Pangolin,O
coronaviruses,O
[,O
"14,15",O
],O
.,O
Our,O
results,O
support,O
this,O
possibility,O
of,O
COVID-19,O
virus,O
genesis,O
though,O
evolution,O
of,O
Bat,O
and,O
Pangolin,O
coronaviruses,O
by,O
accumulation,O
of,O
point,O
mutations,O
and,O
recombination,O
.,O
The,O
SARS,O
-,O
CoV-2,O
Orf9b,O
biotin,O
-,O
streptavidin,O
affinity,O
purification,O
mass,O
spectrometry,O
data,O
are,O
deposited,O
on,O
ProteomeXchange,S-Repository
 ,O
(,O
Project,O
accession,O
:,O
PXD019803,S-AccessionNumber
),O
.,O
In,O
this,O
study,O
",",O
I,O
mined,O
the,O
NCBI,S-Repository
 ,O
expressed,O
sequence,O
tag,O
(,O
est,O
),O
database,O
to,O
discover,O
sequences,O
related,O
to,O
SARS‐CoV‐2,O
.,O
RNA,O
extraction,O
",",O
library,O
construction,O
",",O
and,O
sequencing,O
was,O
performed,O
previously,O
by,O
Zhong,O
et,O
al,O
 ,O
and,O
Adams,O
et,O
al,O
 ,O
and,O
uploaded,O
to,O
GenBank,S-Repository
 ,O
on,O
the,O
expressed,O
sequence,O
tag,O
(,O
est,O
),O
database,O
.,O
To,O
identify,O
novel,O
coronavirus,O
sequences,O
",",O
translated,O
nucleotide,O
BLAST,O
(,O
tblastn,O
),O
database,O
searches,O
were,O
performed,O
by,O
searching,O
for,O
SARS‐CoV‐2,O
sequences,O
in,O
the,O
NCBI,S-Repository
 ,O
expressed,O
sequence,O
tag,O
(,O
est,O
),O
database,O
.,O
SARS‐CoV‐2,O
protein,O
sequences,O
(,O
amino,O
acids,O
266‐13,O
 ,O
468,O
and,O
13,O
 ,O
468‐21,O
 ,O
555,O
),O
used,O
to,O
search,O
the,O
database,O
(,O
Figure,O
S1,O
),O
.,O
We,O
then,O
identified,O
the,O
submitting,O
laboratories,O
through,O
the,O
NCBI,O
database,O
and,O
found,O
that,O
both,O
cDNA,O
libraries,O
were,O
submitted,O
by,O
laboratories,O
at,O
the,O
Institute,O
of,O
Hydrobiology,O
",",O
Chinese,O
Academy,O
of,O
Sciences,O
",",O
in,O
Wuhan,O
",",O
China,O
.,O
On,O
this,O
basis,O
of,O
the,O
structure,O
of,O
3CL,O
hydrolase,O
(,O
Mpro,O
),O
of,O
2019‐nCoV,O
",",O
the,O
joint,O
team,O
integrated,O
the,O
strategy,O
of,O
virtual,O
screening,O
and,O
enzymology,O
test,O
",",O
focused,O
on,O
the,O
drug,O
screening,O
for,O
the,O
marketed,O
drugs,O
",",O
as,O
well,O
as,O
the,O
self‐built,O
“,O
database,O
of,O
high‐yield,O
compounds,O
”,O
and,O
“,O
database,O
of,O
compounds,O
from,O
medicinal,O
plants,O
”,O
",",O
and,O
quickly,O
found,O
30,O
kinds,O
of,O
possible,O
treatments,O
for,O
2019‐nCoV,O
drugs,O
",",O
active,O
natural,O
products,O
",",O
and,O
traditional,O
Chinese,O
medicine,O
.,O
The,O
research,O
team,O
built,O
the,O
protein,O
structure,O
of,O
2019‐nCoV,O
PLP,O
by,O
using,O
homology,O
modeling,O
method,O
",",O
defined,O
its,O
drug‐binding,O
pocket,O
",",O
and,O
screened,O
the,O
active,O
molecules,O
from,O
the,O
existing,O
drug,O
compound,O
library,O
of,O
ZINC,O
",",O
the,O
database,O
of,O
traditional,O
Chinese,O
medicine,O
and,O
natural,O
products,O
established,O
by,O
their,O
own,O
laboratory,O
by,O
using,O
the,O
computer‐aided,O
structure‐based,O
virtual,O
screening,O
method,O
.,O
After,O
triphosphate,O
in,O
vivo,O
",",O
it,O
is,O
incorporated,O
into,O
the,O
newly,O
synthesized,O
RNA,O
chain,O
of,O
the,O
virus,O
as,O
a,O
substrate,O
",",O
and,O
then,O
the,O
synthesis,O
of,O
the,O
virus,O
genome,O
is,O
interrupted,O
.,O
",",O
 ,O
",",O
 ,O
",",O
 ,O
",",O
The,O
program,O
compares,O
nucleotide,O
or,O
protein,O
sequences,O
to,O
sequence,O
databases,O
and,O
calculates,O
the,O
statistical,O
significance,O
of,O
matches,O
.,O
COVID‐2019,O
pneumonia,O
continues,O
to,O
spread,O
on,O
a,O
global,O
scale,O
.,O
",",O
 ,O
",",O
 ,O
",",O
 ,O
",",O
Protease,O
inhibitor,O
is,O
a,O
kind,O
of,O
drug,O
targeting,O
protease,O
to,O
treat,O
AIDS,O
.,O
At,O
present,O
",",O
the,O
National,O
Health,O
Commission,O
has,O
recommended,O
that,O
anti‐AIDS,O
drugs,O
can,O
be,O
included,O
in,O
the,O
trial,O
.,O
The,O
world,O
continues,O
to,O
wait,O
expectantly,O
for,O
health,O
researchers,O
to,O
develop,O
effective,O
prevention,O
tools,O
",",O
tests,O
",",O
vaccines,O
",",O
and,O
treatments,O
for,O
COVID-19,O
.,O
Many,O
forms,O
of,O
COVID-19,O
health,O
research,O
involve,O
the,O
processing,O
of,O
personal,O
data,O
",",O
including,O
human,O
health,O
or,O
genetic,O
data,O
.,O
The,O
aim,O
of,O
our,O
analysis,O
is,O
to,O
help,O
research,O
institutions,O
navigate,O
European,O
data,O
protection,O
law,O
within,O
the,O
COVID-19,O
crisis,O
.,O
At,O
first,O
glance,O
",",O
consent,O
appears,O
to,O
be,O
a,O
straightforward,O
solution,O
for,O
processing,O
personal,O
data,O
in,O
COVID-19,O
research,O
",",O
as,O
it,O
coincides,O
with,O
the,O
research,O
ethics,O
principle,O
of,O
consent,O
.,O
Where,O
people,O
are,O
in,O
a,O
critical,O
status,O
of,O
health,O
",",O
which,O
will,O
be,O
the,O
case,O
for,O
most,O
hospitalized,O
patients,O
with,O
COVID-19,O
",",O
obtaining,O
consent,O
may,O
not,O
be,O
practically,O
possible,O
.,O
With,O
this,O
position,O
in,O
mind,O
",",O
it,O
is,O
particularly,O
unfortunate,O
that,O
the,O
EDPB,O
guidelines,O
on,O
COVID-19,O
and,O
research,O
make,O
no,O
mention,O
that,O
broader,O
consent,O
is,O
suitable,O
for,O
pandemic,O
research,O
[,O
6,O
],O
.,O
For,O
ongoing,O
research,O
studies,O
",",O
deleting,O
individual,O
data,O
sets,O
may,O
not,O
render,O
the,O
research,O
impossible,O
",",O
although,O
having,O
to,O
repeat,O
analyses,O
could,O
be,O
cumbersome,O
.,O
For,O
completed,O
research,O
studies,O
",",O
however,O
",",O
the,O
situation,O
is,O
different,O
",",O
as,O
altering,O
the,O
underlying,O
database,O
may,O
undermine,O
scientific,O
reproducibility,O
.,O
As,O
scientific,O
research,O
on,O
COVID-19,O
aims,O
to,O
benefit,O
society,O
as,O
a,O
whole,O
",",O
using,O
the,O
legal,O
basis,O
of,O
a,O
task,O
performed,O
in,O
the,O
public,O
interest,O
appears,O
to,O
be,O
a,O
natural,O
choice,O
.,O
It,O
is,O
also,O
the,O
choice,O
suggested,O
by,O
the,O
EDPB,O
as,O
more,O
appropriate,O
than,O
consent,O
for,O
research,O
in,O
clinical,O
trials,O
[,O
13,O
],O
and,O
is,O
one,O
of,O
the,O
potential,O
legal,O
grounds,O
mentioned,O
in,O
the,O
EDPB,O
’s,O
guidelines,O
on,O
COVID-19,O
and,O
research,O
.,O
The,O
EDPB,O
remains,O
silent,O
on,O
the,O
subject,O
in,O
their,O
guidelines,O
on,O
COVID-19,O
and,O
research,O
;,O
however,O
",",O
dedicated,O
guidance,O
on,O
the,O
subject,O
of,O
further,O
processing,O
is,O
expected,O
[,O
9,O
],O
.,O
This,O
may,O
pose,O
challenges,O
for,O
research,O
on,O
COVID-19,O
",",O
where,O
a,O
broad,O
consent,O
model,O
would,O
be,O
necessary,O
to,O
cover,O
the,O
full,O
range,O
from,O
disease,O
mechanisms,O
to,O
transmission,O
pathways,O
to,O
psychological,O
or,O
socioeconomic,O
consequences,O
of,O
the,O
disease,O
.,O
There,O
are,O
two,O
likely,O
options,O
for,O
processing,O
health,O
and,O
genetic,O
data,O
for,O
research,O
in,O
the,O
COVID-19,O
context,O
.,O
This,O
is,O
also,O
demonstrated,O
by,O
the,O
EDPB,O
’s,O
guidelines,O
on,O
COVID-19,O
and,O
research,O
[,O
6,O
],O
.,O
Moreover,O
",",O
the,O
continued,O
validity,O
of,O
adequacy,O
decisions,O
may,O
be,O
imperiled,O
if,O
recipient,O
third,O
countries,O
adopt,O
aggressive,O
data,O
collection,O
and,O
processing,O
practices,O
in,O
response,O
to,O
COVID-19,O
[,O
"28,29",O
],O
.,O
The,O
EDPB,O
furthermore,O
notes,O
that,O
explicit,O
consent,O
is,O
only,O
suitable,O
for,O
certain,O
situations,O
",",O
such,O
as,O
for,O
private,O
entities,O
conducting,O
COVID-19,O
research,O
;,O
however,O
",",O
it,O
provides,O
no,O
further,O
guidance,O
other,O
than,O
its,O
guidelines,O
on,O
COVID-19,O
and,O
research,O
(,O
paragraph,O
67,O
),O
[,O
6,O
],O
.,O
In,O
the,O
specific,O
situation,O
of,O
the,O
COVID-19,O
outbreak,O
",",O
the,O
EDPB,O
has,O
conceded,O
“,O
that,O
the,O
fight,O
against,O
COVID-19,O
has,O
been,O
recognized,O
by,O
the,O
EU,O
and,O
most,O
of,O
its,O
Member,O
States,O
as,O
an,O
important,O
public,O
interest,O
",",O
”,O
grounding,O
this,O
claim,O
in,O
provisions,O
of,O
EU,O
law,O
interpreted,O
through,O
the,O
prism,O
of,O
national,O
measures,O
by,O
Member,O
States,O
adopted,O
in,O
response,O
to,O
the,O
crisis,O
(,O
paragraphs,O
62,O
-,O
67,O
),O
[,O
6,O
],O
.,O
Along,O
these,O
lines,O
",",O
a,O
joint,O
statement,O
has,O
been,O
signed,O
by,O
more,O
than,O
550,O
researchers,O
worldwide,O
calling,O
for,O
privacy,O
preserving,O
technologies,O
",",O
strict,O
limitation,O
to,O
COVID-19,O
purposes,O
",",O
and,O
a,O
voluntary,O
basis,O
for,O
the,O
use,O
of,O
any,O
contact,O
tracing,O
app,O
[,O
39,O
],O
.,O
This,O
requirement,O
is,O
arguably,O
disproportionate,O
even,O
in,O
normal,O
circumstances,O
;,O
however,O
",",O
even,O
in,O
the,O
present,O
state,O
of,O
the,O
COVID-19,O
crisis,O
",",O
it,O
is,O
only,O
applicable,O
to,O
clinical,O
trials,O
",",O
observational,O
medicinal,O
product,O
studies,O
",",O
and,O
compassionate,O
therapeutic,O
use,O
that,O
is,O
essential,O
for,O
combating,O
the,O
disease,O
as,O
well,O
as,O
for,O
COVID-19,O
research,O
projects,O
of,O
the,O
Institutes,O
of,O
Scientific,O
Hospitalization,O
and,O
Treatment,O
funded,O
by,O
the,O
Ministry,O
of,O
Health,O
.,O
Before,O
they,O
process,O
special,O
categories,O
of,O
data,O
in,O
the,O
COVID-19,O
context,O
",",O
research,O
institutions,O
will,O
most,O
likely,O
need,O
to,O
perform,O
data,O
protection,O
impact,O
assessments,O
(,O
DPIAs,O
),O
",",O
which,O
act,O
as,O
both,O
a,O
safeguard,O
and,O
a,O
mechanism,O
for,O
enhancing,O
transparency,O
and,O
accountability,O
.,O
Our,O
analysis,O
demonstrates,O
that,O
variation,O
across,O
national,O
implementations,O
hampers,O
a,O
coordinated,O
global,O
research,O
response,O
in,O
the,O
fight,O
against,O
COVID-19,O
.,O
The,O
subsequently,O
published,O
guidelines,O
on,O
COVID-19,O
and,O
research,O
[,O
6,O
],O
contain,O
only,O
limited,O
advice,O
that,O
takes,O
into,O
account,O
specific,O
challenges,O
in,O
the,O
research,O
contexts,O
(,O
eg,O
",",O
hospitalized,O
people,O
who,O
are,O
unable,O
to,O
give,O
consent,O
",",O
challenges,O
in,O
information,O
-,O
giving,O
obligations,O
),O
.,O
Researchers,O
must,O
collaborate,O
globally,O
to,O
rapidly,O
respond,O
to,O
the,O
COVID-19,O
pandemic,O
.,O
The,O
COVID-19,O
experience,O
provides,O
lessons,O
for,O
national,O
legislatures,O
.,O
Early,O
clinical,O
descriptions,O
of,O
the,O
first,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2)–caused,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
cases,O
at,O
the,O
end,O
of,O
2019,O
rapidly,O
highlighted,O
distinct,O
patterns,O
of,O
disease,O
progression,O
(,O
),O
.,O
On,O
the,O
basis,O
of,O
data,O
from,O
patients,O
with,O
laboratory,O
-,O
confirmed,O
COVID-19,O
from,O
mainland,O
China,O
",",O
admission,O
to,O
intensive,O
care,O
unit,O
(,O
ICU,O
),O
",",O
invasive,O
mechanical,O
ventilation,O
",",O
or,O
death,O
occurred,O
in,O
6.1,O
%,O
of,O
cases,O
(,O
),O
",",O
and,O
the,O
death,O
rate,O
from,O
recent,O
current,O
French,O
data,O
was,O
0.70,O
%,O
(,O
),O
.,O
However,O
",",O
little,O
is,O
known,O
about,O
the,O
immunological,O
features,O
and,O
the,O
molecular,O
mechanisms,O
involved,O
in,O
COVID-19,O
severity,O
.,O
We,O
next,O
evaluated,O
the,O
response,O
of,O
whole,O
blood,O
cells,O
to,O
IFN,O
-,O
α,O
stimulation,O
(,O
),O
and,O
observed,O
a,O
comparable,O
increase,O
in,O
ISG,O
score,O
upon,O
IFN,O
-,O
α,O
stimulation,O
between,O
groups,O
of,O
any,O
severity,O
and,O
controls,O
(,O
Fig,O
.,O
3H,O
),O
",",O
suggesting,O
that,O
the,O
potential,O
for,O
response,O
to,O
type,O
I,O
IFN,O
was,O
not,O
affected,O
in,O
COVID-19,O
patients,O
.,O
Overall,O
",",O
these,O
data,O
suggest,O
that,O
infected,O
patients,O
had,O
no,O
detectable,O
circulating,O
IFN,O
-,O
β,O
and,O
that,O
an,O
impaired,O
IFN,O
-,O
α,O
production,O
characterized,O
the,O
most,O
severe,O
COVID-19,O
cases,O
.,O
Severe,O
COVID-19,O
was,O
reported,O
to,O
be,O
associated,O
with,O
hypercytokinaemia,O
(,O
",",O
),O
.,O
Interleukin-6,O
(,O
IL-6,O
),O
",",O
a,O
key,O
player,O
of,O
the,O
exacerbated,O
inflammatory,O
response,O
in,O
COVID-19,O
(,O
),O
",",O
was,O
not,O
detected,O
in,O
peripheral,O
blood,O
at,O
the,O
transcriptional,O
level,O
(,O
fig,O
.,O
S9B,O
),O
",",O
contrasting,O
with,O
high,O
amounts,O
of,O
IL-6,O
protein,O
(,O
Fig,O
.,O
4B,O
),O
.,O
These,O
observations,O
are,O
in,O
accordance,O
with,O
published,O
studies,O
in,O
bronchoalveolar,O
fluids,O
from,O
COVID-19,O
patients,O
",",O
describing,O
the,O
key,O
role,O
of,O
monocytes,O
(,O
),O
.,O
In,O
this,O
study,O
",",O
we,O
identified,O
an,O
impaired,O
type,O
I,O
IFN,O
response,O
in,O
severe,O
and,O
critical,O
COVID-19,O
patients,O
",",O
accompanied,O
by,O
high,O
blood,O
viral,O
load,O
and,O
an,O
excessive,O
NF,O
-,O
κB,O
–,O
driven,O
inflammatory,O
response,O
associated,O
with,O
increased,O
TNF,O
-,O
α,O
and,O
IL-6,O
.,O
We,O
observed,O
that,O
SARS,O
-,O
CoV-2,O
infection,O
was,O
characterized,O
by,O
an,O
absence,O
of,O
circulating,O
IFN,O
-,O
β,O
in,O
COVID-19,O
patients,O
with,O
all,O
disease,O
-,O
severity,O
grades,O
.,O
In,O
addition,O
",",O
most,O
severe,O
COVID-19,O
patients,O
displayed,O
impaired,O
IFN,O
-,O
α,O
production,O
that,O
was,O
associated,O
with,O
lower,O
viral,O
clearance,O
.,O
It,O
will,O
be,O
important,O
to,O
assess,O
in,O
severe,O
and,O
critical,O
COVID-19,O
patients,O
whether,O
this,O
reduced,O
type,O
I,O
IFN,O
production,O
is,O
present,O
at,O
the,O
onset,O
of,O
infection,O
",",O
whether,O
the,O
production,O
is,O
delayed,O
",",O
or,O
whether,O
IFN,O
production,O
is,O
exhausted,O
after,O
an,O
initial,O
peak,O
.,O
Comorbidities,O
are,O
risk,O
factors,O
for,O
severe,O
COVID-19,O
that,O
could,O
negatively,O
affect,O
IFN,O
production,O
and,O
in,O
contrast,O
exacerbate,O
inflammatory,O
responses,O
(,O
",",O
),O
.,O
In,O
this,O
respect,O
",",O
data,O
from,O
Bost,B-Creator
et,I-Creator
al.,E-Creator
 ,O
describe,O
a,O
reduced,O
type,O
I,O
IFN,O
signature,O
in,O
bronchoalveolar,O
lavage,O
macrophages,O
from,O
severe,O
COVID-19,O
patients,O
",",O
supporting,O
the,O
validity,O
of,O
our,O
analysis,O
(,O
),O
.,O
Accordingly,O
",",O
IFN,O
-,O
λ,O
has,O
been,O
proposed,O
as,O
a,O
therapeutic,O
in,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
and,O
other,O
such,O
viral,O
respiratory,O
diseases,O
(,O
see,O
the,O
Perspective,O
by,O
Grajales,O
-,O
Reyes,O
and,O
Colonna,O
),O
.,O
Broggi,O
et,O
al,O
.,O
report,O
that,O
COVID-19,O
patient,O
morbidity,O
correlates,O
with,O
the,O
high,O
expression,O
of,O
type,O
I,O
and,O
III,O
IFNs,O
in,O
the,O
lung,O
.,O
Complicating,O
this,O
picture,O
",",O
Hadjadj,O
et,O
al,O
.,O
observed,O
that,O
peripheral,O
blood,O
immune,O
cells,O
from,O
severe,O
and,O
critical,O
COVID-19,O
patients,O
have,O
diminished,O
type,O
I,O
IFN,O
and,O
enhanced,O
proinflammatory,O
interleukin-6,O
–,O
and,O
tumor,O
necrosis,O
factor,O
-,O
α,O
–,O
fueled,O
responses,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
characterized,O
by,O
distinct,O
patterns,O
of,O
disease,O
progression,O
that,O
suggest,O
diverse,O
host,O
immune,O
responses,O
.,O
We,O
performed,O
an,O
integrated,O
immune,O
analysis,O
on,O
a,O
cohort,O
of,O
50,O
COVID-19,O
patients,O
with,O
various,O
disease,O
severity,O
.,O
These,O
data,O
suggest,O
that,O
type,O
I,O
IFN,O
deficiency,O
in,O
the,O
blood,O
could,O
be,O
a,O
hallmark,O
of,O
severe,O
COVID-19,O
and,O
provide,O
a,O
rationale,O
for,O
combined,O
therapeutic,O
approaches,O
.,O
SARS,O
-,O
CoV-2,O
is,O
a,O
virus,O
that,O
causes,O
the,O
ongoing,O
COVID-19,O
pandemic,O
",",O
an,O
acute,O
respiratory,O
distress,O
syndrome,O
which,O
represents,O
the,O
most,O
serious,O
problem,O
for,O
global,O
health,O
(,O
Cascella,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
However,O
",",O
since,O
March,O
2020,O
",",O
some,O
manufacturers,O
reported,O
the,O
shortage,O
of,O
supplies,O
related,O
to,O
COVID-19,O
driven,O
by,O
the,O
sudden,O
increase,O
in,O
global,O
demand,O
for,O
RNA,O
extraction,O
kits,O
.,O
However,O
",",O
heating,O
oropharyngeal,O
swabs,O
is,O
not,O
as,O
sensitive,O
or,O
accurate,O
as,O
RT,O
-,O
qPCR,O
reactions,O
performed,O
on,O
purified,O
samples,O
",",O
detecting,O
97.4,O
%,O
of,O
the,O
COVID-19,O
-,O
positive,O
patients,O
with,O
no,O
false,O
positives,O
results,O
(,O
Fomsgaard,O
and,O
Rosenstierne,O
",",O
2020,O
),O
.,O
Also,O
",",O
Chelex-100,O
was,O
incorporated,O
as,O
a,O
protective,O
agent,O
during,O
extraction,O
at,O
high,O
temperatures,O
because,O
this,O
reagent,O
favors,O
chelating,O
groups,O
to,O
bind,O
to,O
cellular,O
components,O
(,O
Lounsbury,O
et,O
al,O
.,O
",",O
2012,O
),O
.,O
This,O
protocol,O
allowed,O
detecting,O
only,O
97.4,O
%,O
of,O
COVID-19,O
-,O
positive,O
patients,O
in,O
comparison,O
to,O
PEG,O
/,O
NaCl,O
precipitation,O
that,O
detected,O
100,O
%,O
of,O
the,O
positive,O
cases,O
.,O
At,O
the,O
end,O
of,O
2019,O
",",O
an,O
outbreak,O
of,O
a,O
new,O
Coronavirus,O
2019,O
(,O
COVID-19,O
),O
emerged,O
in,O
Wuhan,O
in,O
China,O
",",O
being,O
called,O
the,O
causative,O
agent,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
[,O
1,O
],O
",",O
[,O
2,O
],O
.,O
According,O
to,O
the,O
World,O
Health,O
Organization,O
",",O
more,O
than,O
5,O
million,O
people,O
are,O
infected,O
in,O
216,O
countries,O
and,O
more,O
than,O
331,O
thousand,O
people,O
died,O
from,O
COVID-19,O
[,O
5,O
],O
.,O
The,O
frequent,O
and,O
persistent,O
clinical,O
manifestations,O
of,O
anosmia,O
/,O
dysgeusia,O
is,O
present,O
in,O
patients,O
with,O
COVID-19,O
",",O
and,O
neurological,O
symptoms,O
are,O
also,O
reported,O
in,O
severe,O
cases,O
",",O
which,O
may,O
be,O
secondary,O
to,O
severe,O
respiratory,O
failure,O
[,O
24,O
],O
.,O
One,O
study,O
showed,O
that,O
a,O
patient,O
with,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
encephalitis,O
had,O
a,O
severe,O
increase,O
in,O
inflammatory,O
cytokines,O
in,O
the,O
CSF,O
",",O
such,O
as,O
Interleukin-8,O
",",O
TNF,O
-,O
α,O
",",O
a,O
finding,O
that,O
demonstrates,O
the,O
inflammatory,O
involvement,O
in,O
neurological,O
repercussions,O
related,O
to,O
COVID-19,O
[,O
28,O
],O
.,O
At,O
the,O
end,O
of,O
2019,O
",",O
there,O
was,O
an,O
outbreak,O
of,O
a,O
new,O
Coronavirus,O
2019,O
(,O
COVID-19,O
disease,O
),O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
is,O
causing,O
huge,O
impacts,O
on,O
health,O
and,O
social,O
care,O
systems,O
globally,O
.,O
Several,O
health,O
authorities,O
have,O
published,O
their,O
guidelines,O
for,O
COVID-19,O
diagnosis,O
and,O
treatment,O
including,O
the,O
administration,O
of,O
antimicrobial,O
agents,O
.,O
Both,O
guidelines,O
for,O
COVID-19,O
management,O
by,O
the,O
UK,O
National,O
Institute,O
for,O
Health,O
and,O
Care,O
Excellence,O
and,O
by,O
World,O
Health,O
Organization,O
discourage,O
antibiotic,O
therapy,O
or,O
prophylaxis,O
for,O
suspected,O
COVID-19,O
patients,O
and,O
confirmed,O
patients,O
with,O
mild,O
symptoms,O
",",O
but,O
suggest,O
to,O
prescribe,O
antibiotics,O
for,O
suspicious,O
bacterial,O
infections,O
.,O
",",O
 ,O
The,O
US,O
National,O
Institutes,O
of,O
Health,O
guideline,O
indicates,O
that,O
no,O
sufficient,O
data,O
supports,O
empirical,O
antibiotic,O
therapy,O
",",O
but,O
acknowledges,O
that,O
some,O
clinicians,O
routinely,O
administer,O
broad,O
-,O
spectrum,O
antibiotics,O
to,O
all,O
patients,O
with,O
moderate,O
or,O
severe,O
hypoxemia,O
.,O
The,O
latest,O
version,O
of,O
Chinese,O
clinical,O
guideline,O
for,O
COVID-19,O
diagnosis,O
and,O
treatment,O
published,O
in,O
March,O
2020,O
only,O
suggests,O
to,O
avoid,O
inappropriate,O
use,O
of,O
antibacterial,O
drugs,O
",",O
especially,O
the,O
broad,O
-,O
spectrum,O
ones,O
",",O
but,O
without,O
clear,O
explicitness,O
for,O
empirical,O
antibiotic,O
therapy,O
or,O
prophylaxis,O
.,O
This,O
suggests,O
that,O
the,O
administration,O
of,O
antibiotics,O
on,O
suspected,O
COVID-19,O
patients,O
is,O
heavily,O
dependent,O
on,O
the,O
judgement,O
and,O
experience,O
of,O
frontline,O
clinicians,O
",",O
especially,O
at,O
the,O
early,O
stage,O
of,O
pandemic,O
outbreak,O
.,O
Therefore,O
",",O
during,O
the,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
(,O
SARS,O
),O
outbreak,O
in,O
2003,O
and,O
the,O
more,O
recent,O
Middle,O
East,O
Respiratory,O
Syndrome,O
(,O
MERS,O
),O
outbreak,O
in,O
2012,O
",",O
most,O
suspected,O
patients,O
were,O
administrated,O
with,O
potent,O
broad,O
-,O
spectrum,O
antibiotics,O
even,O
before,O
the,O
confirmation,O
of,O
the,O
aetiological,O
agents,O
.,O
",",O
 ,O
This,O
empirical,O
procedure,O
may,O
be,O
applied,O
to,O
treat,O
COVID-19,O
.,O
In,O
the,O
early,O
outbreaks,O
of,O
COVID-19,O
in,O
Wuhan,O
",",O
China,O
occurred,O
in,O
late,O
2019,O
",",O
Chen,O
et,O
 ,O
al,O
.,O
reported,O
that,O
77,O
(,O
71,O
%,O
),O
of,O
their,O
patients,O
(,O
n,O
 ,O
=,O
 ,O
99,O
),O
received,O
antibiotic,O
treatment,O
and,O
only,O
1,O
(,O
1,O
%,O
),O
patients,O
developed,O
bacterial,O
co,O
-,O
infection,O
.,O
For,O
the,O
COVID-19,O
",",O
only,O
8,O
%,O
of,O
patients,O
with,O
co,O
-,O
infections,O
were,O
reported,O
",",O
although,O
72,O
%,O
of,O
the,O
patients,O
received,O
antimicrobial,O
therapy,O
.,O
Lansbury,O
L,O
and,O
colleagues,O
have,O
written,O
to,O
this,O
Journal,O
for,O
their,O
systematically,O
search,O
from,O
literature,O
between,O
1,O
January,O
2020,O
to,O
17,O
April,O
2020,O
for,O
studying,O
secondary,O
infections,O
in,O
COVID-19,O
patients,O
.,O
From,O
their,O
results,O
",",O
only,O
7,O
%,O
of,O
hospitalised,O
COVID-19,O
patients,O
had,O
bacterial,O
co,O
-,O
infections,O
.,O
In,O
this,O
context,O
",",O
the,O
article,O
sheds,O
light,O
on,O
the,O
potential,O
of,O
plants,O
and,O
plant,O
-,O
based,O
drugs,O
for,O
their,O
use,O
in,O
treating,O
COVID-19,O
.,O
This,O
altogether,O
accentuates,O
the,O
importance,O
of,O
plant,O
-,O
based,O
drugs,O
in,O
treating,O
COVID-19,O
patients,O
.,O
Coronavirus,O
disease,O
",",O
or,O
COVID-19,O
",",O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
may,O
be,O
more,O
severe,O
in,O
patients,O
with,O
chronic,O
lung,O
disease,O
",",O
including,O
patients,O
with,O
asthma,O
(,O
1,O
),O
.,O
Among,O
patients,O
with,O
asthma,O
",",O
it,O
is,O
possible,O
that,O
demographic,O
or,O
biological,O
factors,O
influence,O
susceptibility,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
or,O
severity,O
of,O
COVID-19,O
disease,O
.,O
We,O
reasoned,O
that,O
differences,O
in,O
ACE2,O
or,O
TMPRSS2,O
gene,O
expression,O
in,O
sputum,O
cells,O
among,O
patients,O
with,O
asthma,O
may,O
identify,O
subgroups,O
at,O
risk,O
for,O
worse,O
COVID-19,O
outcomes,O
.,O
In,O
particular,O
",",O
we,O
hypothesized,O
that,O
comorbidities,O
such,O
as,O
diabetes,O
mellitus,O
or,O
hypertension,O
may,O
affect,O
ACE2,O
or,O
TMPRSS2,O
gene,O
expression,O
in,O
sputum,O
cells,O
",",O
because,O
these,O
diseases,O
are,O
reported,O
to,O
influence,O
the,O
severity,O
of,O
COVID-19,O
or,O
its,O
outcome,O
(,O
1,O
",",O
4,O
),O
.,O
Models,O
incorporate,O
the,O
same,O
demographic,O
features,O
in,O
Figure,O
3,O
and,O
the,O
three,O
asthma,O
control,O
factors,O
.,O
ACE2,O
and,O
TMPRSS2,O
expression,O
mediate,O
SARS,O
-,O
CoV-2,O
infection,O
of,O
host,O
lung,O
cells,O
(,O
3,O
),O
",",O
and,O
it,O
is,O
reasonable,O
to,O
infer,O
that,O
increases,O
in,O
their,O
expression,O
in,O
lung,O
cells,O
will,O
increase,O
susceptibility,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
or,O
lead,O
to,O
more,O
severe,O
COVID-19,O
disease,O
.,O
Although,O
gene,O
expression,O
for,O
ACE2,O
and,O
TMPRSS2,O
did,O
not,O
differ,O
from,O
health,O
in,O
asthma,O
",",O
we,O
report,O
that,O
males,O
",",O
African,O
Americans,O
",",O
and,O
patients,O
with,O
diabetes,O
mellitus,O
have,O
increased,O
expression,O
of,O
ACE2,O
and,O
TMPRSS2,O
in,O
their,O
sputum,O
cells,O
",",O
and,O
these,O
patient,O
subgroups,O
should,O
therefore,O
be,O
monitored,O
for,O
poor,O
COVID-19,O
outcomes,O
.,O
In,O
contrast,O
",",O
we,O
report,O
lower,O
expression,O
of,O
ACE2,O
and,O
TMPRSS2,O
in,O
sputum,O
cells,O
from,O
patients,O
with,O
asthma,O
taking,O
ICS,O
",",O
and,O
this,O
finding,O
warrants,O
prospective,O
research,O
to,O
determine,O
if,O
ICS,O
use,O
predicts,O
decreased,O
susceptibility,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
or,O
decreased,O
COVID-19,O
morbidity,O
.,O
The,O
higher,O
expression,O
of,O
ACE2,O
that,O
we,O
report,O
in,O
male,O
patients,O
is,O
notable,O
because,O
of,O
the,O
high,O
mortality,O
of,O
COVID-19,O
in,O
males,O
(,O
1,O
",",O
5,O
),O
.,O
This,O
finding,O
is,O
interesting,O
",",O
because,O
diabetes,O
is,O
a,O
risk,O
factor,O
for,O
severe,O
morbidity,O
or,O
death,O
from,O
COVID-19,O
(,O
1,O
),O
.,O
Hypertension,O
is,O
also,O
a,O
risk,O
factor,O
for,O
COVID-19,O
morbidity,O
(,O
1,O
),O
",",O
but,O
we,O
did,O
not,O
find,O
increases,O
in,O
ACE2,O
expression,O
in,O
sputum,O
cells,O
from,O
patients,O
with,O
asthma,O
with,O
and,O
without,O
hypertension,O
.,O
The,O
higher,O
expression,O
of,O
ACE2,O
in,O
African,O
Americans,O
is,O
also,O
noteworthy,O
",",O
because,O
COVID-19,O
outcomes,O
in,O
African,O
Americans,O
",",O
Africans,O
",",O
or,O
other,O
persons,O
of,O
African,O
descent,O
have,O
not,O
yet,O
been,O
reported,O
in,O
any,O
detail,O
.,O
The,O
similar,O
increases,O
in,O
both,O
genes,O
in,O
the,O
same,O
patient,O
subgroups,O
provide,O
a,O
mechanism,O
for,O
a,O
“,O
double,O
hit,O
”,O
susceptibility,O
for,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
COVID-19,O
morbidity,O
in,O
these,O
patients,O
.,O
Non,O
–,O
asthma,O
-,O
related,O
factors,O
",",O
such,O
as,O
male,O
sex,O
",",O
African,O
American,O
race,O
",",O
and,O
metabolic,O
disease,O
(,O
diabetes,O
mellitus,O
),O
",",O
may,O
be,O
more,O
important,O
and,O
more,O
generalizable,O
risks,O
for,O
susceptibility,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
more,O
severe,O
COVID-19,O
morbidity,O
.,O
Rationale,O
:,O
Coronavirus,O
disease,O
(,O
COVID-19,O
),O
is,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
We,O
reasoned,O
that,O
differences,O
in,O
ACE2,O
or,O
TMPRSS2,O
gene,O
expression,O
in,O
sputum,O
cells,O
among,O
patients,O
with,O
asthma,O
may,O
identify,O
subgroups,O
at,O
risk,O
for,O
COVID-19,O
morbidity,O
.,O
Conclusions,O
:,O
Higher,O
expression,O
of,O
ACE2,O
and,O
TMPRSS2,O
in,O
males,O
",",O
African,O
Americans,O
",",O
and,O
patients,O
with,O
diabetes,O
mellitus,O
provides,O
rationale,O
for,O
monitoring,O
these,O
asthma,O
subgroups,O
for,O
poor,O
COVID-19,O
outcomes,O
.,O
The,O
lower,O
expression,O
of,O
ACE2,O
and,O
TMPRSS2,O
with,O
ICS,O
use,O
warrants,O
prospective,O
study,O
of,O
ICS,O
use,O
as,O
a,O
predictor,O
of,O
decreased,O
susceptibility,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
decreased,O
COVID-19,O
morbidity,O
.,O
An,O
outbreak,O
of,O
a,O
viral,O
respiratory,O
illness,O
(,O
officially,O
named,O
by,O
the,O
World,O
Health,O
Organization,O
coronavirus,O
disease,O
",",O
COVID-19,O
),O
caused,O
by,O
the,O
newly,O
discovered,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
started,O
around,O
mid,O
-,O
December,O
2019,O
",",O
in,O
the,O
city,O
of,O
Wuhan,O
",",O
Hubei,O
province,O
",",O
China,O
[,O
1,O
],O
.,O
The,O
outbreak,O
subsequently,O
spread,O
further,O
and,O
as,O
at,O
31,O
March,O
2020,O
",",O
"750,890",O
cases,O
of,O
COVID-19,O
have,O
been,O
confirmed,O
worldwide,O
including,O
"668,345",O
outside,O
China,O
[,O
2,O
],O
.,O
Since,O
20,O
February,O
2020,O
",",O
sustained,O
local,O
transmission,O
has,O
been,O
documented,O
in,O
Italy,O
[,O
3,O
],O
",",O
where,O
to,O
date,O
",",O
"98,716",O
COVID-19,O
cases,O
testing,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
have,O
been,O
diagnosed,O
",",O
with,O
"10,943",O
deaths,O
[,O
4,O
],O
.,O
The,O
reads,O
were,O
trimmed,O
for,O
quality,O
and,O
length,O
and,O
assembled,O
by,O
mapping,O
to,O
the,O
reference,O
genome,O
from,O
Wuhan,O
",",O
China,O
(,O
GenBank,S-Repository
 ,O
accession,O
number,O
:,O
NC_045512.2,S-AccessionNumber
),O
using,O
Geneious,O
Prime,O
(,O
www.geneious.com,O
),O
[,O
5,O
],O
.,O
Viral,O
sequences,O
from,O
the,O
two,O
patients,O
were,O
deposited,O
in,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID,E-Dataset
;,O
https://www.gisaid.org/epiflu-applications/next-hcov-19-app/,S-URL
 ,O
),O
.,O
To,O
analyse,O
the,O
obtained,O
SARS,O
-,O
CoV-2,O
genomes,O
respectively,O
derived,O
from,O
the,O
infected,O
Chinese,O
tourist,O
(,O
GISAID,S-Dataset
 ,O
accession,O
ID,O
:,O
EPI_ISL_412974,S-AccessionNumber
),O
and,O
the,O
Italian,O
patient,O
(,O
GISAID,S-Dataset
 ,O
accession,O
ID,O
:,O
EPI_ISL_412973,S-AccessionNumber
),O
in,O
a,O
phylogenetic,O
context,O
",",O
a,O
dataset,O
of,O
40,O
available,O
SARS,O
-,O
Cov-2,O
complete,O
genomes,O
from,O
different,O
countries,O
was,O
retrieved,O
from,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
",",O
last,O
access,O
2,O
March,O
2020,O
;,O
Supplementary,O
material,O
),O
.,O
The,O
viral,O
genome,O
sequence,O
of,O
the,O
Chinese,O
tourist,O
(,O
GISAID,S-Dataset
 ,O
accession,O
ID,O
:,O
EPI_ISL_412974,S-AccessionNumber
),O
was,O
identical,O
to,O
that,O
retrieved,O
from,O
one,O
sample,O
of,O
another,O
Chinese,O
tourist,O
",",O
hospitalised,O
at,O
the,O
same,O
hospital,O
in,O
Rome,O
(,O
GISAID,S-Dataset
 ,O
accession,O
ID,O
:,O
EPI_ISL_410546,S-AccessionNumber
),O
.,O
The,O
latter,O
was,O
closely,O
related,O
to,O
that,O
of,O
another,O
sample,O
taken,O
from,O
the,O
same,O
patient,O
(,O
GISAID,S-Dataset
 ,O
accession,O
ID,O
:,O
EPI_ISL_410545,S-AccessionNumber
),O
.,O
The,O
genome,O
-,O
wide,O
SNPs,O
are,O
reported,O
in,O
Table,O
1,O
(,O
positions,O
referred,O
respect,O
to,O
the,O
reference,O
sequence,O
;,O
GenBank,S-Repository
 ,O
accession,O
number,O
:,O
NC_045512,S-AccessionNumber
),O
.,O
The,O
genome,O
sequence,O
from,O
the,O
Chinese,O
tourist,O
hospitalised,O
in,O
Rome,O
differed,O
in,O
two,O
nt,O
positions,O
from,O
that,O
of,O
the,O
COVID-19,O
patient,O
in,O
Wuhan,O
(,O
NC_045512,S-AccessionNumber
),O
",",O
while,O
the,O
genome,O
sequence,O
isolated,O
from,O
the,O
Italian,O
patient,O
showed,O
four,O
nt,O
variations,O
(,O
Table,O
1,O
),O
.,O
Second,O
",",O
airborne,O
pathogens,O
usually,O
exhibit,O
a,O
relatively,O
low,O
50,O
%,O
infectious,O
dose,O
(,O
ID50,O
),O
value,O
.,O
Edouard,O
Lansiaux,O
has,O
just,O
shown,O
that,O
subjects,O
from,O
the,O
regions,O
of,O
Puglia,O
",",O
Sardinia,O
and,O
Sicilia,O
in,O
Italy,O
have,O
a,O
high,O
prevalence,O
of,O
Beta,O
-,O
thalassemia,O
and,O
are,O
",",O
thus,O
",",O
more,O
resistant,O
to,O
the,O
coronavirus,O
pneumonia,O
called,O
SARSCoV2,O
",",O
(,O
formerly,O
known,O
as,O
2019,O
-,O
nCoV,O
),O
",",O
that,O
causes,O
the,O
COVID19,O
disease,O
[,O
1,O
],O
.,O
We,O
should,O
like,O
to,O
add,O
that,O
Ferrara,O
",",O
(,O
"132,000",O
inhabitants,O
),O
",",O
a,O
town,O
in,O
Northern,O
Italy,O
whose,O
origins,O
are,O
from,O
the,O
Renaissance,O
",",O
situated,O
in,O
the,O
region,O
of,O
Emilia,O
Romagna,O
",",O
(,O
4449,O
million,O
inhabitants,O
",",O
"27,842",O
COVID+,O
patients,O
",",O
the,O
third,O
place,O
most,O
affected,O
in,O
Italy,O
),O
",",O
is,O
also,O
very,O
resistant,O
to,O
the,O
COVID-19,O
pandemic,O
.,O
On,O
the,O
2nd,O
June,O
2020,O
",",O
Italy,O
counted,O
"33,530",O
deaths,O
and,O
"233,197",O
cases,O
COVID+,O
.,O
A,O
study,O
has,O
showed,O
a,O
heme,O
attack,O
on,O
the,O
1,O
-,O
beta,O
chain,O
of,O
haemoglobin,O
by,O
COVID-19,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
caused,O
by,O
SARS,O
-,O
CoV-2,O
is,O
a,O
pandemic,O
as,O
of,O
Mar.,O
2020,O
.,O
African,O
Americans,O
and,O
Latinos,O
are,O
disproportionately,O
affected,O
by,O
COVID-19,O
and,O
show,O
significantly,O
higher,O
mortality,O
compared,O
to,O
the,O
other,O
race,O
and,O
ethnic,O
groups,O
in,O
the,O
US,O
(,O
Wadhera,O
et,O
al,O
.,O
",",O
2020,O
),O
and,O
in,O
the,O
UK,O
(,O
Kirby,O
",",O
2020,O
),O
.,O
Of,O
note,O
",",O
a,O
3p21.31,O
gene,O
cluster,O
—,O
SLC6A20,O
",",O
LZTFL1,O
",",O
CCR9,O
",",O
FYCO1,O
",",O
CXCR6,O
and,O
XCR1,O
—,O
is,O
associated,O
with,O
genetic,O
susceptibility,O
for,O
severe,O
COVID-19,O
cases,O
with,O
respiratory,O
failure,O
(,O
Ellinghaus,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
To,O
find,O
allelic,O
variation,O
across,O
populations,O
in,O
the,O
genes,O
that,O
are,O
known,O
be,O
involved,O
in,O
viral,O
entry,O
to,O
the,O
host,O
cells,O
and,O
sensing,O
of,O
viral,O
RNA,O
in,O
host,O
immune,O
cells,O
",",O
we,O
surveyed,O
publicly,O
available,O
databases,O
of,O
genomic,O
variants,O
.,O
Recent,O
studies,O
demonstrated,O
that,O
an,O
inhibitor,O
of,O
the,O
protease,O
activity,O
of,O
TMPRSS2,O
—,O
camostat,O
mesylate,O
—,O
attenuated,O
SARS,O
-,O
CoV-2,O
entry,O
into,O
lung,O
epithelial,O
cells,O
suggesting,O
a,O
promising,O
candidate,O
for,O
potential,O
intervention,O
against,O
COVID-19,O
(,O
Hoffmann,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
list,O
of,O
reported,O
genetic,O
variants,O
in,O
the,O
genes,O
and,O
their,O
allele,O
frequencies,O
(,O
AFs,O
),O
were,O
compiled,O
from,O
three,O
population,O
-,O
scale,O
genomic,O
variants,O
databases,O
—,O
gnomAD,S-Repository
 ,O
(,O
Karczewski,B-Creator
et,I-Creator
"al.,",I-Creator
2020,E-Creator
),O
",",O
Korean,B-Repository
Reference,I-Repository
Genome,I-Repository
Database,E-Repository
 ,O
(,O
Jung,B-Creator
et,I-Creator
"al.,",I-Creator
2020,E-Creator
),O
",",O
and,O
TogoVar,S-Repository
 ,O
(,O
a,O
Japanese,O
genetic,O
variation,O
database,O
available,O
at,O
https://togovar.biosciencedbc.jp/,S-URL
),O
—,O
and,O
three,O
whole,O
-,O
genome,O
sequencing,O
datasets,O
(,O
i.e.,O
",",O
1000,B-Dataset
Genomes,I-Dataset
Project,E-Dataset
 ,O
(,O
Clarke,B-Creator
et,I-Creator
"al.,",I-Creator
2017,E-Creator
),O
",",O
Gene-Tissue,B-Dataset
Expression,E-Dataset
 ,O
(,O
Consortium,B-Creator
et,I-Creator
"al.,",I-Creator
2017,E-Creator
),O
",",O
and,O
Simons,B-Dataset
Genome,I-Dataset
Diversity,I-Dataset
Project,E-Dataset
 ,O
(,O
Mallick,B-Creator
et,I-Creator
"al.,",I-Creator
2016,E-Creator
),O
),O
.,O
However,O
",",O
it,O
was,O
found,O
with,O
higher,O
AF,O
of,O
0.23,O
%,O
at,O
Japanese,O
genetic,O
variation,O
database,O
(,O
N,O
 ,O
=,O
 ,O
3552,O
),O
.,O
Especially,O
",",O
ACE2,O
and,O
TLR7,O
seem,O
to,O
be,O
under,O
strong,O
selection,O
pressure,O
as,O
reflected,O
in,O
their,O
relatively,O
lower,O
number,O
of,O
loss,O
-,O
of,O
-,O
function,O
variants,O
than,O
expected,O
in,O
large,O
variant,O
databases,O
such,O
as,O
gnomAD,S-Repository
 ,O
(,O
Karczewski,B-Creator
et,I-Creator
"al.,",I-Creator
2020,E-Creator
):,O
three,O
observed,O
variants,O
out,O
of,O
31,O
expected,O
ones,O
for,O
ACE2,O
and,O
two,O
observed,O
variants,O
out,O
of,O
20.7,O
expected,O
ones,O
for,O
TLR7,O
.,O
Moreover,O
",",O
nonsynonymous,O
variants,O
in,O
these,O
genes,O
were,O
mostly,O
of,O
very,O
low,O
frequencies,O
which,O
suggests,O
the,O
chance,O
of,O
gene,O
function,O
altered,O
by,O
these,O
variants,O
would,O
be,O
unlikely,O
",",O
compared,O
to,O
the,O
incidence,O
of,O
COVID-19,O
around,O
the,O
globe,O
.,O
Therefore,O
",",O
underlying,O
medical,O
conditions,O
",",O
age,O
",",O
environmental,O
factors,O
(,O
e.g.,O
",",O
air,O
pollution,O
",",O
smoking,O
",",O
and,O
humidity,O
),O
",",O
and,O
a,O
healthcare,O
disparity,O
influence,O
morbidity,O
and,O
mortality,O
from,O
COVID-19,O
considering,O
the,O
allelic,O
spectrum,O
for,O
the,O
key,O
genes,O
associated,O
with,O
viral,O
entry,O
.,O
The,O
population,O
-,O
scale,O
genotype,O
databases,O
and,O
datasets,O
used,O
in,O
this,O
study,O
have,O
limitations,O
from,O
relatively,O
small,O
sample,O
size,O
and,O
imbalanced,O
and,O
incomplete,O
representation,O
of,O
various,O
human,O
populations,O
.,O
Thus,O
",",O
there,O
could,O
be,O
unreported,O
variants,O
in,O
ACE2,O
",",O
TMPRSS2,O
",",O
and,O
TLR3/7/8,O
that,O
may,O
be,O
associated,O
with,O
change,O
of,O
susceptibility,O
to,O
COVID-19,O
.,O
With,O
additional,O
population,O
-,O
scale,O
genomic,O
databases,O
for,O
diverse,O
populations,O
",",O
it,O
will,O
be,O
possible,O
to,O
identify,O
the,O
individuals,O
with,O
rare,O
genetic,O
variants,O
such,O
as,O
rs758278442,O
in,O
the,O
interacting,O
domain,O
of,O
ACE2,O
and,O
the,O
genetic,O
predisposition,O
to,O
cytokine,O
storm,O
that,O
causes,O
an,O
acute,O
progress,O
of,O
illness,O
in,O
young,O
people,O
.,O
The,O
COVID-19,O
pandemic,O
highlighted,O
healthcare,O
disparities,O
in,O
multiple,O
countries,O
.,O
Non,O
-,O
genetic,O
factors,O
are,O
likely,O
to,O
contribute,O
differential,O
population,O
characteristics,O
affected,O
by,O
COVID-19,O
.,O
Most,O
SARS,O
-,O
CoV-2,O
infections,O
are,O
asymptomatic,O
or,O
benign,O
",",O
but,O
SARS,O
-,O
CoV-2,O
infectious,O
disease,O
2019,O
(,O
COVID-19,O
),O
can,O
cause,O
life,O
-,O
threatening,O
disease,O
",",O
which,O
typically,O
begins,O
with,O
pneumonia,O
.,O
Severe,O
COVID-19,O
occurs,O
much,O
more,O
frequently,O
in,O
patients,O
over,O
the,O
age,O
of,O
50,O
years,O
and/or,O
with,O
comorbid,O
conditions,O
such,O
as,O
pulmonary,O
",",O
cardiovascular,O
",",O
and,O
metabolic,O
disorders,O
(,O
Figure,O
 ,O
1,O
),O
.,O
Why,O
are,O
previously,O
healthy,O
children,O
",",O
adolescents,O
",",O
young,O
",",O
or,O
middle,O
-,O
aged,O
adults,O
being,O
admitted,O
to,O
intensive,O
care,O
for,O
respiratory,O
failure,O
",",O
encephalitis,O
",",O
or,O
Kawasaki,O
disease,O
",",O
due,O
to,O
COVID-19,O
?,O
Why,O
would,O
a,O
40,O
-,O
year,O
-,O
old,O
man,O
who,O
completed,O
a,O
marathon,O
in,O
October,O
2019,O
find,O
himself,O
intubated,O
and,O
ventilated,O
for,O
COVID-19,O
respiratory,O
failure,O
in,O
April,O
2020,O
?,O
The,O
COVID,O
Human,O
Genetic,O
Effort,O
(,O
https://www.covidhge.com/,O
),O
proposes,O
that,O
previously,O
healthy,O
",",O
young,O
patients,O
with,O
severe,O
COVID-19,O
carry,O
causal,O
genetic,O
variants,O
.,O
This,O
hypothesis,O
is,O
not,O
yet,O
supported,O
by,O
specific,O
genetic,O
epidemiological,O
studies,O
of,O
COVID-19,O
",",O
but,O
it,O
follows,O
a,O
long,O
line,O
of,O
classical,O
genetic,O
studies,O
since,O
1905,O
",",O
relating,O
to,O
diverse,O
infections,O
in,O
plants,O
and,O
animals,O
",",O
including,O
humans,O
(,O
Casanova,O
and,O
Abel,O
",",O
2020,O
),O
.,O
The,O
protein,O
encoded,O
by,O
Mx,O
",",O
a,O
gene,O
cloned,O
by,O
cell,O
complementation,O
",",O
protects,O
mice,O
from,O
influenza,O
virus,O
(,O
Staeheli,O
et,O
 ,O
al,O
.,O
",",O
1986,O
),O
and,O
is,O
potentially,O
relevant,O
to,O
COVID-19,O
.,O
Other,O
examples,O
more,O
closely,O
related,O
to,O
COVID-19,O
include,O
influenza,O
virus,O
pneumonia,O
",",O
which,O
can,O
be,O
caused,O
by,O
inborn,O
errors,O
impairing,O
antiviral,O
type,O
I,O
and,O
III,O
IFN,O
immunity,O
(,O
IFN,O
-,O
α,O
/,O
β,O
and,O
-λ,O
),O
",",O
including,O
IRF7,O
",",O
IRF9,O
",",O
and,O
TLR3,O
deficiencies,O
",",O
in,O
circulating,O
plasmacytoid,O
dendritic,O
cells,O
and/or,O
pulmonary,O
epithelial,O
cells,O
(,O
Ciancanelli,O
et,O
 ,O
al,O
.,O
",",O
2015,O
",",O
Hernandez,O
et,O
 ,O
al,O
.,O
",",O
2018,O
",",O
Lim,O
et,O
 ,O
al,O
.,O
",",O
2019,O
),O
",",O
and,O
rhinovirus,O
pneumonia,O
",",O
which,O
can,O
be,O
caused,O
by,O
a,O
deficiency,O
of,O
IFN,O
-,O
inducing,O
MDA5,O
(,O
Asgari,O
et,O
 ,O
al,O
.,O
",",O
2017,O
",",O
Lamborn,O
et,O
 ,O
al,O
.,O
",",O
2017,O
),O
.,O
COVID-19,O
is,O
a,O
completely,O
new,O
disease,O
",",O
and,O
the,O
current,O
pandemic,O
dwarfs,O
previous,O
SARS,O
-,O
CoV-1,O
and,O
MERS,O
-,O
CoV,O
outbreaks,O
.,O
COVID-19,O
provides,O
us,O
with,O
a,O
tragic,O
but,O
unparalleled,O
opportunity,O
to,O
define,O
precisely,O
the,O
genetic,O
requirements,O
for,O
the,O
control,O
of,O
an,O
emerging,O
",",O
virulent,O
",",O
viral,O
infection,O
.,O
Amid,O
the,O
uncertainties,O
concerning,O
the,O
genetic,O
architecture,O
of,O
COVID-19,O
suceptibility,O
",",O
only,O
one,O
thing,O
is,O
almost,O
certain,O
:,O
as,O
for,O
other,O
infectious,O
diseases,O
",",O
there,O
will,O
be,O
considerable,O
genetic,O
heterogeneity,O
",",O
reflecting,O
the,O
multiple,O
layers,O
of,O
host,O
defense,O
that,O
a,O
virus,O
must,O
overcome,O
to,O
lead,O
to,O
mortality,O
.,O
The,O
analysis,O
and,O
comparison,O
of,O
genetic,O
variants,O
from,O
a,O
large,O
number,O
of,O
individuals,O
from,O
diverse,O
backgrounds,O
will,O
be,O
crucial,O
",",O
as,O
we,O
can,O
not,O
solely,O
rely,O
on,O
current,O
databases,O
of,O
data,O
for,O
“,O
healthy,O
”,O
individuals,O
to,O
identify,O
rare,O
variants,O
",",O
which,O
include,O
individuals,O
never,O
before,O
exposed,O
to,O
SARS,O
-,O
CoV-2,O
.,O
Once,O
candidate,O
genotypes,O
have,O
been,O
identified,O
",",O
their,O
contribution,O
to,O
the,O
pathogenicity,O
of,O
severe,O
COVID-19,O
will,O
be,O
investigated,O
with,O
in,O
-,O
depth,O
molecular,O
",",O
cellular,O
",",O
and,O
immunological,O
approaches,O
.,O
In,O
these,O
genetic,O
studies,O
",",O
we,O
aim,O
to,O
discover,O
the,O
pathogenesis,O
of,O
unexplained,O
",",O
severe,O
COVID-19,O
in,O
young,O
",",O
previously,O
healthy,O
patients,O
.,O
The,O
COVID-19,O
pandemic,O
should,O
make,O
us,O
consider,O
an,O
alternative,O
approach,O
to,O
studying,O
infectious,O
diseases,O
.,O
This,O
paradigm,O
shift,O
would,O
open,O
up,O
new,O
avenues,O
for,O
studying,O
host,O
-,O
pathogen,O
interactions,O
in,O
the,O
course,O
of,O
evolution,O
",",O
controlling,O
the,O
current,O
COVID-19,O
threat,O
in,O
the,O
general,O
population,O
",",O
and,O
developing,O
the,O
infrastructure,O
required,O
to,O
thwart,O
future,O
emerging,O
threats,O
.,O
By,O
August,O
2020,O
",",O
the,O
COVID-19,O
(,O
Coronavirus,O
Disease-2019,O
),O
pandemic,O
caused,O
more,O
than,O
20,O
million,O
confirmed,O
infections,O
and,O
more,O
than,O
700000,O
deaths,O
(,O
),O
.,O
Most,O
of,O
COVID-19,O
cases,O
are,O
mild,O
",",O
while,O
about,O
15,O
%,O
develop,O
severe,O
disease,O
that,O
results,O
in,O
acute,O
respiratory,O
distress,O
syndrome,O
associated,O
with,O
dysregulated,O
immune,O
response,O
",",O
systemic,O
inflammation,O
and,O
cytokine,O
storm,O
.,O
The,O
high,O
fatality,O
rate,O
of,O
COVID-19,O
may,O
be,O
partly,O
due,O
to,O
excessive,O
production,O
of,O
cytokines,O
and,O
inflammatory,O
mediators(cytokine,O
storm,O
),O
leading,O
to,O
a,O
hyperactive,O
non,O
-,O
productive,O
immune,O
state,O
causing,O
lung,O
and,O
other,O
organs,O
injury,O
(,O
Zhou,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
As,O
of,O
August,O
12,O
",",O
2020,O
",",O
there,O
are,O
more,O
than,O
200,O
host,O
genetics,O
studies,O
–,O
with,O
different,O
study,O
designs,O
–,O
trying,O
to,O
identify,O
possible,O
associations,O
between,O
human,O
genetic,O
variants,O
and,O
the,O
prognosis,O
of,O
COVID-19,O
patients,O
.,O
Most,O
of,O
these,O
studies,O
are,O
Genome,O
-,O
Wide,O
Association,O
Studies,O
(,O
GWAS,O
),O
and,O
depend,O
on,O
the,O
association,O
of,O
genetic,O
variations,O
with,O
different,O
phenotypes,O
such,O
as,O
severe,O
COVID-19,O
disease,O
(,O
),O
.,O
It,O
is,O
essential,O
for,O
these,O
investigators,O
to,O
have,O
a,O
list,O
of,O
candidate,O
genes,O
that,O
are,O
likely,O
to,O
be,O
involved,O
in,O
COVID-19,O
pathogenesis,O
.,O
Genomics,O
England,O
used,O
wide,O
inclusion,O
criteria,O
to,O
design,O
a,O
gene,O
panel,O
to,O
investigate,O
COVID-19,O
.,O
In,O
our,O
review,O
",",O
we,O
refine,O
this,O
panel,O
and,O
create,O
a,O
gene,O
list,O
of,O
the,O
most,O
likely,O
genes,O
that,O
might,O
be,O
involved,O
in,O
severe,O
COVID-19,O
disease,O
based,O
on,O
a,O
set,O
of,O
criteria,O
discussed,O
below,O
in,O
the,O
methods,O
section,O
.,O
These,O
criteria,O
dictate,O
that,O
our,O
curated,O
gene,O
list,O
contains,O
only,O
studies,O
on,O
humans,O
and,O
that,O
genetic,O
mutations,O
predisposed,O
to,O
severe,O
viral,O
infections,O
in,O
otherwise,O
healthy,O
individuals,O
(,O
in,O
case,O
report,O
studies,O
),O
or,O
predisposed,O
to,O
SARS,O
-,O
CoV,O
or,O
SARS,O
-,O
CoV-2,O
in,O
GWAS,O
studies,O
providing,O
the,O
highest,O
evidence,O
for,O
possible,O
involvement,O
in,O
severe,O
COVID-19,O
disease,O
.,O
This,O
gene,O
list,O
can,O
benefit,O
investigators,O
in,O
two,O
ways,O
:,O
the,O
first,O
one,O
is,O
to,O
make,O
sure,O
that,O
those,O
genes,O
are,O
present,O
in,O
gene,O
panels,O
used,O
for,O
host,O
genetic,O
studies,O
as,O
they,O
are,O
likely,O
candidates,O
of,O
association,O
with,O
severe,O
COVID-19,O
disease,O
.,O
In,O
addition,O
",",O
we,O
provide,O
new,O
insights,O
and,O
different,O
hypotheses,O
for,O
genes,O
involved,O
in,O
severe,O
COVID-19,O
disease,O
based,O
on,O
our,O
reviews,O
of,O
different,O
viral,O
susceptibility,O
studies,O
and,O
briefly,O
review,O
the,O
COVID-19,O
host,O
genetics,O
studies,O
published,O
up,O
to,O
this,O
date,O
.,O
Next,O
",",O
we,O
checked,O
the,O
OMIM,S-Repository
 ,O
database,O
to,O
find,O
the,O
related,O
studies,O
.,O
We,O
identified,O
40,O
genes,O
that,O
we,O
expect,O
to,O
be,O
highly,O
involved,O
in,O
host,O
genetic,O
susceptibility,O
to,O
severe,O
COVID-19,O
",",O
and,O
hence,O
deserve,O
consideration,O
during,O
design,O
and,O
interpretation,O
of,O
case,O
report,O
and,O
GWAS,O
studies,O
of,O
COVID-19,O
and,O
also,O
during,O
a,O
meta,O
-,O
analysis,O
of,O
different,O
GWAS,O
studies,O
.,O
In,O
some,O
cases,O
",",O
a,O
single,O
gene,O
(,O
e.g.,O
",",O
TLR3,O
),O
was,O
involved,O
in,O
predisposition,O
to,O
several,O
viruses,O
(,O
Lim,O
et,O
al,O
.,O
",",O
2019,O
;,O
Zhang,O
et,O
al,O
.,O
",",O
2007,O
),O
and,O
a,O
single,O
mutation,O
(,O
P,O
554S,O
),O
predisposed,O
to,O
different,O
viral,O
infections,O
(,O
HSE,O
and,O
ARDS,O
due,O
to,O
IAV,O
),O
which,O
support,O
our,O
hypothesis,O
of,O
the,O
possible,O
involvement,O
of,O
our,O
reviewed,O
genes,O
in,O
COVID-19,O
susceptibility,O
",",O
and,O
hence,O
the,O
need,O
for,O
a,O
candidate,O
gene,O
list,O
(,O
Lim,O
et,O
al,O
.,O
",",O
2019,O
;,O
Zhang,O
et,O
al,O
.,O
",",O
2007,O
),O
.,O
Accordingly,O
",",O
polymorphisms,O
in,O
C,O
-,O
lectin,O
genes,O
might,O
explain,O
severe,O
COVID-19,O
disease,O
.,O
Consequently,O
",",O
we,O
suggest,O
dendritic,O
cells,O
might,O
play,O
the,O
role,O
of,O
the,O
safe,O
house,O
for,O
SARS,O
-,O
CoV-2,O
explaining,O
many,O
cases,O
of,O
recurrent,O
COVID-19,O
disease,O
(,O
Ravioli,O
et,O
al,O
.,O
",",O
2020,O
;,O
Loconsole,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Inflammasome,O
activation,O
is,O
one,O
of,O
the,O
main,O
theories,O
for,O
explanation,O
of,O
the,O
cytokine,O
storm,O
during,O
COVID-19,O
causing,O
severe,O
manifestations,O
in,O
around,O
15,O
%,O
of,O
the,O
infected,O
population,O
(,O
van,O
den,O
Berg,O
and,O
te,O
Velde,O
",",O
2020,O
;,O
Rodrigues,O
et,O
al,O
.,O
",",O
2020,O
;,O
Freeman,O
and,O
Swartz,O
",",O
2020,O
),O
.,O
NLRP3,O
activation,O
in,O
COVID-19,O
patients,O
was,O
proven,O
in,O
vitro,O
in,O
PBMCs,O
and,O
tissues,O
of,O
COVID-19,O
patients,O
.,O
Additionally,O
",",O
higher,O
levels,O
of,O
IL-18,O
and,O
Casp1p20(Inflammasome,O
products,O
),O
-in,O
the,O
sera,O
of,O
COVID-19,O
patients-,O
were,O
associated,O
with,O
COVID-19,O
severity,O
and,O
poor,O
prognosis,O
(,O
Rodrigues,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Hence,O
",",O
we,O
invite,O
researchers,O
to,O
study,O
the,O
possible,O
involvement,O
of,O
NLRP1,O
in,O
severe,O
COVID-19,O
disease,O
.,O
We,O
searched,O
for,O
IL-18,O
inhibition,O
as,O
a,O
possible,O
treatment,O
option,O
for,O
severe,O
COVID-19,O
using,O
the,O
keywords,O
“,O
COVID-19,O
”,O
and,O
“,O
IL-18,O
”,O
in,O
clinicaltrials.gov,O
and,O
found,O
no,O
registered,O
clinical,O
trials,O
.,O
Accordingly,O
",",O
we,O
think,O
that,O
IL-18,O
inhibition,O
can,O
provide,O
a,O
therapeutic,O
option,O
in,O
patients,O
with,O
severe,O
COVID-19,O
disease,O
.,O
We,O
suggest,O
that,O
Inhibition,O
of,O
EndoU,O
in,O
SARS,O
-,O
CoV-2,O
might,O
represent,O
a,O
potential,O
therapeutic,O
target,O
in,O
COVID-19,O
patients,O
.,O
Additionally,O
",",O
higher,O
expression,O
of,O
antiviral,O
genes,O
is,O
not,O
always,O
a,O
good,O
prognostic,O
factor,O
as,O
in,O
the,O
example,O
of,O
MxA,O
which,O
we,O
should,O
investigate,O
and,O
take,O
into,O
consideration,O
during,O
interpretation,O
of,O
differential,O
gene,O
expression,O
studies,O
of,O
COVID-19,O
.,O
Accordingly,O
",",O
studying,O
close,O
family,O
members,O
is,O
essential,O
to,O
understand,O
the,O
penetrance,O
of,O
the,O
suspected,O
mutation,O
and,O
the,O
inheritance,O
pattern,O
which,O
can,O
help,O
us,O
in,O
prevention,O
and,O
prediction,O
of,O
severe,O
COVID-19,O
disease,O
in,O
susceptible,O
relatives,O
of,O
patients,O
.,O
Severe,O
COVID-19,O
risk,O
factors,O
include,O
old,O
age,O
",",O
smoking,O
and,O
preexisting,O
medical,O
conditions,O
such,O
as,O
diabetes,O
mellitus,O
",",O
hypertension,O
and,O
cardiovascular,O
disease,O
(,O
Ellinghaus,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Unexpected,O
clinical,O
manifestations,O
or,O
complications,O
from,O
infection,O
-e.g,O
.,O
COVID-19-,O
in,O
otherwise,O
healthy,O
individuals,O
are,O
a,O
suggestion,O
of,O
the,O
genetic,O
origin,O
of,O
susceptibility,O
.,O
Statistical,O
methods,O
are,O
essential,O
to,O
compare,O
genetic,O
variants,O
in,O
those,O
patients,O
with,O
a,O
matched,O
control,O
(,O
e.g.,O
general,O
population,O
or,O
other,O
family,O
members,O
who,O
tested,O
positive,O
without,O
severe,O
manifestation,O
or,O
complication,O
from,O
COVID-19,O
),O
.,O
Case,O
report,O
studies,O
of,O
COVID-19,O
represents,O
an,O
opportunity,O
for,O
researchers,O
to,O
identify,O
the,O
largest,O
number,O
of,O
genes,O
associated,O
with,O
severe,O
viral,O
infections,O
in,O
humans,O
and,O
to,O
confirm,O
previous,O
case,O
-,O
report,O
studies,O
of,O
viral,O
susceptibility,O
.,O
In,O
our,O
case,O
",",O
severe,O
COVID-19,O
affects,O
a,O
significant,O
number,O
of,O
the,O
population,O
and,O
different,O
factors,O
have,O
been,O
associated,O
with,O
severe,O
manifestation,O
",",O
and,O
it,O
is,O
time,O
for,O
GWAS,O
to,O
discover,O
the,O
role,O
of,O
common,O
and,O
rare,O
variants,O
-with,O
different,O
effect,O
sizes-,O
in,O
the,O
pathogenesis,O
of,O
the,O
disease,O
.,O
Accordingly,O
",",O
we,O
invite,O
GWAS,O
investigators,O
to,O
widen,O
their,O
inclusion,O
criteria,O
to,O
include,O
all,O
patients,O
of,O
different,O
age,O
groups,O
to,O
find,O
common,O
and,O
rare,O
variants,O
associated,O
with,O
severe,O
COVID-19,O
.,O
We,O
predict,O
that,O
GWAS,O
studies,O
are,O
more,O
able,O
to,O
discover,O
gene,O
regulation,O
elements,O
involved,O
in,O
COVID-19,O
susceptibility,O
more,O
than,O
case,O
report,O
studies,O
because,O
of,O
the,O
tendency,O
to,O
suspect,O
genetic,O
mutation,O
with,O
deleterious,O
effect,O
on,O
proteins,O
and,O
neglect,O
gene,O
regulatory,O
elements,O
in,O
case,O
report,O
studies,O
as,O
we,O
can,O
see,O
on,O
the,O
IUIS,O
list,O
and,O
also,O
because,O
of,O
the,O
wide,O
use,O
of,O
WGS,O
instead,O
of,O
WES,O
in,O
GWAS,O
(,O
Tangye,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
As,O
of,O
August,O
21,O
",",O
2020,O
",",O
we,O
found,O
5,O
studies,O
(,O
one,O
of,O
them,O
is,O
a,O
preprint,O
),O
associating,O
COVID-19,O
severity,O
with,O
different,O
genes,O
as,O
in,O
Table,O
2,O
(,O
Ellinghaus,O
et,O
al,O
.,O
",",O
2020,O
;,O
Kuo,O
et,O
al,O
.,O
",",O
2020,O
;,O
Lu,O
et,O
al,O
.,O
",",O
2020,O
;,O
Wu,O
et,O
al,O
.,O
",",O
2020,O
;,O
Zhao,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Three,O
studies,O
reported,O
that,O
ABO,O
genes,O
are,O
associated,O
with,O
severity,O
of,O
COVID-19,O
disease,O
and,O
that,O
blood,O
group,O
A,O
individuals,O
are,O
more,O
susceptible,O
to,O
risk,O
of,O
infection,O
and,O
severe,O
manifestation,O
while,O
blood,O
group,O
O,O
has,O
a,O
protective,O
effect,O
(,O
Wu,O
et,O
al,O
.,O
",",O
2020,O
;,O
Zhao,O
et,O
al,O
.,O
",",O
2020,O
;,O
Ellinghaus,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
largest,O
COVID-19,O
GWAS,O
published,O
recently,O
associates,O
the,O
locus,O
3p21.31,O
with,O
severe,O
manifestations,O
of,O
COVID-19(Mechanical,O
ventilation,O
),O
.,O
We,O
suggest,O
CCR1,O
and,O
CCR9,O
as,O
a,O
potential,O
therapeutic,O
target,O
in,O
COVID-19,O
patients,O
which,O
needs,O
further,O
investigations,O
.,O
Other,O
associated,O
genes,O
with,O
severe,O
COVID-19,O
are,O
described,O
in,O
Table,O
2,O
.,O
During,O
our,O
review,O
of,O
genes,O
potentially,O
involved,O
in,O
the,O
COVID-19,O
response,O
",",O
we,O
excluded,O
genes,O
differentially,O
expressed,O
in,O
patients,O
such,O
as,O
ACE2,O
and,O
TMPRSS2,O
genes,O
whose,O
polymorphisms,O
were,O
not,O
proven,O
to,O
be,O
associated,O
with,O
severe,O
COVID-19,O
(,O
Wen,O
et,O
al,O
.,O
",",O
2020,O
;,O
Sungnak,O
et,O
al,O
.,O
",",O
2020,O
;,O
Bilinska,O
et,O
al,O
.,O
",",O
2020,O
;,O
Hoffmann,O
et,O
al,O
.,O
",",O
2020,O
),O
because,O
we,O
wanted,O
our,O
study,O
to,O
be,O
restricted,O
to,O
genes,O
with,O
mutations,O
involved,O
directly,O
in,O
association,O
with,O
the,O
severe,O
disease,O
.,O
SARS,O
-,O
CoV-2,O
is,O
an,O
emergent,O
viral,O
disease,O
that,O
caused,O
millions,O
of,O
COVID-19,O
cases,O
all,O
over,O
the,O
world,O
.,O
There,O
is,O
increasing,O
evidence,O
that,O
severe,O
manifestations,O
of,O
COVID-19,O
might,O
be,O
attributed,O
to,O
human,O
genetic,O
variants,O
in,O
genes,O
related,O
to,O
immune,O
deficiency,O
and,O
or,O
inflammasome,O
activation,O
(,O
cytokine,O
storm,O
),O
.,O
Objective,O
 ,O
Identify,O
the,O
candidate,O
genes,O
that,O
are,O
likely,O
to,O
aid,O
in,O
explaining,O
severe,O
COVID-19,O
and,O
provide,O
insights,O
to,O
understand,O
the,O
pathogenesis,O
of,O
severe,O
COVID-19,O
.,O
In,O
this,O
article,O
",",O
we,O
systematically,O
reviewed,O
genes,O
related,O
to,O
viral,O
susceptibility,O
that,O
were,O
reported,O
in,O
human,O
genetic,O
studies,O
(,O
Case,O
-,O
reports,O
and,O
GWAS,O
),O
to,O
understand,O
the,O
role,O
of,O
host,O
viral,O
interactions,O
and,O
to,O
provide,O
insights,O
into,O
the,O
pathogenesis,O
of,O
severe,O
COVID-19,O
.,O
We,O
found,O
40,O
genes,O
associated,O
with,O
viral,O
susceptibility,O
and,O
21,O
of,O
them,O
were,O
associated,O
with,O
severe,O
SARS,O
-,O
CoV,O
disease,O
and,O
severe,O
COVID-19,O
.,O
This,O
compilation,O
represents,O
a,O
list,O
of,O
candidate,O
genes,O
that,O
are,O
likely,O
to,O
aid,O
in,O
explaining,O
severe,O
COVID-19,O
which,O
are,O
worthy,O
of,O
inclusion,O
in,O
gene,O
panels,O
and,O
during,O
meta,O
-,O
analysis,O
of,O
different,O
variants,O
in,O
host,O
genetics,O
studies,O
of,O
COVID-19,O
.,O
In,O
addition,O
",",O
we,O
provide,O
several,O
hypotheses,O
for,O
severe,O
COVID-19,O
and,O
possible,O
therapeutic,O
targets,O
.,O
The,O
recent,O
spread,O
of,O
a,O
novel,O
coronavirus,O
",",O
SARS‐CoV‐2,O
",",O
causing,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
",",O
represents,O
a,O
global,O
health,O
emergency,O
of,O
inconceivable,O
severity,O
",",O
characterized,O
by,O
a,O
remarkable,O
morbidity,O
and,O
mortality,O
worldwide,O
.,O
Coronavirus,O
disease-2019,O
(,O
COVID-19,O
),O
",",O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
-,O
coronavirus-2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
is,O
now,O
one,O
of,O
the,O
deadliest,O
pandemics,O
in,O
modern,O
history,O
.,O
The,O
mode,O
of,O
infection,O
of,O
COVID-19,O
is,O
thought,O
to,O
be,O
direct,O
entry,O
of,O
the,O
SARS,O
-,O
CoV-2,O
virus,O
into,O
cells,O
via,O
the,O
human,O
angiotensin,O
-,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
receptor,O
",",O
which,O
is,O
expressed,O
predominantly,O
in,O
the,O
lungs,O
but,O
also,O
throughout,O
the,O
cardiovascular,O
system,O
(,O
1,O
),O
.,O
Thus,O
",",O
although,O
the,O
most,O
virulent,O
manifestation,O
of,O
COVID-19,O
is,O
acute,O
respiratory,O
distress,O
syndrome,O
",",O
reports,O
from,O
Europe,O
and,O
China,O
have,O
also,O
demonstrated,O
cardiac,O
injury,O
reflected,O
through,O
elevated,O
troponin,O
concentrations,O
among,O
infected,O
patients,O
(,O
2,O
",",O
3,O
",",O
4,O
",",O
5,O
),O
.,O
In,O
these,O
limited,O
case,O
series,O
",",O
troponin,O
elevation,O
was,O
more,O
common,O
in,O
patients,O
with,O
pre,O
-,O
existing,O
cardiovascular,O
disease,O
(,O
CVD,O
),O
and,O
",",O
when,O
present,O
",",O
was,O
associated,O
with,O
higher,O
rates,O
of,O
adverse,O
outcomes,O
in,O
patients,O
hospitalized,O
with,O
COVID-19,O
(,O
6,O
),O
.,O
During,O
the,O
study,O
period,O
",",O
"3,069",O
COVID-19,O
positive,O
patients,O
were,O
hospitalized,O
at,O
1,O
of,O
5,O
MSHS,O
New,O
York,O
City,O
hospitals,O
.,O
Of,O
"2,736",O
COVID-19,O
patients,O
included,O
in,O
our,O
study,O
",",O
506,O
(,O
18.5,O
%,O
),O
died,O
",",O
"1,132",O
(,O
41.4,O
%,O
),O
were,O
discharged,O
",",O
and,O
"1,098",O
(,O
40.1,O
%,O
),O
remained,O
hospitalized,O
at,O
the,O
time,O
of,O
data,O
freeze,O
for,O
this,O
report,O
.,O
Although,O
pulmonary,O
manifestations,O
are,O
its,O
most,O
common,O
consequence,O
",",O
COVID-19,O
causes,O
systemic,O
inflammation,O
with,O
varying,O
presentations,O
of,O
cardiac,O
involvement,O
as,O
well,O
(,O
10,O
),O
.,O
In,O
this,O
multihospital,O
retrospective,O
cohort,O
study,O
of,O
nearly,O
"3,000",O
patients,O
",",O
we,O
demonstrate,O
the,O
following,O
observations,O
:,O
1,O
),O
myocardial,O
injury,O
is,O
common,O
among,O
patients,O
hospitalized,O
with,O
COVID-19,O
but,O
is,O
more,O
often,O
mild,O
",",O
associated,O
with,O
low,O
-,O
level,O
elevation,O
in,O
troponin,O
concentration,O
;,O
2,O
),O
more,O
significant,O
myocardial,O
injury,O
may,O
be,O
associated,O
with,O
more,O
than,O
a,O
tripling,O
in,O
risk,O
of,O
mortality,O
;,O
and,O
3,O
),O
COVID-19,O
patients,O
with,O
a,O
history,O
of,O
CVD,O
are,O
more,O
likely,O
to,O
experience,O
myocardial,O
injury,O
than,O
patients,O
without,O
CVD,O
but,O
without,O
obvious,O
corroborating,O
evidence,O
for,O
primary,O
acute,O
myocardial,O
infarction,O
(,O
Central,O
Illustration,O
),O
.,O
Despite,O
several,O
reports,O
of,O
COVID-19,O
associated,O
myocarditis,O
",",O
to,O
date,O
",",O
no,O
case,O
has,O
demonstrated,O
COVID-19,O
genome,O
in,O
cardiac,O
tissue,O
on,O
biopsy,O
or,O
autopsy,O
accompanied,O
by,O
troponin,O
elevation,O
consistent,O
with,O
criteria,O
used,O
to,O
diagnose,O
myocarditis,O
(,O
3,O
",",O
4,O
",",O
"5,14",O
",",O
15,O
",",O
16,O
),O
.,O
Other,O
postulated,O
mechanisms,O
by,O
which,O
COVID-19,O
leads,O
to,O
cardiovascular,O
morbidity,O
include,O
direct,O
myocardial,O
injury,O
as,O
a,O
result,O
of,O
the,O
inflammatory,O
cascade,O
or,O
cytokine,O
release,O
",",O
microvascular,O
damage,O
due,O
to,O
disseminated,O
intravascular,O
coagulation,O
and,O
thrombosis,O
",",O
direct,O
entry,O
of,O
SARS,O
-,O
CoV-2,O
into,O
myocardial,O
cells,O
via,O
binding,O
to,O
ACE2,O
receptors,O
",",O
hypoxemia,O
combined,O
with,O
increased,O
metabolic,O
demands,O
of,O
acute,O
illness,O
leading,O
to,O
myocardial,O
injury,O
akin,O
to,O
type,O
2,O
myocardial,O
infarction,O
",",O
and,O
finally,O
",",O
acute,O
coronary,O
syndrome,O
from,O
acute,O
inflammation,O
-,O
triggered,O
destabilization,O
of,O
atheromas,O
(,O
17,O
",",O
18,O
",",O
19,O
),O
.,O
In,O
a,O
recent,O
case,O
series,O
of,O
18,O
patients,O
with,O
COVID-19,O
infection,O
and,O
ST,O
-,O
segment,O
elevation,O
on,O
electrocardiogram,O
",",O
10,O
were,O
deemed,O
to,O
have,O
noncoronary,O
myocardial,O
injury,O
by,O
virtue,O
of,O
nonobstructive,O
disease,O
on,O
coronary,O
angiography,O
and/or,O
normal,O
wall,O
motion,O
 ,O
on,O
echocardiography,O
(,O
20,O
),O
.,O
Despite,O
lower,O
troponin,O
 ,O
concentrations,O
in,O
this,O
group,O
",",O
9,O
died,O
as,O
opposed,O
to,O
4,O
of,O
8,O
in,O
the,O
ST,O
-,O
segment,O
elevation,O
MI,O
group,O
",",O
which,O
may,O
suggest,O
higher,O
mortality,O
associated,O
with,O
nonischemic,O
mediated,O
myocardial,O
injury,O
in,O
the,O
setting,O
of,O
COVID-19,O
;,O
however,O
",",O
more,O
data,O
are,O
needed,O
.,O
The,O
benefit,O
of,O
statins,O
in,O
the,O
setting,O
of,O
myocardial,O
injury,O
is,O
well,O
established,O
(,O
27,O
",",O
28,O
",",O
29,O
),O
",",O
yet,O
whether,O
statins,O
confer,O
an,O
anti,O
-,O
inflammatory,O
effect,O
or,O
allow,O
for,O
amelioration,O
of,O
endothelial,O
dysfunction,O
in,O
COVID-19,O
have,O
not,O
been,O
elucidated,O
.,O
Interestingly,O
",",O
higher,O
BMI,O
was,O
associated,O
with,O
increased,O
mortality,O
in,O
the,O
setting,O
of,O
COVID-19,O
among,O
our,O
cohort,O
",",O
consistent,O
with,O
a,O
prior,O
report,O
(,O
30,O
),O
.,O
The,O
degree,O
of,O
myocardial,O
injury,O
",",O
as,O
reflected,O
by,O
troponin,O
elevation,O
",",O
and,O
associated,O
outcomes,O
among,O
U.S.,O
hospitalized,O
patients,O
with,O
coronavirus,O
disease-2019,O
(,O
COVID-19,O
),O
are,O
unknown,O
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
describe,O
the,O
degree,O
of,O
myocardial,O
injury,O
and,O
associated,O
outcomes,O
in,O
a,O
large,O
hospitalized,O
cohort,O
with,O
laboratory,O
-,O
confirmed,O
COVID-19,O
.,O
Methods,O
 ,O
Patients,O
with,O
COVID-19,O
admitted,O
to,O
1,O
of,O
5,O
Mount,O
Sinai,O
Health,O
System,O
hospitals,O
in,O
New,O
York,O
City,O
between,O
February,O
27,O
",",O
2020,O
",",O
and,O
April,O
12,O
",",O
2020,O
",",O
with,O
troponin,O
-,O
I,O
(,O
normal,O
value,O
 ,O
<,O
0.03,O
 ,O
ng,O
/,O
ml,O
),O
measured,O
within,O
24,O
 ,O
h,O
of,O
admission,O
were,O
included,O
(,O
n,O
 ,O
=,O
 ,O
"2,736",O
),O
.,O
Conclusions,O
 ,O
Myocardial,O
injury,O
is,O
prevalent,O
among,O
patients,O
hospitalized,O
with,O
COVID-19,O
;,O
however,O
",",O
troponin,O
concentrations,O
were,O
generally,O
present,O
at,O
low,O
levels,O
.,O
Troponin,O
elevation,O
among,O
patients,O
hospitalized,O
with,O
COVID-19,O
is,O
associated,O
with,O
higher,O
risk,O
of,O
 ,O
mortality,O
.,O
The,O
fast,O
-,O
spreading,O
of,O
COVID-19,O
raised,O
a,O
notion,O
that,O
mutations,O
may,O
drive,O
its,O
evolution,O
.,O
The,O
genome,O
of,O
COVID-19,O
is,O
evoluted,O
from,O
SARS-,O
CoV,O
and,O
MERS,O
CoV6,O
.,O
Comparison,O
of,O
the,O
genome,O
sequences,O
of,O
the,O
COVID-19,O
",",O
SARS,O
-,O
CoV,O
",",O
and,O
MERS,O
-,O
CoV,O
showed,O
that,O
2019,O
-,O
CoV,O
has,O
better,O
sequence,O
identity,O
with,O
SARS,O
-,O
CoV,O
than,O
the,O
MERS,O
CoV6,O
.,O
Kabir,O
et,O
al,O
.,O
[,O
3,O
],O
extensively,O
reviewed,O
factors,O
that,O
affect,O
COVID-19,O
genetic,O
diversity,O
and,O
its,O
evolution,O
.,O
The,O
COVID-19,O
has,O
a,O
unique,O
amino,O
acid,O
sequence,O
from,O
other,O
coronaviruses,O
entirely,O
in,O
the,O
regions,O
of,O
1ab,O
polyprotein,O
and,O
surface,O
glycoprotein,O
or,O
S,O
-,O
protein,O
.,O
Studies,O
indicate,O
that,O
the,O
human,O
receptor,O
for,O
COVID-19,O
could,O
be,O
angiotensin,O
-,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
virus,O
is,O
spreading,O
rapidly,O
worldwide,O
",",O
and,O
the,O
global,O
interested,O
scientists,O
are,O
endeavoring,O
to,O
discover,O
drugs,O
for,O
its,O
efficacious,O
treatment,O
.,O
Chloroquine,O
phosphate,O
",",O
an,O
old,O
drug,O
for,O
the,O
treatment,O
of,O
malaria,O
",",O
is,O
shown,O
to,O
have,O
apparent,O
efficacy,O
and,O
acceptable,O
safety,O
against,O
COVID-19,O
associated,O
pneumonia,O
in,O
multicenter,O
clinical,O
trials,O
conducted,O
in,O
China,O
[,O
5,O
],O
.,O
Excessive,O
inflammation,O
",",O
oxidation,O
",",O
and,O
an,O
exaggerated,O
immune,O
response,O
very,O
likely,O
contribute,O
to,O
COVID-19,O
pathology,O
.,O
The,O
authors,O
in,O
this,O
report,O
concluded,O
that,O
a,O
synthesized,O
mRNA,O
of,O
COVID,O
19,O
vaccine,O
-,O
induced,O
anti,O
–,O
SARS,O
-,O
CoV-2,O
immune,O
responses,O
in,O
all,O
participants,O
",",O
and,O
no,O
trial,O
-,O
limiting,O
safety,O
concerns,O
were,O
identified,O
.,O
Recently,O
",",O
a,O
complete,O
genome,O
sequence,O
for,O
a,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
strain,O
isolated,O
from,O
an,O
oropharyngeal,O
swab,O
specimen,O
of,O
a,O
Nepalese,O
patient,O
with,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
was,O
published,O
in,O
GenBank,S-Repository
 ,O
(,O
accession,O
number,O
NC_045512,S-AccessionNumber
),O
",",O
excluding,O
the,O
poly(A,O
),O
tail,O
of,O
the,O
genome,O
[,O
14,O
],O
.,O
Taking,O
this,O
advantage,O
",",O
we,O
hypothesized,O
that,O
designing,O
a,O
synthetic,O
miRNA,O
complemented,O
to,O
COVID-19,O
at,O
3′,O
UTR,O
and,O
another,O
essential,O
region,O
",",O
including,O
ORF9,O
",",O
which,O
encodes,O
a,O
nucleocapsid,O
phosphoprotein,O
(,O
N,O
),O
.,O
This,O
protein,O
is,O
a,O
basic,O
RNA,O
-,O
binding,O
protein,O
encoded,O
in,O
the,O
most,O
3′,O
protein,O
of,O
the,O
COVID,O
genome,O
",",O
plays,O
both,O
structural,O
and,O
non,O
-,O
structural,O
roles,O
in,O
infection,O
.,O
The,O
3′,O
UTR,O
region,O
and,O
ORF9,O
of,O
COVID-19,O
were,O
identified,O
using,O
the,O
sequence,O
(,O
Acc,O
.,O
#,O
:,O
NC_045512,S-AccessionNumber
),O
.,O
Therefore,O
",",O
Thei,O
-,O
score,O
designer,O
(,O
www.med.nagoya-u.ac.jp/neurogenetics/i_Score/i_score.html,O
),O
was,O
used,O
to,O
deduce,O
some,O
candidates,O
of,O
miRNAs,O
complemented,O
of,O
COVID-19,O
.,O
As,O
pandemic,O
",",O
COVID-19,O
",",O
and,O
its,O
consequences,O
on,O
the,O
global,O
economy,O
",",O
we,O
hypothesized,O
a,O
new,O
approach,O
for,O
the,O
treatment,O
of,O
COVID-19,O
paints,O
.,O
This,O
approach,O
includes,O
designing,O
a,O
mix,O
of,O
miRNAs,O
targeting,O
several,O
regions,O
on,O
COVID-19,O
open,O
reading,O
frame,O
(,O
ORF,O
),O
and,O
3,O
UTR,O
and,O
suitable,O
delivery,O
system,O
targeting,O
respiratory,O
system,O
tissues,O
.,O
The,O
emergence,O
and,O
spread,O
of,O
2019,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
and,O
the,O
possible,O
development,O
of,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
it,O
brings,O
",",O
has,O
led,O
us,O
to,O
a,O
public,O
health,O
crisis,O
",",O
threatening,O
the,O
world,O
and,O
its,O
population,O
",",O
since,O
and,O
all,O
groups,O
and,O
ages,O
are,O
susceptible,O
(,O
Singhal,O
",",O
2020,O
),O
.,O
Infected,O
patients,O
may,O
never,O
develop,O
any,O
symptoms,O
;,O
and,O
the,O
ones,O
affected,O
by,O
COVID-19,O
may,O
present,O
variable,O
clinical,O
conditions,O
",",O
from,O
loss,O
of,O
smell,O
and,O
taste,O
",",O
to,O
mild,O
respiratory,O
issues,O
",",O
and,O
with,O
the,O
possibility,O
of,O
severe,O
symptoms,O
such,O
as,O
respiratory,O
insufficiency,O
",",O
that,O
can,O
result,O
in,O
death,O
(,O
Singhal,O
",",O
2020,O
),O
.,O
The,O
SARS,O
-,O
CoV-2,O
virus,O
particles,O
are,O
transmitted,O
by,O
symptomatic,O
or,O
asymptomatic,O
carrier,O
people,O
",",O
and,O
in,O
the,O
case,O
of,O
people,O
developing,O
COVID-19,O
",",O
the,O
propagation,O
begins,O
days,O
before,O
the,O
onset,O
of,O
symptoms,O
",",O
in,O
form,O
of,O
large,O
droplets,O
during,O
coughing,O
and,O
sneezing,O
(,O
Rothe,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
and,O
possibly,O
even,O
during,O
normal,O
conversations,O
",",O
what,O
results,O
in,O
a,O
disseminated,O
mass,O
contagion,O
(,O
Stadnytskyi,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
face,O
of,O
this,O
scenario,O
",",O
of,O
a,O
highly,O
infective,O
disease,O
with,O
potential,O
to,O
cause,O
death,O
",",O
it,O
has,O
been,O
previously,O
shown,O
that,O
people,O
with,O
a,O
pre,O
-,O
existing,O
chronic,O
medical,O
condition,O
such,O
as,O
obesity,O
are,O
more,O
susceptible,O
to,O
develop,O
severe,O
COVID-19,O
outcomes,O
(,O
Chen,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Obesity,O
has,O
an,O
impact,O
on,O
pulmonary,O
function,O
as,O
it,O
leads,O
to,O
decreased,O
functional,O
capacity,O
and,O
respiratory,O
system,O
compliance,O
;,O
a,O
fact,O
that,O
may,O
explain,O
the,O
impact,O
of,O
COVID-19,O
on,O
these,O
patients,O
.,O
Furthermore,O
",",O
increased,O
inflammatory,O
cytokines,O
may,O
contribute,O
to,O
the,O
increased,O
morbidity,O
associated,O
with,O
obesity,O
in,O
COVID-19,O
infections,O
(,O
Dietz,O
and,O
Santos,O
-,O
Burgoa,O
",",O
2020,O
),O
.,O
The,O
more,O
frequent,O
development,O
of,O
severe,O
form,O
of,O
COVID-19,O
in,O
patients,O
with,O
chronic,O
medical,O
conditions,O
is,O
possibly,O
related,O
to,O
the,O
role,O
of,O
angiotensin,O
-,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
in,O
the,O
viral,O
infection,O
(,O
Wang,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Adipocytes,O
and,O
adipocyte,O
-,O
like,O
cells,O
",",O
such,O
as,O
pulmonary,O
lipofibroblasts,O
",",O
may,O
play,O
an,O
important,O
role,O
in,O
the,O
pathogenic,O
response,O
to,O
COVID-19,O
",",O
especially,O
in,O
obese,O
and,O
diabetic,O
individuals,O
;,O
in,O
these,O
individuals,O
",",O
the,O
ACE2,O
is,O
increased,O
which,O
turns,O
adipose,O
tissue,O
into,O
a,O
potential,O
target,O
and,O
viral,O
reservoir,O
(,O
Kruglikov,O
and,O
Scherer,O
",",O
2020,O
),O
.,O
Recently,O
",",O
a,O
molecular,O
study,O
conducted,O
with,O
700,O
lung,O
transcriptome,O
samples,O
from,O
patients,O
with,O
comorbidities,O
",",O
cardiovascular,O
diseases,O
",",O
familial,O
primary,O
pulmonary,O
hypertension,O
",",O
hypertension,O
and,O
pulmonary,O
hypertension,O
",",O
associated,O
with,O
severe,O
COVID-19,O
showed,O
that,O
ACE2,O
is,O
more,O
expressed,O
in,O
these,O
patients,O
than,O
in,O
control,O
individuals,O
(,O
Pinto,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
addition,O
",",O
there,O
are,O
other,O
reports,O
that,O
contain,O
other,O
several,O
genes,O
with,O
potential,O
importance,O
for,O
SARS,O
-,O
CoV-2,O
 ,O
cell,O
cycle,O
and,O
invasion,O
/,O
attachment,O
",",O
that,O
have,O
been,O
shown,O
to,O
be,O
up,O
-,O
regulated,O
in,O
patients,O
with,O
severe,O
COVID-19,O
comorbidities,O
",",O
such,O
as,O
:,O
ADAM,O
metallopeptidase,O
domain,O
10,O
(,O
ADAM10,O
),O
",",O
toll,O
like,O
receptor,O
3,O
(,O
TLR3,O
),O
",",O
histone,O
acetyltransferase,O
1,O
(,O
HAT1,O
),O
",",O
histone,O
deacetylase,O
2,O
(,O
HDAC2,O
),O
",",O
lysine,O
demethylase,O
5B,O
(,O
KDM5B,O
),O
",",O
sirtuin,O
1,O
(,O
SIRT1,O
),O
",",O
member,O
RAS,O
oncogene,O
family,O
(,O
RAB1A,O
),O
",",O
transmembrane,O
serine,O
protease,O
2,O
(,O
TMPRSS2,O
),O
",",O
and,O
furin,O
paired,O
basic,O
amino,O
acid,O
cleaving,O
enzyme,O
(,O
FURIN,O
),O
(,O
Pinto,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
RNA,O
-,O
Seq,O
analysis,O
was,O
selected,O
in,O
order,O
to,O
perform,O
a,O
“,O
free,O
”,O
investigation,O
of,O
the,O
genes,O
expressed,O
in,O
the,O
cells,O
",",O
because,O
RNA,O
-,O
Seq,O
does,O
not,O
require,O
predesigned,O
probes,O
",",O
the,O
data,O
sets,O
are,O
unbiased,O
",",O
allowing,O
for,O
hypothesis,O
-,O
free,O
experimental,O
design,O
.,O
ACE2,O
is,O
widely,O
expressed,O
in,O
adipocytes,O
and,O
enriched,O
in,O
adipocytes,O
of,O
individuals,O
with,O
obesity,O
and,O
type,O
II,O
diabetes,O
;,O
there,O
are,O
ACE2,O
regulator,O
genes,O
in,O
the,O
human,O
lung,O
",",O
and,O
the,O
protein,O
is,O
used,O
by,O
SARS,O
-,O
CoV-2,O
to,O
infect,O
alveolar,O
epithelial,O
cells,O
",",O
resulting,O
in,O
the,O
development,O
of,O
COVID-19,O
(,O
Kruglikov,O
and,O
Scherer,O
",",O
2020,O
),O
.,O
In,O
our,O
transcriptome,O
data,O
from,O
human,O
subcutaneous,O
adipocytes,O
",",O
there,O
was,O
no,O
detection,O
of,O
ACE2,O
expression,O
",",O
what,O
is,O
probably,O
due,O
to,O
the,O
fact,O
that,O
the,O
subcutaneous,O
adipocytes,O
used,O
are,O
from,O
normal,O
individuals,O
",",O
and,O
the,O
expression,O
of,O
ACE2,O
is,O
low,O
to,O
the,O
point,O
that,O
it,O
might,O
be,O
undetected,O
by,O
the,O
parameters,O
determined,O
in,O
our,O
study,O
for,O
the,O
RNA,O
-,O
seq,O
technique,O
;,O
however,O
the,O
cell,O
line,O
showed,O
the,O
expression,O
of,O
multiple,O
genes,O
related,O
to,O
severe,O
COVID-,O
19,O
",",O
such,O
as,O
FURIN,O
",",O
ADAM10,O
",",O
TLR3,O
",",O
KDM5B,O
",",O
SIRT1,O
and,O
TRIB3,O
.,O
FURIN,O
cleaves,O
SARS,O
-,O
CoV-2,O
spike,O
(,O
S,O
),O
glycoprotein,O
",",O
the,O
key,O
protein,O
used,O
to,O
infect,O
mammal,O
cells,O
(,O
Walls,O
et,O
al,O
.,O
",",O
2020,O
),O
;,O
ADAM10,O
is,O
correlated,O
with,O
ACE2,O
cleavage,O
regulation,O
in,O
human,O
airway,O
epithelia,O
(,O
Jia,O
et,O
al,O
.,O
",",O
2009,O
),O
;,O
TLR3,O
plays,O
an,O
important,O
role,O
in,O
the,O
innate,O
response,O
to,O
SARS,O
-,O
CoV,O
or,O
MERS,O
-,O
CoV,O
infection,O
and,O
regulates,O
ACE2,O
cleavage,O
(,O
Totura,O
et,O
al,O
.,O
",",O
2015,O
),O
;,O
KDM5B,O
regulates,O
positively,O
ACE2,O
(,O
Wu,O
et,O
al,O
.,O
",",O
2018,O
),O
;,O
in,O
more,O
than,O
57,O
%,O
addressed,O
studies,O
",",O
researchers,O
found,O
that,O
SIRT1,O
was,O
upregulated,O
in,O
the,O
lung,O
of,O
patients,O
with,O
severe,O
COVID-19,O
comorbidities,O
;,O
all,O
these,O
genes,O
favor,O
the,O
viral,O
infection,O
and,O
can,O
be,O
potential,O
targets,O
for,O
preventing,O
SARS,O
-,O
CoV-2,O
spread,O
(,O
Pinto,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
On,O
the,O
other,O
hand,O
",",O
TRIB3,O
gene,O
has,O
been,O
linked,O
to,O
fatty,O
acid,O
synthesis,O
control,O
and,O
insulin,O
resistance,O
",",O
in,O
addition,O
to,O
regulating,O
plasma,O
levels,O
of,O
triglycerides,O
and,O
HDL,O
cholesterol,O
in,O
humans,O
(,O
Angyal,O
and,O
Kiss,O
-,O
Toth,O
",",O
2012,O
),O
and,O
was,O
previously,O
reported,O
to,O
decrease,O
virus,O
infection,O
and,O
replication,O
;,O
so,O
TRIB3,O
can,O
be,O
considered,O
a,O
therapeutic,O
target,O
for,O
COVID-19,O
(,O
Moraes,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
clinical,O
characteristics,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
are,O
varied,O
and,O
are,O
similar,O
to,O
those,O
described,O
above,O
by,O
ARDS,O
e,O
ALI,O
(,O
Chen,O
et,O
al,O
.,O
",",O
2020,O
;,O
Rubenfeld,O
et,O
al,O
.,O
",",O
2005,O
;,O
Wheeler,O
and,O
Bernard,O
",",O
2007,O
;,O
Matthay,O
et,O
al,O
.,O
",",O
2012,O
;,O
Imai,O
et,O
al,O
.,O
",",O
2008,O
;,O
Yu,O
et,O
al,O
.,O
",",O
2016,O
),O
",",O
a,O
fact,O
that,O
reinforces,O
testing,O
irisin,O
in,O
cases,O
of,O
COVID-19,O
.,O
The,O
data,O
presented,O
by,O
Pinto,O
et,O
al,O
.,O
(,O
2020,O
),O
and,O
Moraes,O
et,O
al,O
.,O
",",O
2020,O
(,O
Moraes,O
et,O
al,O
.,O
",",O
2020,O
),O
offer,O
gene,O
targets,O
for,O
preventing,O
severe,O
COVID-19,O
.,O
In,O
conclusion,O
",",O
irisin,O
presented,O
a,O
very,O
positive,O
effect,O
in,O
the,O
regulation,O
of,O
diverse,O
genes,O
related,O
to,O
the,O
COVID-19,O
outcome,O
in,O
the,O
adipose,O
tissue,O
",",O
causing,O
reduction,O
of,O
genes,O
implicated,O
in,O
elevated,O
viral,O
infection,O
",",O
and,O
increase,O
in,O
genes,O
that,O
block,O
virus,O
-,O
cell,O
cleavage,O
;,O
these,O
results,O
indicate,O
that,O
irisin,O
treatment,O
could,O
end,O
in,O
a,O
reduction,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
rate,O
in,O
human,O
cells,O
.,O
The,O
obesity,O
is,O
associated,O
with,O
an,O
increased,O
recruitment,O
of,O
macrophages,O
in,O
the,O
adipose,O
tissue,O
(,O
Weisberg,O
et,O
al,O
.,O
",",O
2003,O
),O
",",O
and,O
irisin,O
modulates,O
macrophage,O
activity,O
by,O
reducing,O
reactive,O
oxygen,O
species,O
(,O
ROS,O
),O
overproduction,O
and,O
increasing,O
the,O
expression,O
of,O
anti,O
-,O
oxidative,O
stress,O
factors,O
(,O
Mazur,O
-,O
Bialy,O
",",O
2017,O
;,O
Mazur,O
-,O
Bialy,O
et,O
al,O
.,O
",",O
2018,O
),O
;,O
thus,O
",",O
the,O
beneficial,O
effects,O
of,O
irisin,O
not,O
only,O
depend,O
on,O
the,O
positive,O
effect,O
on,O
the,O
regulation,O
of,O
diverse,O
genes,O
related,O
to,O
the,O
COVID-19,O
outcome,O
in,O
the,O
adipose,O
tissue,O
",",O
but,O
also,O
to,O
its,O
anti,O
-,O
inflammatory,O
properties,O
related,O
to,O
the,O
targeting,O
of,O
macrophages,O
.,O
Since,O
the,O
respiratory,O
system,O
is,O
the,O
most,O
considerably,O
affected,O
in,O
COVID-19,O
",",O
the,O
effect,O
of,O
irisin,O
in,O
the,O
lung,O
tissue,O
and,O
the,O
resulting,O
gene,O
expression,O
must,O
be,O
tested,O
.,O
This,O
might,O
evoke,O
a,O
COVID-19,O
therapeutic,O
strategy,O
to,O
stimulate,O
TRIB3,O
expression,O
and,O
decrease,O
ACE2,O
regulatory,O
genes,O
",",O
possibly,O
aiding,O
patients,O
with,O
both,O
mild,O
outcomes,O
as,O
well,O
as,O
the,O
ones,O
suffering,O
from,O
severe,O
COVID-19,O
.,O
Obesity,O
patients,O
are,O
more,O
susceptible,O
to,O
develop,O
COVID-19,O
severe,O
outcome,O
due,O
to,O
the,O
role,O
of,O
angiotensin,O
-,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
in,O
the,O
viral,O
infection,O
.,O
Our,O
results,O
",",O
in,O
human,O
subcutaneous,O
adipocytes,O
cell,O
culture,O
",",O
indicate,O
a,O
positive,O
effect,O
of,O
irisin,O
on,O
the,O
expression,O
of,O
multiple,O
genes,O
related,O
to,O
viral,O
infection,O
by,O
SARS,O
-,O
CoV-2,O
;,O
furthermore,O
",",O
translatable,O
for,O
other,O
tissues,O
and,O
organs,O
targeted,O
by,O
the,O
novel,O
coronavirus,O
and,O
present,O
",",O
thus,O
",",O
promising,O
approaches,O
for,O
the,O
treatment,O
of,O
COVID-19,O
infection,O
as,O
therapeutic,O
strategy,O
to,O
decrease,O
ACE2,O
regulatory,O
genes,O
.,O
This,O
virus,O
",",O
SARS,O
-,O
CoV-2,O
",",O
which,O
causes,O
the,O
COVID-19,O
disease,O
",",O
emerged,O
in,O
China,O
from,O
bats,O
into,O
a,O
presumed,O
intermediate,O
species,O
and,O
then,O
into,O
humans,O
.,O
In,O
early,O
March,O
2020,O
",",O
the,O
GISAID,S-Dataset
 ,O
database,O
(,O
https://www.gisaid.org/,S-URL
),O
contained,O
a,O
compilation,O
of,O
253,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
complete,O
and,O
partial,O
genomes,O
contributed,O
by,O
clinicians,O
and,O
researchers,O
from,O
across,O
the,O
world,O
since,O
December,O
2019,O
.,O
The,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
Avian,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
was,O
founded,O
in,O
2006,O
",",O
and,O
",",O
since,O
2010,O
",",O
has,O
been,O
hosted,O
by,O
the,O
German,O
Federal,O
Ministry,O
of,O
Food,O
",",O
Agriculture,O
and,O
Consumer,O
Protection,O
.,O
GISAID,S-Dataset
 ,O
has,O
also,O
become,O
a,O
coronavirus,O
repository,O
since,O
December,O
2019,O
.,O
As,O
of,O
4,O
March,O
2020,O
",",O
the,O
cutoff,O
point,O
for,O
our,O
phylogenetic,O
analysis,O
",",O
the,O
GISAID,S-Dataset
 ,O
database,O
(,O
https://www.gisaid.org/,S-URL
),O
had,O
compiled,O
254,O
coronavirus,O
genomes,O
",",O
isolated,O
from,O
244,O
humans,O
",",O
nine,O
Chinese,O
pangolins,O
",",O
and,O
one,O
bat,O
Rhinolophus,O
affinis,O
(,O
BatCoVRaTG13,O
from,O
Yunnan,O
Province,O
",",O
China,O
),O
.,O
The,O
network,O
faithfully,O
traces,O
routes,O
of,O
infections,O
for,O
documented,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
cases,O
",",O
indicating,O
that,O
phylogenetic,O
networks,O
can,O
likewise,O
be,O
successfully,O
used,O
to,O
help,O
trace,O
undocumented,O
COVID-19,O
infection,O
sources,O
",",O
which,O
can,O
then,O
be,O
quarantined,O
to,O
prevent,O
recurrent,O
spread,O
of,O
the,O
disease,O
worldwide,O
.,O
Objective,O
 ,O
Management,O
of,O
acute,O
severe,O
UC,O
(,O
ASUC,O
),O
during,O
the,O
novel,O
COVID-19,O
pandemic,O
presents,O
significant,O
dilemmas,O
.,O
We,O
aimed,O
to,O
provide,O
COVID-19,O
-,O
specific,O
guidance,O
using,O
current,O
British,O
Society,O
of,O
Gastroenterology,O
(,O
BSG,O
),O
guidelines,O
as,O
a,O
reference,O
point,O
.,O
We,O
convened,O
a,O
RAND,O
appropriateness,O
panel,O
comprising,O
14,O
gastroenterologists,O
and,O
an,O
IBD,O
nurse,O
consultant,O
supplemented,O
by,O
surgical,O
and,O
COVID-19,O
experts,O
.,O
Patients,O
with,O
a,O
positive,O
swab,O
should,O
be,O
discussed,O
with,O
COVID-19,O
specialists,O
.,O
As,O
per,O
BSG,O
guidance,O
",",O
intravenous,O
hydrocortisone,O
was,O
considered,O
appropriate,O
as,O
initial,O
management,O
;,O
only,O
in,O
patients,O
with,O
COVID-19,O
pneumonia,O
was,O
its,O
use,O
deemed,O
uncertain,O
.,O
Delaying,O
colectomy,O
because,O
of,O
COVID-19,O
was,O
deemed,O
inappropriate,O
.,O
Steroid,O
tapering,O
as,O
per,O
BSG,O
guidance,O
was,O
deemed,O
appropriate,O
for,O
all,O
patients,O
apart,O
from,O
those,O
with,O
COVID-19,O
pneumonia,O
in,O
whom,O
a,O
4–6,O
 ,O
week,O
taper,O
was,O
preferred,O
.,O
We,O
have,O
suggested,O
COVID-19,O
-,O
specific,O
adaptations,O
to,O
the,O
BSG,O
ASUC,O
guideline,O
using,O
a,O
RAND,O
panel,O
.,O
Patients,O
with,O
cancer,O
are,O
at,O
increased,O
risk,O
of,O
contracting,O
SARS,O
-,O
CoV-2,O
and,O
have,O
a,O
high,O
mortality,O
rate,O
from,O
COVID-19,O
(,O
Lee,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
https://www.asco.org/sites/new-www.asco.org/files/content-files/2020-ASCO-Guide-Cancer-COVID19.pdf,O
),O
.,O
It,O
is,O
important,O
that,O
newly,O
launched,O
geographically,O
diverse,O
and,O
national,O
cancer,O
efforts,O
",",O
such,O
as,O
the,O
UK,B-Dataset
Coronavirus,I-Dataset
Cancer,I-Dataset
Monitoring,I-Dataset
Project,E-Dataset
 ,O
(,O
UK,B-Dataset
Coronavirus,I-Dataset
Cancer,I-Dataset
Monitoring,I-Dataset
Project,E-Dataset
",",O
2020,O
),O
",",O
collates,O
evidence,O
on,O
whether,O
such,O
an,O
approach,O
has,O
utility,O
in,O
reducing,O
COVID-19,O
infection,O
and,O
mortality,O
.,O
As,O
of,O
4,O
April,O
2020,O
",",O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
",",O
caused,O
by,O
the,O
novel,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
[,O
1,O
],O
",",O
has,O
infected,O
more,O
than,O
1.2,O
million,O
people,O
worldwide,O
and,O
the,O
increase,O
in,O
cases,O
has,O
been,O
exponential,O
.,O
Viral,O
genomes,O
were,O
aligned,O
using,O
MAFFT,O
v7.427,O
[,O
6,O
],O
with,O
762,O
high,O
-,O
coverage,O
viral,O
genomes,O
deposited,O
in,O
the,O
GISAID,B-Dataset
(Global,I-Dataset
Initiative,I-Dataset
for,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
"Data,",E-Dataset
 ,O
recently,O
adapted,O
to,O
include,O
SARS,O
-,O
CoV-2,O
genomes,O
),O
database,O
[,O
7,O
",",O
8,O
],O
as,O
of,O
March,O
20,O
",",O
2020,O
",",O
in,O
addition,O
to,O
the,O
most,O
recent,O
viral,O
genomes,O
sequenced,O
in,O
California,O
as,O
of,O
May,O
3,O
",",O
2020,O
[,O
9,O
],O
",",O
for,O
a,O
total,O
of,O
983,O
sequences,O
.,O
Assembled,O
SARS,O
-,O
CoV-2,O
genomes,O
in,O
this,O
study,O
were,O
uploaded,O
to,O
the,O
GISAID,S-Dataset
 ,O
database,O
[,O
7,O
",",O
8,O
],O
(,O
accession,O
numbers,O
EPI_ISL_417330,S-AccessionNumber
",",O
EPI_ISL_417331,S-AccessionNumber
",",O
EPI_ISL_429881,S-AccessionNumber
",",O
EPI_ISL_EPI_ISL450232,S-AccessionNumber
 ,O
-,O
EPI_ISL450240,S-AccessionNumber
),O
and,O
were,O
also,O
submitted,O
to,O
the,O
National,B-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,I-Repository
(NCBI),I-Repository
GenBank,E-Repository
 ,O
database,O
(,O
accession,O
numbers,O
MT419851,S-AccessionNumber
",",O
MT419852,S-AccessionNumber
",",O
MT419860,S-AccessionNumber
",",O
MT510718-726,S-AccessionNumber
),O
.,O
Raw,O
sequence,O
data,O
were,O
submitted,O
to,O
the,O
NCBI,B-Repository
Sequence,I-Repository
Read,I-Repository
Archive,I-Repository
(SRA),E-Repository
 ,O
database,O
(,O
BioProject,O
accession,O
number,O
PRJNA629889,S-AccessionNumber
 ,O
and,O
umbrella,O
BioProject,O
accession,O
number,O
PRJNA171119,S-AccessionNumber
),O
.,O
Data,O
from,O
these,O
patients,O
with,O
COVID-19,O
were,O
matched,O
with,O
102,O
randomly,O
selected,O
negative,O
controls,O
who,O
were,O
patients,O
who,O
tested,O
negative,O
for,O
SARS,O
-,O
CoV-2,O
over,O
the,O
same,O
time,O
period,O
.,O
Among,O
the,O
46,O
COVID-19,O
–,O
positive,O
patients,O
",",O
the,O
median,O
age,O
was,O
44,O
years,O
",",O
46,O
%,O
were,O
female,O
",",O
and,O
65,O
%,O
were,O
outpatients,O
(,O
Supplementary,O
Table,O
1,O
),O
.,O
We,O
noted,O
that,O
a,O
travel,O
history,O
within,O
2,O
weeks,O
of,O
symptom,O
onset,O
(,O
median,O
date,O
",",O
11,O
March,O
2020,O
),O
was,O
significantly,O
associated,O
with,O
COVID-19,O
infection,O
(,O
odds,O
ratio,O
[,O
OR,O
],O
",",O
3.8,O
;,O
95,O
%,O
confidence,O
interval,O
[,O
CI,O
],O
1.8–8.4,O
),O
",",O
comprising,O
43,O
%,O
(,O
20/46,O
),O
of,O
newly,O
diagnosed,O
cases,O
(,O
Figure,O
1A,O
),O
.,O
Out,O
of,O
the,O
20,O
travelers,O
with,O
COVID-19,O
infection,O
",",O
there,O
were,O
significant,O
associations,O
for,O
prior,O
travel,O
to,O
Europe,O
(,O
5,O
travelers,O
;,O
OR,O
",",O
6.1,O
;,O
95,O
%,O
CI,O
1.1,O
-,O
32.7,O
),O
",",O
travel,O
outside,O
of,O
San,O
Francisco,O
to,O
other,O
cities,O
within,O
California,O
or,O
other,O
states,O
(,O
United,O
States,O
),O
(,O
14,O
travelers,O
;,O
OR,O
:,O
4.0,O
;,O
1.6–10.0,O
),O
",",O
and,O
specifically,O
travel,O
to,O
New,O
York,O
(,O
6,O
travelers,O
;,O
OR,O
",",O
32.9,O
;,O
95,O
%,O
CI,O
1.8,O
-,O
598,O
),O
as,O
compared,O
with,O
17,O
travelers,O
without,O
infection,O
(,O
Figure,O
1B,O
and,O
Supplementary,O
Tables,O
2,O
and,O
3,O
),O
.,O
One,O
cluster,O
of,O
3,O
positive,O
cases,O
associated,O
with,O
COVID-19,O
infection,O
in,O
an,O
airport,O
worker,O
was,O
categorized,O
as,O
a,O
case,O
of,O
community-,O
rather,O
than,O
travel,O
-,O
associated,O
transmission,O
.,O
No,O
significant,O
associations,O
were,O
found,O
with,O
regard,O
to,O
close,O
contacts,O
with,O
persons,O
with,O
known,O
COVID-19,O
infection,O
or,O
frontline,O
healthcare,O
workers,O
.,O
Those,O
who,O
did,O
not,O
have,O
a,O
recent,O
travel,O
history,O
",",O
a,O
close,O
contact,O
who,O
was,O
COVID-19,O
positive,O
",",O
or,O
were,O
not,O
a,O
frontline,O
healthcare,O
worker,O
were,O
categorized,O
as,O
community,O
transmission,O
with,O
an,O
unknown,O
source,O
of,O
infection,O
and,O
comprised,O
39,O
%,O
of,O
cases,O
.,O
We,O
defined,O
genomic,O
clades,O
through,O
the,O
GISAID,S-Dataset
 ,O
nomenclature,O
found,O
at,O
that,O
point,O
in,O
time,O
on,O
20,O
March,O
2020,O
[,O
7,O
",",O
8,O
],O
.,O
Real,O
-,O
time,O
dissemination,O
of,O
epidemiological,O
survey,O
data,O
from,O
positive,O
COVID-19,O
cases,O
is,O
critical,O
to,O
support,O
efforts,O
to,O
contain,O
or,O
reduce,O
spread,O
of,O
viral,O
infection,O
in,O
the,O
community,O
.,O
Our,O
evaluation,O
of,O
diagnosed,O
COVID-19,O
cases,O
in,O
San,O
Francisco,O
in,O
early,O
March,O
2020,O
associates,O
with,O
travelers,O
from,O
New,O
York,O
prior,O
to,O
the,O
recognized,O
spike,O
in,O
New,O
York,O
cases,O
in,O
late,O
March,O
(,O
Figure,O
1C,O
),O
.,O
Travel,O
from,O
New,O
York,O
was,O
underrecognized,O
as,O
a,O
risk,O
factor,O
for,O
COVID-19,O
infection,O
in,O
the,O
United,O
States,O
in,O
early,O
March,O
.,O
Guidelines,O
for,O
COVID-19,O
testing,O
have,O
not,O
included,O
screening,O
for,O
domestic,O
travel,O
.,O
Cryptogenic,O
transmission,O
of,O
COVID-19,O
by,O
individuals,O
with,O
mild,O
illness,O
or,O
asymptomatic,O
infection,O
is,O
a,O
tremendous,O
challenge,O
to,O
the,O
containment,O
of,O
COVID-19,O
[,O
15,O
",",O
16,O
],O
.,O
In,O
early,O
-,O
to,O
-,O
mid,O
March,O
2020,O
",",O
20,O
of,O
46,O
(,O
43,O
%,O
),O
COVID-19,O
cases,O
at,O
a,O
tertiary,O
care,O
hospital,O
in,O
San,O
Francisco,O
",",O
California,O
were,O
travel,O
related,O
.,O
As,O
an,O
outbreak,O
of,O
COVID-19,O
emerged,O
during,O
the,O
manuscript,O
review,O
process,O
",",O
we,O
rapidly,O
incorporated,O
a,O
new,O
test,O
for,O
the,O
novel,O
coronavirus,O
SARS,O
-,O
CoV-2,O
into,O
a,O
coronavirus,O
panel,O
taken,O
from,O
the,O
HV,O
panel,O
",",O
demonstrating,O
the,O
power,O
of,O
this,O
modular,O
master,O
set,O
to,O
be,O
adapted,O
to,O
real,O
-,O
world,O
challenges,O
(,O
Fig,O
.,O
2d,O
),O
.,O
For,O
4,O
-,O
channel,O
datasets,O
",",O
analysis,O
of,O
3,O
-,O
colour,O
space,O
was,O
performed,O
directly,O
on,O
normalized,O
intensities,O
.,O
For,O
5,O
-,O
channel,O
datasets,O
",",O
droplets,O
were,O
divided,O
into,O
UV,O
intensity,O
bins,O
for,O
downstream,O
analysis,O
(,O
Extended,O
Data,O
Fig,O
.,O
4,O
),O
.,O
For,O
5,O
-,O
channel,O
datasets,O
",",O
UV,O
intensity,O
bins,O
were,O
recombined,O
after,O
assignments,O
to,O
create,O
the,O
full,O
dataset,O
.,O
For,O
167,O
of,O
the,O
169,O
HV10,O
species,O
",",O
it,O
was,O
possible,O
to,O
design,O
primer,O
sets,O
using,O
ADAPT,O
/,O
primer3,O
that,O
cover,O
>,O
90,O
%,O
of,O
the,O
genomes,O
in,O
the,O
database,O
with,O
fewer,O
than,O
10,O
primer,O
pairs,O
.,O
We,O
improved,O
our,O
design,O
approach,O
throughout,O
the,O
process,O
by,O
incorporating,O
new,O
features,O
into,O
each,O
round,O
of,O
design,O
.,O
In,O
the,O
work,O
presented,O
here,O
",",O
the,O
radius,O
of,O
the,O
sliding,O
distance,O
filter,O
was,O
set,O
to,O
achieve,O
at,O
least,O
99.5,O
%,O
correct,O
classification,O
in,O
the,O
test,O
dataset,O
",",O
corresponding,O
to,O
the,O
removal,O
of,O
6,O
%,O
of,O
droplets,O
.,O
Using,O
CARMEN,O
–,O
Cas13,O
",",O
we,O
developed,O
a,O
multiplexed,O
assay,O
that,O
simultaneously,O
differentiates,O
all,O
169,O
human,O
-,O
associated,O
viruses,O
with,O
at,O
least,O
10,O
published,O
genome,O
sequences,O
and,O
rapidly,O
incorporated,O
an,O
additional,O
crRNA,O
to,O
detect,O
the,O
causative,O
agent,O
of,O
the,O
2020,O
COVID-19,O
pandemic,O
.,O
As,O
of,O
May,O
31,O
",",O
2020,O
",",O
nearly,O
6,O
million,O
cases,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
and,O
over,O
"350,000",O
deaths,O
from,O
the,O
disease,O
",",O
have,O
been,O
reported,O
worldwide,O
[,O
1,O
],O
.,O
A,O
novel,O
coronavirus,O
is,O
the,O
cause,O
of,O
COVID-19,O
.,O
This,O
new,O
finding,O
provides,O
a,O
clue,O
for,O
understanding,O
the,O
previously,O
unresolved,O
physiological,O
roles,O
of,O
the,O
proteasome,O
-,O
dependent,O
degradation,O
of,O
the,O
SARS,O
-,O
CoV-2,O
N,O
protein,O
during,O
pathogenesis,O
of,O
COVID-19,O
.,O
These,O
results,O
suggest,O
that,O
PA28γ,O
binding,O
is,O
important,O
in,O
regulating,O
20S,O
proteasome,O
activity,O
",",O
which,O
in,O
turn,O
regulates,O
levels,O
of,O
the,O
critical,O
nCoV,O
N,O
nucleocapsid,O
protein,O
of,O
SARS,O
-,O
CoV-2,O
",",O
furthering,O
our,O
understanding,O
of,O
the,O
pathogenesis,O
of,O
COVID-19,O
.,O
However,O
",",O
the,O
role,O
and,O
timing,O
of,O
tracheostomy,O
for,O
patients,O
requiring,O
critical,O
care,O
for,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
unclear,O
.,O
Early,O
guidelines,O
from,O
both,O
the,O
UK,O
and,O
national,O
bodies,O
proposed,O
a,O
cautious,O
approach,O
to,O
tracheostomy,O
in,O
patients,O
with,O
COVID-19,O
—,O
avoiding,O
before,O
10,O
days,O
of,O
intubation,O
and,O
giving,O
serious,O
consideration,O
before,O
performing,O
at,O
all,O
between,O
10,O
and,O
21,O
days,O
after,O
intubation,O
",",O
allowing,O
for,O
a,O
sufficient,O
decline,O
in,O
viral,O
load,O
.,O
With,O
a,O
dedicated,O
24,O
h,O
on,O
call,O
tracheostomy,O
service,O
competent,O
in,O
percutaneous,O
and,O
surgical,O
techniques,O
",",O
and,O
access,O
to,O
dedicated,O
COVID,O
emergency,O
theatres,O
",",O
the,O
choice,O
of,O
performing,O
a,O
surgical,O
or,O
percutaneous,O
tracheostomy,O
depended,O
only,O
on,O
patient,O
body,O
habitus,O
",",O
adequate,O
neck,O
extension,O
",",O
and,O
grade,O
of,O
direct,O
laryngoscopy,O
.,O
COVID-19,O
-,O
related,O
laryngeal,O
oedema,O
",",O
and,O
upper,O
airway,O
oedema,O
from,O
prone,O
-,O
positioning,O
also,O
increased,O
the,O
risk,O
of,O
failure,O
of,O
extubation,O
.,O
These,O
factors,O
all,O
guided,O
a,O
more,O
interventionalist,O
approach,O
adopted,O
by,O
our,O
COVID-19,O
airway,O
team,O
.,O
In,O
the,O
absence,O
of,O
an,O
evidence,O
base,O
",",O
many,O
guidelines,O
based,O
on,O
expert,O
opinion,O
were,O
published,O
referencing,O
the,O
role,O
of,O
tracheostomy,O
in,O
COVID-19,O
.,O
Later,O
guidelines,O
from,O
an,O
expert,O
working,O
group,O
adopted,O
a,O
more,O
moderate,O
stance,O
and,O
the,O
results,O
of,O
this,O
study,O
provide,O
support,O
for,O
this,O
approach,O
.,O
",",O
 ,O
Tracheostomy,O
timing,O
in,O
COVID-19,O
patients,O
should,O
take,O
into,O
consideration,O
the,O
safety,O
and,O
ideal,O
timing,O
for,O
patient,O
outcomes,O
",",O
and,O
the,O
safety,O
of,O
healthcare,O
personnel,O
performing,O
the,O
tracheostomy,O
.,O
",",O
However,O
",",O
tracheostomy,O
occurred,O
in,O
both,O
trial,O
arms,O
much,O
earlier,O
after,O
intubation,O
than,O
is,O
recommended,O
in,O
the,O
COVID-19,O
setting,O
.,O
Among,O
the,O
tracheostomy,O
team,O
",",O
none,O
of,O
the,O
clinicians,O
developed,O
COVID-19,O
symptoms,O
during,O
the,O
study,O
period,O
and,O
subsequent,O
antibody,O
testing,O
at,O
2,O
weeks,O
after,O
the,O
study,O
period,O
was,O
negative,O
in,O
all,O
but,O
one,O
surgeon,O
",",O
who,O
developed,O
COVID-19,O
before,O
commencing,O
on,O
the,O
team,O
.,O
In,O
addition,O
",",O
none,O
of,O
the,O
SLT,O
or,O
ODP,O
team,O
members,O
involved,O
developed,O
COVID-19,O
symptoms,O
.,O
Our,O
experience,O
in,O
a,O
much,O
larger,O
cohort,O
supports,O
the,O
assertion,O
that,O
tracheostomy,O
can,O
be,O
performed,O
with,O
low,O
risk,O
to,O
COVID-19,O
patients,O
and,O
healthcare,O
workers,O
.,O
Prolonged,O
continuous,O
sedation,O
requirements,O
are,O
a,O
recognised,O
feature,O
of,O
ventilated,O
COVID-19,O
patients,O
.,O
The,O
role,O
of,O
tracheostomy,O
in,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
unclear,O
",",O
with,O
several,O
consensus,O
guidelines,O
advising,O
against,O
this,O
practice,O
.,O
We,O
developed,O
both,O
a,O
dedicated,O
airway,O
team,O
and,O
coordinated,O
education,O
programme,O
to,O
facilitate,O
ward,O
management,O
of,O
tracheostomised,O
COVID-19,O
patients,O
.,O
Here,O
",",O
we,O
report,O
outcomes,O
in,O
the,O
first,O
100,O
COVID-19,O
patients,O
who,O
underwent,O
tracheostomy,O
at,O
our,O
institution,O
.,O
This,O
was,O
a,O
prospective,O
observational,O
cohort,O
study,O
of,O
patients,O
confirmed,O
to,O
have,O
COVID-19,O
who,O
required,O
mechanical,O
ventilation,O
at,O
Queen,O
Elizabeth,O
Hospital,O
",",O
Birmingham,O
",",O
UK,O
.,O
Secondary,O
outcomes,O
included,O
duration,O
of,O
ventilation,O
",",O
ICU,O
stay,O
",",O
and,O
healthcare,O
workers,O
directly,O
involved,O
in,O
tracheostomy,O
care,O
acquiring,O
COVID-19,O
.,O
Results,O
 ,O
A,O
total,O
of,O
164,O
patients,O
with,O
COVID-19,O
were,O
admitted,O
to,O
the,O
ICU,O
between,O
March,O
9,O
",",O
2020,O
and,O
April,O
21,O
",",O
2020,O
.,O
No,O
healthcare,O
workers,O
developed,O
COVID-19,O
.,O
Conclusion,O
 ,O
Independent,O
of,O
the,O
severity,O
of,O
critical,O
illness,O
from,O
COVID-19,O
",",O
30,O
-,O
day,O
survival,O
was,O
higher,O
and,O
ICU,O
stay,O
shorter,O
in,O
patients,O
receiving,O
tracheostomy,O
.,O
Early,O
tracheostomy,O
appears,O
to,O
be,O
safe,O
in,O
COVID-19,O
.,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
is,O
the,O
cause,O
of,O
COVID-19,O
",",O
a,O
major,O
pandemic,O
that,O
threatens,O
millions,O
of,O
lives,O
and,O
the,O
global,O
economy,O
(,O
1,O
),O
.,O
It,O
is,O
also,O
crucial,O
for,O
protecting,O
populations,O
of,O
wildlife,O
species,O
in,O
native,O
habitats,O
and,O
under,O
human,O
care,O
",",O
particularly,O
nonhuman,O
primates,O
",",O
which,O
may,O
be,O
susceptible,O
to,O
COVID-19,O
(,O
10,O
),O
.,O
We,O
drew,O
on,O
the,O
rapidly,O
growing,O
database,O
of,O
annotated,O
vertebrate,O
genomes,O
",",O
including,O
new,O
genomes,O
produced,O
by,O
the,O
Genomes,B-Repository
10K,E-Repository
-affiliated,O
Bat1K,B-Dataset
Consortium,E-Dataset
",",O
Zoonomia,S-Dataset
",",O
and,O
Vertebrate,B-Dataset
Genomes,I-Dataset
Project,E-Dataset
",",O
and,O
other,O
sources,O
(,O
30,O
",",O
31,O
),O
.,O
Nonetheless,O
",",O
our,O
predictions,O
provide,O
a,O
useful,O
starting,O
point,O
for,O
the,O
selection,O
of,O
appropriate,O
animal,O
models,O
for,O
COVID-19,O
research,O
and,O
identification,O
of,O
species,O
that,O
may,O
be,O
at,O
risk,O
for,O
human,O
-,O
to,O
-,O
animal,O
or,O
animal,O
-,O
to,O
-,O
animal,O
transmissions,O
of,O
SARS,O
-,O
CoV-2,O
.,O
Of,O
the,O
19,O
catarrhine,O
primates,O
analyzed,O
",",O
18/19,O
scored,O
very,O
high,O
for,O
binding,O
of,O
their,O
ACE2,O
to,O
SARS,O
-,O
CoV-2,O
S,O
and,O
one,O
scored,O
high,O
(,O
the,O
Angola,O
colobus,O
),O
;,O
the,O
18,O
species,O
scoring,O
very,O
high,O
had,O
25/25,O
binding,O
residues,O
identical,O
to,O
human,O
ACE2,O
",",O
including,O
rhesus,O
macaques,O
",",O
which,O
are,O
known,O
to,O
be,O
infected,O
by,O
SARS,O
-,O
CoV-2,O
and,O
develop,O
COVID-19,O
-,O
like,O
clinical,O
symptoms,O
(,O
3,O
",",O
43,O
),O
.,O
Chiroptera,O
represents,O
a,O
clade,O
of,O
mammals,O
that,O
are,O
of,O
high,O
interest,O
in,O
COVID-19,O
research,O
because,O
several,O
bat,O
species,O
are,O
known,O
to,O
harbor,O
coronaviruses,O
",",O
including,O
those,O
most,O
closely,O
related,O
to,O
SARS,O
-,O
CoV-2,O
(,O
1,O
),O
.,O
Presently,O
",",O
there,O
is,O
a,O
tremendous,O
need,O
for,O
animal,O
models,O
to,O
study,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
pathogenesis,O
",",O
as,O
the,O
only,O
species,O
currently,O
known,O
to,O
be,O
infected,O
and,O
show,O
similar,O
symptoms,O
of,O
COVID-19,O
is,O
rhesus,O
macaque,O
.,O
The,O
sources,O
and,O
accession,O
numbers,O
for,O
the,O
genomes,O
or,O
proteins,O
retrieved,O
from,O
NCBI,S-Repository
 ,O
are,O
listed,O
in,O
Dataset,O
S1,O
.,O
The,O
novel,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
is,O
the,O
cause,O
of,O
COVID-19,O
",",O
a,O
major,O
pandemic,O
that,O
threatens,O
millions,O
of,O
human,O
lives,O
and,O
the,O
global,O
economy,O
.,O
This,O
can,O
assist,O
the,O
identification,O
of,O
intermediate,O
hosts,O
for,O
SARS,O
-,O
CoV-2,O
and,O
hence,O
reduce,O
the,O
opportunity,O
for,O
a,O
future,O
outbreak,O
of,O
COVID-19,O
.,O
The,O
novel,O
coronavirus,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
is,O
the,O
cause,O
of,O
COVID-19,O
.,O
Here,O
",",O
we,O
utilized,O
a,O
unique,O
dataset,O
of,O
ACE2,O
sequences,O
from,O
410,O
vertebrate,O
species,O
",",O
including,O
252,O
mammals,O
",",O
to,O
study,O
the,O
conservation,O
of,O
ACE2,O
and,O
its,O
potential,O
to,O
be,O
used,O
as,O
a,O
receptor,O
by,O
SARS,O
-,O
CoV-2,O
.,O
Our,O
results,O
",",O
if,O
confirmed,O
by,O
additional,O
experimental,O
data,O
",",O
may,O
lead,O
to,O
the,O
identification,O
of,O
intermediate,O
host,O
species,O
for,O
SARS,O
-,O
CoV-2,O
",",O
guide,O
the,O
selection,O
of,O
animal,O
models,O
of,O
COVID-19,O
",",O
and,O
assist,O
the,O
conservation,O
of,O
animals,O
both,O
in,O
native,O
habitats,O
and,O
in,O
human,O
care,O
.,O
The,O
novel,O
coronavirus,O
(,O
2019,O
-,O
nCoV,O
),O
has,O
recently,O
emerged,O
",",O
causing,O
COVID-19,O
outbreaks,O
and,O
significant,O
societal,O
/,O
global,O
disruption,O
.,O
Importantly,O
",",O
COVID-19,O
infection,O
resembles,O
SARS,O
-,O
like,O
complications,O
.,O
However,O
",",O
the,O
lack,O
of,O
knowledge,O
about,O
the,O
underlying,O
genetic,O
mechanisms,O
of,O
COVID-19,O
warrants,O
the,O
development,O
of,O
prospective,O
control,O
measures,O
.,O
To,O
understand,O
the,O
pathogenetic,O
behavior,O
of,O
2019,O
-,O
nCoV,O
",",O
we,O
compared,O
gene,O
expression,O
datasets,O
of,O
viral,O
infections,O
closest,O
to,O
2019,O
-,O
nCoV,O
with,O
four,O
COVID-19,O
clinical,O
presentations,O
followed,O
by,O
functional,O
enrichment,O
of,O
shared,O
dysregulated,O
genes,O
.,O
Among,O
the,O
dysregulated,O
genes,O
",",O
SARS,O
-,O
CoV,O
shared,O
≤19,O
upregulated,O
and,O
≤22,O
downregulated,O
genes,O
with,O
each,O
of,O
different,O
COVID-19,O
complications,O
.,O
Besides,O
",",O
14,O
genes,O
were,O
common,O
to,O
different,O
SARS,O
-,O
CoV,O
comorbidities,O
that,O
might,O
influence,O
COVID-19,O
disease,O
.,O
We,O
also,O
observed,O
similarities,O
in,O
pathways,O
that,O
can,O
lead,O
to,O
COVID-19,O
and,O
SARS,O
-,O
CoV,O
diseases,O
.,O
Finally,O
",",O
protein,O
–,O
chemical,O
interactions,O
suggest,O
cyclosporine,O
",",O
resveratrol,O
and,O
quercetin,O
as,O
promising,O
drug,O
candidates,O
against,O
COVID-19,O
as,O
well,O
as,O
other,O
SARS,O
-,O
like,O
viral,O
infections,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
caused,O
by,O
a,O
novel,O
coronavirus,O
(,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
[,O
SARS,O
-,O
CoV-2,O
],O
),O
",",O
which,O
primarily,O
affects,O
the,O
respiratory,O
system,O
.,O
Patients,O
with,O
COVID-19,O
present,O
with,O
variable,O
disease,O
symptoms,O
and,O
severity,O
",",O
some,O
can,O
be,O
severe,O
",",O
resulting,O
in,O
hospitalization,O
",",O
respiratory,O
failure,O
",",O
or,O
even,O
death,O
.,O
A,O
recent,O
meta,O
-,O
analysis,O
of,O
35,O
COVID-19,O
studies,O
reported,O
that,O
the,O
pooled,O
prevalence,O
of,O
digestive,O
symptoms,O
was,O
15,O
%,O
and,O
pooled,O
prevalence,O
of,O
digestive,O
system,O
comorbidities,O
was,O
4,O
%,O
.,O
In,O
addition,O
",",O
SARS,O
-,O
CoV-2,O
virus,O
was,O
detected,O
in,O
the,O
feces,O
and,O
anal,O
swabs,O
in,O
patients,O
with,O
COVID-19,O
and,O
can,O
infect,O
human,O
intestinal,O
epithelium.3,O
",",O
4,O
",",O
5,O
Altogether,O
these,O
data,O
suggest,O
that,O
the,O
GI,O
tract,O
is,O
an,O
important,O
extrapulmonary,O
site,O
for,O
SARS,O
-,O
CoV-2,O
infection,O
.,O
Our,O
recent,O
study,O
showed,O
that,O
the,O
gut,O
bacterial,O
microbiome,O
was,O
significantly,O
altered,O
in,O
patients,O
with,O
COVID-19,O
with,O
a,O
significant,O
expansion,O
of,O
opportunistic,O
pathogens,O
in,O
the,O
gut,O
",",O
which,O
was,O
associated,O
with,O
disease,O
severity,O
and,O
fecal,O
SARS,O
-,O
CoV-2,O
shedding,O
.,O
It,O
is,O
unclear,O
if,O
the,O
gut,O
mycobiome,O
is,O
also,O
altered,O
and,O
whether,O
fungal,O
pathogens,O
cobloom,O
in,O
COVID-19,O
and,O
underlie,O
disease,O
course,O
.,O
In,O
this,O
pilot,O
study,O
",",O
we,O
hypothesize,O
that,O
the,O
intestinal,O
fungal,O
microbiome,O
(,O
mycobiome,O
),O
is,O
altered,O
in,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
COVID-19,O
is,O
associated,O
with,O
blooms,O
of,O
certain,O
fungi,O
in,O
the,O
gut,O
.,O
We,O
prospectively,O
included,O
30,O
patients,O
with,O
COVID-19,O
(,O
Table,O
 ,O
1,O
",",O
Figure,O
 ,O
1,O
",",O
Supplementary,O
Figure,O
 ,O
1,O
),O
",",O
admitted,O
between,O
February,O
16,O
",",O
2020,O
",",O
and,O
April,O
1,O
",",O
2020,O
",",O
in,O
Hong,O
Kong,O
",",O
China,O
",",O
followed,O
from,O
hospital,O
admission,O
until,O
discharge,O
.,O
We,O
investigated,O
intestinal,O
fungal,O
compositions,O
in,O
patients,O
with,O
COVID-19,O
as,O
compared,O
with,O
healthy,O
individuals,O
and,O
patients,O
with,O
community,O
-,O
acquired,O
pneumonia,O
",",O
and,O
their,O
temporal,O
changes,O
over,O
time,O
of,O
hospitalization,O
",",O
via,O
broad,O
-,O
target,O
deep,O
shotgun,O
metagenomics,O
sequencing,O
.,O
This,O
prospective,O
study,O
involved,O
30,O
patients,O
with,O
COVID-19,O
hospitalized,O
with,O
laboratory,O
-,O
confirmed,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
9,O
patients,O
hospitalized,O
with,O
community,O
-,O
acquired,O
pneumonia,O
(,O
pneumonia,O
controls,O
),O
",",O
and,O
30,O
healthy,O
individuals,O
(,O
controls,O
),O
(,O
Table,O
 ,O
1,O
),O
.,O
Thirty,O
hospitalized,O
patients,O
with,O
COVID-19,O
were,O
admitted,O
between,O
February,O
16,O
",",O
2020,O
",",O
and,O
April,O
1,O
",",O
2020,O
",",O
in,O
Hong,O
Kong,O
",",O
China,O
",",O
and,O
were,O
followed,O
from,O
hospital,O
admission,O
until,O
discharge,O
(,O
Figure,O
 ,O
1,O
),O
.,O
Patients,O
with,O
COVID-19,O
and,O
pneumonia,O
controls,O
were,O
admitted,O
to,O
the,O
Prince,O
of,O
Wales,O
Hospital,O
or,O
the,O
United,O
Christian,O
Hospital,O
",",O
Hong,O
Kong,O
.,O
Severity,O
of,O
COVID-19,O
infection,O
was,O
categorized,O
as,O
(,O
1,O
),O
mild,O
",",O
if,O
there,O
was,O
no,O
radiographic,O
evidence,O
of,O
pneumonia,O
;,O
(,O
2,O
),O
moderate,O
",",O
if,O
pneumonia,O
was,O
present,O
along,O
with,O
fever,O
and,O
respiratory,O
tract,O
symptoms,O
;,O
(,O
3,O
),O
severe,O
",",O
if,O
respiratory,O
rate,O
≥30,O
/,O
min,O
",",O
oxygen,O
saturation,O
≤93,O
%,O
when,O
breathing,O
ambient,O
air,O
",",O
or,O
PaO2,O
/,O
FiO2,O
≤300,O
mm,O
Hg,O
(,O
1,O
mm,O
Hg,O
 ,O
=,O
0.133,O
kPa,O
),O
;,O
or,O
(,O
4,O
),O
critical,O
",",O
if,O
there,O
was,O
respiratory,O
failure,O
requiring,O
mechanical,O
ventilation,O
",",O
shock,O
",",O
or,O
organ,O
failure,O
requiring,O
intensive,O
care,O
.,O
Fecal,O
samples,O
from,O
patients,O
with,O
COVID-19,O
were,O
collected,O
serially,O
2,O
to,O
3,O
times,O
per,O
week,O
until,O
discharge,O
.,O
Contaminating,O
human,O
reads,O
were,O
filtering,O
using,O
Kneaddata,O
(,O
Reference,O
database,O
:,O
GRCh38,O
p12,O
),O
with,O
default,O
parameters,O
.,O
Nonmetric,O
multidimensional,O
scaling,O
analyses,O
were,O
performed,O
on,O
all,O
baseline,O
fecal,O
mycobiomes,O
between,O
groups,O
",",O
and,O
serial,O
fecal,O
mycobiomes,O
in,O
each,O
COVID-19,O
case,O
during,O
the,O
disease,O
course,O
",",O
based,O
on,O
Bray,O
-,O
Curtis,O
dissimilarities,O
using,O
vegan,O
package,O
(,O
v2.5–3,O
),O
.,O
Differential,O
fungal,O
taxa,O
between,O
patients,O
with,O
COVID-19,O
(,O
at,O
baseline,O
or,O
across,O
all,O
time,O
points,O
during,O
hospitalization,O
),O
and,O
healthy,O
controls,O
were,O
identified,O
using,O
LefSE,O
.,O
A,O
total,O
of,O
30,O
patients,O
hospitalized,O
with,O
COVID-19,O
",",O
30,O
healthy,O
controls,O
",",O
and,O
9,O
patients,O
hospitalized,O
with,O
community,O
-,O
acquired,O
pneumonia,O
were,O
included,O
(,O
Table,O
 ,O
1,O
;,O
Supplementary,O
Table,O
 ,O
1,O
),O
.,O
All,O
patients,O
with,O
COVID-19,O
presented,O
with,O
respiratory,O
symptoms,O
and,O
4,O
also,O
had,O
diarrhea,O
at,O
presentation,O
.,O
To,O
understand,O
alterations,O
of,O
the,O
gut,O
mycobiome,O
that,O
underlies,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
we,O
compared,O
baseline,O
fecal,O
mycobiome,O
composition,O
(,O
first,O
time,O
point,O
of,O
stool,O
sampling,O
after,O
hospitalization,O
),O
between,O
patients,O
with,O
COVID-19,O
",",O
healthy,O
controls,O
",",O
and,O
pneumonia,O
controls,O
.,O
At,O
the,O
whole,O
fungal,O
community,O
level,O
",",O
fecal,O
mycobiome,O
of,O
healthy,O
controls,O
densely,O
clustered,O
together,O
",",O
whereas,O
that,O
of,O
patients,O
with,O
COVID-19,O
formed,O
a,O
substantially,O
broader,O
cluster,O
significantly,O
different,O
from,O
that,O
of,O
controls,O
(,O
PERMANOVA,O
test,O
",",O
P,O
 ,O
=,O
.001,O
",",O
Figure,O
 ,O
2,O
A,O
),O
.,O
Fecal,O
mycobiome,O
was,O
more,O
heterogeneous,O
across,O
patients,O
with,O
COVID-19,O
than,O
controls,O
",",O
as,O
demonstrated,O
by,O
an,O
approximately,O
6,O
-,O
fold,O
increase,O
in,O
interindividual,O
mycobiome,O
dissimilarity,O
in,O
patients,O
with,O
COVID-19,O
relative,O
to,O
controls,O
(,O
P,O
<,O
2.22e-16,O
",",O
Figure,O
 ,O
2,O
B,O
),O
.,O
Patients,O
with,O
community,O
-,O
acquired,O
pneumonia,O
also,O
showed,O
heterogeneous,O
fecal,O
mycobiome,O
configurations,O
(,O
Figure,O
 ,O
2,O
B,O
),O
",",O
indicating,O
that,O
both,O
 ,O
community,O
-,O
acquired,O
pneumonia,O
and,O
COVID-19,O
–,O
associated,O
pneumonia,O
were,O
associated,O
with,O
fungal,O
dysbiosis,O
in,O
the,O
gut,O
.,O
We,O
next,O
identified,O
differential,O
fungal,O
species,O
in,O
fecal,O
samples,O
between,O
patients,O
with,O
COVID-19,O
and,O
healthy,O
controls,O
adjusting,O
for,O
antibiotics,O
use,O
and,O
comorbidities,O
.,O
We,O
found,O
that,O
Candida,O
albicans,O
was,O
significantly,O
enriched,O
in,O
6,O
(,O
20,O
%,O
),O
of,O
30,O
patients,O
with,O
COVID-19,O
but,O
was,O
absent,O
in,O
healthy,O
controls,O
(,O
false,O
discovery,O
rate,O
P,O
 ,O
=,O
.04,O
",",O
Figure,O
 ,O
2,O
C,O
),O
.,O
These,O
data,O
suggest,O
that,O
gut,O
mycobiome,O
was,O
significantly,O
altered,O
in,O
patients,O
with,O
COVID-19,O
with,O
an,O
increase,O
in,O
Candida,O
species,O
.,O
We,O
investigated,O
longitudinal,O
dynamics,O
of,O
the,O
gut,O
mycobiome,O
in,O
COVID-19,O
over,O
time,O
of,O
hospitalization,O
and,O
explored,O
whether,O
recovery,O
from,O
SAR,O
-,O
CoV-2,O
infection,O
was,O
associated,O
with,O
restoration,O
of,O
gut,O
mycobiome,O
to,O
a,O
community,O
similar,O
to,O
that,O
of,O
healthy,O
individuals,O
.,O
The,O
gut,O
mycobiome,O
in,O
most,O
(,O
22,O
of,O
30,O
),O
patients,O
with,O
COVID-19,O
was,O
stable,O
over,O
the,O
course,O
of,O
hospitalization,O
and,O
remained,O
similar,O
to,O
that,O
of,O
healthy,O
controls,O
at,O
the,O
latest,O
follow,O
-,O
up,O
(,O
Figure,O
 ,O
3,O
),O
.,O
The,O
diversity,O
of,O
the,O
fecal,O
mycobiome,O
did,O
not,O
differ,O
between,O
healthy,O
controls,O
and,O
patients,O
with,O
COVID-19,O
at,O
baseline,O
(,O
Figure,O
 ,O
4,O
A,O
),O
.,O
In,O
contrast,O
",",O
the,O
diversity,O
and,O
richness,O
of,O
the,O
gut,O
mycobiome,O
were,O
both,O
significantly,O
higher,O
in,O
patients,O
with,O
community,O
-,O
acquired,O
pneumonia,O
than,O
patients,O
with,O
COVID-19,O
at,O
baseline,O
(,O
Figure,O
 ,O
4,O
A,O
and,O
B,O
",",O
P,O
<,O
.05,O
and,O
<,O
.01,O
",",O
respectively,O
),O
.,O
At,O
the,O
last,O
follow,O
-,O
up,O
after,O
hospitalization,O
",",O
patients,O
with,O
COVID-19,O
showed,O
a,O
2.5,O
-,O
fold,O
higher,O
diversity,O
of,O
the,O
fecal,O
mycobiome,O
compared,O
with,O
healthy,O
controls,O
(,O
P,O
 ,O
<,O
.05,O
",",O
Figure,O
 ,O
4,O
A,O
),O
.,O
Overall,O
",",O
during,O
disease,O
course,O
",",O
the,O
diversity,O
of,O
the,O
fecal,O
mycobiome,O
showed,O
constant,O
changes,O
in,O
53,O
%,O
(,O
16,O
of,O
30,O
),O
of,O
patients,O
with,O
COVID-19,O
(,O
Supplementary,O
Figure,O
 ,O
1,O
),O
.,O
Altogether,O
these,O
data,O
suggest,O
that,O
the,O
gut,O
mycobiome,O
was,O
unstable,O
in,O
a,O
subset,O
of,O
patients,O
with,O
COVID-19,O
during,O
the,O
time,O
of,O
hospitalization,O
.,O
These,O
data,O
indicate,O
persistent,O
gut,O
fungal,O
dysbiosis,O
despite,O
disease,O
resolution,O
in,O
a,O
subset,O
of,O
patients,O
with,O
COVID-19,O
.,O
Across,O
all,O
time,O
points,O
during,O
hospitalization,O
",",O
C.,O
 ,O
albicans,O
",",O
Candida,O
auris,O
and,O
Aspergillus,O
flavus,O
were,O
overrepresented,O
in,O
fecal,O
samples,O
of,O
patients,O
with,O
COVID-19,O
;,O
these,O
species,O
however,O
were,O
absent,O
in,O
healthy,O
controls,O
(,O
Figure,O
 ,O
4,O
C,O
",",O
Supplementary,O
Figures,O
 ,O
2,O
and,O
3,O
",",O
and,O
Figure,O
 ,O
5,O
A,O
),O
.,O
Two,O
fungal,O
species,O
from,O
the,O
genus,O
Aspergillus,O
",",O
A.,O
 ,O
flavus,O
and,O
Aspergillus,O
niger,O
",",O
known,O
to,O
cause,O
pulmonary,O
aspergillosis,O
and,O
respiratory,O
illnesses,O
(,O
particularly,O
cough,O
),O
",",O
",",O
 ,O
were,O
detected,O
in,O
serial,O
fecal,O
samples,O
of,O
6,O
and,O
4,O
patients,O
with,O
COVID-19,O
",",O
respectively,O
",",O
during,O
hospitalization,O
(,O
Figure,O
 ,O
5,O
),O
.,O
All,O
6,O
patients,O
presented,O
with,O
cough,O
and,O
varying,O
degree,O
of,O
COVID-19,O
severity,O
.,O
A.,O
 ,O
niger,O
was,O
absent,O
at,O
baseline,O
but,O
showed,O
a,O
low,O
relative,O
abundance,O
of,O
<,O
1,O
%,O
in,O
4,O
of,O
30,O
patients,O
with,O
COVID-19,O
over,O
time,O
of,O
hospitalization,O
(,O
Figure,O
 ,O
5,O
B,O
),O
.,O
These,O
data,O
indicate,O
cobloom,O
of,O
opportunistic,O
fungal,O
pathogens,O
",",O
Candida,O
species,O
and,O
Aspergillus,O
species,O
",",O
in,O
the,O
gut,O
of,O
patients,O
with,O
COVID-19,O
over,O
the,O
disease,O
course,O
.,O
We,O
showed,O
for,O
the,O
first,O
time,O
that,O
the,O
gut,O
mycobiome,O
was,O
disturbed,O
in,O
patients,O
with,O
COVID-19,O
.,O
These,O
data,O
suggest,O
that,O
gut,O
microbiota,O
changes,O
induced,O
by,O
SARS,O
-,O
CoV-2,O
",",O
might,O
at,O
least,O
in,O
part,O
",",O
be,O
stochastic,O
",",O
therefore,O
leading,O
to,O
transition,O
from,O
a,O
stable,O
to,O
unstable,O
microbial,O
community,O
state,O
in,O
COVID-19,O
.,O
In,O
line,O
with,O
our,O
findings,O
in,O
patients,O
with,O
COVID-19,O
",",O
a,O
highly,O
heterogeneous,O
assembly,O
of,O
microbial,O
community,O
in,O
response,O
to,O
disease,O
stressors,O
have,O
been,O
reported,O
in,O
the,O
gut,O
of,O
patients,O
with,O
inflammatory,O
bowel,O
disease,O
and,O
in,O
the,O
lungs,O
of,O
patients,O
with,O
human,O
immunodeficiency,O
virus,O
/,O
AIDs,O
.,O
",",O
",",O
 ,O
Human,O
immunodeficiency,O
virus,O
/,O
AIDs,O
is,O
associated,O
with,O
decreased,O
CD4,O
+,O
In,O
favor,O
of,O
this,O
hypothesis,O
",",O
the,O
overall,O
gut,O
mycobiome,O
was,O
unstable,O
in,O
a,O
subset,O
of,O
patients,O
with,O
COVID-19,O
over,O
time,O
of,O
hospitalization,O
",",O
and,O
these,O
individuals,O
ended,O
up,O
with,O
a,O
different,O
gut,O
mycobiome,O
composition,O
compared,O
with,O
that,O
of,O
healthy,O
individuals,O
.,O
In,O
addition,O
",",O
gut,O
mycobiome,O
diversity,O
of,O
patients,O
with,O
COVID-19,O
at,O
the,O
last,O
follow,O
-,O
up,O
during,O
hospitalization,O
was,O
significantly,O
higher,O
than,O
that,O
of,O
healthy,O
individuals,O
.,O
These,O
data,O
indicate,O
expansion,O
of,O
fungi,O
in,O
the,O
gut,O
of,O
patients,O
with,O
COVID-19,O
and,O
SARS,O
-,O
CoV-2,O
infection,O
may,O
be,O
associated,O
with,O
a,O
persistent,O
gut,O
mycobiome,O
dysbiosis,O
in,O
some,O
patients,O
.,O
Secondary,O
fungal,O
infection,O
or,O
coinfection,O
in,O
patients,O
with,O
COVID-19,O
during,O
the,O
pandemic,O
is,O
garnering,O
increased,O
attention,O
.,O
Specific,O
enrichments,O
of,O
opportunistic,O
fungal,O
pathogens,O
",",O
Candida,O
and,O
Aspergillus,O
lineages,O
",",O
were,O
observed,O
in,O
patients,O
with,O
COVID-19,O
during,O
the,O
disease,O
course,O
.,O
Among,O
them,O
",",O
C.,O
 ,O
albicans,O
was,O
overrepresented,O
in,O
COVID-19,O
.,O
Aspergillus,O
infections,O
were,O
recently,O
reported,O
in,O
respiratory,O
tract,O
secretions,O
and,O
tracheal,O
aspirates,O
in,O
patients,O
with,O
COVID-19,O
from,O
2,O
studies,O
(,O
detection,O
rate,O
of,O
10,O
%,O
and,O
20,O
%,O
",",O
respectively,O
",",O
in,O
cohorts,O
from,O
China,O
and,O
France,O
),O
.,O
",",O
 ,O
Population,O
-,O
based,O
studies,O
have,O
reported,O
19,O
%,O
to,O
33,O
%,O
incidence,O
of,O
pulmonary,O
aspergillosis,O
in,O
patients,O
with,O
COVID-19.31,O
",",O
32,O
",",O
33,O
Aspergillus,O
is,O
a,O
genus,O
of,O
ubiquitous,O
fungi,O
that,O
cause,O
a,O
variety,O
of,O
pulmonary,O
and,O
respiratory,O
symptoms,O
.,O
To,O
date,O
",",O
there,O
are,O
a,O
lack,O
of,O
data,O
on,O
whether,O
fungal,O
pathogens,O
exist,O
in,O
the,O
gut,O
of,O
patients,O
with,O
COVID-19,O
.,O
In,O
this,O
case,O
series,O
",",O
we,O
provide,O
the,O
first,O
evidence,O
demonstrating,O
the,O
presence,O
of,O
opportunistic,O
Aspergillus,O
pathogens,O
in,O
the,O
feces,O
of,O
patients,O
with,O
COVID-19,O
;,O
A.,O
 ,O
flavus,O
were,O
detected,O
in,O
the,O
feces,O
of,O
20,O
%,O
of,O
patients,O
with,O
COVID-19,O
via,O
metagenomics,O
sequencing,O
.,O
All,O
6,O
patients,O
with,O
COVID-19,O
who,O
had,O
fecal,O
A.,O
 ,O
flavus,O
presented,O
with,O
cough,O
during,O
hospitalization,O
",",O
suggestive,O
of,O
a,O
systemic,O
effect,O
of,O
Aspergillus,O
infection,O
and,O
the,O
intricate,O
link,O
between,O
the,O
GI,O
and,O
respiratory,O
systems,O
.,O
Two,O
of,O
the,O
3,O
patients,O
(,O
CoV1,O
and,O
3,O
),O
who,O
had,O
both,O
fungal,O
species,O
A.,O
 ,O
flavus,O
and,O
A.,O
 ,O
niger,O
in,O
their,O
feces,O
presented,O
with,O
critical,O
COVID-19,O
and,O
were,O
admitted,O
to,O
intensive,O
care,O
unit,O
",",O
and,O
the,O
third,O
case,O
(,O
CoV7,O
),O
had,O
high,O
fever,O
and,O
moderate,O
COVID-19,O
severity,O
.,O
Patient,O
CoV19,O
who,O
had,O
mild,O
COVID-19,O
showed,O
clearance,O
of,O
A.,O
 ,O
flavus,O
and,O
A.,O
 ,O
niger,O
over,O
time,O
of,O
hospitalization,O
.,O
Although,O
the,O
overall,O
gut,O
mycobiome,O
structure,O
in,O
patients,O
with,O
COVID-19,O
gradually,O
resembled,O
that,O
of,O
healthy,O
individuals,O
over,O
time,O
of,O
hospitalization,O
(,O
Figure,O
 ,O
3,O
),O
",",O
Aspergillus,O
species,O
continued,O
to,O
be,O
present,O
in,O
a,O
subset,O
of,O
patients,O
with,O
COVID-19,O
(,O
CoV3,O
and,O
CoV15,O
),O
even,O
after,O
nasopharyngeal,O
clearance,O
of,O
SARS,O
-,O
CoV-2,O
(,O
Figure,O
 ,O
5,O
),O
.,O
The,O
post,O
-,O
recovery,O
existence,O
of,O
Aspergillus,O
species,O
underscores,O
a,O
potential,O
prolonged,O
detrimental,O
effect,O
of,O
secondary,O
fungal,O
infection,O
on,O
host,O
health,O
after,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
cautioning,O
on,O
long,O
-,O
term,O
monitoring,O
of,O
patients,O
with,O
COVID-19,O
after,O
recovery,O
.,O
Similar,O
to,O
patients,O
with,O
COVID-19,O
",",O
blooms,O
of,O
opportunistic,O
fungal,O
pathogens,O
",",O
Candida,O
species,O
and,O
Aspergillus,O
species,O
",",O
were,O
also,O
seen,O
in,O
patients,O
with,O
community,O
-,O
acquired,O
pneumonia,O
.,O
In,O
contrast,O
",",O
patients,O
with,O
community,O
-,O
acquired,O
pneumonia,O
showed,O
more,O
heterogeneous,O
gut,O
mycobiome,O
configurations,O
than,O
patients,O
with,O
COVID-19,O
",",O
indicating,O
that,O
the,O
gut,O
mycobiome,O
in,O
community,O
-,O
acquired,O
pneumonia,O
may,O
be,O
more,O
“,O
dysbiotic,O
”,O
than,O
that,O
in,O
COVID-19,O
.,O
In,O
addition,O
",",O
the,O
diversity,O
and,O
richness,O
of,O
the,O
gut,O
mycobiome,O
were,O
both,O
significantly,O
lower,O
in,O
patients,O
with,O
COVID-19,O
than,O
patients,O
with,O
community,O
-,O
acquired,O
pneumonia,O
.,O
These,O
data,O
collectively,O
suggest,O
that,O
patients,O
with,O
COVID-19,O
have,O
a,O
similar,O
but,O
less,O
severe,O
dysbiosis,O
of,O
gut,O
mycobiome,O
compared,O
with,O
patients,O
with,O
community,O
-,O
acquired,O
pneumonia,O
.,O
We,O
performed,O
deep,O
shotgun,O
metagenomic,O
sequencing,O
analysis,O
of,O
fecal,O
samples,O
from,O
30,O
patients,O
with,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
in,O
Hong,O
Kong,O
",",O
from,O
February,O
5,O
through,O
May,O
12,O
",",O
2020,O
.,O
We,O
compared,O
fecal,O
mycobiome,O
compositions,O
of,O
patients,O
with,O
COVID-19,O
with,O
those,O
from,O
9,O
subjects,O
with,O
community,O
-,O
acquired,O
pneumonia,O
and,O
30,O
healthy,O
individuals,O
(,O
controls,O
),O
.,O
Results,O
 ,O
Patients,O
with,O
COVID-19,O
had,O
significant,O
alterations,O
in,O
their,O
fecal,O
mycobiomes,O
compared,O
with,O
controls,O
",",O
characterized,O
by,O
enrichment,O
of,O
Candia,O
albicans,O
and,O
a,O
highly,O
heterogeneous,O
mycobiome,O
configuration,O
",",O
at,O
time,O
of,O
hospitalization,O
.,O
Although,O
fecal,O
mycobiomes,O
of,O
22,O
patients,O
with,O
COVID-19,O
did,O
not,O
differ,O
significantly,O
from,O
those,O
of,O
controls,O
during,O
times,O
of,O
hospitalization,O
",",O
8,O
of,O
30,O
patients,O
with,O
COVID-19,O
had,O
continued,O
significant,O
differences,O
in,O
fecal,O
mycobiome,O
composition,O
",",O
through,O
the,O
last,O
sample,O
collected,O
.,O
The,O
diversity,O
of,O
the,O
fecal,O
mycobiome,O
of,O
the,O
last,O
sample,O
collected,O
from,O
patients,O
with,O
COVID-19,O
was,O
2.5,O
-,O
fold,O
higher,O
than,O
that,O
of,O
controls,O
(,O
P,O
<,O
.05,O
),O
.,O
Samples,O
collected,O
at,O
all,O
timepoints,O
from,O
patients,O
with,O
COVID-19,O
had,O
increased,O
proportions,O
of,O
opportunistic,O
fungal,O
pathogens,O
",",O
Candida,O
albicans,O
",",O
Candida,O
auris,O
",",O
and,O
Aspergillus,O
flavus,O
compared,O
with,O
controls,O
.,O
Two,O
respiratory,O
-,O
associated,O
fungal,O
pathogens,O
",",O
A.,O
 ,O
flavus,O
and,O
Aspergillus,O
niger,O
",",O
were,O
detected,O
in,O
fecal,O
samples,O
from,O
a,O
subset,O
of,O
patients,O
with,O
COVID-19,O
",",O
even,O
after,O
clearance,O
of,O
SARS,O
-,O
CoV-2,O
from,O
nasopharyngeal,O
samples,O
and,O
resolution,O
of,O
respiratory,O
symptoms,O
.,O
In,O
a,O
pilot,O
study,O
",",O
we,O
found,O
heterogeneous,O
configurations,O
of,O
the,O
fecal,O
mycobiome,O
",",O
with,O
enrichment,O
of,O
fungal,O
pathogens,O
from,O
the,O
genera,O
Candida,O
and,O
Aspergillus,O
",",O
during,O
hospitalization,O
of,O
30,O
patients,O
with,O
COVID-19,O
compared,O
with,O
controls,O
.,O
Unstable,O
gut,O
mycobiomes,O
and,O
prolonged,O
dysbiosis,O
persisted,O
in,O
a,O
subset,O
of,O
patients,O
with,O
COVID-19,O
up,O
to,O
12,O
days,O
after,O
nasopharyngeal,O
clearance,O
of,O
SARS,O
-,O
CoV-2,O
.,O
The,O
outbreak,O
of,O
COVID-19,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
has,O
gradually,O
expanded,O
to,O
pandemic,O
(,O
Wang,O
et,O
 ,O
al,O
.,O
",",O
2020a,O
;,O
World,O
Health,O
Organization,O
",",O
2020b,O
),O
",",O
due,O
to,O
the,O
strong,O
infectivity,O
of,O
the,O
virus,O
.,O
In,O
order,O
to,O
extend,O
the,O
cell,O
-,O
based,O
data,O
to,O
tissue,O
-,O
specific,O
mode,O
",",O
we,O
collected,O
population,O
-,O
based,O
proteomic,O
datasets,O
",",O
from,O
human,O
lung,O
(,O
Mertins,B-Creator
"et al.,",I-Creator
2018,E-Creator
),O
",",O
colon,O
(,O
Vasaikar,B-Creator
"et al.,",I-Creator
2019,E-Creator
),O
",",O
kidney,O
(,O
Clark,B-Creator
"et al.,",I-Creator
2019,E-Creator
),O
",",O
liver,O
(,O
Gao,B-Creator
"et al.,",I-Creator
2019,E-Creator
),O
",",O
and,O
heart,O
(,O
Doll,B-Creator
"et al.,",I-Creator
2017,E-Creator
),O
.,O
The,O
first,O
four,O
datasets,O
are,O
from,O
the,O
National,B-Repository
Cancer,I-Repository
Institute,I-Repository
Clinical,I-Repository
Proteomic,I-Repository
Tumor,I-Repository
Analysis,I-Repository
Consortium,I-Repository
(CPTAC),E-Repository
",",O
which,O
include,O
various,O
normal,O
tissues,O
.,O
First,O
",",O
we,O
checked,O
RNA,O
and,O
antibody,O
-,O
based,O
protein,O
data,O
for,O
three,O
receptors,O
and,O
TMPRSS2,O
",",O
from,O
a,O
variety,O
of,O
tissues,O
in,O
the,O
Human,B-Repository
Protein,I-Repository
Atlas,I-Repository
(HPA),E-Repository
 ,O
database,O
(,O
https://www.proteinatlas.org/,S-URL
),O
.,O
Then,O
",",O
we,O
collected,O
mass,O
spectrometry,O
-,O
based,O
proteomic,O
data,O
of,O
normal,O
tissues,O
of,O
four,O
organs,O
from,O
CPTAC,S-Repository
 ,O
database,O
and,O
a,O
set,O
of,O
data,O
of,O
normal,O
heart,O
(,O
Doll,B-Creator
"et al.,",I-Creator
2017,E-Creator
),O
",",O
including,O
two,O
parts,O
",",O
respectively,O
",",O
from,O
cavities,O
and,O
vessels,O
.,O
The,O
correlation,O
between,O
each,O
two,O
proteins,O
across,O
individuals,O
in,O
each,O
dataset,O
was,O
used,O
as,O
the,O
weight,O
of,O
the,O
edge,O
.,O
According,O
to,O
the,O
threshold,O
that,O
we,O
set,O
",",O
TMPRSS2,O
is,O
not,O
associated,O
with,O
the,O
three,O
receptors,O
in,O
the,O
String,O
database,O
and,O
TMPRSS2,O
is,O
not,O
found,O
in,O
two,O
tissues,O
of,O
the,O
heart,O
.,O
Next,O
",",O
we,O
extracted,O
45,O
upregulated,O
proteins,O
in,O
host,O
cells,O
affected,O
by,O
24,O
-,O
h,O
SARS,O
-,O
CoV-2,O
infection,O
from,O
a,O
recently,O
reported,O
dataset,O
(,O
Bojkova,B-Creator
"et al.,",I-Creator
2020,E-Creator
),O
.,O
There,O
are,O
also,O
interactions,O
between,O
the,O
nodes,O
obtained,O
from,O
the,O
two,O
datasets,O
.,O
The,O
data,O
downloaded,O
from,O
CPTAC,S-Repository
 ,O
database,O
provide,O
relative,O
protein,O
abundance,O
by,O
sample,O
.,O
For,O
patients,O
with,O
COVID-19,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
the,O
damages,O
to,O
multiple,O
organs,O
have,O
been,O
clinically,O
observed,O
.,O
Based,O
on,O
collected,O
proteomic,O
datasets,O
from,O
human,O
lung,O
",",O
colon,O
",",O
kidney,O
",",O
liver,O
",",O
and,O
heart,O
",",O
we,O
constructed,O
a,O
virus,O
-,O
receptor,O
network,O
",",O
a,O
virus,O
-,O
interaction,O
network,O
",",O
and,O
a,O
virus,O
-,O
perturbation,O
network,O
.,O
The,O
present,O
analysis,O
implies,O
that,O
SARS,O
-,O
CoV-2,O
could,O
affect,O
multi,O
-,O
targets,O
in,O
diverse,O
host,O
tissues,O
",",O
and,O
the,O
treatment,O
of,O
COVID-19,O
would,O
be,O
a,O
complex,O
task,O
.,O
The,O
global,O
outbreak,O
of,O
COVID-19,O
has,O
emerged,O
as,O
a,O
severe,O
threat,O
to,O
human,O
health,O
(,O
–,O
),O
.,O
COVID-19,O
is,O
caused,O
by,O
a,O
novel,O
coronavirus,O
",",O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
which,O
is,O
an,O
enveloped,O
",",O
positive,O
-,O
strand,O
RNA,O
virus,O
that,O
causes,O
symptoms,O
such,O
as,O
cough,O
",",O
headache,O
",",O
dyspnea,O
",",O
myalgia,O
",",O
fever,O
",",O
and,O
severe,O
pneumonia,O
in,O
humans,O
(,O
",",O
–,O
),O
.,O
The,O
SARS,O
-,O
CoV-2,O
S,O
protein,O
–,O
targeting,O
monoclonal,O
antibodies,O
(,O
mAbs,O
),O
with,O
potent,O
neutralizing,O
activity,O
are,O
a,O
focus,O
in,O
the,O
development,O
of,O
therapeutic,O
interventions,O
for,O
COVID-19,O
(,O
–,O
),O
.,O
We,O
isolated,O
and,O
characterized,O
monoclonal,O
antibodies,O
(,O
mAbs,O
),O
from,O
10,O
convalescent,O
COVID-19,O
patients,O
.,O
This,O
points,O
to,O
the,O
NTD,O
as,O
a,O
promising,O
target,O
for,O
therapeutic,O
mAbs,O
against,O
COVID-19,O
.,O
The,O
ongoing,O
pandemic,O
of,O
COVID-19,O
which,O
originated,O
at,O
Wuhan,O
and,O
its,O
progressing,O
rate,O
of,O
transmission,O
into,O
188,O
countries,O
and,O
territories,O
has,O
created,O
a,O
havoc,O
in,O
the,O
society,O
declaring,O
it,O
as,O
a,O
global,O
health,O
emergency,O
by,O
WHO,O
on,O
30,O
January,O
2020,O
(,O
Rasmussen,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Since,O
then,O
",",O
the,O
situation,O
has,O
been,O
deteriorating,O
in,O
the,O
European,O
provinces,O
and,O
American,O
regions,O
",",O
where,O
the,O
South,O
Asian,O
countries,O
have,O
also,O
been,O
carrying,O
a,O
worse,O
COVID-19,O
burden,O
.,O
Currently,O
more,O
than,O
400,O
genome,O
sequences,O
SARS,O
-,O
CoV2,O
are,O
available,O
at,O
NCBI,S-Repository
 ,O
databases,O
and,O
that,O
gives,O
a,O
plethora,O
of,O
information,O
to,O
aid,O
the,O
development,O
of,O
the,O
drug,O
and,O
vaccine,O
.,O
The,O
SARS,O
-,O
CoV-2,O
miRNA,O
prediction,O
was,O
carried,O
out,O
using,O
the,O
complete,O
genome,O
sequence,O
of,O
SARS,O
-,O
CoV2,O
carrying,O
accession,O
number,O
(,O
NC_045512.2,S-AccessionNumber
",",O
MT435086,S-AccessionNumber
",",O
MT339041,S-AccessionNumber
",",O
MT066156,S-AccessionNumber
 ,O
and,O
MT507794.1,S-AccessionNumber
),O
for,O
China,O
",",O
India,O
",",O
USA,O
",",O
Italy,O
and,O
Jamaica,O
respectively,O
;,O
obtained,O
from,O
the,O
National,B-Repository
Centre,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,I-Repository
(NCBI),E-Repository
.,O
Human,O
miRNA,O
sequences,O
are,O
available,O
in,O
the,O
miRBase,S-Repository
 ,O
database,O
(,O
http://www.mirbase.org,S-URL
),O
.,O
Each,O
of,O
the,O
Candidate,O
precursor,O
miRNAs,O
was,O
searched,O
for,O
the,O
nucleotide,O
similarity,O
with,O
all,O
human,O
miRNAs,O
by,O
using,O
the,O
SSEARCH,O
(,O
it,O
is,O
useful,O
for,O
finding,O
a,O
short,O
sequence,O
within,O
the,O
library,O
of,O
miRNA,O
),O
menu,O
of,O
the,O
miRbase,S-Repository
 ,O
database,O
.,O
Gene,O
ID,O
’s,O
of,O
target,O
genes,O
were,O
used,O
for,O
this,O
analysis,O
to,O
find,O
GO,O
terms,O
related,O
to,O
gene,O
products,O
(,O
Chen,O
and,O
Glover,O
",",O
2016,O
;,O
Dalmer,O
and,O
Clugston,O
",",O
2019,O
;,O
Hu,O
et,O
al,O
.,O
",",O
2019,O
),O
.,O
The,O
sequences,O
of,O
all,O
the,O
five,O
viral,O
SARS,O
-,O
CoV2,O
miRNA,O
candidate,O
precursors,O
obtained,O
was,O
searched,O
using,O
SSEARCH,O
menu,O
the,O
miRbase,S-Repository
 ,O
database,O
for,O
finding,O
the,O
nucleotide,O
similarity,O
with,O
all,O
human,O
microRNAs,O
using,O
the,O
default,O
parameters,O
(,O
E,O
-,O
cut,O
off,O
value,O
:,O
10,O
",",O
Maximum,O
no,O
.,O
of,O
hits,O
:,O
100,O
",",O
Specific,O
organism,O
:,O
human,O
),O
.,O
However,O
",",O
in,O
SARS,O
-,O
CoV2,O
;,O
only,O
2–11,O
%,O
infected,O
patients,O
carry,O
liver,O
morbidities,O
but,O
remains,O
indistinct,O
whether,O
the,O
liver,O
damage,O
in,O
COVID-19,O
patients,O
was,O
caused,O
by,O
a,O
viral,O
infection,O
or,O
drug,O
toxicity,O
(,O
Liu,O
et,O
al,O
.,O
",",O
n.d,O
.,O
),O
.,O
Another,O
phenomenon,O
associated,O
is,O
the,O
basal,O
transcription,O
machinery,O
of,O
the,O
SARS,O
-,O
CoV2,O
(,O
TAF,O
’s,O
),O
of,O
TFIID,O
complex,O
which,O
could,O
prevent,O
the,O
RNA,O
polymerase,O
II,O
to,O
assemble,O
on,O
the,O
promoters,O
of,O
the,O
host,O
genes,O
at,O
the,O
initiation,O
step,O
that,O
can,O
specifically,O
block,O
the,O
transcription,O
.,O
Predicted,O
miRNAs,O
from,O
SARS,O
-,O
CoV2,O
viral,O
genomes,O
were,O
used,O
for,O
effective,O
hybridization,O
sequence,O
identification,O
along,O
the,O
nucleotide,O
similarities,O
with,O
human,O
miRNAs,O
from,O
miRbase,S-Repository
 ,O
database,O
.,O
Since,O
its,O
first,O
occurrence,O
in,O
December,O
2019,O
in,O
China,O
",",O
the,O
SARS,O
-,O
CoV-2,O
outbreak,O
",",O
leading,O
to,O
COronaVIrus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
",",O
spread,O
around,O
the,O
world,O
.,O
Although,O
other,O
studies,O
have,O
already,O
evaluated,O
mismatches,O
in,O
primers,O
and,O
probes,O
used,O
for,O
SARS,O
-,O
CoV-2,O
detection,O
",",O
they,O
have,O
often,O
only,O
incorporated,O
a,O
limited,O
number,O
of,O
genome,O
sequences,O
or,O
RT,O
-,O
qPCR,O
assays,O
",",O
or,O
only,O
evaluated,O
the,O
situation,O
at,O
a,O
single,O
time,O
point,O
[,O
"28,35,36,37,38",O
],O
.,O
Seven,O
RT,O
-,O
qPCR,O
tests,O
originated,O
from,O
the,O
WHO,O
technical,O
guidance,O
published,O
for,O
laboratory,O
testing,O
of,O
SARS,O
-,O
CoV-2,O
in,O
humans,O
[,O
27,O
],O
and,O
were,O
developed,O
by,O
(,O
in,O
no,O
specific,O
order,O
),O
the,O
Chinese,O
Center,O
for,O
Disease,O
Control,O
and,O
prevention,O
(,O
CDC,O
),O
(,O
Assays_1,O
(,O
ORF1b,O
and,O
N,O
),O
),O
",",O
the,O
German,O
Charité,O
Hospital,O
(,O
Assays_2,O
(,O
RdRp,O
-,O
P1,O
",",O
RdRp,O
-,O
P2,O
",",O
E,O
",",O
and,O
N,O
),O
),O
",",O
the,O
French,O
Institut,O
Pasteur,O
(,O
Assays_3,O
(,O
RdRp,O
-,O
IP2,O
",",O
RdRp,O
-,O
IP4,O
",",O
and,O
E,O
),O
),O
",",O
the,O
US,O
CDC,O
(,O
Assays_4,O
(,O
N-1,O
",",O
N-2,O
",",O
and,O
N-3,O
),O
),O
",",O
the,O
Japanese,O
National,O
Institute,O
for,O
Infectious,O
Diseases,O
(,O
NIID,O
),O
(,O
Assay_5_N,O
),O
",",O
the,O
Hong,O
-,O
Kongese,O
Faculty,O
of,O
Medicine,O
HKU,O
Med,O
(,O
Assays_6,O
(,O
RdRp,O
/,O
nsp14,O
and,O
N,O
),O
),O
",",O
and,O
the,O
Thai,O
National,O
Institute,O
of,O
Health,O
(,O
NIH,O
),O
(,O
Assay_7_N,O
),O
.,O
Other,O
assays,O
(,O
5,O
),O
were,O
retrieved,O
from,O
the,O
literature,O
or,O
from,O
a,O
working,O
document,O
of,O
the,O
European,O
Commission,O
inventorying,O
the,O
diagnostic,O
tests,O
developed,O
for,O
COVID-19,O
[,O
34]—i.e,O
.,O
",",O
Assays_8,O
(,O
RdRp,O
/,O
Hel,O
",",O
S,O
",",O
and,O
N,O
),O
),O
",",O
Assays_9_ORF1a,O
",",O
Assays_10,O
(,O
RdRp,O
",",O
S,O
",",O
E,O
",",O
and,O
N,O
),O
",",O
Assays_11,O
(,O
N-1,O
",",O
N-2,O
",",O
ORF1a-3,O
",",O
ORF1a-4,O
",",O
S-5,O
",",O
and,O
S-6,O
),O
",",O
and,O
Assay_12_E.,O
A,O
total,O
of,O
3590,O
SARS,O
-,O
CoV-2,O
genomes,O
",",O
sequenced,O
from,O
samples,O
collected,O
before,O
the,O
7th,O
of,O
April,O
2020,O
",",O
were,O
downloaded,O
from,O
the,O
GISAID,B-Dataset
EpiCoV,E-Dataset
 ,O
database,O
",",O
the,O
NCBI,B-Repository
Virus,E-Repository
 ,O
database,O
",",O
and,O
the,O
CNGB,B-Repository
hCoV-19,E-Repository
 ,O
database,O
.,O
For,O
exclusivity,O
testing,O
",",O
2624,O
non,O
-,O
SARS,O
-,O
CoV-2,O
genomes,O
belonging,O
to,O
other,O
members,O
of,O
the,O
Coronaviridae,O
family,O
and,O
other,O
common,O
respiratory,O
viruses,O
were,O
downloaded,O
from,O
the,O
NCBI,B-Repository
Virus,E-Repository
 ,O
database,O
and,O
ViralZone,S-Repository
.,O
With,O
the,O
aim,O
of,O
evaluating,O
the,O
stability,O
of,O
the,O
assay,O
’s,O
specificity,O
over,O
time,O
",",O
a,O
second,O
batch,O
of,O
SARS,O
-,O
CoV-2,O
genomes,O
(,O
1165,O
),O
",",O
sequenced,O
from,O
samples,O
collected,O
between,O
the,O
7th,O
of,O
April,O
and,O
the,O
7th,O
of,O
May,O
2020,O
",",O
was,O
downloaded,O
from,O
the,O
GISAID,B-Dataset
EpiCoV,E-Dataset
 ,O
and,O
NCBI,B-Repository
Virus,E-Repository
 ,O
databases,O
.,O
After,O
clearing,O
this,O
dataset,O
from,O
low,O
-,O
quality,O
sequences,O
and,O
the,O
clustering,O
of,O
identical,O
genomes,O
",",O
968,O
representative,O
unique,O
SARS,O
-,O
CoV-2,O
genomes,O
were,O
obtained,O
.,O
The,O
other,O
primers,O
and,O
probe,O
sets,O
evaluated,O
with,O
this,O
more,O
recent,O
dataset,O
all,O
demonstrated,O
a,O
100,O
%,O
inclusivity,O
",",O
except,O
Assay_2_RdRp,O
-,O
P1,O
",",O
Assay_2_RdRp,O
-,O
P2,O
",",O
and,O
Assay_8_N,O
",",O
which,O
showed,O
an,O
inclusivity,O
of,O
between,O
99,O
%,O
and,O
100,O
%,O
.,O
Interestingly,O
",",O
when,O
the,O
inclusivity,O
of,O
Assays,O
1,O
(,O
ORF1b,O
and,O
N,O
),O
",",O
Assays_2,O
(,O
RdRp,O
-,O
P1,O
",",O
RdRp,O
-,O
P2,O
",",O
E,O
",",O
and,O
N,O
),O
",",O
Assays_4,O
(,O
N-1,O
",",O
N-2,O
",",O
and,O
N-3,O
),O
",",O
and,O
Assays_8,O
(,O
RdRp,O
/,O
Hel,O
",",O
S,O
",",O
and,O
N,O
),O
was,O
evaluated,O
again,O
with,O
a,O
new,O
dataset,O
of,O
SARS,O
-,O
CoV-2,O
genomes,O
downloaded,O
one,O
month,O
after,O
the,O
first,O
one,O
;,O
some,O
of,O
these,O
SNPs,O
were,O
not,O
detected,O
any,O
more,O
",",O
while,O
few,O
new,O
ones,O
were,O
observed,O
.,O
To,O
better,O
appreciate,O
any,O
bias,O
",",O
it,O
would,O
be,O
beneficial,O
to,O
add,O
to,O
the,O
public,O
databases,O
enough,O
relevant,O
metadata,O
with,O
the,O
exact,O
information,O
on,O
how,O
the,O
SARS,O
-,O
CoV-2,O
positive,O
samples,O
were,O
determined,O
(,O
including,O
which,O
RT,O
-,O
qPCR,O
assay,O
was,O
used,O
",",O
if,O
determined,O
as,O
such,O
),O
",",O
and,O
how,O
the,O
libraries,O
for,O
the,O
WGS,O
of,O
the,O
viral,O
genome,O
were,O
made,O
",",O
as,O
this,O
information,O
is,O
not,O
always,O
available,O
.,O
This,O
positive,O
signal,O
is,O
not,O
surprising,O
",",O
as,O
a,O
close,O
genomic,O
similarity,O
was,O
observed,O
between,O
the,O
first,O
SARS,O
-,O
CoV,O
and,O
the,O
bat,O
-,O
coronavirus,O
suspected,O
to,O
be,O
the,O
origin,O
of,O
the,O
COVID-19,O
zoonosis,O
.,O
The,O
diversity,O
in,O
the,O
amplicon,O
sequences,O
was,O
very,O
limited,O
and,O
remained,O
unchanged,O
when,O
using,O
a,O
new,O
dataset,O
of,O
SARS,O
-,O
CoV-2,O
genomes,O
collected,O
one,O
month,O
after,O
the,O
first,O
one,O
",",O
indicating,O
that,O
this,O
locus,O
is,O
a,O
good,O
RT,O
-,O
qPCR,O
target,O
",",O
although,O
this,O
should,O
be,O
re,O
-,O
evaluated,O
on,O
regular,O
basis,O
.,O
Moreover,O
",",O
to,O
determine,O
if,O
new,O
stable,O
mutations,O
will,O
appear,O
in,O
SARS,O
-,O
CoV-2,O
",",O
potentially,O
impacting,O
the,O
specificity,O
of,O
RT,O
-,O
qPCR,O
tests,O
",",O
an,O
evaluation,O
similar,O
to,O
what,O
was,O
presented,O
in,O
this,O
study,O
should,O
be,O
conducted,O
regularly,O
and,O
definitely,O
as,O
soon,O
as,O
a,O
vaccine,O
or,O
treatment,O
is,O
in,O
place,O
",",O
as,O
new,O
data,O
are,O
uploaded,O
to,O
the,O
genomic,O
databases,O
daily,O
.,O
Firstly,O
",",O
the,O
genome,O
sequence,O
for,O
the,O
same,O
sample,O
can,O
potentially,O
be,O
deposited,O
in,O
multiple,O
databases,O
that,O
",",O
however,O
",",O
all,O
use,O
different,O
identifiers,O
that,O
can,O
not,O
be,O
reconciled,O
.,O
SCREENED,O
is,O
available,O
as,O
an,O
open,O
-,O
source,O
tool,O
that,O
can,O
be,O
executed,O
through,O
a,O
user,O
-,O
friendly,O
interface,O
using,O
the,O
Galaxy,O
Workflow,O
Management,O
system,O
[,O
57,O
],O
incorporated,O
in,O
the,O
public,O
Galaxy,O
@Sciensano,O
instance,O
(,O
https://galaxy.sciensano.be,O
",",O
Sciensano,O
",",O
Brussels,O
",",O
Belgium,O
),O
",",O
or,O
alternatively,O
that,O
can,O
be,O
downloaded,O
(,O
https://github.com/BioinformaticsPlatformWIV-ISP/SCREENED,O
",",O
GitHub,O
",",O
San,O
-,O
Francisco,O
",",O
CA,O
",",O
USA,O
),O
to,O
be,O
run,O
locally,O
on,O
the,O
Linux,O
command,O
line,O
.,O
The,O
current,O
COronaVIrus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
started,O
in,O
December,O
2019,O
.,O
COVID-19,O
cases,O
are,O
confirmed,O
by,O
the,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
biological,O
samples,O
by,O
RT,O
-,O
qPCR,O
.,O
Till,O
date,O
",",O
the,O
Integrated,O
Disease,O
Surveillance,O
Programme,O
(,O
IDSP,O
),O
",",O
a,O
national,O
health,O
programme,O
",",O
Government,O
of,O
India,O
",",O
has,O
collected,O
samples,O
from,O
symptomatic,O
travellers,O
in,O
liaison,O
with,O
the,O
State,O
-,O
level,O
Viral,O
Research,O
and,O
Diagnostic,O
Laboratories,O
(,O
VRDLs,O
),O
",",O
Department,O
of,O
Health,O
Research,O
.,O
These,O
sequences,O
were,O
also,O
compared,O
with,O
the,O
available,O
GenBank,S-Repository
 ,O
sequences,O
to,O
monitor,O
the,O
mutations,O
and,O
understand,O
their,O
relation,O
with,O
other,O
known,O
SARS,O
-,O
CoV-2,O
available,O
in,O
the,O
public,O
database,O
.,O
Full,O
-,O
length,O
genome,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
were,O
downloaded,O
from,O
the,O
GISAID,S-Dataset
 ,O
database17,O
(,O
Supplementary,O
Table,O
I,O
(,O
available,O
from,O
),O
),O
.,O
Multiple,O
sequence,O
alignment,O
was,O
performed,O
using,O
the,O
MEGA,O
software,O
version,O
7.018,O
with,O
retrieved,O
sequences,O
from,O
two,O
of,O
the,O
three,O
positive,O
cases,O
and,O
the,O
available,O
GISAID,S-Dataset
 ,O
sequences,O
.,O
The,O
FastQ,O
files,O
were,O
reference,O
mapped,O
with,O
the,O
available,O
Wuhan,O
seafood,O
pneumonia,O
virus,O
(,O
Wuhan,O
Hu-1,O
),O
complete,O
SARS,O
-,O
CoV-2,O
genome,O
(,O
accession,O
number,O
:,O
NC,B-AccessionNumber
045512.2,E-AccessionNumber
),O
.,O
Prediction,O
of,O
conformational,O
B,O
-,O
cell,O
epitopes,O
revealed,O
that,O
one,O
of,O
these,O
(,O
residue,O
positions,O
341,O
-,O
505,O
),O
in,O
the,O
spike,O
protein,O
incorporates,O
two,O
of,O
the,O
predicted,O
linear,O
epitopes,O
(,O
327,O
-,O
342,O
and,O
404,O
-,O
419,O
),O
having,O
good,O
antigenicity,O
along,O
with,O
a,O
favourable,O
IFN,O
-,O
γ,O
response,O
that,O
enables,O
differentiation,O
and,O
proliferation,O
of,O
the,O
B,O
-,O
cells25,O
.,O
The,O
sequences,O
of,O
Indian,O
SARS,O
-,O
CoV-2,O
though,O
not,O
identical,O
showed,O
high,O
(,O
~99.98,O
%,O
),O
identity,O
with,O
Wuhan,O
seafood,O
market,O
pneumonia,O
virus,O
(,O
accession,O
number,O
:,O
NC,B-AccessionNumber
045512,E-AccessionNumber
),O
.,O
As,O
government,O
restrictions,O
put,O
in,O
place,O
to,O
slow,O
the,O
acceleration,O
of,O
the,O
coronavirus,O
disease-2019,O
(,O
COVID-19,O
),O
pandemic,O
start,O
to,O
ease,O
",",O
many,O
people,O
",",O
including,O
elite,O
athletes,O
",",O
will,O
begin,O
to,O
return,O
back,O
to,O
their,O
normal,O
daily,O
activities,O
.,O
Although,O
the,O
majority,O
of,O
risk,O
factors,O
for,O
severe,O
COVID-19,O
—,O
hypertension,O
",",O
respiratory,O
system,O
disease,O
",",O
obesity,O
",",O
older,O
age,O
",",O
and,O
cardiovascular,O
disease,O
—,O
are,O
exceptionally,O
rare,O
in,O
elite,O
athletes,O
",",O
when,O
athletes,O
train,O
in,O
groups,O
or,O
common,O
training,O
areas,O
",",O
they,O
are,O
not,O
immune,O
from,O
contracting,O
the,O
illness,O
;,O
and,O
",",O
although,O
the,O
subsequent,O
risk,O
of,O
death,O
is,O
low,O
",",O
it,O
is,O
not,O
zero,O
.,O
It,O
has,O
been,O
estimated,O
that,O
22,O
%,O
of,O
the,O
global,O
population,O
are,O
at,O
increased,O
risk,O
of,O
severe,O
COVID-19,O
if,O
infected,O
.,O
One,O
area,O
with,O
potential,O
early,O
promise,O
is,O
that,O
of,O
genetic,O
testing,O
",",O
with,O
a,O
number,O
of,O
genetic,O
variants,O
tentatively,O
associated,O
with,O
an,O
increased,O
susceptibility,O
to,O
",",O
and,O
an,O
increased,O
chance,O
of,O
complications,O
from,O
",",O
contracting,O
COVID-19,O
.,O
",",O
So,O
far,O
",",O
4,O
studies4,O
",",O
5,O
",",O
6,O
",",O
7,O
have,O
shown,O
that,O
at,O
least,O
6,O
DNA,O
polymorphisms,O
might,O
be,O
implicated,O
in,O
COVID-19,O
severity,O
",",O
with,O
the,O
ABO,O
blood,O
group,O
(,O
ABO,O
),O
rs657152,O
A,O
",",O
angiotensin,O
I,O
converting,O
enzyme,O
(,O
ACE,O
),O
D,O
",",O
apolipoprotein,O
E,O
(,O
APOE,O
),O
rs429358,O
C,O
",",O
leucine,O
zipper,O
transcription,O
factor,O
like,O
1,O
(,O
LZTFL1,O
),O
rs11385942,O
GA,O
",",O
transmembrane,O
protein,O
189,O
-,O
ubiquitin,O
-,O
conjugating,O
enzyme,O
E2,O
variant,O
1,O
(,O
TMEM189,O
-,O
UBE2V1,O
),O
rs6020298,O
A,O
",",O
and,O
transmembrane,O
serine,O
protease,O
2,O
(,O
TMPRSS2,O
),O
rs12329760,O
We,O
thus,O
hypothesized,O
that,O
polygenic,O
risk,O
scores,O
for,O
COVID-19,O
severity,O
based,O
on,O
6,O
DNA,O
polymorphisms,O
may,O
vary,O
across,O
different,O
sporting,O
groups,O
(,O
endurance,O
and,O
power,O
oriented,O
),O
.,O
Using,O
the,O
1000,B-Repository
Genomes,E-Repository
 ,O
database,O
and,O
our,O
own,O
data,O
of,O
802,O
Russian,O
elite,O
athletes,O
and,O
224,O
controls,O
(,O
Supplementary,O
Table,O
3,O
and,O
Supplementary,O
Methods,O
),O
",",O
we,O
first,O
identified,O
the,O
proportion,O
of,O
subjects,O
with,O
increased,O
risk,O
in,O
each,O
population,O
.,O
In,O
conclusion,O
",",O
we,O
identified,O
that,O
team,O
sport,O
",",O
power,O
",",O
and,O
combat,O
athletes,O
possess,O
a,O
higher,O
genetic,O
risk,O
for,O
COVID-19,O
severity,O
than,O
untrained,O
subjects,O
or,O
endurance,O
athletes,O
.,O
Highlights,O
    ,O
•,O
 ,O
Predictive,O
genetic,O
testing,O
of,O
an,O
asymptomatic,O
person,O
has,O
considerable,O
potential,O
to,O
predict,O
future,O
risk,O
of,O
coronavirus,O
disease-2019,O
(,O
COVID-19,O
),O
severity,O
.,O
Risk,O
alleles,O
for,O
COVID-19,O
severity,O
due,O
to,O
the,O
pleiotropic,O
effects,O
are,O
associated,O
with,O
performance,O
-,O
related,O
traits,O
.,O
Team,O
sport,O
",",O
power,O
",",O
and,O
combat,O
athletes,O
possess,O
a,O
higher,O
genetic,O
risk,O
for,O
COVID-19,O
severity,O
than,O
untrained,O
subjects,O
or,O
endurance,O
athletes,O
.,O
Acute,O
kidney,O
injury,O
(,O
AKI,O
),O
is,O
a,O
life,O
-,O
threatening,O
disorder,O
",",O
although,O
the,O
rate,O
of,O
AKI,O
in,O
COVID-19,O
is,O
relatively,O
rare,O
.,O
According,O
to,O
reports,O
from,O
Wuhan,O
",",O
China,O
",",O
among,O
138,O
hospitalized,O
patients,O
with,O
COVID-19,O
",",O
only,O
5,O
(,O
3.6,O
%,O
),O
patients,O
developed,O
AKI,O
and,O
2,O
(,O
1.5,O
%,O
),O
patients,O
required,O
continuous,O
renal,O
replacement,O
therapy,O
(,O
CRRT,O
),O
[,O
1,O
],O
.,O
There,O
are,O
no,O
data,O
about,O
managing,O
CRRT,O
",",O
including,O
prevention,O
of,O
secondary,O
infection,O
and,O
control,O
(,O
IPC,O
),O
in,O
COVID-19,O
patients,O
.,O
Here,O
",",O
we,O
report,O
a,O
case,O
of,O
a,O
patient,O
with,O
severe,O
COVID-19,O
who,O
required,O
CRRT,O
.,O
A,O
septuagenarian,O
male,O
suffering,O
from,O
COVID-19,O
was,O
referred,O
to,O
our,O
hospital,O
.,O
According,O
to,O
a,O
recent,O
report,O
from,O
Wuhan,O
",",O
China,O
",",O
among,O
52,O
critically,O
ill,O
adult,O
patients,O
with,O
COVID-19,O
pneumonia,O
who,O
were,O
admitted,O
to,O
the,O
ICU,O
",",O
12,O
(,O
23,O
%,O
),O
patients,O
developed,O
AKI,O
and,O
9,O
(,O
17,O
%,O
),O
required,O
renal,O
replacement,O
therapy,O
(,O
RRT,O
),O
[,O
6,O
],O
.,O
With,O
the,O
increasing,O
number,O
of,O
COVID-19,O
patients,O
",",O
the,O
need,O
for,O
RRT,O
is,O
likely,O
to,O
increase,O
.,O
Although,O
the,O
recommendation,O
by,O
the,O
WHO,O
for,O
the,O
use,O
of,O
personal,O
protective,O
equipment,O
for,O
COVID-19,O
did,O
not,O
include,O
CRRT,O
[,O
8,O
],O
",",O
we,O
considered,O
the,O
risk,O
of,O
aerosol,O
generation,O
during,O
CRRT,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
report,O
describing,O
the,O
management,O
of,O
CRRT,O
including,O
IPC,O
among,O
COVID-19,O
patients,O
.,O
From,O
our,O
experience,O
",",O
we,O
suggest,O
clinical,O
practice,O
and,O
IPC,O
for,O
delivering,O
RRT,O
in,O
the,O
acute,O
phase,O
in,O
COVID-19,O
patients,O
who,O
develop,O
AKI,O
(,O
Table,O
2,O
),O
.,O
The,O
outbreak,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
a,O
global,O
health,O
threat,O
.,O
Recently,O
",",O
we,O
had,O
a,O
critically,O
ill,O
COVID-19,O
patient,O
who,O
developed,O
severe,O
AKI,O
and,O
needed,O
continuous,O
RRT,O
(,O
CRRT,O
),O
.,O
Due,O
to,O
unstable,O
hemodynamic,O
status,O
in,O
critically,O
ill,O
patients,O
",",O
CRRT,O
should,O
be,O
the,O
first,O
choice,O
for,O
severe,O
AKI,O
in,O
COVID-19,O
patients,O
.,O
We,O
suggest,O
prevention,O
of,O
clinical,O
infection,O
and,O
control,O
during,O
administration,O
of,O
RRT,O
in,O
the,O
acute,O
phase,O
of,O
COVID-19,O
patients,O
with,O
AKI,O
or,O
multiple,O
organ,O
failure,O
.,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus-2,O
(,O
SARS,O
-,O
CoV-2,O
),O
and,O
its,O
associated,O
disease,O
known,O
as,O
COVID-19,O
",",O
was,O
originated,O
in,O
Wuhan,O
",",O
China,O
(,O
Zhu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Among,O
others,O
",",O
symptoms,O
of,O
COVID-19,O
include,O
fever,O
",",O
cough,O
and,O
shortness,O
of,O
breath,O
(,O
Chen,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Generally,O
",",O
the,O
mutation,O
occurs,O
when,O
an,O
error,O
is,O
incorporated,O
in,O
a,O
viral,O
genome,O
(,O
Fleischmann,O
",",O
1996,O
),O
.,O
The,O
genomic,O
sequences,O
of,O
Indian,O
SARS,O
-,O
CoV-2,O
virus,O
was,O
collected,O
from,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
2,O
in,O
fasta,O
format,O
on,O
11th,O
June,O
2020,O
.,O
The,O
dataset,O
contains,O
566,O
genomes,O
with,O
sequence,O
ID,O
and,O
sequence,O
in,O
fasta,O
format,O
.,O
We,O
have,O
extracted,O
the,O
date,O
from,O
the,O
sequence,O
ID,O
to,O
show,O
the,O
number,O
of,O
sequences,O
uploaded,O
per,O
month,O
.,O
Moreover,O
",",O
the,O
original,O
and,O
shorter,O
sequence,O
IDs,O
(,O
for,O
better,O
visualization,O
),O
and,O
the,O
length,O
of,O
each,O
genome,O
are,O
mentioned,O
in,O
the,O
supplementary,O
Table,O
S1,O
.,O
The,O
wave,O
of,O
COVID-19,O
is,O
a,O
big,O
threat,O
to,O
the,O
human,O
population,O
.,O
Forster,O
et,O
al,O
.,O
(,O
1,O
),O
performed,O
a,O
phylogenetic,O
network,O
analysis,O
with,O
160,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
genomes,O
from,O
a,O
public,O
database,O
and,O
proposed,O
a,O
network,O
of,O
ancestral,O
nodes,O
and,O
derived,O
types,O
",",O
suggesting,O
virus,O
adaptability,O
to,O
specific,O
geographical,O
regions,O
.,O
SARS,O
-,O
CoV-2,O
has,O
caused,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
across,O
the,O
country,O
and,O
abroad,O
.,O
A,O
total,O
of,O
83,O
 ,O
157,O
COVID-19,O
cases,O
with,O
4.02,O
%,O
mortality,O
has,O
been,O
reported,O
in,O
China,O
up,O
to,O
7,O
April,O
2020,O
[,O
4,O
],O
.,O
A,O
COVID-19,O
patient,O
usually,O
presents,O
with,O
fever,O
",",O
a,O
nonproductive,O
cough,O
",",O
myalgia,O
and,O
malaise,O
.,O
The,O
transmission,O
dynamics,O
of,O
COVID-19,O
in,O
hospitals,O
in,O
the,O
initial,O
period,O
",",O
especially,O
among,O
HCWs,O
",",O
are,O
important,O
for,O
deeper,O
understanding,O
of,O
the,O
epidemiology,O
of,O
the,O
disease,O
.,O
Nasopharyngeal,O
and/or,O
oropharyngeal,O
swabs,O
were,O
obtained,O
from,O
all,O
COVID-19,O
cases,O
for,O
SARS,O
-,O
CoV-2,O
nucleic,O
acid,O
assay,O
",",O
and,O
22,O
were,O
processed,O
using,O
whole,O
-,O
genome,O
sequencing,O
.,O
After,O
the,O
25,O
HCWs,O
',O
onset,O
of,O
illness,O
",",O
10,O
out,O
of,O
43,O
family,O
members,O
were,O
confirmed,O
as,O
COVID-19,O
cases,O
via,O
nucleotide,O
tests,O
.,O
In,O
summary,O
",",O
from,O
5,O
to,O
29,O
January,O
2020,O
",",O
25,O
HCWs,O
and,O
10,O
family,O
members,O
out,O
of,O
seven,O
families,O
were,O
diagnosed,O
with,O
COVID-19,O
in,O
a,O
single,O
hospital,O
.,O
We,O
obtained,O
12,O
whole,O
-,O
genome,O
sequences,O
(,O
GenBank,S-Repository
 ,O
accession,O
numbers,O
MT079843,S-AccessionNumber
–,O
MT079854,S-AccessionNumber
),O
after,O
implementing,O
de,O
novo,O
sequencing,O
from,O
22,O
swab,O
specimens,O
from,O
22,O
COVID-19,O
patients,O
.,O
Sequencing,O
analysis,O
of,O
the,O
sequences,O
of,O
12,O
COVID-19,O
cases,O
.,O
WHUHnCoV001,O
–,O
WHUHnCoV008,O
",",O
WHUHnCoV011,O
",",O
WHUHnCoV012,O
",",O
WHUHnCoV0020,O
and,O
WHUHnCoV021,O
are,O
the,O
sample,O
IDs,O
.,O
The,O
letters,O
following,O
them,O
represent,O
the,O
corresponding,O
patient,O
IDs,O
from,O
figure,O
1b,O
.,O
a,O
),O
Full,O
-,O
genome,O
structure,O
and,O
mutation,O
information,O
compared,O
with,O
Wuhan,O
-,O
Hu-1,O
(,O
GenBank,S-Repository
 ,O
accession,O
number,O
NC_0455122,S-AccessionNumber
),O
.,O
At,O
the,O
very,O
early,O
stage,O
of,O
the,O
outbreak,O
of,O
COVID-19,O
in,O
Wuhan,O
City,O
and,O
Hubei,O
Province,O
in,O
China,O
",",O
we,O
lacked,O
efficient,O
viral,O
identification,O
capacity,O
to,O
diagnose,O
probable,O
COVID-19,O
cases,O
.,O
There,O
were,O
no,O
effective,O
prevention,O
measures,O
in,O
general,O
hospital,O
settings,O
to,O
isolate,O
and,O
manage,O
the,O
suspected,O
COVID-19,O
cases,O
",",O
or,O
valid,O
containment,O
measures,O
to,O
block,O
the,O
transmission,O
pathways,O
[,O
12,O
],O
.,O
HCWs,O
are,O
the,O
highest,O
risk,O
occupational,O
population,O
in,O
outbreaks,O
of,O
such,O
acute,O
respiratory,O
infectious,O
diseases,O
",",O
such,O
as,O
SARS,O
and,O
COVID-19,O
",",O
which,O
are,O
transmitted,O
by,O
contact,O
or,O
respiratory,O
droplets,O
",",O
aerosols,O
or,O
fomites,O
[,O
24,O
],O
.,O
Here,O
",",O
we,O
have,O
described,O
several,O
clusters,O
of,O
COVID-19,O
cases,O
in,O
a,O
hospital,O
",",O
showing,O
person,O
-,O
to,O
-,O
person,O
transmission,O
of,O
SARS,O
-,O
CoV-2,O
",",O
and,O
have,O
assessed,O
the,O
epidemiological,O
features,O
of,O
COVID-19,O
.,O
Some,O
patients,O
had,O
no,O
fever,O
but,O
only,O
mild,O
symptoms,O
such,O
as,O
nasal,O
congestion,O
",",O
which,O
may,O
have,O
led,O
to,O
patients,O
being,O
overlooked,O
",",O
causing,O
a,O
wider,O
spread,O
of,O
COVID-19,O
.,O
We,O
collected,O
and,O
analysed,O
data,O
on,O
exposure,O
history,O
",",O
illness,O
timelines,O
and,O
epidemiological,O
characteristics,O
from,O
25,O
healthcare,O
workers,O
with,O
laboratory,O
-,O
confirmed,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
and,O
two,O
healthcare,O
workers,O
in,O
whom,O
COVID-19,O
was,O
highly,O
suspected,O
",",O
as,O
well,O
as,O
10,O
of,O
their,O
family,O
members,O
with,O
COVID-19,O
",",O
between,O
5,O
January,O
and,O
12,O
February,O
2020,O
.,O
As,O
of,O
March,O
24,O
",",O
2020,O
",",O
the,O
worldwide,O
tracking,O
for,O
COVID‐19,O
infections,O
reported,O
"1,603,433",O
cases,O
including,O
"95,716",O
deaths,O
(,O
Worldometers,S-Dataset
",",O
2020,O
),O
.,O
Among,O
the,O
18,O
countries,O
that,O
have,O
reported,O
more,O
than,O
"20,000",O
COVID‐19,O
cases,O
",",O
the,O
total,O
number,O
of,O
cases,O
per,O
population,O
ranged,O
from,O
"3,277",O
per,O
million,O
people,O
in,O
Spain,O
to,O
57,O
per,O
million,O
cases,O
in,O
China,O
and,O
the,O
total,O
death,O
rate,O
among,O
these,O
countries,O
ranged,O
from,O
330,O
per,O
million,O
in,O
Spain,O
to,O
2,O
per,O
million,O
in,O
China,O
(,O
Worldometers,S-Dataset
",",O
2020,O
),O
.,O
Differences,O
among,O
the,O
host,O
",",O
particularly,O
the,O
sex,O
of,O
the,O
patient,O
and,O
presence,O
of,O
selected,O
comorbid,O
diseases,O
and,O
immunosuppressive,O
state,O
have,O
been,O
identified,O
as,O
risk,O
factors,O
from,O
severe,O
COVID‐19,O
(,O
China‐CCDC,O
",",O
2020,O
;,O
World,O
Health,O
Organization,O
",",O
2020,O
),O
.,O
An,O
increased,O
association,O
with,O
the,O
use,O
of,O
angiotensin‐converting,O
enzyme,O
inhibitors,O
(,O
ACEIs,O
),O
and,O
angiotensin,O
II,O
receptor,O
blockers,O
(,O
ARBs,O
),O
has,O
been,O
reported,O
for,O
severe,O
COVID‐19,O
cases,O
(,O
Zhou,O
",",O
Yang,O
",",O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
however,O
",",O
the,O
clinical,O
relevance,O
of,O
this,O
finding,O
is,O
uncertain,O
and,O
possibly,O
influenced,O
by,O
the,O
presence,O
of,O
confounders,O
(,O
Gracia‐Ramos,O
",",O
 ,O
2020,O
),O
.,O
Further,O
attention,O
has,O
been,O
drawn,O
to,O
the,O
ACE2,O
receptor,O
as,O
antimalarials,O
",",O
which,O
can,O
interfere,O
with,O
ACE2,O
expression,O
",",O
have,O
resulted,O
in,O
increased,O
clearing,O
of,O
the,O
SARS‐CoV‐2,O
clearance,O
among,O
COVID‐19,O
patients,O
(,O
Gautret,O
et,O
 ,O
al,O
.,O
",",O
 ,O
2020,O
),O
.,O
The,O
initial,O
wild‐type,O
structure,O
of,O
the,O
human,O
ACE2,O
(,O
hACE2,O
),O
was,O
selected,O
from,O
the,O
X‐ray,O
crystal,O
complex,O
structure,O
between,O
hACE2,O
with,O
SARS‐CoV‐2,O
spike,O
(,O
S,O
),O
protein,O
from,O
Protein,O
Data,O
Bank,O
(,O
Berman,O
",",O
Henrick,O
",",O
Nakamura,O
",",O
&,O
Markley,O
",",O
2007,O
),O
(,O
PDB,O
ID,O
:,O
6LZG,O
),O
.,O
We,O
also,O
found,O
that,O
there,O
was,O
some,O
variability,O
of,O
genetic,O
expression,O
of,O
hACE2,O
among,O
various,O
populations,O
",",O
but,O
the,O
magnitude,O
of,O
the,O
differences,O
was,O
small,O
and,O
so,O
it,O
is,O
unclear,O
if,O
this,O
has,O
any,O
impact,O
based,O
on,O
this,O
subtle,O
differences,O
in,O
susceptibility,O
or,O
severity,O
of,O
COVID‐19,O
among,O
various,O
ethnicities,O
.,O
We,O
also,O
did,O
not,O
notice,O
a,O
differential,O
expression,O
of,O
hACE2,O
between,O
the,O
sexes,O
",",O
even,O
though,O
it,O
is,O
widely,O
reported,O
that,O
males,O
have,O
a,O
worse,O
prognosis,O
than,O
females,O
for,O
complications,O
of,O
COVID‐19,O
(,O
Zhou,O
",",O
Yu,O
",",O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
There,O
appears,O
to,O
be,O
large,O
regional,O
variation,O
for,O
susceptibility,O
",",O
severity,O
",",O
and,O
mortality,O
for,O
COVID‐19,O
infections,O
.,O
Angiotensin,O
Enzyme,O
and,O
Receptor,O
are,O
now,O
active,O
targets,O
for,O
potential,O
treatment,O
of,O
COVID‐19,O
.,O
We,O
searched,O
the,O
29.9,O
 ,O
kb,O
genome,O
of,O
SARS,O
-,O
CoV-2,O
stored,O
in,O
the,O
China,B-Repository
National,I-Repository
Microbiological,I-Repository
Data,I-Repository
Center,E-Repository
 ,O
(,O
accession,O
number,O
CNP0000881,S-AccessionNumber
),O
for,O
PQSs,O
using,O
QGRS,O
-,O
Mapper,O
[,O
13,O
],O
.,O
The,O
National,B-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,I-Repository
database,I-Repository
(NCBI),E-Repository
 ,O
harbors,O
more,O
than,O
50,O
sequenced,O
genomes,O
of,O
CoVs,O
",",O
including,O
bat,O
CoVs,O
",",O
Middle,O
East,O
respiratory,O
syndrome,O
-,O
related,O
CoV,O
(,O
MERS,O
-,O
CoV,O
),O
and,O
SARS,O
-,O
CoV.,O
HDOCK,O
incorporates,O
the,O
binding,O
interface,O
information,O
into,O
the,O
docking,O
concept,O
",",O
which,O
accepts,O
both,O
sequences,O
and,O
structures,O
as,O
input,O
for,O
the,O
protein,O
docking,O
prediction,O
[,O
47,O
],O
.,O
RNA,O
sequence,O
of,O
SARS,O
-,O
CoV-2,O
was,O
obtained,O
from,O
the,O
China,B-Repository
National,I-Repository
Microbiological,I-Repository
Data,I-Repository
Center,E-Repository
 ,O
(,O
accession,O
number,O
CNP0000881,S-AccessionNumber
),O
.,O
The,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
was,O
discovered,O
as,O
the,O
viral,O
pathogen,O
that,O
causes,O
COVID-19,O
.,O
When,O
COVID-19,O
quickly,O
spread,O
outside,O
China,O
",",O
sequencing,O
of,O
the,O
viral,O
genome,O
was,O
conducted,O
from,O
infected,O
patients,O
in,O
other,O
countries,O
to,O
compare,O
the,O
sequence,O
with,O
the,O
reference,O
sequence,O
.,O
Intriguingly,O
",",O
genomic,O
sequence,O
of,O
SARS,O
-,O
CoV-2,O
of,O
the,O
first,O
two,O
COVID-19,O
patients,O
diagnosed,O
in,O
Italy,O
during,O
January,O
and,O
February,O
2020,O
already,O
showed,O
mutations,O
compared,O
to,O
the,O
reference,O
sequence,O
established,O
in,O
China,O
[,O
1,O
],O
.,O
However,O
",",O
this,O
recent,O
study,O
[,O
2,O
],O
did,O
not,O
explore,O
the,O
association,O
between,O
genetic,O
variation,O
in,O
SARS,O
-,O
CoV-2,O
and,O
the,O
severity,O
of,O
COVID-19,O
.,O
Another,O
analysis,O
of,O
86,O
genomic,O
sequences,O
obtained,O
from,O
GISAID,S-Dataset
 ,O
database,O
(,O
https://www.gisaid.org/,S-URL
),O
identified,O
3,O
deletions,O
in,O
the,O
genomes,O
of,O
SARS,O
-,O
CoV-2,O
from,O
Japan,O
",",O
USA,O
and,O
Australia,O
",",O
and,O
93,O
mutations,O
over,O
the,O
entire,O
SARS,O
-,O
CoV-2,O
genomes,O
[,O
3,O
],O
.,O
Pachetti,O
et,O
al,O
.,O
[,O
4,O
],O
analyzed,O
220,O
SARS,O
-,O
CoV-2,O
genomic,O
sequences,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
and,O
found,O
8,O
novel,O
mutation,O
hot,O
spots,O
:,O
5,O
of,O
them,O
were,O
predominantly,O
observed,O
in,O
Europe,O
and,O
3,O
were,O
exclusively,O
present,O
in,O
North,O
America,O
but,O
none,O
of,O
them,O
was,O
detected,O
in,O
Asia,O
.,O
Therefore,O
",",O
it,O
is,O
an,O
urgent,O
need,O
to,O
explore,O
the,O
association,O
of,O
the,O
mutation,O
pattern,O
of,O
SARS,O
-,O
CoV-2,O
genome,O
with,O
the,O
severity,O
and,O
fatality,O
of,O
COVID-19,O
.,O
Based,O
on,O
the,O
above,O
discussion,O
",",O
we,O
hypothesize,O
that,O
the,O
genetic,O
variation,O
in,O
SARS,O
-,O
CoV-2,O
may,O
explain,O
variable,O
severity,O
of,O
COVID-19,O
in,O
the,O
population,O
.,O
Analysis,O
of,O
sequencing,O
data,O
of,O
SARS,O
-,O
CoV-2,O
genome,O
showed,O
evidence,O
of,O
mutation,O
at,O
the,O
beginning,O
of,O
the,O
worldwide,O
spread,O
of,O
COVID-19,O
[,O
1,O
],O
.,O
On,O
26,O
February,O
",",O
the,O
Director‐General,O
of,O
the,O
WHO,O
announced,O
that,O
the,O
number,O
of,O
new,O
cases,O
of,O
the,O
disease,O
",",O
now,O
officially,O
known,O
as,O
COVID‐19,O
",",O
reported,O
outside,O
China,O
since,O
the,O
day,O
before,O
had,O
for,O
the,O
first,O
time,O
exceeded,O
the,O
number,O
of,O
new,O
cases,O
in,O
China,O
(,O
https://www.who.int/dg/speeches/detail/who‐director‐general‐s‐opening‐remarks‐at‐the‐mission‐briefing‐on‐covid‐19‐‐‐26‐february‐2020,O
),O
.,O
The,O
results,O
were,O
mapped,O
and,O
aligned,O
to,O
the,O
reference,O
genome,O
obtained,O
from,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
",",O
accession,O
ID,O
:,O
EPI_ISL_412973,S-AccessionNumber
),O
using,O
Geneious,O
software,O
",",O
v.,O
9.1.5,O
(,O
http://www.geneious.com,O
),O
.,O
A,O
root‐to‐tip,O
regression,O
analysis,O
was,O
made,O
using,O
TempEst,O
in,O
order,O
to,O
investigate,O
the,O
temporal,O
signal,O
of,O
the,O
dataset,O
.,O
Root‐to‐tip,O
regression,O
analysis,O
of,O
the,O
temporal,O
signal,O
from,O
the,O
dataset,O
revealed,O
a,O
relatively,O
weak,O
association,O
between,O
genetic,O
distances,O
and,O
sampling,O
days,O
(,O
a,O
correlation,O
coefficient,O
of,O
0.46,O
and,O
a,O
coefficient,O
of,O
determination,O
[,O
R,O
2,O
],O
of,O
0.21,O
),O
(,O
Figure,O
 ,O
1,O
),O
.,O
The,O
present,O
phylogenetic,O
analysis,O
confirms,O
that,O
the,O
common,O
origin,O
of,O
the,O
SARS‐CoV‐2,O
strains,O
characterized,O
so,O
far,O
was,O
several,O
weeks,O
before,O
the,O
first,O
cases,O
of,O
COVID‐19,O
pneumonia,O
were,O
described,O
in,O
China,O
.,O
The,O
German,O
sequence,O
at,O
the,O
outgroup,O
of,O
the,O
clade,O
came,O
from,O
a,O
COVID‐19,O
outbreak,O
reported,O
between,O
20,O
and,O
24,O
January,O
and,O
occurring,O
after,O
business,O
meetings,O
with,O
a,O
Shanghai,O
business,O
woman,O
who,O
tested,O
positive,O
after,O
returning,O
to,O
China,O
.,O
This,O
report,O
describes,O
the,O
isolation,O
",",O
molecular,O
characterization,O
",",O
and,O
phylogenetic,O
analysis,O
of,O
the,O
first,O
three,O
complete,O
genomes,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS‐CoV‐2,O
),O
isolated,O
from,O
three,O
patients,O
involved,O
in,O
the,O
first,O
outbreak,O
of,O
COVID‐19,O
in,O
Lombardy,O
",",O
Italy,O
.,O
On,O
11,O
February,O
2020,O
",",O
the,O
International,O
Committee,O
on,O
Taxonomy,O
of,O
Viruses,O
officially,O
renamed,O
2019,O
-,O
nCoV,O
",",O
which,O
is,O
responsible,O
for,O
the,O
current,O
outbreak,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
Notably,O
",",O
the,O
current,O
COVID-19,O
outbreak,O
is,O
characterized,O
by,O
its,O
significant,O
dispersal,O
into,O
many,O
major,O
urban,O
centers,O
in,O
China,O
and,O
beyond,O
",",O
further,O
facilitating,O
its,O
continued,O
spread,O
from,O
person,O
to,O
person,O
(,O
Chan,O
et,O
al,O
.,O
",",O
2020,O
;,O
Li,O
et,O
al,O
.,O
",",O
2020a,O
),O
",",O
and,O
has,O
caused,O
considerable,O
morbidity,O
and,O
mortality,O
in,O
China,O
and,O
elsewhere,O
.,O
Although,O
the,O
number,O
of,O
confirmed,O
cases,O
of,O
COVID-19,O
worldwide,O
has,O
excessed,O
12,O
million,O
",",O
it,O
showed,O
that,O
countries,O
had,O
only,O
discovered,O
on,O
average,O
about,O
6,O
%,O
of,O
coronavirus,O
infections,O
and,O
the,O
true,O
number,O
of,O
infected,O
people,O
worldwide,O
may,O
already,O
have,O
reached,O
several,O
tens,O
of,O
millions(https://medicalxpress.com,O
/,O
news/2020,O
-,O
04,O
-,O
covid,O
-,O
average,O
-,O
actual,O
-,O
infections,O
-,O
worldwide.html,O
),O
.,O
These,O
factors,O
will,O
contribute,O
the,O
subsequent,O
COVID-19,O
outbreaks,O
",",O
and,O
many,O
scientists,O
believe,O
that,O
COVID-19,O
outbreaks,O
will,O
be,O
recurrence,O
.,O
Therefore,O
",",O
identifying,O
the,O
animal,O
source,O
of,O
SARS,O
-,O
CoV-2,O
is,O
still,O
a,O
top,O
research,O
priority,O
for,O
controlling,O
the,O
COVID-19,O
outbreak,O
.,O
Since,O
the,O
first,O
whole,O
-,O
genome,O
sequence,O
(,O
Wuhan,O
-,O
Hu-1,O
;,O
GenBank,S-Repository
 ,O
accession,O
number,O
MN908947,S-AccessionNumber
",",O
also,O
named,O
hCoV-19,O
/,O
Wuhan,O
/,O
Hu-1/2019,O
with,O
accession,O
ID,O
EPI_ISL_402125,S-AccessionNumber
 ,O
in,O
GISAID,S-Repository
),O
of,O
the,O
novel,O
coronavirus,O
",",O
SARS,O
-,O
CoV-2,O
",",O
which,O
was,O
isolated,O
from,O
a,O
41,O
-,O
year,O
old,O
man,O
who,O
worked,O
at,O
Wuhan,O
Huanan,O
Seafood,O
Wholesale,O
Market,O
",",O
was,O
shared,O
online,O
on,O
11,O
January,O
",",O
2020,O
",",O
that,O
first,O
genome,O
became,O
the,O
baseline,O
for,O
researchers,O
to,O
track,O
the,O
SARS,O
-,O
CoV-2,O
virus,O
as,O
it,O
spreads,O
around,O
the,O
world,O
(,O
Wu,O
et,O
al,O
.,O
",",O
2020b,O
),O
.,O
Since,O
the,O
start,O
of,O
the,O
COVID-19,O
outbreak,O
and,O
the,O
identification,O
of,O
the,O
pandemic,O
virus,O
",",O
laboratories,O
around,O
the,O
world,O
are,O
generating,O
viral,O
genome,O
sequence,O
data,O
with,O
unprecedented,O
speed,O
",",O
researchers,O
have,O
sequenced,O
and,O
shared,O
some,O
66,O
000,O
viral,O
genomes,O
from,O
around,O
the,O
world,O
on,O
14,O
July,O
",",O
2020,O
.,O
Such,O
a,O
vast,O
amount,O
of,O
available,O
genetic,O
data,O
presents,O
a,O
unique,O
opportunity,O
for,O
researchers,O
to,O
trace,O
the,O
origin,O
and,O
spread,O
of,O
COVID-19,O
outbreaks,O
in,O
different,O
countries,O
and,O
gain,O
real,O
-,O
time,O
insights,O
into,O
the,O
pandemic,O
",",O
enabling,O
real,O
-,O
time,O
progress,O
in,O
the,O
understanding,O
of,O
the,O
new,O
disease,O
and,O
in,O
the,O
research,O
and,O
development,O
of,O
candidate,O
medical,O
countermeasures,O
.,O
As,O
of,O
19,O
February,O
2020,O
",",O
more,O
than,O
100,O
genomes,O
of,O
human,O
-,O
obtained,O
SARS,O
-,O
CoV-2,O
strains,O
have,O
been,O
released,O
on,O
GISAID,S-Dataset
 ,O
(,O
http://gisaid.org/,S-URL
),O
(,O
Elbe,B-Creator
and,I-Creator
"Buckland-Merrett,",I-Creator
2017,E-Creator
),O
.,O
The,O
dataset,O
used,O
in,O
present,O
study,O
was,O
also,O
not,O
randomized,O
.,O
The,O
final,O
dataset,O
(,O
“,O
dataset_112,O
”,O
),O
included,O
112,O
genomes,O
of,O
SARS,O
-,O
CoV-2,O
from,O
Australia,O
(,O
n,O
=,O
8),O
",",O
Belgium,O
(,O
n,O
=,O
1,O
),O
",",O
China,O
(,O
n,O
=,O
53,O
),O
",",O
Finland,O
(,O
n,O
=,O
1,O
),O
",",O
France,O
(,O
n,O
=,O
10,O
),O
",",O
Germany,O
(,O
n,O
=,O
1,O
),O
",",O
Japan,O
(,O
n,O
=,O
7,O
),O
",",O
Korea,O
(,O
n,O
=,O
1,O
),O
",",O
Nepal,O
(,O
n,O
=,O
1,O
),O
",",O
Singapore,O
(,O
n,O
=,O
11,O
),O
",",O
Thailand,O
(,O
n,O
=,O
2,O
),O
",",O
UK,O
(,O
n,O
=,O
2,O
),O
",",O
and,O
USA,O
(,O
n,O
=,O
14,O
),O
with,O
sampling,O
dates,O
between,O
24,O
December,O
2019,O
and,O
9,O
February,O
2020,O
.,O
We,O
first,O
aligned,O
the,O
collected,O
dataset,O
(,O
“,O
dataset_112,O
”,O
),O
using,O
MAFFT,O
v7.222,O
(,O
Katoh,O
and,O
Standley,O
",",O
2013,O
),O
and,O
subsequently,O
edited,O
the,O
alignment,O
manually,O
using,O
BioEdit,O
v7.2.5,O
(,O
Hall,O
",",O
1999,O
),O
.,O
To,O
assess,O
recombination,O
of,O
our,O
dataset,O
(,O
“,O
dataset_112,O
”,O
),O
",",O
we,O
employed,O
the,O
pairwise,O
homoplasy,O
index,O
(,O
PHI,O
),O
to,O
measure,O
similarity,O
between,O
closely,O
linked,O
sites,O
using,O
SplitsTree,O
v4.15.1,O
(,O
Huson,O
and,O
Bryant,O
",",O
2006,O
),O
and,O
the,O
default,O
recombination,O
detection,O
methods,O
using,O
the,O
Recombination,O
Detection,O
Program,O
(,O
RDP,O
),O
v4.100,O
(,O
Martin,O
et,O
al,O
.,O
",",O
2015,O
),O
.,O
The,O
best,O
-,O
fit,O
nucleotide,O
substitution,O
model,O
for,O
“,O
dataset_112,O
”,O
was,O
identified,O
according,O
to,O
the,O
Bayesian,O
information,O
criterion,O
(,O
BIC,O
),O
method,O
with,O
three,O
(,O
24,O
candidate,O
models,O
),O
or,O
11,O
(,O
88,O
candidate,O
models,O
),O
substitution,O
schemes,O
in,O
jModelTest,O
v2.1.10,O
(,O
Darriba,O
et,O
al,O
.,O
",",O
2012,O
),O
.,O
To,O
evaluate,O
the,O
phylogenetic,O
signals,O
of,O
“,O
dataset_112,O
”,O
",",O
we,O
performed,O
likelihood,O
-,O
mapping,O
analysis,O
(,O
Schmidt,O
and,O
von,O
Haeseler,O
",",O
2007,O
),O
using,O
TREE,O
-,O
PUZZLE,O
v5.3,O
(,O
Schmidt,O
et,O
al,O
.,O
",",O
2002,O
),O
",",O
with,O
280,O
000,O
randomly,O
chosen,O
quartets,O
for,O
the,O
dataset,O
.,O
Split,O
network,O
analysis,O
was,O
performed,O
for,O
“,O
dataset_112,O
”,O
using,O
Kishino,O
-,O
Yano-85,O
(,O
Kimura,O
",",O
1980,O
),O
distance,O
transformation,O
with,O
the,O
NeighborNet,O
method,O
",",O
which,O
can,O
be,O
loosely,O
thought,O
of,O
as,O
a,O
“,O
hybrid,O
”,O
between,O
the,O
neighbor,O
-,O
joining,O
(,O
NJ,O
),O
and,O
split,O
decomposition,O
methods,O
",",O
implemented,O
in,O
TREE,O
-,O
PUZZLE,O
v5.3,O
(,O
Schmidt,O
et,O
al,O
.,O
",",O
2002,O
),O
.,O
Maximum,O
-,O
likelihood,O
(,O
ML,O
),O
phylogenetic,O
trees,O
for,O
the,O
dataset,O
were,O
estimated,O
using,O
PhyML,O
v3.1,O
(,O
Guindon,O
et,O
al,O
.,O
",",O
2010,O
),O
under,O
a,O
Hasegawa,O
-,O
Kishino,O
-,O
Yano,O
(,O
HKY,O
),O
(,O
Kimura,O
",",O
1980,O
),O
nucleotide,O
substitution,O
model,O
with,O
a,O
proportion,O
of,O
invariable,O
sites,O
",",O
which,O
was,O
identified,O
as,O
the,O
best,O
fitting,O
model,O
for,O
ML,O
inference,O
by,O
jModelTest,O
v2.1.10,O
(,O
Darriba,O
et,O
al,O
.,O
",",O
2012,O
),O
.,O
Analysis,O
of,O
temporal,O
molecular,O
evolutionary,O
signals,O
for,O
the,O
dataset,O
was,O
conducted,O
using,O
TempEst,O
v1.5,O
(,O
Rambaut,O
et,O
al,O
.,O
",",O
2016,O
),O
.,O
We,O
also,O
estimated,O
the,O
evolutionary,O
rate,O
and,O
time,O
to,O
the,O
most,O
recent,O
common,O
ancestor,O
(,O
TMRCA,O
),O
for,O
“,O
dataset_112,O
”,O
using,O
ML,O
dating,O
in,O
the,O
TreeTime,O
package,O
(,O
Sagulenko,O
et,O
al,O
.,O
",",O
2018,O
),O
.,O
To,O
estimate,O
the,O
Bayesian,O
molecular,O
clock,O
phylogenies,O
of,O
SARS,O
-,O
CoV-2,O
",",O
Bayesian,O
inference,O
analyses,O
were,O
performed,O
for,O
“,O
dataset_112,O
”,O
through,O
a,O
Markov,O
chain,O
Monte,O
Carlo,O
(,O
MCMC,O
),O
(,O
Yang,O
and,O
Rannala,O
",",O
1997,O
),O
framework,O
implemented,O
in,O
BEAST,O
v1.8.4,O
(,O
Drummond,O
et,O
al,O
.,O
",",O
2012,O
),O
",",O
with,O
the,O
BEAGLE,O
v2.1.2,O
library,O
program,O
(,O
Suchard,O
and,O
Rambaut,O
",",O
2009,O
),O
used,O
for,O
computational,O
enhancement,O
.,O
For,O
model,O
selection,O
",",O
we,O
tested,O
five,O
coalescent,O
tree,O
priors,O
for,O
our,O
dataset,O
:,O
a,O
constant,O
-,O
size,O
population,O
(,O
Kingman,O
",",O
1982,O
),O
",",O
an,O
exponential,O
growth,O
population,O
with,O
growth,O
rate,O
parameterization,O
(,O
Griffiths,O
and,O
Tavare,O
",",O
1994,O
),O
",",O
another,O
exponential,O
growth,O
population,O
with,O
doubling,O
time,O
parameterization,O
(,O
Griffiths,O
and,O
Tavare,O
",",O
1994,O
),O
",",O
a,O
Bayesian,O
skyline,O
tree,O
prior,O
(,O
five,O
groups,O
",",O
piecewise,O
-,O
constant,O
model,O
),O
(,O
Drummond,O
et,O
al,O
.,O
",",O
2005,O
),O
",",O
and,O
a,O
Bayesian,O
Skygrid,O
tree,O
prior,O
(,O
five,O
population,O
sizes,O
across,O
our,O
0.2,O
year,O
interval,O
",",O
allowing,O
a,O
different,O
population,O
size,O
to,O
be,O
estimated,O
for,O
14.6,O
days,O
(,O
d,O
),O
),O
(,O
Gill,O
et,O
al,O
.,O
",",O
2013,O
),O
.,O
For,O
“,O
dataset_112,O
”,O
",",O
a,O
HKY,O
(,O
Kimura,O
",",O
1980,O
),O
nucleotide,O
substitution,O
model,O
with,O
a,O
proportion,O
of,O
invariable,O
sites,O
was,O
the,O
model,O
of,O
best,O
fit,O
across,O
the,O
two,O
different,O
substitution,O
schemes,O
(,O
i.e.,O
",",O
24,O
and,O
88,O
candidate,O
models,O
),O
according,O
to,O
the,O
BIC,O
method,O
",",O
and,O
was,O
thus,O
used,O
in,O
subsequent,O
likelihood,O
-,O
mapping,O
and,O
phylogenetic,O
analyses,O
.,O
The,O
PHI,O
test,O
of,O
“,O
dataset_112,O
”,O
did,O
not,O
find,O
statistically,O
significant,O
evidence,O
of,O
recombination,O
(,O
p,O
=,O
1.0,O
),O
.,O
Our,O
likelihood,O
-,O
mapping,O
analysis,O
revealed,O
that,O
the,O
quartets,O
from,O
“,O
dataset_112,O
”,O
were,O
primarily,O
distributed,O
in,O
the,O
center,O
(,O
63.2,O
%,O
),O
rather,O
than,O
the,O
corners,O
(,O
36.8,O
%,O
),O
or,O
sides,O
(,O
0,O
%,O
),O
of,O
the,O
triangle,O
",",O
indicating,O
a,O
strong,O
star,O
-,O
like,O
topology,O
signal,O
",",O
which,O
may,O
be,O
due,O
to,O
exponential,O
epidemic,O
spread,O
(,O
Fig,O
.,O
1,O
A,O
),O
",",O
in,O
accordance,O
with,O
previous,O
studies,O
(,O
Li,O
et,O
al,O
.,O
",",O
2020b,O
;,O
Li,O
et,O
al,O
.,O
",",O
2020c,O
;,O
Li,O
et,O
al,O
.,O
",",O
2020d,O
),O
.,O
The,O
split,O
network,O
generated,O
for,O
“,O
dataset_112,O
”,O
using,O
the,O
NeighborNet,O
method,O
revealed,O
the,O
existence,O
of,O
polytomies,O
",",O
and,O
thus,O
was,O
highly,O
unresolved,O
.,O
This,O
indicated,O
that,O
the,O
phylogenetic,O
relationship,O
of,O
our,O
dataset,O
was,O
probably,O
best,O
represented,O
by,O
a,O
star,O
-,O
like,O
phylogenetic,O
tree,O
rather,O
than,O
a,O
strictly,O
bifurcating,O
tree,O
(,O
Fig,O
.,O
1B,O
),O
",",O
suggesting,O
possible,O
rapid,O
early,O
spread,O
of,O
SARS,O
-,O
CoV-2,O
",",O
in,O
accordance,O
with,O
the,O
likelihood,O
-,O
mapping,O
results,O
.,O
ML,O
phylogenetic,O
analysis,O
of,O
“,O
dataset_112,O
”,O
also,O
showed,O
star,O
-,O
like,O
topology,O
(,O
Fig,O
.,O
2,O
),O
",",O
indicating,O
the,O
introduction,O
of,O
a,O
new,O
virus,O
to,O
an,O
immunologically,O
naive,O
population,O
",",O
in,O
accordance,O
with,O
the,O
likelihood,O
-,O
mapping,O
and,O
split,O
network,O
results,O
.,O
Root,O
-,O
to,O
-,O
tip,O
linear,O
regression,O
analyses,O
between,O
genetic,O
divergence,O
and,O
sampling,O
date,O
using,O
the,O
best,O
-,O
fitting,O
root,O
",",O
which,O
minimizes,O
the,O
mean,O
of,O
the,O
squares,O
of,O
the,O
residuals,O
",",O
showed,O
that,O
“,O
dataset_112,O
”,O
had,O
a,O
minor,O
positive,O
temporal,O
signal,O
(,O
R,O
=,O
0.087,O
;,O
correlation,O
coefficient,O
=,O
0.2945,O
),O
",",O
thus,O
suggesting,O
a,O
minor,O
clocklike,O
pattern,O
of,O
molecular,O
evolution,O
(,O
Fig,O
.,O
3,O
),O
.,O
The,O
ML,O
dating,O
analyses,O
between,O
root,O
-,O
to,O
-,O
tip,O
genetic,O
divergence,O
and,O
sampling,O
date,O
also,O
showed,O
that,O
our,O
dataset,O
had,O
a,O
minor,O
strong,O
positive,O
temporal,O
signal,O
(,O
R,O
=,O
0.09,O
),O
(,O
Supplementary,O
Fig,O
.,O
1,O
),O
.,O
The,O
evolutionary,O
rate,O
and,O
TMRCA,O
date,O
estimates,O
of,O
SARS,O
-,O
CoV-2,O
for,O
“,O
dataset_112,O
”,O
were,O
5.35,O
×,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
and,O
19,O
October,O
2019,O
",",O
respectively,O
",",O
in,O
accordance,O
with,O
the,O
root,O
-,O
to,O
-,O
tip,O
regression,O
results,O
using,O
TempEst,O
v1.5,O
(,O
Rambaut,O
et,O
al,O
.,O
",",O
2016,O
),O
.,O
Based,O
on,O
Bayesian,O
time,O
-,O
scaled,O
phylogenetic,O
analysis,O
using,O
the,O
tip,O
-,O
dating,O
method,O
",",O
the,O
estimated,O
TMRCA,O
dates,O
and,O
evolutionary,O
rates,O
of,O
SARS,O
-,O
CoV-2,O
for,O
“,O
dataset_112,O
”,O
ranged,O
from,O
12,O
November,O
2019,O
to,O
7,O
December,O
2019,O
(,O
95,O
%,O
BCI,O
:,O
11,O
October,O
2019,O
and,O
21,O
December,O
2019,O
),O
and,O
from,O
8.37,O
×,O
10−4,O
to,O
1.12,O
×,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
(,O
95,O
%,O
BCI,O
:,O
5.06,O
×,O
10−4–1.53,O
×,O
10−3,O
),O
",",O
respectively,O
(,O
Table,O
1,O
),O
.,O
The,O
best,O
-,O
fitting,O
combination,O
was,O
an,O
UCLN,O
relaxed,O
molecular,O
clock,O
along,O
with,O
an,O
exponential,O
growth,O
tree,O
prior,O
model,O
with,O
growth,O
rate,O
parameterization,O
",",O
as,O
shown,O
by,O
the,O
marginal,O
likelihood,O
estimates,O
for,O
“,O
dataset_112,O
”,O
when,O
comparing,O
the,O
two,O
clock,O
models,O
and,O
five,O
tree,O
prior,O
models,O
.,O
Thus,O
",",O
the,O
TMRCA,O
date,O
and,O
evolutionary,O
rate,O
estimates,O
of,O
SARS,O
-,O
CoV-2,O
for,O
“,O
dataset_112,O
”,O
with,O
the,O
best,O
-,O
fitting,O
combination,O
were,O
12,O
November,O
2019,O
(,O
95,O
%,O
BCI,O
:,O
11,O
October,O
2019,O
and,O
09,O
December,O
2019,O
),O
and,O
9.90,O
×,O
10−4,O
substitutions,O
per,O
site,O
per,O
year,O
(,O
95,O
%,O
BCI,O
:,O
6.29,O
×,O
10−4–1.35,O
×,O
10−3,O
),O
",",O
respectively,O
(,O
Table,O
1,O
),O
.,O
The,O
estimates,O
of,O
the,O
MCC,O
phylogenetic,O
relationships,O
among,O
the,O
SARS,O
-,O
CoV-2,O
genomes,O
for,O
our,O
dataset,O
from,O
the,O
Bayesian,O
coalescent,O
framework,O
using,O
the,O
tip,O
-,O
dating,O
method,O
",",O
as,O
well,O
as,O
the,O
exponential,O
coalescent,O
tree,O
prior,O
with,O
doubling,O
time,O
parameterization,O
and,O
UCLN,O
relaxed,O
molecular,O
clock,O
",",O
are,O
displayed,O
in,O
Fig,O
.,O
4,O
.,O
As,O
shown,O
",",O
“,O
dataset_112,O
”,O
exhibited,O
more,O
genetic,O
diversity,O
than,O
our,O
previous,O
datasets,O
(,O
Li,B-Creator
et,I-Creator
"al.,",I-Creator
2020b,E-Creator
;,O
Li,B-Creator
et,I-Creator
al.,E-Creator
 ,O
Analysis,O
showed,O
that,O
the,O
R,O
estimates,O
of,O
SARS,O
-,O
CoV-2,O
for,O
“,O
dataset_112,O
”,O
experienced,O
complex,O
phylodynamics,O
characterized,O
by,O
at,O
least,O
two,O
growing,O
and,O
two,O
declining,O
phases,O
(,O
Fig,O
.,O
5,O
),O
.,O
The,O
mean,O
R,O
estimates,O
of,O
SARS,O
-,O
CoV-2,O
for,O
our,O
dataset,O
ranged,O
from,O
0.336,O
to,O
4.137,O
",",O
and,O
the,O
first,O
growth,O
phase,O
had,O
more,O
uncertainty,O
compared,O
to,O
the,O
remaining,O
phases,O
due,O
to,O
the,O
wider,O
95,O
%,O
highest,O
posterior,O
density,O
(,O
HPD,O
),O
interval,O
of,O
R,O
estimates,O
.,O
Notably,O
",",O
we,O
found,O
very,O
low,O
R,O
estimates,O
of,O
SARS,O
-,O
CoV-2,O
for,O
“,O
dataset_112″,O
during,O
the,O
recent,O
sampling,O
time,O
period,O
.,O
To,O
investigate,O
the,O
global,O
epidemic,O
spread,O
of,O
SARS,O
-,O
CoV-2,O
",",O
we,O
performed,O
comprehensive,O
evolutionary,O
analyses,O
of,O
112,O
genomes,O
from,O
“,O
dataset_112,O
”,O
.,O
Split,O
network,O
analysis,O
of,O
SARS,O
-,O
CoV-2,O
based,O
on,O
“,O
dataset_112,O
”,O
using,O
the,O
NeighborNet,O
method,O
was,O
more,O
resolved,O
over,O
time,O
as,O
more,O
genome,O
sequences,O
were,O
added,O
to,O
our,O
study,O
compared,O
with,O
our,O
previous,O
results,O
(,O
Li,O
et,O
al,O
.,O
",",O
2020d,O
),O
.,O
These,O
results,O
are,O
also,O
consistent,O
with,O
our,O
ML,O
phylogenetic,O
analyses,O
",",O
which,O
showed,O
a,O
more,O
bifurcating,O
tree,O
topology,O
from,O
“,O
dataset_112,O
”,O
compared,O
to,O
our,O
previous,O
results,O
(,O
Li,O
et,O
al,O
.,O
",",O
2020c,O
;,O
Li,O
et,O
al,O
.,O
",",O
2020d,O
;,O
Li,O
et,O
al,O
.,O
",",O
2020e,O
),O
",",O
(,O
Fig,O
.,O
2,O
),O
.,O
Our,O
dataset,O
still,O
had,O
a,O
minor,O
positive,O
temporal,O
signal,O
based,O
on,O
regression,O
analysis,O
using,O
TempEst,O
v1.5,O
(,O
Rambaut,O
et,O
al,O
.,O
",",O
2016,O
),O
and,O
ML,O
dating,O
analysis,O
using,O
TreeTime,O
package,O
(,O
Sagulenko,O
et,O
al,O
.,O
",",O
2018,O
),O
compared,O
to,O
our,O
previous,O
results,O
(,O
Li,O
et,O
al,O
.,O
",",O
2020d,O
),O
.,O
Furthermore,O
",",O
the,O
estimated,O
TMRCA,O
dates,O
and,O
evolutionary,O
rates,O
of,O
SARS,O
-,O
CoV-2,O
for,O
“,O
dataset_112,O
”,O
were,O
found,O
to,O
be,O
nearly,O
identical,O
using,O
both,O
analyses,O
(,O
Fig,O
.,O
3,O
and,O
Supplementary,O
Fig,O
.,O
1,O
),O
",",O
consistent,O
with,O
earlier,O
results,O
(,O
Li,O
et,O
al,O
.,O
",",O
2020d,O
),O
.,O
The,O
estimated,O
TMRCA,O
dates,O
of,O
SARS,O
-,O
CoV-2,O
based,O
on,O
“,O
dataset_112,O
”,O
using,O
TempEst,O
v1.5,O
(,O
Rambaut,O
et,O
al,O
.,O
",",O
2016,O
),O
(,O
19,O
October,O
2019,O
),O
and,O
ML,O
dating,O
analysis,O
using,O
TreeTime,O
(,O
Sagulenko,O
et,O
al,O
.,O
",",O
2018,O
),O
(,O
19,O
October,O
2019,O
),O
were,O
also,O
identical,O
to,O
our,O
previous,O
results,O
(,O
Li,O
et,O
al,O
.,O
",",O
2020d,O
),O
.,O
However,O
",",O
the,O
estimated,O
evolutionary,O
rates,O
of,O
SARS,O
-,O
CoV-2,O
for,O
“,O
dataset_112,O
”,O
using,O
TempEst,O
v1.5,O
(,O
Rambaut,O
et,O
al,O
.,O
",",O
2016,O
),O
(,O
5.3504,O
×,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
),O
and,O
ML,O
dating,O
analysis,O
using,O
TreeTime,O
(,O
Sagulenko,O
et,O
al,O
.,O
",",O
2018,O
),O
(,O
5.35,O
×,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
),O
were,O
very,O
distinct,O
to,O
our,O
prior,O
results,O
(,O
Li,O
et,O
al,O
.,O
",",O
2020d,O
),O
using,O
TempEst,O
v1.5,O
(,O
Rambaut,O
et,O
al,O
.,O
",",O
2016,O
),O
(,O
3.3452,O
×,O
10−4,O
substitutions,O
per,O
site,O
per,O
year,O
),O
and,O
ML,O
dating,O
analysis,O
using,O
TreeTime,O
(,O
Sagulenko,O
et,O
al,O
.,O
",",O
2018,O
),O
(,O
3.34,O
×,O
10−4,O
substitutions,O
per,O
site,O
per,O
year,O
),O
.,O
The,O
estimated,O
TMRCA,O
dates,O
and,O
evolutionary,O
rates,O
of,O
SARS,O
-,O
CoV-2,O
for,O
“,O
dataset_112,O
”,O
were,O
very,O
similar,O
across,O
different,O
clocks,O
using,O
the,O
tip,O
-,O
dating,O
method,O
",",O
but,O
very,O
distinct,O
across,O
different,O
coalescent,O
tree,O
priors,O
(,O
e.g.,O
",",O
parametric,O
coalescent,O
and,O
nonparametric,O
coalescent,O
models,O
),O
(,O
Table,O
1,O
),O
.,O
In,O
summary,O
",",O
the,O
TMRCA,O
date,O
and,O
evolutionary,O
rate,O
estimates,O
of,O
SARS,O
-,O
CoV-2,O
for,O
“,O
dataset_112,O
”,O
are,O
still,O
sensitive,O
to,O
the,O
tree,O
prior,O
",",O
and,O
additional,O
genomes,O
should,O
make,O
these,O
estimates,O
more,O
robust,O
towards,O
the,O
tree,O
prior,O
choice,O
.,O
We,O
employed,O
the,O
BDSKY,O
model,O
(,O
Stadler,O
et,O
al,O
.,O
",",O
2013,O
),O
and,O
found,O
that,O
the,O
R,O
estimates,O
of,O
SARS,O
-,O
CoV-2,O
for,O
“,O
dataset_112,O
”,O
experienced,O
a,O
complex,O
phylodynamic,O
history,O
(,O
Fig,O
.,O
5,O
),O
.,O
For,O
the,O
epidemiological,O
analysis,O
of,O
SARS,O
-,O
CoV-2,O
from,O
“,O
dataset_112,O
”,O
",",O
the,O
non,O
-,O
random,O
and,O
non,O
-,O
well,O
-,O
mixing,O
of,O
the,O
sampled,O
population,O
",",O
and,O
the,O
non,O
-,O
constant,O
sampling,O
effort,O
may,O
be,O
potential,O
strong,O
sources,O
of,O
bias,O
in,O
the,O
estimates,O
of,O
SARS,O
-,O
CoV-2,O
epidemic,O
parameters,O
",",O
which,O
is,O
an,O
issue,O
for,O
all,O
molecular,O
evolutionary,O
studies,O
using,O
real,O
world,O
data,O
.,O
It,O
is,O
important,O
to,O
note,O
that,O
there,O
is,O
currently,O
not,O
enough,O
genomic,O
data,O
from,O
the,O
early,O
COVID-19,O
outbreak,O
period,O
to,O
interpret,O
the,O
early,O
history,O
of,O
global,O
transmissions,O
of,O
COVID-19,O
from,O
few,O
genomes,O
in,O
detail,O
.,O
The,O
95,O
%,O
BCI,O
estimates,O
for,O
the,O
evolutionary,O
rates,O
and,O
TMRCA,O
dates,O
are,O
averaged,O
over,O
many,O
plausible,O
phylogenetic,O
reconstructions,O
of,O
the,O
genome,O
data,O
;,O
thus,O
",",O
as,O
more,O
patients,O
with,O
COVID-19,O
are,O
sampled,O
and,O
more,O
SARS,O
-,O
CoV-2,O
genomes,O
become,O
available,O
",",O
we,O
expect,O
these,O
estimates,O
will,O
become,O
narrower,O
.,O
To,O
investigate,O
the,O
evolutionary,O
and,O
epidemiological,O
dynamics,O
of,O
the,O
current,O
COVID-19,O
outbreak,O
",",O
a,O
total,O
of,O
112,O
genomes,O
of,O
SARS,O
-,O
CoV-2,O
strains,O
sampled,O
from,O
China,O
and,O
12,O
other,O
countries,O
with,O
sampling,O
dates,O
between,O
24,O
December,O
2019,O
and,O
9,O
February,O
2020,O
were,O
analyzed,O
.,O
The,O
novel,O
betacoronavirus,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
which,O
causes,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
was,O
first,O
reported,O
in,O
Wuhan,O
",",O
China,O
in,O
December,O
2019,O
[,O
1,O
",",O
2,O
],O
.,O
According,O
to,O
the,O
World,O
Health,O
Organization,O
",",O
the,O
current,O
outbreak,O
of,O
COVID-19,O
has,O
nearly,O
11.5,O
million,O
confirmed,O
cases,O
worldwide,O
with,O
more,O
than,O
"530,000",O
deaths,O
",",O
as,O
of,O
July,O
6,O
",",O
2020,O
.,O
Although,O
the,O
estimated,O
fatality,O
rate,O
in,O
the,O
confirmed,O
cases,O
is,O
6.6,O
%,O
in,O
SARS,O
-,O
CoV-2,O
",",O
which,O
is,O
lower,O
than,O
those,O
of,O
SARS,O
-,O
CoV,O
and,O
MERS,O
-,O
CoV,O
",",O
9.6,O
%,O
and,O
34.3,O
%,O
",",O
respectively,O
[,O
4,O
],O
",",O
there,O
is,O
an,O
urgent,O
need,O
for,O
its,O
effective,O
treatment,O
based,O
on,O
antivirals,O
and,O
vaccines,O
that,O
reduce,O
the,O
mortality,O
and,O
morbidity,O
rates,O
of,O
COVID-19,O
.,O
However,O
",",O
up,O
to,O
now,O
",",O
the,O
causes,O
of,O
the,O
large,O
country,O
-,O
by,O
-,O
country,O
difference,O
of,O
the,O
mortality,O
rates,O
related,O
to,O
COVID-19,O
have,O
not,O
been,O
clearly,O
understood,O
.,O
Full,O
-,O
length,O
viral,O
nucleotide,O
sequence,O
of,O
the,O
reference,O
SARS,O
-,O
CoV-2,O
(,O
accession,O
number,O
MN908947,S-AccessionNumber
),O
[,O
1,O
],O
was,O
downloaded,O
from,O
the,O
NCBI,B-Repository
GenBank,E-Repository
.,O
Briefly,O
",",O
we,O
first,O
aligned,O
each,O
of,O
the,O
SARS,O
-,O
CoV-2,O
sequences,O
to,O
the,O
reference,O
sequence,O
SARS,O
-,O
CoV-2_Wuhan,O
-,O
Hu-1,O
(,O
accession,O
number,O
MN908947,S-AccessionNumber
),O
using,O
BLAT,O
software,O
[,O
7,O
],O
.,O
After,O
the,O
alignment,O
",",O
we,O
extracted,O
nucleotide,O
sequences,O
corresponding,O
to,O
individual,O
proteins,O
of,O
SARS,O
-,O
CoV-2,O
",",O
translated,O
them,O
into,O
amino,O
acid,O
sequences,O
",",O
and,O
then,O
compared,O
them,O
to,O
reference,O
amino,O
acid,O
sequences,O
of,O
SARS,O
-,O
CoV-2_Wuhan,O
-,O
Hu-1,O
(,O
accession,O
numbers,O
QHD43415,S-AccessionNumber
-,O
QHD43423,S-AccessionNumber
",",O
QHI42199,S-AccessionNumber
),O
.,O
Data,O
on,O
numbers,O
of,O
confirmed,O
cases,O
and,O
deaths,O
related,O
to,O
COVID-19,O
were,O
obtained,O
from,O
the,O
Worldometer,S-Dataset
 ,O
(,O
https://www.worldometers.info/coronavirus/,S-URL
),O
on,O
7,O
May,O
2020,O
(,O
Supplementary,O
Table,O
 ,O
1,O
),O
.,O
Multiple,O
regression,O
analysis,O
was,O
used,O
to,O
test,O
for,O
an,O
independent,O
contribution,O
of,O
identified,O
factors,O
to,O
fatality,O
rates,O
of,O
COVID-19,O
.,O
Correlation,O
analysis,O
of,O
variant,O
frequencies,O
of,O
SARS,O
-,O
CoV-2,O
ORF1ab,O
4715L,O
(,O
a,O
),O
or,O
S,O
614,O
G,O
(,O
b,O
),O
with,O
fatality,O
rates,O
of,O
COVID-19,O
among,O
28,O
countries,O
.,O
Several,O
other,O
factors,O
are,O
investigated,O
in,O
association,O
with,O
mortality,O
related,O
to,O
COVID-19,O
.,O
Ecological,O
studies,O
have,O
suggested,O
that,O
countries,O
that,O
mandate,O
BCG,O
vaccination,O
for,O
the,O
population,O
have,O
a,O
lower,O
number,O
of,O
infections,O
and,O
a,O
reduced,O
mortality,O
from,O
COVID-19,O
",",O
although,O
the,O
association,O
is,O
still,O
controversial,O
and,O
the,O
underlying,O
mechanism,O
has,O
not,O
been,O
clarified,O
[,O
9,O
",",O
14,O
",",O
15,O
],O
.,O
Concordant,O
to,O
our,O
results,O
",",O
a,O
few,O
reports,O
demonstrated,O
that,O
S,O
614,O
G,O
variant,O
was,O
associated,O
with,O
the,O
mortality,O
related,O
to,O
COVID-19,O
[,O
13,O
",",O
22,O
],O
.,O
Since,O
immune,O
responses,O
through,O
HLA,O
and,O
T,O
cells,O
are,O
important,O
to,O
protect,O
from,O
virus,O
infections,O
and,O
also,O
known,O
to,O
be,O
involved,O
in,O
the,O
progression,O
of,O
COVID-19,O
",",O
we,O
screened,O
epitopes,O
around,O
the,O
mutations,O
associated,O
with,O
fatality,O
rates,O
(,O
Supplementary,O
Table,O
 ,O
3,O
),O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
outbreak,O
",",O
caused,O
by,O
SARS,O
-,O
CoV-2,O
",",O
has,O
rapidly,O
expanded,O
to,O
a,O
global,O
pandemic,O
.,O
However,O
",",O
numbers,O
of,O
infected,O
cases,O
",",O
deaths,O
",",O
and,O
mortality,O
rates,O
related,O
to,O
COVID-19,O
vary,O
from,O
country,O
to,O
country,O
.,O
Through,O
a,O
hierarchical,O
clustering,O
based,O
on,O
the,O
mutant,O
frequencies,O
",",O
we,O
classified,O
the,O
28,O
countries,O
into,O
three,O
clusters,O
showing,O
different,O
fatality,O
rates,O
of,O
COVID-19,O
.,O
Our,O
findings,O
suggest,O
that,O
SARS,O
-,O
CoV-2,O
mutations,O
as,O
well,O
as,O
BCG,O
-,O
vaccination,O
status,O
and,O
a,O
host,O
genetic,O
factor,O
",",O
HLA,O
genotypes,O
might,O
affect,O
the,O
susceptibility,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
or,O
severity,O
of,O
COVID-19,O
.,O
This,O
novel,O
strain,O
of,O
coronavirus,O
has,O
been,O
identified,O
as,O
 ,O
the,O
causative,O
agent,O
for,O
the,O
epidemic,O
of,O
acute,O
respiratory,O
distress,O
syndrome,O
(,O
also,O
referred,O
to,O
as,O
coronavirus,O
disease,O
2019,O
[,O
COVID-19,O
],O
),O
in,O
Wuhan,O
",",O
China.1,O
",",O
2,O
",",O
3,O
Since,O
then,O
",",O
the,O
COVID-19,O
outbreak,O
has,O
rapidly,O
swept,O
all,O
of,O
the,O
provinces,O
of,O
China,O
 ,O
and,O
has,O
disseminated,O
globally,O
to,O
216,O
countries,O
and,O
territories,O
through,O
travel,O
.,O
COVID-19,O
is,O
a,O
potential,O
zoonotic,O
disease,O
with,O
a,O
low,O
to,O
moderate,O
mortality,O
rate,O
(,O
2%–5,O
%,O
),O
and,O
is,O
primarily,O
transmitted,O
through,O
droplet,O
and,O
direct,O
contact,O
with,O
infected,O
individuals,O
or,O
incubation,O
carriers,O
.,O
COVID-19,O
patients,O
develop,O
dynamic,O
innate,O
and,O
adaptive,O
immune,O
responses,O
to,O
SARS,O
-,O
CoV-2.7,O
",",O
8,O
",",O
9,O
SARS,O
-,O
CoV-2,O
has,O
a,O
preferential,O
tropism,O
for,O
airway,O
epithelial,O
cells,O
mediated,O
through,O
the,O
accessibility,O
of,O
the,O
angiotensin,O
-,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
receptor.10,O
",",O
11,O
",",O
12,O
",",O
13,O
The,O
common,O
clinical,O
manifestations,O
of,O
fever,O
and,O
cough,O
in,O
conjunction,O
with,O
laboratory,O
results,O
of,O
progressively,O
increasing,O
neutrophil,O
counts,O
and,O
leukocytopenia,O
in,O
serum,O
samples,O
taken,O
from,O
COVID-19,O
patients,O
at,O
various,O
stages,O
of,O
the,O
illness,O
indicate,O
uncontrolled,O
neutrophil,O
extravasation,O
and,O
activation,O
.,O
A,O
large,O
number,O
of,O
macrophages,O
and,O
neutrophils,O
were,O
found,O
in,O
alveolar,O
cavities,O
in,O
COVID-19,O
fatalities,O
",",O
suggesting,O
their,O
roles,O
in,O
cytokine,O
storms,O
.,O
While,O
uncontrolled,O
neutrophil,O
activity,O
and,O
aberrant,O
cytokine,O
response,O
contribute,O
to,O
SARS,O
-,O
CoV-2,O
pathogenesis,O
in,O
COVID-19,O
",",O
how,O
SARS,O
-,O
CoV-2,O
causes,O
these,O
immunological,O
changes,O
",",O
especially,O
the,O
 ,O
enhancement,O
of,O
neutrophil,O
chemotaxis,O
and,O
activation,O
",",O
remains,O
largely,O
undetermined,O
.,O
The,O
disruption,O
of,O
these,O
intraviral,O
PPIs,O
by,O
repurposing,O
small,O
molecule,O
or,O
peptide,O
drugs,O
that,O
target,O
specific,O
epitopes,O
can,O
be,O
a,O
treatment,O
strategy,O
against,O
COVID-19,O
.,O
SARS,O
-,O
CoV-2,O
infection,O
can,O
lead,O
to,O
imbalanced,O
host,O
immune,O
responses,O
such,O
as,O
diminished,O
type,O
I,O
and,O
type,O
III,O
interferon,O
(,O
IFN,O
),O
signaling,O
",",O
as,O
well,O
as,O
strong,O
chemotactic,O
and,O
inflammatory,O
response,O
in,O
infected,O
cell,O
lines,O
",",O
animal,O
models,O
",",O
and,O
COVID-19,O
patients,O
",",O
",",O
",",O
 ,O
Nsp10,O
may,O
regulate,O
IL-8,O
levels,O
by,O
targeting,O
NKRF,O
and,O
shapes,O
the,O
unique,O
immune,O
signature,O
in,O
COVID-19,O
.,O
To,O
elucidate,O
the,O
mechanism,O
and,O
effect,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
in,O
patients,O
",",O
we,O
determined,O
the,O
global,O
proteome,O
profile,O
changes,O
in,O
PBMCs,O
samples,O
taken,O
from,O
healthy,O
donors,O
compared,O
with,O
PBMCs,O
collected,O
from,O
COVID-19,O
patients,O
with,O
mild,O
or,O
severe,O
symptoms,O
.,O
The,O
PBMC,O
samples,O
were,O
obtained,O
from,O
the,O
Shanghai,B-Repository
Public,I-Repository
Health,I-Repository
Clinical,I-Repository
Center,E-Repository
 ,O
and,O
include,O
6,O
healthy,O
donors,O
",",O
22,O
COVID-19,O
patients,O
with,O
mild,O
symptoms,O
(,O
COVID-19,O
-,O
MS,O
),O
",",O
and,O
13,O
COVID-19,O
patients,O
with,O
severe,O
symptoms,O
(,O
COVID-19,O
-,O
SS,O
),O
(,O
Table,O
S2,O
),O
.,O
A,O
total,O
of,O
"5,521",O
proteins,O
were,O
quantified,O
according,O
to,O
criteria,O
and,O
included,O
in,O
global,O
proteomic,O
profiling,O
to,O
reveal,O
a,O
list,O
of,O
726,O
proteins,O
found,O
to,O
be,O
differentially,O
expressed,O
(,O
|log2,O
[,O
fold,O
change]|,O
≥,O
0.58,O
",",O
adjusted,O
p,O
≤,O
0.01,O
",",O
n,O
≥,O
3,O
),O
in,O
the,O
PBMCs,O
of,O
COVID-19,O
-,O
MS,O
compared,O
with,O
those,O
of,O
healthy,O
donors,O
;,O
333,O
proteins,O
showed,O
a,O
statistically,O
significant,O
increase,O
",",O
while,O
393,O
proteins,O
showed,O
a,O
reduction,O
in,O
expression,O
when,O
comparing,O
COVID-19,O
-,O
MS,O
with,O
control,O
(,O
Figures,O
3,O
A,O
",",O
S4A,O
",",O
and,O
S4B,O
;,O
Table,O
S3,O
),O
.,O
Analysis,O
of,O
the,O
global,O
proteomic,O
changes,O
reveals,O
significantly,O
reduced,O
levels,O
of,O
PF4,O
",",O
GP1BA,O
",",O
SERPINA5,O
",",O
HBB,O
",",O
HBD,O
",",O
C1QBP,O
",",O
HRG,O
",",O
and,O
RAC1,O
in,O
the,O
COVID-19,O
-,O
MS,O
PBMC,O
cohort,O
(,O
Figure,O
 ,O
3B,O
),O
.,O
RAC1,O
also,O
directly,O
interacts,O
with,O
SigmaR1,O
",",O
a,O
potential,O
therapeutic,O
target,O
for,O
COVID-19,O
.,O
Overall,O
",",O
our,O
functional,O
analysis,O
reveals,O
the,O
complexity,O
of,O
host,O
responses,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
in,O
mildly,O
symptomatic,O
COVID-19,O
patients,O
",",O
highlighting,O
the,O
abnormal,O
regulations,O
in,O
blood,O
coagulation,O
and,O
hemostasis,O
.,O
Next,O
",",O
we,O
compared,O
the,O
proteome,O
change,O
between,O
PBMCs,O
isolated,O
from,O
COVID-19,O
-,O
SS,O
and,O
COVID-19,O
-,O
MS,O
patients,O
.,O
Among,O
"6,235",O
quantified,O
proteins,O
(,O
n,O
≥,O
3,O
),O
",",O
366,O
proteins,O
were,O
found,O
to,O
be,O
significantly,O
differentially,O
expressed,O
(,O
|log2,O
[,O
fold,O
change]|,O
≥,O
0.58,O
",",O
adjusted,O
p,O
≤,O
0.01,O
),O
between,O
the,O
PMBCs,O
of,O
COVID-19,O
-,O
SS,O
and,O
COVID-19,O
-,O
MS,O
.,O
A,O
total,O
of,O
209,O
of,O
these,O
proteins,O
were,O
upregulated,O
and,O
157,O
of,O
these,O
proteins,O
were,O
downregulated,O
in,O
COVID-19,O
-,O
SS,O
as,O
compared,O
to,O
COVID-19,O
-,O
MS,O
(,O
Figures,O
3D,O
",",O
3E,O
",",O
S4D,O
",",O
and,O
S4E,O
;,O
Table,O
S3,O
),O
.,O
The,O
expression,O
levels,O
of,O
neutrophil,O
surface,O
receptors,O
(,O
CXCR1,O
",",O
Siglec5,O
",",O
and,O
CD177,O
),O
and,O
neutrophil,O
granule,O
contents,O
(,O
DEFA1,O
),O
were,O
dramatically,O
upregulated,O
in,O
COVID-19,O
-,O
SS,O
(,O
Figures,O
3D,O
and,O
3E,O
),O
",",O
which,O
is,O
consistent,O
with,O
the,O
elevated,O
neutrophil,O
population,O
in,O
COVID-19,O
patients,O
.,O
",",O
 ,O
Consistent,O
with,O
RNA,O
sequencing,O
results,O
from,O
COVID-19,O
patients,O
",",O
",",O
Laboratory,O
results,O
reveal,O
increased,O
neutrophils,O
counts,O
to,O
∼90,O
%,O
of,O
the,O
white,O
blood,O
cell,O
count,O
as,O
COVID-19,O
progresses,O
to,O
critical,O
stages,O
.,O
14,O
",",O
15,O
",",O
16,O
The,O
elevation,O
of,O
IL-8,O
and,O
IL-6,O
but,O
not,O
IL-17,O
in,O
PMBCs,O
collected,O
from,O
severe,O
symptomatic,O
COVID-19,O
patients,O
indicates,O
critical,O
roles,O
for,O
IL-8,O
and,O
IL-6,O
in,O
the,O
severe,O
inflammatory,O
response,O
induced,O
by,O
SARS,O
-,O
CoV-2,O
infection,O
(,O
Figures,O
3,O
G,O
",",O
3H,O
",",O
and,O
S4H,O
),O
.,O
In,O
addition,O
",",O
a,O
cluster,O
of,O
genes,O
related,O
to,O
blood,O
coagulation,O
was,O
dramatically,O
upregulated,O
in,O
COVID-19,O
-,O
SS,O
as,O
compared,O
to,O
COVID-19,O
-,O
MS,O
(,O
Figure,O
 ,O
S4,O
G,O
),O
",",O
supporting,O
the,O
hypothesis,O
that,O
the,O
abnormal,O
blood,O
clotting,O
contributes,O
to,O
de,O
ath,O
in,O
some,O
severe,O
COVID-19,O
patients,O
.,O
As,O
compared,O
to,O
COVID-19,O
-,O
MS,O
",",O
the,O
downregulated,O
proteins,O
of,O
COVID-19,O
-,O
SS,O
are,O
highly,O
enriched,O
in,O
T,O
 ,O
cell,O
activation,O
",",O
T,O
 ,O
cell,O
receptor,O
(,O
TCR,O
),O
signaling,O
",",O
viral,O
transcription,O
",",O
viral,O
gene,O
expression,O
",",O
translation,O
initiation,O
",",O
and,O
lymphocyte,O
co,O
-,O
stimulation,O
(,O
Figures,O
3F,O
and,O
S4F,O
),O
.,O
The,O
expression,O
of,O
TCR,O
subunits,O
(,O
CD3e,O
",",O
CD3,O
g,O
",",O
and,O
CD247,O
),O
",",O
T,O
 ,O
cell,O
surface,O
molecules,O
(,O
CD4,O
",",O
CD8a,O
",",O
CD8b,O
",",O
CD2,O
",",O
CD5,O
",",O
and,O
CD7,O
),O
",",O
major,O
histocompatibility,O
complex,O
(,O
MHC,O
),O
class,O
II,O
molecules,O
(,O
HLA,O
-,O
DRA,O
),O
",",O
TCR,O
signaling,O
kinases,O
and,O
adaptors,O
(,O
LCK,O
",",O
FYN,O
",",O
SKAP1,O
",",O
CARD11,O
",",O
CAMK4,O
",",O
and,O
BTN3A1,O
),O
",",O
and,O
T,O
 ,O
cell,O
differentiation,O
and,O
survival,O
(,O
BCL11B,O
),O
were,O
dramatically,O
diminished,O
in,O
COVID-19,O
-,O
SS,O
compared,O
to,O
COVID-19,O
-,O
MS,O
(,O
Figures,O
3D,O
and,O
3E,O
),O
",",O
suggesting,O
a,O
failure,O
of,O
T,O
 ,O
cell,O
activation,O
and,O
function,O
.,O
These,O
results,O
demonstrate,O
that,O
severe,O
COVID-19,O
patients,O
undergo,O
a,O
functional,O
decline,O
in,O
adaptive,O
immunity,O
",",O
which,O
correlates,O
with,O
their,O
lower,O
T,O
 ,O
cell,O
population,O
.,O
14,O
",",O
15,O
",",O
16,O
From,O
the,O
quantitative,O
proteome,O
analysis,O
of,O
PBMCs,O
",",O
it,O
is,O
clear,O
that,O
SARS,O
-,O
CoV-2,O
triggers,O
IL-8,O
expression,O
and,O
increases,O
neutrophil,O
count,O
",",O
which,O
may,O
mediate,O
the,O
manifestation,O
of,O
acute,O
respiratory,O
distress,O
syndrome,O
in,O
COVID-19,O
patients,O
.,O
Establishing,O
viral,O
-,O
viral,O
and,O
virus,O
-,O
host,O
PPI,O
networks,O
is,O
of,O
high,O
priority,O
to,O
understand,O
the,O
host,O
response,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
guide,O
the,O
design,O
of,O
potential,O
drug,O
candidates,O
for,O
COVID-19,O
.,O
While,O
nsp10,O
-,O
NKRF,O
interaction,O
was,O
not,O
captured,O
by,O
the,O
Krogan,O
group,O
",",O
we,O
have,O
confirmed,O
that,O
nsp10,O
is,O
associated,O
with,O
endogenous,O
NKRF,O
in,O
HEK293,O
T,O
cells,O
",",O
suggesting,O
that,O
our,O
dataset,O
could,O
serve,O
as,O
a,O
valuable,O
additional,O
resource,O
for,O
host,O
targets,O
that,O
are,O
potentially,O
involved,O
in,O
SARS,O
-,O
CoV-2,O
immune,O
evasion,O
and,O
pathogenesis,O
.,O
Our,O
quantitative,O
proteomic,O
analysis,O
using,O
PBMC,O
samples,O
derived,O
from,O
both,O
mild,O
and,O
severe,O
COVID-19,O
patients,O
begins,O
to,O
address,O
this,O
gap,O
in,O
knowledge,O
.,O
Since,O
our,O
viral,O
-,O
host,O
interactome,O
analysis,O
indicates,O
that,O
SARS,O
-,O
CoV-2,O
viral,O
proteins,O
may,O
modulate,O
and,O
evade,O
host,O
innate,O
immune,O
response,O
by,O
interacting,O
with,O
key,O
kinases,O
and,O
adaptors,O
of,O
the,O
immune,O
signaling,O
pathway,O
",",O
it,O
is,O
not,O
surprising,O
that,O
COVID-19,O
patients,O
fail,O
to,O
mount,O
robust,O
antiviral,O
IFN,O
responses,O
.,O
From,O
our,O
quantitative,O
proteomic,O
analysis,O
",",O
neutrophilia,O
",",O
leukocytopenia,O
",",O
and,O
hypercoagulation,O
were,O
observed,O
in,O
PBMCs,O
of,O
COVID-19,O
-,O
SS,O
patients,O
as,O
compared,O
to,O
COVID-19,O
-,O
MS,O
patients,O
",",O
supporting,O
the,O
hypothesis,O
that,O
imbalanced,O
inflammatory,O
cytokine,O
production,O
",",O
such,O
as,O
IL-8,O
and,O
IL-6,O
dysregulation,O
",",O
contributes,O
to,O
the,O
overactivation,O
of,O
neutrophils,O
and,O
regulation,O
of,O
the,O
bloodclotting,O
cascade,O
.,O
",",O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
study,O
to,O
characterize,O
the,O
PBMC,O
proteome,O
profile,O
in,O
both,O
mild,O
and,O
severe,O
cases,O
of,O
COVID-19,O
infection,O
",",O
and,O
it,O
contextualizes,O
the,O
overall,O
clinical,O
features,O
of,O
COVID-19,O
patients,O
at,O
the,O
protein,O
level,O
.,O
Follow,O
-,O
up,O
work,O
is,O
required,O
to,O
tease,O
out,O
the,O
detailed,O
mechanisms,O
involved,O
and,O
translate,O
the,O
therapeutic,O
relevance,O
of,O
these,O
findings,O
in,O
targeting,O
the,O
cytokine,O
storm,O
in,O
COVID-19,O
.,O
The,O
datasets,O
generated,O
during,O
this,O
study,O
were,O
deposited,O
to,O
the,O
ProteomeXchange,B-Repository
Consortium,E-Repository
 ,O
(,O
http://proteomecentral.proteomexchange.org,S-URL
),O
via,O
the,O
iProX,O
partner,O
repository,O
with,O
the,O
dataset,O
identifier,O
IPX0002285000,S-AccessionNumber
.,O
The,O
trypsin,O
-,O
digested,O
peptides,O
were,O
desalted,O
by,O
monospin,O
C18,O
and,O
loaded,O
on,O
a,O
home,O
-,O
made,O
40,O
 ,O
cm,O
-,O
long,O
pulled,O
-,O
tip,O
analytical,O
column,O
(,O
75,O
 ,O
μm,O
ID,O
x,O
360,O
 ,O
μm,O
OD,O
",",O
ReproSil,O
-,O
Pur,O
C18,O
-,O
AQ,O
1.9,O
 ,O
μm,O
resin,O
",",O
Dr.,O
Maisch,O
GmbH,O
),O
",",O
connected,O
to,O
a,O
Thermo,O
Easy,O
-,O
nLC1000,O
HPLC,O
system,O
.,O
The,O
acquired,O
MS,O
/,O
MS,O
data,O
were,O
analyzed,O
against,O
a,O
UniProtKB,B-Repository
Human,E-Repository
 ,O
database,O
(,O
database,O
released,O
on,O
Sept.,O
30,O
",",O
2018,O
),O
containing,O
SARS,O
-,O
CoV-2,O
viral,O
proteins,O
using,O
Maxquant,O
V1.6.10.43,O
.,O
To,O
accurately,O
estimate,O
peptide,O
probabilities,O
and,O
false,O
discovery,O
rates,O
(,O
FDR,O
),O
",",O
we,O
used,O
a,O
decoy,O
database,O
containing,O
the,O
reversed,O
sequences,O
of,O
all,O
the,O
proteins,O
appended,O
to,O
the,O
target,O
database,O
.,O
MiST,O
algorithm,O
was,O
used,O
to,O
calculate,O
the,O
statistical,O
significance,O
of,O
the,O
dataset,O
.,O
The,O
information,O
of,O
35,O
patients,O
with,O
confirmed,O
SARS,O
-,O
CoV-2,O
infection,O
(,O
13,O
COVID-19,O
patients,O
with,O
severe,O
symptoms,O
and,O
22,O
COVID-19,O
patients,O
with,O
mild,O
symptoms,O
),O
and,O
6,O
health,O
donors,O
as,O
control,O
are,O
listed,O
in,O
Table,O
S2,O
",",O
including,O
age,O
(,O
47,O
-,O
73,O
),O
",",O
sex,O
",",O
and,O
symptoms,O
.,O
Basically,O
",",O
protein,O
samples,O
were,O
combined,O
to,O
generate,O
3,O
control,O
sample,O
pools,O
from,O
6,O
healthy,O
donors,O
 ,O
(,O
one,O
sample,O
pool,O
was,O
excluded,O
from,O
the,O
list,O
for,O
the,O
sample,O
quality,O
issue,O
),O
",",O
13,O
mild,O
-,O
case,O
sample,O
pools,O
from,O
22,O
COVID-19,O
-,O
MS,O
patients,O
",",O
and,O
10,O
severe,O
-,O
case,O
sample,O
pools,O
from,O
13,O
COVID-19,O
-,O
SS,O
patients,O
according,O
to,O
the,O
protein,O
concentrations,O
of,O
all,O
the,O
samples,O
due,O
to,O
the,O
limited,O
protein,O
amounts,O
extracted,O
from,O
the,O
variable,O
PBMCs,O
of,O
each,O
case,O
(,O
Table,O
S2,O
),O
.,O
Briefly,O
",",O
the,O
datasets,O
were,O
merged,O
by,O
matching,O
the,O
protein,O
accession,O
numbers,O
of,O
each,O
dataset,O
using,O
in,O
-,O
house,O
developed,O
Python,O
scripts,O
(,O
comparepg.py,O
),O
.,O
Protein,O
features,O
with,O
less,O
than,O
3,O
quantitative,O
values,O
in,O
each,O
condition,O
(,O
H&MS,O
or,O
MS&SS,O
),O
were,O
removed,O
from,O
the,O
dataset,O
to,O
make,O
sure,O
each,O
quantitative,O
protein,O
in,O
the,O
list,O
have,O
at,O
least,O
3,O
values,O
for,O
H,O
cases,O
",",O
MS,O
cases,O
",",O
and,O
SS,O
cases,O
during,O
the,O
proteomics,O
analysis,O
.,O
MiST,O
algorithm,O
was,O
used,O
to,O
calculate,O
the,O
statistical,O
significance,O
of,O
the,O
dataset,O
.,O
The,O
acquired,O
MS,O
/,O
MS,O
data,O
were,O
analyzed,O
against,O
a,O
UniProtKB,B-Repository
human,E-Repository
 ,O
(,O
database,O
released,O
on,O
Sept.,O
30,O
",",O
2018,O
),O
by,O
Maxquant,O
V1.6.10.43,O
using,O
the,O
default,O
setting,O
.,O
The,O
ongoing,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus-2,O
(,O
SARS,O
-,O
CoV-2,O
),O
is,O
a,O
global,O
public,O
health,O
concern,O
due,O
to,O
relatively,O
easy,O
person,O
-,O
to,O
-,O
person,O
transmission,O
and,O
the,O
current,O
lack,O
of,O
effective,O
antiviral,O
therapy,O
.,O
Quantitative,O
proteomics,O
was,O
used,O
to,O
investigate,O
the,O
peripheral,O
blood,O
mononuclear,O
cell,O
(,O
PBMC,O
),O
proteome,O
signature,O
in,O
COVID-19,O
.,O
We,O
elucidated,O
286,O
host,O
proteins,O
targeted,O
by,O
SARS,O
-,O
CoV-2,O
and,O
>,O
350,O
host,O
proteins,O
that,O
are,O
significantly,O
perturbed,O
in,O
COVID-19,O
-,O
derived,O
PBMCs,O
.,O
This,O
signature,O
in,O
severe,O
COVID-19,O
PBMCs,O
reveals,O
a,O
significant,O
upregulation,O
of,O
cellular,O
proteins,O
related,O
to,O
neutrophil,O
activation,O
and,O
blood,O
coagulation,O
",",O
as,O
well,O
as,O
a,O
downregulation,O
of,O
proteins,O
mediating,O
T,O
 ,O
cell,O
receptor,O
signaling,O
.,O
From,O
the,O
interactome,O
",",O
we,O
further,O
identified,O
that,O
non,O
-,O
structural,O
protein,O
10,O
interacts,O
with,O
NF,O
-,O
κB,O
-,O
repressing,O
factor,O
(,O
NKRF,O
),O
to,O
facilitate,O
interleukin-8,O
(,O
IL-8,O
),O
induction,O
",",O
which,O
potentially,O
contributes,O
to,O
IL-8,O
-,O
mediated,O
chemotaxis,O
of,O
neutrophils,O
and,O
the,O
overexuberant,O
host,O
inflammatory,O
response,O
observed,O
in,O
COVID-19,O
patients,O
.,O
Funding,O
 ,O
National,O
Key,O
Research,O
and,O
Development,O
Project,O
of,O
China,O
",",O
National,O
Natural,O
Science,O
Foundation,O
of,O
China,O
",",O
National,O
Science,O
and,O
Technology,O
Major,O
Project,O
",",O
Program,O
for,O
Professor,O
of,O
Special,O
Appointment,O
(,O
Eastern,O
Scholar,O
),O
at,O
Shanghai,O
Institutions,O
of,O
Higher,O
Learning,O
",",O
Shanghai,O
Science,O
and,O
Technology,O
Commission,O
",",O
Shanghai,O
Municipal,O
Health,O
Commission,O
",",O
Shanghai,O
Municipal,O
Key,O
Clinical,O
Specialty,O
",",O
Innovative,O
Research,O
Team,O
of,O
High,O
-,O
level,O
Local,O
Universities,O
in,O
Shanghai,O
",",O
Interdisciplinary,O
Program,O
of,O
Shanghai,O
Jiao,O
Tong,O
University,O
",",O
SII,O
Challenge,O
Fund,O
for,O
COVID-19,O
Research,O
",",O
Chinese,O
Academy,O
of,O
Sciences,O
(,O
CAS,O
),O
Large,O
Research,O
Infrastructure,O
of,O
Maintenance,O
and,O
Remolding,O
Project,O
",",O
and,O
Chinese,O
Academy,O
of,O
Sciences,O
Key,O
Technology,O
Talent,O
Program,O
.,O
The,O
COVID-19,O
pandemic,O
is,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
",",O
but,O
little,O
is,O
known,O
about,O
the,O
functions,O
of,O
its,O
viral,O
proteins,O
.,O
Quantitative,O
proteomic,O
analysis,O
revealed,O
elevated,O
levels,O
of,O
IL-6,O
and,O
IL-8,O
in,O
PBMCs,O
collected,O
from,O
severe,O
COVID-19,O
patients,O
compared,O
with,O
mild,O
ones,O
",",O
and,O
the,O
functional,O
annotation,O
of,O
differentially,O
expressed,O
proteins,O
implicate,O
pathways,O
involved,O
in,O
neutrophil,O
activation,O
",",O
T,O
 ,O
cell,O
receptor,O
signaling,O
",",O
and,O
the,O
coagulation,O
cascade,O
.,O
Combining,O
virus,O
-,O
host,O
interactome,O
with,O
COVID-19,O
proteomic,O
analysis,O
",",O
the,O
authors,O
found,O
that,O
nsp10,O
interacts,O
with,O
NKRF,O
to,O
mediate,O
IL-8,O
expression,O
",",O
providing,O
a,O
potential,O
molecular,O
mechanism,O
for,O
SARS,O
-,O
CoV-2,O
-,O
induced,O
cytokine,O
storm,O
and,O
marking,O
it,O
as,O
a,O
possible,O
emerging,O
therapeutic,O
target,O
.,O
Li,O
et,O
 ,O
al,O
.,O
establish,O
the,O
SARS,O
-,O
CoV-2,O
intraviral,O
and,O
virus,O
-,O
host,O
protein,O
-,O
protein,O
interaction,O
networks,O
and,O
reveal,O
the,O
overall,O
proteome,O
signature,O
in,O
PBMCS,O
from,O
COVID-19,O
patients,O
by,O
quantitative,O
proteomic,O
analysis,O
.,O
Levels,O
of,O
specific,O
immune,O
mediators,O
in,O
the,O
first,O
plasma,O
samples,O
collected,O
from,O
patients,O
with,O
COVID-19,O
during,O
hospitalisation,O
were,O
quantified,O
by,O
multiplex,O
microbead,O
-,O
based,O
immunoassays,O
.,O
Protein,O
–,O
protein,O
interaction,O
networks,O
of,O
these,O
immune,O
mediators,O
and,O
previously,O
reported,O
host,O
proteins,O
targeted,O
by,O
SARS,O
-,O
CoV-2,O
ORF8,O
were,O
predicted,O
and,O
illustrated,O
with,O
the,O
Search,O
Tool,O
for,O
the,O
Retrieval,O
of,O
Interacting,O
Genes,O
/,O
Proteins,O
(,O
STRING,O
),O
database,O
version,O
11.0,O
),O
.,O
All,O
these,O
interactions,O
were,O
derived,O
from,O
high,O
-,O
throughput,O
lab,O
experiments,O
and,O
previous,O
knowledge,O
in,O
curated,O
databases,O
at,O
a,O
confidence,O
threshold,O
of,O
0·5,O
.,O
We,O
observed,O
that,O
patients,O
infected,O
with,O
the,O
∆382,O
variant,O
had,O
lower,O
concentrations,O
of,O
proinflammatory,O
cytokines,O
",",O
chemokines,O
",",O
and,O
growth,O
factors,O
that,O
are,O
strongly,O
associated,O
with,O
severe,O
COVID-19.15,O
",",O
16,O
Notably,O
",",O
patients,O
with,O
pneumonia,O
from,O
the,O
∆382,O
variant,O
had,O
higher,O
concentrations,O
of,O
SDF-1α,O
",",O
which,O
is,O
usually,O
downregulated,O
during,O
hypoxia,O
.,O
Lymphopenia,O
and,O
functional,O
exhaustion,O
of,O
T,O
cells,O
correlate,O
with,O
disease,O
severity,O
in,O
COVID-19,O
.,O
Significant,O
CD4,O
-,O
positive,O
and,O
CD8,O
-,O
positive,O
T,O
-,O
cell,O
responses,O
to,O
ORF8,O
have,O
also,O
been,O
described,O
in,O
patients,O
who,O
recover,O
from,O
COVID-19,O
.,O
Exact,O
logistic,O
regression,O
was,O
used,O
to,O
examine,O
the,O
association,O
between,O
the,O
infection,O
groups,O
and,O
the,O
development,O
of,O
hypoxia,O
requiring,O
supplemental,O
oxygen,O
(,O
an,O
indicator,O
of,O
severe,O
COVID-19,O
",",O
the,O
primary,O
endpoint,O
),O
.,O
The,O
novel,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
outbreak,O
occurred,O
in,O
December,O
2019,O
and,O
in,O
the,O
following,O
months,O
this,O
epidemic,O
was,O
declared,O
as,O
a,O
global,O
health,O
emergency,O
by,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
with,O
more,O
than,O
600,O
thousand,O
deaths,O
reported,O
till,O
date,O
[,O
1,O
],O
.,O
Similar,O
to,O
SARS,O
-,O
CoV,O
and,O
the,O
Middle,O
East,O
respiratory,O
syndrome,O
(,O
MERS,O
),O
",",O
severe,O
symptoms,O
such,O
as,O
acute,O
respiratory,O
distress,O
syndrome,O
(,O
ARDS,O
),O
and,O
multiple,O
organ,O
failure,O
were,O
observed,O
in,O
nearly,O
20,O
%,O
patients,O
suffering,O
from,O
COVID-19,O
infection,O
[,O
2,O
],O
.,O
Recently,O
",",O
it,O
has,O
also,O
been,O
reported,O
as,O
a,O
receptor,O
for,O
the,O
spike,O
protein,O
of,O
SARS,O
-,O
CoV-2,O
and,O
plays,O
pivotal,O
roles,O
during,O
the,O
COVID-19,O
infection,O
[,O
4,O
],O
.,O
Notably,O
",",O
COVID-19,O
patients,O
with,O
severe,O
symptoms,O
also,O
seem,O
to,O
suffer,O
from,O
various,O
other,O
health,O
conditions,O
including,O
cardiovascular,O
disease,O
(,O
CVD,O
),O
",",O
hypertension,O
and,O
diabetes,O
[,O
5,O
],O
.,O
Thus,O
",",O
it,O
is,O
likely,O
that,O
the,O
extent,O
of,O
COVID-19,O
infection,O
gets,O
more,O
pronounced,O
by,O
ACE2,O
in,O
patients,O
with,O
comorbidities,O
",",O
which,O
in,O
turn,O
may,O
cause,O
additional,O
myocardial,O
damage,O
.,O
In,O
our,O
pervious,O
review,O
",",O
we,O
summarized,O
the,O
state,O
of,O
art,O
of,O
investigation,O
and,O
potential,O
therapeutic,O
strategies,O
for,O
COVID-19,O
patients,O
with,O
cardiac,O
disease,O
[,O
8,O
],O
.,O
In,O
this,O
study,O
",",O
we,O
investigate,O
several,O
in,O
-,O
silico,O
identified,O
miRNAs,O
which,O
could,O
regulate,O
ACE2,O
in,O
vitro,O
and,O
therefore,O
provide,O
a,O
potential,O
strategy,O
to,O
develop,O
novel,O
therapeutic,O
candidates,O
for,O
COVID-19,O
.,O
As,O
one,O
of,O
the,O
main,O
receptors,O
of,O
SARS,O
-,O
CoV-2,O
[,O
4,O
],O
",",O
ACE2,O
is,O
considered,O
as,O
a,O
potential,O
target,O
for,O
COVID-19,O
prevention,O
.,O
Another,O
multi,O
-,O
organ,O
autopsy,O
study,O
of,O
COVID-19,O
patients,O
revealed,O
the,O
presence,O
of,O
SARS,O
-,O
CoV-2,O
viral,O
RNA,O
in,O
the,O
heart,O
tissue,O
[,O
11,O
],O
.,O
To,O
fight,O
the,O
COVID-19,O
pandemic,O
in,O
the,O
absence,O
of,O
vaccines,O
",",O
it,O
is,O
necessary,O
to,O
identify,O
promising,O
drugs,O
which,O
act,O
against,O
SARS,O
-,O
CoV-2,O
infection,O
in,O
cardiomyocytes,O
and,O
such,O
in,O
vitro,O
translational,O
platforms,O
can,O
immensely,O
aid,O
in,O
this,O
process,O
.,O
Vaccine,O
is,O
one,O
of,O
the,O
most,O
efficient,O
tools,O
to,O
prevent,O
COVID-19,O
.,O
By,O
April,O
2020,O
",",O
115,O
vaccine,O
candidates,O
for,O
COVID-19,O
were,O
reported,O
",",O
out,O
of,O
which,O
73,O
targets,O
were,O
selected,O
for,O
pre,O
-,O
clinical,O
investigation,O
.,O
Of,O
note,O
",",O
patients,O
with,O
pre,O
-,O
existing,O
CVDs,O
are,O
more,O
likely,O
to,O
suffer,O
from,O
severe,O
symptoms,O
of,O
COVID-19,O
[,O
5,O
],O
.,O
However,O
",",O
the,O
contradicting,O
effects,O
of,O
ACE2,O
in,O
CVDs,O
and,O
COVID-19,O
infection,O
should,O
be,O
considered,O
carefully,O
.,O
Thus,O
",",O
it,O
is,O
a,O
big,O
challenge,O
to,O
ascertain,O
the,O
therapeutic,O
time,O
window,O
for,O
targeting,O
ACE2,O
in,O
COVID-19,O
patients,O
with,O
CVDs,O
.,O
Nevertheless,O
",",O
a,O
miR-200c,O
based,O
therapy,O
may,O
help,O
to,O
bridge,O
the,O
time,O
till,O
an,O
effective,O
COVID-19,O
vaccine,O
is,O
available,O
to,O
the,O
world,O
.,O
The,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
declared,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
as,O
a,O
public,O
health,O
emergency,O
of,O
international,O
concern,O
as,O
more,O
than,O
15,O
million,O
cases,O
were,O
reported,O
by,O
24th,O
July,O
2020,O
.,O
Angiotensin,O
-,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
is,O
a,O
COVID-19,O
entry,O
receptor,O
regulating,O
host,O
cell,O
infection,O
.,O
We,O
report,O
the,O
first,O
miRNA,O
candidate,O
that,O
can,O
target,O
ACE2,O
in,O
cardiomyocytes,O
and,O
thus,O
may,O
be,O
exploited,O
as,O
a,O
preventive,O
strategy,O
to,O
treat,O
cardiovascular,O
complications,O
of,O
COVID-19,O
.,O
A,O
novel,O
human,O
coronavirus,O
",",O
now,O
provisionally,O
called,O
‘,O
SARS,O
-,O
CoV-2,O
’,O
",",O
was,O
identified,O
as,O
the,O
cause,O
of,O
this,O
disease,O
",",O
now,O
named,O
‘,O
COVID-19,O
’,O
.,O
There,O
have,O
been,O
reports,O
of,O
COVID-19,O
associated,O
neurological,O
manifestations,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
CNS,O
demyelinating,O
disease,O
has,O
not,O
been,O
associated,O
with,O
COVID-19,O
so,O
far,O
;,O
however,O
",",O
other,O
coronaviruses,O
were,O
previously,O
associated,O
with,O
CNS,O
demyelinating,O
autoimmune,O
diseases,O
",",O
including,O
MS,O
exacerbations,O
[,O
5,O
],O
and,O
autoreactive,O
T,O
cells,O
able,O
to,O
recognize,O
myelin,O
antigens,O
[,O
6,O
",",O
7,O
],O
.,O
COVID-19,O
is,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
",",O
a,O
novel,O
beta,O
coronavirus,O
and,O
now,O
affecting,O
more,O
than,O
210,O
countries,O
",",O
areas,O
or,O
territories,O
(,O
WHO,O
2020,O
;,O
Zhou,O
et,O
al,O
.,O
2020,O
;,O
Zhu,O
et,O
al,O
.,O
2020,O
),O
.,O
The,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
has,O
declared,O
the,O
COVID-19,O
outbreak,O
as,O
a,O
global,O
pandemic,O
.,O
SARS,O
-,O
CoV-2,O
is,O
highly,O
contagious,O
with,O
an,O
estimated,O
R0,O
of,O
2–3,O
and,O
causes,O
COVID-19,O
with,O
a,O
wide,O
range,O
of,O
clinical,O
manifestations,O
including,O
asymptomatic,O
infection,O
to,O
severe,O
pneumonia,O
with,O
deadly,O
outcome,O
(,O
Hellewell,O
et,O
al,O
.,O
According,O
to,O
different,O
reports,O
published,O
so,O
far,O
",",O
COVID-19,O
has,O
a,O
mortality,O
rate,O
of,O
2%–10,O
%,O
(,O
Li,O
et,O
al,O
.,O
2020b,O
;,O
Yang,O
et,O
al,O
.,O
2020a,O
),O
.,O
COVID-19,O
has,O
an,O
incubation,O
period,O
of,O
2–14,O
 ,O
days,O
(,O
Jiang,O
et,O
al,O
.,O
2020,O
),O
.,O
Therefore,O
",",O
a,O
highly,O
sensitive,O
and,O
specific,O
laboratory,O
method,O
is,O
essential,O
for,O
early,O
diagnosis,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
which,O
is,O
critical,O
for,O
appropriate,O
management,O
of,O
suspected,O
COVID-19,O
patients,O
.,O
In,O
fact,O
",",O
a,O
sequential,O
change,O
of,O
positive,O
-,O
to,O
-,O
negative,O
-,O
to,O
-,O
positive,O
results,O
could,O
not,O
be,O
properly,O
explained,O
but,O
could,O
cause,O
great,O
concern,O
about,O
potential,O
viral,O
reactivation,O
and,O
re,O
-,O
infection,O
in,O
cured,O
COVID-19,O
patients,O
(,O
Chen,O
et,O
al,O
.,O
2020a,O
;,O
Ye,O
et,O
al,O
.,O
2020,O
),O
.,O
SARS,O
-,O
CoV-2,O
RT,O
-,O
PCR,O
may,O
fail,O
to,O
provide,O
a,O
positive,O
result,O
with,O
specimens,O
from,O
COVID-19,O
patients,O
.,O
A,O
retrospective,O
analysis,O
showed,O
that,O
only,O
39.1,O
%,O
of,O
573,O
sputum,O
specimens,O
and,O
19.2,O
%,O
of,O
579,O
throat,O
specimens,O
from,O
COVID-19,O
patients,O
collected,O
at,O
different,O
time,O
points,O
were,O
consistently,O
tested,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
RNAs,O
by,O
RT,O
-,O
PCR,O
(,O
Fig,O
.,O
 ,O
1A,O
",",O
1B,O
),O
.,O
To,O
validate,O
the,O
performance,O
of,O
these,O
cutoff,O
values,O
",",O
these,O
cutoff,O
values,O
were,O
applied,O
to,O
data,O
for,O
253,O
specimens,O
from,O
patients,O
with,O
conflicting,O
positive,O
and,O
negative,O
test,O
results,O
and,O
for,O
that,O
from,O
patients,O
with,O
multiple,O
samples,O
and,O
data,O
for,O
254,O
pairs,O
of,O
sputum,O
and,O
throat,O
swab,O
specimens,O
from,O
confirmed,O
COVID-19,O
patients,O
",",O
respectively,O
.,O
In,O
recent,O
reports,O
",",O
recovered,O
COVID-19,O
patients,O
",",O
defined,O
by,O
negative,O
test,O
results,O
for,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
at,O
least,O
two,O
independent,O
tests,O
",",O
were,O
found,O
repeatedly,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
RNA,O
testing,O
during,O
post,O
-,O
discharge,O
monitoring,O
(,O
Chen,O
et,O
al,O
.,O
2020a,O
),O
.,O
In,O
addition,O
",",O
contradicting,O
test,O
results,O
from,O
the,O
same,O
patients,O
are,O
not,O
rare,O
in,O
the,O
diagnosis,O
and,O
clinical,O
care,O
for,O
COVID-19,O
patients,O
.,O
Multiple,O
sputum,O
and,O
throat,O
swab,O
specimens,O
from,O
161,O
confirmed,O
COVID-19,O
patients,O
were,O
tested,O
with,O
a,O
commercial,O
fluorescent,O
RT,O
-,O
PCR,O
kit,O
targeting,O
the,O
ORF1ab,O
and,O
N,O
regions,O
of,O
SARS,O
-,O
CoV-2,O
genome,O
.,O
The,O
clinical,O
presentation,O
of,O
COVID-19,O
varies,O
from,O
asymptomatic,O
or,O
mild,O
respiratory,O
symptoms,O
",",O
to,O
severe,O
pneumonia,O
with,O
respiratory,O
failure,O
and,O
death,O
",",O
mainly,O
in,O
elderly,O
with,O
other,O
chronic,O
underlying,O
diseases,O
[,O
5,O
],O
.,O
As,O
the,O
global,O
scientific,O
community,O
is,O
in,O
the,O
race,O
for,O
finding,O
novel,O
therapies,O
for,O
the,O
disease,O
",",O
in,O
late,O
April,O
2020,O
over,O
500,O
interventional,O
clinical,O
studies,O
on,O
the,O
current,O
COVID-19,O
have,O
been,O
registered,O
at,O
ClinicalTrials.gov,O
[,O
6,O
],O
.,O
While,O
waiting,O
for,O
a,O
preventative,O
vaccine,O
",",O
most,O
of,O
the,O
therapeutic,O
strategies,O
against,O
COVID-19,O
are,O
currently,O
based,O
on,O
slowing,O
down,O
the,O
virus,O
replication,O
(,O
i.e.,O
by,O
using,O
antivirals,O
adopted,O
for,O
other,O
viruses,O
),O
",",O
and,O
on,O
reducing,O
severe,O
forms,O
of,O
disease,O
(,O
i.e.,O
by,O
counteracting,O
the,O
cytokine,O
storm,O
syndrome,O
),O
.,O
Conceptually,O
",",O
the,O
protein,O
sequence,O
and,O
structure,O
similarity,O
of,O
SARS,O
-,O
CoV-2,O
with,O
other,O
types,O
of,O
coronavirus,O
might,O
help,O
to,O
develop,O
effective,O
anti,O
-,O
COVID-19,O
 ,O
approaches,O
.,O
Based,O
on,O
this,O
evidence,O
",",O
we,O
speculate,O
that,O
the,O
use,O
of,O
G4,O
-,O
mediated,O
antiviral,O
drugs,O
may,O
represent,O
a,O
significant,O
turning,O
point,O
in,O
the,O
therapeutic,O
management,O
of,O
COVID-19,O
.,O
Here,O
",",O
we,O
used,O
the,O
Quadruplex,O
forming,O
G,O
-,O
Rich,O
Sequences,O
(,O
QGRS,O
),O
Mapper,O
",",O
a,O
web,O
-,O
based,O
server,O
database,O
[,O
19,O
],O
",",O
that,O
generates,O
detailed,O
information,O
on,O
composition,O
and,O
distribution,O
of,O
PG4FS,O
.,O
This,O
finding,O
suggests,O
that,O
G4s,O
ligands,O
could,O
represent,O
a,O
potential,O
therapeutic,O
strategy,O
for,O
COVID-19,O
.,O
Interestingly,O
",",O
after,O
a,O
search,O
in,O
the,O
DrugBank,S-Repository
 ,O
database,O
(,O
https://www.drugbank.ca,S-URL
/,O
",",O
version,O
5.1.5,O
",",O
released,O
2020,O
-,O
01,O
-,O
03,O
),O
",",O
we,O
retrieved,O
18,O
entries,O
for,O
FDA,O
-,O
approved,O
compounds,O
that,O
have,O
the,O
term,O
“,O
helicase,O
”,O
as,O
a,O
target,O
(,O
Table,O
 ,O
2,O
),O
.,O
It,O
is,O
plausible,O
that,O
most,O
of,O
these,O
molecules,O
have,O
already,O
been,O
tested,O
during,O
this,O
emergency,O
period,O
caused,O
by,O
COVID-19,O
",",O
with,O
unknown,O
large,O
-,O
scale,O
effect,O
.,O
As,O
of,O
today,O
",",O
no,O
FDA,O
-,O
approved,O
therapies,O
to,O
treat,O
COVID-19,O
or,O
other,O
coronaviruses,O
exist,O
.,O
Moreover,O
",",O
as,O
recently,O
emerged,O
from,O
the,O
work,O
by,O
Zhou,O
et,O
al,O
.,O
[,O
8,O
],O
",",O
the,O
search,O
and,O
use,O
of,O
FDA,O
-,O
approved,O
or,O
investigational,O
drugs,O
that,O
are,O
outside,O
the,O
scope,O
of,O
the,O
original,O
clinical,O
indication,O
",",O
currently,O
known,O
as,O
drug,O
repositioning,O
",",O
could,O
be,O
a,O
promising,O
approach,O
to,O
find,O
a,O
rapid,O
strategy,O
to,O
limit,O
the,O
effects,O
of,O
the,O
COVID-19,O
pandemic,O
.,O
Here,O
",",O
we,O
outline,O
the,O
existing,O
evidence,O
indicating,O
that,O
G4,O
ligands,O
and,O
inhibitors,O
of,O
SARS,O
-,O
CoV-2,O
helicase,O
may,O
exert,O
some,O
antiviral,O
activity,O
reducing,O
viral,O
replication,O
and,O
can,O
represent,O
a,O
potential,O
therapeutic,O
approach,O
to,O
tackle,O
the,O
COVID-19,O
pandemic,O
due,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
.,O
We,O
also,O
discuss,O
how,O
repositioning,O
of,O
FDA,O
-,O
approved,O
drugs,O
against,O
helicase,O
activity,O
of,O
other,O
viruses,O
",",O
could,O
represent,O
a,O
rapid,O
strategy,O
to,O
limit,O
deaths,O
associated,O
with,O
COVID-19,O
pandemic,O
.,O
SARS,O
-,O
CoV-2,O
",",O
the,O
virus,O
that,O
causes,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
can,O
spread,O
rapidly,O
in,O
high,O
-,O
risk,O
congregate,O
settings,O
such,O
as,O
skilled,O
nursing,O
facilities,O
(,O
SNFs,O
),O
(,O
),O
.,O
In,O
Minnesota,O
",",O
SNF,O
-,O
associated,O
cases,O
accounted,O
for,O
"3,950",O
(,O
8,O
%,O
),O
of,O
"48,711",O
COVID-19,O
cases,O
reported,O
through,O
July,O
21,O
",",O
2020,O
;,O
35,O
%,O
of,O
SNF,O
-,O
associated,O
cases,O
involved,O
health,O
care,O
personnel,O
(,O
HCP,O
*,O
),O
",",O
including,O
six,O
deaths,O
.,O
During,O
April,O
–,O
June,O
2020,O
",",O
the,O
Minnesota,O
Department,O
of,O
Health,O
(,O
MDH,O
),O
",",O
with,O
CDC,O
assistance,O
",",O
conducted,O
weekly,O
serial,O
testing,O
at,O
two,O
SNFs,O
experiencing,O
COVID-19,O
outbreaks,O
.,O
As,O
part,O
of,O
comprehensive,O
COVID-19,O
preparation,O
and,O
response,O
",",O
including,O
early,O
identification,O
of,O
cases,O
",",O
SNFs,O
should,O
conduct,O
serial,O
testing,O
of,O
residents,O
and,O
HCP,O
",",O
maximize,O
HCP,O
testing,O
participation,O
",",O
ensure,O
availability,O
of,O
personal,O
protective,O
equipment,O
(,O
PPE,O
),O
",",O
and,O
enhance,O
IPC,O
practices,O
(,O
–,O
),O
.,O
Interim,O
guidance,O
for,O
HCP,O
mask,O
use,O
and,O
SNF,O
visitor,O
restriction,O
was,O
implemented,O
statewide,O
by,O
March,O
31,O
",",O
2020,O
;,O
however,O
",",O
during,O
April,O
",",O
an,O
increase,O
in,O
COVID-19,O
diagnoses,O
and,O
deaths,O
among,O
SNF,O
residents,O
in,O
Minnesota,O
occurred,O
.,O
Paul,O
metropolitan,O
area,O
contacted,O
MDH,O
after,O
identifying,O
multiple,O
confirmed,O
resident,O
and,O
HCP,O
COVID-19,O
cases,O
.,O
Starting,O
in,O
mid,O
-,O
March,O
",",O
HCP,O
were,O
screened,O
daily,O
for,O
COVID-19,O
–,O
compatible,O
symptoms,O
",",O
and,O
symptomatic,O
HCP,O
were,O
sent,O
home,O
per,O
MDH,O
and,O
CDC,O
guidance,O
.,O
Data,O
on,O
symptoms,O
",",O
demographic,O
characteristics,O
",",O
and,O
HCP,O
work,O
assignment,O
were,O
collected,O
from,O
resident,O
charts,O
",",O
MDH,O
COVID-19,O
case,O
interviews,O
",",O
and,O
SNF,O
administrator,O
interviews,O
.,O
Residents,O
with,O
positive,O
SARS,O
-,O
CoV-2,O
test,O
results,O
were,O
moved,O
to,O
a,O
COVID-19,O
care,O
unit,O
within,O
each,O
facility,O
",",O
and,O
HCP,O
with,O
positive,O
test,O
results,O
were,O
excluded,O
from,O
work,O
for,O
at,O
least,O
10,O
days,O
(,O
),O
.,O
Before,O
serial,O
testing,O
(,O
April,O
17–29,O
),O
",",O
COVID-19,O
was,O
laboratory,O
-,O
confirmed,O
in,O
14,O
(,O
18,O
%,O
),O
symptomatic,O
residents,O
.,O
Date,O
of,O
serial,O
testing,O
round,O
and,O
daily,O
specimen,O
test,O
"results*,†,§",O
for,O
SARS,O
-,O
CoV-2,O
detection,O
by,O
reverse,O
transcription,O
–,O
polymerase,O
chain,O
reaction,O
(,O
RT,O
-,O
PCR,O
),O
testing,O
—,O
two,O
skilled,O
nursing,O
facilities,O
",",O
Minnesota,O
",",O
April,O
–,O
June,O
2020,O
During,O
April,O
15–29,O
",",O
15,O
(,O
10,O
%,O
),O
symptomatic,O
HCP,O
at,O
facility,O
A,O
received,O
diagnoses,O
of,O
confirmed,O
COVID-19,O
by,O
their,O
health,O
care,O
providers,O
(,O
Figure,O
1,O
),O
.,O
Overall,O
",",O
among,O
182,O
residents,O
tested,O
",",O
114,O
(,O
63,O
%,O
),O
COVID-19,O
cases,O
were,O
identified,O
;,O
19,O
(,O
17,O
%,O
),O
were,O
hospitalized,O
",",O
and,O
40,O
(,O
35,O
%,O
),O
died,O
.,O
Among,O
the,O
31,O
HCP,O
COVID-19,O
cases,O
",",O
18,O
(,O
58,O
%,O
),O
HCP,O
worked,O
on,O
the,O
first,O
floor,O
",",O
where,O
21,O
(,O
88,O
%,O
),O
of,O
24,O
infected,O
residents,O
were,O
initially,O
identified,O
.,O
Among,O
114,O
total,O
HCP,O
COVID-19,O
cases,O
diagnosed,O
at,O
facilities,O
A,O
and,O
B,O
",",O
73,O
(,O
64,O
%,O
),O
were,O
in,O
nurses,O
or,O
nursing,O
assistants,O
who,O
provided,O
direct,O
resident,O
care,O
.,O
Phylogenetic,O
trees,O
showing,O
genetic,O
distance,O
between,O
available,O
*,O
SARS,O
-,O
CoV-2,O
virus,O
specimens,O
collected,O
from,O
health,O
care,O
personnel,O
(,O
HCP,O
),O
and,O
residents,O
at,O
facility,O
A†,O
and,O
facility,O
B§,O
—,O
Minnesota,O
",",O
April,O
–,O
June,O
2020,O
Serial,O
testing,O
of,O
residents,O
and,O
all,O
HCP,O
",",O
until,O
no,O
new,O
cases,O
are,O
detected,O
after,O
14,O
days,O
(,O
),O
",",O
together,O
with,O
IPC,O
strengthening,O
",",O
are,O
critical,O
strategies,O
necessary,O
to,O
control,O
COVID-19,O
outbreaks,O
in,O
SNFs,O
.,O
Because,O
residents,O
and,O
HCP,O
can,O
sustain,O
SARS,O
-,O
CoV-2,O
transmission,O
and,O
HCP,O
present,O
an,O
ongoing,O
risk,O
for,O
introducing,O
SARS,O
-,O
CoV-2,O
-,O
from,O
the,O
community,O
",",O
barriers,O
to,O
HCP,O
testing,O
must,O
be,O
addressed,O
and,O
overcome,O
for,O
test,O
-,O
based,O
approaches,O
to,O
successfully,O
reduce,O
COVID-19,O
–,O
related,O
morbidity,O
and,O
mortality,O
.,O
Eleven,O
per,O
cent,O
of,O
the,O
participants,O
reported,O
having,O
comorbidities,O
and,O
36.3,O
%,O
reported,O
having,O
had,O
COVID-19,O
-,O
compatible,O
symptoms,O
in,O
the,O
previous,O
months,O
.,O
Thirty,O
-,O
nine,O
participants,O
(,O
6.7,O
%,O
),O
had,O
been,O
previously,O
diagnosed,O
with,O
COVID-19,O
confirmed,O
by,O
rRT,O
-,O
PCR,O
",",O
of,O
which,O
only,O
one,O
had,O
required,O
hospital,O
admission,O
(,O
Table,O
 ,O
1,O
and,O
Supplementary,O
Table,O
 ,O
1,O
),O
.,O
Around,O
15,O
%,O
(,O
6/39,O
),O
of,O
HCW,O
who,O
had,O
been,O
previously,O
diagnosed,O
with,O
COVID-19,O
by,O
rRT,O
-,O
PCR,O
did,O
not,O
show,O
a,O
detectable,O
response,O
of,O
any,O
of,O
the,O
antibody,O
isotypes,O
(,O
Supplementary,O
Table,O
 ,O
2,O
),O
.,O
Twenty,O
per,O
cent,O
(,O
11/54,O
),O
of,O
seropositive,O
participants,O
did,O
not,O
report,O
COVID-19,O
compatible,O
symptoms,O
in,O
the,O
previous,O
months,O
.,O
Around,O
39,O
%,O
(,O
21/54,O
),O
of,O
seropositive,O
HCW,O
had,O
never,O
been,O
diagnosed,O
of,O
COVID-19,O
",",O
although,O
10,O
of,O
these,O
(,O
47.6,O
%,O
),O
reported,O
past,O
COVID-19,O
-,O
compatible,O
symptoms,O
.,O
The,O
odds,O
of,O
being,O
seropositive,O
were,O
higher,O
in,O
participants,O
who,O
reported,O
having,O
had,O
any,O
COVID-19,O
-,O
compatible,O
symptom,O
in,O
the,O
previous,O
months,O
(,O
adjusted,O
OR,O
:,O
8.8,O
",",O
95,O
%,O
CI,O
4.41–17.73,O
",",O
p,O
 ,O
<,O
 ,O
0.0001,O
),O
(,O
Table,O
 ,O
3,O
),O
.,O
The,O
professional,O
category,O
",",O
working,O
in,O
COVID-19,O
units,O
",",O
daily,O
contact,O
with,O
patients,O
",",O
close,O
contact,O
with,O
a,O
COVID-19,O
case,O
",",O
comorbidities,O
or,O
sex,O
",",O
did,O
not,O
show,O
any,O
statistically,O
significant,O
association,O
with,O
presence,O
of,O
antibodies,O
to,O
SARS,O
-,O
CoV-2,O
(,O
Table,O
 ,O
3,O
",",O
Supplementary,O
Fig,O
.,O
 ,O
2,O
),O
.,O
IgA,O
levels,O
were,O
higher,O
in,O
participants,O
reporting,O
COVID-19,O
-,O
compatible,O
symptoms,O
in,O
the,O
previous,O
months,O
than,O
in,O
those,O
reporting,O
being,O
asymptomatic,O
(,O
p,O
 ,O
=,O
 ,O
0.041,O
),O
(,O
Fig,O
.,O
 ,O
3c,O
),O
",",O
and,O
among,O
symptomatic,O
individuals,O
",",O
duration,O
of,O
symptoms,O
>,O
10,O
days,O
was,O
associated,O
with,O
higher,O
IgM,O
levels,O
(,O
p,O
 ,O
=,O
 ,O
0.022,O
),O
(,O
Fig,O
.,O
 ,O
3d,O
),O
.,O
Among,O
them,O
",",O
23.1,O
%,O
(,O
15/65,O
),O
did,O
not,O
report,O
any,O
COVID-19,O
compatible,O
symptom,O
in,O
the,O
previous,O
months,O
.,O
Forty,O
per,O
cent,O
(,O
26/65,O
),O
had,O
not,O
been,O
previously,O
diagnosed,O
with,O
COVID-19,O
",",O
although,O
12,O
of,O
them,O
reported,O
COVID-19,O
compatible,O
symptoms,O
.,O
Five,O
microliters,O
of,O
RNA,O
solution,O
were,O
added,O
to,O
15,O
 ,O
μl,O
of,O
rRT,O
-,O
PCR,O
master,O
mix,O
(,O
Luna,O
Universal,O
Probe,O
One,O
-,O
Step,O
RT,O
-,O
qPCR,O
Kit,O
;,O
New,O
England,O
Biolabs,O
),O
and,O
used,O
for,O
amplification,O
of,O
SARS,O
-,O
CoV-2,O
N1,O
and,O
N2,O
regions,O
",",O
as,O
well,O
as,O
the,O
human,O
RNase,O
P,O
gene,O
as,O
control,O
",",O
using,O
probes,O
",",O
primers,O
and,O
cycling,O
conditions,O
described,O
in,O
the,O
CDC-006,O
-,O
00019,O
CDC,O
/,O
DDID,O
/,O
NCIRD/,O
Division,O
of,O
Viral,O
Diseases,O
protocol,O
(,O
3/30/2020,O
release,O
",",O
Supplementary,O
Note,O
 ,O
1,O
),O
.,O
Each,O
batch,O
of,O
RNA,O
extractions,O
and,O
rRT,O
-,O
PCR,O
reactions,O
included,O
three,O
positive,O
controls,O
(,O
EURM-019,O
single,O
stranded,O
RNA,O
fragments,O
of,O
SARS,O
-,O
CoV-2,O
provided,O
by,O
the,O
European,O
Commission,O
Joint,O
Research,O
Centre,O
),O
",",O
2019,O
-,O
nCoV_N_Positive,O
Control,O
(,O
IDT,O
integrated,O
technologies,O
",",O
ref,O
.,O
10006625,O
),O
and,O
Hs_RPP30,O
Positive,O
Control,O
(,O
IDT,O
integrated,O
technologies,O
",",O
ref,O
.,O
10006626,O
),O
",",O
as,O
well,O
as,O
negative,O
controls,O
.,O
Next,O
",",O
10,O
 ,O
μl,O
of,O
test,O
plasma,O
samples,O
(,O
final,O
dilution,O
1/500,O
),O
",",O
10,O
 ,O
μl,O
of,O
a,O
positive,O
control,O
(,O
pool,O
of,O
20,O
plasmas,O
from,O
subjects,O
with,O
a,O
positive,O
SARS,O
-,O
CoV-2,O
rRT,O
-,O
PCR,O
",",O
at,O
four,O
dilutions,O
",",O
1/500,O
",",O
1/2000,O
",",O
1/8000,O
and,O
1/32000,O
",",O
for,O
QA,O
/,O
QC,O
),O
",",O
and,O
10,O
 ,O
μl,O
of,O
two,O
negative,O
controls,O
(,O
plasmas,O
from,O
European,O
subjects,O
collected,O
before,O
the,O
COVID-19,O
pandemic,O
",",O
at,O
1/500,O
),O
",",O
were,O
added,O
per,O
plate,O
.,O
Sensitivity,O
of,O
the,O
assay,O
using,O
samples,O
from,O
participants,O
previously,O
diagnosed,O
with,O
COVID-19,O
and,O
with,O
more,O
than,O
10,O
days,O
since,O
the,O
onset,O
of,O
symptoms,O
was,O
97,O
%,O
for,O
IgA,O
and,O
IgG,O
and,O
75,O
%,O
for,O
IgM,O
",",O
with,O
specificities,O
of,O
100,O
%,O
for,O
IgG,O
and,O
IgM,O
and,O
98,O
%,O
for,O
IgA,O
(,O
Supplementary,O
table,O
 ,O
4,O
),O
.,O
The,O
area,O
under,O
the,O
receiver,O
operating,O
characteristic,O
curve,O
(,O
AUC,O
),O
was,O
>,O
0.97,O
for,O
each,O
of,O
the,O
isotypes,O
using,O
these,O
same,O
samples,O
(,O
Supplementary,O
Fig,O
.,O
 ,O
1a,O
),O
and,O
>,O
0.87,O
using,O
samples,O
from,O
any,O
participant,O
previously,O
diagnosed,O
with,O
COVID-19,O
regardless,O
of,O
the,O
time,O
since,O
onset,O
of,O
symptoms,O
(,O
Supplementary,O
Fig,O
.,O
 ,O
1b,O
),O
.,O
Among,O
those,O
with,O
evidence,O
of,O
past,O
or,O
current,O
infection,O
",",O
40.0,O
%,O
(,O
26/65,O
),O
had,O
not,O
been,O
previously,O
diagnosed,O
with,O
COVID-19,O
.,O
Here,O
we,O
report,O
a,O
relatively,O
low,O
seroprevalence,O
of,O
antibodies,O
among,O
HCW,O
at,O
the,O
peak,O
of,O
the,O
COVID-19,O
epidemic,O
in,O
Spain,O
.,O
A,O
large,O
proportion,O
of,O
HCW,O
with,O
past,O
or,O
present,O
infection,O
had,O
not,O
been,O
previously,O
diagnosed,O
with,O
COVID-19,O
",",O
which,O
calls,O
for,O
active,O
periodic,O
rRT,O
-,O
PCR,O
testing,O
in,O
hospital,O
settings,O
.,O
Symptoms,O
associated,O
with,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
are,O
quite,O
diverse,O
",",O
ranging,O
from,O
fever,O
",",O
muscle,O
aches,O
",",O
cough,O
and,O
shortness,O
of,O
breath,O
.,O
Searching,O
against,O
UniProt,S-Repository
 ,O
database,O
(,O
UniProt,B-Repository
Consortium,E-Repository
),O
[,O
65,O
],O
resulted,O
in,O
matches,O
for,O
the,O
polyprotein,O
(,O
wORF1ab,O
),O
",",O
all,O
four,O
structural,O
proteins,O
(,O
wS,O
",",O
wE,O
",",O
wM,O
",",O
and,O
wN,O
),O
",",O
and,O
six,O
ORFs,O
(,O
wORF3a,O
",",O
wORF6,O
",",O
wORF7a,O
",",O
wORF7b,O
",",O
wORF8,O
",",O
and,O
wORF10,O
),O
",",O
also,O
referred,O
to,O
as,O
the,O
accessory,O
proteins,O
.,O
Our,O
search,O
resulted,O
in,O
three,O
new,O
homologs,O
of,O
ORF8,O
not,O
reported,O
in,O
UniProt,S-Repository
 ,O
that,O
were,O
originated,O
from,O
three,O
different,O
isolates,O
of,O
bat,O
SARS,O
-,O
like,O
coronavirus,O
:,O
bat,O
-,O
SL,O
-,O
CoVZC45,O
(,O
GenBank,S-Repository
 ,O
ID,O
:,O
MG772933,S-AccessionNumber
",",O
collected,O
in,O
2017,O
),O
",",O
bat,O
-,O
SL,O
-,O
CoVZXC21,O
(,O
GenBank,S-Repository
 ,O
ID,O
:,O
MG772934,S-AccessionNumber
",",O
collected,O
in,O
2015,O
),O
",",O
and,O
RaTG13,O
(,O
GenBank,S-Repository
 ,O
ID,O
:,O
MN996532,S-AccessionNumber
",",O
collected,O
in,O
2013,O
),O
.,O
To,O
expedite,O
the,O
advancement,O
of,O
our,O
knowledge,O
",",O
we,O
leveraged,O
data,O
about,O
the,O
related,O
coronaviruses,O
that,O
is,O
readily,O
available,O
in,O
public,O
databases,O
and,O
integrated,O
these,O
data,O
into,O
a,O
single,O
computational,O
pipeline,O
.,O
The,O
emergence,O
of,O
novel,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
which,O
causes,O
the,O
respiratory,O
disease,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
triggered,O
a,O
global,O
pandemic,O
that,O
has,O
led,O
to,O
an,O
unprecedented,O
worldwide,O
public,O
health,O
emergency,O
(,O
1,O
),O
.,O
Incorporation,O
of,O
substitution,O
mutations,O
would,O
require,O
a,O
more,O
complex,O
representation,O
of,O
the,O
data,O
",",O
which,O
is,O
outside,O
of,O
the,O
scope,O
of,O
this,O
study,O
.,O
Crystal,O
structures,O
of,O
the,O
RBDs,O
of,O
the,O
spike,O
glycoproteins,O
of,O
SARS,O
-,O
CoV,O
(,O
Protein,B-Repository
Data,I-Repository
Bank,I-Repository
[PDB],E-Repository
 ,O
ID,O
code,O
2ajf,S-AccessionNumber
),O
(,O
27,O
),O
",",O
SARS,O
-,O
CoV-2,O
(,O
PDB,S-Repository
 ,O
ID,O
code,O
6m0j,S-AccessionNumber
),O
(,O
28,O
),O
and,O
MERS,O
-,O
CoV,O
(,O
PDB,S-Repository
 ,O
ID,O
code,O
4l72,S-AccessionNumber
),O
(,O
23,O
),O
complexed,O
with,O
their,O
respective,O
receptors,O
",",O
and,O
the,O
full,O
cryoelectron,O
microscopy,O
structure,O
of,O
the,O
SARS,O
-,O
CoV-2,O
spike,O
glycoprotein,O
(,O
PDB,S-Repository
 ,O
ID,O
code,O
6vxx,S-AccessionNumber
),O
(,O
29,O
),O
were,O
downloaded,O
from,O
the,O
PDB,S-Repository
 ,O
(,O
30,O
),O
.,O
The,O
ongoing,O
COVID-19,O
pandemic,O
is,O
an,O
urgent,O
",",O
global,O
threat,O
.,O
Here,O
we,O
analyze,O
the,O
genome,O
of,O
the,O
virus,O
that,O
causes,O
COVID-19,O
",",O
SARS,O
-,O
CoV-2,O
",",O
along,O
with,O
other,O
members,O
of,O
the,O
coronavirus,O
family,O
.,O
Coronaviruses,O
(,O
CoVs,O
),O
induced,O
three,O
major,O
outbreaks,O
of,O
respiratory,O
distress,O
syndrome,O
in,O
the,O
last,O
decades,O
including,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
in,O
2003,O
with,O
an,O
epicenter,O
in,O
Guangdong,O
",",O
China,O
[,O
1,O
],O
",",O
Middle,O
East,O
respiratory,O
syndrome,O
(,O
MERS,O
),O
in,O
2012,O
in,O
Saudi,O
Arabia,O
[,O
2,O
],O
",",O
and,O
novel,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
firstly,O
observed,O
in,O
Wuhan,O
province,O
",",O
China,O
",",O
in,O
late,O
2019,O
[,O
3,O
],O
.,O
The,O
COVID-19,O
symptoms,O
vary,O
from,O
mild,O
to,O
severe,O
that,O
can,O
eventually,O
lead,O
to,O
death,O
.,O
The,O
human,O
-,O
to,O
-,O
human,O
transmission,O
of,O
COVID-19,O
is,O
reported,O
to,O
occur,O
by,O
respiratory,O
droplets,O
or,O
direct,O
contact,O
with,O
the,O
patients,O
[,O
4,O
",",O
5,O
],O
.,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
announced,O
COVID-19,O
as,O
a,O
pandemic,O
on,O
11th,O
March,O
2020,O
[,O
6,O
],O
.,O
The,O
number,O
of,O
infected,O
cases,O
and,O
deaths,O
by,O
COVID-19,O
is,O
sharply,O
rising,O
daily,O
.,O
According,O
to,O
the,O
WHO,O
report,O
",",O
as,O
of,O
18th,O
April,O
2020,O
",",O
COVID-19,O
has,O
spread,O
to,O
more,O
than,O
200,O
countries,O
and,O
territories,O
with,O
over,O
"2,160,207",O
confirmed,O
cases,O
and,O
over,O
"146,088",O
confirmed,O
deaths,O
worldwide,O
.,O
Novel,O
coronavirus,O
(,O
2019,O
-,O
nCoV,O
),O
also,O
known,O
as,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
is,O
the,O
causative,O
agent,O
of,O
COVID-19,O
[,O
9,O
],O
.,O
This,O
functional,O
prominence,O
of,O
Mpro,O
in,O
the,O
viral,O
life,O
cycle,O
",",O
along,O
with,O
the,O
lack,O
of,O
closely,O
associated,O
homologues,O
in,O
humans,O
",",O
makes,O
the,O
Mpro,O
a,O
promising,O
target,O
for,O
COVID-19,O
antiviral,O
drug,O
design,O
[,O
13–17,O
],O
.,O
Many,O
research,O
groups,O
have,O
carried,O
out,O
the,O
repurposing,O
process,O
",",O
and,O
to,O
date,O
many,O
approved,O
drugs,O
are,O
being,O
tried,O
in,O
more,O
than,O
100,O
clinical,O
trial,O
studies,O
",",O
but,O
as,O
of,O
now,O
",",O
none,O
of,O
them,O
turned,O
out,O
to,O
be,O
completely,O
effective,O
for,O
COVID-19,O
treatment,O
.,O
Unfortunately,O
",",O
no,O
vaccine,O
has,O
been,O
developed,O
/,O
approved,O
yet,O
to,O
combat,O
COVID-19,O
[,O
18,O
],O
.,O
To,O
meet,O
this,O
urgent,O
medical,O
need,O
for,O
an,O
effective,O
drug,O
for,O
COVID-19,O
",",O
we,O
planned,O
to,O
identify,O
potential,O
SARS,O
-,O
CoV-2,O
Mpro,O
inhibitors,O
as,O
possible,O
anti,O
-,O
COVID-19,O
agents,O
",",O
by,O
carrying,O
out,O
screening,O
of,O
a,O
drug,O
library,O
containing,O
drugs,O
and,O
diagnostic,O
agents,O
(,O
approved,O
by,O
FDA,O
or,O
other,O
world,O
authorities,O
),O
[,O
19,O
",",O
20,O
],O
and,O
the,O
Asinex,B-Dataset
BioDesign,E-Dataset
 ,O
library,O
[,O
21,O
],O
.,O
The,O
resulted,O
scaffolds,O
",",O
mainly,O
from,O
Asinex,B-Dataset
BioDesign,E-Dataset
 ,O
library,O
",",O
are,O
discussed,O
in,O
detail,O
that,O
could,O
be,O
utilized,O
as,O
potential,O
hits,O
for,O
further,O
drug,O
development,O
to,O
find,O
out,O
an,O
acceptable,O
drug,O
treatment,O
of,O
COVID-19,O
.,O
Asinex,B-Dataset
BioDesign,E-Dataset
 ,O
library,O
[,O
21,O
],O
",",O
which,O
consists,O
of,O
pharmacologically,O
important,O
structural,O
features,O
from,O
natural,O
products,O
in,O
the,O
chemical,O
scaffolds,O
having,O
synthetic,O
feasibility,O
",",O
was,O
obtained,O
from,O
Asinex,S-Repository
 ,O
database,O
and,O
"175,815",O
molecules,O
(,O
database,O
updated,O
in,O
early,O
2020,O
),O
were,O
prepared,O
using,O
LigPrep,O
module,O
[,O
25,O
],O
.,O
On,O
the,O
basis,O
of,O
protein,O
amino,O
acids,O
present,O
",",O
excluded,O
volume,O
was,O
calculated,O
to,O
avoid,O
false,O
selection,O
of,O
ligands,O
during,O
screening,O
of,O
the,O
database,O
.,O
Abstract,O
 ,O
The,O
Co,O
rona,O
vi,O
rus,O
D,O
isease,O
(,O
COVID-19,O
),O
is,O
caused,O
because,O
of,O
novel,O
coronavirus,O
(,O
SARS,O
-,O
CoV-2,O
),O
pathogen,O
detected,O
in,O
China,O
for,O
the,O
first,O
time,O
",",O
and,O
from,O
there,O
it,O
spread,O
across,O
the,O
globe,O
creating,O
a,O
worldwide,O
pandemic,O
of,O
severe,O
respiratory,O
complications,O
.,O
These,O
could,O
be,O
used,O
as,O
potential,O
molecules,O
or,O
hits,O
for,O
further,O
drug,O
development,O
to,O
obtain,O
clinically,O
useful,O
therapeutic,O
agents,O
for,O
the,O
treatment,O
of,O
COVID-19,O
.,O
At,O
the,O
date,O
of,O
23,O
April,O
",",O
there,O
were,O
about,O
"2,700,000",O
confirmed,O
cases,O
of,O
COVID-19,O
(,O
probably,O
an,O
under,O
-,O
estimated,O
count,O
",",O
due,O
to,O
the,O
high,O
proportion,O
of,O
asymptomatic,O
patients,O
that,O
are,O
not,O
tested,O
),O
and,O
almost,O
"190,000",O
deaths,O
recorded,O
worldwide,O
.,O
These,O
epidemiological,O
figures,O
are,O
mainly,O
due,O
to,O
the,O
rapid,O
spreading,O
of,O
COVID-19,O
in,O
Lombardy,O
and,O
Northern,O
Italian,O
regions,O
of,O
the,O
Po,O
Valley,O
(,O
Padana,O
Plain,O
),O
",",O
an,O
area,O
characterized,O
by,O
constant,O
high,O
concentrations,O
of,O
particulate,O
matter,O
(,O
PM10,O
and,O
PM2.5,O
),O
",",O
already,O
recognized,O
as,O
one,O
of,O
the,O
most,O
polluted,O
zones,O
in,O
Europe,O
[,O
2,O
],O
.,O
Lombardy,O
accounts,O
for,O
56,O
%,O
of,O
the,O
overall,O
COVID-19,O
confirmed,O
cases,O
",",O
45,O
%,O
of,O
hospital,O
admissions,O
and,O
55,O
%,O
of,O
total,O
deaths,O
",",O
followed,O
by,O
Emilia,O
Romagna,O
(,O
15,O
%,O
of,O
cases,O
and,O
13,O
%,O
of,O
deaths,O
),O
",",O
Piedmont,O
(,O
12,O
%,O
of,O
cases,O
and,O
8,O
%,O
of,O
deaths,O
),O
",",O
and,O
Veneto,O
(,O
11,O
%,O
of,O
cases,O
and,O
5,O
%,O
of,O
deaths,O
),O
[,O
2,O
],O
.,O
The,O
Italian,O
Society,O
of,O
Environmental,O
Medicine,O
(,O
SIMA,O
),O
has,O
been,O
the,O
first,O
to,O
hypothesize,O
—,O
by,O
releasing,O
a,O
specific,O
Position,O
Paper,O
on,O
16,O
March,O
—,O
a,O
possible,O
link,O
between,O
the,O
high,O
mortality,O
rates,O
observed,O
in,O
Northern,O
Italy,O
due,O
to,O
COVID-19,O
and,O
the,O
PM,O
concentrations,O
[,O
"3,4",O
],O
.,O
A,O
significant,O
correlation,O
was,O
found,O
between,O
the,O
geographical,O
distribution,O
of,O
the,O
daily,O
PM10,O
exceedances,O
in,O
110,O
Italian,O
Provinces,O
(,O
number,O
of,O
days,O
exceeding,O
the,O
PM10,O
law,O
limit,O
of,O
50,O
µg,O
/,O
m3,O
),O
and,O
the,O
spreading,O
of,O
the,O
COVID-19,O
infection,O
before,O
the,O
shutdown,O
decided,O
by,O
the,O
Government,O
[,O
2,O
],O
.,O
These,O
first,O
observations,O
suggest,O
that,O
particulate,O
matter,O
could,O
be,O
regarded,O
—,O
if,O
not,O
as,O
a,O
“,O
carrier,O
”,O
or,O
a,O
“,O
boosting,O
factor”—at,O
least,O
as,O
an,O
indicator,O
of,O
the,O
severity,O
of,O
COVID-19,O
infection,O
in,O
terms,O
of,O
diffusion,O
and,O
health,O
outcomes,O
observed,O
in,O
Northern,O
Italy,O
.,O
Meanwhile,O
",",O
a,O
survey,O
carried,O
out,O
in,O
the,O
U.S.,O
by,O
the,O
Harvard,O
School,O
of,O
Public,O
Health,O
has,O
suggested,O
a,O
strong,O
association,O
between,O
increases,O
in,O
particulate,O
matter,O
concentration,O
and,O
mortality,O
rates,O
due,O
to,O
COVID-19,O
",",O
with,O
The,O
Lancet,O
scientific,O
community,O
highlighting,O
the,O
need,O
for,O
adopting,O
a,O
planetary,O
health,O
perspective,O
on,O
COVID-19,O
outbreak,O
[,O
"6,7",O
],O
.,O
At,O
the,O
present,O
",",O
no,O
assumptions,O
can,O
be,O
made,O
concerning,O
the,O
correlation,O
between,O
the,O
possible,O
presence,O
of,O
the,O
virus,O
on,O
PM,O
and,O
COVID-19,O
outbreak,O
progression,O
.,O
However,O
",",O
based,O
on,O
the,O
available,O
literature,O
",",O
there,O
is,O
already,O
enough,O
evidence,O
to,O
consider,O
the,O
airborne,O
route,O
",",O
with,O
a,O
potential,O
role,O
of,O
particulate,O
matter,O
",",O
as,O
a,O
possible,O
additional,O
factor,O
for,O
interpreting,O
the,O
anomalous,O
COVID-19,O
outbreaks,O
observed,O
in,O
Northern,O
Italy,O
and,O
in,O
the,O
U.S.,O
",",O
as,O
well,O
as,O
in,O
other,O
areas,O
characterized,O
by,O
high,O
PM,O
concentrations,O
[,O
"8,9,10,11,12,13,14,15,16,17,18",O
],O
.,O
On,O
these,O
bases,O
",",O
in,O
the,O
frame,O
of,O
the,O
One,O
Health,O
approach,O
that,O
can,O
be,O
applied,O
to,O
the,O
international,O
emergency,O
generated,O
by,O
the,O
SARS,O
-,O
COV-2,O
as,O
it,O
involves,O
the,O
interactions,O
between,O
humans,O
and,O
environment,O
",",O
the,O
Italian,O
Society,O
of,O
Environmental,O
Medicine,O
and,O
the,O
UNESCO,O
Chair,O
on,O
Health,O
Education,O
and,O
Sustainable,O
Development,O
support,O
the,O
vision,O
of,O
Sir,O
Andy,O
Haines,O
",",O
who,O
has,O
called,O
for,O
the,O
adoption,O
of,O
urgent,O
actions,O
to,O
counteract,O
climate,O
changes,O
and,O
the,O
alteration,O
of,O
ecosystems,O
that,O
might,O
trigger,O
new,O
and,O
unexpected,O
threats,O
to,O
human,O
health,O
such,O
as,O
that,O
of,O
COVID-19,O
",",O
which,O
we,O
are,O
so,O
dramatically,O
experiencing,O
worldwide,O
[,O
19,O
],O
.,O
The,O
presence,O
of,O
SARS,O
-,O
COV-2,O
RNA,O
on,O
PM10,O
of,O
outdoor,O
air,O
samples,O
in,O
any,O
city,O
of,O
the,O
world,O
could,O
represent,O
a,O
potential,O
early,O
indicator,O
of,O
COVID-19,O
diffusion,O
.,O
Actually,O
",",O
it,O
could,O
be,O
proposed,O
that,O
air,O
pollution,O
could,O
influence,O
the,O
COVID-19,O
outbreak,O
progression,O
in,O
a,O
direct,O
way,O
or,O
also,O
indirectly,O
",",O
by,O
enhancing,O
the,O
host,O
susceptibility,O
to,O
viral,O
infection,O
and,O
independently,O
increasing,O
the,O
baseline,O
risk,O
of,O
cardiovascular,O
events,O
or,O
complications,O
",",O
chronic,O
obstructive,O
pulmonary,O
diseases,O
(,O
COPD,O
),O
",",O
and,O
other,O
conditions,O
that,O
are,O
known,O
to,O
increase,O
the,O
severity,O
of,O
viral,O
infections,O
.,O
On,O
the,O
other,O
hand,O
",",O
COVID-19,O
has,O
clearly,O
shown,O
its,O
potential,O
to,O
become,O
a,O
hospital,O
infection,O
",",O
at,O
least,O
in,O
Europe,O
and,O
U.S.,O
(,O
whose,O
healthcare,O
systems,O
are,O
usually,O
centralized,O
at,O
hospital,O
level,O
),O
",",O
with,O
10,O
%,O
of,O
infected,O
people,O
being,O
healthcare,O
workers,O
",",O
and,O
a,O
huge,O
proportion,O
of,O
cases,O
and,O
deaths,O
possibly,O
related,O
to,O
infections,O
acquired,O
in,O
hospital,O
setting,O
or,O
nursing,O
homes,O
[,O
"23,24",O
],O
.,O
At,O
the,O
present,O
",",O
many,O
research,O
groups,O
are,O
working,O
on,O
COVID-19,O
clinical,O
features,O
and,O
on,O
the,O
diffusion,O
of,O
SARS,O
-,O
COV-2,O
in,O
outdoor,O
or,O
indoor,O
air,O
(,O
especially,O
in,O
hospital,O
settings,O
),O
as,O
well,O
as,O
in,O
water,O
/,O
wastewater,O
.,O
A,O
number,O
of,O
nations,O
were,O
forced,O
to,O
declare,O
a,O
total,O
shutdown,O
due,O
to,O
COVID-19,O
infection,O
",",O
as,O
extreme,O
measure,O
to,O
cope,O
with,O
dramatic,O
impact,O
of,O
the,O
pandemic,O
",",O
with,O
remarkable,O
consequences,O
both,O
in,O
terms,O
of,O
negative,O
health,O
outcomes,O
and,O
economic,O
loses,O
.,O
On,O
16,O
March,O
",",O
a,O
Position,O
Paper,O
launched,O
by,O
the,O
Italian,O
Society,O
of,O
Environmental,O
Medicine,O
(,O
SIMA,O
),O
hypothesized,O
for,O
the,O
first,O
time,O
a,O
possible,O
link,O
between,O
the,O
dramatic,O
impact,O
of,O
COVID-19,O
outbreak,O
in,O
Northern,O
Italy,O
and,O
the,O
high,O
concentrations,O
of,O
particulate,O
matter,O
(,O
PM,O
10,O
and,O
PM,O
2.5,O
),O
that,O
characterize,O
this,O
area,O
",",O
along,O
with,O
its,O
well,O
-,O
known,O
specific,O
climatic,O
conditions,O
.,O
Thereafter,O
",",O
a,O
survey,O
carried,O
out,O
in,O
the,O
U.S.,O
by,O
the,O
Harvard,O
School,O
of,O
Public,O
Health,O
suggested,O
a,O
strong,O
association,O
between,O
increases,O
in,O
particulate,O
matter,O
concentration,O
and,O
mortality,O
rates,O
due,O
to,O
COVID-19,O
.,O
Although,O
no,O
assumptions,O
can,O
be,O
made,O
concerning,O
the,O
link,O
between,O
this,O
first,O
experimental,O
finding,O
and,O
COVID-19,O
outbreak,O
progression,O
or,O
severity,O
",",O
the,O
presence,O
of,O
SARS,O
-,O
COV-2,O
RNA,O
on,O
PM,O
10,O
of,O
outdoor,O
air,O
samples,O
in,O
any,O
city,O
of,O
the,O
world,O
could,O
represent,O
a,O
potential,O
early,O
indicator,O
of,O
COVID-19,O
diffusion,O
.,O
Similarly,O
to,O
SARS,O
",",O
epidemiological,O
links,O
between,O
the,O
majority,O
of,O
COVID-19,O
cases,O
and,O
Huanan,O
South,O
China,O
Seafood,O
Market,O
",",O
a,O
live,O
-,O
animal,O
market,O
",",O
have,O
been,O
reported,O
.,O
A,O
total,O
of,O
"76,775",O
confirmed,O
cases,O
of,O
“,O
Coronavirus,O
Disease,O
2019,O
”,O
(,O
COVID-19,O
),O
were,O
reported,O
up,O
to,O
February,O
21st,O
2020,O
",",O
from,O
which,O
2247,O
died,O
and,O
"18,855",O
recovered,O
.,O
Indeed,O
",",O
it,O
is,O
suggested,O
that,O
SARS,O
-,O
CoV-2,O
genomic,O
variants,O
that,O
emerge,O
from,O
inter-,O
and,O
intra,O
-,O
host,O
evolution,O
might,O
be,O
associated,O
with,O
susceptibility,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
the,O
severity,O
of,O
COVID-19,O
[,O
24,O
],O
.,O
All,O
datasets,O
available,O
in,O
SRA,S-Repository
 ,O
up,O
to,O
February,O
20th,O
",",O
2020,O
were,O
analysed,O
.,O
The,O
third,O
41,O
-,O
year,O
-,O
old,O
male,O
patient,O
(,O
SRR1097138,S-AccessionNumber
/,O
PRJNA603194,S-AccessionNumber
),O
",",O
presented,O
acute,O
onset,O
of,O
common,O
COVID19,O
symptoms,O
.,O
The,O
raw,O
read,O
data,O
were,O
aligned,O
on,O
the,O
complete,O
(,O
"29,891",O
bp,O
),O
SARS,O
-,O
CoV-2,O
reference,O
sequence,O
(,O
GenBank,S-Repository
 ,O
accession,O
no,O
.,O
For,O
the,O
datasets,O
analyzed,O
in,O
this,O
study,O
(,O
average,O
read,O
depth,O
133.5x,O
–,O
598.2x,O
),O
and,O
based,O
on,O
the,O
assessed,O
read,O
quality,O
 ,O
>,O
 ,O
Q30,O
 ,O
=,O
 ,O
88.2–92.7,O
%,O
",",O
LoFreq,O
has,O
calling,O
sensitivity,O
=,O
∼1,O
%,O
and,O
PPV,O
 ,O
=,O
 ,O
100,O
[,O
39,O
],O
.,O
The,O
colocalization,O
of,O
the,O
intra,O
-,O
host,O
SNVs,O
and,O
population,O
level,O
SNPs,O
retrieved,O
from,O
www.GISAID.org,S-URL
 ,O
on,O
February,O
18th,O
2020,O
",",O
with,O
primers,O
and,O
probes,O
coordinates,O
was,O
also,O
examined,O
",",O
to,O
identify,O
potential,O
interferences,O
with,O
all,O
currently,O
available,O
molecular,O
diagnostic,O
assays,O
[,O
42,O
],O
.,O
More,O
studies,O
based,O
on,O
genomic,O
datasets,O
accompanied,O
by,O
clinical,O
metadata,O
are,O
needed,O
",",O
in,O
order,O
to,O
accurately,O
define,O
associations,O
between,O
intra,O
-,O
host,O
SARS,O
-,O
CoV-2,O
genomic,O
variants,O
",",O
the,O
progression,O
and,O
the,O
clinical,O
outcome,O
of,O
COVID19,O
.,O
In,O
December,O
2019,O
",",O
an,O
outbreak,O
of,O
atypical,O
pneumonia,O
(,O
Coronavirus,O
disease,O
2019,O
-COVID-19,O
),O
associated,O
with,O
a,O
novel,O
coronavirus,O
(,O
SARS,O
-,O
CoV-2,O
),O
was,O
reported,O
in,O
Wuhan,O
city,O
",",O
Hubei,O
province,O
",",O
China,O
.,O
The,O
pandemic,O
Corona,O
Virus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
is,O
an,O
urgent,O
public,O
health,O
emergency,O
and,O
made,O
a,O
serious,O
impact,O
in,O
global,O
health,O
and,O
economy,O
(,O
https://www.cdc.gov/coronavirus/2019-ncov,O
),O
.,O
Furthermore,O
",",O
there,O
are,O
about,O
106,O
complete,O
and,O
validated,O
sequence,O
data,O
sets,O
available,O
in,O
the,O
NCBI,S-Repository
 ,O
database,O
(,O
https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/,S-URL
),O
and,O
(,O
https://bigd.big.ac.cn/ncov/,S-URL
),O
.,O
Surprisingly,O
",",O
we,O
noticed,O
several,O
hundreds,O
of,O
point,O
mutations,O
or,O
SNPs,O
among,O
the,O
different,O
isolates,O
from,O
all,O
over,O
the,O
world,O
with,O
different,O
sequence,O
data,O
sets,O
(,O
Fig,O
.,O
1A,O
and,O
B,O
),O
and,O
(,O
Fig,O
.,O
S1A,O
and,O
S2,O
),O
.,O
The,O
morbidity,O
of,O
SARS,O
-,O
CoV-2,O
(,O
COVID-19,O
),O
is,O
reaching,O
3,O
Million,O
landmark,O
causing,O
and,O
a,O
serious,O
public,O
health,O
concern,O
globally,O
and,O
it,O
is,O
enigmatic,O
how,O
several,O
antiviral,O
and,O
antibody,O
treatments,O
were,O
not,O
effective,O
in,O
the,O
different,O
period,O
across,O
the,O
globe,O
.,O
However,O
",",O
as,O
for,O
SARS,O
and,O
MERS,O
",",O
SARS,O
-,O
CoV-2,O
RNA,O
has,O
been,O
detected,O
in,O
stool,O
samples,O
from,O
patients,O
exhibiting,O
symptoms,O
of,O
COVID-19,O
and,O
from,O
asymptomatic,O
carriers,O
(,O
He,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Pan,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Wölfel,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Young,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Zhang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Wu,O
et,O
 ,O
al,O
.,O
",",O
2020a,O
;,O
Wurtzer,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
",",O
and,O
wastewater,O
testing,O
has,O
been,O
suggested,O
as,O
a,O
non,O
-,O
invasive,O
early,O
-,O
warning,O
tool,O
for,O
monitoring,O
the,O
status,O
and,O
trend,O
of,O
COVID-19,O
infection,O
and,O
as,O
an,O
instrument,O
for,O
tuning,O
public,O
health,O
response,O
(,O
Daughton,O
",",O
2020,O
;,O
Mallapaty,O
",",O
2020,O
;,O
Naddeo,O
and,O
Liu,O
",",O
2020,O
),O
.,O
The,O
sets,O
of,O
primers,O
and,O
probe,O
(,O
2019,O
-,O
nCoV,O
RUO,O
Kit,O
),O
as,O
well,O
as,O
the,O
positive,O
control,O
(,O
2019,O
-,O
nCoV_N_Positive,O
Control,O
",",O
2,O
 ,O
×,O
 ,O
105,O
genome,O
copies,O
(,O
gc)/μL,O
),O
were,O
provided,O
by,O
IDT,O
(,O
Integrated,O
DNA,O
Technologies,O
",",O
Leuven,O
",",O
Belgium,O
),O
.,O
As,O
expected,O
",",O
biobanked,O
samples,O
collected,O
in,O
October,O
2019,O
",",O
before,O
the,O
first,O
COVID-19,O
case,O
was,O
documented,O
",",O
tested,O
negative,O
for,O
all,O
the,O
three,O
RT,O
-,O
qPCR,O
assays,O
thus,O
excluding,O
false,O
positive,O
reactions,O
.,O
Epidemiological,O
data,O
on,O
COVID-19,O
in,O
the,O
Murcia,O
Region,O
have,O
been,O
retrieved,O
from,O
the,O
publically,O
available,O
repository,O
of,O
the,O
“Servicio,B-Repository
de,I-Repository
epidemiologia”,E-Repository
 ,O
of,O
the,O
“,O
Consejería,O
de,O
Salud,O
de,O
la,O
Región,O
de,O
Murcia,O
”,O
(,O
available,O
at,O
http://www.murciasalud.es/principal.php,S-URL
),O
Epidemiological,O
dataa,O
summary,O
of,O
COVID-19,O
cases,O
in,O
the,O
area,O
of,O
study,O
.,O
Therefore,O
",",O
our,O
outcomes,O
support,O
that,O
WBE,O
could,O
be,O
used,O
as,O
an,O
early,O
warning,O
tool,O
to,O
monitor,O
the,O
status,O
of,O
COVID-19,O
infection,O
within,O
a,O
community,O
.,O
Our,O
wastewater,O
data,O
do,O
not,O
quantitatively,O
resemble,O
the,O
prevalence,O
of,O
COVID-19,O
confirmed,O
cases,O
.,O
For,O
instance,O
",",O
not,O
all,O
COVID-19,O
positive,O
patients,O
excrete,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
faeces,O
",",O
and,O
when,O
it,O
occurs,O
",",O
the,O
titers,O
and,O
the,O
duration,O
of,O
shedding,O
vary,O
among,O
individuals,O
and,O
across,O
time,O
(,O
He,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Pan,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Wölfel,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Xu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
has,O
caused,O
more,O
than,O
"200,000",O
reported,O
COVID-19,O
cases,O
in,O
Spain,O
resulting,O
in,O
more,O
than,O
"20,800",O
deaths,O
as,O
of,O
April,O
21,O
",",O
2020,O
.,O
Faecal,O
shedding,O
of,O
SARS,O
-,O
CoV-2,O
RNA,O
from,O
COVID-19,O
patients,O
has,O
extensively,O
been,O
reported,O
.,O
Therefore,O
",",O
we,O
investigated,O
the,O
occurrence,O
of,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
six,O
wastewater,O
treatments,O
plants,O
(,O
WWTPs,O
),O
serving,O
the,O
major,O
municipalities,O
within,O
the,O
Region,O
of,O
Murcia,O
(,O
Spain,O
),O
",",O
the,O
area,O
with,O
the,O
lowest,O
COVID-19,O
prevalence,O
within,O
Iberian,O
Peninsula,O
.,O
This,O
environmental,O
surveillance,O
data,O
were,O
compared,O
to,O
declared,O
COVID-19,O
cases,O
at,O
municipality,O
level,O
",",O
revealing,O
that,O
members,O
of,O
the,O
community,O
were,O
shedding,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
their,O
stool,O
even,O
before,O
the,O
first,O
cases,O
were,O
reported,O
by,O
local,O
or,O
national,O
authorities,O
in,O
many,O
of,O
the,O
cities,O
where,O
wastewaters,O
have,O
been,O
sampled,O
.,O
The,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
in,O
wastewater,O
in,O
early,O
stages,O
of,O
the,O
spread,O
of,O
COVID-19,O
highlights,O
the,O
relevance,O
of,O
this,O
strategy,O
as,O
an,O
early,O
indicator,O
of,O
the,O
infection,O
within,O
a,O
specific,O
population,O
.,O
None,O
of,O
the,O
tertiary,O
effluent,O
samples,O
(,O
n,O
 ,O
=,O
 ,O
12,O
),O
tested,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
.,O
   ,O
•,O
 ,O
SARS,O
-,O
CoV-2,O
RNA,O
was,O
detected,O
in,O
wastewater,O
before,O
the,O
first,O
COVID-19,O
cases,O
were,O
declared,O
by,O
local,O
authorities,O
.,O
By,O
phylogenetic,O
analysis,O
of,O
the,O
four,O
structural,O
genes,O
",",O
our,O
sequences,O
clustered,O
with,O
all,O
the,O
SARS,O
-,O
CoV-2,O
reference,O
sequences,O
issued,O
from,O
the,O
NCBI,S-Repository
 ,O
database,O
",",O
and,O
were,O
distinct,O
from,O
the,O
other,O
human,O
coronaviruses,O
(,O
Supplementary,O
Material,O
Fig,O
.,O
 ,O
S1,O
),O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
which,O
is,O
an,O
enveloped,O
",",O
non,O
-,O
segmented,O
",",O
positive,O
-,O
sense,O
RNA,O
virus,O
(,O
1,O
),O
.,O
Developing,O
a,O
vaccine,O
during,O
or,O
after,O
the,O
pandemic,O
outbreaks,O
is,O
too,O
slow,O
to,O
provide,O
timely,O
responses,O
against,O
COVID-19,O
",",O
and,O
risks,O
many,O
lives,O
.,O
These,O
changes,O
could,O
be,O
incorporated,O
into,O
the,O
four,O
essential,O
viral,O
genes,O
(,O
S,O
",",O
N,O
",",O
M,O
",",O
and,O
E,O
),O
.,O
(,O
2,O
),O
These,O
genes,O
would,O
then,O
be,O
subcloned,O
individually,O
into,O
integrating,O
gene,O
delivery,O
vehicles,O
",",O
such,O
as,O
lentiviral,O
vectors,O
(,O
9,O
),O
or,O
transposons,O
(,O
10,O
",",O
11,O
),O
.,O
Lentiviral,O
vectors,O
could,O
generate,O
a,O
stable,O
cell,O
line,O
that,O
is,O
transgenic,O
for,O
the,O
highly,O
immunogenic,O
antigenic,O
determinants,O
of,O
COVID-19,O
(,O
15,O
),O
",",O
and,O
would,O
be,O
able,O
to,O
continuously,O
secrete,O
VLPs,O
into,O
the,O
culture,O
media,O
(,O
16,O
),O
.,O
NCBI,S-Repository
 ,O
database,O
was,O
used,O
for,O
the,O
retrieval,O
of,O
Corona,O
viruses,O
(,O
RdRp,O
region,O
),O
sequences,O
.,O
The,O
accession,O
no,O
MT042778,S-AccessionNumber
 ,O
was,O
used,O
as,O
query,O
sequence,O
in,O
the,O
NCBI,S-Repository
 ,O
Blast,O
for,O
obtaining,O
highly,O
similar,O
sequence,O
.,O
A,O
cryo,O
-,O
EM,O
structure,O
of,O
RdRp,O
from,O
SARs,O
-,O
CoV-2,O
was,O
downloaded,O
from,O
RCSB,S-Repository
 ,O
using,O
PDB,S-Repository
 ,O
ID,O
:,O
6M71,S-AccessionNumber
 ,O
[,O
19,O
],O
.,O
The,O
database,O
of,O
compounds,O
from,O
medicinal,O
plants,O
from,O
Northern,O
south,O
Africa,O
was,O
retrieved,O
from,O
NANPDB,S-Repository
 ,O
(,O
https://african-compounds.org/nanpdb/,S-URL
),O
[,O
24,O
],O
.,O
This,O
database,O
is,O
a,O
diverse,O
source,O
of,O
natural,O
drugs,O
from,O
617,O
source,O
species,O
",",O
which,O
comes,O
from,O
146,O
families,O
of,O
plants,O
",",O
animals,O
",",O
bacteria,O
",",O
and,O
fungi,O
.,O
The,O
database,O
was,O
then,O
converted,O
to.mdb,O
format,O
to,O
be,O
used,O
as,O
input,O
for,O
Molecular,O
Operating,O
Environment,O
(,O
MOE,O
v2016,O
),O
[,O
25,O
],O
.,O
A,O
cryo,O
-,O
EM,O
structure,O
of,O
RdRp,O
from,O
SARs,O
-,O
CoV-2,O
was,O
used,O
to,O
identify,O
novel,O
drugs,O
from,O
Northern,B-Repository
South,I-Repository
African,I-Repository
medicinal,I-Repository
compounds,I-Repository
database,I-Repository
(NANPDB),E-Repository
 ,O
by,O
using,O
computational,O
virtual,O
screening,O
and,O
molecular,O
docking,O
approaches,O
.,O
Italy,O
is,O
one,O
of,O
the,O
countries,O
with,O
the,O
highest,O
number,O
of,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
cases,O
(,O
",",O
),O
.,O
The,O
analysis,O
of,O
sequence,O
data,O
shown,O
in,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org,S-URL
),O
indicates,O
that,O
the,O
initial,O
introduction,O
of,O
SARS,O
-,O
CoV-2,O
in,O
Italy,O
through,O
2,O
infected,O
tourists,O
in,O
January,O
was,O
effectively,O
contained,O
(,O
),O
",",O
and,O
no,O
further,O
circulation,O
of,O
similar,O
clade,O
V,O
strains,O
has,O
been,O
so,O
far,O
detected,O
.,O
We,O
analyzed,O
nasopharyngeal,O
swab,O
(,O
n,O
=,O
6,O
),O
and,O
bronchoalveolar,O
lavage,O
(,O
n,O
=,O
3,O
),O
samples,O
from,O
9,O
patients,O
with,O
COVID-19,O
to,O
perform,O
SARS,O
-,O
CoV-2,O
whole,O
-,O
genome,O
reconstruction,O
and,O
mutational,O
analysis,O
.,O
We,O
named,O
the,O
sequences,O
INMI3,O
–,O
INMI10,O
for,O
their,O
detection,O
at,O
National,O
Institute,O
for,O
Infectious,O
Diseases,O
and,O
analyzed,O
them,O
together,O
with,O
the,O
previously,O
published,O
INMI1,O
and,O
INMI2,O
(,O
),O
",",O
along,O
with,O
all,O
the,O
sequences,O
from,O
Italy,O
posted,O
to,O
GISAID,S-Dataset
 ,O
database,O
by,O
April,O
11,O
",",O
2020,O
.,O
We,O
submitted,O
consensus,O
sequences,O
to,O
GISAID,S-Dataset
.,O
data,O
",",O
https://doi.org/10.1101/2020.04.17.046086,O
),O
in,O
phylogenetic,O
analysis,O
;,O
for,O
comparison,O
to,O
previously,O
published,O
reports,O
",",O
we,O
maintained,O
references,O
to,O
clades,O
reported,O
in,O
GISAID,S-Dataset
.,O
INMI1,O
and,O
INMI2,O
are,O
included,O
in,O
clade,O
V,O
according,O
to,O
GISAID,S-Dataset
 ,O
phylogenetics,O
",",O
as,O
reported,O
(,O
),O
",",O
and,O
clade,O
B2,O
;,O
the,O
clade,O
includes,O
other,O
sequences,O
from,O
EU,O
countries,O
",",O
but,O
no,O
additional,O
sequences,O
from,O
Italy,O
.,O
All,O
other,O
INMI,O
sequences,O
cluster,O
with,O
the,O
GISAID,S-Dataset
 ,O
G,O
clade,O
",",O
and,O
with,O
the,O
B1,O
clade,O
;,O
we,O
focused,O
subsequent,O
analysis,O
on,O
clade,O
B1,O
(,O
Figure,O
),O
.,O
Of,O
note,O
",",O
in,O
both,O
clusters,O
the,O
sequences,O
from,O
Italy,O
are,O
intermixed,O
with,O
sequences,O
from,O
other,O
EU,O
countries,O
",",O
which,O
can,O
also,O
be,O
seen,O
in,O
the,O
broader,O
phylogenetic,O
analysis,O
on,O
GISAID,S-Dataset
",",O
in,O
which,O
more,O
EU,O
sequences,O
are,O
analyzed,O
.,O
Although,O
viral,O
RNA,O
can,O
be,O
detected,O
in,O
multiple,O
organs,O
in,O
COVID-19,O
patients,O
",",O
infectious,O
SARS,O
-,O
CoV-2,O
has,O
only,O
been,O
isolated,O
from,O
respiratory,O
specimens,O
[,O
"3,4",O
],O
.,O
Since,O
the,O
viral,O
receptor,O
",",O
angiotensin,O
-,O
convertase-2,O
(,O
ACE2,O
),O
protein,O
",",O
is,O
expressed,O
in,O
the,O
kidney,O
",",O
the,O
testis,O
and,O
the,O
bladder,O
[,O
"5,6",O
],O
and,O
viral,O
RNA,O
has,O
been,O
detected,O
in,O
the,O
sink,O
and,O
toilet,O
of,O
COVID-19,O
patients,O
",",O
the,O
virus,O
may,O
be,O
secreted,O
through,O
the,O
urinary,O
system,O
[,O
7,O
],O
.,O
Full,O
-,O
length,O
viral,O
genome,O
sequence,O
was,O
acquired,O
by,O
next,O
-,O
generation,O
sequencing,O
(,O
Accession,O
number,O
MT446312,S-AccessionNumber
),O
with,O
5,O
nucleotide,O
mutations,O
as,O
compared,O
to,O
the,O
original,O
Wuhan,O
viral,O
stain,O
(,O
Accession,O
number,O
NC045512.2,S-AccessionNumber
),O
(,O
Table,O
S1,O
),O
.,O
ABSTRACT,O
 ,O
SARS,O
-,O
CoV-2,O
caused,O
a,O
major,O
outbreak,O
of,O
severe,O
pneumonia,O
(,O
COVID-19,O
),O
in,O
humans,O
.,O
Viral,O
RNA,O
was,O
detected,O
in,O
multiple,O
organs,O
in,O
COVID-19,O
patients,O
.,O
Here,O
",",O
infectious,O
SARS,O
-,O
CoV-2,O
was,O
successfully,O
isolated,O
from,O
urine,O
of,O
a,O
COVID-19,O
patient,O
.,O
Currently,O
",",O
multiple,O
databases,O
/,O
platforms,O
",",O
such,O
as,O
DrugBank,S-Repository
 ,O
Database,O
",",O
Comparative,B-Repository
Toxicogenomics,I-Repository
Database,I-Repository
(CTD),E-Repository
",",O
Traditional,B-Repository
Chinese,I-Repository
Medicine,I-Repository
Systems,I-Repository
Pharmacology,I-Repository
Database,I-Repository
and,I-Repository
Analysis,I-Repository
Platform,I-Repository
(TCMSP),E-Repository
 ,O
and,O
Integrative,O
Pharmacology,O
-,O
based,O
Research,O
Platform,O
of,O
Traditional,O
Chinese,O
Medicine,O
(,O
TCMIP,O
),O
",",O
were,O
commonly,O
applied,O
to,O
acquire,O
potential,O
targets,O
of,O
small,O
molecular,O
compounds,O
[,O
"31,32,33",O
],O
.,O
Basically,O
",",O
the,O
target,O
information,O
in,O
these,O
three,O
databases,O
is,O
complementary,O
",",O
a,O
combination,O
of,O
which,O
could,O
provide,O
relatively,O
comprehensive,O
compound,O
-,O
target,O
interactions,O
.,O
DAVID,O
Bioinformatics,O
Resources,O
6.8,O
[,O
42,O
],O
was,O
applied,O
to,O
perform,O
GO,O
analysis,O
for,O
the,O
hub,O
targets,O
.,O
In,O
addition,O
",",O
the,O
analysis,O
of,O
specific,O
GO,O
annotation,O
involved,O
in,O
immune,O
system,O
processes,O
was,O
carried,O
out,O
with,O
ClueGo,O
(,O
Version,O
2.5.6,O
),O
[,O
43,O
],O
",",O
a,O
Cytoscape,O
plug,O
-,O
in,O
integrating,O
EBI,O
-,O
Uniport,O
GO,O
annotation,O
database,O
(,O
updated,O
in,O
Mar,O
2019,O
),O
.,O
Three,O
public,O
databases,O
were,O
used,O
to,O
mine,O
the,O
potential,O
targets,O
for,O
the,O
three,O
(,O
phyto-,O
),O
nutrients,O
in,O
VCG,O
Plus,O
.,O
Comparing,O
the,O
results,O
with,O
“,O
virus,O
diseases,O
”,O
and,O
“,O
immune,O
system,O
disease,O
”,O
gene,O
data,O
in,O
CTD,S-Repository
",",O
it,O
was,O
found,O
that,O
179,O
targets,O
existed,O
in,O
both,O
the,O
“,O
virus,O
diseases,O
”,O
and,O
“,O
immune,O
system,O
disease,O
”,O
gene,O
database,O
.,O
According,O
to,O
the,O
KEGG,O
database,O
",",O
the,O
obtained,O
pathways,O
are,O
mainly,O
concentrated,O
on,O
categories,O
of,O
signal,O
transduction,O
involved,O
in,O
environmental,O
information,O
processes,O
",",O
immune,O
systems,O
involved,O
in,O
organismal,O
systems,O
",",O
infectious,O
diseases,O
involved,O
in,O
human,O
diseases,O
and,O
other,O
pathways,O
.,O
The,O
severe,O
respiratory,O
disease,O
COVID-19,O
was,O
first,O
noticed,O
in,O
late,O
December,O
2019,O
(,O
),O
.,O
At,O
the,O
beginning,O
of,O
May,O
",",O
COVID-19,O
had,O
spread,O
to,O
~150,O
countries,O
and,O
infected,O
more,O
than,O
3.3,O
million,O
people,O
(,O
),O
.,O
The,O
etiological,O
agent,O
of,O
COVID-19,O
(,O
),O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
(,O
),O
",",O
was,O
identified,O
as,O
a,O
new,O
member,O
of,O
the,O
genus,O
Betacoronavirus,O
",",O
which,O
includes,O
a,O
diverse,O
reservoir,O
of,O
coronaviruses,O
(,O
CoVs,O
),O
isolated,O
from,O
bats,O
(,O
–,O
),O
.,O
While,O
hundreds,O
of,O
new,O
SARS,O
-,O
CoV-2,O
sequences,O
are,O
added,O
to,O
the,O
GISAID,B-Dataset
(Global,I-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data),E-Dataset
 ,O
repertoire,O
every,O
day,O
(,O
),O
",",O
we,O
note,O
that,O
the,O
RBM,O
region,O
currently,O
remains,O
highly,O
conserved,O
.,O
No,O
amino,O
acid,O
within,O
6,O
Å,O
of,O
the,O
ACE2,O
binding,O
site,O
has,O
repeated,O
variations,O
",",O
with,O
the,O
exception,O
of,O
G476S,O
",",O
a,O
very,O
rare,O
mutation,O
found,O
in,O
eight,O
sequences,O
from,O
a,O
local,O
cluster,O
in,O
the,O
Washington,O
state,O
",",O
out,O
of,O
6400,O
total,O
sequences,O
from,O
GISAID,O
(,O
13,O
April,O
2020,O
),O
.,O
An,O
analysis,O
of,O
6400,O
SARS,O
-,O
CoV-2,O
sequences,O
from,O
GISAID,S-Dataset
 ,O
(,O
",",O
),O
identifies,O
only,O
one,O
very,O
rare,O
mutation,O
",",O
G476S,O
that,O
is,O
a,O
direct,O
ACE2,O
contact,O
residue,O
.,O
All,O
43,O
CoV,O
complete,O
genome,O
sequences,O
were,O
obtained,O
from,O
GenBank,S-Repository
 ,O
and,O
GISAID,S-Dataset
 ,O
(,O
",",O
),O
and,O
were,O
selected,O
to,O
be,O
representative,O
of,O
the,O
diversity,O
(,O
tables,O
S2,O
and,O
S3,O
),O
.,O
Pan_SL,O
-,O
CoV_GD,O
/,O
P1La,O
sequence,O
was,O
generated,O
by,O
combining,O
Pan_SL,O
-,O
CoV_GD,O
/,O
P1L,O
(,O
),O
with,O
some,O
additional,O
sequences,O
from,O
the,O
National,B-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,I-Repository
(NCBI),I-Repository
BioProject,E-Repository
 ,O
database,O
PRJNA5732983,S-AccessionNumber
 ,O
(,O
",",O
),O
to,O
have,O
a,O
maximal,O
coverage,O
of,O
the,O
complete,O
genome,O
sequence,O
for,O
analysis,O
.,O
Recombination,O
regions,O
and,O
breakpoints,O
were,O
also,O
analyzed,O
using,O
the,O
LANL,O
(,O
Los,O
Alamos,O
National,O
Laboratory,O
),O
database,O
(,O
),O
tool,O
RIP,O
(,O
),O
with,O
a,O
400,O
-,O
bp,O
window,O
.,O
Cumulative,O
plots,O
of,O
the,O
average,O
behavior,O
of,O
each,O
codon,O
for,O
all,O
pairwise,O
comparisons,O
in,O
the,O
input,O
data,O
",",O
for,O
insertions,O
and,O
deletions,O
(,O
indels,O
),O
",",O
synonymous,O
(,O
syn,O
),O
",",O
and,O
nonsynonymous,O
(,O
nonsyn,O
),O
mutations,O
and,O
values,O
of,O
the,O
ratios,O
of,O
the,O
rate,O
of,O
synonymous,O
nucleotide,O
substitutions,O
per,O
synonymous,O
site,O
and,O
nonsynonymous,O
substitutions,O
per,O
nonsynonymous,O
site,O
(,O
dN,O
/,O
dS,O
or,O
ω,O
),O
",",O
were,O
obtained,O
using,O
the,O
LANL,O
database,O
tool,O
SNAP,O
(,O
),O
.,O
COVID-19,O
has,O
become,O
a,O
global,O
pandemic,O
caused,O
by,O
the,O
novel,O
coronavirus,O
SARS,O
-,O
CoV-2,O
.,O
The,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
viral,O
pandemic,O
that,O
causes,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
the,O
worst,O
respiratory,O
disease,O
outbreak,O
of,O
the,O
generation,O
",",O
if,O
not,O
a,O
century,O
",",O
and,O
currently,O
crippling,O
the,O
entire,O
global,O
fabric,O
of,O
the,O
human,O
socioeconomic,O
life,O
.,O
With,O
no,O
known,O
efficacious,O
therapy,O
for,O
COVID-19,O
",",O
repurposing,O
other,O
known,O
antiviral,O
drugs,O
and,O
pathologies,O
related,O
to,O
the,O
lethal,O
episode,O
of,O
COVID-19,O
are,O
our,O
best,O
approach,O
for,O
rigorous,O
experimental,O
(,O
in,O
 ,O
vitro,O
and,O
in,O
 ,O
vivo,O
),O
tests,O
and,O
clinical,O
trials,O
.,O
Good,O
examples,O
of,O
antiviral,O
drugs,O
with,O
protease,O
and,O
polymerase,O
mechanism,O
of,O
action,O
are,O
indinavir,O
",",O
saquinavir,O
",",O
lopinavir,O
/,O
ritonavir,O
and,O
remdesivir,O
",",O
which,O
gained,O
attention,O
in,O
recent,O
weeks,O
for,O
clinical,O
trial,O
of,O
COVID-19,O
infection,O
(,O
1,O
),O
.,O
On,O
these,O
bases,O
",",O
studies,O
on,O
the,O
potential,O
of,O
viral,O
helicase,O
inhibitors,O
in,O
SARS,O
-,O
CoV-2,O
infection,O
or,O
COVID-19,O
is,O
well,O
justified,O
.,O
Highlighting,O
the,O
experience,O
gained,O
from,O
targeting,O
Nsp13,O
in,O
similar,O
coronaviruses,O
(,O
SARS,O
-,O
CoV,O
and,O
MERS,O
),O
and,O
known,O
inhibitors,O
",",O
the,O
article,O
calls,O
for,O
research,O
on,O
helicase,O
inhibitors,O
as,O
potential,O
COVID-19,O
therapy,O
.,O
The,O
outbreak,O
of,O
the,O
novel,O
coronavirus,O
disease,O
COVID-19,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
COV-2,O
),O
started,O
in,O
Wuhan,O
",",O
Hubei,O
",",O
China,O
from,O
December,O
2019,O
",",O
and,O
has,O
been,O
spread,O
out,O
to,O
the,O
world,O
[,O
1,O
",",O
2,O
],O
.,O
This,O
case,O
report,O
describes,O
the,O
symptoms,O
",",O
diagnosis,O
and,O
treatments,O
of,O
one,O
unconventional,O
COVID-19,O
pneumonia,O
case,O
in,O
our,O
hospital,O
during,O
early,O
period,O
of,O
the,O
outbreak,O
when,O
having,O
very,O
little,O
understanding,O
on,O
the,O
virus,O
and,O
the,O
infection,O
.,O
However,O
",",O
COVID-19,O
ribonucleic,O
acid,O
test,O
was,O
negative,O
using,O
nasopharyngeal,O
swabs,O
done,O
by,O
Shenzhen,O
Center,O
for,O
Disease,O
Control,O
(,O
Shenzhen,O
CDC,O
),O
.,O
According,O
to,O
the,O
seventh,O
edition,O
of,O
Novel,O
Coronavirus,O
Pneumonia,O
(,O
NCP,O
),O
treatment,O
plan,O
issued,O
by,O
National,O
Health,O
Commission,O
of,O
the,O
People,O
’s,O
Republic,O
of,O
China,O
",",O
this,O
patient,O
in,O
the,O
case,O
report,O
is,O
considered,O
as,O
a,O
severely,O
ill,O
case,O
of,O
the,O
COVID-19,O
pneumonia,O
.,O
As,O
reported,O
by,O
Dr.,O
Yang,O
Yang,O
and,O
his,O
group,O
",",O
the,O
nucleic,O
acid,O
of,O
SARS,O
-,O
COV-2,O
could,O
be,O
detected,O
from,O
BALF,O
samples,O
of,O
critically,O
ill,O
patients,O
with,O
COVID-19,O
pneumonia,O
while,O
not,O
from,O
the,O
upper,O
respiratory,O
tract,O
specimens,O
of,O
some,O
patients,O
[,O
10,O
],O
.,O
Our,O
report,O
highlights,O
the,O
importance,O
to,O
carry,O
out,O
bronchoscopy,O
and,O
detection,O
of,O
SARS,O
-,O
COV-2,O
RNA,O
from,O
BALF,O
samples,O
as,O
complementary,O
interventions,O
in,O
addition,O
to,O
monitoring,O
epidemiological,O
changes,O
",",O
clinical,O
symptoms,O
and,O
chest,O
CT,O
findings,O
of,O
the,O
unconventional,O
COVID-19,O
pneumonia,O
cases,O
like,O
the,O
one,O
described,O
in,O
this,O
report,O
",",O
which,O
will,O
be,O
informative,O
and,O
clinically,O
significant,O
in,O
guiding,O
the,O
prognosis,O
of,O
the,O
disease,O
.,O
The,O
novel,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
outbreak,O
started,O
in,O
Wuhan,O
",",O
Hubei,O
",",O
China,O
since,O
Dec,O
2019,O
and,O
cases,O
of,O
infection,O
have,O
been,O
continuously,O
reported,O
in,O
various,O
countries,O
.,O
Nucleic,O
acid,O
detection,O
is,O
considered,O
as,O
the,O
gold,O
standard,O
for,O
the,O
diagnosis,O
of,O
COVID-19,O
.,O
Strategies,O
to,O
limit,O
the,O
severe,O
pandemic,O
and,O
to,O
manage,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
patients,O
strongly,O
depend,O
on,O
readily,O
available,O
",",O
accurate,O
and,O
reliable,O
RT,O
-,O
PCR,O
assays,O
to,O
detect,O
the,O
genome,O
of,O
the,O
causative,O
agent,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
in,O
biosamples,O
.,O
This,O
stool,O
sample,O
was,O
from,O
a,O
5,O
-,O
year,O
-,O
old,O
child,O
with,O
COVID-19,O
[,O
7,O
],O
and,O
was,O
chosen,O
because,O
of,O
high,O
initial,O
PCR,O
signals,O
and,O
sufficient,O
sample,O
availability,O
to,O
generate,O
large,O
quantities,O
of,O
eluate,O
for,O
further,O
distribution,O
.,O
When,O
compared,O
with,O
all,O
genomes,O
available,O
on,O
GISAID,S-Dataset
 ,O
(,O
"9,184",O
SARS,O
-,O
CoV-2,O
genomes,O
on,O
15,O
April,O
2020,O
",",O
Supplement,O
),O
",",O
the,O
regions,O
used,O
for,O
amplification,O
in,O
the,O
CDC,O
and,O
Charité,O
protocol,O
are,O
highly,O
conserved,O
:,O
Only,O
1.55,O
%,O
",",O
0.45,O
%,O
and,O
2.4,O
%,O
of,O
genome,O
sequences,O
contain,O
any,O
kind,O
of,O
mismatch,O
within,O
the,O
primer,O
/,O
probe,O
regions,O
of,O
the,O
CDC,O
N1,O
",",O
N2,O
and,O
N3,O
protocols,O
",",O
respectively,O
",",O
and,O
0.25,O
%,O
",",O
0.29,O
%,O
and,O
0.67,O
%,O
in,O
the,O
primer,O
/,O
probe,O
regions,O
of,O
the,O
Charité,O
E,O
",",O
RdRp,O
and,O
N,O
protocols,O
",",O
respectively,O
.,O
Of,O
note,O
",",O
in,O
a,O
routine,O
clinical,O
setting,O
",",O
the,O
CDC,O
N1,O
reaction,O
also,O
detected,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
nucleic,O
acid,O
extracts,O
from,O
37,O
of,O
83,O
sera,O
(,O
45,O
%,O
),O
from,O
COVID-19,O
patients,O
in,O
intensive,O
care,O
units,O
",",O
with,O
a,O
positive,O
correlation,O
of,O
their,O
Cp,O
values,O
with,O
those,O
of,O
the,O
corresponding,O
respiratory,O
material,O
(,O
Spearman,O
Rank,O
correlation,O
co,O
-,O
efficient,O
r=0.4285,O
",",O
p,O
(,O
two,O
-,O
tailed,O
),O
<,O
0.0001,O
(,O
data,O
not,O
shown,O
),O
),O
.,O
Containment,O
strategies,O
and,O
clinical,O
management,O
of,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
patients,O
during,O
the,O
current,O
pandemic,O
depend,O
on,O
reliable,O
diagnostic,O
PCR,O
assays,O
for,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
(,O
13,O
),O
",",O
has,O
become,O
an,O
unprecedented,O
public,O
health,O
crisis,O
.,O
Coronavirus,O
Resource,O
Center,O
at,O
Johns,O
Hopkins,O
University,O
of,O
Medicine,O
has,O
reported,O
a,O
total,O
of,O
"23,638",O
deaths,O
as,O
worldwide,O
COVID-19,O
infections,O
surpass,O
"500,000",O
(,O
as,O
of,O
5,O
PM,O
EST,O
on,O
March,O
26,O
",",O
2020,O
),O
.,O
On,O
March,O
16,O
",",O
2020,O
",",O
the,O
White,O
House,O
",",O
collaborating,O
with,O
research,O
institutes,O
and,O
tech,O
companies,O
",",O
issued,O
a,O
call,O
to,O
action,O
for,O
global,O
artificial,O
intelligence,O
(,O
AI,O
),O
researchers,O
for,O
developing,O
novel,O
text,O
and,O
data,O
-,O
mining,O
techniques,O
to,O
assist,O
COVID-19,O
-,O
related,O
research,O
.,O
The,O
Allen,O
Institute,O
for,O
AI,O
in,O
partnership,O
with,O
leading,O
research,O
groups,O
issued,O
an,O
open,O
-,O
source,O
",",O
weekly,O
updated,O
COVID-19,B-Dataset
Open,I-Dataset
Research,I-Dataset
Dataset,E-Dataset
 ,O
(,O
2,O
),O
",",O
which,O
continuously,O
documents,O
COVID-19,O
-,O
related,O
scholarly,O
articles,O
to,O
accelerate,O
novel,O
research,O
projects,O
urgently,O
requiring,O
real,O
-,O
time,O
data,O
.,O
The,O
large,O
-,O
scale,O
data,O
of,O
COVID-19,O
patients,O
can,O
be,O
integrated,O
and,O
analyzed,O
by,O
advanced,O
machine,O
learning,O
algorithms,O
to,O
better,O
understand,O
the,O
pattern,O
of,O
viral,O
spread,O
",",O
further,O
improve,O
diagnostic,O
speed,O
and,O
accuracy,O
",",O
develop,O
novel,O
effective,O
therapeutic,O
approaches,O
",",O
and,O
potentially,O
identify,O
the,O
most,O
susceptible,O
people,O
based,O
on,O
personalized,O
genetic,O
and,O
physiological,O
characteristics,O
.,O
Inspirationally,O
",",O
within,O
a,O
short,O
period,O
of,O
time,O
since,O
COVID-19,O
outbreak,O
",",O
advanced,O
machine,O
learning,O
techniques,O
have,O
been,O
used,O
in,O
taxonomic,O
classification,O
of,O
COVID-19,O
genomes,O
(,O
8),O
",",O
CRISPR,O
-,O
based,O
COVID-19,O
detection,O
assay,O
(,O
6,O
),O
",",O
survival,O
prediction,O
of,O
severe,O
COVID-19,O
patients,O
(,O
11,O
),O
",",O
and,O
discovering,O
potential,O
drug,O
candidates,O
against,O
COVID-19,O
(,O
4,O
),O
.,O
Personalized,O
protective,O
strategies,O
can,O
greatly,O
benefit,O
from,O
precise,O
classifications,O
of,O
the,O
population,O
based,O
on,O
categorized,O
COVID-19,O
susceptibility,O
.,O
The,O
earlier,O
observation,O
that,O
elderly,O
people,O
have,O
a,O
higher,O
risk,O
to,O
COVID-19,O
is,O
challenged,O
by,O
a,O
recent,O
finding,O
that,O
more,O
and,O
more,O
young,O
adults,O
suffer,O
from,O
severe,O
COVID-19,O
symptoms,O
",",O
indicating,O
an,O
urgent,O
need,O
of,O
a,O
comprehensive,O
risk,O
evaluation,O
based,O
on,O
personalized,O
genetic,O
and,O
physiological,O
characteristics,O
.,O
Fang,O
et,O
al,O
.,O
(,O
3,O
),O
hypothesized,O
that,O
increased,O
expression,O
of,O
ACE2,O
",",O
from,O
using,O
ACE2,O
-,O
stimulating,O
drugs,O
to,O
treat,O
hypertension,O
and,O
diabetes,O
",",O
could,O
actually,O
worsen,O
clinical,O
outcomes,O
of,O
COVID-19,O
infection,O
.,O
Therefore,O
",",O
biochemistry,O
(,O
e.g.,O
",",O
ACE2,O
expression,O
level,O
),O
and,O
clinical,O
data,O
(,O
e.g.,O
",",O
age,O
",",O
respiratory,O
pattern,O
",",O
viral,O
load,O
",",O
and,O
survival,O
),O
of,O
COVID-19,O
patients,O
with,O
underlying,O
medical,O
conditions,O
can,O
be,O
analyzed,O
by,O
machine,O
learning,O
approaches,O
to,O
not,O
only,O
identify,O
any,O
reliable,O
features,O
(,O
e.g.,O
",",O
ACE2,O
),O
for,O
risk,O
prediction,O
",",O
but,O
also,O
further,O
perform,O
risk,O
classification,O
and,O
prediction,O
for,O
a,O
balanced,O
preparation,O
of,O
ongoing,O
disease,O
treatment,O
and,O
COVID-19,O
defense,O
(,O
Fig,O
.,O
1,O
),O
.,O
ACE2,O
genetic,O
polymorphism,O
",",O
represented,O
by,O
diverse,O
genetic,O
variants,O
in,O
human,O
genome,O
",",O
has,O
been,O
shown,O
to,O
affect,O
virus,O
-,O
binding,O
activity,O
(,O
1,O
),O
",",O
suggesting,O
a,O
possible,O
genetic,O
predisposition,O
to,O
COVID-19,O
infection,O
.,O
Therefore,O
",",O
machine,O
learning,O
analysis,O
of,O
genetic,O
variants,O
from,O
asymptomatic,O
",",O
mild,O
or,O
severe,O
COVID-19,O
patients,O
can,O
be,O
performed,O
to,O
classify,O
and,O
predict,O
people,O
based,O
on,O
their,O
vulnerability,O
or,O
resistance,O
to,O
potential,O
COVID-19,O
infection,O
",",O
by,O
which,O
the,O
machine,O
learning,O
model,O
can,O
also,O
return,O
those,O
prioritized,O
genetic,O
variants,O
",",O
such,O
as,O
ACE2,O
polymorphism,O
",",O
in,O
their,O
decision,O
-,O
making,O
process,O
as,O
important,O
features,O
for,O
functional,O
and,O
mechanistic,O
studies,O
(,O
Fig,O
.,O
1,O
),O
.,O
Neural,O
network,O
classifiers,O
were,O
developed,O
for,O
large,O
-,O
scale,O
screening,O
of,O
COVID-19,O
patients,O
based,O
on,O
their,O
distinct,O
respiratory,O
pattern,O
(,O
10,O
),O
.,O
Similarly,O
",",O
a,O
deep,O
learning,O
-,O
based,O
analysis,O
system,O
of,O
thoracic,O
CT,O
images,O
was,O
constructed,O
for,O
automated,O
detection,O
and,O
monitoring,O
of,O
COVID-19,O
patients,O
over,O
time,O
(,O
5,O
),O
.,O
Rapid,O
development,O
of,O
automated,O
diagnostic,O
systems,O
based,O
on,O
artificial,O
intelligence,O
and,O
machine,O
learning,O
not,O
only,O
can,O
contribute,O
to,O
increased,O
diagnostic,O
accuracy,O
and,O
speed,O
but,O
will,O
also,O
protect,O
healthcare,O
workers,O
by,O
decreasing,O
their,O
contacts,O
with,O
COVID-19,O
patients,O
(,O
Fig,O
.,O
1,O
),O
.,O
An,O
effective,O
therapeutic,O
strategy,O
is,O
urgently,O
needed,O
to,O
treat,O
rapidly,O
growing,O
COVID-19,O
patients,O
worldwide,O
.,O
As,O
there,O
is,O
no,O
effective,O
drug,O
proven,O
to,O
treat,O
COVID-19,O
patients,O
",",O
it,O
is,O
critical,O
to,O
develop,O
efficient,O
approaches,O
to,O
repurpose,O
clinically,O
approved,O
drugs,O
or,O
design,O
new,O
drugs,O
against,O
SARS,O
-,O
CoV-2,O
.,O
AlphaFold,O
(,O
9,O
),O
",",O
which,O
is,O
a,O
deep,O
learning,O
system,O
developed,O
by,O
Google,O
DeepMind,O
",",O
has,O
released,O
predicted,O
protein,O
structures,O
associated,O
with,O
COVID-19,O
",",O
which,O
can,O
take,O
months,O
by,O
traditional,O
experimental,O
approaches,O
",",O
serving,O
as,O
valuable,O
information,O
for,O
COVID-19,O
vaccine,O
formulation,O
.,O
Moreover,O
",",O
COVID-19,O
vaccine,O
candidates,O
were,O
proposed,O
by,O
a,O
newly,O
developed,O
Vaxign,O
reverse,O
vaccinology,O
tool,O
integrated,O
with,O
machine,O
learning,O
(,O
7,O
),O
.,O
The,O
tremendous,O
amount,O
of,O
COVID-19,O
treatment,O
data,O
in,O
worldwide,O
hospitals,O
also,O
require,O
advanced,O
machine,O
learning,O
methods,O
for,O
analyzing,O
personalized,O
therapeutic,O
effects,O
for,O
evaluating,O
new,O
patients,O
",",O
such,O
as,O
hospitalization,O
prediction,O
",",O
which,O
can,O
not,O
only,O
provide,O
better,O
care,O
for,O
each,O
patient,O
but,O
also,O
contribute,O
to,O
local,O
hospital,O
arrangement,O
and,O
operation,O
(,O
Fig,O
.,O
1,O
),O
.,O
As,O
artificial,O
intelligence,O
and,O
machine,O
learning,O
scientists,O
have,O
been,O
eagerly,O
searching,O
and,O
waiting,O
for,O
real,O
-,O
time,O
data,O
generated,O
by,O
this,O
pandemic,O
around,O
the,O
world,O
",",O
timely,O
delivery,O
of,O
COVID-19,O
patient,O
data,O
",",O
such,O
as,O
physiological,O
characteristics,O
and,O
therapeutic,O
outcome,O
of,O
COVID-19,O
patients,O
",",O
followed,O
by,O
subsequent,O
data,O
transformation,O
for,O
easy,O
access,O
",",O
is,O
extremely,O
important,O
",",O
but,O
challenging,O
.,O
Figure,O
1,O
is,O
a,O
schematic,O
representation,O
of,O
the,O
workflow,O
",",O
but,O
there,O
are,O
several,O
steps,O
in,O
the,O
process,O
that,O
currently,O
limit,O
the,O
application,O
of,O
machine,O
learning,O
and,O
artificial,O
intelligence,O
to,O
combat,O
COVID-19,O
.,O
Availability,O
of,O
COVID-19,O
-,O
related,O
clinical,O
data,O
",",O
which,O
can,O
be,O
managed,O
and,O
processed,O
into,O
easily,O
accessible,O
databases,O
",",O
is,O
a,O
key,O
current,O
barrier,O
.,O
In,O
addition,O
to,O
these,O
initiatives,O
",",O
integrating,O
COVID-19,O
-,O
related,O
clinical,O
data,O
with,O
existing,O
biobanks,O
",",O
such,O
as,O
the,O
UK,B-Repository
Biobank,E-Repository
",",O
with,O
pre,O
-,O
existing,O
data,O
of,O
those,O
patients,O
(,O
if,O
already,O
in,O
biobanks,O
),O
",",O
such,O
as,O
their,O
genotype,O
and,O
physiological,O
characteristics,O
",",O
could,O
maximize,O
our,O
efforts,O
toward,O
a,O
faster,O
and,O
feasible,O
approach,O
for,O
meaningful,O
data,O
-,O
mining,O
by,O
bioinformaticians,O
and,O
computational,O
scientists,O
.,O
A,O
centralized,O
collection,O
of,O
worldwide,O
COVID-19,O
patient,O
data,O
will,O
be,O
beneficial,O
for,O
future,O
artificial,O
intelligence,O
and,O
machine,O
learning,O
research,O
to,O
develop,O
predictive,O
",",O
diagnostic,O
",",O
and,O
therapeutic,O
strategies,O
against,O
COVID-19,O
and,O
similar,O
pandemics,O
in,O
future,O
.,O
Targeted,O
screening,O
of,O
suspected,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
cases,O
",",O
as,O
well,O
as,O
a,O
series,O
of,O
successive,O
nationwide,O
travel,O
restrictions,O
",",O
were,O
put,O
in,O
place,O
to,O
curtail,O
SARS,O
-,O
CoV-2,O
introductions,O
into,O
the,O
continental,O
United,O
States,O
from,O
outbreak,O
hotspots,O
in,O
China,O
(,O
2,O
February,O
2020,O
),O
",",O
Iran,O
(,O
2,O
March,O
2020,O
),O
",",O
mainland,O
European,O
countries,O
(,O
13,O
March,O
2020,O
),O
",",O
and,O
the,O
United,O
Kingdom,O
and,O
Ireland,O
(,O
16,O
March,O
2020,O
),O
(,O
–,O
),O
.,O
Despite,O
these,O
measures,O
",",O
the,O
first,O
COVID-19,O
case,O
in,O
New,O
York,O
State,O
was,O
identified,O
in,O
New,O
York,O
City,O
(,O
NYC,O
),O
on,O
29,O
February,O
2020,O
.,O
As,O
of,O
2,O
May,O
2020,O
",",O
there,O
were,O
"312,977",O
confirmed,O
COVID-19,O
cases,O
in,O
New,O
York,O
state,O
",",O
including,O
"172,354",O
(,O
55,O
%,O
),O
in,O
NYC,O
[,O
New,O
York,O
State,O
Department,O
of,O
Health,O
(,O
NYS,O
DOH,O
),O
;,O
https://coronavirus.health.ny.gov,O
],O
.,O
We,O
performed,O
phylogenetic,O
analysis,O
of,O
the,O
84,O
distinct,O
patient,O
isolates,O
",",O
together,O
with,O
2363,O
sequences,O
deposited,O
in,O
GISAID,S-Dataset
 ,O
up,O
to,O
1,O
April,O
2020,O
(,O
Fig,O
.,O
2A,O
),O
.,O
This,O
clade,O
is,O
largely,O
composed,O
of,O
isolates,O
obtained,O
from,O
patients,O
with,O
COVID-19,O
in,O
Europe,O
(,O
72,O
%,O
),O
(,O
Fig,O
.,O
2B,O
),O
",",O
suggesting,O
that,O
introductions,O
from,O
Europe,O
account,O
for,O
the,O
majority,O
of,O
cases,O
found,O
in,O
NYC,O
in,O
the,O
first,O
weeks,O
of,O
March,O
2020,O
.,O
(,O
A,O
),O
ML,O
phylodynamic,O
inference,O
of,O
84,O
SARS,O
-,O
CoV-2,O
sequences,O
from,O
New,O
York,O
from,O
this,O
study,O
in,O
a,O
global,O
background,O
of,O
2363,O
sequences,O
available,O
in,O
the,O
GISAID,S-Dataset
 ,O
EpiCoV,O
database,O
as,O
of,O
1,O
April,O
2020,O
.,O
Science,O
this,O
issue,O
p.,O
297,O
  ,O
New,O
York,O
City,O
became,O
an,O
epicenter,O
for,O
COVID-19,O
cases,O
that,O
originated,O
in,O
Europe,O
and,O
elsewhere,O
in,O
the,O
United,O
States,O
.,O
To,O
identify,O
the,O
early,O
transmission,O
events,O
underlying,O
the,O
rapid,O
spread,O
of,O
the,O
virus,O
in,O
the,O
NYC,O
metropolitan,O
area,O
",",O
we,O
sequenced,O
the,O
virus,O
that,O
causes,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
in,O
patients,O
seeking,O
care,O
at,O
the,O
Mount,O
Sinai,O
Health,O
System,O
.,O
Abstract,O
  ,O
Background,O
 ,O
COVID-19,O
has,O
highlighted,O
deficiencies,O
in,O
the,O
testing,O
capacity,O
of,O
many,O
developed,O
countries,O
during,O
the,O
early,O
stages,O
of,O
pandemics,O
.,O
Driven,O
by,O
a,O
desire,O
to,O
reduce,O
potential,O
infections,O
during,O
the,O
COVID-19,O
pandemic,O
",",O
health,O
authorities,O
and,O
professional,O
bodies,O
in,O
the,O
United,O
Kingdom,O
(,O
UK,O
),O
[,O
1,O
],O
",",O
Canada,O
[,O
2,O
],O
and,O
Australia,O
[,O
3,O
],O
have,O
issued,O
urgent,O
statements,O
designed,O
to,O
limit,O
the,O
need,O
for,O
pregnant,O
women,O
to,O
attend,O
prolonged,O
appointments,O
at,O
pathology,O
testing,O
centers,O
for,O
OGTTs,O
.,O
Clearly,O
",",O
they,O
differ,O
in,O
many,O
ways,O
",",O
both,O
pre,O
and,O
post,O
COVID-19,O
.,O
For,O
comparison,O
of,O
GDM,O
frequency,O
using,O
the,O
pre,O
and,O
post,O
COVID-19,O
diagnostic,O
processes,O
and,O
criteria,O
",",O
we,O
have,O
considered,O
national,O
diagnostic,O
criteria,O
.,O
Table,O
1,O
shows,O
the,O
current,O
recommendations,O
for,O
GDM,O
testing,O
in,O
each,O
of,O
the,O
three,O
countries,O
",",O
their,O
revised,O
recommendations,O
for,O
use,O
during,O
the,O
COVID-19,O
pandemic,O
(,O
indicated,O
by,O
the,O
column,O
entitled,O
“,O
Modified,O
GDM,O
diagnostic,O
approach,O
during,O
COVID-19,O
pandemic,O
”,O
),O
and,O
the,O
specific,O
diagnostic,O
process,O
and,O
threshold(s,O
),O
evaluated,O
in,O
the,O
current,O
study,O
(,O
indicated,O
by,O
the,O
column,O
entitled,O
“,O
Post,O
-,O
COVID,O
approach,O
tested,O
in,O
current,O
paper,O
”,O
),O
.,O
Each,O
participant,O
was,O
classified,O
into,O
the,O
following,O
groups,O
for,O
each,O
of,O
the,O
UK,O
",",O
Canadian,O
and,O
Australian,O
diagnostic,O
criteria,O
(,O
as,O
specified,O
in,O
Table,O
1,O
):,O
1,O
),O
“,O
Missed,O
GDM,O
”,O
-,O
GDM,O
by,O
local,O
pre,O
COVID-19,O
criteria,O
but,O
not,O
identified,O
as,O
GDM,O
using,O
local,O
post,O
COVID-19,O
criteria,O
;,O
2,O
),O
GDM,O
by,O
local,O
post,O
COVID-19,O
criteria,O
;,O
and,O
3,O
),O
not,O
GDM,O
by,O
both,O
pre,O
and,O
post,O
COVID-19,O
local,O
criteria,O
.,O
Using,O
the,O
newly,O
recommended,O
national,O
COVID-19,O
processes,O
and,O
criteria,O
would,O
result,O
in,O
markedly,O
reduced,O
GDM,O
frequency,O
in,O
the,O
UK,O
(,O
81,O
%,O
reduction,O
to,O
2.5,O
%,O
),O
and,O
Canada,O
(,O
82,O
%,O
reduction,O
to,O
1.7,O
%,O
),O
",",O
with,O
a,O
less,O
marked,O
25,O
%,O
reduction,O
to,O
12.7,O
%,O
in,O
Australia,O
(,O
Fig,O
.,O
1,O
),O
.,O
Considering,O
the,O
UK,O
situation,O
(,O
Table,O
3,O
),O
",",O
the,O
684,O
women,O
currently,O
classified,O
as,O
GDM,O
but,O
who,O
would,O
not,O
be,O
detected,O
(,O
“,O
missed,O
”,O
),O
under,O
the,O
post,O
COVID-19,O
guidelines,O
demonstrate,O
statistically,O
significantly,O
higher,O
rates,O
of,O
preterm,O
birth,O
",",O
LGA,O
",",O
primary,O
CS,O
",",O
neonatal,O
hyperinsulinemia,O
and,O
neonatal,O
adiposity,O
than,O
non,O
GDM,O
women,O
.,O
Considering,O
the,O
Canadian,O
criteria,O
(,O
Table,O
4,O
),O
",",O
the,O
524,O
women,O
currently,O
classified,O
as,O
GDM,O
but,O
considered,O
non,O
GDM,O
under,O
post,O
COVID-19,O
guidelines,O
demonstrate,O
increased,O
risks,O
(,O
compared,O
to,O
non,O
-,O
GDM,O
women,O
),O
for,O
all,O
the,O
outcomes,O
listed,O
for,O
the,O
UK,O
",",O
including,O
pregnancy,O
related,O
hypertension,O
.,O
The,O
253,O
women,O
with,O
IADPSG,O
GDM,O
",",O
who,O
would,O
be,O
“,O
missed,O
”,O
under,O
the,O
proposed,O
Australian,O
post,O
COVID-19,O
process,O
(,O
fasting,O
glucose,O
followed,O
by,O
selective,O
OGTT,O
",",O
no,O
change,O
in,O
diagnostic,O
thresholds,O
),O
have,O
outcome,O
frequencies,O
similar,O
to,O
those,O
of,O
non,O
GDM,O
women,O
",",O
whilst,O
those,O
who,O
would,O
remain,O
in,O
the,O
GDM,O
group,O
with,O
post,O
COVID-19,O
testing,O
show,O
significantly,O
higher,O
risks,O
for,O
all,O
listed,O
outcomes,O
.,O
Table,O
3,O
",",O
Table,O
4,O
",",O
Table,O
5,O
also,O
document,O
the,O
proportion,O
of,O
pregnancy,O
complications,O
which,O
occurred,O
amongst,O
GDM,O
women,O
using,O
pre,O
COVID-19,O
diagnostic,O
processes,O
",",O
but,O
which,O
would,O
be,O
“,O
missed,O
”,O
post,O
COVID-19,O
as,O
these,O
women,O
would,O
no,O
longer,O
be,O
classified,O
as,O
GDM,O
and,O
therefore,O
would,O
no,O
longer,O
receive,O
any,O
additional,O
care,O
.,O
Perhaps,O
unsurprisingly,O
",",O
the,O
three,O
different,O
suggested,O
modifications,O
in,O
diagnostic,O
strategies,O
proposed,O
for,O
GDM,O
testing,O
in,O
response,O
to,O
the,O
COVID-19,O
pandemic,O
also,O
appear,O
to,O
have,O
different,O
potential,O
advantages,O
and,O
disadvantages,O
[,O
14,O
],O
.,O
The,O
UK,O
(,O
1,O
),O
and,O
Canadian,O
(,O
2,O
),O
strategies,O
both,O
prioritize,O
avoidance,O
of,O
OGTTs,O
with,O
the,O
intention,O
of,O
reducing,O
potential,O
COVID-19,O
exposure,O
.,O
In,O
the,O
case,O
of,O
the,O
Canadian,O
criteria,O
(,O
Table,O
4,O
),O
",",O
the,O
“,O
Missed,O
GDM,O
”,O
women,O
carry,O
risks,O
which,O
are,O
comparable,O
to,O
those,O
who,O
would,O
still,O
be,O
detected,O
under,O
post,O
COVID-19,O
guidelines,O
and,O
the,O
percentage,O
of,O
GDM,O
outcomes,O
missed,O
generally,O
exceeds,O
the,O
overall,O
reduction,O
in,O
GDM,O
prevalence,O
.,O
However,O
",",O
we,O
acknowledge,O
that,O
",",O
for,O
the,O
UK,O
and,O
Canada,O
",",O
our,O
processes,O
do,O
not,O
precisely,O
match,O
current,O
or,O
proposed,O
(,O
post,O
COVID-19,O
),O
testing,O
recommendations,O
for,O
GDM,O
.,O
The,O
COVID-19,O
pandemic,O
poses,O
a,O
variety,O
of,O
serious,O
challenges,O
to,O
pregnancy,O
care,O
[,O
22,O
],O
and,O
GDM,O
detection,O
and,O
management,O
are,O
only,O
one,O
part,O
of,O
a,O
complex,O
and,O
rapidly,O
evolving,O
set,O
of,O
adaptations,O
to,O
care,O
(,O
e.g.,O
use,O
of,O
telehealth,O
or,O
telephone,O
visits,O
),O
designed,O
to,O
both,O
optimize,O
pregnancy,O
outcomes,O
and,O
protect,O
pregnant,O
women,O
and,O
health,O
care,O
staff,O
.,O
A,O
woman,O
who,O
contracts,O
COVID-19,O
infection,O
during,O
pregnancy,O
clearly,O
may,O
acquire,O
this,O
through,O
household,O
or,O
community,O
transmission,O
",",O
rather,O
than,O
specifically,O
at,O
a,O
pathology,O
collection,O
centre,O
",",O
so,O
our,O
primary,O
clinical,O
aim,O
should,O
be,O
to,O
reduce,O
avoidable,O
exposure,O
and,O
to,O
encourage,O
general,O
protective,O
measures,O
in,O
other,O
settings,O
.,O
Australia,O
has,O
experienced,O
far,O
fewer,O
COVID-19,O
cases,O
than,O
the,O
UK,O
or,O
Canada,O
",",O
and,O
testing,O
recommendations,O
have,O
already,O
been,O
modified,O
",",O
with,O
routine,O
OGTTs,O
again,O
recommended,O
where,O
COVID-19,O
transmission,O
risk,O
is,O
considered,O
low,O
[,O
23,O
],O
",",O
the,O
strategy,O
described,O
in,O
this,O
paper,O
recommended,O
for,O
moderate,O
risk,O
situations,O
and,O
fasting,O
glucose,O
testing,O
alone,O
preferred,O
if,O
COVID-19,O
risk,O
is,O
considered,O
high,O
.,O
Highlights,O
    ,O
•,O
 ,O
Guidelines,O
for,O
GDM,O
diagnosis,O
during,O
COVID,O
have,O
changed,O
.,O
We,O
assessed,O
how,O
altered,O
diagnostic,O
processes,O
and,O
criteria,O
for,O
gestational,O
diabetes,O
mellitus,O
(,O
GDM,O
),O
recommended,O
by,O
the,O
United,O
Kingdom,O
(,O
UK,O
),O
",",O
Canada,O
and,O
Australia,O
for,O
use,O
during,O
the,O
COVID-19,O
pandemic,O
would,O
affect,O
both,O
GDM,O
frequency,O
and,O
related,O
adverse,O
outcomes,O
.,O
All,O
post,O
COVID-19,O
modified,O
pathways,O
reduced,O
GDM,O
frequency,O
–,O
UK,O
(,O
81,O
%,O
),O
",",O
Canada,O
(,O
82,O
%,O
),O
and,O
Australia,O
(,O
25,O
%,O
),O
.,O
Canadian,O
women,O
whose,O
GDM,O
would,O
remain,O
undetected,O
post,O
COVID-19,O
(,O
missed,O
GDMs,O
),O
displayed,O
similar,O
rates,O
of,O
pregnancy,O
complications,O
to,O
those,O
with,O
post,O
COVID-19,O
GDM,O
.,O
Each,O
has,O
both,O
potential,O
benefits,O
in,O
terms,O
of,O
reduction,O
in,O
potential,O
exposure,O
to,O
COVID-19,O
and,O
costs,O
in,O
terms,O
of,O
missed,O
opportunities,O
to,O
influence,O
pregnancy,O
and,O
postpartum,O
outcomes,O
.,O
Caused,O
by,O
SARS,O
-,O
CoV-2,O
",",O
this,O
disease,O
was,O
named,O
as,O
COVID-19,O
by,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
and,O
quickly,O
spreads,O
all,O
over,O
the,O
world,O
[,O
8,O
],O
.,O
The,O
COVID-19,O
outbreak,O
was,O
declared,O
an,O
epidemic,O
by,O
the,O
World,O
Health,O
Organization,O
after,O
causing,O
the,O
death,O
of,O
tens,O
of,O
thousands,O
of,O
people,O
[,O
9,O
],O
.,O
The,O
COVID-19,O
epidemic,O
is,O
continuing,O
to,O
be,O
a,O
major,O
problem,O
for,O
the,O
whole,O
world,O
[,O
8,O
],O
",",O
[,O
11,O
],O
.,O
As,O
COVID-19,O
",",O
the,O
largest,O
epidemic,O
of,O
modern,O
times,O
turned,O
into,O
a,O
pandemic,O
",",O
an,O
urgent,O
search,O
was,O
started,O
throughout,O
the,O
world,O
for,O
a,O
therapeutic,O
drug,O
against,O
COVID-19,O
to,O
control,O
the,O
epidemic,O
and,O
decrease,O
the,O
high,O
mortality,O
rates,O
.,O
In,O
COVID-19,O
",",O
the,O
reason,O
why,O
the,O
disease,O
was,O
very,O
mild,O
in,O
some,O
people,O
and,O
very,O
severe,O
in,O
others,O
is,O
thought,O
to,O
be,O
related,O
to,O
the,O
amount,O
of,O
retinol,O
previously,O
stored,O
in,O
the,O
patient,O
's,O
liver,O
.,O
In,O
COVID-19,O
",",O
the,O
falling,O
levels,O
of,O
retinoic,O
acids,O
",",O
which,O
are,O
rapidly,O
depleted,O
in,O
the,O
body,O
",",O
and,O
the,O
resulting,O
excessive,O
cytokine,O
release,O
syndrome,O
",",O
are,O
responsible,O
for,O
most,O
of,O
the,O
disease,O
",",O
severe,O
clinical,O
and,O
symptoms,O
.,O
Two,O
separate,O
clinical,O
studies,O
from,O
Egypt,O
reported,O
to,O
the,O
US,O
NIH,O
clinical,O
trials,O
are,O
underway,O
to,O
determine,O
the,O
effectiveness,O
of,O
Isotretinoin,O
",",O
a,O
retinoic,O
acid,O
derivative,O
",",O
in,O
COVID-19,O
[,O
22,O
],O
.,O
The,O
clinical,O
picture,O
",",O
which,O
is,O
common,O
in,O
severe,O
COVID-19,O
patients,O
and,O
is,O
referred,O
to,O
as,O
“,O
pink,O
eye,O
”,O
[,O
23,O
],O
",",O
[,O
24,O
],O
",",O
is,O
nothing,O
more,O
than,O
conjunctivitis,O
seen,O
in,O
severe,O
vitamin,O
A,O
deficiency,O
.,O
Although,O
attempts,O
are,O
made,O
to,O
explain,O
the,O
taste,O
and,O
olfactory,O
disorders,O
in,O
COVID-19,O
patients,O
with,O
ACE2,O
receptors,O
it,O
is,O
clear,O
that,O
it,O
takes,O
place,O
through,O
retinoic,O
acid,O
receptors,O
[,O
25,O
],O
.,O
This,O
also,O
suggest,O
that,O
vitamin,O
A,O
deficiency,O
also,O
develops,O
in,O
COVID-19,O
.,O
The,O
findings,O
and,O
symptoms,O
that,O
arise,O
in,O
the,O
nervous,O
system,O
and,O
eyes,O
of,O
COVID-19,O
patients,O
are,O
nothing,O
but,O
the,O
results,O
of,O
retinoic,O
acid,O
deficiency,O
manifested,O
through,O
retinoid,O
acid,O
receptors,O
.,O
Dizziness,O
",",O
headache,O
",",O
impaired,O
consciousness,O
",",O
acute,O
cerebrovascular,O
disorder,O
",",O
ataxia,O
and,O
epilepsy,O
are,O
observed,O
in,O
COVID-19,O
patients,O
as,O
central,O
nervous,O
system,O
involvement,O
and,O
hypogeusia,O
",",O
hyposmia,O
",",O
hypopsia,O
and,O
neuralgia,O
are,O
observed,O
as,O
peripheral,O
nervous,O
system,O
involvement,O
.,O
Acute,O
hemorrhagic,O
necrotizing,O
encephalopathy,O
cases,O
related,O
to,O
COVID-19,O
were,O
also,O
reported,O
.,O
The,O
first,O
Guillain,O
-,O
Barré,O
syndrome,O
that,O
could,O
be,O
related,O
to,O
COVID-19,O
was,O
reported,O
by,O
Zhao,O
et,O
al,O
[,O
28,O
],O
.,O
It,O
could,O
be,O
considered,O
that,O
the,O
reason,O
for,O
observing,O
autoimmune,O
diseases,O
such,O
as,O
Kawasaki,O
in,O
COVID-19,O
is,O
related,O
to,O
this,O
mechanism,O
.,O
The,O
first,O
Guillain,O
-,O
Barré,O
syndrome,O
that,O
could,O
be,O
related,O
to,O
COVID-19,O
was,O
reported,O
by,O
Zhao,O
et,O
al,O
[,O
28,O
],O
.,O
This,O
may,O
increase,O
the,O
tendency,O
to,O
thrombosis,O
in,O
addition,O
to,O
hypoxia,O
and,O
endothelial,O
damage,O
in,O
COVID-19,O
.,O
In,O
some,O
COVID-19,O
patients,O
",",O
the,O
cause,O
of,O
inadequate,O
antibody,O
response,O
may,O
be,O
due,O
to,O
retinol,O
depletion,O
.,O
Vitamin,O
A,O
deficiency,O
increases,O
mortality,O
in,O
AIDS,O
.,O
Vitamin,O
A,O
replacement,O
also,O
provides,O
benefit,O
for,O
other,O
infections,O
in,O
AIDS,O
.,O
A,O
deficiency,O
increases,O
mortality,O
in,O
AIDS,O
[,O
56,O
],O
.,O
The,O
frequency,O
of,O
Measles,O
",",O
Chicken,O
Pox,O
",",O
RSV,O
",",O
AIDS,O
and,O
pneumonia,O
increase,O
in,O
vitamin,O
A,O
deficiency,O
[,O
57,O
],O
.,O
All,O
the,O
drugs,O
bound,O
to,O
a,O
certain,O
protocol,O
by,O
the,O
COVID-19,O
Science,O
and,O
Advisory,O
Board,O
in,O
our,O
country,O
",",O
as,O
in,O
many,O
countries,O
throughout,O
the,O
world,O
",",O
and,O
used,O
in,O
COVID-19,O
treatment,O
",",O
inhibit,O
the,O
cytochrome,O
P450,O
system,O
(,O
Table,O
1,O
),O
.,O
The,O
table,O
below,O
shows,O
the,O
drugs,O
included,O
in,O
the,O
COVID-19,O
treatment,O
protocol,O
and,O
their,O
stimulation,O
/,O
inhibition,O
status,O
on,O
the,O
CYP,O
P450,O
system,O
.,O
The,O
study,O
conducted,O
in,O
China,O
found,O
this,O
drug,O
to,O
be,O
unsuccessful,O
against,O
COVID-19,O
[,O
36,O
],O
.,O
In,O
this,O
respect,O
",",O
the,O
use,O
of,O
alcohol,O
has,O
a,O
negative,O
impact,O
on,O
COVID-19,O
prognosis,O
.,O
French,O
people,O
were,O
consuming,O
high,O
amounts,O
of,O
red,O
wine,O
on,O
the,O
first,O
days,O
of,O
the,O
COVID-19,O
pandemic,O
.,O
It,O
was,O
stated,O
that,O
red,O
wine,O
(,O
not,O
white,O
wine,O
),O
consumption,O
protected,O
people,O
from,O
COVID-19,O
and,O
that,O
it,O
was,O
even,O
good,O
for,O
the,O
patients,O
.,O
The,O
reason,O
why,O
COVID-19,O
progresses,O
more,O
in,O
males,O
than,O
females,O
(,O
ignoring,O
smoking,O
),O
is,O
that,O
the,O
cytochrome,O
oxidase,O
system,O
is,O
less,O
inhibited,O
in,O
males,O
than,O
females,O
.,O
In,O
this,O
case,O
",",O
all,O
drugs,O
and,O
compounds,O
that,O
inhibit,O
the,O
liver,O
cytochrome,O
P450,O
oxidase,O
system,O
may,O
be,O
effective,O
against,O
COVID-19,O
by,O
preventing,O
retinoic,O
acid,O
metabolism,O
.,O
In,O
fact,O
",",O
it,O
is,O
not,O
difficult,O
to,O
predict,O
that,O
even,O
Ketoconazole,O
",",O
which,O
is,O
used,O
as,O
an,O
antifungal,O
",",O
can,O
have,O
significant,O
efficacy,O
in,O
COVID-19,O
treatment,O
as,O
a,O
strong,O
cytochrome,O
oxidase,O
P450,O
inhibitor,O
(,O
if,O
sufficient,O
retinoic,O
acid,O
is,O
available,O
in,O
the,O
body,O
),O
[,O
30,O
],O
.,O
Retinoic,O
acids,O
",",O
zinc,O
and,O
RAMBAs,O
may,O
work,O
against,O
COVID-19,O
",",O
which,O
continues,O
with,O
full,O
intensity,O
.,O
COVID-19,O
and,O
previously,O
defined,O
sepsis,O
",",O
SIRS,O
and,O
ARDS,O
are,O
each,O
retinoic,O
acid,O
depletion,O
syndrome,O
.,O
We,O
claim,O
that,O
retinoic,O
acid,O
metabolism,O
is,O
defective,O
in,O
most,O
inflammatory,O
diseases,O
",",O
particularly,O
COVID-19,O
(,O
cytokine,O
storm,O
),O
sepsis,O
",",O
SIRS,O
and,O
ARDS,O
.,O
We,O
used,O
the,O
open,O
COVID-19,O
sequencing,O
available,O
and,O
the,O
bioinformatics,O
protocols,O
developed,O
by,O
the,O
ARTIC,O
network,O
.,O
Raw,O
files,O
were,O
base,O
-,O
called,O
with,O
Guppy,O
",",O
demultiplexed,O
and,O
trimmed,O
with,O
Porechop,O
(,O
https://github.com/rrwick/Porechop,O
),O
and,O
mapped,O
against,O
reference,O
sequence,O
Wuhan,O
-,O
Hu-1,O
(,O
GenBank,S-Repository
 ,O
Accession,O
Number,O
MN908947,S-AccessionNumber
),O
.,O
We,O
conducted,O
the,O
genome,O
sequencing,O
and,O
analysis,O
of,O
the,O
first,O
confirmed,O
COVID-19,O
infections,O
in,O
Brazil,O
.,O
Rapid,O
sequencing,O
coupled,O
with,O
phylogenetic,O
analyses,O
in,O
the,O
context,O
of,O
travel,O
history,O
corroborate,O
multiple,O
independent,O
importations,O
from,O
Italy,O
and,O
local,O
spread,O
during,O
the,O
initial,O
stage,O
of,O
COVID-19,O
transmission,O
in,O
Brazil,O
.,O
The,O
outbreak,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
has,O
been,O
spreading,O
rapidly,O
throughout,O
the,O
globe,O
",",O
resulting,O
in,O
~0.8,O
million,O
confirmed,O
infections,O
as,O
of,O
March,O
31,O
",",O
2020,O
.,O
On,O
March,O
11,O
",",O
2020,O
",",O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
declared,O
the,O
COVID-19,O
outbreak,O
a,O
pandemic,O
.,O
COVID-19,O
is,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
a,O
positive,O
-,O
sense,O
single,O
-,O
stranded,O
RNA,O
virus,O
that,O
belongs,O
to,O
the,O
genus,O
Betacoronavirus,O
within,O
the,O
family,O
Coronaviridae,O
[,O
"1,2",O
],O
.,O
The,O
pandemic,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
caused,O
by,O
SARS,O
-,O
CoV-2,O
has,O
posed,O
a,O
severe,O
threat,O
to,O
global,O
public,O
health,O
.,O
Subgroups,O
of,O
patients,O
with,O
COVID-19,O
have,O
been,O
identified,O
who,O
appear,O
to,O
be,O
at,O
increased,O
risk,O
of,O
morbidity,O
and,O
mortality,O
",",O
including,O
patients,O
of,O
older,O
age,O
",",O
male,O
sex,O
(,O
vs,O
female,O
),O
",",O
and,O
those,O
with,O
comorbidities,O
",",O
such,O
as,O
hypertension,O
",",O
chronic,O
lung,O
disease,O
",",O
diabetes,O
",",O
and,O
cancer,O
.,O
Since,O
COVID-19,O
began,O
to,O
spread,O
across,O
the,O
globe,O
in,O
early,O
2020,O
",",O
patients,O
with,O
cancer,O
were,O
identified,O
as,O
a,O
particularly,O
susceptible,O
subgroup,O
of,O
the,O
population,O
.,O
Therefore,O
",",O
labelling,O
all,O
patients,O
with,O
cancer,O
as,O
susceptible,O
to,O
COVID-19,O
is,O
probably,O
neither,O
reasonable,O
nor,O
informative,O
.,O
As,O
a,O
consequence,O
of,O
generic,O
advice,O
given,O
to,O
people,O
who,O
are,O
clinically,O
susceptible,O
to,O
COVID-19,O
",",O
patients,O
with,O
cancer,O
(,O
of,O
any,O
age,O
",",O
sex,O
",",O
tumour,O
subtype,O
",",O
and,O
stage,O
),O
have,O
been,O
labelled,O
as,O
at,O
high,O
risk,O
from,O
COVID-19,O
",",O
which,O
has,O
led,O
to,O
sweeping,O
changes,O
in,O
management,O
for,O
all,O
cancer,O
types,O
during,O
the,O
past,O
few,O
months,O
",",O
including,O
shortening,O
of,O
radiotherapy,O
",",O
switching,O
from,O
intravenous,O
to,O
oral,O
chemotherapy,O
regimens,O
",",O
and,O
modifications,O
in,O
immunotherapy,O
use.5,O
",",O
6,O
",",O
7,O
",",O
8,O
These,O
changes,O
were,O
instigated,O
with,O
little,O
evidence,O
to,O
support,O
them,O
",",O
perhaps,O
reasonably,O
in,O
an,O
acute,O
pandemic,O
situation,O
.,O
From,O
the,O
UK,B-Repository
Coronavirus,I-Repository
Cancer,I-Repository
Monitoring,I-Repository
Project,I-Repository
(UKCCMP),E-Repository
",",O
we,O
report,O
the,O
first,O
analysis,O
",",O
to,O
our,O
knowledge,O
",",O
of,O
the,O
complex,O
interaction,O
between,O
patient,O
demographics,O
and,O
tumour,O
subtype,O
",",O
to,O
more,O
accurately,O
estimate,O
the,O
risk,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
COVID-19,O
in,O
patients,O
with,O
cancer,O
.,O
We,O
aimed,O
to,O
describe,O
the,O
clinical,O
outcomes,O
of,O
COVID-19,O
in,O
patients,O
with,O
cancer,O
entered,O
into,O
the,O
UKCCMP,S-Repository
 ,O
registry,O
and,O
compare,O
primary,O
cancer,O
subtype,O
prevalence,O
and,O
case,O
fatality,O
with,O
UK,B-Creator
Office,I-Creator
for,I-Creator
National,I-Creator
Statistics,E-Creator
 ,O
cancer,O
incidence,O
data,O
.,O
The,O
UKCCMP,S-Repository
 ,O
database,O
of,O
UK,O
patients,O
with,O
COVID-19,O
who,O
have,O
cancer,O
was,O
designed,O
as,O
a,O
public,O
health,O
surveillance,O
registry,O
for,O
the,O
COVID-19,O
pandemic,O
and,O
a,O
prospective,O
",",O
observational,O
cohort,O
study,O
.,O
The,O
database,O
was,O
set,O
up,O
to,O
support,O
rapid,O
clinical,O
decision,O
making,O
",",O
in,O
accordance,O
with,O
the,O
UK,O
Policy,O
Framework,O
for,O
Health,O
and,O
Social,O
Care,O
Research,O
",",O
the,O
UK,O
National,O
Research,O
Ethics,O
Service,O
",",O
and,O
the,O
UK,O
Governance,O
Arrangement,O
for,O
Research,O
Ethics,O
Committees,O
.,O
Management,O
of,O
patients,O
with,O
cancer,O
with,O
COVID-19,O
was,O
directed,O
by,O
the,O
patient,O
's,O
clinician,O
team,O
without,O
input,O
from,O
the,O
UKCCMP,S-Repository
 ,O
and,O
was,O
based,O
on,O
local,O
policies,O
and,O
standard,O
UK,O
clinical,O
practice,O
at,O
the,O
time,O
of,O
this,O
study,O
.,O
Decisions,O
about,O
intensive,O
care,O
unit,O
admission,O
and,O
ventilation,O
were,O
guided,O
by,O
the,O
UK,O
National,O
Health,O
Service,O
National,O
Institute,O
of,O
Health,O
and,O
Care,O
Excellence,O
COVID-19,O
rapid,O
guidelines,O
.,O
Case,O
reporting,O
of,O
patient,O
tumour,O
stage,O
and,O
demographics,O
was,O
lead,O
by,O
a,O
COVID-19,O
emergency,O
response,O
reporting,O
individual,O
(,O
ERRI,O
),O
",",O
using,O
data,O
from,O
clinical,O
records,O
or,O
from,O
direct,O
assessment,O
.,O
Tumour,O
subtype,O
and,O
demographic,O
analyses,O
used,O
the,O
latest,O
release,O
of,O
the,O
Cancer,B-Dataset
Registration,I-Dataset
Statistics,E-Dataset
",",O
England,O
",",O
2017,O
",",O
which,O
is,O
the,O
most,O
recent,O
cancer,O
registration,O
database,O
in,O
England,O
and,O
involves,O
registrations,O
of,O
patients,O
from,O
Jan,O
1,O
to,O
Dec,O
31,O
",",O
2017,O
.,O
1044,O
patients,O
with,O
active,O
cancer,O
and,O
documented,O
SARS,O
-,O
CoV-2,O
infection,O
or,O
COVID-19,O
disease,O
were,O
registered,O
in,O
the,O
UKCCMP,S-Repository
 ,O
database,O
from,O
March,O
18,O
",",O
2020,O
",",O
with,O
outcomes,O
censored,O
on,O
May,O
8,O
",",O
2020,O
.,O
Patients,O
were,O
followed,O
up,O
from,O
the,O
point,O
of,O
COVID-19,O
diagnosis,O
to,O
either,O
discharge,O
from,O
hospital,O
or,O
death,O
.,O
We,O
compared,O
the,O
demographics,O
and,O
cancer,O
subtype,O
of,O
patients,O
with,O
cancer,O
with,O
COVID-19,O
from,O
the,O
UKCCMP,S-Repository
 ,O
registry,O
with,O
those,O
from,O
the,O
population,O
of,O
patients,O
represented,O
in,O
the,O
ONS,O
cancer,O
census,O
",",O
which,O
was,O
used,O
as,O
a,O
control,O
group,O
.,O
We,O
found,O
that,O
patients,O
with,O
cancer,O
with,O
COVID-19,O
were,O
significantly,O
more,O
likely,O
to,O
be,O
men,O
(,O
595,O
[,O
56·9,O
%,O
],O
of,O
1044,O
UKCCMP,S-Repository
 ,O
patients,O
vs,O
145,O
 ,O
034,O
[,O
51·3,O
%,O
],O
of,O
282,O
 ,O
878,O
ONS,O
patients,O
;,O
OR,O
1·26,O
",",O
95,O
%,O
CI,O
1·12–1·43,O
;,O
p=0·0002,O
),O
compared,O
with,O
the,O
ONS,O
control,O
population,O
",",O
but,O
the,O
age,O
distribution,O
of,O
patients,O
with,O
cancer,O
who,O
contracted,O
COVID-19,O
did,O
not,O
differ,O
between,O
the,O
two,O
groups,O
(,O
appendix,O
p,O
2,O
),O
.,O
Patients,O
with,O
haematological,O
malignancies,O
appeared,O
to,O
be,O
at,O
significantly,O
increased,O
risk,O
of,O
COVID-19,O
infection,O
",",O
including,O
those,O
with,O
leukaemia,O
(,O
OR,O
2·82,O
",",O
95,O
%,O
CI,O
2·21–3·55,O
;,O
p<0·0001,O
),O
",",O
myeloma,O
(,O
2·03,O
",",O
1·42–2·83,O
;,O
p=0·0001,O
),O
",",O
and,O
lymphoma,O
(,O
1·63,O
",",O
1·28–2·06,O
;,O
p<0·0001,O
;,O
table,O
1,O
),O
.,O
By,O
contrast,O
",",O
patients,O
with,O
lung,O
cancer,O
and,O
prostate,O
cancer,O
were,O
relatively,O
under,O
-,O
represented,O
in,O
the,O
UKCCMP,S-Repository
 ,O
population,O
compared,O
with,O
the,O
control,O
ONS,O
population,O
(,O
table,O
1,O
),O
.,O
319,O
(,O
30·6,O
%,O
),O
of,O
1044,O
patients,O
in,O
the,O
UKCCMP,S-Repository
 ,O
cohort,O
died,O
",",O
295,O
(,O
92·5,O
%,O
),O
of,O
whom,O
had,O
a,O
cause,O
of,O
death,O
recorded,O
as,O
due,O
to,O
COVID-19,O
.,O
The,O
all,O
-,O
cause,O
case,O
–,O
fatality,O
rate,O
in,O
patients,O
with,O
cancer,O
after,O
COVID-19,O
infection,O
was,O
significantly,O
associated,O
with,O
increasing,O
age,O
(,O
figure,O
1,O
;,O
appendix,O
pp,O
2–3,O
),O
.,O
Additionally,O
",",O
the,O
all,O
-,O
cause,O
case,O
–,O
fatality,O
rate,O
in,O
patients,O
with,O
cancer,O
once,O
they,O
had,O
contracted,O
COVID-19,O
was,O
significantly,O
associated,O
with,O
sex,O
(,O
212,O
[,O
35·6,O
%,O
],O
of,O
595,O
male,O
patients,O
vs,O
105,O
[,O
23·6,O
%,O
],O
of,O
445,O
female,O
patients,O
;,O
OR,O
1·92,O
",",O
95,O
%,O
CI,O
1·51–2·45,O
;,O
p<0·0001,O
),O
.,O
On,O
univariable,O
analysis,O
",",O
we,O
observed,O
a,O
significantly,O
higher,O
risk,O
of,O
death,O
from,O
COVID-19,O
in,O
patients,O
with,O
prostate,O
cancer,O
(,O
OR,O
2·14,O
",",O
95,O
%,O
CI,O
1·17–3·96,O
;,O
p=0·014,O
),O
and,O
leukaemia,O
(,O
2·03,O
",",O
1·04–3·97,O
;,O
p=0·038,O
),O
",",O
and,O
a,O
significantly,O
lower,O
risk,O
of,O
death,O
from,O
COVID-19,O
for,O
patients,O
with,O
breast,O
cancer,O
(,O
0·53,O
",",O
0·28–1·00,O
;,O
p=0·049,O
),O
and,O
female,O
genital,O
cancers,O
(,O
0·36,O
",",O
0·13–0·87,O
;,O
p=0·031,O
;,O
table,O
2,O
;,O
figure,O
2,O
;,O
appendix,O
p,O
3,O
),O
.,O
In,O
multivariable,O
analyses,O
",",O
we,O
found,O
no,O
increased,O
case,O
–,O
fatality,O
rate,O
due,O
to,O
COVID-19,O
in,O
patients,O
with,O
lung,O
cancer,O
compared,O
with,O
the,O
rest,O
of,O
the,O
UKCCMP,S-Repository
 ,O
population,O
(,O
table,O
2,O
),O
.,O
We,O
undertook,O
a,O
specific,O
detailed,O
analysis,O
of,O
227,O
patients,O
with,O
haematological,O
malignancies,O
who,O
were,O
diagnosed,O
with,O
COVID-19,O
.,O
108,O
(,O
47·6,O
%,O
),O
of,O
227,O
patients,O
with,O
haematological,O
malignancies,O
had,O
received,O
recent,O
chemotherapy,O
within,O
4,O
weeks,O
of,O
COVID-19,O
presentation,O
",",O
compared,O
with,O
241,O
(,O
29·5,O
%,O
),O
of,O
817,O
patients,O
with,O
non,O
-,O
haematological,O
malignancies,O
(,O
appendix,O
p,O
5,O
),O
.,O
However,O
",",O
after,O
correction,O
for,O
age,O
and,O
sex,O
",",O
patients,O
with,O
haematological,O
malignancies,O
who,O
had,O
recent,O
chemotherapy,O
had,O
an,O
increased,O
risk,O
of,O
death,O
during,O
COVID-19,O
-,O
associated,O
hospital,O
admission,O
(,O
OR,O
2·09,O
",",O
95,O
%,O
CI,O
1·09–4·08,O
;,O
p=0·028,O
),O
.,O
Patients,O
with,O
haematological,O
malignancies,O
were,O
at,O
a,O
greater,O
risk,O
of,O
having,O
a,O
more,O
severe,O
COVID-19,O
clinical,O
phenotype,O
",",O
to,O
require,O
more,O
intensive,O
supportive,O
interventions,O
",",O
and,O
to,O
suffer,O
an,O
increased,O
risk,O
of,O
death,O
compared,O
with,O
patients,O
with,O
non,O
-,O
haematological,O
malignancies,O
.,O
In,O
multivariable,O
analyses,O
",",O
patients,O
with,O
leukaemia,O
had,O
a,O
significantly,O
higher,O
risk,O
of,O
COVID-19,O
-,O
related,O
death,O
",",O
after,O
taking,O
into,O
account,O
age,O
and,O
sex,O
.,O
15,O
",",O
16,O
However,O
",",O
this,O
finding,O
contrasts,O
with,O
the,O
results,O
of,O
an,O
American,O
cohort,O
study,O
",",O
which,O
did,O
not,O
suggest,O
increased,O
mortality,O
from,O
COVID-19,O
in,O
patients,O
with,O
haematological,O
malignancies,O
.,O
Large,O
COVID-19,O
cancer,O
cohorts,O
of,O
predominantly,O
solid,O
organ,O
tumours,O
have,O
shown,O
no,O
significant,O
excess,O
mortality,O
risk,O
from,O
recent,O
chemotherapy,O
.,O
Additionally,O
",",O
once,O
COVID-19,O
was,O
established,O
in,O
patients,O
with,O
lung,O
cancer,O
",",O
we,O
did,O
not,O
observe,O
an,O
increased,O
case,O
–,O
fatality,O
rate,O
compared,O
with,O
the,O
remaining,O
population,O
with,O
cancer,O
and,O
COVID-19,O
in,O
the,O
UKCCMP,S-Repository
 ,O
cohort,O
",",O
suggesting,O
that,O
patients,O
with,O
lung,O
cancer,O
are,O
not,O
a,O
specifically,O
susceptible,O
group,O
.,O
First,O
",",O
there,O
are,O
methodological,O
differences,O
in,O
our,O
study,O
;,O
we,O
compared,O
patients,O
with,O
lung,O
cancer,O
and,O
COVID-19,O
to,O
patients,O
with,O
cancer,O
without,O
COVID-19,O
",",O
rather,O
than,O
to,O
people,O
who,O
did,O
not,O
have,O
cancer,O
.,O
Third,O
",",O
lung,O
cancer,O
is,O
the,O
most,O
common,O
cancer,O
in,O
China,O
",",O
and,O
hence,O
would,O
be,O
over,O
-,O
represented,O
in,O
Chinese,O
patients,O
with,O
COVID-19,O
and,O
cancer,O
.,O
Additionally,O
",",O
we,O
observed,O
a,O
low,O
admission,O
rate,O
of,O
patients,O
with,O
cancer,O
to,O
the,O
intensive,O
care,O
unit,O
",",O
which,O
could,O
affect,O
COVID-19,O
outcomes,O
in,O
patients,O
with,O
cancer,O
in,O
the,O
UK,O
.,O
Background,O
 ,O
Patients,O
with,O
cancer,O
are,O
purported,O
to,O
have,O
poor,O
COVID-19,O
outcomes,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
investigate,O
COVID-19,O
risk,O
according,O
to,O
tumour,O
subtype,O
and,O
patient,O
demographics,O
in,O
patients,O
with,O
cancer,O
in,O
the,O
UK,O
.,O
We,O
compared,O
adult,O
patients,O
with,O
cancer,O
enrolled,O
in,O
the,O
UK,B-Repository
Coronavirus,I-Repository
Cancer,I-Repository
Monitoring,I-Repository
Project,I-Repository
(UKCCMP),E-Repository
 ,O
cohort,O
between,O
March,O
18,O
and,O
May,O
8,O
",",O
2020,O
",",O
with,O
a,O
parallel,O
non,O
-,O
COVID-19,O
UK,O
cancer,O
control,O
population,O
from,O
the,O
UK,B-Creator
Office,I-Creator
for,I-Creator
National,I-Creator
Statistics,E-Creator
 ,O
(,O
2017,O
data,O
),O
.,O
We,O
analysed,O
the,O
effect,O
of,O
tumour,O
subtype,O
and,O
patient,O
demographics,O
(,O
age,O
and,O
sex,O
),O
on,O
prevalence,O
and,O
mortality,O
from,O
COVID-19,O
using,O
univariable,O
and,O
multivariable,O
models,O
.,O
Findings,O
 ,O
319,O
(,O
30·6,O
%,O
),O
of,O
1044,O
patients,O
in,O
the,O
UKCCMP,S-Repository
 ,O
cohort,O
died,O
",",O
295,O
(,O
92·5,O
%,O
),O
of,O
whom,O
had,O
a,O
cause,O
of,O
death,O
recorded,O
as,O
due,O
to,O
COVID-19,O
.,O
Patients,O
with,O
haematological,O
malignancies,O
(,O
leukaemia,O
",",O
lymphoma,O
",",O
and,O
myeloma,O
),O
had,O
a,O
more,O
severe,O
COVID-19,O
trajectory,O
compared,O
with,O
patients,O
with,O
solid,O
organ,O
tumours,O
(,O
odds,O
ratio,O
[,O
OR,O
],O
1·57,O
",",O
95,O
%,O
CI,O
1·15–2·15,O
;,O
p<0·0043,O
),O
.,O
After,O
correction,O
for,O
age,O
and,O
sex,O
",",O
patients,O
with,O
haematological,O
malignancies,O
who,O
had,O
recent,O
chemotherapy,O
had,O
an,O
increased,O
risk,O
of,O
death,O
during,O
COVID-19,O
-,O
associated,O
hospital,O
admission,O
(,O
OR,O
2·09,O
",",O
95,O
%,O
CI,O
1·09–4·08,O
;,O
p=0·028,O
),O
.,O
Interpretation,O
 ,O
Patients,O
with,O
cancer,O
with,O
different,O
tumour,O
types,O
have,O
differing,O
susceptibility,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
COVID-19,O
phenotypes,O
.,O
Our,O
results,O
could,O
be,O
useful,O
to,O
assist,O
physicians,O
in,O
informed,O
risk,O
–,O
benefit,O
discussions,O
to,O
explain,O
COVID-19,O
risk,O
and,O
enable,O
an,O
evidenced,O
-,O
based,O
approach,O
to,O
national,O
social,O
isolation,O
policies,O
.,O
It,O
was,O
therefore,O
termed,O
SARS,O
-,O
CoV-2,O
and,O
the,O
disease,O
it,O
causes,O
was,O
named,O
COVID-19,O
(,O
Corona,O
Virus,O
Disease,O
2019,O
),O
[,O
3,O
],O
.,O
Several,O
real,O
time,O
RT,O
-,O
PCR,O
assays,O
protocols,O
for,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
RNA,O
have,O
been,O
developed,O
and,O
approved,O
from,O
Centers,O
for,O
Disease,O
Control,O
and,O
Prevention,O
Nucleic,O
acid,O
in,O
US,O
and,O
are,O
now,O
widely,O
employed,O
to,O
diagnose,O
COVID-19,O
disease,O
[,O
7,O
",",O
8,O
],O
.,O
Moreover,O
",",O
recent,O
meta,O
-,O
analysis,O
on,O
4243,O
COVID-19,O
patients,O
reported,O
that,O
stool,O
samples,O
from,O
48.1,O
%,O
of,O
patients,O
tested,O
positive,O
for,O
virus,O
RNA,O
",",O
among,O
these,O
patients,O
70.3,O
%,O
tested,O
positive,O
for,O
RNA,O
virus,O
even,O
after,O
respiratory,O
specimens,O
tested,O
negative,O
[,O
11,O
],O
.,O
Between,O
March,O
4,O
and,O
April,O
20,O
",",O
2020,O
",",O
we,O
collected,O
every,O
5,O
 ,O
days,O
respiratory,O
and,O
fecal,O
specimens,O
from,O
fifteen,O
COVID-19,O
patients,O
.,O
We,O
selected,O
15,O
positive,O
novel,O
coronavirus,O
disease,O
19,O
(,O
COVID-19,O
),O
patients,O
with,O
mild,O
or,O
no,O
symptom,O
.,O
Diagnostic,O
microbiology,O
:,O
Boosting,O
confidence,O
in,O
COVID-19,O
detection,O
 ,O
A,O
design,O
strategy,O
for,O
virus,O
detection,O
tests,O
could,O
lead,O
to,O
improved,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
coronavirus,O
.,O
Source,O
:,O
*,O
Ref,O
.,O
6,O
",",O
‡Ref,O
.,O
7,O
Multiple,O
sequence,O
alignment,O
of,O
21,O
full,O
genomes,O
obtained,O
and,O
1563,O
full,O
-,O
genome,O
sequences,O
(,O
Supplementary,O
Table,O
(,O
available,O
from,O
),O
),O
available,O
at,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
database,O
(,O
as,O
of,O
March,O
26,O
",",O
2020,O
),O
was,O
carried,O
out,O
in,O
MAFFT,O
v.7.4509,O
.,O
This,O
tree,O
was,O
used,O
to,O
reduce,O
the,O
dataset,O
to,O
121,O
sequences,O
",",O
on,O
the,O
basis,O
of,O
country,O
and,O
the,O
genetic,O
variant,O
identified,O
based,O
on,O
the,O
GISAID,S-Dataset
 ,O
classification,O
.,O
Phylogenetic,O
trees,O
based,O
on,O
full,O
-,O
genome,O
sequences,O
deposited,O
and,O
available,O
at,O
GISAID,S-Dataset
 ,O
revealed,O
the,O
diversification,O
and,O
the,O
clustering,O
of,O
sequences,O
into,O
groups,O
",",O
based,O
on,O
the,O
genetic,O
variants,O
.,O
To,O
date,O
",",O
there,O
are,O
no,O
other,O
sequences,O
from,O
Iran,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
.,O
Since,O
December,O
2019,O
",",O
the,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
due,O
to,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
originating,O
from,O
Wuhan,O
",",O
China,O
",",O
has,O
been,O
causing,O
a,O
pandemic,O
across,O
the,O
world,O
[,O
"1,2",O
],O
.,O
MT451874,S-AccessionNumber
",",O
MT451876,S-AccessionNumber
",",O
MT451877,S-AccessionNumber
",",O
MT451878,S-AccessionNumber
",",O
MT451880,S-AccessionNumber
",",O
MT451881,S-AccessionNumber
",",O
MT451882,S-AccessionNumber
",",O
MT451883,S-AccessionNumber
",",O
MT451884,S-AccessionNumber
",",O
MT451885,S-AccessionNumber
",",O
MT451886,S-AccessionNumber
",",O
MT451887,S-AccessionNumber
",",O
MT451888,S-AccessionNumber
",",O
MT451889,S-AccessionNumber
",",O
MT451890,S-AccessionNumber
",",O
MT435079,S-AccessionNumber
",",O
MT435080,S-AccessionNumber
",",O
MT435081,S-AccessionNumber
",",O
MT435082,S-AccessionNumber
",",O
MT435083,S-AccessionNumber
",",O
MT435084,S-AccessionNumber
",",O
MT435085,S-AccessionNumber
",",O
MT435086,S-AccessionNumber
",",O
MT415320,S-AccessionNumber
",",O
MT415321,S-AccessionNumber
",",O
MT415322,S-AccessionNumber
",",O
MT415323,S-AccessionNumber
",",O
MT358637,S-AccessionNumber
",",O
MT012098,S-AccessionNumber
 ,O
and,O
MT050493,S-AccessionNumber
 ,O
of,O
SARS,O
-,O
CoV2,O
from,O
Indian,O
patients,O
are,O
available,O
in,O
the,O
NCBI,S-Repository
 ,O
database,O
and,O
that,O
are,O
considered,O
for,O
this,O
present,O
study,O
[,O
25,O
],O
.,O
It,O
is,O
worth,O
mentioning,O
that,O
the,O
OF3a,O
-,O
Type-3,O
and,O
ORF3a,O
-,O
Type-4,O
genes,O
were,O
blasted,O
in,O
the,O
NCBI,S-Repository
 ,O
database,O
and,O
do,O
not,O
find,O
any,O
100,O
%,O
similar,O
sequence,O
with,O
100,O
%,O
query,O
coverage,O
.,O
The,O
numbers,O
1,O
",",O
2,O
",",O
3,O
",",O
denote,O
the,O
ORF3a,O
gene,O
/,O
Genome,O
ID,O
from,O
the,O
top,O
to,O
bottom,O
of,O
the,O
first,O
column,O
of,O
Table,O
6,O
",",O
respectively,O
.,O
A,O
global,O
emergency,O
due,O
to,O
the,O
COVID-19,O
pandemic,O
demands,O
various,O
studies,O
related,O
to,O
genes,O
and,O
genomes,O
of,O
the,O
SARS,O
-,O
CoV2,O
.,O
We,O
read,O
with,O
interest,O
a,O
recent,O
article,O
in,O
this,O
journal,O
regarding,O
co,O
-,O
infections,O
in,O
people,O
with,O
COVID-19,O
.,O
Rapid,O
and,O
simultaneous,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
",",O
the,O
cause,O
of,O
COVID-19,O
",",O
and,O
co,O
-,O
infections,O
is,O
essential,O
for,O
clinical,O
management,O
of,O
COVID-19,O
patients,O
.,O
Detection,O
of,O
SARS,O
-,O
CoV-2,O
and,O
co,O
-,O
infections,O
in,O
the,O
obtained,O
sequence,O
data,O
was,O
carried,O
out,O
using,O
a,O
combination,O
of,O
publically,O
availably,O
pipelines,O
namely,O
IDseq,O
(,O
idseq.net,O
),O
and,O
DISCVR,O
(,O
https://bioinformatics.cvr.ac.uk/software/discvr/,O
),O
.,O
SARS,O
-,O
CoV-2,O
was,O
detected,O
in,O
sequence,O
data,O
obtained,O
from,O
all,O
eight,O
RT,O
-,O
PCR,O
positive,O
NTS,O
samples,O
by,O
both,O
IDseq,O
and,O
DISCVR,O
",",O
but,O
not,O
in,O
the,O
NTS,O
sample,O
.,O
Notably,O
",",O
the,O
vast,O
majority,O
of,O
SARS,O
-,O
CoV-2,O
infections,O
are,O
asymptomatic,O
or,O
mild,O
",",O
while,O
COVID-19,O
patients,O
present,O
with,O
signs,O
/,O
symptoms,O
undistinguished,O
with,O
respiratory,O
diseases,O
caused,O
by,O
other,O
viruses,O
.,O
The,O
rapid,O
spread,O
of,O
the,O
COVID-19,O
pandemic,O
is,O
a,O
sparking,O
challenge,O
for,O
the,O
entire,O
world,O
",",O
and,O
climate,O
change,O
may,O
also,O
affect,O
the,O
emergence,O
of,O
this,O
novel,O
coronavirus,O
.,O
The,O
recent,O
emerging,O
evidences,O
suggested,O
that,O
the,O
transmission,O
of,O
COVID-19,O
is,O
associated,O
with,O
weather,O
conditions,O
",",O
with,O
dry,O
and,O
cold,O
conditions,O
appeared,O
to,O
boost,O
the,O
spreading,O
of,O
the,O
infections,O
.,O
Moreover,O
",",O
the,O
per,O
day,O
mortality,O
rate,O
of,O
COVID-19,O
is,O
positively,O
associated,O
with,O
diurnal,O
temperature,O
range,O
(,O
DTR,O
),O
but,O
negatively,O
with,O
relative,O
humidity,O
.,O
Therefore,O
",",O
this,O
study,O
has,O
targeted,O
the,O
genome,O
-,O
wide,O
mutational,O
spectra,O
covering,O
nucleotide,O
",",O
aa,O
and,O
deletion,O
mutations,O
in,O
"2,492",O
complete,O
(,O
and/or,O
near,O
complete,O
),O
genomes,O
of,O
SARS,O
-,O
CoV-2,O
retrieved,O
from,O
the,O
global,B-Dataset
initiative,I-Dataset
on,I-Dataset
sharing,I-Dataset
all,I-Dataset
influenza,I-Dataset
data,I-Dataset
(GISAID),E-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
up,O
to,O
30,O
March,O
2020,O
(,O
Supplementary,O
Fig,O
.,O
 ,O
1,O
",",O
Supplementary,O
Table,O
1a,O
),O
.,O
Nucleotide,O
(,O
nt,O
),O
sequence,O
alignment,O
revealed,O
a,O
total,O
of,O
"1,516",O
mutations,O
(,O
synonymous,O
vs,O
nonsynonymous,O
ratio,O
 ,O
=,O
 ,O
2.5:1,O
),O
across,O
the,O
entire,O
set,O
of,O
genomes,O
of,O
the,O
SARS,O
-,O
CoV-2,O
strains,O
compared,O
to,O
the,O
NCBI,S-Repository
 ,O
reference,O
strain,O
",",O
Wuhan,O
-,O
Hu-1,O
(,O
Accession,O
NC_045512,S-AccessionNumber
),O
.,O
To,O
our,O
knowledge,O
and,O
based,O
on,O
this,O
dataset,O
",",O
the,O
24,O
-,O
nt,O
deletion,O
(,O
G32,O
:,O
L39,O
),O
is,O
only,O
found,O
in,O
Japanese,O
strain,O
.,O
Also,O
",",O
the,O
high,O
morbidity,O
and,O
mortality,O
of,O
immune,O
-,O
compromised,O
patients,O
infected,O
by,O
COVID-19,O
might,O
be,O
correlated,O
with,O
the,O
disastrous,O
consequences,O
of,O
these,O
mutations,O
.,O
Further,O
phylogenic,O
study,O
targeting,O
those,O
unique,O
mutations,O
may,O
guide,O
to,O
proper,O
global,O
phylodynamics,O
of,O
the,O
virus,O
and,O
modulate,O
the,O
regional,O
control,O
strategy,O
against,O
the,O
COVID-19,O
pandemic,O
.,O
Temperate,O
European,O
countries,O
such,O
as,O
Italy,O
",",O
Spain,O
",",O
France,O
",",O
Netherlands,O
and,O
England,O
are,O
major,O
COVID-19,O
infected,O
countries,O
with,O
higher,O
mortality,O
rates,O
at,O
this,O
initial,O
stage,O
.,O
Regardless,O
of,O
the,O
importance,O
of,O
geography,O
on,O
the,O
COVID-19,O
 ,O
epidemiology,O
",",O
the,O
effects,O
of,O
global,O
mobility,O
upon,O
the,O
genetic,O
diversity,O
and,O
molecular,O
evolution,O
of,O
SARS,O
-,O
CoV-2,O
are,O
underappreciated,O
and,O
only,O
beginning,O
to,O
be,O
comprehended,O
.,O
Moreover,O
",",O
the,O
recent,O
monograph,O
on,O
the,O
spatial,O
epidemiology,O
of,O
COVID-19,O
makes,O
no,O
reference,O
to,O
the,O
genetic,O
variation,O
of,O
SARS,O
-,O
CoV-2,O
.,O
To,O
decipher,O
the,O
genetic,O
variations,O
",",O
we,O
retrieved,O
two,O
thousand,O
four,O
hundred,O
and,O
ninety,O
-,O
two,O
(,O
n,O
 ,O
=,O
 ,O
"2,492",O
),O
complete,O
or,O
near,O
-,O
complete,O
genomes,O
of,O
SARS,O
-,O
CoV-2,O
available,O
at,O
the,O
global,B-Dataset
initiative,I-Dataset
on,I-Dataset
sharing,I-Dataset
all,I-Dataset
influenza,I-Dataset
data,I-Dataset
(GISAID),E-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
up,O
to,O
30,O
March,O
2020,O
.,O
To,O
estimate,O
the,O
case,O
fatality,O
(,O
mortality,O
),O
rates,O
of,O
SARS,O
-,O
CoV-2,O
infections,O
",",O
we,O
collected,O
information,O
on,O
total,O
infected,O
cases,O
",",O
and,O
total,O
reported,O
deaths,O
in,O
these,O
countries,O
from,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
COVID-19,O
Reports,O
up,O
to,O
March,O
30,O
",",O
2020,O
.,O
We,O
aligned,O
the,O
SARS,O
-,O
CoV-2,O
genome,O
sequences,O
using,O
MAFFT,O
online,O
server,O
using,O
default,O
parameters,O
",",O
and,O
the,O
complete,O
genome,O
sequence,O
SARS,O
-,O
CoV-2,O
Wuhan,O
-,O
Hu-1,O
strain,O
(,O
Accession,O
NC_045512,S-AccessionNumber
",",O
Version,O
NC_045512.2,S-AccessionNumber
),O
was,O
used,O
as,O
a,O
reference,O
genome,O
.,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus-2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
a,O
novel,O
evolutionary,O
divergent,O
RNA,O
virus,O
",",O
is,O
responsible,O
for,O
the,O
present,O
devastating,O
COVID-19,O
pandemic,O
.,O
To,O
explore,O
the,O
genomic,O
signatures,O
",",O
we,O
comprehensively,O
analyzed,O
"2,492",O
complete,O
and/or,O
near,O
-,O
complete,O
genome,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
strains,O
reported,O
from,O
across,O
the,O
globe,O
to,O
the,O
GISAID,S-Dataset
 ,O
database,O
up,O
to,O
30,O
March,O
2020,O
.,O
We,O
used,O
the,O
complete,O
genome,O
sequence,O
SARS,O
-,O
CoV-2,O
Wuhan,O
-,O
Hu-1,O
strain,O
(,O
Accession,O
NC_045512,S-AccessionNumber
",",O
Version,O
NC_045512.2,S-AccessionNumber
),O
as,O
a,O
reference,O
genome,O
.,O
The,O
annotated,O
genomes,O
(,O
n,O
 ,O
=,O
 ,O
"2,492",O
),O
have,O
been,O
retrieved,O
from,O
publicly,O
open,O
database,O
",",O
the,O
global,B-Dataset
initiative,I-Dataset
on,I-Dataset
sharing,I-Dataset
all,I-Dataset
influenza,I-Dataset
data,I-Dataset
(GISAID),E-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
up,O
to,O
March,O
30,O
",",O
2020,O
.,O
Further,O
information,O
regarding,O
the,O
accession,O
numbers,O
of,O
the,O
studied,O
genomes,O
could,O
be,O
found,O
in,O
the,O
Supplementary,O
Data,O
1,O
.,O
In,O
December,O
2019,O
",",O
a,O
coronavirus,O
disease,O
(,O
named,O
as,O
COVID-19,O
later,O
),O
was,O
reported,O
in,O
Wuhan,O
city,O
",",O
which,O
rapidly,O
spread,O
throughout,O
China,O
and,O
then,O
to,O
many,O
other,O
countries,O
in,O
the,O
world,O
(,O
Li,O
et,O
 ,O
al,O
.,O
",",O
2020a,O
",",O
Zhu,O
et,O
 ,O
al,O
.,O
",",O
2020b,O
),O
.,O
The,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
declared,O
COVID-19,O
as,O
a,O
pandemic,O
on,O
March,O
11,O
",",O
2020,O
.,O
The,O
HFH4,O
-,O
hACE2,O
mice,O
were,O
intranasally,O
infected,O
with,O
3,O
×,O
104,O
TCID50,O
virus,O
each,O
and,O
sacrificed,O
to,O
collect,O
tissue,O
and,O
blood,O
samples,O
at,O
1,O
",",O
3,O
",",O
5,O
",",O
and,O
7,O
 ,O
days,O
post,O
-,O
infection,O
(,O
DPI,O
),O
(,O
Figure,O
 ,O
1,O
A,O
),O
.,O
All,O
the,O
dying,O
mice,O
(,O
dead,O
or,O
lost,O
>,O
20,O
%,O
body,O
weigh,O
),O
showed,O
significantly,O
decreased,O
lymphocyte,O
numbers,O
",",O
which,O
is,O
one,O
of,O
the,O
key,O
clinical,O
hallmarks,O
of,O
COVID-19,O
patients,O
(,O
Wang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
lung,O
isolates,O
indicated,O
two,O
mutations,O
",",O
C14554,O
T,O
(,O
nsp13,O
",",O
L372F,O
),O
and,O
C23525,O
T,O
(,O
spike,O
",",O
H644Y,O
),O
",",O
compared,O
with,O
the,O
genome,O
 ,O
of,O
SARS,O
-,O
CoV-2,O
-,O
WIV04,O
(,O
GISAID,S-Dataset
:,O
EPI_ISL_402124,S-AccessionNumber
),O
.,O
The,O
viral,O
titers,O
in,O
the,O
infected,O
lung,O
ranged,O
from,O
9.4,O
 ,O
×,O
103,O
to,O
9.1,O
 ,O
×,O
105TCID50,O
per,O
gram,O
of,O
tissue,O
",",O
as,O
determined,O
by,O
serial,O
dilution,O
of,O
VeroE6,O
cell,O
lines,O
(,O
Figure,O
 ,O
S5,O
),O
.,O
These,O
mice,O
generated,O
antibodies,O
against,O
SARS,O
-,O
CoV-2,O
that,O
could,O
neutralize,O
100,O
TCID50,O
viruses,O
at,O
dilutions,O
of,O
1:10,O
to,O
1:40,O
(,O
Table,O
S4,O
),O
.,O
We,O
then,O
intranasally,O
infected,O
the,O
three,O
SARS,O
-,O
CoV-2,O
survivors,O
and,O
another,O
three,O
healthy,O
mice,O
with,O
7,O
×,O
105,O
TCID50,O
virus,O
/,O
each,O
.,O
COVID-19,O
patients,O
commonly,O
exhibit,O
pneumonia,O
with,O
typical,O
signs,O
including,O
fever,O
",",O
cough,O
",",O
dyspnea,O
",",O
and,O
bilateral,O
lung,O
infiltration,O
(,O
Guan,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Some,O
alveolar,O
cells,O
were,O
dissolved,O
and,O
necrotic,O
",",O
and,O
some,O
terminal,O
bronchioles,O
were,O
blocked,O
",",O
which,O
simulated,O
the,O
pathological,O
findings,O
in,O
COVID-19,O
patients,O
(,O
Xu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
During,O
routine,O
blood,O
examination,O
",",O
lymphopenia,O
is,O
a,O
common,O
feature,O
in,O
COVID-19,O
patients,O
",",O
and,O
some,O
patients,O
had,O
high,O
-,O
level,O
aspartate,O
 ,O
amino,O
 ,O
transferase,O
 ,O
(,O
AST,O
),O
and,O
creatine,O
kinase,O
(,O
CK,O
),O
(,O
Chen,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Guan,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
There,O
are,O
few,O
reports,O
about,O
organ,O
tropism,O
of,O
virus,O
infection,O
in,O
the,O
patients,O
of,O
COVID-19,O
",",O
but,O
multiple,O
organ,O
infections,O
have,O
been,O
reported,O
in,O
SARS,O
patients,O
(,O
Gu,O
et,O
 ,O
al,O
.,O
",",O
2005,O
),O
.,O
In,O
summary,O
",",O
a,O
human,O
ACE2,O
mouse,O
model,O
that,O
partially,O
simulated,O
the,O
pathology,O
of,O
COVID-19,O
",",O
will,O
be,O
a,O
valuable,O
platform,O
for,O
testing,O
vaccines,O
and,O
other,O
potential,O
therapeutics,O
.,O
The,O
successful,O
establishment,O
of,O
an,O
animal,O
model,O
for,O
COVID-19,O
pathogenesis,O
will,O
be,O
valuable,O
for,O
evaluating,O
vaccines,O
and,O
therapeutics,O
to,O
combat,O
SARS,O
-,O
CoV-2,O
.,O
Three,O
days,O
after,O
inoculation,O
",",O
CPE,O
was,O
scored,O
",",O
and,O
the,O
Reed,O
-,O
Muench,O
formula,O
was,O
used,O
to,O
calculate,O
the,O
TCID50,O
.,O
Mice,O
were,O
anaesthetised,O
with,O
tribromoethanol,O
(,O
Avertin,O
),O
(,O
250,O
 ,O
mg,O
/,O
kg,O
),O
and,O
intranasally,O
infected,O
with,O
3∗104,O
TCID50,O
(,O
for,O
naive,O
infection,O
),O
or,O
7∗105,O
TCID50,O
(,O
for,O
the,O
viral,O
challenge,O
),O
SARS,O
-,O
CoV-2,O
in,O
50,O
 ,O
μL,O
DMEM,O
per,O
mouse,O
.,O
COVID-19,O
has,O
spread,O
worldwide,O
since,O
2019,O
and,O
is,O
now,O
a,O
severe,O
threat,O
to,O
public,O
health,O
.,O
The,O
infected,O
mice,O
generated,O
typical,O
interstitial,O
pneumonia,O
and,O
pathology,O
that,O
were,O
similar,O
to,O
those,O
of,O
COVID-19,O
patients,O
.,O
Graphical,O
Abstract,O
     ,O
A,O
SARS,O
-,O
CoV-2,O
hACE2,O
transgenic,O
mouse,O
infection,O
model,O
recapitulates,O
a,O
number,O
of,O
infection,O
symptoms,O
and,O
pathology,O
in,O
COVID-19,O
patients,O
.,O
Some,O
studies,O
listed,O
platelet,O
counting,O
as,O
economic,O
",",O
ubiquitous,O
and,O
ephemeral,O
in,O
discriminating,O
the,O
coronavirus,O
disease,O
(,O
COVID,O
),O
into,O
severe,O
/,O
moderate,O
as,O
thrombocytopenia,O
is,O
linked,O
to,O
COVID-19,O
[,O
6,O
],O
.,O
We,O
have,O
postulated,O
virion,O
propagation,O
and,O
causes,O
of,O
pneumonia,O
in,O
COVID-19,O
.,O
This,O
",",O
in,O
turn,O
",",O
led,O
to,O
inflammation,O
and,O
loss,O
of,O
platelets,O
via,O
deposition,O
in,O
peripheral,O
microvascular,O
beds,O
",",O
thereby,O
heralding,O
symptom,O
-,O
thrombocytopenia,O
and,O
intravascular,O
coagulopathy,O
in,O
COVID-19,O
.,O
Severe,O
acute,O
 ,O
respiratory,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
a,O
single,O
-,O
stranded,O
RNA,O
virus,O
that,O
binds,O
to,O
the,O
angiotensin,O
-,O
converting,O
enzyme,O
2,O
receptor,O
and,O
causes,O
the,O
illness,O
called,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
has,O
precipitated,O
devastating,O
personal,O
",",O
economic,O
",",O
and,O
societal,O
repercussions,O
worldwide.1,O
",",O
2,O
",",O
3,O
",",O
4,O
SARS,O
-,O
CoV-2,O
usually,O
causes,O
a,O
 ,O
mild,O
",",O
self,O
-,O
limited,O
illness,O
",",O
but,O
approximately,O
15,O
%,O
of,O
affected,O
individuals,O
have,O
a,O
more,O
severe,O
",",O
sometimes,O
life,O
-,O
threatening,O
course,O
",",O
with,O
the,O
risk,O
of,O
poor,O
outcomes,O
increasing,O
with,O
age,O
and,O
comorbidities,O
.,O
5,O
",",O
6,O
",",O
7,O
Diffuse,O
alveolar,O
damage,O
and,O
acute,O
respiratory,O
distress,O
syndrome,O
are,O
the,O
most,O
common,O
presentations,O
in,O
severe,O
COVID-19,O
.,O
Profound,O
dysregulation,O
of,O
innate,O
and,O
acquired,O
immunity,O
can,O
occur,O
with,O
more,O
severe,O
COVID-19,O
",",O
including,O
significant,O
lymphopenia,O
as,O
a,O
direct,O
result,O
of,O
viral,O
-,O
induced,O
apoptosis,O
and,O
necrosis,O
of,O
lymphocytes,O
in,O
the,O
spleen,O
and,O
lymph,O
nodes,O
.,O
The,O
persistent,O
interferon,O
response,O
can,O
result,O
in,O
systemic,O
hyperinflammation,O
",",O
also,O
known,O
as,O
cytokine,O
storm,O
.,O
",",O
 ,O
Several,O
of,O
the,O
cytokines,O
elevated,O
in,O
severe,O
COVID-19,O
patients,O
(,O
tumor,O
necrosis,O
factor,O
[,O
TNF,O
],O
",",O
interleukin,O
6,O
",",O
and,O
interleukin,O
17,O
),O
are,O
also,O
elevated,O
in,O
patients,O
with,O
psoriatic,O
disease,O
.,O
15,O
",",O
16,O
",",O
17,O
The,O
current,O
model,O
of,O
COVID-19,O
is,O
that,O
immune,O
suppression,O
in,O
early,O
infection,O
may,O
be,O
harmful,O
by,O
allowing,O
uncontrolled,O
SARS,O
-,O
CoV-2,O
replication,O
and,O
dissemination,O
but,O
may,O
be,O
helpful,O
in,O
severe,O
illness,O
by,O
limiting,O
organ,O
damage,O
from,O
a,O
dysregulated,O
hyperimmune,O
response,O
.,O
Many,O
treatments,O
used,O
for,O
psoriatic,O
disease,O
directly,O
or,O
indirectly,O
impact,O
immune,O
pathways,O
involved,O
in,O
COVID-19.19,O
",",O
20,O
",",O
21,O
",",O
22,O
Patients,O
and,O
providers,O
are,O
concerned,O
about,O
the,O
safety,O
of,O
immunomodulating,O
agents,O
in,O
the,O
setting,O
of,O
the,O
COVID-19,O
pandemic,O
.,O
These,O
concerns,O
are,O
particularly,O
relevant,O
given,O
that,O
many,O
of,O
the,O
comorbidities,O
associated,O
with,O
psoriasis,O
and,O
psoriatic,O
 ,O
arthritis,O
",",O
including,O
obesity,O
",",O
diabetes,O
",",O
and,O
cardiovascular,O
disease,O
",",O
are,O
risk,O
factors,O
for,O
the,O
development,O
of,O
severe,O
COVID-19,O
.,O
",",O
To,O
address,O
the,O
questions,O
posed,O
by,O
patients,O
and,O
providers,O
",",O
the,O
National,O
Psoriasis,O
Foundation,O
(,O
NPF,O
),O
commissioned,O
a,O
COVID-19,O
task,O
force,O
(,O
TF,O
),O
to,O
develop,O
scientifically,O
based,O
guidance,O
that,O
promotes,O
optimal,O
management,O
of,O
psoriatic,O
disease,O
during,O
the,O
pandemic,O
.,O
Patients,O
with,O
psoriatic,O
disease,O
appear,O
to,O
have,O
similar,O
rates,O
of,O
infection,O
with,O
SARS,O
-,O
CoV-2,O
and,O
COVID-19,O
outcomes33,O
",",O
34,O
",",O
35,O
",",O
36,O
",",O
37,O
as,O
the,O
general,O
population,O
(,O
Guidance,O
1.1,O
),O
.,O
First,O
",",O
a,O
few,O
reports,O
suggest,O
that,O
patients,O
with,O
psoriasis,O
may,O
be,O
more,O
prone,O
to,O
infection,O
with,O
COVID-19,O
or,O
have,O
worse,O
outcomes.38,O
",",O
39,O
",",O
40,O
For,O
example,O
",",O
a,O
United,O
Kingdom,O
study,O
with,O
more,O
than,O
17,O
million,O
patients,O
found,O
a,O
small,O
but,O
statistically,O
increased,O
risk,O
of,O
death,O
from,O
COVID-19,O
(,O
fully,O
adjusted,O
hazards,O
ratio,O
",",O
1.19,O
;,O
95,O
%,O
confidence,O
interval,O
",",O
1.11,O
-,O
1.27,O
),O
in,O
individuals,O
with,O
psoriasis,O
",",O
rheumatoid,O
arthritis,O
",",O
or,O
lupus,O
.,O
Additionally,O
",",O
patients,O
with,O
psoriatic,O
disease,O
may,O
be,O
prone,O
to,O
thrombotic,O
complications,O
that,O
can,O
also,O
occur,O
in,O
COVID-19.41,O
",",O
42,O
",",O
43,O
",",O
44,O
",",O
45,O
",",O
46,O
",",O
47,O
",",O
48,O
",",O
49,O
",",O
50,O
",",O
51,O
",",O
52,O
",",O
53,O
",",O
54,O
",",O
55,O
There,O
was,O
unanimous,O
agreement,O
that,O
severity,O
of,O
COVID-19,O
is,O
driven,O
by,O
risk,O
factors,O
such,O
as,O
older,O
age,O
and,O
comorbidities,O
(,O
Guidance,O
1.2,O
),O
.,O
",",O
",",O
56,O
",",O
57,O
",",O
58,O
",",O
59,O
Psoriatic,O
disease,O
—,O
particularly,O
severe,O
psoriasis,O
—,O
is,O
associated,O
with,O
many,O
of,O
the,O
comorbidities,O
that,O
drive,O
COVID-19,O
mortality,O
.,O
",",O
",",O
The,O
existing,O
literature,O
suggests,O
that,O
treatments,O
for,O
psoriasis,O
or,O
psoriatic,O
arthritis,O
",",O
or,O
both,O
",",O
do,O
not,O
meaningfully,O
alter,O
the,O
risk,O
of,O
acquiring,O
SARS,O
-,O
CoV-2,O
infection,O
or,O
having,O
worse,O
COVID-19,O
outcomes,O
(,O
Guidance,O
2.1,O
),O
.,O
",",O
",",O
61,O
",",O
62,O
",",O
63,O
",",O
64,O
",",O
65,O
",",O
66,O
",",O
67,O
",",O
68,O
",",O
69,O
",",O
70,O
",",O
71,O
",",O
72,O
",",O
73,O
",",O
74,O
",",O
75,O
",",O
76,O
",",O
77,O
",",O
78,O
",",O
79,O
",",O
80,O
",",O
81,O
",",O
82,O
",",O
83,O
",",O
84,O
",",O
85,O
Cyclosporine,O
",",O
the,O
most,O
broadly,O
immunosuppressive,O
of,O
psoriasis,O
treatments,O
",",O
was,O
not,O
found,O
to,O
alter,O
the,O
risk,O
of,O
COVID-19,O
in,O
130,O
patients,O
in,O
Italy,O
with,O
psoriasis,O
or,O
atopic,O
dermatitis,O
(,O
2,O
became,O
infected,O
with,O
SARS,O
-,O
CoV-2,O
and,O
recovered,O
without,O
hospitalization,O
),O
.,O
One,O
study,O
suggested,O
that,O
patients,O
with,O
psoriasis,O
on,O
biologics,O
were,O
more,O
likely,O
to,O
be,O
hospitalized,O
for,O
COVID-19,O
but,O
did,O
not,O
adjust,O
for,O
risk,O
factors,O
known,O
to,O
drive,O
poor,O
COVID-19,O
outcomes,O
.,O
The,O
rheumatology,O
literature,O
also,O
suggests,O
that,O
treatments,O
used,O
for,O
psoriatic,O
disease,O
",",O
such,O
as,O
TNF,O
inhibitors,O
and,O
methotrexate,O
",",O
do,O
not,O
negatively,O
impact,O
"COVID-19,87",O
",",O
88,O
",",O
89,O
",",O
90,O
with,O
1,O
large,O
registry,O
(,O
600,O
case,O
reports,O
from,O
40,O
countries,O
),O
finding,O
that,O
TNF,O
inhibitors,O
are,O
associated,O
with,O
a,O
reduced,O
adjusted,O
odds,O
of,O
COVID-19,O
hospitalization,O
compared,O
with,O
patients,O
with,O
rheumatic,O
conditions,O
not,O
treated,O
with,O
TNF,O
inhibitors,O
.,O
Similarly,O
",",O
adverse,O
effects,O
of,O
TNF,O
inhibitors,O
on,O
COVID-19,O
were,O
not,O
observed,O
in,O
large,O
registries,O
of,O
patients,O
with,O
inflammatory,O
bowel,O
disease,O
.,O
",",O
 ,O
Small,O
case,O
series,O
have,O
reported,O
poor,O
COVID-19,O
outcomes,O
in,O
patients,O
on,O
Janus,O
kinase,O
inhibitors,O
for,O
psoriatic,O
arthritis,O
and,O
secukinumab,O
for,O
ankylosing,O
spondylitis,O
;,O
however,O
",",O
these,O
isolated,O
reports,O
could,O
be,O
due,O
to,O
selection,O
bias,O
",",O
chance,O
",",O
or,O
underlying,O
comorbidity,O
.,O
By,O
contrast,O
",",O
an,O
analysis,O
of,O
approximately,O
1400,O
patients,O
from,O
the,O
rheumatology,O
",",O
gastroenterology,O
",",O
and,O
dermatology,O
literature,O
concluded,O
that,O
biologic,O
or,O
targeted,O
synthetic,O
disease,O
-,O
modifying,O
antirheumatic,O
drug,O
therapy,O
has,O
not,O
 ,O
been,O
associated,O
with,O
more,O
severe,O
COVID-19,O
outcomes,O
.,O
By,O
contrast,O
",",O
studies,O
in,O
the,O
rheumatology,O
and,O
gastroenterology,O
literature,O
have,O
observed,O
that,O
long,O
-,O
term,O
use,O
of,O
oral,O
corticosteroids,O
is,O
associated,O
with,O
worse,O
COVID-19,O
outcomes,O
(,O
ie,O
",",O
hospitalization,O
or,O
a,O
composite,O
outcome,O
of,O
 ,O
any,O
or,O
all,O
of,O
intensive,O
care,O
unit,O
admission,O
",",O
ventilator,O
use,O
",",O
or,O
death,O
),O
.,O
",",O
Psoriasis,O
",",O
even,O
when,O
involving,O
the,O
face,O
or,O
hands,O
",",O
is,O
not,O
a,O
contraindication,O
to,O
face,O
coverings,O
and,O
hand,O
washing,O
",",O
respectively,O
",",O
and,O
a,O
variety,O
of,O
approaches,O
can,O
be,O
applied,O
to,O
mitigate,O
skin,O
irritation,O
(,O
E,O
-,O
Table,O
 ,O
VII,O
",",O
available,O
via,O
Mendeley,B-Repository
Data,E-Repository
",",O
V2,O
",",O
at,O
https://doi.org/10.17632/w5m8jf94m8,S-DOI
),O
.106,O
",",O
107,O
",",O
108,O
Patients,O
with,O
psoriatic,O
disease,O
should,O
receive,O
the,O
seasonal,O
inactivated,O
(,O
eg,O
",",O
killed,O
),O
influenza,O
vaccine,O
",",O
which,O
is,O
of,O
special,O
importance,O
to,O
individual,O
and,O
public,O
health,O
during,O
the,O
COVID-19,O
pandemic,O
(,O
Guidance,O
4.4,O
),O
.,O
Patients,O
with,O
psoriatic,O
disease,O
who,O
become,O
infected,O
with,O
SARS,O
-,O
CoV-2,O
should,O
monitor,O
their,O
symptoms,O
(,O
Supplemental,O
E,O
-,O
Table,O
VIII,O
),O
",",O
discuss,O
management,O
of,O
their,O
psoriatic,O
disease,O
treatments,O
with,O
their,O
health,O
care,O
providers,O
",",O
and,O
should,O
be,O
prescribed,O
and,O
adhere,O
to,O
evidence,O
-,O
based,O
COVID-19,O
treatments,O
",",O
if,O
available,O
(,O
Guidance,O
5.1,O
and,O
5.2,O
),O
.,O
",",O
110,O
",",O
111,O
",",O
112,O
The,O
mortality,O
benefit,O
of,O
initiation,O
of,O
corticosteroids,O
in,O
patients,O
with,O
severe,O
COVID-19,O
outweighs,O
the,O
risks,O
of,O
potentially,O
precipitating,O
a,O
psoriasis,O
flare,O
",",O
and,O
therefore,O
",",O
acute,O
systemic,O
corticosteroids,O
are,O
not,O
contraindicated,O
for,O
the,O
management,O
of,O
COVID-19,O
in,O
patients,O
with,O
psoriatic,O
disease,O
(,O
Guidance,O
5.3,O
),O
.,O
Consistent,O
with,O
guidance,O
from,O
the,O
Food,O
and,O
Drug,O
Administration,O
and,O
the,O
American,O
College,O
of,O
Physicians,O
",",O
the,O
use,O
of,O
hydroxychloroquine,O
or,O
chloroquine,O
is,O
not,O
recommended,O
to,O
prevent,O
or,O
treat,O
COVID-19,O
in,O
patients,O
with,O
psoriatic,O
disease,O
outside,O
of,O
a,O
clinical,O
trial,O
(,O
guidance,O
5.4,O
),O
.,O
114,O
",",O
115,O
",",O
116,O
",",O
117,O
",",O
118,O
",",O
119,O
",",O
120,O
",",O
121,O
",",O
122,O
",",O
123,O
",",O
124,O
",",O
125,O
",",O
126,O
Patients,O
with,O
psoriatic,O
disease,O
should,O
be,O
aware,O
that,O
infection,O
with,O
SARS,O
-,O
CoV-2,O
may,O
result,O
in,O
a,O
flare,O
of,O
psoriasis,O
",",O
which,O
may,O
occur,O
due,O
to,O
discontinuation,O
of,O
psoriasis,O
treatments,O
",",O
treatment,O
of,O
COVID-19,O
with,O
antimalarial,O
drugs,O
",",O
or,O
due,O
to,O
triggering,O
of,O
inflammation,O
as,O
part,O
of,O
COVID-19,O
illness,O
(,O
Guidance,O
5.6,O
),O
.,O
",",O
127,O
",",O
128,O
",",O
129,O
Patients,O
with,O
psoriatic,O
disease,O
who,O
become,O
infected,O
with,O
SARS,O
-,O
CoV-2,O
should,O
follow,O
CDC,O
guidance130,O
",",O
131,O
",",O
132,O
",",O
133,O
on,O
home,O
isolation,O
and,O
discuss,O
with,O
 ,O
their,O
health,O
care,O
providers,O
when,O
they,O
can,O
end,O
home,O
quarantine,O
(,O
Guidance,O
5.7,O
;,O
Supplemental,O
E,O
-,O
Table,O
IX,O
),O
.,O
",",O
The,O
persistence,O
of,O
1,O
or,O
more,O
symptoms,O
of,O
COVID-19,O
",",O
such,O
as,O
fatigue,O
or,O
joint,O
pain,O
",",O
beyond,O
the,O
acute,O
phase,O
of,O
the,O
illness,O
can,O
occur,O
and,O
may,O
complicate,O
the,O
decision,O
to,O
restart,O
psoriasis,O
or,O
psoriatic,O
arthritis,O
medications,O
.,O
For,O
example,O
",",O
studies,O
evaluating,O
the,O
safety,O
of,O
treatments,O
for,O
psoriasis,O
and,O
psoriatic,O
arthritis,O
in,O
the,O
setting,O
of,O
COVID-19,O
involve,O
small,O
case,O
series,O
or,O
large,O
collections,O
of,O
case,O
reports,O
and,O
thus,O
should,O
be,O
considered,O
preliminary,O
.,O
Large,O
-,O
scale,O
",",O
longer,O
-,O
term,O
",",O
population,O
-,O
based,O
studies,O
with,O
appropriate,O
comparator,O
groups,O
",",O
adjustment,O
for,O
relevant,O
confounding,O
variables,O
",",O
and,O
complete,O
ascertainment,O
of,O
clinically,O
important,O
COVID-19,O
outcomes,O
are,O
urgently,O
needed,O
.,O
To,O
provide,O
guidance,O
about,O
management,O
of,O
psoriatic,O
disease,O
during,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
.,O
These,O
statements,O
provide,O
guidance,O
for,O
the,O
management,O
of,O
patients,O
with,O
psoriatic,O
disease,O
on,O
topics,O
ranging,O
from,O
how,O
the,O
disease,O
and,O
its,O
treatments,O
impact,O
COVID-19,O
risk,O
and,O
outcome,O
",",O
how,O
medical,O
care,O
can,O
be,O
optimized,O
during,O
the,O
pandemic,O
",",O
what,O
patients,O
should,O
do,O
to,O
lower,O
their,O
risk,O
of,O
getting,O
infected,O
with,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
and,O
what,O
they,O
should,O
do,O
if,O
they,O
develop,O
COVID-19,O
.,O
Nevertheless,O
",",O
17,O
 ,O
years,O
later,O
",",O
SARS‐CoV‐2,O
brought,O
a,O
much,O
more,O
severe,O
and,O
widespread,O
pandemic,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
to,O
the,O
world,O
(,O
Wu,O
et,O
 ,O
al,O
.,O
",",O
 ,O
2020,O
;,O
Zhu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Up,O
to,O
17,O
June,O
2020,O
",",O
about,O
6,O
 ,O
months,O
after,O
the,O
first,O
reported,O
case,O
of,O
COVID‐19,O
",",O
SARS‐CoV‐2,O
has,O
caused,O
"8,179,520",O
confirmed,O
infections,O
and,O
"441,491",O
deaths,O
worldwide,O
",",O
far,O
surpassing,O
the,O
SARS,O
pandemic,O
.,O
The,O
high,O
transmissibility,O
of,O
SARS‐CoV‐2,O
is,O
probably,O
a,O
major,O
reason,O
for,O
the,O
rapid,O
development,O
of,O
COVID‐19,O
epidemic,O
and,O
more,O
studies,O
on,O
the,O
transmission,O
of,O
pathogenic,O
HCoV,O
is,O
urgently,O
required,O
.,O
Full‐length,O
SARS‐CoV‐2,O
spike,O
(,O
GenBank,S-Repository
 ,O
accession,O
number,O
MN908947.3,S-AccessionNumber
),O
",",O
SARS‐CoV,O
BJ01,O
spike,O
(,O
GenBank,S-Repository
 ,O
accession,O
number,O
AY278488.2,S-AccessionNumber
),O
and,O
pangolin‐CoV,O
GD1,O
spike,O
(,O
GISAID,S-Dataset
 ,O
accession,O
number,O
:,O
EPI_ISL_410721,S-AccessionNumber
),O
were,O
all,O
synthesized,O
by,O
Sangon,O
and,O
subcloned,O
into,O
the,O
pcDNA3.1,O
vectors,O
with,O
a,O
C‐terminal,O
HA,O
tag,O
.,O
Typically,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
CoV,O
(,O
SARS‐CoV,O
),O
caused,O
SARS,O
pandemic,O
in,O
2003,O
and,O
SARS‐CoV‐2,O
caused,O
the,O
ongoing,O
COVID‐19,O
pandemic,O
.,O
As,O
of,O
Apr.,O
22,O
",",O
2020,O
",",O
the,O
World,O
Health,O
Organization,O
(,O
2020,O
),O
has,O
reported,O
over,O
2.4,O
million,O
confirmed,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
patients,O
and,O
169,O
151,O
deaths,O
.,O
Recent,O
articles,O
have,O
uncovered,O
genomic,O
characteristics,O
and,O
clinical,O
features,O
of,O
COVID-19,O
(,O
Chan,O
et,O
al,O
.,O
",",O
2020,O
;,O
Chang,O
et,O
al,O
.,O
",",O
2020,O
;,O
Guan,O
et,O
al,O
.,O
",",O
2020,O
;,O
Zhu,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
while,O
our,O
understanding,O
of,O
COVID-19,O
is,O
still,O
limited,O
.,O
As,O
suggested,O
by,O
guidelines,O
promoted,O
by,O
the,O
General,O
Office,O
of,O
National,O
Health,O
Commission,O
of,O
the,O
People,O
’s,O
Republic,O
of,O
China,O
(,O
2020,O
),O
(,O
from,O
Versions,O
1,O
to,O
6,O
),O
",",O
discharged,O
standards,O
for,O
COVID-19,O
were,O
still,O
dependent,O
on,O
viral,O
real,O
-,O
time,O
polymerase,O
chain,O
reaction,O
(,O
RT,O
-,O
PCR,O
),O
tests,O
of,O
respiratory,O
specimens,O
",",O
showing,O
that,O
recovered,O
COVID-19,O
patients,O
with,O
twice,O
negative,O
RT,O
-,O
PCR,O
could,O
meet,O
discharge,O
criteria,O
.,O
Patient,O
1,O
",",O
a,O
40,O
-,O
year,O
-,O
old,O
female,O
",",O
presented,O
with,O
fever,O
and,O
a,O
mild,O
dry,O
cough,O
on,O
Jan.,O
17,O
",",O
2020,O
(,O
Day,O
−4,O
),O
after,O
contact,O
with,O
a,O
colleague,O
from,O
Wuhan,O
",",O
China,O
",",O
4,O
d,O
previously,O
",",O
who,O
was,O
confirmed,O
to,O
have,O
COVID-19,O
.,O
She,O
was,O
diagnosed,O
with,O
COVID-19,O
in,O
our,O
center,O
on,O
Jan.,O
21,O
(,O
Day,O
1,O
),O
with,O
a,O
positive,O
RT,O
-,O
PCR,O
test,O
in,O
sputum,O
and,O
bilateral,O
infiltration,O
lesions,O
on,O
chest,O
CT,O
images,O
(,O
Fig,O
.,O
1a,O
),O
.,O
Patient,O
2,O
",",O
a,O
50,O
-,O
year,O
-,O
old,O
male,O
",",O
had,O
fever,O
for,O
8,O
d,O
and,O
was,O
confirmed,O
to,O
have,O
COVID-19,O
on,O
Jan.,O
23,O
",",O
2020,O
(,O
Day,O
1,O
),O
in,O
our,O
center,O
.,O
Our,O
study,O
describes,O
two,O
cases,O
with,O
subsequently,O
positive,O
nucleic,O
acid,O
results,O
in,O
patients,O
of,O
COVID-19,O
who,O
met,O
discharge,O
criteria,O
and,O
this,O
raises,O
concern,O
about,O
the,O
transmission,O
risk,O
associated,O
with,O
discharged,O
COVID-19,O
patients,O
.,O
As,O
of,O
Apr.,O
22,O
",",O
2020,O
",",O
the,O
World,O
Health,O
Organization,O
(,O
2020,O
),O
has,O
reported,O
over,O
2.4,O
million,O
confirmed,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
patients,O
and,O
169,O
151,O
deaths,O
.,O
Recent,O
articles,O
have,O
uncovered,O
genomic,O
characteristics,O
and,O
clinical,O
features,O
of,O
COVID-19,O
(,O
Chan,O
et,O
al,O
.,O
",",O
2020,O
;,O
Chang,O
et,O
al,O
.,O
",",O
2020,O
;,O
Guan,O
et,O
al,O
.,O
",",O
2020,O
;,O
Zhu,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
while,O
our,O
understanding,O
of,O
COVID-19,O
is,O
still,O
limited,O
.,O
As,O
suggested,O
by,O
guidelines,O
promoted,O
by,O
the,O
General,O
Office,O
of,O
National,O
Health,O
Commission,O
of,O
the,O
People,O
’s,O
Republic,O
of,O
China,O
(,O
2020,O
),O
(,O
from,O
Versions,O
1,O
to,O
6,O
),O
",",O
discharged,O
standards,O
for,O
COVID-19,O
were,O
still,O
dependent,O
on,O
viral,O
real,O
-,O
time,O
polymerase,O
chain,O
reaction,O
(,O
RT,O
-,O
PCR,O
),O
tests,O
of,O
respiratory,O
specimens,O
",",O
showing,O
that,O
recovered,O
COVID-19,O
patients,O
with,O
twice,O
negative,O
RT,O
-,O
PCR,O
could,O
meet,O
discharge,O
criteria,O
.,O
The,O
novel,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
a,O
viral,O
outbreak,O
caused,O
by,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
-,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
first,O
arose,O
in,O
Wuhan,O
",",O
China,O
",",O
in,O
December,O
2019,O
",",O
and,O
it,O
was,O
declared,O
a,O
Public,O
Health,O
Emergency,O
of,O
International,O
Concern,O
on,O
January,O
30,O
",",O
2020,O
(,O
WHO,O
",",O
2020b,O
),O
.,O
Seven,O
months,O
into,O
the,O
COVID-19,O
pandemic,O
",",O
the,O
number,O
of,O
cumulative,O
cases,O
continues,O
to,O
steadily,O
increase,O
.,O
COVID-19,O
has,O
placed,O
an,O
unparalleled,O
burden,O
on,O
the,O
health,O
systems,O
and,O
economies,O
of,O
all,O
affected,O
countries,O
",",O
with,O
a,O
projected,O
serious,O
impact,O
on,O
African,O
countries,O
that,O
are,O
already,O
saddled,O
with,O
weak,O
health,O
care,O
provision,O
and,O
economic,O
systems,O
.,O
Mass,O
testing,O
is,O
being,O
advocated,O
",",O
and,O
this,O
requires,O
molecular,O
techniques,O
",",O
the,O
current,O
gold,O
standard,O
for,O
COVID-19,O
detection,O
",",O
as,O
recommended,O
by,O
the,O
World,O
Health,O
Organisation,O
(,O
WHO,O
),O
(,O
WHO,O
/,O
Africa,O
",",O
2020,O
),O
.,O
The,O
use,O
of,O
high,O
-,O
throughput,O
next,O
-,O
generation,O
sequencing,O
tools,O
can,O
provide,O
additional,O
data,O
to,O
refine,O
strategies,O
to,O
fight,O
against,O
COVID-19,O
.,O
While,O
SARS,O
-,O
CoV-2,O
sequence,O
data,O
are,O
an,O
integral,O
part,O
of,O
the,O
information,O
used,O
for,O
making,O
decisions,O
on,O
other,O
continents,O
(,O
Lu,O
et,O
al,O
.,O
",",O
2020,O
",",O
Zhu,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
Africa,O
has,O
yet,O
to,O
integrate,O
this,O
information,O
into,O
our,O
decision,O
making,O
for,O
managing,O
COVID-19,O
outbreaks,O
within,O
the,O
continent,O
.,O
To,O
the,O
present,O
",",O
only,O
900,O
SARS,O
-,O
CoV-2,O
genome,O
sequences,O
from,O
14,O
African,O
countries,O
have,O
been,O
uploaded,O
out,O
of,O
a,O
total,O
of,O
"62,267",O
whole,O
-,O
genome,O
sequences,O
in,O
GISAID,S-Dataset
 ,O
(,O
GISAID,S-Dataset
",",O
2020,O
),O
",",O
an,O
online,O
database,O
for,O
the,O
rapid,O
sharing,O
of,O
viral,O
genomes,O
and,O
clinical,O
and,O
epidemiological,O
data,O
.,O
Africa,O
has,O
recorded,O
approximately,O
"642,387",O
cases,O
and,O
close,O
to,O
"10,789",O
deaths,O
from,O
COVID-19,O
(,O
WHO,O
",",O
2020a,O
),O
.,O
The,O
above,O
narrative,O
could,O
be,O
different,O
if,O
each,O
country,O
appreciated,O
the,O
need,O
for,O
genetic,O
data,O
and,O
deliberately,O
empowered,O
at,O
least,O
one,O
molecular,O
laboratory,O
involved,O
in,O
COVID-19,O
detection,O
and,O
diagnostics,O
with,O
sequencing,O
technologies,O
.,O
Recently,O
",",O
the,O
African,O
Union,O
Commission,O
/,O
ACDC,O
formally,O
launched,O
the,O
Partnership,O
to,O
Accelerate,O
COVID-19,O
Testing,O
(,O
PACT,O
),O
on,O
June,O
4,O
",",O
2020,O
.,O
The,O
goals,O
of,O
PACT,O
are,O
to,O
improve,O
testing,O
for,O
COVID-19,O
",",O
enhance,O
the,O
training,O
of,O
health,O
workers,O
across,O
the,O
continent,O
",",O
establish,O
a,O
central,O
procurement,O
system,O
at,O
ACDC,O
and,O
deploy,O
one,O
million,O
community,O
health,O
workers,O
to,O
perform,O
contact,O
tracing,O
of,O
confirmed,O
cases,O
at,O
the,O
community,O
level,O
(,O
ACDC,O
",",O
2020,O
),O
.,O
To,O
respond,O
to,O
epidemics,O
such,O
as,O
COVID-19,O
",",O
genomic,O
data,O
generation,O
for,O
real,O
-,O
time,O
decision,O
making,O
could,O
be,O
enhanced,O
by,O
the,O
adoption,O
and,O
decentralised,O
application,O
of,O
small,O
",",O
portable,O
and,O
easily,O
operated,O
experimental,O
tools,O
such,O
as,O
the,O
Oxford,O
Nanopore,O
technology,O
-,O
MinION,O
sequencer,O
",",O
Illumina,O
MiniSeq,O
or,O
the,O
BGI,O
-,O
DNBSeq,O
across,O
all,O
countries,O
.,O
The,O
health,O
impacts,O
of,O
COVID-19,O
are,O
much,O
more,O
devastating,O
in,O
resource,O
-,O
poor,O
settings,O
such,O
as,O
Africa,O
.,O
•,O
 ,O
SARS,O
-,O
CoV-2,O
genome,O
samples,O
from,O
Africa,O
are,O
underrepresented,O
in,O
the,O
GISAID,S-Dataset
 ,O
data,O
repository,O
.,O
Genomic,O
technologies,O
are,O
vital,O
for,O
enhancing,O
the,O
understanding,O
and,O
development,O
of,O
intervention,O
approaches,O
against,O
these,O
pathogens,O
",",O
including,O
Ebola,O
and,O
the,O
novel,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
Soon,O
after,O
the,O
COVID-19,O
outbreak,O
",",O
China,O
initiated,O
several,O
in,O
vitro,O
studies,O
and,O
clinical,O
trials,O
to,O
discover,O
effective,O
antiviral,O
drugs,O
.,O
Our,O
results,O
are,O
promising,O
and,O
may,O
be,O
considered,O
for,O
both,O
in,O
vitro,O
and,O
in,O
vivo,O
clinical,O
trials,O
for,O
inhibition,O
of,O
COVID-19,O
.,O
Based,O
on,O
similarity,O
in,O
amino,O
acid,O
residues,O
of,O
both,O
RdRps,O
",",O
a,O
reference,O
template,O
of,O
SARS,O
-,O
CoV,O
RdRp,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6NUR,S-AccessionNumber
;,O
kindly,O
provided,O
by,O
the,O
Ward,O
lab,O
),O
was,O
used,O
for,O
further,O
analysis,O
[,O
52,O
],O
.,O
The,O
binding,O
pocket,O
of,O
the,O
RdRp,O
—,O
GLY616,O
",",O
TRP617,O
",",O
ASP618,O
",",O
TYR619,O
",",O
LEU758,O
",",O
SER759,O
",",O
ASP760,O
",",O
ASP761,O
",",O
ALA762,O
",",O
LYS798,O
",",O
TYS799,O
",",O
TRP800,O
",",O
GLU811,O
",",O
PHE812,O
",",O
CIS813,O
",",O
and/or,O
SER814,O
—,O
was,O
found,O
using,O
the,O
MOE,O
SiteFinder,O
algorithm,O
",",O
and,O
most,O
optimal,O
docked,O
compounds,O
were,O
selected,O
based,O
on,O
higher,O
S,O
-,O
score,O
and,O
lower,O
RMSD,O
with,O
a,O
reference,O
inhibitor,O
(,O
PubChem,S-Repository
 ,O
CID,O
:,O
10445549,S-AccessionNumber
),O
.,O
CID123624208,S-AccessionNumber
 ,O
and,O
CID11687749,S-AccessionNumber
—,O
were,O
selected,O
from,O
the,O
docking,O
analysis,O
.,O
In,O
this,O
study,O
",",O
we,O
identified,O
interspecies,O
divergence,O
among,O
all,O
the,O
94,O
validated,O
viral,O
genomic,O
sequences,O
belonging,O
to,O
the,O
family,O
Coronavirinae,O
retrieved,O
from,O
the,O
NCBI,S-Repository
 ,O
database,O
.,O
The,O
accessions,O
",",O
origin,O
and,O
taxonomic,O
classification,O
of,O
all,O
sequences,O
are,O
given,O
in,O
Additional,O
file,O
1,O
.,O
Most,O
of,O
the,O
accessions,O
in,O
clade,O
I,O
belong,O
to,O
the,O
Betacoronaviruses,O
",",O
indicating,O
they,O
all,O
are,O
closely,O
related,O
to,O
each,O
other,O
",",O
while,O
only,O
one,O
and,O
two,O
accessions,O
belong,O
to,O
alpha,O
-,O
CoV,O
and,O
gamma,O
-,O
CoV,O
",",O
respectively,O
",",O
thereby,O
representing,O
some,O
distance,O
with,O
respect,O
to,O
the,O
Betacoronavirus,O
members,O
.,O
For,O
accessions,O
",",O
origin,O
and,O
other,O
relevant,O
data,O
",",O
see,O
Additional,O
file,O
1,O
The,O
SARS,O
-,O
CoV-2,O
RdRp,O
protein,O
sequence,O
was,O
queried,O
using,O
pBLAST,O
and,O
94,O
validated,O
sequences,O
were,O
downloaded,O
from,O
the,O
NCBI,S-Repository
 ,O
database,O
for,O
evaluating,O
its,O
phylogenetic,O
relationship,O
with,O
other,O
viral,O
RdRp,O
proteins,O
.,O
Most,O
of,O
the,O
viral,O
RdRps,O
in,O
clade,O
I,O
belong,O
to,O
beta,O
-,O
CoV,O
;,O
the,O
same,O
is,O
true,O
for,O
clades,O
II,O
and,O
III,O
with,O
most,O
accessions,O
belonging,O
to,O
beta,O
-,O
CoV,O
",",O
while,O
a,O
few,O
remain,O
unclassified,O
and,O
require,O
more,O
research,O
for,O
proper,O
designation,O
.,O
Accession,O
QHR63299.1,S-AccessionNumber
 ,O
was,O
also,O
unclassified,O
but,O
shows,O
close,O
association,O
with,O
other,O
SARS,O
RdRp,O
relatives,O
(,O
Fig,O
.,O
 ,O
5,O
),O
.,O
SARS,O
-,O
CoV-2,O
accession,O
(,O
red,O
circle,O
),O
is,O
closely,O
associated,O
with,O
other,O
SARS,O
RdRp,O
proteins,O
(,O
blue,O
circle,O
),O
.,O
For,O
accessions,O
",",O
origin,O
and,O
other,O
relevant,O
data,O
",",O
see,O
Additional,O
file,O
1,O
:,O
Data,O
2,O
Compounds,O
with,O
 ,O
>,O
 ,O
95,O
%,O
structural,O
similarity,O
to,O
Galidesivir,O
were,O
selected,O
for,O
ligand,O
-,O
based,O
virtual,O
screening,O
from,O
the,O
PubChem,S-Repository
 ,O
database,O
.,O
A,O
total,O
of,O
1061,O
compounds,O
were,O
retrieved,O
and,O
Pfizer,O
’s,O
rule,O
of,O
five,O
was,O
applied,O
to,O
all,O
the,O
compounds,O
",",O
out,O
of,O
which,O
677,O
were,O
aligned,O
after,O
minimizing,O
energy,O
in,O
a,O
new,O
database,O
for,O
docking,O
with,O
the,O
protein,O
of,O
interest,O
RdRp,O
.,O
CID123624208,S-AccessionNumber
 ,O
and,O
CID11687749,S-AccessionNumber
 ,O
interactions,O
with,O
RdRP,O
are,O
presented,O
in,O
Figs,O
.,O
 ,O
6,O
and,O
7,O
.,O
ADMET,O
profiling,O
for,O
drug,O
-,O
like,O
compounds,O
demonstrated,O
positive,O
results,O
for,O
blood,O
–,O
brain,O
barrier,O
(,O
BBB,O
),O
",",O
human,O
intestinal,O
absorption,O
(,O
HIA,O
),O
",",O
renal,O
organic,O
cation,O
transporter,O
(,O
ROCT,O
),O
for,O
CID11687749,S-AccessionNumber
 ,O
and,O
CID123624208,S-AccessionNumber
 ,O
(,O
Table,O
 ,O
3,O
),O
",",O
whereas,O
CaCO2,O
permeability,O
results,O
were,O
found,O
to,O
be,O
negative,O
for,O
both,O
the,O
compounds,O
.,O
CID123624208,S-AccessionNumber
 ,O
and,O
CID11687749,S-AccessionNumber
 ,O
were,O
the,O
best,O
suggested,O
drug,O
-,O
like,O
compounds,O
analyzed,O
through,O
in,O
silico,O
analysis,O
and,O
may,O
act,O
as,O
strong,O
inhibitors,O
against,O
SARS,O
-,O
CoV-2,O
.,O
Our,O
study,O
indicates,O
that,O
the,O
novel,O
predicted,O
drug,O
-,O
like,O
compounds,O
CID123624208,S-AccessionNumber
 ,O
and,O
CID11687749,S-AccessionNumber
 ,O
have,O
a,O
strong,O
affinity,O
with,O
the,O
residues,O
of,O
the,O
RdRp,O
catalytic,O
domain,O
(,O
Figs,O
.,O
 ,O
6,O
",",O
7,O
),O
.,O
Thus,O
",",O
in,O
summary,O
",",O
Galidesivir,O
and,O
the,O
two,O
drugs,O
-,O
like,O
compounds,O
CID123624208,S-AccessionNumber
 ,O
and,O
CID11687749,S-AccessionNumber
 ,O
screened,O
in,O
the,O
present,O
study,O
could,O
more,O
likely,O
have,O
potential,O
as,O
therapeutic,O
drugs,O
targeting,O
SARS,O
-,O
CoV-2,O
.,O
The,O
anti,O
-,O
polymerase,O
drugs,O
predicted,O
here,O
—,O
CID123624208,S-AccessionNumber
 ,O
and,O
CID11687749,S-AccessionNumber
—,O
may,O
be,O
considered,O
for,O
in,O
vitro,O
and,O
in,O
vivo,O
clinical,O
trials,O
.,O
Coronaviruses,O
have,O
gained,O
much,O
attention,O
as,O
the,O
causative,O
agents,O
for,O
the,O
outbreaks,O
of,O
human,O
respiratory,O
syndromes,O
such,O
as,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
",",O
Middle,O
East,O
respiratory,O
syndrome,O
(,O
MERS,O
),O
and,O
most,O
recently,O
coronavirus,O
disease-2019,O
(,O
COVID-19,O
),O
.,O
In,O
addition,O
",",O
COVID-19,O
has,O
shown,O
rapid,O
global,O
spread,O
resulting,O
in,O
many,O
infected,O
individuals,O
as,O
cases,O
increase,O
above,O
"1,200,000",O
and,O
counting,O
(,O
7,O
April,O
2020,O
),O
[,O
1,O
],O
.,O
Analysis,O
of,O
the,O
SARS,O
-,O
CoV2,O
(,O
COVID-19,O
),O
sequence,O
indicated,O
that,O
it,O
shows,O
77.2,O
%,O
amino,O
acid,O
identity,O
with,O
SARS,O
-,O
CoV,O
(,O
SARS,O
),O
with,O
the,O
non,O
-,O
structural,O
proteins,O
(,O
nsp,O
's,O
),O
7–10,O
showing,O
between,O
97.1,O
%,O
to,O
98.8,O
%,O
identity,O
[,O
2,O
],O
.,O
Coronavirus,O
are,O
the,O
causative,O
agents,O
in,O
many,O
globally,O
concerning,O
respiratory,O
disease,O
outbreaks,O
such,O
as,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
",",O
Middle,O
East,O
respiratory,O
syndrome,O
(,O
MERS,O
),O
and,O
coronavirus,O
disease-2019,O
(,O
COVID-19,O
),O
.,O
The,O
rapid,O
international,O
spread,O
of,O
novel,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
(,O
1,O
),O
has,O
resulted,O
in,O
"5,103,006",O
confirmed,O
cases,O
and,O
"333,401deaths",O
worldwide,O
as,O
of,O
May,O
23,O
",",O
2020,O
(,O
2,O
),O
.,O
COVID-19,O
is,O
caused,O
by,O
SARS,O
-,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
infection,O
in,O
the,O
lower,O
respiratory,O
tract,O
(,O
3,O
),O
",",O
but,O
the,O
mechanisms,O
underlying,O
infection,O
remain,O
poorly,O
understood,O
(,O
4,O
),O
.,O
As,O
information,O
is,O
still,O
emerging,O
about,O
the,O
health,O
consequences,O
of,O
COVID-19,O
",",O
assisted,O
reproductive,O
treatments,O
(,O
ARTs,O
),O
have,O
been,O
delayed,O
due,O
to,O
fear,O
of,O
the,O
unknown,O
impact,O
of,O
SARS,O
-,O
Cov-2,O
on,O
fertility,O
(,O
10,O
",",O
11,O
),O
.,O
The,O
clinical,O
presentation,O
of,O
COVID-19,O
ranges,O
from,O
mild,O
respiratory,O
symptoms,O
to,O
severe,O
progressive,O
pneumonia,O
",",O
gastrointestinal,O
symptoms,O
",",O
fecal,O
shedding,O
",",O
multiorgan,O
failure,O
",",O
and,O
even,O
death,O
(,O
32,O
",",O
33,O
),O
",",O
but,O
few,O
studies,O
have,O
focused,O
on,O
the,O
virus,O
’s,O
effect,O
on,O
fertility,O
and,O
damage,O
to,O
reproductive,O
tissues,O
",",O
or,O
on,O
concerns,O
regarding,O
the,O
use,O
of,O
reproductive,O
treatments,O
.,O
Numerous,O
transcriptomic,O
studies,O
have,O
sought,O
to,O
understand,O
gene,O
expression,O
changes,O
throughout,O
the,O
menstrual,O
cycle,O
(,O
40,O
),O
",",O
and,O
most,O
of,O
these,O
data,O
sets,O
are,O
available,O
in,O
public,O
repositories,O
",",O
such,O
as,O
the,O
Gene,B-Repository
Expression,I-Repository
Omnibus,I-Repository
(GEO),E-Repository
 ,O
database,O
(,O
41,O
),O
.,O
The,O
keywords,O
searched,O
in,O
PubMed,O
(,O
44,O
),O
included,O
all,O
possible,O
combinations,O
between,O
“,O
SARS,O
-,O
CoV-2,O
",",O
”,O
“,O
COVID-19,O
",",O
”,O
“,O
coronavirus,O
",",O
”,O
“,O
cell,O
entry,O
mechanisms,O
",",O
”,O
“,O
long,O
-,O
term,O
implications,O
",",O
”,O
and,O
“,O
fertility,O
.,O
”,O
Public,O
transcriptomic,O
data,O
sets,O
were,O
used,O
to,O
analyze,O
expression,O
of,O
SARS,O
-,O
CoV-2,O
infectivity,O
-,O
related,O
genes,O
throughout,O
the,O
menstrual,O
cycle,O
.,O
Endometrial,O
transcriptomic,O
experiments,O
for,O
control,O
patients,O
(,O
without,O
any,O
known,O
endometrial,O
pathology,O
),O
were,O
systematically,O
searched,O
in,O
the,O
GEO,S-Repository
 ,O
database,O
(,O
41,O
),O
with,O
no,O
restrictions,O
on,O
publication,O
date,O
or,O
language,O
and,O
according,O
to,O
preferred,O
reporting,O
items,O
for,O
systematic,O
reviews,O
and,O
meta,O
-,O
analyses,O
(,O
PRISMA,O
),O
guidelines,O
(,O
45,O
),O
.,O
Experiments,O
were,O
selected,O
if,O
Transcriptomic,O
raw,O
data,O
were,O
downloaded,O
from,O
the,O
GEO,S-Repository
 ,O
database,O
and,O
processed,O
according,O
to,O
the,O
standards,O
of,O
the,O
technology,O
used,O
(,O
microarrays,O
or,O
RNA,O
-,O
seq,O
),O
using,O
limma,O
R,O
-,O
package,O
(,O
version,O
3.34.9,O
),O
(,O
46,O
),O
.,O
To,O
integrate,O
the,O
included,O
endometrial,O
transcriptomic,O
experiments,O
",",O
several,O
steps,O
were,O
followed,O
as,O
recommended,O
by,O
Tajti,O
et,O
 ,O
al,O
.,O
(,O
49,O
):,O
after,O
being,O
independently,O
normalized,O
",",O
selected,O
studies,O
were,O
joined,O
in,O
a,O
unique,O
data,O
set,O
",",O
and,O
batch,O
effects,O
were,O
corrected,O
using,O
linear,O
models,O
(,O
limma,O
R,O
package,O
),O
(,O
43,O
),O
.,O
The,O
thresholds,O
respectively,O
correspond,O
to,O
1,O
%,O
to,O
10,O
%,O
",",O
11,O
%,O
to,O
50,O
%,O
",",O
and,O
51,O
%,O
to,O
100,O
%,O
categories,O
of,O
gene,O
expression,O
values,O
of,O
the,O
entire,O
integrated,O
data,O
set,O
.,O
A,O
unique,O
combined,O
data,O
set,O
with,O
a,O
population,O
of,O
109,O
patients,O
was,O
obtained,O
",",O
comprising,O
29,O
samples,O
in,O
the,O
proliferative,O
phase,O
",",O
29,O
in,O
the,O
early,O
secretory,O
phase,O
",",O
43,O
in,O
the,O
medium,O
secretory,O
phase,O
",",O
and,O
eight,O
in,O
the,O
late,O
secretory,O
phase,O
(,O
Table,O
 ,O
1,O
),O
.,O
Last,O
row,O
indicates,O
the,O
total,O
number,O
of,O
samples,O
accounted,O
and,O
genes,O
in,O
common,O
between,O
all,O
data,O
sets,O
for,O
all,O
menstrual,O
cycle,O
phases,O
(,O
53,O
",",O
54,O
",",O
55,O
),O
.,O
To,O
make,O
data,O
sets,O
comparable,O
after,O
the,O
integration,O
of,O
all,O
samples,O
",",O
this,O
batch,O
effect,O
was,O
removed,O
(,O
Fig,O
.,O
 ,O
1A,O
",",O
right,O
),O
.,O
Low,O
",",O
medium,O
",",O
and,O
high,O
expression,O
thresholds,O
correspond,O
to,O
1,O
%,O
to,O
10,O
%,O
",",O
11,O
%,O
to,O
50,O
%,O
",",O
and,O
51,O
%,O
to,O
100,O
%,O
categories,O
of,O
gene,O
expression,O
values,O
of,O
the,O
entire,O
integrated,O
data,O
set,O
",",O
respectively,O
.,O
Viral,O
genes,O
are,O
positioned,O
in,O
their,O
schematized,O
cell,O
locations,O
as,O
stablished,O
by,O
GeneCards,O
database,O
>,O
Localization,O
section,O
(,O
release,O
4.14,O
),O
(,O
56,O
),O
.,O
Because,O
our,O
study,O
integrates,O
data,O
sets,O
from,O
GEO,S-Repository
",",O
this,O
approach,O
is,O
limited,O
by,O
the,O
study,O
design,O
.,O
To,O
determine,O
the,O
susceptibility,O
of,O
the,O
endometrium,O
to,O
infection,O
by,O
—,O
and,O
thereby,O
potential,O
damage,O
from,O
—,O
SARS,O
-,O
CoV-2,O
.,O
   ,O
Design,O
 ,O
Analysis,O
of,O
SARS,O
-,O
Cov-2,O
infection,O
-,O
related,O
gene,O
expression,O
from,O
endometrial,O
transcriptomic,O
data,O
sets,O
.,O
Viral,O
genome,O
sequences,O
from,O
pangolins,O
were,O
retrieved,O
from,O
the,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org,S-URL
),O
database,O
",",O
whereas,O
all,O
other,O
genome,O
sequences,O
were,O
downloaded,O
from,O
the,O
NCBI,B-Repository
(National,I-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information),E-Repository
 ,O
database,O
(,O
http://www.ncbi.nlm.nih.gov/,S-URL
),O
Thus,O
",",O
the,O
final,O
genome,O
dataset,O
included,O
SARS,O
-,O
CoV-2,O
(,O
reference,O
genome,O
",",O
Wuhan,O
-,O
Hu-1,O
),O
",",O
three,O
bat,O
viruses,O
(,O
BatCoV,O
RaTG13,O
",",O
bat,O
-,O
SL,O
-,O
CoVZC45,O
and,O
bat,O
-,O
SL,O
-,O
CoVZXC21,O
),O
",",O
and,O
the,O
two,O
pangolin,O
viruses,O
(,O
Fig,O
.,O
1a,O
),O
.,O
The,O
9b,O
protein,O
encoded,O
by,O
SARS,O
-,O
CoV,O
is,O
incorporated,O
into,O
mature,O
virions,O
(,O
Xu,O
et,O
al,O
.,O
",",O
2009,O
),O
but,O
is,O
dispensable,O
for,O
viral,O
replication,O
in,O
vitro,O
and,O
in,O
vivo,O
(,O
von,O
Brunn,O
et,O
al,O
.,O
",",O
2007,O
;,O
DeDiego,O
et,O
al,O
.,O
",",O
2008,O
),O
.,O
Presently,O
",",O
more,O
than,O
350,O
sequences,O
of,O
virus,O
isolated,O
from,O
several,O
countries,O
are,O
shared,O
in,O
GISAID,S-Dataset
 ,O
database,O
.,O
All,O
the,O
351,O
sequences,O
available,O
of,O
COVID-19,O
isolated,O
from,O
humans,O
have,O
been,O
downloaded,O
from,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
databank,O
.,O
A,O
dataset,O
has,O
been,O
built,O
including,O
sequences,O
from,O
human,O
and,O
excluding,O
sequences,O
from,O
animals,O
(,O
like,O
bat,O
or,O
pangolin,O
),O
.,O
The,O
complete,O
dataset,O
was,O
assessed,O
for,O
presence,O
of,O
phylogenetic,O
signal,O
by,O
applying,O
the,O
likelihood,O
mapping,O
analysis,O
implemented,O
in,O
the,O
IQ,O
-,O
TREE,O
1.6.8,O
software,O
(,O
http://www.iqtree.org,O
),O
.,O
A,O
comparison,O
of,O
data,O
from,O
evolutionary,O
and,O
phylogenetic,O
analysis,O
leads,O
us,O
to,O
hypothesize,O
that,O
the,O
mutations,O
are,O
probably,O
unrelated,O
to,O
a,O
strain,O
or,O
a,O
sub,O
-,O
family,O
of,O
the,O
COVID-19,O
but,O
are,O
due,O
to,O
independent,O
converging,O
evolution,O
of,O
the,O
virus,O
that,O
promote,O
these,O
changes,O
in,O
the,O
viral,O
genome,O
.,O
As,O
of,O
12,O
July,O
2020,O
",",O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
has,O
caused,O
over,O
12.5,O
million,O
cases,O
and,O
561,O
thousand,O
deaths,O
globally,O
(,O
),O
.,O
However,O
",",O
despite,O
the,O
thousands,O
of,O
virus,O
genomes,O
deposited,O
on,O
public,O
access,O
databases,O
",",O
there,O
is,O
a,O
lack,O
of,O
consistent,O
sampling,O
structure,O
",",O
and,O
limited,O
data,O
from,O
Brazil,O
(,O
–,O
),O
",",O
which,O
hampers,O
accurate,O
reconstructions,O
of,O
virus,O
movement,O
and,O
transmission,O
using,O
phylogenetic,O
analyses,O
.,O
We,O
then,O
focused,O
our,O
sequencing,O
efforts,O
on,O
generating,O
a,O
large,O
and,O
spatially,O
representative,O
genomic,O
dataset,O
with,O
curated,O
metadata,O
in,O
order,O
to,O
maximise,O
the,O
association,O
between,O
the,O
number,O
of,O
sequences,O
and,O
the,O
number,O
of,O
SARS,O
-,O
CoV-2,O
confirmed,O
cases,O
per,O
state,O
.,O
When,O
we,O
include,O
63,O
additional,O
available,O
sequences,O
from,O
Brazil,O
deposited,O
in,O
GISAID,S-Dataset
 ,O
(,O
29,O
),O
(,O
see,O
data,O
S1,O
and,O
S2,O
),O
",",O
we,O
find,O
the,O
data,O
set,O
is,O
representative,O
of,O
the,O
spatial,O
heterogeneity,O
of,O
the,O
Brazilian,O
epidemic,O
.,O
We,O
estimated,O
maximum,O
likelihood,O
and,O
molecular,O
clock,O
phylogenies,O
for,O
a,O
global,O
dataset,O
with,O
a,O
total,O
of,O
"1,182",O
genomes,O
sampled,O
from,O
24,O
Dec,O
2019,O
to,O
30,O
Apr,O
2020,O
(,O
root,O
-,O
to,O
-,O
tip,O
genetic,O
distance,O
correlation,O
with,O
sampling,O
dates,O
",",O
r2,O
=,O
0.53,O
;,O
Fig,O
.,O
3A,O
and,O
fig,O
.,O
S7,O
),O
.,O
We,O
provide,O
a,O
comprehensive,O
analysis,O
of,O
SARS,O
-,O
CoV-2,O
spread,O
in,O
Brazil,O
that,O
shows,O
the,O
importance,O
of,O
community,O
and,O
nation,O
-,O
wide,O
measures,O
to,O
control,O
the,O
COVID-19,O
epidemic,O
Brazil,O
.,O
Sequencing,O
of,O
427,O
new,O
genomes,O
and,O
analysis,O
of,O
a,O
geographically,O
representative,O
genomic,O
dataset,O
identified,O
>,O
100,O
international,O
virus,O
introductions,O
in,O
Brazil,O
.,O
Our,O
analysis,O
provides,O
clues,O
for,O
pathogenesis,O
and,O
targeted,O
therapy,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
The,O
outbreak,O
of,O
corona,O
virus,O
disease,O
2019,O
(,O
COVID-19,O
),O
caused,O
by,O
SARS,O
-,O
CoV-2,O
infection,O
is,O
spreading,O
globally,O
and,O
quickly,O
",",O
leading,O
to,O
emerging,O
health,O
issues,O
.,O
Our,O
discovery,O
provides,O
clues,O
for,O
pathogenesis,O
and,O
targeted,O
drug,O
therapy,O
towards,O
ACE2,O
expression,O
for,O
prevention,O
and,O
adjuvant,O
therapy,O
of,O
COVID-19,O
.,O
However,O
",",O
as,O
the,O
antiretroviral,O
activities,O
of,O
these,O
and,O
other,O
A3,O
proteins,O
require,O
viral,O
particle,O
incorporation,O
in,O
virus,O
-,O
producing,O
cells,O
(,O
37,O
),O
",",O
A3,O
-,O
related,O
effects,O
could,O
be,O
excluded,O
in,O
the,O
postentry,O
restriction,O
as,O
all,O
of,O
our,O
viral,O
stocks,O
were,O
produced,O
in,O
293,O
T,O
cells,O
.,O
However,O
",",O
a,O
putative,O
P.,O
alecto,O
TRIM5,O
orthologue,O
with,O
78,O
%,O
coverage,O
and,O
57,O
%,O
identity,O
to,O
human,O
TRIM5α,O
(,O
GenBank,S-Repository
 ,O
accession,O
no,O
.,O
ELK09387.1,S-AccessionNumber
),O
was,O
previously,O
annotated,O
during,O
a,O
high,O
-,O
throughput,O
analysis,O
of,O
multiple,O
bat,O
genomes,O
(,O
17,O
),O
.,O
The,O
5′RACE,O
-,O
derived,O
TRIM5,O
transcript,O
(,O
Genbank,S-Repository
 ,O
accession,O
no,O
.,O
MT649092,S-AccessionNumber
),O
was,O
aligned,O
with,O
the,O
putative,O
TRIM5,O
orthologue,O
ELK09387.1,S-AccessionNumber
.,O
Having,O
identified,O
and,O
cloned,O
the,O
full,O
-,O
length,O
P.,O
alecto,O
TRIM5,O
cDNA,O
",",O
we,O
used,O
a,O
lentiviral,O
vector,O
to,O
stably,O
express,O
the,O
predicted,O
protein,O
with,O
an,O
N,O
-,O
terminally,O
incorporated,O
hemagglutinin,O
(,O
HA,O
),O
epitope,O
tag,O
in,O
CrFK,O
cells,O
(,O
Fig,O
.,O
 ,O
4A,O
),O
.,O
A,O
cDNA,O
with,O
99.6,O
%,O
amino,O
acid,O
identity,O
to,O
the,O
longest,O
predicted,O
P.,O
alecto,O
MX2,O
isoform,O
(,O
NCBI,S-Repository
 ,O
accession,O
no,O
.,O
There,O
were,O
a,O
total,O
of,O
401,O
positions,O
in,O
the,O
final,O
data,O
set,O
.,O
The,O
COVID-19,O
pandemic,O
suggests,O
that,O
bat,O
innate,O
immune,O
systems,O
are,O
insufficiently,O
characterized,O
relative,O
to,O
the,O
medical,O
importance,O
of,O
these,O
animals,O
.,O
The,O
COVID-19,O
pandemic,O
has,O
resulted,O
in,O
nearly,O
7,O
million,O
confirmed,O
infections,O
and,O
>,O
400,O
 ,O
000,O
deaths,O
as,O
of,O
June,O
7,O
",",O
2020,O
",",O
with,O
3,O
billion,O
people,O
under,O
lockdown,O
worldwide,O
.,O
Early,O
in,O
the,O
history,O
of,O
GenBank,S-Repository
",",O
Michael,O
Waterman,O
presciently,O
wrote,O
that,O
“,O
Entering,O
new,O
sequences,O
into,O
the,O
databases,O
requires,O
the,O
database,O
staff,O
to,O
analyze,O
and,O
interpret,O
the,O
sequences,O
and,O
the,O
associated,O
scientific,O
literature,O
[,O
4,O
],O
.,O
”,O
Even,O
earlier,O
",",O
Margaret,O
Dayhoff,O
had,O
justified,O
her,O
enormous,O
efforts,O
at,O
sequence,O
database,O
curation,O
reasoning,O
that,O
“,O
a,O
carefully,O
verified,O
collection,O
[,O
of,O
sequences,O
],O
was,O
more,O
economical,O
in,O
the,O
long,O
run,O
than,O
a,O
quick,O
and,O
dirty,O
collection,O
”,O
[,O
5,O
],O
.,O
VAPiD,O
[,O
7,O
],O
is,O
designed,O
to,O
simplify,O
the,O
submission,O
of,O
complete,O
viral,O
genome,O
sequences,O
to,O
GenBank,S-Repository
 ,O
by,O
adding,O
metadata,O
",",O
and,O
annotating,O
each,O
input,O
sequence,O
based,O
on,O
comparison,O
with,O
its,O
best,O
-,O
matching,O
reference,O
sequence,O
in,O
a,O
large,O
reference,O
dataset,O
derived,O
from,O
GenBank,S-Repository
.,O
VIGOR,O
[,O
8,O
",",O
9,O
],O
annotates,O
input,O
sequences,O
by,O
first,O
identifying,O
the,O
most,O
relevant,O
reference,O
database,O
in,O
its,O
collection,O
and,O
then,O
comparing,O
all,O
reference,O
protein,O
and,O
mature,O
peptide,O
sequences,O
in,O
that,O
database,O
to,O
the,O
input,O
sequence,O
to,O
determine,O
its,O
annotation,O
and,O
to,O
identify,O
certain,O
types,O
of,O
errors,O
.,O
Additional,O
programs,O
for,O
viral,O
annotation,O
include,O
VGAS,O
[,O
10,O
],O
",",O
which,O
incorporates,O
ab,O
initio,O
ORF,O
prediction,O
as,O
well,O
as,O
similarity,O
-,O
based,O
annotation,O
",",O
and,O
VIGA,O
[,O
11,O
],O
which,O
can,O
be,O
optimized,O
for,O
speed,O
for,O
huge,O
metagenomics,O
datasets,O
.,O
VADR,O
compares,O
each,O
input,O
sequence,O
to,O
a,O
library,O
of,O
homology,O
models,O
of,O
viral,O
species,O
built,O
from,O
reference,O
sequences,O
from,O
the,O
RefSeq,S-Repository
 ,O
database,O
[,O
12,O
],O
",",O
identifies,O
the,O
most,O
similar,O
model,O
",",O
and,O
uses,O
that,O
model,O
to,O
compute,O
an,O
alignment,O
to,O
the,O
RefSeq,S-Repository
 ,O
from,O
which,O
feature,O
annotation,O
boundaries,O
(,O
e.g.,O
coding,O
sequences,O
(,O
denoted,O
CDS,O
),O
",",O
mature,O
peptides,O
",",O
ncRNAs,O
),O
are,O
derived,O
.,O
Additionally,O
",",O
v-build.pl,O
uses,O
the,O
makeblastdb,O
program,O
from,O
BLAST,O
v2.9.0,O
+,O
[,O
15,O
],O
to,O
create,O
a,O
BLAST,O
database,O
from,O
amino,O
acid,O
translations,O
of,O
the,O
RefSeq,S-Repository
 ,O
CDS,O
features,O
.,O
v-annotate.pl,O
uses,O
this,O
database,O
with,O
blastx,O
to,O
validate,O
its,O
nucleotide,O
-,O
based,O
predictions,O
of,O
CDS,O
features,O
.,O
We,O
ran,O
the,O
VADR,O
v1.0,O
v-annotate.pl,O
script,O
with,O
default,O
parameters,O
on,O
the,O
four,O
sequence,O
datasets,O
.,O
Table,O
 ,O
5,O
lists,O
each,O
type,O
of,O
fatal,O
VADR,O
alert,O
observed,O
in,O
one,O
of,O
the,O
four,O
datasets,O
with,O
counts,O
of,O
instances,O
reported,O
and,O
sequences,O
for,O
which,O
one,O
or,O
more,O
instances,O
was,O
reported,O
.,O
The,O
next,O
most,O
common,O
alert,O
",",O
noannotn,O
",",O
occurs,O
for,O
2753,O
sequences,O
",",O
2236,O
of,O
which,O
are,O
in,O
the,O
DP,O
dataset,O
",",O
indicating,O
that,O
no,O
similar,O
RefSeq,S-Repository
 ,O
was,O
found,O
for,O
these,O
sequences,O
during,O
the,O
classification,O
stage,O
.,O
The,O
34,O
fatal,O
alert,O
codes,O
reported,O
at,O
least,O
once,O
for,O
any,O
test,O
dataset,O
are,O
listed,O
sorted,O
by,O
total,O
number,O
of,O
reports,O
.,O
4,O
fatal,O
alert,O
types,O
(,O
unexdivg,O
",",O
lowsimis,O
",",O
incsbgrp,O
and,O
indfstrp,O
),O
were,O
not,O
reported,O
for,O
any,O
of,O
the,O
four,O
test,O
sets,O
and,O
are,O
not,O
shown,O
.,O
Therefore,O
",",O
here,O
",",O
we,O
report,O
VAPiD,O
tests,O
only,O
on,O
the,O
NC,O
and,O
DC,O
(,O
complete,O
),O
datasets,O
.,O
The,O
version,O
of,O
VIGOR,O
we,O
tested,O
(,O
VIGOR3,O
),O
lacks,O
a,O
Dengue,O
virus,O
database,O
",",O
so,O
we,O
tested,O
VIGOR,O
only,O
on,O
the,O
Norovirus,O
NC,O
and,O
NP,O
.,O
Table,O
 ,O
6,O
shows,O
the,O
number,O
of,O
sequences,O
that,O
pass,O
and,O
fail,O
with,O
each,O
of,O
the,O
three,O
methods,O
for,O
the,O
datasets,O
on,O
which,O
they,O
were,O
tested,O
.,O
Table,O
 ,O
7,O
further,O
compares,O
the,O
results,O
of,O
VADR,O
and,O
VAPiD,O
on,O
the,O
NC,O
and,O
DC,O
datasets,O
",",O
and,O
Table,O
 ,O
8,O
further,O
compares,O
the,O
results,O
of,O
VADR,O
and,O
VIGOR,O
on,O
the,O
NC,O
and,O
NP,O
datasets,O
.,O
To,O
determine,O
whether,O
this,O
is,O
the,O
case,O
or,O
not,O
in,O
our,O
test,O
sets,O
",",O
we,O
examine,O
the,O
set,O
of,O
sequences,O
that,O
fail,O
each,O
method,O
in,O
turn,O
below,O
.,O
In,O
our,O
tests,O
of,O
the,O
NC,O
and,O
DC,O
datasets,O
",",O
VAPiD,O
failed,O
43,O
total,O
sequences,O
;,O
12,O
of,O
these,O
were,O
also,O
failed,O
by,O
VADR,O
and,O
31,O
were,O
passed,O
by,O
VADR,O
and,O
VIGOR,O
(,O
Table,O
 ,O
7,O
),O
.,O
In,O
our,O
tests,O
of,O
the,O
NC,O
and,O
NP,O
datasets,O
",",O
VIGOR,O
failed,O
seven,O
total,O
sequences,O
",",O
all,O
seven,O
of,O
which,O
also,O
fail,O
VADR,O
(,O
Table,O
 ,O
8),O
.,O
In,O
our,O
tests,O
of,O
the,O
NC,O
",",O
NP,O
",",O
and,O
DC,O
datasets,O
",",O
VADR,O
failed,O
53,O
sequences,O
;,O
18,O
of,O
these,O
were,O
also,O
failed,O
by,O
VAPiD,O
and/or,O
VIGOR,O
as,O
mentioned,O
above,O
(,O
exactly,O
one,O
sequence,O
",",O
FV536857.1,S-AccessionNumber
",",O
in,O
the,O
NC,O
dataset,O
failed,O
all,O
three,O
methods,O
),O
",",O
and,O
35,O
passed,O
VAPiD,O
and/or,O
VIGOR,O
(,O
Table,O
 ,O
8),O
.,O
In,O
the,O
set,O
of,O
4171,O
sequences,O
that,O
passed,O
VADR,O
in,O
the,O
full,O
DC,O
dataset,O
of,O
4580,O
sequences,O
",",O
VADR,O
annotated,O
between,O
4,O
and,O
9,O
stem_loop,O
features,O
and,O
exactly,O
1,O
ncRNA,O
feature,O
in,O
each,O
sequence,O
for,O
a,O
total,O
of,O
"35,676",O
stem_loop,O
features,O
and,O
4171,O
ncRNA,O
features,O
.,O
In,O
the,O
set,O
of,O
"17,276",O
sequences,O
that,O
passed,O
VADR,O
in,O
the,O
full,O
"20,973",O
sequence,O
DP,O
dataset,O
",",O
VADR,O
annotated,O
between,O
1,O
and,O
6,O
stem_loop,O
features,O
in,O
2335,O
sequences,O
",",O
and,O
exactly,O
one,O
ncRNA,O
feature,O
in,O
623,O
of,O
those,O
2327,O
sequences,O
for,O
a,O
total,O
of,O
5157,O
stem_loop,O
features,O
and,O
623,O
ncRNA,O
features,O
.,O
The,O
failures,O
of,O
some,O
sequences,O
from,O
the,O
test,O
datasets,O
that,O
pass,O
VAPiD,O
and/or,O
VIGOR,O
can,O
be,O
attributed,O
to,O
this,O
",",O
as,O
discussed,O
in,O
the,O
Results,O
section,O
.,O
All,O
data,O
generated,O
or,O
analyzed,O
during,O
this,O
study,O
are,O
included,O
in,O
this,O
published,O
article,O
",",O
its,O
supplementary,O
material,O
",",O
or,O
NCBI’s,S-Repository
 ,O
GenBank,S-Repository
 ,O
database,O
.,O
The,O
sequence,O
dataset,O
was,O
aligned,O
using,O
MAFTT,O
v.7.450,O
software,O
 ,O
and,O
manually,O
edited,O
by,O
Bioedit,O
program,O
v.,O
7.0.5,O
.,O
As,O
was,O
suspected,O
",",O
most,O
of,O
the,O
identified,O
mutations,O
were,O
located,O
in,O
the,O
S,O
(,O
spike,O
),O
gene,O
",",O
which,O
encompasses,O
positions,O
between,O
21,O
 ,O
563,O
and,O
25,O
 ,O
384,O
 ,O
base,O
pair,O
(,O
GenBank,S-Repository
 ,O
accession,O
number,O
:,O
MN908947,S-AccessionNumber
),O
.,O
The,O
enrichment,O
probe,O
set,O
contains,O
502,O
single‐stranded,O
DNA,O
biotin‐labeled,O
probes,O
at,O
2×,O
tiling,O
designed,O
based,O
on,O
all,O
available,O
SARS‐CoV‐2,O
viral,O
sequences,O
",",O
downloaded,O
from,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID,E-Dataset
;,O
https://www.gisaid.org/,S-URL
),O
on,O
1,O
February,O
2020,O
",",O
and,O
it,O
can,O
be,O
used,O
to,O
enrich,O
for,O
SARS‐CoV‐2,O
sequences,O
without,O
prior,O
knowledge,O
of,O
type,O
or,O
subtype,O
.,O
Five,O
clades,O
could,O
be,O
identified,O
and,O
labeled,O
",",O
corresponding,O
to,O
the,O
full,O
genome,O
tree,O
delivered,O
by,O
GISAID,S-Dataset
 ,O
(,O
see,O
Figure,O
S1,O
),O
.,O
Following,O
the,O
CDC,O
health,O
and,O
safety,O
guidelines,O
",",O
marked,O
enrichment,O
was,O
demonstrated,O
in,O
a,O
virus,O
strain,O
sample,O
from,O
cell,O
culture,O
",",O
three,O
nasopharyngeal,O
swab,O
samples,O
(,O
cycle,O
threshold,O
[,O
C,O
 ,O
t,O
],O
values,O
:,O
32.36,O
",",O
36.72,O
",",O
and,O
38.44,O
),O
from,O
patients,O
diagnosed,O
with,O
COVID‐19,O
(,O
positive,O
control,O
),O
and,O
four,O
throat,O
swab,O
samples,O
from,O
patients,O
without,O
COVID‐19,O
(,O
negative,O
controls,O
),O
",",O
respectively,O
.,O
To,O
the,O
Editor,O
—,O
The,O
2019,O
novel,O
coronavirus,O
disease,O
(,O
2019,O
-,O
nCoV,O
or,O
COVID-19,O
),O
recently,O
reported,O
from,O
Wuhan,O
(,O
China,O
),O
",",O
which,O
has,O
cases,O
in,O
Thailand,O
",",O
Japan,O
",",O
South,O
Korea,O
",",O
and,O
the,O
United,O
States,O
",",O
has,O
been,O
confirmed,O
as,O
a,O
new,O
coronavirus,O
[,O
1,O
],O
.,O
COVID-19,O
is,O
caused,O
by,O
an,O
RNA,O
virus,O
that,O
produces,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
(,O
SARS,O
),O
.,O
After,O
this,O
stage,O
the,O
1st,O
step,O
of,O
protection,O
may,O
take,O
place,O
by,O
the,O
use,O
of,O
shRNAs,O
that,O
may,O
be,O
incorporated,O
within,O
the,O
host,O
cell,O
far,O
before,O
the,O
infection,O
.,O
After,O
the,O
uptake,O
of,O
this,O
nanoconjugate,O
the,O
shRNA,O
-,O
plasmid,O
is,O
incorporated,O
within,O
the,O
genome,O
of,O
the,O
cell,O
and,O
start,O
transcribing,O
the,O
pre,O
-,O
shRNA,O
.,O
Currently,O
",",O
there,O
is,O
no,O
such,O
vaccine,O
for,O
COVID-19,O
although,O
some,O
are,O
in,O
clinical,O
trials,O
.,O
COVID-19,O
is,O
the,O
pandemic,O
outbreak,O
that,O
is,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
virus,O
from,O
December,O
",",O
2019,O
.,O
In,O
this,O
article,O
we,O
are,O
intended,O
to,O
propose,O
a,O
hypothesis,O
on,O
the,O
development,O
of,O
a,O
vaccine,O
that,O
is,O
molecular,O
in,O
nature,O
to,O
work,O
against,O
COVID-19,O
.,O
The,O
World,O
Health,O
Organization,O
declare,O
this,O
outbreak,O
as,O
a,O
public,O
health,O
emergency,O
of,O
international,O
concern,O
on,O
30th,O
January,O
 ,O
2020,O
 ,O
and,O
the,O
disease,O
caused,O
by,O
this,O
specific,O
virus,O
species,O
have,O
recently,O
been,O
designated,O
as,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
.,O
Available,O
complete,O
genome,O
sequences,O
of,O
64,O
SARS‐CoV‐2,O
strains,O
recently,O
isolated,O
from,O
30th,O
December,O
 ,O
2019,O
to,O
9th,O
March,O
2020,O
in,O
Europe,O
(,O
including,O
Netherland,O
",",O
Luxembourg,O
",",O
Switzerland,O
",",O
Ireland,O
",",O
France,O
",",O
Italy,O
",",O
Germany,O
",",O
Portugal,O
",",O
and,O
England,O
),O
",",O
North,O
America,O
(,O
including,O
USA,O
",",O
Canada,O
and,O
Mexico,O
),O
",",O
South,O
America,O
(,O
including,O
Chile,O
and,O
Brazil,O
),O
",",O
and,O
South,O
East,O
Asia,O
(,O
including,O
Hong,O
Kong,O
",",O
Singapore,O
",",O
Japan,O
",",O
South,O
Korea,O
",",O
Taiwan,O
and,O
China,O
),O
were,O
obtained,O
from,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
Avian,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
database,O
.,O
For,O
accession,O
number,O
",",O
country,O
of,O
origin,O
and,O
date,O
of,O
isolation,O
",",O
see,O
the,O
Supplementary,O
Material,O
Table,O
 ,O
1,O
.,O
Then,O
",",O
the,O
evolutionary,O
model,O
that,O
best,O
fit,O
the,O
sequence,O
dataset,O
was,O
determined,O
using,O
MEGA‐X,O
program,O
.,O
DensiTree,O
draws,O
all,O
the,O
trees,O
in,O
the,O
dataset,O
simultaneously,O
",",O
but,O
instead,O
of,O
using,O
opaque,O
lines,O
",",O
transparency,O
is,O
used,O
when,O
drawing,O
the,O
trees,O
.,O
As,O
many,O
early,O
cases,O
of,O
COVID‐19,O
were,O
linked,O
to,O
the,O
Huanan,O
market,O
in,O
Wuhan,O
",",O
 ,O
it,O
is,O
possible,O
that,O
an,O
animal,O
source,O
was,O
present,O
at,O
this,O
location,O
.,O
Currently,O
",",O
there,O
is,O
only,O
one,O
complete,O
2019,O
-,O
nCoV,O
genome,O
(,O
29870,O
-,O
bp,O
",",O
excluding,O
the,O
poly(A,O
),O
tail,O
),O
in,O
GenBank,S-Repository
 ,O
(,O
accession,O
number,O
MN908947,S-AccessionNumber
),O
.,O
Our,O
pair,O
-,O
wise,O
sequence,O
analysis,O
demonstrated,O
that,O
bat,O
SARS,O
-,O
like,O
coronavirus,O
(,O
Genbank,S-Repository
 ,O
accession,O
number,O
MG772933,S-AccessionNumber
),O
was,O
the,O
closest,O
relative,O
to,O
2019,O
-,O
nCoV,O
",",O
sharing,O
88,O
%,O
nucleotide,O
similarity,O
(,O
Fig,O
.,O
1,O
),O
.,O
After,O
multiple,O
sample,O
collections,O
and,O
laboratory,O
analyses,O
",",O
the,O
pathogen,O
was,O
identified,O
as,O
a,O
novel,O
coronavirus,O
named,O
 ,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
by,O
the,O
International,O
Committee,O
of,O
Taxonomy,O
of,O
Viruses,O
[,O
1,O
],O
",",O
and,O
the,O
disease,O
was,O
named,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
by,O
the,O
World,O
Health,O
Organization,O
on,O
February,O
11,O
",",O
2020,O
[,O
2,O
],O
.,O
Other,O
countries,O
such,O
as,O
Japan,O
",",O
South,O
Korea,O
",",O
Thailand,O
",",O
Singapore,O
",",O
and,O
the,O
United,O
States,O
also,O
reported,O
COVID-19,O
cases,O
in,O
their,O
countries,O
[,O
4,O
],O
.,O
The,O
rapid,O
spread,O
of,O
COVID-19,O
has,O
already,O
caused,O
great,O
public,O
attention,O
and,O
many,O
heated,O
discussions,O
",",O
and,O
the,O
Chinese,O
mass,O
media,O
have,O
been,O
reporting,O
relevant,O
information,O
about,O
the,O
virus,O
and,O
the,O
outbreak,O
.,O
Data,O
from,O
Chinese,O
news,O
and,O
related,O
articles,O
were,O
collected,O
from,O
the,O
WiseSearch,S-Dataset
 ,O
database,O
[,O
6,O
],O
.,O
The,O
WiseSearch,S-Dataset
 ,O
database,O
is,O
one,O
of,O
the,O
most,O
reputable,O
",",O
ever,O
-,O
growing,O
Chinese,O
media,O
content,O
databases,O
",",O
containing,O
the,O
news,O
and,O
article,O
data,O
from,O
more,O
than,O
1500,O
print,O
media,O
sources,O
and,O
over,O
"10,000",O
internet,O
media,O
sources,O
.,O
It,O
is,O
famous,O
for,O
its,O
reproducibility,O
",",O
timeliness,O
",",O
great,O
coverage,O
",",O
and,O
high,O
data,O
integrity,O
compared,O
with,O
the,O
other,O
database,O
[,O
7,O
],O
.,O
The,O
news,O
and,O
article,O
data,O
in,O
the,O
WiseSearch,S-Dataset
 ,O
database,O
are,O
updated,O
in,O
a,O
timely,O
manner,O
[,O
6,O
],O
.,O
We,O
also,O
built,O
a,O
document,O
-,O
term,O
matrix,O
and,O
used,O
term,O
frequency,O
–,O
inverse,O
document,O
frequency,O
(,O
TF,O
–,O
IDF,O
),O
to,O
process,O
the,O
data,O
.,O
TF,O
–,O
IDF,O
is,O
a,O
numerical,O
statistic,O
that,O
is,O
used,O
to,O
reflect,O
the,O
importance,O
of,O
a,O
word,O
to,O
an,O
article,O
in,O
a,O
corpus,O
[,O
19,O
],O
.,O
To,O
seek,O
a,O
suitable,O
LDA,O
topic,O
number,O
and,O
the,O
explanations,O
to,O
investigate,O
the,O
relationship,O
between,O
the,O
COVID-19,O
crisis,O
and,O
news,O
reports,O
",",O
we,O
conducted,O
multiple,O
studies,O
.,O
We,O
selected,O
topic,O
1,O
and,O
the,O
system,O
visualized,O
the,O
word,O
frequency,O
distribution,O
relative,O
to,O
the,O
full,O
corpus,O
.,O
The,O
increase,O
in,O
the,O
number,O
of,O
cases,O
on,O
February,O
12,O
and,O
13,O
",",O
2020,O
",",O
was,O
due,O
to,O
the,O
updated,O
diagnosis,O
criteria,O
in,O
the,O
COVID-19,O
protocol,O
(,O
fifth,O
version,O
),O
[,O
28,O
],O
.,O
University,O
affinitive,O
hospitals,O
and,O
university,O
alumni,O
associations,O
participated,O
actively,O
in,O
the,O
fight,O
against,O
COVID-19,O
.,O
The,O
COVID-19,O
crisis,O
has,O
aroused,O
great,O
public,O
concern,O
in,O
China,O
and,O
around,O
the,O
world,O
.,O
Topic,O
modeling,O
provides,O
an,O
alternative,O
perspective,O
to,O
investigate,O
the,O
relationship,O
between,O
media,O
reports,O
and,O
the,O
COVID-19,O
outbreak,O
.,O
Although,O
several,O
COVID-19,O
cases,O
were,O
found,O
in,O
December,O
2019,O
",",O
we,O
observed,O
few,O
news,O
reports,O
about,O
them,O
",",O
showing,O
that,O
the,O
press,O
media,O
did,O
not,O
focus,O
on,O
this,O
disease,O
at,O
that,O
time,O
.,O
These,O
two,O
themes,O
indicate,O
that,O
the,O
mass,O
media,O
adopts,O
a,O
people,O
-,O
oriented,O
principle,O
when,O
reporting,O
on,O
the,O
COVID-19,O
crisis,O
",",O
contributing,O
to,O
the,O
warm,O
society,O
phenomenon,O
.,O
This,O
study,O
is,O
the,O
first,O
step,O
to,O
understanding,O
the,O
Chinese,O
mass,O
media,O
’s,O
role,O
during,O
the,O
COVID-19,O
crisis,O
.,O
First,O
",",O
we,O
included,O
a,O
large,O
number,O
of,O
Chinese,O
news,O
articles,O
about,O
COVID-19,O
from,O
the,O
WiseSearch,S-Dataset
 ,O
mass,O
media,O
database,O
",",O
which,O
only,O
covers,O
text,O
news,O
articles,O
.,O
Some,O
relative,O
studies,O
introduced,O
sentiment,O
analysis,O
to,O
investigate,O
the,O
emotional,O
differences,O
in,O
the,O
message,O
content,O
[,O
35,O
],O
;,O
it,O
would,O
be,O
valuable,O
if,O
we,O
could,O
also,O
apply,O
sentiment,O
analysis,O
to,O
supervise,O
the,O
news,O
and,O
investigate,O
the,O
public,O
’s,O
reaction,O
to,O
news,O
related,O
to,O
COVID-19,O
.,O
In,O
December,O
2019,O
",",O
a,O
few,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
cases,O
were,O
first,O
reported,O
in,O
Wuhan,O
",",O
Hubei,O
",",O
China,O
.,O
As,O
this,O
dreadful,O
disease,O
spreads,O
rapidly,O
",",O
the,O
mass,O
media,O
has,O
been,O
active,O
in,O
community,O
education,O
on,O
COVID-19,O
by,O
delivering,O
health,O
information,O
about,O
this,O
novel,O
coronavirus,O
",",O
such,O
as,O
its,O
pathogenesis,O
",",O
spread,O
",",O
prevention,O
",",O
and,O
containment,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
collect,O
media,O
reports,O
on,O
COVID-19,O
and,O
investigate,O
the,O
patterns,O
of,O
media,O
-,O
directed,O
health,O
communications,O
as,O
well,O
as,O
the,O
role,O
of,O
the,O
media,O
in,O
this,O
ongoing,O
COVID-19,O
crisis,O
in,O
China,O
.,O
We,O
adopted,O
the,O
WiseSearch,S-Dataset
 ,O
database,O
to,O
extract,O
related,O
news,O
articles,O
about,O
the,O
coronavirus,O
from,O
major,O
press,O
media,O
between,O
January,O
1,O
",",O
2020,O
",",O
and,O
February,O
20,O
",",O
2020,O
.,O
Comparing,O
the,O
number,O
of,O
articles,O
for,O
each,O
day,O
and,O
the,O
outbreak,O
development,O
",",O
we,O
noted,O
that,O
mass,O
media,O
news,O
reports,O
in,O
China,O
lagged,O
behind,O
the,O
development,O
of,O
COVID-19,O
.,O
The,O
COVID-19,O
crisis,O
has,O
become,O
a,O
worldwide,O
issue,O
",",O
and,O
society,O
has,O
become,O
concerned,O
about,O
donations,O
and,O
support,O
as,O
well,O
as,O
mental,O
health,O
among,O
others,O
.,O
We,O
recommend,O
that,O
future,O
work,O
addresses,O
the,O
mass,O
media,O
’s,O
actual,O
impact,O
on,O
readers,O
during,O
the,O
COVID-19,O
crisis,O
through,O
sentiment,O
analysis,O
of,O
news,O
data,O
.,O
The,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
declared,O
the,O
current,O
COVID-19,O
a,O
public,O
health,O
emergency,O
of,O
international,O
concern,O
on,O
January,O
30,O
",",O
2020,O
[,O
1,O
],O
.,O
The,O
causative,O
agent,O
of,O
the,O
current,O
outbreak,O
",",O
which,O
has,O
originated,O
in,O
Wuhan,O
City,O
in,O
China,O
",",O
was,O
identified,O
as,O
a,O
novel,O
 ,O
coronavirus,O
on,O
 ,O
January,O
7,O
",",O
2020,O
[,O
5,O
],O
",",O
and,O
the,O
disease,O
has,O
been,O
named,O
COVID-19,O
.,O
Many,O
countries,O
worldwide,O
are,O
making,O
every,O
effort,O
to,O
prevent,O
the,O
spread,O
of,O
COVID-19,O
.,O
The,O
probable,O
transmission,O
from,O
individuals,O
before,O
the,O
onset,O
of,O
symptoms,O
or,O
very,O
early,O
minimal,O
symptoms,O
makes,O
COVID-19,O
much,O
more,O
difficult,O
to,O
control,O
.,O
Beside,O
the,O
protracted,O
conflicts,O
in,O
many,O
countries,O
in,O
the,O
region,O
",",O
lack,O
of,O
infrastructure,O
",",O
limited,O
resources,O
",",O
inadequate,O
prevention,O
control,O
practices,O
",",O
poor,O
preparedness,O
capacity,O
",",O
and,O
inadequate,O
laboratory,O
infrastructures,O
and,O
resources,O
in,O
many,O
countries,O
in,O
the,O
EMR,O
are,O
among,O
the,O
main,O
barriers,O
to,O
adequately,O
detect,O
and,O
respond,O
to,O
COVID-19,O
.,O
Not,O
only,O
has,O
it,O
created,O
a,O
page,O
titled,O
“,O
COVID-19,O
Updates,O
”,O
to,O
post,O
hourly,O
updates,O
on,O
the,O
virus,O
and,O
its,O
spread,O
",",O
but,O
it,O
has,O
also,O
created,O
a,O
private,O
group,O
titled,O
“,O
FETP,O
Professionals,O
",",O
”,O
which,O
serves,O
as,O
a,O
space,O
for,O
FETP,O
directors,O
",",O
advisors,O
",",O
and,O
coordinators,O
to,O
discuss,O
key,O
issues,O
of,O
concern,O
in,O
this,O
regard,O
.,O
The,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
declared,O
the,O
current,O
COVID-19,O
a,O
public,O
health,O
emergency,O
of,O
international,O
concern,O
on,O
January,O
30,O
",",O
2020,O
.,O
This,O
viewpoint,O
article,O
aims,O
to,O
highlight,O
the,O
contribution,O
of,O
the,O
Global,O
Health,O
Development,O
(,O
GHD)/Eastern,O
Mediterranean,O
Public,O
Health,O
Network,O
(,O
EMPHNET,O
),O
and,O
the,O
EMR,O
’s,O
Field,O
Epidemiology,O
Training,O
Program,O
(,O
FETPs,O
),O
to,O
prepare,O
for,O
and,O
respond,O
to,O
the,O
current,O
COVID-19,O
threat,O
.,O
It,O
is,O
essential,O
that,O
GHD,O
/,O
EMPHNET,O
and,O
FETPs,O
continue,O
building,O
the,O
capacity,O
to,O
respond,O
to,O
COVID-19,O
and,O
intensify,O
support,O
for,O
preparedness,O
and,O
response,O
to,O
public,O
health,O
emergencies,O
.,O
Abstract,O
 ,O
Nationwide,O
shortages,O
of,O
tests,O
that,O
detect,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
and,O
diagnose,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
have,O
led,O
the,O
US,O
Food,O
and,O
Drug,O
Administration,O
(,O
FDA,O
),O
to,O
significantly,O
relax,O
regulations,O
regarding,O
COVID-19,O
diagnostic,O
testing,O
.,O
To,O
date,O
the,O
FDA,O
has,O
given,O
emergency,O
use,O
authorization,O
(,O
EUA,O
),O
to,O
48,O
COVID-19,O
in,O
vitro,O
diagnostic,O
tests,O
and,O
21,O
high,O
complexity,O
molecular,O
-,O
based,O
laboratory,O
developed,O
tests,O
",",O
as,O
well,O
as,O
implemented,O
policies,O
that,O
give,O
broad,O
authority,O
to,O
clinical,O
laboratories,O
and,O
commercial,O
manufacturers,O
in,O
the,O
development,O
",",O
distribution,O
",",O
and,O
use,O
of,O
COVID-19,O
diagnostic,O
tests,O
.,O
The,O
world,O
is,O
currently,O
experiencing,O
the,O
devastating,O
effects,O
of,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
caused,O
by,O
the,O
newly,O
emerged,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
COVID-19,O
has,O
severely,O
challenged,O
the,O
health,O
care,O
systems,O
in,O
most,O
countries,O
around,O
the,O
world,O
",",O
with,O
increased,O
demand,O
for,O
rapid,O
diagnosis,O
and,O
treatment,O
of,O
seriously,O
ill,O
patients,O
.,O
"28,274",O
-,O
"29,533",O
),O
",",O
spike,O
(,O
S,O
",",O
nt,O
"21,563",O
-,O
"25,384",O
),O
and,O
open,O
reading,O
frame,O
1ab,O
(,O
ORF1ab,O
",",O
nt,O
266,O
-,O
"13,467",O
),O
of,O
SARS,O
-,O
CoV-2,O
WA1,O
strain,O
(,O
GenBank,S-Repository
 ,O
accession,O
number,O
MN985325.1,S-AccessionNumber
),O
were,O
designed,O
and,O
manufactured,O
by,O
a,O
commercial,O
company,O
(,O
Advanced,O
Cell,O
Diagnostics,O
[,O
ACD,O
],O
",",O
Newark,O
",",O
CA,O
;,O
Table,O
 ,O
1,O
),O
.,O
The,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
outbreak,O
has,O
spread,O
globally,O
and,O
caused,O
a,O
pandemic,O
that,O
has,O
led,O
to,O
almost,O
"10,000,000",O
diagnosed,O
cases,O
and,O
"500,000",O
deaths,O
as,O
of,O
June,O
28,O
",",O
2020,O
[,O
1,O
],O
.,O
The,O
impact,O
of,O
COVID-19,O
can,O
be,O
greater,O
in,O
vulnerable,O
populations,O
.,O
In,O
the,O
midst,O
of,O
the,O
COVID-19,O
pandemic,O
",",O
it,O
is,O
advisable,O
that,O
pregnant,O
women,O
should,O
stay,O
at,O
home,O
and,O
receive,O
necessary,O
antenatal,O
care,O
via,O
online,O
antenatal,O
care,O
programs,O
.,O
Network,O
operators,O
need,O
to,O
be,O
improved,O
to,O
guarantee,O
the,O
widespread,O
use,O
of,O
internet,O
services,O
during,O
the,O
COVID-19,O
outbreak,O
.,O
People,O
across,O
the,O
world,O
have,O
been,O
greatly,O
affected,O
by,O
the,O
ongoing,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
pandemic,O
.,O
Here,O
",",O
we,O
report,O
how,O
the,O
COVID-19,O
pandemic,O
brings,O
not,O
only,O
opportunities,O
for,O
the,O
development,O
and,O
popularization,O
of,O
online,O
antenatal,O
care,O
programs,O
but,O
also,O
challenges,O
.,O
As,O
many,O
early,O
cases,O
of,O
COVID-19,O
were,O
linked,O
to,O
the,O
Huanan,O
market,O
in,O
Wuhan,O
",",O
it,O
is,O
possible,O
that,O
an,O
animal,O
source,O
was,O
present,O
at,O
this,O
location,O
.,O
Most,O
patients,O
with,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
or,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
present,O
with,O
acute,O
onset,O
of,O
fever,O
",",O
myalgia,O
",",O
cough,O
",",O
dyspnea,O
",",O
and,O
radiological,O
evidence,O
of,O
ground,O
-,O
glass,O
lung,O
opacities,O
compatible,O
with,O
atypical,O
pneumonia,O
(,O
5–7,O
),O
.,O
Therefore,O
",",O
clinical,O
features,O
and,O
epidemiological,O
links,O
to,O
Wuhan,O
alone,O
are,O
not,O
reliable,O
for,O
establishing,O
the,O
diagnosis,O
of,O
COVID-19,O
.,O
As,O
evidenced,O
by,O
previous,O
epidemics,O
caused,O
by,O
SARS,O
-,O
CoV,O
and,O
Middle,O
East,O
respiratory,O
syndrome,O
coronavirus,O
(,O
MERS,O
-,O
CoV,O
),O
",",O
highly,O
sensitive,O
and,O
specific,O
laboratory,O
diagnostics,O
for,O
COVID-19,O
are,O
essential,O
for,O
case,O
identification,O
",",O
contact,O
tracing,O
",",O
animal,O
source,O
finding,O
",",O
and,O
rationalization,O
of,O
infection,O
control,O
measures,O
(,O
14–16,O
),O
.,O
Because,O
of,O
these,O
limitations,O
",",O
reverse,O
transcription,O
-,O
PCR,O
(,O
RT,O
-,O
PCR,O
),O
remains,O
the,O
most,O
useful,O
laboratory,O
diagnostic,O
test,O
for,O
COVID-19,O
worldwide,O
.,O
The,O
availability,O
of,O
the,O
complete,O
genome,O
of,O
SARS,O
-,O
CoV-2,O
early,O
in,O
the,O
epidemic,O
facilitated,O
the,O
development,O
of,O
specific,O
primers,O
and,O
standardized,O
laboratory,O
protocols,O
for,O
COVID-19,O
(,O
18,O
",",O
19,O
),O
.,O
In,O
this,O
study,O
",",O
we,O
developed,O
novel,O
",",O
highly,O
sensitive,O
and,O
specific,O
real,O
-,O
time,O
RT,O
-,O
PCR,O
assays,O
for,O
COVID-19,O
and,O
compared,O
their,O
performances,O
with,O
that,O
of,O
the,O
established,O
RdRp,O
-,O
P2,O
assay,O
using,O
both,O
in,O
vitro,O
and,O
patient,O
specimens,O
.,O
Clinical,O
evaluation,O
using,O
different,O
types,O
of,O
clinical,O
specimens,O
from,O
patients,O
with,O
laboratory,O
-,O
confirmed,O
COVID-19,O
showed,O
that,O
our,O
novel,O
assay,O
targeting,O
a,O
different,O
region,O
of,O
the,O
RdRp,O
/,O
Hel,O
was,O
significantly,O
more,O
sensitive,O
and,O
specific,O
than,O
the,O
RdRp,O
-,O
P2,O
assay,O
.,O
SARS,O
-,O
CoV-2,O
was,O
isolated,O
from,O
a,O
patient,O
with,O
laboratory,O
-,O
confirmed,O
COVID-19,O
in,O
Hong,O
Kong,O
(,O
22,O
),O
.,O
The,O
viral,O
isolate,O
was,O
amplified,O
by,O
one,O
additional,O
passage,O
in,O
VeroE6,O
cells,O
to,O
make,O
working,O
stocks,O
of,O
the,O
virus,O
(,O
1.8,O
 ,O
×,O
 ,O
107,O
50,O
%,O
tissue,O
culture,O
infective,O
doses,O
[,O
TCID50]/ml,O
),O
.,O
For,O
the,O
clinical,O
evaluation,O
study,O
",",O
a,O
total,O
of,O
273,O
(,O
120,O
respiratory,O
tract,O
and,O
153,O
non,O
-,O
respiratory,O
tract,O
),O
clinical,O
specimens,O
were,O
collected,O
from,O
15,O
patients,O
with,O
laboratory,O
-,O
confirmed,O
COVID-19,O
in,O
Hong,O
Kong,O
whose,O
nasopharyngeal,O
aspirate,O
/,O
swabs,O
",",O
throat,O
swabs,O
",",O
and/or,O
sputum,O
specimens,O
tested,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
RNA,O
by,O
the,O
RdRp2,O
assay,O
(,O
22,O
),O
.,O
Three,O
novel,O
real,O
-,O
time,O
COVID-19,O
RT,O
-,O
PCR,O
assays,O
targeting,O
the,O
RdRp,O
/,O
Hel,O
",",O
S,O
",",O
and,O
N,O
genes,O
of,O
SARS,O
-,O
CoV-2,O
were,O
developed,O
(,O
see,O
Table,O
S1,O
in,O
the,O
supplemental,O
material,O
),O
.,O
To,O
determine,O
the,O
analytical,O
sensitivity,O
of,O
the,O
COVID-19,O
assays,O
",",O
we,O
first,O
evaluated,O
their,O
LODs,O
using,O
viral,O
genomic,O
RNA,O
extracted,O
from,O
culture,O
lysates,O
and,O
clinical,O
specimens,O
.,O
The,O
LOD,O
of,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
",",O
COVID-19,O
-,O
S,O
",",O
and,O
COVID-19,O
-,O
N,O
was,O
1.8,O
 ,O
×,O
 ,O
10,O
°,O
TCID50,O
/,O
ml,O
",",O
while,O
the,O
LOD,O
of,O
RdRp,O
-,O
P2,O
was,O
1,O
log,O
unit,O
higher,O
(,O
1.8,O
 ,O
×,O
 ,O
101,O
TCID50,O
/,O
ml,O
),O
(,O
Table,O
1,O
),O
.,O
The,O
LOD,O
of,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
and,O
COVID-19,O
-,O
N,O
(,O
10−5,O
fold,O
dilution,O
),O
was,O
1,O
log,O
unit,O
lower,O
than,O
that,O
of,O
COVID-19,O
-,O
S,O
and,O
RdRp,O
-,O
P2,O
(,O
10−4,O
fold,O
dilution,O
),O
(,O
Table,O
1,O
),O
.,O
On,O
the,O
basis,O
of,O
these,O
results,O
",",O
we,O
then,O
selected,O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
and,O
COVID-19,O
-,O
N,O
assays,O
for,O
further,O
evaluation,O
and,O
determined,O
their,O
LODs,O
using,O
in,O
vitro,O
viral,O
RNA,O
transcripts,O
(,O
Table,O
2,O
),O
.,O
The,O
LODs,O
of,O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
and,O
COVID-19,O
-,O
N,O
assays,O
using,O
serial,O
dilutions,O
of,O
in,O
vitro,O
viral,O
RNA,O
transcripts,O
as,O
calculated,O
with,O
probit,O
analysis,O
were,O
11.2,O
RNA,O
copies,O
/,O
reaction,O
(,O
95,O
%,O
confidence,O
interval,O
",",O
 ,O
7.2,O
to,O
52.6,O
RNA,O
copies,O
/,O
reaction,O
),O
and,O
21.3,O
RNA,O
copies,O
/,O
reaction,O
(,O
95,O
%,O
confidence,O
interval,O
",",O
 ,O
11.6,O
to,O
177.0,O
copies,O
/,O
reaction,O
),O
",",O
respectively,O
.,O
Test,O
results,O
used,O
for,O
the,O
calculation,O
of,O
limits,O
of,O
detection,O
of,O
the,O
COVID-19,O
real,O
-,O
time,O
RT,O
-,O
PCR,O
assays,O
with,O
genomic,O
RNA,O
for,O
SARS,O
-,O
CoV-2,O
in,O
culture,O
lysates,O
and,O
clinical,O
specimens,O
Among,O
the,O
273,O
specimens,O
collected,O
from,O
these,O
15,O
patients,O
",",O
77,O
(,O
28.2,O
%,O
),O
were,O
positive,O
by,O
the,O
RdRp,O
-,O
P2,O
assay,O
(,O
Table,O
3,O
),O
.,O
The,O
novel,O
COVID-2019,O
-,O
RdRp,O
/,O
Hel,O
assay,O
was,O
positive,O
for,O
all,O
of,O
these,O
77,O
specimens,O
.,O
Additionally,O
",",O
the,O
COVID-2019,O
-,O
RdRp,O
/,O
Hel,O
assay,O
was,O
positive,O
for,O
another,O
42,O
specimens,O
(,O
119,O
positive,O
specimens,O
of,O
273,O
total,O
specimens,O
[,O
43.6,O
%,O
],O
by,O
COVID-2019,O
-,O
RdRp,O
/,O
Hel,O
versus,O
77,O
positive,O
specimens,O
of,O
273,O
total,O
specimens,O
[,O
28.2,O
%,O
],O
by,O
RdRp,O
-,O
P2,O
;,O
P,O
<,O
0.001,O
),O
",",O
including,O
29/120,O
(,O
24.2,O
%,O
),O
respiratory,O
tract,O
specimens,O
and,O
13/153,O
(,O
8.5,O
%,O
),O
non,O
-,O
respiratory,O
tract,O
specimens,O
that,O
were,O
negative,O
by,O
the,O
RdRp,O
-,O
P2,O
assay,O
.,O
The,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
was,O
significantly,O
more,O
sensitive,O
than,O
the,O
RdRp,O
-,O
P2,O
assay,O
for,O
the,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
nasopharyngeal,O
aspirates,O
/,O
swabs,O
or,O
throat,O
swabs,O
(,O
P,O
 ,O
=,O
 ,O
0.043,O
),O
",",O
saliva,O
(,O
P,O
<,O
0.001,O
),O
",",O
and,O
plasma,O
(,O
P,O
=,O
0.001,O
),O
specimens,O
.,O
As,O
shown,O
in,O
Fig,O
.,O
1,O
",",O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
consistently,O
detected,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
these,O
samples,O
with,O
a,O
higher,O
sensitivity,O
than,O
the,O
RdRp-2,O
assay,O
throughout,O
the,O
patients,O
’,O
course,O
of,O
illness,O
up,O
to,O
day,O
12,O
(,O
nasopharyngeal,O
aspirates,O
/,O
swabs,O
and/or,O
throat,O
swabs,O
),O
to,O
day,O
18,O
(,O
saliva,O
),O
.,O
To,O
investigate,O
whether,O
the,O
novel,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
and,O
COVID-19,O
-,O
N,O
assays,O
cross,O
-,O
react,O
with,O
SARS,O
-,O
CoV,O
",",O
other,O
human,O
-,O
pathogenic,O
coronaviruses,O
",",O
and,O
respiratory,O
viruses,O
",",O
we,O
used,O
the,O
assays,O
to,O
test,O
17,O
culture,O
isolates,O
of,O
coronaviruses,O
(,O
SARS,O
-,O
CoV,O
",",O
MERS,O
-,O
CoV,O
",",O
human,O
coronavirus,O
HCoV,O
-,O
OC43,O
",",O
HCoV-229E,O
",",O
and,O
HCoV,O
-,O
NL63,O
),O
",",O
adenovirus,O
",",O
human,O
metapneumovirus,O
",",O
influenza,O
A,O
(,O
H1N1,O
and,O
H3N2,O
),O
viruses,O
",",O
influenza,O
B,O
virus,O
",",O
influenza,O
C,O
virus,O
",",O
parainfluenza,O
viruses,O
types,O
1,O
to,O
4,O
",",O
rhinovirus,O
",",O
and,O
respiratory,O
syncytial,O
virus,O
.,O
To,O
investigate,O
whether,O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
was,O
specific,O
for,O
SARS,O
-,O
CoV-2,O
in,O
clinical,O
specimens,O
",",O
we,O
used,O
the,O
assay,O
to,O
test,O
22,O
archived,O
nasopharyngeal,O
aspirates,O
/,O
swabs,O
and,O
throat,O
swabs,O
that,O
were,O
positive,O
for,O
other,O
respiratory,O
pathogens,O
by,O
FilmArray,O
RP2,O
from,O
22,O
patients,O
with,O
upper,O
and/or,O
lower,O
respiratory,O
tract,O
symptoms,O
.,O
As,O
shown,O
in,O
Table,O
5,O
",",O
none,O
of,O
these,O
specimens,O
was,O
positive,O
by,O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
",",O
suggesting,O
that,O
the,O
assay,O
was,O
specific,O
for,O
the,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
nasopharyngeal,O
aspirates,O
/,O
swabs,O
and,O
throat,O
swabs,O
containing,O
DNA,O
/,O
RNA,O
of,O
other,O
human,O
-,O
pathogenic,O
coronaviruses,O
and,O
respiratory,O
pathogens,O
.,O
Lack,O
of,O
cross,O
-,O
reactivity,O
between,O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
and,O
other,O
respiratory,O
pathogens,O
in,O
clinical,O
specimens,O
For,O
COVID-19,O
",",O
the,O
protocols,O
of,O
a,O
number,O
of,O
RT,O
-,O
PCR,O
assays,O
used,O
by,O
different,O
institutes,O
have,O
recently,O
been,O
made,O
available,O
online,O
(,O
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance,O
),O
.,O
Importantly,O
",",O
the,O
in,O
-,O
use,O
evaluation,O
data,O
of,O
these,O
assays,O
using,O
a,O
large,O
number,O
of,O
clinical,O
specimens,O
from,O
patients,O
with,O
confirmed,O
COVID-19,O
are,O
lacking,O
.,O
We,O
showed,O
that,O
the,O
novel,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
was,O
highly,O
sensitive,O
and,O
specific,O
for,O
the,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
vitro,O
and,O
in,O
COVID-19,O
patient,O
specimens,O
.,O
Among,O
the,O
three,O
assays,O
developed,O
in,O
this,O
study,O
",",O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
has,O
the,O
lowest,O
LOD,O
with,O
in,O
vitro,O
viral,O
RNA,O
transcripts,O
(,O
11.2,O
RNA,O
copies,O
/,O
reaction,O
;,O
95,O
%,O
confidence,O
interval,O
;,O
 ,O
7.2,O
to,O
52.6,O
RNA,O
copies,O
/,O
reaction,O
),O
.,O
The,O
LOD,O
with,O
genomic,O
RNA,O
was,O
also,O
very,O
low,O
(,O
1.80,O
TCID50,O
/,O
ml,O
),O
.,O
Importantly,O
",",O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
was,O
significantly,O
more,O
sensitive,O
(,O
P,O
≤,O
0.001,O
),O
than,O
the,O
established,O
RdRp,O
-,O
P2,O
assay,O
for,O
the,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
both,O
respiratory,O
tract,O
and,O
non,O
-,O
respiratory,O
tract,O
clinical,O
specimens,O
.,O
The,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
detected,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
42/273,O
(,O
15.4,O
%,O
),O
additional,O
specimens,O
that,O
tested,O
negative,O
by,O
the,O
RdRp,O
-,O
P2,O
assay,O
.,O
These,O
findings,O
are,O
clinically,O
and,O
epidemiologically,O
relevant,O
",",O
because,O
asymptomatic,O
and,O
mildly,O
symptomatic,O
cases,O
of,O
COVID-19,O
have,O
been,O
increasingly,O
recognized,O
",",O
and,O
these,O
patients,O
with,O
cryptic,O
pneumonia,O
may,O
serve,O
as,O
a,O
potential,O
source,O
for,O
propagating,O
the,O
epidemic,O
(,O
2,O
",",O
8),O
.,O
Given,O
the,O
large,O
number,O
of,O
patients,O
(,O
>,O
"60,000",O
cases,O
in,O
China,O
at,O
the,O
time,O
of,O
writing,O
),O
involved,O
in,O
this,O
expanding,O
epidemic,O
",",O
the,O
additional,O
positive,O
specimens,O
detected,O
by,O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
might,O
translate,O
into,O
thousands,O
of,O
specimens,O
that,O
would,O
otherwise,O
be,O
considered,O
SARS,O
-,O
CoV-2,O
negative,O
by,O
the,O
less,O
-,O
sensitive,O
RdRp,O
-,O
P2,O
assay,O
.,O
Regarding,O
the,O
different,O
types,O
of,O
clinical,O
specimens,O
",",O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
was,O
significantly,O
more,O
sensitive,O
than,O
the,O
RdRp,O
-,O
P2,O
assay,O
for,O
the,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
nasopharyngeal,O
aspirates,O
/,O
swabs,O
or,O
throat,O
swabs,O
",",O
saliva,O
specimens,O
",",O
and,O
plasma,O
specimens,O
.,O
False,O
-,O
negative,O
results,O
might,O
arise,O
from,O
testing,O
nasopharyngeal,O
aspirate,O
/,O
swabs,O
or,O
throat,O
swabs,O
with,O
low,O
viral,O
loads,O
in,O
COVID-19,O
",",O
SARS,O
",",O
and,O
MERS,O
patients,O
(,O
2,O
",",O
30–33,O
),O
.,O
RT,O
-,O
PCR,O
assays,O
with,O
higher,O
sensitivity,O
",",O
such,O
as,O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
",",O
might,O
help,O
to,O
reduce,O
the,O
false,O
-,O
negative,O
rate,O
among,O
these,O
specimens,O
which,O
are,O
frequently,O
the,O
only,O
specimens,O
available,O
for,O
establishing,O
the,O
diagnosis,O
of,O
COVID-19,O
.,O
We,O
have,O
previously,O
shown,O
that,O
saliva,O
has,O
a,O
high,O
concordance,O
rate,O
with,O
nasopharyngeal,O
aspirates,O
for,O
the,O
detection,O
of,O
influenza,O
viral,O
RNA,O
and,O
might,O
also,O
be,O
a,O
suitable,O
specimen,O
for,O
diagnosing,O
COVID-19,O
(,O
22,O
",",O
34,O
),O
.,O
The,O
use,O
of,O
the,O
highly,O
sensitive,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
to,O
test,O
saliva,O
specimens,O
from,O
suspected,O
cases,O
of,O
COVID-19,O
might,O
be,O
a,O
simple,O
and,O
rapid,O
way,O
to,O
avoid,O
the,O
need,O
of,O
aerosol,O
-,O
generating,O
procedures,O
during,O
collection,O
of,O
nasopharyngeal,O
aspirates,O
and,O
suction,O
of,O
sputum,O
",",O
especially,O
in,O
regions,O
most,O
heavily,O
affected,O
by,O
the,O
ongoing,O
COVID-19,O
outbreak,O
where,O
there,O
are,O
insufficient,O
supplies,O
of,O
full,O
personal,O
protective,O
equipment,O
(,O
13,O
),O
.,O
SARS,O
-,O
CoV-2,O
RNAemia,O
has,O
been,O
reported,O
in,O
a,O
small,O
proportion,O
of,O
COVID-19,O
patients,O
(,O
2,O
",",O
5,O
),O
.,O
However,O
",",O
as,O
shown,O
in,O
our,O
clinical,O
evaluation,O
in,O
which,O
the,O
RdRp,O
-,O
P2,O
assay,O
gave,O
negative,O
test,O
results,O
for,O
all,O
10,O
plasma,O
specimens,O
that,O
gave,O
positive,O
test,O
results,O
by,O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
",",O
the,O
genuine,O
incidence,O
of,O
SARS,O
-,O
CoV-2,O
RNAemia,O
might,O
be,O
underestimated,O
by,O
less,O
sensitive,O
RT,O
-,O
PCR,O
assays,O
.,O
Thus,O
",",O
serial,O
monitoring,O
of,O
the,O
plasma,O
viral,O
load,O
in,O
COVID-19,O
patients,O
with,O
the,O
highly,O
sensitive,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
should,O
be,O
considered,O
to,O
provide,O
prognostic,O
insights,O
and,O
facilitate,O
treatment,O
decisions,O
.,O
The,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
was,O
highly,O
specific,O
and,O
exhibited,O
no,O
cross,O
-,O
reactivity,O
with,O
other,O
common,O
respiratory,O
pathogens,O
in,O
vitro,O
and,O
in,O
nasopharyngeal,O
aspirates,O
.,O
This,O
cross,O
-,O
reactivity,O
would,O
be,O
especially,O
important,O
for,O
laboratories,O
in,O
areas,O
where,O
SARS,O
-,O
CoV,O
might,O
reemerge,O
and,O
cocirculate,O
with,O
SARS,O
-,O
CoV-2,O
",",O
as,O
the,O
differences,O
in,O
clinical,O
progression,O
between,O
SARS,O
and,O
COVID-19,O
remain,O
incompletely,O
understood,O
at,O
this,O
stage,O
.,O
Highly,O
sensitive,O
and,O
specific,O
laboratory,O
diagnostics,O
are,O
important,O
for,O
controlling,O
the,O
rapidly,O
evolving,O
SARS,O
-,O
CoV-2,O
-,O
associated,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
epidemic,O
.,O
Highly,O
sensitive,O
and,O
specific,O
laboratory,O
diagnostics,O
are,O
important,O
for,O
controlling,O
the,O
rapidly,O
evolving,O
SARS,O
-,O
CoV-2,O
-,O
associated,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
epidemic,O
.,O
Among,O
the,O
three,O
novel,O
assays,O
",",O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
had,O
the,O
lowest,O
limit,O
of,O
detection,O
in,O
vitro,O
(,O
1.8,O
50,O
%,O
tissue,O
culture,O
infective,O
doses,O
[,O
TCID,O
50,O
],O
/ml,O
with,O
genomic,O
RNA,O
and,O
11.2,O
RNA,O
copies,O
/,O
reaction,O
with,O
in,O
vitro,O
RNA,O
transcripts,O
),O
.,O
Among,O
273,O
specimens,O
from,O
15,O
patients,O
with,O
laboratory,O
-,O
confirmed,O
COVID-19,O
in,O
Hong,O
Kong,O
",",O
77,O
(,O
28.2,O
%,O
),O
were,O
positive,O
by,O
both,O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
and,O
RdRp,O
-,O
P2,O
assays,O
.,O
The,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
was,O
positive,O
for,O
an,O
additional,O
42,O
RdRp,O
-,O
P2,O
-,O
negative,O
specimens,O
(,O
119/273,O
[,O
43.6,O
%,O
],O
versus,O
77/273,O
[,O
28.2,O
%,O
],O
;,O
P,O
<,O
0.001,O
),O
",",O
including,O
29/120,O
(,O
24.2,O
%,O
),O
respiratory,O
tract,O
specimens,O
and,O
13/153,O
(,O
8.5,O
%,O
),O
non,O
-,O
respiratory,O
tract,O
specimens,O
.,O
The,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
did,O
not,O
cross,O
-,O
react,O
with,O
other,O
human,O
-,O
pathogenic,O
coronaviruses,O
and,O
respiratory,O
pathogens,O
in,O
cell,O
culture,O
and,O
clinical,O
specimens,O
",",O
whereas,O
the,O
RdRp,O
-,O
P2,O
assay,O
cross,O
-,O
reacted,O
with,O
SARS,O
-,O
CoV,O
in,O
cell,O
culture,O
.,O
The,O
highly,O
sensitive,O
and,O
specific,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
may,O
help,O
to,O
improve,O
the,O
laboratory,O
diagnosis,O
of,O
COVID-19,O
.,O
Significance,O
Statement,O
 ,O
Kidney,O
involvement,O
may,O
occur,O
in,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
and,O
can,O
be,O
severe,O
among,O
Black,O
individuals,O
.,O
In,O
this,O
study,O
of,O
collapsing,O
glomerulopathy,O
in,O
six,O
Black,O
patients,O
with,O
COVID-19,O
",",O
the,O
authors,O
found,O
that,O
all,O
six,O
had,O
variants,O
in,O
the,O
gene,O
encoding,O
apo,O
L1,O
(,O
APOL1,O
),O
that,O
are,O
more,O
common,O
among,O
those,O
of,O
African,O
descent,O
and,O
linked,O
by,O
past,O
research,O
to,O
susceptibility,O
to,O
collapsing,O
glomerulopathy,O
in,O
non,O
–,O
COVID-19,O
patients,O
.,O
Visual,O
Abstract,O
        ,O
Background,O
 ,O
Kidney,O
involvement,O
is,O
a,O
feature,O
of,O
COVID-19,O
and,O
it,O
can,O
be,O
severe,O
in,O
Black,O
patients,O
.,O
To,O
investigate,O
genetic,O
",",O
histopathologic,O
",",O
and,O
molecular,O
features,O
in,O
six,O
Black,O
patients,O
with,O
COVID-19,O
presenting,O
with,O
AKI,O
and,O
de,O
novo,O
nephrotic,O
-,O
range,O
proteinuria,O
",",O
we,O
obtained,O
biopsied,O
kidney,O
tissue,O
",",O
which,O
was,O
examined,O
by,O
in,O
situ,O
hybridization,O
for,O
viral,O
detection,O
and,O
by,O
NanoString,O
for,O
COVID-19,O
and,O
acute,O
tubular,O
injury,O
–,O
associated,O
genes,O
.,O
This,O
case,O
series,O
included,O
six,O
Black,O
patients,O
with,O
COVID-19,O
(,O
four,O
men,O
",",O
two,O
women,O
),O
",",O
mean,O
age,O
55,O
years,O
.,O
Conclusions,O
 ,O
Collapsing,O
glomerulopathy,O
in,O
Black,O
patients,O
with,O
COVID-19,O
was,O
associated,O
with,O
high,O
-,O
risk,O
APOL1,O
variants,O
.,O
Given,O
this,O
entity,O
’s,O
resemblance,O
with,O
HIV,O
-,O
associated,O
nephropathy,O
",",O
we,O
propose,O
the,O
term,O
COVID-19,O
–,O
associated,O
nephropathy,O
to,O
describe,O
it,O
.,O
Recently,O
",",O
novel,O
coronavirus,O
(,O
virus,O
",",O
SARS,O
-,O
COV2,O
;,O
disease,O
",",O
COVID-19,O
),O
infection,O
and,O
its,O
related,O
mortality,O
are,O
so,O
severe,O
internationally,O
that,O
the,O
WHO,O
declared,O
it,O
as,O
a,O
pandemic,O
.,O
They,O
concluded,O
that,O
this,O
triple,O
drug,O
treatment,O
has,O
a,O
superior,O
effect,O
in,O
curing,O
COVID-19,O
patients,O
than,O
lopinavir,O
-,O
ritonavir,O
or,O
ribavirin,O
alone,O
(,O
Hung,O
et,O
al,O
.,O
2020,O
),O
.,O
Thus,O
",",O
clinical,O
trials,O
of,O
IFN,O
-,O
beta,O
supplement,O
could,O
be,O
considered,O
an,O
effective,O
treatment,O
for,O
COVID-19,O
.,O
Taken,O
together,O
",",O
an,O
IFN,O
-,O
beta,O
supplement,O
might,O
aid,O
in,O
preventing,O
COVID-19,O
infection,O
and,O
help,O
in,O
development,O
of,O
herd,O
immunity,O
.,O
COVID‐19,O
is,O
global,O
pandemic,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus‐2,O
(,O
SARS‐COV‐2,O
),O
.,O
To,O
provide,O
further,O
insight,O
",",O
root‐mean‐square,O
deviation,O
(,O
rmsd,O
),O
tool,O
and,O
population,O
distribution,O
plot,O
were,O
used,O
to,O
investigate,O
the,O
conformations,O
sampled,O
by,O
the,O
two,O
biosystems,O
in,O
comparison,O
with,O
the,O
open,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6vyb,S-AccessionNumber
),O
 ,O
and,O
closed,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6vxx,S-AccessionNumber
),O
states,O
.,O
To,O
further,O
establish,O
these,O
findings,O
",",O
the,O
conformations,O
sampled,O
were,O
also,O
compared,O
with,O
that,O
of,O
S2‐post‐fusion,O
core,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6lxt,S-AccessionNumber
),O
.,O
The,O
conformations,O
sampled,O
by,O
S2,O
unit,O
in,O
the,O
G614,O
biosystem,O
were,O
predominantly,O
those,O
of,O
the,O
post‐fusion,O
core,O
(,O
Figure,O
1d,O
),O
",",O
while,O
the,O
wild,O
type,O
sampled,O
the,O
pre‐fusion,O
core,O
conformation,O
(,O
data,O
not,O
shown,O
),O
;,O
and,O
clearly,O
",",O
the,O
conformations,O
of,O
the,O
RBD,O
of,O
G614,O
biosystem,O
were,O
those,O
previously,O
characterized,O
to,O
bind,O
ACE2,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6lzg,S-AccessionNumber
",",O
Figure,O
1e,O
),O
but,O
not,O
the,O
wild,O
type,O
.,O
The,O
results,O
obtained,O
from,O
comparison,O
with,O
antibody,O
(,O
B38,O
",",O
PDB,S-Repository
 ,O
ID,O
:,O
7bz5,S-AccessionNumber
),O
‐bound,O
conformation,O
revealed,O
a,O
rather,O
unusual,O
pattern,O
.,O
Abstract,O
 ,O
D614,O
G,O
spike,O
glycoprotein,O
(,O
sgp,O
),O
mutation,O
in,O
rapidly,O
spreading,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus‐2,O
(,O
SARS‐COV‐2,O
),O
is,O
associated,O
with,O
enhanced,O
fitness,O
and,O
higher,O
transmissibility,O
in,O
new,O
cases,O
of,O
COVID‐19,O
but,O
the,O
underlying,O
mechanism,O
is,O
unknown,O
.,O
The,O
causative,O
agent,O
of,O
COVID‐19,O
;,O
SARS‐COV‐2,O
has,O
acquired,O
a,O
rare,O
mutation,O
(,O
G23403A,O
),O
in,O
the,O
region,O
encoding,O
spike,O
glycoprotein,O
(,O
D614,O
G,O
),O
resulting,O
in,O
enhanced,O
fitness,O
and,O
higher,O
transmissibility,O
.,O
The,O
COVID-19,O
pandemic,O
caused,O
by,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
had,O
a,O
dramatic,O
impact,O
on,O
the,O
health,O
of,O
millions,O
of,O
people,O
and,O
became,O
a,O
challenge,O
for,O
the,O
worldwide,O
health,O
systems,O
[,O
1,O
",",O
2,O
],O
.,O
In,O
this,O
work,O
we,O
explored,O
the,O
landscape,O
of,O
ACE2,O
and,O
TMPRSS2,O
regulation,O
mediated,O
by,O
miRNAs,O
and,O
isomiRs,O
in,O
different,O
human,O
organs,O
using,O
bioinformatic,O
analysis,O
of,O
publicly,O
available,O
paired,O
miRNA,O
/,O
mRNA,O
-,O
sequencing,O
datasets,O
.,O
The,O
latter,O
included,O
hsa,O
-,O
miR-125a-5p,O
(,O
targeting,O
ACE2,O
in,O
esophagus,O
",",O
kidney,O
and,O
lung,O
),O
",",O
as,O
well,O
as,O
hsa,O
-,O
miR-199a-5p,O
(,O
regulating,O
expression,O
of,O
TMPRSS2,O
in,O
liver,O
",",O
stomach,O
and,O
uterine,O
corpus,O
",",O
see,O
Fig,O
3,O
),O
.,O
In,O
order,O
to,O
determine,O
the,O
other,O
players,O
involved,O
in,O
the,O
interplay,O
between,O
hsa,O
-,O
let-7e-5p,O
/,O
hsa,O
-,O
miR-125a-5p,O
and,O
ACE2,O
/,O
TMPRSS2,O
genes,O
we,O
searched,O
for,O
proteins,O
regulating,O
the,O
transcription,O
of,O
those,O
miRNAs,O
using,O
literature,O
-,O
curated,O
interaction,O
databases,O
.,O
Thus,O
",",O
lysine,O
-,O
specific,O
demethylase,O
5B,O
(,O
JARID1B,O
",",O
encoded,O
by,O
the,O
KDM5B,O
gene,O
),O
had,O
been,O
previously,O
shown,O
to,O
repress,O
the,O
transcription,O
of,O
hsa,O
-,O
let-7e,O
/,O
hsa,O
-,O
mir-125a,O
miRNAs,O
and,O
miR-200,O
family,O
(,O
including,O
miR-141,O
",",O
miR-200a,O
",",O
miR-200b,O
",",O
miR-200c,O
and,O
miR-429,O
),O
by,O
promoting,O
H3K4me3,O
histone,O
mark,O
demethylation,O
within,O
the,O
regulatory,O
regions,O
of,O
miRNAs,O
",",O
thereby,O
facilitating,O
epigenetic,O
repression,O
of,O
their,O
transcription,O
.,O
As,O
a,O
result,O
",",O
JARID1B,O
epigenetic,O
activity,O
can,O
indirectly,O
regulate,O
expression,O
of,O
ACE2,O
and,O
TMPRSS2,O
.,O
To,O
explore,O
putative,O
interactions,O
between,O
JARID1B,O
and,O
ACE2,O
/,O
TMPRSS2,O
genes,O
more,O
deeply,O
we,O
analyzed,O
publicly,O
available,O
single,O
-,O
cell,O
RNA,O
sequencing,O
(,O
scRNA,O
-,O
seq,O
),O
data,O
obtained,O
from,O
certain,O
human,O
organs,O
(,O
annotated,O
and,O
deposited,O
by,O
Sungnak,B-Creator
et,I-Creator
al.,E-Creator
 ,O
[,O
26,O
],O
),O
.,O
Specifically,O
",",O
the,O
mean,O
dropout,O
rate,O
(,O
i.e.,O
the,O
ratio,O
of,O
the,O
number,O
of,O
cells,O
with,O
no,O
JARID1B,O
",",O
ACE2,O
or,O
TMPRSS2,O
aligned,O
reads,O
to,O
the,O
total,O
number,O
of,O
cells,O
),O
across,O
all,O
cell,O
types,O
was,O
87.9,O
%,O
for,O
KDM5B,O
",",O
99.1,O
%,O
for,O
ACE2,O
and,O
93.2,O
%,O
for,O
TMPRSS2,O
.,O
To,O
overcome,O
the,O
issue,O
caused,O
by,O
high,O
dropout,O
rates,O
we,O
calculated,O
the,O
mean,O
expression,O
of,O
each,O
gene,O
for,O
all,O
cell,O
types,O
from,O
the,O
explored,O
datasets,O
(,O
see,O
S3,O
Table,O
),O
.,O
Using,O
the,O
literature,O
-,O
curated,O
interaction,O
database,O
we,O
have,O
found,O
strong,O
indications,O
that,O
the,O
JARID1B,O
gene,O
can,O
repress,O
let-7e,O
/,O
miR-125a,O
as,O
well,O
as,O
miR-200,O
families,O
presumably,O
via,O
epigenetic,O
mechanisms,O
.,O
Thus,O
",",O
Mitra,O
et,O
al,O
.,O
[,O
31,O
],O
have,O
previously,O
provided,O
experimental,O
evidence,O
that,O
the,O
JARID1B,O
gene,O
represses,O
transcription,O
of,O
the,O
let-7e,O
and,O
miR-125a,O
by,O
promoting,O
H3K4me3,O
demethylation,O
.,O
Specifically,O
",",O
shRNA,O
-,O
mediated,O
knockdown,O
of,O
JARID1B,O
in,O
MCF-7,O
and,O
T47D,O
cells,O
led,O
to,O
a,O
several,O
-,O
fold,O
increase,O
in,O
expression,O
of,O
both,O
miRNAs,O
",",O
while,O
simultaneous,O
ChIP,O
analysis,O
confirmed,O
the,O
H3K4,O
demethylation,O
of,O
the,O
corresponding,O
regulatory,O
DNA,O
sequences,O
.,O
In,O
another,O
report,O
",",O
Enkhbaatar,O
et,O
al,O
.,O
[,O
32,O
],O
showed,O
that,O
JARID1B,O
represses,O
transcription,O
of,O
miR-200,O
family,O
by,O
a,O
similar,O
mechanism,O
.,O
Specifically,O
",",O
the,O
overexpression,O
of,O
JARID1B,O
in,O
lung,O
cancer,O
cell,O
line,O
A549,O
resulted,O
in,O
3,O
-,O
fold,O
decrease,O
of,O
miR-200a,O
and,O
miR-200c,O
expression,O
while,O
JARID1B,O
knockdown,O
led,O
to,O
1.5,O
-,O
fold,O
increase,O
of,O
their,O
steady,O
-,O
state,O
levels,O
.,O
Therefore,O
",",O
our,O
results,O
go,O
in,O
accordance,O
with,O
the,O
experimental,O
data,O
showing,O
the,O
existence,O
of,O
regulatory,O
network,O
involving,O
let-7e,O
/,O
miR-125a,O
/,O
miR-200,O
families,O
",",O
histone,O
demethylase,O
JARID1B,O
as,O
well,O
as,O
ACE2,O
/,O
TMPRSS2,O
",",O
and,O
further,O
suggest,O
a,O
new,O
way,O
for,O
regulating,O
ACE2,O
expression,O
.,O
Furthermore,O
",",O
our,O
single,O
-,O
cell,O
RNA,O
sequencing,O
data,O
analysis,O
strongly,O
supports,O
the,O
existence,O
of,O
such,O
interactions,O
in,O
other,O
cells,O
",",O
and,O
indicates,O
that,O
in,O
the,O
majority,O
of,O
human,O
cells,O
ACE2,O
and,O
TMPRSS2,O
are,O
not,O
expressed,O
without,O
JARID1B.,O
In,O
particular,O
",",O
high,O
expression,O
levels,O
of,O
JARID1B,O
",",O
ACE2,O
and,O
TMPRSS2,O
in,O
human,O
respiratory,O
epithelium,O
cells,O
intimate,O
that,O
further,O
investigation,O
of,O
the,O
identified,O
regulatory,O
network,O
could,O
expand,O
our,O
understanding,O
of,O
the,O
viral,O
infection,O
pathogenesis,O
.,O
The,O
potential,O
interactions,O
between,O
ACE2,O
and,O
histone,O
modifiers,O
such,O
as,O
HAT1,O
",",O
HDAC2,O
",",O
and,O
JARID1B,O
in,O
the,O
lung,O
has,O
been,O
previously,O
shown,O
by,O
Pinto,O
and,O
co,O
-,O
authors,O
[,O
33,O
],O
.,O
Furthermore,O
",",O
Gordon,O
D.,O
et,O
al,O
.,O
suggested,O
the,O
inhibition,O
of,O
histone,O
deacetylase,O
2,O
(,O
HDAC2,O
),O
to,O
be,O
used,O
as,O
a,O
promising,O
strategy,O
for,O
COVID-19,O
therapy,O
[,O
34,O
],O
.,O
Interestingly,O
",",O
Valproic,O
acid,O
was,O
also,O
shown,O
to,O
directly,O
inhibit,O
JARID1B,O
in,O
human,O
embryonic,O
kidney,O
cells,O
(,O
HEK,O
293,O
),O
[,O
35,O
],O
and,O
H9,O
human,O
embryonic,O
stem,O
cells,O
(,O
H9,O
hESC,O
),O
[,O
36,O
],O
.,O
The,O
data,O
included,O
samples,O
from,O
several,O
tissues,O
:,O
19,O
for,O
bladder,O
(,O
TCGA-BLCA,S-Dataset
),O
",",O
104,O
for,O
breast,O
(,O
TCGA-BRCA,S-Dataset
),O
",",O
8,O
for,O
colon,O
(,O
TCGA-COAD,S-Dataset
),O
",",O
11,O
for,O
esophagus,O
(,O
TCGA-ESCA,S-Dataset
),O
",",O
127,O
for,O
kidney,O
(,O
TCGA-KICH,S-Dataset
",",O
TCGA-KIRC,S-Dataset
",",O
TCGA-KIRP,S-Dataset
),O
",",O
50,O
for,O
liver,O
(,O
TCGA-LIHC,S-Dataset
),O
",",O
58,O
for,O
lung,O
(,O
TCGA-LUAD,S-Dataset
",",O
TCGA-LUSC,S-Dataset
),O
",",O
52,O
for,O
prostate,O
(,O
TCGA-PRAD,S-Dataset
),O
",",O
32,O
for,O
stomach,O
(,O
TCGA-STAD,S-Dataset
),O
",",O
58,O
for,O
thyroid,O
(,O
TCGA-THCA,S-Dataset
),O
and,O
22,O
for,O
uterine,O
corpus,O
(,O
TCGA-UCEC,S-Dataset
),O
.,O
TransmiR,O
v2.0,O
[,O
47,O
],O
literature,O
-,O
curated,O
database,O
was,O
used,O
to,O
extract,O
information,O
on,O
protein,O
-,O
miRNA,O
regulatory,O
interactions,O
.,O
Development,O
of,O
novel,O
approaches,O
for,O
regulating,O
the,O
expression,O
of,O
angiotensin,O
-,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
and,O
transmembrane,O
serine,O
protease,O
2,O
(,O
TMPRSS2,O
),O
is,O
becoming,O
increasingly,O
important,O
within,O
the,O
context,O
of,O
the,O
ongoing,O
COVID-19,O
pandemic,O
since,O
these,O
enzymes,O
play,O
a,O
crucial,O
role,O
in,O
cell,O
infection,O
.,O
In,O
particular,O
",",O
we,O
found,O
that,O
lysine,O
-,O
specific,O
demethylase,O
5B,O
(,O
JARID1B,O
),O
",",O
encoded,O
by,O
the,O
KDM5B,O
gene,O
",",O
can,O
indirectly,O
affect,O
ACE2,O
/,O
TMPRSS2,O
expression,O
by,O
repressing,O
transcription,O
of,O
hsa,O
-,O
let-7e,O
/,O
hsa,O
-,O
mir-125a,O
and,O
hsa,O
-,O
mir-141,O
/,O
hsa,O
-,O
miR-200,O
miRNA,O
families,O
which,O
are,O
targeting,O
these,O
genes,O
.,O
The,O
entire,O
world,O
is,O
currently,O
under,O
the,O
big,O
threat,O
of,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
caused,O
by,O
the,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
2,O
(,O
SARS,O
CoV2,O
),O
virus,O
.,O
Epidemiological,O
surveys,O
show,O
that,O
diabetic,O
patients,O
are,O
at,O
high,O
risk,O
to,O
contract,O
COVID-19,O
infection,O
[,O
1,O
],O
.,O
More,O
importantly,O
",",O
they,O
are,O
also,O
the,O
major,O
victims,O
of,O
COVID-19,O
associated,O
mortalities,O
.,O
In,O
a,O
study,O
done,O
by,O
the,O
COVID-19,O
surveillance,O
group,O
of,O
Italy,O
on,O
3200,O
patients,O
",",O
34,O
%,O
of,O
481,O
nonsurvivors,O
had,O
diabetes,O
[,O
3,O
],O
.,O
Similarly,O
",",O
reports,O
from,O
the,O
Centers,O
for,O
Diabetes,O
Control,O
and,O
Prevention,O
",",O
United,O
States,O
show,O
that,O
11,O
%,O
of,O
COVID-19,O
patients,O
have,O
diabetes,O
[,O
5,O
],O
.,O
The,O
most,O
populated,O
country,O
like,O
India,O
",",O
more,O
than,O
70,O
%,O
of,O
COVID-19,O
-,O
associated,O
mortalities,O
are,O
due,O
to,O
comorbidities,O
including,O
diabetes,O
",",O
hypertension,O
",",O
CVD,O
",",O
and,O
pulmonary,O
problems,O
.,O
The,O
diabetic,O
population,O
has,O
crossed,O
120,O
million,O
worldwide,O
in,O
2019,O
and,O
this,O
in,O
turn,O
poses,O
an,O
increased,O
threat,O
for,O
further,O
COVID-19,O
infection,O
and,O
related,O
mortalities,O
in,O
these,O
patients,O
in,O
upcoming,O
days,O
.,O
Hence,O
",",O
understanding,O
the,O
pathobiology,O
behind,O
the,O
increased,O
mortality,O
in,O
COVID-19,O
-,O
affected,O
diabetic,O
patients,O
is,O
highly,O
essential,O
to,O
develop,O
prominent,O
prognostic,O
biomarkers,O
and,O
accurate,O
therapies,O
that,O
save,O
their,O
lives,O
.,O
Furin,O
cleaves,O
this,O
S1,O
/,O
S2,O
site,O
and,O
allows,O
viral,O
entry,O
into,O
host,O
cells,O
which,O
in,O
turn,O
leads,O
to,O
the,O
onset,O
of,O
COVID-19,O
infection,O
in,O
humans,O
(,O
Fig,O
.,O
1,O
),O
[,O
9,O
],O
.,O
This,O
in,O
turn,O
broadens,O
the,O
cell,O
tropism,O
of,O
the,O
SARS,O
CoV2,O
virus,O
and,O
may,O
probably,O
be,O
the,O
reason,O
behind,O
the,O
multiple,O
organ,O
damages,O
observed,O
in,O
COVID-19,O
patients,O
.,O
This,O
is,O
proven,O
by,O
the,O
fact,O
that,O
organs,O
severely,O
affected,O
by,O
SARS,O
CoV2,O
infection,O
in,O
COVID-19,O
patients,O
including,O
lungs,O
",",O
liver,O
",",O
kidney,O
express,O
high,O
levels,O
of,O
furin,O
.,O
Hence,O
",",O
furin,O
overexpression,O
in,O
diabetes,O
patients,O
may,O
be,O
the,O
key,O
reason,O
behind,O
their,O
increased,O
risk,O
to,O
contract,O
COVID-19,O
infection,O
.,O
Blood,O
clots,O
are,O
other,O
major,O
fatal,O
complications,O
that,O
cause,O
increased,O
mortalities,O
in,O
COVID-19,O
patients,O
[,O
13,O
],O
.,O
Hence,O
",",O
furin,O
might,O
also,O
be,O
associated,O
with,O
COVID-19,O
-,O
related,O
mortalities,O
that,O
occur,O
due,O
to,O
blood,O
clots,O
.,O
This,O
in,O
turn,O
might,O
increase,O
the,O
susceptibility,O
of,O
diabetes,O
patients,O
to,O
contract,O
COVID-19,O
infection,O
.,O
Hence,O
",",O
it,O
is,O
highly,O
plausible,O
that,O
furin,O
might,O
be,O
the,O
major,O
risk,O
factor,O
for,O
the,O
increased,O
mortality,O
of,O
COVID-19,O
infected,O
diabetes,O
patients,O
.,O
Detailed,O
investigations,O
on,O
the,O
correlation,O
between,O
plasma,O
furin,O
levels,O
",",O
viral,O
load,O
",",O
and,O
severity,O
of,O
fatal,O
complications,O
in,O
COVID-19,O
-,O
infected,O
diabetes,O
patients,O
are,O
very,O
much,O
needed,O
to,O
decipher,O
the,O
link,O
between,O
furin,O
and,O
prognosis,O
status,O
in,O
these,O
patients,O
.,O
These,O
findings,O
will,O
aid,O
in,O
determining,O
if,O
plasma,O
furin,O
could,O
act,O
as,O
a,O
prominent,O
prognostic,O
biomarker,O
in,O
COVID-19,O
patients,O
.,O
Also,O
",",O
it,O
will,O
provide,O
clues,O
for,O
the,O
utilization,O
of,O
furin,O
inhibitors,O
to,O
save,O
the,O
lives,O
of,O
COVID-19,O
-,O
infected,O
diabetes,O
patients,O
.,O
On,O
January,O
23,O
",",O
2020,O
",",O
a,O
case,O
of,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
was,O
detected,O
in,O
Toronto,O
",",O
Canada,O
(,O
),O
;,O
since,O
then,O
",",O
multiple,O
cases,O
have,O
been,O
identified,O
across,O
Canada,O
.,O
The,O
next,O
day,O
",",O
we,O
collected,O
200,O
μL,O
of,O
mid,O
-,O
turbinate,O
swab,O
samples,O
from,O
2,O
COVID-19,O
patients,O
",",O
mixed,O
it,O
with,O
200,O
μL,O
of,O
DMEM,O
containing,O
16,O
μg,O
/,O
mL,O
TPCK,O
-,O
treated,O
trypsin,O
and,O
inoculated,O
the,O
cells,O
.,O
Supernatant,O
from,O
the,O
cells,O
was,O
used,O
to,O
determine,O
virus,O
titers,O
(,O
50,O
%,O
tissue,O
culture,O
infectious,O
dose,O
[,O
TCID50]/mL,O
),O
according,O
to,O
the,O
Spearman,O
and,O
Karber,O
method,O
(,O
",",O
),O
as,O
outlined,O
previously,O
(,O
),O
.,O
For,O
primary,O
antibody,O
staining,O
",",O
we,O
used,O
a,O
combination,O
of,O
6.6,O
μg,O
/,O
mL,O
rabbit,O
anti,O
-,O
SARS,O
-,O
CoV-2,O
N,O
(,O
BioVision,O
",",O
https://www.biovision.com,O
),O
plus,O
10,O
μg,O
/,O
mL,O
recombinant,O
human,O
anti,O
-,O
SARS,O
-,O
CoV-2,O
spike,O
S1,O
(,O
GenScript,O
",",O
https://www.genscript.com,O
),O
and,O
1:100,O
diluted,O
serum,O
from,O
a,O
recovered,O
COVID-19,O
patient,O
(,O
OM8073,O
),O
(,O
Figure,O
1,O
",",O
panels,O
A,O
",",O
B,O
),O
.,O
Furthermore,O
",",O
maximum,O
-,O
likelihood,O
phylogenetic,O
analysis,O
including,O
>,O
"1,900",O
SARS,O
-,O
CoV-2,O
isolates,O
from,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org,S-URL
),O
placed,O
both,O
SARS,O
-,O
CoV-2,O
/,O
SB2,O
and,O
SARS,O
-,O
CoV-2,O
/,O
SB3,O
-,O
TYAGNC,O
within,O
a,O
clade,O
of,O
isolates,O
from,O
patients,O
around,O
the,O
globe,O
but,O
with,O
evidence,O
of,O
travel,O
history,O
associated,O
with,O
the,O
COVID-19,O
outbreak,O
in,O
Iran,O
(,O
Appendix,O
Figure,O
2,O
),O
.,O
To,O
enhance,O
our,O
ability,O
to,O
detect,O
SARS,O
-,O
CoV-2,O
proteins,O
in,O
these,O
cells,O
",",O
we,O
immunostained,O
the,O
cells,O
by,O
using,O
a,O
cocktail,O
of,O
antibodies,O
that,O
included,O
SARS,O
-,O
CoV-2,O
S1,O
antibody,O
",",O
SARS,O
-,O
CoV-2,O
N,O
antibody,O
",",O
and,O
diluted,O
serum,O
from,O
a,O
recovered,O
COVID-19,O
patient,O
(,O
Figure,O
1,O
",",O
panels,O
A,O
and,O
B,O
),O
.,O
We,O
report,O
the,O
isolation,O
of,O
2,O
replication,O
competent,O
SARS,O
-,O
CoV-2,O
virus,O
samples,O
from,O
COVID-19,O
patients,O
in,O
Canada,O
.,O
After,O
only,O
2,O
months,O
",",O
the,O
epidemic,O
of,O
COVID‐19,O
is,O
already,O
larger,O
than,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
coronavirus,O
(,O
SARS‐CoV,O
),O
outbreak,O
",",O
which,O
during,O
2002/2003,O
lasted,O
8,O
months,O
and,O
infected,O
8096,O
people,O
",",O
with,O
a,O
mortality,O
rate,O
of,O
9·5,O
%,O
.,O
This,O
lack,O
of,O
homologous,O
DNA,O
sequences,O
was,O
a,O
bit,O
surprising,O
",",O
as,O
Lu,O
et,O
al,O
.,O
(,O
12,O
),O
recently,O
published,O
a,O
phylogenetic,O
tree,O
based,O
on,O
50,O
genome,O
sequences,O
(,O
including,O
10,O
2019_nCoV,O
isolates,O
),O
with,O
high,O
bootstrap,O
values,O
",",O
which,O
can,O
only,O
be,O
obtained,O
with,O
sufficient,O
degrees,O
of,O
conservation,O
between,O
members,O
of,O
the,O
data,O
set,O
.,O
However,O
",",O
the,O
database,O
is,O
highly,O
biased,O
towards,O
particular,O
bat,O
species,O
that,O
were,O
specifically,O
sampled,O
in,O
search,O
of,O
the,O
source,O
of,O
SARS,O
.,O
Coronavirus,O
disease,O
(,O
COVID-19,O
),O
",",O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
has,O
spread,O
rapidly,O
around,O
the,O
world,O
since,O
the,O
first,O
cases,O
were,O
reported,O
in,O
late,O
2019,O
(,O
",",O
),O
.,O
Prior,O
to,O
April,O
9,O
",",O
2020,O
",",O
Heilongjiang,O
Province,O
",",O
China,O
",",O
had,O
not,O
reported,O
a,O
new,O
COVID-19,O
diagnosis,O
since,O
March,O
11,O
",",O
2020,O
.,O
We,O
defined,O
confirmed,O
COVID-19,O
cases,O
as,O
persons,O
who,O
tested,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
and,O
had,O
clinical,O
symptoms,O
.,O
On,O
April,O
9,O
",",O
investigators,O
also,O
learned,O
that,O
A0,O
",",O
B1.1,O
’s,O
neighbor,O
",",O
had,O
returned,O
on,O
March,O
19,O
from,O
the,O
United,O
States,O
",",O
where,O
COVID-19,O
cases,O
had,O
been,O
detected,O
.,O
Emerging,O
infectious,O
diseases,O
(,O
EIDs,O
),O
represent,O
a,O
significant,O
challenge,O
to,O
global,O
health,O
.,O
The,O
frequency,O
of,O
EID,O
outbreaks,O
has,O
dramatically,O
increased,O
over,O
the,O
last,O
decades,O
.,O
Most,O
EIDs,O
have,O
a,O
zoonotic,O
origin,O
;,O
more,O
than,O
70,O
%,O
of,O
them,O
are,O
caused,O
by,O
pathogens,O
originating,O
from,O
wildlife,O
[,O
1,O
],O
.,O
The,O
ongoing,O
outbreak,O
with,O
the,O
new,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
responsible,O
for,O
the,O
COVID-19,O
pandemic,O
",",O
is,O
a,O
perfect,O
illustration,O
of,O
the,O
potential,O
impact,O
and,O
the,O
global,O
consequences,O
resulting,O
from,O
a,O
single,O
cross,O
-,O
species,O
transmission,O
from,O
an,O
animal,O
virus,O
.,O
It,O
is,O
thus,O
important,O
to,O
be,O
prepared,O
for,O
new,O
EID,O
outbreaks,O
.,O
The,O
current,O
COVID-19,O
outbreak,O
with,O
the,O
SARS,O
-,O
CoV-2,O
virus,O
",",O
is,O
the,O
seventh,O
coronavirus,O
(,O
CoV,O
),O
identified,O
in,O
humans,O
since,O
the,O
1960s,O
[,O
"6,7",O
],O
.,O
Here,O
we,O
conducted,O
a,O
pilot,O
study,O
on,O
the,O
presence,O
of,O
CoVs,O
in,O
bats,O
in,O
Guinea,O
",",O
West,O
Africa,O
",",O
a,O
country,O
with,O
a,O
high,O
likelihood,O
for,O
EID,O
outbreaks,O
and,O
where,O
humans,O
are,O
frequently,O
directly,O
or,O
indirectly,O
exposed,O
to,O
bats,O
(,O
A.K.,O
Keita,O
",",O
personal,O
observation,O
),O
.,O
The,O
new,O
sequences,O
were,O
deposited,O
in,O
the,O
GenBank,S-Repository
 ,O
under,O
accession,O
numbers,O
MT586773,S-AccessionNumber
-,O
MT586805,S-AccessionNumber
.,O
The,O
new,O
sequences,O
were,O
deposited,O
in,O
GenBank,S-Repository
 ,O
under,O
accession,O
numbers,O
MT586830,S-AccessionNumber
-,O
MT586867,S-AccessionNumber
.,O
Zoonoses,O
can,O
constitute,O
a,O
threat,O
for,O
public,O
health,O
that,O
can,O
have,O
a,O
global,O
importance,O
",",O
as,O
seen,O
with,O
the,O
current,O
COVID-19,O
pandemic,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
(,O
SARS,O
-,O
CoV2,O
),O
.,O
The,O
outbreak,O
of,O
coronavirus,O
COVID-19,O
has,O
become,O
a,O
most,O
challenging,O
health,O
emergency,O
in,O
over,O
the,O
world,O
[,O
"4,5",O
],O
.,O
The,O
number,O
of,O
deaths,O
associated,O
COVID-19,O
is,O
greatly,O
higher,O
than,O
the,O
other,O
two,O
coronaviruses,O
(,O
SARS,O
-,O
CoV,O
and,O
MERS,O
-,O
CoV,O
),O
",",O
and,O
the,O
outbreak,O
is,O
still,O
ongoing,O
",",O
which,O
global,O
concern,O
to,O
the,O
public,O
health,O
and,O
economics,O
[,O
14,O
],O
.,O
The,O
most,O
common,O
symptoms,O
of,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
are,O
fever,O
",",O
tiredness,O
",",O
and,O
dry,O
cough,O
.,O
There,O
are,O
no,O
specific,O
vaccines,O
or,O
treatments,O
for,O
COVID-19,O
[,O
17,O
],O
.,O
That,O
could,O
be,O
used,O
as,O
peptide,O
vaccines,O
against,O
SARS,O
-,O
CoV-2,O
/,O
COVID-19,O
.,O
The,O
S,O
protein,O
sequence,O
was,O
retrieved,O
from,O
NCBI,S-Repository
 ,O
at,O
http://www.ncbi.nlm.nih.gov/protein,S-URL
 ,O
and,O
saved,O
in,O
FASTA,O
format,O
for,O
further,O
analyses,O
;,O
then,O
Protein,O
BLAST,O
(,O
http://blast.ncbi.nlm.nih.gov/Blast.cgi,O
),O
against,O
reference,O
sequence,O
on,O
the,O
database,O
was,O
performed,O
using,O
Blosum80,O
matrix,O
to,O
collect,O
homologous,O
sequences,O
between,O
different,O
Coronaviruses,O
.,O
S,O
protein,O
sequence,O
with,O
accession,O
No,O
.,O
QII57161.1,S-AccessionNumber
 ,O
is,O
available,O
as,O
a,O
query,O
for,O
protein,O
BLAST,O
against,O
Coronavirus,O
producing,O
a,O
set,O
of,O
sequences,O
containing,O
various,O
species,O
of,O
Coronaviruses,O
.,O
The,O
best,O
epitopes,O
recommended,O
by,O
this,O
server,O
are,O
‘,O
‘,O
LNEVAKNLNESLIDLQELGK,O
’,O
‘,O
",",O
“,O
TLVKQLSSNFGAISSVLNDI,O
”,O
",",O
“,O
QQLIRAAEIRASANLAATKM,O
”,O
and,O
“,O
KEELDKYFKNHTSPDVDLGD,O
”,O
at,O
regions,O
1186–1205,O
",",O
961–980,O
",",O
1010–1029,O
and,O
1149–1168,O
respectively,O
.,O
Coronavirus,O
disease,O
(,O
COVID-19,O
),O
is,O
an,O
infectious,O
disease,O
caused,O
by,O
a,O
newly,O
discovered,O
coronavirus,O
that,O
it,O
disease,O
spreads,O
in,O
over,O
the,O
world,O
.,O
Most,O
people,O
infected,O
with,O
the,O
COVID-19,O
virus,O
will,O
experience,O
mild,O
to,O
moderate,O
respiratory,O
illness,O
and,O
recover,O
without,O
requiring,O
special,O
treatment,O
.,O
At,O
this,O
time,O
",",O
there,O
are,O
no,O
specific,O
vaccines,O
or,O
treatments,O
for,O
COVID-19,O
.,O
The,O
pandemic,O
of,O
COVID-19,O
",",O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
has,O
posed,O
a,O
serious,O
threat,O
to,O
global,O
public,O
health,O
",",O
calling,O
for,O
the,O
development,O
of,O
reliable,O
diagnostic,O
tests,O
",",O
able,O
to,O
identify,O
(,O
and,O
possibly,O
quantify,O
),O
SARS,O
-,O
CoV-2,O
.,O
The,O
persistently,O
negative,O
rtPCR,O
results,O
in,O
patients,O
with,O
clinical,O
suspects,O
of,O
COVID-19,O
",",O
and,O
no,O
alternative,O
diagnosis,O
",",O
could,O
be,O
related,O
to,O
the,O
lower,O
viral,O
titers,O
that,O
characterize,O
the,O
most,O
widely,O
used,O
nasopharyngeal,O
samples,O
[,O
7,O
],O
in,O
comparison,O
to,O
other,O
respiratory,O
specimens,O
",",O
such,O
as,O
sputum,O
[,O
8,O
],O
",",O
as,O
well,O
as,O
to,O
the,O
replication,O
kinetics,O
of,O
the,O
virus,O
.,O
Standing,O
the,O
necessity,O
of,O
a,O
limitation,O
(,O
as,O
much,O
as,O
possible,O
),O
of,O
false,O
negative,O
results,O
in,O
COVID-19,O
diagnosis,O
",",O
the,O
use,O
of,O
ddPCR,O
could,O
provide,O
a,O
critical,O
support,O
[,O
8,O
],O
.,O
All,O
patients,O
were,O
symptomatic,O
with,O
exception,O
of,O
one,O
(,O
COVID-19,O
contact,O
),O
and,O
thus,O
immediately,O
hospitalized,O
and,O
tested,O
for,O
SARS,O
-,O
CoV-2,O
rtPCR,O
",",O
whose,O
result,O
was,O
negative,O
.,O
Of,O
note,O
",",O
a,O
severe,O
COVID-19,O
manifestation,O
characterized,O
14,O
of,O
the,O
19,O
patients,O
with,O
a,O
ddPCR,O
confirmed,O
SARS,O
-,O
CoV-2,O
infection,O
(,O
73.7,O
%,O
",",O
S1,O
Table,O
),O
.,O
The,O
SARS,O
-,O
CoV-2,O
RNA,O
positivity,O
in,O
the,O
5,O
samples,O
with,O
a,O
serological,O
assay,O
not,O
available,O
(,O
ID,O
1,O
",",O
4,O
",",O
8,O
",",O
12,O
",",O
13,O
),O
was,O
further,O
confirmed,O
by,O
using,O
a,O
second,O
assay,O
adapted,O
for,O
ddPCR,O
and,O
targeting,O
two,O
different,O
portions,O
of,O
RdRp,O
[,O
17,O
],O
.,O
SARS,O
-,O
CoV-2,O
was,O
detected,O
at,O
later,O
time,O
points,O
also,O
by,O
standard,O
qualitative,O
rtPCR,O
for,O
three,O
of,O
these,O
five,O
patients,O
(,O
ID,O
1,O
",",O
4,O
",",O
8,O
",",O
S1,O
Table,O
),O
.,O
By,O
using,O
this,O
reliable,O
",",O
reproducible,O
and,O
highly,O
sensitive,O
assay,O
",",O
we,O
could,O
improve,O
the,O
efficiency,O
of,O
COVID-19,O
diagnosis,O
on,O
nasopharyngeal,O
swabs,O
even,O
at,O
a,O
very,O
early,O
stage,O
of,O
viral,O
replication,O
",",O
or,O
in,O
anatomical,O
districts,O
where,O
the,O
virus,O
is,O
present,O
at,O
lower,O
levels,O
",",O
such,O
as,O
the,O
oropharyngeal,O
or,O
the,O
nasopharyngeal,O
samples,O
[,O
8,O
",",O
9,O
],O
.,O
In,O
the,O
context,O
of,O
COVID-19,O
diagnosis,O
",",O
two,O
recent,O
studies,O
highlight,O
the,O
best,O
performances,O
of,O
ddPCR,O
in,O
detecting,O
low,O
viral,O
load,O
samples,O
[,O
"19,20",O
],O
.,O
In,O
particular,O
",",O
without,O
this,O
assay,O
",",O
no,O
molecular,O
laboratory,O
confirmation,O
of,O
SARS,O
-,O
CoV-2,O
would,O
have,O
been,O
available,O
at,O
hospitalization,O
for,O
12,O
patients,O
",",O
all,O
characterized,O
by,O
a,O
severe,O
COVID-19,O
manifestation,O
and,O
with,O
evidence,O
of,O
bilateral,O
interstitial,O
pneumonia,O
",",O
and,O
for,O
two,O
patients,O
affected,O
by,O
pneumonia,O
with,O
pleuritis,O
(,O
n,O
=,O
1,O
),O
",",O
and,O
lung,O
cancer,O
(,O
n,O
=,O
1,O
),O
",",O
for,O
whom,O
the,O
mere,O
clinical,O
evaluation,O
excluded,O
the,O
COVID-19,O
.,O
Since,O
SARS,O
-,O
CoV-2,O
-,O
based,O
disease,O
(,O
COVID-19,O
),O
spreads,O
as,O
a,O
pandemic,O
",",O
the,O
necessity,O
of,O
a,O
highly,O
sensitive,O
molecular,O
diagnosis,O
that,O
can,O
drastically,O
reduce,O
false,O
negatives,O
reverse,O
transcription,O
PCR,O
(,O
rtPCR,O
),O
results,O
",",O
raises,O
as,O
a,O
major,O
clinical,O
need,O
.,O
Here,O
we,O
evaluated,O
the,O
performance,O
of,O
a,O
ddPCR,O
-,O
based,O
assay,O
to,O
quantify,O
SARS,O
-,O
CoV-2,O
titer,O
in,O
55,O
suspected,O
COVID-19,O
cases,O
with,O
negative,O
rtPCR,O
results,O
thanks,O
to,O
in,O
-,O
house,O
ddPCR,O
assay,O
(,O
targeting,O
RdRp,O
and,O
host,O
RNaseP,O
),O
.,O
In,O
15,O
of,O
them,O
(,O
78.9,O
%,O
),O
",",O
chest,O
CT,O
showed,O
a,O
classical,O
COVID-19,O
bilateral,O
interstitial,O
pneumonia,O
;,O
14,O
patients,O
(,O
73.7,O
%,O
),O
showed,O
severe,O
COVID-19,O
manifestations,O
.,O
Thanks,O
to,O
a,O
ddPCR,O
-,O
based,O
assay,O
",",O
we,O
achieved,O
a,O
rapid,O
and,O
accurate,O
SARS,O
-,O
CoV-2,O
diagnosis,O
in,O
rtPCR,O
-,O
negative,O
respiratory,O
samples,O
of,O
individuals,O
with,O
COVID-19,O
suspect,O
",",O
allowing,O
the,O
rapid,O
taking,O
care,O
and,O
correct,O
management,O
of,O
these,O
patients,O
.,O
Subsequently,O
",",O
the,O
virus,O
spread,O
globally,O
causing,O
a,O
pathological,O
condition,O
which,O
was,O
termed,O
as,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
and,O
the,O
pathogen,O
was,O
named,O
as,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
The,O
synonymous,O
codon,O
usage,O
data,O
of,O
human,O
",",O
dog,O
",",O
cat,O
",",O
pig,O
",",O
horse,O
and,O
cattle,O
were,O
retrieved,O
from,O
the,O
codon,O
usage,O
database,O
(,O
http://www.kazusa.or.jp/codon/,S-URL
),O
",",O
whereas,O
for,O
bat,O
",",O
the,O
sequence,O
of,O
Pteropus,O
vampyrus,O
(,O
NW_011888782,S-AccessionNumber
),O
was,O
retrieved,O
from,O
NCBI,S-Repository
 ,O
(,O
https://www.ncbi.nlm.nih.gov,S-URL
),O
and,O
by,O
using,O
online,O
program,O
‘,O
Countcodon,O
’,O
(,O
available,O
at,O
:,O
http://www.kazusa.or.jp/codon/countcodon.html,O
),O
the,O
reference,O
codon,O
usage,O
table,O
for,O
bat,O
was,O
prepared,O
.,O
Another,O
web,O
-,O
based,O
tool,O
was,O
used,O
to,O
obtain,O
the,O
tRNA,O
database,O
(,O
GtRNAdb,S-Repository
:,O
Genomic,O
tRNA,O
database,O
),O
.,O
Higher,O
average,O
CAI,O
values,O
of,O
human,O
compared,O
to,O
dog,O
observed,O
in,O
the,O
present,O
study,O
indicated,O
that,O
dog,O
is,O
less,O
susceptible,O
to,O
COVID,O
19,O
than,O
human,O
.,O
In,O
the,O
UK,O
",",O
the,O
death,O
toll,O
from,O
severe,O
COVID-19,O
is,O
among,O
the,O
highest,O
worldwide,O
.,O
Severe,O
COVID-19,O
is,O
characterised,O
by,O
respiratory,O
failure,O
",",O
with,O
so,O
-,O
called,O
cytokine,O
storm,O
occurring,O
in,O
some,O
patient,O
subsets,O
.,O
Pathological,O
correlates,O
are,O
required,O
to,O
understand,O
the,O
pathophysiology,O
of,O
COVID-19,O
.,O
In,O
anticipation,O
of,O
the,O
COVID-19,O
pandemic,O
",",O
our,O
group,O
produced,O
national,O
guidelines,O
for,O
autopsy,O
performance,O
in,O
suspected,O
COVID-19,O
cases,O
.,O
COVID-19,O
is,O
caused,O
by,O
infection,O
with,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2).4,O
",",O
5,O
Although,O
SARS,O
-,O
CoV-2,O
and,O
its,O
predecessor,O
SARS,O
-,O
CoV,O
(,O
causing,O
severe,O
acute,O
respiratory,O
syndrome,O
[,O
SARS,O
],O
),O
are,O
similar,O
on,O
a,O
molecular,O
and,O
clinical,O
level,O
",",O
COVID-19,O
has,O
a,O
lower,O
death,O
rate,O
(,O
4,O
%,O
for,O
COVID-19,O
vs,O
15,O
%,O
for,O
SARS,O
),O
and,O
a,O
substantially,O
higher,O
death,O
toll,O
(,O
700,O
 ,O
539,O
deaths,O
worldwide,O
from,O
COVID-19,O
as,O
of,O
Aug,O
5,O
",",O
2020,O
vs,O
774,O
from,O
SARS,O
),O
than,O
SARS,O
due,O
to,O
a,O
higher,O
basic,O
reproduction,O
number,O
.,O
Various,O
autopsy,O
series,O
on,O
COVID-19,O
have,O
begun,O
to,O
emerge,O
in,O
the,O
literature.7,O
",",O
8,O
",",O
9,O
",",O
10,O
",",O
11,O
",",O
12,O
",",O
13,O
",",O
14,O
",",O
15,O
Here,O
",",O
we,O
document,O
the,O
major,O
pathological,O
findings,O
of,O
ten,O
post,O
-,O
mortem,O
examinations,O
done,O
on,O
patients,O
with,O
clinically,O
confirmed,O
COVID-19,O
.,O
The,O
conclusion,O
by,O
Copin,O
and,O
colleagues,O
that,O
COVID-19,O
-,O
related,O
lung,O
injury,O
“,O
is,O
not,O
diffuse,O
alveolar,O
damage,O
”,O
might,O
relate,O
to,O
their,O
sampling,O
strategy,O
and,O
chronicity,O
(,O
five,O
patients,O
had,O
spent,O
approximately,O
3,O
weeks,O
on,O
a,O
ventilator,O
),O
.,O
Reports,O
of,O
lung,O
histology,O
in,O
early,O
COVID-19,O
also,O
suggest,O
a,O
degree,O
of,O
lymphocytic,O
pneumonia,O
",",O
although,O
DAD,O
is,O
probably,O
superimposed,O
on,O
this,O
over,O
time,O
in,O
the,O
majority,O
of,O
fatal,O
cases,O
.,O
Pulmonary,O
macrophage,O
infiltration,O
and,O
multinucleated,O
giant,O
cell,O
reactions,O
are,O
prominent,O
",",O
similar,O
to,O
other,O
series.8,O
",",O
9,O
",",O
10,O
",",O
11,O
",",O
12,O
Definite,O
evidence,O
of,O
tissue,O
-,O
related,O
lymphocyte,O
depletion,O
in,O
COVID-19,O
will,O
require,O
quantitative,O
analysis,O
comparing,O
tissues,O
from,O
COVID-19,O
patients,O
with,O
DAD,O
associated,O
with,O
other,O
conditions,O
and,O
unaffected,O
tissues,O
.,O
Several,O
cases,O
of,O
invasive,O
pulmonary,O
aspergillosis,O
have,O
been,O
reported,O
in,O
patients,O
with,O
severe,O
COVID-19,O
pneumonia,O
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
description,O
of,O
histologically,O
proven,O
mucormycosis,O
in,O
patients,O
with,O
COVID-19,O
and,O
suggests,O
that,O
other,O
human,O
fungal,O
pathogens,O
",",O
including,O
members,O
of,O
Mucoromycotina,O
",",O
can,O
complicate,O
COVID-19,O
-,O
associated,O
infections,O
.,O
Numerous,O
clinical,O
features,O
",",O
including,O
raised,O
serum,O
D,O
-,O
dimer,O
concentrations,O
",",O
raised,O
pro,O
-,O
calcitonin,O
concentrations,O
",",O
and,O
imaging,O
findings,O
",",O
suggest,O
thrombosis,O
is,O
prominent,O
in,O
patients,O
with,O
COVID-19,O
.,O
Thrombotic,O
features,O
were,O
universal,O
among,O
patients,O
who,O
underwent,O
full,O
autopsies,O
(,O
all,O
nine,O
patients,O
had,O
thrombi,O
in,O
at,O
least,O
one,O
major,O
organ,O
),O
and,O
have,O
been,O
noted,O
to,O
be,O
prominent,O
in,O
other,O
COVID-19,O
autopsy,O
series,O
.,O
Whether,O
thrombosis,O
in,O
COVID-19,O
is,O
more,O
common,O
than,O
in,O
other,O
causes,O
of,O
DAD,O
remains,O
uncertain,O
;,O
however,O
",",O
our,O
data,O
support,O
thrombosis,O
as,O
being,O
a,O
striking,O
feature,O
in,O
these,O
patients,O
.,O
A,O
study,O
suggested,O
endotheliitis,O
as,O
a,O
prominent,O
feature,O
in,O
patients,O
with,O
severe,O
COVID-19,O
",",O
but,O
this,O
was,O
not,O
a,O
prominent,O
feature,O
in,O
our,O
patients,O
.,O
A,O
raised,O
cytokine,O
profile,O
has,O
been,O
documented,O
in,O
a,O
subset,O
of,O
patients,O
with,O
severe,O
COVID-19,O
.,O
A,O
substantial,O
feature,O
in,O
COVID-19,O
is,O
lymphocyte,O
depletion,O
",",O
and,O
this,O
is,O
supported,O
in,O
our,O
series,O
by,O
the,O
spleen,O
and,O
lymph,O
node,O
findings,O
.,O
When,O
compared,O
with,O
those,O
with,O
mild,O
disease,O
",",O
patients,O
with,O
severe,O
COVID-19,O
tend,O
to,O
have,O
a,O
higher,O
neutrophil,O
to,O
lymphocyte,O
ratio,O
and,O
higher,O
CD4,O
-,O
positive,O
to,O
CD8,O
-,O
positive,O
T,O
-,O
cell,O
ratio,O
.,O
We,O
have,O
corroborated,O
this,O
evidence,O
by,O
documenting,O
a,O
low,O
number,O
of,O
T,O
cells,O
(,O
especially,O
CD8,O
-,O
positive,O
T,O
cells,O
and,O
FOXP3,O
-,O
positive,O
regulatory,O
T,O
cells,O
),O
in,O
the,O
spleen,O
and,O
lymph,O
nodes,O
in,O
severe,O
fatal,O
COVID-19,O
.,O
A,O
report,O
identified,O
low,O
viral,O
load,O
in,O
the,O
brain,O
of,O
three,O
of,O
18,O
patients,O
with,O
COVID-19,O
",",O
but,O
could,O
not,O
detect,O
the,O
virus,O
in,O
subsequent,O
immunohistochemistry,O
and,O
concluded,O
that,O
the,O
viral,O
genomes,O
might,O
have,O
been,O
present,O
in,O
the,O
blood,O
.,O
Pancreatic,O
pathology,O
was,O
a,O
major,O
unexpected,O
pathology,O
in,O
this,O
series,O
",",O
which,O
had,O
not,O
been,O
previously,O
reported,O
in,O
COVID-19,O
autopsies,O
or,O
large,O
clinical,O
COVID-19,O
series,O
.,O
Serum,O
amylase,O
is,O
not,O
part,O
of,O
the,O
routine,O
care,O
bundle,O
for,O
COVID-19,O
in,O
our,O
Trust,O
.,O
Most,O
cases,O
had,O
evidence,O
of,O
hepatic,O
steatosis,O
",",O
which,O
is,O
consistent,O
with,O
clinical,O
findings,O
that,O
obesity,O
is,O
a,O
risk,O
factor,O
for,O
poor,O
outcome,O
in,O
COVID-19,O
",",O
and,O
liver,O
cirrhosis,O
or,O
bridging,O
fibrosis,O
was,O
prominent,O
in,O
this,O
cohort,O
.,O
Background,O
 ,O
Severe,O
COVID-19,O
has,O
a,O
high,O
mortality,O
rate,O
.,O
Comprehensive,O
pathological,O
descriptions,O
of,O
COVID-19,O
are,O
scarce,O
and,O
limited,O
in,O
scope,O
.,O
We,O
aimed,O
to,O
describe,O
the,O
histopathological,O
findings,O
and,O
viral,O
tropism,O
in,O
patients,O
who,O
died,O
of,O
severe,O
COVID-19,O
.,O
In,O
this,O
case,O
series,O
",",O
patients,O
were,O
considered,O
eligible,O
if,O
they,O
were,O
older,O
than,O
18,O
years,O
",",O
with,O
premortem,O
diagnosis,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
infection,O
and,O
COVID-19,O
listed,O
clinically,O
as,O
the,O
direct,O
cause,O
of,O
death,O
.,O
Between,O
March,O
1,O
and,O
April,O
30,O
",",O
2020,O
",",O
full,O
post,O
-,O
mortem,O
examinations,O
were,O
done,O
on,O
nine,O
patients,O
with,O
confirmed,O
COVID-19,O
",",O
including,O
sampling,O
of,O
all,O
major,O
organs,O
.,O
Our,O
series,O
supports,O
clinical,O
data,O
showing,O
that,O
the,O
four,O
dominant,O
interrelated,O
pathological,O
processes,O
in,O
severe,O
COVID-19,O
are,O
diffuse,O
alveolar,O
damage,O
",",O
thrombosis,O
",",O
haemophagocytosis,O
",",O
and,O
immune,O
cell,O
depletion,O
.,O
Additionally,O
",",O
we,O
report,O
here,O
several,O
novel,O
autopsy,O
findings,O
including,O
pancreatitis,O
",",O
pericarditis,O
",",O
adrenal,O
micro,O
-,O
infarction,O
",",O
secondary,O
disseminated,O
mucormycosis,O
",",O
and,O
brain,O
microglial,O
activation,O
",",O
which,O
require,O
additional,O
investigation,O
to,O
understand,O
their,O
role,O
in,O
COVID-19,O
.,O
Briefly,O
",",O
reads,O
containing,O
adaptor,O
sequences,O
and,O
low,O
-,O
complex,O
regions,O
were,O
removed,O
from,O
the,O
dataset,O
.,O
All,O
non,O
-,O
human,O
and,O
non,O
-,O
repeat,O
sequence,O
reads,O
were,O
then,O
compared,O
to,O
a,O
reference,O
virus,O
database,O
(,O
downloaded,O
from,O
https://ftp.ncbi.nih.gov/blast/db/ref_viruses_rep_genomes.tar.gz,S-URL
),O
and,O
the,O
non,O
-,O
redundant,O
protein,O
database,O
(,O
nr,O
),O
using,O
blastn,O
and,O
diamond,O
blastx,O
programs,O
[,O
4,O
],O
",",O
respectively,O
.,O
Taxonomy,O
lineage,O
information,O
was,O
obtained,O
for,O
each,O
blast,O
hits,O
by,O
matching,O
the,O
accession,O
number,O
with,O
the,O
taxonomy,O
database,O
",",O
which,O
was,O
subsequently,O
used,O
to,O
identify,O
reads,O
of,O
virus,O
origin,O
.,O
The,O
entire,O
viral,O
genome,O
is,O
"29,881",O
 ,O
nt,O
in,O
length,O
(,O
GenBank,S-Repository
 ,O
MN988668,S-AccessionNumber
 ,O
and,O
MN988669,S-AccessionNumber
",",O
Sequence,B-Repository
Read,I-Repository
Archive,E-Repository
 ,O
database,O
Bioproject,O
accession,O
PRJNA601736,S-AccessionNumber
),O
and,O
is,O
classified,O
into,O
β,O
-,O
coronavirus,O
genus,O
.,O
In,O
this,O
paper,O
we,O
discuss,O
ethical,O
implications,O
of,O
the,O
use,O
of,O
mobile,O
phone,O
apps,O
in,O
the,O
control,O
of,O
the,O
COVID-19,O
pandemic,O
.,O
However,O
",",O
the,O
high,O
proportion,O
of,O
pre,O
-,O
symptomatic,O
transmission,O
in,O
COVID-19,O
means,O
that,O
standard,O
contact,O
tracing,O
methods,O
are,O
too,O
slow,O
to,O
stop,O
the,O
progression,O
of,O
infection,O
through,O
the,O
population,O
.,O
The,O
recent,O
pandemic,O
of,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
which,O
is,O
caused,O
by,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
has,O
become,O
one,O
of,O
the,O
major,O
health,O
concerns,O
of,O
the,O
21st,O
century,O
[,O
1,O
],O
.,O
Therefore,O
",",O
drug,O
-,O
repurposing,O
attempts,O
aimed,O
at,O
identification,O
of,O
efficient,O
therapeutic,O
agents,O
for,O
the,O
treatment,O
of,O
COVID-19,O
has,O
emerged,O
as,O
a,O
promising,O
approach,O
to,O
compensate,O
for,O
this,O
urgent,O
need,O
.,O
Studies,O
were,O
selected,O
as,O
they,O
provide,O
the,O
latest,O
curated,O
data,O
regarding,O
the,O
dataset,O
.,O
The,O
effect,O
of,O
USP13,O
(,O
Affymetrix,S-Repository
 ,O
ID,O
:,O
226902_at,S-AccessionNumber
),O
mRNA,O
expression,O
levels,O
on,O
overall,O
survival,O
was,O
assessed,O
via,O
Kaplan,O
-,O
Meier,O
Plotter,O
(,O
https://kmplot.com/analysis/,O
),O
[,O
21,O
],O
.,O
In,O
order,O
to,O
analyze,O
the,O
effect,O
of,O
USP13,O
somatic,O
copy,O
number,O
alterations,O
on,O
immune,O
cell,O
infiltration,O
",",O
TIMER,O
analysis,O
was,O
performed,O
on,O
all,O
TCGA,S-Repository
 ,O
datasets,O
",",O
which,O
showed,O
significant,O
correlation,O
in,O
Head,O
-,O
Neck,O
Squamous,O
Cell,O
Carcinoma,O
(,O
HNSC,O
),O
",",O
LUAD,O
",",O
LUSC,O
",",O
STAD,O
and,O
OV,O
tumors,O
(,O
Fig,O
.,O
4,O
),O
.,O
COVID-19,O
is,O
currently,O
one,O
of,O
the,O
most,O
urgent,O
health,O
issues,O
that,O
need,O
immediate,O
attention,O
worldwide,O
.,O
One,O
explanation,O
for,O
this,O
unexpected,O
result,O
could,O
be,O
that,O
different,O
analyses,O
might,O
have,O
been,O
run,O
on,O
different,O
datasets,O
for,O
the,O
same,O
cancer,O
type,O
.,O
Aims,O
 ,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
which,O
is,O
caused,O
by,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
is,O
a,O
major,O
health,O
concern,O
worldwide,O
.,O
Although,O
the,O
latest,O
data,O
are,O
not,O
yet,O
available,O
",",O
it,O
is,O
likely,O
that,O
the,O
vaccination,O
rate,O
would,O
not,O
change,O
significantly,O
in,O
2020,O
.,O
Identification,O
and,O
rapid,O
global,O
spread,O
of,O
the,O
novel,O
SARS,O
-,O
CoV-2,O
coronavirus,O
with,O
first,O
cases,O
of,O
the,O
disease,O
COVID-19,O
being,O
detected,O
in,O
Europe,O
in,O
January,O
2020,O
[,O
1,O
],O
necessitated,O
the,O
development,O
and,O
deployment,O
of,O
diagnostic,O
tests,O
for,O
the,O
specific,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
genome,O
sequences,O
in,O
human,O
samples,O
.,O
Examination,O
of,O
a,O
publicly,O
available,O
gene,O
expression,O
data,O
set,O
(,O
Gene,B-Repository
Expression,I-Repository
Omnibus,I-Repository
[GEO],E-Repository
 ,O
accession,O
number,O
GSE147507,S-AccessionNumber
),O
from,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
infection,O
of,O
A549,O
human,O
lung,O
cells,O
also,O
showed,O
a,O
significant,O
upregulation,O
of,O
CD47,O
compared,O
to,O
mock,O
-,O
infected,O
controls,O
(,O
Fig,O
.,O
 ,O
1D,O
),O
.,O
To,O
examine,O
CD47,O
expression,O
in,O
human,O
viral,O
infection,O
",",O
we,O
first,O
compared,O
transcriptional,O
levels,O
of,O
CD47,O
from,O
publicly,O
available,O
microarray,O
data,O
(,O
GEO,S-Repository
 ,O
accession,O
number,O
GSE38597,S-AccessionNumber
),O
from,O
healthy,O
and,O
hepatitis,O
C,O
virus,O
(,O
HCV,O
),O
patient,O
liver,O
biopsy,O
specimens,O
.,O
La,O
Crosse,O
virus,O
(,O
LACV,O
),O
infections,O
were,O
performed,O
with,O
a,O
1978,O
human,O
isolate,O
provided,O
as,O
a,O
gift,O
from,O
Stephen,O
Whitehead,O
(,O
NIAID,O
",",O
NIH,O
),O
.,O
All,O
antibodies,O
were,O
from,O
BD,O
Biosciences,O
",",O
BioLegend,O
",",O
or,O
eBioscience,O
/,O
Thermo,O
Fisher,O
Scientific,O
",",O
including,O
Brilliant,O
Violet,O
605,O
-,O
anti,O
-,O
CD11b,O
(,O
clone,O
M1/70,O
),O
",",O
phycoerythrin,O
(,O
PE)-CF594,O
-,O
anti,O
-,O
CD19,O
(,O
clone,O
ID3,O
),O
",",O
PE,O
-,O
Cy7,O
-,O
anti,O
-,O
CD11c,O
(,O
clone,O
HL3,O
),O
",",O
PE,O
-,O
Cy7,O
-,O
anti,O
-,O
Ter119,O
(,O
clone,O
TER-119,O
),O
",",O
Alexa,O
Fluor,O
647,O
-,O
anti,O
-,O
CD47,O
(,O
clone,O
MIAP301,O
),O
",",O
and,O
fluorescein,O
isothiocyanate,O
(,O
FITC)-anti,O
-,O
major,O
histocompatibility,O
complex,O
class,O
II,O
(,O
MHCII,O
),O
(,O
I,O
-,O
A,O
/,O
I,O
-,O
E,O
),O
(,O
catalog,O
number,O
FAB6118F,O
),O
;,O
lymphocyte,O
populations,O
were,O
initially,O
gated,O
on,O
single,O
live,O
cells,O
on,O
the,O
basis,O
of,O
forward,O
scatter,O
(,O
FSC,O
),O
versus,O
side,O
scatter,O
(,O
SSC,O
),O
.,O
A,O
publicly,O
available,O
gene,O
expression,O
data,O
set,O
from,O
SARS,O
-,O
CoV-2,O
infection,O
of,O
A549,O
cells,O
(,O
accession,O
number,O
GSE147507,S-AccessionNumber
),O
(,O
n,O
 ,O
=,O
 ,O
10,O
),O
was,O
downloaded,O
from,O
the,O
Gene,B-Repository
Expression,I-Repository
Omnibus,I-Repository
(GEO),E-Repository
.,O
Considering,O
the,O
epidemic,O
nature,O
SARS,O
-,O
CoV-2,O
in,O
the,O
COVID-19,O
outbreak,O
",",O
identifying,O
the,O
intermediate,O
and,O
original,O
host,O
of,O
SARS,O
-,O
CoV-2,O
is,O
crucial,O
for,O
preventing,O
new,O
large,O
-,O
scale,O
infection,O
and,O
transmission,O
of,O
viruses,O
.,O
The,O
host,O
identification,O
was,O
also,O
based,O
on,O
these,O
95,O
complete,O
SARS,O
-,O
CoV-2,O
records,O
from,O
GISAID,S-Dataset
.,O
The,O
COVID-19,O
outbreak,O
in,O
Wuhan,O
this,O
time,O
was,O
firstly,O
located,O
at,O
a,O
so,O
-,O
called,O
seafood,O
market,O
",",O
but,O
actually,O
it,O
was,O
a,O
live,O
animal,O
market,O
because,O
a,O
variety,O
of,O
animals,O
were,O
for,O
sale,O
in,O
this,O
seafood,O
market,O
for,O
a,O
long,O
time,O
.,O
We,O
collected,O
823,O
coronaviruses,O
with,O
other,O
animal,O
hosts,O
on,O
NCBI,S-Repository
 ,O
and,O
3,O
pangolin,O
-,O
CoVs,O
from,O
GISAID,S-Dataset
 ,O
and,O
compared,O
these,O
826,O
records,O
with,O
the,O
95,O
SARS,O
-,O
CoV-2,O
strains,O
.,O
All,O
the,O
accession,O
numbers,O
of,O
the,O
datasets,O
are,O
shown,O
in,O
Supplementary,O
files,O
S1,O
",",O
S2,O
and,O
S3,O
.,O
The,O
biological,O
distance,O
between,O
two,O
sequences,O
can,O
be,O
expressed,O
as,O
the,O
Euclidean,O
distance,O
between,O
the,O
two,O
corresponding,O
natural,O
vectors,O
in,O
12,O
-,O
dim,O
space,O
",",O
as,O
applied,O
on,O
many,O
datasets,O
[,O
25,O
],O
.,O
Therefore,O
",",O
for,O
a,O
dataset,O
of,O
n,O
sequences,O
",",O
the,O
relationship,O
is,O
here,O
described,O
as,O
a,O
 ,O
pairwise,O
distance,O
matrix,O
.,O
For,O
a,O
dataset,O
of,O
n,O
units,O
",",O
we,O
first,O
find,O
the,O
neighbor,O
of,O
each,O
unit,O
by,O
searching,O
for,O
the,O
smallest,O
distance,O
from,O
each,O
unit,O
to,O
any,O
other,O
units,O
.,O
Patients,O
possibly,O
became,O
infected,O
during,O
their,O
stay,O
in,O
Wuhan,O
",",O
but,O
showed,O
no,O
obvious,O
symptoms,O
during,O
the,O
incubation,O
",",O
and,O
after,O
returning,O
to,O
home,O
city,O
/,O
province,O
",",O
had,O
fever,O
or,O
dry,O
cough,O
that,O
further,O
confirmed,O
to,O
be,O
COVID-19,O
.,O
Though,O
we,O
have,O
filtered,O
out,O
these,O
sequences,O
",",O
it,O
also,O
decreases,O
the,O
size,O
of,O
dataset,O
.,O
In,O
[,O
50,O
],O
",",O
the,O
author,O
collected,O
86,O
complete,O
or,O
near,O
-,O
complete,O
genomes,O
of,O
SARS,O
-,O
CoV-2,O
strains,O
on,O
GISAID,O
",",O
and,O
performed,O
pair,O
-,O
wise,O
nucleotide,O
sequence,O
alignment,O
by,O
ClustalX2,O
.,O
The,O
severe,O
respiratory,O
disease,O
COVID-19,O
was,O
initially,O
reported,O
in,O
Wuhan,O
",",O
China,O
",",O
in,O
December,O
2019,O
",",O
and,O
spread,O
into,O
many,O
provinces,O
from,O
Wuhan,O
.,O
As,O
of,O
2,O
May,O
",",O
2020,O
",",O
over,O
3,O
million,O
COVID-19,O
cases,O
had,O
been,O
confirmed,O
",",O
and,O
"235,290",O
deaths,O
had,O
been,O
reported,O
globally,O
",",O
and,O
the,O
numbers,O
are,O
still,O
increasing,O
.,O
It,O
is,O
plausible,O
that,O
different,O
strategies,O
will,O
contribute,O
to,O
eventually,O
defeat,O
the,O
Covid-19,O
:,O
small,O
anti,O
-,O
viral,O
molecules,O
are,O
being,O
tested,O
to,O
block,O
the,O
infection,O
",",O
and,O
the,O
nucleotide,O
analogue,O
Remdesivir,O
has,O
recently,O
been,O
approved,O
by,O
FDA,O
as,O
“,O
standard,O
of,O
care,O
”,O
for,O
patients,O
with,O
COVID-19,O
[,O
1,O
],O
.,O
We,O
quantified,O
virus,O
infectivity,O
with,O
the,O
50,O
%,O
tissue,O
culture,O
infectious,O
dose,O
TCID50,O
assay,O
",",O
and,O
estimated,O
the,O
corresponding,O
plaque,O
forming,O
units,O
(,O
PFU)/ml,O
using,O
the,O
conversion,O
PFU,O
/,O
ml,O
=,O
0.7,O
TCID50,O
.,O
The,O
results,O
are,O
reported,O
as,O
the,O
estimate,O
plaque,O
forming,O
units,O
(,O
PFU)/ml,O
using,O
the,O
conversion,O
PFU,O
/,O
ml,O
=,O
0.7,O
TCID50,O
 ,O
by,O
applying,O
the,O
Poisson,O
distribution,O
.,O
It,O
is,O
also,O
important,O
to,O
note,O
that,O
the,O
previous,O
results,O
with,O
H1N1,O
virus,O
utilized,O
a,O
fluorescent,O
focus,O
assay,O
to,O
assess,O
virus,O
survival,O
in,O
contrast,O
to,O
this,O
work,O
which,O
used,O
the,O
TCID50,O
assay,O
.,O
While,O
both,O
assays,O
are,O
widely,O
used,O
to,O
accurately,O
determine,O
viral,O
infectivity,O
",",O
the,O
former,O
employs,O
immunofluorescence,O
to,O
detect,O
a,O
specific,O
viral,O
antigen,O
",",O
instead,O
of,O
depending,O
on,O
cytopathic,O
effects,O
as,O
in,O
the,O
TCID50,O
assay,O
.,O
The,O
dataset,O
file,O
generated,O
during,O
and/or,O
analysed,O
during,O
the,O
current,O
study,O
is,O
available,O
in,O
the,O
Open,B-Repository
Science,I-Repository
Framework,I-Repository
(OSF),E-Repository
 ,O
repository,O
",",O
identifier,O
:,O
DOI,B-DOI
10.17605/OSF.IO/KGZAF,E-DOI
.,O
After,O
exposure,O
to,O
SARS,O
-,O
COV-2,O
",",O
susceptible,O
individuals,O
can,O
develop,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
consisting,O
of,O
symptoms,O
that,O
may,O
range,O
from,O
fever,O
and,O
cough,O
to,O
severe,O
respiratory,O
illness,O
;,O
in,O
some,O
cases,O
",",O
COVID-19,O
is,O
life,O
-,O
threatening,O
(,O
Centers,O
for,O
Disease,O
Control,O
and,O
Prevention,O
",",O
2020a,O
;,O
Wadman,O
",",O
2020,O
),O
.,O
Since,O
the,O
onset,O
of,O
the,O
outbreak,O
",",O
more,O
than,O
10,O
million,O
COVID-19,O
cases,O
have,O
been,O
confirmed,O
",",O
accounting,O
for,O
more,O
than,O
"500,000",O
deaths,O
(,O
COVID-19,O
",",O
2020,O
),O
.,O
By,O
April,O
2019,O
",",O
the,O
states,O
of,O
New,O
York,O
and,O
Michigan,O
were,O
the,O
most,O
severely,O
affected,O
(,O
COVID-19,O
",",O
2020,O
),O
",",O
given,O
that,O
the,O
metropolitan,O
areas,O
of,O
New,O
York,O
City,O
and,O
Detroit,O
possess,O
large,O
populations,O
subject,O
to,O
health,O
disparities,O
that,O
include,O
limited,O
access,O
to,O
health,O
care,O
",",O
chronic,O
exposure,O
to,O
pollution,O
",",O
and,O
pre,O
-,O
existing,O
cardiovascular,O
conditions,O
(,O
Centers,O
for,O
Disease,O
Control,O
and,O
Prevention,O
",",O
2020b,O
),O
.,O
Pregnant,O
women,O
and,O
their,O
fetuses,O
represent,O
a,O
potential,O
high,O
-,O
risk,O
population,O
in,O
light,O
of,O
the,O
COVID-19,O
outbreak,O
 ,O
(,O
Dashraath,O
et,O
al,O
.,O
",",O
2020,O
;,O
Liu,O
et,O
al,O
.,O
",",O
2020,O
;,O
Rasmussen,O
et,O
al,O
.,O
",",O
2020,O
;,O
Ashokka,O
et,O
al,O
.,O
",",O
2020,O
;,O
Della,O
Gatta,O
et,O
al,O
.,O
",",O
2020,O
;,O
Weber,O
LeBrun,O
et,O
al,O
.,O
",",O
2020,O
;,O
Tekbali,O
",",O
2020,O
;,O
Vintzileos,O
",",O
2020,O
;,O
Lokken,O
",",O
2020,O
),O
given,O
that,O
viral,O
infections,O
such,O
as,O
influenza,O
 ,O
(,O
Neuzil,O
et,O
al,O
.,O
",",O
1998,O
;,O
Lindsay,O
et,O
al,O
.,O
",",O
2006,O
;,O
Jamieson,O
et,O
al,O
.,O
",",O
2006,O
;,O
Cervantes,O
-,O
Gonzalez,O
and,O
Launay,O
",",O
2010,O
;,O
Pandemic,O
H1N1,O
Influenza,O
in,O
Pregnancy,O
Working,O
Group,O
et,O
al,O
.,O
",",O
2010,O
;,O
Mosby,O
et,O
al,O
.,O
",",O
2011,O
;,O
Pazos,O
et,O
al,O
.,O
",",O
2012,O
;,O
Raj,O
et,O
al,O
.,O
",",O
2014,O
),O
",",O
varicella,O
 ,O
(,O
Triebwasser,O
et,O
al,O
.,O
",",O
1967,O
;,O
Paryani,O
and,O
Arvin,O
",",O
1986,O
;,O
Esmonde,O
et,O
al,O
.,O
",",O
1989,O
;,O
Haake,O
et,O
al,O
.,O
",",O
1990,O
;,O
Swamy,O
and,O
Dotters,O
-,O
Katz,O
",",O
2019,O
),O
",",O
Ebola,O
 ,O
(,O
Olgun,O
",",O
2018,O
;,O
Muehlenbachs,O
et,O
al,O
.,O
",",O
2017,O
),O
",",O
and,O
measles,O
 ,O
(,O
Christensen,O
et,O
al,O
.,O
",",O
1954,O
;,O
Atmar,O
et,O
al,O
.,O
",",O
1992,O
),O
show,O
increased,O
severity,O
in,O
this,O
physiological,O
state,O
.,O
Consequently,O
",",O
the,O
clinical,O
characteristics,O
of,O
pregnant,O
women,O
with,O
COVID-19,O
appear,O
similar,O
to,O
those,O
of,O
non,O
-,O
pregnant,O
adults,O
 ,O
(,O
Yu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Yet,O
",",O
recent,O
reports,O
have,O
shown,O
that,O
severe,O
COVID-19,O
can,O
lead,O
to,O
maternal,O
death,O
 ,O
(,O
Hantoushzadeh,O
et,O
al,O
.,O
",",O
2020,O
;,O
Blitz,O
",",O
2020,O
),O
.,O
Consistently,O
",",O
infants,O
born,O
to,O
mothers,O
with,O
COVID-19,O
test,O
negative,O
for,O
SARS,O
-,O
CoV-2,O
",",O
do,O
not,O
develop,O
serious,O
clinical,O
symptoms,O
(,O
e.g.,O
",",O
fever,O
",",O
cough,O
",",O
diarrhea,O
",",O
or,O
abnormal,O
radiologic,O
or,O
hematologic,O
evidence,O
),O
",",O
and,O
are,O
promptly,O
discharged,O
from,O
the,O
hospital,O
 ,O
(,O
Chen,O
et,O
al,O
.,O
",",O
2020c,O
),O
.,O
Case,O
reports,O
have,O
shown,O
that,O
a,O
small,O
fraction,O
of,O
neonates,O
born,O
to,O
women,O
with,O
COVID-19,O
tested,O
positive,O
for,O
the,O
virus,O
at,O
1–4,O
days,O
of,O
life,O
 ,O
(,O
Zeng,O
et,O
al,O
.,O
",",O
2020a,O
;,O
Alzamora,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
yet,O
these,O
neonates,O
subsequently,O
tested,O
negative,O
on,O
day,O
6,O
-,O
7,O
 ,O
(,O
Zeng,O
et,O
al,O
.,O
",",O
2020a,O
),O
.,O
In,O
addition,O
",",O
serological,O
studies,O
revealed,O
that,O
a,O
few,O
neonates,O
born,O
to,O
mothers,O
with,O
COVID-19,O
had,O
increased,O
concentrations,O
of,O
SARS,O
-,O
CoV-2,O
immunoglobulin,O
(,O
Ig)M,O
as,O
well,O
as,O
IgG,O
 ,O
(,O
Zeng,O
et,O
al,O
.,O
",",O
2020b,O
;,O
Dong,O
et,O
al,O
.,O
",",O
2020b,O
),O
.,O
In,O
the,O
first,O
case,O
report,O
",",O
the,O
viral,O
RNA,O
was,O
detected,O
in,O
amniotic,O
fluid,O
from,O
a,O
woman,O
who,O
was,O
severely,O
affected,O
and,O
died,O
of,O
COVID-19,O
 ,O
(,O
Zamaniyan,O
",",O
2020,O
),O
.,O
Our,O
first,O
-,O
trimester,O
data,O
are,O
in,O
agreement,O
with,O
a,O
prior,O
report,O
showing,O
minimal,O
expression,O
of,O
ACE2,O
at,O
the,O
human,O
maternal,O
-,O
fetal,O
interface,O
(,O
Zheng,O
et,O
al,O
.,O
",",O
2020,O
),O
;,O
however,O
",",O
the,O
same,O
dataset,O
was,O
recently,O
used,O
to,O
report,O
the,O
opposite,O
(,O
Li,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Finally,O
",",O
we,O
explored,O
the,O
expression,O
of,O
ACE2,O
and,O
TMPRSS2,O
in,O
third,O
-,O
trimester,O
placental,O
tissues,O
by,O
mining,O
two,O
microarray,O
datasets,O
that,O
we,O
have,O
previously,O
reported,O
(,O
Kim,O
et,O
al,O
.,O
",",O
2009,O
;,O
Toft,O
et,O
al,O
.,O
",",O
2008,O
),O
.,O
This,O
reduced,O
expression,O
contrasts,O
with,O
the,O
high,O
expression,O
of,O
ACE2,O
and,O
TMPRSS2,O
in,O
nasal,O
goblet,O
and,O
ciliated,O
cells,O
within,O
the,O
human,O
airways,O
",",O
lungs,O
",",O
and,O
gastrointestinal,O
tract,O
",",O
which,O
are,O
targeted,O
during,O
COVID-19,O
(,O
Muus,O
",",O
2020,O
;,O
Wang,O
",",O
2020b,O
;,O
HCA,O
Lung,O
Biological,O
Network,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
expression,O
of,O
additional,O
SARS,O
-,O
CoV-2,O
-,O
related,O
receptors,O
or,O
proteins,O
in,O
the,O
human,O
placenta,O
is,O
shown,O
in,O
Figure,O
2,O
",",O
CoV,O
-,O
Alt,O
;,O
however,O
",",O
further,O
research,O
is,O
required,O
to,O
test,O
their,O
participation,O
in,O
the,O
pathogenesis,O
of,O
COVID-19,O
.,O
Therefore,O
",",O
it,O
is,O
unlikely,O
that,O
this,O
protein,O
alone,O
is,O
a,O
sufficient,O
requirement,O
for,O
SARS,O
-,O
CoV-2,O
viral,O
entry,O
",",O
and,O
other,O
proteins,O
may,O
be,O
required,O
to,O
explain,O
the,O
cell,O
type,O
primarily,O
affected,O
by,O
COVID-19,O
.,O
The,O
cellular,O
receptors,O
and,O
mechanisms,O
that,O
could,O
be,O
exploited,O
by,O
SARS,O
-,O
CoV-2,O
are,O
still,O
under,O
investigation,O
(,O
Gordon,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
yet,O
single,O
-,O
cell,O
atlases,O
can,O
help,O
to,O
identify,O
cell,O
types,O
with,O
a,O
similar,O
transcriptional,O
profile,O
to,O
those,O
that,O
are,O
known,O
to,O
participate,O
in,O
COVID-19,O
.,O
Data,O
for,O
third,O
-,O
trimester,O
samples,O
previously,O
collected,O
by,O
our,O
group,O
are,O
available,O
through,O
NIH,B-Repository
dbGAP,E-Repository
 ,O
(,O
accession,O
number,O
phs001886.v2.p1,S-AccessionNumber
),O
",",O
and,O
newly,O
generated,O
second,O
-,O
trimester,O
scRNA,O
-,O
seq,O
and,O
third,O
-,O
trimester,O
snRNA,O
-,O
seq,O
data,O
are,O
being,O
deposited,O
into,O
the,O
same,O
repository,O
(,O
Supplementary,O
file,O
1,O
),O
.,O
Gene,O
expression,O
data,O
for,O
the,O
study,O
by,O
Kim,B-Creator
et,I-Creator
"al.,",I-Creator
2009,E-Creator
 ,O
was,O
available,O
from,O
the,O
www.ebi.ac.uk/microarray-as/ae/,S-URL
 ,O
database,O
(,O
entry,O
ID,O
:,O
E-TABM-577,S-AccessionNumber
),O
",",O
while,O
data,O
for,O
the,O
study,O
by,O
Toft,B-Creator
et,I-Creator
"al.,",I-Creator
2008,E-Creator
 ,O
is,O
available,O
in,O
our,O
data,O
repertoire,O
.,O
The,O
pandemic,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
caused,O
by,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
has,O
affected,O
more,O
than,O
10,O
million,O
people,O
",",O
including,O
pregnant,O
women,O
.,O
The,O
GenBank,S-Repository
 ,O
accession,O
numbers,O
(,O
LC494126,S-AccessionNumber
-,O
LC494192,S-AccessionNumber
),O
for,O
each,O
BCoV,O
isolate,O
are,O
summarized,O
in,O
Table,O
S1,O
.,O
By,O
February,O
14,O
",",O
2020,O
",",O
a,O
total,O
of,O
"66,576",O
confirmed,O
cases,O
of,O
COVID-19,O
",",O
people,O
infected,O
with,O
SARS,O
-,O
CoV-2,O
",",O
were,O
reported,O
in,O
China,O
",",O
leading,O
to,O
1524,O
deaths,O
",",O
per,O
the,O
Chinese,B-Creator
CDC,E-Creator
 ,O
(,O
http://2019ncov.chinacdc.cn/2019-nCoV/,S-URL
),O
.,O
The,O
sequences,O
of,O
BetaCoV,O
were,O
downloaded,O
on,O
February,O
3,O
",",O
2020,O
from,O
the,O
GISAID,S-Dataset
 ,O
platform,O
.,O
A,O
total,O
of,O
58,O
accessions,O
were,O
available,O
",",O
among,O
which,O
BetaCoV,O
/,O
bat,O
/,O
Yunnan,O
/,O
RaTG13/2013,O
is,O
a,O
known,O
close,O
relative,O
of,O
SARS,O
-,O
CoV-2,O
.,O
Four,O
accessions,O
",",O
namely,O
",",O
BetaCov,O
/,O
Italy,O
/,O
INM1/2020,O
",",O
BetaCov,O
/,O
Italy,O
/,O
INM2/2020,O
",",O
BetaCoV,O
/,O
Kanagawa/1/2020,O
",",O
and,O
BetaCoV,O
/,O
USA,O
/,O
IL1/2020,O
",",O
were,O
excluded,O
because,O
of,O
the,O
short,O
-,O
truncated,O
sequences,O
or,O
multiple,O
ambiguous,O
nucleotides,O
.,O
A,O
total,O
of,O
54,O
accessions,O
(,O
Supplementary,O
Table,O
1,O
),O
isolated,O
from,O
humans,O
were,O
utilized,O
in,O
the,O
following,O
analysis,O
.,O
Here,O
",",O
two,O
accessions,O
(,O
BetaCoV,O
/,O
Shenzhen,O
/,O
SZTH-001/2020,O
and,O
BetaCoV,O
/,O
Shenzhen,O
/,O
SZTH-004/2020,O
),O
from,O
Shenzhen,O
",",O
which,O
had,O
5,O
and,O
16,O
mutations,O
",",O
respectively,O
",",O
were,O
excluded,O
",",O
considering,O
the,O
possible,O
experimental,O
issues,O
.,O
Furthermore,O
",",O
a,O
history,O
of,O
cigarette,O
smoke,O
exposure,O
",",O
the,O
major,O
risk,O
factor,O
for,O
the,O
development,O
of,O
COPD,O
",",O
has,O
been,O
associated,O
with,O
more,O
severe,O
disease,O
in,O
patients,O
infected,O
with,O
a,O
novel,O
coronavirus,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
the,O
causative,O
agent,O
in,O
the,O
ongoing,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
(,O
),O
.,O
Mice,O
with,O
homozygous,O
loss,O
of,O
Miz1,O
showed,O
up,O
-,O
regulation,O
in,O
the,O
expression,O
of,O
angiotensin,O
-,O
converting,O
enzyme,O
2,O
(,O
Ace2,O
),O
",",O
the,O
receptor,O
for,O
SARS,O
-,O
CoV-2,O
",",O
which,O
is,O
the,O
causative,O
organism,O
in,O
the,O
current,O
COVID-19,O
pandemic,O
(,O
),O
.,O
Reads,O
were,O
aligned,O
using,O
TopHat2,O
to,O
the,O
mm10,O
reference,O
genome,O
",",O
differential,O
expression,O
was,O
assessed,O
using,O
edgeR,O
",",O
and,O
enrichment,O
analysis,O
was,O
performed,O
using,O
curated,O
databases,O
including,O
GO,O
or,O
KEGG,O
PATHWAY,O
mapping,O
.,O
The,O
tandem,O
mass,O
spectra,O
were,O
searched,O
against,O
the,O
UniProt,S-Repository
 ,O
mouse,O
protein,O
database,O
",",O
and,O
sequences,O
of,O
known,O
contaminants,O
such,O
as,O
keratin,O
and,O
porcine,O
trypsin,O
concatenated,O
to,O
a,O
decoy,O
database,O
in,O
which,O
the,O
sequence,O
for,O
each,O
entry,O
in,O
the,O
original,O
database,O
was,O
reversed,O
.,O
Our,O
data,O
suggest,O
that,O
Miz1,O
down,O
-,O
regulation,O
–,O
induced,O
sustained,O
activation,O
of,O
NF,O
-,O
κB,O
–,O
dependent,O
inflammation,O
in,O
the,O
lung,O
epithelium,O
is,O
sufficient,O
to,O
induce,O
progressive,O
lung,O
and,O
airway,O
destruction,O
that,O
recapitulates,O
features,O
of,O
COPD,O
",",O
with,O
implications,O
for,O
COVID-19,O
.,O
The,O
novel,O
coronavirus,O
disease,O
(,O
COVID‐19,O
),O
has,O
spread,O
worldwide,O
",",O
resulting,O
in,O
numerous,O
cases,O
of,O
morbidity,O
and,O
death,O
.,O
Generally,O
",",O
COVID‐19,O
has,O
an,O
incubation,O
period,O
of,O
2–7,O
days,O
",",O
[,O
Therefore,O
",",O
early,O
accurate,O
diagnosis,O
and,O
isolation,O
of,O
patients,O
is,O
key,O
to,O
controlling,O
the,O
COVID‐19,O
pandemic,O
.,O
Therefore,O
",",O
nucleic,O
acid,O
detection,O
continues,O
to,O
be,O
the,O
gold,O
standard,O
for,O
COVID‐19,O
diagnosis,O
",",O
with,O
several,O
such,O
methods,O
having,O
been,O
employed,O
for,O
detection,O
of,O
the,O
COVID‐19,O
causative,O
virus,O
",",O
SARS‐CoV‐2,O
.,O
[,O
],O
which,O
can,O
facilitate,O
infection,O
transmission,O
through,O
delayed,O
patient,O
isolation,O
and,O
treatment,O
",",O
resulting,O
in,O
continued,O
COVID‐19,O
spread,O
.,O
],O
Additional,O
new,O
methods,O
based,O
on,O
isothermal,O
PCR,O
amplification,O
are,O
also,O
available,O
",",O
such,O
as,O
Abbott,O
's,O
ID,O
Now,O
instrument,O
",",O
which,O
can,O
interpret,O
results,O
in,O
minutes,O
.,O
],O
Cross‐infection,O
during,O
the,O
diagnosis,O
process,O
both,O
propagates,O
the,O
spread,O
of,O
SARS‐CoV‐2,O
and,O
subjects,O
COVID‐19,O
patients,O
to,O
other,O
respiratory,O
viruses,O
.,O
However,O
",",O
detection,O
of,O
virulence,O
mutations,O
",",O
virus,O
typing,O
",",O
and,O
epidemiological,O
analysis,O
are,O
critical,O
for,O
the,O
prevention,O
and,O
control,O
of,O
COVID‐19,O
.,O
To,O
test,O
the,O
SARS‐CoV‐2,O
detection,O
efficiency,O
by,O
NTS,O
",",O
we,O
used,O
standard,O
plasmids,O
harboring,O
COVID‐19,O
virus,O
S,O
and,O
N,O
genes,O
to,O
simulate,O
SARS‐CoV‐2,O
.,O
Evaluation,O
of,O
the,O
target,O
distribution,O
of,O
the,O
datasets,O
revealed,O
that,O
in,O
higher‐copy,O
samples,O
(,O
1000,O
and,O
3000,O
copies,O
per,O
reaction,O
),O
",",O
all,O
targeted,O
regions,O
were,O
detected,O
(,O
Figure,O
2c,O
",",O
d,O
),O
.,O
The,O
samples,O
were,O
divided,O
into,O
two,O
groups,O
:,O
i,O
),O
45,O
nasopharyngeal,O
swabs,O
from,O
outpatients,O
with,O
suspected,O
COVID‐19,O
early,O
in,O
the,O
epidemic,O
(,O
January,O
2020,O
),O
",",O
for,O
whom,O
detailed,O
records,O
and,O
suitable,O
clinical,O
data,O
were,O
unavailable,O
",",O
preventing,O
us,O
from,O
confirming,O
SARD‐CoV‐2,O
infection,O
.,O
ii,O
),O
16,O
nasopharyngeal,O
swabs,O
from,O
hospitalized,O
patients,O
who,O
had,O
been,O
diagnosed,O
with,O
COVID‐19,O
by,O
clinicians,O
through,O
comprehensive,O
results,O
of,O
nucleic,O
acid,O
tests,O
",",O
chest,O
computed,O
tomography,O
scans,O
",",O
blood,O
tests,O
",",O
and,O
clinical,O
symptoms,O
and,O
",",O
hence,O
",",O
for,O
whom,O
nucleic,O
acid,O
samples,O
tested,O
positive,O
for,O
SARS‐CoV‐2,O
.,O
Therefore,O
",",O
we,O
next,O
evaluated,O
samples,O
retained,O
from,O
hospitalized,O
patients,O
with,O
confirmed,O
COVID‐19,O
subjected,O
to,O
RT‐qPCR,O
testing,O
(,O
kit,O
1,O
",",O
Figure,O
1,O
),O
on,O
February,O
11,O
and,O
12,O
",",O
2020,O
.,O
These,O
results,O
suggest,O
that,O
NTS,O
could,O
identify,O
positive,O
COVID‐19,O
infected,O
cases,O
",",O
seems,O
has,O
higher,O
identification,O
ability,O
than,O
RT‐qPCR,O
.,O
Furthermore,O
",",O
genome,O
wide,O
allele,O
frequency,O
analysis,O
(,O
Experimental,O
Section,O
),O
of,O
50,O
NTS,O
positive,O
samples,O
",",O
as,O
well,O
as,O
1145,O
recently,O
published,O
(,O
before,O
March,O
24,O
",",O
2020,O
),O
SARS‐CoV‐2,O
genomes,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
[,O
],O
also,O
indicated,O
a,O
common,O
SNP,O
at,O
position,O
28144,O
(,O
Figure,O
7a,O
),O
",",O
with,O
a,O
similar,O
allele,O
frequency,O
(,O
26.7,O
%,O
of,O
NTS,O
and,O
28.3,O
%,O
of,O
GISAID,S-Dataset
),O
.,O
To,O
verify,O
the,O
ability,O
of,O
NTS,O
to,O
detect,O
SARS‐CoV‐2,O
and,O
other,O
respiratory,O
viruses,O
within,O
a,O
single,O
assay,O
",",O
13,O
of,O
the,O
45,O
suspected,O
COVID‐19,O
outpatient,O
samples,O
were,O
subjected,O
to,O
simultaneous,O
detection,O
analysis,O
.,O
],O
was,O
used,O
to,O
map,O
the,O
reads,O
of,O
each,O
sample,O
against,O
the,O
virus,O
genome,O
reference,O
database,O
.,O
All,O
virus,O
genomic,O
sequences,O
were,O
downloaded,O
on,O
January,O
20,O
",",O
2020,O
",",O
from,O
NCBI,S-Repository
 ,O
Refseq,S-Repository
 ,O
FTP,O
(,O
http://ftp.ncbi.nlm.nih.gov/refseq/release/viral/,S-URL
),O
;,O
the,O
SARS‐CoV‐2,O
genome,O
was,O
added,O
to,O
the,O
BLAST,S-Repository
 ,O
database,O
because,O
the,O
genome,O
was,O
not,O
collected,O
in,O
the,O
virus,O
Refseq,S-Repository
 ,O
database,O
prior,O
to,O
January,O
20,O
",",O
2020,O
.,O
The,O
ongoing,O
global,O
novel,O
coronavirus,O
pneumonia,O
COVID‐19,O
outbreak,O
has,O
engendered,O
numerous,O
cases,O
of,O
infection,O
and,O
death,O
.,O
COVID‐19,O
diagnosis,O
relies,O
upon,O
nucleic,O
acid,O
detection,O
;,O
however,O
",",O
currently,O
recommended,O
methods,O
exhibit,O
high,O
false‐negative,O
rates,O
and,O
are,O
unable,O
to,O
identify,O
other,O
respiratory,O
virus,O
infections,O
",",O
thereby,O
resulting,O
in,O
patient,O
misdiagnosis,O
and,O
impeding,O
epidemic,O
containment,O
.,O
Parallel,O
testing,O
with,O
approved,O
real‐time,O
reverse,O
transcription‐polymerase,O
chain,O
reaction,O
kits,O
for,O
SARS‐CoV‐2,O
and,O
NTS,O
using,O
61,O
nucleic,O
acid,O
samples,O
from,O
suspected,O
COVID‐19,O
cases,O
show,O
that,O
NTS,O
identifies,O
more,O
infected,O
patients,O
(,O
22/61,O
),O
as,O
positive,O
",",O
while,O
also,O
effectively,O
monitoring,O
for,O
mutated,O
nucleic,O
acid,O
sequences,O
",",O
categorizing,O
types,O
of,O
SARS‐CoV‐2,O
",",O
and,O
detecting,O
other,O
respiratory,O
viruses,O
in,O
the,O
test,O
sample,O
.,O
NTS,O
is,O
thus,O
suitable,O
for,O
COVID‐19,O
diagnosis,O
;,O
moreover,O
",",O
this,O
platform,O
can,O
be,O
further,O
extended,O
for,O
diagnosing,O
other,O
viruses,O
and,O
pathogens,O
.,O
The,O
availability,O
of,O
the,O
virus,O
genome,O
sequence,O
(,O
GenBank,S-Repository
 ,O
ID,O
:,O
MN908947.3,S-AccessionNumber
),O
makes,O
it,O
possible,O
to,O
identify,O
treatments,O
.,O
However,O
",",O
2019‐nCoV,O
shares,O
82,O
 ,O
%,O
sequence,O
identity,O
with,O
severe,O
acute,O
respiratory,O
syndrome‐related,O
coronavirus,O
(,O
SARS‐CoV,O
",",O
GenBank,S-Repository
 ,O
ID,O
:,O
NC_004718.3,S-AccessionNumber
),O
and,O
more,O
than,O
90,O
 ,O
%,O
sequence,O
identity,O
in,O
several,O
essential,O
enzymes,O
(,O
see,O
figures,O
below,O
),O
.,O
Both,O
crystal,O
and,O
cryo‐EM,O
structures,O
of,O
the,O
SARS‐CoV,O
spike‐ACE2,O
complex,O
(,O
PDB,S-Repository
 ,O
IDs,O
:,O
2AJF,S-AccessionNumber
 ,O
and,O
6ACD,S-AccessionNumber
),O
have,O
showed,O
that,O
only,O
regions,O
1,O
and,O
2,O
engage,O
in,O
hydrogen,O
bonding,O
and,O
hydrophobic,O
interactions,O
with,O
ACE2,O
.,O
33,O
Exonuclease,O
activity,O
by,O
the,O
enzyme,O
nsp14,O
has,O
been,O
shown,O
to,O
be,O
able,O
to,O
remove,O
mismatches,O
as,O
well,O
as,O
incorporated,O
nucleoside,O
analogues,O
",",O
and,O
inactivation,O
of,O
nsp14′s,O
exonuclease,O
activity,O
has,O
been,O
shown,O
to,O
increase,O
the,O
efficacy,O
of,O
nucleosides,O
like,O
RBV.32,O
",",O
34,O
In,O
order,O
to,O
develop,O
nucleoside,O
analogues,O
to,O
effectively,O
inhibit,O
viral,O
RNA,O
replication,O
",",O
the,O
nucleoside,O
must,O
either,O
evade,O
detection,O
by,O
the,O
exonuclease,O
or,O
must,O
outcompete,O
exonuclease,O
activity,O
.,O
Abstract,O
  ,O
Background,O
 ,O
Waning,O
immunity,O
occurs,O
in,O
patients,O
who,O
have,O
recovered,O
from,O
COVID-19,O
.,O
Whole,O
genome,O
sequencing,O
was,O
performed,O
directly,O
on,O
respiratory,O
specimens,O
collected,O
during,O
two,O
episodes,O
of,O
COVID-19,O
in,O
a,O
patient,O
.,O
Compared,O
to,O
viral,O
genomes,O
in,O
GISAID,S-Dataset
",",O
the,O
first,O
virus,O
genome,O
has,O
a,O
stop,O
codon,O
at,O
position,O
64,O
of,O
orf8,O
leading,O
to,O
a,O
truncation,O
of,O
58,O
amino,O
acids,O
",",O
and,O
was,O
phylogenetically,O
closely,O
related,O
to,O
strains,O
collected,O
in,O
March,O
/,O
April,O
2020,O
",",O
while,O
the,O
second,O
virus,O
genome,O
was,O
closely,O
related,O
to,O
strains,O
collected,O
in,O
July,O
/,O
August,O
2020,O
.,O
Exclusion,O
criteria,O
included,O
current,O
symptoms,O
consistent,O
with,O
COVID-19,O
.,O
Some,O
groups,O
seem,O
particularly,O
vulnerable,O
to,O
severe,O
COVID-19,O
",",O
notably,O
the,O
elderly,O
and,O
those,O
with,O
existing,O
health,O
conditions,O
.,O
Apparent,O
familial,O
or,O
heritable,O
variations,O
in,O
susceptibility,O
to,O
disease,O
have,O
long,O
been,O
recognized,O
",",O
for,O
example,O
in,O
relation,O
to,O
tuberculosis,O
",",O
malaria,O
",",O
leprosy,O
",",O
and,O
HIV,O
",",O
and,O
preliminary,O
reports,O
are,O
emerging,O
in,O
relation,O
to,O
COVID-19,O
.,O
",",O
The,O
scientific,O
community,O
has,O
acted,O
rapidly,O
to,O
establish,O
the,O
COVID-19,B-Repository
Host,I-Repository
Genetics,I-Repository
initiative,E-Repository
",",O
which,O
includes,O
127,O
studies,O
in,O
a,O
global,O
collaboration,O
to,O
investigate,O
the,O
genomes,O
of,O
those,O
infected,O
by,O
coronavirus,O
.,O
Leading,O
commercial,O
genetic,O
companies,O
have,O
also,O
launched,O
studies,O
of,O
COVID-19,O
susceptibility,O
",",O
drawing,O
on,O
their,O
substantial,O
privately,O
held,O
data,O
sets,O
.,O
This,O
commentary,O
highlights,O
the,O
need,O
for,O
COVID-19,O
host,O
genetics,O
to,O
engage,O
with,O
questions,O
related,O
to,O
the,O
role,O
of,O
genetic,O
susceptibility,O
factors,O
in,O
creating,O
potential,O
inequalities,O
in,O
the,O
ability,O
to,O
work,O
or,O
access,O
public,O
space,O
",",O
stigma,O
",",O
and,O
inequalities,O
in,O
the,O
quality,O
and,O
scope,O
of,O
data,O
.,O
It,O
may,O
also,O
enable,O
employers,O
to,O
extend,O
steps,O
to,O
protect,O
staff,O
",",O
minimize,O
the,O
likelihood,O
of,O
workplace,O
illness,O
",",O
and,O
help,O
them,O
maintain,O
a,O
healthy,O
workforce,O
",",O
for,O
example,O
in,O
line,O
with,O
recommendations,O
from,O
the,O
US,O
Equal,O
Employment,O
Opportunity,O
Commission,O
on,O
COVID-19,O
.,O
However,O
",",O
here,O
COVID-19,O
research,O
encounters,O
well,O
-,O
described,O
challenges,O
associated,O
with,O
the,O
population,O
distribution,O
of,O
genetic,O
data,O
",",O
and,O
the,O
consequent,O
privileging,O
of,O
specific,O
groups,O
in,O
genetic,O
analyses,O
.,O
The,O
data,O
sets,O
used,O
for,O
genome,O
-,O
wide,O
association,O
studies,O
(,O
GWAS,O
),O
are,O
skewed,O
toward,O
Northern,O
European,O
ancestry,O
populations,O
",",O
who,O
account,O
for,O
nearly,O
80,O
%,O
of,O
individuals,O
in,O
GWAS,O
catalogs,O
—,O
with,O
70,O
%,O
of,O
participants,O
recruited,O
from,O
the,O
UK,O
",",O
United,O
States,O
",",O
and,O
Iceland,O
alone,O
.,O
",",O
Inequalities,O
in,O
existing,O
genetic,O
data,O
sets,O
have,O
implications,O
for,O
efforts,O
to,O
understand,O
genetic,O
influences,O
on,O
susceptibility,O
to,O
COVID-19,O
",",O
to,O
predict,O
which,O
groups,O
are,O
most,O
likely,O
to,O
be,O
affected,O
",",O
and,O
to,O
estimate,O
the,O
wider,O
prevalence,O
of,O
identified,O
variants,O
.,O
This,O
is,O
not,O
a,O
problem,O
unique,O
to,O
COVID,O
research,O
.,O
Such,O
problems,O
may,O
compound,O
existing,O
concerns,O
related,O
to,O
the,O
quality,O
of,O
data,O
underpinning,O
existing,O
COVID-19,O
diagnostic,O
and,O
predictive,O
models,O
",",O
and,O
the,O
absence,O
of,O
relevant,O
features,O
",",O
including,O
ethnicity,O
",",O
from,O
clinical,O
data,O
sets,O
.,O
",",O
Given,O
emerging,O
evidence,O
of,O
ethnic,O
and,O
gender,O
differences,O
related,O
to,O
COVID,O
consequences,O
",",O
it,O
is,O
essential,O
that,O
host,O
genetic,O
analyses,O
build,O
on,O
this,O
progress,O
to,O
ensure,O
the,O
collection,O
of,O
data,O
of,O
sufficient,O
scale,O
",",O
scope,O
",",O
and,O
quality,O
to,O
provide,O
equitable,O
access,O
to,O
benefits,O
that,O
accrue,O
from,O
research,O
.,O
All,O
SARS,O
-,O
CoV-2,O
genomes,O
sequences,O
in,O
the,O
final,O
dataset,O
from,O
May,O
2020,O
were,O
copied,O
into,O
a,O
separate,O
FASTA,O
file,O
(,O
n,O
 ,O
=,O
 ,O
778,O
sequences,O
),O
",",O
then,O
100,O
bases,O
were,O
trimmed,O
from,O
the,O
5′,O
and,O
3,O
’,O
ends,O
of,O
each,O
sequence,O
to,O
remove,O
low,O
-,O
quality,O
degenerate,O
nucleotides,O
.,O
To,O
assess,O
the,O
inclusivity,O
of,O
oligonucleotides,O
from,O
these,O
assays,O
",",O
we,O
curated,O
a,O
dataset,O
of,O
"15,001",O
SARS,O
-,O
CoV-2,O
genome,O
sequences,O
from,O
specimens,O
collected,O
between,O
Dec,O
31,O
",",O
2019,O
and,O
May,O
31,O
",",O
2020,O
.,O
The,O
composition,O
of,O
the,O
dataset,O
by,O
region,O
and,O
collection,O
month,O
is,O
shown,O
in,O
Fig,O
.,O
1,O
.,O
Using,O
PCR_strainer,O
",",O
we,O
identified,O
genomes,O
in,O
our,O
dataset,O
with,O
nucleotide,O
mismatches,O
in,O
locations,O
targeted,O
by,O
the,O
early,O
SARS,O
-,O
CoV-2,O
LDTs,O
described,O
above,O
.,O
Two,O
sets,O
of,O
oligonucleotides,O
had,O
mismatches,O
against,O
all,O
"15,001",O
SARS,O
-,O
CoV-2,O
reference,O
genomes,O
in,O
our,O
dataset,O
:,O
the,O
Charité,O
group,O
’s,O
RdRP,O
gene,O
assay,O
and,O
the,O
Japan,O
NIID,O
’s,O
N,O
gene,O
assay,O
.,O
One,O
of,O
these,O
variants,O
",",O
which,O
we,O
will,O
call,O
the,O
‘,O
AAC,O
’,O
variant,O
",",O
was,O
present,O
in,O
18.8,O
%,O
of,O
genomes,O
in,O
our,O
dataset,O
(,O
Table,O
3,O
),O
.,O
Next,O
",",O
we,O
constructed,O
a,O
phylogeny,O
of,O
all,O
SARS,O
-,O
CoV-2,O
genomes,O
in,O
our,O
dataset,O
from,O
May,O
2020,O
",",O
the,O
most,O
recent,O
completed,O
month,O
at,O
the,O
time,O
of,O
writing,O
(,O
Fig,O
.,O
4,O
),O
.,O
Furthermore,O
",",O
this,O
clade,O
closely,O
overlapped,O
with,O
the,O
GISAID,S-Dataset
 ,O
‘,O
GR,O
’,O
clade,O
:,O
99.5,O
%,O
of,O
genomes,O
with,O
the,O
‘,O
AAC,O
’,O
variant,O
were,O
identified,O
as,O
members,O
of,O
Clade,O
‘,O
GR,O
’,O
",",O
and,O
100,O
%,O
of,O
genomes,O
identified,O
as,O
members,O
of,O
clade,O
‘,O
GR,O
’,O
contained,O
the,O
‘,O
AAC,O
’,O
variant,O
.,O
Single,O
mismatches,O
in,O
the,O
Charité,O
group,O
and,O
Japan,O
NIID,O
assays,O
were,O
uniform,O
and,O
pervasive,O
",",O
suggesting,O
they,O
were,O
artefacts,O
of,O
the,O
oligonucleotide,O
design,O
process,O
.,O
The,O
mismatch,O
in,O
the,O
Japan,O
NIID,O
’s,O
assay,O
was,O
due,O
to,O
an,O
error,O
in,O
the,O
first,O
reported,O
SARS,O
-,O
CoV-2,O
genome,O
assembly,O
",",O
and,O
investigations,O
by,O
the,O
assay,O
’s,O
designers,O
did,O
not,O
find,O
any,O
impact,O
on,O
clinical,O
performance,O
[,O
11,O
],O
.,O
Mismatches,O
in,O
the,O
Charité,O
group,O
and,O
Japan,O
NIID,O
assays,O
were,O
both,O
14,O
positions,O
from,O
the,O
more,O
-,O
crucial,O
3,O
’,O
end,O
of,O
the,O
primers,O
.,O
Indeed,O
",",O
as,O
stated,O
above,O
",",O
the,O
Japan,O
NIID,O
group,O
failed,O
to,O
observe,O
a,O
difference,O
in,O
detection,O
between,O
primers,O
with,O
and,O
without,O
the,O
mismatch,O
[,O
11,O
],O
.,O
Of,O
the,O
"384,096",O
 ,O
contigs,O
assembled,O
by,O
Megahit,O
",",O
the,O
longest,O
(,O
"30,474",O
 ,O
nucleotides,O
(,O
nt,O
),O
),O
had,O
a,O
high,O
abundance,O
and,O
was,O
closely,O
related,O
to,O
a,O
bat,O
SARS,O
-,O
like,O
coronavirus,O
(,O
CoV,O
),O
isolate,O
—,O
bat,O
SL,O
-,O
CoVZC45,O
(,O
GenBank,S-Repository
 ,O
accession,O
number,O
MG772933,S-AccessionNumber
),O
—,O
that,O
had,O
previously,O
been,O
sampled,O
in,O
China,O
",",O
with,O
a,O
nucleotide,O
identity,O
of,O
89.1,O
%,O
(,O
Supplementary,O
Tables,O
1,O
",",O
2,O
),O
.,O
This,O
virus,O
strain,O
was,O
designated,O
as,O
WH,O
-,O
Human,O
1,O
coronavirus,O
(,O
WHCV,O
),O
(,O
and,O
has,O
also,O
been,O
referred,O
to,O
as,O
‘,O
2019,O
-,O
nCoV,O
’,O
),O
and,O
its,O
whole,O
genome,O
sequence,O
(,O
"29,903",O
 ,O
nt,O
),O
has,O
been,O
assigned,O
GenBank,S-Repository
 ,O
accession,O
number,O
MN908947,S-AccessionNumber
.,O
The,O
viral,O
genome,O
organization,O
of,O
WHCV,O
was,O
determined,O
by,O
sequence,O
alignment,O
to,O
two,O
representative,O
members,O
of,O
the,O
genus,O
Betacoronavirus,O
:,O
a,O
coronavirus,O
associated,O
with,O
humans,O
(,O
SARS,O
-,O
CoV,O
Tor2,O
",",O
GenBank,S-Repository
 ,O
accession,O
number,O
AY274119,S-AccessionNumber
),O
and,O
a,O
coronavirus,O
associated,O
with,O
bats,O
(,O
bat,O
SL,O
-,O
CoVZC45,O
",",O
GenBank,S-Repository
 ,O
accession,O
number,O
MG772933,S-AccessionNumber
),O
.,O
Sequence,O
reads,O
generated,O
in,O
this,O
study,O
are,O
available,O
from,O
the,O
NCBI,S-Creator
 ,O
Sequence,B-Repository
Read,I-Repository
Archive,I-Repository
(SRA),E-Repository
 ,O
database,O
under,O
BioProject,O
accession,O
number,O
PRJNA603194,S-AccessionNumber
.,O
The,O
complete,O
genome,O
sequence,O
of,O
WHCV,O
has,O
been,O
deposited,O
in,O
GenBank,S-Repository
 ,O
under,O
accession,O
number,O
MN908947,S-AccessionNumber
.,O
A,O
total,O
of,O
447,O
patients,O
were,O
enrolled,O
in,O
mainland,O
China,O
",",O
and,O
617,O
were,O
from,O
other,O
Asian,O
sites,O
;,O
the,O
corresponding,O
numbers,O
of,O
patients,O
with,O
COVID-19,O
were,O
"78,497",O
and,O
ranged,O
from,O
0,O
to,O
"1,766",O
",",O
respectively,O
(,O
Fig,O
1,O
),O
.,O
Overall,O
",",O
"37,846",O
genes,O
targeted,O
by,O
"48,804",O
probes,O
were,O
analyzed,O
for,O
all,O
samples,O
(,O
Gene,B-Repository
Expression,I-Repository
Omnibus,E-Repository
 ,O
accession,O
number,O
GSE36961,S-AccessionNumber
),O
",",O
and,O
8443,O
genes,O
(,O
22,O
%,O
of,O
the,O
transcriptome,O
),O
were,O
expressed,O
differentially,O
between,O
HCM,O
and,O
controls,O
based,O
on,O
a,O
false,O
discovery,O
rate,O
q,O
-,O
value,O
less,O
than,O
0.05,O
.,O
Given,O
the,O
current,O
and,O
devastating,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
(,O
>,O
2.5,O
million,O
confirmed,O
cases,O
),O
that,O
has,O
claimed,O
more,O
than,O
"172,000",O
lives,O
worldwide,O
in,O
less,O
than,O
4,O
months,O
(,O
April,O
21,O
",",O
2020,O
),O
",",O
it,O
was,O
noteworthy,O
that,O
the,O
most,O
up,O
-,O
regulated,O
gene,O
in,O
HCM,O
samples,O
was,O
ACE2,O
(,O
3.53,O
-,O
fold,O
;,O
q,O
-,O
value=1.30×10−23,O
),O
.,O
This,O
viral,O
internalization,O
may,O
result,O
in,O
loss,O
of,O
membrane,O
ACE2,O
and,O
a,O
subsequent,O
increase,O
in,O
the,O
angiotensin,O
II,O
to,O
angiotensin-(1,O
-,O
7,O
),O
ratio,O
",",O
which,O
in,O
turn,O
allows,O
excessive,O
angiotensin,O
II,O
and,O
unopposed,O
angiotensin,O
type,O
1,O
receptor,O
–,O
mediated,O
lung,O
injury,O
in,O
patients,O
with,O
COVID-19,O
infection,O
and,O
the,O
development,O
of,O
severe,O
acute,O
respiratory,O
distress,O
syndrome,O
.,O
Nevertheless,O
",",O
widespread,O
ACE2,O
expression,O
may,O
contribute,O
to,O
the,O
multiorgan,O
dysfunction,O
seen,O
in,O
patients,O
with,O
COVID-19,O
infection,O
.,O
",",O
The,O
marked,O
5,O
-,O
fold,O
increase,O
in,O
ACE2,O
protein,O
in,O
HCM,O
may,O
provide,O
a,O
mechanism,O
to,O
explain,O
higher,O
rates,O
of,O
severe,O
outcomes,O
in,O
COVID-19,O
–,O
infected,O
patients,O
who,O
also,O
have,O
cardiovascular,O
comorbid,O
conditions,O
",",O
as,O
well,O
as,O
the,O
direct,O
cardiac,O
damage,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
infections,O
.,O
Although,O
the,O
incidence,O
of,O
COVID-19,O
infection,O
seems,O
highest,O
in,O
the,O
elderly,O
or,O
immunocompromised,O
",",O
a,O
large,O
number,O
of,O
affected,O
patients,O
and,O
those,O
requiring,O
hospitalization,O
have,O
significant,O
comorbid,O
conditions,O
",",O
including,O
highly,O
prevalent,O
cardiovascular,O
diseases,O
such,O
as,O
HTN,O
or,O
CHF,O
.,O
In,O
early,O
studies,O
",",O
7.2,O
%,O
of,O
all,O
COVID-19,O
–,O
infected,O
patients,O
and,O
22,O
%,O
of,O
patients,O
admitted,O
to,O
ICUs,O
showed,O
evidence,O
of,O
myocardial,O
injury,O
with,O
elevated,O
high,O
-,O
sensitivity,O
troponin,O
I,O
levels,O
or,O
new,O
ECG,O
abnormalities,O
with,O
clinical,O
manifestations,O
of,O
myocardial,O
ischemia,O
or,O
myocarditis,O
.,O
Although,O
initial,O
reports,O
suggested,O
potentially,O
worse,O
outcomes,O
in,O
patients,O
with,O
COVID-19,O
infection,O
who,O
were,O
using,O
ACEis,O
",",O
",",O
 ,O
a,O
subsequent,O
review,O
article,O
concluded,O
that,O
there,O
was,O
insufficient,O
evidence,O
for,O
this,O
claim,O
",",O
prompting,O
all,O
major,O
cardiac,O
societies,O
to,O
advise,O
that,O
patients,O
with,O
heart,O
disease,O
treated,O
with,O
these,O
medications,O
should,O
continue,O
to,O
use,O
them,O
as,O
prescribed,O
.,O
Furthermore,O
",",O
a,O
large,O
study,O
among,O
1128,O
patients,O
with,O
HTN,O
and,O
diagnosed,O
with,O
COVID-19,O
infection,O
showed,O
that,O
the,O
unadjusted,O
mortality,O
rate,O
was,O
significantly,O
lower,O
in,O
those,O
for,O
whom,O
HTN,O
was,O
treated,O
with,O
ACEi,O
/,O
ARBs,O
(,O
3.7,O
%,O
vs,O
9.8,O
%,O
;,O
P=.001,O
),O
.,O
In,O
light,O
of,O
these,O
findings,O
",",O
a,O
clinical,O
trial,O
has,O
been,O
launched,O
testing,O
the,O
effect,O
of,O
losartan,O
in,O
study,O
-,O
eligible,O
patients,O
with,O
COVID-19,O
infection,O
(,O
NCT04312009,S-AccessionNumber
;,O
Figure,O
 ,O
4,O
),O
.,O
Notably,O
",",O
in,O
the,O
context,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
the,O
transcript,O
for,O
angiotensin,O
I,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
",",O
a,O
negative,O
regulator,O
of,O
the,O
angiotensin,O
system,O
",",O
was,O
the,O
single,O
most,O
up,O
-,O
regulated,O
gene,O
in,O
HCM,O
(,O
fold,O
-,O
change,O
",",O
3.53,O
;,O
q,O
-,O
value,O
=,O
1.30×10,O
−23,O
),O
",",O
which,O
was,O
confirmed,O
by,O
qRT,O
-,O
PCR,O
in,O
triplicate,O
(,O
fold,O
change,O
",",O
3.78,O
;,O
P,O
=,O
5.22×10,O
−4,O
),O
",",O
and,O
Western,O
blot,O
confirmed,O
greater,O
than,O
5,O
-,O
fold,O
overexpression,O
of,O
ACE2,O
protein,O
(,O
fold,O
change,O
",",O
5.34,O
;,O
P,O
=,O
1.66×10,O
−6,O
),O
.,O
However,O
",",O
given,O
that,O
 ,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
uses,O
ACE2,O
for,O
viral,O
entry,O
",",O
this,O
5,O
-,O
fold,O
increase,O
in,O
ACE2,O
protein,O
may,O
confer,O
increased,O
risk,O
for,O
COVID-19,O
manifestations,O
and,O
outcomes,O
in,O
patients,O
with,O
increased,O
ACE2,O
transcript,O
expression,O
and,O
protein,O
levels,O
in,O
the,O
heart,O
.,O
To,O
analyse,O
the,O
phylogenetic,O
relationship,O
between,O
different,O
coronaviruses,O
",",O
591,O
genomes,O
were,O
downloaded,O
from,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Database,I-Dataset
(GISAID),E-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
.,O
To,O
prevent,O
anomaly,O
in,O
the,O
data,O
represented,O
",",O
complete,O
genomes,O
and,O
only,O
high,O
coverage,O
datasets,O
were,O
utilized,O
.,O
We,O
investigated,O
the,O
phylogenetic,O
analysis,O
of,O
591,O
genomic,O
sequences,O
of,O
hCoV,O
obtained,O
from,O
GISAID,S-Dataset
 ,O
database,O
using,O
RAxML,O
methods,O
.,O
Since,O
December,O
2019,O
",",O
a,O
pneumonia,O
associated,O
with,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
named,O
as,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
by,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
",",O
emerged,O
in,O
Wuhan,O
",",O
China,O
(,O
1–3,O
),O
.,O
Although,O
remdesivir,O
was,O
reported,O
to,O
possess,O
potential,O
antiviral,O
effect,O
in,O
one,O
COVID-19,O
patient,O
from,O
the,O
United,O
States,O
",",O
randomized,O
controlled,O
trials,O
of,O
this,O
drug,O
are,O
ongoing,O
to,O
determine,O
its,O
safety,O
and,O
efficacy,O
(,O
6,O
),O
.,O
Moreover,O
",",O
the,O
corticosteroid,O
treatment,O
for,O
COVID-19,O
lung,O
injury,O
remains,O
controversial,O
",",O
due,O
to,O
delayed,O
clearance,O
of,O
viral,O
infection,O
and,O
complications,O
(,O
7,O
",",O
8),O
.,O
Since,O
the,O
effective,O
vaccine,O
and,O
specific,O
antiviral,O
medicines,O
are,O
unavailable,O
",",O
it,O
is,O
an,O
urgent,O
need,O
to,O
look,O
for,O
an,O
alternative,O
strategy,O
for,O
COVID-19,O
treatment,O
",",O
especially,O
among,O
severe,O
patients,O
.,O
Since,O
the,O
virological,O
and,O
clinical,O
characteristics,O
share,O
similarity,O
among,O
SARS,O
",",O
Middle,O
East,O
Respiratory,O
Syndrome,O
(,O
MERS,O
),O
",",O
and,O
COVID-19,O
(,O
15,O
),O
",",O
CP,O
therapy,O
might,O
be,O
a,O
promising,O
treatment,O
option,O
for,O
COVID-19,O
rescue,O
(,O
16,O
),O
.,O
Patients,O
who,O
have,O
recovered,O
from,O
COVID-19,O
with,O
a,O
high,O
neutralizing,O
antibody,O
titer,O
may,O
be,O
a,O
valuable,O
donor,O
source,O
of,O
CP,O
.,O
Nevertheless,O
",",O
the,O
potential,O
clinical,O
benefit,O
and,O
risk,O
of,O
convalescent,O
blood,O
products,O
in,O
COVID-19,O
remains,O
uncertain,O
.,O
Hence,O
",",O
we,O
performed,O
this,O
pilot,O
study,O
in,O
three,O
participating,O
hospitals,O
to,O
explore,O
the,O
feasibility,O
of,O
CP,O
treatment,O
in,O
10,O
severe,O
COVID-19,O
patients,O
.,O
Among,O
the,O
first,O
batch,O
of,O
CP,O
samples,O
from,O
40,O
recovered,O
COVID-19,O
patients,O
",",O
39,O
showed,O
high,O
antibody,O
titers,O
of,O
at,O
least,O
1:160,O
",",O
whereas,O
only,O
one,O
had,O
an,O
antibody,O
titer,O
of,O
1:32,O
.,O
From,O
January,O
23,O
",",O
2020,O
",",O
to,O
February,O
19,O
",",O
2020,O
",",O
10,O
severe,O
COVID-19,O
patients,O
(,O
six,O
males,O
and,O
four,O
females,O
),O
were,O
enrolled,O
and,O
received,O
CP,O
transfusion,O
.,O
Lymphocytopenia,O
",",O
an,O
important,O
index,O
for,O
prognosis,O
in,O
COVID-19,O
(,O
2,O
),O
",",O
tended,O
to,O
be,O
improved,O
after,O
CP,O
transfusion,O
(,O
median,O
:,O
0.65,O
×,O
109,O
per,O
L,O
vs.,O
0.76,O
×,O
109,O
per,O
L,O
),O
",",O
7,O
out,O
of,O
10,O
patients,O
showing,O
an,O
increase,O
of,O
lymphocyte,O
counts,O
(,O
Fig,O
.,O
2,O
),O
.,O
Recent,O
studies,O
on,O
COVID-19,O
demonstrated,O
that,O
the,O
lymphocyte,O
counts,O
in,O
the,O
peripheral,O
blood,O
were,O
remarkably,O
decreased,O
and,O
the,O
levels,O
of,O
cytokines,O
in,O
the,O
plasma,O
from,O
patients,O
requiring,O
intensive,O
care,O
unit,O
(,O
ICU,O
),O
support,O
",",O
including,O
IL-6,O
",",O
IL-10,O
",",O
TNF,O
-,O
ɑ,O
",",O
and,O
granulocyte,O
-,O
macrophage,O
colony,O
-,O
stimulating,O
factor,O
",",O
were,O
significantly,O
higher,O
than,O
in,O
those,O
who,O
did,O
not,O
require,O
ICU,O
conditions,O
(,O
2,O
",",O
18,O
),O
.,O
CP,O
",",O
obtained,O
from,O
recovered,O
COVID-19,O
patients,O
who,O
had,O
established,O
humoral,O
immunity,O
against,O
the,O
virus,O
",",O
contains,O
a,O
large,O
quantity,O
of,O
neutralizing,O
antibodies,O
capable,O
of,O
neutralizing,O
SARS,O
-,O
CoV-2,O
and,O
eradicating,O
the,O
pathogen,O
from,O
blood,O
circulation,O
and,O
pulmonary,O
tissues,O
(,O
19,O
),O
.,O
Based,O
on,O
our,O
preliminary,O
results,O
",",O
CP,O
therapy,O
can,O
be,O
an,O
easily,O
accessible,O
",",O
promising,O
",",O
and,O
safe,O
rescue,O
option,O
for,O
severe,O
COVID-19,O
patients,O
.,O
In,O
the,O
present,O
study,O
",",O
recently,O
recovered,O
COVID-19,O
patients,O
",",O
who,O
were,O
infected,O
by,O
SARS,O
-,O
CoV-2,O
with,O
neutralizing,O
antibody,O
titer,O
above,O
1:640,O
and,O
recruited,O
from,O
local,O
hospitals,O
",",O
should,O
be,O
considered,O
as,O
suitable,O
donors,O
.,O
The,O
antibody,O
titers,O
in,O
CP,O
in,O
COVID-19,O
seem,O
thus,O
higher,O
than,O
those,O
used,O
in,O
the,O
treatment,O
of,O
MERS,O
patient,O
(,O
1:80,O
),O
(,O
12,O
),O
.,O
All,O
patients,O
were,O
diagnosed,O
as,O
having,O
severe,O
COVID-19,O
according,O
to,O
the,O
WHO,O
Interim,O
Guidance,O
(,O
30,O
),O
and,O
the,O
Guideline,O
of,O
Diagnosis,O
and,O
Treatment,O
of,O
COVID-19,O
of,O
National,O
Health,O
Commission,O
of,O
China,O
(,O
version,O
5.0,O
),O
(,O
31,O
),O
",",O
with,O
confirmation,O
by,O
real,O
-,O
time,O
RT,O
-,O
PCR,O
assay,O
.,O
Significance,O
 ,O
COVID-19,O
is,O
currently,O
a,O
big,O
threat,O
to,O
global,O
health,O
.,O
These,O
results,O
indicate,O
that,O
CP,O
can,O
serve,O
as,O
a,O
promising,O
rescue,O
option,O
for,O
severe,O
COVID-19,O
",",O
while,O
the,O
randomized,O
trial,O
is,O
warranted,O
.,O
Currently,O
",",O
there,O
are,O
no,O
approved,O
specific,O
antiviral,O
agents,O
for,O
novel,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
This,O
study,O
showed,O
CP,O
therapy,O
was,O
well,O
tolerated,O
and,O
could,O
potentially,O
improve,O
the,O
clinical,O
outcomes,O
through,O
neutralizing,O
viremia,O
in,O
severe,O
COVID-19,O
cases,O
.,O
The,O
novel,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
which,O
causes,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
is,O
a,O
pandemic,O
that,O
has,O
infected,O
more,O
than,O
3.2,O
million,O
people,O
around,O
the,O
world,O
and,O
caused,O
more,O
than,O
"250,000",O
deaths,O
as,O
of,O
May,O
4,O
",",O
2020,O
(,O
),O
",",O
including,O
>,O
1.2,O
million,O
cases,O
in,O
the,O
United,O
States,O
(,O
US,O
),O
and,O
>,O
"52,000",O
in,O
California,O
.,O
In,O
particular,O
",",O
Washington,O
State,O
has,O
reported,O
a,O
series,O
of,O
COVID-19,O
cases,O
from,O
Jan,O
21,O
to,O
Mar,O
18,O
",",O
following,O
the,O
identification,O
of,O
the,O
earliest,O
case,O
reported,O
in,O
the,O
US,O
",",O
WA1,O
",",O
on,O
Jan,O
19,O
",",O
suggesting,O
the,O
presence,O
of,O
a,O
persistent,O
transmission,O
chain,O
in,O
the,O
community,O
(,O
",",O
),O
.,O
However,O
",",O
real,O
-,O
time,O
genomic,O
epidemiology,O
data,O
of,O
COVID-19,O
to,O
inform,O
public,O
health,O
interventions,O
in,O
California,O
have,O
been,O
lacking,O
to,O
date,O
.,O
Here,O
we,O
used,O
this,O
method,O
and/or,O
tiling,O
multiplex,O
PCR,O
to,O
recover,O
viral,O
genomes,O
from,O
COVID-19,O
patients,O
in,O
Northern,O
California,O
and,O
perform,O
phylogenetic,O
analyses,O
to,O
better,O
understand,O
the,O
genetic,O
diversity,O
of,O
SARS,O
-,O
CoV-2,O
in,O
the,O
US,O
and,O
the,O
nature,O
of,O
transmission,O
of,O
virus,O
lineages,O
in,O
the,O
community,O
.,O
We,O
screened,O
a,O
total,O
of,O
62,O
respiratory,O
swab,O
samples,O
from,O
54,O
COVID-19,O
patients,O
available,O
from,O
hospitals,O
and,O
clinics,O
at,O
University,O
of,O
California,O
",",O
San,O
Francisco,O
(,O
UCSF,O
),O
",",O
the,O
California,O
Department,O
of,O
Public,O
Health,O
(,O
CDPH,O
),O
",",O
and,O
8,O
county,O
public,O
health,O
departments,O
in,O
Northern,O
California,O
(,O
table,O
S1,O
),O
.,O
Phylogenetic,O
analysis,O
revealed,O
that,O
the,O
36,O
SARS,O
-,O
CoV-2,O
genomes,O
from,O
California,O
generated,O
in,O
this,O
study,O
were,O
dispersed,O
across,O
the,O
evolutionary,O
tree,O
of,O
SARS,O
-,O
CoV-2,O
that,O
was,O
built,O
from,O
789,O
worldwide,O
genomes,O
deposited,O
into,O
GISAID,S-Dataset
 ,O
as,O
of,O
March,O
20,O
",",O
2020,O
(,O
Fig,O
.,O
2A,O
),O
.,O
This,O
suggested,O
that,O
the,O
virus,O
from,O
UC19,O
could,O
be,O
basally,O
positioned,O
relative,O
to,O
the,O
cruise,O
ship,O
strains,O
from,O
voyage,O
B,O
",",O
and,O
that,O
COVID-19,O
infections,O
associated,O
with,O
voyage,O
A,O
may,O
have,O
been,O
passed,O
onto,O
passengers,O
and,O
crew,O
on,O
voyage,O
B.,O
Three,O
patients,O
examined,O
in,O
this,O
study,O
(,O
CA3,O
",",O
CA4,O
",",O
and,O
UC12,O
),O
had,O
COVID-19,O
infections,O
associated,O
with,O
international,O
travel,O
or,O
exposure,O
to,O
international,O
travelers,O
.,O
In,O
Santa,O
Clara,O
County,O
",",O
we,O
sequenced,O
7,O
genomes,O
from,O
individuals,O
who,O
were,O
part,O
of,O
a,O
local,O
outbreak,O
of,O
COVID-19,O
at,O
a,O
large,O
workplace,O
facility,O
with,O
multiple,O
employers,O
",",O
large,O
areas,O
of,O
shared,O
space,O
",",O
and,O
heavy,O
pedestrian,O
traffic,O
.,O
The,O
genomic,O
epidemiology,O
of,O
the,O
COVID-19,O
cases,O
associated,O
with,O
community,O
spread,O
studied,O
here,O
do,O
not,O
show,O
any,O
predominant,O
SARS,O
-,O
CoV-2,O
lineage,O
circulating,O
in,O
Northern,O
California,O
.,O
In,O
addition,O
",",O
WA1,O
lineage,O
viruses,O
have,O
been,O
identified,O
in,O
COVID-19,O
cases,O
from,O
many,O
states,O
including,O
Minnesota,O
",",O
Connecticut,O
",",O
Utah,O
",",O
Virginia,O
",",O
and,O
New,O
York,O
(,O
",",O
),O
.,O
Undersampling,O
of,O
virus,O
genomes,O
is,O
due,O
in,O
part,O
to,O
the,O
high,O
proportion,O
of,O
cases,O
(,O
80,O
%,O
),O
with,O
asymptomatic,O
or,O
mild,O
disease,O
(,O
–,O
),O
and,O
limited,O
diagnostic,O
testing,O
for,O
COVID-19,O
infection,O
to,O
date,O
in,O
California,O
and,O
throughout,O
the,O
US,O
.,O
Despite,O
this,O
",",O
our,O
study,O
shows,O
that,O
robust,O
insights,O
into,O
COVID-19,O
transmission,O
are,O
achievable,O
if,O
virus,O
genomic,O
diversity,O
is,O
combined,O
and,O
jointly,O
interpreted,O
with,O
detailed,O
epidemiological,O
case,O
data,O
.,O
Our,O
data,O
suggest,O
concerning,O
trends,O
in,O
this,O
direction,O
",",O
such,O
as,O
the,O
association,O
between,O
the,O
WA1,O
lineage,O
and,O
community,O
-,O
acquired,O
COVID-19,O
cases,O
in,O
several,O
counties,O
of,O
Northern,O
California,O
",",O
and,O
a,O
virus,O
from,O
the,O
SCC1,O
lineage,O
detected,O
in,O
residents,O
of,O
neighboring,O
San,O
Mateo,O
and,O
Solano,O
County,O
.,O
The,O
COVID-19,O
pandemic,O
caused,O
by,O
the,O
novel,O
coronavirus,O
SARS,O
-,O
CoV-2,O
has,O
spread,O
globally,O
",",O
with,O
>,O
"52,000",O
cases,O
in,O
California,O
as,O
of,O
May,O
4,O
",",O
2020,O
.,O
The,O
sudden,O
epidemic,O
outbreak,O
of,O
the,O
new,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
in,O
Wu,O
Han,O
City,O
",",O
China,O
",",O
has,O
rapidly,O
spread,O
all,O
over,O
the,O
world,O
",",O
leading,O
to,O
one,O
of,O
the,O
worst,O
pandemic,O
outbreaks,O
since,O
the,O
Spanish,O
Flu,O
that,O
occurred,O
100,O
years,O
ago,O
(,O
1,O
),O
.,O
Based,O
on,O
that,O
",",O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
declared,O
the,O
COVID-19,O
outbreak,O
a,O
pandemic,O
on,O
March,O
11th,O
2020,O
.,O
Herein,O
",",O
we,O
will,O
discuss,O
the,O
pathological,O
progression,O
of,O
this,O
disease,O
along,O
with,O
the,O
activated,O
inflammatory,O
response,O
that,O
underlies,O
the,O
lethal,O
complications,O
of,O
COVID-19,O
.,O
We,O
will,O
also,O
evaluate,O
the,O
current,O
status,O
of,O
Thalidomide,O
usage,O
as,O
an,O
anti,O
-,O
inflammatory,O
therapy,O
for,O
COVID-19,O
induced,O
pneumonia,O
and,O
acute,O
lung,O
injury,O
(,O
ALI,O
),O
.,O
Since,O
the,O
human,O
respiratory,O
system,O
is,O
the,O
primary,O
target,O
for,O
coronavirus,O
pathogens,O
",",O
abnormal,O
respiratory,O
findings,O
are,O
highly,O
detected,O
in,O
COVID-19,O
patients,O
.,O
This,O
cytokine,O
storm,O
initiates,O
lung,O
injures,O
and,O
is,O
considered,O
the,O
primary,O
clinical,O
cause,O
of,O
death,O
among,O
COVID-19,O
patients,O
(,O
11,O
),O
.,O
Thus,O
",",O
if,O
kept,O
untreated,O
",",O
COVID-19,O
can,O
cause,O
damage,O
to,O
the,O
heart,O
",",O
the,O
liver,O
",",O
and,O
the,O
kidneys,O
",",O
as,O
well,O
as,O
to,O
organ,O
systems,O
such,O
as,O
the,O
blood,O
and,O
the,O
immune,O
system,O
(,O
13,O
),O
.,O
Among,O
the,O
tested,O
anti,O
-,O
inflammatory,O
drugs,O
are,O
the,O
non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
(,O
NSAID,O
),O
drugs,O
",",O
glucocorticoids,O
",",O
intravenous,O
immunoglobulin,O
therapy,O
",",O
NK,O
cell,O
-,O
based,O
immunotherapy,O
",",O
immunosuppressants,O
",",O
and,O
inflammatory,O
cytokines,O
antagonists,O
(,O
17,O
",",O
19,O
),O
.,O
Although,O
some,O
of,O
these,O
drugs,O
have,O
shown,O
to,O
be,O
efficient,O
in,O
COVID-19,O
treatment,O
",",O
yet,O
the,O
accompanying,O
adverse,O
side,O
effects,O
or,O
the,O
reported,O
non,O
-,O
significant,O
outcomes,O
did,O
not,O
support,O
their,O
further,O
usage,O
(,O
4,O
",",O
20,O
",",O
21,O
),O
.,O
So,O
far,O
",",O
chloroquine,O
and,O
hydroxychloroquine,O
usage,O
have,O
been,O
highly,O
applauded,O
and,O
was,O
given,O
an,O
emergency,O
approval,O
by,O
the,O
FDA,O
to,O
slow,O
the,O
progression,O
of,O
COVID-19,O
among,O
critical,O
cases,O
.,O
The,O
above,O
cases,O
are,O
characterized,O
by,O
similar,O
disease,O
manifestations,O
",",O
pathogenicity,O
",",O
and,O
progression,O
as,O
the,O
ones,O
encountered,O
in,O
COVID-19,O
cases,O
.,O
Similar,O
to,O
COVID-19,O
",",O
Paraquat,O
(,O
PQ,O
),O
poisoning,O
is,O
known,O
to,O
be,O
associated,O
with,O
respiratory,O
distress,O
due,O
to,O
the,O
alveolar,O
epithelial,O
cell,O
disruption,O
",",O
hemorrhage,O
",",O
and,O
the,O
infiltration,O
of,O
inflammatory,O
cells,O
into,O
the,O
interstitial,O
and,O
alveolar,O
spaces,O
which,O
ends,O
up,O
with,O
fibroblastic,O
proliferation,O
",",O
collagen,O
deposition,O
",",O
and,O
progressive,O
fibrosis,O
.,O
In,O
both,O
(,O
PQ,O
),O
and,O
(,O
BLM)-induced,O
pulmonary,O
fibrosis,O
models,O
",",O
the,O
core,O
pro,O
-,O
inflammatory,O
cytokines,O
underlying,O
the,O
pathogenicity,O
of,O
these,O
conditions,O
such,O
as,O
TNF,O
-,O
α,O
",",O
IL-6,O
",",O
IL-1β,O
",",O
and,O
TGF,O
-,O
β,O
are,O
common,O
with,O
that,O
of,O
COVID-19,O
cases,O
(,O
38,O
",",O
39,O
),O
.,O
Based,O
on,O
the,O
above,O
",",O
Thalidomide,O
could,O
be,O
hypothetically,O
listed,O
among,O
the,O
potential,O
drugs,O
to,O
be,O
tested,O
in,O
treating,O
respiratory,O
complications,O
associated,O
with,O
COVID-19,O
based,O
on,O
its,O
potent,O
anti,O
-,O
inflammatory,O
properties,O
and,O
its,O
activity,O
in,O
attenuating,O
exaggerated,O
inflammation,O
and,O
cytokine,O
storms,O
(,O
Figure,O
1,O
),O
.,O
On,O
February,O
26th,O
2020,O
",",O
a,O
case,O
-,O
report,O
preprint,O
manuscript,O
was,O
published,O
online,O
with,O
a,O
single,O
Chinese,O
patient,O
with,O
severe,O
COVID-19,O
pneumonia,O
being,O
treated,O
with,O
Thalidomide,O
in,O
combination,O
with,O
low,O
-,O
dose,O
glucocorticoids,O
and,O
anti,O
-,O
viral,O
therapy,O
(,O
43,O
),O
.,O
The,O
results,O
presented,O
Thalidomide,O
as,O
a,O
promising,O
therapeutic,O
drug,O
to,O
treat,O
severe,O
cases,O
of,O
COVID-19,O
.,O
The,O
first,O
clinical,O
trial,O
(,O
NCT04273581,S-AccessionNumber
),O
would,O
address,O
the,O
efficacy,O
and,O
safety,O
of,O
this,O
drug,O
in,O
combination,O
with,O
low,O
-,O
dose,O
hormones,O
for,O
treating,O
severe,O
COVID-19,O
cases,O
.,O
The,O
second,O
trial,O
(,O
NCT04273529,S-AccessionNumber
),O
would,O
investigate,O
the,O
efficacy,O
and,O
safety,O
of,O
this,O
drug,O
as,O
an,O
adjuvant,O
treatment,O
for,O
moderate,O
new,O
COVID-19,O
cases,O
with,O
pneumonia,O
.,O
In,O
this,O
trial,O
",",O
Thalidomide,O
(,O
100,O
mg,O
),O
will,O
be,O
used,O
for,O
14,O
days,O
to,O
treat,O
lung,O
inflammation,O
in,O
100,O
participants,O
with,O
COVID-19,O
(,O
44,O
",",O
45,O
),O
.,O
Thus,O
",",O
using,O
this,O
drug,O
for,O
treating,O
respiratory,O
conditions,O
such,O
as,O
those,O
encountered,O
by,O
COVID-19,O
should,O
be,O
further,O
investigated,O
before,O
proceeding,O
.,O
Currently,O
",",O
the,O
only,O
available,O
case,O
-,O
report,O
on,O
the,O
efficacy,O
of,O
Thalidomide,O
in,O
treating,O
severe,O
COVID-19,O
cases,O
is,O
not,O
sufficient,O
to,O
promote,O
the,O
usage,O
of,O
the,O
drug,O
due,O
to,O
several,O
reasons,O
.,O
Aside,O
from,O
being,O
a,O
non,O
-,O
peer,O
reviewed,O
article,O
that,O
describes,O
the,O
outcomes,O
in,O
only,O
one,O
COVID-19,O
patient,O
",",O
the,O
combination,O
of,O
Thalidomide,O
with,O
corticosteroids,O
might,O
be,O
a,O
drawback,O
since,O
the,O
latter,O
were,O
reported,O
to,O
cause,O
lung,O
injury,O
",",O
and,O
thus,O
",",O
their,O
usage,O
is,O
not,O
clinically,O
supported,O
(,O
20,O
),O
.,O
Second,O
",",O
the,O
two,O
clinical,O
trials,O
that,O
aim,O
at,O
studying,O
the,O
efficacy,O
and,O
safety,O
of,O
this,O
drug,O
in,O
COVID-19,O
patients,O
were,O
initiated,O
by,O
the,O
same,O
author,O
who,O
published,O
the,O
discussed,O
single,O
case,O
-,O
report,O
.,O
Thus,O
",",O
further,O
studies,O
on,O
the,O
usage,O
of,O
Thalidomide,O
in,O
COVID-19,O
cases,O
should,O
take,O
into,O
account,O
the,O
resultant,O
induced,O
birth,O
defects,O
and,O
the,O
severe,O
toxicities,O
that,O
are,O
encountered,O
during,O
its,O
intake,O
",",O
such,O
as,O
sensorimotor,O
peripheral,O
neuropathy,O
",",O
somnolence,O
",",O
acute,O
pulmonary,O
toxicities,O
",",O
and,O
thromboembolic,O
events,O
(,O
22,O
",",O
51–53,O
),O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
is,O
a,O
worldwide,O
threatening,O
health,O
issue,O
.,O
In,O
the,O
absence,O
of,O
an,O
effective,O
anti,O
-,O
viral,O
molecule,O
and,O
until,O
the,O
formulation,O
of,O
a,O
successful,O
vaccine,O
",",O
anti,O
-,O
inflammatory,O
drugs,O
might,O
offer,O
a,O
complementary,O
tool,O
for,O
controlling,O
the,O
associated,O
complications,O
of,O
COVID-19,O
and,O
thus,O
decreasing,O
the,O
subsequent,O
fatalities,O
.,O
Drug,O
repurposing,O
for,O
several,O
molecules,O
has,O
emerged,O
as,O
a,O
rapid,O
temporary,O
solution,O
for,O
COVID-19,O
.,O
Based,O
on,O
just,O
one,O
-,O
case,O
report,O
that,O
presented,O
positive,O
outcomes,O
in,O
a,O
patient,O
treated,O
amongst,O
others,O
with,O
Thalidomide,O
",",O
two,O
clinical,O
trials,O
on,O
the,O
efficacy,O
and,O
safety,O
of,O
Thalidomide,O
in,O
treating,O
severe,O
respiratory,O
complications,O
in,O
COVID-19,O
patients,O
were,O
registered,O
.,O
Herein,O
",",O
we,O
will,O
discuss,O
the,O
theoretical,O
effectiveness,O
of,O
Thalidomide,O
in,O
attenuating,O
inflammatory,O
complications,O
that,O
are,O
encountered,O
in,O
COVID-19,O
patients,O
while,O
pinpointing,O
the,O
lack,O
of,O
the,O
needed,O
evidences,O
to,O
move,O
forward,O
with,O
this,O
drug,O
.,O
Removal,O
of,O
unincorporated,O
ddNTP,O
’s,O
",",O
salts,O
",",O
and,O
dye,O
blobs,O
were,O
performed,O
by,O
BigDye,O
XTerminator,O
Purification,O
Kit,O
(,O
Applied,O
Biosystems,O
",",O
San,O
Diego,O
",",O
CA,O
",",O
USA,O
),O
.,O
The,O
genomic,O
data,O
was,O
analyzed,O
and,O
submitted,O
to,O
a,O
public,O
database,O
(,O
GenBank,S-Repository
),O
under,O
accession,O
numbers,O
MK858156,S-AccessionNumber
-,O
MK858164,S-AccessionNumber
 ,O
and,O
MN735679,S-AccessionNumber
-,O
MN735682,S-AccessionNumber
 ,O
(,O
Supplementary,O
Table,O
S1,O
),O
.,O
Potential,O
recombination,O
events,O
among,O
MERS,O
-,O
CoV,O
S,O
gene,O
complete,O
reference,O
sequences,O
retrieved,O
from,O
GenBank,S-Repository
 ,O
sequence,O
database,O
(,O
n,O
=,O
147,O
),O
and,O
the,O
study,O
strains,O
(,O
n,O
=,O
13,O
),O
(,O
Supplementary,O
Table,O
S1,O
),O
were,O
identified,O
using,O
automated,O
RDP,O
",",O
GENECONV,O
",",O
BOOTSCAN,O
",",O
MaxChi,O
",",O
CHIMAERA,O
",",O
and,O
SISCAN,O
methods,O
provided,O
in,O
RDP4,O
software,O
[,O
34,O
],O
.,O
The,O
resulting,O
N,O
protein,O
-,O
gRNA,O
ribonucleoprotein,O
complexes,O
are,O
finally,O
incorporated,O
into,O
the,O
forming,O
viral,O
particles,O
through,O
interactions,O
with,O
the,O
C,O
terminus,O
of,O
the,O
M,O
proteins,O
(,O
25,O
),O
.,O
Virus,O
titers,O
of,O
the,O
culture,O
supernatants,O
were,O
determined,O
on,O
LR7,O
cells,O
with,O
a,O
dilution,O
factor,O
of,O
3,O
",",O
and,O
the,O
50,O
%,O
tissue,O
culture,O
infectious,O
dose,O
(,O
TCID50,O
),O
units,O
per,O
milliliter,O
of,O
supernatant,O
were,O
calculated,O
according,O
to,O
the,O
Reed,O
-,O
Muench,O
method,O
(,O
53,O
),O
.,O
TCID50,O
per,O
milliliter,O
values,O
were,O
then,O
converted,O
into,O
PFU,O
per,O
microliter,O
as,O
follows,O
:,O
TCID50,O
per,O
milliliter,O
 ,O
×,O
 ,O
0.00069,O
(,O
54,O
),O
.,O
ABSTRACT,O
 ,O
Coronavirus,O
(,O
CoV,O
),O
nucleocapsid,O
(,O
N,O
),O
proteins,O
are,O
key,O
for,O
incorporating,O
genomic,O
RNA,O
into,O
progeny,O
viral,O
particles,O
.,O
Available,O
datasets,O
are,O
more,O
sparse,O
for,O
incidence,O
",",O
and,O
the,O
patterns,O
are,O
inconsistent,O
between,O
studies,O
.,O
Analysis,O
of,O
datasets,O
",",O
specifically,O
of,O
serosurveys,O
",",O
needs,O
to,O
account,O
for,O
the,O
kinetics,O
of,O
waning,O
immunity,O
and,O
effects,O
of,O
imperfect,O
assays,O
to,O
draw,O
meaningful,O
inferences,O
.,O
We,O
conducted,O
searches,O
of,O
the,O
PubMed,O
database,O
on,O
March,O
20,O
",",O
2020,O
using,O
the,O
search,O
term,O
“,O
coronavirus,O
”,O
and,O
each,O
of,O
the,O
following,O
terms,O
or,O
phrases,O
:,O
“,O
serolog,O
*,O
”,O
",",O
“,O
serop,O
*,O
”,O
",",O
“,O
cross,O
reactivity,O
”,O
",",O
“,O
antibod,O
*,O
human,O
coronavirus,O
”,O
",",O
and,O
“,O
complement,O
fixation,O
”,O
.,O
Articles,O
included,O
electronic,O
",",O
ahead,O
-,O
of,O
-,O
print,O
publications,O
available,O
in,O
the,O
PubMed,S-Repository
 ,O
database,O
.,O
Many,O
public,O
health,O
responses,O
and,O
modeled,O
scenarios,O
for,O
COVID-19,O
outbreaks,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
assume,O
that,O
infection,O
results,O
in,O
an,O
immune,O
response,O
that,O
protects,O
individuals,O
from,O
future,O
infections,O
or,O
illness,O
for,O
some,O
amount,O
of,O
time,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
a,O
pandemic,O
infection,O
caused,O
by,O
a,O
positive,O
-,O
sense,O
RNA,O
betacoronavirus,O
named,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
Acute,O
respiratory,O
distress,O
syndrome,O
(,O
ARDS,O
),O
and,O
multiorgan,O
dysfunction,O
are,O
among,O
the,O
leading,O
causes,O
of,O
death,O
in,O
critically,O
ill,O
patients,O
with,O
COVID-19,O
.,O
Elevated,O
concentrations,O
of,O
proinflammatory,O
cytokines,O
and,O
chemokines,O
including,O
interleukin,O
(,O
IL)-2,O
",",O
IL-6,O
",",O
interferon,O
gamma,O
–,O
induced,O
protein,O
10,O
",",O
macrophage,O
inflammatory,O
protein,O
alpha,O
",",O
monocyte,O
chemotactic,O
protein,O
1,O
and,O
tumour,O
necrosis,O
factor,O
-,O
alpha,O
(,O
TNF,O
-,O
α,O
),O
[,O
"1,2",O
],O
suggest,O
that,O
a,O
cytokine,O
release,O
syndrome,O
may,O
play,O
a,O
major,O
role,O
in,O
the,O
pathology,O
of,O
COVID-19,O
.,O
Given,O
the,O
limited,O
number,O
of,O
cases,O
analysed,O
",",O
these,O
findings,O
could,O
simply,O
be,O
due,O
to,O
chance,O
;,O
however,O
",",O
it,O
also,O
adds,O
to,O
other,O
evidence,O
suggesting,O
that,O
ICIs,O
are,O
protective,O
rather,O
than,O
harmful,O
in,O
patients,O
with,O
COVID-19,O
.,O
There,O
is,O
increasing,O
recognition,O
that,O
a,O
state,O
of,O
impaired,O
host,O
immunity,O
accompanied,O
by,O
a,O
significant,O
cell,O
degeneration,O
in,O
secondary,O
lymphoid,O
tissues,O
follows,O
the,O
initial,O
hyperinflammatory,O
phase,O
of,O
COVID-19,O
.,O
First,O
",",O
critically,O
ill,O
high,O
-,O
risk,O
patients,O
with,O
COVID-19,O
often,O
present,O
with,O
lymphocytopenia,O
:,O
Second,O
",",O
patients,O
with,O
COVID-19,O
have,O
high,O
levels,O
of,O
serum,O
IL-6,O
",",O
IL-10,O
and,O
TNF,O
-,O
α,O
and,O
express,O
increased,O
levels,O
of,O
exhaustion,O
markers,O
PD-1,O
and,O
T,O
-,O
cell,O
immunoglobulin,O
mucin-3,O
on,O
the,O
surface,O
of,O
their,O
peripheral,O
T,O
cells,O
",",O
which,O
in,O
turn,O
impair,O
T,O
-,O
cell,O
effector,O
functions,O
and,O
prevent,O
functional,O
memory,O
[,O
9,O
],O
.,O
Finally,O
",",O
compared,O
with,O
cases,O
of,O
pneumonia,O
not,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
",",O
patients,O
with,O
COVID-19,O
have,O
decreased,O
B,O
cell,O
and,O
Th,O
counts,O
but,O
a,O
comparable,O
number,O
of,O
the,O
main,O
cytokine,O
storm,O
(,O
CS,O
),O
players,O
including,O
monocytes,O
",",O
neutrophils,O
and,O
natural,O
killer,O
cells,O
[,O
10,O
],O
.,O
These,O
latest,O
data,O
suggest,O
that,O
viral,O
damage,O
is,O
direct,O
rather,O
than,O
inflammatory,O
driven,O
and,O
strongly,O
supports,O
the,O
use,O
of,O
immune,O
-,O
activating,O
drugs,O
that,O
have,O
been,O
little,O
considered,O
to,O
date,O
for,O
fear,O
of,O
exacerbating,O
the,O
inflammatory,O
reaction,O
and,O
causing,O
a,O
CS,O
.,O
Currently,O
",",O
there,O
are,O
no,O
finally,O
verified,O
data,O
and,O
no,O
antiviral,O
drugs,O
licensed,O
by,O
the,O
US,O
Food,O
and,O
Drug,O
Administration,O
and,O
European,O
Medicines,O
Agency,O
for,O
treating,O
patients,O
with,O
COVID-19,O
or,O
for,O
managing,O
their,O
complications,O
.,O
Since,O
its,O
first,O
outbreak,O
in,O
China,O
",",O
COVID-19,O
was,O
empirically,O
treated,O
with,O
antiviral,O
and,O
respiratory,O
supportive,O
therapies,O
mainly,O
agents,O
already,O
used,O
in,O
prior,O
SARS,O
epidemics,O
.,O
Thus,O
",",O
this,O
provides,O
an,O
opportunity,O
for,O
the,O
research,O
community,O
to,O
better,O
outline,O
the,O
value,O
of,O
immune,O
-,O
modulating,O
agents,O
in,O
the,O
treatment,O
of,O
COVID-19,O
.,O
Based,O
on,O
the,O
promising,O
results,O
from,O
an,O
open,O
-,O
label,O
study,O
in,O
21,O
patients,O
with,O
severe,O
and,O
critical,O
COVID-19,O
[,O
16,O
],O
",",O
tocilizumab,O
—,O
a,O
human,O
monoclonal,O
antibody,O
that,O
binds,O
to,O
both,O
soluble,O
and,O
membrane,O
-,O
bound,O
IL-6,O
receptors,O
(,O
IL-6Rs)—is,O
currently,O
being,O
investigated,O
to,O
address,O
cytokine,O
release,O
syndrome,O
in,O
patients,O
with,O
severe,O
ARDS,O
",",O
which,O
includes,O
randomised,O
",",O
controlled,O
trials,O
(,O
ChiCTR2000029765,S-AccessionNumber
;,O
NCT04320615,S-AccessionNumber
),O
and,O
single,O
-,O
arm,O
trials,O
(,O
ChiCTR2000030796,S-AccessionNumber
;,O
NCT04317092,S-AccessionNumber
),O
.,O
Genetic,O
differences,O
in,O
HLA,O
alleles,O
have,O
been,O
recently,O
recognised,O
to,O
confer,O
differential,O
viral,O
susceptibility,O
and,O
severity,O
of,O
COVID-19,O
[,O
19,O
],O
.,O
These,O
findings,O
highlight,O
that,O
genetic,O
variability,O
in,O
the,O
immune,O
system,O
may,O
affect,O
susceptibility,O
to,O
(,O
and,O
severity,O
of,O
),O
SARS,O
-,O
CoV-2,O
;,O
therefore,O
",",O
strategies,O
to,O
boost,O
immune,O
responses,O
at,O
this,O
stage,O
are,O
certainly,O
important,O
for,O
individuals,O
particularly,O
vulnerable,O
to,O
COVID-19,O
.,O
While,O
confirmed,O
cases,O
of,O
the,O
deadly,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
have,O
exceeded,O
4.7,O
million,O
globally,O
",",O
scientists,O
are,O
pushing,O
forward,O
with,O
efforts,O
to,O
develop,O
vaccines,O
and,O
treatments,O
in,O
an,O
attempt,O
to,O
slow,O
the,O
pandemic,O
and,O
lessen,O
the,O
disease,O
's,O
damage,O
.,O
Although,O
no,O
proven,O
effective,O
therapies,O
for,O
treating,O
patients,O
with,O
COVID-19,O
or,O
for,O
managing,O
their,O
complications,O
currently,O
exist,O
",",O
the,O
rapidly,O
expanding,O
knowledge,O
regarding,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
and,O
its,O
interplay,O
with,O
hosts,O
provides,O
a,O
significant,O
number,O
of,O
potential,O
drug,O
targets,O
 ,O
and,O
the,O
potential,O
to,O
repurpose,O
drugs,O
already,O
tested,O
in,O
other,O
diseases,O
.,O
SARS,O
-,O
CoV-2,O
is,O
the,O
etiologic,O
agent,O
of,O
COVID-19,O
which,O
is,O
now,O
considered,O
a,O
pandemic,O
[,O
[,O
1,O
],O
",",O
[,O
2,O
],O
",",O
[,O
3,O
],O
",",O
[,O
4,O
],O
],O
.,O
SARS,O
-,O
CoV-2,O
is,O
the,O
etiologic,O
agent,O
of,O
COVID-19,O
.,O
The,O
National,O
Institute,O
of,O
Allergy,O
and,O
Infectious,O
Diseases,O
Systems,O
Biology,O
for,O
Infectious,O
Disease,O
Research,O
Program,O
was,O
established,O
to,O
support,O
research,O
focusing,O
on,O
multi,O
-,O
omics,O
approaches,O
and,O
dataset,O
integration,O
to,O
develop,O
and,O
validate,O
predictive,O
models,O
of,O
infectious,O
disease,O
initiation,O
",",O
progression,O
",",O
and,O
outcomes,O
[,O
2,O
],O
.,O
Lipidomics,O
software,O
1,O
:,O
LIQUID,O
:,O
an,O
open,O
-,O
source,O
software,O
for,O
identifying,O
lipids,O
[,O
33,O
],O
.,O
The,O
subsequent,O
datasets,O
are,O
analyzed,O
using,O
MSCovert,O
for,O
spectrum,O
to,O
peak,O
list,O
conversion,O
",",O
mzRefinery,O
for,O
mass,O
recalibration,O
",",O
and,O
MS,O
-,O
GF+,O
for,O
peptide,O
/,O
protein,O
identification,O
[,O
28–30,O
],O
.,O
The,O
lipid,O
phase,O
is,O
dried,O
in,O
vacuo,O
",",O
reconstituted,O
in,O
methanol,O
",",O
and,O
analyzed,O
via,O
a,O
Waters,O
Acquity,O
UPLC,O
H,O
-,O
class,O
system,O
and,O
Velos,O
Pro,O
Orbitrap,O
mass,O
spectrometer,O
",",O
and,O
lipid,O
identifications,O
are,O
made,O
via,O
the,O
LIQUID,O
software,O
[,O
33,O
],O
.,O
Launch,O
LIQUID,O
program,O
[,O
33,O
],O
and,O
upload,O
a,O
.raw,O
or,O
.mzXL,O
data,O
file,O
using,O
the,O
drop,O
down,O
menu,O
.,O
Individuals,O
infected,O
with,O
SARS‐CoV‐19,O
have,O
a,O
variety,O
of,O
clinical,O
manifestations,O
of,O
the,O
disease,O
described,O
as,O
COVID‐19,O
(,O
Huang,O
et,O
 ,O
al,O
.,O
",",O
 ,O
2020,O
),O
.,O
While,O
almost,O
all,O
patients,O
develop,O
COVID,O
pneumonia,O
",",O
approximately,O
29,O
%,O
cases,O
progress,O
to,O
acute,O
respiratory,O
distress,O
syndrome,O
which,O
occurs,O
10–12,O
 ,O
days,O
after,O
the,O
onset,O
of,O
symptoms,O
(,O
Huang,O
et,O
 ,O
al,O
.,O
",",O
 ,O
2020,O
),O
.,O
The,O
upregulation,O
of,O
HLA‐DR,O
expression,O
in,O
lung,O
tissue,O
of,O
patients,O
affected,O
with,O
COVID,O
pneumonia,O
(,O
Wang,O
et,O
 ,O
al,O
.,O
",",O
 ,O
2020,O
),O
suggests,O
that,O
this,O
process,O
is,O
instrumental,O
in,O
the,O
immunological,O
control,O
of,O
the,O
disease,O
process,O
and,O
therefore,O
must,O
be,O
considered,O
to,O
be,O
biologically,O
relevant,O
.,O
It,O
could,O
be,O
argued,O
that,O
the,O
use,O
of,O
the,O
UK,O
deceased,O
donors,O
as,O
a,O
control,O
population,O
in,O
this,O
study,O
has,O
simply,O
highlighted,O
more,O
frequent,O
occurrence,O
of,O
antigens,O
common,O
to,O
BAME,O
communities,O
in,O
our,O
COVID‐19,O
population,O
requiring,O
hospital,O
support,O
for,O
their,O
disease,O
.,O
HLA‐DRB1,O
*,O
10,O
and,O
A*26,O
are,O
common,O
within,O
all,O
European,O
subregions,O
(,O
Sanchez‐Mazas,O
et,O
al,O
.,O
",",O
2017,O
),O
and,O
offer,O
an,O
independent,O
mechanistic,O
explanation,O
for,O
severity,O
of,O
clinical,O
disease,O
in,O
COVID‐19,O
patients,O
which,O
is,O
independent,O
of,O
skin,O
colour,O
or,O
other,O
immunogenetic,O
variation,O
due,O
to,O
heritage,O
.,O
In,O
December,O
2019,O
",",O
SARS,O
-,O
CoV-2,O
emerged,O
",",O
causing,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
.,O
The,O
biological,O
mechanisms,O
that,O
may,O
govern,O
differences,O
in,O
the,O
number,O
of,O
SARS,O
and,O
COVID-19,O
cases,O
remain,O
undefined,O
.,O
Furthermore,O
",",O
a,O
clinical,O
study,O
with,O
an,O
anti,O
-,O
CD147,O
intervention,O
reduced,O
symptoms,O
and,O
duration,O
of,O
hospital,O
admission,O
for,O
COVID-19,O
patients,O
[,O
27,O
],O
.,O
Our,O
computational,O
analysis,O
used,O
publicly,O
available,O
microarray,O
gene,O
expression,O
datasets,O
from,O
airway,O
epithelial,O
cells,O
of,O
515,O
unique,O
subjects,O
",",O
single,O
cell,O
sequencing,O
data,O
from,O
10,O
subjects,O
",",O
and,O
the,O
FANTOM5,S-Dataset
 ,O
dataset,O
for,O
promoter,O
activities,O
of,O
74,O
lung,O
-,O
related,O
cell,O
and,O
tissue,O
types,O
.,O
Our,O
proteomic,O
analysis,O
used,O
data,O
from,O
the,O
Human,B-Repository
Proteome,I-Repository
Map,E-Repository
 ,O
[,O
31,O
],O
and,O
a,O
dataset,O
from,O
primary,O
human,O
airway,O
epithelial,O
cells,O
grown,O
under,O
air,O
–,O
liquid,O
interface,O
culture,O
conditions,O
[,O
32,O
],O
.,O
Our,O
protein,O
expression,O
data,O
are,O
consistent,O
with,O
low,O
ACE2promoter,O
activity,O
in,O
a,O
variety,O
of,O
lung,O
epithelial,O
cell,O
samples,O
and,O
low,O
ACE2,O
gene,O
expression,O
in,O
both,O
microarray,O
and,O
single,O
cell,O
RNA,O
sequencing,O
(,O
scRNAseq,O
),O
datasets,O
.,O
Public,O
microarray,O
experiments,O
using,O
Affymetrix,O
chips,O
(,O
HuGene-1.0,O
-,O
st,O
-,O
v1,O
and,O
HG,O
-,O
U133,O
Plus,O
2,O
),O
on,O
airway,O
epithelial,O
cell,O
samples,O
collected,O
from,O
nasal,O
(,O
GSE19190,S-AccessionNumber
),O
or,O
bronchial,O
(,O
GSE11906,S-AccessionNumber
),O
brushings,O
of,O
healthy,O
nonsmokers,O
were,O
obtained,O
from,O
the,O
NCBI,B-Repository
Gene,I-Repository
Expression,I-Repository
Omnibus,I-Repository
(GEO),E-Repository
 ,O
database,O
[,O
33,O
",",O
34,O
],O
.,O
For,O
all,O
dataset,O
samples,O
",",O
raw,O
intensity,O
values,O
and,O
annotation,O
data,O
were,O
downloaded,O
using,O
the,O
GEOquery,O
R,O
package,O
(,O
version,O
2.52.0,O
),O
[,O
35,O
],O
from,O
the,O
Bioconductor,O
project,O
[,O
36,O
],O
.,O
All,O
gene,O
expression,O
data,O
were,O
unified,O
into,O
a,O
single,O
dataset,O
that,O
was,O
then,O
normalised,O
by,O
robust,O
multiarray,O
average,O
(,O
RMA,O
),O
normalisation,O
",",O
and,O
only,O
genes,O
present,O
in,O
both,O
of,O
the,O
Affymetrix,O
platforms,O
(,O
n=16,O
 ,O
013,O
),O
were,O
kept,O
for,O
subsequent,O
analyses,O
.,O
The,O
FANTOM5,S-Dataset
 ,O
promoterome,O
dataset,O
[,O
39,O
],O
for,O
the,O
hg38,O
assembly,O
[,O
40,O
],O
was,O
used,O
to,O
examine,O
promoter,O
activity,O
of,O
SARS,O
-,O
CoV-2,O
-,O
related,O
human,O
genes,O
",",O
namely,O
ACE2,O
",",O
TMPRSS2,O
",",O
ADAM17,O
",",O
CTSL,O
",",O
CD147,O
and,O
GRP78,O
.,O
The,O
dataset,O
consists,O
of,O
CAGE,O
promoter,O
activity,O
data,O
for,O
1866,O
primary,O
cells,O
",",O
cell,O
lines,O
and,O
tissues,O
from,O
humans,O
",",O
and,O
is,O
quantified,O
as,O
normalised,O
transcripts,O
per,O
million,O
(,O
TPM,O
),O
.,O
Publicly,O
available,O
human,O
proteomic,O
data,O
from,O
the,O
datasets,O
of,O
Kim,B-Creator
et,I-Creator
al.,E-Creator
 ,O
[,O
31,O
],O
and,O
Foster,B-Creator
et,I-Creator
al.,E-Creator
 ,O
[,O
32,O
],O
were,O
used,O
to,O
evaluate,O
SARS,O
-,O
CoV-2,O
receptor,O
-,O
related,O
protein,O
expression,O
in,O
different,O
human,O
tissues,O
and,O
experimental,O
conditions,O
.,O
Expression,O
values,O
were,O
extracted,O
from,O
the,O
dataset,O
of,O
Kim,B-Creator
et,I-Creator
al.,E-Creator
 ,O
[,O
31,O
],O
for,O
ACE2,O
",",O
TMPRSS2,O
",",O
ADAM17,O
",",O
CTSL,O
",",O
CD147,O
and,O
GRP78,O
",",O
using,O
CDH1,O
as,O
a,O
control,O
for,O
airway,O
cells,O
.,O
Proteomic,O
data,O
from,O
the,O
dataset,O
of,O
Foster,B-Creator
et,I-Creator
al.,E-Creator
 ,O
[,O
32,O
],O
consist,O
of,O
bronchial,O
epithelial,O
cells,O
collected,O
from,O
healthy,O
nonsmokers,O
(,O
n=4,O
;,O
males,O
),O
and,O
exposed,O
to,O
PBS,O
control,O
vehicle,O
.,O
The,O
immunogen,O
for,O
the,O
GRP78,O
Atlas,O
Antibodies,O
primary,O
antibody,O
is,O
the,O
recombinant,O
protein,O
epitope,O
signature,O
tag,O
antigen,O
sequence,O
",",O
EKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSSEDKETMEKAVEEKIEWLESHQDADIEDFKAKKKELEEIVQPIISKL,O
.,O
We,O
first,O
examined,O
these,O
genes,O
in,O
a,O
curated,O
dataset,O
of,O
upper,O
and,O
lower,O
airway,O
epithelial,O
cell,O
gene,O
expression,O
from,O
the,O
nasal,O
sinus,O
to,O
the,O
12th,O
generation,O
of,O
airway,O
in,O
the,O
lung,O
(,O
figure,O
1,O
),O
.,O
Following,O
our,O
observation,O
of,O
consistent,O
expression,O
along,O
the,O
upper,O
and,O
lower,O
airways,O
of,O
candidate,O
genes,O
important,O
in,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
we,O
determined,O
whether,O
sex,O
or,O
age,O
affected,O
gene,O
expression,O
levels,O
in,O
healthy,O
individuals,O
using,O
a,O
curated,O
dataset,O
of,O
bronchial,O
brushings,O
from,O
504,O
healthy,O
subjects,O
(,O
supplementary,O
table,O
S1,O
),O
.,O
For,O
quantitative,O
analyses,O
related,O
to,O
age,O
and,O
gene,O
expression,O
",",O
our,O
curated,O
database,O
was,O
divided,O
into,O
datasets,O
that,O
used,O
either,O
the,O
HG,O
-,O
U133,O
Plus,O
2,O
or,O
HuGene-1.0,O
-,O
st,O
-,O
v1,O
microarray,O
due,O
to,O
differences,O
in,O
age,O
distributions,O
.,O
In,O
the,O
HuGene-1.0,O
-,O
st,O
-,O
v1,O
dataset,O
(,O
n=181,O
),O
",",O
which,O
included,O
a,O
greater,O
proportion,O
of,O
older,O
individuals,O
(,O
>,O
50,O
 ,O
years,O
),O
",",O
we,O
observed,O
reduced,O
ACE2,O
gene,O
expression,O
with,O
age,O
(,O
figure,O
2e,O
;,O
p<0.05,O
),O
.,O
Promoter,O
activity,O
data,O
of,O
each,O
of,O
the,O
candidate,O
genes,O
important,O
in,O
SARS,O
-,O
CoV-2,O
binding,O
and,O
infection,O
were,O
extracted,O
and,O
analysed,O
from,O
the,O
FANTOM5,S-Dataset
 ,O
dataset,O
",",O
which,O
includes,O
1866,O
primary,O
cells,O
",",O
cell,O
lines,O
",",O
and,O
tissue,O
sample,O
types,O
(,O
figure,O
3,O
),O
.,O
Both,O
microarray,O
gene,O
expression,O
analysis,O
and,O
promoter,O
activity,O
were,O
consistent,O
with,O
results,O
of,O
candidate,O
gene,O
expression,O
in,O
a,O
scRNAseq,O
dataset,O
of,O
10,O
healthy,O
subjects,O
(,O
supplementary,O
figure,O
S1,O
),O
.,O
We,O
therefore,O
interrogated,O
a,O
publicly,O
available,O
proteomic,O
dataset,O
derived,O
from,O
primary,O
human,O
airway,O
epithelial,O
cells,O
grown,O
under,O
air,O
–,O
liquid,O
interface,O
culture,O
conditions,O
[,O
32,O
],O
",",O
examining,O
the,O
same,O
candidates,O
.,O
Collectively,O
",",O
two,O
proteomic,O
datasets,O
from,O
distinct,O
lung,O
sample,O
formats,O
provide,O
complementary,O
and,O
consistent,O
expression,O
profiles,O
of,O
candidate,O
molecules,O
important,O
in,O
SARS,O
-,O
CoV-2,O
infection,O
.,O
The,O
global,O
COVID-19,O
pandemic,O
that,O
emerged,O
in,O
late,O
2019,O
is,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
.,O
Using,O
a,O
curated,O
microarray,O
gene,O
expression,O
dataset,O
generated,O
from,O
bronchial,O
brushings,O
of,O
504,O
healthy,O
subjects,O
that,O
considers,O
the,O
limitations,O
of,O
merging,O
multiple,O
datasets,O
from,O
distinct,O
sources,O
",",O
we,O
observed,O
that,O
sex,O
did,O
not,O
correlate,O
with,O
gene,O
expression,O
of,O
any,O
candidate,O
host,O
molecule,O
involved,O
in,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
that,O
ACE2,O
and,O
TMPRSS2,O
were,O
the,O
lowest,O
expressed,O
genes,O
of,O
interest,O
examined,O
.,O
In,O
one,O
dataset,O
",",O
ACE2,O
gene,O
expression,O
modestly,O
decreased,O
with,O
age,O
",",O
although,O
protein,O
level,O
confirmation,O
was,O
not,O
possible,O
.,O
Importantly,O
",",O
these,O
elegant,O
transcriptomic,O
analyses,O
confirm,O
our,O
observations,O
in,O
bulk,O
tissue,O
microarray,O
datasets,O
.,O
Consortium,O
-,O
based,O
publicly,O
available,O
datasets,O
represent,O
another,O
parallel,O
approach,O
to,O
confirm,O
our,O
data,O
.,O
We,O
have,O
used,O
the,O
FANTOM5,S-Dataset
 ,O
dataset,O
containing,O
CAGE,O
promoter,O
activation,O
data,O
for,O
1866,O
primary,O
cells,O
",",O
cell,O
lines,O
and,O
tissue,O
samples,O
from,O
humans,O
[,O
39,O
],O
to,O
examine,O
the,O
level,O
of,O
promoter,O
activity,O
for,O
each,O
candidate,O
SARS,O
-,O
CoV-2,O
receptor,O
gene,O
.,O
In,O
December,O
2019,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
emerged,O
",",O
causing,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
.,O
To,O
determine,O
the,O
expression,O
and,O
in,O
situ,O
localisation,O
of,O
candidate,O
SARS,O
-,O
CoV-2,O
receptors,O
in,O
the,O
respiratory,O
mucosa,O
",",O
we,O
analysed,O
gene,O
expression,O
datasets,O
from,O
airway,O
epithelial,O
cells,O
of,O
515,O
healthy,O
subjects,O
",",O
gene,O
promoter,O
activity,O
analysis,O
using,O
the,O
FANTOM5,S-Dataset
 ,O
dataset,O
containing,O
120,O
distinct,O
sample,O
types,O
",",O
single,O
cell,O
RNA,O
sequencing,O
(,O
scRNAseq,O
),O
of,O
10,O
healthy,O
subjects,O
",",O
proteomic,O
datasets,O
",",O
immunoblots,O
on,O
multiple,O
airway,O
epithelial,O
cell,O
types,O
",",O
and,O
immunohistochemistry,O
on,O
98,O
human,O
lung,O
samples,O
.,O
We,O
demonstrate,O
absent,O
to,O
low,O
ACE2,O
promoter,O
activity,O
in,O
a,O
variety,O
of,O
lung,O
epithelial,O
cell,O
samples,O
and,O
low,O
ACE2,O
gene,O
expression,O
in,O
both,O
microarray,O
and,O
scRNAseq,O
datasets,O
of,O
epithelial,O
cell,O
populations,O
.,O
This,O
set,O
of,O
identified,O
DEGs,O
was,O
firstly,O
evaluated,O
in,O
databases,O
comprising,O
hotspot,O
genes,O
known,O
to,O
be,O
involved,O
in,O
aging,O
and,O
various,O
lung,O
diseases,O
(,O
COPD,O
",",O
pneumonia,O
",",O
pulmonary,O
fibrosis,O
",",O
and,O
asthma,O
",",O
etc,O
.,O
),O
.,O
An,O
overlap,O
of,O
the,O
DEGs,O
with,O
genes,O
in,O
the,O
database,O
indicated,O
that,O
aging,O
is,O
a,O
major,O
contributing,O
factor,O
for,O
chronic,O
respiratory,O
diseases,O
and,O
infection,O
(,O
Fig,O
.,O
 ,O
2b,O
;,O
Supplementary,O
information,O
",",O
Fig,O
.,O
S3a,O
),O
.,O
These,O
data,O
identified,O
AT1,O
and,O
AT2,O
as,O
susceptible,O
cell,O
types,O
for,O
COVID-19,O
in,O
the,O
lung,O
.,O
Alarming,O
findings,O
report,O
that,O
COVID-19,O
causes,O
pervasive,O
endotheliitis,O
and,O
blood,O
clots,O
",",O
and,O
viral,O
particles,O
have,O
been,O
detected,O
in,O
endothelial,O
cells,O
of,O
COVID-19,O
victims,O
.,O
We,O
focused,O
our,O
attention,O
on,O
IL7,O
",",O
as,O
our,O
bulk,O
RNA,O
-,O
seq,O
analysis,O
had,O
revealed,O
that,O
IL7,O
was,O
not,O
only,O
commonly,O
upregulated,O
in,O
the,O
aged,O
lung,O
(,O
P,O
value,O
 ,O
=,O
 ,O
0.024,O
),O
",",O
heart,O
(,O
P,O
value,O
 ,O
=,O
 ,O
0.058,O
),O
",",O
and,O
aorta,O
(,O
P,O
value,O
 ,O
=,O
 ,O
0.006,O
),O
(,O
Fig,O
.,O
 ,O
6a,O
–,O
c,O
;,O
Supplementary,O
information,O
",",O
Fig,O
.,O
S8,O
),O
",",O
but,O
was,O
also,O
among,O
the,O
cytokines,O
that,O
drive,O
the,O
immune,O
overreaction,O
known,O
as,O
cytokine,O
storm,O
in,O
patients,O
with,O
COVID-19,O
(,O
Fig,O
.,O
 ,O
6a,O
–,O
c,O
;,O
Supplementary,O
information,O
",",O
Table,O
 ,O
S6,O
),O
.,O
Altogether,O
",",O
these,O
findings,O
add,O
new,O
insights,O
into,O
ACE2,O
regulation,O
in,O
aged,O
VECs,O
and,O
suggest,O
that,O
geroprotective,O
strategies,O
may,O
reduce,O
COVID-19,O
severity,O
in,O
the,O
elderly,O
.,O
In,O
this,O
study,O
",",O
we,O
analyzed,O
the,O
single,O
-,O
nucleus,O
transcriptomic,O
maps,O
of,O
aged,O
primate,O
respiratory,O
and,O
cardiovascular,O
tissues,O
to,O
understand,O
the,O
cellular,O
and,O
molecular,O
basis,O
for,O
their,O
vulnerabilities,O
to,O
age,O
-,O
related,O
diseases,O
and,O
COVID-19,O
(,O
Fig,O
.,O
 ,O
6k,O
),O
.,O
Altogether,O
",",O
we,O
here,O
depict,O
the,O
first,O
transcriptomic,O
atlas,O
of,O
the,O
aged,O
primate,O
cardiopulmonary,O
system,O
",",O
which,O
provides,O
mechanistic,O
insights,O
into,O
how,O
aging,O
-,O
related,O
inflammation,O
and,O
susceptibility,O
to,O
microorganismal,O
infection,O
are,O
interconnected,O
to,O
increase,O
the,O
vulnerability,O
of,O
older,O
human,O
to,O
COVID-19,O
.,O
HAECs,O
were,O
cultured,O
in,O
6,O
-,O
well,O
plates,O
(,O
Corning,O
Incorporated,O
",",O
3516,O
),O
with,O
EGM-2,O
medium,O
to,O
reach,O
~80,O
%,O
confluence,O
.,O
Aging,O
is,O
a,O
major,O
risk,O
factor,O
for,O
many,O
diseases,O
",",O
especially,O
in,O
highly,O
prevalent,O
cardiopulmonary,O
comorbidities,O
and,O
infectious,O
diseases,O
including,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
.,O
Altogether,O
",",O
our,O
findings,O
depict,O
the,O
first,O
transcriptomic,O
atlas,O
of,O
the,O
aged,O
primate,O
cardiopulmonary,O
system,O
and,O
provide,O
vital,O
insights,O
into,O
age,O
-,O
linked,O
susceptibility,O
to,O
SARS,O
-,O
CoV-2,O
",",O
suggesting,O
that,O
geroprotective,O
strategies,O
may,O
reduce,O
COVID-19,O
severity,O
in,O
the,O
elderly,O
.,O
The,O
accession,O
numbers,O
for,O
the,O
raw,O
snRNA,O
-,O
seq,O
data,O
reported,O
in,O
this,O
paper,O
in,O
Genome,B-Repository
Sequence,I-Repository
Archive,I-Repository
(GSA),E-Repository
:,O
CRA002577,S-AccessionNumber
 ,O
(,O
lung,O
),O
",",O
CRA002689,S-AccessionNumber
 ,O
(,O
heart,O
),O
.,O
The,O
accession,O
numbers,O
for,O
the,O
raw,O
bulk,O
RNA,O
-,O
seq,O
data,O
in,O
GSA,S-Repository
:,O
CRA002810,S-AccessionNumber
.,O
It,O
is,O
believed,O
that,O
this,O
is,O
the,O
same,O
virus,O
as,O
that,O
also,O
called,O
SARS,O
-,O
CoV-2,O
or,O
COVID-19,O
virus,O
after,O
the,O
disease,O
now,O
designated,O
COVID-19,O
.,O
At,O
the,O
time,O
of,O
final,O
writing,O
of,O
this,O
text,O
",",O
the,O
WHO,O
named,O
the,O
disease,O
COVID-19,O
",",O
so,O
one,O
can,O
reasonably,O
speak,O
of,O
the,O
“,O
COVID-10,O
”,O
or,O
“,O
Covid-19,O
virus,O
”,O
.,O
Renaming,O
the,O
believed,O
causative,O
agent,O
of,O
COVID-19,O
to,O
indicate,O
it,O
as,O
a,O
type,O
of,O
SARS,O
does,O
not,O
alleviate,O
the,O
concern,O
that,O
different,O
strains,O
use,O
different,O
mechanisms,O
:,O
very,O
few,O
point,O
mutations,O
might,O
change,O
the,O
modes,O
of,O
cell,O
entry,O
.,O
The,O
very,O
recent,O
close,O
match,O
with,O
a,O
SARS,O
virus,O
entry,O
in,O
the,O
databases,O
makes,O
the,O
assumptions,O
used,O
in,O
the,O
present,O
paper,O
much,O
more,O
plausible,O
",",O
however,O
.,O
It,O
shows,O
that,O
after,O
circa,O
150,O
arbitrarily,O
selected,O
proteins,O
are,O
brought,O
into,O
the,O
training,O
set,O
.,O
",",O
the,O
predictions,O
begin,O
to,O
change,O
and,O
improve,O
dramatically,O
as,O
more,O
and,O
more,O
homologous,O
proteins,O
of,O
similar,O
folded,O
structure,O
are,O
encountered,O
and,O
the,O
coverage,O
of,O
sampled,O
proteins,O
spans,O
the,O
commoner,O
protein,O
families,O
Obvious,O
pre,O
-,O
known,O
homologues,O
were,O
discarded,O
in,O
that,O
study,O
[,O
34,O
],O
",",O
but,O
the,O
above,O
concern,O
still,O
applies,O
.,O
ID,O
:,O
ALB35880.1,S-AccessionNumber
 ,O
the,O
internal,O
match,O
with,O
the,O
FIEDLL,O
motif,O
is,O
not,O
significant,O
and,O
the,O
NVL,O
and,O
following,O
sequence,O
usually,O
carry,O
no,O
cleavage,O
arginine,O
R,O
at,O
the,O
corresponding,O
point,O
.,O
TLADAGFIKQYGDCTo,O
compare,O
",",O
an,O
alternative,O
to,O
the,O
part,O
in,O
brackets,O
is,O
RRSFIDELAFGRG,O
:,O
it,O
is,O
an,O
example,O
of,O
a,O
tentative,O
specific,O
design,O
“,O
hunch,O
”,O
based,O
on,O
a,O
section,O
of,O
a,O
human,O
semaphorin,O
(,O
GenBank,S-Repository
 ,O
NP_001243276.1,S-AccessionNumber
),O
produced,O
in,O
response,O
to,O
lung,O
diseases,O
",",O
a,O
suggestive,O
biologically,O
-,O
related,O
match,O
with,O
conservative,O
replacements,O
but,O
not,O
one,O
suggested,O
by,O
the,O
general,O
rules,O
and,O
probably,O
coincidental,O
.,O
Early,O
alternative,O
choices,O
of,O
binding,O
protein,O
as,O
model,O
included,O
growth,O
hormone,O
secretagogue,O
receptor,O
type,O
1,O
GenPept,S-Repository
 ,O
accession,O
NP_796304,S-AccessionNumber
 ,O
because,O
of,O
some,O
evidence,O
in,O
the,O
literature,O
of,O
the,O
action,O
of,O
anthraquinone,O
",",O
emoghrelin,O
derivatives,O
",",O
and,O
indanthrone,O
",",O
amongst,O
others,O
",",O
which,O
have,O
some,O
of,O
the,O
features,O
of,O
emodin,O
",",O
and,O
because,O
of,O
an,O
initial,O
suspicion,O
that,O
a,O
sequence,O
segment,O
in,O
growth,O
hormone,O
receptor,O
might,O
contribute,O
to,O
binding,O
and,O
had,O
some,O
features,O
relating,O
to,O
the,O
current,O
peptide,O
of,O
interest,O
",",O
but,O
none,O
of,O
the,O
alternatives,O
were,O
ultimately,O
seen,O
as,O
persuasive,O
as,O
the,O
steroid,O
dehydrogenase,O
choice,O
.,O
This,O
paper,O
concerns,O
study,O
of,O
the,O
genome,O
of,O
the,O
Wuhan,O
Seafood,O
Market,O
isolate,O
believed,O
to,O
represent,O
the,O
causative,O
agent,O
of,O
the,O
disease,O
COVID-19,O
.,O
Highlights,O
    ,O
•,O
 ,O
Bioinformatics,O
studies,O
are,O
carried,O
out,O
on,O
the,O
COVID-19,O
virus,O
.,O
   ,O
•,O
PCR,O
tests,O
for,O
theaccurate,O
and,O
fastSARS,O
-,O
CoV-2,O
testing,O
are,O
crucial,O
for,O
the,O
identification,O
of,O
carriers,O
and,O
control,O
the,O
spreading,O
of,O
COVID19,O
.,O
During,O
the,O
first,O
months,O
of,O
the,O
COVID19,O
pandemic,O
we,O
faced,O
a,O
demand,O
for,O
SARS,O
-,O
Cov-2,O
testing,O
that,O
exceeded,O
our,O
qtPCR,O
capacity,O
.,O
Nowadays,O
",",O
the,O
COVID,O
19,O
pandemic,O
scenario,O
is,O
being,O
increasing,O
over,O
the,O
world,O
.,O
Moreover,O
",",O
the,O
severity,O
of,O
the,O
atypical,O
pneumonia,O
caused,O
by,O
SARS‐CoV‐2,O
(,O
COVID‐2019,O
),O
",",O
often,O
requiring,O
multiweek,O
hospital,O
stays,O
and,O
the,O
use,O
of,O
invasive,O
ventilators,O
",",O
",",O
 ,O
",",O
  ,O
highlights,O
the,O
need,O
for,O
therapeutics,O
to,O
lessen,O
the,O
severity,O
of,O
individual,O
infections,O
.,O
Initial,O
trials,O
using,O
antibody‐containing,O
plasma,O
of,O
convalescent,O
COVID‐19,O
patients,O
has,O
also,O
shown,O
promise,O
in,O
lessening,O
the,O
severity,O
of,O
the,O
disease,O
.,O
(,O
c,O
),O
Structural,O
overlay,O
of,O
the,O
SARS‐CoV‐2,O
N2b,O
dimer,O
(,O
blue,O
),O
and,O
the,O
equivalent,O
domain,O
of,O
SARS‐CoV‐N,O
(,O
PDB,S-Repository
 ,O
ID,O
2CJR,S-AccessionNumber
),O
Our,O
structures,O
also,O
overlay,O
closely,O
with,O
four,O
other,O
recently,O
deposited,O
structures,O
of,O
the,O
SARS‐CoV‐2,O
N2b,O
domain,O
(,O
PDB,S-Repository
 ,O
IDs,O
6WJI,S-AccessionNumber
",",O
6YUN,S-AccessionNumber
",",O
6ZCO,S-AccessionNumber
",",O
and,O
7C22,S-AccessionNumber
;,O
all,O
unpublished,O
),O
.,O
One,O
of,O
these,O
structures,O
(,O
PDB,S-Repository
 ,O
ID,O
7C22,S-AccessionNumber
),O
adopts,O
the,O
same,O
space,O
group,O
and,O
unit,O
cell,O
parameters,O
as,O
our,O
structure,O
of,O
untagged,O
N2b,O
.,O
Since,O
the,O
first,O
genome,O
sequence,O
of,O
SARS‐CoV‐2,O
was,O
reported,O
in,O
January,O
2020,O
",",O
",",O
  ,O
over,O
"38,000",O
full,O
genomic,O
sequences,O
have,O
been,O
deposited,O
in,O
public,O
databases,O
(,O
as,O
of,O
June,O
3,O
",",O
2020,O
),O
.,O
While,O
many,O
of,O
these,O
substitutions,O
arise,O
only,O
once,O
in,O
our,O
dataset,O
and,O
may,O
therefore,O
reflect,O
errors,O
in,O
sequencing,O
or,O
sequence,O
assembly,O
",",O
most,O
likely,O
reflect,O
true,O
variation,O
among,O
circulating,O
strains,O
of,O
SARS‐CoV‐2,O
.,O
The,O
most,O
common,O
substitutions,O
are,O
R203,O
K,O
and,O
G204R,O
",",O
which,O
occur,O
together,O
as,O
the,O
result,O
of,O
a,O
common,O
trinucleotide,O
substitution,O
in,O
genomic,O
positions,O
"28,881–28,883",O
",",O
from,O
GGG,O
to,O
AAC,O
(,O
"~4,100",O
of,O
the,O
"38,318",O
sequences,O
in,O
our,O
dataset,O
;,O
Figure,O
S2a,O
",",O
b,O
),O
.,O
While,O
positions,O
203,O
and,O
204,O
accounted,O
for,O
over,O
two‐thirds,O
of,O
the,O
total,O
individual,O
amino,O
acid,O
substitutions,O
in,O
this,O
dataset,O
",",O
the,O
N2a,O
domain,O
shows,O
a,O
strong,O
enrichment,O
of,O
mutations,O
even,O
when,O
these,O
positions,O
are,O
not,O
considered,O
(,O
Figure,O
2a,O
),O
.,O
(,O
b,O
),O
Surface,O
views,O
of,O
the,O
N,O
protein,O
N1b,O
domain,O
(,O
PDB,S-Repository
 ,O
ID,O
6VYO,S-AccessionNumber
;,O
Center,O
for,O
Structural,O
Genomics,O
of,O
Infectious,O
Diseases,O
[,O
CSGID,O
],O
",",O
unpublished,O
),O
.,O
Two,O
high‐resolution,O
crystal,O
structures,O
of,O
the,O
SARS‐CoV‐2,O
N1b,O
domain,O
have,O
been,O
determined,O
(,O
PDB,S-Repository
 ,O
ID,O
6M3M,S-AccessionNumber
 ,O
and,O
6VYO,S-AccessionNumber
),O
",",O
 ,O
and,O
a,O
recent,O
NMR,O
study,O
determined,O
a,O
solution,O
structure,O
of,O
the,O
domain,O
and,O
defined,O
its,O
likely,O
RNA,O
binding,O
surface,O
(,O
Figure,O
2b,O
),O
.,O
In,O
keeping,O
with,O
its,O
functional,O
importance,O
",",O
the,O
identified,O
RNA,O
binding,O
surface,O
shows,O
only,O
a,O
single,O
mutation,O
in,O
this,O
dataset,O
(,O
Figure,O
2b,O
;,O
middle,O
panel,O
),O
.,O
Prior,O
work,O
with,O
the,O
Murine,O
Hepatitis,O
Virus,O
N,O
protein,O
showed,O
that,O
this,O
region,O
can,O
",",O
on,O
its,O
own,O
",",O
incorporate,O
into,O
nucleocapsid,O
structures,O
that,O
lack,O
the,O
associated,O
Membrane,O
(,O
M,O
),O
protein,O
",",O
suggesting,O
that,O
the,O
region,O
mediates,O
a,O
homotypic,O
interaction,O
between,O
N,O
proteins,O
.,O
Given,O
the,O
severity,O
of,O
the,O
ongoing,O
COVID‐19,O
pandemic,O
",",O
a,O
deep,O
understanding,O
of,O
the,O
SARS‐CoV‐2,O
life,O
cycle,O
is,O
urgently,O
needed,O
.,O
N,O
protein,O
constructs,O
(,O
NFL,O
[,O
residues,O
2–419,O
],O
",",O
N1ab,O
[,O
2–175,O
],O
",",O
N1ab2a,O
[,O
2–246,O
],O
",",O
N1b,O
[,O
49–175,O
],O
",",O
N1b2a,O
[,O
49–246,O
],O
",",O
N2b,O
[,O
247–364,O
],O
",",O
N2b3,O
[,O
247–419,O
],O
),O
were,O
amplified,O
by,O
PCR,O
from,O
the,O
IDT,O
2019‐nCoV,O
N,O
positive,O
control,O
plasmid,O
(,O
IDT,O
cat,O
.,O
Diffraction,O
data,O
were,O
collected,O
at,O
beamline,O
24ID‐E,O
at,O
the,O
Advanced,O
Photon,O
Source,O
.,O
Diffraction,O
datasets,O
were,O
processed,O
with,O
the,O
RAPD,O
pipeline,O
(,O
https://github.com/RAPD/RAPD/,O
),O
",",O
which,O
uses,O
XDS,O
 ,O
for,O
indexing,O
and,O
data,O
reduction,O
",",O
and,O
the,O
CCP4,O
programs,O
AIMLESS,O
 ,O
and,O
TRUNCATE,O
 ,O
for,O
scaling,O
and,O
conversion,O
to,O
structure,O
factors,O
.,O
The,O
structure,O
of,O
untagged,O
N2b,O
was,O
determined,O
by,O
molecular,O
replacement,O
in,O
PHASER,O
 ,O
using,O
a,O
dimer,O
of,O
the,O
SARS‐CoV,O
N2b,O
domain,O
(,O
PDB,S-Repository
 ,O
ID,O
2GIB,S-AccessionNumber
),O
 ,O
as,O
a,O
template,O
.,O
Data,O
collection,O
statistics,O
",",O
refinement,O
statistics,O
",",O
and,O
database,O
accession,O
numbers,O
for,O
diffraction,O
data,O
and,O
final,O
structures,O
can,O
be,O
found,O
in,O
Table,O
S1,O
.,O
We,O
used,O
the,O
NextStrain,S-Repository
 ,O
database,O
 ,O
to,O
visualize,O
the,O
prevalence,O
of,O
the,O
N,O
protein,O
G204R,O
mutation,O
",",O
which,O
is,O
diagnostic,O
of,O
the,O
GGG,O
➔,O
AAC,O
trinucleotide,O
substitution,O
in,O
positions,O
"28,881–28,883",O
.,O
The,O
COVID‐2019,O
pandemic,O
is,O
the,O
most,O
severe,O
acute,O
public,O
health,O
threat,O
of,O
the,O
twenty‐first,O
century,O
.,O
This,O
virus,O
belongs,O
to,O
the,O
genera,O
Betacoronavirus,O
and,O
has,O
been,O
designated,O
as,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
and,O
the,O
disease,O
is,O
named,O
as,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
[,O
7,O
],O
.,O
As,O
of,O
April,O
14,O
",",O
2020,O
",",O
the,O
outbreak,O
of,O
COVID-19,O
has,O
resulted,O
in,O
"1,844,863",O
confirmed,O
cases,O
and,O
"117,021",O
deaths,O
worldwide,O
[,O
8,O
],O
",",O
among,O
which,O
393,O
confirmed,O
cases,O
and,O
6,O
deaths,O
were,O
reported,O
in,O
Taiwan,O
[,O
9,O
],O
.,O
With,O
rapidly,O
increasing,O
number,O
of,O
infections,O
",",O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
[,O
10,O
],O
provides,O
a,O
platform,O
for,O
sharing,O
SARS,O
-,O
CoV-2,O
sequences,O
and,O
their,O
metadata,O
.,O
Three,O
major,O
clades,O
",",O
including,O
clade,O
G,O
(,O
with,O
G,O
variant,O
at,O
position,O
614,O
within,O
the,O
spike,O
protein,O
",",O
as,O
S,O
-,O
D614,O
G,O
),O
",",O
clade,O
S,O
(,O
ORF8,O
-,O
L84S,O
),O
",",O
and,O
clade,O
V,O
(,O
ORF3a,O
-,O
G251V,O
),O
",",O
were,O
designated,O
by,O
the,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/hcov-19-analysis-update/,S-URL
),O
.,O
SPAdes,O
(,O
version,O
3.14.0,O
),O
[,O
14,O
],O
was,O
then,O
used,O
to,O
perform,O
de,O
novo,O
assembly,O
for,O
constructing,O
contig,O
sequences,O
",",O
and,O
BLASTN,O
was,O
used,O
to,O
query,O
the,O
assembled,O
contigs,O
by,O
searching,O
the,O
nucleotide,O
sequence,O
(,O
NT,O
),O
database,O
of,O
the,O
National,B-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,I-Repository
(NCBI),E-Repository
.,O
To,O
specifically,O
determine,O
the,O
SARS,O
-,O
CoV-2,O
genome,O
of,O
interest,O
",",O
on,O
the,O
other,O
hand,O
",",O
we,O
used,O
a,O
reference,O
strain,O
Wuhan-1,O
(,O
accession,O
number,O
MN908947.3,S-AccessionNumber
),O
as,O
the,O
mapping,O
template,O
and,O
used,O
an,O
iterative,O
mapping,O
approach,O
[,O
15,O
],O
to,O
increase,O
the,O
read,O
depth,O
and,O
coverage,O
.,O
In,O
total,O
",",O
genomic,O
data,O
of,O
26,O
strains,O
were,O
deposited,O
in,O
the,O
GISAID,S-Dataset
 ,O
with,O
accession,O
numbers,O
also,O
given,O
in,O
Table,O
1,O
.,O
We,O
also,O
downloaded,O
all,O
complete,O
and,O
high,O
-,O
coverage,O
genomes,O
of,O
SARS,O
-,O
CoV-2,O
from,O
GISAID,S-Dataset
 ,O
as,O
of,O
March,O
14,O
",",O
2020,O
and,O
obtained,O
332,O
sequences,O
after,O
removing,O
those,O
with,O
sequence,O
gaps,O
or,O
ambiguous,O
nucleotides,O
.,O
Complete,O
genomic,O
data,O
of,O
20,O
SARS,O
-,O
CoV-2,O
strains,O
obtained,O
in,O
this,O
study,O
were,O
derived,O
from,O
3,O
specimens,O
(,O
CGMH,O
-,O
CGU-01,O
",",O
-07,O
",",O
and,O
-08,O
),O
and,O
17,O
isolates,O
(,O
-02,O
to,O
-06,O
and,O
-09,O
to,O
-20,O
),O
",",O
and,O
have,O
been,O
uploaded,O
in,O
GISAID,S-Dataset
.,O
Figure,O
1A,O
shows,O
the,O
NGS,O
coverage,O
and,O
depth,O
distribution,O
of,O
CGMH,O
-,O
CGU-01,O
",",O
which,O
has,O
an,O
identical,O
genome,O
as,O
the,O
Wuhan-1,O
strain,O
(,O
accession,O
number,O
MN908947.3,S-AccessionNumber
),O
.,O
To,O
better,O
illustrate,O
phylogenetic,O
clades,O
",",O
we,O
designated,O
and,O
numbered,O
yellow,O
clade,O
as,O
IV,O
harbouring,O
ORF1ab,O
-,O
V378I,O
mutation,O
in,O
this,O
study,O
and,O
three,O
others,O
(,O
blue,O
clade,O
I,O
of,O
ORF8,O
-,O
L84S,O
",",O
gray,O
clade,O
II,O
of,O
ORF3a,O
-,O
G251V,O
",",O
and,O
pink,O
clade,O
III,O
of,O
S,O
-,O
D614,O
G,O
),O
identified,O
based,O
on,O
previous,O
GISAID,S-Dataset
 ,O
annotations,O
of,O
clades,O
S,O
",",O
V,O
",",O
and,O
G,O
",",O
respectively,O
.,O
Five,O
Australian,O
strains,O
(,O
NSW05,O
",",O
NSW06,O
",",O
NSW11,O
",",O
NSW12,O
",",O
and,O
NSW13,O
),O
[,O
19,O
],O
and,O
one,O
German,O
strain,O
(,O
BavPat2,O
",",O
according,O
to,O
the,O
metadata,O
from,O
the,O
GISAID,S-Dataset
),O
from,O
patients,O
having,O
a,O
travel,O
history,O
to,O
Iran,O
were,O
also,O
grouped,O
in,O
this,O
clade,O
.,O
COVID-19,O
can,O
be,O
transmitted,O
via,O
close,O
contact,O
with,O
infected,O
patients,O
.,O
In,O
addition,O
to,O
the,O
signature,O
mutation,O
S,O
-,O
D614,O
G,O
annotated,O
by,O
GISAID,S-Dataset
 ,O
in,O
clade,O
III,O
",",O
all,O
the,O
Taiwanese,O
genomes,O
shared,O
two,O
ORF1ab,O
mutations,O
C2772,O
T,O
and,O
C14144,O
T,O
(,O
P4715L,O
),O
(,O
Figure,O
3E,O
),O
.,O
Ou,O
et,O
al,O
.,O
recently,O
detected,O
Haemophilus,O
parainfluenzae,O
and,O
Moraxella,O
catarrhalis,O
from,O
sputum,O
samples,O
collected,O
from,O
a,O
severe,O
COVID-19,O
case,O
[,O
37,O
],O
.,O
ABSTRACT,O
 ,O
Taiwan,O
experienced,O
two,O
waves,O
of,O
imported,O
infections,O
with,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
.,O
This,O
study,O
describes,O
results,O
of,O
PCR,O
and,O
viral,O
RNA,O
testing,O
for,O
SARS,O
-,O
CoV-2,O
in,O
bronchoalveolar,O
fluid,O
",",O
sputum,O
",",O
feces,O
",",O
blood,O
",",O
and,O
urine,O
specimens,O
from,O
patients,O
with,O
COVID-19,O
infection,O
in,O
China,O
to,O
identify,O
possible,O
means,O
of,O
non,O
-,O
respiratory,O
transmission,O
.,O
Following,O
the,O
first,O
case,O
reports,O
in,O
Hubei,O
province,O
",",O
China,O
",",O
in,O
 ,O
late,O
2019,O
",",O
a,O
pandemic,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
was,O
declared,O
by,O
the,O
World,O
Health,O
Organization,O
in,O
March,O
2020,O
.,O
Although,O
COVID-19,O
causes,O
minimal,O
or,O
mild,O
illness,O
in,O
most,O
",",O
a,O
small,O
but,O
appreciable,O
proportion,O
of,O
individuals,O
require,O
oxygen,O
therapy,O
and,O
often,O
admission,O
to,O
an,O
intensive,O
care,O
unit,O
(,O
ICU,O
),O
.,O
The,O
ensuing,O
unprecedented,O
pressure,O
on,O
hospital,O
wards,O
and,O
ICUs,O
has,O
necessitated,O
rapid,O
re,O
-,O
deployment,O
of,O
staff,O
and,O
capacity,O
towards,O
the,O
management,O
of,O
COVID-19,O
cases,O
with,O
deprioritisation,O
of,O
non,O
-,O
emergency,O
clinical,O
services,O
",",O
including,O
diagnostics,O
and,O
elective,O
specialist,O
surgery,O
.,O
ICU,O
COVID-19,O
mortality,O
",",O
distribution,O
by,O
age,O
and,O
duration,O
of,O
stay,O
and,O
proportion,O
referred,O
into,O
ICU,O
were,O
obtained,O
from,O
ICNARC,B-Repository
(Intensive,I-Repository
Care,I-Repository
National,I-Repository
Audit,I-Repository
and,I-Repository
Research,I-Repository
Centre),E-Repository
 ,O
and,O
data,O
from,O
hospitalised,O
UK,O
cases,O
.,O
",",O
 ,O
Because,O
of,O
lack,O
of,O
UK,O
data,O
",",O
data,O
from,O
Wuhan,O
were,O
used,O
as,O
the,O
basis,O
for,O
the,O
age,O
distribution,O
of,O
community,O
infection,O
",",O
age,O
-,O
specific,O
likelihoods,O
of,O
admission,O
from,O
community,O
to,O
hospital,O
and,O
case,O
fatality,O
rates,O
for,O
non,O
-,O
ICU,O
COVID-19,O
patients,O
",",O
 ,O
(,O
see,O
supplementary,O
Table,O
 ,O
S1,O
",",O
available,O
at,O
Annals,O
of,O
Oncology,O
online,O
),O
.,O
To,O
compare,O
life,O
-,O
years,O
associated,O
with,O
timely,O
cancer,O
surgery,O
with,O
those,O
afforded,O
by,O
hospitalisation,O
of,O
COVID-19,O
patients,O
",",O
we,O
modelled,O
a,O
volume,O
of,O
community,O
-,O
ascertained,O
COVID-19,O
infection,O
",",O
resulting,O
in,O
an,O
equivalent,O
volume,O
of,O
hospital,O
admissions,O
to,O
cancer,O
surgeries,O
(,O
see,O
supplementary,O
Table,O
 ,O
S1,O
",",O
available,O
at,O
Annals,O
of,O
Oncology,O
online,O
),O
.,O
Accounting,O
for,O
nosocomial,O
COVID-19,O
infection,O
",",O
for,O
cancers,O
with,O
a,O
relatively,O
good,O
overall,O
prognosis,O
",",O
delay,O
of,O
surgery,O
by,O
3,O
months,O
had,O
a,O
minimal,O
impact,O
on,O
survival,O
:,O
<,O
1,O
%,O
for,O
all,O
stage,O
1,O
ER+,O
and,O
HER2,O
+,O
breast,O
cancers,O
",",O
for,O
example,O
.,O
In,O
older,O
patients,O
(,O
aged,O
>,O
70,O
),O
",",O
for,O
early,O
stage,O
colorectal,O
",",O
kidney,O
and,O
ER+,O
breast,O
cancers,O
",",O
the,O
current,O
impact,O
on,O
survival,O
of,O
COVID,O
-,O
related,O
mortality,O
exceeded,O
the,O
impact,O
of,O
3,O
or,O
even,O
6,O
months,O
',O
delay,O
(,O
Table,O
 ,O
2,O
;,O
see,O
also,O
supplementary,O
Table,O
 ,O
S3,O
",",O
available,O
at,O
Annals,O
of,O
Oncology,O
online,O
),O
.,O
Prior,O
to,O
the,O
COVID-19,O
crisis,O
",",O
each,O
year,O
cancer,O
surgery,O
was,O
directly,O
responsible,O
for,O
1,O
717,O
051,O
LYGs,O
.,O
For,O
contextualisation,O
",",O
we,O
compare,O
the,O
impact,O
of,O
cancer,O
surgery,O
delay,O
with,O
hospital,O
care,O
for,O
patients,O
with,O
community,O
-,O
acquired,O
COVID-19,O
infection,O
.,O
COVID-19,O
ICU,O
admission,O
for,O
those,O
aged,O
40–49,O
yielded,O
on,O
average,O
27.5,O
LYGs,O
and,O
0.8,O
RALYGs,O
.,O
These,O
estimates,O
are,O
inherently,O
conservative,O
as,O
they,O
do,O
not,O
take,O
into,O
account,O
the,O
impact,O
on,O
life,O
expectancy,O
of,O
the,O
excess,O
comorbidities,O
associated,O
with,O
many,O
hospitalised,O
COVID-19,O
cases,O
.,O
COVID-19,O
community,O
-,O
acquired,O
infection,O
of,O
683,O
083,O
individuals,O
would,O
result,O
in,O
94,O
912,O
hospital,O
admissions,O
(,O
i.e.,O
the,O
equivalent,O
number,O
to,O
number,O
of,O
annual,O
admissions,O
for,O
cancer,O
surgery,O
;,O
Table,O
4,O
),O
.,O
This,O
represents,O
on,O
average,O
5.08,O
LYGs,O
and,O
0.46,O
RALYGs,O
per,O
hospitalised,O
COVID-19,O
patient,O
.,O
This,O
will,O
serve,O
to,O
minimise,O
nosocomial,O
acquisition,O
and,O
mortality,O
from,O
COVID-19,O
",",O
to,O
protect,O
staff,O
and,O
also,O
to,O
provide,O
reassurance,O
to,O
the,O
public,O
regarding,O
uptake,O
of,O
diagnostics,O
and,O
surgery,O
for,O
cancer,O
.,O
Background,O
 ,O
Cancer,O
diagnostics,O
and,O
surgery,O
have,O
been,O
disrupted,O
by,O
the,O
response,O
of,O
health,O
care,O
services,O
to,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
.,O
Using,O
health,O
care,O
resource,O
costing,O
",",O
we,O
contextualise,O
attributable,O
lives,O
saved,O
and,O
life,O
-,O
years,O
gained,O
(,O
LYGs,O
),O
from,O
cancer,O
surgery,O
to,O
equivalent,O
volumes,O
of,O
COVID-19,O
hospitalisations,O
.,O
For,O
94,O
912,O
hospital,O
COVID-19,O
admissions,O
",",O
there,O
are,O
482,O
022,O
LYGs,O
requiring,O
1,O
052,O
949,O
HCRUs,O
.,O
Hospitalisation,O
of,O
community,O
-,O
acquired,O
COVID-19,O
patients,O
yields,O
on,O
average,O
per,O
patient,O
5.08,O
LYG,O
and,O
0.46,O
RALYGs,O
.,O
Delay,O
of,O
3/6,O
months,O
in,O
surgery,O
for,O
incident,O
cancers,O
would,O
mitigate,O
19%/43,O
%,O
of,O
LYGs,O
",",O
respectively,O
",",O
by,O
hospitalisation,O
of,O
an,O
equivalent,O
volume,O
of,O
admissions,O
for,O
community,O
-,O
acquired,O
COVID-19,O
.,O
Highlights,O
    ,O
•,O
 ,O
Lockdown,O
and,O
re,O
-,O
deployment,O
due,O
to,O
the,O
COVID-19,O
pandemic,O
have,O
caused,O
significant,O
disruption,O
to,O
cancer,O
diagnosis,O
and,O
management,O
.,O
The,O
resource,O
-,O
adjusted,O
benefit,O
in,O
avoiding,O
delay,O
in,O
cancer,O
management,O
compares,O
favourably,O
with,O
admission,O
for,O
COVID-19,O
infection,O
.,O
Recent,O
release,O
of,O
the,O
high,O
-,O
resolution,O
crystal,O
structure,O
for,O
the,O
main,O
proteinase,O
3CLpro,O
(,O
Protein,B-Repository
Data,I-Repository
Bank,E-Repository
",",O
PDB,S-Repository
 ,O
ID,O
:,O
6Y2G,S-AccessionNumber
),O
",",O
describing,O
an,O
additional,O
amide,O
bond,O
with,O
the,O
α,O
-,O
ketoamide,O
inhibitor,O
pyridone,O
ring,O
to,O
enhance,O
the,O
half,O
-,O
life,O
of,O
the,O
compound,O
in,O
plasma,O
[,O
16,O
],O
is,O
suggested,O
to,O
accelerate,O
the,O
targeted,O
drug,O
discovery,O
efforts,O
.,O
The,O
complete,O
genomes,O
of,O
SARS,O
-,O
Cov-2,O
from,O
all,O
over,O
the,O
world,O
have,O
been,O
deposited,O
at,O
The,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
Avian,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
[,O
19,O
],O
database,O
and,O
more,O
sequences,O
continue,O
to,O
be,O
deposited,O
with,O
the,O
passage,O
of,O
time,O
.,O
This,O
may,O
be,O
attained,O
by,O
freely,O
accessing,O
the,O
GISAID,S-Dataset
 ,O
database,O
and,O
processing,O
the,O
data,O
to,O
enhance,O
our,O
understanding,O
of,O
the,O
fine,O
biochemical,O
and,O
genetic,O
differences,O
that,O
differentiate,O
this,O
virus,O
from,O
the,O
previously,O
known,O
strains,O
[,O
20,O
],O
.,O
PDB,S-Repository
 ,O
ID,O
:,O
3TNT,S-AccessionNumber
",",O
SARS,O
main,O
protease,O
was,O
selected,O
as,O
reference,O
to,O
analyse,O
the,O
variants,O
in,O
SARS,O
-,O
CoV-2,O
3CLpro,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6Y2G,S-AccessionNumber
),O
.,O
The,O
dataset,O
comprises,O
of,O
flavones,O
and,O
biflavanoids,O
",",O
anti,O
-,O
viral,O
",",O
anti,O
-,O
malarial,O
and,O
vitamins,O
as,O
SARS,O
-,O
CoV-2,O
3CLpro,O
inhibitors,O
[,O
16,O
],O
.,O
In,O
total,O
17,O
repurposed,O
drugs,O
were,O
collected,O
from,O
the,O
Pubchem,S-Repository
 ,O
database,O
[,O
33,O
],O
.,O
Two,O
-,O
dimensional,O
(,O
2D,O
),O
structures,O
were,O
downloaded,O
from,O
the,O
Pubchem,S-Repository
 ,O
database,O
in.sdf,O
format,O
.,O
Crystal,O
structure,O
of,O
the,O
SARS,O
-,O
CoV-2,O
3CLpro,O
was,O
retrieved,O
from,O
PDB,S-Repository
 ,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6Y2G,S-AccessionNumber
),O
.,O
Chain,O
A,O
of,O
PDB,O
ID,O
:,O
6Y2,O
G,O
containing,O
alpha,O
-,O
ketoamide,O
(,O
O6,O
K,O
),O
inhibitor,O
was,O
used,O
for,O
identification,O
of,O
substrate,O
binding,O
site,O
.,O
A,O
total,O
of,O
9761,O
SARS,O
-,O
CoV-2,O
genomes,O
were,O
retrieved,O
from,O
The,O
GISAID,S-Dataset
 ,O
database,O
(,O
https://www.gisaid.org,S-URL
),O
that,O
contain,O
3,O
sequences,O
from,O
bat,O
(,O
Betacoronavirus,O
),O
and,O
9,O
sequences,O
from,O
Malayan,O
Pangolin,O
(,O
Manis,O
javanica,O
),O
(,O
Additional,O
file,O
1,O
:,O
Table,O
S1,O
),O
.,O
We,O
have,O
divided,O
our,O
dataset,O
into,O
6,O
different,O
geographic,O
areas,O
:,O
Europe,O
(,O
20.31,O
%,O
),O
",",O
North,O
America,O
(,O
21.13,O
%,O
),O
",",O
Asia,O
(,O
35.37,O
%,O
),O
",",O
Oceania,O
(,O
20.86,O
%,O
),O
",",O
South,O
America,O
(,O
16.63,O
%,O
),O
and,O
Africa,O
(,O
10.35,O
%,O
),O
.,O
SARS,O
-,O
CoV-2,O
patient,O
genome,O
sequences,O
deposited,O
in,O
GISAID,S-Dataset
 ,O
database,O
from,O
more,O
than,O
60,O
different,O
countries,O
(,O
a,O
),O
radial,O
and,O
(,O
b,O
),O
unrooted,O
phylogeny,O
created,O
by,O
Nextstrain,S-Repository
 ,O
program,O
[,O
66,O
],O
(,O
c,O
),O
Pie,O
chart,O
representation,O
of,O
number,O
of,O
SARS,O
-,O
CoV-2,O
patient,O
genomes,O
deposited,O
in,O
GISAID,S-Dataset
 ,O
till,O
15th,O
April,O
2020,O
from,O
six,O
different,O
regions,O
;,O
Asia,O
(,O
orange,O
",",O
35.37,O
%,O
),O
",",O
Oceania,O
(,O
purple,O
",",O
20.86,O
%,O
),O
",",O
North,O
America,O
(,O
brown,O
",",O
21.13,O
%,O
),O
",",O
Europe,O
(,O
blue,O
",",O
20.31,O
%,O
),O
",",O
Africa,O
(,O
red,O
",",O
10.35,O
%,O
),O
and,O
South,O
America,O
(,O
black,O
",",O
16.63,O
%,O
),O
.,O
Our,O
study,O
highlights,O
the,O
presence,O
of,O
additional,O
“,O
conserved,O
mutations,O
”,O
in,O
the,O
South,O
American,O
and,O
African,O
communities,O
",",O
considering,O
only,O
those,O
occurring,O
 ,O
≥,O
 ,O
5,O
times,O
in,O
our,O
database,O
.,O
SARS,O
and,O
SARS,O
-,O
CoV-2,O
complete,O
genomes,O
were,O
collected,O
from,O
NCBI,S-Repository
",",O
GenBank,S-Repository
 ,O
database,O
(,O
NC_004718,S-AccessionNumber
 ,O
and,O
NC_045512,S-AccessionNumber
),O
.,O
Re,O
-,O
docking,O
of,O
O6,O
K,O
inhibitor,O
occupied,O
the,O
similar,O
docking,O
pose,O
in,O
the,O
SARS,O
-,O
CoV-2,O
3CLpro,O
catalytic,O
dyad,O
active,O
site,O
as,O
previously,O
reported,O
in,O
the,O
crystal,O
structure,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6Y2G,S-AccessionNumber
),O
(,O
Fig,O
.,O
 ,O
5c,O
",",O
d,O
),O
.,O
Furthermore,O
",",O
we,O
report,O
that,O
in,O
isolates,O
of,O
human,O
Wuhan,O
SARS,O
-,O
CoV-2,O
there,O
is,O
an,O
85.98,O
%,O
similarity,O
in,O
identity,O
to,O
Pangolin,O
-,O
SARS,O
-,O
CoV,O
",",O
which,O
suggests,O
that,O
Pangolin,O
may,O
be,O
associated,O
with,O
the,O
evolution,O
of,O
subsequent,O
outbreaks,O
of,O
COVID-19,O
.,O
SARS,O
-,O
CoV-2,O
host,O
genomes,O
were,O
collected,O
from,O
The,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
database,O
containing,O
9,O
genomes,O
from,O
pangolin,O
-,O
CoV,O
origin,O
and,O
3,O
genomes,O
from,O
bat,O
-,O
CoV,O
origin,O
",",O
Wuhan,O
SARS,O
-,O
CoV2,O
reference,O
genome,O
was,O
collected,O
from,O
GeneBank,S-Repository
 ,O
database,O
.,O
GISAID,S-Dataset
 ,O
database,O
(,O
https://www.gisaid.org/,S-URL
),O
",",O
SARS,O
-,O
CoV-2,O
isolate,O
Wuhan,O
-,O
Hu-1,O
",",O
complete,O
genome,O
(,O
https://www.ncbi.nlm.nih.gov/nuccore/1798174254,S-URL
),O
It,O
has,O
the,O
potential,O
to,O
yield,O
complex,O
and,O
predictive,O
biomarker,O
signatures,O
that,O
support,O
clinical,O
decision,O
making,O
",",O
as,O
well,O
as,O
to,O
enable,O
the,O
prediction,O
of,O
patient,O
trajectories,O
via,O
machine,O
learning,O
methods,O
with,O
datasets,O
of,O
sufficient,O
depth,O
and,O
size,O
(,O
Ahadi,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
We,O
first,O
benchmarked,O
the,O
platform,O
on,O
a,O
cohort,O
-,O
based,O
epidemiological,O
study,O
",",O
Generation,O
Scotland,O
(,O
GS,O
),O
(,O
Smith,O
et,O
 ,O
al,O
.,O
",",O
2013,O
),O
",",O
and,O
at,O
considerably,O
higher,O
throughput,O
",",O
demonstrated,O
a,O
level,O
of,O
precision,O
and,O
consistency,O
that,O
",",O
to,O
our,O
knowledge,O
",",O
is,O
yet,O
unachieved,O
in,O
comparable,O
large,O
-,O
scale,O
proteomic,O
studies,O
.,O
We,O
then,O
employed,O
this,O
workflow,O
in,O
an,O
immediate,O
response,O
to,O
the,O
SARS,O
-,O
CoV-2,O
pandemic,O
outbreak,O
in,O
Germany,O
",",O
by,O
applying,O
it,O
to,O
a,O
cohort,O
that,O
includes,O
the,O
first,O
COVID-19,O
patients,O
hospitalized,O
at,O
the,O
Charité,O
Universitätsmedizin,O
Berlin,O
.,O
We,O
measured,O
samples,O
from,O
a,O
primary,O
exploratory,O
cohort,O
comprising,O
thirty,O
-,O
one,O
COVID-19,O
patients,O
to,O
identify,O
clinical,O
classifiers,O
",",O
candidate,O
biomarkers,O
as,O
well,O
as,O
potential,O
targets,O
that,O
picture,O
the,O
host,O
immune,O
response,O
specific,O
to,O
a,O
SARS,O
-,O
CoV-2,O
infection,O
(,O
Figure,O
 ,O
4A,O
),O
.,O
We,O
identified,O
protein,O
expression,O
signatures,O
that,O
can,O
classify,O
COVID-19,O
patients,O
according,O
to,O
WHO,O
grading,O
",",O
introduced,O
as,O
of,O
April,O
2020,O
(,O
World,O
Health,O
Organization,O
",",O
2020,O
),O
.,O
First,O
",",O
a,O
spectral,O
library,O
is,O
automatically,O
“,O
refined,O
”,O
using,O
the,O
dataset,O
in,O
question,O
:,O
only,O
detectable,O
peptide,O
precursors,O
are,O
retained,O
",",O
and,O
their,O
reference,O
spectra,O
and,O
retention,O
times,O
are,O
replaced,O
with,O
empirically,O
observed,O
.,O
We,O
applied,O
the,O
developed,O
workflow,O
for,O
the,O
analysis,O
of,O
serum,O
and,O
citrate,O
plasma,O
samples,O
for,O
two,O
independent,O
COVID-19,O
cohorts,O
that,O
included,O
patients,O
who,O
were,O
among,O
the,O
first,O
that,O
were,O
hospitalized,O
at,O
Charité,O
Universitätsmedizin,O
Berlin,O
",",O
between,O
March,O
1st,O
and,O
March,O
26th,O
2020,O
.,O
Severity,O
of,O
COVID-19,O
was,O
graded,O
using,O
the,O
WHO,O
ordinal,O
outcome,O
scale,O
of,O
clinical,O
improvement,O
(,O
score,O
3,O
 ,O
=,O
hospitalized,O
",",O
no,O
oxygen,O
therapy,O
;,O
score,O
4,O
 ,O
=,O
oxygen,O
by,O
mask,O
or,O
nasal,O
prongs,O
;,O
score,O
5,O
 ,O
=,O
non,O
-,O
invasive,O
ventilation,O
or,O
high,O
-,O
flow,O
oxygen,O
;,O
score,O
6,O
 ,O
=,O
intubation,O
and,O
mechanical,O
ventilation,O
;,O
score,O
7,O
 ,O
=,O
ventilation,O
and,O
additional,O
organ,O
support,O
),O
(,O
World,O
Health,O
Organization,O
",",O
2020,O
),O
(,O
Table,O
S2,O
),O
.,O
Four,O
patients,O
(,O
13,O
%,O
),O
died,O
from,O
COVID-19,O
",",O
and,O
4,O
patients,O
remain,O
hospitalized,O
at,O
the,O
time,O
of,O
writing,O
.,O
Successively,O
",",O
a,O
control,O
group,O
",",O
consisting,O
of,O
15,O
healthy,O
volunteers,O
and,O
17,O
further,O
patients,O
suffering,O
from,O
COVID-19,O
",",O
was,O
recruited,O
at,O
the,O
same,O
hospital,O
and,O
used,O
for,O
validation,O
of,O
the,O
biomarkers,O
discovered,O
(,O
Table,O
S1,O
),O
.,O
Protein,O
responses,O
based,O
on,O
COVID-19,O
severity,O
were,O
obtained,O
from,O
a,O
cohort,O
of,O
31,O
hospitalized,O
SARS,O
-,O
CoV-2,O
infected,O
patients,O
.,O
Severity,O
of,O
COVID-19,O
was,O
graded,O
using,O
the,O
WHO,O
ordinal,O
outcome,O
scale,O
of,O
clinical,O
improvement,O
(,O
World,O
Health,O
Organization,O
",",O
2020,O
),O
.,O
(,O
C,O
),O
Heatmap,O
shows,O
protein,O
signatures,O
that,O
report,O
on,O
COVID-19,O
severity,O
.,O
In,O
the,O
exploratory,O
cohort,O
",",O
which,O
included,O
104,O
serum,O
samples,O
obtained,O
from,O
the,O
31,O
of,O
the,O
earliest,O
COVID-19,O
patients,O
",",O
we,O
quantified,O
297,O
protein,O
groups,O
among,O
which,O
229,O
unique,O
proteins,O
were,O
detected,O
with,O
75,O
%,O
data,O
completeness,O
.,O
To,O
account,O
for,O
this,O
biological,O
limitation,O
",",O
we,O
applied,O
very,O
strict,O
filtering,O
to,O
the,O
dataset,O
",",O
namely,O
",",O
we,O
only,O
tested,O
for,O
differential,O
abundance,O
of,O
proteins,O
which,O
had,O
at,O
least,O
five,O
different,O
peptide,O
precursors,O
identified,O
at,O
least,O
in,O
one,O
of,O
the,O
acquisitions,O
.,O
Next,O
",",O
to,O
validate,O
the,O
biomarkers,O
",",O
we,O
processed,O
the,O
validation,O
cohort,O
(,O
Table,O
S1,O
),O
and,O
recorded,O
96,O
proteomes,O
in,O
triplicates,O
for,O
15,O
healthy,O
volunteers,O
and,O
17,O
COVID-19,O
patients,O
(,O
Table,O
S1,O
),O
.,O
We,O
illustrate,O
the,O
quantitative,O
variability,O
of,O
the,O
validated,O
biomarkers,O
for,O
COVID-19,O
severity,O
on,O
a,O
heatmap,O
(,O
Figure,O
 ,O
4C,O
),O
and,O
as,O
boxplots,O
(,O
Figures,O
4D,O
),O
as,O
well,O
as,O
summarize,O
their,O
potential,O
connection,O
to,O
COVID-19,O
in,O
Table,O
S3,O
.,O
To,O
exclude,O
the,O
possibility,O
that,O
concentration,O
changes,O
in,O
these,O
markers,O
are,O
due,O
to,O
frequent,O
confounders,O
",",O
like,O
age,O
",",O
we,O
have,O
plotted,O
the,O
variability,O
of,O
the,O
same,O
proteins,O
in,O
the,O
GS,O
cohort,O
",",O
with,O
age,O
spanning,O
from,O
37,O
to,O
79,O
",",O
on,O
samples,O
that,O
have,O
been,O
collected,O
before,O
the,O
COVID-19,O
outbreak,O
.,O
We,O
note,O
that,O
for,O
identified,O
proteins,O
the,O
change,O
between,O
mild,O
and,O
severe,O
COVID-19,O
substantially,O
exceeds,O
the,O
variation,O
seen,O
in,O
the,O
general,O
population,O
(,O
Figure,O
 ,O
4D,O
),O
.,O
A,O
PCA,O
categorizes,O
the,O
individuals,O
according,O
to,O
the,O
severity,O
of,O
COVID-19,O
(,O
Figure,O
 ,O
4B,O
),O
.,O
Moreover,O
",",O
we,O
illustrate,O
the,O
concentration,O
changes,O
of,O
the,O
biomarkers,O
validated,O
in,O
the,O
control,O
cohort,O
",",O
upon,O
grouping,O
of,O
the,O
patients,O
according,O
the,O
WHO,O
severity,O
criteria,O
",",O
ranging,O
from,O
scale,O
3,O
(,O
hospitalized,O
",",O
no,O
oxygen,O
therapy,O
),O
to,O
the,O
most,O
critical,O
(,O
scale,O
7,O
),O
in,O
a,O
heatmap,O
(,O
Table,O
S1,O
for,O
the,O
grading,O
of,O
each,O
patient,O
),O
",",O
which,O
graphically,O
illustrates,O
how,O
level,O
changes,O
in,O
these,O
proteins,O
reflect,O
a,O
progression,O
from,O
mild,O
to,O
severe,O
COVID-19,O
(,O
Figure,O
 ,O
4C,O
),O
.,O
First,O
",",O
two,O
patients,O
(,O
#,O
13,O
and,O
#,O
32,O
),O
in,O
the,O
group,O
of,O
critical,O
patients,O
",",O
which,O
later,O
died,O
from,O
COVID-19,O
",",O
clearly,O
clustered,O
in,O
the,O
heatmap,O
and,O
indeed,O
had,O
one,O
of,O
the,O
most,O
pronounced,O
proteomic,O
signatures,O
(,O
Figure,O
 ,O
4C,O
),O
",",O
implying,O
that,O
proteomics,O
bears,O
the,O
potential,O
to,O
support,O
predictions,O
of,O
clinical,O
trajectories,O
.,O
When,O
we,O
first,O
obtained,O
the,O
dataset,O
",",O
two,O
individuals,O
(,O
patients,O
4,O
and,O
6,O
),O
initially,O
clinically,O
assessed,O
as,O
severe,O
(,O
Kurth,O
et,O
al,O
.,O
",",O
2020,O
),O
clustered,O
with,O
patients,O
that,O
suffered,O
from,O
the,O
mild,O
form,O
of,O
COVID-19,O
(,O
Figure,O
 ,O
S3,O
),O
.,O
These,O
results,O
triggered,O
a,O
retrospective,O
assessment,O
",",O
which,O
revealed,O
that,O
patient,O
4,O
turned,O
out,O
to,O
be,O
suffering,O
from,O
type,O
B,O
influenza,O
rather,O
than,O
a,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
whereas,O
patient,O
6,O
was,O
classified,O
as,O
severe,O
due,O
to,O
recent,O
chemo,O
-,O
immunotherapy,O
due,O
to,O
a,O
hematological,O
malignancy,O
",",O
applied,O
just,O
ten,O
days,O
before,O
his,O
COVID-19,O
-,O
related,O
hospitalization,O
.,O
We,O
have,O
",",O
as,O
a,O
consequence,O
",",O
excluded,O
patient,O
4,O
from,O
the,O
COVID-19,O
dataset,O
(,O
all,O
results,O
shown,O
in,O
Figure,O
 ,O
4,O
),O
.,O
We,O
also,O
observe,O
upregulation,O
of,O
fibrinogen,O
",",O
a,O
coagulation,O
factor,O
",",O
and,O
SERPINA10,O
",",O
an,O
inhibitor,O
of,O
the,O
F10a,O
coagulation,O
factor,O
",",O
further,O
highlighting,O
the,O
importance,O
of,O
coagulation,O
in,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
established,O
by,O
previous,O
observations,O
of,O
elevated,O
coagulation,O
in,O
severe,O
COVID-19,O
cases,O
(,O
Zhou,O
et,O
 ,O
al,O
.,O
",",O
2020a,O
),O
.,O
A,O
parallel,O
study,O
by,O
(,O
Shen,O
et,O
al,O
.,O
",",O
2020,O
),O
used,O
a,O
more,O
conventional,O
and,O
time,O
consuming,O
(,O
120×,O
pre,O
-,O
fractionation,O
consolidated,O
in,O
40,O
fractions,O
with,O
TMT-16,O
plex,O
),O
proteomics,O
method,O
to,O
characterize,O
plasma,O
samples,O
from,O
99,O
study,O
participants,O
",",O
including,O
46,O
samples,O
from,O
patients,O
with,O
COVID-19,O
diagnosed,O
in,O
China,O
.,O
For,O
instance,O
",",O
we,O
can,O
not,O
confirm,O
the,O
downregulation,O
of,O
pro,O
-,O
platelet,O
basic,O
protein,O
(,O
PPBP,O
),O
and,O
platelet,O
factor,O
4,O
(,O
PF4,O
),O
in,O
severe,O
COVID-19,O
as,O
highlighted,O
by,O
Shen,O
et,O
 ,O
al,O
.,O
Extensive,O
worldwide,O
efforts,O
have,O
been,O
directed,O
recently,O
into,O
finding,O
drug,O
targets,O
for,O
COVID-19,O
treatment,O
.,O
For,O
example,O
",",O
pro,O
-,O
inflammatory,O
signaling,O
via,O
IL-6,O
has,O
been,O
determined,O
to,O
be,O
a,O
marker,O
of,O
severe,O
COVID-19,O
(,O
Chen,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Ruan,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
and,O
preliminary,O
results,O
on,O
the,O
inhibition,O
of,O
IL-6,O
receptor,O
(,O
IL-6R,O
),O
with,O
tocilizumab,O
seem,O
to,O
indicate,O
clinical,O
improvement,O
(,O
Coomes,O
and,O
Haghbayan,O
",",O
2020,O
),O
.,O
Here,O
",",O
we,O
discovered,O
several,O
proteins,O
that,O
are,O
differentially,O
expressed,O
with,O
the,O
severity,O
of,O
COVID-19,O
that,O
are,O
linked,O
to,O
IL-6,O
-,O
mediated,O
proinflammatory,O
cytokine,O
signaling,O
:,O
(,O
1,O
),O
the,O
CD14,O
-,O
LBP,O
LPS,O
recognition,O
system,O
",",O
(,O
2,O
),O
upregulation,O
of,O
LRG1,O
",",O
an,O
angiogenesis,O
and,O
anti,O
-,O
apoptotic,O
factor,O
associated,O
with,O
inflammation,O
",",O
and,O
(,O
3,O
),O
upregulation,O
of,O
the,O
LGALS3BP,O
",",O
an,O
inducer,O
of,O
IL-6,O
.,O
Here,O
",",O
we,O
observed,O
upregulation,O
of,O
both,O
monocyte,O
differentiation,O
antigen,O
CD14,O
(,O
~2.7×,O
),O
and,O
LBP,O
(,O
~3.9×,O
),O
in,O
severe,O
COVID-19,O
.,O
Of,O
note,O
",",O
the,O
glycosylphosphatidylinositol,O
(,O
GPI)-anchored,O
form,O
of,O
CD14,O
is,O
primarily,O
displayed,O
by,O
monocytes,O
and,O
macrophages,O
(,O
Marcos,O
et,O
 ,O
al,O
.,O
",",O
2010,O
),O
",",O
while,O
the,O
proportion,O
of,O
CD14+CD16,O
+,O
inflammatory,O
monocytes,O
in,O
the,O
peripheral,O
blood,O
increases,O
along,O
with,O
COVID-19,O
severity,O
(,O
Zhou,O
et,O
 ,O
al,O
.,O
",",O
2020b,O
),O
.,O
Given,O
that,O
CD14,O
is,O
a,O
potent,O
activator,O
of,O
pro,O
-,O
inflammatory,O
cytokine,O
signaling,O
(,O
Zanoni,O
and,O
Granucci,O
",",O
2013,O
),O
",",O
it,O
might,O
present,O
a,O
potential,O
therapeutic,O
target,O
for,O
COVID-19,O
.,O
Given,O
the,O
previously,O
reported,O
association,O
of,O
the,O
Middle,O
East,O
respiratory,O
syndrome,O
(,O
MERS,O
),O
infection,O
with,O
lung,O
fibrosis,O
(,O
Zhao,O
et,O
 ,O
al,O
.,O
",",O
2008,O
),O
and,O
emerging,O
reports,O
(,O
British,O
Thoracic,O
Society,O
",",O
2020,O
),O
of,O
lung,O
fibrosis,O
in,O
a,O
substantial,O
proportion,O
of,O
COVID-19,O
survivors,O
",",O
we,O
hypothesize,O
that,O
the,O
~2.1×,O
elevation,O
of,O
serum,O
LRG1,O
levels,O
 ,O
we,O
observe,O
in,O
critical,O
COVID-19,O
cases,O
in,O
comparison,O
with,O
the,O
mild,O
cases,O
might,O
indicate,O
the,O
increased,O
risk,O
of,O
fibrosis,O
",",O
highlighting,O
LRG1,O
as,O
yet,O
another,O
potential,O
therapeutic,O
candidate,O
for,O
COVID-19,O
treatment,O
.,O
Inhibition,O
of,O
galectin-3,O
-,O
mediated,O
signaling,O
pathways,O
hence,O
represents,O
another,O
potential,O
therapeutic,O
target,O
against,O
COVID-19,O
.,O
Going,O
forward,O
",",O
it,O
will,O
be,O
important,O
to,O
assess,O
GSN,O
levels,O
in,O
at,O
-,O
risk,O
populations,O
for,O
severe,O
COVID-19,O
",",O
e.g.,O
",",O
patients,O
with,O
diabetes,O
.,O
The,O
development,O
of,O
therapies,O
to,O
stabilize,O
the,O
GSN,O
levels,O
could,O
hence,O
be,O
of,O
direct,O
therapeutic,O
value,O
for,O
treating,O
COVID-19,O
.,O
Although,O
decreased,O
APOA1,O
levels,O
have,O
been,O
observed,O
in,O
systemic,O
inflammatory,O
response,O
(,O
Kumaraswamy,O
et,O
 ,O
al,O
.,O
",",O
2012,O
;,O
Sirniö,O
et,O
 ,O
al,O
.,O
",",O
2017,O
),O
",",O
including,O
in,O
COVID-19,O
(,O
Nie,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
",",O
a,O
potential,O
explanation,O
of,O
the,O
downregulation,O
we,O
observe,O
here,O
would,O
also,O
be,O
provided,O
",",O
if,O
naturally,O
lower,O
APOA1,O
and,O
hence,O
a,O
different,O
metabolic,O
condition,O
of,O
the,O
individual,O
were,O
associated,O
with,O
a,O
higher,O
risk,O
of,O
severe,O
SARS,O
-,O
CoV-2,O
disease,O
progression,O
.,O
The,O
raw,O
data,O
of,O
the,O
acquired,O
commercial,O
plasma,O
and,O
serum,O
control,O
samples,O
within,O
the,O
GS,O
study,O
have,O
been,O
deposited,O
to,O
the,O
ProteomeXchange,B-Repository
Consortium,E-Repository
 ,O
via,O
PRIDE,O
(,O
Perez,O
-,O
Riverol,O
et,O
 ,O
al,O
.,O
",",O
2019,O
),O
partner,O
repository,O
with,O
the,O
dataset,O
identifier,O
Pride,O
:,O
PXD018874,S-AccessionNumber
.,O
Sampling,O
was,O
performed,O
as,O
part,O
of,O
the,O
Pa,O
-,O
COVID-19,O
study,O
",",O
a,O
prospective,O
observational,O
cohort,O
study,O
assessing,O
pathophysiology,O
and,O
clinical,O
characteristics,O
of,O
patients,O
with,O
COVID-19,O
at,O
Charité,O
Universitätsmedizin,O
Berlin,O
(,O
Kurth,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
study,O
assesses,O
epidemiological,O
and,O
demographic,O
parameters,O
",",O
medical,O
history,O
",",O
clinical,O
course,O
",",O
morbidity,O
and,O
quality,O
of,O
life,O
during,O
hospital,O
stay,O
of,O
COVID-19,O
patients,O
.,O
Treatment,O
and,O
medical,O
interventions,O
follow,O
standard,O
of,O
care,O
as,O
recommended,O
by,O
current,O
international,O
and,O
German,O
guidelines,O
for,O
COVID-19,O
.,O
The,O
Pa,O
-,O
COVID-19,O
study,O
is,O
carried,O
out,O
according,O
to,O
the,O
Declaration,O
of,O
Helsinki,O
and,O
the,O
principles,O
of,O
Good,O
Clinical,O
Practice,O
(,O
ICH,O
1996,O
),O
where,O
applicable,O
and,O
was,O
approved,O
by,O
the,O
ethics,O
committee,O
of,O
Charité-,O
Universitätsmedizin,O
Berlin,O
(,O
EA2/066/20,O
),O
.,O
Human,O
UniProt,S-Repository
 ,O
(,O
UniProt,S-Repository
 ,O
Consortium,O
",",O
2019,O
),O
isoform,O
sequence,O
database,O
(,O
3AUP000005640,S-AccessionNumber
),O
was,O
used,O
to,O
annotate,O
the,O
library,O
.,O
The,O
library,O
was,O
first,O
automatically,O
refined,O
based,O
on,O
the,O
dataset,O
in,O
question,O
at,O
0.01,O
global,O
q,O
-,O
value,O
(,O
using,O
the,O
“,O
Generate,O
spectral,O
library,O
”,O
option,O
in,O
DIA,O
-,O
NN,O
),O
.,O
As,O
we,O
were,O
specifically,O
interested,O
in,O
proteins,O
which,O
could,O
serve,O
as,O
biomarkers,O
of,O
COVID-19,O
severity,O
",",O
the,O
test,O
was,O
performed,O
using,O
the,O
Kendall,O
’s,O
Tau,O
test,O
for,O
the,O
Theil,O
-,O
Sen,O
trend,O
estimator,O
(,O
as,O
implemented,O
in,O
the,O
EnvStats,O
R,O
package,O
(,O
Millard,O
",",O
2014,O
),O
),O
against,O
the,O
disease,O
severity,O
as,O
classified,O
according,O
to,O
the,O
WHO,O
ordinal,O
scale,O
(,O
Table,O
S1,O
),O
.,O
In,O
the,O
case,O
of,O
this,O
dataset,O
",",O
however,O
",",O
we,O
observed,O
very,O
significant,O
differences,O
in,O
the,O
variance,O
",",O
e.g.,O
many,O
proteins,O
seem,O
a,O
lot,O
more,O
variable,O
between,O
patients,O
with,O
severe,O
and,O
critical,O
COVID-19,O
than,O
mild,O
COVID-19,O
.,O
The,O
COVID-19,O
pandemic,O
is,O
an,O
unprecedented,O
global,O
challenge,O
",",O
and,O
point,O
-,O
of,O
-,O
care,O
diagnostic,O
classifiers,O
are,O
urgently,O
required,O
.,O
We,O
use,O
our,O
platform,O
on,O
samples,O
collected,O
from,O
a,O
cohort,O
of,O
early,O
hospitalized,O
cases,O
of,O
the,O
SARS,O
-,O
CoV-2,O
pandemic,O
and,O
identify,O
27,O
potential,O
biomarkers,O
that,O
are,O
differentially,O
expressed,O
depending,O
on,O
the,O
WHO,O
severity,O
grade,O
of,O
COVID-19,O
.,O
In,O
total,O
",",O
this,O
work,O
supports,O
the,O
development,O
of,O
routine,O
proteomic,O
assays,O
to,O
aid,O
clinical,O
decision,O
making,O
and,O
generate,O
hypotheses,O
about,O
potential,O
COVID-19,O
therapeutic,O
targets,O
.,O
A,O
standardized,O
",",O
ultra,O
-,O
high,O
-,O
throughput,O
clinical,O
platform,O
for,O
serum,O
and,O
plasma,O
proteomics,O
   ,O
•,O
 ,O
Platform,O
enables,O
high,O
precision,O
quantification,O
of,O
180,O
human,O
proteomes,O
per,O
day,O
at,O
low,O
cost,O
   ,O
•,O
 ,O
27,O
biomarkers,O
are,O
differentially,O
expressed,O
between,O
WHO,O
severity,O
grades,O
for,O
COVID-19,O
   ,O
•,O
 ,O
Biomarkers,O
include,O
proteins,O
not,O
previously,O
associated,O
with,O
COVID-19,O
infection,O
     ,O
Messner,O
et,O
 ,O
al,O
.,O
present,O
a,O
standardized,O
",",O
low,O
-,O
cost,O
",",O
ultra,O
-,O
high,O
-,O
throughput,O
platform,O
for,O
serum,O
and,O
plasma,O
proteomics,O
designed,O
for,O
clinical,O
use,O
and,O
apply,O
it,O
to,O
a,O
cohort,O
of,O
hospitalized,O
COVID-19,O
patients,O
.,O
They,O
identify,O
27,O
potential,O
biomarkers,O
that,O
are,O
differentially,O
expressed,O
depending,O
on,O
the,O
WHO,O
severity,O
grade,O
of,O
COVID-19,O
.,O
At,O
different,O
time,O
points,O
postinfection,O
(,O
hpi,O
),O
",",O
cells,O
were,O
harvested,O
for,O
determining,O
host,O
and,O
viral,O
RNA,O
levels,O
by,O
quantitative,O
PCR,O
analysis,O
",",O
and,O
the,O
supernatants,O
were,O
collected,O
and,O
subjected,O
to,O
TCID50,O
assays,O
for,O
measuring,O
viral,O
titers,O
.,O
The,O
pandemic,O
of,O
COVID-19,O
has,O
posed,O
an,O
unprecedented,O
threat,O
to,O
global,O
public,O
health,O
.,O
However,O
",",O
the,O
interplay,O
between,O
the,O
viral,O
pathogen,O
of,O
COVID-19,O
",",O
SARS,O
-,O
CoV-2,O
",",O
and,O
host,O
innate,O
immunity,O
is,O
poorly,O
understood,O
.,O
Care,O
homes,O
have,O
been,O
disproportionately,O
affected,O
by,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
with,O
high,O
rates,O
of,O
severe,O
illness,O
and,O
deaths,O
among,O
the,O
vulnerable,O
residents,O
with,O
multiple,O
comorbidities,O
.,O
Detailed,O
investigations,O
of,O
care,O
homes,O
experiencing,O
a,O
COVID-19,O
outbreak,O
identified,O
high,O
rates,O
of,O
SARS,O
-,O
CoV-2,O
positivity,O
among,O
residents,O
and,O
staff,O
",",O
most,O
of,O
whom,O
were,O
asymptomatic,O
at,O
the,O
time,O
of,O
testing.1,O
",",O
2,O
",",O
3,O
In,O
England,O
",",O
the,O
first,O
imported,O
cases,O
of,O
COVID-19,O
were,O
reported,O
at,O
the,O
end,O
of,O
January,O
2020,O
and,O
autochthonous,O
transmission,O
was,O
confirmed,O
a,O
month,O
later,O
.,O
London,O
was,O
one,O
of,O
the,O
earliest,O
and,O
worst,O
affected,O
cities,O
in,O
England,O
and,O
large,O
outbreaks,O
of,O
COVID-19,O
were,O
reported,O
in,O
care,O
homes,O
during,O
the,O
peak,O
of,O
the,O
pandemic,O
.,O
By,O
May,O
01,O
",",O
2020,O
",",O
there,O
had,O
been,O
excess,O
of,O
"22,000",O
deaths,O
among,O
care,O
home,O
residents,O
during,O
the,O
COVID-19,O
pandemic,O
",",O
accounting,O
for,O
54,O
%,O
of,O
all,O
the,O
excess,O
mortality,O
in,O
England,O
and,O
Wales,O
.,O
Six,O
London,O
care,O
homes,O
reporting,O
a,O
suspected,O
outbreak,O
(,O
≥2,O
suspected,O
cases,O
),O
of,O
COVID-19,O
to,O
Public,O
Health,O
England,O
during,O
April,O
10–13,O
",",O
2020,O
were,O
investigated,O
.,O
Across,O
the,O
six,O
care,O
homes,O
experiencing,O
a,O
COVID,O
-,O
outbreak,O
",",O
254,O
of,O
474,O
(,O
54,O
%,O
),O
staff,O
members,O
were,O
working,O
during,O
April,O
10–13,O
",",O
2020,O
",",O
and,O
provided,O
a,O
nasal,O
swab,O
and,O
53,O
(,O
21,O
%,O
),O
tested,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
",",O
including,O
12,O
(,O
23,O
%,O
),O
who,O
were,O
symptomatic,O
at,O
the,O
time,O
of,O
swabbing,O
.,O
Within,O
the,O
small,O
cohort,O
of,O
SARS,O
-,O
CoV-2,O
positive,O
staff,O
",",O
genomic,O
analysis,O
identified,O
two,O
pairs,O
of,O
samples,O
that,O
were,O
not,O
separated,O
when,O
placed,O
in,O
the,O
context,O
of,O
the,O
background,O
of,O
SARS,O
-,O
CoV-2,O
genomic,O
samples,O
from,O
across,O
greater,O
London,O
(,O
COVID-19,B-Dataset
Genomics,I-Dataset
UK,I-Dataset
Consortium,E-Dataset
:,O
https://www.cogconsortium.uk/,S-URL
),O
dataset,O
(,O
n,O
 ,O
=,O
 ,O
"27,768",O
),O
",",O
indicating,O
a,O
higher,O
likelihood,O
of,O
transmission,O
between,O
the,O
individuals,O
.,O
A,O
putative,O
cluster,O
involving,O
staff,O
from,O
care,O
home,O
A,O
(,O
highlighted,O
in,O
red,O
),O
was,O
not,O
present,O
when,O
these,O
sequences,O
were,O
compared,O
with,O
the,O
COG,S-Dataset
 ,O
dataset,O
",",O
suggesting,O
that,O
transmission,O
between,O
care,O
home,O
staff,O
was,O
unlikely,O
in,O
this,O
case,O
.,O
In,O
six,O
London,O
care,O
homes,O
experiencing,O
a,O
COVID-19,O
outbreak,O
during,O
the,O
peak,O
of,O
the,O
pandemic,O
",",O
21,O
%,O
of,O
staff,O
tested,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
and,O
",",O
of,O
those,O
positive,O
",",O
only,O
23,O
%,O
were,O
symptomatic,O
at,O
the,O
time,O
of,O
testing,O
.,O
Additionally,O
",",O
in,O
many,O
countries,O
including,O
the,O
UK,O
and,O
the,O
US,O
",",O
care,O
homes,O
are,O
heavily,O
reliant,O
on,O
temporary,O
“,O
bank,O
”,O
or,O
agency,O
staff,O
to,O
provide,O
cover,O
for,O
their,O
staff,O
in,O
case,O
of,O
shortages,O
or,O
sick,O
leave,O
.,O
",",O
 ,O
Staff,O
are,O
also,O
recognised,O
sources,O
of,O
infection,O
",",O
especially,O
respiratory,O
and,O
gastrointestinal,O
viruses,O
",",O
in,O
care,O
homes,O
",",O
and,O
COVID-19,O
is,O
no,O
exception,O
.,O
",",O
The,O
staff,O
members,O
put,O
themselves,O
at,O
increased,O
risk,O
of,O
COVID-19,O
and,O
their,O
risk,O
of,O
severe,O
disease,O
may,O
be,O
increased,O
by,O
pre,O
-,O
existing,O
health,O
condition,O
;,O
care,O
workers,O
have,O
among,O
the,O
highest,O
mortality,O
rates,O
among,O
all,O
occupations,O
.,O
",",O
 ,O
Infected,O
care,O
home,O
workers,O
also,O
put,O
their,O
household,O
members,O
at,O
risk,O
of,O
COVID-19,O
and,O
",",O
depending,O
on,O
the,O
careers,O
of,O
the,O
household,O
members,O
potentially,O
contribute,O
to,O
ongoing,O
transmission,O
in,O
the,O
community,O
.,O
10,O
",",O
11,O
",",O
12,O
Highlights,O
    ,O
•,O
 ,O
21,O
%,O
of,O
255,O
staff,O
working,O
in,O
6,O
care,O
homes,O
with,O
a,O
COVID-19,O
outbreak,O
were,O
SARS,O
-,O
CoV-2,O
positive,O
.,O
Background,O
 ,O
Care,O
homes,O
have,O
been,O
disproportionately,O
affected,O
by,O
the,O
COVID-19,O
pandemic,O
and,O
continue,O
to,O
suffer,O
large,O
outbreaks,O
even,O
when,O
community,O
infection,O
rates,O
are,O
declining,O
",",O
thus,O
representing,O
important,O
pockets,O
of,O
transmission,O
.,O
We,O
assessed,O
occupational,O
risk,O
factors,O
for,O
SARS,O
-,O
CoV-2,O
infection,O
among,O
staff,O
in,O
six,O
care,O
homes,O
experiencing,O
a,O
COVID-19,O
outbreak,O
during,O
the,O
peak,O
of,O
the,O
pandemic,O
in,O
London,O
",",O
England,O
.,O
During,O
the,O
initial,O
period,O
of,O
the,O
epidemic,O
",",O
many,O
patients,O
were,O
diagnosed,O
with,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
only,O
after,O
developing,O
critical,O
illness,O
or,O
even,O
at,O
the,O
time,O
of,O
death,O
",",O
whereas,O
asymptomatic,O
or,O
paucisymptomatic,O
patients,O
were,O
untested,O
",",O
leading,O
to,O
an,O
underestimation,O
of,O
the,O
denominator,O
.,O
In,O
addition,O
",",O
several,O
mutated,O
strains,O
of,O
SARS‐CoV‐2,O
are,O
constantly,O
emerging,O
",",O
",",O
  ,O
while,O
the,O
infectivity,O
rates,O
and,O
COVID‐19‐associated,O
number,O
of,O
deaths,O
are,O
decreasing,O
.,O
Besides,O
SARS,O
-,O
CoV,O
",",O
there,O
are,O
five,O
well,O
known,O
human,O
coronaviruses,O
(,O
HCoVs,O
),O
",",O
such,O
as,O
HCoV,O
-,O
OC43,O
",",O
HCoV,O
-,O
NL63,O
",",O
HCoV,O
-,O
HKU1,O
",",O
Middle,O
East,O
respiratory,O
syndrome,O
CoV,O
(,O
MERS,O
-,O
CoV,O
),O
",",O
and,O
coronavirus,O
COVID-19,O
(,O
formerly,O
known,O
as,O
Wuhan,O
coronavirus,O
and,O
2019,O
-,O
nCoV,O
),O
[,O
5,O
],O
.,O
Among,O
them,O
",",O
SARS,O
-,O
CoV,O
",",O
MERS,O
-,O
CoV,O
",",O
and,O
COVID-19,O
are,O
highly,O
pathogenic,O
HCoVs,O
",",O
and,O
their,O
spread,O
initiated,O
global,O
outbreaks,O
with,O
high,O
fatality,O
rates,O
in,O
2003,O
",",O
2012,O
",",O
and,O
2020,O
",",O
respectively,O
[,O
"6,7",O
],O
.,O
Nowadays,O
",",O
COVID-19,O
has,O
caused,O
a,O
big,O
outbreak,O
in,O
China,O
and,O
is,O
spreading,O
globally,O
by,O
a,O
limited,O
people,O
-,O
to,O
-,O
people,O
transmission,O
",",O
resulting,O
in,O
"2,319,066",O
confirmed,O
cases,O
including,O
"157,920",O
deaths,O
in,O
213,O
countries,O
",",O
areas,O
or,O
territories,O
",",O
with,O
cases,O
during,O
the,O
period,O
from,O
31st,O
December,O
2019,O
to,O
21st,O
April,O
2020,O
(,O
https://www.who.int/emergencies/diseases/novel-coronavirus-2019,O
),O
.,O
The,O
mortality,O
rate,O
of,O
these,O
pathogenic,O
coronaviruses,O
ranges,O
from,O
6.8,O
%,O
for,O
COVID-19,O
patients,O
to,O
35,O
%,O
for,O
MERS,O
patients,O
.,O
Moreover,O
",",O
an,O
increase,O
in,O
the,O
plasma,O
level,O
of,O
CXCL10,O
is,O
found,O
in,O
the,O
severe,O
pneumonia,O
patients,O
infected,O
with,O
MERS,O
-,O
CoV,O
and,O
COVID-19,O
",",O
which,O
is,O
linked,O
with,O
the,O
infiltration,O
of,O
immune,O
cells,O
into,O
alveolar,O
space,O
",",O
peribranchial,O
",",O
and,O
perivascular,O
of,O
the,O
lung,O
[,O
"12,13",O
],O
.,O
SARS,O
-,O
CoV,O
unique,O
domain,O
(,O
SUD,O
),O
appears,O
in,O
SARS,O
-,O
CoV,O
",",O
as,O
also,O
found,O
in,O
other,O
coronaviruses,O
like,O
MERS,O
CoV,O
and,O
COVID-19,O
.,O
Moreover,O
",",O
amino,O
acid,O
alignment,O
of,O
SARS,O
-,O
SUD,O
with,O
MERS,O
-,O
CoV,O
and,O
COVID-19,O
shows,O
15,O
%,O
and,O
75,O
%,O
identity,O
",",O
respectively,O
.,O
The,O
nucleotide,O
sequences,O
of,O
SARS,O
-,O
CoV,O
full,O
-,O
length,O
SUD,O
",",O
SUD,O
-,O
NM,O
",",O
and,O
SUD,O
-,O
MC,O
within,O
the,O
SARS,O
-,O
CoV,O
genome,O
nucleotides,O
3887–4941,O
",",O
3887–4673,O
",",O
and,O
4311–4880,O
(,O
GenBank,S-Repository
 ,O
accession,O
no,O
.,O
AY291451,S-AccessionNumber
),O
",",O
respectively,O
",",O
were,O
amplified,O
using,O
PCR,O
with,O
specific,O
primer,O
pairs,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
the,O
infectious,O
disease,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
has,O
led,O
to,O
a,O
global,O
pandemic,O
.,O
Emerging,O
evidence,O
has,O
described,O
several,O
risk,O
factors,O
(,O
e.g.,O
",",O
older,O
age,O
",",O
cardiovascular,O
disease,O
",",O
chronic,O
lung,O
disease,O
),O
for,O
COVID-19,O
severity,O
and,O
mortality,O
[,O
[,O
1,O
],O
",",O
[,O
2,O
],O
",",O
[,O
3,O
],O
],O
.,O
The,O
Centers,O
for,O
Disease,O
Control,O
and,O
Prevention,O
(,O
CDC,O
),O
list,O
severe,O
obesity,O
(,O
body,O
mass,O
index,O
[,O
BMI,O
],O
of,O
≥40,O
 ,O
kg,O
/,O
m2,O
),O
as,O
a,O
risk,O
factor,O
for,O
severe,O
illness,O
from,O
COVID-19,O
[,O
5,O
],O
.,O
Despite,O
the,O
clinical,O
and,O
research,O
significance,O
",",O
no,O
study,O
has,O
examined,O
the,O
relationship,O
of,O
obesity,O
—,O
let,O
alone,O
of,O
its,O
related,O
traits,O
(,O
e.g.,O
",",O
central,O
obesity,O
),O
and,O
their,O
genetic,O
factors,O
—,O
with,O
severe,O
COVID-19,O
.,O
Using,O
standardized,O
protocols,O
",",O
the,O
study,O
has,O
collected,O
comprehensive,O
phenotypic,O
information,O
(,O
such,O
as,O
demographics,O
",",O
anthropometric,O
measures,O
[,O
e.g.,O
",",O
height,O
",",O
weight,O
",",O
waist,O
and,O
hip,O
circumference,O
],O
and,O
medical,O
history,O
),O
",",O
tested,O
for,O
biochemical,O
assays,O
",",O
performed,O
genome,O
-,O
wide,O
genotyping,O
",",O
and,O
longitudinally,O
measured,O
health,O
outcomes,O
(,O
e.g.,O
",",O
hospitalizations,O
),O
through,O
linkages,O
to,O
national,O
datasets,O
.,O
In,O
the,O
current,O
study,O
",",O
we,O
analyzed,O
the,O
first,O
set,O
of,O
the,O
UK,B-Repository
Biobank,E-Repository
 ,O
data,O
with,O
laboratory,O
-,O
confirmed,O
COVID-19,O
status,O
",",O
which,O
were,O
released,O
on,O
April,O
16,O
",",O
2020,O
.,O
These,O
hospitalized,O
patients,O
with,O
SARS,O
-,O
CoV-2,O
infection,O
had,O
“,O
severe,O
COVID-19,O
”,O
[,O
"22,23",O
],O
.,O
The,O
detailed,O
information,O
on,O
released,O
COVID-19,O
data,O
can,O
be,O
found,O
elsewhere,O
[,O
22,O
],O
.,O
Second,O
",",O
to,O
visualize,O
the,O
relationship,O
of,O
BMI,O
and,O
two,O
markers,O
of,O
central,O
obesity,O
(,O
i.e.,O
",",O
waist,O
circumference,O
and,O
waist,O
-,O
to,O
-,O
hip,O
ratio,O
),O
with,O
the,O
risk,O
of,O
developing,O
severe,O
COVID-19,O
",",O
we,O
used,O
generalized,O
additive,O
models,O
with,O
penalized,O
cubic,O
regression,O
splines,O
.,O
Next,O
",",O
to,O
examine,O
the,O
relationship,O
between,O
the,O
genetic,O
predisposition,O
for,O
obesity,O
traits,O
and,O
the,O
risk,O
of,O
developing,O
severe,O
COVID-19,O
",",O
we,O
computed,O
a,O
polygenic,O
risk,O
score,O
(,O
PRS,O
),O
for,O
each,O
of,O
three,O
obesity,O
measures,O
—,O
i.e.,O
",",O
BMI,O
",",O
BMI,O
-,O
adjusted,O
waist,O
circumference,O
",",O
and,O
BMI,O
-,O
adjusted,O
waist,O
-,O
to,O
-,O
hip,O
ratio,O
",",O
according,O
to,O
prior,O
research,O
[,O
26,O
],O
",",O
using,O
genome,O
-,O
wide,O
genotyping,O
data,O
from,O
the,O
Genetic,B-Repository
Investigation,I-Repository
of,I-Repository
Anthropometric,I-Repository
Traits,I-Repository
(GIANT),E-Repository
 ,O
consortium,O
and,O
UK,B-Repository
Biobank,E-Repository
.,O
In,O
brief,O
",",O
we,O
retrieved,O
the,O
genome,O
-,O
wide,O
association,O
study,O
(,O
GWAS,O
),O
summary,O
statistics,O
of,O
BMI,O
(,O
nmax,O
 ,O
=,O
 ,O
"322,154",O
),O
[,O
27,O
],O
",",O
BMI,O
-,O
adjusted,O
waist,O
circumference,O
(,O
nmax,O
 ,O
=,O
 ,O
"231,355",O
),O
[,O
28,O
],O
",",O
and,O
BMI,O
-,O
adjusted,O
waist,O
-,O
to,O
-,O
hip,O
ratio,O
(,O
nmax,O
 ,O
=,O
 ,O
"210,086",O
),O
[,O
28,O
],O
from,O
the,O
GIANT,S-Repository
 ,O
consortium,O
data,O
as,O
an,O
independent,O
base,O
dataset,O
.,O
We,O
then,O
applied,O
the,O
LDpred,O
method,O
[,O
29,O
],O
to,O
compute,O
model,O
coefficients,O
using,O
approximately,O
"1,480,000",O
single,O
nucleotide,O
polymorphisms,O
(,O
SNPs,O
),O
",",O
and,O
computed,O
a,O
PRS,O
for,O
each,O
trait,O
in,O
an,O
independent,O
target,O
dataset,O
(,O
n,O
 ,O
=,O
 ,O
"459,331",O
),O
from,O
the,O
UK,B-Repository
Biobank,E-Repository
.,O
Lastly,O
",",O
we,O
investigated,O
the,O
association,O
of,O
derived,O
PRSs,O
with,O
the,O
risk,O
of,O
severe,O
COVID-19,O
in,O
the,O
UK,B-Repository
Biobank,E-Repository
 ,O
by,O
fitting,O
logistic,O
regression,O
models,O
adjusting,O
for,O
age,O
",",O
sex,O
",",O
30,O
ancestry,O
principal,O
components,O
(,O
which,O
account,O
for,O
population,O
stratification,O
),O
",",O
and,O
genotyping,O
array,O
.,O
The,O
UK,B-Repository
Biobank,E-Repository
 ,O
also,O
identified,O
a,O
total,O
of,O
641,O
patients,O
with,O
severe,O
COVID-19,O
.,O
Fig,O
.,O
1,O
shows,O
the,O
relationship,O
of,O
BMI,O
and,O
markers,O
of,O
central,O
obesity,O
with,O
the,O
risk,O
of,O
developing,O
severe,O
COVID-19,O
.,O
For,O
example,O
",",O
BMI,O
was,O
positively,O
associated,O
with,O
the,O
risk,O
of,O
severe,O
COVID-19,O
(,O
unadjusted,O
OR,O
1.35,O
per,O
5,O
 ,O
kg,O
/,O
m2,O
increase,O
;,O
95,O
%,O
CI,O
1.26–1.45,O
;,O
P,O
 ,O
<,O
 ,O
0.001,O
;,O
Fig,O
.,O
1A,O
),O
.,O
Compared,O
to,O
adults,O
with,O
normal,O
weight,O
",",O
those,O
with,O
a,O
higher,O
BMI,O
had,O
a,O
dose,O
-,O
response,O
increase,O
in,O
the,O
risk,O
of,O
developing,O
severe,O
COVID-19,O
",",O
with,O
the,O
following,O
ORs,O
:,O
for,O
overweight,O
",",O
1.55,O
(,O
95,O
%,O
CI,O
1.26–1.91,O
;,O
P,O
 ,O
<,O
 ,O
0.001,O
),O
;,O
for,O
class,O
I,O
obesity,O
",",O
1.92,O
(,O
95,O
%,O
CI,O
1.51–2.44,O
;,O
P,O
 ,O
<,O
 ,O
0.001,O
),O
;,O
for,O
class,O
II,O
obesity,O
",",O
OR,O
3.06,O
(,O
95,O
%,O
CI,O
2.26–4.14,O
;,O
P,O
 ,O
<,O
 ,O
0.001,O
),O
;,O
and,O
for,O
class,O
III,O
obesity,O
",",O
3.45,O
(,O
95,O
%,O
CI,O
2.28–5.21,O
;,O
P,O
 ,O
<,O
 ,O
0.001,O
),O
(,O
Fig,O
.,O
2,O
),O
.,O
Likewise,O
",",O
adults,O
with,O
central,O
obesity,O
were,O
at,O
higher,O
risk,O
of,O
severe,O
COVID-19,O
.,O
To,O
examine,O
the,O
relationship,O
of,O
the,O
individual,O
's,O
overall,O
genetic,O
risks,O
for,O
obesity,O
and,O
central,O
obesity,O
with,O
the,O
risk,O
of,O
developing,O
severe,O
COVID-19,O
",",O
we,O
examined,O
the,O
associations,O
of,O
the,O
derived,O
PRSs,O
with,O
the,O
outcome,O
risk,O
(,O
Table,O
3,O
),O
.,O
Consistent,O
with,O
these,O
observations,O
",",O
a,O
recent,O
sentinel,O
surveillance,O
of,O
1482,O
adults,O
hospitalized,O
with,O
COVID-19,O
in,O
14,O
U.S.,O
states,O
reported,O
that,O
obesity,O
was,O
the,O
second,O
most,O
prevalent,O
underlying,O
condition,O
(,O
48,O
%,O
prevalence,O
),O
",",O
following,O
hypertension,O
[,O
30,O
],O
.,O
Additionally,O
",",O
retrospective,O
studies,O
—,O
either,O
from,O
single,O
centers,O
[,O
[,O
9,O
],O
",",O
[,O
10,O
],O
",",O
[,O
11,O
],O
",",O
[,O
12,O
],O
",",O
[,O
13,O
],O
",",O
[,O
14,O
],O
",",O
[,O
15,O
],O
",",O
[,O
16,O
],O
],O
or,O
health,O
systems,O
[,O
"3,18]—have",O
reported,O
associations,O
between,O
obesity,O
and,O
higher,O
morbidity,O
of,O
COVID-19,O
.,O
For,O
example,O
",",O
in,O
a,O
single,O
-,O
center,O
analysis,O
of,O
389,O
patients,O
hospitalized,O
for,O
COVID-19,O
in,O
China,O
",",O
Cai,O
et,O
al,O
.,O
reported,O
patients,O
with,O
obesity,O
(,O
defined,O
by,O
BMI,O
of,O
≥28,O
 ,O
kg,O
/,O
m2,O
),O
had,O
higher,O
severity,O
of,O
illness,O
[,O
9,O
],O
.,O
Similarly,O
",",O
in,O
another,O
single,O
-,O
center,O
case,O
-,O
control,O
study,O
of,O
150,O
patients,O
hospitalized,O
for,O
COVID-19,O
in,O
China,O
",",O
Gao,O
et,O
al,O
.,O
found,O
that,O
patients,O
with,O
obesity,O
(,O
defined,O
by,O
BMI,O
of,O
≥25,O
 ,O
kg,O
/,O
m2,O
),O
had,O
a,O
longer,O
hospital,O
length,O
-,O
of,O
-,O
stay,O
and,O
higher,O
disease,O
severity,O
[,O
11,O
],O
.,O
These,O
earlier,O
studies,O
—,O
albeit,O
from,O
different,O
patient,O
populations,O
and,O
settings,O
with,O
varying,O
definitions,O
of,O
obesity,O
and,O
outcomes,O
—,O
collectively,O
indicate,O
that,O
obesity,O
is,O
a,O
risk,O
factor,O
for,O
severe,O
illness,O
from,O
COVID-19,O
.,O
The,O
current,O
study,O
builds,O
on,O
these,O
prior,O
reports,O
",",O
and,O
extends,O
them,O
by,O
demonstrating,O
",",O
in,O
a,O
large,O
cohort,O
",",O
the,O
relations,O
of,O
obesity,O
-,O
related,O
traits,O
(,O
including,O
central,O
obesity,O
),O
and,O
their,O
genetic,O
predisposition,O
with,O
the,O
risk,O
of,O
developing,O
severe,O
COVID-19,O
.,O
The,O
exact,O
mechanisms,O
linking,O
the,O
observed,O
obesity,O
(,O
and,O
its,O
genetic,O
predisposition,O
),O
to,O
severe,O
COVID-19,O
are,O
likely,O
multifactorial,O
—,O
which,O
stem,O
from,O
obesity,O
-,O
related,O
changes,O
in,O
pulmonary,O
physiology,O
and,O
the,O
genetics,O
to,O
alterations,O
in,O
immune,O
response,O
and,O
inflammatory,O
profiles,O
",",O
endothelial,O
dysfunction,O
",",O
and,O
metabolic,O
dysfunction,O
[,O
31]—and,O
warrant,O
clarification,O
.,O
The,O
observed,O
relation,O
between,O
the,O
genetic,O
preposition,O
to,O
obesity,O
and,O
severe,O
COVID-19,O
also,O
suggest,O
the,O
role,O
of,O
genetics,O
in,O
the,O
pathogenesis,O
of,O
severe,O
COVID-19,O
.,O
Fourth,O
",",O
a,O
recent,O
non,O
-,O
COVID-19,O
study,O
also,O
demonstrated,O
that,O
patients,O
with,O
a,O
higher,O
BMI,O
had,O
higher,O
expression,O
of,O
ACE2,O
(,O
the,O
SARS,O
-,O
CoV-2,O
receptor,O
[,O
38,O
],O
),O
in,O
their,O
bronchial,O
epithelium,O
[,O
39,O
],O
",",O
suggesting,O
an,O
increased,O
susceptibility,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
in,O
patients,O
with,O
obesity,O
.,O
Notwithstanding,O
the,O
complexity,O
",",O
the,O
identification,O
of,O
obesity,O
and,O
its,O
genetic,O
predisposition,O
as,O
a,O
culprit,O
of,O
COVID-19,O
morbidity,O
is,O
an,O
important,O
finding,O
.,O
Our,O
observations,O
should,O
encourage,O
future,O
research,O
disentangling,O
the,O
complex,O
web,O
of,O
the,O
pathogen,O
",",O
obesity,O
",",O
airway,O
and,O
systemic,O
inflammation,O
",",O
and,O
COVID-19,O
pathobiology,O
.,O
The,O
observed,O
relationship,O
between,O
PRS,O
for,O
BMI,O
and,O
risks,O
of,O
severe,O
COVID-19,O
has,O
several,O
clinical,O
and,O
research,O
implications,O
.,O
The,O
use,O
of,O
PRS,O
strengthens,O
the,O
causal,O
inference,O
",",O
such,O
as,O
the,O
causal,O
effects,O
of,O
obesity,O
on,O
severity,O
of,O
COVID-19,O
.,O
This,O
complexity,O
has,O
hindered,O
efforts,O
to,O
robustly,O
examine,O
the,O
effect,O
of,O
these,O
obesity,O
-,O
related,O
factors,O
on,O
various,O
disease,O
conditions,O
",",O
including,O
COVID-19,O
.,O
By,O
contrast,O
",",O
the,O
use,O
of,O
PRS,O
—,O
which,O
captures,O
and,O
summarizes,O
the,O
cumulative,O
effects,O
of,O
many,O
common,O
DNA,O
variants,O
[,O
42]—effectively,O
captures,O
the,O
obesity,O
-,O
related,O
genetic,O
factors,O
(,O
i.e.,O
",",O
well,O
-,O
defined,O
exposure,O
),O
",",O
and,O
hence,O
potentially,O
enables,O
us,O
to,O
examine,O
its,O
effects,O
on,O
severe,O
COVID-19,O
that,O
are,O
independent,O
from,O
the,O
aforementioned,O
confounders,O
.,O
In,O
contrast,O
",",O
the,O
use,O
of,O
PRS,O
for,O
obesity,O
-,O
related,O
traits,O
and,O
careful,O
investigations,O
of,O
individuals,O
at,O
the,O
extremes,O
of,O
its,O
distribution,O
(,O
even,O
without,O
a,O
clinically,O
-,O
evident,O
obesity,O
trait,O
),O
potentially,O
enables,O
us,O
to,O
uncover,O
new,O
causal,O
risk,O
factors,O
for,O
the,O
development,O
of,O
severe,O
COVID-19,O
as,O
well,O
as,O
to,O
identify,O
individuals,O
at,O
risk,O
.,O
Furthermore,O
",",O
biological,O
profiling,O
of,O
these,O
individuals,O
at,O
the,O
extremes,O
of,O
obesity,O
-,O
related,O
PRS,O
distribution,O
may,O
identify,O
molecular,O
pathways,O
that,O
link,O
obesity,O
to,O
severe,O
COVID-19,O
",",O
thereby,O
potentially,O
leading,O
to,O
the,O
development,O
of,O
novel,O
prevention,O
",",O
prediction,O
",",O
and,O
treatment,O
strategies,O
.,O
Anthropometric,O
measurements,O
performed,O
at,O
assessment,O
visits,O
may,O
have,O
not,O
accurately,O
reflected,O
the,O
exposure,O
data,O
at,O
the,O
COVID-19,O
inception,O
.,O
Yet,O
",",O
the,O
PRS,O
for,O
BMI,O
—,O
time,O
-,O
invariant,O
genetic,O
data,O
—,O
was,O
also,O
significantly,O
associated,O
with,O
the,O
risk,O
of,O
developing,O
severe,O
COVID-19,O
.,O
However,O
",",O
the,O
study,O
focused,O
on,O
severe,O
COVID-19,O
requiring,O
inpatient,O
management,O
",",O
thereby,O
mitigating,O
",",O
at,O
least,O
partially,O
",",O
this,O
problem,O
.,O
Finally,O
",",O
the,O
study,O
sample,O
consisted,O
mainly,O
of,O
white,O
individuals,O
and,O
we,O
focused,O
on,O
severe,O
COVID-19,O
.,O
We,O
must,O
cautiously,O
generalize,O
the,O
inferences,O
to,O
other,O
populations,O
or,O
patients,O
with,O
mild,O
-,O
to,O
-,O
moderate,O
COVID-19,O
.,O
Nevertheless,O
",",O
our,O
inferences,O
are,O
directly,O
relevant,O
to,O
hundreds,O
of,O
thousands,O
of,O
patients,O
hospitalized,O
for,O
COVID-19,O
[,O
44,O
],O
.,O
We,O
aimed,O
to,O
examine,O
the,O
associations,O
of,O
obesity,O
-,O
related,O
traits,O
(,O
body,O
mass,O
index,O
[,O
BMI,O
],O
",",O
central,O
obesity,O
),O
and,O
their,O
genetic,O
predisposition,O
with,O
the,O
risk,O
of,O
developing,O
severe,O
COVID-19,O
in,O
a,O
population,O
-,O
based,O
data,O
.,O
The,O
outcome,O
was,O
severe,O
COVID-19,O
",",O
defined,O
by,O
hospitalization,O
for,O
laboratory,O
-,O
confirmed,O
COVID-19,O
.,O
The,O
UK,B-Repository
Biobank,E-Repository
 ,O
identified,O
641,O
patients,O
with,O
severe,O
COVID-19,O
.,O
Compared,O
to,O
adults,O
with,O
normal,O
weight,O
",",O
those,O
with,O
a,O
higher,O
BMI,O
had,O
a,O
dose,O
-,O
response,O
increases,O
in,O
the,O
risk,O
of,O
severe,O
COVID-19,O
",",O
with,O
the,O
following,O
adjusted,O
ORs,O
:,O
for,O
25.0–29.9,O
 ,O
kg,O
/,O
m,O
2,O
",",O
1.40,O
(,O
95%CI,O
1.14–1.73,O
;,O
P,O
=,O
 ,O
0.002,O
),O
;,O
for,O
30.0–34.9,O
 ,O
kg,O
/,O
m,O
2,O
",",O
1.73,O
(,O
95%CI,O
1.36–2.20,O
;,O
P,O
<,O
 ,O
0.001,O
),O
;,O
for,O
35.0–39.9,O
 ,O
kg,O
/,O
m,O
2,O
",",O
2.82,O
(,O
95%CI,O
2.08–3.83,O
;,O
P,O
<,O
 ,O
0.001,O
),O
;,O
and,O
for,O
≥40.0,O
 ,O
kg,O
/,O
m,O
2,O
",",O
3.30,O
(,O
95%CI,O
2.17–5.03,O
;,O
P,O
 ,O
<,O
 ,O
0.001,O
),O
.,O
Likewise,O
",",O
central,O
obesity,O
was,O
associated,O
with,O
significantly,O
higher,O
risk,O
of,O
severe,O
COVID-19,O
(,O
P,O
 ,O
<,O
 ,O
0.001,O
),O
.,O
In,O
this,O
large,O
population,O
-,O
based,O
cohort,O
",",O
individuals,O
with,O
more,O
-,O
severe,O
obesity,O
",",O
central,O
obesity,O
",",O
or,O
genetic,O
predisposition,O
for,O
obesity,O
are,O
at,O
higher,O
risk,O
of,O
developing,O
severe,O
-,O
COVID-19,O
.,O
Individuals,O
with,O
more,O
-,O
severe,O
obesity,O
",",O
central,O
obesity,O
are,O
at,O
higher,O
risk,O
of,O
developing,O
severe,O
-,O
COVID-19,O
.,O
   ,O
•,O
The,O
genetic,O
predisposition,O
for,O
obesity,O
as,O
measured,O
by,O
polygenic,O
risk,O
score,O
is,O
at,O
higher,O
risk,O
of,O
developing,O
severe,O
-,O
COVID-19,O
.,O
The,O
BMI,O
-,O
severe,O
COVID-19,O
associations,O
were,O
consistent,O
across,O
the,O
sex,O
strata,O
",",O
except,O
women,O
with,O
class,O
I,O
obesity,O
had,O
a,O
non,O
-,O
significant,O
increase,O
in,O
the,O
risk,O
of,O
severe,O
COVID-19,O
.,O
•,O
 ,O
Adults,O
with,O
both,O
class,O
III,O
obesity,O
and,O
diabetes,O
or,O
adults,O
with,O
both,O
a,O
larger,O
waist,O
circumference,O
and,O
diabetes,O
appeared,O
to,O
have,O
a,O
larger,O
magnitude,O
of,O
BMI,O
-,O
severe,O
COVID-19,O
association,O
compared,O
to,O
those,O
without,O
diabetes,O
.,O
According,O
to,O
data,O
from,O
the,O
World,B-Creator
Health,I-Creator
Organization,I-Creator
(WHO),E-Creator
",",O
Coronavirus,O
Disease,O
2019,O
or,O
COVID-19,O
(,O
Gorbalenya,O
et,O
al,O
.,O
",",O
2020,O
),O
has,O
been,O
diagnosed,O
in,O
over,O
"6,057,853",O
people,O
from,O
more,O
than,O
200,O
countries,O
or,O
territories,O
and,O
caused,O
over,O
"371,166",O
deaths,O
worldwide,O
as,O
of,O
1,O
June,O
2020,O
(,O
World,O
Health,O
Organization,O
",",O
2020a,O
),O
.,O
Therefore,O
",",O
the,O
QIAstat,O
-,O
Dx,O
SARS,O
-,O
CoV-2,O
assay,O
remains,O
highly,O
specific,O
and,O
sensitive,O
against,O
SARS,O
-,O
CoV-2,O
even,O
in,O
light,O
of,O
genomic,O
variations,O
from,O
the,O
first,O
five,O
months,O
of,O
the,O
COVID-19,O
outbreak,O
(,O
Visseaux,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
As,O
of,O
week,O
21,O
",",O
2020,O
",",O
the,O
complete,O
set,O
of,O
available,O
SARS,O
-,O
CoV-2,O
genomes,O
from,O
GISAID,S-Dataset
 ,O
and,O
GenBank,S-Repository
 ,O
databases,O
were,O
used,O
in,O
this,O
study,O
.,O
Considering,O
that,O
the,O
sequence,O
of,O
SARS,O
-,O
CoV-2,O
is,O
similar,O
to,O
the,O
SARS,O
-,O
CoV,O
and,O
that,O
SARS,O
-,O
CoV-2,O
appears,O
to,O
use,O
the,O
same,O
ACE2,O
receptor,O
to,O
enter,O
cells,O
",",O
analyses,O
of,O
ACE2,O
expression,O
and,O
distribution,O
in,O
lung,O
and,O
related,O
biological,O
processes,O
may,O
help,O
us,O
understand,O
the,O
pathogenesis,O
and,O
design,O
therapeutic,O
strategies,O
for,O
COVID-19,O
.,O
COVID-19,O
patients,O
often,O
have,O
underlying,O
diseases,O
",",O
including,O
chronic,O
respiratory,O
disease,O
and,O
cardiovascular,O
disease,O
.,O
To,O
investigate,O
the,O
virus,O
-,O
related,O
potential,O
biological,O
processes,O
associated,O
with,O
ACE2,O
",",O
we,O
extracted,O
the,O
expression,O
profiles,O
of,O
15,O
healthy,O
non,O
-,O
smokers,O
from,O
dataset,O
GSE89809,S-AccessionNumber
 ,O
and,O
divided,O
them,O
into,O
two,O
groups,O
:,O
high,O
and,O
low,O
-,O
expression,O
level,O
of,O
ACE2,O
.,O
This,O
may,O
be,O
related,O
to,O
pyroptosis,O
",",O
which,O
has,O
been,O
suggested,O
as,O
another,O
pathogenic,O
mechanism,O
involved,O
in,O
COVID-19,O
infection,O
.,O
The,O
fact,O
that,O
tissue,O
injury,O
and,O
death,O
may,O
be,O
related,O
to,O
a,O
pro,O
-,O
inflammatory,O
process,O
resulting,O
from,O
the,O
viral,O
infection,O
suggests,O
that,O
the,O
use,O
of,O
IL-1β,O
blockers,O
or,O
IL-18,O
blockers,O
may,O
have,O
some,O
benefit,O
in,O
COVID-19,O
patients,O
.,O
In,O
view,O
of,O
the,O
role,O
of,O
the,O
ACE2,O
receptor,O
in,O
the,O
ability,O
of,O
SARS,O
-,O
CoV-2,O
to,O
enter,O
host,O
cells,O
[,O
20,O
],O
",",O
the,O
question,O
arises,O
as,O
to,O
the,O
effect,O
of,O
ACE,O
inhibitors,O
and,O
angiotensin,O
-,O
receptor,O
blockers,O
(,O
ARBs,O
),O
in,O
the,O
pathogenesis,O
of,O
COVID-19,O
.,O
At,O
present,O
there,O
is,O
no,O
strong,O
evidence,O
to,O
discontinue,O
ACE,O
inhibitors,O
or,O
ARBs,O
in,O
patients,O
with,O
COVID-19,O
",",O
nor,O
conversely,O
",",O
to,O
use,O
these,O
drugs,O
as,O
treatment,O
for,O
COVID-19,O
.,O
It,O
is,O
postulated,O
that,O
this,O
may,O
be,O
related,O
to,O
the,O
higher,O
mortality,O
in,O
Chinese,O
patients,O
with,O
COVID-19,O
who,O
have,O
hypertension,O
as,O
a,O
comorbidity,O
.,O
If,O
ACE2,O
is,O
downregulated,O
by,O
SARS,O
-,O
CoV-2,O
S,O
protein,O
binding,O
to,O
ACE2,O
",",O
this,O
may,O
explain,O
why,O
cardiac,O
impairment,O
is,O
observed,O
to,O
be,O
a,O
significant,O
characteristic,O
of,O
patients,O
who,O
die,O
from,O
COVID-19,O
[,O
32,O
],O
This,O
illustrates,O
a,O
proposed,O
mechanism,O
of,O
the,O
effects,O
of,O
ACE2,O
in,O
COVID-19,O
infection,O
.,O
In,O
conclusion,O
",",O
COVID-19,O
is,O
a,O
global,O
pandemic,O
that,O
has,O
already,O
caused,O
over,O
"110,000",O
deaths,O
worldwide,O
so,O
far,O
.,O
These,O
findings,O
may,O
help,O
clinicians,O
and,O
researchers,O
gain,O
more,O
insight,O
into,O
the,O
pathogenesis,O
and,O
use,O
this,O
to,O
design,O
therapeutic,O
strategies,O
for,O
COVID-19,O
.,O
In,O
this,O
study,O
",",O
we,O
utilized,O
previously,O
uploaded,O
information,O
on,O
ACE2,O
expression,O
in,O
various,O
conditions,O
including,O
SARS,O
-,O
CoA,O
to,O
evaluate,O
the,O
role,O
of,O
ACE2,O
in,O
SARS,O
-,O
CoV,O
and,O
extrapolate,O
that,O
to,O
COVID-19,O
.,O
However,O
",",O
based,O
on,O
the,O
elevated,O
expression,O
of,O
ACE2,O
in,O
cigarette,O
smokers,O
",",O
we,O
speculate,O
that,O
long,O
-,O
term,O
smoking,O
may,O
be,O
a,O
risk,O
factor,O
for,O
COVID-19,O
.,O
Our,O
findings,O
may,O
help,O
clinicians,O
and,O
researchers,O
gain,O
more,O
insight,O
into,O
the,O
pathogenesis,O
of,O
SARS,O
-,O
CoV-2,O
and,O
design,O
therapeutic,O
strategies,O
for,O
COVID-19,O
.,O
Strains,O
",",O
GenBank,S-Repository
 ,O
accessions,O
and,O
other,O
details,O
are,O
listed,O
in,O
Table,O
S1,O
.,O
Furthermore,O
",",O
human,O
genomes,O
with,O
unrealistically,O
large,O
(,O
>,O
30,O
),O
numbers,O
of,O
single,O
-,O
nucleotide,O
variations,O
(,O
SNVs,O
),O
were,O
removed,O
from,O
the,O
datasets,O
.,O
Briefly,O
",",O
a,O
whole,O
SARS,O
-,O
CoV-2,O
sequence,O
(,O
Wuhan,O
-,O
Hu-1,O
",",O
GenBank,S-Repository
 ,O
accession,O
number,O
MN908947,S-AccessionNumber
;,O
previously,O
called,O
NC_045512,S-AccessionNumber
),O
was,O
mapped,O
to,O
the,O
RaTG13,O
(,O
GenBank,S-Repository
 ,O
accession,O
MN996532,S-AccessionNumber
),O
accession,O
as,O
the,O
reference,O
.,O
Synonymous,O
and,O
nonsynonymous,O
mutations,O
in,O
SARS,O
-,O
CoV-2,O
reading,O
frames,O
were,O
determined,O
according,O
to,O
annotated,O
accession,O
MN908947,S-AccessionNumber
.,O
The,O
datasets,O
contained,O
152,O
SNVs,O
",",O
of,O
which,O
84,O
(,O
55,O
%,O
),O
were,O
shared,O
between,O
at,O
least,O
two,O
accessions,O
;,O
68,O
(,O
45,O
%,O
),O
were,O
singletons,O
(,O
Table,O
S4,O
",",O
sheet,O
1,O
),O
.,O
We,O
determined,O
the,O
frequency,O
of,O
CpG,O
dinucleotide,O
in,O
17,O
human,O
(,O
including,O
eight,O
randomly,O
selected,O
SARS,O
-,O
CoV-2,O
accessions,O
),O
",",O
nine,O
bat,O
",",O
and,O
eight,O
other,O
animal,O
Betacoronaviruses,O
(,O
Figure,O
5a,O
),O
.,O
In,O
December,O
2019,O
",",O
the,O
Chinese,O
government,O
reported,O
several,O
human,O
pneumonia,O
cases,O
in,O
Wuhan,O
city,O
and,O
designated,O
the,O
disease,O
as,O
coronavirus,O
disease,O
2019,O
(,O
COVID,O
19,O
),O
(,O
Wang,O
et,O
al,O
.,O
",",O
2020a,O
),O
.,O
Major,O
symptoms,O
of,O
COVID-19,O
include,O
fever,O
",",O
cough,O
",",O
dyspnoea,O
",",O
and,O
muscular,O
soreness,O
.,O
There,O
were,O
some,O
patients,O
with,O
COVID,O
19,O
",",O
where,O
atypical,O
symptoms,O
like,O
diarrhea,O
and,O
vomiting,O
were,O
also,O
found,O
(,O
Ding,O
",",O
2020,O
;,O
Wang,O
",",O
2020,O
;,O
Zhu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Later,O
on,O
",",O
the,O
International,O
Committee,O
on,O
Taxonomy,O
of,O
Viruses,O
(,O
ICTV,O
),O
officially,O
designated,O
the,O
virus,O
as,O
SARS,O
-,O
CoV-2,O
.,O
WHO,O
on,O
March,O
11,O
",",O
2020,O
",",O
has,O
declared,O
the,O
COVID-19,O
outbreak,O
as,O
a,O
global,O
pandemic,O
(,O
Cucinotta,O
and,O
Vanelli,O
",",O
2020,O
),O
.,O
The,O
SARS,O
-,O
CoV-2,O
isolate,O
with,O
GenBank,S-Repository
 ,O
accession,O
ID,O
‘,O
NC_045512,S-AccessionNumber
’,O
",",O
as,O
downloaded,O
from,O
NCBI,S-Repository
 ,O
(,O
https://www.ncbi.nlm.nih.gov/nuccore/NC_045512,S-URL
),O
was,O
used,O
as,O
the,O
reference,O
strain,O
in,O
this,O
study,O
.,O
The,O
protein,O
sequences,O
of,O
Bat,O
coronavirus,O
RaTG13,O
(,O
GenBank,S-Repository
 ,O
Accession,O
ID,O
MN996532.1,S-AccessionNumber
),O
",",O
Pangolin,O
coronavirus,O
(,O
MT072864.1,S-AccessionNumber
),O
",",O
and,O
two,O
SARS,O
-,O
CoV,O
strains,O
TW11,O
(,O
AY502924.1,S-AccessionNumber
),O
and,O
GD01,O
(,O
AY278489.2,S-AccessionNumber
),O
were,O
downloaded,O
from,O
NCBI,S-Repository
 ,O
(,O
https://www.ncbi.nlm.nih.gov/protein,S-URL
),O
.,O
For,O
this,O
purpose,O
",",O
we,O
have,O
used,O
SWISS,O
-,O
MODEL,O
(,O
https://swissmodel.expasy.org/,O
),O
homology,O
modelling,O
online,O
server,O
with,O
Spike,O
glycoprotein,O
sequence,O
(,O
uniprt_ID,O
:,O
P0DTC2,S-AccessionNumber
),O
and,O
three,O
individual,O
PDBs,S-Repository
 ,O
were,O
used,O
as,O
a,O
template,O
to,O
generate,O
three,O
conformations,O
.,O
Minor,O
(,O
less,O
frequently,O
),O
mutated,O
residues,O
that,O
showed,O
variations,O
in,O
Nextstrain,S-Repository
 ,O
data,O
compared,O
to,O
NCBI,S-Repository
 ,O
virus,O
database,O
were,O
excluded,O
from,O
the,O
analysis,O
.,O
To,O
further,O
validate,O
these,O
findings,O
",",O
we,O
visualized,O
these,O
major,O
substitutions,O
by,O
observing,O
the,O
phylogeny,O
of,O
SARS,O
-,O
CoV-2,O
in,O
Nextstrain,O
",",O
which,O
contains,O
a,O
curated,O
database,O
of,O
more,O
than,O
"10,000",O
SARS,O
-,O
CoV-2,O
sequences,O
",",O
depicted,O
in,O
the,O
form,O
of,O
phylogenetic,O
trees,O
(,O
Fig,O
.,O
2,O
),O
.,O
As,O
observed,O
previously,O
",",O
substitutions,O
at,O
5828th,O
and,O
5865th,O
position,O
co,O
-,O
occurred,O
even,O
in,O
this,O
large,O
sample,O
set,O
of,O
Nextstrain,S-Repository
 ,O
data,O
.,O
Overall,O
",",O
the,O
mutation,O
profile,O
that,O
we,O
identified,O
with,O
664,O
samples,O
showed,O
excellent,O
concordance,O
with,O
the,O
Nextstrain,S-Repository
 ,O
data,O
comprising,O
"~10,000",O
samples,O
.,O
The,O
analysis,O
of,O
the,O
larger,O
Nextstrain,S-Repository
 ,O
dataset,O
indicated,O
that,O
D614,O
G,O
mutation,O
is,O
significantly,O
more,O
prevalent,O
",",O
indeed,O
.,O
Comparing,O
the,O
inert,O
‘,O
DOWN,O
',O
and,O
active,O
‘,O
UP,O
’,O
conformations,O
(,O
PDB,S-Repository
_,O
ID,O
s,O
:,O
6VXX,S-AccessionNumber
 ,O
and,O
6VYB,S-AccessionNumber
 ,O
respectively,O
),O
",",O
it,O
is,O
found,O
that,O
RBD,O
moves,O
as,O
a,O
rigid,O
-,O
body,O
in,O
a,O
hinge,O
bending,O
motion,O
around,O
its,O
linker,O
region,O
with,O
NTD,O
and,O
CTD2,O
with,O
all,O
-,O
atom,O
rmsd,O
for,O
198,O
residues,O
is,O
around,O
2.8,O
 ,O
Å,O
(,O
Fig,O
.,O
3B,O
),O
.,O
Those,O
strains,O
that,O
corresponded,O
to,O
structures,O
with,O
low,O
stabilities,O
were,O
consequently,O
found,O
to,O
have,O
low,O
transmission,O
capabilities,O
as,O
verified,O
in,O
the,O
Nextstrain,S-Repository
 ,O
data,O
.,O
However,O
",",O
considering,O
only,O
the,O
disparity,O
in,O
the,O
effectiveness,O
of,O
transmission,O
among,O
the,O
different,O
spike,O
protein,O
variants,O
",",O
we,O
have,O
two,O
important,O
suggestions,O
to,O
the,O
different,O
nations,O
in,O
tackling,O
and,O
curbing,O
the,O
spread,O
of,O
COVID-19,O
with,O
greater,O
efficacy,O
.,O
First,O
and,O
foremost,O
",",O
the,O
mutational,O
profile,O
of,O
a,O
patient,O
found,O
to,O
be,O
COVID-19,O
positive,O
needs,O
to,O
be,O
analysed,O
",",O
specifically,O
at,O
these,O
key,O
sites,O
of,O
five,O
proteins,O
",",O
either,O
by,O
Sanger,O
sequencing,O
or,O
designing,O
probes,O
corresponding,O
to,O
these,O
regions,O
.,O
However,O
",",O
our,O
hypothesis,O
and,O
interpretation,O
of,O
the,O
mutations,O
show,O
good,O
concordance,O
as,O
evidenced,O
by,O
the,O
Nextstrain,S-Repository
 ,O
data,O
.,O
We,O
have,O
identified,O
frequently,O
mutated,O
residues,O
by,O
aligning,O
~660,O
SARS,O
-,O
CoV-2,O
genomes,O
and,O
validated,O
in,O
"10,000",O
datasets,O
available,O
in,O
GISAID,S-Dataset
 ,O
Nextstrain,S-Repository
.,O
Identification,O
of,O
frequently,O
mutated,O
variants,O
among,O
COVID-19,O
patients,O
might,O
be,O
useful,O
for,O
better,O
clinical,O
management,O
",",O
contact,O
tracing,O
",",O
and,O
containment,O
of,O
the,O
disease,O
.,O
Most,O
people,O
who,O
develop,O
COVID-19,O
after,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
infection,O
present,O
with,O
paucisymptomatic,O
and,O
non,O
-,O
severe,O
disease,O
.,O
However,O
",",O
approximately,O
20,O
%,O
of,O
patients,O
develop,O
severe,O
COVID-19,O
requiring,O
hospitalisation,O
",",O
including,O
5,O
%,O
who,O
are,O
admitted,O
to,O
the,O
intensive,O
care,O
unit,O
(,O
ICU,O
),O
.,O
The,O
ongoing,O
COVID-19,O
outbreak,O
has,O
led,O
to,O
an,O
unprecedented,O
health,O
crisis,O
.,O
Hence,O
",",O
it,O
is,O
crucial,O
to,O
identify,O
individuals,O
who,O
are,O
susceptible,O
to,O
developing,O
severe,O
COVID-19,O
and,O
could,O
require,O
hospitalisation,O
",",O
especially,O
in,O
the,O
ICU,O
.,O
Studies,O
from,O
Chinese,O
cohorts,O
of,O
patients,O
with,O
COVID-19,O
have,O
identified,O
several,O
risk,O
factors,O
of,O
severe,O
COVID-19,O
including,O
age,O
",",O
cardiomyopathy,O
",",O
and,O
obesity,O
-,O
related,O
complications,O
such,O
as,O
type,O
2,O
diabetes,O
and,O
hypertension,O
.,O
However,O
",",O
to,O
our,O
knowledge,O
",",O
only,O
few,O
studies,O
so,O
far,O
have,O
included,O
information,O
regarding,O
the,O
BMI,O
of,O
patients,O
with,O
COVID-19,O
",",O
which,O
suggest,O
a,O
high,O
prevalence,O
of,O
obesity,O
in,O
patients,O
with,O
severe,O
COVID-19.4,O
",",O
5,O
",",O
6,O
",",O
7,O
Data,O
from,O
New,O
York,O
City,O
suggest,O
that,O
obesity,O
",",O
as,O
defined,O
by,O
BMI,O
of,O
at,O
least,O
30,O
kg,O
/,O
m2,O
",",O
might,O
be,O
a,O
risk,O
factor,O
for,O
ICU,O
admission,O
among,O
patients,O
with,O
COVID-19,O
",",O
especially,O
among,O
those,O
younger,O
than,O
60,O
years,O
.,O
Additionally,O
",",O
preliminary,O
analyses,O
from,O
Lille,O
University,O
Hospital,O
have,O
reported,O
differences,O
in,O
BMI,O
distribution,O
in,O
ICU,O
patients,O
with,O
COVID-19,O
compared,O
with,O
ICU,O
patients,O
without,O
COVID-19,O
.,O
On,O
March,O
27,O
",",O
2020,O
",",O
357,O
patients,O
were,O
hospitalised,O
in,O
Lyon,O
University,O
Hospital,O
with,O
COVID-19,O
",",O
of,O
whom,O
17,O
patients,O
had,O
no,O
data,O
on,O
BMI,O
(,O
appendix,O
p,O
5,O
),O
.,O
340,O
patients,O
with,O
confirmed,O
",",O
severe,O
COVID-19,O
were,O
included,O
in,O
our,O
population,O
",",O
including,O
230,O
(,O
68,O
%,O
),O
patients,O
with,O
non,O
-,O
critical,O
COVID-19,O
and,O
110,O
(,O
32,O
%,O
),O
patients,O
with,O
critical,O
COVID-19,O
(,O
appendix,O
p,O
5,O
),O
.,O
Our,O
retrospective,O
non,O
-,O
COVID-19,O
ICU,O
comparison,O
group,O
included,O
1210,O
patients,O
with,O
BMI,O
values,O
admitted,O
to,O
ICU,O
units,O
in,O
Lyon,O
University,O
Hospital,O
on,O
March,O
27,O
each,O
year,O
between,O
2007,O
and,O
2019,O
(,O
appendix,O
p,O
5,O
),O
.,O
85,O
(,O
25,O
%,O
),O
of,O
340,O
patients,O
with,O
severe,O
COVID-19,O
had,O
obesity,O
",",O
compared,O
with,O
15·3,O
%,O
in,O
the,O
French,O
adult,O
population,O
in,O
2014,O
(,O
appendix,O
p,O
8),O
.,O
After,O
standardisation,O
on,O
age,O
and,O
sex,O
",",O
the,O
prevalence,O
of,O
obesity,O
was,O
1·35,O
times,O
(,O
95,O
%,O
CI,O
1·08–1·66,O
),O
higher,O
in,O
patients,O
with,O
severe,O
COVID-19,O
than,O
in,O
the,O
general,O
French,O
population,O
(,O
p=0·0034,O
;,O
figure,O
1,O
;,O
appendix,O
pp,O
6–8,O
),O
.,O
In,O
multivariable,O
logistic,O
regression,O
adjusted,O
for,O
age,O
and,O
sex,O
",",O
the,O
prevalence,O
of,O
obesity,O
remained,O
higher,O
in,O
patients,O
with,O
critical,O
COVID-19,O
than,O
in,O
those,O
with,O
non,O
-,O
critical,O
COVID-19,O
(,O
OR,O
1·96,O
[,O
95,O
%,O
CI,O
1·13–3·42,O
],O
;,O
p=0·018,O
;,O
appendix,O
pp,O
7–8,O
),O
.,O
Among,O
the,O
1210,O
patients,O
in,O
our,O
retrospective,O
ICU,O
non,O
-,O
COVID-19,O
comparison,O
group,O
",",O
314,O
(,O
26,O
%,O
),O
patients,O
had,O
obesity,O
(,O
appendix,O
p,O
9,O
),O
.,O
The,O
prevalence,O
of,O
obesity,O
was,O
numerically,O
higher,O
in,O
patients,O
with,O
critical,O
COVID-19,O
than,O
in,O
ICU,O
patients,O
without,O
COVID-19,O
(,O
p=0·066,O
;,O
appendix,O
p,O
9,O
),O
.,O
After,O
adjustment,O
for,O
age,O
and,O
sex,O
",",O
odds,O
of,O
obesity,O
were,O
significantly,O
higher,O
in,O
patients,O
with,O
critical,O
COVID-19,O
(,O
OR,O
1·69,O
[,O
95,O
%,O
CI,O
1·10–2·56,O
],O
;,O
p=0·017,O
;,O
figure,O
2A,O
),O
.,O
Our,O
findings,O
are,O
in,O
agreement,O
with,O
preliminary,O
findings,O
from,O
a,O
population,O
comprising,O
124,O
patients,O
with,O
critical,O
COVID-19,O
and,O
306,O
ICU,O
patients,O
without,O
COVID-19,O
from,O
Lille,O
University,O
Hospital,O
(,O
appendix,O
p,O
5,O
),O
.,O
As,O
observed,O
in,O
the,O
Lyon,O
population,O
",",O
the,O
prevalence,O
of,O
obesity,O
in,O
patients,O
with,O
critical,O
COVID-19,O
in,O
the,O
Lille,O
population,O
was,O
2·88,O
times,O
(,O
95,O
%,O
CI,O
2·19–3·66,O
),O
higher,O
than,O
in,O
the,O
French,O
general,O
population,O
after,O
standardisation,O
on,O
age,O
and,O
sex,O
(,O
p<0·0001,O
;,O
figure,O
1,O
;,O
appendix,O
p,O
6,O
),O
.,O
Among,O
the,O
306,O
ICU,O
patients,O
in,O
the,O
Lille,O
population,O
without,O
COVID-19,O
",",O
79,O
(,O
26,O
%,O
),O
had,O
obesity,O
.,O
The,O
prevalence,O
of,O
obesity,O
was,O
higher,O
in,O
patients,O
with,O
critical,O
COVID-19,O
than,O
in,O
ICU,O
patients,O
without,O
COVID-19,O
(,O
p<0·0001,O
;,O
appendix,O
p,O
9,O
),O
.,O
The,O
prevalence,O
of,O
obesity,O
in,O
patients,O
with,O
critical,O
COVID-19,O
was,O
higher,O
than,O
in,O
ICU,O
patients,O
without,O
COVID-19,O
in,O
the,O
Lille,O
population,O
(,O
OR,O
2·86,O
[,O
95,O
%,O
CI,O
1·78–4·61,O
],O
;,O
p=0·017,O
;,O
figure,O
2B,O
),O
after,O
standardisation,O
on,O
age,O
and,O
sex,O
.,O
Finally,O
",",O
in,O
exploratory,O
analyses,O
",",O
we,O
looked,O
at,O
whether,O
specific,O
risk,O
factors,O
other,O
than,O
obesity,O
were,O
associated,O
with,O
critical,O
COVID-19,O
versus,O
non,O
-,O
critical,O
COVID-19,O
in,O
univariable,O
analyses,O
(,O
appendix,O
pp,O
9–10,O
),O
.,O
In,O
multivariable,O
analyses,O
",",O
odds,O
of,O
critical,O
COVID-19,O
versus,O
non,O
-,O
critical,O
COVID-19,O
were,O
higher,O
in,O
patients,O
with,O
obesity,O
than,O
in,O
patients,O
without,O
obesity,O
when,O
adjusted,O
for,O
age,O
and,O
sex,O
(,O
appendix,O
p,O
9,O
),O
.,O
This,O
study,O
reports,O
a,O
significant,O
association,O
between,O
the,O
prevalence,O
of,O
obesity,O
and,O
severe,O
COVID-19,O
",",O
including,O
critical,O
COVID-19,O
",",O
and,O
suggests,O
that,O
obesity,O
might,O
be,O
a,O
risk,O
factor,O
of,O
pejorative,O
evolution,O
of,O
COVID-19,O
",",O
increasing,O
the,O
risk,O
of,O
ICU,O
admission,O
.,O
Preliminary,O
analyses,O
from,O
Lille,O
University,O
Hospital,O
",",O
using,O
the,O
same,O
cohort,O
of,O
patients,O
",",O
have,O
also,O
reported,O
a,O
higher,O
prevalence,O
of,O
invasive,O
mechanical,O
intubation,O
in,O
male,O
patients,O
and,O
those,O
with,O
higher,O
BMI,O
",",O
especially,O
at,O
least,O
35,O
kg,O
/,O
m2,O
in,O
ICU,O
patients,O
with,O
COVID-19,O
.,O
Our,O
study,O
helps,O
to,O
fill,O
this,O
gap,O
in,O
knowledge,O
by,O
providing,O
evidence,O
of,O
a,O
higher,O
prevalence,O
of,O
obesity,O
among,O
patients,O
with,O
severe,O
COVID-19,O
",",O
especially,O
those,O
admitted,O
to,O
the,O
ICU,O
.,O
We,O
acknowledge,O
that,O
the,O
findings,O
in,O
our,O
study,O
might,O
not,O
be,O
generalised,O
to,O
other,O
centres,O
depending,O
on,O
the,O
clinical,O
algorithm,O
implemented,O
for,O
ICU,O
admission,O
and,O
ICU,O
capacity,O
and,O
recommendations,O
for,O
the,O
intensive,O
care,O
management,O
of,O
COVID-19,O
should,O
be,O
considered,O
in,O
future,O
research,O
.,O
Finally,O
",",O
the,O
comparison,O
of,O
the,O
prevalence,O
of,O
obesity,O
with,O
the,O
general,O
population,O
is,O
based,O
only,O
on,O
our,O
sample,O
of,O
patients,O
with,O
COVID-19,O
",",O
and,O
a,O
population,O
-,O
based,O
study,O
would,O
be,O
needed,O
to,O
precisely,O
assess,O
the,O
demographics,O
of,O
patients,O
with,O
COVID-19,O
with,O
respect,O
to,O
the,O
general,O
population,O
.,O
Emerging,O
in,O
late,O
2019,O
",",O
the,O
novel,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
caused,O
by,O
SARS,O
-,O
CoV-2,O
has,O
disseminated,O
rapidly,O
around,O
the,O
globe,O
and,O
has,O
been,O
declared,O
a,O
pandemic,O
[,O
"5,6",O
],O
.,O
After,O
initially,O
optimizing,O
the,O
hydrolysis,O
probe,O
-,O
based,O
version,O
of,O
the,O
assay,O
to,O
show,O
that,O
it,O
reached,O
the,O
sensitivity,O
of,O
our,O
previously,O
published,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
(,O
data,O
not,O
shown,O
),O
",",O
we,O
used,O
only,O
the,O
primers,O
(,O
nsp2f,O
:,O
5′-ATGCATTTGCATCAGAGGCT-3′,O
",",O
nsp2r,O
:,O
5′-TTGTTATAGCGGCCTTCTGT-3′,O
),O
",",O
to,O
develop,O
the,O
subsequent,O
probe,O
-,O
free,O
",",O
COVID-19,O
-,O
nsp2,O
real,O
-,O
time,O
RT,O
-,O
PCR,O
assay,O
.,O
To,O
determine,O
the,O
analytical,O
sensitivity,O
of,O
the,O
COVID-19,O
-,O
nsp2,O
assay,O
",",O
the,O
limit,O
of,O
detection,O
(,O
LOD,O
),O
was,O
evaluated,O
by,O
using,O
viral,O
genomic,O
RNA,O
extracted,O
from,O
a,O
culture,O
isolate,O
of,O
SARS,O
-,O
CoV-2,O
.,O
The,O
LOD,O
of,O
the,O
COVID-19,O
-,O
nsp2,O
assay,O
was,O
1.8,O
TCID50,O
/,O
mL,O
(,O
Table,O
2,O
),O
.,O
Using,O
TNA,O
extracted,O
from,O
SARS,O
-,O
CoV-2,O
isolate,O
at,O
different,O
concentrations,O
",",O
the,O
new,O
COVID-19,O
-,O
nsp2,O
assay,O
was,O
performed,O
in,O
triplicate,O
for,O
each,O
concentration,O
to,O
evaluate,O
the,O
intra-,O
and,O
inter,O
-,O
assay,O
variations,O
.,O
To,O
evaluate,O
the,O
diagnostic,O
performance,O
of,O
the,O
assay,O
",",O
59,O
clinical,O
specimens,O
(,O
23,O
positive,O
and,O
36,O
negative,O
),O
from,O
14,O
confirmed,O
cases,O
(,O
defined,O
as,O
at,O
least,O
one,O
respiratory,O
specimen,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
by,O
our,O
previously,O
established,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
),O
[,O
24,O
],O
were,O
used,O
.,O
Twenty,O
-,O
three,O
were,O
positive,O
(,O
including,O
22,O
respiratory,O
specimens,O
and,O
1,O
stool,O
specimen,O
",",O
with,O
Cp,O
values,O
ranged,O
from,O
18.69,O
to,O
36.21,O
),O
and,O
36,O
were,O
negative,O
(,O
including,O
four,O
respiratory,O
and,O
32,O
non,O
-,O
respiratory,O
specimens,O
),O
by,O
the,O
COVID-19,O
-,O
nsp2,O
assay,O
.,O
The,O
melting,O
curve,O
from,O
COVID-19,O
-,O
nsp2,O
-,O
positive,O
specimens,O
showed,O
a,O
unique,O
peak,O
with,O
the,O
melting,O
temperature,O
of,O
around,O
80,O
°,O
C,O
.,O
The,O
results,O
from,O
the,O
two,O
assays,O
were,O
100,O
%,O
concordant,O
",",O
and,O
no,O
additional,O
positive,O
result,O
was,O
detected,O
from,O
the,O
specimens,O
previously,O
tested,O
negative,O
by,O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
.,O
Early,O
in,O
the,O
COVID-19,O
outbreak,O
",",O
when,O
the,O
virus,O
was,O
reported,O
to,O
be,O
related,O
to,O
the,O
SARS,O
-,O
CoV,O
and,O
the,O
exact,O
genomic,O
variation,O
of,O
the,O
virus,O
was,O
not,O
adequately,O
known,O
[,O
25,O
],O
",",O
multiple,O
groups,O
developed,O
and,O
published,O
assays,O
based,O
on,O
conserved,O
regions,O
that,O
could,O
potentially,O
detect,O
additional,O
coronaviruses,O
[,O
"26,27",O
],O
(,O
see,O
also,O
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance,O
),O
.,O
In,O
the,O
present,O
study,O
",",O
we,O
demonstrated,O
that,O
the,O
diagnostic,O
performance,O
of,O
the,O
hydrolysis,O
probe,O
-,O
free,O
COVID-19,O
-,O
nsp2,O
assay,O
was,O
comparable,O
to,O
that,O
of,O
our,O
previously,O
developed,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
[,O
24,O
],O
.,O
The,O
current,O
nsp2,O
assay,O
was,O
highly,O
specific,O
(,O
without,O
cross,O
-,O
reaction,O
with,O
other,O
common,O
respiratory,O
viruses,O
),O
and,O
comparable,O
to,O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
in,O
terms,O
of,O
analytical,O
sensitivity,O
.,O
The,O
diagnostic,O
sensitivity,O
and,O
specificity,O
of,O
the,O
nsp2,O
assay,O
was,O
100,O
%,O
in,O
comparison,O
with,O
the,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
in,O
this,O
study,O
.,O
Furthermore,O
",",O
the,O
PCR,O
reaction,O
time,O
of,O
the,O
nsp2,O
assay,O
was,O
within,O
an,O
hour,O
",",O
which,O
is,O
shorter,O
than,O
that,O
of,O
the,O
previously,O
developed,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
[,O
24,O
],O
;,O
this,O
is,O
a,O
distinct,O
advantage,O
in,O
clinical,O
laboratories,O
",",O
as,O
rapid,O
results,O
can,O
facilitate,O
the,O
timely,O
triage,O
of,O
suspected,O
COVID-19,O
cases,O
and,O
guide,O
infection,O
control,O
and,O
patient,O
management,O
.,O
As,O
COVID-19,O
unfolded,O
into,O
a,O
pandemic,O
",",O
rapid,O
",",O
robust,O
and,O
sensitive,O
diagnostic,O
testing,O
became,O
a,O
priority,O
in,O
containment,O
-,O
based,O
control,O
strategies,O
.,O
As,O
nucleic,O
acid,O
amplification,O
-,O
based,O
testing,O
allows,O
exquisite,O
sensitivity,O
(,O
1.8,O
TCID50,O
/,O
mL,O
in,O
our,O
case,O
),O
and,O
can,O
be,O
readily,O
adopted,O
in,O
laboratories,O
with,O
basic,O
molecular,O
facilities,O
",",O
it,O
is,O
an,O
essential,O
tool,O
in,O
the,O
clinical,O
management,O
and,O
triage,O
of,O
patients,O
.,O
The,O
robust,O
design,O
of,O
the,O
optimized,O
assay,O
",",O
requiring,O
only,O
one,O
pair,O
of,O
SARS,O
-,O
CoV-2,O
-,O
specific,O
primers,O
to,O
diagnose,O
COVID-19,O
infection,O
in,O
humans,O
",",O
avoids,O
the,O
potential,O
logistics,O
",",O
reagent,O
and,O
manpower,O
constraints,O
in,O
performing,O
multiple,O
or,O
cascade,O
testing,O
or,O
the,O
use,O
of,O
relatively,O
costly,O
reporter,O
probes,O
.,O
Using,O
the,O
software,O
tool,O
",",O
degenerate,O
bases,O
may,O
be,O
strategically,O
incorporated,O
into,O
the,O
COVID-19,O
-,O
nsp2,O
assay,O
primers,O
to,O
broaden,O
the,O
specificity,O
",",O
or,O
additional,O
targets,O
may,O
be,O
iteratively,O
identified,O
from,O
further,O
coronavirus,O
pan,O
-,O
genome,O
analyses,O
.,O
The,O
GolayMetaMiner,O
software,O
first,O
downloads,O
the,O
genomes,O
of,O
the,O
target,O
and,O
non,O
-,O
target,O
species,O
from,O
the,O
NCBI,S-Repository
 ,O
nucleotide,O
database,O
and,O
generates,O
a,O
pool,O
of,O
nucleotide,O
k,O
-,O
mers,O
(,O
k,O
=,O
12,O
by,O
default,O
),O
for,O
both,O
forward,O
and,O
reverse,O
directions,O
of,O
the,O
non,O
-,O
target,O
genomes,O
.,O
The,O
longer,O
of,O
the,O
two,O
SARS,O
-,O
CoV-2,O
genomes,O
sequenced,O
by,O
our,O
group,O
[,O
23,O
],O
",",O
HKU,O
-,O
SZ-005b,O
",",O
was,O
used,O
as,O
the,O
reference,O
genome,O
(,O
--primary_target,O
MN975262,S-AccessionNumber
),O
",",O
and,O
a,O
list,O
of,O
accession,O
numbers,O
of,O
publicly,O
available,O
SARS,O
-,O
CoV-2,O
genomes,O
were,O
used,O
as,O
secondary,O
targets,O
(,O
--secondary_target_list,O
SARS-CoV-2_genomes.txt,O
),O
;,O
the,O
accession,O
number,O
of,O
the,O
reference,O
genome,O
was,O
manually,O
commented,O
out,O
with,O
a,O
“,O
#,O
”,O
to,O
avoid,O
double,O
-,O
counting,O
the,O
reference,O
genome,O
in,O
estimating,O
conservedness,O
.,O
The,O
lists,O
of,O
accession,O
numbers,O
of,O
the,O
96,O
SARS,O
-,O
CoV-2,O
and,O
104,O
non,O
-,O
SARS,O
-,O
CoV-2,O
coronavirus,O
genomes,O
are,O
available,O
in,O
Supplementary,O
Materials,O
.,O
SARS,O
-,O
CoV-2,O
was,O
isolated,O
from,O
the,O
nasopharyngeal,O
aspirate,O
specimen,O
of,O
a,O
laboratory,O
-,O
confirmed,O
COVID-19,O
patient,O
in,O
Hong,O
Kong,O
as,O
previously,O
described,O
[,O
42,O
],O
.,O
The,O
viral,O
isolate,O
stock,O
(,O
1.8,O
×,O
107,O
50,O
%,O
tissue,O
culture,O
infective,O
doses,O
[,O
TCID50]/mL,O
),O
was,O
prepared,O
using,O
VeroE6,O
cells,O
as,O
previously,O
described,O
[,O
"20,24,43",O
],O
.,O
For,O
assay,O
performance,O
evaluation,O
",",O
59,O
archived,O
clinical,O
specimens,O
(,O
26,O
respiratory,O
specimens,O
including,O
nasopharyngeal,O
aspirate,O
/,O
swab,O
",",O
throat,O
swab,O
",",O
endotracheal,O
aspirate,O
",",O
sputum,O
and,O
saliva,O
",",O
and,O
33,O
non,O
-,O
respiratory,O
specimens,O
including,O
plasma,O
",",O
urine,O
",",O
rectal,O
swab,O
/,O
stool,O
),O
from,O
14,O
patients,O
with,O
laboratory,O
-,O
confirmed,O
COVID-19,O
were,O
used,O
[,O
24,O
],O
.,O
These,O
specimens,O
were,O
evaluated,O
previously,O
using,O
the,O
established,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
assay,O
[,O
24,O
],O
.,O
The,O
pandemic,O
novel,O
coronavirus,O
infection,O
",",O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
",",O
has,O
affected,O
at,O
least,O
190,O
countries,O
or,O
territories,O
",",O
with,O
"465,915",O
confirmed,O
cases,O
and,O
"21,031",O
deaths,O
.,O
The,O
new,O
COVID-19,O
-,O
nsp2,O
assay,O
had,O
a,O
limit,O
of,O
detection,O
(,O
LOD,O
),O
of,O
1.8,O
TCID,O
50,O
/mL,O
and,O
did,O
not,O
amplify,O
other,O
human,O
-,O
pathogenic,O
coronaviruses,O
and,O
respiratory,O
viruses,O
.,O
Evaluation,O
of,O
the,O
new,O
assay,O
using,O
59,O
clinical,O
specimens,O
from,O
14,O
confirmed,O
cases,O
showed,O
100,O
%,O
concordance,O
with,O
our,O
previously,O
developed,O
COVID-19,O
-,O
RdRp,O
/,O
Hel,O
reference,O
assay,O
.,O
A,O
rapid,O
",",O
sensitive,O
",",O
SARS,O
-,O
CoV-2,O
-,O
specific,O
real,O
-,O
time,O
RT,O
-,O
PCR,O
assay,O
",",O
COVID-19,O
-,O
nsp2,O
",",O
was,O
developed,O
.,O
ALV,O
has,O
experienced,O
substantial,O
clinical,O
testing,O
and,O
safety,O
database,O
development,O
with,O
more,O
than,O
2000,O
patients,O
treated,O
for,O
up,O
to,O
48,O
weeks,O
.,O
This,O
was,O
supported,O
by,O
a,O
spectrometric,O
profiling,O
study,O
showing,O
the,O
incorporation,O
of,O
CypA,O
into,O
SARS,O
-,O
CoV,O
virions,O
(,O
Neuman,O
et,O
 ,O
al,O
.,O
",",O
2008,O
),O
.,O
With,O
the,O
current,O
outbreak,O
of,O
coronavirus,O
disease-2019,O
(,O
COVID-19,O
),O
[,O
1,O
],O
",",O
debates,O
are,O
taking,O
place,O
around,O
the,O
consequences,O
this,O
pandemic,O
would,O
have,O
on,O
different,O
aspects,O
of,O
the,O
human,O
health,O
including,O
obesity,O
.,O
During,O
this,O
critical,O
period,O
of,O
COVID-19,O
pandemic,O
",",O
the,O
mental,O
health,O
is,O
among,O
what,O
health,O
professionals,O
are,O
most,O
concerned,O
about,O
.,O
Within,O
the,O
context,O
of,O
diet,O
choice,O
",",O
the,O
socioeconomic,O
crisis,O
expected,O
to,O
develop,O
during,O
and,O
after,O
the,O
current,O
COVID-19,O
crisis,O
[,O
18,O
],O
",",O
[,O
19,O
],O
would,O
lead,O
to,O
inflation,O
of,O
different,O
products,O
prices,O
.,O
Moreover,O
",",O
patients,O
who,O
get,O
the,O
respiratory,O
illness,O
of,O
COVID-19,O
might,O
have,O
reduced,O
lung,O
function,O
[,O
21,O
],O
",",O
[,O
22,O
],O
(,O
possibly,O
even,O
after,O
they,O
recover,O
),O
",",O
which,O
would,O
limit,O
their,O
ability,O
to,O
perform,O
physical,O
activity,O
due,O
to,O
the,O
respiratory,O
failure,O
.,O
Herein,O
",",O
we,O
have,O
illustrated,O
how,O
selected,O
COVID-19,O
pandemic,O
-,O
related,O
concepts,O
do,O
increase,O
obesity,O
risk,O
and,O
therefore,O
multiple,O
obesity,O
-,O
related,O
morbidities,O
including,O
cardiovascular,O
diseases,O
",",O
diabetes,O
",",O
etc,O
[,O
23,O
],O
.,O
Obesity,O
and,O
those,O
morbidities,O
resulting,O
from,O
measures,O
implemented,O
to,O
prevent,O
COVID-19,O
spread,O
and,O
limit,O
its,O
mortality,O
would,O
",",O
ironically,O
",",O
make,O
the,O
individuals,O
more,O
vulnerable,O
to,O
COVID-19,O
[,O
24,O
],O
.,O
Importantly,O
",",O
it,O
is,O
of,O
an,O
extreme,O
importance,O
to,O
make,O
sure,O
we,O
do,O
not,O
replace,O
COVID-19,O
pandemic,O
with,O
another,O
pandemic(s,O
),O
such,O
as,O
obesity,O
which,O
is,O
already,O
epidemic,O
[,O
25,O
],O
.,O
A,O
novel,O
coronavirus,O
(,O
CoV,O
),O
",",O
designated,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS)-CoV-2,O
",",O
underlies,O
a,O
pandemic,O
infection,O
",",O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
which,O
rapidly,O
spread,O
globally,O
and,O
has,O
been,O
proclaimed,O
a,O
severe,O
public,O
health,O
emergency,O
of,O
international,O
concern,O
(,O
PHEIC,O
),O
by,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
(,O
Wang,O
et,O
 ,O
al,O
.,O
",",O
2020a,O
),O
.,O
By,O
June,O
30,O
",",O
2020,O
",",O
more,O
than,O
200,O
countries,O
and,O
territories,O
reported,O
COVID-19,O
infections,O
",",O
together,O
comprising,O
"10,185,374",O
confirmed,O
cases,O
and,O
"503,862",O
 ,O
deaths,O
(,O
data,O
from,O
WHO,S-Creator
",",O
the,O
Centers,B-Creator
for,I-Creator
Disease,I-Creator
Control,I-Creator
and,I-Creator
Prevention,I-Creator
[CDC],E-Creator
",",O
and,O
the,O
European,B-Creator
Centre,I-Creator
for,I-Creator
Disease,I-Creator
Prevention,I-Creator
and,I-Creator
Control,I-Creator
[ECDC],E-Creator
 ,O
are,O
at,O
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports,S-URL
),O
.,O
After,O
COVID-19,O
diagnosis,O
",",O
other,O
symptoms,O
can,O
be,O
detected,O
by,O
routine,O
blood,O
examination,O
.,O
The,O
neutrophils,O
in,O
38,O
%,O
of,O
COVID-19,O
patients,O
were,O
above,O
the,O
normal,O
range,O
",",O
while,O
the,O
hemoglobin,O
in,O
51,O
%,O
COVID-19,O
patients,O
lies,O
below,O
the,O
normal,O
range,O
",",O
according,O
to,O
research,O
at,O
the,O
Jinyintan,O
Hospital,O
in,O
Wuhan,O
",",O
China,O
.,O
In,O
addition,O
",",O
lymphocyte,O
levels,O
decreased,O
in,O
35,O
%,O
of,O
patients,O
(,O
Chen,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
",",O
suggesting,O
possible,O
dysfunctional,O
cell,O
-,O
mediated,O
immunity,O
in,O
COVID-19,O
patients,O
.,O
It,O
has,O
been,O
reported,O
that,O
interleukin-6,O
(,O
IL-6,O
),O
concentrations,O
and,O
ferritin,O
increase,O
with,O
illness,O
deterioration,O
in,O
non,O
-,O
survivors,O
compared,O
with,O
survivors,O
within,O
a,O
subgroup,O
of,O
patients,O
with,O
COVID-19,O
(,O
Zhou,O
et,O
 ,O
al,O
.,O
",",O
2020a,O
),O
.,O
To,O
investigate,O
the,O
pathogenesis,O
and,O
mechanism,O
of,O
SARS,O
-,O
CoV-2,O
infections,O
in,O
COVID-19,O
patients,O
",",O
blood,O
samples,O
were,O
collected,O
from,O
three,O
healthy,O
controls,O
",",O
two,O
IAV,O
-,O
infected,O
patients,O
",",O
and,O
five,O
COVID-19,O
patients,O
",",O
including,O
four,O
patients,O
(,O
COV-1,O
to,O
COV-4,O
),O
with,O
uncomplicated,O
disease,O
courses,O
and,O
one,O
patient,O
(,O
COV-5,O
),O
that,O
subsequently,O
progressed,O
to,O
severe,O
disease,O
(,O
Figure,O
 ,O
1,O
A,O
;,O
Table,O
S1,O
),O
.,O
However,O
",",O
COVID-19,O
has,O
distinct,O
clinical,O
signatures,O
compared,O
to,O
IAV,O
infections,O
",",O
including,O
high,O
morbidity,O
and,O
mortality,O
.,O
COVID-19,O
patients,O
were,O
enrolled,O
within,O
5–10,O
 ,O
days,O
of,O
symptom,O
onset,O
based,O
on,O
positive,O
nucleic,O
acid,O
testing,O
results,O
",",O
and,O
the,O
day,O
when,O
PBMCs,O
were,O
first,O
collected,O
was,O
named,O
day,O
1,O
.,O
After,O
filtering,O
out,O
cells,O
with,O
low,O
quality,O
",",O
we,O
obtained,O
transcriptome,O
datasets,O
from,O
"46,022",O
cells,O
with,O
an,O
average,O
of,O
"2,000",O
cells,O
for,O
each,O
participant,O
at,O
each,O
time,O
point,O
(,O
Figure,O
 ,O
1B,O
),O
.,O
To,O
uncover,O
immune,O
cell,O
populations,O
in,O
COVID-19,O
",",O
we,O
performed,O
unsupervised,O
clustering,O
and,O
obtained,O
15,O
cell,O
populations,O
(,O
Figure,O
 ,O
1C,O
),O
.,O
The,O
proportion,O
of,O
plasma,O
cells,O
and,O
cycling,O
plasma,O
cells,O
were,O
increased,O
significantly,O
in,O
both,O
COVID-19-,O
and,O
IAV,O
-,O
infected,O
patients,O
(,O
Figures,O
2B,O
and,O
S2,O
),O
",",O
and,O
there,O
was,O
no,O
difference,O
between,O
these,O
two,O
types,O
of,O
virus,O
infection,O
.,O
As,O
expected,O
",",O
when,O
examining,O
the,O
functions,O
of,O
upregulated,O
genes,O
in,O
B,O
cells,O
of,O
COVID-19,O
patients,O
compared,O
with,O
healthy,O
donors,O
",",O
protein,O
complex,O
assembly,O
and,O
protein,O
-,O
transport,O
-,O
related,O
pathways,O
were,O
especially,O
enriched,O
",",O
which,O
may,O
be,O
because,O
a,O
large,O
number,O
of,O
proteins,O
are,O
synthesized,O
during,O
this,O
process,O
(,O
Figure,O
 ,O
2C,O
),O
.,O
T,O
 ,O
cells,O
of,O
COVID-19,O
(,O
Figure,O
 ,O
2E,O
),O
.,O
Taken,O
together,O
",",O
these,O
results,O
demonstrated,O
that,O
elevated,O
plasma,O
cells,O
and,O
increased,O
activation,O
of,O
T,O
 ,O
cells,O
and,O
NK,O
cells,O
in,O
COVID-19,O
patients,O
may,O
contribute,O
to,O
defense,O
against,O
the,O
virus,O
.,O
Gene,O
Ontology,O
(,O
GO,O
),O
analyses,O
were,O
performed,O
to,O
gain,O
insight,O
into,O
functions,O
of,O
different,O
cell,O
subsets,O
between,O
COVID-19,O
patients,O
and,O
healthy,O
controls,O
.,O
Consistently,O
",",O
“,O
defense,O
response,O
to,O
virus,O
signaling,O
”,O
genes,O
were,O
also,O
enriched,O
in,O
T,O
",",O
B,O
",",O
and,O
NK,O
cells,O
of,O
all,O
five,O
COVID-19,O
patients,O
on,O
D1,O
and,O
D4,O
",",O
but,O
not,O
D16,O
(,O
Figures,O
3A,O
and,O
S3A,O
),O
",",O
implying,O
an,O
ongoing,O
immune,O
response,O
against,O
SARS,O
-,O
CoV-2,O
virus,O
.,O
Differentially,O
expressed,O
genes,O
(,O
DEGs,O
),O
in,O
these,O
transcriptomic,O
profiles,O
were,O
then,O
compared,O
between,O
COVID-19,O
patients,O
and,O
healthy,O
controls,O
.,O
The,O
expression,O
of,O
these,O
four,O
genes,O
was,O
also,O
much,O
higher,O
in,O
COVID-19,O
patients,O
compared,O
to,O
healthy,O
controls,O
at,O
the,O
bulk,O
level,O
(,O
Figure,O
 ,O
3C,O
),O
.,O
To,O
achieve,O
this,O
",",O
we,O
divided,O
the,O
disease,O
processes,O
of,O
COVID-19,O
patients,O
from,O
symptom,O
onset,O
to,O
discharge,O
into,O
four,O
stages,O
(,O
Table,O
S3,O
),O
.,O
Expression,O
of,O
IRF1,O
",",O
TP53,O
",",O
and,O
CASP3,O
was,O
increased,O
in,O
T,O
",",O
B,O
",",O
and,O
NK,O
cell,O
subsets,O
in,O
COVID-19,O
patients,O
compared,O
to,O
controls,O
",",O
while,O
BCL2L11,O
exhibited,O
different,O
patterns,O
in,O
different,O
cell,O
subsets,O
.,O
In,O
addition,O
to,O
the,O
XAF1,O
related,O
apoptosis,O
pathway,O
",",O
expression,O
of,O
genes,O
in,O
other,O
apoptosis,O
-,O
linked,O
pathways,O
",",O
including,O
TNF,O
and,O
Fas,O
pathways,O
(,O
Elmore,O
",",O
2007,O
),O
",",O
was,O
examined,O
in,O
both,O
COVID-19,O
patients,O
and,O
healthy,O
controls,O
(,O
Figures,O
3F,O
and,O
S3E,O
),O
.,O
The,O
expression,O
of,O
TNFSF10,O
(,O
TRAIL,O
),O
and,O
its,O
receptor,O
TNFRSF10A,O
were,O
increased,O
in,O
T,O
 ,O
cells,O
from,O
COVID-19,O
patients,O
relative,O
to,O
healthy,O
controls,O
.,O
Other,O
TNF,O
path,O
members,O
",",O
including,O
TNFRSF1B,O
",",O
were,O
also,O
relatively,O
upregulated,O
in,O
COVID-19,O
patients,O
.,O
As,O
for,O
the,O
FAS,O
path,O
",",O
the,O
expression,O
of,O
FAS,O
",",O
FASLG,O
",",O
and,O
FADD,O
were,O
upregulated,O
in,O
T,O
 ,O
cells,O
of,O
COVID-19,O
patients,O
",",O
though,O
not,O
significantly,O
(,O
Figure,O
 ,O
3F,O
),O
.,O
In,O
B,O
and,O
NK,O
cell,O
subsets,O
",",O
TNFSF10,O
and,O
FADD,O
were,O
notably,O
increased,O
in,O
COVID-19,O
patients,O
with,O
other,O
genes,O
increased,O
mildly,O
",",O
except,O
that,O
Fas,O
in,O
B,O
cells,O
and,O
TRADD,O
in,O
NK,O
cells,O
were,O
subtly,O
decreased,O
(,O
Figure,O
 ,O
S3E,O
),O
.,O
Taken,O
together,O
",",O
we,O
find,O
that,O
upregulated,O
genes,O
relevant,O
to,O
the,O
XAF1,O
",",O
TNF,O
",",O
and,O
Fas,O
pathways,O
may,O
lead,O
to,O
increased,O
T,O
 ,O
cell,O
apoptosis,O
in,O
COVID-19,O
patients,O
.,O
Next,O
",",O
we,O
sought,O
to,O
identify,O
the,O
immune,O
molecular,O
signatures,O
associated,O
with,O
COVID-19,O
and,O
IAV,O
infection,O
.,O
Thus,O
",",O
we,O
compared,O
the,O
expression,O
of,O
cytokines,O
",",O
cytokine,O
receptors,O
",",O
and,O
transcription,O
factors,O
in,O
T,O
 ,O
cell,O
subsets,O
",",O
NK,O
cells,O
",",O
and,O
DCs,O
among,O
COVID-19,O
patients,O
",",O
IAV,O
patients,O
",",O
and,O
healthy,O
controls,O
(,O
Figures,O
4,O
A,O
and,O
S4A,O
),O
.,O
As,O
the,O
gene,O
clustering,O
pattern,O
suggested,O
",",O
upregulated,O
genes,O
in,O
COVID-19,O
patients,O
mostly,O
encode,O
proinflammatory,O
cytokines,O
",",O
cytokine,O
receptors,O
",",O
and,O
IFN,O
-,O
responsive,O
transcription,O
factors,O
",",O
while,O
in,O
IAV,O
patients,O
",",O
proinflammatory,O
transcription,O
factors,O
and,O
virus,O
-,O
interacting,O
host,O
factors,O
seem,O
to,O
be,O
highly,O
expressed,O
.,O
Expression,O
of,O
STAT3,O
was,O
elevated,O
in,O
IAV,O
patients,O
compared,O
to,O
COVID-19,O
patients,O
and,O
healthy,O
controls,O
and,O
seemed,O
to,O
correlate,O
with,O
time,O
post,O
admission,O
.,O
For,O
COVID-19,O
patients,O
",",O
STAT1,O
",",O
a,O
major,O
transcription,O
factor,O
activated,O
in,O
response,O
to,O
interferon,O
",",O
was,O
upregulated,O
in,O
activated,O
CD4,O
+,O
We,O
measured,O
plasma,O
concentrations,O
of,O
IL-6,O
during,O
hospitalization,O
of,O
these,O
COVID-19,O
patients,O
and,O
after,O
leaving,O
the,O
hospital,O
(,O
Figure,O
 ,O
S4D,O
),O
.,O
There,O
was,O
a,O
rising,O
phase,O
of,O
IL-6,O
in,O
most,O
COVID-19,O
patients,O
",",O
indicating,O
an,O
active,O
inflammatory,O
response,O
",",O
which,O
is,O
also,O
observed,O
in,O
IAV,O
patients,O
(,O
Yu,O
et,O
 ,O
al,O
.,O
",",O
2011,O
),O
.,O
T,O
 ,O
cells,O
",",O
naive,O
T,O
 ,O
cells,O
",",O
and,O
DCs,O
of,O
COVID-19,O
patients,O
compared,O
to,O
IAV,O
patients,O
and,O
healthy,O
controls,O
(,O
Figures,O
4C,O
and,O
S4A,O
),O
.,O
Meanwhile,O
",",O
expression,O
of,O
IL6ST,O
 ,O
was,O
upregulated,O
in,O
various,O
cell,O
types,O
from,O
COVID-19,O
patients,O
and,O
IAV,O
patients,O
compared,O
to,O
healthy,O
controls,O
.,O
Based,O
on,O
clinical,O
observations,O
that,O
plasma,O
concentrations,O
of,O
inflammatory,O
cytokines,O
",",O
such,O
as,O
IFN,O
-,O
α2,O
",",O
IL-7,O
",",O
IL-17,O
",",O
and,O
IL-10,O
were,O
higher,O
in,O
COVID-19,O
patients,O
than,O
in,O
healthy,O
adults,O
(,O
Huang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
",",O
we,O
compared,O
expression,O
levels,O
of,O
their,O
corresponding,O
receptors,O
in,O
activated,O
CD4,O
+,O
T,O
 ,O
cells,O
",",O
MAIT,O
cells,O
",",O
and,O
NK,O
cells,O
across,O
COVID-19,O
patients,O
",",O
IAV,O
patients,O
",",O
and,O
healthy,O
controls,O
.,O
Upregulation,O
of,O
IFNAR1,O
",",O
the,O
α,O
chain,O
of,O
the,O
interferon,O
α,O
/,O
β,O
receptor,O
",",O
was,O
significant,O
in,O
these,O
cell,O
types,O
in,O
COVID-19,O
patients,O
compared,O
to,O
healthy,O
controls,O
.,O
T,O
 ,O
cells,O
of,O
COVID-19,O
patients,O
compared,O
to,O
other,O
groups,O
",",O
indicating,O
that,O
CD4,O
+,O
Here,O
",",O
we,O
performed,O
scRNA,O
-,O
seq,O
on,O
PBMCs,O
from,O
COVID-19,O
patients,O
.,O
Among,O
all,O
the,O
immune,O
cell,O
clusters,O
",",O
the,O
percentage,O
of,O
plasma,O
cells,O
was,O
increased,O
significantly,O
among,O
all,O
five,O
COVID-19,O
patients,O
compared,O
with,O
healthy,O
controls,O
.,O
IFNα2,O
and,O
IFNγ,O
have,O
also,O
been,O
strongly,O
associated,O
with,O
lung,O
injury,O
in,O
COVID-19,O
(,O
Liu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Consistently,O
",",O
“,O
IFN,O
-,O
I,O
response,O
”,O
was,O
enriched,O
in,O
different,O
PBMC,O
subsets,O
of,O
COVID-19,O
patients,O
in,O
our,O
study,O
.,O
Moreover,O
",",O
severe,O
COVID-19,O
patients,O
showed,O
a,O
stronger,O
response,O
to,O
IFNs,O
and,O
virus,O
infection,O
compared,O
to,O
mild,O
patients,O
and,O
healthy,O
ones,O
.,O
This,O
indicates,O
that,O
the,O
intensity,O
of,O
the,O
interferon,O
response,O
may,O
both,O
indicate,O
the,O
severity,O
of,O
COVID-19,O
disease,O
and,O
distinguish,O
COVID-19,O
patients,O
from,O
healthy,O
individuals,O
.,O
According,O
to,O
our,O
results,O
",",O
upregulated,O
XAF1,O
expression,O
may,O
be,O
involved,O
in,O
increased,O
T,O
 ,O
cell,O
apoptosis,O
in,O
COVID-19,O
patients,O
",",O
cooperating,O
with,O
other,O
genes,O
",",O
including,O
IRF1,O
",",O
TP53,O
",",O
BCL2L11,O
",",O
and,O
CASP3,O
(,O
Jeong,O
et,O
 ,O
al,O
.,O
",",O
2018,O
;,O
Zou,O
et,O
 ,O
al,O
.,O
",",O
2012,O
),O
.,O
Consistently,O
",",O
TP53,O
expression,O
was,O
increased,O
in,O
COVID-19,O
patients,O
in,O
another,O
COVID-19,O
study,O
(,O
Xiong,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
addition,O
to,O
XAF1,O
-,O
induced,O
apoptosis,O
",",O
the,O
extrinsic,O
pathway,O
of,O
apoptosis,O
",",O
including,O
TNF,O
-,O
α,O
/,O
TNFR1,O
and,O
Fas,O
/,O
FasL,O
path,O
(,O
Elmore,O
",",O
2007,O
),O
",",O
were,O
also,O
found,O
to,O
be,O
involved,O
in,O
different,O
cell,O
subtypes,O
in,O
COVID-19,O
patients,O
.,O
Moreover,O
",",O
plasma,O
TNF,O
-,O
α,O
was,O
reported,O
to,O
be,O
increased,O
in,O
severe,O
cases,O
of,O
COVID-19,O
(,O
Chen,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Huang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
",",O
and,O
TNF,O
expression,O
was,O
upregulated,O
in,O
PBMCs,O
of,O
COVID-19,O
patients,O
in,O
our,O
study,O
",",O
demonstrating,O
a,O
correlation,O
between,O
increased,O
TNF,O
-,O
α,O
secretion,O
and,O
TNF,O
-,O
α,O
-,O
induced,O
apoptosis,O
in,O
COVID-19,O
patients,O
(,O
Rath,O
and,O
Aggarwal,O
",",O
1999,O
),O
.,O
Taken,O
together,O
",",O
we,O
found,O
that,O
the,O
upregulated,O
genes,O
relevant,O
to,O
XAF1,O
",",O
TNF,O
",",O
and,O
Fas,O
pathways,O
may,O
lead,O
to,O
increased,O
T,O
 ,O
cell,O
apoptosis,O
in,O
COVID-19,O
patients,O
.,O
We,O
analyzed,O
the,O
expression,O
of,O
cytokines,O
",",O
cytokines,O
receptors,O
",",O
and,O
transcription,O
factors,O
that,O
are,O
essential,O
in,O
the,O
immune,O
responses,O
to,O
viral,O
infection,O
and,O
pinpointed,O
gene,O
expression,O
patterns,O
in,O
COVID-19,O
patients,O
that,O
differ,O
from,O
IAV,O
patients,O
.,O
The,O
fact,O
that,O
expression,O
of,O
most,O
cytokines,O
was,O
not,O
detected,O
in,O
PBMCs,O
might,O
indicate,O
that,O
serum,O
cytokines,O
largely,O
arise,O
from,O
the,O
infection,O
site,O
",",O
i.e.,O
",",O
the,O
lower,O
respiratory,O
tract,O
for,O
COVID-19,O
.,O
We,O
found,O
that,O
plasma,O
concentrations,O
of,O
IL-6,O
are,O
above,O
normal,O
levels,O
in,O
the,O
majority,O
of,O
COVID-19,O
patients,O
",",O
consistent,O
with,O
other,O
studies,O
(,O
Chen,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Our,O
data,O
show,O
that,O
expression,O
of,O
IL6R,O
and,O
IL6ST,O
was,O
upregulated,O
in,O
patients,O
with,O
COVID-19,O
",",O
and,O
we,O
suggest,O
that,O
increased,O
expression,O
of,O
IL6R,O
and,O
IL6ST,O
might,O
synergize,O
with,O
elevated,O
IL-6,O
to,O
induce,O
a,O
strong,O
inflammatory,O
response,O
",",O
indicating,O
that,O
patients,O
might,O
benefit,O
from,O
IL-6,O
or,O
IL-6R,O
antagonist,O
treatment,O
.,O
Five,O
patients,O
with,O
COVID-19,O
were,O
recruited,O
in,O
the,O
Fifth,O
Medical,O
Center,O
of,O
PLA,O
General,O
Hospital,O
from,O
January,O
to,O
February,O
2020,O
.,O
Influenza,O
virus,O
infection,O
",",O
respiratory,O
syncytial,O
virus,O
infection,O
and,O
adenovirus,O
infection,O
were,O
excluded,O
in,O
all,O
patients,O
with,O
COVID-19,O
.,O
The,O
genome,O
of,O
SARS,O
-,O
CoV-2,O
was,O
downloaded,O
from,O
NCBI,S-Repository
 ,O
(,O
https://www.ncbi.nlm.nih.gov/,S-URL
),O
with,O
the,O
accession,O
number,O
GenBank,S-Repository
:,O
NC_045512.2,S-AccessionNumber
.,O
Then,O
",",O
the,O
integrated,O
dataset,O
was,O
scaled,O
and,O
PCA,O
was,O
calculated,O
.,O
We,O
used,O
Mfuzz,O
(,O
Kumar,O
and,O
Futschik,O
",",O
2007,O
),O
to,O
identify,O
time,O
dependent,O
transcriptional,O
program,O
in,O
COVID-19,O
patients,O
.,O
The,O
samples,O
from,O
COVID-19,O
patients,O
were,O
grouped,O
according,O
to,O
the,O
disease,O
progression,O
stage,O
(,O
Table,O
S3,O
),O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
poses,O
a,O
current,O
world,O
-,O
wide,O
public,O
health,O
threat,O
.,O
Here,O
",",O
we,O
report,O
the,O
single,O
-,O
cell,O
transcriptional,O
landscape,O
of,O
longitudinally,O
collected,O
peripheral,O
blood,O
mononuclear,O
cells,O
(,O
PBMCs,O
),O
in,O
both,O
COVID-19-,O
and,O
influenza,O
A,O
virus,O
(,O
IAV)-infected,O
patients,O
.,O
We,O
observed,O
increase,O
of,O
plasma,O
cells,O
in,O
both,O
COVID-19,O
and,O
IAV,O
patients,O
and,O
XIAP,O
associated,O
factor,O
1,O
(,O
XAF1)-,O
",",O
tumor,O
necrosis,O
factor,O
(,O
TNF)-,O
",",O
and,O
FAS,O
-,O
induced,O
T,O
 ,O
cell,O
apoptosis,O
in,O
COVID-19,O
patients,O
.,O
Further,O
analyses,O
revealed,O
distinct,O
signaling,O
pathways,O
activated,O
in,O
COVID-19,O
(,O
STAT1,O
and,O
IRF3,O
),O
versus,O
IAV,O
(,O
STAT3,O
and,O
NFκB,O
),O
patients,O
and,O
substantial,O
differences,O
in,O
the,O
expression,O
of,O
key,O
factors,O
.,O
These,O
factors,O
include,O
relatively,O
increase,O
of,O
interleukin,O
(,O
IL,O
),O
6R,O
and,O
IL6ST,O
expression,O
in,O
COVID-19,O
patients,O
but,O
similarly,O
increased,O
IL-6,O
concentrations,O
compared,O
to,O
IAV,O
patients,O
",",O
supporting,O
the,O
clinical,O
observations,O
of,O
increased,O
proinflammatory,O
cytokines,O
in,O
COVID-19,O
patients,O
.,O
Thus,O
",",O
we,O
provide,O
the,O
landscape,O
of,O
PBMCs,O
and,O
unveil,O
distinct,O
immune,O
response,O
pathways,O
in,O
COVID-19,O
and,O
IAV,O
patients,O
.,O
We,O
generated,O
a,O
single,O
-,O
cell,O
atlas,O
of,O
PBMCs,O
in,O
both,O
COVID-19,O
and,O
influenza,O
patients,O
   ,O
•,O
 ,O
Plasma,O
cells,O
increase,O
significantly,O
in,O
both,O
COVID-19,O
and,O
influenza,O
patients,O
   ,O
•,O
 ,O
COVID-19,O
is,O
featured,O
with,O
XAF1-,O
",",O
TNF-,O
",",O
and,O
FAS,O
-,O
induced,O
T,O
 ,O
cell,O
apoptosis,O
   ,O
•,O
 ,O
COVID-19,O
activates,O
distinct,O
pathway,O
 ,O
(,O
STAT1,O
/,O
IRF3,O
),O
versus,O
influenza,O
(,O
STAT3,O
/,O
NFκB,O
),O
     ,O
COVID-19,O
and,O
influenza,O
are,O
both,O
respiratory,O
infections,O
with,O
cytokine,O
release,O
syndrome,O
.,O
However,O
",",O
some,O
recent,O
coronavirus,O
infections,O
have,O
resulted,O
in,O
serious,O
morbidity,O
and,O
mortality,O
",",O
including,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
(,O
SARS,O
-,O
CoV,O
),O
[,O
2–4,O
],O
",",O
Middle,O
East,O
respiratory,O
syndrome,O
coronavirus,O
(,O
MERS,O
-,O
CoV,O
),O
[,O
5,O
",",O
6,O
],O
",",O
and,O
SARS,O
-,O
CoV-2,O
",",O
which,O
are,O
responsible,O
for,O
the,O
current,O
worldwide,O
pandemic,O
",",O
COVID-19,O
.,O
In,O
Abelin,O
et,O
al,O
.,O
[,O
34,O
],O
",",O
we,O
demonstrated,O
that,O
improved,O
HLA,O
-,O
II,O
binding,O
prediction,O
led,O
to,O
improved,O
immunogenicity,O
prediction,O
by,O
validating,O
this,O
approach,O
on,O
a,O
data,O
set,O
of,O
immune,O
responses,O
to,O
a,O
diverse,O
collection,O
of,O
pathogens,O
and,O
allergens,O
[,O
35,O
",",O
36,O
],O
.,O
Here,O
",",O
we,O
specifically,O
validated,O
the,O
binding,O
predictors,O
utilizing,O
Coronaviridae,O
family,O
peptides,O
that,O
had,O
been,O
assayed,O
for,O
T,O
cell,O
reactivity,O
or,O
MHC,O
binding,O
from,O
the,O
Virus,B-Repository
Pathogen,I-Repository
Resource,I-Repository
(ViPR),E-Repository
 ,O
database,O
[,O
34,O
],O
.,O
The,O
ViPR,S-Repository
 ,O
database,O
integrates,O
viral,O
pathogen,O
data,O
from,O
internally,O
curated,O
data,O
",",O
researcher,O
submissions,O
",",O
and,O
data,O
from,O
various,O
external,O
sources,O
.,O
Experimentally,O
determined,O
epitopes,O
for,O
the,O
Coronaviridae,O
family,O
for,O
human,O
hosts,O
were,O
retrieved,O
from,O
the,O
ViPR,S-Repository
 ,O
database,O
(,O
https://www.viprbrc.org/,S-URL
;,O
accessed,O
March,O
5,O
",",O
 ,O
2020,O
),O
[,O
39,O
],O
.,O
To,O
build,O
a,O
validation,O
dataset,O
",",O
both,O
positives,O
and,O
negatives,O
for,O
T,O
cell,O
assays,O
and,O
MHC,O
binding,O
assays,O
were,O
obtained,O
.,O
Peptide,O
-,O
HLA,O
-,O
I,O
allele,O
pairs,O
in,O
the,O
ViPR,S-Repository
 ,O
validation,O
dataset,O
were,O
scored,O
using,O
our,O
HLA,O
-,O
I,O
binding,O
predictor,O
",",O
a,O
neural,O
network,O
trained,O
on,O
mono,O
-,O
allelic,O
MS,O
data,O
[,O
33,O
],O
.,O
Similarly,O
",",O
peptide,O
-,O
HLA,O
-,O
II,O
allele,O
pairs,O
in,O
the,O
ViPR,S-Repository
 ,O
validation,O
dataset,O
were,O
scored,O
using,O
our,O
HLA,O
-,O
II,O
binding,O
predictor,O
",",O
a,O
recently,O
published,O
convolutional,O
neural,O
network,O
-,O
based,O
model,O
also,O
trained,O
on,O
mono,O
-,O
allelic,O
MS,O
data,O
[,O
34,O
],O
.,O
In,O
vitro,O
MHC,O
binding,O
assays,O
",",O
which,O
represent,O
the,O
vast,O
majority,O
of,O
the,O
ViPR,S-Repository
 ,O
dataset,O
",",O
do,O
not,O
require,O
endogenous,O
processing,O
and,O
presentation,O
for,O
a,O
positive,O
binding,O
result,O
.,O
The,O
GenBank,S-Repository
 ,O
reference,O
sequence,O
for,O
SARS,O
-,O
CoV-2,O
(,O
accession,O
:,O
NC_045512.2,S-AccessionNumber
",",O
https://www.ncbi.nlm.nih.gov/nuccore/NC_045512,S-URL
),O
was,O
used,O
for,O
this,O
study,O
.,O
In,O
addition,O
",",O
due,O
to,O
its,O
high,O
expression,O
level,O
in,O
recently,O
published,O
proteomic,O
datasets,O
[,O
40–42,O
],O
",",O
ORF9b,O
",",O
as,O
annotated,O
by,O
UniProt,S-Repository
 ,O
(,O
P0DTD2,S-AccessionNumber
",",O
https://www.uniprot.org/proteomes/UP000464024,S-URL
),O
",",O
was,O
also,O
used,O
for,O
epitope,O
predictions,O
.,O
When,O
comparing,O
our,O
20,O
SARS,O
-,O
CoV-2,O
-,O
predicted,O
epitopes,O
with,O
the,O
ViPR,S-Repository
 ,O
dataset,O
",",O
8,O
epitopes,O
were,O
previously,O
assayed,O
and,O
confirmed,O
as,O
HLA,O
-,O
A02:01,O
binders,O
.,O
SARS,O
-,O
CoV-2,O
proteomic,O
datasets,O
were,O
downloaded,O
from,O
the,O
PRIDE,S-Repository
 ,O
repository,O
(,O
Bojkova,B-Creator
et,I-Creator
al.,E-Creator
 ,O
[,O
40,O
],O
:,O
PXD017710,S-AccessionNumber
",",O
https://www.ebi.ac.uk/pride/archive/projects/PXD017710,S-URL
;,O
Bezstarosti,B-Creator
et,I-Creator
al.,E-Creator
 ,O
[,O
41,O
],O
:,O
PXD018760,S-AccessionNumber
",",O
https://www.ebi.ac.uk/pride/archive/projects/PXD018760,S-URL
;,O
Davidson,B-Creator
et,I-Creator
al.,E-Creator
 ,O
[,O
42,O
],O
:,O
PXD018241,S-AccessionNumber
",",O
https://www.ebi.ac.uk/pride/archive/projects/PXD018241,S-URL
),O
.,O
For,O
the,O
dataset,O
from,O
Bojkova,B-Creator
et,I-Creator
al.,E-Creator
 ,O
[,O
40,O
],O
which,O
employed,O
isobaric,O
mass,O
tags,O
",",O
TMT11,O
was,O
added,O
as,O
a,O
fixed,O
modification,O
to,O
peptide,O
N,O
-,O
termini,O
and,O
lysines,O
",",O
and,O
13C6,O
-,O
15N2,O
-,O
TMT11,O
-,O
lysine,O
and,O
13C6,O
-,O
15N4,O
-,O
arginine,O
were,O
added,O
as,O
variable,O
modifications,O
.,O
All,O
datasets,O
were,O
searched,O
against,O
the,O
SARS,O
-,O
CoV-2,O
proteome,O
(,O
UniProtKB,S-Repository
",",O
28,O
April,O
2020,O
",",O
14,O
entries,O
),O
concatenated,O
to,O
databases,O
containing,O
either,O
the,O
Homo,O
sapiens,O
proteome,O
(,O
[,O
40,O
],O
",",O
UCSC,O
Genome,O
Browser,O
hg19,O
annotation,O
",",O
"63,691",O
entries,O
),O
or,O
the,O
Chlorocebus,O
sabaeus,O
proteome,O
(,O
[,O
41,O
",",O
42,O
],O
UniProtKB,S-Repository
",",O
9229,O
entries,O
),O
.,O
Spectral,O
counts,O
were,O
normalized,O
to,O
the,O
length,O
of,O
each,O
protein,O
",",O
and,O
the,O
maximum,O
value,O
within,O
each,O
dataset,O
was,O
set,O
to,O
100,O
%,O
.,O
To,O
that,O
end,O
",",O
we,O
used,O
the,O
ViPR,S-Repository
 ,O
database,O
[,O
39,O
],O
",",O
which,O
lists,O
the,O
results,O
of,O
T,O
cell,O
immunogenicity,O
and,O
MHC,O
-,O
peptide,O
binding,O
assays,O
for,O
both,O
HLA,O
-,O
I,O
and,O
HLA,O
-,O
II,O
alleles,O
for,O
viral,O
pathogen,O
epitopes,O
.,O
We,O
used,O
all,O
assays,O
of,O
Coronaviridae,O
family,O
viruses,O
with,O
human,O
hosts,O
from,O
ViPR,S-Repository
 ,O
as,O
our,O
validation,O
dataset,O
.,O
For,O
HLA,O
-,O
I,O
",",O
within,O
the,O
validation,O
dataset,O
",",O
there,O
were,O
a,O
total,O
of,O
4445,O
unique,O
peptide,O
-,O
HLA,O
allele,O
pairs,O
that,O
were,O
assayed,O
for,O
MHC,O
binding,O
",",O
using,O
variations,O
of,O
(,O
1,O
),O
cellular,O
MHC,O
or,O
purified,O
MHC,O
",",O
(,O
2,O
),O
a,O
direct,O
or,O
competitive,O
assay,O
",",O
and,O
(,O
3,O
),O
measurement,O
by,O
fluorescence,O
or,O
radioactivity,O
.,O
We,O
then,O
applied,O
our,O
HLA,O
-,O
I,O
binding,O
predictor,O
to,O
the,O
peptide,O
-,O
MHC,O
allele,O
pairs,O
in,O
the,O
validation,O
dataset,O
and,O
compared,O
the,O
computed,O
HLA,O
-,O
I,O
percent,O
ranks,O
of,O
these,O
pairs,O
with,O
the,O
reported,O
MHC,O
binding,O
assay,O
results,O
(,O
Additional,O
 ,O
file,O
 ,O
8,O
:,O
Table,O
S8,O
),O
.,O
In,O
total,O
",",O
there,O
were,O
4445,O
peptide,O
-,O
HLA,O
-,O
I,O
allele,O
pairs,O
in,O
the,O
ViPR,S-Repository
 ,O
dataset,O
we,O
obtained,O
(,O
see,O
the,O
“,O
Methods,O
”,O
section,O
),O
.,O
There,O
were,O
259,O
unique,O
peptide,O
-,O
MHC,O
allele,O
pairs,O
assayed,O
by,O
MHC,O
binding,O
assays,O
in,O
the,O
ViPR,S-Repository
 ,O
validation,O
dataset,O
for,O
HLA,O
-,O
II,O
.,O
This,O
comparison,O
could,O
not,O
be,O
performed,O
with,O
the,O
“,O
Negative,O
”,O
pairs,O
as,O
an,O
independent,O
group,O
since,O
there,O
was,O
only,O
one,O
negative,O
result,O
in,O
the,O
validation,O
dataset,O
for,O
HLA,O
-,O
II,O
.,O
Similar,O
to,O
the,O
HLA,O
-,O
I,O
T,O
cell,O
assays,O
",",O
there,O
were,O
too,O
few,O
recorded,O
HLA,O
-,O
II,O
T,O
cell,O
assays,O
in,O
our,O
validation,O
dataset,O
to,O
determine,O
percent,O
rank,O
differences,O
between,O
peptide,O
-,O
HLA,O
II,O
allele,O
pairs,O
testing,O
positive,O
and,O
negative,O
.,O
We,O
first,O
performed,O
the,O
analysis,O
for,O
HLA,O
-,O
I,O
peptide,O
binding,O
and,O
computed,O
the,O
likelihood,O
of,O
each,O
peptide,O
of,O
lengths,O
8–12,O
amino,O
acids,O
from,O
the,O
13,O
SARS,O
-,O
CoV-2,O
ORFs,O
to,O
bind,O
to,O
any,O
HLA,O
-,O
I,O
allele,O
in,O
our,O
database,O
.,O
To,O
test,O
the,O
validity,O
of,O
the,O
SARS,O
-,O
CoV-2,O
-,O
predicted,O
peptide,O
-,O
HLA,O
pairs,O
",",O
we,O
looked,O
for,O
peptide,O
sequences,O
in,O
the,O
Coronaviridae,O
portion,O
of,O
the,O
ViPR,S-Repository
 ,O
database,O
which,O
exactly,O
matched,O
SARS,O
-,O
CoV-2,O
peptide,O
sequences,O
(,O
Fig,O
.,O
2d,O
),O
.,O
A,O
total,O
of,O
374,O
HLA,O
-,O
I,O
peptide,O
-,O
MHC,O
allele,O
pairs,O
from,O
SARS,O
-,O
CoV-2,O
had,O
both,O
a,O
percent,O
rank,O
lower,O
than,O
1,O
%,O
by,O
our,O
predictor,O
and,O
were,O
found,O
in,O
the,O
HLA,O
-,O
I,O
MHC,O
binding,O
validation,O
dataset,O
.,O
As,O
a,O
comparison,O
",",O
we,O
also,O
tested,O
for,O
overlap,O
between,O
epitopes,O
predicted,O
to,O
have,O
low,O
likelihood,O
of,O
MHC,O
binding,O
(,O
percent,O
rank,O
50,O
%,O
or,O
higher,O
),O
and,O
the,O
validation,O
dataset,O
.,O
Despite,O
the,O
significantly,O
smaller,O
number,O
of,O
peptide,O
-,O
MHC,O
allele,O
pairs,O
that,O
were,O
tested,O
for,O
T,O
cell,O
reactivity,O
in,O
the,O
validation,O
dataset,O
",",O
10,O
assayed,O
pairs,O
were,O
also,O
highly,O
predicted,O
by,O
our,O
HLA,O
-,O
I,O
binding,O
predictor,O
.,O
No,O
low,O
-,O
scoring,O
pairs,O
(,O
percent,O
rank,O
of,O
50,O
%,O
or,O
above,O
),O
were,O
reported,O
in,O
the,O
validation,O
dataset,O
.,O
In,O
order,O
to,O
determine,O
the,O
relative,O
abundance,O
of,O
SARS,O
-,O
CoV-2,O
proteins,O
",",O
we,O
analyzed,O
three,O
publicly,O
available,O
proteomic,O
datasets,O
that,O
acquired,O
unbiased,O
LC,O
-,O
MS,O
/,O
MS,O
on,O
tryptic,O
digestions,O
of,O
SARS,O
-,O
CoV-2,O
-,O
infected,O
host,O
cells,O
[,O
40–42,O
],O
.,O
Specifically,O
",",O
it,O
confirmed,O
that,O
the,O
N,O
protein,O
is,O
the,O
most,O
abundant,O
viral,O
protein,O
across,O
all,O
three,O
datasets,O
following,O
SARS,O
-,O
CoV-2,O
infection,O
(,O
Fig,O
.,O
 ,O
5,O
),O
.,O
This,O
finding,O
is,O
corroborated,O
by,O
reports,O
of,O
N,O
-,O
derived,O
peptides,O
being,O
detected,O
in,O
gargle,O
solution,O
samples,O
from,O
COVID-19,O
patients,O
[,O
57,O
],O
.,O
Our,O
database,O
of,O
supported,O
HLA,O
-,O
I,O
and,O
HLA,O
-,O
II,O
alleles,O
provides,O
us,O
with,O
the,O
ability,O
to,O
not,O
only,O
identify,O
many,O
peptide,O
-,O
MHC,O
allele,O
pairs,O
",",O
but,O
to,O
generate,O
a,O
narrow,O
list,O
of,O
peptides,O
with,O
many,O
potential,O
HLA,O
pairings,O
that,O
could,O
be,O
presented,O
by,O
the,O
entire,O
US,O
",",O
European,O
",",O
and,O
Asian,O
-,O
Pacific,O
Islander,O
populations,O
.,O
T,O
cell,O
responses,O
to,O
a,O
small,O
set,O
of,O
epitopes,O
from,O
the,O
S,O
protein,O
in,O
COVID-19,O
patient,O
or,O
healthy,O
donor,O
PBMCs,O
.,O
T,O
cell,O
responses,O
in,O
COVID-19,O
patients,O
from,O
healthy,O
donor,O
samples,O
collected,O
before,O
or,O
during,O
the,O
pandemic,O
.,O
Their,O
data,O
also,O
show,O
that,O
10,O
additional,O
peptides,O
sporadically,O
induce,O
responses,O
in,O
2–3,O
individuals,O
from,O
either,O
the,O
healthy,O
donor,O
or,O
the,O
COVID-19,O
patient,O
cohorts,O
(,O
total,O
of,O
31,O
individuals,O
),O
.,O
While,O
focusing,O
on,O
a,O
small,O
set,O
of,O
two,O
COVID-19,O
patients,O
and,O
one,O
healthy,O
donor,O
",",O
Chour,O
et,O
al,O
.,O
[,O
61,O
],O
 ,O
demonstrate,O
that,O
five,O
HLA,O
-,O
A02:01,O
-,O
restricted,O
epitopes,O
from,O
the,O
S,O
protein,O
elicited,O
a,O
CD8,O
+,O
The,O
differences,O
in,O
training,O
data,O
lead,O
to,O
algorithms,O
that,O
prioritize,O
substantially,O
different,O
epitope,O
sets,O
",",O
even,O
for,O
well,O
-,O
studied,O
alleles,O
.,O
Additional,O
file,O
10,O
:,O
Table,O
S10,O
.,O
spectral,O
counts,O
from,O
published,O
SARS,O
-,O
CoV-2,O
proteomic,O
datasets,O
.,O
MS,O
/,O
MS,O
spectra,O
assigned,O
to,O
peptides,O
from,O
SARS,O
-,O
CoV-2,O
proteins,O
were,O
tallied,O
across,O
datasets,O
",",O
divided,O
by,O
protein,O
length,O
",",O
and,O
normalized,O
within,O
each,O
dataset,O
to,O
generate,O
Fig,O
.,O
5,O
.,O
Additional,O
file,O
13,O
.,O
The,O
ongoing,O
COVID-19,O
pandemic,O
has,O
created,O
an,O
urgency,O
to,O
identify,O
novel,O
vaccine,O
targets,O
for,O
protective,O
immunity,O
against,O
SARS,O
-,O
CoV-2,O
.,O
We,O
first,O
validated,O
HLA,O
-,O
I,O
and,O
HLA,O
-,O
II,O
predictions,O
on,O
Coronaviridae,O
family,O
epitopes,O
deposited,O
in,O
the,O
Virus,B-Repository
Pathogen,I-Repository
Database,I-Repository
and,I-Repository
Analysis,I-Repository
Resource,I-Repository
(ViPR),E-Repository
 ,O
database,O
.,O
From,O
our,O
SARS,O
-,O
CoV-2,O
-,O
predicted,O
peptide,O
-,O
HLA,O
-,O
I,O
allele,O
pairs,O
",",O
374,O
pairs,O
identically,O
matched,O
what,O
was,O
previously,O
reported,O
in,O
the,O
ViPR,S-Repository
 ,O
database,O
",",O
originating,O
from,O
other,O
coronaviruses,O
with,O
identical,O
sequences,O
.,O
All,O
data,O
generated,O
or,O
analyzed,O
during,O
this,O
study,O
are,O
included,O
in,O
this,O
published,O
article,O
",",O
its,O
supplementary,O
information,O
files,O
",",O
or,O
the,O
following,O
external,O
sources,O
:,O
SARS,O
-,O
CoV-2,O
reference,O
sequences,O
used,O
in,O
this,O
study,O
were,O
obtained,O
from,O
GenBank,S-Repository
 ,O
(,O
accession,O
:,O
NC_045512.2,S-AccessionNumber
",",O
https://www.ncbi.nlm.nih.gov/nuccore/NC_045512,S-URL
),O
and,O
ORF9b,O
",",O
as,O
annotated,O
by,O
UniProt,S-Repository
 ,O
(,O
P0DTD2,S-AccessionNumber
",",O
https://www.uniprot.org/proteomes/UP000464024,S-URL
),O
.,O
SARS,O
-,O
CoV-2,O
proteomic,O
datasets,O
were,O
downloaded,O
from,O
the,O
PRIDE,S-Repository
 ,O
repository,O
(,O
Bojkova,B-Creator
et,I-Creator
al.,E-Creator
 ,O
[,O
40,O
],O
:,O
PXD017710,S-AccessionNumber
",",O
https://www.ebi.ac.uk/pride/archive/projects/PXD017710,S-URL
;,O
Bezstarosti,B-Creator
et,I-Creator
al.,E-Creator
 ,O
[,O
41,O
],O
:,O
PXD018760,S-AccessionNumber
",",O
https://www.ebi.ac.uk/pride/archive/projects/PXD018760,S-URL
;,O
Davidson,B-Creator
et,I-Creator
al.,E-Creator
 ,O
[,O
42,O
],O
:,O
PXD018241,S-AccessionNumber
",",O
https://www.ebi.ac.uk/pride/archive/projects/PXD018241,S-URL
),O
.,O
Global,O
public,O
health,O
concern,O
with,O
pandemic,O
notion,O
of,O
COVID-19,O
was,O
declared,O
on,O
January,O
30th,O
",",O
2020,O
by,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
",",O
2020a,O
",",O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
",",O
2020b,O
.,O
Again,O
",",O
an,O
adverse,O
situation,O
has,O
also,O
been,O
announced,O
on,O
13,O
March,O
2020,O
for,O
increasing,O
the,O
infections,O
of,O
COVID-19,O
(,O
Kunz,O
and,O
Minder,O
",",O
2020,O
),O
.,O
Some,O
common,O
clinical,O
manifestations,O
of,O
COVID-19,O
are,O
fever,O
",",O
sputum,O
production,O
and,O
shortness,O
in,O
breath,O
",",O
cough,O
",",O
fatigue,O
",",O
sore,O
throat,O
and,O
headache,O
which,O
leads,O
to,O
severe,O
cases,O
of,O
pneumonia,O
.,O
Though,O
several,O
early,O
studies,O
showed,O
that,O
the,O
mortality,O
rate,O
for,O
SARS,O
-,O
CoV-2,O
is,O
not,O
as,O
high,O
(,O
2–3,O
%,O
),O
",",O
the,O
latest,O
global,O
death,O
rate,O
for,O
COVID-19,O
is,O
3.4,O
%,O
which,O
indicates,O
the,O
increasing,O
trends,O
(,O
Wu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
investigation,O
of,O
Chinese,O
Center,O
for,O
Diseases,O
Control,O
and,O
Prevention,O
(,O
2020,O
),O
revealed,O
that,O
the,O
prevalence,O
of,O
COVID-19,O
is,O
more,O
apparent,O
in,O
the,O
people,O
ages,O
50,O
 ,O
years,O
rather,O
than,O
the,O
lower,O
age,O
groups,O
(,O
Jeong,O
-,O
ho,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Though,O
the,O
species,O
of,O
SARS,O
-,O
CoV-1,O
and,O
bat,O
coronavirus,O
shares,O
sufficient,O
sequence,O
similarities,O
with,O
the,O
COVID-19,O
",",O
the,O
known,O
way,O
mechanism,O
of,O
infection,O
to,O
the,O
host,O
",",O
and,O
the,O
death,O
rate,O
is,O
quite,O
different,O
in,O
case,O
of,O
the,O
novel,O
coronavirus,O
.,O
In,O
addition,O
",",O
there,O
is,O
an,O
evolutionary,O
distance,O
between,O
SARS,O
-,O
CoV-1,O
and,O
bat,O
coronavirus,O
as,O
well,O
as,O
the,O
COVID-19,O
(,O
Hu,O
et,O
al,O
.,O
",",O
2018,O
;,O
Wu,O
et,O
al,O
.,O
",",O
2020,O
;,O
Wu,O
2020,O
),O
.,O
While,O
some,O
natural,O
metabolites,O
and,O
traditional,O
medication,O
may,O
come,O
up,O
with,O
comfort,O
and,O
take,O
the,O
edge,O
off,O
few,O
symptoms,O
of,O
COVID-19,O
",",O
there,O
is,O
no,O
proof,O
that,O
existing,O
treatment,O
procedures,O
can,O
effectively,O
combat,O
against,O
the,O
diseased,O
condition,O
(,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
",",O
2020a,O
",",O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
",",O
2020b,O
),O
.,O
Reverse,O
vaccinology,O
approach,O
",",O
on,O
the,O
other,O
hand,O
",",O
is,O
an,O
effective,O
way,O
to,O
develop,O
vaccine,O
against,O
COVID-19,O
.,O
At,O
present,O
",",O
a,O
suitable,O
peptide,O
vaccine,O
to,O
combat,O
COVID-19,O
is,O
urgently,O
necessary,O
that,O
could,O
efficiently,O
generate,O
enough,O
immune,O
response,O
to,O
destroy,O
the,O
virus,O
.,O
Complete,O
Genomes,O
of,O
the,O
COVID-19,O
and,O
other,O
coronaviruses,O
were,O
retrieved,O
from,O
the,O
NCBI,S-Repository
 ,O
(,O
https://www.ncbi.nlm.nih.gov/,S-URL
),O
",",O
using,O
the,O
keyword,O
‘,O
coronavirus,O
’,O
and,O
the,O
search,O
option,O
‘,O
nucleotide,O
’,O
.,O
For,O
the,O
retrieval,O
of,O
the,O
domain,O
sequences,O
of,O
the,O
stated,O
protein,O
sequences,O
",",O
InterPro,S-Repository
 ,O
database,O
(,O
https://www.ebi.ac.uk/interpro/,S-URL
),O
was,O
utilized,O
.,O
Among,O
496,O
proteins,O
(,O
available,O
in,O
the,O
NCBI,S-Repository
 ,O
database,O
),O
from,O
different,O
strains,O
of,O
novel,O
corona,O
virus,O
",",O
four,O
structural,O
proteins,O
",",O
i.e.,O
spike,O
glycoprotein,O
",",O
membrane,O
glycoprotein,O
",",O
envelope,O
protein,O
and,O
nucleocapsid,O
protein,O
",",O
were,O
prioritized,O
for,O
further,O
investigation,O
(,O
File,O
S2,O
),O
.,O
Homologous,O
sequence,O
sets,O
of,O
the,O
chosen,O
antigenic,O
proteins,O
were,O
retrieved,O
from,O
the,O
NCBI,S-Repository
 ,O
database,O
by,O
utilizing,O
BLASTp,O
tool,O
.,O
For,O
construction,O
of,O
novel,O
corona,O
vaccine,O
",",O
the,O
chosen,O
adjuvants,O
i.e.,O
L7,O
/,O
L12,O
ribosomal,O
protein,O
",",O
beta,O
defensin,O
(,O
a,O
45,O
mer,O
peptide,O
),O
and,O
HABA,O
protein,O
(,O
M.,O
tuberculosis,O
",",O
accession,O
number,O
:,O
AGV15514.1,S-AccessionNumber
),O
were,O
used,O
(,O
Rana,O
and,O
Akhter,O
",",O
2016,O
),O
.,O
Several,O
linkers,O
such,O
as,O
EAAAK,O
",",O
GGGS,O
",",O
GPGPG,O
and,O
KK,O
in,O
association,O
with,O
PADRE,O
sequence,O
were,O
incorporated,O
to,O
construct,O
fruitful,O
vaccine,O
sequences,O
against,O
COVID-19,O
.,O
These,O
61,O
species,O
of,O
corona,O
viruses,O
included,O
7,O
pathogenic,O
species,O
(,O
Fig,O
.,O
2,O
),O
",",O
which,O
are,O
:,O
COVID-19,O
or,O
SARS,O
-,O
CoV-2,O
",",O
SARS,O
-,O
CoV-1,O
virus,O
",",O
MERS,O
virus,O
",",O
HCoV,O
-,O
HKU1,O
",",O
HCoV,O
-,O
OC43,O
",",O
HCoV,O
-,O
NL63,O
",",O
HCoV-229E,O
COVID-19,O
or,O
SARS,O
-,O
COV-2,O
formed,O
clade,O
with,O
SARS,O
-,O
COV-1,O
and,O
bat,O
beta,O
-,O
coronaviruses,O
(,O
Fig,O
.,O
2,O
),O
",",O
which,O
is,O
consistent,O
with,O
the,O
previous,O
finding,O
(,O
Ceraolo,O
and,O
Giorgi,O
2020,O
),O
.,O
Though,O
SARS,O
-,O
CoV-1,O
belongs,O
to,O
the,O
same,O
sub,O
-,O
genus,O
as,O
the,O
COVID-19,O
",",O
the,O
bat,O
coronaviruses,O
belong,O
to,O
two,O
different,O
sub,O
-,O
genera,O
including,O
Hibecovirus,O
and,O
Nobecovirus,O
(,O
File,O
S1,O
),O
.,O
SARS,O
-,O
CoV-1,O
contains,O
an,O
extra,O
domain,O
",",O
namely,O
spike,O
glycoprotein,O
N,O
-,O
terminal,O
domain,O
(,O
IPR032500,S-AccessionNumber
),O
",",O
which,O
is,O
also,O
present,O
in,O
some,O
the,O
sub,O
-,O
genera,O
(,O
Embecovirus,O
),O
of,O
beta,O
-,O
coronavirus,O
",",O
but,O
not,O
in,O
COVID-19,O
.,O
One,O
important,O
finding,O
in,O
our,O
study,O
is,O
that,O
the,O
COVID-19,O
candidates,O
do,O
not,O
contain,O
the,O
domain,O
spike,O
glycoprotein,O
(,O
IPR042578,S-AccessionNumber
),O
",",O
which,O
is,O
present,O
in,O
the,O
SARS,O
-,O
CoV-1,O
(,O
Fig,O
.,O
3,O
),O
.,O
Most,O
of,O
them,O
fall,O
within,O
the,O
S1,O
spike,O
protein,O
",",O
which,O
is,O
654,O
amino,O
acid,O
long,O
in,O
SARS,O
-,O
CoV-1,O
",",O
while,O
672,O
amino,O
acids,O
long,O
in,O
COVID-19,O
.,O
The,O
RGD,O
motif,O
which,O
is,O
conserved,O
within,O
the,O
COVID-19,O
is,O
present,O
in,O
the,O
vicinity,O
of,O
the,O
S1,O
protein,O
.,O
Again,O
",",O
the,O
receptor,O
binding,O
domain,O
and,O
receptor,O
binding,O
motif,O
analyses,O
disclose,O
variations,O
within,O
several,O
region,O
between,O
the,O
COVID19,O
and,O
SARS,O
-,O
CoV-1,O
(,O
File,O
S2,O
),O
.,O
The,O
domain,O
-,O
based,O
phylogenetic,O
analysis,O
reflects,O
two,O
main,O
divisions,O
",",O
where,O
the,O
all,O
the,O
novel,O
beta,O
-,O
coronavirus,O
i.e.,O
",",O
COVID19,O
form,O
clade,O
with,O
the,O
SARS,O
-,O
CoV-1,O
;,O
while,O
other,O
beta,O
-,O
coronavirus,O
fall,O
in,O
another,O
clade,O
which,O
further,O
divide,O
to,O
give,O
rise,O
different,O
sub,O
-,O
genera,O
.,O
This,O
clearly,O
shows,O
that,O
the,O
COVID-19,O
exerts,O
specific,O
ancestral,O
connection,O
to,O
the,O
SARS,O
-,O
CoV-1,O
in,O
terms,O
of,O
spike,O
glycoproteins,O
.,O
Interestingly,O
",",O
our,O
study,O
also,O
revealed,O
close,O
relatedness,O
of,O
both,O
the,O
SARS,O
-,O
CoV-1,O
and,O
COVID-19,O
to,O
the,O
bat,O
beta,O
-,O
coronavirus,O
that,O
belongs,O
to,O
the,O
Hibecovirus,O
sub,O
-,O
genus,O
.,O
The,O
phylogenetic,O
study,O
and,O
MSA,O
also,O
revealed,O
that,O
",",O
the,O
functional,O
portion,O
of,O
the,O
spike,O
glycoprotein,O
domain,O
and,O
spike,O
glycoprotein,O
N,O
-,O
terminal,O
domain,O
might,O
be,O
lost,O
from,O
the,O
COVID-19,O
during,O
the,O
course,O
of,O
evolution,O
.,O
The,O
length,O
of,O
the,O
domains,O
for,O
the,O
COVID-19,O
",",O
SARS,O
-,O
CoV,O
and,O
MARS,O
virus,O
are,O
75,O
",",O
76,O
and,O
82,O
amino,O
acids,O
",",O
respectively,O
.,O
The,O
average,O
length,O
of,O
the,O
COVID-19,O
envelope,O
proteins,O
is,O
75,O
amino,O
acids,O
long,O
.,O
Though,O
the,O
computational,O
analysis,O
of,O
CoVID-19,O
envelope,O
protein,O
secondary,O
structure,O
shows,O
2,O
transmembrane,O
domains,O
",",O
our,O
domain,O
analysis,O
shows,O
only,O
one,O
such,O
domain,O
in,O
their,O
structures,O
.,O
Unlike,O
to,O
earlier,O
finding,O
",",O
we,O
got,O
that,O
gamma,O
-,O
coronavirus,O
candidate,O
in,O
our,O
study,O
shows,O
close,O
connection,O
with,O
both,O
SARS,O
-,O
CoV-1,O
and,O
COVID-19,O
in,O
terms,O
of,O
envelope,O
proteins,O
.,O
Computational,O
analysis,O
of,O
secondary,O
structures,O
shows,O
some,O
variations,O
of,O
COVID-19,O
with,O
SARS,O
-,O
CoV-1,O
and,O
MERS,O
virus,O
(,O
File,O
S3,O
),O
.,O
According,O
to,O
our,O
domain,O
-,O
based,O
phylogeny,O
study,O
of,O
nucleocapsid,O
proteins,O
",",O
we,O
found,O
the,O
close,O
approximation,O
of,O
the,O
COVID-19,O
with,O
the,O
SARS,O
-,O
CoV-1,O
",",O
which,O
is,O
consistent,O
with,O
the,O
findings,O
of,O
phylogeny,O
of,O
whole,O
genome,O
.,O
Strikingly,O
",",O
unlike,O
spike,O
and,O
membrane,O
proteins,O
",",O
the,O
closest,O
homologs,O
of,O
COVID-19,O
are,O
not,O
only,O
the,O
SARS,O
-,O
COV-1,O
and,O
bat,O
coronaviruses,O
(,O
Sub,O
-,O
genus,O
:,O
Hibecovirus,O
and,O
Nobecovirus,O
),O
",",O
but,O
it,O
also,O
includes,O
the,O
MERS,O
viruses,O
and,O
other,O
proteins,O
which,O
is,O
from,O
the,O
Merbecovirus,O
sub,O
-,O
genus,O
.,O
A,O
total,O
31,O
",",O
24,O
",",O
29,O
and,O
29,O
sequences,O
of,O
spike,O
glycoprotein,O
",",O
membrane,O
protein,O
",",O
envelope,O
protein,O
and,O
nucleocapsid,O
protein,O
were,O
retrieved,O
from,O
the,O
NCBI,S-Repository
 ,O
database,O
belonging,O
to,O
different,O
strains,O
of,O
SARS,O
-,O
CoV-2,O
.,O
Among,O
the,O
potential,O
SARS,O
-,O
CoV-2,O
vaccines,O
in,O
the,O
pipeline,O
",",O
four,O
have,O
nucleic,O
acid,O
based,O
designs,O
",",O
four,O
involve,O
non,O
-,O
replicating,O
viruses,O
or,O
protein,O
constructs,O
",",O
two,O
contain,O
live,O
attenuated,O
virus,O
and,O
one,O
involves,O
a,O
viral,O
vector,O
(,O
Pang,O
et,O
al,O
.,O
2020,O
),O
",",O
while,O
only,O
one,O
",",O
called,O
mRNA-1273,O
(,O
developed,O
by,O
NIAID,O
collaboration,O
with,O
Moderna,O
",",O
Inc.,O
),O
",",O
has,O
confirmed,O
to,O
start,O
phase-1,O
trial,O
(,O
NIH,O
News,O
Event,O
",",O
2020,O
),O
.,O
However,O
",",O
in,O
this,O
study,O
we,O
emphasized,O
on,O
a,O
different,O
approaches,O
by,O
prioritizing,O
the,O
advantages,O
of,O
different,O
genome,O
and,O
proteome,O
database,O
using,O
the,O
immunoinformatic,O
approach,O
.,O
Researchers,O
have,O
already,O
considered,O
Envelope,O
(,O
E,O
),O
protein,O
for,O
vaccine,O
candidacy,O
against,O
COVID-19,O
due,O
to,O
high,O
antigenicity,O
(,O
Abdelmageed,O
et,O
al,O
.,O
2020,O
),O
.,O
Our,O
results,O
infer,O
a,O
significant,O
level,O
of,O
similarities,O
within,O
the,O
COVID-19,O
and,O
SARS,O
-,O
CoV-1,O
which,O
was,O
also,O
aligned,O
with,O
the,O
previous,O
findings,O
(,O
Jaimes,O
et,O
al,O
.,O
",",O
2020,O
;,O
Sun,O
et,O
al,O
.,O
",",O
2020a,O
",",O
Sun,O
et,O
al,O
.,O
",",O
2020b,O
;,O
Wu,O
2020,O
),O
.,O
The,O
sequence,O
similarities,O
between,O
the,O
SARS,O
-,O
CoV,O
",",O
bat,O
coronaviruses,O
and,O
the,O
COVID-19,O
from,O
the,O
reported,O
studies,O
(,O
Hu,O
et,O
al,O
.,O
Interestingly,O
",",O
the,O
COVID-19,O
envelope,O
proteins,O
form,O
clade,O
with,O
the,O
Turkey,O
coronavirus,O
which,O
belongs,O
to,O
gamma,O
-,O
coronavirus,O
genus,O
.,O
Overall,O
",",O
the,O
COVID-19,O
might,O
go,O
through,O
complex,O
adaptation,O
strategies,O
in,O
order,O
to,O
be,O
transmitted,O
into,O
the,O
human,O
via,O
different,O
animals,O
.,O
The,O
potential,O
B,O
cell,O
epitopes,O
were,O
generated,O
by,O
three,O
different,O
algorithms,O
(,O
Bepipred,O
linear,O
epitope,O
prediction,O
2.0,O
",",O
Kolaskar,O
and,O
Tongaonkar,O
antigenicity,O
prediction,O
and,O
Emini,O
surface,O
accessibility,O
prediction,O
),O
from,O
IEDB,S-Repository
 ,O
database,O
(,O
Table,O
3,O
),O
.,O
Top,O
putative,O
epitopes,O
were,O
combined,O
with,O
appropriate,O
adjuvants,O
and,O
linkers,O
to,O
construct,O
a,O
novel,O
multiepitope,O
subunit,O
vaccine,O
against,O
COVID-19,O
.,O
The,O
structure,O
of,O
ACE2,O
-,O
PD,O
in,O
complex,O
with,O
SARS,O
-,O
CoV-2,O
-,O
RBD,O
was,O
retrieved,O
from,O
Protein,B-Repository
Data,I-Repository
Bank,I-Repository
(PDB),E-Repository
 ,O
file,O
PDB,S-Repository
 ,O
ID,O
6VW1,S-AccessionNumber
",",O
while,O
the,O
structure,O
of,O
ACE2,O
-,O
PD,O
complexed,O
with,O
SARS,O
-,O
CoV,O
-,O
RBD,O
has,O
PDB,S-Repository
 ,O
ID,O
2AJF,S-AccessionNumber
(,O
19,O
),O
(,O
Figure,O
),O
.,O
The,O
virus,O
causes,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
with,O
common,O
symptoms,O
such,O
as,O
fever,O
",",O
cough,O
",",O
shortness,O
of,O
breath,O
and,O
fatigue,O
.,O
",",O
Early,O
data,O
indicated,O
that,O
about,O
20,O
%,O
of,O
patients,O
develop,O
severe,O
COVID-19,O
requiring,O
hospitalization,O
",",O
including,O
5,O
%,O
who,O
are,O
admitted,O
to,O
the,O
intensive,O
care,O
unit,O
.,O
The,O
mortality,O
from,O
COVID-19,O
is,O
higher,O
in,O
people,O
older,O
than,O
65,O
years,O
and,O
in,O
people,O
with,O
underlying,O
comorbidities,O
",",O
such,O
as,O
chronic,O
lung,O
disease,O
",",O
serious,O
heart,O
conditions,O
",",O
high,O
blood,O
pressure,O
",",O
obesity,O
and,O
diabetes,O
.,O
–,O
Therefore,O
",",O
systematic,O
tracking,O
of,O
demographic,O
and,O
clinical,O
patient,O
information,O
",",O
as,O
well,O
as,O
strain,O
information,O
is,O
indispensable,O
to,O
effectively,O
combat,O
COVID-19,O
.,O
In,O
total,O
",",O
we,O
downloaded,O
15,O
 ,O
755,O
genome,O
sequences,O
from,O
the,O
following,O
databases,O
:,O
the,O
Chinese,B-Repository
National,I-Repository
Microbiology,I-Repository
Data,I-Repository
Center,E-Repository
 ,O
on,O
1,O
February,O
2020,O
;,O
the,O
Chinese,B-Repository
National,I-Repository
Genomics,I-Repository
Data,I-Repository
Center,E-Repository
 ,O
Genome,O
Warehouse,O
on,O
4,O
February,O
2020,O
;,O
GISAID,S-Dataset
 ,O
on,O
1,O
May,O
2020,O
and,O
GenBank,S-Repository
 ,O
on,O
1,O
May,O
2020,O
.,O
Methods,O
 ,O
Between,O
1,O
February,O
and,O
1,O
May,O
2020,O
",",O
we,O
downloaded,O
10,O
 ,O
022,O
SARS,O
CoV-2,O
genomes,O
from,O
four,O
databases,O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
pandemic,O
",",O
an,O
infectious,O
disease,O
caused,O
by,O
a,O
novel,O
strain,O
of,O
human,O
coronavirus,O
",",O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS‐CoV‐2,O
),O
",",O
 ,O
has,O
become,O
the,O
focus,O
of,O
attention,O
worldwide,O
.,O
Since,O
its,O
first,O
report,O
in,O
late,O
December,O
2019,O
in,O
Wuhan,O
",",O
China,O
",",O
 ,O
COVID‐19,O
has,O
aggressively,O
spread,O
across,O
the,O
world,O
and,O
dramatically,O
impacted,O
people,O
's,O
health,O
and,O
daily,O
life,O
.,O
As,O
of,O
July,O
1,O
",",O
2020,O
",",O
according,O
to,O
the,O
Situation,O
Report,O
issued,O
by,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
",",O
the,O
number,O
of,O
confirmed,O
COVID‐19,O
cases,O
reported,O
in,O
over,O
two,O
hundred,O
regions,O
exceeded,O
10.3,O
million,O
with,O
around,O
508,O
 ,O
000,O
deaths,O
.,O
The,O
clinical,O
patterns,O
of,O
COVID‐19,O
ranged,O
from,O
asymptomatic,O
cases,O
to,O
critically,O
ill,O
patients,O
.,O
Fever,O
",",O
dry,O
cough,O
",",O
and,O
radiological,O
changes,O
in,O
lungs,O
tend,O
to,O
be,O
common,O
clinical,O
manifestations,O
in,O
COVID‐19,O
patients,O
.,O
According,O
to,O
data,O
provided,O
by,O
the,O
China,O
National,O
Health,O
Commission,O
",",O
the,O
mortality,O
rate,O
of,O
COVID‐19,O
patients,O
was,O
7.7,O
%,O
in,O
Wuhan,O
",",O
 ,O
which,O
was,O
higher,O
than,O
the,O
world,O
average,O
(,O
4.9,O
%,O
),O
.,O
As,O
the,O
number,O
of,O
infected,O
and,O
fatal,O
cases,O
is,O
rising,O
across,O
the,O
globe,O
",",O
there,O
is,O
a,O
pressing,O
need,O
to,O
investigate,O
the,O
clinical,O
",",O
radiological,O
",",O
and,O
laboratory,O
characteristics,O
",",O
and,O
more,O
importantly,O
",",O
the,O
mortality,O
risk,O
factors,O
in,O
severe,O
COVID‐19,O
patients,O
.,O
However,O
",",O
the,O
mortality,O
risk,O
factors,O
of,O
COVID‐19,O
patients,O
have,O
not,O
yet,O
been,O
previously,O
reported,O
in,O
detail,O
.,O
289,O
patients,O
with,O
positive,O
real‐time,O
reverse,O
transcription‐polymerase,O
chain,O
reaction,O
(,O
rRT‐PCR,O
),O
results,O
of,O
SARS‐CoV‐2,O
nucleic,O
acid,O
test,O
were,O
diagnosed,O
as,O
COVID‐19,O
and,O
included,O
in,O
the,O
analysis,O
set,O
.,O
In,O
accordance,O
with,O
the,O
criteria,O
stated,O
in,O
the,O
clinical,O
guidelines,O
for,O
hospital,O
discharge,O
of,O
a,O
COVID‐19,O
patient,O
",",O
 ,O
all,O
the,O
following,O
four,O
conditions,O
should,O
be,O
met,O
:,O
(,O
a,O
),O
normal,O
temperature,O
lasting,O
longer,O
than,O
3,O
 ,O
days,O
",",O
(,O
b,O
),O
significantly,O
improved,O
respiratory,O
symptoms,O
",",O
(,O
c,O
),O
substantially,O
improved,O
acute,O
exudative,O
lesions,O
on,O
chest,O
CT,O
images,O
",",O
and,O
(,O
d,O
),O
two,O
consecutive,O
negative,O
nucleic,O
acid,O
test,O
results,O
of,O
respiratory,O
tract,O
samples,O
(,O
at,O
least,O
24,O
 ,O
hours,O
apart,O
),O
.,O
A,O
total,O
of,O
289,O
patients,O
with,O
COVID‐19,O
were,O
included,O
in,O
this,O
study,O
.,O
Multivariate,O
analysis,O
indicated,O
that,O
the,O
age,O
of,O
patients,O
(,O
OR,O
",",O
1.04,O
;,O
95,O
%,O
CI,O
",",O
1.00‐1.08,O
),O
",",O
smoking,O
history,O
(,O
OR,O
",",O
5.21,O
;,O
95,O
%,O
CI,O
",",O
1.39‐19.52,O
),O
",",O
chest,O
tightness,O
/,O
dyspnea,O
(,O
OR,O
",",O
3.03,O
;,O
95,O
%,O
CI,O
",",O
1.18‐7.79,O
),O
",",O
number,O
of,O
affected,O
lobes,O
on,O
admission,O
(,O
OR,O
",",O
1.71,O
;,O
95,O
%,O
CI,O
",",O
1.06‐2.78,O
),O
",",O
and,O
CRP,O
levels,O
on,O
admission,O
(,O
OR,O
",",O
1.01,O
;,O
95,O
%,O
CI,O
",",O
1.00‐1.02,O
),O
were,O
risk,O
factors,O
associated,O
with,O
death,O
in,O
cases,O
with,O
severe,O
COVID‐19,O
(,O
Table,O
 ,O
4,O
",",O
Figure,O
 ,O
1,O
),O
.,O
Risk,O
factors,O
associated,O
with,O
death,O
in,O
critically,O
ill,O
 ,O
COVID‐19,O
patients,O
Of,O
the,O
289,O
laboratory‐confirmed,O
COVID‐19,O
cases,O
in,O
this,O
study,O
",",O
most,O
of,O
the,O
patients,O
were,O
more,O
than,O
50,O
 ,O
years,O
old,O
",",O
with,O
an,O
almost,O
1:1,O
female‐male,O
ratio,O
.,O
The,O
present,O
study,O
supports,O
the,O
association,O
of,O
elderly,O
age,O
and,O
increased,O
mortality,O
rate,O
in,O
COVID‐19,O
patients,O
",",O
in,O
accordance,O
with,O
a,O
previous,O
study,O
.,O
Several,O
studies,O
have,O
reported,O
that,O
hypertension,O
",",O
hypoxia,O
",",O
leukocytosis,O
",",O
lymphopenia,O
",",O
and,O
high,O
serum,O
LDH,O
levels,O
were,O
independent,O
predictors,O
for,O
in‐hospital,O
death,O
.,O
",",O
 ,O
",",O
 ,O
",",O
  ,O
However,O
",",O
in,O
the,O
present,O
study,O
",",O
only,O
dyspnea,O
and,O
leukocytosis,O
were,O
found,O
to,O
be,O
independent,O
risk,O
factors,O
of,O
death,O
in,O
critically,O
ill,O
COVID‐19,O
patients,O
.,O
Previous,O
reports,O
identified,O
that,O
lower,O
baseline,O
levels,O
and/or,O
progressively,O
decreasing,O
platelet,O
counts,O
were,O
associated,O
with,O
higher,O
mortality,O
of,O
COVID‐19,O
patients,O
.,O
Elevated,O
IL‐6,O
",",O
which,O
is,O
the,O
trigger,O
of,O
CRP,O
synthesis,O
in,O
the,O
liver,O
",",O
was,O
also,O
observed,O
in,O
COVID‐19,O
patients,O
.,O
A,O
cytokine,O
storm,O
has,O
been,O
suggested,O
as,O
a,O
culprit,O
for,O
poor,O
prognosis,O
of,O
critically,O
ill,O
COVID‐19,O
patients,O
.,O
Wang,O
et,O
al,O
identified,O
higher,O
levels,O
of,O
CRP,O
in,O
nonsurvivors,O
compared,O
with,O
survivors,O
within,O
15,O
 ,O
days,O
of,O
COVID‐19,O
hospitalization,O
.,O
Wu,O
et,O
al,O
found,O
that,O
elevated,O
high‐sensitivity,O
CRP,O
was,O
significantly,O
associated,O
with,O
higher,O
risks,O
of,O
acute,O
respiratory,O
distress,O
syndrome,O
(,O
ARDS,O
),O
in,O
COVID‐19,O
patients,O
.,O
The,O
data,O
suggested,O
that,O
CRP,O
was,O
a,O
marker,O
of,O
a,O
developing,O
cytokine,O
storm,O
in,O
COVID‐19,O
patients,O
and,O
was,O
associated,O
with,O
disease,O
mortality,O
.,O
In,O
a,O
recent,O
study,O
",",O
 ,O
higher,O
NLR,O
was,O
suggested,O
to,O
be,O
independent,O
risk,O
factors,O
of,O
mortality,O
in,O
hospitalized,O
COVID‐19,O
patients,O
.,O
Similarly,O
",",O
Mehra,O
et,O
al,O
 ,O
demonstrated,O
that,O
current,O
smokers,O
had,O
higher,O
in‐hospital,O
death,O
rate,O
in,O
COVID‐19,O
patients,O
.,O
In,O
view,O
of,O
these,O
results,O
",",O
smoking,O
should,O
not,O
be,O
considered,O
a,O
preventive,O
measure,O
for,O
COVID‐19,O
and,O
as,O
a,O
public,O
health,O
issue,O
should,O
be,O
discouraged,O
at,O
all,O
times,O
.,O
Although,O
smoking,O
is,O
a,O
major,O
cause,O
of,O
chronic,O
obstructive,O
pulmonary,O
disease,O
(,O
COPD,O
),O
",",O
a,O
recent,O
study,O
reported,O
that,O
COPD,O
did,O
not,O
increase,O
the,O
risk,O
of,O
COVID‐19,O
patients,O
requiring,O
admission,O
to,O
the,O
intensive,O
care,O
unit,O
(,O
ICU,O
),O
.,O
The,O
higher,O
levels,O
of,O
ACE2,O
expression,O
in,O
the,O
lower,O
respiratory,O
tract,O
of,O
current,O
smokers,O
may,O
contribute,O
to,O
the,O
increased,O
risk,O
of,O
developing,O
severe,O
COVID‐19,O
.,O
",",O
The,O
strong,O
positive,O
correlations,O
identified,O
between,O
the,O
affected,O
lobe,O
numbers,O
",",O
patients,O
’,O
age,O
",",O
neutrophil,O
",",O
and,O
lymphocyte,O
counts,O
indicate,O
that,O
more,O
severe,O
pneumonia,O
was,O
associated,O
with,O
elderly,O
age,O
and,O
higher,O
degree,O
of,O
lymphopenia,O
",",O
indicating,O
that,O
the,O
numbers,O
of,O
affected,O
lobes,O
could,O
be,O
a,O
possible,O
risk,O
factor,O
for,O
severe,O
cases,O
and,O
in‐hospital,O
mortality,O
of,O
severe,O
COVID‐19,O
patients,O
.,O
As,O
previously,O
reported,O
",",O
eosinopenia,O
may,O
be,O
an,O
indicator,O
for,O
SARS‐CoV‐2,O
infection,O
",",O
 ,O
and,O
the,O
degree,O
of,O
eosinopenia,O
was,O
associated,O
with,O
the,O
severity,O
of,O
COVID‐19,O
.,O
",",O
  ,O
Persistent,O
eosinopenia,O
may,O
be,O
a,O
predictor,O
of,O
disease,O
severity,O
and,O
adverse,O
clinical,O
outcome,O
during,O
hospitalization,O
",",O
which,O
is,O
consistent,O
with,O
the,O
results,O
reported,O
by,O
Xie,O
et,O
al,O
.,O
The,O
anti‐viral,O
effect,O
exhausts,O
eosinophils,O
and,O
may,O
be,O
the,O
cause,O
of,O
eosinopenia,O
in,O
COVID‐19,O
patients,O
.,O
Lymphopenia,O
is,O
prominent,O
in,O
adult,O
COVID‐19,O
patients,O
",",O
but,O
not,O
in,O
pediatric,O
patients,O
.,O
However,O
",",O
multivariate,O
regression,O
analysis,O
did,O
not,O
identify,O
D‐dimer,O
as,O
an,O
independent,O
risk,O
factor,O
of,O
the,O
mortality,O
in,O
severe,O
COVID‐19,O
patients,O
.,O
This,O
was,O
consistent,O
with,O
a,O
previous,O
study,O
conducted,O
by,O
Chen,O
et,O
al,O
",",O
 ,O
but,O
different,O
from,O
the,O
result,O
from,O
Zhou,O
et,O
al,O
",",O
which,O
showed,O
that,O
elevated,O
D‐dimer,O
was,O
associated,O
with,O
poor,O
prognosis,O
of,O
hospitalized,O
COVID‐19,O
patients,O
.,O
A,O
recent,O
study,O
on,O
COVID‐19,O
patients,O
in,O
Wuhan,O
revealed,O
an,O
extremely,O
high,O
incidence,O
of,O
thrombosis,O
(,O
41/48,O
",",O
85.4,O
%,O
),O
in,O
severe,O
patients,O
with,O
a,O
death,O
rate,O
of,O
31.7,O
%,O
(,O
13/41,O
),O
.,O
In,O
addition,O
",",O
elevated,O
D‐dimer,O
levels,O
could,O
occur,O
in,O
deep,O
venous,O
thrombosis,O
(,O
DVT,O
),O
and,O
in,O
capillary,O
microthrombi,O
",",O
secondary,O
to,O
pulmonary,O
capillary,O
endothelial,O
injury,O
",",O
contributing,O
to,O
the,O
death,O
of,O
severe,O
COVID‐19,O
patients,O
.,O
Venous,O
thromboembolism,O
(,O
VTE,O
),O
had,O
a,O
higher,O
incidence,O
in,O
ICU,O
COVID‐19,O
patients,O
than,O
those,O
on,O
the,O
wards,O
",",O
and,O
the,O
incidence,O
increased,O
along,O
with,O
the,O
duration,O
of,O
hospitalization,O
.,O
A,O
study,O
of,O
184,O
ICU,O
COVID‐19,O
patients,O
reported,O
that,O
computed,O
tomography,O
pulmonary,O
angiography,O
(,O
CTPA,O
),O
and/or,O
ultrasonography,O
confirmed,O
VTE,O
was,O
27,O
%,O
and,O
arterial,O
thrombotic,O
events,O
was,O
3.7,O
%,O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
has,O
become,O
a,O
global,O
pandemic,O
",",O
with,O
10%‐20,O
%,O
of,O
severe,O
cases,O
and,O
over,O
508,O
 ,O
000,O
deaths,O
worldwide,O
.,O
This,O
study,O
aims,O
to,O
address,O
the,O
risk,O
factors,O
associated,O
with,O
the,O
severity,O
of,O
COVID‐19,O
patients,O
and,O
the,O
mortality,O
of,O
severe,O
patients,O
.,O
Methods,O
 ,O
289,O
hospitalized,O
laboratory‐confirmed,O
COVID‐19,O
patients,O
were,O
included,O
in,O
this,O
study,O
.,O
Conclusions,O
 ,O
Survived,O
severe,O
and,O
nonsurvived,O
COVID‐19,O
patients,O
had,O
distinct,O
clinical,O
and,O
laboratory,O
characteristics,O
",",O
which,O
were,O
separated,O
by,O
principle,O
component,O
analysis,O
.,O
Elder,O
age,O
",",O
increased,O
number,O
of,O
affected,O
lobes,O
",",O
higher,O
levels,O
of,O
serum,O
CRP,O
",",O
chest,O
tightness,O
/,O
dyspnea,O
",",O
and,O
smoking,O
history,O
were,O
risk,O
factors,O
for,O
mortality,O
of,O
severe,O
COVID‐19,O
patients,O
.,O
This,O
study,O
compares,O
the,O
clinical,O
",",O
radiological,O
",",O
and,O
laboratory,O
characteristicsand,O
longitudinal,O
variations,O
in,O
laboratory,O
parameters,O
of,O
the,O
289,O
hospitalized,O
patients,O
with,O
COVID‐19,O
with,O
different,O
severity,O
and,O
clinical,O
outcomes,O
.,O
We,O
propose,O
that,O
elder,O
age,O
",",O
a,O
greater,O
number,O
of,O
affected,O
lobe(s,O
),O
",",O
elevated,O
C‐CRP,O
level,O
and,O
increased,O
prevalence,O
of,O
chest,O
tightness,O
/,O
dyspnea,O
and,O
smoking,O
history,O
may,O
be,O
associated,O
with,O
the,O
fatal,O
outcome,O
of,O
patients,O
with,O
severe,O
COVID‐19,O
.,O
Abbreviations,O
:,O
BUN,O
",",O
blood,O
urea,O
nitrogen,O
;,O
COVID‐19,O
",",O
coronavirus,O
infectious,O
disease,O
2019,O
;,O
CRP,O
",",O
C‐reactive,O
protein,O
;,O
NLR,O
",",O
neutrophil‐to‐leucocyte,O
ratio,O
;,O
PC1/2,O
",",O
principal,O
component,O
1/2,O
;,O
PCT,O
",",O
procalcitonin,O
.,O
To,O
determine,O
the,O
suitability,O
of,O
NHP,O
species,O
for,O
modeling,O
COVID-19,O
",",O
we,O
experimentally,O
inoculated,O
three,O
species,O
of,O
monkeys,O
belonging,O
to,O
two,O
families,O
(,O
Old,O
World,O
and,O
New,O
World,O
monkeys,O
),O
with,O
SARS,O
-,O
CoV-2,O
(,O
Fig,O
.,O
1a,O
and,O
Supplementary,O
Table,O
1,O
),O
according,O
to,O
the,O
methods,O
described,O
for,O
a,O
reported,O
SARS,O
model,O
",",O
followed,O
by,O
comprehensive,O
comparisons,O
of,O
the,O
clinical,O
signs,O
of,O
COVID-19,O
",",O
viral,O
shedding,O
and,O
replication,O
",",O
and,O
host,O
responses,O
to,O
viral,O
infection,O
.,O
Detection,O
of,O
viral,O
genomic,O
RNA,O
is,O
the,O
most,O
important,O
evidence,O
for,O
the,O
diagnosis,O
of,O
COVID-19,O
due,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
.,O
In,O
the,O
present,O
study,O
",",O
the,O
dynamics,O
of,O
viral,O
shedding,O
in,O
the,O
NHP,O
models,O
were,O
similar,O
to,O
those,O
reported,O
in,O
COVID-19,O
patients,O
.,O
The,O
lung,O
is,O
widely,O
considered,O
to,O
be,O
the,O
target,O
organ,O
of,O
SARS,O
-,O
CoV-2,O
replication,O
since,O
a,O
large,O
viral,O
copy,O
number,O
was,O
detected,O
in,O
bronchoalveolar,O
lavage,O
fluid,O
from,O
COVID-19,O
patients,O
.,O
Importantly,O
",",O
we,O
also,O
detected,O
viral,O
RNA,O
in,O
the,O
spleen,O
and,O
blood,O
of,O
our,O
model,O
",",O
which,O
is,O
consistent,O
with,O
the,O
clinical,O
findings,O
that,O
SARS,O
-,O
CoV-2,O
is,O
present,O
in,O
patients,O
’,O
spleens,O
and,O
blood,O
and,O
correlated,O
with,O
the,O
severity,O
of,O
COVID-19,O
.,O
In,O
terms,O
of,O
host,O
responses,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
our,O
NHP,O
model,O
partially,O
recapitulates,O
COVID-19,O
through,O
at,O
least,O
three,O
features,O
.,O
Typical,O
histopathology,O
of,O
pneumonia,O
is,O
observed,O
in,O
COVID-19,O
patients,O
in,O
additional,O
to,O
mild,O
inflammation,O
in,O
liver,O
.,O
The,O
COVID-19,O
-,O
associated,O
cytokine,O
storm,O
is,O
reported,O
to,O
be,O
an,O
important,O
pathogenic,O
factor,O
and,O
a,O
potential,O
promising,O
therapeutic,O
target,O
in,O
COVID-19,O
patients,O
.,O
Although,O
not,O
consistent,O
with,O
those,O
in,O
COVID-19,O
patients,O
",",O
the,O
cytokines,O
induced,O
in,O
our,O
model,O
could,O
be,O
used,O
as,O
markers,O
for,O
the,O
evaluation,O
of,O
anti,O
-,O
inflammatory,O
drugs,O
.,O
Elevated,O
serum,O
IL-6,O
is,O
clinically,O
correlated,O
with,O
the,O
severity,O
of,O
COVID-19,O
and,O
regarded,O
as,O
an,O
important,O
biomarker,O
.,O
In,O
a,O
reported,O
NHP,O
model,O
of,O
COVID-19,O
",",O
the,O
level,O
of,O
IL-6,O
peaked,O
at,O
1,O
dpi,O
and,O
decreased,O
to,O
0,O
at,O
3,O
dpi,O
.,O
Identification,O
of,O
a,O
suitable,O
nonhuman,O
primate,O
(,O
NHP,O
),O
model,O
of,O
COVID-19,O
remains,O
challenging,O
.,O
Collectively,O
",",O
these,O
data,O
revealed,O
the,O
different,O
susceptibilities,O
of,O
Old,O
World,O
and,O
New,O
World,O
monkeys,O
to,O
SARS,O
-,O
CoV-2,O
and,O
identified,O
M.,O
mulatta,O
as,O
the,O
most,O
suitable,O
for,O
modeling,O
COVID-19,O
.,O
The,O
data,O
sets,O
used,O
for,O
the,O
current,O
study,O
are,O
available,O
from,O
the,O
corresponding,O
author,O
upon,O
reasonable,O
request,O
.,O
Coronavirus,O
disease−19,O
(,O
COVID-19,O
),O
is,O
a,O
pandemic,O
disease,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
CoV-2,O
),O
which,O
originated,O
in,O
the,O
Wuhan,O
city,O
of,O
China,O
",",O
spreading,O
across,O
215,O
countries,O
and,O
affecting,O
more,O
than,O
7.2,O
million,O
people,O
worldwide,O
",",O
and,O
cases,O
are,O
still,O
increasing,O
further,O
(,O
https://www.worldometers.info/coronavirus/,S-URL
),O
.,O
The,O
diagnosis,O
of,O
coronavirus,O
disease−19,O
(,O
COVID-19,O
),O
relies,O
on,O
the,O
detection,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
CoV-2,O
),O
RNA,O
by,O
real,O
-,O
time,O
reverse,O
-,O
transcription,O
polymerase,O
chain,O
reaction,O
in,O
respiratory,O
samples,O
.,O
Rapid,O
increase,O
in,O
the,O
COVID-19,O
cases,O
across,O
the,O
world,O
requires,O
fast,O
and,O
efficient,O
testing,O
as,O
testing,O
capacity,O
is,O
a,O
bottleneck,O
in,O
diagnosis,O
.,O
Highlights,O
    ,O
•,O
 ,O
Utility,O
of,O
pooling,O
samples,O
in,O
COVID-19,O
testing,O
to,O
save,O
time,O
",",O
cost,O
",",O
and,O
manpower,O
.,O
Abstract,O
 ,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
is,O
a,O
sudden,O
viral,O
contagion,O
that,O
appeared,O
at,O
the,O
end,O
of,O
last,O
year,O
in,O
Wuhan,O
city,O
",",O
the,O
Chinese,O
province,O
of,O
Hubei,O
",",O
China,O
.,O
The,O
fast,O
spread,O
of,O
COVID-19,O
has,O
led,O
to,O
a,O
dangerous,O
threat,O
to,O
worldwide,O
health,O
.,O
In,O
this,O
research,O
",",O
an,O
automated,O
system,O
is,O
created,O
to,O
differentiate,O
between,O
the,O
COVID-19,O
",",O
SARS,O
-,O
CoV,O
and,O
MERS,O
-,O
CoV,O
epidemics,O
by,O
using,O
their,O
genomic,O
sequences,O
recorded,O
in,O
the,O
NCBI,B-Repository
GenBank,E-Repository
 ,O
in,O
order,O
to,O
facilitate,O
the,O
diagnosis,O
process,O
and,O
increase,O
the,O
accuracy,O
of,O
disease,O
detection,O
in,O
less,O
time,O
.,O
The,O
selected,O
database,O
contains,O
76,O
genes,O
for,O
each,O
epidemic,O
.,O
Hence,O
",",O
while,O
we,O
await,O
for,O
the,O
results,O
of,O
the,O
efficacy,O
of,O
camostat,O
in,O
a,O
very,O
recently,O
initiated,O
human,O
clinical,O
trial,O
with,O
COVID19,O
patients,O
(,O
https://clinicaltrials.gov/ct2/show/NCT04321096,O
),O
",",O
this,O
report,O
wishes,O
to,O
incentivize,O
once,O
again,O
private,O
and,O
public,O
efforts,O
to,O
consider,O
developing,O
new,O
pan,O
-,O
serine,O
protease,O
inhibitors,O
",",O
perhaps,O
taking,O
advantage,O
of,O
several,O
agents,O
already,O
being,O
reported,O
in,O
pre,O
-,O
clinical,O
studies,O
[,O
"36,37,38,39,40",O
],O
",",O
into,O
emergency,O
therapeutics,O
to,O
combat,O
the,O
new,O
coronavirus,O
SARS,O
-,O
CoV2,O
and,O
to,O
ward,O
off,O
future,O
similar,O
pandemics,O
that,O
are,O
likely,O
to,O
occur,O
when,O
pathogens,O
acquire,O
the,O
further,O
optimized,O
furin,O
cleavage,O
sites,O
within,O
their,O
priming,O
entry,O
mechanisms,O
.,O
Accession,O
numbers,O
for,O
sequences,O
used,O
in,O
this,O
study,O
can,O
be,O
found,O
in,O
Table,O
1,O
and,O
the,O
test,O
.,O
GSAID,S-Dataset
 ,O
is,O
a,O
free,O
-,O
to,O
-,O
use,O
resource,O
",",O
but,O
requires,O
registration,O
prior,O
to,O
accessing,O
.,O
On,O
April,O
27,O
",",O
2020,O
",",O
the,O
first,O
five,O
sequences,O
from,O
the,O
state,O
of,O
West,O
Bengal,O
(,O
Eastern,O
India,O
),O
were,O
deposited,O
on,O
GISAID,S-Dataset
",",O
a,O
global,O
initiative,O
for,O
sharing,O
avian,O
flu,O
data,O
.,O
To,O
test,O
the,O
hypothesis,O
and,O
to,O
estimate,O
the,O
extent,O
to,O
which,O
exposition,O
to,O
air,O
pollution,O
can,O
increase,O
the,O
risk,O
of,O
viral,O
infections,O
",",O
we,O
performed,O
a,O
statistical,O
analysis,O
correlating,O
the,O
number,O
of,O
infected,O
people,O
and,O
COVID-19,O
mortality,O
indexes,O
in,O
the,O
period,O
20,O
February–31,O
March,O
2020,O
to,O
the,O
particulate,O
matter,O
(,O
PM)2.5,O
concentration,O
levels,O
in,O
110,O
Italian,O
provinces,O
in,O
the,O
period,O
16–26,O
February,O
2020,O
.,O
The,O
CAMS,O
near,O
-,O
real,O
-,O
time,O
reanalysis,O
is,O
the,O
most,O
recent,O
global,O
reanalysis,O
data,O
set,O
of,O
atmospheric,O
composition,O
and,O
air,O
quality,O
[,O
14,O
],O
",",O
with,O
a,O
demonstrated,O
unprecedented,O
level,O
of,O
accuracy,O
and,O
space,O
–,O
time,O
resolution,O
.,O
Data,O
on,O
the,O
population,O
for,O
all,O
Italian,O
provinces,O
has,O
been,O
extracted,O
from,O
the,O
ISTAT,S-Dataset
 ,O
Dataset,O
[,O
15,O
],O
",",O
while,O
the,O
number,O
of,O
infected,O
patients,O
has,O
been,O
extracted,O
from,O
the,O
Italian,B-Creator
Civil,I-Creator
Protection,I-Creator
Department,E-Creator
 ,O
database,O
[,O
16,O
],O
.,O
The,O
number,O
of,O
deaths,O
due,O
to,O
COVID-19,O
over,O
the,O
time,O
period,O
20,O
February–31,O
March,O
2020,O
for,O
the,O
110,O
Italian,O
provinces,O
are,O
from,O
the,O
Italian,B-Dataset
Statistics,I-Dataset
Institute,I-Dataset
(ISTAT),E-Dataset
 ,O
report,O
[,O
1,O
],O
.,O
The,O
“,O
mortality,O
rate,O
”,O
for,O
COVID-19,O
was,O
defined,O
as,O
the,O
number,O
of,O
deaths,O
normalized,O
to,O
the,O
province,O
population,O
[,O
18,O
],O
",",O
which,O
quantifies,O
the,O
frequency,O
of,O
death,O
occurrence,O
in,O
a,O
defined,O
population,O
.,O
Surface,O
PM2.5,O
concentration,O
measurements,O
from,O
ground,O
stations,O
and,O
COVID-19,O
epidemiology,O
are,O
shown,O
in,O
Figure,O
3,O
for,O
the,O
110,O
Italian,O
provinces,O
with,O
color,O
-,O
coded,O
maps,O
.,O
Visual,O
inspection,O
reveals,O
good,O
overlap,O
in,O
the,O
intensity,O
scale,O
between,O
PM2.5,O
concentration,O
values,O
",",O
averaged,O
over,O
the,O
period,O
15–26,O
February,O
2020,O
(,O
panel,O
A,O
),O
",",O
and,O
COVID-19,O
epidemiology,O
over,O
the,O
period,O
20,O
February–31,O
March,O
2020,O
",",O
e.g.,O
",",O
the,O
incidence,O
of,O
COVID-19,O
cases,O
(,O
panel,O
B,O
),O
",",O
the,O
mortality,O
rate,O
(,O
panel,O
C,O
),O
and,O
the,O
case,O
fatality,O
rate,O
(,O
panel,O
D,O
),O
.,O
The,O
correlations,O
between,O
PM2.5,O
and,O
COVID-19,O
cases,O
and,O
outcome,O
were,O
statistically,O
significant,O
.,O
In,O
detail,O
",",O
we,O
found,O
a,O
positive,O
correlation,O
(,O
r,O
=,O
0.67,O
",",O
p,O
<,O
0.0001,O
),O
between,O
the,O
average,O
PM2.5,O
level,O
in,O
the,O
period,O
15–26,O
February,O
2020,O
and,O
the,O
incidence,O
of,O
COVID-19,O
(,O
infected,O
/,O
population,O
ratio,O
),O
in,O
the,O
period,O
20,O
February–31,O
March,O
2020,O
(,O
Figure,O
4,O
",",O
panel,O
A,O
),O
.,O
Different,O
reports,O
from,O
China,O
",",O
which,O
was,O
first,O
affected,O
by,O
the,O
pandemic,O
and,O
has,O
relevant,O
pollution,O
problems,O
",",O
found,O
significant,O
links,O
between,O
different,O
pollutants,O
",",O
including,O
PM2.5,O
",",O
and,O
COVID-19,O
confirmed,O
cases,O
[,O
"29,30",O
],O
and,O
similar,O
associations,O
were,O
evidenced,O
in,O
the,O
United,O
States,O
[,O
31,O
],O
.,O
In,O
Italy,O
",",O
the,O
association,O
of,O
pollution,O
with,O
increased,O
rates,O
of,O
COVID-19,O
cases,O
was,O
first,O
proposed,O
by,O
Conticini,O
et,O
al,O
.,O
[,O
32,O
],O
.,O
Soon,O
after,O
",",O
Fattorini,O
and,O
Regoli,O
[,O
33,O
],O
demonstrated,O
a,O
statistically,O
significant,O
correlation,O
with,O
various,O
pollutants,O
(,O
NO2,O
",",O
O3,O
",",O
PM2.5,O
and,O
PM10,O
),O
with,O
the,O
number,O
of,O
COVID-19,O
cases,O
in,O
71,O
Italian,O
provinces,O
.,O
Being,O
confirmatory,O
of,O
previous,O
general,O
results,O
",",O
data,O
from,O
our,O
study,O
give,O
an,O
in,O
-,O
deep,O
look,O
at,O
the,O
strength,O
of,O
correlation,O
between,O
PM2.5,O
and,O
the,O
extent,O
of,O
the,O
COVID-19,O
outbreak,O
.,O
In,O
particular,O
",",O
we,O
performed,O
correlation,O
analysis,O
:,O
(,O
i,O
),O
considering,O
data,O
from,O
all,O
Italian,O
provinces,O
and,O
(,O
ii,O
),O
considering,O
the,O
COVID-19,O
cases,O
and,O
outcomes,O
normalized,O
by,O
the,O
population,O
(,O
incidence,O
and,O
mortality,O
rate,O
),O
or,O
by,O
the,O
infected,O
population,O
(,O
case,O
fatality,O
risk,O
),O
.,O
Enhanced,O
persistence,O
of,O
the,O
virus,O
in,O
the,O
air,O
",",O
promotion,O
of,O
a,O
pro,O
-,O
inflammatory,O
state,O
",",O
immune,O
dysregulation,O
",",O
disturbance,O
of,O
pulmonary,O
surfactant,O
homeostasis,O
and,O
increased,O
expression,O
of,O
the,O
viral,O
receptor,O
ACE-2,O
[,O
36,O
],O
have,O
been,O
proposed,O
as,O
possible,O
links,O
between,O
air,O
pollution,O
and,O
COVID-19,O
.,O
The,O
differential,O
expression,O
level,O
of,O
ACE-2,O
in,O
various,O
human,O
tissues,O
explains,O
the,O
COVID-19,O
symptomatology,O
:,O
it,O
is,O
extensively,O
expressed,O
in,O
the,O
upper,O
part,O
of,O
the,O
esophagus,O
",",O
in,O
the,O
lung,O
",",O
in,O
enterocytes,O
[,O
37,O
],O
.,O
Accordingly,O
",",O
the,O
different,O
prevalence,O
and,O
severity,O
of,O
COVID-19,O
in,O
male,O
and,O
females,O
gave,O
rise,O
to,O
the,O
hypothesis,O
of,O
differential,O
",",O
gender,O
-,O
related,O
expression,O
of,O
ACE-2,O
.,O
Similarly,O
",",O
ACE-2,O
up,O
-,O
regulation,O
following,O
treatment,O
with,O
anti,O
-,O
hypertensive,O
drugs,O
such,O
a,O
angiotensin,O
AT1,O
receptor,O
blockers,O
",",O
has,O
been,O
proposed,O
as,O
contributing,O
to,O
the,O
increased,O
susceptibility,O
of,O
aged,O
peoples,O
to,O
COVID-19,O
[,O
39,O
],O
.,O
Notably,O
",",O
following,O
the,O
binding,O
of,O
the,O
viral,O
spike,O
protein,O
",",O
the,O
level,O
of,O
ACE-2,O
on,O
the,O
cell,O
surface,O
decreases,O
[,O
47,O
],O
",",O
shifting,O
the,O
ACE,O
/,O
ACE-2,O
balance,O
towards,O
activation,O
of,O
the,O
inflammatory,O
cascade,O
",",O
which,O
represent,O
a,O
hallmark,O
of,O
COVID-19,O
.,O
The,O
COVID-19,O
/,O
SARS,O
-,O
CoV-2,O
pandemic,O
struck,O
health,O
",",O
social,O
and,O
economic,O
systems,O
worldwide,O
",",O
and,O
represents,O
an,O
open,O
challenge,O
for,O
scientists,O
—,O
coping,O
with,O
the,O
high,O
inter,O
-,O
individual,O
variability,O
of,O
COVID-19,O
",",O
and,O
for,O
policy,O
makers,O
—,O
coping,O
with,O
the,O
responsibility,O
to,O
understand,O
environmental,O
factors,O
affecting,O
its,O
severity,O
across,O
different,O
geographical,O
areas,O
.,O
Air,O
quality,O
and,O
COVID-19,O
epidemiological,O
data,O
from,O
110,O
Italian,O
provinces,O
were,O
studied,O
by,O
correlation,O
analysis,O
",",O
to,O
evaluate,O
the,O
association,O
between,O
particulate,O
matter,O
(,O
PM,O
),O
2.5,O
concentrations,O
and,O
incidence,O
",",O
mortality,O
rate,O
and,O
case,O
fatality,O
risk,O
of,O
COVID-19,O
in,O
the,O
period,O
20,O
February–31,O
March,O
2020,O
.,O
Positive,O
correlations,O
between,O
PM,O
2.5,O
levels,O
and,O
the,O
incidence,O
(,O
r,O
=,O
0.67,O
",",O
p,O
<,O
0.0001,O
),O
",",O
the,O
mortality,O
rate,O
(,O
r,O
=,O
0.65,O
",",O
p,O
<,O
0.0001,O
),O
and,O
the,O
case,O
fatality,O
rate,O
(,O
r,O
=,O
0.7,O
",",O
p,O
<,O
0.0001,O
),O
of,O
COVID-19,O
were,O
found,O
.,O
Infectious,O
virus,O
titers,O
ranged,O
from,O
100.75,O
to,O
102.75,O
TCID50,O
/,O
ml,O
(,O
median,O
tissue,O
culture,O
infectious,O
dose,O
per,O
ml,O
),O
in,O
the,O
donor,O
ferrets,O
",",O
from,O
100.75,O
to,O
103.5,O
TCID50,O
/,O
ml,O
in,O
the,O
direct,O
contact,O
ferrets,O
and,O
from,O
100.75,O
to,O
104.25,O
TCID50,O
/,O
ml,O
in,O
the,O
indirect,O
recipient,O
ferrets,O
.,O
Four,O
donor,O
ferrets,O
were,O
inoculated,O
intranasally,O
with,O
6,O
 ,O
×,O
 ,O
105,O
TCID50,O
of,O
SARS,O
-,O
CoV-2,O
virus,O
diluted,O
in,O
500,O
 ,O
μl,O
of,O
phosphate,O
-,O
buffered,O
saline,O
(,O
PBS,O
),O
(,O
250,O
 ,O
μl,O
instilled,O
dropwise,O
in,O
each,O
nostril,O
),O
and,O
were,O
housed,O
individually,O
in,O
a,O
cage,O
.,O
COVID-19,O
has,O
become,O
a,O
planetary,O
emergency,O
which,O
is,O
seriously,O
threatening,O
human,O
health,O
[,O
1,O
",",O
2,O
],O
.,O
E,O
sequences,O
differ,O
from,O
the,O
homologous,O
proteins,O
also,O
at,O
positions,O
55,O
-,O
56,O
",",O
where,O
the,O
dyad,O
Ser,O
-,O
Phe,O
replaces,O
Thr,O
-,O
Val,O
(,O
except,O
in,O
Bat,O
coronavirus,O
isolate,O
BtKY72,O
",",O
accession,O
code,O
KY352407,S-AccessionNumber
),O
.,O
The,O
size,O
of,O
each,O
Envelope,O
variant,O
cluster,O
is,O
reported,O
in,O
Table,O
1,O
along,O
with,O
accession,O
codes,O
and,O
definitions,O
of,O
the,O
isolates,O
.,O
The,O
size,O
of,O
each,O
Membrane,O
variant,O
cluster,O
is,O
reported,O
in,O
Table,O
1,O
along,O
with,O
accession,O
codes,O
and,O
definitions,O
of,O
the,O
isolates,O
.,O
Noteworthy,O
",",O
the,O
protein,O
from,O
the,O
Sars,O
-,O
CoV-2,O
NIHE,O
isolate,O
(,O
accession,O
code,O
MT127115,S-AccessionNumber
),O
possesses,O
an,O
Arg,O
instead,O
of,O
a,O
conserved,O
Gly,O
at,O
position,O
89,O
(,O
Figure,O
3,O
),O
.,O
According,O
to,O
the,O
accepted,O
theories,O
",",O
the,O
current,O
COVID-19,O
pandemic,O
has,O
been,O
caused,O
by,O
the,O
cross,O
-,O
species,O
transmission,O
of,O
a,O
β,O
-,O
coronavirus,O
normally,O
hosted,O
by,O
Bats,O
and,O
",",O
perhaps,O
",",O
Pangolin,O
to,O
humans,O
[,O
3,O
",",O
26,O
],O
.,O
In,O
this,O
paper,O
",",O
E,O
and,O
M,O
proteins,O
from,O
797,O
Sars,O
-,O
CoV-2,O
genomes,O
have,O
been,O
compared,O
to,O
the,O
counterparts,O
taken,O
from,O
the,O
most,O
closely,O
related,O
virus,O
also,O
to,O
evaluate,O
the,O
potential,O
role,O
of,O
amino,O
acid,O
mutations,O
in,O
the,O
epizootic,O
origin,O
of,O
COVID-19,O
.,O
The,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
is,O
a,O
new,O
viral,O
infection,O
caused,O
by,O
the,O
severe,O
acute,O
respiratory,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
We,O
firstly,O
collected,O
the,O
representative,O
SARS,O
-,O
COV-2,O
genome,O
(,O
MN908947,S-AccessionNumber
",",O
https://www.ncbi.nlm.nih.gov/nuccore/MN908947,S-URL
),O
and,O
the,O
mutation,O
information,O
of,O
the,O
SARS,O
-,O
COV-2,O
genomes,O
from,O
the,O
2019nCoVR,S-Dataset
 ,O
database,O
(,O
Zhao,O
et,O
al.2020,O
),O
",",O
which,O
is,O
available,O
at,O
https://bigd.big.ac.cn/ncov/,S-URL
.,O
The,O
2019nCoVR,S-Dataset
 ,O
database,O
not,O
only,O
integrates,O
genomic,O
and,O
proteomic,O
sequences,O
of,O
SARS,O
-,O
COV-2,O
from,O
different,O
resources,O
",",O
but,O
also,O
provides,O
a,O
series,O
of,O
scientific,O
services,O
",",O
such,O
as,O
variation,O
visualization,O
",",O
variation,O
annotations,O
",",O
AI,O
diagnosis,O
",",O
etc,O
.,O
In,O
addition,O
",",O
we,O
also,O
analyzed,O
the,O
mutations,O
of,O
the,O
target,O
sequences,O
by,O
comparing,O
all,O
the,O
143,O
high,O
quality,O
strains,O
in,O
the,O
2019nCoVR,S-Dataset
 ,O
database,O
(,O
as,O
of,O
March,O
15,O
",",O
2020,O
),O
.,O
The,O
spike,O
protein,O
",",O
the,O
major,O
envelope,O
protein,O
of,O
HCoV,O
-,O
NL63,O
",",O
specifically,O
binds,O
to,O
the,O
zinc,O
peptidase,O
angiotensin,O
-,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
identified,O
as,O
the,O
receptor,O
for,O
pathogenic,O
coronaviruses,O
SARS,O
-,O
CoV,O
and,O
COVID-19,O
(,O
formerly,O
known,O
as,O
Wuhan,O
coronavirus,O
",",O
2019,O
-,O
nCoV,O
",",O
and,O
SARS,O
-,O
CoV-2,O
),O
[,O
"16,17,18,19",O
],O
.,O
The,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
named,O
the,O
disease,O
COVID-19,O
",",O
short,O
for,O
“,O
coronavirus,O
disease,O
2019,O
”,O
.,O
As,O
of,O
27,O
May,O
2020,O
",",O
the,O
WHO,O
reported,O
a,O
total,O
of,O
5,O
 ,O
488,O
 ,O
825,O
COVID-19,O
cases,O
and,O
349,O
 ,O
095,O
deaths,O
globally,O
[,O
3,O
],O
",",O
which,O
brought,O
a,O
great,O
challenge,O
to,O
public,O
health,O
worldwide,O
.,O
Its,O
genome,O
sequence,O
has,O
been,O
released,O
and,O
reported,O
by,O
Chinese,O
scientists,O
and,O
submitted,O
to,O
the,O
GenBank,S-Repository
 ,O
database,O
on,O
12,O
January,O
2020,O
[,O
5,O
],O
.,O
Protein,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
were,O
retrieved,O
from,O
the,O
NCBI,S-Repository
 ,O
database,O
(,O
YP_009724390,S-AccessionNumber
",",O
YP_009724397,S-AccessionNumber
),O
.,O
Prediction,O
of,O
discontinuous,O
epitopes,O
on,O
spike,O
protein,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6VSB,S-AccessionNumber
 ,O
chain,O
B,O
),O
was,O
conducted,O
via,O
DiscoTope,O
2.0,O
server,O
[,O
19,O
],O
.,O
This,O
method,O
is,O
based,O
on,O
surface,O
accessibility,O
",",O
residue,O
statistics,O
",",O
and,O
spatial,O
information,O
in,O
a,O
compiled,O
data,O
set,O
of,O
discontinuous,O
epitopes,O
discovered,O
by,O
X,O
-,O
ray,O
crystallography,O
of,O
antigen,O
/,O
antibody,O
complex,O
structure,O
.,O
All,O
protein,O
sequences,O
were,O
downloaded,O
from,O
NCBI,S-Repository
 ,O
database,O
with,O
accession,O
IDs,O
shown,O
in,O
Fig,O
.,O
2a,O
.,O
These,O
peptides,O
were,O
scanned,O
on,O
the,O
IEDB,S-Repository
 ,O
database,O
.,O
The,O
genome,O
sequence,O
and,O
protein,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
were,O
retrieved,O
from,O
the,O
National,B-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,I-Repository
(NCBI),E-Repository
 ,O
database,O
.,O
After,O
the,O
announcement,O
by,O
the,O
UK,O
Government,O
on,O
March,O
23,O
",",O
2020,O
",",O
of,O
implementation,O
of,O
a,O
nationwide,O
lockdown,O
to,O
combat,O
the,O
COVID-19,O
pandemic,O
",",O
hospital,O
referrals,O
for,O
non,O
-,O
COVID-19,O
-,O
related,O
illnesses,O
have,O
decreased,O
substantially,O
.,O
As,O
the,O
lockdown,O
is,O
lifted,O
",",O
a,O
surge,O
in,O
presentations,O
for,O
non,O
-,O
COVID-19,O
-,O
related,O
medical,O
issues,O
is,O
anticipated,O
.,O
For,O
the,O
calculation,O
of,O
the,O
case,O
-,O
fatality,O
rate,O
associated,O
with,O
unselected,O
COVID-19,O
infection,O
",",O
we,O
used,O
published,O
data,O
from,O
China,O
because,O
UK,O
COVID-19,O
case,O
-,O
fatality,O
rate,O
estimates,O
were,O
only,O
available,O
for,O
patients,O
who,O
had,O
been,O
admitted,O
to,O
hospital,O
.,O
To,O
calculate,O
COVID-19,O
-,O
related,O
mortality,O
in,O
patients,O
with,O
cancer,O
",",O
we,O
first,O
estimated,O
peri,O
-,O
surgical,O
mortality,O
from,O
nosocomial,O
infection,O
as,O
the,O
product,O
of,O
operation,O
-,O
specific,O
duration,O
of,O
surgical,O
admission,O
",",O
age,O
-,O
specific,O
case,O
-,O
fatality,O
rates,O
",",O
and,O
the,O
rate,O
of,O
nosocomial,O
infection,O
per,O
day,O
(,O
1,O
%,O
",",O
2,O
%,O
",",O
5,O
%,O
",",O
or,O
10,O
%,O
),O
.,O
Then,O
we,O
estimated,O
COVID-19,O
-,O
related,O
mortality,O
in,O
the,O
community,O
ascribing,O
the,O
patient,O
a,O
year,O
of,O
active,O
cancer,O
management,O
status,O
;,O
this,O
estimate,O
was,O
the,O
product,O
of,O
the,O
likelihood,O
of,O
community,O
-,O
acquired,O
COVID-19,O
during,O
the,O
year,O
(,O
1,O
%,O
",",O
10,O
%,O
",",O
20,O
%,O
",",O
or,O
50,O
%,O
),O
",",O
age,O
-,O
specific,O
case,O
-,O
fatality,O
rates,O
",",O
and,O
the,O
increase,O
in,O
COVID-19,O
case,O
-,O
fatality,O
rate,O
as,O
a,O
consequence,O
of,O
cancer,O
as,O
a,O
comorbidity,O
(,O
two,O
times,O
or,O
five,O
times,O
),O
.,O
To,O
estimate,O
10,O
-,O
year,O
survival,O
for,O
individuals,O
diagnosed,O
with,O
stage,O
I,O
–,O
III,O
cancer,O
who,O
have,O
no,O
delay,O
in,O
treatment,O
",",O
we,O
used,O
NCRAS,S-Repository
 ,O
10,O
-,O
year,O
survival,O
data,O
and,O
adjusted,O
for,O
COVID-19,O
-,O
related,O
peri,O
-,O
surgical,O
and,O
community,O
mortality,O
.,O
To,O
estimate,O
10,O
-,O
year,O
survival,O
associated,O
with,O
delay,O
",",O
we,O
applied,O
the,O
delay,O
HR,O
relating,O
to,O
the,O
specified,O
number,O
of,O
days,O
of,O
delay,O
",",O
along,O
with,O
the,O
COVID-19,O
-,O
related,O
peri,O
-,O
surgical,O
and,O
community,O
mortality,O
",",O
to,O
the,O
NCRAS,S-Repository
 ,O
10,O
-,O
year,O
survival,O
(,O
formulas,O
are,O
in,O
appendix,O
1,O
[,O
pp,O
1–3,O
],O
),O
.,O
We,O
combined,O
per,O
-,O
day,O
rates,O
of,O
nosocomial,O
infection,O
with,O
the,O
age,O
-,O
specific,O
COVID-19,O
case,O
-,O
fatality,O
rates,O
to,O
quantify,O
the,O
COVID-19,O
-,O
related,O
fatality,O
associated,O
with,O
investigatory,O
referral,O
.,O
Unless,O
otherwise,O
specified,O
",",O
we,O
applied,O
the,O
default,O
values,O
for,O
likelihood,O
of,O
community,O
-,O
acquired,O
COVID-19,O
",",O
which,O
was,O
20,O
%,O
",",O
and,O
per,O
-,O
day,O
rate,O
of,O
nosocomial,O
infection,O
",",O
which,O
was,O
2,O
%,O
",",O
which,O
were,O
selected,O
to,O
be,O
conservatively,O
high,O
.,O
For,O
cancer,O
-,O
related,O
increase,O
in,O
mortality,O
due,O
to,O
community,O
-,O
acquired,O
COVID-19,O
",",O
we,O
used,O
a,O
default,O
value,O
of,O
two,O
times,O
",",O
which,O
is,O
at,O
the,O
low,O
-,O
to,O
-,O
intermediate,O
end,O
of,O
the,O
published,O
estimates,O
(,O
reflecting,O
a,O
non,O
-,O
metastatic,O
cancer,O
population,O
;,O
appendix,O
1,O
p,O
1,O
),O
.,O
Issues,O
of,O
capacity,O
and,O
delays,O
in,O
diagnosis,O
are,O
of,O
global,O
interest,O
as,O
part,O
of,O
moving,O
towards,O
benchmarked,O
metrics,O
(,O
eg,O
",",O
International,O
Cancer,O
Benchmarking,O
Partnership).3,O
",",O
23,O
Our,O
analyses,O
at,O
the,O
level,O
of,O
referral,O
are,O
subject,O
to,O
the,O
limitations,O
of,O
data,O
collection,O
for,O
diagnostic,O
-,O
conversion,O
rates,O
",",O
which,O
were,O
only,O
available,O
at,O
the,O
level,O
of,O
tumour,O
-,O
referral,O
group,O
",",O
precluding,O
analyses,O
specific,O
to,O
age,O
stratum,O
or,O
tumour,O
type,O
-,O
specific,O
symptomatology,O
.,O
The,O
severity,O
of,O
local,O
COVID-19,O
patterns,O
",",O
method,O
-,O
specific,O
diagnostic,O
capacity,O
",",O
and,O
organisation,O
of,O
cancer,O
services,O
will,O
all,O
have,O
an,O
effect,O
",",O
as,O
will,O
local,O
variation,O
in,O
pathway,O
innovations,O
in,O
both,O
diagnostics,O
(,O
FIT,O
triage,O
",",O
colonography,O
),O
and,O
treatment,O
(,O
a,O
priori,O
use,O
of,O
radiotherapy,O
and,O
hormonal,O
treatments,O
),O
.,O
Background,O
 ,O
During,O
the,O
COVID-19,O
lockdown,O
",",O
referrals,O
via,O
the,O
2,O
-,O
week,O
-,O
wait,O
urgent,O
pathway,O
for,O
suspected,O
cancer,O
in,O
England,O
",",O
UK,O
",",O
are,O
reported,O
to,O
have,O
decreased,O
by,O
up,O
to,O
84,O
%,O
.,O
Using,O
referral,O
-,O
to,O
-,O
diagnosis,O
conversion,O
rates,O
and,O
COVID-19,O
case,O
-,O
fatality,O
rates,O
",",O
we,O
also,O
estimated,O
the,O
survival,O
increment,O
per,O
patient,O
referred,O
.,O
The,O
SARS,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
pandemic,O
is,O
a,O
global,O
challenge,O
",",O
which,O
the,O
scientific,O
community,O
has,O
tackled,O
by,O
mounting,O
extensive,O
global,O
collaborations,O
",",O
combining,O
expertise,O
in,O
diverse,O
areas,O
and,O
applying,O
cutting,O
-,O
edge,O
techniques,O
",",O
to,O
dissect,O
mechanisms,O
underlying,O
coronavirus,O
disease-19,O
(,O
COVID-19,O
),O
pathology,O
.,O
The,O
Human,B-Repository
Cell,I-Repository
Atlas,E-Repository
 ,O
consortium,O
in,O
collaborative,O
work,O
on,O
COVID-19,O
The,O
ongoing,O
worldwide,O
outbreak,O
of,O
the,O
novel,O
coronavirus,O
SARS,O
-,O
CoV-2,O
(,O
COVID-19,O
),O
started,O
as,O
an,O
epidemic,O
event,O
in,O
the,O
city,O
of,O
Wuhan,O
",",O
China,O
in,O
late,O
December,O
2019,O
and,O
evolved,O
as,O
a,O
pandemic,O
declared,O
by,O
March,O
2020,O
(,O
World,O
Health,O
Organization,O
",",O
2020,O
",",O
L.,O
Wang,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
According,O
to,O
the,O
report,O
of,O
the,O
World,O
Health,O
Organization,O
as,O
of,O
29,O
April,O
2020,O
",",O
the,O
current,O
outbreak,O
of,O
COVID-19,O
",",O
has,O
affected,O
over,O
"3,160,540",O
people,O
and,O
killed,O
>,O
"219,253",O
people,O
in,O
>,O
200,O
countries,O
throughout,O
the,O
world,O
",",O
and,O
only,O
few,O
countries,O
appear,O
to,O
have,O
passed,O
the,O
peak,O
.,O
In,O
Italy,O
have,O
been,O
recorded,O
"201,505",O
confirmed,O
COVID-19,O
cases,O
and,O
"27,359",O
fatalities,O
.,O
In,O
Italy,O
outbreak,O
of,O
COVID-19,O
started,O
in,O
Lombardy,O
county,O
",",O
first,O
3,O
COVID-19,O
cases,O
have,O
been,O
reported,O
on,O
15,O
February,O
2020,O
.,O
Early,O
studies,O
estimated,O
the,O
risk,O
of,O
COVID-19,O
cases,O
importation,O
to,O
Europe,O
by,O
air,O
travel,O
from,O
infected,O
areas,O
in,O
China,O
(,O
Pullano,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Also,O
",",O
air,O
pollution,O
is,O
exacerbating,O
the,O
susceptibility,O
and,O
severity,O
of,O
respiratory,O
viral,O
infections,O
like,O
as,O
coronaviruses,O
(,O
SARS,O
",",O
MARS,O
and,O
COVID-19,O
),O
",",O
with,O
a,O
high,O
impact,O
on,O
host,O
morbidity,O
and,O
mortality,O
and,O
public,O
health,O
all,O
over,O
the,O
world,O
(,O
Manisalidis,O
et,O
al,O
.,O
",",O
2020,O
;,O
Pothirat,O
et,O
al,O
.,O
",",O
2019,O
),O
.,O
Besides,O
environmental,O
pollution,O
",",O
climate,O
change,O
and,O
increased,O
frequency,O
of,O
extreme,O
events,O
as,O
a,O
recorded,O
feedback,O
of,O
anthropogenic,O
pollution,O
can,O
also,O
affect,O
the,O
geographical,O
distribution,O
of,O
several,O
infectious,O
diseases,O
including,O
COVID-19,O
(,O
Kawasaki,O
et,O
al,O
.,O
",",O
2019,O
;,O
Linares,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
As,O
an,O
infectious,O
viral,O
disease,O
SARS,O
-,O
CoV-2,O
(,O
COVID-2019,O
),O
arised,O
from,O
viruses,O
",",O
like,O
previous,O
outbreaks,O
:,O
2002–2003,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
(,O
SARS,O
-,O
CoV,O
),O
viruses,O
and,O
2012–2015,O
Middle,O
East,O
Respiratory,O
Syndrome,O
(,O
MERS,O
-,O
CoV,O
),O
",",O
belongs,O
to,O
human,O
Beta,O
coronaviruses,O
category,O
.,O
COVID-19,O
is,O
a,O
spherical,O
or,O
pleomorphic,O
enveloped,O
particle,O
with,O
an,O
average,O
diameter,O
size,O
of,O
0.1,O
 ,O
μm,O
in,O
the,O
range,O
of,O
0.06–0.14,O
 ,O
μm,O
",",O
and,O
contains,O
single,O
-,O
stranded,O
(,O
positive,O
-,O
sense,O
),O
RNA,O
associated,O
with,O
a,O
nucleoprotein,O
within,O
a,O
capsid,O
comprised,O
of,O
matrix,O
protein,O
(,O
Mousavizadeh,O
and,O
Ghasemi,O
",",O
2020,O
;,O
Y.,O
Advanced,O
new,O
studies,O
attribute,O
the,O
fatalities,O
of,O
COVID-19,O
to,O
cytokine,O
storm,O
syndrome,O
(,O
Guo,O
et,O
al,O
.,O
",",O
2020,O
;,O
Mehta,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
also,O
known,O
as,O
hypercytokinemia,O
",",O
which,O
is,O
characterized,O
by,O
an,O
uncontrolled,O
release,O
of,O
pro,O
-,O
inflammatory,O
cytokines,O
(,O
Tisoncik,O
et,O
al,O
.,O
",",O
2012,O
),O
",",O
being,O
a,O
severe,O
reaction,O
of,O
the,O
immunity,O
system,O
",",O
leading,O
to,O
death,O
.,O
Table,O
1,O
summarizes,O
the,O
Pearson,O
coefficients,O
and,O
p,O
-,O
values,O
descriptive,O
statistics,O
of,O
COVID-19,O
Milan,O
cases,O
(,O
Total,O
confirmed,O
",",O
Daily,O
New,O
positive,O
and,O
Total,O
Deaths,O
),O
and,O
daily,O
average,O
ground,O
level,O
gaseous,O
pollutants,O
O3,O
and,O
NO2,O
concentrations,O
together,O
daily,O
average,O
climate,O
variables,O
(,O
Planetary,O
Boundary,O
Layer,O
height,O
",",O
air,O
temperature,O
",",O
relative,O
humidity,O
",",O
wind,O
speed,O
intensity,O
and,O
precipitation,O
rate,O
),O
.,O
Due,O
to,O
COVID-19,O
pandemic,O
event,O
",",O
starting,O
with,O
the,O
end,O
of,O
February,O
2020,O
lockdown,O
(,O
as,O
can,O
be,O
seen,O
on,O
Fig,O
.,O
2,O
),O
",",O
where,O
drastic,O
measures,O
for,O
reduction,O
of,O
air,O
pollution,O
were,O
adopted,O
to,O
limit,O
the,O
spread,O
of,O
the,O
coronavirus,O
",",O
our,O
study,O
revealed,O
different,O
concentrations,O
levels,O
for,O
O3,O
and,O
NO2,O
corresponding,O
to,O
pre,O
-,O
pandemic,O
period,O
(,O
January,O
–,O
February,O
),O
and,O
beyond,O
lockdown,O
(,O
March,O
–,O
April,O
),O
2020,O
",",O
namely,O
:,O
NO2,O
in,O
Milan,O
city,O
has,O
decreased,O
by,O
approximately,O
64.7,O
%,O
",",O
while,O
O3,O
has,O
increased,O
by,O
a,O
factor,O
of,O
2.25,O
.,O
Our,O
results,O
have,O
shown,O
that,O
the,O
severe,O
reductions,O
in,O
NO2,O
and,O
other,O
air,O
pollution,O
emissions,O
during,O
Milan,O
's,O
COVID-19,O
lockdown,O
led,O
to,O
substantial,O
increases,O
in,O
ground,O
level,O
O3,O
",",O
which,O
in,O
turn,O
increased,O
atmospheric,O
oxidizing,O
capacity,O
and,O
enhanced,O
formation,O
of,O
secondary,O
aerosols,O
",",O
with,O
subsequent,O
negative,O
impact,O
on,O
human,O
respiratory,O
health,O
and,O
increasing,O
of,O
COVID-19,O
confirmed,O
and,O
fatalities,O
numbers,O
.,O
For,O
this,O
reason,O
we,O
considered,O
O3,O
as,O
a,O
COVID,O
incubator,O
.,O
Also,O
this,O
study,O
found,O
that,O
daily,O
average,O
ground,O
level,O
ozone,O
concentrations,O
values,O
were,O
positive,O
correlated,O
with,O
all,O
COVID-19,O
cases,O
(,O
confirmed,O
Total,O
",",O
confirmed,O
Daily,O
New,O
positive,O
and,O
Total,O
Deaths,O
),O
as,O
can,O
be,O
seen,O
in,O
Table,O
1,O
and,O
Fig,O
.,O
2,O
.,O
A,O
similar,O
result,O
was,O
recently,O
reported,O
for,O
COVID-19,O
infections,O
and,O
ozone,O
in,O
Italy,O
(,O
Pansini,O
and,O
Fornacca,O
",",O
2020,O
),O
.,O
Also,O
",",O
was,O
found,O
a,O
negative,O
correlation,O
between,O
average,O
ground,O
levels,O
of,O
NO2,O
and,O
COVID-19,O
cases,O
(,O
Total,O
",",O
confirmed,O
Daily,O
New,O
positive,O
cases,O
and,O
Total,O
Deaths,O
),O
as,O
can,O
be,O
seen,O
in,O
Table,O
1,O
and,O
Fig,O
.,O
Based,O
on,O
our,O
analysis,O
was,O
found,O
that,O
daily,O
average,O
PBL,O
values,O
were,O
positive,O
correlated,O
with,O
all,O
COVID-19,O
cases,O
(,O
confirmed,O
Total,O
",",O
confirmed,O
Daily,O
New,O
positive,O
and,O
Total,O
Deaths,O
),O
as,O
can,O
be,O
seen,O
in,O
Fig,O
.,O
3,O
.,O
Furthermore,O
",",O
air,O
temperature,O
also,O
contributes,O
towards,O
the,O
transmission,O
of,O
the,O
virus,O
(,O
Chen,O
et,O
al,O
.,O
",",O
2020,O
;,O
Ma,O
et,O
al,O
.,O
",",O
2020,O
;,O
Shi,O
et,O
al,O
.,O
",",O
2020,O
),O
suggesting,O
that,O
humidity,O
and,O
temperature,O
will,O
play,O
an,O
important,O
role,O
in,O
COVID-19,O
mortality,O
rate,O
.,O
Climate,O
indicators,O
and,O
air,O
temperature,O
are,O
well,O
correlated,O
with,O
the,O
spread,O
of,O
COVID-19,O
(,O
Poole,O
",",O
2020,O
;,O
Ahmadi,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
This,O
can,O
explain,O
the,O
high,O
rate,O
of,O
total,O
COVID-19,O
positive,O
cases,O
registered,O
in,O
the,O
metropolitan,O
area,O
of,O
Milan,O
",",O
possibly,O
attributed,O
to,O
bronchial,O
hyperreactivity,O
and,O
immune,O
disorders,O
through,O
several,O
pathways,O
.,O
Among,O
the,O
climate,O
variables,O
",",O
wind,O
speed,O
has,O
a,O
weakly,O
inverse,O
relationship,O
with,O
the,O
recorded,O
COVID-19,O
cases,O
(,O
Total,O
confirmed,O
",",O
Daily,O
New,O
positive,O
),O
",",O
as,O
can,O
be,O
seen,O
in,O
Table,O
2,O
.,O
Statistical,O
Pearson,O
correlation,O
shows,O
that,O
precipitation,O
rate,O
recorded,O
in,O
Milan,O
metropolitan,O
region,O
had,O
important,O
effects,O
on,O
the,O
transmission,O
and,O
severity,O
of,O
respiratory,O
viral,O
infection,O
COVID-19,O
",",O
being,O
negatively,O
correlated,O
with,O
Daily,O
New,O
positive,O
cases,O
(,O
R2,O
 ,O
=,O
 ,O
0.21,O
with,O
significant,O
p,O
-,O
value,O
of,O
0.09,O
 ,O
>,O
 ,O
0.05,O
and,O
also,O
low,O
negatively,O
correlations,O
with,O
Total,O
COVID-19,O
and,O
Total,O
Deaths,O
cases,O
with,O
significant,O
p,O
-,O
values,O
 ,O
>,O
 ,O
0.05,O
",",O
as,O
can,O
be,O
seen,O
in,O
Table,O
1,O
.,O
Omega,O
meteorological,O
chart,O
950,O
 ,O
mb,O
(,O
0.762,O
 ,O
km,O
above,O
sea,O
level,O
),O
is,O
a,O
better,O
choice,O
for,O
our,O
analysis,O
because,O
daily,O
average,O
PBL,O
value,O
recorded,O
for,O
Milan,O
area,O
was,O
(,O
797.53,O
 ,O
±,O
 ,O
568.35,O
),O
m.,O
NOAA,O
satellite,O
Omega,O
image,O
for,O
Italy,O
in,O
Europe,O
(,O
Fig,O
.,O
6,O
),O
shows,O
existing,O
atmospheric,O
thermal,O
inversion,O
conditions,O
over,O
Milan,O
and,O
Lombardy,O
region,O
",",O
associated,O
with,O
accumulation,O
near,O
the,O
ground,O
of,O
high,O
air,O
pollutants,O
concentrations,O
(,O
non,O
-,O
viable,O
aerosols,O
and,O
viable,O
-,O
bioaerosols,O
including,O
viruses,O
like,O
as,O
coronaviruses,O
",",O
bacteria,O
",",O
fungi,O
",",O
etc,O
.,O
),O
leading,O
to,O
a,O
higher,O
risk,O
of,O
COVID-19,O
infections,O
development,O
(,O
Ogen,O
",",O
2020,O
),O
.,O
Local,O
favorable,O
stagnant,O
atmospheric,O
conditions,O
due,O
to,O
local,O
topography,O
of,O
Milan,O
area,O
",",O
the,O
preexisting,O
high,O
levels,O
of,O
air,O
pollutants,O
during,O
January,O
–,O
February,O
2020,O
can,O
explain,O
the,O
high,O
incidence,O
of,O
people,O
's,O
respiratory,O
diseases,O
and,O
increased,O
susceptibility,O
to,O
new,O
viral,O
infections,O
COVID-19,O
.,O
Long,O
-,O
term,O
conditions,O
of,O
population,O
exposure,O
(,O
several,O
years,O
before,O
2020,O
),O
when,O
the,O
number,O
of,O
days,O
in,O
which,O
the,O
regulatory,O
limits,O
of,O
O3,O
",",O
NO2,O
",",O
PM2.5,O
and,O
PM10,O
have,O
been,O
exceeded,O
(,O
EEA,O
",",O
European,O
Environmental,O
Agency,O
",",O
2019,O
",",O
EEA,O
",",O
European,O
Environmental,O
Agency,O
",",O
2020,O
;,O
Remuzzi,O
and,O
Remuzzi,O
",",O
2020,O
),O
in,O
Milan,O
metropolitan,O
region,O
as,O
well,O
as,O
short,O
-,O
term,O
exposure,O
to,O
high,O
ground,O
levels,O
of,O
O3,O
",",O
NO2,O
",",O
PM2.5,O
and,O
PM10,O
can,O
be,O
correlated,O
with,O
the,O
decreased,O
people,O
's,O
immunity,O
and,O
immunopathology,O
to,O
viruses,O
",",O
and,O
high,O
fatality,O
COVID-19,O
rates,O
observed,O
in,O
Milan,O
and,O
Lombardy,O
region,O
.,O
As,O
an,O
important,O
result,O
",",O
our,O
analysis,O
show,O
the,O
direct,O
correlation,O
of,O
daily,O
averaged,O
ground,O
levels,O
O3,O
and,O
NO2,O
",",O
with,O
meteorological,O
factors,O
on,O
COVID-19,O
infections,O
outbreak,O
in,O
Milan,O
.,O
In,O
spite,O
of,O
cold,O
season,O
investigated,O
period,O
(,O
winter,O
-,O
early,O
spring,O
),O
collected,O
data,O
",",O
when,O
usually,O
recorded,O
urban,O
ozone,O
levels,O
have,O
lower,O
values,O
than,O
its,O
summer,O
peak,O
concentrations,O
",",O
the,O
findings,O
of,O
this,O
study,O
demonstrate,O
that,O
ground,O
level,O
ozone,O
possible,O
acts,O
as,O
a,O
COVID-19,O
virus,O
incubator,O
",",O
being,O
positively,O
correlated,O
with,O
COVID-19,O
infections,O
and,O
fatalities,O
(,O
Fig,O
.,O
7,O
),O
.,O
It,O
seems,O
that,O
under,O
specific,O
climate,O
conditions,O
(,O
Bashir,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
air,O
pollution,O
acts,O
as,O
a,O
carrier,O
of,O
the,O
COVID-19,O
virus,O
",",O
facilitating,O
its,O
transmission,O
and,O
spreading,O
",",O
allowing,O
its,O
survival,O
in,O
active,O
form,O
with,O
different,O
residence,O
times,O
.,O
Association,O
between,O
Milan,O
",",O
with,O
several,O
days,O
of,O
smog,O
and,O
haze,O
",",O
which,O
favor,O
air,O
pollutants,O
accumulation,O
near,O
the,O
ground,O
level,O
in,O
cold,O
and,O
dry,O
winter,O
to,O
spring,O
seasons,O
and,O
the,O
highest,O
number,O
of,O
COVID-19,O
infection,O
cases,O
(,O
Total,O
confirmed,O
",",O
Daily,O
New,O
positive,O
and,O
Total,O
Deaths,O
),O
",",O
thereby,O
is,O
supports,O
the,O
possibility,O
as,O
the,O
degree,O
of,O
air,O
pollution,O
and,O
local,O
topography,O
together,O
climate,O
conditions,O
may,O
contribute,O
to,O
accelerated,O
diffusion,O
of,O
COVID-19,O
cases,O
.,O
Exhibited,O
positive,O
correlations,O
of,O
ambient,O
ozone,O
levels,O
and,O
negative,O
correlations,O
of,O
NO,O
2,O
with,O
the,O
increased,O
rates,O
of,O
COVID-19,O
infections,O
(,O
Total,O
number,O
",",O
Daily,O
New,O
positive,O
and,O
Total,O
Deaths,O
cases,O
),O
",",O
can,O
be,O
attributed,O
to,O
airborne,O
bioaerosols,O
distribution,O
.,O
At,O
this,O
moment,O
it,O
is,O
not,O
clear,O
if,O
through,O
airborne,O
diffusion,O
",",O
in,O
the,O
presence,O
of,O
outdoor,O
and,O
indoor,O
aerosols,O
",",O
this,O
protein,O
“,O
spike,O
”,O
of,O
the,O
new,O
COVID-19,O
is,O
involved,O
in,O
the,O
infectious,O
agent,O
transmission,O
from,O
a,O
reservoir,O
to,O
a,O
susceptible,O
host,O
during,O
the,O
highest,O
nosocomial,O
outbreak,O
in,O
some,O
agglomerated,O
industrialized,O
urban,O
areas,O
like,O
Milan,O
is,O
.,O
Also,O
",",O
in,O
spite,O
of,O
collected,O
data,O
for,O
cold,O
season,O
(,O
winter,O
-,O
early,O
spring,O
),O
period,O
",",O
when,O
usually,O
ozone,O
levels,O
have,O
lower,O
values,O
than,O
in,O
summer,O
",",O
the,O
findings,O
of,O
this,O
study,O
support,O
possibility,O
as,O
O,O
3,O
can,O
acts,O
as,O
a,O
COVID-19,O
virus,O
incubator,O
.,O
Institute,B-Repository
for,I-Repository
Scientific,I-Repository
Information,I-Repository
(ISI),I-Repository
Web,I-Repository
Science,E-Repository
",",O
Scopus,S-Repository
",",O
MEDLINE,S-Repository
 ,O
and,O
Google,B-Repository
Scholar,E-Repository
 ,O
databases,O
were,O
used,O
to,O
search,O
using,O
MeSH,O
(,O
Medical,O
Subject,O
Headings,O
),O
",",O
free,O
text,O
words,O
and,O
all,O
possible,O
combination,O
.,O
Thus,O
",",O
it,O
seems,O
that,O
the,O
immunoinformatics,O
-,O
based,O
approachs,O
are,O
required,O
to,O
investigate,O
the,O
immunogenic,O
epitopes,O
and,O
vaccine,O
design,O
using,O
data,O
from,O
proteins,O
sequencing,O
of,O
the,O
COVID-19,O
.,O
In,O
these,O
studies,O
",",O
the,O
proteins,O
of,O
COVID-19,O
virus,O
that,O
have,O
an,O
essential,O
role,O
in,O
virulence,O
of,O
the,O
virus,O
was,O
selected,O
and,O
then,O
its,O
antigenic,O
properties,O
was,O
examined,O
.,O
More,O
for,O
the,O
most,O
part,O
",",O
our,O
deliberate,O
assistance,O
highlights,O
the,O
potential,O
importance,O
of,O
past,O
clinical,O
and,O
exploratory,O
considerations,O
for,O
SARS,O
-,O
CoV,O
",",O
and,O
is,O
used,O
in,O
conjunction,O
with,O
growing,O
information,O
for,O
SARS,O
-,O
CoV-2,O
",",O
in,O
the,O
search,O
for,O
compelling,O
immunizations,O
to,O
combat,O
the,O
COVID-19,O
outbreak,O
.,O
The,O
beginning,O
of,O
2020,O
was,O
marked,O
as,O
the,O
emergence,O
of,O
a,O
COVID-19,O
outbreak,O
caused,O
by,O
a,O
new,O
coronavirus,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
To,O
date,O
",",O
more,O
than,O
10.7,O
million,O
cases,O
of,O
the,O
disease,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
",",O
termed,O
COVID-19,O
",",O
have,O
been,O
reported,O
globally,O
[,O
"8,9",O
],O
.,O
On,O
26,O
February,O
2020,O
",",O
the,O
first,O
confirmed,O
case,O
of,O
COVID-19,O
was,O
reported,O
in,O
São,O
Paulo,O
(,O
SP,O
),O
state,O
",",O
Brazil,O
[,O
11,O
],O
.,O
Two,O
months,O
later,O
(,O
28,O
April,O
2020,O
),O
",",O
"61,888",O
cases,O
and,O
"4,205",O
deaths,O
attributed,O
to,O
COVID-19,O
had,O
been,O
reported,O
in,O
Brazil,O
[,O
12,O
],O
.,O
Initial,O
phylogenetic,O
analysis,O
using,O
the,O
first,O
two,O
SARS,O
-,O
CoV-2,O
complete,O
genomes,O
isolated,O
in,O
São,O
Paulo,O
from,O
travellers,O
returning,O
from,O
Italy,O
revealed,O
two,O
independent,O
introductions,O
into,O
the,O
country,O
relative,O
to,O
the,O
data,O
set,O
available,O
at,O
that,O
time,O
[,O
13,O
],O
.,O
Due,O
to,O
its,O
large,O
population,O
size,O
and,O
strong,O
connections,O
to,O
active,O
neighbouring,O
states,O
such,O
as,O
São,O
Paulo,O
and,O
Rio,O
de,O
Janeiro,O
",",O
the,O
state,O
of,O
MG,O
is,O
likely,O
to,O
be,O
highly,O
affected,O
by,O
the,O
COVID-19,O
pandemic,O
.,O
Public,O
SARS,O
-,O
CoV-2,O
complete,O
genome,O
sequences,O
available,O
up,O
to,O
15,O
April,O
2020,O
were,O
retrieved,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
(,O
https://www.gisaid.org/,S-URL
),O
.,O
Four,O
data,O
sets,O
of,O
complete,O
or,O
near,O
-,O
complete,O
SARS,O
-,O
CoV-2,O
genome,O
sequences,O
were,O
generated,O
.,O
Data,O
set,O
1,O
(,O
n,O
 ,O
=,O
 ,O
"3,102",O
),O
comprised,O
the,O
data,O
reported,O
in,O
this,O
study,O
(,O
n,O
 ,O
=,O
 ,O
40,O
),O
plus,O
publicly,O
available,O
SARS,O
-,O
CoV-2,O
sequences,O
(,O
n,O
 ,O
=,O
 ,O
"3,062",O
),O
from,O
GISAID,S-Dataset
.,O
Subsequently,O
",",O
to,O
investigate,O
the,O
evolutionary,O
behaviour,O
of,O
SARS,O
-,O
CoV-2,O
within,O
the,O
three,O
different,O
SARS,O
-,O
CoV-2,O
lineages,O
(,O
A,O
",",O
B,O
and,O
B.1,O
),O
",",O
Bayesian,O
molecular,O
clock,O
analysis,O
was,O
conducted,O
on,O
three,O
smaller,O
subsets,O
of,O
data,O
for,O
each,O
of,O
the,O
three,O
lineages,O
identified,O
in,O
the,O
ML,O
phylogeny,O
and,O
containing,O
isolates,O
from,O
MG,O
(,O
data,O
set,O
2,O
for,O
subset,O
A,O
n,O
 ,O
=,O
 ,O
100,O
;,O
data,O
set,O
3,O
for,O
subset,O
B,O
n,O
 ,O
=,O
 ,O
84,O
;,O
data,O
set,O
4,O
for,O
subset,O
B.1,O
n,O
 ,O
=,O
 ,O
169,O
),O
.,O
We,O
computed,O
MCMC,O
(,O
Markov,O
chain,O
Monte,O
Carlo,O
),O
triplicate,O
runs,O
of,O
100,O
million,O
states,O
each,O
",",O
sampling,O
every,O
10.000,O
steps,O
for,O
each,O
data,O
set,O
.,O
By,O
the,O
28th,O
April,O
2020,O
",",O
more,O
than,O
"61,888",O
COVID-19,O
cases,O
were,O
confirmed,O
in,O
Brazil,O
",",O
"1,578",O
of,O
which,O
were,O
from,O
MG,O
(,O
Figure,O
2A,O
),O
[,O
30,O
],O
.,O
Over,O
this,O
period,O
",",O
MG,O
registered,O
71,O
COVID-19,O
-,O
related,O
deaths,O
and,O
the,O
capital,O
city,O
",",O
Belo,O
Horizonte,O
",",O
with,O
an,O
estimated,O
population,O
of,O
2.5,O
million,O
people,O
",",O
reported,O
555,O
cases,O
[,O
"30,31",O
],O
.,O
Temporal,O
trends,O
reveal,O
a,O
growth,O
in,O
the,O
number,O
of,O
cases,O
in,O
MG,O
",",O
although,O
with,O
SP,O
accounting,O
for,O
the,O
largest,O
number,O
of,O
cases,O
and,O
deaths,O
(,O
"24,041",O
cases,O
;,O
"2,049",O
deaths,O
),O
by,O
COVID-19,O
up,O
to,O
28th,O
April,O
2020,O
.,O
We,O
used,O
Nanopore,O
sequencing,O
to,O
generate,O
complete,O
genomes,O
from,O
40,O
COVID-19,O
patients,O
in,O
15,O
different,O
municipalities,O
in,O
MG,O
(,O
Table,O
1,O
),O
.,O
All,O
sequences,O
generated,O
in,O
this,O
study,O
have,O
been,O
submitted,O
to,O
the,O
GISAID,S-Dataset
 ,O
following,O
WHO,O
guidelines,O
[,O
38,O
],O
.,O
To,O
explore,O
the,O
epidemiological,O
history,O
of,O
the,O
virus,O
in,O
MG,O
",",O
we,O
performed,O
a,O
maximum,O
likelihood,O
(,O
ML,O
),O
phylogenetic,O
analysis,O
on,O
the,O
40,O
new,O
sequences,O
combined,O
with,O
another,O
"3,062",O
sequences,O
deposited,O
in,O
GISAID,S-Dataset
 ,O
up,O
to,O
15,O
April,O
2020,O
.,O
Aside,O
from,O
sublineage,O
B.1,O
",",O
two,O
sequences,O
were,O
assigned,O
to,O
lineage,O
B,O
in,O
our,O
ML,O
phylogeny,O
(,O
isolates,O
CV22,O
and,O
CV36,O
",",O
with,O
the,O
former,O
reporting,O
travel,O
to,O
Germany,O
),O
",",O
while,O
one,O
sequence,O
could,O
be,O
assigned,O
to,O
lineage,O
A,O
(,O
isolate,O
CV7,O
),O
who,O
reported,O
travel,O
to,O
European,O
countries,O
(,O
full,O
results,O
from,O
the,O
Pangolin,O
COVID-19,O
lineage,O
assigner,O
are,O
presented,O
in,O
Supplementary,O
Table,O
S2,O
),O
.,O
One,O
of,O
these,O
clusters,O
(,O
Figure,O
4d,O
),O
",",O
with,O
a,O
posterior,O
probability,O
of,O
100,O
%,O
",",O
was,O
formed,O
by,O
isolates,O
CV34,O
and,O
CV36,O
that,O
arose,O
from,O
local,O
contacts,O
with,O
a,O
confirmed,O
and,O
a,O
suspected,O
COVID-19,O
case,O
",",O
respectively,O
.,O
The,O
mean,O
time,O
of,O
the,O
most,O
recent,O
common,O
ancestor,O
of,O
all,O
Brazilian,O
strains,O
analysed,O
in,O
this,O
study,O
was,O
estimated,O
to,O
be,O
from,O
27,O
January,O
to,O
22,O
February,O
2020,O
",",O
and,O
range,O
that,O
includes,O
the,O
first,O
COVID-19,O
confirmed,O
case,O
reported,O
in,O
21,O
February,O
2020,O
[,O
49,O
],O
.,O
These,O
findings,O
highlight,O
the,O
nature,O
of,O
the,O
COVID-19,O
epidemic,O
in,O
MG,O
and,O
reinforce,O
the,O
need,O
for,O
real,O
-,O
time,O
and,O
continued,O
genomic,O
surveillance,O
strategies,O
to,O
better,O
understand,O
and,O
prepare,O
for,O
the,O
epidemic,O
spread,O
of,O
emerging,O
viral,O
pathogens,O
..,O
The,O
central,O
page,O
of,O
the,O
coronavirus,O
server,O
(,O
see,O
Fig,O
.,O
 ,O
1a,O
",",O
),O
provides,O
an,O
interactive,O
view,O
of,O
the,O
SARS,O
-,O
CoV-2,O
genome,O
(,O
GenBank,S-Repository
 ,O
ID,O
:,O
MN908947.3,S-AccessionNumber
),O
",",O
with,O
information,O
on,O
boundaries,O
of,O
the,O
predicted,O
proteins,O
",",O
currently,O
available,O
SARS,O
-,O
CoV-2,O
structures,O
and,O
a,O
histogram,O
of,O
the,O
amino,O
-,O
acid,O
mutation,O
frequency,O
.,O
In,O
the,O
future,O
we,O
plan,O
to,O
incorporate,O
ab,O
initio,O
models,O
.,O
The,O
example,O
in,O
Figure,O
 ,O
1b,O
shows,O
the,O
SARS,O
-,O
CoV-2,O
structure,O
of,O
the,O
complex,O
between,O
nsp10,O
and,O
nsp16,O
[,O
PDB,S-Repository
 ,O
ID,O
:,O
6w4h,S-AccessionNumber
 ,O
(,O
Rosas,O
-,O
Lemus,O
),O
],O
.,O
This,O
mutation,O
",",O
P323,O
>,O
L,O
(,O
genomic,O
position,O
14,O
 ,O
408,O
),O
",",O
is,O
located,O
at,O
the,O
interface,O
between,O
nsp12,O
and,O
nsp8,O
proteins,O
in,O
the,O
RdRp,O
complex,O
",",O
as,O
shown,O
on,O
the,O
experimental,O
structure,O
of,O
the,O
nsp7,O
/,O
nsp8,O
/,O
nsp12,O
complex,O
[,O
PDB,S-Repository
 ,O
ID,O
:,O
6yyt,S-AccessionNumber
 ,O
(,O
Hillen,O
),O
],O
(,O
Fig,O
.,O
 ,O
1c,O
",",O
top,O
),O
.,O
The,O
second,O
example,O
shows,O
the,O
most,O
widespread,O
mutation,O
in,O
Spike,O
glycoprotein,O
-,O
D614,O
>,O
G,O
(,O
genomic,O
position,O
23,O
 ,O
403,O
),O
",",O
visualized,O
here,O
on,O
the,O
experimental,O
structure,O
of,O
the,O
spike,O
protein,O
and,O
the,O
human,O
ACE2,O
receptor,O
[,O
PDB,S-Repository
 ,O
ID,O
:,O
6vxx,S-AccessionNumber
 ,O
(,O
Laha,O
),O
],O
(,O
Fig,O
.,O
 ,O
1c,O
",",O
bottom,O
),O
.,O
As,O
the,O
COVID-19,O
pandemic,O
is,O
spreading,O
around,O
the,O
world,O
",",O
the,O
SARS,O
-,O
CoV-2,O
virus,O
is,O
evolving,O
with,O
mutations,O
that,O
potentially,O
change,O
and,O
fine,O
-,O
tune,O
functions,O
of,O
the,O
proteins,O
coded,O
in,O
its,O
genome,O
.,O
The,O
COVID-19,O
pandemic,O
began,O
following,O
a,O
cross,O
-,O
species,O
transmission,O
event,O
of,O
the,O
causative,O
virus,O
",",O
SARS,O
-,O
CoV-2,O
",",O
sometime,O
in,O
late,O
2019,O
(,O
Gorbalenya,O
et,O
 ,O
al,O
.,O
We,O
re,O
-,O
analyze,O
viral,O
CpG,O
deficiency,O
data,O
to,O
incorporate,O
key,O
pangolin,O
viral,O
genomes,O
that,O
were,O
available,O
but,O
omitted,O
from,O
Xia,O
’s,O
study,O
.,O
Abstract,O
 ,O
Due,O
to,O
the,O
scope,O
and,O
impact,O
of,O
the,O
COVID-19,O
pandemic,O
there,O
exists,O
a,O
strong,O
desire,O
to,O
understand,O
where,O
the,O
SARS,O
-,O
CoV-2,O
virus,O
came,O
from,O
and,O
how,O
it,O
jumped,O
species,O
boundaries,O
to,O
humans,O
.,O
As,O
the,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
caused,O
by,O
the,O
novel,O
coronavirus,O
",",O
SARS,O
-,O
CoV-2,O
spreads,O
globally,O
",",O
differences,O
in,O
adverse,O
clinical,O
management,O
outcomes,O
have,O
been,O
associated,O
with,O
age,O
>,O
65,O
years,O
",",O
male,O
gender,O
",",O
and,O
comorbidities,O
such,O
as,O
smoking,O
",",O
diabetes,O
",",O
hypertension,O
",",O
cardiovascular,O
comorbidity,O
",",O
and,O
immunosuppression,O
.,O
In,O
addition,O
to,O
ethnicity,O
",",O
socioeconomic,O
factors,O
",",O
prior,O
vaccinations,O
",",O
exposure,O
to,O
other,O
coronaviruses,O
",",O
and,O
other,O
factors,O
need,O
to,O
be,O
considered,O
to,O
explain,O
the,O
geographical,O
and,O
regional,O
variations,O
in,O
susceptibility,O
and,O
severity,O
of,O
the,O
clinical,O
expression,O
of,O
COVID-19,O
disease,O
and,O
outcomes,O
.,O
In,O
the,O
United,O
States,O
",",O
there,O
have,O
been,O
disproportionate,O
COVID-19,O
death,O
rates,O
among,O
African,O
Americans,O
at,O
around,O
2.6,O
times,O
higher,O
than,O
that,O
of,O
other,O
groups,O
.,O
Some,O
individuals,O
with,O
COVID-19,O
experienced,O
neurological,O
symptoms,O
",",O
e.g.,O
",",O
Guillain,O
Barre,O
Syndrome,O
(,O
Zhao,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
suggesting,O
an,O
autoimmune,O
background,O
",",O
which,O
has,O
been,O
associated,O
with,O
MHC,O
alleles,O
(,O
Hasan,O
et,O
al,O
.,O
",",O
2014,O
),O
.,O
Such,O
aspects,O
should,O
be,O
considered,O
while,O
examining,O
neurological,O
symptoms,O
in,O
patients,O
after,O
COVID-19,O
recovery,O
",",O
and,O
also,O
in,O
SARS,O
-,O
CoV-2,O
vaccination,O
efforts,O
.,O
In,O
order,O
to,O
test,O
this,O
possibility,O
",",O
we,O
analyzed,O
the,O
most,O
frequent,O
MHC,O
class,O
I,O
and,O
II,O
alleles,O
in,O
Europe,O
",",O
Asia,O
",",O
and,O
Africa,O
for,O
binding,O
to,O
the,O
mutations,O
in,O
ORF8,O
(,O
L84S,O
),O
and,O
ORF3a,O
(,O
G251V,O
),O
(,O
see,O
supplementary,O
data,O
sets,O
),O
.,O
For,O
MHC,O
class,O
I,O
",",O
starting,O
with,O
a,O
peptide,O
with,O
the,O
mutation,O
site,O
in,O
the,O
middle,O
(,O
flanked,O
by,O
seven,O
amino,O
acid,O
residues,O
to,O
the,O
left,O
and,O
right,O
",",O
resulting,O
in,O
a,O
15mer,O
peptide,O
),O
for,O
ORF8,O
(,O
L84S,O
),O
(,O
GNYTVSCLPFTINCQ,O
and,O
GNYTVSCSPFTINCQ,O
),O
and,O
for,O
ORF3a,O
(,O
G251V,O
),O
(,O
VQIHTIDGSSGVVNP,O
and,O
VQIHTIDVSSGVVNP,O
),O
",",O
we,O
tested,O
all,O
possible,O
combinations,O
of,O
length,O
from,O
8,O
to,O
14,O
residues,O
for,O
MHC,O
class,O
I,O
binding,O
",",O
For,O
MHC,O
class,O
II,O
",",O
starting,O
with,O
a,O
peptide,O
with,O
33,O
residues,O
with,O
the,O
mutation,O
site,O
in,O
the,O
middle,O
for,O
ORF8,O
(,O
L84S,O
),O
(,O
KSPIQYIDIGNYTVSCL,O
/,O
SPFTINCQEPKLGSLVV,O
),O
and,O
for,O
ORF3a,O
(,O
G251V,O
),O
(,O
KIVDEPEEHVQIHTIDG,O
/,O
VSSGVVNPVMEPIYDEP,O
),O
",",O
we,O
tested,O
all,O
possible,O
combinations,O
to,O
bind,O
to,O
MHC,O
class,O
II,O
alleles,O
listed,O
in,O
the,O
supplementary,O
data,O
set,O
since,O
MHC,O
class,O
II,O
molecules,O
can,O
accommodate,O
longer,O
peptides,O
",",O
and,O
nominal,O
epitopes,O
may,O
‘,O
glide,O
’,O
within,O
the,O
MHC,O
class,O
II,O
peptide,O
binding,O
cleft,O
(,O
Rammensee,O
",",O
1995,O
),O
.,O
We,O
could,O
not,O
identify,O
differences,O
in,O
MHC,O
class,O
I,O
or,O
class,O
II,O
binding,O
characteristics,O
(,O
see,O
Appendix-,O
supplementary,O
data,O
sets,O
Tables,O
S1,O
",",O
S2,O
and,O
S3,O
),O
except,O
for,O
three,O
MHC,O
class,O
II,O
alleles,O
",",O
i.e.,O
",",O
DRB3,O
*,O
02:02,O
",",O
DRB1,O
*,O
09:01,O
",",O
and,O
DRB1,O
*,O
04:01,O
",",O
that,O
do,O
not,O
allow,O
binding,O
of,O
the,O
wildtype,O
",",O
but,O
accommodate,O
the,O
SARS,O
-,O
CoV-2,O
ORF8,O
(,O
L84S,O
),O
variant,O
(,O
Table,O
1,O
),O
and,O
also,O
two,O
MHC,O
class,O
II,O
alleles,O
HLA,O
-,O
DPA1,O
*,O
01:03,O
/,O
DPB1,O
*,O
02:01,O
that,O
do,O
the,O
opposite,O
:,O
they,O
accommodate,O
the,O
wildtype,O
but,O
not,O
the,O
SARS,O
-,O
CoV-2,O
ORF8,O
(,O
L84S,O
),O
variant,O
(,O
Table,O
1,O
),O
.,O
Of,O
the,O
"11,970",O
SARS,O
-,O
CoV-2,O
sequences,O
deposited,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
by,O
April,O
27th,O
",",O
2020,O
",",O
85,O
%,O
exhibit,O
the,O
amino,O
acid,O
Leucine,O
at,O
the,O
position,O
84,O
and,O
15,O
%,O
exhibit,O
Serine,O
.,O
Genetic,O
factors,O
such,O
as,O
the,O
HLA,O
type,O
of,O
patients,O
may,O
play,O
a,O
role,O
in,O
regard,O
to,O
disease,O
severity,O
and,O
clinical,O
outcome,O
of,O
patients,O
with,O
COVID-19,O
.,O
Taking,O
the,O
data,O
deposited,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
",",O
we,O
made,O
predictions,O
using,O
the,O
IEDB,O
analysis,O
resource,O
(,O
TepiTool,O
),O
to,O
gauge,O
how,O
variants,O
in,O
the,O
SARS,O
-,O
CoV-2,O
genome,O
may,O
change,O
peptide,O
binding,O
to,O
the,O
most,O
frequent,O
MHC,O
-,O
class,O
I,O
and,O
-II,O
alleles,O
in,O
Africa,O
",",O
Asia,O
and,O
Europe,O
.,O
MHC,O
4,O
-,O
digit,O
typing,O
along,O
with,O
viral,O
sequence,O
analysis,O
should,O
be,O
considered,O
in,O
studies,O
examining,O
clinical,O
outcomes,O
in,O
patients,O
with,O
COVID-19,O
.,O
By,O
de,O
novo,O
assembly,O
and,O
targeted,O
PCR,O
",",O
we,O
obtained,O
a,O
"29,891",O
-,O
base,O
-,O
pair,O
CoV,O
genome,O
that,O
shared,O
79.6,O
%,O
sequence,O
identity,O
to,O
SARS,O
-,O
CoV,O
BJ01,O
(,O
GenBank,S-Repository
 ,O
accession,O
number,O
AY278488.2,S-AccessionNumber
),O
.,O
This,O
sequence,O
has,O
been,O
submitted,O
to,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
(,O
accession,O
number,O
EPI_ISL_402124,S-AccessionNumber
),O
.,O
Four,O
more,O
full,O
-,O
length,O
genome,O
sequences,O
of,O
2019,O
-,O
nCoV,O
(,O
WIV02,O
",",O
WIV05,O
",",O
WIV06,O
and,O
WIV07,O
),O
(,O
GISAID,S-Dataset
 ,O
accession,O
numbers,O
EPI_ISL_402127–402130,S-AccessionNumber
),O
that,O
were,O
more,O
than,O
99.9,O
%,O
identical,O
to,O
each,O
other,O
were,O
subsequently,O
obtained,O
from,O
four,O
additional,O
patients,O
using,O
next,O
-,O
generation,O
sequencing,O
and,O
PCR,O
(,O
Extended,O
Data,O
Table,O
2,O
),O
.,O
We,O
carried,O
out,O
full,O
-,O
length,O
sequencing,O
on,O
this,O
RNA,O
sample,O
(,O
GISAID,S-Dataset
 ,O
accession,O
number,O
EPI_ISL_402131,S-AccessionNumber
),O
.,O
We,O
demonstrate,O
that,O
all,O
samples,O
were,O
able,O
to,O
neutralize,O
100,O
TCID50,O
(,O
50,O
%,O
tissue,O
-,O
culture,O
-,O
infective,O
dose,O
),O
of,O
2019,O
-,O
nCoV,O
at,O
a,O
dilution,O
of,O
1:40–1:80,O
.,O
Sequence,O
data,O
that,O
support,O
the,O
findings,O
of,O
this,O
study,O
have,O
been,O
deposited,O
in,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
with,O
accession,O
numbers,O
EPI_ISL_402124,S-AccessionNumber
",",O
EPI_ISL_402127–EPI_ISL_402130,S-AccessionNumber
 ,O
and,O
EPI_ISL_402131,S-AccessionNumber
;,O
GenBank,S-Repository
 ,O
with,O
accession,O
numbers,O
MN996527,S-AccessionNumber
–,O
MN996532,S-AccessionNumber
;,O
National,B-Repository
Genomics,I-Repository
Data,I-Repository
Center,E-Repository
",",O
Beijing,B-Repository
Institute,I-Repository
of,I-Repository
Genomics,E-Repository
",",O
Chinese,B-Repository
Academy,I-Repository
of,I-Repository
Sciences,E-Repository
 ,O
(,O
https://bigd.big.ac.cn/databases?lang=en,S-URL
),O
with,O
accession,O
numbers,O
SAMC133236,S-AccessionNumber
–,O
SAMC133240,S-AccessionNumber
 ,O
and,O
SAMC133252,S-AccessionNumber
.,O
Since,O
the,O
beginning,O
of,O
the,O
COVID-19,O
pandemic,O
",",O
viral,O
genomes,O
have,O
been,O
generated,O
at,O
an,O
unprecedented,O
rate,O
",",O
with,O
over,O
"60,000",O
sequences,O
on,O
GISAID,S-Dataset
 ,O
by,O
early,O
July,O
2020,O
(,O
gisaid.org,S-URL
),O
.,O
These,O
analyses,O
can,O
now,O
occur,O
in,O
near,O
real,O
-,O
time,O
[,O
"1,2",O
],O
and,O
have,O
yielded,O
important,O
insights,O
into,O
the,O
early,O
COVID-19,O
pandemic,O
in,O
the,O
United,O
States,O
",",O
Brazil,O
",",O
and,O
South,O
Africa,O
[,O
3–7,O
],O
.,O
These,O
dashboards,O
often,O
communicate,O
data,O
at,O
global,O
",",O
national,O
",",O
and,O
in,O
the,O
US,O
",",O
state,O
and,O
county,O
levels,O
",",O
but,O
do,O
not,O
(,O
yet,O
),O
incorporate,O
any,O
genomic,O
data,O
or,O
analysis,O
.,O
With,O
these,O
initiatives,O
in,O
mind,O
",",O
we,O
propose,O
three,O
guiding,O
principles,O
for,O
genomic,O
epidemiologists,O
looking,O
to,O
communicate,O
their,O
locally,O
focused,O
results,O
in,O
the,O
context,O
of,O
the,O
current,O
COVID-19,O
pandemic,O
(,O
Box,O
1,O
),O
.,O
We,O
believe,O
that,O
presenting,O
results,O
rapidly,O
",",O
and,O
tailored,O
to,O
a,O
non,O
-,O
expert,O
audience,O
",",O
can,O
serve,O
as,O
a,O
template,O
for,O
effective,O
public,O
health,O
response,O
to,O
COVID-19,O
and,O
other,O
emerging,O
viral,O
diseases,O
.,O
The,O
authors,O
believe,O
that,O
presenting,O
results,O
rapidly,O
",",O
and,O
tailored,O
to,O
a,O
non,O
-,O
expert,O
audience,O
",",O
can,O
serve,O
as,O
a,O
template,O
for,O
effective,O
public,O
health,O
communication,O
for,O
COVID-19,O
and,O
other,O
emerging,O
viral,O
diseases,O
.,O
It,O
has,O
been,O
reported,O
that,O
in,O
severe,O
cases,O
of,O
COVID-19,O
",",O
hypoxaemia,O
is,O
induced,O
by,O
the,O
pneumonic,O
process,O
and,O
might,O
have,O
several,O
adverse,O
effects,O
in,O
patients,O
(,O
Rello,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Therefore,O
",",O
in,O
prolonged,O
hypoxia,O
induction,O
via,O
COVID-19,O
",",O
the,O
UPR,O
is,O
triggered,O
to,O
help,O
the,O
cells,O
to,O
survive,O
.,O
However,O
",",O
prolonged,O
hypoxia,O
would,O
possibly,O
drive,O
UPR,O
role,O
from,O
survival,O
to,O
death,O
and,O
apoptotic,O
mode,O
",",O
which,O
possibly,O
is,O
one,O
of,O
the,O
causes,O
of,O
cellular,O
and,O
organ,O
damage,O
in,O
COVID-19,O
cases,O
.,O
Usage,O
of,O
Zinc,O
and,O
Zinc,O
ionophores,O
may,O
enhance,O
the,O
therapeutic,O
effects,O
of,O
targeting,O
autophagy,O
and,O
replication,O
in,O
COVID-19,O
by,O
several,O
compounds,O
which,O
along,O
pyrithione,O
include,O
dithiocarbamates,O
",",O
disulfiram,O
and,O
quinoline,O
derivatives,O
such,O
as,O
clioquinol,O
.,O
The,O
pathologic,O
source,O
of,O
this,O
disease,O
was,O
a,O
new,O
RNA,O
virus,O
from,O
Coronaviridae,O
family,O
",",O
which,O
was,O
named,O
COVID-19,O
.,O
The,O
present,O
pandemic,O
situation,O
of,O
the,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
(,O
COVID-19,O
),O
is,O
caused,O
by,O
the,O
RNA,O
virus,O
SARS,O
-,O
CoV2,O
which,O
is,O
characterized,O
by,O
its,O
rapid,O
mutations,O
up,O
to,O
a,O
million,O
times,O
higher,O
than,O
that,O
of,O
their,O
hosts,O
[,O
1,O
],O
.,O
From,O
the,O
NCBI,S-Repository
 ,O
virus,O
database,O
",",O
all,O
the,O
protein,O
sequences,O
of,O
3617,O
SARS,O
-,O
CoV2,O
genomes,O
were,O
fetched,O
.,O
In,O
the,O
NCBI,S-Repository
 ,O
database,O
",",O
as,O
on,O
June,O
6,O
",",O
2020,O
",",O
total,O
number,O
of,O
available,O
complete,O
genome,O
sequences,O
of,O
SARS,O
-,O
CoV2,O
across,O
the,O
world,O
is,O
3617,O
.,O
In,O
the,O
NCBI,S-Repository
 ,O
database,O
",",O
as,O
on,O
June,O
6,O
",",O
2020,O
",",O
total,O
number,O
of,O
available,O
complete,O
genome,O
sequences,O
of,O
SARS,O
-,O
CoV2,O
across,O
the,O
world,O
is,O
3617,O
on,O
which,O
the,O
present,O
study,O
of,O
mutation,O
over,O
the,O
envelope,O
protein,O
is,O
performed,O
.,O
.,O
   ,O
•,O
In,O
December,O
31,O
",",O
2019,O
",",O
the,O
epidemic,O
of,O
novel,O
human,O
coronavirus,O
(,O
COVID-19,O
),O
was,O
first,O
detected,O
in,O
Wuhan,O
city,O
",",O
Hubei,O
province,O
",",O
China,O
",",O
which,O
has,O
caused,O
pneumonia,O
by,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
The,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
has,O
reported,O
that,O
the,O
main,O
route,O
to,O
spread,O
of,O
the,O
COVID-19,O
virus,O
is,O
human,O
-,O
to,O
-,O
human,O
transmission,O
.,O
COVID-19,O
has,O
a,O
very,O
contagious,O
nature,O
and,O
rapidly,O
spreads,O
to,O
all,O
developed,O
and,O
developing,O
countries,O
(,O
WHO,O
",",O
2020a,O
;,O
WHO,O
",",O
2020b,O
;,O
Ma,O
et,O
al,O
.,O
",",O
2020,O
;,O
Wang,O
et,O
al,O
.,O
",",O
2020,O
;,O
Sohrabi,O
et,O
al,O
.,O
",",O
2020,O
;,O
Noorimotlagh,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
Islamic,O
Republic,O
(,O
IR,O
),O
of,O
Iran,O
",",O
on,O
February,O
19,O
",",O
2020,O
",",O
the,O
Ministry,O
of,O
Health,O
and,O
Medical,O
Education,O
official,O
announcement,O
reported,O
the,O
first,O
death,O
caused,O
by,O
COVID-19,O
(,O
Takian,O
et,O
al,O
.,O
",",O
2020,O
;,O
Faridi,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
According,O
to,O
WHO,O
situation,O
report-108,O
on,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
outbreak,O
",",O
on,O
May,O
7,O
",",O
2020,O
",",O
Iran,O
was,O
reported,O
to,O
have,O
"103,330",O
and,O
6496,O
total,O
confirmed,O
cases,O
and,O
total,O
deaths,O
",",O
respectively,O
",",O
which,O
was,O
the,O
highest,O
ranking,O
among,O
Eastern,O
Mediterranean,O
countries,O
(,O
WHO,O
",",O
2020a,O
),O
.,O
The,O
very,O
high,O
prevalence,O
of,O
COVID-19,O
in,O
the,O
world,O
has,O
triggered,O
rigorous,O
investigations,O
to,O
determine,O
the,O
clinical,O
characteristics,O
and,O
severity,O
of,O
the,O
novel,O
coronavirus,O
disease,O
and,O
its,O
potential,O
transmission,O
route,O
including,O
airborne,O
transmission,O
.,O
The,O
present,O
study,O
was,O
carried,O
out,O
on,O
May,O
7,O
",",O
2020,O
",",O
in,O
Shahid,O
Mustafa,O
Khomeini,O
Hospital,O
wards,O
in,O
Ilam,O
province,O
",",O
East,O
of,O
Iran,O
",",O
assigned,O
for,O
patients,O
',O
treatment,O
with,O
confirmed,O
COVID-19,O
.,O
Ilam,O
",",O
with,O
"580,000",O
population,O
",",O
was,O
then,O
reported,O
to,O
have,O
576,O
and,O
54,O
confirmed,O
COVID-19,O
cases,O
and,O
deaths,O
",",O
respectively,O
.,O
All,O
of,O
the,O
suspected,O
and,O
confirmed,O
cases,O
of,O
COVID-19,O
in,O
the,O
other,O
cities,O
were,O
transferred,O
to,O
Shahid,O
Mustafa,O
Khomeini,O
Hospital,O
.,O
In,O
the,O
present,O
study,O
",",O
the,O
liquid,O
impinger,O
biosampler,O
(,O
liquid,O
-,O
phase,O
sampler,O
",",O
SKC,O
biosampler,O
),O
was,O
consumed,O
as,O
a,O
highly,O
efficient,O
technique,O
to,O
capture,O
airborne,O
viruses,O
in,O
bio,O
-,O
aerosol,O
sampling,O
of,O
the,O
COVID-19,O
virus,O
in,O
the,O
different,O
wards,O
of,O
the,O
hospital,O
.,O
The,O
novel,O
human,O
coronavirus,O
(,O
COVID-19,O
),O
has,O
recently,O
emerged,O
and,O
rapidly,O
spread,O
through,O
all,O
developed,O
and,O
developing,O
countries,O
and,O
caused,O
a,O
pandemic,O
with,O
great,O
health,O
burden,O
worldwide,O
.,O
As,O
depicted,O
in,O
Table,O
3,O
",",O
there,O
were,O
183,O
patients,O
confirmed,O
with,O
COVID-19,O
with,O
different,O
conditions,O
from,O
severe,O
and,O
critical,O
to,O
mild,O
circumstances,O
.,O
Ong,O
et,O
al,O
.,O
(,O
2020,O
),O
suggest,O
that,O
environment,O
",",O
due,O
to,O
the,O
significant,O
contamination,O
caused,O
by,O
respiratory,O
droplets,O
and,O
fecal,O
shedding,O
of,O
patients,O
with,O
confirmed,O
COVID-19,O
",",O
is,O
the,O
potential,O
medium,O
of,O
transmission,O
(,O
Ong,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
However,O
",",O
the,O
main,O
routes,O
of,O
preventing,O
and,O
limiting,O
the,O
exposure,O
to,O
COVID-19,O
recommended,O
by,O
WHO,O
are,O
hand,O
washing,O
and,O
observing,O
social,O
distance,O
(,O
WHO,O
",",O
2020a,O
;,O
Morawska,O
and,O
Cao,O
",",O
2020,O
),O
.,O
These,O
measures,O
could,O
not,O
prevent,O
people,O
infection,O
through,O
inhalation,O
of,O
small,O
droplets,O
and,O
aerosols,O
emission,O
by,O
a,O
COVID-19,O
patients,O
(,O
in,O
many,O
cases,O
they,O
are,O
asymptomatic,O
),O
that,O
can,O
travel,O
distance,O
of,O
meters,O
or,O
10,O
of,O
meters,O
in,O
the,O
air,O
and,O
transmit,O
the,O
viable,O
virus,O
of,O
SARS,O
-,O
CoV-2,O
.,O
In,O
another,O
similar,O
study,O
",",O
about,O
aerodynamic,O
characteristics,O
and,O
RNA,O
concentration,O
of,O
SARS,O
-,O
CoV-2,O
aerosol,O
in,O
Wuhan,O
hospitals,O
during,O
COVID-19,O
outbreak,O
",",O
Liu,O
et,O
al,O
.,O
(,O
2020,O
),O
confirmed,O
that,O
the,O
resuspension,O
process,O
of,O
the,O
virus,O
aerosol,O
",",O
which,O
deposit,O
on,O
protective,O
apparel,O
or,O
floor,O
surface,O
",",O
could,O
be,O
a,O
potential,O
transmission,O
route,O
.,O
On,O
December,O
31,O
",",O
2019,O
",",O
the,O
novel,O
human,O
coronavirus,O
(,O
COVID-19,O
),O
was,O
identified,O
in,O
Wuhan,O
",",O
China,O
and,O
swiftly,O
spread,O
in,O
all,O
nations,O
and,O
territories,O
around,O
the,O
globe,O
.,O
Therefore,O
",",O
we,O
examined,O
the,O
potential,O
aerosol,O
transmission,O
of,O
the,O
virus,O
through,O
hospital,O
wards,O
indoor,O
air,O
by,O
confirmed,O
COVID-19,O
patients,O
on,O
May,O
7,O
",",O
2020,O
.,O
Accordingly,O
",",O
we,O
found,O
two,O
positive,O
air,O
samples,O
(,O
in,O
the,O
ICU,O
),O
out,O
of,O
14,O
ones,O
taken,O
from,O
different,O
wards,O
with,O
confirmed,O
COVID-19,O
patients,O
.,O
Coronavirus,O
disease-2019,O
(,O
COVID-19,O
),O
has,O
led,O
to,O
>,O
22,O
million,O
affected,O
(,O
1,O
),O
and,O
>,O
"784,000",O
deaths,O
worldwide,O
.,O
Accordingly,O
",",O
it,O
has,O
been,O
hypothesized,O
that,O
inflammation,O
associated,O
with,O
SARS,O
-,O
CoV-2,O
infection,O
leads,O
to,O
a,O
“,O
COVID-19,O
–,O
related,O
coagulopathy,O
”,O
(,O
5,O
),O
",",O
resulting,O
in,O
increased,O
thrombosis,O
(,O
6,O
),O
.,O
Observational,O
analyses,O
have,O
suggested,O
potential,O
benefit,O
for,O
in,O
-,O
hospital,O
use,O
of,O
anticoagulation,O
(,O
AC,O
),O
in,O
COVID-19,O
treatment,O
(,O
"9,10",O
),O
.,O
Survival,O
in,O
days,O
was,O
calculated,O
as,O
time,O
from,O
hospital,O
admission,O
to,O
in,O
-,O
hospital,O
death,O
",",O
discharge,O
",",O
or,O
the,O
date,O
of,O
dataset,O
lock,O
(,O
May,O
7,O
",",O
2020,O
),O
.,O
Overall,O
",",O
"1,073",O
(,O
24.4,O
%,O
),O
patients,O
died,O
during,O
the,O
study,O
period,O
",",O
"2,892",O
(,O
65.9,O
%,O
),O
were,O
discharged,O
alive,O
",",O
and,O
424,O
(,O
9.7,O
%,O
),O
were,O
still,O
hospitalized,O
by,O
dataset,O
freeze,O
date,O
.,O
Autopsies,O
were,O
performed,O
on,O
COVID-19,O
positive,O
patients,O
at,O
Mount,O
Sinai,O
Health,O
System,O
starting,O
on,O
March,O
20,O
",",O
2020,O
",",O
with,O
72,O
completed,O
by,O
May,O
7,O
",",O
2020,O
(,O
8),O
.,O
Thromboembolic,O
disease,O
has,O
emerged,O
as,O
an,O
important,O
complication,O
among,O
hospitalized,O
patients,O
with,O
COVID-19,O
.,O
The,O
mechanisms,O
by,O
which,O
thrombotic,O
disease,O
may,O
occur,O
in,O
the,O
setting,O
of,O
COVID-19,O
infection,O
include,O
inflammation,O
",",O
hypoxia,O
",",O
and,O
potentially,O
pharmacotherapeutic,O
interactions,O
(,O
"2,4,12,13",O
),O
.,O
As,O
such,O
",",O
the,O
potential,O
benefit,O
of,O
AC,O
in,O
the,O
treatment,O
of,O
COVID-19,O
is,O
based,O
on,O
the,O
prevention,O
and,O
treatment,O
of,O
microvascular,O
and,O
macrovascular,O
thrombosis,O
.,O
In,O
our,O
cohort,O
of,O
patients,O
hospitalized,O
with,O
COVID-19,O
",",O
a,O
strong,O
association,O
of,O
AC,O
with,O
approximately,O
50,O
%,O
reduced,O
hazard,O
of,O
in,O
-,O
hospital,O
mortality,O
was,O
observed,O
(,O
Figure,O
 ,O
1A,O
),O
.,O
As,O
mortality,O
rates,O
for,O
patients,O
with,O
COVID-19,O
who,O
undergo,O
intubation,O
for,O
respiratory,O
failure,O
range,O
from,O
30,O
%,O
to,O
80,O
%,O
(,O
16,O
",",O
17,O
",",O
18,O
),O
",",O
we,O
analyzed,O
the,O
association,O
between,O
AC,O
and,O
intubation,O
.,O
Background,O
 ,O
Thromboembolic,O
disease,O
is,O
common,O
in,O
coronavirus,O
disease-2019,O
(,O
COVID-19,O
),O
.,O
Conclusions,O
 ,O
AC,O
was,O
associated,O
with,O
lower,O
mortality,O
and,O
intubation,O
among,O
hospitalized,O
COVID-19,O
patients,O
.,O
The,O
connection,O
between,O
the,O
reality,O
of,O
the,O
COVID‐19,O
in,O
the,O
US,O
and,O
around,O
the,O
world,O
and,O
the,O
magical,O
realism,O
in,O
a,O
story,O
set,O
in,O
a,O
Caribbean,O
Sea,O
harbor,O
town,O
in,O
Colombia,O
is,O
tenuous,O
at,O
best,O
.,O
There,O
are,O
some,O
parallels,O
",",O
though,O
:,O
anxiety,O
",",O
fear,O
",",O
and,O
suffering,O
throughout,O
the,O
population,O
",",O
and,O
the,O
frantic,O
search,O
for,O
a,O
cure,O
for,O
those,O
seriously,O
affected,O
by,O
COVID‐19,O
",",O
similar,O
to,O
Dr.,O
Urbino,O
’s,O
passion,O
for,O
finding,O
a,O
cholera,O
cure,O
in,O
the,O
book,O
.,O
Other,O
similarities,O
between,O
the,O
current,O
COVID‐19,O
pandemic,O
and,O
the,O
fictional,O
cholera,O
outbreak,O
described,O
by,O
García,O
Márquez,O
include,O
personal,O
resilience,O
and,O
indomitable,O
spirit,O
under,O
trying,O
circumstances,O
…,O
and,O
that,O
life,O
after,O
the,O
pandemic,O
is,O
not,O
the,O
same,O
.,O
Other,O
lessons,O
learned,O
during,O
the,O
COVID‐19,O
pandemic,O
for,O
medical,O
genetics,O
practice,O
include,O
the,O
utility,O
of,O
telemedicine,O
",",O
which,O
until,O
now,O
was,O
largely,O
used,O
only,O
for,O
patients,O
in,O
remote,O
locations,O
",",O
but,O
which,O
may,O
well,O
become,O
the,O
new,O
norm,O
after,O
being,O
employed,O
successfully,O
while,O
patients,O
",",O
their,O
families,O
and,O
healthcare,O
providers,O
are,O
isolated,O
at,O
home,O
.,O
Lessons,O
learned,O
from,O
these,O
new,O
models,O
of,O
teaching,O
the,O
next,O
generation,O
of,O
healthcare,O
professionals,O
in,O
medical,O
genetics,O
and,O
genomics,O
may,O
well,O
be,O
incorporated,O
in,O
(,O
re)designing,O
future,O
didactics,O
in,O
our,O
field,O
.,O
COVID-19,O
was,O
declared,O
a,O
pandemic,O
by,O
the,O
World,O
Health,O
Organization,O
",",O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
Respiratory,O
failure,O
is,O
the,O
most,O
common,O
mortality,O
outcome,O
in,O
COVID-19,O
patients,O
",",O
yet,O
serious,O
and,O
even,O
fatal,O
manifestations,O
are,O
seen,O
across,O
multiple,O
organ,O
systems,O
",",O
including,O
the,O
brain,O
(,O
Helms,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Pleasure,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
and,O
gastrointestinal,O
tract,O
(,O
Goyal,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
one,O
retrospective,O
study,O
of,O
more,O
than,O
400,O
COVID-19,O
patients,O
",",O
nearly,O
20,O
%,O
had,O
suffered,O
in,O
-,O
hospital,O
cardiac,O
injury,O
",",O
which,O
was,O
a,O
significant,O
independent,O
risk,O
factor,O
for,O
mortality,O
(,O
Shi,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Nearly,O
25,O
%,O
of,O
patients,O
have,O
gastrointestinal,O
manifestations,O
including,O
anorexia,O
",",O
diarrhea,O
",",O
vomiting,O
",",O
and,O
abdominal,O
pain,O
",",O
and,O
these,O
symptoms,O
are,O
associated,O
with,O
worse,O
COVID-19,O
outcomes,O
(,O
Pan,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
A,O
recent,O
clinical,O
study,O
among,O
"7,300",O
COVID-19,O
patients,O
also,O
showed,O
a,O
strong,O
correlation,O
between,O
poor,O
COVID-19,O
outcomes,O
and,O
type,O
2,O
diabetes,O
(,O
Zhu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Recent,O
clinical,O
studies,O
suggest,O
that,O
diabetes,O
is,O
not,O
only,O
a,O
risk,O
factor,O
for,O
severe,O
COVID-19,O
disease,O
",",O
but,O
also,O
that,O
SARS,O
-,O
CoV-2,O
infection,O
can,O
induce,O
new,O
-,O
onset,O
diabetes,O
(,O
Bornstein,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Currently,O
",",O
there,O
are,O
no,O
vaccines,O
or,O
effective,O
treatment,O
options,O
for,O
COVID-19,O
due,O
to,O
limited,O
knowledge,O
of,O
SARS,O
-,O
CoV-2,O
viral,O
biology,O
.,O
A,O
human,O
cell,O
-,O
based,O
platform,O
to,O
study,O
viral,O
tropism,O
would,O
be,O
a,O
first,O
step,O
toward,O
defining,O
cell,O
types,O
permissive,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
for,O
modeling,O
COVID-19,O
disease,O
across,O
multiple,O
organ,O
systems,O
.,O
To,O
determine,O
the,O
relative,O
permissiveness,O
of,O
hPSC,O
-,O
derived,O
cells,O
and,O
organoids,O
to,O
SARS,O
-,O
CoV-2,O
viral,O
entry,O
",",O
we,O
used,O
a,O
vesicular,O
stomatitis,O
virus,O
(,O
VSV)-based,O
SARS,O
-,O
CoV-2,O
pseudo,O
-,O
entry,O
virus,O
",",O
for,O
which,O
the,O
backbone,O
was,O
provided,O
by,O
a,O
VSV,O
pseudo,O
-,O
typed,O
ΔG,O
-,O
luciferase,O
virus,O
with,O
the,O
SARS,O
-,O
CoV-2,O
Spike,O
protein,O
incorporated,O
in,O
the,O
surface,O
of,O
the,O
viral,O
particle,O
instead,O
(,O
Nie,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Whitt,O
",",O
2010,O
),O
.,O
Humanized,O
mice,O
carrying,O
human,O
pancreatic,O
endocrine,O
cells,O
in,O
 ,O
vivo,O
provide,O
a,O
unique,O
platform,O
for,O
modeling,O
COVID-19,O
.,O
In,O
brief,O
",",O
hPSC,O
-,O
derived,O
pancreatic,O
endocrine,O
cells,O
were,O
transplanted,O
under,O
the,O
kidney,O
capsule,O
of,O
SCID,O
-,O
beige,O
mice,O
(,O
Figure,O
 ,O
2,O
G,O
),O
.,O
As,O
it,O
is,O
technically,O
challenging,O
to,O
obtain,O
pancreatic,O
samples,O
from,O
COVID-19,O
patients,O
",",O
we,O
compared,O
transcript,O
profiles,O
from,O
lung,O
autopsy,O
samples,O
from,O
healthy,O
donors,O
or,O
COVID-19,O
patients,O
and,O
identified,O
a,O
robust,O
upregulation,O
of,O
chemokines,O
",",O
including,O
CCL2,O
",",O
CXCL5,O
",",O
and,O
CXCL6,O
",",O
in,O
the,O
COVID-19,O
patient,O
samples,O
as,O
has,O
been,O
described,O
previously,O
(,O
Figure,O
 ,O
3,O
G,O
;,O
Blanco,O
-,O
Melo,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Together,O
",",O
the,O
data,O
suggest,O
that,O
SARS,O
-,O
CoV-2,O
-,O
infected,O
pancreatic,O
endocrine,O
cells,O
show,O
robust,O
chemokine,O
induction,O
",",O
which,O
is,O
similar,O
to,O
what,O
is,O
found,O
in,O
autopsy,O
samples,O
from,O
COVID-19,O
patients,O
.,O
Consistent,O
with,O
results,O
using,O
hepatocyte,O
organoids,O
",",O
KEGG,O
GSEA,O
comparing,O
mock,O
infected,O
with,O
SARS,O
-,O
CoV-2,O
-,O
infected,O
cholangiocyte,O
organoids,O
revealed,O
the,O
upregulation,O
of,O
inflammatory,O
pathways,O
",",O
including,O
cytokine,O
-,O
cytokine,O
receptor,O
interaction,O
and,O
IL-17,O
signaling,O
(,O
Figure,O
 ,O
4N,O
",",O
Table,O
S1,O
),O
",",O
which,O
is,O
consistent,O
with,O
previous,O
findings,O
in,O
COVID-19,O
lung,O
autopsy,O
samples,O
(,O
Han,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Although,O
respiratory,O
failure,O
is,O
the,O
most,O
common,O
adverse,O
outcome,O
for,O
COVID-19,O
patients,O
",",O
they,O
often,O
present,O
with,O
additional,O
clinical,O
complications,O
involving,O
the,O
metabolic,O
",",O
cardiac,O
",",O
neurological,O
",",O
and,O
gastrointestinal,O
systems,O
.,O
Although,O
human,O
coronaviruses,O
previously,O
had,O
not,O
been,O
considered,O
to,O
infect,O
liver,O
cells,O
",",O
our,O
results,O
are,O
consistent,O
with,O
current,O
COVID-19,O
clinical,O
observations,O
that,O
more,O
than,O
50,O
%,O
of,O
patients,O
have,O
evidence,O
of,O
viral,O
hepatitis,O
(,O
Ong,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
A,O
recent,O
clinical,O
study,O
showed,O
a,O
strong,O
correlation,O
between,O
COVID-19,O
and,O
type,O
2,O
diabetes,O
(,O
Zhu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Closer,O
monitoring,O
of,O
individuals,O
with,O
high,O
risk,O
for,O
diabetes,O
is,O
needed,O
to,O
evaluate,O
the,O
contribution,O
of,O
SARS,O
-,O
CoV-2,O
in,O
previously,O
infected,O
COVID-19,O
patients,O
to,O
progression,O
toward,O
type,O
1,O
or,O
type,O
2,O
diabetes,O
.,O
SARS,O
-,O
CoV-2,O
",",O
isolate,O
USA,O
-,O
WA1/2020,O
(,O
NR-52281,O
),O
was,O
deposited,O
by,O
the,O
Center,O
for,O
Disease,O
Control,O
and,O
Prevention,O
and,O
obtained,O
through,O
BEI,O
Resources,O
",",O
NIAID,O
",",O
NIH,O
.,O
SARS,O
-,O
CoV-2,O
has,O
caused,O
the,O
COVID-19,O
pandemic,O
.,O
COVID-19,O
pathophysiology,O
includes,O
respiratory,O
failure,O
but,O
involves,O
other,O
organ,O
systems,O
including,O
gut,O
",",O
liver,O
",",O
heart,O
",",O
and,O
pancreas,O
.,O
Recent,O
clinical,O
studies,O
show,O
a,O
strong,O
association,O
with,O
COVID-19,O
and,O
diabetes,O
.,O
SARS,O
-,O
CoV-2,O
infection,O
caused,O
striking,O
expression,O
of,O
chemokines,O
",",O
as,O
also,O
seen,O
in,O
primary,O
human,O
COVID-19,O
pulmonary,O
autopsy,O
samples,O
.,O
hPSC,O
-,O
derived,O
cells,O
/,O
organoids,O
provide,O
valuable,O
models,O
for,O
understanding,O
the,O
cellular,O
responses,O
of,O
human,O
tissues,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
for,O
disease,O
modeling,O
of,O
COVID-19,O
.,O
Graphical,O
Abstract,O
     ,O
Yang,O
et,O
 ,O
al,O
.,O
show,O
that,O
hPSC,O
-,O
derived,O
cells,O
and,O
organoids,O
provide,O
valuable,O
models,O
to,O
study,O
SARS,O
-,O
CoV-2,O
tropism,O
and,O
to,O
model,O
COVID-19,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
emerged,O
in,O
late,O
2019,O
and,O
has,O
been,O
declared,O
a,O
pandemic,O
[,O
1,O
],O
.,O
Clinical,O
presentation,O
of,O
COVID-19,O
varies,O
widely,O
",",O
ranging,O
from,O
asymptomatic,O
to,O
mild,O
or,O
severe,O
forms,O
[,O
"2,3",O
],O
.,O
Although,O
epitopes,O
mapping,O
within,O
all,O
SARS,O
-,O
CoV-2,O
structural,O
proteins,O
have,O
been,O
shown,O
to,O
elicit,O
NtAb,O
",",O
the,O
receptor,O
-,O
binding,O
domain,O
(,O
RBD,O
),O
of,O
the,O
viral,O
spike,O
protein,O
(,O
S,O
),O
is,O
immunodominant,O
and,O
a,O
highly,O
specific,O
target,O
of,O
most,O
potent,O
NtAbs,O
in,O
COVID-19,O
patients,O
[,O
[,O
6,O
],O
",",O
[,O
7,O
],O
",",O
[,O
8,O
],O
",",O
[,O
9,O
],O
],O
.,O
The,O
involvement,O
of,O
functional,O
antibodies,O
in,O
SARS,O
-,O
CoV-2,O
clearance,O
and,O
modulation,O
of,O
COVID-19,O
severity,O
remains,O
to,O
be,O
precisely,O
defined,O
[,O
10,O
],O
.,O
Moreover,O
",",O
passive,O
immunization,O
of,O
critically,O
ill,O
COVID-19,O
patients,O
with,O
plasma,O
from,O
individuals,O
who,O
had,O
recovered,O
from,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
seroconverted,O
was,O
associated,O
with,O
improved,O
clinical,O
outcomes,O
in,O
uncontrolled,O
case,O
series,O
[,O
"13,14",O
],O
.,O
In,O
this,O
context,O
",",O
higher,O
antibody,O
titers,O
",",O
either,O
neutralizing,O
or,O
not,O
",",O
have,O
been,O
reported,O
to,O
be,O
present,O
in,O
patients,O
developing,O
severe,O
forms,O
of,O
COVID-19,O
when,O
compared,O
to,O
mildly,O
symptomatic,O
individuals,O
who,O
did,O
not,O
require,O
hospitalization,O
[,O
[,O
17,O
],O
",",O
[,O
18,O
],O
",",O
[,O
19,O
],O
",",O
[,O
20,O
],O
",",O
[,O
21,O
],O
",",O
[,O
22,O
],O
",",O
[,O
23,O
],O
],O
.,O
All,O
patients,O
presented,O
with,O
pneumonia,O
and,O
imaging,O
/,O
laboratory,O
findings,O
compatible,O
with,O
COVID-19,O
[,O
"2,3",O
],O
.,O
We,O
considered,O
high,O
NtAb50,O
titers,O
those,O
≥1/160,O
",",O
as,O
this,O
is,O
the,O
minimum,O
NtAb,O
titer,O
of,O
plasma,O
from,O
COVID-19,O
convalescent,O
individuals,O
recommended,O
by,O
the,O
FDA,O
for,O
therapeutic,O
use,O
[,O
30,O
],O
.,O
As,O
expected,O
",",O
ICU,O
patients,O
were,O
hospitalized,O
for,O
longer,O
periods,O
and,O
the,O
median,O
serum,O
levels,O
of,O
several,O
pro,O
-,O
inflammatory,O
biomarkers,O
",",O
(,O
LDH,O
",",O
dimer,O
-,O
D,O
and,O
IL-6,O
),O
were,O
significantly,O
higher,O
in,O
ICU,O
patients,O
",",O
further,O
confirming,O
their,O
association,O
with,O
COVID-19,O
severity,O
[,O
[,O
2,O
],O
",",O
[,O
3,O
],O
",",O
[,O
4,O
],O
",",O
[,O
5,O
],O
],O
.,O
Avidity,O
of,O
SARS,O
-,O
CoV-2,O
IgGs,O
in,O
sera,O
from,O
COVID-19,O
patients,O
was,O
assessed,O
by,O
a,O
conventional,O
urea,O
dissociation,O
assay,O
[,O
26,O
],O
.,O
Very,O
weak,O
(,O
Rho=>0.0–<0.2,O
),O
or,O
weak,O
(,O
Rho=>0.2–<0.4,O
),O
correlations,O
(,O
either,O
positive,O
or,O
negative,O
),O
were,O
found,O
between,O
SARS,O
-,O
CoV-2,O
RBD,O
IgG,O
levels,O
or,O
NtAb50,O
titers,O
and,O
all,O
selected,O
biomarkers,O
when,O
considering,O
the,O
entire,O
data,O
set,O
(,O
Fig,O
.,O
6,O
),O
or,O
when,O
analyses,O
were,O
done,O
separately,O
for,O
specimens,O
collected,O
at,O
different,O
time,O
frames,O
after,O
the,O
onset,O
of,O
symptoms,O
(,O
days,O
1–15,O
or,O
days,O
15–30,O
;,O
not,O
shown,O
),O
.,O
Here,O
",",O
in,O
addition,O
to,O
further,O
characterizing,O
the,O
antibody,O
response,O
to,O
SARS,O
-,O
CoV-2,O
in,O
hospitalized,O
COVID-19,O
patients,O
",",O
we,O
mainly,O
aimed,O
to,O
determine,O
whether,O
a,O
relationship,O
could,O
be,O
established,O
between,O
the,O
magnitude,O
of,O
SARS,O
-,O
CoV-2,O
RBD,O
IgG,O
and,O
NtAb,O
levels,O
and,O
the,O
“,O
inflammatory,O
state,O
”,O
of,O
patients,O
",",O
which,O
has,O
been,O
shown,O
to,O
directly,O
correlate,O
with,O
COVID-19,O
severity,O
and,O
prognosis,O
[,O
[,O
2,O
],O
",",O
[,O
3,O
],O
",",O
[,O
4,O
],O
",",O
[,O
5,O
],O
],O
.,O
Previous,O
studies,O
have,O
reported,O
a,O
correlation,O
between,O
RBD,O
IgG,O
levels,O
and,O
NtAb,O
titers,O
in,O
patients,O
with,O
comparable,O
or,O
less,O
severe,O
clinical,O
presentations,O
of,O
COVID-19,O
",",O
using,O
either,O
live,O
native,O
SARS,O
-,O
CoV-2,O
virus,O
",",O
engineered,O
SARS,O
-,O
CoV-2,O
pseudotype,O
virus,O
systems,O
or,O
replication,O
-,O
competent,O
SARS,O
-,O
CoV-2,O
chimeric,O
viruses,O
[,O
"18,22,[30",O
],O
",",O
[,O
31,O
],O
",",O
[,O
32,O
],O
",",O
[,O
33,O
],O
",",O
[,O
34,O
],O
",",O
[,O
35,O
],O
",",O
[,O
36,O
],O
],O
.,O
The,O
alleged,O
association,O
between,O
high,O
SARS,O
-,O
CoV-2,O
antibody,O
levels,O
and,O
COVID-19,O
severity,O
[,O
[,O
17,O
],O
",",O
[,O
18,O
],O
",",O
[,O
19,O
],O
",",O
[,O
20,O
],O
",",O
[,O
21,O
],O
",",O
[,O
22,O
],O
],O
is,O
a,O
matter,O
of,O
concern,O
.,O
Wang,O
et,O
al,O
.,O
[,O
18,O
],O
also,O
reported,O
higher,O
NtAb50,O
titers,O
quantitated,O
by,O
a,O
pseudotyped,O
-,O
virus,O
based,O
neutralization,O
assay,O
in,O
severely,O
ill,O
patients,O
as,O
compared,O
to,O
mild,O
COVID-19,O
patients,O
.,O
Other,O
studies,O
including,O
relatively,O
small,O
cohorts,O
also,O
pointed,O
to,O
an,O
association,O
of,O
COVID-19,O
severity,O
with,O
SARS,O
-,O
CoV-2,O
NtAb,O
[,O
"20,22,38",O
],O
.,O
Disregulated,O
synthesis,O
and,O
release,O
of,O
pro,O
-,O
inflammatory,O
cytokines,O
is,O
thought,O
to,O
be,O
a,O
pathogenetic,O
hallmark,O
of,O
most,O
severe,O
forms,O
of,O
COVID-19,O
[,O
"4,5",O
],O
.,O
Although,O
the,O
mechanisms,O
of,O
COVID-19,O
–,O
induced,O
lung,O
injury,O
remain,O
unclear,O
",",O
the,O
so,O
-,O
called,O
“,O
cytokine,O
storm,O
”,O
may,O
likely,O
play,O
a,O
critical,O
role,O
in,O
the,O
process,O
of,O
disease,O
worsening,O
and,O
thus,O
in,O
COVID-19,O
prognosis,O
[,O
40,O
],O
.,O
Taken,O
together,O
",",O
these,O
data,O
argue,O
against,O
a,O
robust,O
relationship,O
between,O
the,O
magnitude,O
of,O
the,O
antibody,O
responses,O
subjected,O
to,O
analysis,O
herein,O
and,O
the,O
state,O
of,O
inflammation,O
in,O
COVID-19,O
patients,O
.,O
•,O
 ,O
NtAb,O
and,O
RBD,O
IgGs,O
levels,O
do,O
not,O
associate,O
with,O
COVID-19,O
severity,O
in,O
hospitalized,O
patients,O
.,O
The,O
involvement,O
of,O
SARS,O
-,O
CoV-2,O
antibodies,O
in,O
mediating,O
immunopathogenetic,O
events,O
in,O
COVID-19,O
patients,O
has,O
been,O
suggested,O
.,O
By,O
using,O
several,O
experimental,O
approaches,O
",",O
we,O
investigated,O
the,O
potential,O
association,O
between,O
SARS,O
-,O
CoV-2,O
IgGs,O
recognizing,O
the,O
spike,O
(,O
S,O
),O
protein,O
receptor,O
-,O
binding,O
domain,O
(,O
RBD,O
),O
",",O
neutralizing,O
antibodies,O
(,O
NtAb,O
),O
targeting,O
S,O
",",O
and,O
COVID-19,O
severity,O
.,O
The,O
data,O
presented,O
herein,O
do,O
not,O
support,O
an,O
association,O
between,O
SARS,O
-,O
CoV-2,O
RBD,O
IgG,O
or,O
NtAb50,O
levels,O
and,O
COVID-19,O
severity,O
.,O
Selected,O
sites,O
are,O
mapped,O
onto,O
the,O
3D,O
structure,O
of,O
models,O
obtained,O
using,O
SARS,O
-,O
CoV,O
proteins,O
as,O
a,O
templates,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6ACG,S-AccessionNumber
 ,O
for,O
panel,O
A,O
",",O
2CJR,S-AccessionNumber
 ,O
for,O
panel,O
B,O
",",O
2HSX,S-AccessionNumber
 ,O
for,O
panel,O
C,O
),O
.,O
These,O
will,O
need,O
to,O
be,O
interpreted,O
in,O
the,O
future,O
",",O
by,O
incorporating,O
epidemiological,O
",",O
biochemical,O
",",O
and,O
additional,O
genetic,O
data,O
.,O
Genome,O
sequences,O
were,O
retrieved,O
from,O
the,O
National,B-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,E-Repository
 ,O
database,O
(,O
NCBI,S-Repository
;,O
https://www.ncbi.nlm.nih.gov/,S-URL
),O
.,O
The,O
three,O
-,O
dimensional,O
(,O
3D,O
),O
structures,O
of,O
SARS,O
-,O
CoV,O
N,O
(,O
PDB,S-Repository
 ,O
identifier,O
[,O
ID,O
],O
:,O
2CJR,S-AccessionNumber
),O
(,O
65,O
),O
and,O
S,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6ACG,S-AccessionNumber
),O
(,O
48,O
),O
proteins,O
were,O
obtained,O
from,O
the,O
Protein,B-Repository
Data,I-Repository
Bank,I-Repository
(PDB),E-Repository
.,O
Biochemists,O
",",O
microbiologists,O
",",O
and,O
ecologists,O
with,O
general,O
molecular,O
training,O
may,O
have,O
the,O
technical,O
skills,O
to,O
run,O
COVID-19,O
assays,O
",",O
but,O
they,O
do,O
n’t,O
have,O
the,O
appropriate,O
certifications,O
.,O
Even,O
so,O
",",O
the,O
urgency,O
of,O
the,O
pandemic,O
has,O
spurred,O
some,O
states,O
to,O
relax,O
legal,O
restrictions,O
on,O
who,O
can,O
perform,O
COVID-19,O
testing,O
.,O
On,O
March,O
12,O
",",O
for,O
example,O
",",O
California,O
Governor,O
Gavin,O
Newsom,O
issued,O
an,O
executive,O
order,O
suspending,O
certification,O
and,O
licensure,O
requirements,O
for,O
any,O
researcher,O
with,O
relevant,O
skills,O
who,O
meets,O
CLIA,O
requirements,O
to,O
run,O
the,O
COVID-19,O
test,O
;,O
such,O
a,O
person,O
may,O
now,O
temporarily,O
run,O
the,O
assays,O
under,O
the,O
supervision,O
of,O
a,O
medical,O
laboratory,O
scientist,O
in,O
a,O
CLIA,O
-,O
certified,O
lab,O
(,O
4,O
),O
.,O
On,O
March,O
19,O
",",O
Louisiana,O
Governor,O
John,O
Bel,O
Edwards,O
issued,O
a,O
proclamation,O
to,O
temporarily,O
suspend,O
some,O
certification,O
and,O
licensure,O
requirements,O
for,O
running,O
COVID-19,O
assays,O
.,O
Now,O
",",O
laboratory,O
personnel,O
“,O
who,O
demonstrate,O
molecular,O
biology,O
polymerase,O
chain,O
reaction,O
(,O
PCR,O
),O
experience,O
”,O
can,O
legally,O
run,O
COVID-19,O
tests,O
if,O
they,O
are,O
supervised,O
by,O
a,O
licensed,O
physician,O
or,O
PhD,O
with,O
related,O
lab,O
experience,O
",",O
according,O
to,O
the,O
proclamation,O
(,O
5,O
),O
.,O
Hence,O
",",O
an,O
ecologist,O
trained,O
in,O
PCR,O
might,O
now,O
be,O
a,O
candidate,O
to,O
run,O
COVID-19,O
assays,O
",",O
if,O
properly,O
supervised,O
",",O
says,O
Vincent,O
Culotta,O
",",O
executive,O
director,O
of,O
the,O
Louisiana,O
State,O
Board,O
of,O
Medical,O
Examiners,O
in,O
New,O
Orleans,O
.,O
The,O
several,O
medical,O
laboratory,O
scientists,O
already,O
working,O
there,O
will,O
oversee,O
at,O
least,O
15,O
Berkeley,O
postdoctoral,O
molecular,O
biologist,O
volunteers,O
",",O
who,O
will,O
run,O
the,O
COVID-19,O
assays,O
.,O
Some,O
testing,O
centers,O
made,O
their,O
own,O
COVID-19,O
assays,O
",",O
choosing,O
their,O
preferred,O
brand,O
of,O
RNA,O
extraction,O
kits,O
",",O
primers,O
",",O
PCR,O
machines,O
",",O
and,O
swabs,O
",",O
Schaletzky,O
explains,O
.,O
After,O
the,O
FDA,O
granted,O
emergency,O
-,O
use,O
authorization,O
for,O
the,O
test,O
in,O
late,O
March,O
",",O
Abbott,O
estimated,O
that,O
it,O
could,O
deliver,O
"50,000",O
COVID-19,O
tests,O
per,O
day,O
(,O
10,O
),O
.,O
This,O
leads,O
to,O
a,O
respiratory,O
disease,O
called,O
COVID-19,O
that,O
was,O
declared,O
a,O
global,O
pandemic,O
in,O
early,O
2020,O
.,O
Discovery,O
of,O
pharmacological,O
interventions,O
that,O
can,O
interrupt,O
this,O
lung,O
tissue,O
to,O
sensory,O
neuronal,O
innervation,O
of,O
the,O
lung,O
signaling,O
could,O
play,O
an,O
important,O
role,O
in,O
treating,O
severe,O
COVID-19,O
cases,O
.,O
There,O
is,O
strong,O
evidence,O
that,O
neurogenic,O
factors,O
play,O
an,O
important,O
role,O
in,O
sepsis,O
(,O
Bryant,O
et,O
al,O
.,O
",",O
2003,O
",",O
Devesa,O
et,O
al,O
.,O
",",O
2011,O
),O
",",O
which,O
also,O
occurs,O
in,O
many,O
severe,O
COVID-19,O
patients,O
(,O
Zhou,O
et,O
al,O
.,O
",",O
2020a,O
),O
.,O
The,O
unprecedented,O
scientific,O
response,O
to,O
the,O
SARS,O
-,O
CoV-2,O
driven,O
pandemic,O
has,O
produced,O
datasets,O
that,O
enable,O
computational,O
determination,O
of,O
probable,O
intercellular,O
signaling,O
between,O
nociceptors,O
and,O
immune,O
signaling,O
or,O
response,O
in,O
the,O
lung,O
.,O
Because,O
these,O
interactions,O
might,O
be,O
a,O
crucial,O
driver,O
of,O
disease,O
severity,O
",",O
we,O
set,O
out,O
to,O
comprehensively,O
catalog,O
these,O
interactions,O
using,O
previously,O
published,O
datasets,O
from,O
COVID-19,O
patients,O
(,O
"Gordon,",B-Creator
et,I-Creator
"al.,",I-Creator
2020,E-Creator
",",O
Huang,B-Creator
et,I-Creator
"al.,",I-Creator
2020b,E-Creator
",",O
Huang,B-Creator
et,I-Creator
"al.,",I-Creator
2020,E-Creator
",",O
Liao,B-Creator
et,I-Creator
"al.,",I-Creator
2020,E-Creator
",",O
Xiong,B-Creator
et,I-Creator
"al.,",I-Creator
2020b,E-Creator
),O
and,O
our,O
own,O
RNA,O
sequencing,O
(,O
RNA,O
-,O
seq,O
),O
datasets,O
from,O
human,O
thoracic,O
DRG,O
(,O
hDRG,O
),O
(,O
Ray,B-Creator
et,I-Creator
"al.,",I-Creator
2018,E-Creator
",",O
North,B-Creator
et,I-Creator
"al.,",I-Creator
2019,E-Creator
),O
.,O
A,O
key,O
finding,O
emerging,O
from,O
the,O
data,O
is,O
that,O
certain,O
interventions,O
used,O
or,O
under,O
development,O
for,O
rheumatic,O
or,O
neuropathic,O
pain,O
might,O
be,O
useful,O
against,O
COVID-19,O
.,O
We,O
first,O
re,O
-,O
analyzed,O
bulk,O
RNA,O
-,O
seq,O
data,O
from,O
published,O
studies,O
by,O
mapping,O
and,O
quantifying,O
relative,O
gene,O
abundance,O
(,O
in,O
counts,O
per,O
million,O
),O
from,O
BALF,O
(,O
National,B-Repository
Genomics,I-Repository
Data,I-Repository
Center,E-Repository
 ,O
accession,O
number,O
:,O
PRJCA002326,S-AccessionNumber
",",O
),O
of,O
severe,O
COVID-19,O
patients,O
(,O
Xiong,B-Creator
et,I-Creator
"al.,",I-Creator
2020b,E-Creator
),O
",",O
compared,O
to,O
BALF,O
(,O
NCBI,B-Repository
SRAdb,E-Repository
 ,O
project,O
SRP230751,S-AccessionNumber
",",O
),O
of,O
healthy,O
controls,O
.,O
Differences,O
between,O
the,O
two,O
COVID-19,O
BALF,O
samples,O
can,O
likely,O
be,O
attributed,O
to,O
variability,O
of,O
the,O
immune,O
response,O
from,O
patient,O
to,O
patient,O
",",O
as,O
well,O
as,O
the,O
lower,O
sequencing,O
depth,O
of,O
the,O
samples,O
",",O
as,O
even,O
after,O
pooling,O
technical,O
replicates,O
for,O
the,O
COVID-19,O
patient,O
samples,O
we,O
had,O
 ,O
~,O
 ,O
12,O
 ,O
M,O
and,O
7,O
 ,O
M,O
sequenced,O
reads,O
.,O
The,O
two,O
COVID-19,O
BALF,O
samples,O
were,O
also,O
found,O
to,O
contain,O
SARS,O
-,O
CoV2,O
viral,O
RNA,O
reads,O
confirming,O
the,O
presence,O
of,O
disease,O
(,O
Xiong,B-Creator
et,I-Creator
"al.,",I-Creator
2020b,E-Creator
),O
.,O
Out,O
of,O
"31,069",O
genes,O
in,O
the,O
reference,O
genome,O
",",O
we,O
detected,O
"18,507",O
and,O
"18,855",O
genes,O
in,O
the,O
control,O
samples,O
",",O
and,O
"13,973",O
and,O
"13,545",O
genes,O
in,O
the,O
COVID-19,O
patient,O
samples,O
;,O
differences,O
being,O
primarily,O
attributable,O
to,O
a,O
decrease,O
in,O
sequencing,O
depth,O
for,O
COVID-19,O
samples,O
.,O
Due,O
to,O
this,O
and,O
the,O
fact,O
that,O
our,O
goal,O
was,O
to,O
identify,O
potentially,O
targetable,O
protein,O
interaction,O
pathways,O
in,O
COVID-19,O
patients,O
",",O
we,O
performed,O
downstream,O
analysis,O
only,O
on,O
1372,O
genes,O
that,O
were,O
upregulated,O
in,O
the,O
COVID-19,O
BALF,O
samples,O
(,O
Supplementary,O
Table,O
1,O
),O
.,O
Genes,O
upregulated,O
in,O
the,O
COVID-19,O
patient,O
samples,O
include,O
a,O
multitude,O
of,O
genes,O
that,O
recapitulate,O
clinical,O
characteristics,O
",",O
such,O
as,O
increased,O
cytokine,O
signaling,O
causing,O
a,O
“,O
cytokine,O
storm,O
”,O
(,O
including,O
CCL2/3/4/7/8,O
",",O
CXCL1/2/6/8/28,O
",",O
CCL3L3,O
",",O
CCL4L2,O
),O
",",O
hypoxia,O
(,O
HIF1A,O
",",O
HLF,O
),O
",",O
and,O
inflammasome,O
and,O
sepsis,O
-,O
related,O
genes,O
(,O
IL1R1/2,O
",",O
IL5RA,O
",",O
IL33,O
",",O
IL31RA,O
),O
.,O
Additionally,O
",",O
we,O
found,O
that,O
upregulation,O
of,O
transcription,O
factor,O
genes,O
in,O
COVID-19,O
samples,O
identifies,O
transcription,O
factors,O
associated,O
with,O
alveolar,O
cell,O
types,O
(,O
EHF,O
",",O
PAX9,O
",",O
ELF3,O
",",O
GHRL2,O
),O
and,O
immune,O
cells,O
(,O
RFX3,O
",",O
SOX5,O
",",O
TP63,O
",",O
HOPX,O
),O
with,O
functions,O
including,O
regulation,O
of,O
antiviral,O
pathways,O
(,O
NR3C2,O
),O
",",O
based,O
on,O
ARCHS4,S-Dataset
 ,O
database,O
(,O
Lachmann,B-Creator
et,I-Creator
"al.,",I-Creator
2018,E-Creator
),O
and,O
the,O
Enrichr,O
gene,O
set,O
enrichment,O
analysis,O
tool,O
(,O
Kuleshov,O
et,O
al,O
.,O
",",O
2016,O
),O
(,O
Supplementary,O
Table,O
2,O
),O
.,O
This,O
suggests,O
that,O
cellular,O
distress,O
and,O
virus,O
-,O
driven,O
cell,O
lysis,O
causes,O
lung,O
cell,O
mRNA,O
content,O
to,O
be,O
detected,O
in,O
COVID-19,O
BALF,O
samples,O
.,O
Immune,O
cell,O
markers,O
like,O
CD4,O
",",O
CD8,O
",",O
and,O
CD68,O
were,O
detected,O
in,O
COVID-19,O
samples,O
",",O
but,O
were,O
not,O
consistently,O
upregulated,O
.,O
However,O
",",O
lymphocyte,O
markers,O
CD24,O
and,O
CD38,O
were,O
upregulated,O
in,O
the,O
COVID-19,O
BALF,O
samples,O
",",O
which,O
is,O
also,O
consistent,O
with,O
reports,O
of,O
lymphocyte,O
induced,O
apoptosis,O
in,O
COVID-19,O
(,O
Huang,O
et,O
al,O
.,O
",",O
2020a,O
),O
.,O
These,O
findings,O
are,O
congruent,O
with,O
reports,O
of,O
increased,O
lactate,O
dehydrogenase,O
as,O
a,O
biomarker,O
of,O
COVID-19,O
severity,O
wherein,O
lactate,O
dehydrogenase,O
is,O
a,O
sign,O
of,O
pyroptosis,O
–,O
inflammasome,O
driven,O
programmed,O
cell,O
death,O
(,O
Rayamajhi,O
et,O
al,O
.,O
",",O
2013,O
",",O
Chen,O
et,O
al,O
.,O
",",O
2020,O
",",O
Han,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
For,O
this,O
purpose,O
",",O
we,O
used,O
our,O
interactome,O
framework,O
(,O
Ramilowski,O
et,O
al,O
.,O
",",O
2015,O
),O
to,O
elucidate,O
possible,O
pharmacological,O
interactions,O
that,O
may,O
be,O
associated,O
with,O
disease,O
in,O
COVID-19,O
samples,O
.,O
We,O
focused,O
first,O
on,O
ligands,O
upregulated,O
in,O
the,O
COVID-19,O
samples,O
and,O
receptors,O
expressed,O
in,O
human,O
thoracic,O
DRG,O
samples,O
",",O
which,O
contain,O
neurons,O
that,O
innervate,O
the,O
lungs,O
(,O
Springall,O
et,O
al,O
.,O
",",O
1987,O
",",O
Kummer,O
et,O
al,O
.,O
",",O
1992,O
),O
.,O
We,O
found,O
that,O
many,O
receptors,O
for,O
cytokines,O
identified,O
as,O
upregulated,O
in,O
COVID-19,O
patients,O
including,O
CCR2,O
",",O
CXCR2,O
",",O
CCR5,O
",",O
and,O
CXCR10,O
",",O
and,O
IL15RA,O
were,O
also,O
expressed,O
in,O
hDRG,O
suggesting,O
a,O
potential,O
direct,O
connection,O
between,O
these,O
cytokines,O
and,O
sensory,O
neuron,O
activation,O
in,O
the,O
lung,O
(,O
Table,O
1,O
),O
.,O
We,O
also,O
noted,O
increased,O
EREG,O
expression,O
in,O
COVID-19,O
samples,O
",",O
which,O
is,O
known,O
to,O
signal,O
via,O
the,O
epidermal,O
growth,O
factor,O
receptor,O
(,O
EGFR,O
),O
to,O
sensitize,O
nociceptors,O
(,O
Martin,O
et,O
al,O
.,O
",",O
2017,O
),O
.,O
A,O
complete,O
list,O
of,O
the,O
interactome,O
featuring,O
differentially,O
increased,O
ligands,O
in,O
BALF,O
from,O
COVID-19,O
samples,O
can,O
be,O
seen,O
in,O
Supplementary,O
Table,O
3,O
",",O
and,O
expression,O
profiles,O
of,O
the,O
mouse,O
orthologs,O
in,O
sensory,O
neurons,O
can,O
be,O
found,O
in,O
Supplementary,O
Table,O
4,O
.,O
The,O
average,O
of,O
gene,O
abundances,O
in,O
the,O
2,O
COVID-19,O
samples,O
",",O
weighted,O
by,O
sequencing,O
depth,O
are,O
shown,O
here,O
.,O
The,O
full,O
dataset,O
is,O
shown,O
in,O
Supplementary,O
Table,O
3,O
.,O
Therefore,O
",",O
we,O
also,O
explored,O
possible,O
interaction,O
points,O
between,O
sensory,O
neurons,O
that,O
are,O
likely,O
to,O
innervate,O
the,O
lung,O
and,O
receptors,O
expressed,O
in,O
BALF,O
samples,O
from,O
patients,O
with,O
COVID-19,O
.,O
Here,O
",",O
we,O
identified,O
a,O
striking,O
number,O
of,O
interactions,O
between,O
Eph,O
ligands,O
found,O
in,O
hDRG,O
and,O
receptors,O
upregulated,O
in,O
COVID-19,O
BALF,O
samples,O
(,O
Table,O
2,O
),O
.,O
Our,O
data,O
suggests,O
potential,O
bidirectional,O
interactions,O
between,O
these,O
receptors,O
and,O
ligands,O
on,O
sensory,O
nerve,O
endings,O
and,O
immune,O
cells,O
in,O
the,O
lung,O
of,O
COVID-19,O
patients,O
.,O
Another,O
prominent,O
interaction,O
was,O
with,O
EGFR,O
ligands,O
and,O
EGFR,O
itself,O
",",O
again,O
suggesting,O
bidirectional,O
interactions,O
between,O
neurons,O
and,O
immune,O
cells,O
in,O
the,O
lung,O
in,O
COVID-19,O
.,O
Finally,O
",",O
we,O
also,O
noted,O
potential,O
interactions,O
between,O
neurexins,O
and,O
neuroligins,O
",",O
which,O
are,O
also,O
involved,O
in,O
junctions,O
between,O
neurons,O
(,O
Levinson,O
and,O
El,O
-,O
Husseini,O
",",O
2005,O
),O
",",O
suggesting,O
that,O
multiple,O
types,O
of,O
mediators,O
may,O
be,O
involved,O
in,O
remodeling,O
nerve,O
ending,O
morphology,O
within,O
the,O
lung,O
driven,O
by,O
immune,O
cell,O
activation,O
in,O
COVID-19,O
.,O
Collectively,O
",",O
these,O
neuron,O
-,O
derived,O
ligands,O
could,O
potentially,O
exacerbate,O
lung,O
inflammation,O
in,O
COVID-19,O
contributing,O
to,O
a,O
positive,O
feedback,O
loop,O
.,O
A,O
complete,O
list,O
of,O
the,O
interactome,O
featuring,O
differentially,O
increased,O
receptors,O
in,O
BALF,O
from,O
COVID-19,O
samples,O
can,O
be,O
seen,O
in,O
Supplementary,O
Table,O
5,O
and,O
expression,O
profiles,O
of,O
the,O
mouse,O
orthologs,O
in,O
sensory,O
neurons,O
can,O
be,O
found,O
in,O
Supplementary,O
Table,O
6,O
.,O
The,O
average,O
of,O
gene,O
abundances,O
in,O
the,O
2,O
COVID-19,O
samples,O
",",O
weighted,O
by,O
sequencing,O
depth,O
are,O
shown,O
here,O
.,O
The,O
full,O
dataset,O
is,O
shown,O
in,O
Supplementary,O
Table,O
5,O
.,O
While,O
our,O
interactome,O
identification,O
from,O
the,O
BALF,O
bulk,O
RNA,O
-,O
seq,O
is,O
a,O
starting,O
point,O
for,O
identifying,O
neuro,O
-,O
immune,O
interactions,O
in,O
COVID-19,O
patient,O
lungs,O
",",O
bulk,O
RNA,O
sequencing,O
has,O
limitations,O
and,O
other,O
approaches,O
are,O
also,O
being,O
used,O
to,O
characterize,O
the,O
immune,O
response,O
in,O
this,O
disease,O
.,O
We,O
therefore,O
studied,O
the,O
emerging,O
COVID-19,O
literature,O
for,O
studies,O
where,O
raw,O
datasets,O
were,O
not,O
publicly,O
available,O
",",O
but,O
the,O
studies,O
provided,O
gene,O
or,O
protein,O
sets,O
that,O
were,O
associated,O
with,O
clinical,O
outcomes,O
or,O
pathologies,O
.,O
In,O
addition,O
to,O
the,O
Xiong,O
et,O
al,O
study,O
(,O
Xiong,O
et,O
al,O
.,O
",",O
2020b,O
),O
",",O
we,O
integrated,O
gene,O
and,O
protein,O
lists,O
from,O
sources,O
that,O
included,O
BALF,O
single,O
-,O
cell,O
RNA,O
-,O
seq,O
(,O
scRNA,O
-,O
seq,O
),O
",",O
blood,O
protein,O
levels,O
and,O
immune,O
cell,O
profiles,O
from,O
COVID-19,O
patients,O
(,O
Liao,O
et,O
al,O
.,O
",",O
2020,O
",",O
Xiong,O
et,O
al,O
.,O
",",O
2020b,O
",",O
Zhou,O
et,O
al,O
.,O
",",O
2020,O
",",O
Zhou,O
et,O
al,O
.,O
",",O
2020b,O
),O
.,O
These,O
findings,O
were,O
consistent,O
with,O
the,O
interactome,O
generated,O
from,O
BALF,O
samples,O
from,O
COVID19,O
patients,O
with,O
prominent,O
interactions,O
for,O
cytokines,O
",",O
chemokines,O
and,O
other,O
inflammatory,O
molecules,O
(,O
Supplementary,O
Table,O
7,O
),O
.,O
These,O
finding,O
implicate,O
the,O
potential,O
off,O
-,O
label,O
utility,O
of,O
anti,O
-,O
rheumatoid,O
arthritis,O
drugs,O
that,O
target,O
TNF,O
(,O
infliximab,O
or,O
etanercept,O
),O
or,O
IL1,O
(,O
anakinra,O
),O
as,O
well,O
as,O
EGFR,O
inhibitors,O
such,O
as,O
cetuximab,O
for,O
interfering,O
with,O
neuro,O
-,O
immune,O
interactions,O
in,O
COVID-19,O
.,O
Bulk,O
hDRG,O
sequencing,O
libraries,O
incorporate,O
mRNA,O
from,O
not,O
just,O
sensory,O
neurons,O
",",O
but,O
also,O
from,O
glial,O
",",O
immune,O
and,O
vascular,O
cells,O
",",O
leading,O
to,O
the,O
possibility,O
of,O
false,O
positives,O
.,O
Additionally,O
",",O
many,O
lung,O
innervating,O
nociceptors,O
are,O
from,O
the,O
nodose,O
or,O
jugular,O
ganglia,O
so,O
our,O
dataset,O
from,O
thoracic,O
hDRG,O
may,O
not,O
represent,O
the,O
full,O
possibility,O
of,O
receptors,O
or,O
ligands,O
that,O
could,O
contribute,O
to,O
lung,O
physiology,O
from,O
sensory,O
afferents,O
.,O
To,O
predict,O
which,O
of,O
the,O
hDRG,O
-,O
expressed,O
ligands,O
or,O
receptors,O
are,O
likely,O
present,O
in,O
human,O
nociceptors,O
",",O
we,O
integrated,O
several,O
mouse,O
datasets,O
.,O
We,O
additionally,O
included,O
two,O
datasets,O
for,O
gene,O
expression,O
in,O
the,O
mouse,O
jugular,O
-,O
nodose,O
complex,O
(,O
JNC,O
),O
",",O
including,O
the,O
Kupari,B-Creator
et,I-Creator
al,E-Creator
 ,O
scRNA,O
-,O
seq,O
dataset,O
(,O
Kupari,B-Creator
et,I-Creator
"al.,",I-Creator
2019,E-Creator
),O
and,O
a,O
study,O
using,O
bulk,O
RNA,O
-,O
seq,O
to,O
study,O
gene,O
expression,O
changes,O
in,O
the,O
JNC,O
following,O
lung,O
inflammation,O
with,O
Lipopolysaccharide,O
(,O
LPS,O
),O
(,O
Kaelberer,B-Creator
et,I-Creator
"al.,",I-Creator
2020,E-Creator
),O
.,O
As,O
mentioned,O
above,O
",",O
EGFR,O
ligands,O
were,O
strongly,O
induced,O
in,O
COVID-19,O
patients,O
.,O
A,O
major,O
focus,O
of,O
current,O
research,O
into,O
SARS,O
-,O
CoV-2,O
and,O
COVID-19,O
is,O
identification,O
of,O
potential,O
therapeutics,O
.,O
Based,O
on,O
this,O
",",O
we,O
intersected,O
differentially,O
expressed,O
BALF,O
ligand,O
and,O
receptor,O
genes,O
in,O
COVID-19,O
samples,O
with,O
mRNAs,O
known,O
to,O
be,O
regulated,O
by,O
eIF4E,O
phosphorylation,O
from,O
previous,O
studies,O
(,O
Furic,O
et,O
al,O
.,O
",",O
2010,O
",",O
Aguilar,O
-,O
Valles,O
et,O
al,O
.,O
",",O
2018,O
",",O
Amorim,O
et,O
al,O
.,O
",",O
2018,O
),O
.,O
To,O
do,O
this,O
we,O
compiled,O
a,O
list,O
of,O
genes,O
shown,O
to,O
be,O
significantly,O
changed,O
in,O
COVID-19,O
patients,O
from,O
the,O
studies,O
we,O
cited,O
and,O
described,O
above,O
(,O
Supplementary,O
Tables,O
3,O
",",O
5,O
and,O
7,O
),O
.,O
We,O
found,O
that,O
8,O
inflammatory,O
mediators,O
upregulated,O
in,O
the,O
BALF,O
of,O
COVID-19,O
patients,O
were,O
reduced,O
in,O
vitro,O
and/or,O
in,O
the,O
brain,O
of,O
animals,O
lacking,O
eIF4E,O
phosphorylation,O
(,O
Table,O
3,O
),O
.,O
CCL2,O
",",O
which,O
is,O
among,O
the,O
most,O
highly,O
upregulated,O
chemokines,O
in,O
COVID-19,O
patients,O
",",O
is,O
one,O
example,O
.,O
Hence,O
",",O
eFT508,O
(,O
also,O
known,O
as,O
Tomivosertib,O
),O
",",O
a,O
MNK1/2,O
inhibitor,O
currently,O
undergoing,O
clinical,O
trials,O
(,O
Reich,O
et,O
al,O
.,O
",",O
2018,O
),O
",",O
may,O
prove,O
beneficial,O
against,O
COVID-19,O
.,O
We,O
also,O
identified,O
potential,O
therapeutics,O
for,O
COVID-19,O
by,O
intersecting,O
the,O
interactomes,O
generated,O
here,O
with,O
the,O
DGIdb,S-Dataset
 ,O
database,O
(,O
Cotto,B-Creator
et,I-Creator
"al.,",I-Creator
2018,E-Creator
),O
.,O
We,O
identified,O
144,O
gene,O
products,O
with,O
characterized,O
antagonists,O
",",O
inhibitors,O
",",O
blockers,O
or,O
modulators,O
in,O
this,O
curated,O
database,O
(,O
a,O
selection,O
of,O
these,O
are,O
shown,O
in,O
Table,O
4,O
",",O
full,O
dataset,O
in,O
Supplementary,O
Table,O
8),O
.,O
This,O
database,O
highlights,O
the,O
potential,O
for,O
targeting,O
cytokines,O
and,O
chemokines,O
",",O
such,O
as,O
CCL2,O
",",O
the,O
CCR2,O
receptor,O
and/or,O
the,O
EGFR,O
receptor,O
in,O
COVID-19,O
.,O
It,O
also,O
reveals,O
several,O
drugs,O
that,O
interact,O
with,O
ephrin,O
–,O
EphB,O
signaling,O
that,O
may,O
have,O
promise,O
if,O
structural,O
remodeling,O
of,O
lung,O
afferent,O
endings,O
contributes,O
to,O
COVID-19,O
pathology,O
.,O
The,O
corresponding,O
gene,O
GRIN2B,O
was,O
strongly,O
induced,O
in,O
BALF,O
samples,O
of,O
COVID-19,O
samples,O
.,O
NMDA,O
receptor,O
activity,O
and,O
localization,O
is,O
strongly,O
influenced,O
by,O
EphB,O
receptors,O
(,O
Hanamura,O
et,O
al,O
.,O
",",O
2017,O
",",O
Henderson,O
and,O
Dalva,O
",",O
2018,O
),O
",",O
which,O
were,O
also,O
dramatically,O
increased,O
in,O
COVID-19,O
BALF,O
samples,O
.,O
We,O
used,O
a,O
computational,O
framework,O
to,O
test,O
the,O
hypothesis,O
that,O
immune,O
cells,O
in,O
the,O
lungs,O
of,O
severe,O
COVID-19,O
patients,O
produce,O
factors,O
that,O
are,O
likely,O
to,O
interact,O
with,O
the,O
sensory,O
neuronal,O
innervation,O
of,O
the,O
lung,O
.,O
Our,O
work,O
finds,O
support,O
for,O
this,O
hypothesis,O
and,O
identifies,O
potential,O
interactions,O
that,O
may,O
be,O
critical,O
drivers,O
of,O
disease,O
severity,O
in,O
COVID-19,O
.,O
To,O
that,O
end,O
",",O
MNK,O
inhibitors,O
",",O
which,O
were,O
also,O
identified,O
by,O
Gordon,O
et,O
al,O
.,O
(,O
Gordon,O
et,O
al,O
.,O
",",O
2020,O
),O
may,O
be,O
particularly,O
useful,O
because,O
they,O
have,O
an,O
effect,O
on,O
coronavirus,O
replication,O
in,O
murine,O
models,O
(,O
Banerjee,O
et,O
al,O
.,O
",",O
2002,O
),O
",",O
interfere,O
with,O
the,O
translation,O
of,O
chemokine,O
and,O
cytokines,O
implicated,O
in,O
COVID-19,O
and,O
reduce,O
excitability,O
of,O
nociceptors,O
(,O
Moy,O
et,O
al,O
.,O
",",O
2017,O
",",O
Megat,O
et,O
al,O
.,O
",",O
2019,O
),O
that,O
may,O
be,O
driving,O
neurogenic,O
inflammation,O
in,O
the,O
disease,O
.,O
Similar,O
results,O
have,O
been,O
found,O
across,O
studies,O
(,O
Huang,O
et,O
al,O
.,O
",",O
2020b,O
",",O
Huang,O
et,O
al,O
.,O
",",O
2020,O
",",O
Liao,O
et,O
al,O
.,O
",",O
2020,O
",",O
Xiong,O
et,O
al,O
.,O
",",O
2020b,O
",",O
Zhou,O
et,O
al,O
.,O
",",O
2020,O
",",O
Zhou,O
et,O
al,O
.,O
",",O
2020b,O
),O
",",O
but,O
there,O
is,O
an,O
obvious,O
need,O
for,O
additional,O
sequencing,O
on,O
lung,O
immune,O
cells,O
from,O
patients,O
with,O
mild,O
and,O
severe,O
COVID-19,O
.,O
Another,O
important,O
caveat,O
is,O
that,O
the,O
directionality,O
of,O
the,O
influence,O
of,O
nociceptor,O
-,O
released,O
factors,O
on,O
lung,O
immunity,O
and,O
COVID-19,O
disease,O
state,O
is,O
not,O
currently,O
clear,O
.,O
Some,O
studies,O
on,O
sepsis,O
",",O
which,O
occurs,O
in,O
severe,O
COVID-19,O
patients,O
",",O
have,O
shown,O
that,O
nociceptors,O
promote,O
mortality,O
in,O
sepsis,O
(,O
Bryant,O
et,O
al,O
.,O
",",O
2003,O
),O
but,O
others,O
show,O
that,O
TRPV1,O
-,O
positive,O
nociceptors,O
are,O
protective,O
against,O
mortality,O
in,O
sepsis,O
(,O
Guptill,O
et,O
al,O
.,O
",",O
2011,O
),O
.,O
We,O
have,O
interpreted,O
our,O
interactome,O
findings,O
under,O
the,O
assumption,O
that,O
neurogenic,O
responses,O
may,O
worsen,O
the,O
disease,O
state,O
in,O
COVID-19,O
",",O
potentially,O
leading,O
to,O
ARDS,O
and,O
fatality,O
",",O
but,O
without,O
perturbational,O
animal,O
model,O
studies,O
or,O
additional,O
human,O
clinical,O
data,O
we,O
can,O
not,O
rule,O
out,O
the,O
possibility,O
that,O
a,O
subset,O
of,O
the,O
interactome,O
mitigates,O
the,O
disease,O
state,O
.,O
It,O
is,O
formally,O
possible,O
that,O
sensory,O
neurons,O
could,O
express,O
ACE2,O
allowing,O
viral,O
infection,O
of,O
these,O
cells,O
",",O
but,O
available,O
datasets,O
are,O
unable,O
to,O
clarify,O
this,O
question,O
.,O
Other,O
datasets,O
used,O
here,O
were,O
based,O
on,O
analysis,O
from,O
datasets,O
described,O
in,O
published,O
studies,O
from,O
other,O
groups,O
.,O
Data,O
for,O
the,O
curated,O
COVID-19,O
interactome,O
were,O
obtained,O
from,O
(,O
Huang,B-Creator
et,I-Creator
"al.,",I-Creator
2020b,E-Creator
",",O
Huang,B-Creator
et,I-Creator
"al.,",I-Creator
2020,E-Creator
",",O
Liao,B-Creator
et,I-Creator
"al.,",I-Creator
2020,E-Creator
",",O
Xiong,B-Creator
et,I-Creator
"al.,",I-Creator
2020b,E-Creator
",",O
Zhou,B-Creator
et,I-Creator
"al.,",I-Creator
2020,E-Creator
),O
",",O
with,O
BALF,O
RNA,O
-,O
seq,O
data,O
from,O
COVID-19,O
patients,O
(,O
National,B-Repository
Genomics,I-Repository
Data,I-Repository
Center,E-Repository
 ,O
sample,O
ids,O
CRR119894-7,S-AccessionNumber
",",O
https://bigd.big.ac.cn/bioproject/browse/PRJCA002326,S-URL
),O
obtained,O
from,O
(,O
Xiong,B-Creator
et,I-Creator
"al.,",I-Creator
2020b,E-Creator
),O
.,O
Mouse,O
bulk,O
RNA,O
-,O
sequencing,O
datasets,O
were,O
obtained,O
from,O
sorted,O
neuronal,O
cell,O
pools,O
from,O
the,O
DRG,O
(,O
Liang,B-Creator
et,I-Creator
"al.,",I-Creator
2019,E-Creator
),O
and,O
whole,O
tissue,O
RNA,O
-,O
seq,O
from,O
the,O
JNC,O
complex,O
before,O
and,O
after,O
LPS,O
injury,O
(,O
Kaelberer,B-Creator
et,I-Creator
"al.,",I-Creator
2020,E-Creator
),O
.,O
The,O
DGIdb,S-Dataset
 ,O
database,O
was,O
used,O
to,O
identify,O
known,O
drugs,O
(,O
Cotto,B-Creator
et,I-Creator
"al.,",I-Creator
2018,E-Creator
),O
that,O
target,O
proteins,O
in,O
our,O
identified,O
interactomes,O
.,O
The,O
interactome,O
database,O
is,O
described,O
in,O
detail,O
in,O
our,O
previous,O
work,O
(,O
Wangzhou,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Replicates,O
from,O
each,O
COVID-19,O
patient,O
were,O
pooled,O
to,O
increase,O
sequencing,O
depth,O
.,O
Due,O
to,O
the,O
higher,O
sequencing,O
depth,O
of,O
the,O
control,O
samples,O
(,O
over,O
40,O
million,O
reads,O
),O
",",O
compared,O
to,O
the,O
COVID-19,O
samples,O
(,O
~7,O
and,O
12,O
million,O
reads,O
after,O
pooling,O
(,O
Xiong,O
et,O
al,O
.,O
",",O
2020b,O
),O
),O
",",O
and,O
due,O
to,O
specific,O
interest,O
in,O
finding,O
therapeutic,O
targets,O
",",O
only,O
genes,O
identified,O
as,O
differentially,O
expressed,O
and,O
increased,O
in,O
relative,O
abundance,O
in,O
COVID-19,O
samples,O
were,O
further,O
analyzed,O
.,O
Differentially,O
expressed,O
gene,O
sets,O
from,O
both,O
tools,O
were,O
intersected,O
to,O
identify,O
genes,O
that,O
are,O
differentially,O
expressed,O
in,O
both,O
models,O
",",O
and,O
only,O
genes,O
with,O
read,O
frequency,O
>,O
1,O
in,O
"200,000",O
genic,O
reads,O
for,O
COVID-19,O
samples,O
were,O
retained,O
to,O
reduce,O
potential,O
effects,O
of,O
sampling,O
variance,O
.,O
Ramilowski,O
et,O
al,O
.,O
(,O
Ramilowski,O
et,O
al,O
.,O
",",O
2015,O
),O
described,O
2557,O
pairs,O
of,O
ligand,O
-,O
receptor,O
interactions,O
that,O
were,O
used,O
to,O
populate,O
the,O
initial,O
interactome,O
database,O
.,O
In,O
order,O
to,O
curate,O
a,O
more,O
complete,O
ligand,O
-,O
receptor,O
list,O
",",O
we,O
collected,O
gene,O
lists,O
from,O
gene,O
family,O
and,O
ontology,O
databases,O
HUGO,S-Repository
 ,O
(,O
Yates,B-Creator
et,I-Creator
"al.,",I-Creator
2017,E-Creator
),O
and,O
GO,S-Repository
 ,O
(,O
Carbon,B-Creator
et,I-Creator
"al.,",I-Creator
2009,E-Creator
),O
.,O
Based,O
on,O
a,O
database,O
(,O
Szklarczyk,O
et,O
al,O
.,O
",",O
2019,O
),O
and,O
the,O
literature,O
",",O
corresponding,O
receptors,O
or,O
ligands,O
for,O
these,O
additional,O
genes,O
were,O
identified,O
and,O
added,O
to,O
the,O
list,O
of,O
ligand,O
-,O
receptor,O
pairs,O
.,O
Not,O
all,O
ligands,O
and,O
receptors,O
are,O
encoded,O
as,O
genes,O
",",O
so,O
we,O
included,O
some,O
additional,O
records,O
in,O
our,O
database,O
",",O
such,O
as,O
enzymes,O
known,O
to,O
synthesize,O
ligands,O
and,O
paired,O
with,O
the,O
corresponding,O
receptor,O
.,O
The,O
entire,O
interactome,O
database,O
is,O
described,O
in,O
detail,O
in,O
(,O
Wangzhou,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
While,O
many,O
of,O
these,O
signaling,O
interactions,O
are,O
likely,O
involved,O
in,O
the,O
immune,O
response,O
of,O
COVID-19,O
",",O
we,O
chose,O
to,O
focus,O
on,O
pairs,O
where,O
the,O
ligand,O
or,O
receptor,O
was,O
shown,O
to,O
be,O
differentially,O
increased,O
or,O
discriminative,O
marker,O
for,O
cell,O
types,O
with,O
differentially,O
increased,O
proportions,O
in,O
the,O
immune,O
response,O
since,O
these,O
are,O
more,O
likely,O
to,O
be,O
successful,O
points,O
of,O
therapeutic,O
intervention,O
.,O
Thus,O
",",O
we,O
filtered,O
the,O
candidate,O
interactome,O
based,O
on,O
the,O
list,O
of,O
differentially,O
expressed,O
genes,O
we,O
obtained,O
from,O
the,O
literature,O
and,O
re,O
-,O
analysis,O
of,O
COVID-19,O
BALF,O
data,O
(,O
Supplementary,O
Tables,O
3,O
",",O
5,O
and,O
7,O
),O
.,O
Potentially,O
relevant,O
gene,O
product,O
–,O
drug,O
interactions,O
(,O
inhibitor,O
",",O
antagonist,O
or,O
blocker,O
),O
based,O
on,O
these,O
interactomes,O
were,O
mined,O
from,O
the,O
dgiDB,S-Dataset
 ,O
database,O
(,O
Supplementary,O
Table,O
8),O
.,O
Two,O
of,O
these,O
help,O
rank,O
immune,O
genes,O
:,O
mean,O
expression,O
level,O
in,O
COVID-19,O
samples,O
",",O
and,O
degree,O
of,O
differential,O
expression,O
(,O
fold,O
change,O
),O
in,O
COVID-19,O
versus,O
control,O
BALF,O
(,O
Supplementary,O
Tables,O
3,O
and,O
5,O
),O
.,O
Two,O
other,O
metrics,O
help,O
rank,O
neuronal,O
genes,O
:,O
gene,O
expression,O
levels,O
in,O
sorted,O
mouse,O
DRG,O
neuron,O
datasets,O
(,O
Liang,B-Creator
et,I-Creator
"al.,",I-Creator
2019,E-Creator
),O
and,O
in,O
mouse,O
DRG,O
neuron,O
scRNA,O
-,O
seq,O
datasets,O
(,O
Usoskin,B-Creator
et,I-Creator
"al.,",I-Creator
2015,E-Creator
),O
",",O
and,O
degree,O
of,O
differential,O
expression,O
(,O
log,O
fold,O
change,O
),O
in,O
LPS,O
based,O
injury,O
models,O
of,O
mouse,O
airway,O
-,O
innervating,O
neurons,O
(,O
Kaelberer,O
et,O
al,O
.,O
",",O
2020,O
),O
(,O
Supplementary,O
Tables,O
4,O
and,O
6,O
),O
.,O
The,O
directionality,O
of,O
changes,O
in,O
the,O
LPS,O
mouse,O
injury,O
model,O
may,O
not,O
necessarily,O
be,O
consistent,O
with,O
changes,O
in,O
COVID-19,O
molecular,O
changes,O
",",O
but,O
are,O
likely,O
to,O
be,O
indicative,O
of,O
genes,O
involved,O
in,O
neuroinflammation,O
in,O
mammalian,O
lungs,O
.,O
To,O
quantify,O
relative,O
gene,O
abundances,O
in,O
(,O
Liang,O
et,O
al,O
.,O
",",O
2019,O
),O
",",O
reported,O
coding,O
gene,O
expressions,O
were,O
renormalized,O
to,O
TPMs,O
across,O
all,O
samples,O
",",O
and,O
samples,O
having,O
a,O
clear,O
bimodal,O
distribution,O
of,O
TPMs,O
were,O
retained,O
for,O
further,O
analysis,O
and,O
quantile,O
normalized,O
",",O
of,O
which,O
the,O
FACS,O
-,O
sorted,O
neuronal,O
datasets,O
are,O
used,O
in,O
our,O
study,O
for,O
integrative,O
analysis,O
.,O
In,O
the,O
(,O
Usoskin,B-Creator
et,I-Creator
"al.,",I-Creator
2015,E-Creator
),O
dataset,O
",",O
the,O
reported,O
fraction,O
of,O
cells,O
for,O
each,O
neuronal,O
subpopulation,O
(,O
where,O
a,O
gene,O
is,O
detected,O
),O
was,O
used,O
.,O
To,O
calculate,O
a,O
similar,O
metric,O
in,O
the,O
(,O
Kupari,B-Creator
et,I-Creator
"al.,",I-Creator
2019,E-Creator
),O
dataset,O
",",O
two,O
steps,O
were,O
performed,O
.,O
•,O
 ,O
Predicts,O
interactome,O
to,O
find,O
signaling,O
between,O
nociceptors,O
and,O
COVID-19,O
patient,O
BALF,O
.,O
•,O
 ,O
Findings,O
reveal,O
potential,O
interventions,O
to,O
reduce,O
neurogenic,O
inflammation,O
in,O
COVID-19,O
.,O
   ,O
•,O
Shows,O
potential,O
for,O
COVID-19,O
clinical,O
trial,O
with,O
existing,O
CCL2,O
",",O
CCR5,O
",",O
EGFR,O
inhibitors,O
.,O
The,O
SARS,O
-,O
CoV-2,O
virus,O
infects,O
cells,O
of,O
the,O
airway,O
and,O
lungs,O
in,O
humans,O
causing,O
the,O
disease,O
COVID-19,O
.,O
Bronchial,O
alveolar,O
lavage,O
fluid,O
(,O
BALF,O
),O
and,O
plasma,O
from,O
mild,O
and,O
severe,O
cases,O
of,O
COVID-19,O
have,O
been,O
profiled,O
using,O
protein,O
measurements,O
and,O
bulk,O
and,O
single,O
cell,O
RNA,O
sequencing,O
.,O
Onset,O
of,O
pneumonia,O
and,O
ARDS,O
can,O
be,O
rapid,O
in,O
COVID-19,O
",",O
suggesting,O
a,O
potential,O
neuronal,O
involvement,O
in,O
pathology,O
and,O
mortality,O
.,O
We,O
sought,O
to,O
quantify,O
how,O
immune,O
cells,O
might,O
interact,O
with,O
sensory,O
innervation,O
of,O
the,O
lung,O
in,O
COVID-19,O
using,O
published,O
data,O
from,O
patients,O
",",O
existing,O
RNA,O
sequencing,O
datasets,O
from,O
human,O
dorsal,O
root,O
ganglion,O
neurons,O
and,O
other,O
sources,O
",",O
and,O
a,O
genome,O
-,O
wide,O
ligand,O
-,O
receptor,O
pair,O
database,O
curated,O
for,O
pharmacological,O
interactions,O
relevant,O
for,O
neuro,O
-,O
immune,O
interactions,O
.,O
Our,O
findings,O
reveal,O
a,O
landscape,O
of,O
ligand,O
-,O
receptor,O
interactions,O
in,O
the,O
lung,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
viral,O
infection,O
and,O
point,O
to,O
potential,O
interventions,O
to,O
reduce,O
the,O
burden,O
of,O
neurogenic,O
inflammation,O
in,O
COVID-19,O
pulmonary,O
disease,O
.,O
In,O
particular,O
",",O
our,O
work,O
highlights,O
opportunities,O
for,O
clinical,O
trials,O
with,O
existing,O
or,O
under,O
development,O
rheumatoid,O
arthritis,O
and,O
other,O
(,O
e.g.,O
CCL2,O
",",O
CCR5,O
or,O
EGFR,O
inhibitors,O
),O
drugs,O
to,O
treat,O
high,O
risk,O
or,O
severe,O
COVID-19,O
cases,O
.,O
In,O
late,O
2019,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV2,O
),O
was,O
identified,O
in,O
Wuhan,O
",",O
China,O
(,O
Li,O
et,O
al,O
.,O
",",O
2020,O
),O
and,O
named,O
COVID-19,O
by,O
WHO,O
.,O
COVID-19,O
(,O
coronavirus,O
disease,O
of,O
2019,O
),O
has,O
surprisingly,O
caught,O
the,O
global,O
community,O
as,O
of,O
August,O
10,O
",",O
2020,O
",",O
the,O
number,O
of,O
COVID-19,O
cases,O
going,O
to,O
reach,O
twenty,O
million,O
(,O
"20,055,196",O
),O
with,O
over,O
seven,O
hundred,O
thousands,O
(,O
"734,536",O
),O
deaths,O
worldwide,O
(,O
https://www.worldometers.info/coronavirus/,S-URL
),O
.,O
.,O
Currently,O
",",O
there,O
are,O
no,O
effective,O
medications,O
against,O
COVID-19,O
/,O
SARS,O
-,O
CoV2,O
although,O
several,O
research,O
groups,O
throughout,O
the,O
world,O
are,O
working,O
to,O
develop,O
the,O
vaccine,O
.,O
Drug,O
repositioning,O
or,O
reprofiling,O
is,O
a,O
promising,O
strategy,O
to,O
conquer,O
the,O
battle,O
against,O
COVID-19,O
in,O
a,O
time,O
-,O
critical,O
manner,O
.,O
Zhou,O
et,O
al,O
(,O
2020,O
),O
confirmed,O
that,O
SARS,O
-,O
CoV2,O
uses,O
the,O
same,O
receptor,O
(,O
ACE2,O
),O
as,O
SARS,O
-,O
CoV,O
",",O
after,O
isolating,O
the,O
BALF,O
(,O
bronchoalveolar,O
lavage,O
fluid,O
),O
of,O
a,O
COVID-19,O
patients.et,O
alIn,O
the,O
war,O
against,O
corona,O
",",O
scientists,O
are,O
working,O
on,O
following,O
possible,O
therapeutics,O
measures,O
:,O
one,O
is,O
against,O
the,O
human,O
cell,O
to,O
prevent,O
virus,O
entry,O
or,O
block,O
the,O
signaling,O
pathways,O
required,O
for,O
viral,O
infection,O
and,O
other,O
therapeutics,O
against,O
the,O
virus,O
itself,O
by,O
preventing,O
the,O
virus,O
replication,O
(,O
non,O
-,O
structural,O
proteins,O
),O
and,O
self,O
-,O
assembly,O
(,O
structural,O
proteins,O
),O
.,O
Chloroquine,O
",",O
an,O
anti,O
-,O
malarial,O
drug,O
has,O
been,O
shown,O
to,O
have,O
antiviral,O
activity,O
at,O
entry,O
and,O
post,O
-,O
entry,O
stages,O
of,O
the,O
COVID-19,O
infection,O
(,O
Gao,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
February,O
2020,O
Thailand,O
health,O
ministry,O
announced,O
marked,O
progress,O
in,O
COVID-19,O
treatment,O
with,O
successful,O
use,O
of,O
a,O
cocktail,O
(,O
combined,O
anti,O
-,O
flu,O
drug,O
oseltamivir,O
with,O
anti,O
-,O
HIV,O
lopinavir,O
and,O
ritonavir,O
),O
against,O
coronavirus,O
(,O
https://www.dawn.com/news/1532081,O
),O
.,O
The,O
3,O
-,O
dimensional,O
structure,O
of,O
the,O
ACE2,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
1R4L,S-AccessionNumber
),O
",",O
SARS,O
-,O
CoV2,O
spike,O
ectodomain,O
structure,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6vyB,S-AccessionNumber
),O
and,O
RdRp,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6M71,S-AccessionNumber
),O
were,O
retrieved,O
from,O
Protein,B-Repository
Data,I-Repository
Bank,I-Repository
(PDB),E-Repository
 ,O
(,O
Berman,B-Creator
et,I-Creator
"al.,",I-Creator
2000,E-Creator
),O
.,O
The,O
structure,O
of,O
the,O
ligand,O
;,O
remdesivir,O
(,O
CID,O
:,O
121304016,S-AccessionNumber
),O
",",O
favipiravir,O
(,O
CID,O
:,O
492405,S-AccessionNumber
),O
",",O
chloroquine,O
(,O
CID,O
:,O
83818,S-AccessionNumber
),O
and,O
SSAA09E2,O
(,O
CID,O
:,O
2738575,S-AccessionNumber
),O
were,O
retrieved,O
from,O
the,O
PubChem,S-Repository
 ,O
database,O
(,O
https://pusbchem.ncbi.nlm.nih.gov/,S-URL
),O
.,O
To,O
find,O
the,O
appropriate,O
binding,O
orientations,O
of,O
the,O
ligand,O
dataset,O
with,O
the,O
respective,O
target,O
automated,O
dockings,O
were,O
performed,O
using,O
AutoDock,O
4.2,O
(,O
Norgan,O
et,O
al,O
.,O
",",O
2011,O
),O
tool,O
following,O
standard,O
protocol,O
.,O
Molecular,O
dynamic,O
(,O
MD,O
),O
simulation,O
studies,O
of,O
attractive,O
drug,O
targets,O
of,O
COVID-19,O
illness,O
",",O
spike,O
protein,O
",",O
RdRp,O
enzyme,O
(,O
Nsp12,O
),O
and,O
human,O
receptor,O
ACE2,O
enzyme,O
in,O
the,O
apo,O
and,O
bound,O
state,O
were,O
performed,O
to,O
assess,O
the,O
folding,O
",",O
stability,O
",",O
conformational,O
changes,O
and,O
dynamic,O
behaviors,O
of,O
all,O
the,O
systems,O
.,O
The,O
strong,O
interaction,O
of,O
both,O
remdesivir,O
and,O
favipiravir,O
with,O
RdRp,O
of,O
SARS,O
-,O
CoV2,O
suggests,O
a,O
worthy,O
option,O
to,O
treat,O
COVID-19,O
disease,O
with,O
these,O
existing,O
antiviral,O
medicines,O
.,O
Thus,O
",",O
RdRp,O
could,O
be,O
an,O
attractive,O
target,O
to,O
stop,O
the,O
COVID-19,O
illness,O
caused,O
by,O
SARS,O
-,O
CoV2,O
.,O
The,O
outbreak,O
of,O
this,O
COVID-19,O
epidemic,O
",",O
triggered,O
the,O
researchers,O
all,O
over,O
the,O
world,O
to,O
explore,O
drugs,O
for,O
potential,O
therapeutics,O
of,O
this,O
SARS,O
-,O
CoV2,O
-,O
induced,O
respiratory,O
disease,O
.,O
Several,O
drugs,O
such,O
as,O
chloroquine,O
",",O
arbidol,O
",",O
remdesivir,O
",",O
and,O
favipiravir,O
are,O
currently,O
undergoing,O
clinical,O
studies,O
to,O
test,O
their,O
efficacy,O
and,O
safety,O
in,O
the,O
treatment,O
of,O
COVID-19,O
in,O
China,O
and,O
all,O
across,O
the,O
world,O
;,O
some,O
promising,O
results,O
was,O
achieved,O
in,O
March,O
2020,O
and,O
anti,O
-,O
malarial,O
drug,O
chloroquine,O
was,O
confirmed,O
as,O
an,O
active,O
drug,O
in,O
treating,O
coronavirus,O
and,O
 ,O
has,O
approved,O
it,O
on,O
March,O
28,O
",",O
2020,O
(,O
Wang,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
an,O
the,O
On,O
June,O
5,O
",",O
2020,O
the,O
investigators,O
from,O
United,O
kingdom,O
recovery,O
trial,O
announced,O
that,O
chloroquine,O
and,O
hydroxychloroquine,O
do,O
not,O
prove,O
promising,O
to,O
reduce,O
the,O
mortality,O
rate,O
of,O
hospitalized,O
COVID-19,O
patients,O
and,O
results,O
were,O
supported,O
by,O
another,O
solidarity,O
trial,O
",",O
the,O
french,O
discovery,O
trial,O
(,O
https://www.sciencemag.org/news/2020,O
),O
.,O
remdesivir,O
and,O
ravipiravir,O
",",O
are,O
just,O
approved,O
for,O
a,O
clinical,O
trial,O
as,O
a,O
drug,O
to,O
treat,O
COVID-19,O
(,O
Maxmen,O
",",O
2020,O
),O
.,O
Although,O
promising,O
results,O
were,O
observed,O
with,O
remdesivir,O
and,O
favipiravir,O
and,O
many,O
pharmaceutical,O
companies,O
are,O
launching,O
generic,O
names,O
for,O
these,O
drugs,O
as,O
COVID-19,O
treatment,O
but,O
to,O
date,O
",",O
we,O
are,O
lacking,O
sufficient,O
pieces,O
of,O
evidence,O
to,O
call,O
any,O
drug,O
as,O
“,O
game,O
-,O
changer,O
”,O
.,O
Similarly,O
",",O
binding,O
of,O
these,O
inhibitors,O
with,O
the,O
ACE2,O
receptor,O
protein,O
is,O
of,O
significant,O
interest,O
and,O
it,O
is,O
speculated,O
based,O
on,O
these,O
results,O
that,O
virus,O
entry,O
could,O
be,O
stopped,O
by,O
blocking,O
the,O
viral,O
host,O
interaction,O
to,O
cure,O
this,O
COVID-19,O
illness,O
(,O
Fig,O
.,O
6,O
A,O
and,O
B,O
),O
.,O
Likewise,O
",",O
our,O
results,O
support,O
the,O
computational,O
(,O
Wuet,O
al,O
",",O
2020,O
),O
and,O
muticlinical,O
studies,O
(,O
Maxmen,O
",",O
2020,O
),O
conducted,O
to,O
find,O
potential,O
therapeutics,O
measures,O
in,O
the,O
war,O
against,O
COVID-19,O
.,O
The,O
rapid,O
breakout,O
of,O
the,O
coronavirus,O
disease,O
of,O
2019,O
(,O
COVID-19,O
),O
has,O
been,O
declared,O
pandemic,O
with,O
serious,O
global,O
concern,O
due,O
to,O
high,O
morbidity,O
and,O
mortality,O
.,O
As,O
we,O
enter,O
the,O
phase,O
beyond,O
limitations,O
there,O
is,O
an,O
urgent,O
need,O
for,O
explicit,O
treatment,O
against,O
COVID-19,O
.,O
A,O
number,O
of,O
multi,O
clinical,O
studies,O
have,O
repurposed,O
combined,O
cocktail,O
(,O
remdesivir,O
 ,O
+,O
 ,O
chloroquine,O
and,O
favipiravir,O
 ,O
+,O
 ,O
chloroquine,O
),O
to,O
be,O
effective,O
against,O
COVID-19,O
.,O
Thus,O
",",O
drug,O
repurposition,O
is,O
an,O
attractive,O
approach,O
with,O
reduced,O
time,O
and,O
cost,O
to,O
treat,O
COVID-19,O
",",O
we,O
do,O
n't,O
have,O
enough,O
time,O
as,O
the,O
whole,O
world,O
is,O
lockdown,O
and,O
we,O
are,O
in,O
urgent,O
need,O
of,O
an,O
obvious,O
therapeutics,O
',O
measures,O
.,O
Annotation,O
of,O
the,O
8,O
newly,O
sequenced,O
genomes,O
MDS2,O
",",O
MDS4,O
",",O
MDS6,O
",",O
MDS11,O
",",O
MDS12,O
",",O
MDS14,O
",",O
MDS15,O
and,O
MDS16,O
",",O
was,O
performed,O
by,O
comparison,O
with,O
the,O
HCoV−OC43,O
isolate,O
from,O
Mexico,O
(,O
Genbank,S-Repository
 ,O
accession,O
KX344031,S-AccessionNumber
),O
[,O
16,O
],O
using,O
BlastN,O
[,O
17,O
],O
.,O
For,O
each,O
of,O
the,O
two,O
datasets,O
",",O
three,O
distantly,O
related,O
bovine,O
coronaviruses,O
served,O
as,O
outgroup,O
and,O
multiple,O
-,O
sequence,O
alignment,O
was,O
built,O
using,O
MUSCLE,O
from,O
SeaView,O
4.6.4,O
followed,O
by,O
a,O
manual,O
correction,O
step,O
taking,O
into,O
account,O
protein,O
coding,O
sequences,O
for,O
coding,O
regions,O
[,O
"18,19",O
],O
.,O
These,O
estimates,O
obtained,O
from,O
two,O
different,O
databases,O
were,O
consistent,O
and,O
show,O
that,O
the,O
strains,O
of,O
the,O
clusters,O
2013,O
emerged,O
from,O
a,O
common,O
ancestor,O
in,O
2010.9,O
and,O
those,O
of,O
2014,O
emerged,O
from,O
another,O
in,O
2011,O
+,O
/-0.5,O
.,O
Due,O
to,O
limited,O
HCoV−OC43,O
full,O
-,O
length,O
genome,O
published,O
in,O
databases,O
",",O
phylogenetic,O
analyses,O
were,O
conducted,O
on,O
S,O
gene,O
sequences,O
.,O
With,O
the,O
gradual,O
reopening,O
of,O
economies,O
and,O
resumption,O
of,O
social,O
life,O
",",O
robust,O
surveillance,O
mechanisms,O
should,O
be,O
implemented,O
to,O
control,O
the,O
ongoing,O
COVID-19,O
pandemic,O
.,O
We,O
performed,O
shotgun,O
transcriptome,O
sequencing,O
using,O
RNA,O
extracted,O
from,O
nasopharyngeal,O
swabs,O
of,O
patients,O
with,O
COVID-19,O
",",O
and,O
compared,O
it,O
to,O
targeted,O
SARS,O
-,O
CoV-2,O
genome,O
amplification,O
and,O
sequencing,O
with,O
respect,O
to,O
virus,O
detection,O
",",O
scalability,O
",",O
and,O
cost,O
-,O
effectiveness,O
.,O
Conclusions,O
 ,O
SARS,O
-,O
CoV-2,O
whole,O
genome,O
sequencing,O
is,O
a,O
practical,O
",",O
cost,O
-,O
effective,O
",",O
and,O
powerful,O
approach,O
for,O
population,O
-,O
based,O
surveillance,O
and,O
control,O
of,O
viral,O
transmission,O
in,O
the,O
next,O
phase,O
of,O
the,O
COVID-19,O
pandemic,O
.,O
In,O
December,O
2019,O
",",O
a,O
novel,O
coronavirus,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
was,O
identified,O
in,O
Wuhan,O
",",O
China,O
",",O
as,O
the,O
etiologic,O
agent,O
of,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
;,O
as,O
of,O
May,O
2020,O
",",O
this,O
virus,O
had,O
spread,O
to,O
more,O
than,O
187,O
countries,O
[,O
"1,2",O
],O
.,O
The,O
implications,O
of,O
misunderstanding,O
the,O
real,O
dynamics,O
of,O
the,O
COVID-19,O
pandemic,O
are,O
extremely,O
dangerous,O
.,O
The,O
GISAID,B-Dataset
(Global,I-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data),E-Dataset
 ,O
database,O
[,O
20,O
],O
was,O
accessed,O
on,O
March,O
18,O
",",O
March,O
25,O
",",O
March,O
30,O
",",O
and,O
April,O
24,O
",",O
2020,O
(,O
Table,O
S1,O
in,O
Multimedia,O
Appendix,O
1,O
and,O
Table,O
S2,O
in,O
Multimedia,O
Appendix,O
2,O
),O
.,O
Our,O
main,O
analyses,O
compared,O
the,O
March,O
30,O
data,O
set,O
with,O
the,O
April,O
24,O
data,O
set,O
.,O
SARS,O
-,O
CoV-2,O
full,O
genome,O
alignments,O
generated,O
from,O
sequences,O
in,O
GISAID,S-Dataset
 ,O
[,O
23,O
],O
at,O
different,O
time,O
points,O
were,O
analyzed,O
as,O
follows,O
.,O
However,O
",",O
in,O
a,O
new,O
tree,O
inferred,O
just,O
one,O
week,O
later,O
",",O
when,O
more,O
than,O
135,O
new,O
full,O
genome,O
sequences,O
were,O
made,O
available,O
on,O
GISAID,S-Dataset
 ,O
[,O
23,O
],O
",",O
the,O
direct,O
link,O
between,O
Germany,O
and,O
Italy,O
in,O
Subclade,O
A,O
disappeared,O
due,O
to,O
additional,O
clustering,O
of,O
previously,O
unsampled,O
sequences,O
from,O
Portugal,O
",",O
Brazil,O
",",O
Wales,O
",",O
and,O
the,O
Netherlands,O
(,O
Figure,O
2b,O
),O
.,O
As,O
the,O
number,O
of,O
available,O
genome,O
sequences,O
is,O
rapidly,O
growing,O
",",O
SARS,O
-,O
CoV-2,O
full,O
genome,O
data,O
sets,O
are,O
steadily,O
showing,O
less,O
than,O
40,O
%,O
unresolved,O
quartets,O
in,O
the,O
center,O
:,O
38.6,O
%,O
on,O
March,O
18,O
(,O
Figure,O
S1c,O
in,O
Multimedia,O
Appendix,O
3,O
),O
",",O
32.3,O
%,O
on,O
March,O
25,O
(,O
Figure,O
S1d,O
in,O
Multimedia,O
Appendix,O
3,O
),O
",",O
28.9,O
%,O
on,O
March,O
30th,O
(,O
Figure,O
S1e,O
in,O
Multimedia,O
Appendix,O
3,O
),O
",",O
and,O
27.6,O
%,O
on,O
April,O
24,O
(,O
Figure,O
S1f,O
in,O
Multimedia,O
Appendix,O
3,O
),O
.,O
The,O
phylogenetic,O
signal,O
is,O
increasing,O
in,O
the,O
global,O
alignment,O
;,O
however,O
",",O
likelihood,O
mapping,O
per,O
country,O
using,O
data,O
from,O
countries,O
reporting,O
the,O
highest,O
numbers,O
of,O
cases,O
(,O
United,O
States,O
",",O
Italy,O
",",O
Spain,O
",",O
Germany,O
",",O
and,O
France,O
),O
indicates,O
that,O
some,O
local,O
data,O
sets,O
lacked,O
sufficient,O
signals,O
up,O
to,O
March,O
30,O
",",O
2020,O
(,O
Figure,O
S6,O
in,O
Multimedia,O
Appendix,O
3,O
),O
.,O
The,O
United,O
States,O
data,O
set,O
comprised,O
mostly,O
sequences,O
collected,O
in,O
Washington,O
State,O
(,O
423/612,O
genomes,O
",",O
69.1,O
%,O
),O
.,O
However,O
",",O
while,O
France,O
and,O
Germany,O
also,O
displayed,O
sufficient,O
temporal,O
signals,O
to,O
allow,O
in,O
-,O
depth,O
molecular,O
epidemiology,O
studies,O
",",O
at,O
least,O
in,O
principle,O
",",O
data,O
sets,O
from,O
the,O
United,O
States,O
(,O
3.9,O
-,O
fold,O
increase,O
on,O
April,O
24,O
with,O
respect,O
to,O
March,O
30,O
),O
",",O
the,O
United,O
Kingdom,O
(,O
5.5,O
-,O
fold,O
increase,O
),O
",",O
and,O
Spain,O
(,O
3.9,O
-,O
fold,O
increase,O
),O
",",O
still,O
showed,O
weak,O
or,O
no,O
temporal,O
signals,O
(,O
Figure,O
S10,O
in,O
Multimedia,O
Appendix,O
3,O
),O
despite,O
the,O
substantial,O
increases,O
in,O
the,O
number,O
of,O
available,O
sequences,O
.,O
More,O
genome,O
sequences,O
",",O
sampled,O
at,O
different,O
time,O
points,O
and,O
from,O
diverse,O
geographic,O
areas,O
",",O
are,O
becoming,O
available,O
daily,O
;,O
therefore,O
",",O
in,O
-,O
depth,O
Bayesian,O
phylodynamic,O
and,O
phylogeographic,O
analyses,O
of,O
the,O
COVID-19,O
pandemic,O
will,O
soon,O
be,O
a,O
viable,O
option,O
.,O
The,O
first,O
step,O
that,O
researchers,O
must,O
take,O
before,O
they,O
complete,O
their,O
phylogenetic,O
studies,O
is,O
determining,O
whether,O
the,O
data,O
set,O
is,O
biased,O
in,O
terms,O
of,O
the,O
number,O
of,O
genomes,O
per,O
given,O
location,O
",",O
host,O
",",O
source,O
",",O
etc,O
.,O
In,O
this,O
study,O
",",O
we,O
did,O
not,O
test,O
for,O
recombination,O
for,O
the,O
SARS,O
-,O
CoV-2,O
data,O
set,O
",",O
as,O
absence,O
of,O
recombination,O
in,O
the,O
human,O
lineage,O
has,O
previously,O
been,O
shown,O
[,O
41,O
],O
;,O
however,O
",",O
because,O
coronaviruses,O
are,O
prone,O
to,O
recombination,O
events,O
",",O
this,O
step,O
should,O
be,O
performed,O
as,O
more,O
sequences,O
become,O
available,O
.,O
We,O
used,O
maximum,O
likelihood,O
–,O
based,O
methods,O
to,O
assess,O
the,O
presence,O
of,O
sufficient,O
information,O
for,O
robust,O
phylogenetic,O
and,O
phylogeographic,O
studies,O
in,O
several,O
SARS,O
-,O
CoV-2,O
sequence,O
alignments,O
assembled,O
from,O
GISAID,B-Dataset
(Global,I-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data),E-Dataset
 ,O
data,O
released,O
between,O
March,O
and,O
April,O
2020,O
.,O
Although,O
the,O
number,O
of,O
high,O
-,O
quality,O
full,O
genomes,O
is,O
growing,O
daily,O
",",O
and,O
sequence,O
data,O
released,O
in,O
April,O
2020,O
contain,O
sufficient,O
phylogenetic,O
information,O
to,O
allow,O
reliable,O
inference,O
of,O
phylogenetic,O
relationships,O
",",O
country,O
-,O
specific,O
SARS,O
-,O
CoV-2,O
data,O
sets,O
still,O
present,O
severe,O
limitations,O
.,O
At,O
present,O
",",O
a,O
total,O
of,O
14,O
full,O
-,O
length,O
genome,O
sequences,O
of,O
2019,O
-,O
nCoV,O
have,O
been,O
submitted,O
to,O
GISAID,S-Dataset
 ,O
and,O
among,O
them,O
only,O
one,O
has,O
been,O
released,O
on,O
GenBank,S-Repository
 ,O
(,O
Accession,O
No,O
:,O
MN908947,S-AccessionNumber
),O
(,O
Ji,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
They,O
selected,O
a,O
series,O
of,O
potential,O
drugs,O
which,O
exist,O
in,O
the,O
market,O
or,O
the,O
self,O
-,O
built,O
database,O
’s,O
high,O
-,O
cost,O
medicinal,O
compounds,O
and,O
medicinal,O
plant,O
sources,O
database,O
compounds,O
.,O
To,O
date,O
",",O
the,O
SARS,O
-,O
CoV-2,O
virus,O
causing,O
the,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
pandemic,O
is,O
spreading,O
throughout,O
the,O
world,O
.,O
The,O
first,O
COVID-19,O
case,O
in,O
Finland,O
was,O
a,O
female,O
Chinese,O
tourist,O
in,O
her,O
30s,O
",",O
who,O
had,O
left,O
Wuhan,O
on,O
22,O
January,O
and,O
arrived,O
in,O
Finland,O
on,O
23,O
January,O
.,O
Suspicion,O
of,O
COVID-19,O
led,O
to,O
her,O
direct,O
transfer,O
to,O
the,O
Lapland,O
Central,O
Hospital,O
in,O
Rovaniemi,O
",",O
where,O
she,O
was,O
isolated,O
and,O
sampled,O
on,O
28,O
and,O
29,O
January,O
for,O
laboratory,O
confirmation,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
(,O
Figure,O
1,O
),O
.,O
Nearly,O
the,O
complete,O
coding,O
region,O
of,O
SARS,O
-,O
CoV-2,O
(,O
GenBank,S-Repository
 ,O
accession,O
number,O
:,O
MT020781,S-AccessionNumber
),O
was,O
sequenced,O
from,O
the,O
NPS,O
collected,O
on,O
Day,O
4,O
(,O
Table,O
),O
and,O
the,O
complete,O
coding,O
region,O
was,O
sequenced,O
from,O
the,O
virus,O
isolate,O
obtained,O
after,O
three,O
passages,O
in,O
Vero,O
E6,O
cells,O
.,O
In,O
the,O
early,O
phase,O
of,O
the,O
COVID-19,O
outbreak,O
",",O
confirmed,O
cases,O
outside,O
China,O
were,O
mostly,O
imported,O
among,O
travellers,O
from,O
Wuhan,O
[,O
7,O
],O
.,O
As,O
at,O
17,O
March,O
2020,O
",",O
358,O
additional,O
laboratory,O
-,O
confirmed,O
cases,O
of,O
COVID-19,O
have,O
been,O
detected,O
in,O
Finland,O
.,O
The,O
risk,O
of,O
widespread,O
national,O
community,O
transmission,O
of,O
COVID-19,O
infection,O
in,O
the,O
European,O
Union,O
",",O
European,O
Economic,O
Area,O
and,O
the,O
United,O
Kingdom,O
in,O
the,O
coming,O
weeks,O
is,O
considered,O
high,O
by,O
the,O
European,O
Centre,O
for,O
Disease,O
Prevention,O
and,O
Control,O
[,O
8,O
],O
.,O
Current,O
guidelines,O
from,O
the,O
World,O
Health,O
Organization,O
for,O
testing,O
COVID-19,O
recommend,O
collection,O
of,O
both,O
acute,O
and,O
convalescent,O
serum,O
samples,O
from,O
patients,O
for,O
serological,O
testing,O
",",O
which,O
can,O
support,O
the,O
identification,O
of,O
the,O
immune,O
response,O
to,O
a,O
specific,O
viral,O
pathogen,O
[,O
10,O
],O
.,O
The,O
first,O
case,O
of,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
in,O
Finland,O
was,O
confirmed,O
on,O
29,O
January,O
2020,O
.,O
From,O
its,O
origin,O
in,O
Wuhan,O
",",O
China,O
",",O
in,O
December,O
2019,O
",",O
the,O
novel,O
coronavirus,O
disease,O
",",O
COVID‐19,O
",",O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS‐CoV‐2,O
),O
virus,O
",",O
has,O
spread,O
rapidly,O
throughout,O
the,O
world,O
[,O
1,O
],O
.,O
In,O
Israel,O
",",O
the,O
first,O
case,O
of,O
the,O
COVID‐19,O
infection,O
was,O
reported,O
on,O
February,O
21st,O
",",O
2020,O
.,O
On,O
March,O
11th,O
",",O
2020,O
",",O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
declared,O
COVID‐19,O
disease,O
a,O
global,O
pandemic,O
[,O
2,O
],O
.,O
Immediate,O
targeted,O
actions,O
were,O
needed,O
to,O
identify,O
risk,O
factors,O
of,O
COVID‐19,O
.,O
In,O
particular,O
",",O
the,O
pronounced,O
impact,O
of,O
vitamin,O
D,O
metabolites,O
on,O
the,O
immune,O
system,O
response,O
",",O
and,O
on,O
the,O
development,O
of,O
COVID‐19,O
infection,O
by,O
the,O
novel,O
SARS‐CoV‐2,O
virus,O
",",O
has,O
been,O
described,O
[,O
5,O
",",O
6,O
",",O
7,O
",",O
8,O
",",O
9,O
",",O
10,O
",",O
11,O
",",O
12,O
",",O
13,O
",",O
14,O
",",O
15,O
],O
.,O
Therefore,O
",",O
we,O
aimed,O
to,O
determine,O
associations,O
between,O
low,O
plasma,O
25(OH)D,O
and,O
the,O
risk,O
of,O
COVID‐19,O
infection,O
and,O
hospitalization,O
",",O
using,O
real‐world,O
Israeli,O
population‐based,O
data,O
.,O
We,O
hypothesized,O
that,O
the,O
mean,O
plasma,O
level,O
of,O
25(OH)D,O
would,O
be,O
significantly,O
lower,O
and,O
",",O
accordingly,O
",",O
the,O
rate,O
of,O
suboptimal,O
plasma,O
25(OH)D,O
levels,O
would,O
be,O
found,O
frequently,O
among,O
persons,O
testing,O
positive,O
for,O
COVID‐19,O
infection,O
",",O
and,O
among,O
persons,O
subsequently,O
hospitalized,O
",",O
in,O
a,O
large,O
population‐based,O
epidemiological,O
study,O
.,O
Of,O
14,O
 ,O
022,O
subjects,O
",",O
aged,O
2,O
 ,O
months,O
to,O
103,O
 ,O
years,O
",",O
who,O
were,O
tested,O
for,O
COVID‐19,O
infection,O
",",O
1416,O
(,O
10.1,O
%,O
),O
had,O
at,O
least,O
one,O
positive,O
result,O
;,O
12,O
 ,O
606,O
(,O
89.9,O
%,O
),O
had,O
only,O
negative,O
results,O
(,O
Fig,O
.,O
 ,O
1,O
),O
.,O
Also,O
for,O
this,O
sample,O
",",O
the,O
proportion,O
of,O
infected,O
individuals,O
was,O
10.02,O
%,O
(,O
782/7807,O
),O
for,O
COVID‐19‐positive,O
(,O
COVID‐19‐P,O
),O
",",O
and,O
7025,O
(,O
89.98,O
%,O
),O
for,O
COVID‐19‐negative,O
(,O
COVID‐19‐N,O
;,O
Fig,O
.,O
 ,O
1,O
),O
.,O
We,O
run,O
an,O
univariate,O
logistic,O
regression,O
analysis,O
",",O
assessing,O
the,O
odds,O
ratio,O
(,O
OR,O
),O
for,O
COVID‐19,O
infections,O
and,O
different,O
categories,O
of,O
plasma,O
25,O
(,O
OH,O
),O
D,O
levels,O
(,O
Table,O
 ,O
1,O
),O
.,O
In,O
a,O
primary,O
univariate,O
analysis,O
",",O
COVID‐19‐P,O
subjects,O
were,O
younger,O
",",O
and,O
more,O
likely,O
to,O
be,O
males,O
and,O
to,O
reside,O
in,O
a,O
lower,O
socioeconomic,O
status,O
(,O
SES,O
),O
area,O
than,O
were,O
COVID‐19‐N,O
subjects,O
(,O
Table,O
 ,O
2,O
),O
.,O
The,O
mean,O
plasma,O
25(OH)D,O
level,O
was,O
significantly,O
lower,O
for,O
COVID‐19‐P,O
subjects,O
(,O
Table,O
 ,O
2,O
),O
",",O
and,O
the,O
proportion,O
of,O
individuals,O
with,O
low,O
vitamin,O
D,O
levels,O
was,O
higher,O
(,O
89.90,O
%,O
vs.,O
84.91,O
%,O
",",O
P,O
 ,O
<,O
 ,O
0.001,O
;,O
Table,O
 ,O
3,O
),O
.,O
Interestinly,O
",",O
the,O
prevalence,O
of,O
dementia,O
",",O
hypertension,O
",",O
cardiovascular,O
disease,O
and,O
chronic,O
lung,O
disorders,O
was,O
greater,O
among,O
persons,O
who,O
were,O
COVID‐19‐N,O
than,O
those,O
who,O
were,O
COVID‐19‐P,O
(,O
P,O
 ,O
<,O
 ,O
0.05,O
",",O
P,O
 ,O
<,O
 ,O
0.001,O
",",O
P,O
 ,O
<,O
 ,O
0.001,O
",",O
P,O
 ,O
<,O
 ,O
0.001,O
;,O
Table,O
 ,O
3,O
),O
.,O
Multivariate,O
analysis,O
",",O
after,O
controlling,O
for,O
the,O
demographic,O
variables,O
",",O
and,O
psychiatric,O
and,O
somatic,O
disorders,O
",",O
demonstrated,O
an,O
independent,O
and,O
significant,O
association,O
between,O
the,O
low,O
25(OH)D,O
levels,O
and,O
the,O
increased,O
likelihood,O
of,O
COVID‐19,O
infection,O
[,O
adjusted,O
OR,O
of,O
1.50,O
(,O
95,O
%,O
confidence,O
interval,O
(,O
CI,O
):,O
1.13–1.98,O
",",O
P,O
 ,O
<,O
 ,O
0.001,O
),O
;,O
Fig,O
.,O
 ,O
2A,O
],O
.,O
The,O
risk,O
of,O
COVID‐19,O
infection,O
was,O
independently,O
positively,O
associated,O
with,O
being,O
male,O
[,O
adjusted,O
OR,O
of,O
1.49,O
(,O
95,O
%,O
CI,O
:,O
1.24–1.79,O
",",O
P,O
 ,O
<,O
 ,O
0.05,O
),O
],O
",",O
aged,O
older,O
than,O
50,O
 ,O
years,O
[,O
adjusted,O
OR,O
of,O
1.56,O
(,O
95,O
%,O
CI,O
:,O
1.26–1.92,O
",",O
P,O
 ,O
<,O
 ,O
0.05,O
),O
],O
and,O
residing,O
in,O
a,O
low,O
–,O
medium,O
SES,O
city,O
or,O
town,O
[,O
adjusted,O
OR,O
of,O
2.06,O
(,O
95,O
%,O
CI,O
:,O
1.65–2.59,O
",",O
P,O
 ,O
<,O
 ,O
0.001,O
),O
],O
(,O
Fig,O
.,O
2B,O
),O
.,O
Independent,O
negative,O
associations,O
were,O
observed,O
between,O
the,O
risk,O
of,O
COVID‐19,O
infection,O
and,O
having,O
a,O
diagnosis,O
of,O
dementia,O
[,O
adjusted,O
OR,O
of,O
0.56,O
(,O
95,O
%,O
CI,O
:,O
0.32–0.98,O
",",O
P,O
 ,O
<,O
 ,O
0.05,O
],O
",",O
of,O
cardiovascular,O
disease,O
[,O
adjusted,O
OR,O
of,O
0.59,O
(,O
95,O
%,O
CI,O
:,O
0.44–0.79,O
P,O
 ,O
<,O
 ,O
0.001,O
],O
and,O
of,O
a,O
chronic,O
lung,O
disorder,O
[,O
adjusted,O
OR,O
of,O
0.58,O
(,O
95,O
%,O
CI,O
:,O
0.42–0.79,O
P,O
 ,O
<,O
 ,O
0.001,O
],O
(,O
Table,O
 ,O
4,O
),O
.,O
Interestingly,O
",",O
the,O
hospitalized,O
COVID‐19‐P,O
individuals,O
were,O
older,O
[,O
58.69,O
 ,O
years,O
(,O
95,O
%,O
CI,O
:,O
54.78‐62.61,O
),O
vs.,O
46.88,O
(,O
95,O
%,O
CI,O
:,O
46.42–47.35,O
),O
],O
",",O
and,O
more,O
likely,O
to,O
be,O
male,O
(,O
47.8,O
%,O
vs.,O
41.3,O
%,O
",",O
P,O
 ,O
<,O
 ,O
0.001,O
),O
and,O
to,O
reside,O
in,O
a,O
city,O
or,O
town,O
of,O
low,O
–,O
medium,O
SES,O
(,O
73.64,O
%,O
vs.,O
69.45,O
%,O
",",O
P,O
 ,O
<,O
 ,O
0.001,O
),O
.,O
In,O
a,O
univariate,O
analysis,O
",",O
a,O
low,O
plasma,O
25(OH)D,O
level,O
was,O
associated,O
with,O
an,O
increased,O
likelihood,O
of,O
hospitalization,O
for,O
COVID‐19,O
infection,O
[,O
crude,O
OR,O
of,O
2.09,O
(,O
95,O
%,O
CI,O
:,O
1.01–4.31,O
",",O
P,O
 ,O
<,O
 ,O
0.05,O
),O
],O
.,O
Therefore,O
",",O
in,O
this,O
analysis,O
",",O
only,O
age,O
over,O
50,O
 ,O
years,O
was,O
statistically,O
significant,O
associated,O
with,O
the,O
likelihood,O
for,O
hospitalization,O
due,O
to,O
COVID‐19,O
[,O
adjusted,O
OR,O
of,O
2.71(95,O
%,O
CI,O
:,O
01.55‐,O
4.78,O
",",O
P,O
 ,O
<,O
 ,O
0.001,O
),O
;,O
Table,O
 ,O
5,O
and,O
Fig,O
.,O
 ,O
3,O
],O
.,O
The,O
main,O
finding,O
of,O
this,O
study,O
was,O
the,O
low,O
plasma,O
25(OH)D,O
level,O
association,O
with,O
COVID‐19,O
hospitalization,O
as,O
a,O
risk,O
factor,O
",",O
particularly,O
",",O
for,O
patients,O
tested,O
positively,O
for,O
COVID‐19,O
",",O
after,O
adjusting,O
for,O
age,O
",",O
gender,O
",",O
SES,O
and,O
chronic,O
",",O
mental,O
and,O
physical,O
disorders,O
.,O
Hence,O
",",O
low,O
25(OH)D,O
level,O
was,O
identified,O
as,O
independently,O
associated,O
with,O
the,O
likelihood,O
of,O
COVID‐19,O
infection,O
.,O
Notably,O
",",O
a,O
recent,O
study,O
from,O
the,O
UK,O
[,O
31,O
",",O
32,O
",",O
33,O
],O
that,O
included,O
449,O
subjects,O
(,O
from,O
the,O
UK,B-Repository
Biobank,E-Repository
),O
with,O
confirmed,O
COVID‐19,O
infection,O
did,O
not,O
find,O
an,O
association,O
between,O
vitamin,O
D,O
metabolite,O
concentration,O
and,O
the,O
risk,O
of,O
viral,O
infections,O
[,O
45,O
],O
as,O
well,O
as,O
COVID‐19,O
infection,O
[,O
5,O
",",O
7,O
",",O
9,O
",",O
10,O
",",O
11,O
",",O
12,O
",",O
13,O
",",O
14,O
",",O
15,O
",",O
19,O
",",O
30,O
",",O
31,O
",",O
32,O
",",O
33,O
",",O
34,O
",",O
35,O
",",O
36,O
",",O
37,O
",",O
39,O
",",O
40,O
",",O
41,O
",",O
42,O
",",O
46,O
],O
.,O
According,O
to,O
our,O
analysis,O
",",O
persons,O
with,O
COVID‐19‐P,O
were,O
younger,O
than,O
noninfected,O
ones,O
.,O
Two‐peak,O
distributions,O
for,O
age,O
groups,O
were,O
demonstrated,O
to,O
confer,O
increased,O
risk,O
for,O
COVID‐19,O
:,O
ages,O
25,O
 ,O
years,O
old,O
and,O
50,O
 ,O
years,O
old,O
(,O
Fig,O
.,O
 ,O
4,O
),O
.,O
Other,O
clinical,O
characteristics,O
that,O
were,O
significantly,O
linked,O
to,O
the,O
likelihood,O
of,O
COVID‐19,O
infection,O
included,O
male,O
gender,O
and,O
low,O
residential,O
SES,O
.,O
Despite,O
its,O
being,O
discussed,O
as,O
a,O
risk,O
factor,O
in,O
prior,O
publications,O
[,O
47,O
",",O
48,O
",",O
49,O
],O
",",O
obesity,O
had,O
not,O
been,O
significantly,O
associated,O
with,O
either,O
an,O
increased,O
risk,O
for,O
COVID‐19,O
infection,O
or,O
with,O
hospitalization,O
due,O
to,O
COVID‐19,O
in,O
this,O
study,O
.,O
Two‐peak,O
age,O
groups,O
as,O
a,O
high,O
risk,O
for,O
COVID‐19,O
:,O
ages,O
25,O
and,O
50,O
 ,O
years,O
old,O
(,O
red,O
bars,O
),O
.,O
This,O
might,O
indeed,O
minimize,O
the,O
risk,O
of,O
COVID‐19,O
infection,O
in,O
that,O
particular,O
group,O
of,O
patients,O
.,O
Finally,O
",",O
in,O
a,O
subset,O
analysis,O
of,O
only,O
COVID‐19‐P,O
subjects,O
",",O
hospitalized,O
patients,O
were,O
significantly,O
older,O
(,O
58.69,O
vs.,O
46.88,O
 ,O
years,O
),O
.,O
To,O
conclude,O
",",O
the,O
plasma,O
25(OH)D,O
level,O
under,O
20,O
ng,O
/,O
mL,O
almost,O
doubled,O
the,O
risk,O
for,O
hospitalization,O
due,O
to,O
the,O
COVID‐19,O
infection,O
in,O
the,O
Israeli,O
studied,O
cohort,O
.,O
An,O
additional,O
strength,O
was,O
the,O
analysis,O
of,O
a,O
multitude,O
of,O
variables,O
that,O
may,O
affect,O
the,O
risk,O
of,O
COVID‐19,O
infection,O
",",O
independent,O
of,O
plasma,O
25(OH)D,O
levels,O
.,O
However,O
",",O
the,O
major,O
weakness,O
of,O
the,O
study,O
was,O
the,O
retrospective,O
database,O
design,O
.,O
Data,O
regarding,O
COVID‐19,O
symptoms,O
and,O
the,O
hospitalization,O
due,O
to,O
COVID‐19,O
infection,O
",",O
and,O
also,O
adverse,O
clinical,O
outcomes,O
(,O
for,O
example,O
",",O
mechanical,O
ventilation,O
),O
should,O
be,O
further,O
assessed,O
.,O
Therefore,O
",",O
our,O
study,O
found,O
that,O
suboptimal,O
plasma,O
vitamin,O
D,O
levels,O
may,O
be,O
a,O
potential,O
risk,O
factor,O
for,O
COVID‐19,O
infection,O
",",O
particularly,O
",",O
for,O
the,O
high,O
hospitalization,O
risks,O
",",O
independent,O
of,O
demographic,O
characteristics,O
and,O
medical,O
conditions,O
.,O
The,O
finding,O
is,O
important,O
",",O
since,O
it,O
could,O
guide,O
healthcare,O
systems,O
in,O
identifying,O
populations,O
at,O
risk,O
",",O
and,O
contribute,O
to,O
interventions,O
aimed,O
to,O
reduce,O
the,O
risk,O
of,O
the,O
COVID‐19,O
infection,O
.,O
More,O
studies,O
are,O
required,O
to,O
assess,O
the,O
effects,O
of,O
vitamin,O
D3,O
supplements,O
on,O
the,O
risk,O
of,O
hospitalizations,O
due,O
to,O
COVID‐19,O
infection,O
.,O
We,O
conducted,O
a,O
population‐based,O
study,O
utilizing,O
data,O
from,O
the,O
Leumit,O
Health,O
Services,O
(,O
LHS,O
),O
database,O
",",O
a,O
large,O
health,O
maintenance,O
organization,O
in,O
Israel,O
that,O
provides,O
services,O
to,O
around,O
730,O
 ,O
000,O
members,O
nationwide,O
.,O
The,O
comprehensive,O
computerized,O
database,O
of,O
LHS,O
is,O
continuously,O
updated,O
with,O
regard,O
to,O
demographics,O
",",O
medical,O
visits,O
",",O
laboratory,O
tests,O
and,O
hospitalizations,O
.,O
The,O
study,O
population,O
included,O
all,O
members,O
of,O
LHS,O
who,O
were,O
tested,O
for,O
COVID‐19,O
infection,O
during,O
the,O
study,O
period,O
and,O
who,O
had,O
at,O
least,O
one,O
previous,O
test,O
for,O
plasma,O
25(OH)D,O
level,O
(,O
7807,O
subjects,O
),O
.,O
COVID‐19,O
testing,O
was,O
done,O
only,O
by,O
physician,O
referral,O
(,O
based,O
on,O
clinical,O
criteria,O
of,O
exposure,O
to,O
confirmed,O
COVID‐19,O
patients,O
or,O
symptoms,O
suggesting,O
COVID‐19,O
),O
using,O
the,O
AllplexTM,O
2019‐nCoV,O
Assay,O
(,O
Seegene,O
Inc.,O
",",O
Seoul,O
",",O
Korea,O
),O
[,O
23,O
],O
.,O
Data,O
of,O
each,O
subject,O
were,O
collected,O
from,O
the,O
LHS,O
computerized,O
database,O
and,O
included,O
age,O
",",O
gender,O
",",O
SES,O
",",O
weight,O
",",O
height,O
",",O
BMI,O
",",O
current,O
smoking,O
status,O
",",O
psychiatric,O
and,O
somatic,O
comorbidities,O
",",O
and,O
hospitalizations,O
as,O
a,O
result,O
of,O
the,O
COVID‐19,O
infection,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
evaluate,O
associations,O
of,O
plasma,O
25(OH)D,O
levels,O
with,O
the,O
likelihood,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
infection,O
and,O
hospitalization,O
.,O
The,O
study,O
population,O
included,O
the,O
14,O
 ,O
000,O
members,O
of,O
Leumit,O
Health,O
Services,O
",",O
who,O
were,O
tested,O
for,O
COVID‐19,O
infection,O
from,O
February,O
1,O
st,O
to,O
April,O
30,O
th,O
",",O
2020,O
",",O
and,O
who,O
had,O
at,O
least,O
one,O
previous,O
blood,O
test,O
for,O
the,O
plasma,O
25(OH)D,O
level,O
.,O
Of,O
7807,O
individuals,O
",",O
782,O
(,O
10.02,O
%,O
),O
were,O
COVID‐19‐positive,O
",",O
and,O
7025,O
(,O
89.98,O
%,O
),O
COVID‐19‐negative,O
.,O
The,O
mean,O
plasma,O
vitamin,O
D,O
level,O
was,O
significantly,O
lower,O
among,O
those,O
who,O
tested,O
positive,O
than,O
negative,O
for,O
COVID‐19,O
[,O
19.00,O
ng,O
/,O
mL,O
(,O
95,O
%,O
confidence,O
interval,O
(,O
CI,O
),O
18.41–19.59,O
),O
vs.,O
20.55,O
(,O
95,O
%,O
CI,O
:,O
20.32–20.78,O
),O
],O
.,O
Univariate,O
analysis,O
demonstrated,O
an,O
association,O
between,O
the,O
low,O
plasma,O
25(OH)D,O
level,O
and,O
increased,O
likelihood,O
of,O
COVID‐19,O
infection,O
[,O
crude,O
odds,O
ratio,O
(,O
OR,O
),O
of,O
1.58,O
(,O
95,O
%,O
CI,O
:,O
1.24–2.01,O
",",O
P,O
<,O
 ,O
0.001,O
),O
],O
",",O
and,O
of,O
hospitalization,O
due,O
to,O
the,O
SARS‐CoV‐2,O
virus,O
[,O
crude,O
OR,O
of,O
2.09,O
(,O
95,O
%,O
CI,O
:,O
1.01–4.30,O
",",O
P,O
<,O
 ,O
0.05,O
),O
],O
.,O
In,O
multivariate,O
analyses,O
that,O
controlled,O
for,O
demographic,O
variables,O
",",O
and,O
psychiatric,O
and,O
somatic,O
disorders,O
",",O
the,O
adjusted,O
OR,O
of,O
COVID‐19,O
infection,O
[,O
1.45,O
(,O
95,O
%,O
CI,O
:,O
1.08–1.95,O
",",O
P,O
<,O
 ,O
0.001,O
),O
],O
and,O
of,O
hospitalization,O
due,O
to,O
the,O
SARS‐CoV‐2,O
virus,O
[,O
1.95,O
(,O
95,O
%,O
CI,O
:,O
0.98–4.845,O
",",O
P,O
=,O
 ,O
0.061,O
),O
],O
were,O
preserved,O
.,O
In,O
the,O
multivariate,O
analyses,O
",",O
age,O
over,O
50,O
 ,O
years,O
",",O
male,O
gender,O
and,O
low,O
–,O
medium,O
socioeconomic,O
status,O
were,O
also,O
positively,O
associated,O
with,O
the,O
risk,O
of,O
COVID‐19,O
infection,O
;,O
age,O
over,O
50,O
 ,O
years,O
was,O
positively,O
associated,O
with,O
the,O
likelihood,O
of,O
hospitalization,O
due,O
to,O
COVID‐19,O
.,O
We,O
concluded,O
that,O
low,O
plasma,O
25(OH)D,O
levels,O
appear,O
to,O
be,O
an,O
independent,O
risk,O
factor,O
for,O
COVID‐19,O
infection,O
and,O
hospitalization,O
.,O
Vitamin,O
D,O
deficiency,O
is,O
recognized,O
as,O
a,O
significant,O
health,O
concern,O
in,O
which,O
there,O
is,O
heightened,O
interest,O
because,O
of,O
the,O
potential,O
impact,O
on,O
COVID‐19,O
risk,O
.,O
In,O
a,O
landmark,O
study,O
involving,O
a,O
large,O
Israeli,O
population,O
",",O
Milana,O
Morgenstern,O
and,O
colleagues,O
found,O
that,O
the,O
plasma,O
level,O
of,O
vitamin,O
D,O
is,O
lower,O
among,O
individuals,O
who,O
have,O
tested,O
positive,O
for,O
COVID‐19,O
and,O
have,O
been,O
hospitalized,O
.,O
This,O
indicates,O
that,O
low,O
vitamin,O
D,O
status,O
is,O
an,O
independent,O
risk,O
factor,O
for,O
severe,O
COVID‐19,O
;,O
male,O
gender,O
and,O
low‐medium,O
socioeconomic,O
status,O
were,O
also,O
shown,O
to,O
be,O
positively,O
associated,O
with,O
the,O
risk,O
of,O
infection,O
.,O
Moreover,O
",",O
age,O
(,O
being,O
>,O
50,O
years,O
old,O
),O
was,O
associated,O
with,O
COVID‐19,O
hospitalization,O
.,O
In,O
December,O
2019,O
",",O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
was,O
described,O
in,O
Wuhan,O
",",O
China,O
(,O
Guan,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Furthermore,O
",",O
particulate,O
matter,O
2.5,O
 ,O
μm,O
or,O
less,O
in,O
diameter,O
(,O
PM2.5,O
),O
",",O
particulate,O
matter,O
10,O
 ,O
μm,O
or,O
less,O
in,O
diameter,O
(,O
PM10,O
),O
",",O
sulfur,O
dioxide,O
(,O
SO2,O
),O
",",O
nitrogen,O
dioxide,O
(,O
NO2,O
),O
",",O
carbon,O
monoxide,O
(,O
CO,O
),O
or,O
ozone,O
(,O
O3,O
),O
have,O
been,O
also,O
associated,O
with,O
COVID-19,O
incidence,O
(,O
Bashir,O
et,O
al,O
.,O
",",O
2020b,O
;,O
Fronza,O
et,O
al,O
.,O
",",O
2020,O
;,O
Jiang,O
et,O
al,O
.,O
",",O
2020,O
;,O
Ogen,O
",",O
2020,O
;,O
Zhu,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
but,O
it,O
remains,O
unclear,O
if,O
these,O
correlations,O
are,O
actually,O
related,O
to,O
causation,O
(,O
Riccò,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Regarding,O
weather,O
conditions,O
",",O
there,O
are,O
several,O
studies,O
that,O
have,O
been,O
published,O
during,O
recent,O
months,O
reporting,O
negative,O
correlation,O
between,O
temperature,O
and,O
COVID-19,O
cases,O
(,O
see,O
for,O
example,O
Luo,O
et,O
al,O
.,O
",",O
2020,O
;,O
Pequeno,O
et,O
al,O
.,O
",",O
2020,O
;,O
Wang,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
humidity,O
and,O
death,O
counts,O
(,O
Ma,O
et,O
al,O
.,O
",",O
2020,O
),O
or,O
rainfall,O
and,O
new,O
daily,O
cases,O
(,O
Menebo,O
",",O
2020,O
),O
.,O
More,O
data,O
is,O
needed,O
to,O
derive,O
more,O
conclusive,O
results,O
and,O
to,O
elucidate,O
the,O
actual,O
impact,O
of,O
ambient,O
factors,O
on,O
COVID-19,O
pandemic,O
.,O
Daily,O
COVID-19,O
total,O
cases,O
and,O
cases,O
diagnosed,O
with,O
polymerase,O
chain,O
reaction,O
(,O
PCR,O
),O
from,O
the,O
autonomous,O
communities,O
and,O
provinces,O
have,O
been,O
obtained,O
from,O
the,O
Ministry,B-Creator
of,I-Creator
Health,I-Creator
of,I-Creator
Spain,I-Creator
(MISAN,E-Creator
",",O
2020,O
),O
.,O
However,O
",",O
this,O
approach,O
has,O
been,O
criticized,O
due,O
to,O
the,O
possible,O
bias,O
produced,O
by,O
the,O
rapid,O
expansion,O
of,O
the,O
number,O
of,O
infected,O
by,O
COVID-19,O
(,O
Baud,O
et,O
al,O
.,O
",",O
2020,O
;,O
Spychalski,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
order,O
to,O
take,O
into,O
account,O
the,O
lockdown,O
effect,O
on,O
the,O
COVID-19,O
incidence,O
",",O
partial,O
correlation,O
was,O
applied,O
(,O
Ahmadi,O
et,O
al,O
.,O
",",O
2020,O
),O
correcting,O
by,O
the,O
number,O
of,O
lockdown,O
days,O
.,O
Taking,O
the,O
different,O
phases,O
of,O
the,O
COVID-19,O
pandemic,O
in,O
Spain,O
(,O
see,O
Introduction,O
section,O
),O
into,O
account,O
",",O
we,O
analyzed,O
the,O
pollutants,O
levels,O
in,O
3,O
periods,O
:,O
prior,O
to,O
lockdown,O
(,O
January,O
23rd,O
to,O
March,O
13th,O
",",O
50,O
 ,O
days,O
),O
",",O
strict,O
lockdown,O
(,O
March,O
14th,O
to,O
May,O
3rd,O
",",O
50,O
 ,O
days,O
),O
and,O
relaxed,O
lockdown,O
(,O
May,O
4th,O
to,O
June,O
20th,O
",",O
47,O
 ,O
days,O
),O
.,O
There,O
are,O
previous,O
studies,O
that,O
associate,O
temperature,O
",",O
solar,O
radiation,O
",",O
wind,O
speed,O
or,O
rainfall,O
with,O
COVID-19,O
cases,O
or,O
deaths,O
in,O
different,O
regions,O
(,O
Bashir,O
et,O
al,O
.,O
",",O
2020a,O
;,O
Guasp,O
et,O
al,O
.,O
",",O
2020,O
;,O
Kifer,O
et,O
al,O
.,O
",",O
2020,O
;,O
Liu,O
et,O
al,O
.,O
",",O
2020,O
;,O
Luo,O
et,O
al,O
.,O
",",O
2020,O
;,O
Pequeno,O
et,O
al,O
.,O
",",O
2020,O
;,O
Rosario,O
et,O
al,O
.,O
",",O
2020,O
;,O
Tosepu,O
et,O
al,O
.,O
",",O
2020,O
;,O
Wang,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
As,O
can,O
be,O
observed,O
",",O
correlations,O
among,O
wind,O
speed,O
and,O
rainfall,O
with,O
cases,O
are,O
very,O
heterogeneous,O
and,O
non,O
-,O
significant,O
for,O
most,O
of,O
the,O
Spanish,O
communities,O
",",O
indicating,O
that,O
these,O
variables,O
were,O
not,O
correlated,O
with,O
the,O
COVID-19,O
incidence,O
in,O
Spain,O
.,O
Therefore,O
",",O
when,O
we,O
calculated,O
partial,O
correlations,O
between,O
temperature,O
",",O
solar,O
radiation,O
and,O
daily,O
detected,O
COVID-19,O
cases,O
controlling,O
the,O
influence,O
of,O
the,O
lockdown,O
(,O
Table,O
3,O
),O
",",O
correlation,O
coefficients,O
were,O
low,O
and,O
non,O
-,O
significant,O
for,O
most,O
of,O
the,O
communities,O
.,O
These,O
results,O
indicate,O
that,O
although,O
temperature,O
and,O
solar,O
radiation,O
may,O
have,O
a,O
role,O
in,O
COVID-19,O
incidence,O
",",O
they,O
are,O
not,O
the,O
main,O
factors,O
and,O
long,O
-,O
term,O
data,O
is,O
required,O
in,O
order,O
to,O
have,O
conclusive,O
results,O
.,O
In,O
this,O
context,O
",",O
large,O
efforts,O
have,O
been,O
made,O
to,O
develop,O
software,O
tools,O
to,O
collect,O
COVID-19,O
global,O
pandemic,O
data,O
",",O
like,O
the,O
dashboard,O
developed,O
by,O
the,O
John,O
Hopkins,O
University,O
(,O
Dong,O
et,O
al,O
.,O
",",O
2020,O
),O
or,O
HealthMap,O
(,O
Xu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
We,O
also,O
used,O
DatAC,O
to,O
explore,O
the,O
relationship,O
between,O
meteorological,O
variables,O
and,O
the,O
amount,O
of,O
daily,O
COVID-19,O
cases,O
",",O
finding,O
heterogeneous,O
and,O
non,O
-,O
significant,O
correlation,O
for,O
wind,O
speed,O
and,O
rainfall,O
",",O
but,O
large,O
and,O
significant,O
negative,O
correlation,O
for,O
temperature,O
and,O
solar,O
radiation,O
in,O
almost,O
all,O
Spanish,O
communities,O
.,O
These,O
results,O
indicate,O
that,O
lockdown,O
",",O
and,O
not,O
temperature,O
nor,O
solar,O
radiation,O
",",O
was,O
the,O
driving,O
factor,O
of,O
the,O
COVID-19,O
pandemic,O
evolution,O
in,O
Spain,O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
has,O
caused,O
an,O
unprecedented,O
global,O
health,O
crisis,O
",",O
with,O
several,O
countries,O
imposing,O
lockdowns,O
to,O
control,O
the,O
coronavirus,O
spread,O
.,O
Data,O
with,O
spatial,O
and,O
temporal,O
information,O
is,O
a,O
key,O
factor,O
to,O
get,O
reliable,O
results,O
and,O
",",O
although,O
there,O
are,O
some,O
data,O
repositories,O
for,O
monitoring,O
the,O
disease,O
both,O
globally,O
and,O
locally,O
",",O
an,O
application,O
that,O
integrates,O
and,O
aggregates,O
data,O
from,O
meteorological,O
and,O
air,O
quality,O
variables,O
with,O
COVID-19,O
information,O
has,O
not,O
been,O
described,O
so,O
far,O
to,O
the,O
best,O
of,O
our,O
knowledge,O
.,O
Here,O
",",O
we,O
present,O
DatAC,B-Dataset
(Data,I-Dataset
Against,I-Dataset
COVID-19),E-Dataset
",",O
a,O
data,O
fusion,O
project,O
with,O
an,O
interactive,O
web,O
frontend,O
that,O
integrates,O
COVID-19,O
and,O
environmental,O
data,O
in,O
Spain,O
.,O
Moreover,O
",",O
the,O
application,O
allowed,O
us,O
to,O
analyze,O
correlations,O
among,O
climate,O
factors,O
",",O
such,O
as,O
ambient,O
temperature,O
",",O
and,O
the,O
incidence,O
of,O
COVID-19,O
in,O
Spain,O
.,O
Coronavirus,O
disease,O
(,O
COVID-19,O
),O
is,O
a,O
pandemic,O
manifesting,O
respiratory,O
illness,O
and,O
first,O
reported,O
in,O
Wuhan,O
",",O
Hubei,O
province,O
of,O
China,O
in,O
December,O
2019,O
.,O
The,O
virus,O
causing,O
COVID-19,O
is,O
named,O
as,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
All,O
available,O
sequences,O
(,O
320,O
whole,O
genome,O
and,O
surface,O
glycoprotein,O
amino,O
acid,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
),O
related,O
to,O
the,O
COVID-19,O
pandemic,O
were,O
retrieved,O
from,O
NCBI,B-Repository
Virus,I-Repository
Variation,I-Repository
Resource,E-Repository
 ,O
repository,O
(,O
https://www.ncbi.nlm.nih.gov/labs/virus/,S-URL
),O
The,O
NCBI,S-Repository
 ,O
reference,O
sequence,O
of,O
SARS,O
-,O
CoV-2,O
 ,O
S,O
glycoprotein,O
",",O
accession,O
number,O
YP_009724390,S-AccessionNumber
 ,O
was,O
used,O
as,O
the,O
canonical,O
sequence,O
for,O
the,O
analyses,O
of,O
spike,O
protein,O
variants,O
.,O
For,O
multiple,O
sequence,O
alignment,O
(,O
MSA,O
),O
",",O
Genome,O
Detective,O
Coronavirus,O
Typing,O
Tool,O
uses,O
a,O
reference,O
dataset,O
of,O
431,O
whole,O
genome,O
sequences,O
(,O
WGS,O
),O
where,O
386,O
WGS,O
were,O
from,O
known,O
nine,O
coronavirus,O
species,O
.,O
The,O
dataset,O
was,O
then,O
aligned,O
with,O
MUSCLE,O
(,O
Edgar,O
",",O
2004,O
),O
.,O
Tree,O
structure,O
was,O
validated,O
by,O
running,O
the,O
analysis,O
on,O
1000,O
bootstraps,O
(,O
Efron,O
et,O
al,O
.,O
",",O
1996,O
),O
replications,O
dataset,O
and,O
the,O
evolutionary,O
distances,O
were,O
calculated,O
using,O
the,O
Poisson,O
correction,O
method,O
(,O
Zuckerkandl,O
and,O
Pauling,O
",",O
1965,O
),O
.,O
Variant,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
were,O
modeled,O
in,O
Swiss,O
-,O
Model,O
(,O
Andrew,O
et,O
al,O
.,O
",",O
2018,O
),O
using,O
the,O
Cryo,O
-,O
EM,O
spike,O
protein,O
structure,O
of,O
SARS,O
-,O
CoV-2,O
(,O
PDB,S-Repository
 ,O
ID,O
6VSB,S-AccessionNumber
;,O
(,O
Wrapp,O
et,O
al,O
.,O
",",O
2020,O
),O
),O
as,O
a,O
template,O
.,O
The,O
superposition,O
showed,O
that,O
most,O
of,O
the,O
residual,O
change,O
was,O
causing,O
incorporation,O
of,O
bulky,O
amino,O
acid,O
residues,O
(,O
T29I,O
",",O
H49Y,O
",",O
L54F,O
",",O
S221W,O
",",O
A348,O
T,O
",",O
H519Q,O
",",O
A520S,O
",",O
A930V,O
",",O
D936Y,O
",",O
and,O
A1078V,O
),O
in,O
place,O
of,O
smaller,O
sized,O
residues,O
except,O
for,O
Y28N,O
",",O
D111N,O
",",O
R408I,O
",",O
D614,O
G,O
",",O
and,O
F797C,O
(,O
Fig,O
.,O
4,O
B,O
—,O
P,O
),O
.,O
COVID-19,O
is,O
one,O
of,O
the,O
most,O
contagious,O
pandemics,O
the,O
world,O
has,O
ever,O
had,O
with,O
"1,250,000",O
confirmed,O
cases,O
to,O
date,O
(,O
April,O
4,O
",",O
2020,O
),O
and,O
the,O
cases,O
have,O
increased,O
as,O
high,O
as,O
5,O
times,O
in,O
less,O
than,O
a,O
month,O
(,O
WHO,O
(,O
World,O
Health,O
Organization,O
),O
",",O
2020,O
),O
.,O
As,O
of,O
19,O
May,O
2020,O
",",O
the,O
coronavirus,O
SARS,O
-,O
CoV-2,O
that,O
causes,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
COVID-19,O
was,O
reported,O
to,O
have,O
infected,O
over,O
5,O
 ,O
million,O
people,O
and,O
killed,O
over,O
320,O
 ,O
000,O
people,O
around,O
the,O
world,O
[,O
1,O
",",O
2,O
],O
.,O
Large,O
cohort,O
studies,O
such,O
as,O
the,O
UK,B-Repository
Biobank,I-Repository
(UKB),E-Repository
",",O
which,O
have,O
gathered,O
detailed,O
epidemiological,O
",",O
medical,O
and,O
genetic,O
records,O
of,O
hundreds,O
of,O
thousands,O
of,O
people,O
",",O
offer,O
the,O
opportunity,O
to,O
uncover,O
risk,O
factors,O
for,O
COVID-19,O
",",O
including,O
the,O
molecular,O
genetic,O
pathways,O
underlying,O
severe,O
disease,O
.,O
The,O
cohort,O
is,O
a,O
particularly,O
appropriate,O
focus,O
for,O
the,O
study,O
of,O
COVID-19,O
",",O
because,O
incidence,O
of,O
this,O
severe,O
disease,O
increases,O
with,O
age,O
[,O
1,O
",",O
4–10,O
],O
.,O
Emergency,O
ICD-10,O
codes,O
for,O
COVID-19,O
have,O
been,O
assigned,O
(,O
U07.1,O
COVID-19,O
",",O
virus,O
identified,O
;,O
U07.2,O
COVID-19,O
",",O
virus,O
not,O
identified,O
;,O
https://www.who.int/classifications/icd/COVID-19-coding-icd10.pdf,O
),O
.,O
However,O
",",O
there,O
are,O
limitations,O
to,O
these,O
data,O
for,O
studying,O
infection,O
",",O
as,O
coding,O
occurs,O
in,O
local,O
National,O
Health,O
Service,O
(,O
NHS,O
),O
Hospital,O
Trusts,O
",",O
with,O
subsequent,O
central,O
collation,O
by,O
the,O
NHS,O
and,O
periodic,O
(,O
currently,O
monthly,O
),O
incorporation,O
of,O
summaries,O
into,O
UKB,S-Repository
.,O
The,O
Public,O
Health,O
England,O
(,O
PHE,O
),O
microbiology,O
database,O
SGSS,B-Dataset
(Second,I-Dataset
Generation,I-Dataset
Surveillance,I-Dataset
System),E-Dataset
 ,O
offers,O
advantages,O
over,O
HES,O
data,O
for,O
the,O
ascertainment,O
of,O
infection,O
in,O
UKB,S-Repository
 ,O
participants,O
",",O
because,O
it,O
provides,O
more,O
granular,O
and,O
highly,O
specific,O
diagnosis,O
of,O
microbiological,O
confirmed,O
infection,O
",",O
including,O
both,O
COVID-19,O
and,O
infections,O
caused,O
by,O
micro,O
-,O
organisms,O
with,O
antimicrobial,O
resistance,O
(,O
AMR,O
),O
.,O
Of,O
note,O
",",O
it,O
only,O
allows,O
identification,O
of,O
microbiologically,O
confirmed,O
disease,O
;,O
in,O
the,O
case,O
of,O
COVID-19,O
",",O
other,O
databases,O
with,O
a,O
more,O
clinical,O
focus,O
also,O
exist,O
",",O
such,O
as,O
the,O
PHE,B-Repository
COVID-19,I-Repository
Hospitalization,I-Repository
in,I-Repository
England,I-Repository
Surveillance,I-Repository
System,I-Repository
(CHESS),E-Repository
 ,O
and,O
Intensive,B-Repository
Care,I-Repository
National,I-Repository
Audit,I-Repository
and,I-Repository
Research,I-Repository
Centre,I-Repository
(ICNARC),E-Repository
 ,O
databases,O
containing,O
individual,O
patient,O
data,O
on,O
critically,O
ill,O
patients,O
in,O
intensive,O
care,O
units,O
.,O
The,O
SGSS,S-Dataset
 ,O
database,O
provides,O
coverage,O
of,O
English,O
UKB,S-Repository
 ,O
participants,O
",",O
who,O
make,O
up,O
89,O
 ,O
%,O
of,O
the,O
cohort,O
based,O
on,O
residence,O
at,O
the,O
time,O
of,O
recruitment,O
.,O
There,O
are,O
specific,O
challenges,O
that,O
arise,O
when,O
frequently,O
linking,O
data,O
between,O
the,O
large,O
SGSS,S-Dataset
 ,O
and,O
UKB,S-Repository
 ,O
participant,O
databases,O
.,O
(,O
2,O
),O
Periodically,O
",",O
the,O
agent,O
updates,O
a,O
database,O
held,O
at,O
PHE,O
Colindale,O
with,O
any,O
new,O
records,O
from,O
SGSS,S-Dataset
 ,O
that,O
it,O
matches,O
with,O
UKB,S-Repository
 ,O
participants,O
.,O
We,O
have,O
tested,O
this,O
system,O
by,O
collecting,O
bacteriology,O
samples,O
in,O
the,O
John,O
Radcliffe,O
Hospital,O
",",O
Oxford,O
",",O
prior,O
to,O
proposed,O
England,O
-,O
wide,O
deployment,O
",",O
although,O
it,O
could,O
also,O
be,O
applied,O
to,O
COVID-19,O
samples,O
.,O
The,O
number,O
of,O
new,O
cases,O
of,O
COVID-19,O
inpatients,O
recorded,O
in,O
SGSS,S-Dataset
 ,O
has,O
increased,O
rapidly,O
since,O
early,O
2020,O
",",O
with,O
close,O
correspondence,O
between,O
the,O
growth,O
in,O
cases,O
among,O
UKB,S-Repository
 ,O
participants,O
and,O
England,O
as,O
a,O
whole,O
(,O
Fig,O
.,O
4,O
),O
.,O
Thus,O
",",O
UKB,S-Repository
 ,O
participants,O
made,O
up,O
0.9,O
 ,O
%,O
of,O
all,O
COVID-19,O
inpatients,O
in,O
SGSS,S-Dataset
.,O
We,O
estimated,O
per,O
capita,O
incidence,O
of,O
our,O
operational,O
definition,O
of,O
severe,O
COVID-19,O
for,O
the,O
period,O
16,O
March,O
–,O
14,O
May,O
2020,O
using,O
SGSS,S-Dataset
 ,O
data,O
",",O
not,O
restricted,O
to,O
UKB,S-Repository
 ,O
participants,O
(,O
Fig,O
.,O
5a,O
),O
.,O
In,O
keeping,O
with,O
other,O
reports,O
(,O
see,O
Introduction,O
),O
",",O
males,O
over,O
50,O
were,O
generally,O
at,O
elevated,O
risk,O
of,O
developing,O
severe,O
COVID-19,O
across,O
England,O
(,O
odds,O
ratio,O
1.41,O
",",O
95,O
 ,O
%,O
 ,O
CI,O
1.39–1.43,O
;,O
Cochran,O
–,O
Mantel,O
–,O
Haenszel,O
test,O
stratified,O
by,O
age,O
group,O
),O
",",O
relative,O
to,O
females,O
over,O
50,O
.,O
Taking,O
these,O
differences,O
into,O
account,O
using,O
the,O
age,O
and,O
sex,O
distribution,O
of,O
the,O
English,O
UKB,S-Repository
 ,O
cohort,O
in,O
early,O
2020,O
and,O
the,O
Office,O
for,O
National,O
Statistics,O
estimates,O
of,O
the,O
English,O
population,O
from,O
mid-2018,O
(,O
https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland,O
),O
",",O
we,O
compared,O
disease,O
incidence,O
in,O
UKB,S-Repository
 ,O
versus,O
the,O
general,O
population,O
.,O
Even,O
taking,O
into,O
account,O
this,O
difference,O
",",O
the,O
relative,O
incidence,O
of,O
severe,O
COVID-19,O
by,O
age,O
and,O
sex,O
was,O
not,O
identical,O
between,O
non-,O
UKB,S-Repository
 ,O
inpatients,O
and,O
UKB,S-Repository
 ,O
inpatients,O
(,O
P=0.005,O
females,O
",",O
P=0.0005,O
males,O
",",O
chi,O
-,O
square,O
goodness,O
-,O
of,O
-,O
fit,O
tests,O
;,O
Fig,O
.,O
5b,O
",",O
c,O
),O
.,O
In,O
conclusion,O
",",O
incidence,O
of,O
severe,O
COVID-19,O
by,O
age,O
and,O
sex,O
is,O
similar,O
but,O
not,O
identical,O
between,O
the,O
English,O
UKB,S-Repository
 ,O
cohort,O
and,O
the,O
rest,O
of,O
the,O
population,O
",",O
with,O
27.4,O
 ,O
%,O
fewer,O
positive,O
inpatients,O
than,O
expected,O
.,O
We,O
investigated,O
the,O
robustness,O
of,O
our,O
method,O
of,O
identifying,O
hospital,O
inpatients,O
",",O
on,O
which,O
we,O
base,O
the,O
definition,O
of,O
severe,O
COVID-19,O
.,O
Fig,O
.,O
6,O
indicates,O
that,O
the,O
alternative,O
definition,O
(,O
grey,O
bars,O
),O
may,O
be,O
more,O
specific,O
",",O
because,O
the,O
odds,O
ratios,O
of,O
severe,O
COVID-19,O
were,O
larger,O
(,O
further,O
from,O
1,O
),O
than,O
under,O
the,O
proposed,O
definition,O
.,O
We,O
conclude,O
that,O
greater,O
sensitivity,O
of,O
the,O
proposed,O
definition,O
(,O
green,O
bars,O
),O
trades,O
off,O
some,O
specificity,O
compared,O
to,O
a,O
more,O
stringent,O
alternative,O
and,O
",",O
therefore,O
",",O
modestly,O
dilutes,O
the,O
magnitude,O
of,O
age-,O
and,O
sex,O
-,O
specific,O
differences,O
in,O
severe,O
COVID-19,O
incidence,O
.,O
Our,O
calculations,O
do,O
not,O
take,O
into,O
consideration,O
boosts,O
in,O
power,O
that,O
can,O
be,O
achieved,O
by,O
various,O
means,O
",",O
including,O
pooling,O
the,O
effects,O
of,O
multiple,O
variants,O
within,O
or,O
between,O
genes,O
using,O
analyses,O
of,O
various,O
kinds,O
[,O
17,O
],O
or,O
meta,O
-,O
analysis,O
of,O
the,O
sort,O
planned,O
by,O
the,O
COVID-19,B-Repository
Host,I-Repository
Genetics,I-Repository
Initiative,E-Repository
 ,O
(,O
www.covid19hg.org,S-URL
),O
",",O
which,O
aims,O
to,O
combine,O
signals,O
across,O
multiple,O
cohorts,O
.,O
Public,O
Health,O
England,O
’s,O
Second,B-Dataset
Generation,I-Dataset
Surveillance,I-Dataset
System,E-Dataset
 ,O
is,O
a,O
centralized,O
microbiology,O
database,O
covering,O
English,O
clinical,O
diagnostics,O
laboratories,O
that,O
provides,O
national,O
surveillance,O
of,O
legally,O
notifiable,O
infections,O
",",O
bacterial,O
isolations,O
and,O
antimicrobial,O
resistance,O
.,O
In,O
this,O
study,O
",",O
we,O
implemented,O
rapid,O
dynamic,O
linkage,O
",",O
which,O
allows,O
us,O
to,O
provide,O
a,O
regular,O
feed,O
of,O
new,O
COVID-19,O
(,O
SARS,O
-,O
CoV-2,O
),O
test,O
results,O
to,O
UKB,S-Repository
 ,O
to,O
facilitate,O
rapid,O
and,O
urgent,O
research,O
into,O
the,O
epidemiological,O
and,O
human,O
genetic,O
risk,O
factors,O
for,O
severe,O
infection,O
in,O
the,O
cohort,O
.,O
Here,O
",",O
we,O
have,O
characterized,O
the,O
first,O
1352,O
cases,O
of,O
COVID-19,O
in,O
UKB,S-Repository
 ,O
participants,O
",",O
of,O
whom,O
895,O
met,O
our,O
working,O
definition,O
of,O
severe,O
COVID-19,O
as,O
inpatients,O
hospitalized,O
on,O
or,O
after,O
16,O
March,O
2020,O
.,O
We,O
found,O
that,O
the,O
incidence,O
of,O
severe,O
COVID-19,O
among,O
UKB,S-Repository
 ,O
cases,O
was,O
27.4,O
 ,O
%,O
lower,O
than,O
the,O
general,O
population,O
in,O
England,O
",",O
although,O
this,O
difference,O
varied,O
significantly,O
by,O
age,O
and,O
sex,O
.,O
The,O
remaining,O
data,O
were,O
then,O
aligned,O
to,O
the,O
local,O
nucleotide,O
database,O
(,O
using,O
Burrows,O
-,O
Wheeler,O
Alignment,O
),O
and,O
non,O
-,O
redundant,O
protein,O
database,O
(,O
using,O
RapSearch,O
),O
",",O
downloaded,O
from,O
the,O
US,B-Repository
National,I-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,E-Repository
 ,O
website,O
",",O
which,O
contain,O
only,O
coronaviruses,O
that,O
have,O
been,O
published,O
.,O
Mapped,O
assemblies,O
were,O
also,O
done,O
using,O
the,O
bat,O
-,O
derived,O
SARS,O
-,O
like,O
coronavirus,O
isolate,O
bat,O
-,O
SL,O
-,O
CoVZC45,O
(,O
accession,O
number,O
MG772933.1,S-AccessionNumber
),O
as,O
a,O
reference,O
.,O
After,O
removing,O
host,O
(,O
human,O
),O
reads,O
",",O
de,O
novo,O
assembly,O
was,O
done,O
and,O
the,O
contigs,O
obtained,O
used,O
as,O
queries,O
to,O
search,O
the,O
non,O
-,O
redundant,O
protein,O
database,O
.,O
A,O
Blastn,O
search,O
of,O
the,O
complete,O
genomes,O
of,O
2019,O
-,O
nCoV,O
revealed,O
that,O
the,O
most,O
closely,O
related,O
viruses,O
available,O
on,O
GenBank,S-Repository
 ,O
were,O
bat,O
-,O
SL,O
-,O
CoVZC45,O
(,O
sequence,O
identity,O
87·99,O
%,O
;,O
query,O
coverage,O
99,O
%,O
),O
and,O
another,O
SARS,O
-,O
like,O
betacoronavirus,O
of,O
bat,O
origin,O
",",O
bat,O
-,O
SL,O
-,O
CoVZXC21,O
(,O
accession,O
number,O
MG772934,S-AccessionNumber
;,O
87·23,O
%,O
;,O
query,O
coverage,O
98,O
%,O
),O
.,O
The,O
subgenus,O
Sarbecovirus,O
could,O
be,O
classified,O
into,O
three,O
well,O
supported,O
clades,O
:,O
two,O
SARS,O
-,O
CoV,O
-,O
related,O
strains,O
from,O
Rhinolophus,O
sp,O
from,O
Bulgaria,O
(,O
accession,O
number,O
GU190215,S-AccessionNumber
),O
and,O
Kenya,O
(,O
KY352407,S-AccessionNumber
),O
formed,O
clade,O
1,O
;,O
the,O
ten,O
2019,O
-,O
nCoV,O
from,O
Wuhan,O
and,O
the,O
two,O
bat,O
-,O
derived,O
SARS,O
-,O
like,O
strains,O
from,O
Zhoushan,O
in,O
eastern,O
China,O
(,O
bat,O
-,O
SL,O
-,O
CoVZC45,O
and,O
bat,O
-,O
SL,O
-,O
CoVZXC21,O
),O
formed,O
clade,O
2,O
",",O
which,O
was,O
notable,O
for,O
the,O
long,O
branch,O
separating,O
the,O
human,O
and,O
bat,O
viruses,O
;,O
and,O
SARS,O
-,O
CoV,O
strains,O
from,O
humans,O
and,O
many,O
genetically,O
similar,O
SARS,O
-,O
like,O
coronaviruses,O
from,O
bats,O
collected,O
from,O
southwestern,O
China,O
formed,O
clade,O
3,O
",",O
with,O
bat,O
-,O
derived,O
coronaviruses,O
also,O
falling,O
in,O
the,O
basal,O
positions,O
(,O
figure,O
3,O
),O
.,O
The,O
three,O
-,O
dimensional,O
structure,O
of,O
2019,O
-,O
nCoV,O
receptor,O
-,O
binding,O
domain,O
was,O
modelled,O
using,O
the,O
Swiss,O
-,O
Model,O
program,O
with,O
the,O
SARS,O
-,O
CoV,O
receptor,O
-,O
binding,O
domain,O
structure,O
(,O
Protein,B-Repository
Data,I-Repository
Bank,E-Repository
 ,O
ID,O
2DD8,S-AccessionNumber
),O
as,O
a,O
template,O
.,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus-2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
causative,O
agent,O
of,O
Coronavirus,O
Disease,O
19,O
(,O
COVID-19,O
),O
",",O
has,O
spread,O
throughout,O
the,O
world,O
since,O
its,O
first,O
emergence,O
in,O
Dec.,O
2019,O
in,O
Wuhan,O
",",O
China,O
.,O
However,O
",",O
a,O
report,O
from,O
COVID-19,B-Repository
Genomics,I-Repository
UK,I-Repository
Consortium,E-Repository
(,O
Report,O
#,O
9,O
-,O
25th,O
June,O
2020,O
),O
showed,O
G614,O
virus,O
has,O
grown,O
1.22,O
times,O
faster,O
than,O
the,O
D614,O
",",O
but,O
the,O
statistical,O
significance,O
was,O
low,O
",",O
indicating,O
the,O
role,O
of,O
other,O
factors,O
such,O
as,O
mutations,O
in,O
other,O
genes,O
.,O
By,O
the,O
end,O
of,O
June,O
2020,O
",",O
91.5,O
%,O
of,O
patients,O
from,O
the,O
U.S.,O
had,O
the,O
D614,O
G,O
mutation,O
(,O
compared,O
to,O
Wuhan,O
-,O
Hu-1,O
isolate,O
",",O
GenBank,S-Repository
 ,O
ID,O
NC_045512.2,S-AccessionNumber
),O
.,O
Editor,O
—,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
associated,O
with,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
has,O
spread,O
rapidly,O
since,O
the,O
early,O
cases,O
identified,O
in,O
Wuhan,O
",",O
China,O
.,O
There,O
were,O
more,O
than,O
16,O
341,O
920,O
laboratory,O
-,O
confirmed,O
COVID-19,O
cases,O
worldwide,O
and,O
87,O
245,O
cases,O
in,O
China,O
as,O
of,O
July,O
28,O
",",O
2020,O
.,O
",",O
 ,O
Among,O
the,O
latter,O
",",O
19,O
%,O
were,O
severe,O
or,O
critically,O
ill,O
patients,O
who,O
required,O
some,O
form,O
of,O
respiratory,O
support,O
as,O
a,O
result,O
of,O
hypoxaemia,O
or,O
respiratory,O
failure,O
.,O
Considering,O
the,O
potential,O
of,O
the,O
COVID-19,O
pandemic,O
to,O
overwhelm,O
healthcare,O
systems,O
",",O
even,O
in,O
developed,O
countries,O
",",O
there,O
is,O
a,O
need,O
to,O
identify,O
subgroups,O
requiring,O
different,O
respiratory,O
support,O
techniques,O
",",O
and,O
those,O
requiring,O
prolonged,O
hospital,O
admission,O
",",O
to,O
inform,O
service,O
provision,O
",",O
allocate,O
scarce,O
medical,O
resources,O
appropriately,O
",",O
and,O
maximise,O
treatment,O
benefits,O
.,O
Previous,O
studies,O
have,O
reported,O
that,O
older,O
age,O
and,O
male,O
sex,O
were,O
risk,O
factors,O
for,O
poor,O
prognosis,O
in,O
COVID-19,O
patients,O
",",O
with,O
limited,O
information,O
about,O
the,O
need,O
for,O
respiratory,O
support,O
.,O
",",O
 ,O
A,O
recent,O
study,O
found,O
high,O
levels,O
of,O
respiratory,O
complications,O
in,O
COVID-19,O
patients,O
requiring,O
surgery,O
",",O
with,O
an,O
associated,O
high,O
mortality,O
.,O
We,O
retrospectively,O
reviewed,O
demographic,O
and,O
clinical,O
data,O
available,O
from,O
electronic,O
medical,O
records,O
at,O
a,O
branch,O
of,O
Tongji,B-Creator
Hospital,E-Creator
 ,O
(,O
Wuhan,O
",",O
China,O
),O
",",O
a,O
1050,O
bed,O
hospital,O
designated,O
for,O
severe,O
and,O
critically,O
ill,O
COVID-19,O
patients,O
.,O
Diagnosis,O
and,O
treatment,O
of,O
COVID-19,O
were,O
performed,O
according,O
to,O
the,O
protocol,O
released,O
by,O
China,O
's,O
National,O
Health,O
Commission,O
.,O
Since,O
the,O
outbreak,O
of,O
COVID-19,O
",",O
the,O
Chinese,O
National,O
Health,O
Commission,O
has,O
published,O
and,O
updated,O
‘,O
Chinese,O
Clinical,O
Guidance,O
for,O
COVID-19,O
Pneumonia,O
Diagnosis,O
and,O
Treatment,O
’,O
.,O
A,O
total,O
of,O
1792,O
patients,O
hospitalised,O
with,O
COVID-19,O
between,O
January,O
27,O
",",O
2020,O
and,O
April,O
20,O
",",O
2020,O
were,O
consecutively,O
included,O
.,O
A,O
strength,O
of,O
the,O
current,O
study,O
is,O
the,O
size,O
of,O
the,O
cohort,O
of,O
COVID-19,O
patients,O
requiring,O
respiratory,O
support,O
.,O
Our,O
findings,O
could,O
be,O
a,O
useful,O
supplement,O
to,O
previous,O
studies,O
of,O
morbidity,O
and,O
mortality,O
from,O
COVID-19,O
",",O
",",O
",",O
 ,O
to,O
help,O
inform,O
allocation,O
of,O
scarce,O
healthcare,O
resources,O
(,O
especially,O
respiratory,O
support,O
),O
and,O
mitigation,O
of,O
adverse,O
effects,O
of,O
the,O
COVID-19,O
pandemic,O
in,O
other,O
countries,O
.,O
A,O
third,O
of,O
patients,O
with,O
COVID-19,O
had,O
abnormal,O
pulmonary,O
function,O
at,O
the,O
time,O
of,O
hospital,O
discharge,O
with,O
a,O
higher,O
percentage,O
in,O
older,O
patients,O
.,O
Our,O
results,O
are,O
consistent,O
with,O
the,O
findings,O
of,O
a,O
previous,O
study,O
in,O
which,O
84.2,O
%,O
of,O
severe,O
cases,O
with,O
COVID-19,O
were,O
discharged,O
with,O
impairment,O
of,O
diffusion,O
capacity,O
.,O
Future,O
studies,O
to,O
address,O
persistent,O
impairment,O
of,O
pulmonary,O
function,O
after,O
COVID-19,O
and,O
the,O
impact,O
of,O
age,O
are,O
warranted,O
.,O
It,O
is,O
clear,O
that,O
health,O
and,O
social,O
care,O
provision,O
",",O
for,O
both,O
acute,O
care,O
and,O
post,O
-,O
COVID-19,O
management,O
",",O
may,O
need,O
to,O
be,O
realigned,O
.,O
Understanding,O
the,O
factors,O
that,O
impact,O
on,O
research,O
in,O
global,O
challenges,O
such,O
as,O
COVID-19,O
is,O
important,O
when,O
good,O
quality,O
clinical,O
guidance,O
is,O
urgently,O
needed,O
.,O
Since,O
then,O
",",O
the,O
coronavirus,O
disease,O
19,O
(,O
COVID-19,O
),O
has,O
rapidly,O
spread,O
across,O
all,O
continents,O
",",O
becoming,O
a,O
public,O
health,O
emergency,O
(,O
pandemic,O
),O
as,O
announced,O
by,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
in,O
early,O
2020,O
[,O
21,O
],O
.,O
The,O
main,O
COVID-19,O
symptoms,O
are,O
fever,O
and,O
cough,O
",",O
but,O
other,O
conditions,O
such,O
as,O
anosmia,O
",",O
cardiovascular,O
and,O
GI,O
disorders,O
have,O
been,O
increasingly,O
reported,O
",",O
thus,O
suggesting,O
the,O
presence,O
of,O
multiple,O
targets,O
of,O
infection,O
outside,O
the,O
respiratory,O
tract,O
[,O
"9,11,23",O
],O
.,O
Moreover,O
",",O
COVID-19,O
has,O
been,O
reported,O
to,O
be,O
particularly,O
more,O
severe,O
in,O
patients,O
with,O
comorbidities,O
unrelated,O
to,O
the,O
respiratory,O
tract,O
",",O
such,O
as,O
hypertension,O
",",O
diabetes,O
and,O
cardiovascular,O
disease,O
[,O
24–27,O
],O
.,O
(,O
2,O
),O
The,O
digestive,O
system,O
",",O
heart,O
",",O
kidneys,O
",",O
respiratory,O
system,O
and,O
peripheral,O
neurons,O
are,O
tissues,O
/,O
cells,O
where,O
SARS,O
-,O
CoV-2,O
might,O
infect,O
",",O
generating,O
different,O
symptoms,O
observable,O
in,O
COVID-19,O
patients,O
[,O
"31,32,90,142,196,250–252",O
],O
.,O
Taking,O
into,O
consideration,O
the,O
high,O
similarity,O
between,O
SARS,O
-,O
CoV,O
and,O
SARS,O
-,O
CoV-2,O
",",O
in,O
regard,O
to,O
sequence,O
conservation,O
and,O
structure,O
of,O
glycoproteins,O
(,O
Walls,O
et,O
al,O
.,O
2020,O
;,O
Hoffmann,O
et,O
al,O
.,O
2020,O
",",O
),O
and,O
that,O
SARS,O
-,O
CoV,O
leads,O
to,O
the,O
down,O
-,O
regulation,O
of,O
ACE2,O
[,O
33,O
],O
",",O
a,O
recent,O
study,O
has,O
suggested,O
that,O
this,O
particular,O
interaction,O
may,O
also,O
occur,O
in,O
COVID-19,O
[,O
34,O
],O
",",O
thus,O
promoting,O
membrane,O
fusion,O
and,O
SARS,O
-,O
CoV-2,O
entry,O
into,O
host,O
cells,O
.,O
Furthermore,O
",",O
the,O
identification,O
of,O
the,O
transmembrane,O
glycoprotein,O
CD147,O
[,O
41,O
],O
as,O
well,O
as,O
the,O
presence,O
of,O
furin,O
-,O
like,O
cleavage,O
sites,O
in,O
the,O
spike,O
(,O
S,O
),O
protein,O
(,O
absent,O
for,O
other,O
SARS,O
-,O
CoVs,O
),O
[,O
42,O
],O
might,O
be,O
associated,O
to,O
viral,O
–,O
host,O
mechanisms,O
of,O
invasion,O
and,O
pathogenicity,O
of,O
COVID-19,O
.,O
As,O
they,O
lose,O
ACE2,O
-,O
mediated,O
protection,O
",",O
Ang,O
-,O
II,O
signaling,O
contributes,O
to,O
the,O
pathological,O
findings,O
observed,O
in,O
COVID-19,O
patients,O
",",O
such,O
as,O
disseminated,O
coagulopathy,O
and,O
acute,O
tissue,O
damage,O
[,O
91,O
],O
.,O
A,O
number,O
of,O
cytokines,O
",",O
including,O
IL-6,O
",",O
IL-1β,O
",",O
tumor,O
necrosis,O
factor,O
α,O
(,O
TNF,O
-,O
α,O
),O
and,O
IFN,O
-,O
γ,O
",",O
have,O
been,O
frequently,O
reported,O
to,O
be,O
elevated,O
in,O
COVID-19,O
[,O
"9,51",O
],O
.,O
CRS,O
is,O
believed,O
to,O
be,O
a,O
major,O
cause,O
of,O
tissue,O
damage,O
in,O
the,O
pathophysiology,O
of,O
COVID-19,O
[,O
52,O
],O
.,O
IL-6,O
",",O
the,O
most,O
important,O
CRS,O
causative,O
cytokine,O
[,O
55,O
],O
",",O
was,O
found,O
to,O
be,O
increased,O
in,O
the,O
serum,O
of,O
COVID-19,O
patients,O
presenting,O
acute,O
respiratory,O
distress,O
syndrome,O
(,O
ARDS,O
),O
[,O
56,O
],O
.,O
Certain,O
cytokines,O
whose,O
levels,O
are,O
elevated,O
in,O
COVID-19,O
patients,O
(,O
i.e.,O
IL-6,O
",",O
IL-1β,O
and,O
IFN,O
-,O
γ,O
),O
",",O
are,O
important,O
activators,O
of,O
the,O
Janus,O
kinase,O
(,O
JAK)/signal,O
transducer,O
of,O
activators,O
of,O
transcription,O
(,O
STAT,O
),O
JAK,O
/,O
STAT,O
pathway,O
and,O
also,O
able,O
to,O
induce,O
NF,O
-,O
kB,O
signaling,O
[,O
57,O
],O
.,O
IL-6,O
",",O
an,O
important,O
player,O
in,O
COVID-19,O
",",O
binds,O
IL-6R,O
and,O
gp130,O
receptors,O
to,O
activate,O
JAK,O
/,O
STAT-3,O
pathway,O
and,O
then,O
contribute,O
to,O
the,O
CRS,O
observed,O
in,O
COVID-19,O
patients,O
[,O
88,O
],O
.,O
Among,O
them,O
",",O
the,O
p38s,O
have,O
already,O
been,O
described,O
to,O
be,O
involved,O
in,O
SARS,O
-,O
CoV,O
infection,O
and,O
",",O
therefore,O
",",O
suggested,O
as,O
putative,O
targets,O
for,O
COVID-19,O
treatment,O
[,O
"68,69",O
],O
.,O
Taken,O
together,O
",",O
we,O
strongly,O
believe,O
that,O
understanding,O
the,O
multitude,O
of,O
signaling,O
routes,O
affected,O
by,O
viral,O
infections,O
",",O
in,O
a,O
cell,O
/,O
tissue,O
-,O
specific,O
manner,O
",",O
can,O
be,O
crucial,O
for,O
the,O
comprehension,O
of,O
the,O
pathobiology,O
as,O
well,O
as,O
the,O
therapeutics,O
for,O
COVID-19,O
.,O
Accordingly,O
",",O
symptoms,O
related,O
to,O
all,O
these,O
systems,O
have,O
been,O
reported,O
in,O
COVID-19,O
patients,O
[,O
9,O
],O
.,O
The,O
main,O
clinical,O
complication,O
due,O
to,O
COVID-19,O
",",O
which,O
also,O
leads,O
to,O
a,O
high,O
fatality,O
rate,O
and,O
affects,O
∼42,O
%,O
of,O
the,O
patients,O
",",O
refers,O
to,O
the,O
ARDS,O
[,O
11,O
],O
.,O
COVID-19,O
patients,O
affected,O
by,O
ARDS,O
develop,O
a,O
severe,O
form,O
of,O
this,O
condition,O
(,O
i.e.,O
PaO2,O
/,O
FiO2,O
ratio,O
<,O
100,O
mmHg,O
),O
in,O
18.9,O
%,O
of,O
the,O
cases,O
[,O
90,O
],O
.,O
In,O
COVID-19,O
-,O
associated,O
ARDS,O
",",O
the,O
cytokine,O
storm,O
consisting,O
of,O
high,O
serum,O
levels,O
of,O
IL-1β,O
",",O
TNF,O
and,O
IL-6,O
is,O
possibly,O
responsible,O
by,O
severe,O
plasma,O
leakage,O
",",O
vascular,O
permeability,O
and,O
disseminated,O
coagulation,O
and,O
thrombosis,O
[,O
"9,57",O
],O
.,O
Even,O
though,O
TLRs,O
are,O
crucial,O
for,O
correct,O
viral,O
defense,O
",",O
the,O
constitutive,O
TLR,O
signaling,O
",",O
particularly,O
due,O
to,O
TLR4,O
[,O
108,O
],O
",",O
might,O
contribute,O
to,O
an,O
excessive,O
inflammation,O
in,O
COVID-19,O
-,O
associated,O
ARDS,O
(,O
Figure,O
4,O
),O
.,O
TLR4,O
polymorphism,O
and,O
dysregulation,O
of,O
associated,O
pathway,O
",",O
could,O
be,O
potentially,O
correlated,O
with,O
COVID-19,O
-,O
mediated,O
suppression,O
of,O
IFN,O
antiviral,O
response,O
in,O
severe,O
patients,O
[,O
110,O
],O
and,O
then,O
contribute,O
to,O
excessive,O
lung,O
inflammation,O
at,O
later,O
stages,O
.,O
TLR4,O
polymorphism,O
might,O
explain,O
the,O
differential,O
susceptibility,O
to,O
ARDS,O
in,O
COVID-19,O
patients,O
[,O
106,O
],O
.,O
Cytokines,O
that,O
are,O
commonly,O
elevated,O
in,O
COVID-19,O
(,O
such,O
as,O
TNF,O
and,O
IL-1β,O
),O
can,O
activate,O
NF,O
-,O
κB,O
-,O
mediated,O
gene,O
expression,O
in,O
immune,O
",",O
bronchial,O
epithelial,O
and,O
other,O
lung,O
cells,O
[,O
114,O
],O
.,O
The,O
use,O
of,O
non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
drugs,O
or,O
synthetic,O
corticoids,O
in,O
COVID-19,O
treatment,O
is,O
still,O
under,O
debate,O
",",O
since,O
NF,O
-,O
kB,O
inhibition,O
must,O
be,O
taken,O
with,O
caution,O
",",O
due,O
to,O
its,O
vital,O
role,O
to,O
elicit,O
antiviral,O
related,O
gene,O
expression,O
[,O
115,O
],O
.,O
Upon,O
further,O
data,O
validation,O
",",O
IL-6,O
and,O
STAT3,O
could,O
serve,O
as,O
promising,O
therapeutic,O
options,O
for,O
preventing,O
the,O
progressive,O
severity,O
of,O
COVID-19,O
-,O
associated,O
ARDS,O
.,O
Altogether,O
",",O
a,O
controlled,O
approach,O
to,O
modulate,O
NLPR3,O
levels,O
and,O
activity,O
could,O
be,O
used,O
as,O
a,O
potential,O
target,O
against,O
ARDS,O
in,O
COVID-19,O
patients,O
.,O
Nevertheless,O
",",O
GI,O
manifestations,O
seem,O
to,O
be,O
less,O
prevalent,O
in,O
COVID-19,O
than,O
SARS,O
and,O
MERS,O
[,O
140,O
],O
.,O
Moreover,O
",",O
it,O
has,O
been,O
assumed,O
that,O
the,O
consumption,O
of,O
animal,O
food,O
from,O
a,O
public,O
market,O
at,O
Wuhan,O
",",O
was,O
responsible,O
by,O
the,O
appearance,O
of,O
the,O
first,O
case,O
of,O
COVID-19,O
in,O
China,O
[,O
24,O
],O
.,O
This,O
relationship,O
",",O
recognized,O
as,O
the,O
gut,O
–,O
lung,O
axis,O
",",O
may,O
help,O
explain,O
the,O
progression,O
and,O
outcome,O
of,O
the,O
digestive,O
and,O
respiratory,O
symptoms,O
in,O
some,O
COVID-19,O
patients,O
[,O
"153,154",O
],O
.,O
The,O
reduced,O
expression,O
of,O
ACE2,O
and,O
B0AT1,O
in,O
the,O
intestine,O
due,O
to,O
virus,O
invasion,O
",",O
leading,O
to,O
low,O
tryptophan,O
availability,O
",",O
represents,O
a,O
possible,O
mechanism,O
of,O
how,O
SARS,O
-,O
CoV-2,O
could,O
lead,O
to,O
digestive,O
symptoms,O
in,O
COVID-19,O
patients,O
[,O
151,O
],O
.,O
Nevertheless,O
",",O
the,O
mechanisms,O
involved,O
in,O
most,O
of,O
these,O
SARS,O
-,O
CoV2,O
-,O
mediated,O
events,O
are,O
still,O
speculative,O
",",O
so,O
more,O
detailed,O
research,O
is,O
required,O
to,O
help,O
better,O
understanding,O
the,O
temporal,O
and,O
prognostic,O
profiles,O
of,O
COVID-19,O
.,O
Patients,O
tested,O
positive,O
for,O
COVID-19,O
present,O
clinical,O
respiratory,O
symptoms,O
related,O
to,O
viral,O
infection,O
",",O
which,O
include,O
fever,O
",",O
cough,O
and,O
myalgia,O
[,O
9,O
],O
.,O
Symptoms,O
affecting,O
both,O
peripheral,O
(,O
PNS,O
),O
and,O
CNS,O
",",O
nervous,O
systems,O
have,O
been,O
reported,O
in,O
∼36,O
%,O
of,O
COVID-19,O
patients,O
",",O
such,O
as,O
headache,O
",",O
acute,O
cerebral,O
diseases,O
",",O
impaired,O
consciousness,O
",",O
seizure,O
",",O
smell,O
/,O
taste,O
impairment,O
",",O
muscle,O
injury,O
and,O
neuralgia,O
[,O
"27,163,164",O
],O
.,O
Some,O
authors,O
have,O
suggested,O
that,O
the,O
lack,O
of,O
SARS,O
-,O
CoV-2,O
in,O
the,O
CSF,O
of,O
COVID-19,O
patients,O
could,O
be,O
mainly,O
related,O
to,O
(,O
i,O
),O
the,O
low,O
sensitivity,O
of,O
the,O
techniques,O
available,O
",",O
(,O
ii,O
),O
the,O
reduced,O
viral,O
levels,O
or,O
(,O
iii,O
),O
clearance,O
of,O
SARS,O
-,O
CoV-2,O
in,O
the,O
CSF,O
compartment,O
[,O
170,O
],O
.,O
Based,O
on,O
these,O
current,O
findings,O
",",O
further,O
studies,O
are,O
still,O
necessary,O
to,O
better,O
elucidate,O
this,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
in,O
the,O
CSF,O
",",O
especially,O
in,O
large,O
cohorts,O
of,O
positive,O
COVID-19,O
individuals,O
.,O
The,O
consequent,O
damage,O
on,O
the,O
olfactory,O
endothelium,O
is,O
part,O
of,O
the,O
clinical,O
symptoms,O
presented,O
by,O
COVID-19,O
patients,O
",",O
particularly,O
related,O
to,O
the,O
PNS,O
",",O
such,O
as,O
anosmia,O
or,O
hyposmia,O
[,O
"27,166",O
],O
.,O
Interestingly,O
",",O
some,O
positive,O
COVID-19,O
patients,O
have,O
been,O
reported,O
to,O
present,O
paranasal,O
sinusitis,O
with,O
the,O
presence,O
of,O
lymph,O
endothelial,O
cells,O
infected,O
by,O
SARS,O
-,O
CoV-2,O
[,O
"181,182",O
],O
.,O
Among,O
the,O
theories,O
suggested,O
for,O
viral,O
neuroinvasion,O
(,O
neuronal,O
retrograde,O
/,O
hematogenous,O
/,O
glymplatic,O
routes,O
),O
",",O
the,O
one,O
regarding,O
synapse,O
-,O
connected,O
route,O
is,O
also,O
related,O
to,O
the,O
trans,O
-,O
synaptic,O
exchange,O
of,O
coronavirus,O
particles,O
from,O
peripheral,O
nerves,O
(,O
innervating,O
infected,O
target,O
-,O
tissues,O
),O
",",O
by,O
which,O
the,O
interneuronal,O
transfer,O
of,O
SARS,O
-,O
CoV-2,O
may,O
occur,O
",",O
that,O
in,O
turn,O
could,O
reach,O
and,O
cause,O
dysfunction,O
of,O
relevant,O
homeostatic,O
brainstem,O
centers,O
",",O
as,O
observed,O
in,O
COVID-19,O
[,O
"183,184",O
],O
.,O
Considering,O
the,O
presence,O
of,O
neurological,O
manifestations,O
(,O
as,O
described,O
in,O
previous,O
studies,O
),O
",",O
the,O
indicative,O
of,O
brain,O
injury,O
in,O
postmortem,O
analysis,O
[,O
185,O
],O
and,O
the,O
controversial,O
aspects,O
of,O
SARS,O
-,O
CoV-2,O
detection,O
in,O
CSF,O
",",O
a,O
recent,O
study,O
has,O
presented,O
neurochemical,O
evidence,O
of,O
brain,O
injury,O
in,O
severe,O
positive,O
COVID-19,O
patients,O
[,O
186,O
],O
.,O
By,O
using,O
two,O
classical,O
blood,O
-,O
based,O
biomarkers,O
for,O
CNS,O
injury,O
",",O
the,O
glial,O
fibrillary,O
acidic,O
protein,O
(,O
GFAp,O
),O
and,O
neurofilament,O
light,O
chain,O
(,O
NfL,O
),O
",",O
it,O
has,O
been,O
shown,O
that,O
moderate,O
/,O
severe,O
COVID-19,O
patients,O
present,O
significantly,O
higher,O
plasma,O
levels,O
of,O
both,O
biomarkers,O
[,O
186,O
],O
.,O
Despite,O
the,O
limitations,O
(,O
including,O
further,O
data,O
validation,O
),O
",",O
these,O
data,O
suggest,O
the,O
existence,O
of,O
astrocytic,O
activation,O
/,O
damage,O
at,O
the,O
beginning,O
of,O
the,O
disease,O
(,O
initial,O
response,O
/,O
higher,O
levels,O
of,O
GFAp,O
),O
",",O
as,O
well,O
as,O
neuronal,O
damage,O
at,O
later,O
stages,O
of,O
a,O
severe,O
condition,O
(,O
illness,O
progression,O
/,O
higher,O
levels,O
of,O
NfL,O
),O
in,O
COVID-19,O
patients,O
[,O
186,O
],O
.,O
Nevertheless,O
",",O
despite,O
the,O
current,O
advances,O
in,O
elucidating,O
the,O
mechanisms,O
of,O
SARS,O
-,O
CoV-2,O
invasion,O
",",O
the,O
clinical,O
symptoms,O
regarding,O
nervous,O
system,O
and,O
their,O
similarity,O
to,O
the,O
other,O
members,O
of,O
the,O
β,O
-,O
coronaviruses,O
",",O
little,O
is,O
known,O
about,O
the,O
nervous,O
system,O
signaling,O
pathways,O
affected,O
in,O
COVID-19,O
.,O
Since,O
RAS,O
has,O
a,O
relevant,O
role,O
in,O
the,O
regulation,O
of,O
brain,O
homeostasis,O
functions,O
",",O
such,O
as,O
modulation,O
of,O
water,O
balance,O
and,O
blood,O
pressure,O
[,O
187,O
],O
",",O
the,O
possible,O
increase,O
in,O
Ang,O
-,O
II,O
levels,O
may,O
be,O
related,O
to,O
the,O
development,O
of,O
severe,O
cases,O
presenting,O
neurological,O
manifestations,O
(,O
i.e.,O
encephalitis,O
and,O
meningitis,O
),O
",",O
as,O
well,O
as,O
in,O
cardiac,O
and,O
lung,O
injuries,O
in,O
some,O
severe,O
COVID-19,O
patients,O
[,O
"27,69,171",O
],O
.,O
In,O
addition,O
",",O
since,O
some,O
COVID-19,O
patients,O
also,O
present,O
apoptosis,O
of,O
endothelial,O
cells,O
",",O
these,O
biological,O
effects,O
might,O
be,O
related,O
to,O
the,O
elevated,O
activity,O
of,O
MAPK,O
signaling,O
[,O
"69,180",O
],O
.,O
With,O
regard,O
to,O
acute,O
cerebral,O
diseases,O
",",O
such,O
as,O
ischemic,O
stroke,O
and,O
cerebral,O
hemorrhage,O
",",O
which,O
are,O
detected,O
in,O
positive,O
COVID-19,O
patients,O
[,O
27,O
],O
",",O
ACE2,O
may,O
also,O
play,O
an,O
important,O
role,O
",",O
since,O
has,O
been,O
associated,O
with,O
damage,O
along,O
the,O
brain,O
endothelium,O
(,O
vascular,O
injury,O
),O
[,O
171,O
],O
.,O
Moreover,O
",",O
COVID-19,O
patients,O
with,O
neurological,O
manifestations,O
may,O
develop,O
immunosuppression,O
and,O
elevated,O
levels,O
of,O
D,O
-,O
dimer,O
(,O
a,O
marker,O
for,O
venous,O
thromboembolism,O
),O
which,O
are,O
associated,O
with,O
a,O
poor,O
prognosis,O
[,O
"27,188",O
],O
.,O
Interesting,O
",",O
patients,O
with,O
severe,O
COVID-19,O
may,O
also,O
present,O
a,O
prominent,O
increase,O
in,O
cytokine,O
release,O
(,O
hypercytokinemia,O
),O
[,O
"9,189",O
],O
that,O
",",O
in,O
the,O
context,O
of,O
the,O
nervous,O
system,O
",",O
can,O
potentially,O
compromise,O
its,O
homeostasis,O
[,O
61,O
],O
.,O
In,O
addition,O
to,O
the,O
neurological,O
manifestations,O
described,O
for,O
the,O
CNS,O
",",O
the,O
PNS,O
also,O
appears,O
to,O
be,O
affected,O
by,O
COVID-19,O
",",O
since,O
patients,O
have,O
presented,O
smell,O
and/or,O
taste,O
impairments,O
",",O
as,O
well,O
as,O
complications,O
due,O
to,O
the,O
large,O
amount,O
of,O
cytokines,O
released,O
systemically,O
in,O
the,O
face,O
of,O
infection,O
.,O
Koralnik,O
and,O
Tyler,O
[,O
190,O
],O
described,O
that,O
COVID-19,O
positive,O
patients,O
developed,O
Guillain,O
–,O
Barre,O
syndrome,O
(,O
GBS,O
),O
after,O
the,O
onset,O
of,O
viral,O
infection,O
",",O
as,O
an,O
immune,O
mediated,O
complication,O
of,O
SARS,O
-,O
CoV-2,O
.,O
In,O
addition,O
",",O
electrophysiological,O
studies,O
performed,O
in,O
these,O
GSB,O
/,O
COVID-19,O
patients,O
have,O
indicated,O
a,O
pattern,O
compatible,O
with,O
demyelination,O
process,O
and,O
axonal,O
neuropathy,O
",",O
even,O
without,O
any,O
positive,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
by,O
RT,O
-,O
PCR,O
in,O
the,O
CSF,O
[,O
191,O
],O
.,O
Despite,O
the,O
low,O
cohort,O
patients,O
analyzed,O
in,O
this,O
study,O
",",O
the,O
authors,O
highlight,O
the,O
necessity,O
of,O
better,O
epidemiological,O
data,O
and,O
further,O
associations,O
between,O
immune,O
diseases,O
and,O
COVID-19,O
",",O
which,O
can,O
promote,O
a,O
better,O
understanding,O
regarding,O
possible,O
pathogenic,O
mechanisms,O
and,O
therapies,O
[,O
190,O
],O
.,O
In,O
fact,O
",",O
patients,O
with,O
CV,O
conditions,O
have,O
presented,O
a,O
case,O
fatality,O
rate,O
of,O
10.5,O
%,O
",",O
which,O
is,O
higher,O
than,O
the,O
the,O
overall,O
COVID-19,O
cases,O
(,O
i.e.,O
fatality,O
rate,O
of,O
2.3,O
%,O
),O
[,O
195,O
],O
.,O
According,O
to,O
a,O
report,O
from,O
the,O
National,O
Health,O
Commission,O
of,O
China,O
",",O
∼12,O
%,O
of,O
patients,O
hospitalized,O
due,O
to,O
COVID-19,O
",",O
without,O
history,O
of,O
CV,O
diseases,O
",",O
have,O
presented,O
elevated,O
troponin,O
levels,O
and,O
a,O
high,O
incidence,O
of,O
cardiac,O
arrest,O
during,O
hospitalization,O
",",O
indicating,O
that,O
not,O
only,O
CV,O
diseases,O
could,O
be,O
a,O
risk,O
factor,O
for,O
COVID-19,O
but,O
the,O
presence,O
of,O
SARS,O
-,O
CoV-2,O
could,O
also,O
promote,O
myocardial,O
injury,O
[,O
196,O
],O
.,O
The,O
impact,O
of,O
the,O
CV,O
diseases,O
in,O
severe,O
COVID-19,O
patients,O
has,O
been,O
clearly,O
demonstrated,O
by,O
a,O
recent,O
study,O
that,O
compared,O
non,O
-,O
surviving,O
and,O
surviving,O
COVID-19,O
patients,O
[,O
180,O
],O
",",O
in,O
which,O
52,O
%,O
of,O
the,O
deceased,O
patients,O
presented,O
heart,O
failure,O
",",O
whereas,O
only,O
12,O
%,O
of,O
the,O
survivors,O
presented,O
the,O
same,O
symptoms,O
.,O
Another,O
study,O
has,O
shown,O
that,O
out,O
of,O
68,O
patients,O
who,O
died,O
from,O
COVID-19,O
",",O
13,O
had,O
previous,O
CV,O
diseases,O
while,O
none,O
of,O
the,O
82,O
patients,O
who,O
survived,O
presented,O
a,O
history,O
of,O
CV,O
condition,O
[,O
197,O
],O
.,O
Despite,O
the,O
evidence,O
",",O
it,O
is,O
still,O
unclear,O
why,O
cardiovascular,O
diseases,O
are,O
so,O
prevalent,O
among,O
the,O
fatalities,O
from,O
COVID-19,O
.,O
According,O
to,O
the,O
evaluation,O
of,O
150,O
COVID-19,O
cases,O
identified,O
in,O
Wuhan,O
",",O
the,O
troponin,O
levels,O
in,O
the,O
serum,O
of,O
non,O
-,O
surviving,O
patients,O
were,O
higher,O
than,O
in,O
patients,O
who,O
recovered,O
from,O
the,O
disease,O
.,O
Furthermore,O
",",O
plaque,O
rupture,O
",",O
ischemia,O
or,O
vasospasm,O
have,O
also,O
been,O
considered,O
as,O
potential,O
causes,O
of,O
CV,O
disease,O
induced,O
by,O
a,O
COVID-19,O
inflammatory,O
response,O
.,O
Despite,O
the,O
fact,O
that,O
further,O
research,O
in,O
vivo,O
still,O
needs,O
to,O
be,O
assessed,O
",",O
this,O
mechanism,O
could,O
be,O
useful,O
as,O
a,O
target,O
toward,O
the,O
treatment,O
of,O
COVID-19,O
and,O
CV,O
disease,O
patients,O
",",O
since,O
it,O
would,O
potentially,O
alleviate,O
an,O
inflammatory,O
response,O
[,O
199,O
],O
.,O
In,O
fact,O
",",O
a,O
number,O
of,O
arguments,O
have,O
been,O
raised,O
in,O
regard,O
to,O
the,O
use,O
and,O
cessation,O
of,O
these,O
drugs,O
during,O
COVID-19,O
treatment,O
in,O
these,O
patients,O
.,O
Thus,O
",",O
given,O
the,O
lack,O
of,O
evidence,O
of,O
their,O
benefit,O
(,O
or,O
harm,O
),O
for,O
therapeutic,O
use,O
in,O
COVID-19,O
",",O
physicians,O
should,O
properly,O
access,O
patients,O
’,O
concerns,O
and,O
evaluate,O
their,O
medical,O
history,O
in,O
other,O
to,O
keep,O
or,O
suspend,O
the,O
prescription,O
for,O
COVID-19,O
patients,O
with,O
CV,O
conditions,O
[,O
198,O
],O
.,O
Although,O
an,O
early,O
study,O
has,O
not,O
identified,O
any,O
cases,O
of,O
acute,O
kidney,O
injury,O
(,O
AKI,O
),O
in,O
a,O
cohort,O
of,O
116,O
COVID-19,O
patients,O
from,O
Wuhan,O
area,O
[,O
209,O
],O
",",O
clinical,O
reports,O
have,O
largely,O
supported,O
the,O
association,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
with,O
kidney,O
conditions,O
.,O
According,O
to,O
a,O
large,O
study,O
including,O
701,O
COVID-19,O
patients,O
",",O
the,O
most,O
frequent,O
finding,O
related,O
to,O
kidney,O
dysfunction,O
was,O
mild,O
to,O
moderate,O
proteinuria,O
(,O
43.9,O
%,O
),O
",",O
possibly,O
due,O
to,O
the,O
disruption,O
of,O
glomerular,O
filtration,O
",",O
while,O
26.7,O
%,O
of,O
patients,O
exhibited,O
hematuria,O
[,O
210,O
],O
.,O
Another,O
report,O
focusing,O
on,O
113,O
non,O
-,O
surviving,O
COVID-19,O
patients,O
pointed,O
out,O
that,O
AKI,O
was,O
highly,O
associated,O
with,O
increased,O
mortality,O
[,O
212,O
],O
.,O
Another,O
study,O
that,O
reviewed,O
records,O
from,O
13,O
academic,O
and,O
community,O
hospitals,O
in,O
metropolitan,O
New,O
York,O
",",O
found,O
that,O
AKI,O
was,O
reported,O
in,O
36.6,O
%,O
of,O
the,O
admitted,O
COVID-19,O
patients,O
",",O
particularly,O
in,O
patients,O
with,O
respiratory,O
failure,O
who,O
required,O
mechanical,O
ventilation,O
(,O
89,O
%,O
of,O
the,O
cases,O
),O
[,O
213,O
],O
.,O
Autopsy,O
findings,O
have,O
demonstrated,O
prominent,O
acute,O
proximal,O
tubular,O
injury,O
",",O
peritubular,O
erythrocyte,O
aggregation,O
and,O
glomerular,O
fibrin,O
thrombi,O
in,O
the,O
kidneys,O
of,O
Chinese,O
COVID-19,O
patients,O
[,O
214,O
],O
.,O
Several,O
pathophysiological,O
mechanisms,O
have,O
been,O
proposed,O
for,O
the,O
renal,O
injuries,O
observed,O
in,O
COVID-19,O
",",O
including,O
organ,O
-,O
crosstalk,O
and,O
systemic,O
-,O
wide,O
effects,O
.,O
Similarly,O
",",O
a,O
heart,O
–,O
kidney,O
cross,O
-,O
talk,O
may,O
also,O
be,O
considered,O
as,O
a,O
contributor,O
of,O
AKI,O
in,O
COVID-19,O
patients,O
",",O
since,O
cardiomyopathy,O
and,O
acute,O
viral,O
myocarditis,O
can,O
equally,O
contribute,O
to,O
renal,O
hypoperfusion,O
",",O
thus,O
leading,O
to,O
a,O
reduction,O
in,O
the,O
glomerular,O
filtration,O
rate,O
[,O
218,O
],O
.,O
It,O
is,O
worth,O
considering,O
that,O
in,O
a,O
study,O
with,O
1099,O
COVID-19,O
patients,O
",",O
septic,O
shock,O
was,O
present,O
in,O
6.4,O
%,O
of,O
severe,O
cases,O
[,O
223,O
],O
",",O
raising,O
the,O
possibility,O
that,O
",",O
for,O
a,O
subset,O
of,O
patients,O
",",O
intrarenal,O
inflammation,O
may,O
be,O
partially,O
responsible,O
for,O
the,O
association,O
of,O
AKI,O
to,O
more,O
severe,O
cases,O
of,O
COVID-19,O
[,O
224,O
],O
.,O
These,O
reports,O
support,O
a,O
direct,O
pathophysiological,O
mechanism,O
for,O
the,O
kidney,O
damage,O
due,O
to,O
COVID-19,O
",",O
following,O
SARS,O
-,O
CoV-2,O
entry,O
via,O
ACE2,O
receptor,O
[,O
9,O
],O
.,O
No,O
effective,O
treatment,O
for,O
COVID-19,O
has,O
been,O
discovered,O
so,O
far,O
.,O
(,O
1,O
),O
Commercially,O
available,O
angiotensin,O
-,O
II,O
receptor,O
antagonists,O
",",O
such,O
as,O
losartan,O
and,O
derivates,O
",",O
could,O
act,O
by,O
mitigating,O
the,O
deleterious,O
effects,O
of,O
AT1R,O
activation,O
in,O
COVID-19,O
[,O
229,O
],O
.,O
(,O
2,O
),O
Blockage,O
of,O
RAS,O
can,O
prevent,O
tissue,O
damage,O
in,O
COVID-19,O
patients,O
[,O
229,O
],O
.,O
Interleukin-6,O
(,O
IL-6,O
),O
is,O
one,O
of,O
the,O
major,O
cytokines,O
involved,O
in,O
COVID-19,O
progression,O
",",O
which,O
leads,O
to,O
CRS,O
and,O
tissue,O
damage,O
due,O
to,O
severe,O
inflammation,O
[,O
51,O
],O
.,O
Currently,O
",",O
most,O
of,O
the,O
proposed,O
drugs,O
for,O
COVID-19,O
treatment,O
are,O
(,O
i,O
),O
ACE,O
inhibitors,O
",",O
(,O
ii,O
),O
blockers,O
of,O
Angiotensin,O
II,O
production,O
",",O
and,O
(,O
iii,O
),O
blockers,O
/,O
antagonists,O
of,O
AT1R,O
(,O
Angiotensin,O
II,O
target,O
),O
such,O
as,O
Losartan,O
and,O
derivatives,O
[,O
229,O
],O
.,O
These,O
molecules,O
counteract,O
the,O
effects,O
of,O
the,O
classical,O
renin,O
-,O
angiotensin,O
system,O
",",O
thus,O
acting,O
as,O
putative,O
therapeutic,O
targets,O
to,O
regulate,O
the,O
increased,O
activation,O
of,O
RAS,O
in,O
COVID-19,O
[,O
229,O
],O
.,O
According,O
to,O
one,O
double,O
-,O
blind,O
",",O
randomized,O
",",O
placebo,O
-,O
controlled,O
trial,O
",",O
which,O
encompassed,O
a,O
total,O
of,O
1063,O
mild,O
COVID-19,O
patients,O
",",O
Remdesivir,O
provided,O
very,O
positive,O
effects,O
by,O
shortening,O
the,O
time,O
to,O
recovery,O
[,O
238,O
],O
.,O
Favipiravir,O
is,O
another,O
example,O
of,O
potential,O
drug,O
that,O
can,O
also,O
inhibit,O
viral,O
replication,O
in,O
COVID-19,O
[,O
"239,240",O
],O
.,O
The,O
humanized,O
anti,O
-,O
IL-6,O
monoclonal,O
antibody,O
Tocilizumab,O
has,O
been,O
empirically,O
used,O
in,O
patients,O
with,O
severe,O
COVID-19,O
.,O
However,O
",",O
Tocilizumab,O
has,O
also,O
been,O
shown,O
to,O
induce,O
liver,O
injury,O
in,O
",",O
at,O
least,O
",",O
one,O
COVID-19,O
patient,O
[,O
243,O
],O
.,O
JAK,O
inhibition,O
has,O
also,O
been,O
considered,O
as,O
a,O
potential,O
therapeutic,O
approach,O
for,O
COVID-19,O
",",O
since,O
a,O
variety,O
of,O
molecules,O
(,O
known,O
to,O
be,O
elevated,O
in,O
COVID-19,O
patients,O
),O
signal,O
JAK,O
/,O
STAT,O
pathways,O
.,O
Likewise,O
",",O
this,O
drug,O
is,O
under,O
clinical,O
trial,O
in,O
COVID-19,O
since,O
it,O
may,O
potentially,O
reduce,O
the,O
cytokine,O
storm,O
in,O
infected,O
tissues,O
",",O
particularly,O
the,O
lungs,O
[,O
"59,246,247",O
],O
.,O
The,O
highly,O
infective,O
coronavirus,O
disease,O
19,O
(,O
COVID-19,O
),O
is,O
caused,O
by,O
a,O
novel,O
strain,O
of,O
coronaviruses,O
–,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
–,O
discovered,O
in,O
December,O
2019,O
in,O
the,O
city,O
of,O
Wuhan,O
(,O
Hubei,O
Province,O
",",O
China,O
),O
.,O
Remarkably,O
",",O
COVID-19,O
has,O
rapidly,O
spread,O
across,O
all,O
continents,O
and,O
turned,O
into,O
a,O
public,O
health,O
emergency,O
",",O
which,O
was,O
ultimately,O
declared,O
as,O
a,O
pandemic,O
by,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
in,O
early,O
2020,O
.,O
Although,O
the,O
mechanistic,O
features,O
underlying,O
the,O
COVID-19,O
progression,O
have,O
not,O
been,O
fully,O
clarified,O
",",O
current,O
evidence,O
have,O
suggested,O
that,O
SARS,O
-,O
CoV-2,O
may,O
primarily,O
behave,O
as,O
other,O
β,O
-,O
coronavirus,O
members,O
.,O
To,O
better,O
understand,O
the,O
development,O
and,O
transmission,O
of,O
COVID-19,O
",",O
unveiling,O
the,O
signaling,O
pathways,O
that,O
may,O
be,O
impacted,O
by,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
at,O
the,O
molecular,O
and,O
cellular,O
levels,O
",",O
is,O
of,O
crucial,O
importance,O
.,O
Furthermore,O
",",O
the,O
potential,O
involvement,O
of,O
these,O
signaling,O
pathways,O
in,O
evoking,O
the,O
onset,O
and,O
progression,O
of,O
COVID-19,O
symptoms,O
in,O
these,O
organ,O
systems,O
are,O
presently,O
discussed,O
.,O
A,O
brief,O
description,O
of,O
future,O
perspectives,O
related,O
to,O
potential,O
COVID-19,O
treatments,O
is,O
also,O
highlighted,O
.,O
SARS,O
-,O
CoV-2,O
is,O
responsible,O
for,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
which,O
includes,O
asymptomatic,O
upper,O
and,O
lower,O
respiratory,O
tract,O
infections,O
.,O
Among,O
the,O
first,O
European,O
cases,O
of,O
COVID-19,O
",",O
six,O
were,O
associated,O
with,O
a,O
cluster,O
of,O
transmissions,O
in,O
the,O
French,O
Alps,O
in,O
late,O
January,O
2020,O
[,O
2,O
],O
.,O
The,O
whole,O
-,O
genome,O
sequence,O
(,O
WGS,O
),O
generated,O
from,O
sample,O
#,O
2,O
was,O
deposited,O
on,O
GISAID,B-Dataset
(Global,I-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data),E-Dataset
 ,O
(,O
EPI_ISL_410486,S-AccessionNumber
),O
.,O
The,O
genome,O
sequences,O
of,O
seven,O
SARS,O
-,O
CoV,O
and,O
475,O
MERS,O
-,O
CoV,O
were,O
also,O
downloaded,O
from,O
the,O
National,B-Repository
Center,I-Repository
for,I-Repository
Biotechnological,I-Repository
Information,I-Repository
(NCBI),E-Repository
 ,O
(,O
https://www.ncbi.nlm.nih.gov/,S-URL
),O
",",O
and,O
the,O
MERS,O
-,O
CoV,O
dataset,O
",",O
which,O
includes,O
samples,O
collected,O
from,O
both,O
humans,O
and,O
camels,O
.,O
In,O
addition,O
",",O
for,O
further,O
exploring,O
evolution,O
and,O
molecular,O
characteristics,O
of,O
SARS,O
-,O
CoV-2,O
based,O
on,O
the,O
larger,O
amount,O
of,O
genomic,O
data,O
",",O
validation,O
datasets,O
of,O
the,O
genome,O
sequences,O
were,O
redownloaded,O
from,O
GISAID,S-Dataset
 ,O
by,O
06,O
April,O
2020,O
and,O
10,O
June,O
2020,O
",",O
resulting,O
in,O
3624,O
and,O
16373,O
sequences,O
",",O
respectively,O
.,O
After,O
alignment,O
of,O
624,O
high,O
-,O
quality,O
SARS,O
-,O
CoV-2,O
genomes,O
and,O
manually,O
deleting,O
two,O
highly,O
divergent,O
genomes,O
(,O
EPI_ISL_415710,S-AccessionNumber
 ,O
and,O
EPI_ISL_414690,S-AccessionNumber
),O
according,O
to,O
the,O
first,O
constructed,O
phylogenetic,O
tree,O
",",O
the,O
aligned,O
dataset,O
of,O
622,O
sequences,O
was,O
phylogenetically,O
analyzed,O
.,O
Information,O
(,O
ID,O
",",O
countries,O
/,O
regions,O
and,O
collection,O
times,O
),O
and,O
variants,O
(,O
NC_045512.2,S-AccessionNumber
 ,O
as,O
reference,O
genome,O
),O
of,O
each,O
genome,O
from,O
each,O
Cluster,O
were,O
extracted,O
.,O
Principal,O
Component,O
Analysis,O
(,O
PCA,O
),O
was,O
analyzed,O
by,O
the,O
GCTA,O
v1.93.1beta,O
(,O
Yang,O
et,O
al,O
.,O
",",O
2011,O
),O
with,O
the,O
specific,O
sites,O
and,O
all,O
SNV,O
datasets,O
.,O
All,O
three,O
datasets,O
exhibited,O
a,O
positive,O
correlation,O
between,O
root,O
-,O
to,O
-,O
tip,O
divergence,O
and,O
sample,O
collecting,O
time,O
(,O
Figure,O
S1,O
),O
",",O
so,O
that,O
they,O
were,O
suitable,O
for,O
molecular,O
clock,O
analysis,O
in,O
BEAST,O
(,O
Bouckaert,O
et,O
al,O
.,O
",",O
2019,O
",",O
Rambaut,O
et,O
al,O
.,O
",",O
2016,O
),O
.,O
The,O
PCA,O
results,O
showed,O
that,O
these,O
nine,O
specific,O
sites,O
could,O
clearly,O
separate,O
the,O
three,O
Clusters,O
",",O
while,O
all,O
SNV,O
dataset,O
could,O
not,O
clearly,O
separate,O
Cluster,O
1,O
and,O
Cluster,O
2,O
(,O
Figure,O
S4,O
),O
",",O
which,O
further,O
suggests,O
that,O
these,O
nine,O
specific,O
sites,O
were,O
the,O
key,O
sites,O
for,O
separating,O
the,O
three,O
Clusters,O
.,O
Four,O
major,O
haplotypes,O
–,O
H1,O
",",O
H2,O
",",O
H3,O
",",O
and,O
H4,O
–,O
three,O
minor,O
haplotypes,O
–,O
H5,O
",",O
H7,O
and,O
H8,O
–,O
close,O
to,O
H1,O
and,O
one,O
minor,O
haplotype,O
–,O
H6,O
–,O
close,O
to,O
H3,O
were,O
found,O
in,O
both,O
datasets,O
.,O
Phylogenetic,O
networks,O
were,O
inferred,O
with,O
697,O
mutations,O
from,O
3624,O
genome,O
datasets,O
",",O
and,O
the,O
network,O
structures,O
of,O
TCS,O
and,O
MSN,O
were,O
similar,O
.,O
However,O
",",O
a,O
pathophysiological,O
function,O
has,O
also,O
be,O
assigned,O
to,O
ACE2,O
",",O
which,O
is,O
as,O
the,O
entry,O
receptor,O
for,O
SARS,O
-,O
Cov-1,O
and,O
the,O
novel,O
SARS,O
-,O
Cov-2,O
viruses,O
",",O
which,O
have,O
been,O
responsible,O
for,O
the,O
sever,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
epidemic,O
in,O
2003,O
and,O
the,O
current,O
coronavirus,O
infectious,O
disease,O
(,O
COVID-19,O
),O
pandemic,O
",",O
respectively,O
[,O
1,O
],O
.,O
The,O
SARS,O
-,O
Cov-2,O
infection,O
resulting,O
in,O
COVID-19,O
symptomatology,O
is,O
characterized,O
by,O
a,O
range,O
of,O
symptoms,O
",",O
including,O
dry,O
cough,O
",",O
fever,O
",",O
myalgia,O
or,O
fatigue,O
",",O
dyspnoea,O
",",O
and,O
pneumonia,O
[,O
"1,9",O
],O
.,O
In,O
addition,O
to,O
systemic,O
and,O
respiratory,O
symptoms,O
",",O
14–36,O
%,O
of,O
severe,O
patients,O
with,O
COVID-19,O
show,O
neurological,O
signs,O
",",O
including,O
dizziness,O
",",O
headache,O
",",O
taste,O
and,O
smell,O
impairment,O
",",O
impaired,O
consciousness,O
",",O
encephalitis,O
",",O
seizures,O
",",O
ataxia,O
",",O
and,O
stroke,O
[,O
"11,12",O
],O
.,O
This,O
finding,O
",",O
together,O
with,O
the,O
evidence,O
of,O
SARS,O
-,O
Cov-2,O
in,O
the,O
cerebrospinal,O
fluid,O
of,O
patients,O
with,O
COVID-19,O
",",O
suggested,O
that,O
the,O
neurotropic,O
effects,O
of,O
SARS,O
-,O
Cov-2,O
may,O
contribute,O
to,O
the,O
morbidity,O
and,O
mortality,O
caused,O
by,O
COVID-19,O
[,O
3,O
],O
.,O
Given,O
the,O
multiple,O
roles,O
of,O
ACE2,O
and,O
its,O
expression,O
pattern,O
in,O
different,O
tissues,O
",",O
the,O
alteration,O
of,O
its,O
expression,O
levels,O
may,O
have,O
an,O
impact,O
on,O
the,O
susceptibility,O
",",O
symptomatology,O
",",O
and,O
outcome,O
of,O
COVID-19,O
.,O
The,O
study,O
was,O
performed,O
by,O
utilizing,O
268,O
DNA,O
samples,O
representative,O
of,O
the,O
Italian,O
general,O
population,O
",",O
which,O
were,O
partially,O
available,O
at,O
the,O
Genomic,B-Creator
Medicine,I-Creator
Laboratory,I-Creator
of,I-Creator
Santa,I-Creator
Lucia,I-Creator
Foundation,I-Creator
Hospital,E-Creator
 ,O
and,O
partially,O
derived,O
from,O
international,O
databases,O
.,O
The,O
genetic,O
data,O
referred,O
to,O
these,O
samples,O
were,O
partially,O
derived,O
by,O
whole,O
exome,O
sequencing,O
(,O
WES,O
),O
",",O
available,O
at,O
the,O
Genomic,B-Creator
Medicine,I-Creator
Laboratory,I-Creator
of,I-Creator
IRCCS,I-Creator
Santa,I-Creator
Lucia,I-Creator
Foundation,I-Creator
Hospital,E-Creator
 ,O
and,O
partially,O
extracted,O
by,O
the,O
Ensembl,S-Repository
 ,O
database,O
[,O
"13,14,15",O
],O
.,O
We,O
therefore,O
selected,O
the,O
SNVs,O
of,O
interest,O
by,O
extracting,O
the,O
variants,O
localized,O
in,O
the,O
exonic,O
and,O
splice,O
site,O
regions,O
of,O
ACE2,O
",",O
whose,O
frequency,O
data,O
were,O
available,O
from,O
the,O
1000,B-Repository
Genomes,E-Repository
 ,O
and,O
GnomAD,S-Repository
 ,O
databases,O
[,O
"15,16,17,18",O
],O
.,O
The,O
Ensembl,S-Repository
 ,O
database,O
[,O
15,O
],O
was,O
also,O
utilized,O
to,O
download,O
the,O
allele,O
frequency,O
data,O
of,O
the,O
34,O
SNVs,O
of,O
interest,O
in,O
the,O
worldwide,O
populations,O
",",O
in,O
order,O
to,O
compare,O
the,O
frequencies,O
between,O
the,O
Italian,O
cohort,O
and,O
the,O
frequencies,O
observed,O
in,O
African,O
",",O
American,O
",",O
Asian,O
",",O
and,O
European,O
populations,O
.,O
The,O
presence,O
of,O
the,O
34,O
SNVs,O
in,O
the,O
Italian,O
samples,O
was,O
evaluated,O
by,O
analyzing,O
the,O
output,O
file,O
derived,O
by,O
the,O
WES,O
and,O
Ensembl,S-Repository
 ,O
databases,O
.,O
To,O
this,O
purpose,O
",",O
VarSite,O
[,O
23,O
],O
",",O
Human,O
Splicing,O
Finder,O
(,O
HSF,O
),O
[,O
24,O
],O
",",O
and,O
Uniprot,S-Repository
 ,O
database,O
[,O
25,O
],O
were,O
interrogated,O
.,O
Moreover,O
",",O
Uniprot,S-Repository
 ,O
annotation,O
database,O
was,O
utilized,O
to,O
retrieve,O
the,O
topological,O
and,O
functional,O
domains,O
organization,O
of,O
proteins,O
.,O
Concerning,O
eQTL,O
analysis,O
",",O
the,O
Genotype-Tissue,B-Dataset
Expression,I-Dataset
(GTex),E-Dataset
 ,O
database,O
[,O
26,O
],O
was,O
utilized,O
to,O
retrieve,O
the,O
eQTLs,O
variants,O
with,O
a,O
significant,O
effect,O
on,O
ACE2,O
expression,O
in,O
different,O
tissues,O
",",O
and,O
Biomart,O
tool,O
[,O
27,O
],O
was,O
used,O
to,O
extract,O
the,O
significant,O
eQTLs,O
distributed,O
on,O
the,O
basis,O
of,O
the,O
affected,O
tissue,O
.,O
GTex,S-Dataset
 ,O
database,O
is,O
a,O
public,O
resource,O
that,O
enables,O
us,O
to,O
study,O
tissue,O
-,O
specific,O
gene,O
expression,O
and,O
regulation,O
",",O
as,O
well,O
as,O
their,O
relationship,O
to,O
genetic,O
variation,O
[,O
26,O
],O
.,O
The,O
final,O
goal,O
of,O
the,O
study,O
has,O
been,O
the,O
research,O
of,O
variants,O
potentially,O
affecting,O
ACE2,O
expression,O
and,O
function,O
",",O
which,O
may,O
contribute,O
to,O
SARS,O
-,O
Cov-2,O
spreading,O
among,O
worldwide,O
populations,O
",",O
and,O
may,O
have,O
a,O
clinical,O
significance,O
regarding,O
the,O
clinical,O
variability,O
and,O
outcome,O
displayed,O
by,O
patients,O
with,O
COVID-19,O
.,O
Successively,O
",",O
all,O
previously,O
discussed,O
variants,O
were,O
evaluated,O
as,O
potential,O
eQTLs,O
in,O
the,O
GTEx,S-Dataset
 ,O
database,O
",",O
and,O
only,O
rs2285666,O
was,O
classified,O
as,O
a,O
significant,O
eQTL,O
in,O
several,O
brain,O
tissues,O
",",O
namely,O
the,O
amygdala,O
",",O
anterior,O
cingulate,O
cortex,O
",",O
basal,O
ganglia,O
",",O
cortex,O
",",O
cerebellum,O
",",O
hippocampus,O
",",O
and,O
hypothalamus,O
(,O
Figure,O
3,O
),O
.,O
This,O
finding,O
suggests,O
that,O
the,O
genetic,O
variability,O
of,O
ACE2,O
may,O
have,O
a,O
greater,O
impact,O
on,O
COVID-19,O
-,O
related,O
symptoms,O
and,O
SARS,O
-,O
Cov-2,O
tissue,O
tropism,O
",",O
rather,O
than,O
on,O
the,O
susceptibility,O
to,O
SARS,O
-,O
Cov-2,O
infection,O
.,O
Considering,O
the,O
broader,O
effect,O
of,O
rs2285666,O
in,O
multiple,O
brain,O
tissues,O
",",O
we,O
decided,O
to,O
look,O
at,O
the,O
distribution,O
of,O
the,O
eQTL,O
variants,O
located,O
in,O
and,O
targeting,O
ACE2,O
in,O
the,O
different,O
brain,O
tissues,O
",",O
which,O
may,O
thereby,O
affect,O
ACE2,O
expression,O
",",O
and,O
in,O
turn,O
",",O
contribute,O
to,O
the,O
neurological,O
symptoms,O
and,O
complications,O
observed,O
in,O
patients,O
with,O
COVID-19,O
.,O
These,O
findings,O
suggest,O
that,O
the,O
alteration,O
of,O
ACE2,O
expression,O
may,O
be,O
involved,O
in,O
different,O
neurological,O
symptoms,O
(,O
seizures,O
",",O
stroke,O
",",O
encephalitis,O
",",O
dizziness,O
",",O
headache,O
",",O
confusion,O
",",O
alteration,O
of,O
body,O
temperature,O
",",O
anosmia,O
",",O
and,O
ataxia,O
),O
observed,O
in,O
COVID-19,O
patients,O
",",O
in,O
relation,O
to,O
the,O
brain,O
-,O
affected,O
area,O
.,O
These,O
findings,O
raise,O
the,O
need,O
for,O
further,O
investigation,O
on,O
the,O
role,O
of,O
ACE2,O
genetic,O
variability,O
in,O
the,O
susceptibility,O
and,O
clinical,O
outcome,O
of,O
patients,O
with,O
COVID-19,O
",",O
especially,O
concerning,O
neurological,O
symptoms,O
.,O
Structural,O
and,O
sequence,O
variants,O
in,O
ACE2,O
gene,O
may,O
affect,O
its,O
expression,O
in,O
different,O
tissues,O
and,O
determine,O
a,O
differential,O
response,O
to,O
SARS,O
-,O
Cov-2,O
infection,O
and,O
the,O
COVID-19,O
-,O
related,O
phenotype,O
.,O
The,O
eQTLs,O
analysis,O
located,O
in,O
and,O
targeting,O
ACE2,O
revealed,O
a,O
high,O
distribution,O
of,O
eQTL,O
variants,O
in,O
different,O
brain,O
tissues,O
",",O
suggesting,O
a,O
possible,O
link,O
between,O
ACE2,O
genetic,O
variability,O
and,O
the,O
neurological,O
complications,O
in,O
patients,O
with,O
COVID-19,O
.,O
Further,O
research,O
is,O
needed,O
to,O
clarify,O
the,O
possible,O
relationship,O
between,O
ACE2,O
expression,O
and,O
the,O
susceptibility,O
to,O
neurological,O
complications,O
in,O
patients,O
with,O
COVID-19,O
.,O
Kaletra,O
(,O
an,O
inhibitor,O
of,O
3,O
-,O
chymotrypsin,O
-,O
like,O
protease,O
of,O
the,O
SARS,O
and,O
MERS,O
),O
",",O
and,O
Ascletis,O
(,O
HIV,O
protease,O
inhibitor,O
),O
were,O
shown,O
to,O
improve,O
clinical,O
outcomes,O
of,O
COVID-19,O
(,O
Wang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
However,O
",",O
the,O
active,O
form,O
(,O
CHEMBL2016761,S-AccessionNumber
),O
of,O
Remdesivir,O
showed,O
perfect,O
docking,O
in,O
the,O
overlapping,O
region,O
of,O
the,O
NTP,O
binding,O
motif,O
urging,O
its,O
validation,O
through,O
clinical,O
trials,O
for,O
COVID-19,O
infection,O
(,O
Chang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
line,O
with,O
this,O
",",O
several,O
studies,O
have,O
recently,O
explored,O
the,O
repurposing,O
of,O
drugs,O
to,O
find,O
an,O
immediate,O
therapeutic,O
strategy,O
for,O
the,O
deadly,O
COVID-19,O
",",O
by,O
mainly,O
targeting,O
SARS,O
-,O
CoV-2,O
main,O
protease,O
(,O
Aanouz,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Al,O
-,O
Khafaji,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Das,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Enmozhi,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Gyebi,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Islam,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Joshi,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Khan,O
",",O
Jha,O
",",O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Khan,O
",",O
Zia,O
",",O
et,O
 ,O
al,O
.,O
The,O
structure,O
of,O
SARS,O
-,O
CoV-2,O
Mpro,O
in,O
complex,O
with,O
N3,O
inhibitor,O
",",O
resolved,O
using,O
X,O
-,O
ray,O
diffraction,O
(,O
resolution,O
of,O
2.16,O
 ,O
Å,O
),O
",",O
was,O
downloaded,O
from,O
RCSB,B-Repository
Protein,I-Repository
Data,I-Repository
Bank,E-Repository
 ,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6LU7,S-AccessionNumber
),O
.,O
The,O
structure,O
of,O
Wi,O
-,O
A,O
(,O
CID,O
265237,S-AccessionNumber
),O
",",O
Wi,O
-,O
N,O
(,O
CID,O
21679027,S-AccessionNumber
),O
and,O
CAPE,O
(,O
CID,O
5281787,S-AccessionNumber
),O
were,O
downloaded,O
from,O
the,O
PubChem,S-Repository
 ,O
database,O
",",O
while,O
the,O
structure,O
of,O
the,O
N3,O
inhibitor,O
was,O
extracted,O
from,O
SARS,O
-,O
CoV-2,O
Mpro,O
-,O
inhibitor,O
complex,O
downloaded,O
from,O
PDB,S-Repository
 ,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6LU7,S-AccessionNumber
),O
.,O
Data,O
presented,O
here,O
predicted,O
that,O
these,O
natural,O
compounds,O
may,O
possess,O
the,O
potential,O
to,O
inhibit,O
the,O
functional,O
activity,O
of,O
SARS,O
-,O
CoV-2,O
protease,O
(,O
an,O
essential,O
protein,O
for,O
virus,O
survival,O
),O
",",O
and,O
hence,O
(,O
i,O
),O
may,O
connect,O
to,O
save,O
time,O
and,O
cost,O
required,O
for,O
designing,O
/,O
development,O
",",O
and,O
initial,O
screening,O
for,O
anti,O
-,O
COVID,O
drugs,O
",",O
(,O
ii,O
),O
may,O
offer,O
some,O
therapeutic,O
value,O
for,O
the,O
management,O
of,O
novel,O
fatal,O
coronavirus,O
disease,O
",",O
(,O
iii,O
),O
warrants,O
prioritized,O
further,O
validation,O
in,O
the,O
laboratory,O
and,O
clinical,O
tests,O
.,O
It,O
is,O
hard,O
to,O
infer,O
whether,O
the,O
mutations,O
in,O
E,O
protein,O
infect,O
and,O
sicken,O
people,O
deferentially,O
due,O
to,O
COVID-19,O
.,O
From,O
the,O
NCBI,B-Repository
virus,E-Repository
 ,O
database,O
",",O
all,O
the,O
protein,O
sequences,O
of,O
4917,O
complete,O
SARS,O
-,O
CoV-2,O
genomes,O
as,O
on,O
date,O
18th,O
June,O
2020,O
as,O
well,O
as,O
other,O
host,O
CoV,O
genomes,O
were,O
fetched,O
.,O
The,O
following,O
is,O
the,O
complete,O
list,O
of,O
seventy,O
-,O
four,O
distinct,O
envelope,O
(,O
E,O
),O
proteins,O
from,O
different,O
host,O
CoVs,O
and,O
their,O
respective,O
protein,O
IDs,O
(,O
Table-2,O
),O
.,O
The,O
E,O
protein,O
is,O
present,O
over,O
all,O
the,O
available,O
4917,O
SARS,O
-,O
CoV-2,O
genomes,O
as,O
on,O
18th,O
June,O
2020,O
in,O
the,O
NCBI,S-Repository
 ,O
database,O
.,O
It,O
is,O
our,O
belief,O
that,O
various,O
missense,O
mutations,O
in,O
the,O
E,O
protein,O
could,O
weaken,O
the,O
SARS,O
-,O
CoV-2,O
and,O
would,O
help,O
us,O
gets,O
rid,O
of,O
COVID-19,O
in,O
future,O
since,O
any,O
virus,O
does,O
not,O
like,O
to,O
destroy,O
its,O
host,O
for,O
its,O
survival,O
for,O
a,O
long,O
to,O
come,O
.,O
Sixteen,O
sequentially,O
different,O
E,O
-proteins,O
were,O
observed,O
from,O
a,O
total,O
of,O
4917,O
available,O
complete,O
SARS,O
-,O
CoV-2,O
genomes,O
as,O
on,O
18th,O
June,O
2020,O
in,O
the,O
NCBI,S-Repository
 ,O
database,O
.,O
At,O
a,O
global,O
level,O
—,O
as,O
excellently,O
elaborated,O
by,O
Prasad,O
et,O
al—4,O
COVID-19,O
both,O
unveiled,O
and,O
exacerbated,O
existing,O
inequalities,O
and,O
injustices,O
within,O
a,O
country,O
",",O
making,O
different,O
populations,O
particularly,O
vulnerable,O
to,O
COVID-19,O
and,O
its,O
sequelae,O
",",O
among,O
them,O
people,O
living,O
in,O
poverty,O
",",O
without,O
shelter,O
",",O
without,O
regular,O
residence,O
",",O
without,O
employment,O
or,O
people,O
living,O
in,O
residential,O
care,O
facilities,O
.,O
They,O
were,O
soon,O
identified,O
as,O
being,O
the,O
most,O
vulnerable,O
in,O
these,O
countries,O
with,O
high,O
risk,O
for,O
COVID-19,O
infection,O
and,O
severe,O
outcomes,O
due,O
to,O
frailty,O
and,O
chronic,O
"comorbidities,8",O
exposed,O
to,O
circumstances,O
with,O
staff,O
shortage,O
",",O
insufficient,O
access,O
to,O
personal,O
protective,O
equipment,O
and,O
limited,O
staff,O
training,O
in,O
infection,O
prevention,O
and,O
control.9,O
At,O
the,O
beginning,O
of,O
the,O
spread,O
of,O
the,O
COVID-19,O
pandemic,O
",",O
health,O
authorities,O
",",O
ethicists,O
and,O
the,O
medical,O
community,O
of,O
high,O
-,O
income,O
countries,O
",",O
however,O
",",O
anxiously,O
focused,O
on,O
the,O
ICUs,O
.,O
In,O
Europe,O
",",O
many,O
hospitals,O
increasingly,O
reported,O
to,O
have,O
quickly,O
maximised,O
resource,O
capacities,O
",",O
reduced,O
postponable,O
interventions,O
and,O
—,O
although,O
challenging,O
—,O
being,O
able,O
to,O
adequately,O
respond,O
to,O
COVID-19,O
related,O
medical,O
needs,O
of,O
the,O
population,O
.,O
This,O
is,O
the,O
story,O
of,O
the,O
COVID-19,O
tragedy,O
observable,O
in,O
many,O
high,O
-,O
income,O
countries,O
in,O
these,O
days,O
",",O
told,O
through,O
the,O
lens,O
of,O
medicine,O
as,O
a,O
social,O
science,O
",",O
focusing,O
history,O
of,O
medicine,O
and,O
social,O
epidemiology,O
:,O
with,O
the,O
pandemic,O
spread,O
of,O
COVID-19,O
",",O
wealthy,O
countries,O
have,O
built,O
their,O
responses,O
informed,O
by,O
natural,O
science,O
and,O
"epidemiology,4",O
focusing,O
the,O
acute,O
setting,O
",",O
personal,O
protective,O
equipment,O
and,O
testing,O
",",O
and,O
establishing,O
ethics,O
guidelines,O
for,O
the,O
expected,O
‘,O
tough,O
’,O
triage,O
of,O
lifesaving,O
resources,O
like,O
ventilators,O
or,O
extracorporeal,O
membrane,O
oxygenation,O
(,O
ECMO,O
),O
in,O
acute,O
hospitals,O
.,O
As,O
COVID-19,O
can,O
affect,O
an,O
individual,O
without,O
(,O
initially,O
),O
being,O
symptomatic,O
",",O
the,O
virus,O
easily,O
spread,O
despite,O
lockdown,O
conditions,O
via,O
healthcare,O
teams,O
and,O
residents,O
’,O
interactions,O
.,O
In,O
many,O
high,O
-,O
income,O
countries,O
",",O
already,O
before,O
COVID-19,O
",",O
a,O
great,O
‘,O
viral,O
dying,O
’,O
can,O
be,O
observable,O
in,O
residential,O
care,O
facilities,O
every,O
winter,O
.,O
Compared,O
with,O
that,O
",",O
COVID-19,O
is,O
much,O
deadlier,O
",",O
and,O
we,O
currently,O
have,O
no,O
vaccination,O
and,O
only,O
very,O
limited,O
treatment,O
options,O
.,O
As,O
the,O
current,O
evidence,O
therefore,O
increasingly,O
"reveals,8–14",O
16,O
age,O
",",O
frailty,O
and,O
comorbidities,O
are,O
important,O
risk,O
factors,O
",",O
but,O
the,O
social,O
context,O
of,O
nursing,O
homes,O
as,O
well,O
as,O
other,O
communal,O
establishments10,O
in,O
many,O
high,O
-,O
income,O
countries,O
contributes,O
",",O
according,O
to,O
Virchow,O
’s,O
social,O
hygiene,O
hypothesis,O
",",O
immensely,O
to,O
the,O
death,O
toll,O
itself,O
",",O
with,O
a,O
variation,O
from,O
zero,O
%,O
(,O
Hong,O
Kong,O
),O
to,O
up,O
to,O
85,O
%,O
of,O
all,O
COVID-19,O
related,O
deaths,O
according,O
to,O
official,O
figures,O
(,O
Canada,O
),O
",",O
with,O
excess,O
rates,O
of,O
nursing,O
home,O
deaths,O
not,O
entirely,O
being,O
dependent,O
on,O
the,O
total,O
share,O
of,O
national,O
COVID-19,O
related,O
deaths,O
.,O
17,O
18,O
The,O
current,O
evidence,O
strongly,O
suggests,O
that,O
the,O
isolation,O
measures,O
have,O
not,O
been,O
effective,O
in,O
preventing,O
the,O
COVID-19,O
spread,O
.,O
For,O
sure,O
",",O
it,O
would,O
be,O
more,O
humane,O
and,O
safer,O
",",O
and,O
",",O
as,O
up,O
to,O
85,O
%,O
of,O
COVID-19,O
related,O
deaths,O
in,O
high,O
-,O
income,O
countries,O
are,O
nursing,O
home,O
residents,O
",",O
with,O
the,O
exception,O
of,O
Hong,O
Kong,O
",",O
implementing,O
whole,O
nursing,O
home,O
repeated,O
testing,O
of,O
staff,O
and,O
residents,O
and,O
a,O
short,O
",",O
sharp,O
quarantine,O
for,O
residents,O
",",O
which,O
should,O
be,O
carefully,O
"evaluated,8",O
and,O
approximately,O
34,O
%,O
of,O
all,O
deaths,O
are,O
people,O
living,O
in,O
communal,O
"establishments,10",O
the,O
next,O
pandemic,O
might,O
not,O
be,O
as,O
deadly,O
",",O
even,O
without,O
having,O
highly,O
effective,O
treatments,O
or,O
a,O
vaccination,O
at,O
hand,O
.,O
To,O
alleviate,O
the,O
global,O
death,O
toll,O
of,O
COVID-19,O
with,O
the,O
variety,O
of,O
contextual,O
and,O
local,O
vulnerabilities,O
and,O
populations,O
needing,O
specific,O
"protection,4",O
like,O
people,O
living,O
in,O
refugee,O
camps,O
",",O
undocumented,O
working,O
migrants,O
in,O
agriculture,O
or,O
the,O
meat,O
industry,O
",",O
often,O
accommodated,O
in,O
large,O
lodgings,O
",",O
as,O
well,O
as,O
those,O
living,O
in,O
poor,O
neighbourhoods,O
",",O
we,O
might,O
finally,O
again,O
refer,O
to,O
Dr,O
Virchow,O
",",O
calling,O
for,O
more,O
social,O
justice,O
",",O
as,O
‘,O
politics,O
is,O
nothing,O
but,O
medicine,O
at,O
a,O
larger,O
scale,O
’,O
.,O
The,O
incredible,O
fast,O
worldwide,O
spread,O
of,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
prompt,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
to,O
declare,O
COVID‐19,O
as,O
a,O
pandemic,O
on,O
11,O
March,O
2020,O
.,O
More,O
than,O
1,O
 ,O
776,O
 ,O
867,O
confirmed,O
cases,O
of,O
COVID‐19,O
and,O
more,O
than,O
111,O
 ,O
828,O
fatalities,O
in,O
185,O
countries,O
have,O
been,O
attributed,O
to,O
SARS‐CoV‐2,O
as,O
of,O
14,O
April,O
2020,O
(,O
https://who.sprinklr.com/,S-URL
),O
.,O
Molecular,O
tests,O
(,O
real‐time,O
reverse,O
transcriptase,O
polymerase,O
chain,O
reaction,O
",",O
RT‐qPCR,O
),O
were,O
generally,O
used,O
to,O
confirm,O
the,O
clinical,O
diagnosis,O
of,O
COVID‐19,O
.,O
Cardiovascular,O
complications,O
with,O
embolism,O
due,O
to,O
COVID‐19,O
have,O
been,O
reported,O
recently,O
.,O
",",O
 ,O
",",O
 ,O
",",O
  ,O
Acute,O
myocardial,O
injury,O
associated,O
with,O
COVID‐19,O
manifested,O
as,O
an,O
increase,O
of,O
high‐sensitivity,O
cardiac,O
troponin,O
levels,O
.,O
Cardiovascular,O
involvement,O
in,O
COVID‐19,O
seems,O
to,O
be,O
a,O
notable,O
complication,O
.,O
First,O
single,O
case,O
reports,O
could,O
show,O
viral,O
particles,O
in,O
interstitial,O
cytopathic,O
macrophages,O
and,O
their,O
surroundings,O
in,O
EMB,O
of,O
a,O
severe,O
COVID‐19,O
shock,O
patient,O
by,O
electron,O
microscopic,O
analyses,O
.,O
Based,O
on,O
the,O
results,O
of,O
currently,O
published,O
research,O
",",O
it,O
seems,O
important,O
to,O
discuss,O
the,O
manifestations,O
and,O
characteristics,O
of,O
myocardial,O
damage,O
induced,O
by,O
COVID‐19,O
.,O
Moreover,O
",",O
patients,O
with,O
COVID‐19,O
are,O
known,O
to,O
be,O
at,O
higher,O
risk,O
of,O
acute,O
pulmonary,O
embolism,O
",",O
and,O
elevated,O
d‐dimer,O
levels,O
on,O
admission,O
are,O
predictive,O
of,O
adverse,O
outcomes,O
for,O
patients,O
with,O
COVID‐19,O
.,O
Bai,O
et,O
al,O
.,O
 ,O
reported,O
vascular,O
thickening,O
to,O
be,O
significantly,O
associated,O
with,O
COVID‐19,O
compared,O
with,O
non,O
–,O
COVID‐19,O
pneumonia,O
(,O
59,O
%,O
vs.,O
22,O
%,O
",",O
P,O
 ,O
<,O
 ,O
0.001,O
),O
.,O
In,O
addition,O
",",O
recent,O
histologically,O
post‐mortem,O
analyses,O
in,O
COVID‐10,O
positive,O
patients,O
revealed,O
lymphocytic,O
endotheliitis,O
in,O
different,O
organs,O
with,O
evidence,O
of,O
direct,O
viral,O
infection,O
",",O
indicating,O
endothelial,O
dysfunction,O
as,O
a,O
possible,O
principle,O
determination,O
of,O
microvascular,O
dysfunction,O
by,O
shifting,O
the,O
vascular,O
equilibrium,O
towards,O
more,O
vasoconstriction,O
with,O
subsequent,O
organ,O
ischaemia,O
and,O
inflammation,O
.,O
Although,O
nearly,O
all,O
organs,O
seemed,O
to,O
be,O
affected,O
by,O
COVID‐19,O
",",O
we,O
currently,O
do,O
not,O
know,O
in‐depth,O
details,O
about,O
the,O
organ‐specific,O
infection,O
by,O
SARS‐CoV‐2,O
.,O
In,O
this,O
regard,O
",",O
Tavazzi,O
and,O
coworkers,O
have,O
shown,O
recently,O
in,O
their,O
case,O
description,O
using,O
electron,O
microscopy,O
on,O
EMBs,O
of,O
a,O
patient,O
with,O
COVID‐19,O
in,O
cardiogenic,O
shock,O
that,O
SARS‐CoV‐2,O
particles,O
could,O
be,O
localized,O
to,O
interstitial,O
macrophages,O
and,O
their,O
surroundings,O
but,O
not,O
in,O
cardiomyocytes,O
.,O
Cardiovascular,O
complications,O
with,O
myocarditis,O
and,O
embolism,O
due,O
to,O
COVID‐19,O
have,O
been,O
reported,O
.,O
In,O
the,O
same,O
context,O
",",O
the,O
recent,O
outbreak,O
of,O
SARS,O
-,O
CoV,O
2,O
(,O
the,O
causative,O
agent,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
),O
in,O
December,O
2019,O
has,O
inflicted,O
204,O
nations,O
",",O
with,O
a,O
total,O
of,O
"896,450",O
confirmed,O
cases,O
and,O
"45,526",O
deaths,O
up,O
to,O
2,O
April,O
2020,O
.,O
From,O
a,O
structural,O
perspective,O
",",O
the,O
genome,O
of,O
coronaviruses,O
encodes,O
four,O
structural,O
proteins,O
:,O
E,O
(,O
envelope,O
protein,O
",",O
the,O
smallest,O
in,O
size,O
",",O
expressed,O
in,O
abundance,O
inside,O
infected,O
cells,O
during,O
the,O
replication,O
cycle,O
but,O
only,O
partially,O
incorporated,O
into,O
the,O
virion,O
envelope,O
),O
[,O
8,O
],O
",",O
M,O
(,O
matrix,O
glycoprotein,O
",",O
responsible,O
for,O
the,O
assembly,O
of,O
virions,O
[,O
"1,9",O
],O
and,O
interacting,O
with,O
S,O
proteins,O
",",O
promoting,O
their,O
retention,O
in,O
the,O
endoplasmic,O
reticulum,O
(,O
ER)–Golgi,O
intermediate,O
for,O
their,O
incorporation,O
into,O
new,O
virions,O
),O
[,O
10,O
],O
",",O
N,O
(,O
nucleocapsid,O
protein,O
",",O
the,O
only,O
protein,O
capable,O
of,O
binding,O
to,O
the,O
virus,O
RNA,O
genome,O
",",O
synthesizing,O
nucleocapsid,O
),O
[,O
11,O
],O
",",O
S,O
(,O
spike,O
protein,O
",",O
mediating,O
the,O
attachment,O
of,O
the,O
virus,O
to,O
host,O
cell,O
receptors,O
),O
[,O
"12,13,14",O
],O
.,O
TMPRSS2,O
expression,O
and,O
variants,O
served,O
as,O
COVID-19,O
modulators,O
in,O
Italian,O
patients,O
[,O
31,O
],O
.,O
Alignment,O
of,O
the,O
template,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
5CE1,S-AccessionNumber
),O
and,O
the,O
target,O
protein,O
is,O
shown,O
in,O
Figure,O
1C.,O
Natural,B-Repository
Product,I-Repository
Activity,I-Repository
and,I-Repository
Species,I-Repository
Source,I-Repository
(NPASS),E-Repository
 ,O
is,O
a,O
freely,O
accessible,O
database,O
containing,O
"30,927",O
natural,O
compounds,O
classified,O
into,O
18,O
different,O
superclasses,O
",",O
which,O
include,O
alkaloids,O
and,O
derivatives,O
",",O
lipids,O
and,O
lipid,O
-,O
like,O
molecules,O
",",O
benzenoids,O
",",O
lignans,O
",",O
neolignans,O
and,O
associated,O
compounds,O
",",O
and,O
so,O
on,O
[,O
32,O
],O
.,O
In,O
silico,O
screening,O
of,O
large,O
databases,O
is,O
a,O
cost,O
-,O
effective,O
and,O
time,O
-,O
saving,O
approach,O
towards,O
drug,O
discovery,O
.,O
NPASS,S-Repository
",",O
a,O
freely,O
accessible,O
database,O
containing,O
"30,927",O
compounds,O
",",O
was,O
used,O
to,O
mine,O
the,O
potent,O
inhibitors,O
.,O
We,O
screened,O
the,O
Natural,B-Repository
Product,I-Repository
Activity,I-Repository
and,I-Repository
Species,I-Repository
Source,I-Repository
database,I-Repository
(NPASS,E-Repository
",",O
available,O
at,O
http://bidd2.nus.edu.sg/NPASS,S-URL
),O
which,O
contains,O
"30,927",O
compounds,O
[,O
32,O
],O
.,O
Based,O
on,O
a,O
report,O
that,O
TMPRSS2,O
mutation,O
makes,O
some,O
individuals,O
more,O
susceptible,O
to,O
COVID-19,O
",",O
a,O
reported,O
mutation,O
V160,O
M,O
suggestive,O
of,O
changed,O
disease,O
susceptibility,O
[,O
31,O
],O
was,O
studied,O
with,O
respect,O
to,O
its,O
docking,O
conformation,O
in,O
the,O
presence,O
of,O
the,O
top,O
compound,O
.,O
To,O
date,O
",",O
there,O
is,O
no,O
specific,O
drug,O
registered,O
to,O
combat,O
the,O
disease,O
it,O
causes,O
",",O
named,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
Further,O
in,O
vitro,O
and,O
in,O
vivo,O
validation,O
is,O
needed,O
to,O
study,O
and,O
develop,O
an,O
anti,O
-,O
COVID-19,O
drug,O
based,O
on,O
the,O
structures,O
of,O
the,O
most,O
promising,O
compounds,O
identified,O
in,O
this,O
study,O
.,O
They,O
were,O
not,O
considered,O
to,O
be,O
highly,O
pathogenic,O
to,O
humans,O
until,O
the,O
last,O
two,O
decades,O
",",O
which,O
have,O
seen,O
three,O
outbreaks,O
of,O
highly,O
transmissible,O
and,O
pathogenic,O
coronaviruses,O
",",O
including,O
SARS,O
-,O
CoV,O
(,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
),O
",",O
MERS,O
-,O
CoV,O
(,O
Middle,O
East,O
respiratory,O
syndrome,O
coronavirus,O
),O
",",O
and,O
SARS,O
-,O
CoV-2,O
(,O
which,O
causes,O
the,O
disease,O
COVID-19,O
),O
.,O
In,O
the,O
face,O
of,O
the,O
ongoing,O
COVID-19,O
pandemic,O
",",O
extensive,O
worldwide,O
research,O
efforts,O
have,O
focused,O
on,O
identifying,O
coronavirus,O
genetic,O
variation,O
and,O
selection,O
[,O
6–8,O
],O
",",O
in,O
order,O
to,O
understand,O
the,O
emergence,O
of,O
host,O
/,O
tissue,O
specificities,O
and,O
to,O
help,O
develop,O
efficient,O
prevention,O
and,O
treatment,O
strategies,O
.,O
Viral,O
genome,O
sequences,O
were,O
downloaded,O
from,O
the,O
Genbank,S-Repository
 ,O
database,O
",",O
as,O
shown,O
in,O
Table,O
 ,O
1,O
.,O
We,O
set,O
the,O
threshold,O
for,O
prediction,O
of,O
a,O
functional,O
ORF,O
to,O
be,O
XME,O
 ,O
≥,O
 ,O
5,O
(,O
i.e.,O
XME,O
score,O
in,O
the,O
reading,O
frame,O
≥5,O
),O
",",O
based,O
on,O
our,O
benchmark,O
studies,O
(,O
data,O
not,O
shown,O
),O
of,O
experimentally,O
validated,O
ORFs,O
in,O
a,O
large,O
set,O
of,O
80,O
genomes,O
[,O
15,O
],O
covering,O
a,O
wide,O
range,O
of,O
viruses,O
(,O
including,O
single,O
-,O
stranded,O
and,O
double,O
-,O
stranded,O
DNA,O
viruses,O
and,O
single,O
-,O
stranded,O
and,O
double,O
-,O
stranded,O
RNA,O
viruses,O
),O
.,O
To,O
avoid,O
any,O
statistical,O
bias,O
",",O
coronavirus,O
genome,O
sequences,O
were,O
excluded,O
from,O
the,O
benchmark,O
.,O
This,O
ORF,O
is,O
not,O
annotated,O
in,O
the,O
SARS,O
-,O
CoV-2,O
reference,O
genome,O
(,O
MT072688,S-AccessionNumber
),O
",",O
but,O
is,O
annotated,O
as,O
ORF3b,O
in,O
the,O
genome,O
of,O
another,O
SARS,O
-,O
CoV-2,O
strain,O
isolated,O
from,O
the,O
first,O
U.S.,O
case,O
of,O
COVID-19,O
(,O
MN985325,S-AccessionNumber
),O
.,O
The,O
datasets,O
analysed,O
during,O
the,O
current,O
study,O
are,O
available,O
in,O
the,O
Genbank,S-Repository
 ,O
viral,O
genomes,O
database,O
",",O
https://www.ncbi.nlm.nih.gov/genome/viruses/,S-URL
The,O
trained,O
DNNs,O
are,O
the,O
core,O
of,O
our,O
virus,O
-,O
host,O
prediction,O
tool,O
VIDHOP,O
(,O
VIrus,O
Deep,O
learning,O
HOst,O
Prediction,O
),O
.,O
VIDHOP,O
also,O
allows,O
the,O
user,O
to,O
train,O
and,O
use,O
models,O
for,O
other,O
viruses,O
.,O
Availability,O
 ,O
VIDHOP,O
is,O
freely,O
available,O
under,O
https://github.com/flomock/vidhop,O
The,O
whole,O
-,O
genome,O
sequence,O
of,O
Wuhan,O
new,O
virus,O
(,O
WH,O
-,O
Human_1,O
),O
was,O
first,O
released,O
on,O
January,O
10,O
",",O
2020,O
(,O
Zhang,O
",",O
2020,O
),O
",",O
followed,O
by,O
additional,O
ones,O
released,O
in,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
(,O
Shu,O
and,O
McCauley,O
",",O
2017,O
),O
.,O
Sequences,O
of,O
S,O
protein,O
were,O
downloaded,O
for,O
known,O
CoVs,O
from,O
UniProt,S-Repository
",",O
and,O
2019,O
-,O
nCoV,O
sequences,O
were,O
obtained,O
from,O
Shanghai,B-Creator
Public,I-Creator
Health,I-Creator
Clinical,I-Creator
Center,E-Creator
 ,O
and,O
GISAID,S-Dataset
 ,O
(,O
Supplementary,O
data,O
),O
.,O
The,O
complete,O
genome,O
sequence,O
of,O
2019,O
-,O
nCoV,O
HKU,O
-,O
SZ-005b,O
was,O
available,O
at,O
GenBank,S-Repository
 ,O
(,O
accession,O
no,O
.,O
MN975262,S-AccessionNumber
),O
(,O
Table,O
1,O
),O
.,O
Multiple,O
alignment,O
of,O
Spike,O
S1,O
amino,O
acid,O
sequences,O
of,O
2019,O
-,O
nCoV,O
HKU,O
-,O
SZ-005b,O
(,O
accession,O
number,O
MN975262,S-AccessionNumber
),O
",",O
bat,O
SARS,O
-,O
like,O
coronavirus,O
isolates,O
bat,O
-,O
SL,O
-,O
CoVZXC21,O
",",O
bat,O
-,O
SL,O
-,O
CoVZXC45,O
",",O
bat,O
-,O
SL,O
-,O
CoV,O
-,O
YNLF_31C,O
",",O
bat,O
-,O
SL,O
-,O
CoV,O
-,O
YNLF_34C,O
and,O
bat,O
SL,O
-,O
CoV,O
HKU3,O
-,O
1,O
(,O
accession,O
number,O
MG772934.1,S-AccessionNumber
 ,O
and,O
MG772933.1,S-AccessionNumber
",",O
KP886808,S-AccessionNumber
",",O
KP886809,S-AccessionNumber
 ,O
and,O
DQ022305,S-AccessionNumber
",",O
respectively,O
),O
",",O
human,O
SARS,O
coronavirus,O
GZ02,O
and,O
Tor2,O
(,O
accession,O
number,O
AY390556,S-AccessionNumber
 ,O
and,O
AY274119,S-AccessionNumber
",",O
respectively,O
),O
and,O
Paguma,O
SARS,O
-,O
CoV,O
(,O
accession,O
number,O
AY515512,S-AccessionNumber
),O
was,O
performed,O
and,O
displayed,O
using,O
CLUSTAL,O
2.1,O
and,O
BOXSHADE,O
3.21,O
",",O
respectively,O
.,O
We,O
calculated,O
a,O
phylogenetic,O
analysis,O
network,O
of,O
the,O
160,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
complete,O
genomes,O
submitted,O
to,O
the,O
international,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
Avian,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
database,O
by,O
early,O
March,O
2020,O
",",O
to,O
produce,O
a,O
snapshot,O
of,O
the,O
beginning,O
of,O
the,O
SARS,O
-,O
CoV-2,O
epidemic,O
(,O
1,O
),O
.,O
Included,O
in,O
the,O
dataset,O
was,O
the,O
closest,O
known,O
nonhuman,O
coronavirus,O
",",O
a,O
bat,O
coronavirus,O
with,O
more,O
than,O
96,O
%,O
sequence,O
similarity,O
to,O
the,O
human,O
virus,O
.,O
We,O
ran,O
the,O
bat,O
sequence,O
as,O
part,O
of,O
the,O
human,O
dataset,O
.,O
Mavian,O
et,O
al,O
.,O
(,O
8),O
state,O
that,O
our,O
findings,O
are,O
based,O
on,O
a,O
nonrepresentative,O
dataset,O
of,O
160,O
genomes,O
",",O
with,O
no,O
significant,O
correlation,O
between,O
prevalence,O
of,O
confirmed,O
cases,O
and,O
number,O
of,O
sequenced,O
strains,O
per,O
country,O
.,O
We,O
respond,O
that,O
our,O
data,O
are,O
based,O
on,O
the,O
first,O
160,O
high,O
-,O
quality,O
genomes,O
collected,O
",",O
sequenced,O
",",O
and,O
uploaded,O
to,O
the,O
international,O
GISAID,S-Dataset
 ,O
database,O
",",O
in,O
order,O
to,O
shed,O
light,O
on,O
the,O
early,O
development,O
of,O
the,O
coronavirus,O
.,O
The,O
early,O
outbreak,O
was,O
centered,O
on,O
China,O
",",O
and,O
naturally,O
in,O
this,O
early,O
dataset,O
China,O
is,O
well,O
represented,O
.,O
Focusing,O
on,O
the,O
seed,O
part,O
of,O
miRNA,O
-,O
like,O
sequences,O
having,O
a,O
putative,O
8,O
nucleotide,O
hybridization,O
seed,O
inhibition,O
effect,O
[,O
19,O
],O
",",O
[,O
20,O
],O
(,O
minimum,O
7,O
),O
",",O
we,O
compare,O
data,O
from,O
different,O
databases,O
[,O
21,O
],O
",",O
[,O
22,O
],O
",",O
[,O
23,O
],O
",",O
[,O
24,O
],O
",",O
[,O
25,O
],O
",",O
[,O
26,O
],O
using,O
BLAST,O
[,O
27,O
],O
.,O
Among,O
the,O
symptoms,O
of,O
the,O
COVID-19,O
disease,O
",",O
anosmia,O
is,O
frequently,O
described,O
.,O
This,O
hypothesis,O
is,O
in,O
agreement,O
with,O
numerous,O
studies,O
showing,O
a,O
decrease,O
of,O
adult,O
human,O
hemoglobin,O
blood,O
concentrations,O
in,O
severe,O
COVID-19,O
cases,O
[,O
46,O
],O
",",O
[,O
47,O
],O
",",O
presenting,O
an,O
increase,O
of,O
the,O
high,O
-,O
sensitivity,O
C,O
-,O
reactive,O
protein,O
as,O
one,O
of,O
the,O
three,O
major,O
predictors,O
of,O
severity,O
[,O
48,O
],O
",",O
like,O
in,O
ß,O
-,O
thalassemia,O
[,O
49,O
],O
and,O
viral,O
infections,O
[,O
50,O
],O
.,O
In,O
[,O
63,O
],O
",",O
it,O
is,O
described,O
a,O
release,O
of,O
massive,O
amounts,O
of,O
calprotectin,O
(,O
S100A8,O
/,O
S100A9,O
),O
in,O
severe,O
cases,O
of,O
COVID-19,O
.,O
All,O
these,O
probabilities,O
are,O
less,O
than,O
5,O
10,O
-,O
2,O
showing,O
the,O
significance,O
of,O
the,O
corresponding,O
associations,O
",",O
which,O
could,O
be,O
at,O
the,O
origin,O
of,O
the,O
brakes,O
observed,O
on,O
many,O
metabolisms,O
",",O
thus,O
explaining,O
the,O
ubiquitous,O
and,O
inconstant,O
nature,O
of,O
the,O
symptoms,O
of,O
COVID-19,O
.,O
They,O
concern,O
indeed,O
many,O
organs,O
",",O
in,O
a,O
sequence,O
and,O
with,O
a,O
duration,O
difficult,O
to,O
anticipate,O
",",O
the,O
cases,O
observed,O
ranging,O
from,O
asymptomatic,O
or,O
mildly,O
affected,O
patients,O
to,O
severe,O
patients,O
suffering,O
from,O
numerous,O
chronic,O
co,O
-,O
morbidities,O
",",O
the,O
worsening,O
of,O
which,O
due,O
to,O
COVID-19,O
leading,O
sometimes,O
to,O
death,O
.,O
We,O
compare,O
RNA,O
subsequences,O
of,O
SARS,O
-,O
CoV-2,O
protein,O
S,O
and,O
RNA,O
-,O
dependent,O
RNA,O
polymerase,O
genes,O
to,O
mRNA,O
sequences,O
of,O
beta,O
-,O
globin,O
and,O
type,O
I,O
interferons,O
;,O
(,O
4,O
),O
Results,O
:,O
RNA,O
subsequences,O
longer,O
than,O
eight,O
nucleotides,O
from,O
SARS,O
-,O
CoV-2,O
genome,O
could,O
hybridize,O
subsequences,O
of,O
the,O
mRNA,O
of,O
beta,O
-,O
globin,O
and,O
of,O
type,O
I,O
interferons,O
;,O
(,O
5,O
),O
Conclusions,O
:,O
Beyond,O
viral,O
protein,O
production,O
",",O
COVID-19,O
might,O
affect,O
vital,O
processes,O
like,O
host,O
oxygen,O
transport,O
and,O
immune,O
response,O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
created,O
an,O
overwhelming,O
need,O
to,O
define,O
host,O
-,O
derived,O
molecular,O
mediators,O
of,O
disease,O
severity,O
evident,O
in,O
hospitalized,O
patients,O
.,O
One,O
approach,O
to,O
dissect,O
protective,O
and,O
pathological,O
immune,O
responses,O
to,O
COVID-19,O
infection,O
is,O
to,O
measure,O
plasma,O
biomarkers,O
correlated,O
to,O
various,O
stages,O
of,O
COVID-19,O
and,O
determine,O
which,O
proinflammatory,O
mediators,O
are,O
modulated,O
in,O
response,O
to,O
therapies,O
improving,O
patient,O
outcomes,O
.,O
Analysis,O
of,O
the,O
differential,O
protein,O
regulation,O
patterns,O
within,O
severity,O
classes,O
of,O
COVID-19,O
cases,O
compared,O
with,O
healthy,O
control,O
(,O
HC,O
),O
revealed,O
strong,O
dysregulation,O
of,O
IFN,O
-,O
γ,O
",",O
IL-6,O
",",O
IL-10,O
",",O
monocyte,O
chemoattractant,O
protein,O
(,O
MCP)-3,O
",",O
CXCL9,O
",",O
CXCL10,O
",",O
CXCL11,O
",",O
ENRAGE,O
",",O
poly(ADP,O
-,O
ribose,O
),O
polymerase,O
1,O
(,O
PARP-1,O
),O
",",O
and,O
IL-1RA,O
(,O
Fig,O
1,O
",",O
A,O
",",O
B,O
-,O
bottom,O
",",O
C,O
),O
.,O
We,O
observed,O
a,O
2,O
-,O
fold,O
increase,O
in,O
IL-19,O
levels,O
and,O
",",O
along,O
with,O
the,O
aforementioned,O
changes,O
in,O
IL-10,O
",",O
MCP-1,O
",",O
-2,O
",",O
and,O
-3,O
",",O
this,O
is,O
consistent,O
with,O
the,O
important,O
role,O
for,O
inflammatory,O
monocytes,O
/,O
macrophages,O
in,O
the,O
immunopathogenesis,O
of,O
patients,O
infected,O
with,O
COVID-19,O
.,O
A,O
-,O
C,O
",",O
Inflammatory,O
panel,O
(,O
Fig,O
1,O
",",O
A,O
),O
or,O
the,O
cardiovascular,O
panel,O
II,O
(,O
Fig,O
1,O
",",O
B,O
),O
FC,O
in,O
baseline,O
protein,O
levels,O
",",O
patients,O
with,O
COVID-19,O
vs,O
HC,O
(,O
n,O
 ,O
=,O
20,O
),O
(,O
bottom,O
),O
.,O
Baseline,O
samples,O
of,O
patients,O
with,O
COVID-19,O
were,O
classified,O
on,O
the,O
basis,O
of,O
patients,O
receiving,O
treatment,O
for,O
2,O
days,O
or,O
less,O
(,O
n,O
 ,O
=,O
25,O
),O
.,O
Correlations,O
of,O
biomarkers,O
and,O
clinical,O
assessments,O
such,O
as,O
Ordinal,O
Scale,O
",",O
nasopharyngeal,O
viral,O
load,O
(,O
the,O
most,O
sensitive,O
viral,O
target,O
gene,O
",",O
N,O
gene,O
",",O
is,O
shown,O
),O
",",O
and,O
inflammation,O
status,O
(,O
CRP,O
",",O
ferritin,O
",",O
LDH,O
),O
are,O
shown,O
for,O
each,O
biomarker,O
across,O
all,O
longitudinal,O
time,O
points,O
for,O
patients,O
with,O
COVID-19,O
treated,O
with,O
baricitinib,O
(,O
top,O
),O
.,O
Our,O
analysis,O
is,O
consistent,O
with,O
a,O
more,O
prominent,O
increase,O
in,O
IFN,O
-,O
γ,O
and,O
IL-10,O
levels,O
in,O
patients,O
with,O
COVID-19,O
as,O
seen,O
in,O
the,O
moderate,O
/,O
severe,O
and,O
critical,O
patients,O
who,O
are,O
more,O
likely,O
to,O
suffer,O
from,O
adult,O
respiratory,O
distress,O
syndrome,O
.,O
This,O
indicates,O
that,O
inflammatory,O
proteins,O
observed,O
in,O
the,O
plasma,O
of,O
patients,O
with,O
COVID-19,O
could,O
be,O
predictive,O
of,O
disease,O
state,O
and,O
potentially,O
clinical,O
outcomes,O
.,O
Pathway,O
mapping,O
of,O
the,O
most,O
prominent,O
biomarkers,O
that,O
are,O
altered,O
in,O
severe,O
patients,O
with,O
COVID-19,O
(,O
see,O
Table,O
E3,O
in,O
this,O
article,O
’s,O
Online,O
Repository,O
at,O
www.jacionline.org,S-URL
),O
suggests,O
changes,O
in,O
cytokines,O
correlated,O
with,O
pneumonia,O
such,O
as,O
IFN,O
-,O
γ,O
and,O
IL-10,O
",",O
along,O
with,O
chemokines,O
such,O
as,O
CXCL10,O
",",O
MCP-3,O
",",O
CCL20,O
",",O
CXCL9,O
",",O
IL-8,O
",",O
ENRAGE,O
",",O
and,O
MCP-2,O
.,O
",",O
In,O
addition,O
to,O
these,O
identified,O
immunologic,O
changes,O
",",O
there,O
is,O
a,O
growing,O
consensus,O
on,O
the,O
thromboembolic,O
risk,O
seen,O
in,O
patients,O
with,O
COVID-19,O
.,O
Severe,O
endothelial,O
injury,O
",",O
vascular,O
thrombosis,O
",",O
and,O
intussusceptive,O
angiogenesis,O
characterizes,O
the,O
lung,O
damage,O
observed,O
",",O
and,O
the,O
incidence,O
of,O
venous,O
thromboembolism,O
among,O
severe,O
and,O
critically,O
ill,O
patients,O
with,O
COVID-19,O
is,O
higher,O
compared,O
with,O
that,O
reported,O
in,O
other,O
studies,O
including,O
patients,O
with,O
other,O
disease,O
conditions,O
.,O
",",O
 ,O
Recent,O
recommendations,O
suggest,O
that,O
all,O
hospitalized,O
patients,O
with,O
COVID-19,O
should,O
receive,O
thromboprophylaxis,O
or,O
full,O
therapeutic,O
-,O
intensity,O
anticoagulation,O
if,O
such,O
an,O
indication,O
is,O
present,O
.,O
These,O
changes,O
suggest,O
potential,O
viral,O
-,O
mediated,O
changes,O
in,O
endothelial,O
function,O
that,O
may,O
provide,O
clues,O
to,O
the,O
increased,O
incidence,O
of,O
thromboembolic,O
risks,O
in,O
patients,O
with,O
COVID-19,O
.,O
Notably,O
",",O
in,O
moderate,O
/,O
severe,O
and,O
critical,O
patients,O
with,O
COVID-19,O
",",O
these,O
plasma,O
markers,O
are,O
elevated,O
relative,O
to,O
mild,O
patients,O
and,O
HCs,O
",",O
which,O
is,O
consistent,O
with,O
thromboembolic,O
risk,O
in,O
these,O
patients,O
potentially,O
attributed,O
to,O
vast,O
changes,O
in,O
the,O
underlying,O
endothelium,O
of,O
the,O
most,O
at,O
-,O
risk,O
patients,O
.,O
Likewise,O
",",O
we,O
observed,O
downregulation,O
of,O
GDF-2,O
in,O
the,O
plasma,O
of,O
patients,O
with,O
COVID-19,O
(,O
Fig,O
1,O
",",O
B,O
),O
.,O
In,O
recent,O
work,O
conducted,O
in,O
COVID-19,O
PBMCs,O
using,O
single,O
-,O
cell,O
RNASeq,O
",",O
it,O
was,O
reported,O
that,O
a,O
reconfiguration,O
of,O
peripheral,O
immune,O
cell,O
phenotype,O
leads,O
to,O
a,O
heterogeneous,O
IFN,O
-,O
stimulated,O
gene,O
signature,O
",",O
HLA,O
class,O
II,O
downregulation,O
",",O
and,O
appearance,O
of,O
a,O
neutrophil,O
population,O
with,O
acute,O
respiratory,O
failure,O
requiring,O
mechanical,O
ventilation,O
.,O
Background,O
 ,O
Physicians,O
treating,O
patients,O
with,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
increasingly,O
believe,O
that,O
the,O
hyperinflammatory,O
acute,O
stage,O
of,O
COVID-19,O
results,O
in,O
a,O
cytokine,O
storm,O
.,O
The,O
circulating,O
biomarkers,O
seen,O
across,O
the,O
spectrum,O
of,O
COVID-19,O
have,O
not,O
been,O
characterized,O
compared,O
with,O
healthy,O
controls,O
",",O
but,O
such,O
analyses,O
are,O
likely,O
to,O
yield,O
insights,O
into,O
the,O
pursuit,O
of,O
interventions,O
that,O
adequately,O
reduce,O
the,O
burden,O
of,O
these,O
cytokine,O
storms,O
.,O
Methods,O
 ,O
Blood,O
samples,O
from,O
adult,O
patients,O
hospitalized,O
with,O
COVID-19,O
were,O
analyzed,O
using,O
high,O
-,O
throughput,O
and,O
ultrasensitive,O
proteomic,O
platforms,O
and,O
compared,O
with,O
age-,O
and,O
sex,O
-,O
matched,O
healthy,O
controls,O
to,O
provide,O
insights,O
into,O
differential,O
regulation,O
of,O
185,O
markers,O
.,O
Results,O
 ,O
Results,O
indicate,O
a,O
dominant,O
hyperinflammatory,O
milieu,O
in,O
the,O
circulation,O
and,O
vascular,O
endothelial,O
damage,O
markers,O
within,O
patients,O
with,O
COVID-19,O
",",O
and,O
strong,O
biomarker,O
association,O
with,O
patient,O
response,O
as,O
measured,O
by,O
Ordinal,O
Scale,O
.,O
Despite,O
strict,O
quarantine,O
measures,O
in,O
Wuhan,O
and,O
surrounding,O
areas,O
",",O
the,O
virus,O
",",O
responsible,O
for,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
",",O
rapidly,O
spread,O
across,O
the,O
globe,O
",",O
leading,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
to,O
declare,O
a,O
pandemic,O
on,O
11,O
March,O
2020,O
.,O
Soon,O
after,O
the,O
emergence,O
of,O
the,O
virus,O
",",O
a,O
specific,O
syndromic,O
surveillance,O
for,O
COVID-19,O
was,O
implemented,O
in,O
France,O
.,O
Strengthened,O
surveillance,O
of,O
COVID-19,O
cases,O
was,O
implemented,O
in,O
France,O
on,O
10,O
January,O
2020,O
",",O
with,O
the,O
objective,O
of,O
identifying,O
imported,O
cases,O
early,O
to,O
prevent,O
secondary,O
transmission,O
in,O
the,O
community,O
.,O
As,O
the,O
COVID-19,O
epidemic,O
progressed,O
in,O
the,O
country,O
",",O
the,O
task,O
of,O
identifying,O
SARS,O
-,O
CoV-2,O
infections,O
was,O
shared,O
with,O
the,O
NRC,O
-,O
associated,O
laboratory,O
in,O
Lyon,O
and,O
then,O
extended,O
to,O
first,O
line,O
hospital,O
laboratories,O
in,O
the,O
whole,O
country,O
",",O
with,O
the,O
NRC,O
at,O
Institut,O
Pasteur,O
focusing,O
on,O
the,O
northern,O
part,O
of,O
France,O
",",O
including,O
the,O
densely,O
populated,O
capital,O
.,O
As,O
the,O
virus,O
continued,O
to,O
spread,O
",",O
it,O
became,O
clear,O
that,O
COVID-19,O
patients,O
could,O
exhibit,O
greatly,O
variable,O
clinical,O
characteristics,O
[,O
4,O
],O
",",O
including,O
a,O
proportion,O
presenting,O
with,O
asymptomatic,O
infection,O
or,O
mild,O
disease,O
[,O
5,O
],O
.,O
We,O
combined,O
the,O
SARS,O
-,O
CoV-2,O
genome,O
sequences,O
generated,O
here,O
",",O
including,O
97,O
from,O
northern,O
France,O
and,O
three,O
from,O
Algeria,O
with,O
recent,O
history,O
of,O
travel,O
to,O
France,O
",",O
with,O
338,O
sequences,O
published,O
and,O
freely,O
available,O
from,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),I-Dataset
EpiCoV,E-Dataset
 ,O
database,O
and/or,O
GenBank,S-Repository
.,O
This,O
dataset,O
enabled,O
to,O
perform,O
a,O
phylogenetic,O
analysis,O
to,O
gain,O
more,O
insight,O
into,O
the,O
initial,O
introductions,O
and,O
spread,O
of,O
the,O
virus,O
in,O
France,O
.,O
Our,O
analysis,O
indicates,O
that,O
the,O
quarantine,O
imposed,O
on,O
the,O
initial,O
imported,O
COVID-19,O
cases,O
",",O
who,O
were,O
captured,O
by,O
the,O
syndromic,O
surveillance,O
in,O
France,O
",",O
appears,O
to,O
have,O
prevented,O
local,O
transmission,O
.,O
The,O
first,O
European,O
cases,O
",",O
who,O
were,O
originally,O
in,O
Île,O
-,O
de,O
-,O
France,O
(,O
IDF,O
),O
and,O
who,O
were,O
previously,O
described,O
elsewhere,O
[,O
6,O
],O
",",O
were,O
direct,O
imports,O
from,O
Hubei,O
",",O
China,O
.,O
They,O
were,O
sampled,O
on,O
24,O
January,O
2020,O
and,O
the,O
two,O
derived,O
respective,O
viral,O
genomes,O
",",O
IDF0372,O
and,O
IDF0373,O
",",O
fall,O
accordingly,O
near,O
the,O
base,O
of,O
the,O
tree,O
",",O
within,O
clade,O
V,O
",",O
according,O
to,O
GISAID,S-Dataset
 ,O
nomenclature,O
(,O
Figure,O
2,O
",",O
Figure,O
3A,O
),O
.,O
The,O
IDF0372,O
and,O
IDF0373,O
genomes,O
were,O
identical,O
and,O
both,O
harboured,O
a,O
G22661,O
T,O
non,O
-,O
synonymous,O
mutation,O
(,O
V367F,O
),O
in,O
the,O
receptor,O
-,O
binding,O
domain,O
of,O
the,O
spike,O
protein,O
",",O
not,O
observed,O
in,O
other,O
genomes,O
.,O
Similarly,O
",",O
IDF0515,O
",",O
obtained,O
from,O
a,O
29,O
January,O
sample,O
",",O
corresponds,O
to,O
a,O
traveller,O
from,O
Hubei,O
",",O
China,O
.,O
This,O
basal,O
genome,O
falls,O
outside,O
of,O
the,O
three,O
major,O
GISAID,S-Dataset
 ,O
proposed,O
clades,O
V,O
",",O
G,O
",",O
and,O
S,O
(,O
Figure,O
2,O
),O
",",O
but,O
carries,O
the,O
G11083,O
T,O
mutation,O
associated,O
with,O
putative,O
lineage,O
V1,O
(,O
Fig,O
.,O
S2,O
),O
",",O
suggesting,O
convergent,O
evolution,O
or,O
a,O
reversion,O
of,O
the,O
V,O
-,O
clade,O
defining,O
G26144,O
T,O
change,O
.,O
Several,O
genomes,O
correspond,O
to,O
patients,O
in,O
GE,O
",",O
Normandie,O
(,O
N,O
),O
",",O
IDF,O
",",O
Hauts,O
-,O
de,O
-,O
France,O
(,O
HF,O
),O
and,O
B,O
with,O
recent,O
history,O
of,O
travel,O
in,O
Europe,O
(,O
GE3067,O
",",O
N1620,O
",",O
IDF2792,O
),O
",",O
United,O
Arab,O
Emirates,O
(,O
IDF2936,O
),O
",",O
Madagascar,O
(,O
HF1993,O
),O
",",O
Egypt,O
(,O
B1623,O
",",O
B2330,O
),O
or,O
linked,O
to,O
Paris,O
airports,O
(,O
IDF1980,O
),O
.,O
Other,O
sequences,O
sampled,O
weeks,O
later,O
(,O
IDF2849,O
",",O
GE1973,O
),O
are,O
more,O
basal,O
to,O
the,O
clade,O
",",O
highlighting,O
the,O
complexity,O
and,O
risk,O
of,O
inferences,O
based,O
on,O
1,O
or,O
2,O
nucleotide,O
substitutions,O
.,O
Because,O
of,O
this,O
",",O
and,O
the,O
scarcity,O
of,O
early,O
sequences,O
in,O
many,O
countries,O
in,O
Europe,O
",",O
country,O
and,O
within,O
-,O
country,O
level,O
phylogeographic,O
estimations,O
are,O
unreliable,O
with,O
the,O
current,O
dataset,O
.,O
Crucially,O
",",O
while,O
all,O
early,O
symptomatic,O
suspected,O
COVID-19,O
cases,O
samples,O
were,O
sent,O
to,O
the,O
NRC,O
for,O
testing,O
",",O
this,O
was,O
no,O
longer,O
the,O
case,O
as,O
the,O
epidemic,O
developed,O
(,O
Figure,O
1A,O
),O
.,O
In,O
addition,O
",",O
pauci-,O
or,O
asymptomatic,O
cases,O
are,O
scarcely,O
represented,O
in,O
our,O
dataset,O
.,O
Managing,O
the,O
immediate,O
demands,O
of,O
the,O
current,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
global,O
pandemic,O
has,O
tested,O
many,O
healthcare,O
systems,O
across,O
the,O
world,O
",",O
to,O
their,O
limits,O
.,O
In,O
the,O
months,O
since,O
the,O
initial,O
outbreak,O
of,O
COVID-19,O
in,O
December,O
2019,O
",",O
worldwide,O
there,O
have,O
been,O
more,O
than,O
7.5,O
millions,O
cases,O
of,O
infection,O
with,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus-2,O
(,O
SARS,O
-,O
Cov-2,O
),O
reported,O
.,O
The,O
treatment,O
needs,O
of,O
COVID-19,O
survivors,O
are,O
not,O
yet,O
fully,O
appreciated,O
.,O
It,O
incorporates,O
the,O
cognitive,O
",",O
physical,O
",",O
and,O
psychological,O
dysfunction,O
reported,O
after,O
ICU,O
discharge,O
that,O
can,O
have,O
profound,O
effects,O
on,O
quality,O
of,O
life,O
.,O
It,O
is,O
likely,O
that,O
those,O
surviving,O
critical,O
illness,O
with,O
COVID-19,O
will,O
be,O
at,O
particular,O
risk,O
of,O
developing,O
chronic,O
pain,O
.,O
Owing,O
to,O
the,O
severity,O
of,O
COVID-19,O
critical,O
illness,O
",",O
it,O
is,O
likely,O
that,O
survivors,O
will,O
have,O
undergone,O
multiple,O
pain,O
-,O
associated,O
interventions,O
.,O
COVID-19,O
survivors,O
are,O
likely,O
to,O
have,O
sustained,O
a,O
prolonged,O
period,O
of,O
immobilisation,O
",",O
sedation,O
",",O
and,O
ventilation,O
",",O
putting,O
them,O
at,O
high,O
risk,O
of,O
associated,O
ICU,O
-,O
acquired,O
weakness,O
(,O
ICUAW,O
),O
.,O
Neuromuscular,O
block,O
is,O
now,O
highlighted,O
in,O
several,O
guideline,O
publications,O
as,O
a,O
strategy,O
to,O
improve,O
ventilation,O
in,O
those,O
with,O
acute,O
respiratory,O
distress,O
syndrome,O
(,O
ARDS,O
),O
associated,O
with,O
COVID-19,O
",",O
;,O
although,O
there,O
is,O
no,O
consensus,O
",",O
some,O
recommendations,O
also,O
include,O
use,O
of,O
corticosteroids,O
in,O
certain,O
populations,O
.,O
The,O
prevalence,O
of,O
ICUAW,O
in,O
the,O
general,O
ARDS,O
population,O
is,O
estimated,O
at,O
25–96,O
%,O
",",O
and,O
although,O
reported,O
after,O
the,O
Middle,O
East,O
respiratory,O
syndrome,O
(,O
MERS,O
),O
epidemic,O
it,O
is,O
yet,O
to,O
be,O
determined,O
in,O
those,O
critically,O
ill,O
with,O
COVID-19,O
.,O
A,O
mainstay,O
of,O
respiratory,O
support,O
through,O
the,O
COVID-19,O
pandemic,O
has,O
been,O
use,O
of,O
repeated,O
patient,O
proning,O
to,O
improve,O
ventilation,O
.,O
Reports,O
of,O
neurological,O
sequelae,O
of,O
COVID-19,O
infection,O
are,O
emerging,O
",",O
indicating,O
both,O
central,O
and,O
peripheral,O
nervous,O
system,O
involvement,O
;,O
symptoms,O
such,O
as,O
confusion,O
",",O
headache,O
and,O
dizziness,O
",",O
and,O
anosmia,O
",",O
ageusia,O
",",O
and,O
nerve,O
pain,O
are,O
now,O
described,O
in,O
retrospective,O
cohorts,O
and,O
case,O
reports,O
.,O
It,O
is,O
now,O
clear,O
that,O
COVID-19,O
itself,O
is,O
associated,O
with,O
painful,O
symptoms,O
",",O
including,O
myalgia,O
",",O
arthralgia,O
",",O
abdominal,O
pain,O
",",O
headache,O
",",O
and,O
chest,O
pain,O
",",O
and,O
even,O
those,O
not,O
admitted,O
to,O
critical,O
care,O
environments,O
may,O
have,O
pain,O
requiring,O
opioids,O
for,O
symptom,O
management,O
.,O
An,O
important,O
area,O
to,O
recognise,O
is,O
the,O
psychological,O
impact,O
of,O
COVID-19,O
",",O
with,O
the,O
unique,O
social,O
restrictions,O
likely,O
to,O
create,O
an,O
additional,O
burden,O
.,O
In,O
COVID-19,O
this,O
may,O
be,O
augmented,O
by,O
separation,O
from,O
personal,O
protective,O
equipment,O
(,O
PPE,O
),O
adding,O
to,O
the,O
already,O
alien,O
environment,O
",",O
breakdown,O
of,O
social,O
networks,O
",",O
and,O
fear,O
of,O
mortality,O
;,O
this,O
increases,O
the,O
potential,O
for,O
development,O
of,O
PTSD,O
",",O
anxiety,O
",",O
and,O
depression,O
",",O
as,O
observed,O
in,O
the,O
SARS,O
outbreak,O
.,O
Even,O
baseline,O
patient,O
characteristics,O
",",O
identified,O
as,O
factors,O
associated,O
with,O
the,O
development,O
of,O
severe,O
COVID-19,O
",",O
overlap,O
with,O
those,O
associated,O
with,O
chronic,O
pain,O
after,O
critical,O
illness,O
",",O
including,O
multi,O
-,O
morbidity,O
and,O
increasing,O
age,O
.,O
Emerging,O
reports,O
from,O
Wuhan,O
",",O
which,O
is,O
now,O
operating,O
several,O
rehabilitation,O
institutions,O
for,O
COVID-19,O
survivors,O
",",O
and,O
Italy,O
indicate,O
a,O
significant,O
symptom,O
burden,O
in,O
COVID-19,O
survivors,O
including,O
anxiety,O
",",O
sleep,O
disorders,O
",",O
fatigue,O
",",O
limited,O
exercise,O
tolerance,O
",",O
and,O
memory,O
and,O
executive,O
function,O
impairment,O
.,O
There,O
is,O
conflicting,O
evidence,O
on,O
the,O
beneficial,O
effects,O
of,O
post,O
-,O
ICU,O
rehabilitation,O
strategies,O
in,O
general,O
on,O
exercise,O
tolerance,O
and,O
health,O
-,O
related,O
quality,O
of,O
life,O
in,O
the,O
pre,O
-,O
COVID,O
era,O
.,O
",",O
 ,O
Qualitative,O
evaluation,O
suggests,O
increased,O
patient,O
satisfaction,O
and,O
reduced,O
anxiety,O
.,O
The,O
make,O
-,O
up,O
of,O
such,O
services,O
may,O
also,O
need,O
to,O
be,O
adjusted,O
to,O
address,O
COVID-19,O
-,O
specific,O
sequelae,O
",",O
and,O
this,O
may,O
represent,O
an,O
opportunity,O
to,O
develop,O
better,O
links,O
between,O
pain,O
and,O
ICU,O
survivorship,O
programmes,O
",",O
and,O
improving,O
dialogue,O
with,O
other,O
specialties,O
such,O
as,O
renal,O
",",O
respiratory,O
",",O
and,O
mental,O
health,O
to,O
build,O
existing,O
collaborations,O
and,O
manage,O
multi,O
-,O
morbidity,O
.,O
Pain,O
services,O
are,O
traditionally,O
multidisciplinary,O
",",O
incorporating,O
physical,O
and,O
psychological,O
expertise,O
with,O
the,O
goal,O
of,O
improving,O
function,O
and,O
quality,O
of,O
life,O
",",O
and,O
could,O
therefore,O
have,O
a,O
great,O
deal,O
to,O
offer,O
overwhelmed,O
critical,O
care,O
services,O
.,O
It,O
causes,O
severe,O
respiratory,O
illness,O
",",O
which,O
the,O
WHO,O
recently,O
named,O
COVID-19,O
disease,O
.,O
A,O
reference,O
dataset,O
of,O
previously,O
published,O
coronavirus,O
whole,O
-,O
genome,O
sequences,O
(,O
WGS,O
),O
was,O
compiled,O
from,O
the,O
Virus,B-Repository
Pathogen,I-Repository
Resource,I-Repository
(VIPR),E-Repository
 ,O
database,O
(,O
www.viprbrc.org,S-URL
),O
.,O
This,O
dataset,O
consisted,O
of,O
386,O
WGS,O
of,O
nine,O
important,O
coronavirus,O
species,O
.,O
To,O
this,O
reference,O
dataset,O
",",O
we,O
added,O
47,O
whole,O
genomes,O
of,O
the,O
current,O
Coronavirus,O
2019,O
(,O
SARS,O
-,O
CoV-2,O
),O
outbreak,O
that,O
originated,O
in,O
Wuhan,O
",",O
China,O
",",O
in,O
December,O
2019,O
.,O
The,O
SARS,O
-,O
CoV-2,O
sequences,O
were,O
downloaded,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
(,O
https://www.gisaid.org,S-URL
),O
together,O
with,O
annotation,O
of,O
its,O
original,O
location,O
",",O
collection,O
date,O
and,O
originating,O
and,O
submitting,O
laboratory,O
.,O
Cluster,O
5,O
(,O
virus,O
named,O
SARS,O
-,O
CoV-2,O
by,O
the,O
ICTV,O
committee,O
and,O
disease,O
named,O
COVID-19,O
by,O
the,O
WHO,O
),O
includes,O
three,O
public,O
sequences,O
from,O
the,O
outbreak,O
.,O
We,O
identified,O
this,O
cluster,O
with,O
many,O
sequences,O
from,O
GISAID,S-Dataset
 ,O
but,O
kept,O
only,O
three,O
ones,O
as,O
these,O
were,O
the,O
first,O
GenBank,S-Repository
 ,O
sequences,O
.,O
Detailed,O
information,O
about,O
the,O
phylogenetic,O
reference,O
datasets,O
is,O
available,O
in,O
Supplementary,O
Table,O
S2,O
.,O
The,O
phylogenetic,O
reference,O
dataset,O
was,O
used,O
to,O
create,O
an,O
automated,O
Coronavirus,O
Typing,O
Tool,O
using,O
the,O
Genome,O
Detective,O
framework,O
(,O
Fonseca,O
;,O
Vilsker,O
),O
.,O
In,O
the,O
second,O
step,O
",",O
a,O
query,O
sequence,O
is,O
aligned,O
against,O
the,O
phylogenetic,O
reference,O
dataset,O
using,O
-add,O
alignment,O
option,O
in,O
the,O
MAFFT,O
software,O
(,O
Katoh,O
and,O
Standley,O
",",O
2013,O
),O
.,O
This,O
table,O
can,O
be,O
expanded,O
to,O
show,O
nucleotide,O
and,O
amino,O
acid,O
mutations,O
that,O
differentiate,O
a,O
query,O
sequence,O
from,O
their,O
species,O
RefSeq,S-Repository
 ,O
or,O
from,O
a,O
sequence,O
in,O
the,O
phylogenetic,O
reference,O
dataset,O
.,O
Tool,O
also,O
allows,O
a,O
query,O
sequence,O
to,O
be,O
analyzed,O
against,O
a,O
sequence,O
in,O
the,O
phylogenetic,O
reference,O
dataset,O
.,O
When,O
the,O
SARS,O
-,O
CoV-2,O
isolated,O
from,O
France,O
(,O
BetaCoV,O
/,O
France,O
/,O
IDF0373/2020,O
),O
was,O
analyzed,O
with,O
our,O
tool,O
and,O
compared,O
with,O
the,O
SARS,O
-,O
CoV-2,O
WH_Human1_China_2019Dec,O
strain,O
(,O
Accession,O
:,O
MN908947,S-AccessionNumber
),O
",",O
this,O
sequence,O
was,O
99.9,O
%,O
identical,O
and,O
had,O
only,O
two,O
NT,O
mutations,O
(,O
Supplementary,O
Table,O
S4C,O
),O
.,O
We,O
developed,O
and,O
released,O
the,O
Genome,O
Detective,O
Coronavirus,O
Typing,O
tool,O
as,O
a,O
free,O
-,O
of,O
-,O
charge,O
resource,O
in,O
the,O
third,O
week,O
of,O
January,O
2020,O
in,O
order,O
to,O
help,O
the,O
rapid,O
characterization,O
of,O
COVID-19,O
infections,O
.,O
Abstract,O
  ,O
Summary,O
 ,O
Genome,O
detective,O
is,O
a,O
web,O
-,O
based,O
",",O
user,O
-,O
friendly,O
software,O
application,O
to,O
quickly,O
and,O
accurately,O
assemble,O
all,O
known,O
virus,O
genomes,O
from,O
next,O
-,O
generation,O
sequencing,O
datasets,O
.,O
The,O
tool,O
also,O
allows,O
tracking,O
of,O
new,O
viral,O
mutations,O
as,O
the,O
outbreak,O
expands,O
globally,O
",",O
which,O
may,O
help,O
to,O
accelerate,O
the,O
development,O
of,O
novel,O
diagnostics,O
",",O
drugs,O
and,O
vaccines,O
to,O
stop,O
the,O
COVID-19,O
disease,O
.,O
On,O
March,O
11th,O
",",O
2020,O
",",O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
has,O
officially,O
declared,O
the,O
novel,O
coronavirus,O
(,O
COVID-19,O
),O
outbreak,O
a,O
global,O
pandemic,O
.,O
Estimates,O
of,O
LOD,O
based,O
on,O
CPE,O
observation,O
on,O
VERO,O
cells,O
were,O
found,O
to,O
be,O
in,O
the,O
range,O
of,O
1,O
 ,O
×,O
 ,O
101–1,O
 ,O
×,O
 ,O
10−2,O
TCID50,O
for,O
a,O
wide,O
group,O
of,O
viral,O
families,O
(,O
Gombold,O
et,O
al,O
.,O
",",O
2014,O
),O
.,O
A,O
dataset,O
of,O
3.995,O
SARS,O
-,O
CoV-2,O
genomic,O
sequences,O
was,O
retrieved,O
from,O
GISAID,S-Dataset
 ,O
database,O
(,O
Elbe,B-Creator
and,I-Creator
"Buckland-Merrett,",I-Creator
2017,E-Creator
),O
.,O
The,O
multi,O
-,O
genome,O
alignment,O
including,O
our,O
genome,O
",",O
GISAID,S-Dataset
 ,O
genomes,O
and,O
reference,O
genome,O
was,O
obtained,O
using,O
the,O
Purple,O
pipeline,O
(,O
Gona,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
(,O
available,O
at,O
https://skynet.unimi.it/index.php/tools/purple-tool/,O
),O
.,O
Phylogenetic,O
analysis,O
(,O
Fig,O
.,O
3,O
),O
revealed,O
that,O
the,O
sequenced,O
strain,O
is,O
closely,O
related,O
to,O
a,O
SARS,O
-,O
CoV-2,O
strain,O
isolated,O
on,O
March,O
",",O
3rd,O
",",O
2020,O
in,O
Milan,O
(,O
GISAID,S-Dataset
 ,O
code,O
EPI_ISL_413489,S-AccessionNumber
),O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
morbidity,O
and,O
mortality,O
has,O
been,O
overwhelmingly,O
concentrated,O
in,O
elderly,O
individuals,O
and,O
those,O
with,O
preexisting,O
comorbidities,O
[,O
1,O
],O
.,O
However,O
",",O
the,O
mechanisms,O
behind,O
increased,O
mortality,O
among,O
older,O
adults,O
and,O
males,O
with,O
COVID-19,O
remain,O
speculative,O
.,O
While,O
genes,O
up,O
-,O
regulated,O
in,O
high,O
viral,O
load,O
samples,O
were,O
dominated,O
by,O
proinflammatory,O
and/or,O
interferon,O
-,O
induced,O
factors,O
such,O
as,O
CXCL9/10,O
",",O
IDO1,O
",",O
and,O
CD80,O
",",O
genes,O
with,O
higher,O
expression,O
in,O
low,O
viral,O
load,O
samples,O
included,O
chemokines,O
for,O
neutrophils,O
(,O
CXCL8,O
",",O
S100A9,O
),O
",",O
and,O
B,O
cell,O
–,O
specific,O
transcripts,O
(,O
FCRL2,O
",",O
IGHG1,O
",",O
IGHM,O
",",O
IGLL5,O
",",O
IGHG2,O
",",O
CD22,O
),O
.,O
Clinically,O
",",O
COVID-19,O
cases,O
tend,O
to,O
be,O
more,O
severe,O
for,O
older,O
adults,O
and,O
males,O
[,O
1,O
],O
.,O
In,O
men,O
",",O
we,O
found,O
down,O
-,O
regulation,O
of,O
B,O
cell,O
–,O
specific,O
transcripts,O
(,O
IGHG1,O
and,O
MSA4A,O
/,O
CD20,O
),O
",",O
down,O
-,O
regulation,O
of,O
the,O
NK,O
cell,O
–,O
activating,O
receptor,O
SLAMF6,O
",",O
and,O
an,O
up,O
-,O
regulation,O
of,O
several,O
inhibitors,O
of,O
NFκB,O
signaling,O
(,O
NDRG1,O
",",O
ARRB2,O
",",O
CD300A,O
",",O
and,O
NFKBID,O
),O
(,O
Fig,O
5D,O
),O
.,O
Furthermore,O
",",O
the,O
reduction,O
in,O
NK,O
cell,O
–,O
activating,O
receptors,O
and,O
up,O
-,O
regulation,O
of,O
negative,O
regulators,O
of,O
immune,O
effector,O
function,O
—,O
and,O
resultant,O
throttling,O
of,O
effector,O
function,O
—,O
is,O
consistent,O
with,O
a,O
more,O
severe,O
manifestation,O
of,O
COVID-19,O
in,O
males,O
.,O
One,O
of,O
the,O
hallmarks,O
of,O
COVID-19,O
is,O
a,O
dysregulated,O
antiviral,O
immune,O
response,O
.,O
COVID-19,O
patients,O
frequently,O
develop,O
interleukin-6,O
(,O
IL-6)-driven,O
cytokine,O
release,O
syndrome,O
(,O
CRS,O
),O
",",O
and,O
elevated,O
serum,O
IL-6,O
correlates,O
with,O
respiratory,O
failure,O
and,O
poor,O
clinical,O
outcomes,O
[,O
37,O
],O
.,O
Treatment,O
with,O
the,O
IL-6,O
receptor,O
blocking,O
antibody,O
tocilizumab,O
has,O
effectively,O
treated,O
COVID-19,O
symptoms,O
in,O
some,O
patients,O
[,O
38,O
],O
.,O
Notably,O
",",O
the,O
dissection,O
of,O
interferon,O
responses,O
in,O
the,O
lower,O
respiratory,O
tract,O
will,O
be,O
important,O
in,O
light,O
of,O
recent,O
findings,O
that,O
type,O
III,O
interferons,O
in,O
particular,O
can,O
disrupt,O
healing,O
and,O
barrier,O
function,O
of,O
lung,O
epithelial,O
cells,O
following,O
viral,O
infection,O
[,O
"39,40",O
],O
",",O
a,O
possible,O
counterindication,O
to,O
the,O
proposed,O
use,O
of,O
type,O
III,O
interferon,O
as,O
treatment,O
for,O
COVID-19,O
.,O
Immune,O
dysfunctions,O
in,O
older,O
individuals,O
are,O
well,O
-,O
characterized,O
[,O
"2,3,32,33",O
],O
and,O
likely,O
contribute,O
to,O
poorer,O
COVID-19,O
outcomes,O
;,O
results,O
from,O
clinical,O
trials,O
of,O
type,O
I,O
and,O
III,O
interferons,O
in,O
severely,O
ill,O
patients,O
are,O
likely,O
to,O
further,O
define,O
the,O
role,O
of,O
interferon,O
signaling,O
in,O
older,O
adults,O
[,O
48–50,O
],O
.,O
The,O
observed,O
increased,O
expression,O
of,O
inhibitors,O
of,O
nuclear,O
factor,O
kappa,O
-,O
B,O
(,O
NF,O
-,O
κB,O
),O
in,O
males,O
with,O
SARS,O
-,O
CoV-2,O
may,O
represent,O
either,O
inappropriate,O
throttling,O
of,O
the,O
antiviral,O
immune,O
response,O
or,O
an,O
adaptive,O
mechanism,O
to,O
reduce,O
deleterious,O
inflammation,O
",",O
a,O
hallmark,O
of,O
COVID-19,O
pathogenesis,O
.,O
Correction,O
for,O
batch,O
effects,O
was,O
incorporated,O
into,O
the,O
design,O
formula,O
and,O
modeling,O
performed,O
using,O
the,O
Wald,O
test,O
with,O
outlier,O
replacement,O
.,O
Gene,O
expression,O
differences,O
attributable,O
to,O
sex,O
or,O
age,O
were,O
incorporated,O
into,O
the,O
design,O
formula,O
as,O
interaction,O
terms,O
.,O
The,O
viral,O
load,O
was,O
expressed,O
as,O
the,O
equivalent,O
of,O
log10,O
equivalents,O
per,O
mL,O
(,O
TCID50eq,O
/,O
mL,O
),O
and,O
compared,O
to,O
that,O
of,O
the,O
pre‐treatment,O
sample,O
.,O
Each,O
sample,O
was,O
tested,O
in,O
duplicate,O
",",O
and,O
the,O
mean,O
is,O
reported,O
as,O
TCID50eq,O
/,O
mL.,O
As,O
shown,O
in,O
Table,O
 ,O
2,O
",",O
positive,O
controls,O
and,O
pre‐treatment,O
samples,O
from,O
all,O
units,O
had,O
a,O
log10,O
TCID50eq,O
/,O
mL,O
equivalent,O
to,O
the,O
infectious,O
viral,O
titre,O
determined,O
by,O
plaque,O
assay,O
as,O
shown,O
in,O
Table,O
 ,O
1,O
.,O
The,O
ongoing,O
outbreak,O
of,O
COVID-19,O
in,O
the,O
Chinese,O
city,O
of,O
Wuhan,O
(,O
Hubei,O
province,O
),O
[,O
1,O
],O
and,O
its,O
alarmingly,O
quick,O
transmission,O
to,O
25,O
other,O
countries,O
across,O
the,O
world,O
[,O
2,O
],O
resulted,O
in,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
declaring,O
a,O
global,O
health,O
emergency,O
on,O
30,O
January,O
2020,O
[,O
3,O
],O
.,O
WHO,O
",",O
in,O
its,O
first,O
emergency,O
meeting,O
[,O
5,O
],O
",",O
estimated,O
the,O
fatality,O
rate,O
of,O
COVID-19,O
to,O
be,O
around,O
4,O
%,O
.,O
A,O
total,O
of,O
120,O
whole,O
genome,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
were,O
downloaded,O
on,O
21,O
February,O
2020,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
(,O
https://www.gisaid.org/CoV2020/,S-URL
),O
We,O
excluded,O
sequences,O
that,O
likely,O
had,O
spurious,O
mutations,O
resulting,O
from,O
sequencing,O
errors,O
",",O
as,O
indicated,O
in,O
the,O
comment,O
field,O
of,O
the,O
GISAID,S-Dataset
 ,O
data,O
.,O
These,O
nucleotide,O
sequences,O
were,O
aligned,O
to,O
the,O
GenBank,S-Repository
 ,O
reference,O
sequence,O
(,O
accession,O
ID,O
:,O
NC_045512.2,S-AccessionNumber
),O
and,O
then,O
translated,O
into,O
amino,O
acid,O
residues,O
according,O
to,O
the,O
coding,O
sequence,O
positions,O
provided,O
along,O
the,O
reference,O
sequence,O
for,O
SARS,O
-,O
CoV-2,O
proteins,O
(,O
orf1a,O
",",O
orf1b,O
",",O
S,O
",",O
ORF3a,O
",",O
E,O
",",O
M,O
",",O
ORF6,O
",",O
ORF7a,O
",",O
ORF7b,O
",",O
ORF8,O
",",O
N,O
",",O
and,O
ORF10,O
),O
.,O
Reference,O
protein,O
sequences,O
for,O
SARS,O
-,O
CoV,O
and,O
MERS,O
-,O
CoV,O
were,O
obtained,O
following,O
the,O
same,O
procedure,O
from,O
GenBank,S-Repository
 ,O
using,O
the,O
accession,O
IDs,O
NC_004718.3,S-AccessionNumber
 ,O
and,O
NC_019843.3,S-AccessionNumber
",",O
respectively,O
.,O
B,O
cell,O
and,O
T,O
cell,O
epitopes,O
were,O
searched,O
on,O
the,O
NIAID,S-Creator
 ,O
Virus,B-Repository
Pathogen,I-Repository
Database,I-Repository
and,I-Repository
Analysis,I-Repository
Resource,I-Repository
(ViPR),E-Repository
 ,O
(,O
https://www.viprbrc.org/,S-URL
;,O
accessed,O
21,O
February,O
2020,O
),O
[,O
29,O
],O
by,O
querying,O
for,O
the,O
virus,O
species,O
name,O
:,O
“,O
Severe,O
acute,O
respiratory,O
syndrome,O
-,O
related,O
coronavirus,O
”,O
from,O
“,O
human,O
”,O
hosts,O
.,O
However,O
",",O
for,O
brevity,O
and,O
to,O
be,O
consistent,O
with,O
the,O
terminology,O
used,O
in,O
the,O
ViPR,S-Repository
 ,O
database,O
",",O
we,O
will,O
not,O
make,O
this,O
qualification,O
",",O
and,O
will,O
simply,O
refer,O
to,O
them,O
as,O
epitopes,O
in,O
this,O
study,O
.,O
The,O
number,O
of,O
B,O
cell,O
and,O
T,O
cell,O
epitopes,O
obtained,O
from,O
the,O
database,O
following,O
the,O
above,O
procedure,O
is,O
listed,O
in,O
Table,O
1,O
.,O
We,O
additionally,O
included,O
the,O
Zaria,O
Bat,O
coronavirus,O
strain,O
(,O
accession,O
ID,O
:,O
HQ166910.1,S-AccessionNumber
),O
to,O
serve,O
as,O
an,O
outgroup,O
.,O
We,O
also,O
computed,O
the,O
population,O
coverage,O
of,O
this,O
specific,O
set,O
of,O
epitopes,O
in,O
China,O
",",O
the,O
country,O
most,O
affected,O
by,O
the,O
COVID-19,O
outbreak,O
",",O
which,O
was,O
estimated,O
to,O
be,O
slightly,O
lower,O
(,O
88.11,O
%,O
),O
",",O
as,O
certain,O
MHC,O
alleles,O
(,O
e.g.,O
",",O
HLA,O
-,O
A*02:01,O
),O
associated,O
with,O
some,O
of,O
these,O
epitopes,O
are,O
less,O
frequent,O
in,O
the,O
Chinese,O
population,O
(,O
Table,O
3,O
),O
.,O
On,O
the,O
other,O
hand,O
",",O
all,O
6,O
SARS,O
-,O
CoV,O
-,O
derived,O
discontinuous,O
B,O
cell,O
epitopes,O
obtained,O
from,O
the,O
ViPR,O
database,O
(,O
Table,O
5,O
),O
were,O
derived,O
from,O
the,O
S,O
protein,O
.,O
A,O
preliminary,O
analysis,O
of,O
linear,O
SARS,O
-,O
CoV,O
-,O
derived,O
B,O
cell,O
epitopes,O
has,O
been,O
reported,O
online,O
on,O
the,O
ViPR,S-Repository
 ,O
database,O
website,O
(,O
https://www.viprbrc.org/brcDocs/documents/announcements/Corona/2019-nCoV-ViPR-report_24JAN2020.pdf,S-URL
),O
.,O
The,O
beginning,O
of,O
2020,O
has,O
seen,O
the,O
emergence,O
of,O
COVID-19,O
outbreak,O
caused,O
by,O
a,O
novel,O
coronavirus,O
",",O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
and,O
first,O
reported,O
from,O
Wuhan,O
",",O
Hubei,O
Province,O
",",O
China,O
[,O
1,O
],O
.,O
Clinical,O
manifestations,O
of,O
COVID-19,O
include,O
acute,O
pneumonia,O
detected,O
via,O
computed,O
tomography,O
imaging,O
or,O
radiological,O
examination,O
.,O
Although,O
the,O
medical,O
diagnosis,O
of,O
COVID-19,O
is,O
rapid,O
and,O
efficient,O
",",O
effective,O
treatments,O
do,O
not,O
yet,O
exist,O
[,O
6,O
],O
.,O
In,O
China,O
",",O
clinical,O
trials,O
are,O
being,O
conducted,O
with,O
patients,O
at,O
Wuhan,O
hospitals,O
to,O
determine,O
whether,O
high,O
doses,O
of,O
VC,O
can,O
manage,O
COVID-19,O
[,O
ClinicalTrials.gov,O
Identifier,O
:,O
NCT04264533,S-AccessionNumber
],O
.,O
Thus,O
",",O
combining,O
VC,O
with,O
existing,O
medicines,O
or,O
bioactive,O
compounds,O
may,O
enhance,O
the,O
former,O
’s,O
therapeutic,O
effectiveness,O
against,O
COVID-19,O
while,O
minimizing,O
side,O
effects,O
.,O
Based,O
on,O
the,O
potent,O
pharmacological,O
properties,O
of,O
both,O
VC,O
and,O
GA,O
",",O
their,O
combined,O
use,O
may,O
effectively,O
manage,O
COVID-19,O
.,O
At,O
this,O
time,O
",",O
no,O
empirical,O
data,O
supports,O
the,O
clinical,O
efficacy,O
of,O
VC,O
 ,O
+,O
 ,O
GA,O
treatment,O
against,O
COVID-19,O
has,O
not,O
been,O
investigated,O
.,O
However,O
",",O
we,O
can,O
perform,O
bioinformatics,O
analysis,O
as,O
a,O
theoretical,O
evaluation,O
of,O
potential,O
anti,O
-,O
COVID-19,O
molecular,O
mechanisms,O
of,O
VC,O
 ,O
+,O
 ,O
GA,O
to,O
support,O
future,O
clinical,O
trials,O
.,O
GA,O
treatment,O
against,O
the,O
novel,O
coronavirus,O
",",O
thereby,O
uncovering,O
anti,O
-,O
COVID-19,O
processes,O
and,O
mechanisms,O
in,O
detail,O
(,O
Figure,O
1,O
),O
.,O
Potential,O
targets,O
were,O
acquired,O
after,O
a,O
thorough,O
analysis,O
of,O
the,O
Traditional,B-Dataset
Chinese,I-Dataset
Medicine,I-Dataset
Systems,I-Dataset
Pharmacology,I-Dataset
(TCMSP),E-Dataset
 ,O
[,O
23,O
],O
",",O
Drugbank,S-Repository
 ,O
[,O
24,O
],O
",",O
SuperPred,S-Dataset
",",O
Swiss,B-Dataset
Target,I-Dataset
Prediction,E-Dataset
 ,O
[,O
25,O
],O
",",O
ChemMapper,S-Dataset
 ,O
[,O
26,O
],O
",",O
Bioinformatics,B-Dataset
Analysis,I-Dataset
Tool,I-Dataset
for,I-Dataset
Molecular,I-Dataset
mechANism,I-Dataset
of,I-Dataset
Traditional,I-Dataset
Chinese,I-Dataset
Medicine,I-Dataset
(BATMAN,I-Dataset
TCM),E-Dataset
 ,O
[,O
27,O
],O
and,O
SuperPred,S-Dataset
 ,O
webserver,O
[,O
28,O
],O
datasets,O
.,O
Functional,O
targets,O
of,O
VC,O
and,O
GA,O
in,O
humans,O
were,O
selected,O
from,O
the,O
Swiss-Prot,S-Repository
 ,O
and,O
Uniprot,S-Repository
 ,O
databases,O
[,O
29,O
],O
.,O
Genecard,S-Repository
 ,O
[,O
30,O
],O
and,O
Online,B-Repository
Mendelian,I-Repository
Inheritance,I-Repository
in,I-Repository
Man,I-Repository
(OMIM),E-Repository
 ,O
[,O
31,O
],O
databases,O
were,O
used,O
to,O
screen,O
SARS,O
-,O
CoV-2,O
pathogenic,O
targets,O
.,O
Custom,O
Venn,O
diagrams,O
(,O
http://bioinformatics.psb.ugent.be/webtools/Venn/,O
),O
were,O
created,O
to,O
show,O
correlative,O
targets,O
of,O
VC,O
and,O
GA,O
against,O
COVID-19,O
.,O
Cytoscape,O
version,O
3.7.1,O
was,O
used,O
to,O
construct,O
visualizations,O
of,O
the,O
component,O
-,O
target,O
-,O
pathway,O
network,O
",",O
GO,O
biological,O
processes,O
and,O
KEGG,O
pathways,O
of,O
VC,O
and,O
GA,O
’s,O
individual,O
and,O
combined,O
effects,O
against,O
COVID-19,O
[,O
34,O
],O
.,O
We,O
performed,O
pairwise,O
comparisons,O
on,O
bioinformational,O
data,O
of,O
the,O
top,O
20,O
biological,O
processes,O
and,O
KEGG,O
-,O
enriched,O
pathways,O
involved,O
in,O
the,O
separate,O
therapeutic,O
effects,O
of,O
VC,O
and,O
GA,O
against,O
COVID-19,O
.,O
We,O
used,O
common,O
targets,O
of,O
VC,O
and,O
GA,O
against,O
SARS,O
-,O
CoV-19,O
as,O
inputs,O
to,O
a,O
STRING,O
database,O
(,O
version,O
11.0,O
),O
[,O
36,O
],O
",",O
creating,O
target,O
-,O
to,O
-,O
target,O
network,O
interactions,O
and,O
a,O
target,O
interaction,O
PPI,O
network,O
diagram,O
.,O
We,O
screened,O
Genecard,S-Repository
 ,O
and,O
OMIM,S-Repository
 ,O
datasets,O
to,O
identify,O
426,O
COVID-19,O
-,O
associated,O
genes,O
.,O
Venn,O
diagrams,O
revealed,O
34,O
VC,O
-,O
intersection,O
(,O
Figure,O
2A,O
),O
and,O
28,O
GA,O
-,O
intersection,O
(,O
Figure,O
2B,O
),O
targets,O
against,O
COVID-19,O
.,O
The,O
results,O
of,O
GO,O
analysis,O
suggested,O
that,O
the,O
biological,O
processes,O
of,O
core,O
VC,O
targets,O
against,O
COVID-19,O
were,O
mainly,O
involved,O
in,O
peptidyl,O
-,O
serine,O
phosphorylation,O
",",O
peptidyl,O
-,O
serine,O
modification,O
",",O
regulation,O
of,O
cell,O
–,O
cell,O
adhesion,O
",",O
cellular,O
response,O
to,O
biotic,O
stimulus,O
",",O
positive,O
regulation,O
of,O
nucleocytoplasmic,O
transport,O
",",O
regulation,O
of,O
leukocyte,O
cell,O
–,O
cell,O
adhesion,O
",",O
regulation,O
of,O
T,O
cell,O
activation,O
",",O
response,O
to,O
lipopolysaccharide,O
",",O
T,O
cell,O
activation,O
",",O
blood,O
coagulation,O
",",O
leukocyte,O
cell,O
–,O
cell,O
adhesion,O
",",O
cellular,O
response,O
to,O
external,O
stimulus,O
",",O
hemostasis,O
",",O
coagulation,O
",",O
response,O
to,O
molecule,O
of,O
bacterial,O
origin,O
",",O
platelet,O
activation,O
",",O
fatty,O
acid,O
metabolic,O
process,O
",",O
positive,O
regulation,O
of,O
cell,O
adhesion,O
",",O
regulation,O
of,O
nucleocytoplasmic,O
transport,O
and,O
positive,O
regulation,O
of,O
protein,O
transport,O
(,O
Figure,O
3A,O
and,O
B,O
and,O
Supplementary,O
Table,O
1,O
",",O
see,O
Supplementary,O
Data,O
available,O
online,O
at,O
https://academic.oup.com/bib,S-URL
),O
.,O
The,O
GO,O
data,O
indicated,O
that,O
functional,O
processes,O
of,O
core,O
GA,O
targets,O
against,O
COVID-19,O
were,O
associated,O
with,O
response,O
to,O
lipopolysaccharide,O
",",O
cellular,O
response,O
to,O
abiotic,O
stimulus,O
",",O
cellular,O
response,O
to,O
environmental,O
stimulus,O
",",O
response,O
to,O
molecule,O
of,O
bacterial,O
origin,O
",",O
placenta,O
development,O
",",O
peptidyl,O
-,O
serine,O
phosphorylation,O
",",O
reproductive,O
structure,O
development,O
",",O
reproductive,O
system,O
development,O
",",O
peptidyl,O
-,O
serine,O
modification,O
",",O
lipopolysaccharide,O
-,O
mediated,O
signaling,O
pathway,O
",",O
cellular,O
response,O
to,O
external,O
stimulus,O
",",O
platelet,O
activation,O
",",O
regulation,O
of,O
cell,O
–,O
cell,O
adhesion,O
",",O
cellular,O
response,O
to,O
mechanical,O
stimulus,O
",",O
positive,O
regulation,O
of,O
establishment,O
of,O
protein,O
localization,O
",",O
peptidyl,O
-,O
tyrosine,O
autophosphorylation,O
",",O
T,O
cell,O
activation,O
",",O
cellular,O
response,O
to,O
lipopolysaccharide,O
",",O
interaction,O
with,O
host,O
and,O
response,O
to,O
mechanical,O
stimulus,O
(,O
Figure,O
4A,O
and,O
B,O
and,O
Supplementary,O
Table,O
3,O
",",O
see,O
Supplementary,O
Data,O
available,O
online,O
at,O
https://academic.oup.com/bib,O
),O
.,O
We,O
then,O
used,O
the,O
‘,O
pathview,O
’,O
package,O
in,O
R,O
to,O
generate,O
network,O
diagrams,O
that,O
highlighted,O
core,O
targets,O
of,O
enriched,O
KEGG,O
pathways,O
for,O
VC,O
against,O
COVID-19,O
(,O
Supplementary,O
Figure,O
1,O
",",O
see,O
Supplementary,O
Data,O
available,O
online,O
at,O
https://academic.oup.com/bib,S-URL
),O
and,O
GA,O
against,O
COVID-19,O
(,O
Supplementary,O
Figure,O
2,O
",",O
see,O
Supplementary,O
Data,O
available,O
online,O
at,O
https://academic.oup.com/bib,S-URL
),O
.,O
We,O
identified,O
17,O
intersecting,O
targets,O
of,O
VC,O
and,O
GA,O
against,O
COVID-19,O
:,O
PRKCE,O
",",O
SLC6A4,O
",",O
CYP2D6,O
",",O
PRKCB,O
",",O
MAPK1,O
",",O
EGFR,O
",",O
DPP4,O
",",O
MAPK3,O
",",O
ABCB1,O
",",O
ATP1A1,O
",",O
MAPK14,O
",",O
LCK,O
",",O
CCR5,O
",",O
PTGS2,O
",",O
PTGS1,O
",",O
PRKCA,O
and,O
PTPRC,O
(,O
Figure,O
5,O
),O
.,O
The,O
top,O
10,O
GO,O
terms,O
of,O
VC,O
 ,O
+,O
 ,O
GA,O
against,O
COVID-19,O
were,O
cellular,O
response,O
to,O
external,O
stimulus,O
(,O
0071496,O
),O
",",O
peptidyl,O
-,O
serine,O
modification,O
(,O
0018209,O
),O
",",O
peptidyl,O
-,O
serine,O
phosphorylation,O
(,O
0018105,O
),O
",",O
platelet,O
activation,O
(,O
0030168,O
),O
",",O
regulation,O
of,O
cell,O
–,O
cell,O
adhesion,O
(,O
0022407,O
),O
",",O
response,O
to,O
lipopolysaccharide,O
(,O
0032496,O
),O
",",O
response,O
to,O
molecule,O
of,O
bacterial,O
origin,O
(,O
0002237,O
),O
",",O
T,O
cell,O
activation,O
(,O
0042110,O
),O
",",O
blood,O
coagulation,O
(,O
0007596,O
),O
and,O
leukocyte,O
cell,O
–,O
cell,O
adhesion,O
(,O
0007159,O
),O
(,O
Table,O
1,O
),O
.,O
GA,O
against,O
COVID-19,O
were,O
AGE,O
-,O
RAGE,O
signaling,O
pathway,O
in,O
diabetic,O
complications,O
(,O
hsa04933,O
),O
",",O
Aldosterone,O
-,O
regulated,O
sodium,O
reabsorption,O
(,O
hsa04960,O
),O
",",O
EGFR,O
tyrosine,O
kinase,O
inhibitor,O
resistance,O
(,O
hsa04960,O
),O
",",O
ErbB,O
signaling,O
pathway,O
(,O
hsa04012,O
),O
",",O
Fc,O
gamma,O
R,O
-,O
mediated,O
phagocytosis,O
(,O
hsa04666,O
),O
",",O
Glioma,O
(,O
hsa05214,O
),O
",",O
GnRH,O
signaling,O
pathway,O
(,O
hsa04912,O
),O
",",O
Human,O
cytomegalovirus,O
infection,O
(,O
hsa04912,O
),O
",",O
Kaposi,O
sarcoma,O
-,O
associated,O
herpesvirus,O
infection,O
(,O
hsa04912,O
),O
",",O
MicroRNAs,O
in,O
cancer,O
(,O
hsa05206,O
),O
",",O
Non,O
-,O
small,O
cell,O
lung,O
cancer,O
(,O
hsa05206,O
),O
",",O
Proteoglycans,O
in,O
cancer,O
(,O
hsa05205,O
),O
",",O
Serotonergic,O
synapse,O
(,O
hsa04726,O
),O
",",O
TCR,O
signaling,O
pathway,O
(,O
hsa04660,O
),O
and,O
VEGF,O
signaling,O
pathway,O
(,O
hsa04370,O
),O
(,O
Table,O
2,O
),O
.,O
Respectively,O
",",O
Figure,O
6A,O
and,O
B,O
shows,O
the,O
heatmaps,O
depicting,O
GO,O
biological,O
processes,O
and,O
KEGG,O
signaling,O
pathways,O
of,O
VC,O
 ,O
+,O
 ,O
GA,O
against,O
COVID-19,O
",",O
respectively,O
.,O
GA,O
-,O
target,O
-,O
GO,O
-,O
KEGG,O
-,O
COVID-19,O
using,O
the,O
top,O
20,O
enriched,O
GO,O
terms,O
and,O
KEGG,O
pathways,O
(,O
Figure,O
7,O
),O
.,O
Our,O
result,O
showed,O
that,O
VC,O
and,O
GA,O
shared,O
10,O
biological,O
processes,O
and,O
15,O
KEGG,O
pathways,O
",",O
representing,O
their,O
combined,O
anti,O
-,O
COVID-19,O
targets,O
.,O
As,O
the,O
COVID-19,O
pandemic,O
has,O
spread,O
worldwide,O
",",O
effective,O
management,O
and,O
treatment,O
strategies,O
targeting,O
SARS,O
-,O
CoV-2,O
are,O
in,O
urgent,O
demand,O
[,O
40,O
],O
.,O
Although,O
VC,O
and,O
GA,O
individually,O
have,O
potent,O
pharmacological,O
efficacy,O
against,O
viral,O
pneumonia,O
[,O
41,O
",",O
42,O
],O
",",O
no,O
study,O
has,O
investigated,O
their,O
combined,O
effects,O
or,O
potential,O
mechanisms,O
against,O
COVID-19,O
.,O
Here,O
",",O
we,O
used,O
a,O
potent,O
strategy,O
of,O
network,O
pharmacology,O
and,O
bioinformatics,O
(,O
including,O
GO,O
and,O
KEGG,O
),O
to,O
uncover,O
the,O
integrative,O
pharmacological,O
mechanism,O
of,O
VC,O
 ,O
+,O
 ,O
GA,O
against,O
COVID-19,O
.,O
GA,O
may,O
be,O
able,O
to,O
suppress,O
COVID-19,O
through,O
their,O
combined,O
antioxidative,O
",",O
antiviral,O
and,O
anti,O
-,O
inflammatory,O
effects,O
",",O
along,O
with,O
immune,O
system,O
activation,O
.,O
GA,O
against,O
COVID-19,O
involved,O
specific,O
modulations,O
of,O
immune,O
responses,O
",",O
such,O
as,O
Fc,O
gamma,O
R,O
-,O
mediated,O
phagocytosis,O
",",O
TCR,O
signaling,O
pathway,O
",",O
VEGF,O
signaling,O
pathway,O
and,O
human,O
cytomegalovirus,O
infection,O
.,O
When,O
VC,O
 ,O
+,O
 ,O
GA,O
activates,O
Fc,O
gamma,O
R,O
-,O
mediated,O
phagocytosis,O
and,O
TCR,O
",",O
these,O
processes,O
may,O
facilitate,O
the,O
host,O
to,O
initiate,O
an,O
immune,O
response,O
against,O
COVID-19,O
.,O
Our,O
molecular,O
functional,O
analysis,O
revealed,O
that,O
key,O
effectors,O
regulate,O
the,O
anti,O
-,O
COVID-19,O
properties,O
just,O
described,O
.,O
GA,O
treatment,O
against,O
COVID-19,O
is,O
LCK,O
",",O
a,O
tyrosine,O
kinase,O
that,O
contributes,O
to,O
intracellular,O
signaling,O
pathways,O
of,O
lymphocytes,O
.,O
It,O
has,O
been,O
reported,O
that,O
COVID-19,O
patients,O
with,O
severe,O
and,O
fatal,O
disease,O
had,O
significantly,O
increase,O
in,O
white,O
blood,O
cell,O
number,O
and,O
decreased,O
lymphocyte,O
and,O
platelet,O
counts,O
[,O
67,O
",",O
68,O
],O
.,O
GA,O
treatment,O
should,O
exert,O
potent,O
antiviral,O
and,O
anti,O
-,O
inflammatory,O
effects,O
through,O
the,O
activation,O
of,O
immune,O
system,O
",",O
suggesting,O
the,O
possible,O
use,O
of,O
VC,O
 ,O
+,O
 ,O
GA,O
as,O
optional,O
treatment,O
of,O
COVID-19,O
.,O
In,O
upcoming,O
clinical,O
treatments,O
for,O
COVID-19,O
",",O
VC,O
 ,O
+,O
 ,O
GA,O
supplementation,O
may,O
potentiate,O
the,O
therapeutic,O
effectiveness,O
of,O
existing,O
medicines,O
such,O
as,O
Remdesivir,O
.,O
However,O
",",O
more,O
studies,O
are,O
needed,O
to,O
confirm,O
the,O
action,O
of,O
VC,O
 ,O
+,O
 ,O
GA,O
on,O
COVID-19,O
",",O
as,O
we,O
currently,O
do,O
not,O
know,O
how,O
the,O
supplements,O
target,O
and,O
influence,O
the,O
virus,O
.,O
We,O
thus,O
find,O
VC,O
 ,O
+,O
 ,O
GA,O
",",O
a,O
promising,O
supplementary,O
treatment,O
against,O
COVID-19,O
",",O
which,O
is,O
worth,O
further,O
investigation,O
.,O
Abstract,O
  ,O
Objective,O
 ,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
a,O
fatal,O
and,O
fast,O
-,O
spreading,O
viral,O
infection,O
.,O
To,O
date,O
",",O
the,O
number,O
of,O
COVID-19,O
patients,O
worldwide,O
has,O
crossed,O
over,O
six,O
million,O
with,O
over,O
three,O
hundred,O
and,O
seventy,O
thousand,O
deaths,O
(,O
according,O
to,O
the,O
data,O
from,O
World,O
Health,O
Organization,O
;,O
updated,O
on,O
2,O
June,O
2020,O
),O
.,O
Although,O
COVID-19,O
can,O
be,O
rapidly,O
diagnosed,O
",",O
efficient,O
clinical,O
treatment,O
of,O
COVID-19,O
remains,O
unavailable,O
",",O
resulting,O
in,O
high,O
fatality,O
.,O
We,O
hypothesized,O
that,O
the,O
combination,O
of,O
VC,O
and,O
GA,O
is,O
a,O
potential,O
option,O
for,O
treating,O
COVID-19,O
.,O
GA,O
treatment,O
for,O
COVID-19,O
",",O
using,O
bioinformational,O
network,O
pharmacology,O
.,O
We,O
uncovered,O
optimal,O
targets,O
",",O
biological,O
processes,O
and,O
Kyoto,O
Encyclopedia,O
of,O
Genes,O
and,O
Genomes,O
(,O
KEGG,O
),O
pathways,O
of,O
VC,O
 ,O
+,O
 ,O
GA,O
against,O
COVID-19,O
.,O
Our,O
findings,O
suggested,O
that,O
combinatorial,O
VC,O
and,O
GA,O
treatment,O
for,O
COVID-19,O
was,O
associated,O
with,O
elevation,O
of,O
immunity,O
and,O
suppression,O
of,O
inflammatory,O
stress,O
",",O
including,O
activation,O
of,O
the,O
T,O
cell,O
receptor,O
signaling,O
pathway,O
",",O
regulation,O
of,O
Fc,O
gamma,O
R,O
-,O
mediated,O
phagocytosis,O
",",O
ErbB,O
signaling,O
pathway,O
and,O
vascular,O
endothelial,O
growth,O
factor,O
signaling,O
pathway,O
.,O
For,O
the,O
first,O
time,O
",",O
our,O
study,O
uncovered,O
the,O
pharmacological,O
mechanism,O
underlying,O
combined,O
VC,O
and,O
GA,O
treatment,O
for,O
COVID-19,O
.,O
The,O
initial,O
publications,O
describing,O
genomic,O
features,O
of,O
SARS,O
-,O
CoV-2,O
[,O
1–4,O
],O
used,O
Illumina,O
and,O
Oxford,O
nanopore,O
data,O
to,O
elucidate,O
the,O
sequence,O
composition,O
of,O
patient,O
specimens,O
(,O
although,O
only,O
Wu,O
and,O
colleagues,O
[,O
3,O
],O
explicitly,O
provided,O
the,O
accession,O
numbers,O
for,O
their,O
raw,O
short,O
-,O
read,O
sequencing,O
data,O
),O
.,O
We,O
preprocessed,O
currently,O
available,O
(,O
as,O
of,O
February,O
19,O
",",O
2020,O
),O
sequencing,O
read,O
data,O
sets,O
for,O
SARS,O
-,O
CoV-2,O
(,O
S1,O
Table,O
),O
by,O
removing,O
adapter,O
contamination,O
and,O
reads,O
derived,O
from,O
human,O
transcripts,O
and,O
combined,O
the,O
resulting,O
data,O
sets,O
.,O
There,O
is,O
no,O
public,O
access,O
to,O
sequence,O
reads,O
that,O
were,O
used,O
to,O
produce,O
these,O
assemblies,O
:,O
as,O
of,O
February,O
19,O
",",O
2020,O
—,O
more,O
than,O
2,O
months,O
since,O
the,O
beginning,O
of,O
the,O
outbreak,O
—,O
there,O
were,O
only,O
six,O
raw,O
data,O
sets,O
(,O
S1,O
Table,O
),O
.,O
Wu,O
and,O
colleagues,O
[,O
3,O
],O
identified,O
two,O
potential,O
recombination,O
breakpoints,O
within,O
the,O
SARS,O
-,O
CoV-2,O
S,O
gene,O
with,O
some,O
segments,O
having,O
higher,O
similarity,O
to,O
Bat,O
ZC45,O
and,O
ZXC21,O
coronaviruses,O
(,O
accessions,O
MG772933,S-AccessionNumber
 ,O
and,O
MG772934,S-AccessionNumber
",",O
respectively,O
),O
",",O
whereas,O
others,O
were,O
more,O
similar,O
to,O
SARS,O
Tor2,O
and,O
SZ3,O
isolates,O
(,O
accessions,O
AY274119,S-AccessionNumber
 ,O
and,O
AY304486,S-AccessionNumber
),O
.,O
The,O
goal,O
of,O
our,O
study,O
was,O
to,O
(,O
1,O
),O
raise,O
awareness,O
of,O
the,O
lack,O
of,O
primary,O
data,O
necessary,O
to,O
effectively,O
respond,O
to,O
global,O
emergencies,O
such,O
as,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
outbreak,O
and,O
(,O
2,O
),O
demonstrate,O
that,O
all,O
analyses,O
can,O
be,O
performed,O
transparently,O
with,O
already,O
-,O
existing,O
open,O
-,O
source,O
publicly,O
available,O
tools,O
and,O
computational,O
infrastructure,O
.,O
Moreover,O
",",O
they,O
should,O
have,O
access,O
to,O
computational,O
infrastructure,O
that,O
can,O
execute,O
these,O
tools,O
and,O
apply,O
them,O
to,O
potentially,O
large,O
next,O
-,O
generation,O
sequencing,O
(,O
NGS,O
),O
data,O
sets,O
.,O
On,O
February,O
21,O
",",O
2020,O
new,O
human,O
data,O
sets,O
SRR11092056,S-AccessionNumber
",",O
SRR11092057,S-AccessionNumber
",",O
SRR11092058,S-AccessionNumber
",",O
and,O
SRR11092064,S-AccessionNumber
 ,O
were,O
added,O
to,O
the,O
SARS,O
-,O
CoV-2,O
archive,O
[,O
22,O
],O
.,O
Our,O
analyses,O
indicate,O
that,O
these,O
data,O
sets,O
contain,O
no,O
useful,O
SARS,O
-,O
CoV-2,O
data,O
[,O
23,O
],O
.,O
The,O
current,O
global,O
pneumonia,O
pandemic,O
has,O
been,O
attributed,O
to,O
an,O
outbreak,O
of,O
a,O
novel,O
coronavirus,O
named,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
which,O
causes,O
the,O
infectious,O
disease,O
known,O
as,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
[,O
1,O
],O
.,O
Symptoms,O
commonly,O
seen,O
in,O
COVID-19,O
patients,O
include,O
fever,O
",",O
cough,O
",",O
sore,O
throat,O
",",O
dyspnoea,O
[,O
"1,4,5",O
],O
.,O
Severe,O
COVID-19,O
manifests,O
as,O
SARS,O
",",O
lung,O
infections,O
",",O
end,O
-,O
stage,O
renal,O
disease,O
and,O
then,O
",",O
death,O
[,O
"5,6",O
],O
.,O
The,O
virus,O
has,O
also,O
been,O
detected,O
in,O
the,O
faeces,O
and,O
urine,O
of,O
COVID-19,O
patients,O
",",O
suggesting,O
a,O
faecal,O
-,O
oral,O
transmission,O
route,O
[,O
1,O
],O
.,O
COVID-19,O
is,O
a,O
tale,O
of,O
the,O
immunopathology,O
of,O
SARS,O
-,O
CoV-2,O
.,O
Therefore,O
",",O
researchers,O
and,O
clinicians,O
should,O
not,O
only,O
look,O
at,O
inhibiting,O
the,O
virus,O
or,O
managing,O
symptoms,O
associated,O
with,O
the,O
disease,O
but,O
also,O
enhance,O
the,O
ability,O
of,O
the,O
immune,O
system,O
both,O
to,O
prevent,O
and,O
combat,O
COVID-19,O
[,O
7,O
],O
.,O
The,O
major,O
damage,O
inflicted,O
by,O
COVID-19,O
is,O
due,O
to,O
the,O
overbearing,O
effect,O
of,O
the,O
immune,O
system,O
on,O
virally,O
infected,O
cells,O
.,O
About,O
80,O
%,O
of,O
COVID-19,O
patients,O
manifest,O
mild,O
to,O
moderate,O
symptoms,O
of,O
the,O
disease,O
which,O
disappear,O
after,O
about,O
6,O
-,O
10,O
days,O
[,O
2,O
],O
.,O
Even,O
though,O
the,O
molecular,O
dynamics,O
underlying,O
morbidity,O
and,O
mortality,O
is,O
yet,O
to,O
be,O
fully,O
understood,O
",",O
it,O
is,O
apparent,O
that,O
severe,O
cases,O
of,O
COVID-19,O
are,O
characterized,O
mainly,O
by,O
an,O
unbalanced,O
immune,O
response,O
[,O
9,O
],O
This,O
objective,O
of,O
this,O
case,O
study,O
is,O
to,O
present,O
the,O
pandemic,O
COVID-19,O
with,O
its,O
associated,O
viremia,O
",",O
cellular,O
oxidation,O
and,O
immune,O
dysfunction,O
.,O
The,O
World,O
Health,O
Organization,O
advices,O
that,O
adults,O
should,O
reduce,O
sugar,O
and,O
salt,O
intake,O
during,O
the,O
COVID-19,O
outbreak,O
[,O
21,O
],O
.,O
The,O
major,O
predilection,O
site,O
of,O
COVID-19,O
are,O
the,O
lungs,O
and,O
excessive,O
oxidative,O
stress,O
of,O
the,O
pneumocytes,O
would,O
make,O
the,O
lungs,O
unfit,O
to,O
combat,O
the,O
disease,O
.,O
Individuals,O
that,O
are,O
constantly,O
on,O
drugs,O
that,O
weaken,O
the,O
immune,O
system,O
especially,O
anticancer,O
chemotherapeutic,O
agents,O
are,O
more,O
likely,O
to,O
have,O
severe,O
COVID-19,O
[,O
28,O
],O
.,O
Immunocompromised,O
individuals,O
have,O
a,O
reduced,O
ability,O
to,O
fight,O
COVID-19,O
and,O
other,O
diseases,O
[,O
"31,32",O
],O
.,O
Mortalities,O
in,O
COVID-19,O
can,O
be,O
largely,O
predicted,O
by,O
the,O
number,O
of,O
comorbidities,O
as,O
8,O
out,O
of,O
10,O
deaths,O
are,O
occurring,O
in,O
individuals,O
with,O
at,O
least,O
one,O
underlying,O
disease,O
[,O
34,O
],O
.,O
Older,O
adults,O
are,O
at,O
high,O
risk,O
for,O
severe,O
illness,O
from,O
COVID-19,O
[,O
35,O
],O
and,O
the,O
elderly,O
people,O
are,O
more,O
prone,O
to,O
more,O
serious,O
outcomes,O
when,O
infected,O
with,O
SARS,O
-,O
CoV-2,O
especially,O
acute,O
respiratory,O
distress,O
syndrome,O
(,O
ARDS,O
),O
and,O
cytokine,O
storm,O
[,O
36,O
],O
.,O
Like,O
other,O
coronavirus,O
infections,O
and,O
influenza,O
",",O
diabetes,O
is,O
a,O
risk,O
factor,O
for,O
severe,O
COVID-19,O
disease,O
.,O
Mortality,O
is,O
three,O
-,O
fold,O
higher,O
in,O
patients,O
with,O
diabetes,O
than,O
normal,O
mortalities,O
in,O
COVID-19,O
[,O
33,O
],O
.,O
Also,O
",",O
complications,O
of,O
diabetes,O
make,O
the,O
management,O
of,O
COVID-19,O
more,O
challenging,O
[,O
32,O
],O
.,O
Individuals,O
with,O
this,O
condition,O
are,O
at,O
risk,O
of,O
having,O
severe,O
forms,O
and,O
complications,O
of,O
COVID-19,O
[,O
39,O
],O
.,O
Emerging,O
data,O
suggests,O
that,O
patients,O
with,O
preexisting,O
CVD,O
are,O
at,O
a,O
high,O
risk,O
of,O
mortality,O
from,O
COVID-19,O
[,O
"4,42",O
],O
.,O
COVID-19,O
also,O
causes,O
cardiovascular,O
complications,O
such,O
as,O
myocarditis,O
",",O
arrhythmias,O
",",O
acute,O
heart,O
failure,O
",",O
acute,O
coronary,O
syndromes,O
",",O
cardiogenic,O
shock,O
and,O
death,O
[,O
42,O
],O
.,O
As,O
found,O
in,O
SARS,O
",",O
there,O
is,O
a,O
suppression,O
of,O
the,O
release,O
of,O
interferons,O
by,O
infected,O
cells,O
which,O
delays,O
immune,O
response,O
in,O
COVID-19,O
[,O
7,O
],O
.,O
SARS,O
-,O
CoV-2,O
also,O
attacks,O
the,O
lymphocytes,O
causing,O
lymphocytopenia,O
which,O
is,O
a,O
common,O
diagnostic,O
marker,O
in,O
COVID-19,O
patients,O
[,O
50,O
],O
.,O
Therefore,O
",",O
supplementary,O
dietary,O
antioxidants,O
are,O
needed,O
in,O
the,O
management,O
of,O
COVID-19,O
to,O
improve,O
immunity,O
[,O
30,O
],O
.,O
The,O
aggressive,O
administration,O
of,O
exogenous,O
antioxidants,O
from,O
natural,O
products,O
would,O
largely,O
impart,O
on,O
clinical,O
outcomes,O
of,O
COVID-19,O
by,O
improving,O
patient,O
’s,O
health,O
",",O
hastening,O
the,O
immunological,O
process,O
and,O
consequently,O
shortening,O
the,O
hospital,O
admission,O
period,O
.,O
Innate,O
immune,O
response,O
:,O
the,O
innate,O
immune,O
system,O
serves,O
as,O
the,O
first,O
line,O
of,O
defense,O
in,O
the,O
combat,O
against,O
the,O
viremia,O
associated,O
with,O
COVID-19,O
.,O
Interestingly,O
",",O
the,O
role,O
of,O
NK,O
cells,O
in,O
SARS,O
infections,O
has,O
not,O
been,O
established,O
but,O
they,O
have,O
been,O
reported,O
to,O
be,O
reduced,O
in,O
peripheral,O
blood,O
in,O
patients,O
with,O
severe,O
cases,O
of,O
COVID-19,O
[,O
50,O
],O
.,O
Interestingly,O
",",O
type,O
1,O
IFN,O
is,O
not,O
detected,O
in,O
COVID-19,O
patients,O
and,O
also,O
not,O
detected,O
in,O
in,O
vitro,O
SARS,O
-,O
CoV-2,O
infected,O
cells,O
[,O
54,O
],O
.,O
The,O
administration,O
of,O
type,O
1,O
IFN,O
to,O
COVID-19,O
would,O
trigger,O
interferon,O
-,O
mediated,O
immune,O
responses,O
which,O
could,O
have,O
a,O
positive,O
impact,O
on,O
the,O
clinical,O
outcome,O
of,O
severe,O
cases,O
[,O
55,O
],O
.,O
This,O
is,O
because,O
as,O
it,O
is,O
with,O
SARS,O
-,O
CoV,O
infection,O
",",O
the,O
acute,O
phase,O
of,O
COVID-19,O
is,O
characterized,O
by,O
a,O
remarkable,O
reduction,O
in,O
CD4,O
T,O
cell,O
population,O
and,O
this,O
could,O
be,O
prolonged,O
reaching,O
a,O
lowest,O
point,O
at,O
days,O
7,O
-,O
9,O
before,O
returning,O
to,O
normal,O
[,O
50,O
],O
.,O
In,O
a,O
47,O
-,O
year,O
-,O
old,O
female,O
patient,O
with,O
mild,O
case,O
of,O
COVID-19,O
",",O
antibodies,O
were,O
detected,O
as,O
early,O
as,O
four,O
days,O
after,O
infection,O
while,O
the,O
virus,O
could,O
be,O
undetected,O
as,O
early,O
as,O
the,O
7th,O
day,O
and,O
there,O
were,O
progressive,O
increases,O
in,O
plasma,O
SARS,O
-,O
CoV-2,O
-,O
binding,O
IgM,O
and,O
IgG,O
[,O
56,O
],O
.,O
Individuals,O
with,O
HLA,O
-,O
B*46,O
:,O
01,O
are,O
reported,O
to,O
be,O
more,O
vulnerable,O
to,O
COVID-19,O
[,O
53,O
],O
.,O
The,O
discovery,O
of,O
the,O
specific,O
HLA,O
molecules,O
and,O
variants,O
involved,O
in,O
COVID-19,O
would,O
enhance,O
knowledge,O
on,O
the,O
unexplained,O
susceptibility,O
to,O
the,O
disease,O
.,O
Unlike,O
in,O
mild,O
cases,O
of,O
COVID-19,O
",",O
severe,O
cases,O
would,O
have,O
an,O
unusually,O
high,O
level,O
of,O
pro,O
-,O
inflammatory,O
cytokines,O
and,O
chemokines,O
such,O
as,O
IL-6,O
",",O
IL-8,O
",",O
MIP-1β,O
",",O
MCP-1,O
and,O
IFN,O
-,O
γ6,O
",",O
in,O
the,O
plasma,O
.,O
T,O
cells,O
are,O
also,O
associated,O
with,O
severe,O
COVID-19,O
[,O
9,O
],O
.,O
To,O
enhance,O
a,O
more,O
effective,O
management,O
of,O
COVID-19,O
",",O
the,O
early,O
prediction,O
of,O
severe,O
cases,O
or,O
high,O
-,O
risk,O
individuals,O
is,O
important,O
.,O
Of,O
all,O
cytokine,O
profiles,O
and,O
the,O
cell,O
counts,O
",",O
the,O
Neutrophil,O
to,O
Lymphocyte,O
Ratio,O
(,O
NLR,O
),O
is,O
the,O
most,O
powerful,O
prognostic,O
indicator,O
in,O
the,O
identification,O
of,O
severe,O
cases,O
of,O
COVID-19,O
[,O
"9,62",O
],O
.,O
In,O
a,O
study,O
of,O
245,O
COVID-19,O
patients,O
admitted,O
in,O
hospital,O
",",O
NLR,O
of,O
patients,O
in,O
the,O
highest,O
interquartile,O
had,O
15.04,O
-,O
fold,O
higher,O
risk,O
of,O
death,O
than,O
patients,O
in,O
the,O
lowest,O
interquartile,O
[,O
62,O
],O
.,O
Hyaluronidase,O
can,O
also,O
be,O
administered,O
intranasally,O
[,O
7,O
],O
and,O
computational,O
approaches,O
present,O
a,O
potential,O
drug,O
discovery,O
option,O
for,O
the,O
COVID-19,O
[,O
66,O
],O
.,O
Chloroquine,O
",",O
a,O
double,O
agent,O
:,O
chloroquine,O
(,O
CQ,O
),O
and,O
its,O
derivative,O
hydroxychloroquine,O
(,O
HCQ,O
),O
have,O
been,O
reported,O
to,O
show,O
good,O
promise,O
in,O
the,O
treatment,O
of,O
COVID-19,O
this,O
is,O
because,O
they,O
present,O
a,O
dual,O
advantage,O
of,O
quelling,O
the,O
cytokine,O
storm,O
and,O
inhibiting,O
the,O
coronavirus,O
[,O
67,O
],O
.,O
CQ,O
has,O
been,O
used,O
to,O
shorten,O
the,O
course,O
of,O
the,O
disease,O
and,O
it,O
has,O
been,O
enlisted,O
as,O
one,O
of,O
the,O
trial,O
drugs,O
in,O
the,O
guidelines,O
for,O
the,O
diagnosis,O
and,O
treatment,O
of,O
COVID-19,O
published,O
by,O
national,O
health,O
commission,O
of,O
China,O
[,O
68,O
],O
.,O
In,O
many,O
countries,O
",",O
clinical,O
trials,O
have,O
been,O
approved,O
to,O
validate,O
the,O
efficacy,O
and,O
to,O
establish,O
the,O
ideal,O
therapeutic,O
dose,O
for,O
the,O
treatment,O
of,O
COVID-19,O
.,O
Recommendations,O
:,O
vaccine,O
and,O
immune,O
development,O
:,O
the,O
race,O
for,O
the,O
development,O
of,O
a,O
vaccine,O
against,O
COVID-19,O
is,O
on,O
with,O
the,O
first,O
clinical,O
trial,O
presently,O
taking,O
place,O
in,O
the,O
UK,O
.,O
An,O
extensive,O
serological,O
survey,O
is,O
also,O
required,O
to,O
determine,O
the,O
antibody,O
titre,O
of,O
post,O
-,O
COVID-19,O
patients,O
.,O
An,O
idea,O
of,O
an,O
immunity,O
passport,O
has,O
been,O
mooted,O
and,O
it,O
involves,O
the,O
certification,O
of,O
COVID-19,O
survivors,O
[,O
71,O
],O
.,O
Apart,O
from,O
the,O
prophylactic,O
benefits,O
",",O
the,O
aggressive,O
consumption,O
of,O
antioxidant,O
beverages,O
has,O
potential,O
therapeutic,O
value,O
in,O
the,O
face,O
of,O
a,O
COVID-19,O
infection,O
.,O
Adequate,O
vitamin,O
C,O
supplementation,O
is,O
also,O
good,O
for,O
the,O
management,O
of,O
COVID-19,O
due,O
to,O
their,O
antioxidant,O
and,O
anti,O
-,O
inflammatory,O
effect,O
.,O
Clinicians,O
should,O
strive,O
to,O
determine,O
the,O
maximum,O
beneficial,O
dose,O
as,O
research,O
shows,O
that,O
many,O
COVID-19,O
patients,O
might,O
be,O
under,O
-,O
dosed,O
with,O
vitamin,O
C.,O
Heavy,O
consumption,O
of,O
refined,O
sugar,O
should,O
be,O
avoided,O
as,O
its,O
oxidative,O
effect,O
impairs,O
immune,O
function,O
[,O
18,O
],O
.,O
Management,O
of,O
COVID-19,O
patients,O
:,O
on,O
admission,O
of,O
COVID-19,O
patients,O
",",O
an,O
early,O
determination,O
of,O
the,O
Neutrophil,O
to,O
Lymphocyte,O
Ratio,O
(,O
NLR,O
),O
would,O
help,O
to,O
determine,O
the,O
degree,O
of,O
severity,O
of,O
cases,O
[,O
64,O
],O
.,O
In,O
this,O
regard,O
",",O
the,O
herbal,O
drink,O
",",O
COVID,O
-,O
organics,O
claimed,O
to,O
combat,O
COVID-19,O
in,O
Madagascar,O
should,O
be,O
investigated,O
.,O
Research,O
and,O
testing,O
:,O
the,O
role,O
of,O
NK,O
cells,O
in,O
combating,O
COVID-19,O
should,O
be,O
investigated,O
since,O
these,O
are,O
the,O
cells,O
responsible,O
for,O
immunosurveillance,O
of,O
virally,O
infected,O
cells,O
[,O
79,O
],O
.,O
Information,O
on,O
the,O
genetic,O
susceptibility,O
to,O
COVID-19,O
can,O
be,O
obtained,O
from,O
extensive,O
HLA,O
profiling,O
of,O
patients,O
especially,O
when,O
the,O
severity,O
of,O
the,O
case,O
can,O
not,O
be,O
associated,O
with,O
any,O
known,O
risk,O
factor,O
[,O
53,O
],O
.,O
A,O
summary,O
of,O
these,O
recommendations,O
is,O
provided,O
in,O
Table,O
1,O
.,O
COVID-19,O
",",O
caused,O
by,O
SARS,O
-,O
CoV-2,O
is,O
a,O
tester,O
of,O
the,O
immune,O
system,O
.,O
This,O
article,O
aims,O
at,O
critically,O
reviewing,O
the,O
key,O
virulence,O
factors,O
of,O
COVID-19,O
which,O
are,O
the,O
viremia,O
",",O
cellular,O
oxidation,O
and,O
immune,O
dysfunction,O
.,O
A,O
better,O
understanding,O
of,O
the,O
pathological,O
dynamics,O
of,O
COVID-19,O
would,O
help,O
the,O
general,O
populace,O
to,O
prepare,O
for,O
possible,O
infection,O
by,O
the,O
invisible,O
enemy,O
.,O
Immunoprophylactic,O
and,O
immunomodulatory,O
strategies,O
are,O
recommended,O
for,O
the,O
different,O
strata,O
of,O
stakeholders,O
combating,O
the,O
pandemic,O
with,O
the,O
hope,O
that,O
morbidities,O
and,O
mortalities,O
associated,O
with,O
COVID-19,O
would,O
be,O
drastically,O
reduced,O
.,O
Frail,O
patients,O
",",O
such,O
as,O
elderly,O
people,O
or,O
those,O
with,O
underlying,O
conditions,O
",",O
are,O
at,O
higher,O
risk,O
of,O
complications,O
related,O
to,O
COVID-19.1,O
Preliminary,O
data,O
suggest,O
an,O
increased,O
risk,O
of,O
developing,O
infection,O
-,O
related,O
severe,O
events,O
(,O
ie,O
",",O
admission,O
to,O
the,O
intensive,O
care,O
unit,O
",",O
mechanical,O
ventilation,O
or,O
death,O
),O
in,O
the,O
case,O
of,O
antitumour,O
treatment,O
administration,O
within,O
two,O
weeks,O
before,O
COVID-19,O
diagnosis,O
.,O
The,O
Italian,O
directives,O
for,O
the,O
management,O
of,O
onco,O
-,O
haematological,O
patients,O
on,O
therapy,O
during,O
the,O
COVID-19,O
pandemic,O
recommend,O
considering,O
treatment,O
delays,O
on,O
a,O
case,O
-,O
by,O
-,O
case,O
basis,O
",",O
taking,O
into,O
account,O
the,O
characteristics,O
of,O
the,O
patient,O
and,O
the,O
disease,O
.,O
Among,O
these,O
patients,O
",",O
16,O
(,O
94,O
%,O
),O
had,O
symptoms,O
related,O
to,O
COVID-19,O
;,O
eight,O
had,O
severe,O
respiratory,O
symptoms,O
",",O
and,O
13,O
(,O
76,O
%,O
),O
were,O
admitted,O
to,O
hospital,O
(,O
table,O
1,O
),O
.,O
At,O
a,O
median,O
follow,O
-,O
up,O
of,O
15,O
days,O
since,O
the,O
confirmed,O
diagnosis,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
the,O
case,O
fatality,O
rate,O
was,O
24,O
%,O
:,O
four,O
patients,O
out,O
of,O
17,O
died,O
due,O
to,O
severe,O
COVID-19,O
",",O
two,O
of,O
whom,O
were,O
on,O
oncological,O
follow,O
-,O
up,O
(,O
ie,O
",",O
off,O
therapy,O
),O
.,O
Similarly,O
",",O
other,O
patients,O
currently,O
in,O
hospital,O
with,O
mild,O
COVID-19,O
syndrome,O
might,O
need,O
to,O
resume,O
their,O
therapeutic,O
plan,O
after,O
complete,O
resolution,O
of,O
their,O
symptoms,O
despite,O
SARS,O
-,O
CoV-2,O
still,O
being,O
detectable,O
potentially,O
for,O
weeks,O
.,O
Based,O
on,O
our,O
preliminary,O
experience,O
",",O
we,O
are,O
opening,O
a,O
new,O
unit,O
that,O
will,O
work,O
as,O
a,O
regional,O
cancer,O
hub,O
for,O
the,O
care,O
of,O
patients,O
with,O
cancer,O
affected,O
by,O
COVID-19,O
within,O
a,O
multidisciplinary,O
team,O
.,O
The,O
current,O
COVID-19,O
pandemic,O
has,O
so,O
far,O
affected,O
approximately,O
"2,350,000",O
people,O
and,O
killed,O
more,O
than,O
"160,000",O
[,O
1,O
],O
.,O
In,O
the,O
GHU,O
PARIS,O
Psychiatrie,O
&,O
Neurosciences,O
(,O
Sainte,O
-,O
Anne,O
hospital,O
",",O
Paris,O
",",O
France,O
),O
we,O
have,O
observed,O
a,O
lower,O
incidence,O
of,O
symptomatic,O
forms,O
of,O
COVID-19,O
among,O
patients,O
(,O
around,O
4,O
%,O
in,O
the,O
Pôle,O
Hospitalo,O
-,O
Universitaire,O
de,O
Psychiatrie,O
Paris,O
15,O
),O
than,O
among,O
our,O
healthcare,O
staff,O
(,O
around,O
14,O
%,O
of,O
nurses,O
and,O
doctors,O
in,O
these,O
same,O
wards,O
),O
.,O
Similar,O
observations,O
have,O
been,O
reported,O
by,O
other,O
COVID,O
units,O
in,O
psychiatric,O
wards,O
in,O
France,O
",",O
Spain,O
and,O
Italy,O
.,O
The,O
SARS,O
-,O
CoV-2,O
coronavirus,O
involved,O
in,O
the,O
current,O
COVID-19,O
epidemic,O
belongs,O
to,O
the,O
2b,O
coronavirus,O
family,O
[,O
16,O
],O
and,O
has,O
many,O
phylogenetic,O
similarities,O
with,O
SARS,O
-,O
CoV-1,O
[,O
17,O
],O
.,O
In,O
cases,O
of,O
severe,O
COVID-19,O
",",O
several,O
elements,O
suggest,O
a,O
dysregulation,O
of,O
the,O
immune,O
system,O
",",O
although,O
the,O
precise,O
mechanisms,O
have,O
not,O
yet,O
been,O
elucidated,O
[,O
18,O
],O
.,O
Because,O
of,O
the,O
respiratory,O
tropism,O
of,O
SARS,O
-,O
CoV-2,O
[,O
28,O
],O
",",O
this,O
marked,O
pulmonary,O
distribution,O
could,O
be,O
of,O
major,O
interest,O
for,O
COVID-19,O
treatment,O
.,O
Finally,O
",",O
due,O
to,O
its,O
lipophilic,O
nature,O
",",O
CPZ,O
can,O
cross,O
the,O
blood,O
-,O
brain,O
barrier,O
[,O
30,O
],O
and,O
could,O
therefore,O
have,O
a,O
therapeutic,O
or,O
prophylactic,O
effect,O
on,O
the,O
neurological,O
forms,O
of,O
COVID-19,O
[,O
31,O
],O
.,O
Patients,O
will,O
be,O
randomized,O
in,O
two,O
groups,O
",",O
one,O
receiving,O
standard,O
COVID-19,O
treatment,O
(,O
standard,O
-,O
of,O
-,O
care,O
",",O
SOC,O
),O
and,O
the,O
other,O
receiving,O
SOC,O
in,O
combination,O
with,O
CPZ,O
(,O
CPZ,O
 ,O
+,O
 ,O
SOC,O
),O
.,O
The,O
reCoVery,O
study,O
design,O
and,O
its,O
objectives,O
are,O
in,O
line,O
with,O
WHO,O
recommendations,O
for,O
conducting,O
pilot,O
studies,O
in,O
the,O
therapeutic,O
management,O
of,O
COVID-19,O
[,O
42,O
],O
.,O
The,O
ongoing,O
COVID-19,O
pandemic,O
has,O
caused,O
approximately,O
"2,350,000",O
infections,O
worldwide,O
and,O
killed,O
more,O
than,O
"160,000",O
individuals,O
.,O
In,O
Sainte,O
-,O
Anne,O
Hospital,O
(,O
GHU,O
PARIS,O
Psychiatrie,O
&,O
Neuroscience,O
",",O
Paris,O
",",O
France,O
),O
we,O
have,O
observed,O
a,O
lower,O
incidence,O
of,O
symptomatic,O
forms,O
of,O
COVID-19,O
among,O
patients,O
than,O
among,O
our,O
clinical,O
staff,O
.,O
We,O
hypothesize,O
that,O
CPZ,O
could,O
reduce,O
the,O
unfavorable,O
course,O
of,O
COVID-19,O
infection,O
among,O
patients,O
requiring,O
respiratory,O
support,O
without,O
the,O
need,O
for,O
ICU,O
care,O
",",O
and,O
that,O
it,O
could,O
also,O
reduce,O
the,O
contagiousness,O
of,O
SARS,O
-,O
CoV-2,O
.,O
This,O
repurposing,O
strategy,O
also,O
avoids,O
numerous,O
developmental,O
and,O
experimental,O
steps,O
",",O
and,O
could,O
save,O
precious,O
time,O
to,O
rapidly,O
establish,O
an,O
anti,O
-,O
COVID-19,O
therapy,O
with,O
well,O
-,O
known,O
",",O
limited,O
and,O
easily,O
managed,O
side,O
effects,O
.,O
COVID-19,O
has,O
become,O
a,O
global,O
public,O
health,O
emergency,O
affecting,O
more,O
than,O
200,O
countries,O
and,O
territories,O
resulting,O
in,O
more,O
than,O
10,O
million,O
reported,O
cases,O
by,O
June,O
30,O
and,O
over,O
"500,000",O
deaths,O
[,O
1,O
],O
.,O
COVID-19,O
spreads,O
via,O
the,O
respiratory,O
route,O
to,O
close,O
contacts,O
and,O
social,O
contact,O
patterns,O
are,O
therefore,O
a,O
key,O
factor,O
shaping,O
the,O
spread,O
of,O
COVID-19,O
and,O
other,O
infectious,O
agents,O
in,O
a,O
population,O
[,O
3,O
",",O
4,O
],O
.,O
Recruitment,O
of,O
participants,O
occurred,O
via,O
sharing,O
of,O
a,O
survey,O
link,O
on,O
the,O
social,O
media,O
platforms,O
Facebook,O
and,O
Twitter,O
to,O
followers,O
and,O
readers,O
of,O
the,O
science.lu,O
website,O
following,O
the,O
publication,O
of,O
a,O
general,O
interest,O
article,O
on,O
COVID-19,O
[,O
8,O
],O
.,O
Similar,O
to,O
these,O
estimates,O
",",O
our,O
results,O
explain,O
the,O
rapid,O
decline,O
in,O
SARS,O
-,O
CoV-19,O
transmission,O
",",O
also,O
resulting,O
in,O
the,O
rapid,O
decline,O
of,O
COVID-19,O
cases,O
observed,O
since,O
the,O
beginning,O
of,O
the,O
lockdown,O
in,O
Luxembourg,O
.,O
This,O
increase,O
in,O
social,O
contacts,O
most,O
likely,O
resulted,O
in,O
the,O
increase,O
of,O
the,O
reproduction,O
number,O
followed,O
by,O
growing,O
COVID-19,O
incidence,O
that,O
had,O
been,O
observed,O
by,O
the,O
end,O
of,O
June,O
.,O
Our,O
results,O
suggest,O
that,O
older,O
individuals,O
are,O
more,O
compliant,O
with,O
restriction,O
measures,O
compared,O
to,O
younger,O
persons,O
",",O
which,O
is,O
expected,O
since,O
the,O
risk,O
of,O
hospitalization,O
and,O
death,O
from,O
COVID-19,O
increases,O
with,O
age,O
[,O
5,O
],O
.,O
While,O
the,O
number,O
of,O
social,O
contacts,O
was,O
substantially,O
lower,O
during,O
the,O
lockdown,O
by,O
more,O
than,O
80,O
%,O
compared,O
to,O
the,O
pre,O
-,O
pandemic,O
period,O
",",O
we,O
observed,O
a,O
more,O
recent,O
121,O
%,O
increase,O
during,O
the,O
post,O
lockdown,O
period,O
showing,O
an,O
increased,O
potential,O
for,O
COVID-19,O
spread,O
.,O
Monitoring,O
social,O
contacts,O
is,O
an,O
important,O
indicator,O
to,O
estimate,O
the,O
possible,O
impact,O
of,O
government,O
interventions,O
on,O
social,O
contacts,O
and,O
the,O
COVID-19,O
spread,O
in,O
the,O
coming,O
months,O
.,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
emerged,O
late,O
in,O
2019,O
in,O
the,O
Hubei,O
province,O
",",O
China,O
",",O
as,O
a,O
cause,O
of,O
respiratory,O
disease,O
occasionally,O
leading,O
to,O
acute,O
respiratory,O
distress,O
syndrome,O
and,O
death,O
(,O
COVID-19,O
),O
(,O
1–4,O
),O
.,O
Four,O
separate,O
data,O
sets,O
of,O
full,O
-,O
length,O
(,O
near-,O
),O
complete,O
genome,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
collected,O
from,O
the,O
start,O
of,O
the,O
pandemic,O
to,O
those,O
most,O
recently,O
deposited,O
on,O
24,O
April,O
2020,O
were,O
aligned,O
and,O
analyzed,O
(,O
accession,O
numbers,O
listed,O
in,O
Table,O
 ,O
S1A,O
in,O
the,O
supplemental,O
material,O
),O
.,O
Each,O
data,O
set,O
showed,O
minimal,O
levels,O
of,O
sequence,O
divergence,O
",",O
with,O
mean,O
pairwise,O
distances,O
ranging,O
from,O
5.5,O
to,O
9.5,O
nucleotide,O
differences,O
between,O
each,O
sequence,O
.,O
First,O
",",O
the,O
ratio,O
of,O
nonsynonymous,O
(,O
amino,O
acid,O
changing,O
),O
to,O
synonymous,O
substitutions,O
(,O
dN,O
/,O
dS,O
),O
was,O
high,O
",",O
in,O
the,O
range,O
of,O
0.57,O
to,O
0.73,O
among,O
the,O
different,O
SARS,O
-,O
CoV-2,O
data,O
sets,O
.,O
This,O
contrasts,O
with,O
a,O
much,O
lower,O
ratio,O
(,O
consistently,O
below,O
<,O
0.22,O
),O
in,O
sequence,O
data,O
sets,O
assembled,O
for,O
the,O
other,O
human,O
coronaviruses,O
(,O
Table,O
 ,O
1,O
),O
.,O
To,O
formally,O
analyze,O
the,O
excess,O
of,O
C→U,O
transitions,O
",",O
we,O
calculated,O
an,O
index,O
of,O
asymmetry,O
(,O
frequency,O
[,O
f][C→U]/f[U→C,O
],O
),O
×,O
(,O
fU,O
/,O
fC,O
),O
and,O
compared,O
this,O
with,O
degrees,O
of,O
sequence,O
divergence,O
and,O
dN,O
/,O
dS,O
ratios,O
in,O
SARS,O
-,O
CoV-2,O
and,O
other,O
coronavirus,O
data,O
sets,O
(,O
Fig,O
.,O
 ,O
2B,O
and,O
C,O
),O
.,O
This,O
comparison,O
showed,O
that,O
the,O
excess,O
of,O
C→U,O
substitutions,O
was,O
most,O
marked,O
among,O
very,O
recently,O
diverged,O
sequences,O
associated,O
with,O
the,O
SARS,O
-,O
CoV-2,O
and,O
SARS,O
-,O
CoV,O
outbreaks,O
and,O
was,O
reduced,O
significantly,O
in,O
sequence,O
data,O
sets,O
of,O
the,O
more,O
divergent,O
human,O
coronaviruses,O
(,O
NL63,O
",",O
OC43,O
",",O
229E,O
",",O
and,O
OC43,O
),O
as,O
sequences,O
accumulated,O
substitutions,O
.,O
These,O
showed,O
mean,O
levels,O
of,O
within,O
-,O
group,O
sequence,O
divergence,O
of,O
0.1,O
%,O
",",O
1.1,O
%,O
",",O
and,O
0.5,O
%,O
",",O
respectively,O
",",O
spanning,O
the,O
range,O
of,O
divergences,O
in,O
the,O
analyzed,O
SARS,O
-,O
CoV-2,O
and,O
other,O
coronavirus,O
data,O
sets,O
.,O
Long,O
bars,O
representing,O
more,O
polymorphic,O
sites,O
were,O
frequently,O
shared,O
between,O
replicate,O
data,O
sets,O
",",O
but,O
unique,O
substitutions,O
(,O
occurring,O
once,O
in,O
the,O
data,O
set,O
[,O
short,O
bars,O
],O
),O
showed,O
largely,O
separate,O
distributions,O
.,O
Substitutions,O
were,O
not,O
focused,O
toward,O
any,O
particular,O
gene,O
or,O
intergenic,O
region,O
",",O
although,O
all,O
three,O
data,O
sets,O
showed,O
marginally,O
higher,O
frequencies,O
of,O
substitutions,O
in,O
the,O
N,O
gene,O
.,O
A,O
selection,O
of,O
sequences,O
showing,O
C→U,O
changes,O
in,O
different,O
genome,O
regions,O
was,O
plotted,O
in,O
a,O
phylogenetic,O
tree,O
containing,O
sequences,O
from,O
the,O
SARS,O
-,O
CoV-2,O
data,O
set,O
(,O
Fig,O
.,O
 ,O
4,O
),O
.,O
With,O
the,O
resolution,O
possible,O
in,O
the,O
tree,O
generated,O
from,O
such,O
a,O
minimally,O
divergent,O
data,O
set,O
",",O
many,O
sequences,O
with,O
shared,O
C→U,O
changes,O
were,O
not,O
monophyletic,O
(,O
e.g.,O
",",O
those,O
with,O
substitutions,O
at,O
positions,O
5784,O
",",O
10319,O
",",O
21575,O
",",O
28657,O
",",O
and,O
28887,O
),O
.,O
On,O
analysis,O
of,O
amino,O
acid,O
sequence,O
changes,O
",",O
a,O
remarkable,O
52,O
%,O
of,O
nonsynonymous,O
transitions,O
in,O
the,O
SARS,O
-,O
CoV-2,O
sequence,O
data,O
set,O
were,O
the,O
consequence,O
of,O
C→U,O
transitions,O
(,O
Fig,O
.,O
 ,O
5,O
),O
",",O
compared,O
to,O
26,O
%,O
",",O
10,O
%,O
",",O
and,O
7,O
%,O
for,O
G→A,O
",",O
U→C,O
",",O
and,O
A→C,O
transitions,O
",",O
respectively,O
.,O
Totals,O
of,O
each,O
transition,O
in,O
the,O
SARS,O
-,O
CoV-2,O
sequence,O
data,O
set,O
split,O
into,O
subtotals,O
based,O
on,O
the,O
identity,O
of,O
the,O
5′,O
(,O
left,O
),O
and,O
3′,O
(,O
right,O
),O
base,O
.,O
Comparison,O
of,O
CpG,O
frequencies,O
of,O
SARS,O
-,O
CoV-2,O
",",O
other,O
coronaviruses,O
",",O
and,O
a,O
set,O
of,O
other,O
mammalian,O
RNA,O
viruses,O
;,O
each,O
data,O
point,O
represents,O
an,O
individual,O
currently,O
classified,O
species,O
;,O
accession,O
numbers,O
are,O
listed,O
in,O
Table,O
 ,O
S1,O
.,O
These,O
accounted,O
for,O
38,O
%,O
to,O
42,O
%,O
of,O
all,O
changes,O
in,O
the,O
four,O
SARS,O
-,O
CoV-2,O
data,O
sets,O
.,O
In,O
seeking,O
alternative,O
nonbiological,O
explanations,O
for,O
this,O
observation,O
",",O
they,O
can,O
not,O
have,O
arisen,O
through,O
misincorporation,O
errors,O
in,O
the,O
nex,O
-,O
generation,O
sequence,O
methods,O
used,O
to,O
produce,O
the,O
data,O
set,O
because,O
the,O
analysis,O
in,O
the,O
present,O
study,O
was,O
restricted,O
to,O
consensus,O
sequences,O
.,O
There,O
was,O
",",O
furthermore,O
",",O
no,O
comparable,O
increase,O
in,O
G→A,O
mutations,O
(,O
Fig,O
.,O
 ,O
2,O
),O
",",O
and,O
the,O
sequence,O
context,O
in,O
which,O
sequencing,O
errors,O
occur,O
(,O
a,O
5′,O
or,O
3′,O
C,O
or,O
G,O
[,O
17,O
],O
),O
did,O
not,O
match,O
the,O
favored,O
context,O
for,O
mutation,O
observed,O
in,O
our,O
data,O
set,O
(,O
Fig,O
.,O
 ,O
6,O
),O
.,O
By,O
definition,O
",",O
a,O
coronavirus,O
RNA,O
genome,O
descends,O
from,O
any,O
other,O
through,O
an,O
equal,O
number,O
of,O
copies,O
of,O
the,O
positive,O
and,O
negative,O
strands,O
—,O
any,O
tendency,O
to,O
misincorporate,O
a,O
U,O
instead,O
of,O
a,O
C,O
would,O
be,O
reflected,O
in,O
a,O
parallel,O
number,O
of,O
G→A,O
mutations,O
where,O
this,O
error,O
occurred,O
on,O
the,O
minus,O
strand,O
(,O
or,O
vice,O
versa,O
),O
.,O
The,O
findings,O
of,O
C→U,O
mutations,O
at,O
the,O
consensus,O
genome,O
sequence,O
level,O
have,O
also,O
been,O
observed,O
within,O
virus,O
populations,O
in,O
a,O
recent,O
analysis,O
of,O
intrahost,O
sequence,O
diversity,O
in,O
lung,O
-,O
derived,O
COVID-19,O
samples,O
(,O
36,O
),O
.,O
The,O
combination,O
of,O
exceptionally,O
long,O
genomes,O
(,O
"≈30,000",O
bases,O
),O
",",O
an,O
otherwise,O
low,O
mutation,O
rate,O
",",O
and,O
the,O
unprecedented,O
size,O
of,O
the,O
present,O
data,O
set,O
of,O
accurate,O
minimally,O
divergent,O
SARS,O
-,O
CoV-2,O
sequences,O
assembled,O
postpandemic,O
has,O
enabled,O
these,O
mutational,O
signatures,O
to,O
be,O
so,O
clearly,O
observed,O
.,O
An,O
RNA,O
editing,O
mechanism,O
of,O
the,O
type,O
discussed,O
above,O
evidently,O
places,O
a,O
huge,O
mutational,O
load,O
on,O
SARS,O
-,O
CoV-2,O
that,O
may,O
underpin,O
the,O
abnormally,O
high,O
dN,O
/,O
dS,O
ratios,O
recorded,O
in,O
SARS,O
-,O
CoV-2,O
and,O
SARS,O
-,O
CoV,O
sequence,O
data,O
sets,O
(,O
Fig,O
.,O
 ,O
1,O
),O
.,O
An,O
additional,O
data,O
set,O
of,O
117,O
well,O
-,O
curated,O
SARS,O
-,O
CoV-2,O
sequences,O
was,O
downloaded,O
from,O
Konsiliarlabor,B-Repository
für,I-Repository
Coronaviren,E-Repository
 ,O
(,O
https://civnb.info/sequences/,S-URL
),O
on,O
13,O
April,O
2020,O
and,O
represents,O
a,O
further,O
independent,O
sample,O
set,O
.,O
A,O
listing,O
of,O
further,O
data,O
sets,O
of,O
SARS,O
-,O
CoV,O
",",O
MERS,O
-,O
CoV,O
",",O
and,O
other,O
human,O
coronaviruses,O
is,O
provided,O
in,O
Table,O
 ,O
1,O
.,O
In,O
evolutionary,O
terms,O
",",O
the,O
contribution,O
of,O
biased,O
",",O
convergent,O
",",O
and,O
context,O
-,O
dependent,O
mutations,O
to,O
sequence,O
change,O
in,O
SARS,O
-,O
CoV-2,O
is,O
substantial,O
",",O
and,O
these,O
processes,O
are,O
not,O
incorporated,O
by,O
standard,O
models,O
used,O
in,O
molecular,O
epidemiology,O
investigations,O
.,O
To,O
understand,O
the,O
early,O
evolutionary,O
events,O
following,O
its,O
emergence,O
",",O
a,O
data,O
set,O
of,O
985,O
complete,O
SARS,O
-,O
CoV-2,O
sequences,O
was,O
assembled,O
.,O
Repeated,O
cycles,O
of,O
mutation,O
and,O
reversion,O
in,O
favored,O
mutational,O
hot,O
spots,O
and,O
the,O
widespread,O
occurrence,O
of,O
amino,O
acid,O
changes,O
with,O
no,O
adaptive,O
value,O
for,O
the,O
virus,O
represent,O
a,O
quite,O
different,O
paradigm,O
of,O
virus,O
sequence,O
change,O
from,O
neutral,O
and,O
Darwinian,O
evolutionary,O
frameworks,O
and,O
are,O
not,O
incorporated,O
by,O
standard,O
models,O
used,O
in,O
molecular,O
epidemiology,O
investigations,O
.,O
In,O
evolutionary,O
terms,O
",",O
the,O
contribution,O
of,O
biased,O
",",O
convergent,O
",",O
and,O
context,O
-,O
dependent,O
mutations,O
to,O
sequence,O
change,O
in,O
SARS,O
-,O
CoV-2,O
is,O
substantial,O
",",O
and,O
these,O
processes,O
are,O
not,O
incorporated,O
by,O
standard,O
models,O
used,O
in,O
molecular,O
epidemiology,O
investigations,O
.,O
This,O
diversity,O
of,O
RNA,O
strains,O
might,O
be,O
correlated,O
to,O
severity,O
and,O
mortality,O
seen,O
in,O
COVID-19,O
(,O
Corona,O
Virus,O
disease-2019,O
),O
.,O
For,O
prediction,O
of,O
human,O
RBPs,O
bound,O
to,O
the,O
UTR,O
of,O
a,O
viral,O
genome,O
",",O
we,O
have,O
used,O
the,O
web,O
-,O
tool,O
‘,O
RBPmap,O
’,O
that,O
enabled,O
prediction,O
of,O
RBP,O
binding,O
on,O
genome,O
sequences,O
from,O
a,O
huge,O
list,O
of,O
experimentally,O
validated,O
motifs,O
of,O
RBPmap,O
database,O
.,O
We,O
have,O
put,O
the,O
reference,O
and,O
mutated,O
5’-,O
and,O
3’-UTR,O
sequences,O
separately,O
as,O
query,O
sequence,O
with,O
the,O
in,O
-,O
built,O
human,O
RBP,O
motifs,O
of,O
the,O
database,O
.,O
For,O
input,O
miRNA,O
sequences,O
",",O
we,O
have,O
obtained,O
a,O
list,O
of,O
all,O
annotated,O
human,O
miRNAs,O
with,O
their,O
sequences,O
in,O
FASTA,O
format,O
from,O
miRBase,S-Repository
 ,O
database,O
[,O
14,O
],O
.,O
The,O
world,O
is,O
going,O
through,O
the,O
critical,O
phase,O
of,O
COVID-19,O
pandemic,O
",",O
caused,O
by,O
human,O
coronavirus,O
",",O
SARS,O
-,O
CoV-2,O
.,O
To,O
have,O
an,O
idea,O
of,O
the,O
global,O
changes,O
in,O
5,O
’,O
and,O
3’-UTR,O
sequences,O
",",O
we,O
downloaded,O
8595,O
complete,O
and,O
high,O
-,O
coverage,O
SARS,O
-,O
CoV-2,O
genome,O
sequence,O
information,O
from,O
human,O
host,O
in,O
FASTA,O
format,O
from,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
from,O
15,O
different,O
geographical,O
regions,O
.,O
The,O
homologous,O
protein,O
structures,O
of,O
2′OMTase,O
with,O
PDB,S-Repository
 ,O
ID,O
:,O
3R24,S-AccessionNumber
 ,O
[,O
"12,13",O
],O
",",O
2XYR,S-AccessionNumber
 ,O
[,O
"12,13",O
],O
from,O
human,O
SARS,O
-,O
CoV,O
and,O
2′OMTase,O
with,O
PDB,S-Repository
 ,O
ID,O
5YN5,S-AccessionNumber
 ,O
from,O
Human,O
betacoronavirus,O
2c,O
EMC/2012,O
[,O
Unpublished,O
],O
were,O
retrieved,O
from,O
Protein,B-Repository
Data,I-Repository
Bank,I-Repository
(PDB),E-Repository
.,O
The,O
topology,O
diagram,O
showing,O
the,O
secondary,O
structures,O
present,O
in,O
2′OMTase,O
was,O
generated,O
by,O
using,O
PDBSum,O
(,O
http://www.ebi.ac.uk/thornton-srv/databases/pdbsum/Generate.html,O
),O
.,O
All,O
the,O
FDA,O
approved,O
drugs,O
were,O
downloaded,O
from,O
the,O
zinc,O
database,O
and,O
DrugBank,S-Repository
 ,O
and,O
converted,O
into,O
3D,O
format,O
for,O
high,O
-,O
throughput,O
virtual,O
screening,O
.,O
The,O
active,O
site,O
volume,O
of,O
homologous,O
2′OMTase,O
for,O
PDB,O
ID,O
3R24_A,O
was,O
946.75,O
 ,O
Å3,O
and,O
for,O
PDB,O
ID,O
2XYR,O
was,O
537.38,O
 ,O
Å3,O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
",",O
as,O
declared,O
by,O
the,O
World,O
Health,O
Organization,O
on,O
11,O
March,O
2020,O
[,O
1,O
],O
",",O
has,O
accumulated,O
6057.853,O
confirmed,O
cases,O
globally,O
until,O
June,O
1,O
[,O
2,O
],O
.,O
The,O
etiologic,O
agent,O
of,O
COVID-19,O
is,O
a,O
novel,O
beta,O
coronavirus,O
[,O
3,O
],O
",",O
which,O
was,O
named,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
by,O
the,O
International,O
Committee,O
on,O
Taxonomy,O
of,O
Viruses,O
[,O
4,O
],O
.,O
The,O
outbreak,O
of,O
the,O
COVID-19,O
pandemic,O
shows,O
marked,O
geographic,O
variation,O
in,O
its,O
prevalence,O
and,O
mortality,O
.,O
It,O
was,O
recently,O
suggested,O
that,O
a,O
renin,O
-,O
angiotensin,O
system,O
(,O
RAS,O
),O
imbalance,O
impacts,O
all,O
stages,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
clinical,O
findings,O
thereof,O
",",O
placing,O
RAS,O
molecules,O
at,O
the,O
center,O
of,O
COVID-19,O
pathophysiology,O
.,O
In,O
this,O
context,O
",",O
Delanghe,O
et,O
al,O
.,O
[,O
49,O
],O
analyzed,O
not,O
only,O
the,O
prevalence,O
and,O
mortality,O
data,O
(,O
per,O
"1,000,000",O
inhabitants,O
),O
of,O
the,O
COVID-19,O
infection,O
of,O
several,O
countries,O
but,O
also,O
the,O
frequency,O
of,O
several,O
polymorphisms,O
in,O
genes,O
of,O
some,O
human,O
plasma,O
proteins,O
",",O
including,O
the,O
ACE,O
I,O
/,O
D,O
polymorphism,O
.,O
The,O
results,O
of,O
this,O
study,O
suggest,O
that,O
the,O
prevalence,O
of,O
COVID-19,O
is,O
significantly,O
correlated,O
with,O
the,O
ACE1,O
polymorphism,O
.,O
In,O
our,O
study,O
",",O
we,O
included,O
only,O
information,O
from,O
the,O
dbSNPs,O
",",O
Ensembl,B-Repository
Genome,I-Repository
Browser,E-Repository
",",O
and,O
1000,B-Repository
Genome,I-Repository
Project,E-Repository
 ,O
databases,O
.,O
Discrete,O
sequence,O
databases,O
of,O
individuals,O
infected,O
with,O
SARS,O
-,O
CoV2,O
were,O
not,O
analyzed,O
.,O
The,O
prevalence,O
and,O
mortality,O
of,O
the,O
outbreak,O
of,O
the,O
COVID-19,O
pandemic,O
show,O
marked,O
geographic,O
variation,O
.,O
The,O
immune,B-Repository
epitope,I-Repository
database,I-Repository
(IEDB),E-Repository
 ,O
population,O
coverage,O
tool,O
(,O
Bui,B-Creator
"et al.,",I-Creator
2006,E-Creator
),O
estimates,O
peptide,O
-,O
HLA,O
binding,O
coverage,O
and,O
the,O
distribution,O
of,O
peptides,O
displayed,O
for,O
a,O
given,O
population,O
but,O
assumes,O
independence,O
between,O
different,O
loci,O
",",O
and,O
thus,O
",",O
does,O
not,O
consider,O
linkage,O
disequilibrium,O
.,O
Immunogenicity,O
data,O
can,O
be,O
incorporated,O
into,O
the,O
peptide,O
scoring,O
process,O
that,O
is,O
used,O
for,O
both,O
vaccine,O
design,O
and,O
evaluation,O
",",O
as,O
shown,O
in,O
italics,O
in,O
Figure,O
 ,O
1,O
.,O
Using,O
this,O
sliding,O
-,O
window,O
approach,O
",",O
we,O
created,O
peptide,O
sets,O
from,O
the,O
SARS,O
-,O
CoV-2,O
(,O
COVID-19,O
),O
and,O
SARS,O
-,O
CoV,O
(,O
human,O
SARS,O
coronavirus,O
),O
proteomes,O
.,O
We,O
obtained,O
the,O
SARS,O
-,O
CoV-2,O
viral,O
proteome,O
from,O
GISAID,S-Dataset
 ,O
(,O
Elbe,B-Creator
and,I-Creator
"Buckland-Merrett,",I-Creator
2017,E-Creator
),O
sequence,O
entry,O
Wuhan,O
/,O
IPBCAMS,O
-,O
WH-01/2019,O
",",O
the,O
first,O
documented,O
case,O
.,O
In,O
EvalVax,O
-,O
Unlinked,O
",",O
we,O
assume,O
independence,O
and,O
use,O
HLA,O
allelic,O
frequencies,O
for,O
"2,392",O
class,O
I,O
alleles,O
and,O
280,O
class,O
II,O
alleles,O
across,O
15,O
geographic,O
regions,O
from,O
the,O
dbMHC,S-Repository
 ,O
database,O
(,O
Helmberg,B-Creator
"et al.,",I-Creator
2004,E-Creator
),O
obtained,O
from,O
the,O
IEDB,S-Repository
 ,O
population,O
coverage,O
tool,O
(,O
Bui,B-Creator
"et al.,",I-Creator
2006,E-Creator
),O
.,O
We,O
validated,O
our,O
computational,O
models,O
on,O
a,O
dataset,O
of,O
SARS,O
-,O
CoV-2,O
peptides,O
evaluated,O
for,O
stability,O
(,O
Prachar,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Grifoni,O
et,O
 ,O
al,O
.,O
(,O
2020b,O
),O
found,O
that,O
peptides,O
from,O
the,O
S,O
",",O
M,O
",",O
and,O
N,O
proteins,O
produced,O
the,O
majority,O
of,O
the,O
CD4,O
+,O
(,O
86,O
%,O
),O
and,O
CD8,O
+,O
(,O
60,O
%,O
),O
T,O
 ,O
cell,O
response,O
in,O
20,O
convalescent,O
COVID-19,O
patients,O
.,O
At,O
present,O
the,O
World,O
Health,O
Organization,O
lists,O
79,O
COVID-19,O
vaccine,O
candidates,O
in,O
clinical,O
or,O
preclinical,O
evaluation,O
(,O
WHO,O
",",O
2020,O
),O
(,O
accessed,O
May,O
16,O
",",O
2020,O
),O
",",O
and,O
the,O
precise,O
designs,O
of,O
most,O
of,O
these,O
vaccines,O
are,O
not,O
public,O
.,O
We,O
encourage,O
the,O
early,O
publication,O
of,O
vaccine,O
designs,O
to,O
enable,O
collaboration,O
and,O
rapid,O
progress,O
toward,O
safe,O
and,O
effective,O
vaccines,O
for,O
COVID-19,O
.,O
For,O
SARS,O
-,O
CoV-2,O
",",O
we,O
obtained,O
the,O
most,O
up,O
to,O
date,O
version,O
of,O
the,O
GISAID,S-Dataset
 ,O
database,O
(,O
Elbe,B-Creator
and,I-Creator
"Buckland-Merrett,",I-Creator
2017,E-Creator
),O
(,O
as,O
of,O
2:02pm,O
EST,O
May,O
13,O
",",O
2020,O
",",O
see,O
Table,O
S4,O
:,O
GISAID,S-Dataset
 ,O
acknowledgements,O
),O
and,O
used,O
Nextstrain,S-Repository
 ,O
(,O
Hadfield,B-Creator
"et al.,",I-Creator
2018,E-Creator
),O
to,O
remove,O
genomes,O
with,O
sequencing,O
errors,O
",",O
translate,O
the,O
genome,O
into,O
proteins,O
",",O
and,O
perform,O
multiple,O
sequence,O
alignments,O
(,O
MSAs,O
),O
.,O
We,O
retrieved,O
"24,468",O
sequences,O
from,O
GISAID,S-Dataset
",",O
and,O
"19,288",O
remained,O
after,O
Nextstrain,S-Repository
 ,O
quality,O
processing,O
.,O
All,O
peptides,O
from,O
SARS,O
-,O
CoV-2,O
were,O
scanned,O
against,O
the,O
entire,O
human,O
proteome,O
downloaded,O
from,O
UniProt,S-Repository
 ,O
(,O
Consortium,O
",",O
2019,O
),O
under,O
Proteome,O
ID,O
UP000005640,S-AccessionNumber
.,O
Grifoni,O
et,O
 ,O
al,O
.,O
(,O
2020b,O
),O
tested,O
T,O
 ,O
cell,O
responses,O
from,O
COVID-19,O
convalescent,O
patients,O
and,O
found,O
that,O
peptides,O
from,O
the,O
S,O
",",O
M,O
",",O
and,O
N,O
proteins,O
of,O
SARS,O
-,O
CoV-2,O
produce,O
the,O
dominant,O
CD4,O
+,O
and,O
CD8,O
+,O
responses,O
when,O
compared,O
to,O
other,O
SARS,O
-,O
CoV-2,O
proteins,O
.,O
We,O
validate,O
our,O
computational,O
models,O
on,O
a,O
dataset,O
of,O
SARS,O
-,O
CoV-2,O
peptides,O
evaluated,O
for,O
stability,O
(,O
Prachar,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
For,O
MHC,O
class,O
I,O
alleles,O
",",O
the,O
dataset,O
contains,O
912,O
unique,O
peptide,O
-,O
HLA,O
pairs,O
",",O
of,O
which,O
185,O
peptides,O
are,O
considered,O
stable,O
(,O
≥,O
60,O
%,O
stability,O
),O
.,O
For,O
MHC,O
class,O
II,O
",",O
the,O
dataset,O
contains,O
93,O
total,O
peptides,O
",",O
of,O
which,O
22,O
are,O
stable,O
.,O
While,O
NetMHCIIpan-4.0,O
with,O
a,O
50,O
nM,O
threshold,O
does,O
not,O
identify,O
any,O
peptides,O
in,O
this,O
dataset,O
as,O
binders,O
",",O
we,O
use,O
this,O
stricter,O
threshold,O
in,O
our,O
vaccine,O
designs,O
as,O
it,O
is,O
more,O
conservative,O
and,O
less,O
likely,O
to,O
admit,O
false,O
positive,O
binders,O
.,O
In,O
the,O
database,O
and,O
literature,O
",",O
a,O
single,O
report,O
on,O
Buffalo,O
-,O
originated,O
coronavirus,O
strain,O
collected,O
from,O
Bangladesh,O
(,O
BufCoV,O
-,O
HKU26,O
-,O
M,O
),O
is,O
available,O
(,O
Lau,O
et,O
al,O
.,O
",",O
2016,O
),O
.,O
The,O
global,O
risk,O
of,O
the,O
2019,O
novel,O
coronavirus,O
(,O
COVID-19,O
[,O
SARS,O
-,O
CoV-2,O
],O
),O
has,O
recently,O
been,O
addressed,O
by,O
many,O
scientists,O
(,O
Bogoch,O
et,O
al,O
.,O
",",O
2020,O
",",O
Chinazzi,O
et,O
al,O
.,O
",",O
2020,O
",",O
Global,O
Health,O
Policy,O
",",O
2020,O
",",O
Wu,O
et,O
al,O
.,O
",",O
2020,O
",",O
Zhu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Outside,O
China,O
",",O
COVID-19,O
transmission,O
has,O
been,O
found,O
in,O
over,O
210,O
countries,O
and,O
territories,O
(,O
Global,O
Health,O
Policy,O
",",O
2020,O
",",O
WHO,O
",",O
2020c,O
),O
.,O
As,O
the,O
outbreak,O
of,O
the,O
2019,O
novel,O
coronavirus,O
(,O
COVID-19,O
[,O
SARS,O
-,O
CoV-2,O
],O
),O
is,O
spreading,O
rapidly,O
",",O
the,O
analysis,O
of,O
epidemiological,O
data,O
of,O
COVID-19,O
is,O
necessary,O
to,O
explore,O
the,O
disease,O
burden,O
and,O
associated,O
factors,O
.,O
Spike,O
(,O
S,O
),O
",",O
membrane,O
(,O
M,O
),O
",",O
envelope,O
(,O
E,O
),O
and,O
nucleocapsid,O
(,O
N,O
),O
protein,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
",",O
HCoV-229E,O
",",O
HCoV,O
-,O
OC43,O
",",O
SARS,O
-,O
CoV,O
",",O
HCoV,O
-,O
NL63,O
",",O
HKU1,O
",",O
MERS,O
-,O
CoV,O
",",O
HKU4,O
",",O
HKU5,O
and,O
BufCoV,O
-,O
HKU26,O
were,O
retrieved,O
from,O
the,O
ViralZone,S-Repository
 ,O
root,O
(,O
https://viralzone.expasy.org/,S-URL
),O
and,O
UniProt,S-Repository
 ,O
(,O
https://www.UniProt.org/,S-URL
),O
databases,O
(,O
Supplementary,O
File,O
1,O
),O
.,O
Additionally,O
",",O
we,O
retrieved,O
epidemiological,O
data,O
for,O
COVID-19,O
from,O
different,O
websites,O
",",O
such,O
as,O
the,O
World,B-Creator
Health,I-Creator
Organization,I-Creator
(WHO),E-Creator
",",O
European,B-Creator
Centre,I-Creator
for,I-Creator
Disease,I-Creator
Prevention,I-Creator
and,I-Creator
Control,I-Creator
(ECDC),E-Creator
",",O
and,O
other,O
online,O
news,O
portals,O
(,O
WHO,S-Creator
",",O
2020c,O
;,O
ECDC,S-Creator
",",O
2020,O
;,O
Pharmaceutical,O
-,O
technology,O
",",O
2020,O
;,O
Reliefweb,O
",",O
2020,O
;,O
Worldometers,O
.,O
COVID-19,O
Coronavirus,O
outbreak,O
",",O
2020,O
),O
.,O
In,O
this,O
study,O
",",O
the,O
conservancy,O
pattern,O
of,O
mostly,O
immunogenic,O
B,O
cell,O
peptide,O
sequences,O
of,O
COVID-19,O
was,O
compared,O
with,O
other,O
homologous,O
sequences,O
retrieved,O
from,O
the,O
NCBI,S-Repository
 ,O
database,O
by,O
using,O
BLASTp,O
(,O
Hasan,O
et,O
al,O
.,O
",",O
2019b,O
),O
.,O
Moreover,O
",",O
homologous,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
 ,O
S,O
",",O
M,O
",",O
E,O
and,O
N,O
proteins,O
were,O
retrieved,O
from,O
the,O
NCBI,S-Repository
 ,O
database,O
(,O
Supplementary,O
File,O
2,O
),O
and,O
were,O
subjected,O
to,O
conservancy,O
analysis,O
with,O
the,O
immunogenic,O
epitopes,O
from,O
SARS,O
-,O
CoV-2,O
proteins,O
.,O
It,O
was,O
found,O
that,O
antigenic,O
sites,O
are,O
almost,O
conserved,O
in,O
all,O
of,O
the,O
homologous,O
protein,O
sequences,O
deposited,O
in,O
the,O
NCBI,S-Repository
 ,O
database,O
(,O
Table,O
2,O
),O
.,O
Cross,O
-,O
checked,O
conservancy,O
analysis,O
of,O
COVID-19,O
antigenic,O
epitopes,O
with,O
SARS,O
-,O
CoV,O
proteins,O
showed,O
that,O
conservancy,O
when,O
cross,O
-,O
checked,O
with,O
other,O
coronaviruses,O
",",O
including,O
BufCoV,O
-,O
HKU26,O
of,O
Bangladesh,O
origin,O
",",O
was,O
not,O
significant,O
(,O
Table,O
3,O
),O
.,O
The,O
3D,O
structures,O
of,O
the,O
SARS,O
-,O
CoV-2,O
proteins,O
were,O
modeled,O
using,O
the,O
I,O
-,O
TASSER,O
server,O
",",O
where,O
‘,O
SARS,O
-,O
CoV,O
complex,O
with,O
human,O
neutralizing,O
S230,O
antibody,O
Fab,O
fragment,O
’,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6NB6,S-AccessionNumber
),O
",",O
‘,O
Membrane,O
protein,O
complex,O
’,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
5X5Y,S-AccessionNumber
),O
",",O
‘,O
Coronavirus,O
Envelope,O
Proteins,O
’,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
2,B-AccessionNumber
MM4,E-AccessionNumber
),O
and,O
‘,O
SARS,O
CoV,O
Nucleocapsid,O
’,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
1SSK,S-AccessionNumber
),O
acted,O
as,O
the,O
top,O
threading,O
templates,O
of,O
the,O
S,O
",",O
M,O
",",O
E,O
and,O
N,O
proteins,O
",",O
respectively,O
.,O
4,O
.,O
Over,O
two,O
and,O
half,O
months,O
",",O
from,O
its,O
outbreak,O
on,O
31,O
December,O
2019,O
to,O
20,O
March,O
2020,O
",",O
COVID-19,O
has,O
spread,O
to,O
up,O
to,O
182,O
countries,O
and,O
territories,O
[,O
Fig,O
.,O
5(i)A,O
],O
and,O
one,O
cruise,O
ship,O
named,O
‘,O
Diamond,O
Princess,O
’,O
in,O
Japan,O
",",O
affecting,O
a,O
total,O
of,O
"253,796persons",O
globally,O
",",O
including,O
in,O
Bangladesh,O
;,O
however,O
",",O
China,O
was,O
the,O
most,O
affected,O
country[Fig,O
.,O
In,O
addition,O
",",O
COVID-19,O
resulted,O
in,O
a,O
substantial,O
burden,O
in,O
Iran,O
",",O
Germany,O
",",O
United,O
States,O
of,O
America,O
(,O
USA,O
),O
",",O
France,O
and,O
South,O
Korea,O
infecting,O
"19,644",O
",",O
"17,372",O
",",O
"14,366",O
",",O
"10,995",O
and,O
8652,O
persons,O
",",O
respectively,O
.,O
Fascinatingly,O
",",O
after,O
25,O
February,O
2020,O
",",O
cases,O
outside,O
China,O
increased,O
more,O
than,O
those,O
in,O
China,O
",",O
which,O
was,O
an,O
alarming,O
signal,O
that,O
COVID-19,O
became,O
a,O
pandemic,O
[,O
Fig,O
.,O
5(i)and,O
Supplementary,O
Fig,O
.,O
1,O
],O
.,O
The,O
first,O
death,O
by,O
COVID-19,O
occurred,O
on,O
11,O
January,O
2000,O
",",O
and,O
by,O
19,O
January,O
2020,O
",",O
another,O
three,O
persons,O
had,O
died,O
.,O
Among,O
182,O
countries,O
and,O
territories,O
",",O
67,O
countries,O
had,O
experienced,O
deaths,O
from,O
the,O
COVID-19,O
outbreak,O
by,O
20,O
March,O
2020,O
.,O
In,O
China,O
",",O
28,O
of,O
34,O
provinces,O
experienced,O
deaths,O
from,O
COVID-19,O
",",O
and,O
the,O
highest,O
death,O
toll,O
occurred,O
in,O
Hubei,O
(,O
3122,O
),O
Province,O
",",O
followed,O
by,O
Henan,O
(,O
22,O
),O
and,O
Heilongjiang,O
(,O
13,O
),O
;,O
in,O
other,O
provinces,O
",",O
the,O
death,O
toll,O
was,O
below,O
ten,O
up,O
until,O
19,O
March,O
2020,O
(,O
Supplementary,O
File,O
4,O
),O
.,O
(,O
A,O
),O
Cumulative,O
confirmed,O
cases,O
of,O
COVID-19,O
in,O
globe,O
and,O
China,O
*,O
from,O
January,O
21,O
",",O
2020,O
to,O
March,O
20,O
",",O
2020,O
*,O
*,O
.,O
(,O
B,O
),O
Cumulative,O
confirmed,O
cases,O
of,O
COVID-19,O
in,O
Hubei,O
province,O
",",O
China,O
*,O
excluding,O
Hubei,O
and,O
outside,O
china,O
from,O
January,O
21,O
",",O
2020,O
to,O
March,O
20,O
",",O
2020,O
*,O
*,O
.,O
(,O
C,O
),O
Cumulative,O
global,O
death,O
toll,O
of,O
COVID-19,O
from,O
January,O
11,O
",",O
2020,O
to,O
March,O
20,O
",",O
2020,O
*,O
.,O
(,O
D,O
),O
Global,O
and,O
country,O
-,O
wise,O
case,O
fatality,O
of,O
COVID-19,O
up,O
to,O
March,O
20,O
",",O
2020,O
*,O
.,O
The,O
COVID-19,O
",",O
caused,O
by,O
novel,O
coronavirus,O
SARS,O
-,O
CoV-2,O
",",O
became,O
a,O
pandemic,O
(,O
Jung,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Although,O
the,O
causative,O
agent,O
of,O
COVID-19,O
has,O
already,O
been,O
declared,O
SARS,O
-,O
CoV-2,O
(,O
Lai,O
et,O
al,O
.,O
",",O
2020,O
",",O
Phan,O
",",O
2020,O
),O
",",O
we,O
adopted,O
a,O
protein,O
-,O
based,O
phylogenetic,O
study,O
to,O
reveal,O
the,O
phylogenetic,O
relationships,O
and,O
divergent,O
links,O
of,O
SARS,O
-,O
CoV-2,O
with,O
other,O
human,O
coronavirus,O
strains,O
.,O
Seven,O
coronaviruses,O
(,O
COVID-19,O
",",O
HCoV-229E,O
",",O
HCoV,O
-,O
OC43,O
",",O
SARS,O
-,O
CoV,O
",",O
HCoV,O
-,O
NL63,O
",",O
HKU1,O
and,O
MERS,O
-,O
CoV,O
),O
",",O
two,O
bat,O
-,O
originated,O
coronaviruses,O
(,O
HKU4,O
and,O
HKU5,O
),O
and,O
one,O
buffalo,O
-,O
originated,O
coronavirus,O
(,O
BufCoV,O
-,O
HKU26,O
),O
reported,O
from,O
Bangladesh,O
were,O
subjected,O
to,O
phylogenetic,O
analysis,O
of,O
four,O
types,O
of,O
their,O
viral,O
proteins,O
(,O
S,O
",",O
M,O
",",O
E,O
and,O
N,O
proteins,O
),O
.,O
In,O
the,O
NCBI,S-Repository
 ,O
database,O
",",O
the,O
gene,O
sequence,O
of,O
a,O
buffalo,O
coronavirus,O
(,O
BufCoV,O
HKU26,O
),O
from,O
domestic,O
water,O
buffaloes,O
(,O
Bubalus,O
bubalis,O
),O
in,O
Bangladesh,O
is,O
available,O
(,O
Lau,O
et,O
al,O
.,O
",",O
2016,O
),O
.,O
COVID-19,O
has,O
already,O
spread,O
to,O
all,O
continents,O
except,O
Antarctica,O
.,O
The,O
temperature,O
could,O
be,O
a,O
factor,O
reducing,O
the,O
risks,O
of,O
COVID-19,O
to,O
Bangladesh,O
",",O
although,O
the,O
country,O
has,O
a,O
high,O
-,O
risk,O
index,O
(,O
Haider,O
et,O
al,O
.,O
",",O
2020a,O
),O
.,O
The,O
high,O
temperature,O
and,O
high,O
humidity,O
can,O
effectively,O
reduce,O
the,O
environmental,O
persistence,O
and,O
transmission,O
of,O
the,O
COVID-19,O
(,O
Wang,O
et,O
al,O
.,O
",",O
2020a,O
),O
",",O
and,O
temperature,O
variation,O
and,O
humidity,O
may,O
be,O
important,O
factors,O
affecting,O
the,O
COVID-19,O
mortality,O
(,O
Ma,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
COVID-19,O
(,O
SARS,O
-,O
CoV-2,O
),O
might,O
have,O
different,O
persistence,O
times,O
on,O
inanimate,O
surfaces,O
",",O
but,O
these,O
times,O
should,O
be,O
similar,O
to,O
those,O
of,O
SARS,O
-,O
associated,O
viruses,O
(,O
3,O
-,O
4,O
days,O
),O
(,O
Kramer,O
et,O
al,O
.,O
",",O
2006,O
),O
.,O
Recently,O
",",O
the,O
authors,O
established,O
that,O
temperature,O
significantly,O
changed,O
COVID-19,O
transmission,O
in,O
429,O
cities,O
",",O
in,O
which,O
COVID-19,O
appeared,O
to,O
spread,O
fastest,O
at,O
8.72,O
°,O
C,O
(,O
Wang,O
et,O
al,O
.,O
",",O
2020b,O
),O
.,O
Thus,O
",",O
in,O
affected,O
countries,O
",",O
COVID-19,O
might,O
disappear,O
with,O
rising,O
temperatures,O
when,O
spring,O
comes,O
.,O
Only,O
20,O
cases,O
(,O
including,O
one,O
death,O
),O
of,O
COVID-19,O
have,O
been,O
confirmed,O
in,O
Bangladesh,O
as,O
of,O
March,O
20,O
",",O
2020,O
.,O
Many,O
of,O
the,O
scientists,O
speculated,O
and,O
revealed,O
that,O
high,O
temperature,O
and,O
humidity,O
have,O
a,O
role,O
in,O
restricting,O
the,O
spread,O
of,O
COVID-19,O
",",O
and,O
the,O
spread,O
of,O
disease,O
would,O
be,O
suppressed,O
in,O
hot,O
and,O
humid,O
weather,O
(,O
Sajadi,O
et,O
al,O
.,O
",",O
2020,O
",",O
Zhang,O
and,O
Zeng,O
",",O
2020,O
),O
",",O
are,O
in,O
the,O
line,O
of,O
our,O
hypothesis,O
.,O
The,O
antigenic,O
sites,O
of,O
COVID-19,O
were,O
also,O
crosschecked,O
with,O
other,O
coronavirus,O
-,O
corresponding,O
proteins,O
(,O
Table,O
3,O
),O
.,O
Similar,O
to,O
COVID-19,O
",",O
the,O
world,O
experienced,O
an,O
epidemic,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
in,O
2003,O
caused,O
by,O
a,O
coronavirus,O
also,O
originating,O
from,O
China,O
(,O
Guangdong,O
Province,O
),O
",",O
which,O
was,O
suggested,O
to,O
be,O
a,O
potential,O
zone,O
of,O
re,O
-,O
emergence,O
of,O
coronaviruses,O
(,O
Lai,O
et,O
al,O
.,O
",",O
2020,O
;,O
WHO,O
",",O
2020d,O
),O
.,O
However,O
",",O
on,O
March,O
14,O
",",O
2020,O
WHO,O
declared,O
Europe,O
as,O
new,O
epicentre,O
of,O
COVID-19,O
outbreak,O
(,O
www.who.int,O
),O
.,O
Within,O
a,O
very,O
short,O
time,O
",",O
COVID-19,O
was,O
transmitted,O
globally,O
(,O
WHO,O
",",O
2020c,O
;,O
COVID-19,O
Coronavirus,O
outbreak,O
",",O
2020,O
),O
",",O
infecting,O
"2,53,796",O
persons,O
globally,O
(,O
WHO,O
",",O
2020c,O
),O
.,O
Therefore,O
",",O
COVID-19,O
has,O
already,O
covered,O
approximately,O
5.52,O
times,O
more,O
countries,O
than,O
SARS,O
and,O
MERS,O
(,O
WHO,O
",",O
2020c,O
;,O
Chen,O
et,O
al,O
.,O
",",O
2005,O
),O
.,O
In,O
addition,O
",",O
up,O
to,O
March,O
20,O
",",O
2020,O
",",O
COVID-19,O
has,O
been,O
attributed,O
30.03,O
and,O
101.76,O
times,O
more,O
cases,O
",",O
and,O
12.85,O
and,O
12.13,O
times,O
more,O
deaths,O
globally,O
than,O
SARS,O
and,O
MERS,O
",",O
respectively,O
(,O
Worldometers,O
.,O
COVID-19,O
Coronavirus,O
outbreak,O
",",O
2020,O
;,O
Chen,O
et,O
al,O
.,O
",",O
2005,O
;,O
WHO,O
",",O
2020b,O
),O
.,O
For,O
example,O
",",O
all,O
of,O
Italy,O
has,O
been,O
placed,O
under,O
lockdown,O
due,O
to,O
COVID-19,O
.,O
The,O
majority,O
of,O
the,O
cases,O
are,O
in,O
mainland,O
China,O
",",O
followed,O
by,O
Italy,O
",",O
Spain,O
",",O
Iran,O
",",O
Germany,O
",",O
USA,O
",",O
France,O
and,O
Korea,O
and,O
the,O
World,O
Health,O
Organization,O
has,O
formally,O
declared,O
the,O
COVID-19,O
outbreak,O
a,O
pandemic,O
in,O
March,O
11,O
",",O
2020,O
(,O
WHO,O
",",O
2020c,O
;,O
Jung,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
case,O
fatality,O
of,O
COVID-19,O
as,O
of,O
March,O
19,O
",",O
2020,O
was,O
4.10,O
%,O
and,O
4.00,O
%,O
globally,O
and,O
in,O
China,O
",",O
respectively,O
.,O
However,O
",",O
the,O
global,O
case,O
fatalities,O
of,O
SARS,O
(,O
9.60,O
%,O
),O
and,O
MERS,O
(,O
34.40,O
%,O
),O
were,O
higher,O
than,O
that,O
of,O
COVID-19,O
(,O
WHO,O
",",O
2020b,O
;,O
Cameron,O
et,O
al,O
.,O
",",O
2008,O
),O
.,O
COVID-19,O
Coronavirus,O
outbreak,O
",",O
2020,O
),O
",",O
which,O
supports,O
our,O
estimate,O
.,O
Despite,O
the,O
lower,O
case,O
fatality,O
than,O
the,O
previous,O
coronaviruses,O
SARS,O
and,O
MERS,O
",",O
COVID-19,O
poses,O
a,O
great,O
burden,O
across,O
the,O
world,O
in,O
terms,O
of,O
geographical,O
coverage,O
",",O
the,O
occurrence,O
of,O
cases,O
",",O
and,O
the,O
cumulative,O
death,O
toll,O
.,O
Over,O
182,O
countries,O
and,O
territories,O
including,O
Bangladesh,O
reported,O
COVID-19,O
cases,O
",",O
with,O
more,O
than,O
"2,53,796",O
people,O
infected,O
globally,O
as,O
of,O
March,O
20,O
",",O
2020,O
(,O
Global,O
Health,O
Policy,O
",",O
2020,O
",",O
WHO,O
",",O
2020c,O
),O
.,O
The,O
COVID-19,O
coronavirus,O
has,O
spread,O
in,O
the,O
neighboring,O
countries,O
of,O
Bangladesh,O
as,O
well,O
.,O
Further,O
comprehensive,O
studies,O
that,O
will,O
combine,O
genomic,O
data,O
",",O
outbreak,O
information,O
",",O
surveillance,O
data,O
",",O
travel,O
restrictions,O
will,O
help,O
to,O
generate,O
information,O
that,O
will,O
be,O
necessary,O
for,O
a,O
well,O
-,O
planned,O
long,O
-,O
term,O
strategy,O
to,O
mitigate,O
COVID-19,O
.,O
SARS,O
-,O
CoV-2,O
",",O
a,O
new,O
coronavirus,O
strain,O
responsible,O
for,O
COVID-19,O
",",O
has,O
emerged,O
in,O
Wuhan,O
City,O
",",O
China,O
",",O
and,O
continuing,O
its,O
global,O
pandemic,O
nature,O
.,O
Descriptive,O
epidemiological,O
analysis,O
on,O
several,O
epidemiological,O
indices,O
was,O
performed,O
on,O
available,O
epidemiological,O
outbreak,O
information,O
from,O
several,O
open,O
databases,O
on,O
COVID-19,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
•,O
 ,O
COVID-19,O
poses,O
a,O
great,O
burden,O
across,O
the,O
world,O
in,O
terms,O
of,O
geographical,O
coverage,O
",",O
occurrence,O
of,O
cases,O
and,O
death,O
toll,O
.,O
Nidoviruses,O
are,O
a,O
group,O
of,O
lipid,O
-,O
enveloped,O
viruses,O
with,O
nonsegmented,O
RNA,O
genomes,O
and,O
are,O
known,O
to,O
infect,O
animals,O
",",O
including,O
molluscs,O
",",O
arthropods,O
",",O
and,O
vertebrates,O
(,O
1,O
),O
",",O
and,O
apparently,O
also,O
the,O
oomycete,O
Plasmopara,O
(,O
NCBI,S-Repository
 ,O
taxonomy,O
ID,O
2692091,S-AccessionNumber
),O
.,O
Recently,O
",",O
a,O
novel,O
coronavirus,O
(,O
SARS,O
-,O
CoV-2,O
),O
was,O
identified,O
as,O
the,O
causative,O
agent,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
a,O
severe,O
respiratory,O
disease,O
that,O
has,O
been,O
infecting,O
humans,O
since,O
late,O
2019,O
(,O
6,O
",",O
7,O
),O
.,O
COVID-19,O
presents,O
itself,O
with,O
an,O
incubation,O
period,O
ranging,O
from,O
1,O
to,O
24,O
 ,O
days,O
followed,O
by,O
the,O
potential,O
development,O
of,O
a,O
constellation,O
of,O
symptoms,O
",",O
including,O
fever,O
",",O
dry,O
cough,O
",",O
fatigue,O
",",O
diarrhea,O
",",O
myalgia,O
",",O
lymphopenia,O
",",O
dyspnea,O
",",O
and,O
bilateral,O
ground,O
-,O
glass,O
opacities,O
in,O
the,O
lungs,O
(,O
10–12,O
),O
.,O
In,O
most,O
moribund,O
patients,O
",",O
COVID-19,O
is,O
accompanied,O
by,O
an,O
inflammatory,O
cytokine,O
storm,O
(,O
12,O
),O
",",O
which,O
suggests,O
that,O
virus,O
-,O
induced,O
immunopathological,O
events,O
may,O
play,O
a,O
role,O
in,O
the,O
development,O
of,O
disease,O
severity,O
.,O
Finally,O
",",O
COVID-19,O
’s,O
ability,O
to,O
be,O
transmitted,O
during,O
asymptomatic,O
stages,O
(,O
14,O
),O
makes,O
prevention,O
challenging,O
.,O
The,O
similarity,O
plot,O
of,O
SARS,O
-,O
CoV-2,O
-,O
related,O
CoVs,O
compared,O
to,O
the,O
human,O
SARS,O
-,O
CoV-2,O
Wuhan,O
-,O
Hu-1,O
genome,O
(,O
GenBank,S-Repository
 ,O
accession,O
no,O
.,O
NC_045512.2,S-AccessionNumber
),O
is,O
drawn,O
based,O
on,O
a,O
multiple,O
-,O
sequence,O
alignment,O
of,O
the,O
whole,O
genomes,O
.,O
For,O
the,O
NCBI,S-Repository
 ,O
accession,O
numbers,O
",",O
refer,O
to,O
the,O
Table,O
 ,O
S2,O
.,O
Consistent,O
with,O
this,O
prediction,O
of,O
being,O
at,O
the,O
interface,O
of,O
a,O
virus,O
-,O
host,O
interaction,O
",",O
several,O
polymorphisms,O
have,O
been,O
reported,O
in,O
the,O
ORF8,O
region,O
of,O
the,O
genome,O
both,O
over,O
the,O
course,O
of,O
the,O
SARS,O
epidemic,O
and,O
during,O
the,O
current,O
COVID-19,O
pandemic,O
.,O
Remarkably,O
",",O
a,O
recent,O
study,O
of,O
patients,O
in,O
Singapore,O
pointed,O
to,O
a,O
382,O
-,O
nt,O
deletion,O
in,O
SARS,O
-,O
CoV-2,O
(,O
48,O
),O
",",O
suggesting,O
parallel,O
disruption,O
of,O
this,O
gene,O
during,O
the,O
COVID-19,O
pandemic,O
.,O
We,O
retrieved,O
the,O
SARS,O
-,O
CoV-2,O
-,O
related,O
CoV,O
genomes,O
by,O
searching,O
against,O
the,O
nonredundant,O
(,O
nr,O
),O
nucleotide,O
database,O
of,O
the,O
National,B-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,I-Repository
(NCBI),E-Repository
 ,O
with,O
the,O
SARS,O
-,O
CoV-2,O
genome,O
sequence,O
(,O
GenBank,S-Repository
 ,O
accession,O
no,O
.,O
To,O
collect,O
protein,O
homologs,O
",",O
iterative,O
sequence,O
profile,O
searches,O
were,O
conducted,O
by,O
the,O
programs,O
PSI,O
-,O
BLAST,O
(,O
position,O
-,O
specific,O
iterated,O
BLAST,O
),O
(,O
35,O
),O
and,O
JACKHMMER,O
(,O
51,O
),O
",",O
which,O
searched,O
against,O
the,O
nonredundant,O
(,O
nr,O
),O
protein,O
database,O
of,O
NCBI,S-Repository
",",O
with,O
a,O
cutoff,O
E,O
value,O
of,O
0.005,O
serving,O
as,O
the,O
significance,O
threshold,O
.,O
By,O
using,O
the,O
HHsearch,O
program,O
(,O
56,O
),O
",",O
we,O
searched,O
with,O
several,O
candidate,O
Ig,O
domains,O
against,O
the,O
Pfam,O
domain,O
database,O
(,O
34,O
),O
",",O
which,O
generated,O
a,O
collection,O
of,O
distinct,O
Ig,O
domains,O
.,O
The,O
ongoing,O
COVID-19,O
pandemic,O
strongly,O
emphasizes,O
the,O
need,O
for,O
a,O
more,O
complete,O
understanding,O
of,O
the,O
biology,O
and,O
pathogenesis,O
of,O
its,O
causative,O
agent,O
SARS,O
-,O
CoV-2,O
.,O
A,O
novel,O
coronavirus,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
was,O
recently,O
identified,O
as,O
the,O
causative,O
agent,O
for,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
outbreak,O
that,O
has,O
generated,O
a,O
global,O
health,O
crisis,O
.,O
In,O
January,O
",",O
2020,O
",",O
a,O
cluster,O
of,O
patients,O
with,O
pneumonia,O
of,O
unknown,O
cause,O
was,O
reported,O
in,O
Wuhan,O
",",O
China,O
;,O
the,O
disease,O
was,O
subsequently,O
named,O
COVID-19,O
",",O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
The,O
clinical,O
spectrum,O
of,O
COVID-19,O
varies,O
from,O
asymptomatic,O
or,O
mild,O
symptomatic,O
infections,O
to,O
severe,O
respiratory,O
symptoms,O
and,O
death,O
",",O
with,O
older,O
age,O
groups,O
generally,O
presenting,O
with,O
more,O
severe,O
disease,O
and,O
higher,O
death,O
rates.2,O
",",O
3,O
Since,O
its,O
identification,O
",",O
SARS,O
-,O
CoV-2,O
has,O
rapidly,O
spread,O
across,O
the,O
globe,O
.,O
On,O
June,O
22,O
",",O
2020,O
",",O
177,O
countries,O
had,O
reported,O
cases,O
of,O
COVID-19,O
",",O
adding,O
up,O
to,O
more,O
than,O
8·9,O
million,O
reported,O
cases,O
and,O
468,O
 ,O
000,O
deaths,O
worldwide,O
.,O
During,O
the,O
WHO,O
–,O
China,O
Joint,O
Mission,O
on,O
COVID-19,O
",",O
2055,O
laboratory,O
confirmed,O
cases,O
were,O
reported,O
in,O
health,O
-,O
care,O
workers,O
from,O
476,O
hospitals,O
in,O
China,O
",",O
mostly,O
(,O
88,O
%,O
),O
from,O
Hubei,O
province,O
.,O
A,O
follow,O
-,O
up,O
study,O
was,O
done,O
at,O
three,O
hospitals,O
to,O
assess,O
the,O
clinical,O
presentations,O
of,O
COVID-19,O
of,O
these,O
health,O
-,O
care,O
workers,O
.,O
PPE,O
was,O
used,O
according,O
to,O
national,O
guidelines,O
that,O
applied,O
during,O
this,O
period,O
of,O
the,O
outbreak.10,O
",",O
11,O
Patients,O
with,O
suspected,O
COVID-19,O
were,O
nursed,O
under,O
strict,O
isolation,O
precautions,O
and,O
health,O
-,O
care,O
workers,O
applied,O
additional,O
PPE,O
(,O
gowns,O
",",O
gloves,O
",",O
goggles,O
",",O
hair,O
cover,O
",",O
and,O
type,O
IIR,O
surgical,O
masks,O
),O
on,O
entering,O
the,O
isolation,O
room,O
.,O
Primers,O
were,O
trimmed,O
using,O
cutadapt,O
",",O
after,O
which,O
a,O
reference,O
-,O
based,O
alignment,O
to,O
the,O
GISAID,B-Dataset
(Global,I-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data),E-Dataset
 ,O
sequence,O
EPI_ISL_412973,S-AccessionNumber
 ,O
was,O
done,O
using,O
minimap2,O
.,O
All,O
available,O
full,O
-,O
length,O
SARS,O
-,O
CoV-2,O
genomes,O
were,O
retrieved,O
from,O
GISAID,S-Dataset
 ,O
on,O
March,O
20,O
",",O
2020,O
(,O
appendix,O
1,O
pp,O
8–65,O
),O
",",O
and,O
aligned,O
with,O
the,O
newly,O
obtained,O
SARS,O
-,O
CoV-2,O
sequences,O
in,O
this,O
study,O
using,O
the,O
multiple,O
sequence,O
alignment,O
software,O
MUSCLE,O
(,O
version,O
3.8.1551,O
),O
.,O
One,O
health,O
-,O
care,O
worker,O
(,O
who,O
reported,O
first,O
symptoms,O
on,O
Feb,O
21,O
",",O
2020,O
),O
attended,O
several,O
carnival,O
events,O
while,O
symptomatic,O
but,O
unaware,O
of,O
having,O
COVID-19,O
.,O
31,O
(,O
32,O
%,O
),O
health,O
-,O
care,O
workers,O
reported,O
close,O
contact,O
with,O
an,O
individual,O
with,O
confirmed,O
COVID-19,O
in,O
the,O
14,O
days,O
before,O
onset,O
of,O
symptoms,O
",",O
either,O
a,O
patient,O
(,O
n=3,O
),O
",",O
colleague,O
(,O
n=18,O
),O
",",O
household,O
member,O
(,O
n=1,O
),O
",",O
or,O
another,O
person,O
outside,O
the,O
hospital,O
(,O
n=9,O
),O
.,O
SARS,O
-,O
CoV-2,O
=,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
.,O
GISAID=Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,E-Dataset
.,O
Most,O
(,O
81–100,O
%,O
),O
health,O
-,O
care,O
workers,O
testing,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
at,O
the,O
three,O
hospitals,O
did,O
not,O
work,O
on,O
a,O
ward,O
with,O
patients,O
with,O
confirmed,O
COVID-19,O
(,O
appendix,O
1,O
p,O
2,O
),O
.,O
In,O
the,O
present,O
study,O
",",O
we,O
combined,O
epidemiological,O
data,O
with,O
WGS,O
to,O
obtain,O
a,O
deeper,O
understanding,O
of,O
the,O
sources,O
and,O
modes,O
of,O
transmission,O
of,O
SARS,O
-,O
CoV-2,O
at,O
three,O
hospitals,O
in,O
the,O
south,O
of,O
the,O
Netherlands,O
",",O
which,O
were,O
the,O
first,O
hospitals,O
to,O
identify,O
patients,O
with,O
COVID-19,O
in,O
the,O
Netherlands,O
.,O
Although,O
possible,O
hospital,O
transmission,O
of,O
SARS,O
-,O
CoV-2,O
and,O
health,O
-,O
care,O
workers,O
with,O
COVID-19,O
have,O
been,O
"reported,3",O
",",O
30,O
",",O
31,O
to,O
our,O
knowledge,O
",",O
our,O
study,O
is,O
the,O
first,O
to,O
use,O
WGS,O
to,O
analyse,O
possible,O
SARS,O
-,O
CoV-2,O
nosocomial,O
transmission,O
.,O
Moreover,O
",",O
the,O
sequence,O
-,O
based,O
analysis,O
could,O
be,O
biased,O
when,O
sampling,O
and,O
sequencing,O
is,O
not,O
done,O
systematically,O
and,O
when,O
sequence,O
data,O
in,O
some,O
areas,O
are,O
scarce,O
",",O
as,O
is,O
the,O
case,O
for,O
COVID-19,O
internationally,O
.,O
On,O
January,O
30,O
",",O
2020,O
",",O
the,O
WHO,O
declared,O
the,O
SARS‐CoV‐2,O
epidemic,O
(,O
COVID‐19,O
),O
a,O
public,O
health,O
emergency,O
of,O
international,O
concern,O
.,O
With,O
a,O
rapid,O
increase,O
in,O
confirmed,O
cases,O
",",O
there,O
is,O
an,O
unmet,O
need,O
of,O
prevention,O
and,O
therapeutic,O
strategies,O
of,O
COVID‐19,O
.,O
Although,O
COVID‐19,O
’s,O
clinical,O
manifestations,O
are,O
dominated,O
by,O
respiratory,O
symptoms,O
",",O
some,O
patients,O
have,O
severe,O
cardiovascular,O
damage3,O
.,O
",",O
4,O
.,O
and,O
kidney,O
disease,O
contributing,O
to,O
multiple,O
organ,O
failure,O
.,O
For,O
example,O
",",O
COVID‐19,O
patients,O
with,O
hypertension,O
have,O
an,O
increased,O
mortality,O
and,O
morbidity,O
with,O
hazard,O
ratio,O
ranging,O
from,O
1.7,O
to,O
3.05,O
",",O
depending,O
on,O
the,O
study,O
.,O
During,O
the,O
epidemic,O
in,O
China,O
",",O
coagulopathy,O
was,O
reported,O
in,O
severe,O
COVID‐19,O
patients,O
.,O
Coagulopathy,O
was,O
also,O
found,O
in,O
fatal,O
cases,O
of,O
COVID‐19,O
patients,O
",",O
including,O
a,O
significantly,O
higher,O
proportion,O
of,O
patients,O
with,O
D‐dimers,O
above,O
500,O
 ,O
ng,O
/,O
mL,O
and,O
prolonged,O
prothrombin,O
time,O
(,O
PT,O
),O
in,O
non‐survivors,O
.,O
The,O
hypothesis,O
of,O
microthrombi,O
in,O
kidneys,O
was,O
also,O
suggested,O
in,O
COVID‐19,O
patients,O
because,O
high,O
creatinine,O
level,O
was,O
correlated,O
with,O
D‐dimers,O
above,O
500,O
 ,O
ng,O
/,O
mL.,O
Circulating,O
endothelial,O
cells,O
(,O
CECs,O
),O
are,O
considered,O
relevant,O
markers,O
of,O
endothelial,O
lesion,O
or,O
dysfunction,O
and,O
were,O
used,O
to,O
explore,O
the,O
potential,O
vascular,O
dysfunction,O
in,O
COVID‐19,O
patients,O
.,O
From,O
March,O
14,O
",",O
2020,O
to,O
March,O
20,O
",",O
2020,O
",",O
all,O
consecutive,O
patients,O
aged,O
over,O
18,O
 ,O
years,O
",",O
presenting,O
to,O
the,O
emergency,O
room,O
of,O
the,O
Georges,O
Pompidou,O
European,O
hospital,O
and,O
fulfilling,O
hospitalization,O
criteria,O
or,O
direct,O
in‐patient,O
referral,O
",",O
with,O
an,O
infectious,O
syndrome,O
suspect,O
of,O
COVID‐19,O
were,O
included,O
.,O
Suspicion,O
of,O
COVID‐19,O
was,O
defined,O
by,O
the,O
presence,O
of,O
at,O
least,O
one,O
of,O
the,O
following,O
:,O
fever,O
",",O
headache,O
",",O
myalgia,O
",",O
cough,O
",",O
dyspnea,O
",",O
rhinorrhea,O
",",O
or,O
digestive,O
symptoms,O
.,O
All,O
COVID‐19‐suspected,O
patients,O
had,O
a,O
clinical,O
evaluation,O
",",O
blood,O
tests,O
",",O
and,O
computed,O
tomography,O
(,O
CT,O
),O
scan,O
",",O
and,O
were,O
tested,O
for,O
SARS‐CoV‐2,O
infection,O
by,O
nasopharyngeal,O
swab,O
before,O
they,O
were,O
transferred,O
to,O
dedicated,O
hospitalization,O
units,O
:,O
medical,O
department,O
or,O
intensive,O
care,O
unit,O
(,O
ICU,O
),O
.,O
This,O
model,O
helped,O
assess,O
the,O
extent,O
to,O
which,O
the,O
level,O
of,O
D‐dimers,O
influenced,O
the,O
predictability,O
of,O
COVID‐19,O
diagnosis,O
.,O
Among,O
the,O
96,O
COVID‐19‐suspected,O
patients,O
included,O
",",O
66,O
were,O
positive,O
for,O
SARS‐CoV‐2,O
.,O
COVID‐19‐positive,O
patients,O
were,O
more,O
likely,O
to,O
be,O
males,O
(,O
N,O
 ,O
=,O
 ,O
44,O
",",O
66.7,O
%,O
),O
than,O
COVID‐19‐negative,O
patients,O
(,O
N,O
 ,O
=,O
 ,O
13,O
",",O
43.3,O
%,O
;,O
P,O
 ,O
=,O
 ,O
.05,O
),O
.,O
Considering,O
clinical,O
features,O
at,O
admission,O
",",O
COVID‐19‐positive,O
patients,O
were,O
more,O
likely,O
to,O
have,O
fever,O
(,O
P,O
 ,O
=,O
 ,O
.02,O
),O
",",O
cough,O
(,O
P,O
 ,O
=,O
 ,O
.03,O
),O
",",O
and,O
interstitial,O
pneumonia,O
at,O
CT,O
scan,O
(,O
P,O
 ,O
=,O
 ,O
.002,O
),O
.,O
In,O
terms,O
of,O
biological,O
features,O
(,O
Table,O
 ,O
3,O
),O
COVID‐19‐positive,O
patients,O
had,O
a,O
significantly,O
lower,O
white,O
blood,O
cell,O
count,O
",",O
including,O
neutrophil,O
count,O
(,O
respectively,O
",",O
P,O
 ,O
=,O
 ,O
.008,O
and,O
0.02,O
),O
.,O
Regarding,O
hemostasis,O
",",O
the,O
proportion,O
of,O
COVID‐19‐positive,O
patients,O
with,O
D‐dimers,O
above,O
500,O
 ,O
ng,O
/,O
mL,O
was,O
significantly,O
higher,O
(,O
74.2,O
%,O
versus,O
43.3,O
%,O
;,O
P,O
 ,O
=,O
 ,O
.007,O
),O
.,O
In,O
the,O
context,O
of,O
COVID‐19‐associated,O
coagulopathy,O
with,O
high,O
levels,O
of,O
D‐dimers,O
",",O
fibrinogen,O
",",O
and,O
CRP,O
at,O
admission,O
",",O
the,O
low,O
level,O
of,O
fibrin,O
monomers,O
and,O
normal,O
antithrombin,O
levels,O
allowed,O
us,O
to,O
exclude,O
a,O
disseminated,O
intravascular,O
coagulation,O
(,O
DIC,O
),O
.,O
When,O
adding,O
D‐dimers,O
above,O
500,O
 ,O
ng,O
/,O
mL,O
to,O
gender,O
and,O
pneumonia,O
at,O
CT,O
scan,O
",",O
ROC,O
curve,O
area,O
(,O
Figure,O
 ,O
1,O
),O
significantly,O
increased,O
from,O
AUC,O
0.73,O
(,O
95,O
%,O
confidence,O
interval,O
[,O
CI,O
],O
0.61‐0.85,O
),O
to,O
AUC,O
0.82,O
(,O
95,O
%,O
CI,O
0.69‐0.95,O
;,O
P,O
 ,O
=,O
 ,O
.02,O
),O
",",O
and,O
confirm,O
the,O
relevance,O
of,O
D‐dimers,O
in,O
diagnosis,O
of,O
COVID‐19,O
at,O
admission,O
in,O
hospital,O
.,O
Among,O
COVID‐19‐positive,O
patients,O
",",O
64,O
%,O
were,O
above,O
this,O
threshold,O
",",O
suggesting,O
a,O
SARS‐CoV‐2‐induced,O
endothelial,O
lesion,O
.,O
For,O
comparison,O
",",O
COVID‐19,O
negative,O
population,O
had,O
fewer,O
CECs,O
(,O
P,O
 ,O
=,O
 ,O
.008,O
;,O
Table,O
 ,O
3,O
),O
with,O
only,O
27,O
%,O
above,O
the,O
normal,O
range,O
(,O
P,O
 ,O
=,O
 ,O
.012,O
),O
.,O
Because,O
the,O
coagulopathy,O
observed,O
in,O
COVID‐19,O
patients,O
could,O
be,O
related,O
to,O
this,O
endothelial,O
lesion,O
",",O
we,O
analyzed,O
whether,O
anticoagulation,O
could,O
impact,O
CEC,O
level,O
.,O
Several,O
Chinese,O
studies,O
found,O
that,O
increased,O
D‐dimer,O
level,O
correlated,O
with,O
in‐hospital,O
"mortality,5",O
.,O
",",O
7,O
.,O
",",O
8,O
.,O
suggesting,O
a,O
COVID‐19‐associated,O
DIC.7,O
.,O
",",O
8,O
.,O
",",O
23,O
.,O
Therefore,O
",",O
the,O
increase,O
of,O
D‐dimers,O
largely,O
reported,O
in,O
COVID‐19,O
patients,O
is,O
probably,O
not,O
related,O
to,O
DIC,O
but,O
might,O
reflect,O
the,O
microthrombi,O
formation,O
.,O
Moreover,O
",",O
a,O
recent,O
study,O
using,O
standardized,O
protective,O
ventilation,O
settings,O
in,O
COVID‐19,O
patients,O
confirmed,O
that,O
oxygenation,O
was,O
severely,O
compromised,O
with,O
a,O
moderate,O
alteration,O
in,O
the,O
respiratory,O
system,O
compliance,O
.,O
In,O
renal,O
disease,O
associated,O
to,O
COVID‐19,O
",",O
thrombotic,O
lesions,O
were,O
proposed,O
",",O
because,O
high,O
D‐dimers,O
were,O
more,O
commonly,O
observed,O
in,O
patients,O
with,O
elevated,O
baseline,O
serum,O
creatinine,O
.,O
In,O
this,O
context,O
",",O
the,O
International,O
Society,O
on,O
Thrombosis,O
and,O
Haemostasis,O
(,O
ISTH,O
),O
has,O
recently,O
recommended,O
measuring,O
D‐dimers,O
",",O
PT,O
ratio,O
",",O
and,O
platelet,O
count,O
in,O
all,O
COVID‐19,O
patients,O
to,O
help,O
stratify,O
those,O
who,O
may,O
benefit,O
from,O
hospitalization,O
and,O
a,O
close,O
monitoring,O
.,O
Therefore,O
",",O
ISTH,O
",",O
the,O
American,O
College,O
of,O
Cardiology,O
",",O
and,O
the,O
French,O
Society,O
for,O
Vascular,O
Medicine,O
suggested,O
the,O
use,O
of,O
prophylactic,O
anticoagulation,O
with,O
low,O
weight,O
molecular,O
heparin,O
(,O
LMWH,O
),O
for,O
COVID‐19,O
patients,O
",",O
in,O
the,O
absence,O
of,O
any,O
contraindications,O
.,O
Indeed,O
",",O
preventive,O
LMWH,O
treatment,O
could,O
be,O
associated,O
with,O
better,O
prognosis,O
in,O
severe,O
COVID‐19,O
patients,O
meeting,O
sepsis‐induced,O
coagulopathy,O
criteria,O
.,O
We,O
further,O
hypothesized,O
that,O
COVID‐19‐induced,O
coagulopathy,O
could,O
be,O
a,O
consequence,O
of,O
endothelial,O
injury,O
",",O
based,O
on,O
the,O
rationale,O
that,O
SARS‐CoV‐2,O
has,O
an,O
endothelial,O
tropism,O
linked,O
to,O
ACE2,O
expression,O
.,O
We,O
found,O
that,O
more,O
than,O
60,O
%,O
of,O
COVID‐19‐positive,O
patients,O
were,O
above,O
this,O
threshold,O
.,O
Increased,O
mortality,O
and/or,O
morbidity,O
of,O
COVID‐19,O
in,O
patients,O
with,O
hypertension,O
has,O
been,O
described,O
in,O
China,O
.,O
However,O
",",O
the,O
main,O
scientific,O
societies,O
of,O
cardiology,O
and,O
more,O
specifically,O
of,O
hypertension,O
took,O
the,O
position,O
not,O
to,O
withdraw,O
ACEi,O
or,O
ARB,O
therapy,O
in,O
COVID‐19,O
.,O
Hence,O
",",O
the,O
Council,O
on,O
Hypertension,O
of,O
the,O
European,O
Society,O
of,O
Cardiology,O
recommended,O
that,O
"""",O
patients,O
should,O
continue,O
treatment,O
with,O
their,O
usual,O
anti‐hypertensive,O
therapy,O
because,O
there,O
is,O
no,O
clinical,O
or,O
scientific,O
evidence,O
to,O
suggest,O
that,O
treatment,O
with,O
ACEIs,O
or,O
ARBs,O
should,O
be,O
discontinued,O
because,O
of,O
the,O
COVID‐19,O
infection,O
.,O
”,O
Indeed,O
",",O
recent,O
studies,O
did,O
not,O
find,O
any,O
association,O
between,O
ACEi,O
or,O
ARBs,O
therapy,O
and,O
worsening,O
in,O
COVID‐19,O
patients,O
.,O
In,O
our,O
population,O
patients,O
treated,O
with,O
curative,O
anticoagulation,O
had,O
a,O
lower,O
level,O
of,O
CECs,O
",",O
so,O
we,O
hypothesized,O
that,O
curative,O
anticoagulation,O
in,O
COVID‐19,O
patients,O
could,O
decrease,O
thrombotic,O
risk,O
and,O
subsequent,O
mortality,O
.,O
First,O
",",O
we,O
are,O
aware,O
that,O
false,O
COVID‐19‐negative,O
patients,O
may,O
exist,O
in,O
our,O
study,O
population,O
due,O
to,O
the,O
imperfect,O
sensitivity,O
of,O
the,O
diagnostic,O
test,O
currently,O
used,O
.,O
Second,O
",",O
the,O
study,O
population,O
size,O
was,O
necessarily,O
small,O
given,O
the,O
emergency,O
of,O
understanding,O
COVID‐19,O
;,O
indeed,O
we,O
decided,O
to,O
investigate,O
the,O
endothelial,O
dysfunction,O
associated,O
to,O
COVID‐19,O
in,O
order,O
to,O
consider,O
new,O
therapeutic,O
alternatives,O
.,O
In,O
conclusion,O
",",O
it,O
therefore,O
seems,O
consistent,O
to,O
open,O
the,O
way,O
to,O
curative,O
anticoagulant,O
treatment,O
as,O
part,O
of,O
the,O
management,O
of,O
COVID‐19,O
patients,O
in,O
order,O
to,O
limit,O
associated,O
coagulopathy,O
and,O
endothelial,O
dysfunction,O
(,O
Figure,O
3,O
),O
.,O
Anticoagulation,O
may,O
not,O
only,O
modify,O
COVID‐19‐associated,O
coagulopathy,O
but,O
also,O
pathophysiology,O
of,O
SARS‐CoV‐2,O
systemic,O
dissemination,O
.,O
Curative,O
anticoagulation,O
could,O
decrease,O
mortality,O
observed,O
in,O
COVID‐19,O
patients,O
.,O
Further,O
studies,O
should,O
evaluate,O
safety,O
and,O
efficacy,O
of,O
curative,O
anticoagulation,O
in,O
COVID‐19,O
patients,O
to,O
prevent,O
worsening,O
of,O
disease,O
and,O
reduction,O
of,O
admittance,O
in,O
ICUs,O
.,O
Background,O
 ,O
Coronavirus,O
disease‐2019,O
(,O
COVID‐19,O
),O
has,O
been,O
associated,O
with,O
cardiovascular,O
complications,O
and,O
coagulation,O
disorders,O
.,O
To,O
explore,O
the,O
coagulopathy,O
and,O
endothelial,O
dysfunction,O
in,O
COVID‐19,O
patients,O
.,O
The,O
study,O
analyzed,O
clinical,O
and,O
biological,O
profiles,O
of,O
patients,O
with,O
suspected,O
COVID‐19,O
infection,O
at,O
admission,O
",",O
including,O
hemostasis,O
tests,O
and,O
quantification,O
of,O
circulating,O
endothelial,O
cells,O
(,O
CECs,O
),O
.,O
Results,O
 ,O
Among,O
96,O
consecutive,O
COVID‐19‐suspected,O
patients,O
fulfilling,O
criteria,O
for,O
hospitalization,O
",",O
66,O
were,O
tested,O
positive,O
for,O
SARS‐CoV‐2,O
.,O
COVID‐19‐positive,O
patients,O
were,O
more,O
likely,O
to,O
present,O
with,O
fever,O
(,O
P,O
=,O
 ,O
.02,O
),O
",",O
cough,O
(,O
P,O
=,O
 ,O
.03,O
),O
",",O
and,O
pneumonia,O
at,O
computed,O
tomography,O
(,O
CT,O
),O
scan,O
(,O
P,O
=,O
 ,O
.002,O
),O
at,O
admission,O
.,O
Prevalence,O
of,O
D‐dimer,O
>,O
500,O
 ,O
ng,O
/,O
mL,O
was,O
higher,O
in,O
COVID‐19‐positive,O
patients,O
(,O
74.2,O
%,O
versus,O
43.3,O
%,O
;,O
P,O
=,O
 ,O
.007,O
),O
.,O
Adding,O
D‐dimers,O
>,O
500,O
 ,O
ng,O
/,O
mL,O
to,O
gender,O
and,O
pneumonia,O
at,O
CT,O
scan,O
in,O
receiver,O
operating,O
characteristic,O
curve,O
analysis,O
significantly,O
increased,O
area,O
under,O
the,O
curve,O
for,O
COVID‐19,O
diagnosis,O
.,O
COVID‐19‐positive,O
patients,O
had,O
significantly,O
more,O
CECs,O
at,O
admission,O
(,O
P,O
=,O
 ,O
.008,O
),O
than,O
COVID‐19‐negative,O
ones,O
.,O
COVID‐19‐positive,O
patients,O
treated,O
with,O
curative,O
anticoagulant,O
prior,O
to,O
admission,O
had,O
fewer,O
CECs,O
(,O
P,O
=,O
 ,O
.02,O
),O
than,O
those,O
without,O
.,O
Conclusion,O
 ,O
Curative,O
anticoagulation,O
could,O
prevent,O
COVID‐19‐associated,O
coagulopathy,O
and,O
endothelial,O
lesion,O
.,O
In,O
total,O
",",O
"15,721",O
SARS,O
-,O
CoV-2,O
genome,O
assemblies,O
available,O
on,O
12,O
May,O
",",O
2020,O
were,O
downloaded,O
from,O
the,O
GISAID,S-Dataset
 ,O
(,O
Shu,B-Creator
and,I-Creator
McCauley,I-Creator
2017,E-Creator
),O
Initiative,O
EpiCoV,O
platform,O
.,O
A,O
pdm09,O
sequences,O
for,O
strains,O
collected,O
between,O
January,O
2009,O
and,O
August,O
2010,O
that,O
contained,O
segments,O
PB2,O
",",O
PB1,O
",",O
PA,O
",",O
HA,O
",",O
NP,O
",",O
NA,O
",",O
MP,O
",",O
and,O
NS,O
were,O
obtained,O
from,O
GISAID,S-Dataset
 ,O
(,O
Shu,B-Creator
and,I-Creator
McCauley,I-Creator
2017,E-Creator
),O
for,O
four,O
segments,O
:,O
RNA,O
polymerase,O
subunit,O
(,O
PB2,O
),O
",",O
hemagglutinin,O
(,O
HA,O
),O
",",O
nucleoprotein,O
(,O
NP,O
),O
",",O
and,O
neuraminidase,O
(,O
NA,O
),O
.,O
Multiple,O
sequence,O
alignment,O
of,O
"1,610",O
full,O
Ebola,O
virus,O
(,O
EBOV,O
),O
genomes,O
sampled,O
between,O
March,O
17,O
",",O
2014,O
and,O
October,O
24,O
",",O
2015,O
in,O
West,O
Africa,O
was,O
downloaded,O
from,O
EbolaID,S-Repository
 ,O
database,O
(,O
Carneiro,B-Creator
and,I-Creator
Pereira,I-Creator
2016,E-Creator
),O
.,O
Phylogenetic,O
tree,O
of,O
"11,204",O
SARS,O
-,O
CoV-2,O
isolates,O
was,O
downloaded,O
from,O
the,O
COVID-19,B-Repository
Genomics,I-Repository
UK,I-Repository
Consortium,E-Repository
 ,O
website,O
(,O
https://www.cogconsortium.uk/,S-URL
",",O
version,O
of,O
April,O
24,O
",",O
2020,O
),O
.,O
In,O
order,O
to,O
remove,O
spurious,O
homoplasic,O
sites,O
",",O
a,O
particular,O
worry,O
of,O
this,O
data,O
set,O
because,O
a,O
mix,O
of,O
technologies,O
and,O
methods,O
have,O
been,O
employed,O
by,O
different,O
contributing,O
research,O
groups,O
",",O
these,O
were,O
filtered,O
using,O
a,O
set,O
of,O
parameters,O
and,O
thresholds,O
defined,O
in,O
(,O
van,O
Dorp,O
et,O
 ,O
al,O
.,O
2020,O
),O
to,O
obtain,O
a,O
set,O
of,O
high,O
-,O
confidence,O
homoplasies,O
.,O
Vertebrate,O
virus,O
sequences,O
were,O
retrieved,O
from,O
the,O
Virosaurus,S-Repository
 ,O
database,O
(,O
Virosaurus,S-Repository
 ,O
databases,O
2020_4.1,O
",",O
Release,O
April,O
2020,O
",",O
file,O
:,O
Virosaurus90v,O
2020_4.1,O
),O
(,O
Gleizes,B-Creator
et,I-Creator
al.,I-Creator
2020,E-Creator
),O
(,O
accessed,O
May,O
7,O
",",O
2020,O
),O
.,O
In,O
this,O
database,O
",",O
complete,O
sequences,O
were,O
clustered,O
at,O
90,O
%,O
to,O
remove,O
redundancy,O
.,O
As,O
in,O
this,O
database,O
",",O
herpesviridae,O
and,O
poxviridae,O
are,O
split,O
in,O
genes,O
rather,O
than,O
full,O
genomes,O
",",O
complete,O
sequences,O
for,O
these,O
viruses,O
were,O
retrieved,O
from,O
NCBI,B-Repository
RefSeq,E-Repository
 ,O
database,O
(,O
Pruitt,B-Creator
et al.,I-Creator
2005,E-Creator
),O
.,O
For,O
virus,O
sequences,O
obtained,O
from,O
the,O
Virosaurus,S-Repository
 ,O
database,O
",",O
the,O
mean,O
was,O
derived,O
to,O
obtain,O
one,O
value,O
per,O
species,O
.,O
The,O
COVID-19,O
pandemic,O
has,O
been,O
slow,O
to,O
arrive,O
in,O
the,O
world,O
’s,O
poorest,O
countries,O
",",O
especially,O
in,O
Africa,O
.,O
To,O
adequately,O
preview,O
the,O
impact,O
of,O
COVID-19,O
on,O
the,O
continent,O
",",O
however,O
",",O
both,O
weaknesses,O
and,O
strengths,O
must,O
be,O
considered,O
.,O
The,O
country,O
-,O
to,O
-,O
country,O
effects,O
of,O
COVID-19,O
could,O
be,O
quite,O
different,O
",",O
and,O
there,O
are,O
resources,O
that,O
may,O
help,O
produce,O
better,O
than,O
expected,O
outcomes,O
.,O
The,O
population,O
structure,O
in,O
Africa,O
is,O
relatively,O
protected,O
against,O
serious,O
COVID-19,O
.,O
Notably,O
",",O
OO,O
simulations,O
have,O
repeatedly,O
foreshadowed,O
the,O
political,O
distrust,O
and,O
altercations,O
that,O
have,O
increased,O
alongside,O
COVID-19,O
in,O
the,O
US,O
.,O
As,O
with,O
COVID-19,O
(,O
Kupferschmidt,O
",",O
2020,O
),O
",",O
these,O
super,O
-,O
spreader,O
events,O
accounted,O
for,O
a,O
significant,O
fraction,O
of,O
cases,O
—,O
in,O
the,O
simulation,O
",",O
30,O
%,O
of,O
all,O
secondary,O
infections,O
were,O
caused,O
by,O
these,O
two,O
participants,O
.,O
At,O
the,O
time,O
of,O
this,O
report,O
in,O
June,O
2020,O
",",O
the,O
number,O
of,O
cases,O
in,O
the,O
United,O
States,O
has,O
reached,O
nearly,O
2.2,O
million,O
",",O
and,O
the,O
number,O
of,O
deaths,O
has,O
exceeded,O
"100,000",O
",",O
according,O
to,O
the,O
Johns,B-Creator
Hopkins,I-Creator
University,E-Creator
 ,O
database,O
(,O
3,O
),O
.,O
SARS,O
-,O
CoV-2,O
is,O
the,O
etiologic,O
agent,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
for,O
which,O
symptoms,O
can,O
vary,O
from,O
mild,O
(,O
e.g.,O
",",O
fever,O
",",O
fatigue,O
",",O
dry,O
cough,O
),O
to,O
severe,O
illness,O
(,O
e.g.,O
",",O
dyspnea,O
",",O
persistent,O
pain,O
or,O
pressure,O
in,O
the,O
chest,O
",",O
hypoxia,O
",",O
confusion,O
),O
",",O
and,O
can,O
ultimately,O
lead,O
to,O
death,O
",",O
particularly,O
for,O
those,O
≥65,O
 ,O
years,O
of,O
age,O
and,O
those,O
with,O
certain,O
underlying,O
medical,O
conditions,O
",",O
such,O
as,O
heart,O
disease,O
",",O
lung,O
disease,O
",",O
or,O
diabetes,O
(,O
4,O
),O
.,O
The,O
majority,O
of,O
the,O
SARS,O
-,O
CoV-2,O
NAATs,O
available,O
today,O
are,O
based,O
on,O
real,O
-,O
time,O
reverse,O
transcription,O
PCR,O
(,O
RT,O
-,O
PCR,O
),O
methods,O
",",O
including,O
the,O
BioFire,O
Defense,O
COVID-19,O
test,O
(,O
BioFire,O
),O
and,O
the,O
Hologic,O
Panther,O
Fusion,O
SARS,O
-,O
CoV-2,O
assay,O
(,O
Fusion,O
),O
evaluated,O
in,O
the,O
present,O
study,O
.,O
The,O
BEI,O
Resources,O
material,O
was,O
provided,O
at,O
a,O
concentration,O
of,O
4.1,O
 ,O
×,O
 ,O
109,O
genome,O
equivalents,O
(,O
GE)/ml,O
(,O
2.8,O
 ,O
×,O
 ,O
105,O
50,O
%,O
tissue,O
culture,O
infective,O
doses,O
[,O
TCID50]/ml,O
before,O
inactivation,O
of,O
the,O
virus,O
),O
",",O
from,O
which,O
the,O
following,O
serial,O
dilutions,O
were,O
prepared,O
(,O
in,O
GE,O
/,O
ml,O
):,O
"1,000",O
",",O
500,O
",",O
250,O
",",O
125,O
",",O
62.5,O
",",O
and,O
31.3,O
.,O
Other,O
comparator,O
studies,O
of,O
the,O
Fusion,O
assay,O
have,O
recently,O
been,O
reported,O
",",O
including,O
the,O
following,O
:,O
a,O
study,O
comparing,O
the,O
Fusion,O
assay,O
to,O
the,O
modified,O
CDC,O
assay,O
",",O
GenMark,O
ePlex,O
",",O
and,O
DiaSorin,O
Simplexa,O
(,O
6,O
),O
;,O
a,O
study,O
comparing,O
Cepheid,O
",",O
ID,O
NOW,O
",",O
and,O
GenMark,O
assays,O
using,O
Fusion,O
as,O
the,O
reference,O
standard,O
(,O
7,O
),O
;,O
a,O
study,O
comparing,O
Fusion,O
",",O
Cepheid,O
",",O
DiaSorin,O
",",O
and,O
cobas,O
assays,O
and,O
a,O
laboratory,O
-,O
developed,O
test,O
(,O
LDT,O
),O
(,O
8),O
;,O
and,O
a,O
study,O
comparing,O
Fusion,O
to,O
an,O
in,O
-,O
house,O
LDT,O
targeting,O
the,O
envelope,O
gene,O
(,O
9,O
),O
.,O
This,O
study,O
compared,O
three,O
of,O
these,O
assays,O
",",O
the,O
Hologic,O
Panther,O
Fusion,O
SARS,O
-,O
CoV-2,O
assay,O
(,O
Fusion,O
),O
",",O
the,O
Hologic,O
Aptima,O
SARS,O
-,O
CoV-2,O
assay,O
(,O
Aptima,O
),O
",",O
and,O
the,O
BioFire,O
Defense,O
COVID-19,O
test,O
(,O
BioFire,O
),O
",",O
to,O
determine,O
analytical,O
and,O
clinical,O
performance,O
as,O
well,O
as,O
workflow,O
.,O
This,O
study,O
compared,O
three,O
of,O
these,O
assays,O
",",O
the,O
Hologic,O
Panther,O
Fusion,O
SARS,O
-,O
CoV-2,O
assay,O
(,O
Fusion,O
),O
",",O
the,O
Hologic,O
Aptima,O
SARS,O
-,O
CoV-2,O
assay,O
(,O
Aptima,O
),O
",",O
and,O
the,O
BioFire,O
Defense,O
COVID-19,O
test,O
(,O
BioFire,O
),O
",",O
to,O
determine,O
analytical,O
and,O
clinical,O
performance,O
as,O
well,O
as,O
workflow,O
.,O
Cold,O
viruses,O
have,O
generally,O
been,O
considered,O
fairly,O
innocuous,O
until,O
the,O
appearance,O
of,O
the,O
severe,O
acute,O
respiratory,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
in,O
2019,O
",",O
which,O
caused,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
global,O
pandemic,O
.,O
In,O
comparison,O
to,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
(,O
SARS,O
-,O
CoV,O
),O
",",O
SARS,O
-,O
CoV-2,O
appears,O
to,O
be,O
more,O
contagious,O
[,O
1,O
],O
",",O
and,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
patients,O
demonstrate,O
varied,O
clinical,O
manifestations,O
distinct,O
from,O
those,O
seen,O
in,O
patients,O
with,O
SARS,O
-,O
CoV,O
and,O
Middle,O
East,O
respiratory,O
syndrome,O
coronavirus,O
infections,O
[,O
2,O
],O
.,O
Collective,O
results,O
from,O
the,O
clinical,O
and,O
epidemiological,O
observations,O
suggest,O
a,O
distinct,O
viral,O
–,O
host,O
interaction,O
in,O
COVID-19,O
patients,O
.,O
This,O
study,O
was,O
designed,O
to,O
better,O
understand,O
the,O
timing,O
and,O
patterns,O
of,O
humoral,O
immune,O
responses,O
to,O
SARS,O
-,O
CoV-2,O
in,O
a,O
cohort,O
of,O
COVID-19,O
patients,O
and,O
evaluate,O
their,O
relationship,O
with,O
the,O
disease,O
course,O
and,O
severity,O
.,O
37,O
patients,O
with,O
COVID-19,O
",",O
with,O
a,O
mean±sd,O
age,O
of,O
52.3±16.3,O
 ,O
years,O
",",O
were,O
enrolled,O
in,O
this,O
study,O
.,O
The,O
enrolled,O
COVID-19,O
patients,O
consisted,O
of,O
25,O
(,O
67.6,O
%,O
),O
males,O
and,O
12,O
(,O
32.4,O
%,O
),O
females,O
.,O
According,O
to,O
the,O
“,O
Guidelines,O
for,O
the,O
Diagnosis,O
and,O
Treatment,O
of,O
Novel,O
Coronavirus,O
(,O
2019,O
-,O
nCoV,O
),O
Infection,O
”,O
published,O
by,O
the,O
National,O
Health,O
Commission,O
of,O
China,O
",",O
the,O
enrolled,O
COVID-19,O
patients,O
were,O
categorised,O
into,O
two,O
groups,O
:,O
20,O
(,O
54.1,O
%,O
),O
severe,O
cases,O
and,O
17,O
(,O
46.0,O
%,O
),O
nonsevere,O
cases,O
[,O
4,O
],O
.,O
The,O
nonsevere,O
group,O
included,O
patients,O
with,O
mild,O
and,O
moderate,O
symptoms,O
who,O
were,O
also,O
required,O
to,O
be,O
admitted,O
to,O
hospital,O
by,O
the,O
COVID-19,O
control,O
policy,O
in,O
China,O
.,O
Critically,O
ill,O
patients,O
met,O
at,O
least,O
one,O
of,O
the,O
extra,O
following,O
conditions,O
in,O
addition,O
to,O
the,O
COVID-19,O
diagnosis,O
:,O
1,O
),O
respiratory,O
failure,O
that,O
required,O
mechanical,O
ventilation,O
;,O
2,O
),O
shock,O
;,O
or,O
3,O
),O
multiple,O
organ,O
failure,O
that,O
required,O
transfer,O
to,O
the,O
intensive,O
care,O
unit,O
.,O
In,O
further,O
subgroup,O
analysis,O
",",O
we,O
found,O
a,O
significant,O
positive,O
association,O
between,O
the,O
level,O
of,O
SARS,O
-,O
CoV-2,O
-,O
specific,O
IgA,O
and,O
the,O
Acute,O
Physiology,O
and,O
Chronic,O
Health,O
Evaluation,O
(,O
APACHE)-II,O
score,O
in,O
critically,O
ill,O
patients,O
with,O
COVID-19,O
(,O
r=0.72,O
",",O
p=0.01,O
),O
",",O
while,O
the,O
level,O
of,O
SARS,O
-,O
CoV-2,O
-,O
specific,O
IgG,O
and,O
IgM,O
did,O
not,O
show,O
correlations,O
with,O
disease,O
severity,O
.,O
Considering,O
the,O
roles,O
of,O
mucosal,O
and,O
systemic,O
IgA,O
in,O
COVID-19,O
",",O
inducing,O
IgA,O
production,O
(,O
using,O
lactoferrin,O
to,O
activate,O
canonical,O
TGF,O
-,O
β,O
signalling,O
[,O
13,O
],O
or,O
retinoic,O
acid,O
to,O
enhance,O
lactoferrin,O
-,O
induced,O
IgA,O
responses,O
[,O
14,O
],O
),O
has,O
been,O
proposed,O
as,O
a,O
novel,O
therapy,O
for,O
severe,O
COVID-19,O
.,O
However,O
",",O
as,O
highlighted,O
by,O
our,O
study,O
",",O
enhanced,O
IgA,O
responses,O
observed,O
in,O
severe,O
COVID-19,O
might,O
confer,O
damaging,O
effects,O
in,O
severe,O
COVID-19,O
.,O
As,O
a,O
result,O
",",O
we,O
hypothesise,O
that,O
severe,O
COVID-19,O
might,O
be,O
at,O
least,O
in,O
part,O
an,O
IgA,O
-,O
mediated,O
disease,O
(,O
related,O
to,O
IgA,O
deposition,O
and,O
vasculitis,O
),O
",",O
which,O
helps,O
to,O
explain,O
common,O
organ,O
injuries,O
in,O
COVID-19,O
",",O
e.g.,O
acute,O
pulmonary,O
embolism,O
",",O
kidney,O
injury,O
",",O
etc,O
.,O
[,O
15,O
],O
.,O
Future,O
investigative,O
efforts,O
are,O
certainly,O
needed,O
to,O
explore,O
the,O
functional,O
significance,O
of,O
mucosal,O
and,O
systemic,O
IgA,O
in,O
COVID-19,O
and,O
whether,O
local,O
interventions,O
at,O
the,O
mucosal,O
level,O
of,O
the,O
nasopharynx,O
/,O
oropharynx,O
could,O
reduce,O
viral,O
load,O
and,O
symptoms,O
.,O
In,O
comparison,O
to,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
(,O
SARS,O
-,O
CoV,O
),O
",",O
SARS,O
-,O
CoV-2,O
appears,O
to,O
be,O
more,O
contagious,O
[,O
1,O
],O
",",O
and,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
patients,O
demonstrate,O
varied,O
clinical,O
manifestations,O
distinct,O
from,O
those,O
seen,O
in,O
patients,O
with,O
SARS,O
-,O
CoV,O
and,O
Middle,O
East,O
respiratory,O
syndrome,O
coronavirus,O
infections,O
[,O
2,O
],O
.,O
Collective,O
results,O
from,O
the,O
clinical,O
and,O
epidemiological,O
observations,O
suggest,O
a,O
distinct,O
viral,O
–,O
host,O
interaction,O
in,O
COVID-19,O
patients,O
.,O
Humoral,O
immune,O
response,O
to,O
SARS,O
-,O
CoV-2,O
showed,O
an,O
early,O
response,O
of,O
IgA,O
",",O
instead,O
of,O
IgM,O
",",O
in,O
COVID-19,O
patients,O
.,O
As,O
highlighted,O
by,O
this,O
study,O
",",O
enhanced,O
IgA,O
responses,O
observed,O
in,O
severe,O
COVID-19,O
might,O
confer,O
damaging,O
effects,O
in,O
severe,O
COVID-19,O
.,O
As,O
of,O
April,O
26,O
",",O
2020,O
",",O
severe,O
acute,O
 ,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
is,O
known,O
to,O
have,O
infected,O
"2,804,796",O
persons,O
globally,O
",",O
and,O
"193,710",O
have,O
had,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
at,O
the,O
time,O
of,O
death,O
(,O
1,O
),O
.,O
Single,O
-,O
cell,O
RNA,O
sequencing,O
(,O
scRNAseq,O
),O
in,O
human,O
and,O
nonhuman,O
primate,O
respiratory,O
tissues,O
has,O
shown,O
coexpression,O
of,O
ACE2,O
and,O
TMPRSS2,O
in,O
pneumocytes,O
in,O
the,O
lungs,O
and,O
goblet,O
secretory,O
cells,O
in,O
the,O
nose,O
(,O
6,O
),O
",",O
indicating,O
that,O
these,O
cell,O
types,O
may,O
serve,O
as,O
foci,O
for,O
infection,O
and,O
potentially,O
explaining,O
the,O
range,O
of,O
respiratory,O
symptoms,O
associated,O
with,O
COVID-19,O
.,O
Coexpression,O
has,O
also,O
been,O
reported,O
in,O
other,O
tissue,O
types,O
",",O
including,O
the,O
ileum,O
",",O
heart,O
",",O
and,O
kidney,O
",",O
for,O
which,O
there,O
are,O
also,O
established,O
COVID-19,O
symptoms,O
(,O
5,O
",",O
7,O
",",O
8,O
",",O
9,O
",",O
10,O
",",O
11,O
),O
.,O
Given,O
that,O
the,O
clinical,O
features,O
of,O
COVID-19,O
appear,O
to,O
be,O
largely,O
determined,O
by,O
the,O
tissues,O
with,O
coexpression,O
of,O
ACE2,O
and,O
TMPRSS2,O
in,O
their,O
constituent,O
cells,O
",",O
it,O
is,O
conceivable,O
that,O
viral,O
infection,O
could,O
have,O
an,O
impact,O
on,O
reproductive,O
function,O
if,O
cells,O
of,O
the,O
male,O
and/or,O
female,O
reproductive,O
systems,O
also,O
express,O
these,O
genes,O
.,O
Reproductive,O
indices,O
are,O
not,O
typically,O
assessed,O
in,O
the,O
intensive,O
care,O
unit,O
setting,O
",",O
and,O
any,O
effects,O
of,O
COVID-19,O
on,O
fertility,O
may,O
not,O
be,O
readily,O
apparent,O
until,O
epidemiological,O
data,O
become,O
available,O
.,O
Understanding,O
whether,O
SARS,O
-,O
CoV-2,O
has,O
the,O
capacity,O
to,O
infect,O
gametes,O
and,O
embryos,O
produced,O
in,O
 ,O
vitro,O
is,O
of,O
great,O
importance,O
when,O
considering,O
the,O
risks,O
of,O
natural,O
and,O
assisted,O
reproduction,O
during,O
the,O
COVID-19,O
pandemic,O
.,O
To,O
visualize,O
“,O
dimensionality,O
”,O
of,O
the,O
dataset,O
",",O
we,O
plotted,O
the,O
principal,O
components,O
using,O
an,O
elbow,O
plot,O
.,O
This,O
indicated,O
that,O
PC,O
1,O
to,O
13,O
explained,O
the,O
majority,O
of,O
the,O
variance,O
in,O
both,O
datasets,O
.,O
Of,O
note,O
",",O
these,O
publicly,O
available,O
bulk,O
RNA,O
and,O
protein,O
datasets,O
were,O
generated,O
independently,O
from,O
the,O
previously,O
described,O
scRNAseq,O
datasets,O
.,O
Published,O
scRNAseq,O
datasets,O
in,O
human,O
testicular,O
(,O
18,O
),O
and,O
nonhuman,O
primate,O
ovarian,O
(,O
19,O
),O
tissue,O
were,O
used,O
to,O
assess,O
the,O
cell,O
-,O
type,O
specific,O
expression,O
pattern,O
of,O
SARS,O
-,O
CoV-2,O
entry,O
receptor,O
ACE2,O
and,O
entry,O
-,O
associated,O
protease,O
TMPRSS2,O
and,O
their,O
coexpression,O
.,O
Additionally,O
",",O
a,O
novel,O
RNAseq,O
dataset,O
was,O
available,O
for,O
human,O
cumulus,O
cells,O
and,O
provided,O
supplementary,O
data,O
on,O
gene,O
expression,O
levels,O
in,O
that,O
cell,O
type,O
.,O
From,O
scRNAseq,O
datasets,O
",",O
we,O
annotated,O
11,O
previously,O
identified,O
cell,O
types,O
of,O
the,O
testes,O
",",O
including,O
somatic,O
niche,O
cells,O
(,O
Leydig,O
cells,O
",",O
endothelial,O
cells,O
",",O
myoid,O
cells,O
",",O
and,O
macrophages,O
),O
and,O
germ,O
cells,O
(,O
differentiating,O
spermatogonia,O
",",O
early,O
primary,O
spermatocytes,O
",",O
late,O
primary,O
spermatocytes,O
",",O
round,O
spermatids,O
",",O
elongated,O
spermatids,O
",",O
and,O
sperm,O
(,O
Fig,O
.,O
 ,O
1A,O
and,O
B,O
),O
.,O
Proteomic,O
expression,O
of,O
ACE2,O
(,O
Fig,O
.,O
 ,O
4,O
A,O
),O
",",O
TMPRSS2,O
(,O
Fig,O
.,O
 ,O
4B,O
),O
",",O
BSG,O
(,O
Fig,O
.,O
 ,O
4C,O
),O
",",O
and,O
CTSL,O
(,O
Fig,O
.,O
 ,O
4D,O
),O
was,O
queried,O
from,O
two,O
publicly,O
available,O
databases,O
",",O
the,O
Human,B-Repository
Protein,I-Repository
Atlas,I-Repository
(HPA),E-Repository
 ,O
and,O
the,O
Human,O
Proteome,O
Map,O
.,O
Protein,O
expression,O
in,O
ovarian,O
",",O
testicular,O
",",O
endometrial,O
",",O
and,O
placental,O
tissue,O
was,O
correlated,O
with,O
bulk,O
cell,O
RNA,O
expression,O
data,O
from,O
four,O
publicly,O
available,O
datasets,O
:,O
the,O
HPA,S-Repository
 ,O
and,O
GTEx,S-Dataset
 ,O
datasets,O
",",O
which,O
both,O
use,O
RNA,O
-,O
seq,O
;,O
the,O
FANTOM5,S-Dataset
 ,O
dataset,O
",",O
which,O
uses,O
cap,O
analysis,O
gene,O
expression,O
;,O
and,O
the,O
HPA,S-Repository
 ,O
consensus,O
dataset,O
",",O
a,O
consensus,O
dataset,O
of,O
the,O
other,O
three,O
RNA,O
datasets,O
.,O
The,O
low,O
sequencing,O
depth,O
of,O
scRNAseq,O
datasets,O
means,O
that,O
many,O
cells,O
will,O
have,O
no,O
expression,O
by,O
chance,O
;,O
therefore,O
",",O
bulk,O
RNAseq,O
datasets,O
",",O
sequenced,O
at,O
higher,O
depths,O
",",O
can,O
serve,O
as,O
a,O
useful,O
point,O
of,O
comparison,O
.,O
There,O
was,O
general,O
agreement,O
between,O
the,O
expression,O
data,O
from,O
the,O
two,O
protein,O
datasets,O
and,O
the,O
RNA,O
datasets,O
.,O
In,O
ovarian,O
cells,O
",",O
TMPRSS2,O
was,O
not,O
detected,O
by,O
either,O
protein,O
profiling,O
platform,O
",",O
which,O
was,O
supported,O
by,O
the,O
external,O
RNA,O
datasets,O
(,O
Fig,O
.,O
 ,O
4B,O
),O
.,O
The,O
underrepresentation,O
of,O
Sertoli,O
cells,O
in,O
the,O
scRNAseq,O
data,O
may,O
account,O
for,O
some,O
of,O
the,O
discrepancy,O
in,O
the,O
ACE2,O
expression,O
profile,O
between,O
these,O
two,O
datasets,O
.,O
TMPRSS2,O
was,O
found,O
to,O
be,O
expressed,O
only,O
at,O
a,O
low,O
level,O
in,O
the,O
RNA,O
datasets,O
and,O
was,O
not,O
detectable,O
by,O
either,O
protein,O
platform,O
(,O
Fig,O
.,O
 ,O
4B,O
),O
.,O
It,O
is,O
not,O
yet,O
clear,O
what,O
effects,O
",",O
if,O
any,O
",",O
the,O
COVID-19,O
pandemic,O
will,O
have,O
on,O
male,O
and,O
female,O
fertility,O
.,O
More,O
recently,O
",",O
Wagner,O
et,O
 ,O
al,O
.,O
(,O
24,O
),O
performed,O
scRNAseq,O
of,O
the,O
outer,O
cortex,O
",",O
containing,O
both,O
germinal,O
and,O
somatic,O
cell,O
types,O
",",O
producing,O
data,O
that,O
could,O
potentially,O
serve,O
as,O
an,O
external,O
validation,O
dataset,O
if,O
expression,O
matrices,O
are,O
made,O
available,O
.,O
As,O
of,O
yet,O
",",O
no,O
autopsy,O
reports,O
in,O
persons,O
with,O
laboratory,O
-,O
confirmed,O
COVID-19,O
at,O
the,O
time,O
of,O
death,O
have,O
assessed,O
SARS,O
-,O
Cov-2,O
replication,O
in,O
the,O
reproductive,O
system,O
.,O
Further,O
experimental,O
data,O
in,O
ovarian,O
tissue,O
from,O
women,O
of,O
reproductive,O
age,O
with,O
COVID-19,O
is,O
needed,O
to,O
confirm,O
whether,O
the,O
female,O
germ,O
cells,O
can,O
be,O
infected,O
.,O
Publicly,O
available,O
developmental,O
scRNAseq,O
databases,O
reveal,O
no,O
coexpression,O
of,O
ACE2,O
and,O
TMPRSS2,O
in,O
fetal,O
tissues,O
",",O
including,O
liver,O
",",O
thymus,O
",",O
skin,O
",",O
bone,O
marrow,O
",",O
and,O
yolk,O
sac,O
(,O
6,O
),O
.,O
These,O
conclusions,O
are,O
supported,O
by,O
the,O
lack,O
of,O
ACE2,O
and,O
TMPRSS2,O
protein,O
expression,O
in,O
endometrial,O
and,O
placental,O
tissue,O
(,O
HPA,S-Repository
/IHC,O
datasets,O
),O
described,O
in,O
this,O
study,O
.,O
The,O
limited,O
clinical,O
data,O
available,O
have,O
also,O
indicated,O
a,O
lack,O
of,O
vertical,O
transmission,O
in,O
newborns,O
of,O
pregnant,O
women,O
who,O
had,O
confirmed,O
COVID-19,O
in,O
the,O
third,O
trimester,O
(,O
29,O
),O
.,O
Additionally,O
",",O
obstetric,O
outcomes,O
for,O
babies,O
born,O
to,O
mothers,O
infected,O
with,O
SARS,O
-,O
CoV-2,O
have,O
not,O
shown,O
any,O
impact,O
of,O
COVID-19,O
on,O
pregnancy,O
(,O
30,O
),O
.,O
Nonetheless,O
",",O
they,O
add,O
to,O
a,O
growing,O
body,O
of,O
evidence,O
suggesting,O
that,O
most,O
aspects,O
of,O
reproduction,O
during,O
the,O
COVID-19,O
pandemic,O
are,O
unlikely,O
to,O
be,O
associated,O
with,O
increased,O
risks,O
of,O
clinical,O
complications,O
.,O
Provided,O
adequate,O
precautions,O
can,O
be,O
instituted,O
to,O
ensure,O
the,O
safety,O
of,O
patients,O
attending,O
fertility,O
clinics,O
",",O
as,O
well,O
as,O
that,O
of,O
clinical,O
staff,O
",",O
it,O
seems,O
reasonable,O
to,O
consider,O
the,O
reintroduction,O
of,O
IVF,O
treatments,O
(,O
at,O
a,O
minimum,O
cycles,O
involving,O
cryopreservation,O
of,O
embryos,O
),O
in,O
countries,O
where,O
the,O
response,O
to,O
COVID-19,O
currently,O
includes,O
a,O
severe,O
restriction,O
or,O
denial,O
of,O
patient,O
access,O
to,O
fertility,O
treatments,O
.,O
There,O
was,O
general,O
agreement,O
between,O
publicly,O
available,O
bulk,O
RNA,O
and,O
protein,O
datasets,O
in,O
terms,O
of,O
ACE2,O
and,O
TMPRSS2,O
expression,O
patterns,O
in,O
testis,O
",",O
ovary,O
",",O
endometrial,O
",",O
and,O
placental,O
cells,O
.,O
The,O
COVID-19,O
pandemic,O
has,O
caused,O
an,O
unprecedented,O
threat,O
to,O
healthcare,O
delivery,O
worldwide,O
.,O
This,O
has,O
had,O
a,O
marked,O
impact,O
on,O
services,O
and,O
patient,O
care,O
for,O
patients,O
without,O
COVID-19,O
.,O
National,O
guidelines,O
recommended,O
that,O
surgery,O
for,O
malignant,O
tumours,O
should,O
continue,O
during,O
the,O
COVID-19,O
pandemic,O
providing,O
adjuvant,O
oncology,O
treatment,O
is,O
available,O
.,O
Data,O
were,O
compared,O
with,O
a,O
baseline,O
MDT,O
workload,O
from,O
the,O
4,O
weeks,O
of,O
February,O
(,O
3–28,O
February,O
2020,O
),O
to,O
provide,O
information,O
on,O
the,O
impact,O
of,O
COVID-19,O
.,O
Project,O
leads,O
were,O
invited,O
to,O
comment,O
with,O
free,O
text,O
on,O
how,O
their,O
unit,O
responded,O
to,O
COVID-19,O
.,O
Using,O
this,O
free,O
text,O
",",O
we,O
developed,O
three,O
groups,O
that,O
arranged,O
units,O
based,O
on,O
commonly,O
expressed,O
themes,O
of,O
how,O
they,O
managed,O
to,O
mitigate,O
the,O
challenges,O
of,O
COVID-19,O
.,O
In,O
total,O
",",O
131,O
patients,O
(,O
10.7,O
%,O
),O
had,O
a,O
change,O
in,O
their,O
initial,O
management,O
due,O
to,O
COVID-19,O
.,O
Project,O
leads,O
commented,O
that,O
COVID-19,O
had,O
less,O
impact,O
on,O
their,O
units,O
or,O
were,O
able,O
to,O
cope,O
with,O
the,O
numbers,O
of,O
referrals,O
.,O
This,O
national,O
study,O
has,O
shown,O
the,O
impact,O
COVID-19,O
has,O
had,O
on,O
MDT,O
decision,O
making,O
for,O
malignant,O
(,O
gliomas,O
and,O
metastases,O
),O
brain,O
tumour,O
patients,O
.,O
Like,O
other,O
cancers,O
",",O
COVID-19,O
has,O
impacted,O
on,O
referrals.8,O
Group,O
analysis,O
identified,O
trends,O
in,O
units,O
that,O
successfully,O
reduced,O
the,O
impact,O
of,O
COVID-19,O
on,O
MDT,O
management,O
.,O
Our,O
findings,O
complement,O
other,O
studies,O
that,O
have,O
shown,O
that,O
the,O
use,O
of,O
the,O
private,O
sector,O
during,O
this,O
COVID-19,O
pandemic,O
results,O
in,O
less,O
disruption,O
to,O
services,O
.,O
11,O
Objectives,O
 ,O
Pressures,O
on,O
healthcare,O
systems,O
due,O
to,O
COVID-19,O
has,O
impacted,O
patients,O
without,O
COVID-19,O
with,O
surgery,O
disproportionally,O
affected,O
.,O
Each,O
unit,O
decided,O
if,O
management,O
decision,O
for,O
each,O
patient,O
had,O
changed,O
due,O
to,O
COVID-19,O
.,O
Conclusion,O
 ,O
COVID-19,O
has,O
had,O
an,O
impact,O
on,O
patients,O
requiring,O
surgery,O
for,O
malignant,O
brain,O
tumours,O
",",O
with,O
patients,O
receiving,O
different,O
treatments,O
—,O
most,O
commonly,O
not,O
receiving,O
surgery,O
or,O
any,O
treatment,O
at,O
all,O
.,O
This,O
study,O
was,O
registered,O
with,O
the,O
Royal,O
College,O
of,O
Surgeons,O
of,O
England,O
’s,O
COVID-19,O
Research,O
Group,O
(,O
https://www.rcseng.ac.uk/coronavirus/rcs-covid-research-group/,O
),O
.,O
In,O
Yichang,O
city,O
",",O
Hubei,O
province,O
",",O
the,O
first,O
outbreak,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
commenced,O
on,O
24,O
January,O
2020,O
in,O
the,O
Yichang,O
Third,O
People,O
's,O
Hospital,O
.,O
With,O
931,O
persons,O
becoming,O
infected,O
and,O
the,O
increasing,O
number,O
of,O
COVID‐19,O
patients,O
",",O
the,O
medical,O
resources,O
of,O
the,O
Yichang,O
Third,O
People,O
's,O
Hospital,O
were,O
in,O
short,O
supply,O
.,O
In,O
this,O
case,O
",",O
Jiangnan,O
District,O
of,O
Yichang,O
Central,O
People,O
's,O
Hospital,O
has,O
been,O
put,O
into,O
use,O
urgently,O
",",O
and,O
nearly,O
30,O
%,O
of,O
COVID‐19,O
confirmed,O
patients,O
in,O
Yichang,O
have,O
been,O
treated,O
in,O
our,O
hospital,O
.,O
However,O
",",O
although,O
there,O
are,O
concerns,O
about,O
whether,O
the,O
use,O
of,O
corticosteroids,O
will,O
slow,O
down,O
the,O
clearance,O
of,O
the,O
coronavirus,O
 ,O
and,O
increase,O
the,O
possibility,O
of,O
opportunistic,O
infections,O
",",O
in,O
severe,O
cases,O
",",O
especially,O
in,O
critically,O
ill,O
COVID‐19,O
patients,O
",",O
the,O
use,O
of,O
corticosteroids,O
seems,O
to,O
be,O
indispensable,O
.,O
",",O
 ,O
",",O
A,O
retrospective,O
comparison,O
study,O
was,O
performed,O
on,O
COVID‐19,O
patients,O
under,O
50,O
years,O
old,O
who,O
were,O
admitted,O
between,O
30,O
January,O
and,O
20,O
February,O
2020,O
.,O
Regardless,O
of,O
whether,O
the,O
patient,O
has,O
a,O
positive,O
nucleic,O
acid,O
test,O
result,O
before,O
hospital,O
admission,O
",",O
we,O
re‐tested,O
the,O
nasopharyngeal,O
swabs,O
for,O
COVID‐19,O
on,O
the,O
first,O
day,O
of,O
admission,O
.,O
Typology,O
of,O
COVID‐19,O
:,O
Mild,O
:,O
the,O
clinical,O
symptoms,O
are,O
mild,O
and,O
no,O
pneumonia,O
manifestations,O
can,O
be,O
found,O
in,O
imaging,O
.,O
COVID‐19,O
is,O
an,O
animal‐derived,O
virus,O
",",O
 ,O
bats,O
may,O
be,O
the,O
host,O
of,O
the,O
virus,O
and,O
intermediate,O
hosts,O
may,O
include,O
pangolins,O
.,O
To,O
date,O
",",O
237,O
cases,O
of,O
COVID‐19,O
diagnosed,O
patients,O
in,O
Yichang,O
City,O
",",O
Hubei,O
Province,O
have,O
been,O
treated,O
in,O
our,O
hospital,O
.,O
The,O
age,O
of,O
all,O
the,O
COVID‐19,O
patients,O
treated,O
in,O
our,O
hospital,O
range,O
from,O
0.5,O
to,O
87,O
years,O
old,O
",",O
and,O
there,O
is,O
no,O
significant,O
difference,O
in,O
the,O
number,O
of,O
infections,O
based,O
on,O
their,O
gender,O
",",O
which,O
indicates,O
that,O
the,O
entire,O
population,O
is,O
susceptible,O
to,O
COVID‐19,O
",",O
regardless,O
of,O
gender,O
or,O
age,O
.,O
Unfortunately,O
",",O
there,O
are,O
still,O
no,O
specific,O
drug,O
to,O
treat,O
COVID‐19,O
at,O
present,O
.,O
In,O
our,O
retrospective,O
non‐randomized,O
study,O
",",O
34,O
patients,O
under,O
50,O
years,O
old,O
and,O
diagnosed,O
with,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
were,O
included,O
.,O
By,O
comparing,O
the,O
clinical,O
data,O
we,O
concluded,O
that,O
corticosteroids,O
therapy,O
can,O
effectively,O
release,O
COVID‐19,O
symptoms,O
such,O
as,O
persistent,O
fever,O
and,O
difficult,O
in,O
breathing,O
",",O
improve,O
oxygenation,O
",",O
and,O
prevent,O
disease,O
progression,O
.,O
Highlights,O
 ,O
1,O
.,O
The,O
use,O
of,O
glucocorticoids,O
prolongs,O
the,O
time,O
required,O
for,O
COVID‐19,O
patients,O
to,O
turn,O
negative,O
consecutively,O
for,O
nucleic,O
acids,O
test,O
.,O
2,O
.,O
The,O
use,O
of,O
glucocorticoids,O
in,O
critical,O
and,O
severe,O
COVID‐19,O
typology,O
patients,O
can,O
prevent,O
the,O
progression,O
of,O
this,O
disease,O
",",O
especially,O
to,O
promote,O
the,O
absorption,O
of,O
CT,O
lesion,O
images,O
 ,O
3,O
.,O
We,O
confirm,O
the,O
safety,O
and,O
necessity,O
of,O
glucocorticoids,O
applications,O
in,O
severe,O
and,O
critical,O
COVID‐19,O
patients,O
.,O
Methods,O
:,O
 ,O
Linear,O
regression,O
",",O
hierarchical,O
clustering,O
",",O
pathway,O
analysis,O
",",O
and,O
network,O
analysis,O
were,O
performed,O
using,O
the,O
E,O
-,O
GEOD-17400,O
data,O
set,O
.,O
The,O
COVID-19,O
pandemic,O
has,O
made,O
brutally,O
clear,O
the,O
need,O
for,O
further,O
research,O
into,O
many,O
aspects,O
of,O
viruses,O
.,O
To,O
assess,O
the,O
concentration,O
of,O
infectious,O
viruses,O
",",O
researchers,O
typically,O
measure,O
the,O
',O
50,O
%,O
tissue,O
-,O
culture,O
infectious,O
dose,O
',O
(,O
TCID50,O
),O
.,O
Measuring,O
TCID50,O
involves,O
infecting,O
replicate,O
cultures,O
of,O
susceptible,O
cells,O
with,O
dilutions,O
of,O
the,O
virus,O
and,O
noting,O
the,O
dilution,O
at,O
which,O
half,O
the,O
replicate,O
dishes,O
become,O
infected,O
.,O
Viral,O
counts,O
reported,O
by,O
TCID50,O
tend,O
to,O
be,O
much,O
lower,O
than,O
RT,O
-,O
qPCR,O
measurements,O
",",O
which,O
could,O
be,O
one,O
reason,O
why,O
studies,O
relying,O
on,O
RNA,O
measurements,O
(,O
Moriarty,O
et,O
al,O
.,O
",",O
2020,O
),O
report,O
the,O
persistence,O
of,O
viral,O
RNA,O
on,O
surfaces,O
for,O
much,O
longer,O
times,O
than,O
studies,O
relying,O
on,O
TCID50,O
(,O
van,O
Doremalen,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
For,O
the,O
common,O
cold,O
",",O
for,O
example,O
",",O
 ,O
~0.1,O
TCID50,O
are,O
sufficient,O
to,O
infect,O
half,O
of,O
the,O
people,O
exposed,O
(,O
Couch,O
et,O
al,O
.,O
",",O
1966,O
),O
.,O
At,O
the,O
time,O
of,O
writing,O
",",O
such,O
assays,O
are,O
not,O
widely,O
available,O
",",O
and,O
so,O
researchers,O
resort,O
to,O
surrogate,O
datasets,O
generated,O
by,O
testing,O
of,O
foreign,O
citizens,O
returning,O
home,O
from,O
infected,O
countries,O
(,O
Verity,O
et,O
al,O
.,O
",",O
2020,O
;,O
Nishiura,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
large,O
-,O
scale,O
semi,O
-,O
random,O
testing,O
in,O
countries,O
such,O
as,O
Iceland,O
",",O
near,O
complete,O
testing,O
of,O
passengers,O
on,O
the,O
Diamond,O
Princess,O
ship,O
(,O
Russell,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
or,O
epidemiological,O
models,O
estimating,O
the,O
number,O
of,O
undocumented,O
cases,O
(,O
Li,O
et,O
al,O
.,O
",",O
2020a,O
;,O
Mizumoto,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
(,O
Godet,O
et,O
al,O
.,O
",",O
1992,O
):,O
"""",O
Based,O
on,O
the,O
estimated,O
molar,O
ratio,O
and,O
assuming,O
that,O
coronavirions,O
bear,O
100,O
(,O
J,O
Gen,O
Virol,O
63,O
:,O
241–245,O
),O
to,O
200,O
spikes,O
",",O
each,O
composed,O
of,O
3,O
s,O
molecules,O
(,O
Virus,O
Research,O
20:107–120,O
),O
it,O
can,O
be,O
inferred,O
that,O
approximately,O
15–30,O
copies,O
of,O
ORF4,O
protein,O
are,O
incorporated,O
into,O
TGEV,O
virions,O
(,O
Purdue,O
strain,O
),O
.,O
"""",O
The,O
COVID-19,O
pandemic,O
is,O
a,O
harsh,O
reminder,O
of,O
the,O
fact,O
that,O
",",O
whether,O
in,O
a,O
single,O
human,O
host,O
or,O
a,O
wave,O
of,O
infection,O
across,O
continents,O
",",O
viral,O
dynamics,O
is,O
often,O
a,O
story,O
about,O
the,O
numbers,O
.,O
The,O
World,O
Health,O
Organization,O
declare,O
this,O
2019,O
-,O
nCoV,O
outbreak,O
as,O
a,O
public,O
health,O
emergency,O
of,O
international,O
concern,O
on,O
January,O
30th,O
",",O
2020,O
(,O
WHO,O
",",O
2020b,O
),O
and,O
the,O
disease,O
caused,O
by,O
this,O
specific,O
virus,O
species,O
have,O
recently,O
been,O
designated,O
as,O
COVID-19,O
(,O
Coronavirus,O
Infectious,O
Disase-19,O
),O
(,O
WHO,O
",",O
2020a,O
),O
.,O
Available,O
and,O
comparable,O
complete,O
genome,O
sequences,O
of,O
81,O
βCoV,O
strains,O
isolated,O
in,O
China,O
",",O
including,O
SARS,O
-,O
CoV-2,O
as,O
well,O
as,O
βCoV,O
isolated,O
from,O
different,O
hosts,O
",",O
were,O
obtained,O
from,O
GenBank,S-Repository
 ,O
database,O
(,O
available,O
at,O
:,O
http://www.ncbi.nlm.nih.gov,S-URL
),O
.,O
For,O
accession,O
number,O
",",O
strain,O
name,O
",",O
host,O
and,O
date,O
of,O
isolation,O
",",O
see,O
Supplementary,O
material,O
Table,O
1,O
.,O
The,O
dataset,O
comprised,O
a,O
total,O
of,O
"725,433",O
codons,O
.,O
By,O
the,O
same,O
approach,O
",",O
Heatmaps,O
were,O
also,O
constructed,O
",",O
which,O
is,O
a,O
data,O
matrix,O
for,O
visualizing,O
values,O
in,O
the,O
dataset,O
by,O
the,O
use,O
of,O
a,O
color,O
gradient,O
.,O
The,O
role,O
of,O
host,O
genetics,O
in,O
impacting,O
susceptibility,O
and,O
severity,O
of,O
COVID-19,O
has,O
been,O
less,O
studied,O
.,O
For,O
example,O
",",O
in,O
Finland,O
with,O
the,O
national,O
network,O
of,O
biobanks,O
covering,O
each,O
hospital,O
district,O
",",O
it,O
is,O
possible,O
to,O
acquire,O
almost,O
‘,O
real,O
-,O
time,O
’,O
updates,O
on,O
COVID-19,O
status,O
of,O
individuals,O
that,O
are,O
already,O
part,O
of,O
the,O
FinnGen,O
study2,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
a,O
respiratory,O
disease,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
[,O
1,O
],O
",",O
which,O
was,O
first,O
identified,O
in,O
Wuhan,O
",",O
China,O
",",O
in,O
December,O
2019,O
",",O
and,O
has,O
rapidly,O
spread,O
globally,O
",",O
resulting,O
in,O
the,O
ongoing,O
pandemic,O
[,O
2,O
],O
.,O
Recently,O
",",O
Korean,O
Society,O
for,O
Laboratory,O
Medicine,O
(,O
KSLM,O
),O
and,O
the,O
Korea,O
Centers,O
for,O
Disease,O
Control,O
and,O
Prevention,O
(,O
KCDC,O
),O
published,O
guidelines,O
for,O
diagnosing,O
COVID-19,O
in,O
clinical,O
laboratories,O
in,O
Korea,O
[,O
3,O
],O
.,O
These,O
guidelines,O
provide,O
appropriate,O
solutions,O
to,O
COVID-19,O
diagnosis,O
.,O
However,O
",",O
many,O
practical,O
and,O
technical,O
issues,O
frequently,O
arise,O
in,O
clinical,O
laboratories,O
conducting,O
COVID-19,O
testing,O
",",O
including,O
those,O
involving,O
nucleic,O
acid,O
extraction,O
",",O
nucleic,O
acid,O
amplification,O
reagents,O
",",O
and,O
interpretation,O
of,O
test,O
results,O
.,O
The,O
COVID-19,O
Diagnosis,O
Test,O
Management,O
Committee,O
was,O
established,O
by,O
the,O
KCDC,O
on,O
Feb,O
28,O
",",O
2020,O
",",O
to,O
provide,O
appropriate,O
solutions,O
to,O
such,O
matters,O
in,O
the,O
field,O
through,O
careful,O
review,O
and,O
counseling,O
by,O
specialized,O
experts,O
in,O
the,O
public,O
and,O
private,O
sectors,O
.,O
On,O
behalf,O
of,O
the,O
COVID-19,O
Diagnosis,O
Test,O
Management,O
Committee,O
",",O
we,O
present,O
supplementary,O
information,O
to,O
the,O
“,O
Guidelines,O
for,O
Laboratory,O
Diagnosis,O
of,O
COVID-19,O
in,O
Korea,O
”,O
to,O
provide,O
solutions,O
for,O
practical,O
issues,O
faced,O
when,O
conducting,O
COVID-19,O
diagnostic,O
testing,O
using,O
real,O
-,O
time,O
reverse,O
transcription,O
(,O
RT)-PCR,O
[,O
3,O
],O
.,O
These,O
practical,O
guidelines,O
are,O
mostly,O
based,O
on,O
expert,O
opinions,O
regarding,O
samples,O
",",O
nucleic,O
acid,O
extraction,O
",",O
nucleic,O
acid,O
amplification,O
reagents,O
",",O
and,O
interpretation,O
of,O
test,O
results,O
and,O
have,O
been,O
formed,O
with,O
the,O
experience,O
from,O
more,O
than,O
"700,000",O
COVID-19,O
tests,O
using,O
five,O
emergency,O
use,O
authorization,O
(,O
EUA,O
),O
assays,O
in,O
Korea,O
.,O
Since,O
eNAT,O
contains,O
guanidine,O
thiocyanate,O
(,O
a,O
type,O
of,O
chaotropic,O
salt,O
),O
that,O
prevents,O
the,O
degradation,O
of,O
nucleic,O
acids,O
in,O
the,O
medium,O
",",O
it,O
is,O
a,O
good,O
option,O
when,O
testing,O
microbial,O
nucleic,O
acids,O
only,O
;,O
the,O
same,O
applies,O
to,O
the,O
COVID-19,O
real,O
-,O
time,O
RT,O
-,O
PCR,O
test,O
.,O
However,O
",",O
heat,O
inactivation,O
of,O
samples,O
through,O
treatment,O
at,O
56,O
°,O
C,O
for,O
30,O
minutes,O
was,O
shown,O
to,O
adversely,O
affect,O
the,O
efficiency,O
of,O
RT,O
-,O
PCR,O
for,O
SARS,O
-,O
CoV-2,O
detection,O
[,O
8,O
],O
;,O
therefore,O
",",O
proteinase,O
K,O
treatment,O
at,O
50–65,O
°,O
C,O
is,O
not,O
recommended,O
for,O
COVID-19,O
real,O
-,O
time,O
RT,O
-,O
PCR,O
.,O
The,O
product,O
manual,O
of,O
the,O
DiaPlexQ,O
2019,O
-,O
nCoV,O
kit,O
(,O
SolGent,O
",",O
Daejeon,O
",",O
Korea,O
),O
states,O
that,O
a,O
sample,O
can,O
indicate,O
COVID-19,O
infection,O
if,O
the,O
result,O
for,O
one,O
of,O
the,O
two,O
genes,O
is,O
positive,O
.,O
This,O
is,O
in,O
contrast,O
with,O
the,O
KSLM,O
guidelines,O
",",O
which,O
specifies,O
that,O
confirmation,O
of,O
COVID-19,O
requires,O
positive,O
results,O
for,O
all,O
genes,O
[,O
3,O
],O
.,O
Both,O
Allplex,O
2019,O
-,O
nCoV,O
(,O
Seegene,O
",",O
Seoul,O
",",O
Korea,O
),O
and,O
Standard,O
M,O
nCoV,O
Real,O
-,O
Time,O
Detection,O
kits,O
(,O
SD,O
Biosensors,O
",",O
Suwon,O
",",O
Korea,O
),O
have,O
the,O
advantage,O
of,O
facilitating,O
the,O
observation,O
of,O
the,O
entire,O
process,O
of,O
COVID-19,O
molecular,O
testing,O
to,O
check,O
nucleic,O
acid,O
extraction,O
",",O
the,O
impact,O
of,O
the,O
PCR,O
inhibitor,O
",",O
and,O
nucleic,O
acid,O
amplification,O
since,O
the,O
IC,O
is,O
directly,O
added,O
to,O
the,O
sample,O
before,O
nucleic,O
acid,O
extraction,O
.,O
The,O
KCDC,O
’s,O
criteria,O
for,O
the,O
quarantine,O
release,O
of,O
patients,O
with,O
COVID-19,O
include,O
clinical,O
improvement,O
with,O
negative,O
results,O
from,O
at,O
least,O
two,O
consecutive,O
respiratory,O
samples,O
collected,O
≥24,O
hours,O
apart,O
[,O
17,O
],O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
a,O
respiratory,O
disease,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
Early,O
detection,O
of,O
COVID-19,O
and,O
immediate,O
isolation,O
of,O
infected,O
patients,O
from,O
the,O
naive,O
population,O
are,O
important,O
to,O
prevent,O
further,O
pandemic,O
spread,O
of,O
the,O
infection,O
.,O
Real,O
-,O
time,O
reverse,O
transcription,O
(,O
RT)-PCR,O
to,O
detect,O
SARS,O
-,O
CoV-2,O
RNA,O
is,O
currently,O
the,O
most,O
reliable,O
diagnostic,O
method,O
for,O
confirming,O
COVID-19,O
worldwide,O
.,O
Guidelines,O
for,O
clinical,O
laboratories,O
on,O
the,O
COVID-19,O
diagnosis,O
have,O
been,O
recently,O
published,O
by,O
Korean,O
Society,O
for,O
Laboratory,O
Medicine,O
and,O
the,O
Korea,O
Centers,O
for,O
Disease,O
Control,O
and,O
Prevention,O
.,O
However,O
",",O
these,O
formal,O
guidelines,O
do,O
not,O
address,O
common,O
practical,O
laboratory,O
issues,O
related,O
to,O
COVID-19,O
real,O
-,O
time,O
RT,O
-,O
PCR,O
testing,O
and,O
their,O
solutions,O
.,O
Therefore,O
",",O
this,O
guideline,O
is,O
intended,O
as,O
a,O
practical,O
and,O
technical,O
supplement,O
to,O
the,O
“,O
Guidelines,O
for,O
Laboratory,O
Diagnosis,O
of,O
COVID-19,O
in,O
Korea,O
”,O
.,O
Coronavirus,O
disease,O
(,O
COVID-19,O
),O
was,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
a,O
newly,O
discovered,O
coronavirus,O
with,O
a,O
size,O
of,O
60–140,O
 ,O
nm,O
",",O
located,O
in,O
the,O
SARB,O
subgene,O
of,O
the,O
Betacoronavirus,O
family,O
[,O
1,O
],O
.,O
As,O
on,O
2:00am,O
CEST,O
",",O
18,O
April,O
2020,O
",",O
there,O
have,O
been,O
"2,160,207",O
confirmed,O
cases,O
of,O
COVID-19,O
",",O
including,O
"146,088",O
deaths,O
globally,O
[,O
3,O
],O
.,O
According,O
to,O
an,O
analysis,O
of,O
"44,672",O
confirmed,O
cases,O
out,O
of,O
"72,314",O
reported,O
cases,O
by,O
the,O
Chinese,O
Center,O
for,O
Disease,O
Control,O
and,O
Prevention,O
(,O
CDC,O
),O
",",O
the,O
crude,O
case,O
fatality,O
rate,O
of,O
the,O
patients,O
with,O
severe,O
COVID-19,O
reached,O
49,O
%,O
.,O
No,O
vaccine,O
for,O
SARS,O
-,O
CoV-2,O
has,O
been,O
published,O
publicly,O
",",O
and,O
there,O
was,O
no,O
medication,O
specific,O
for,O
the,O
treatment,O
of,O
COVID-19,O
so,O
far,O
[,O
6,O
],O
.,O
It,O
was,O
proved,O
that,O
Traditional,O
Chinese,O
Medicine,O
(,O
TCM,O
),O
could,O
obviously,O
shorten,O
fever,O
duration,O
and,O
symptomatic,O
relief,O
of,O
the,O
patients,O
with,O
severe,O
COVID-19,O
[,O
7–9,O
],O
.,O
Up,O
to,O
now,O
",",O
‘,O
three,O
medicines,O
and,O
three,O
formulas,O
’,O
have,O
been,O
proven,O
effective,O
in,O
treating,O
the,O
COVID-19,O
.,O
Among,O
them,O
",",O
Huashi,O
Baidu,O
formula,O
(,O
HSBDF,O
),O
was,O
used,O
as,O
an,O
auxiliary,O
medicine,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
severe,O
COVID-19,O
.,O
According,O
to,O
the,O
theory,O
of,O
TCM,O
",",O
the,O
core,O
pathogenesis,O
of,O
COVID-19,O
was,O
the,O
wet,O
epidemic,O
caused,O
by,O
the,O
cold,O
and,O
humidity,O
outside,O
the,O
lung,O
and,O
spleen,O
",",O
which,O
was,O
transformed,O
into,O
heat,O
and,O
lead,O
to,O
heat,O
stagnation,O
due,O
to,O
the,O
imbalance,O
of,O
qi,O
mechanism,O
and,O
endogenous,O
stagnated,O
heat,O
[,O
11,O
],O
.,O
The,O
combination,O
of,O
SARS,O
-,O
CoV-2,O
and,O
ACE2,O
was,O
the,O
main,O
cause,O
of,O
COVID-19,O
.,O
The,O
protein,O
targets,O
associated,O
with,O
active,O
compounds,O
were,O
retrieved,O
from,O
the,O
TCMSP,S-Repository
 ,O
database,O
(,O
http://lsp.nwsuaf.edu.cn/tcmsp.php,S-URL
),O
",",O
which,O
provided,O
information,O
of,O
6511,O
drug,O
molecules,O
and,O
3987,O
targets,O
as,O
well,O
as,O
the,O
interactions,O
between,O
them,O
[,O
19,O
],O
.,O
As,O
an,O
authoritative,O
database,O
of,O
protein,O
sequences,O
",",O
UniProt,B-Repository
Knowledgebase,I-Repository
(UniProtKB),E-Repository
 ,O
comprised,O
"54,247,468",O
sequence,O
items,O
[,O
24,O
],O
.,O
The,O
targets,O
",",O
including,O
the,O
gene,O
names,O
and,O
gene,O
ID,O
",",O
were,O
further,O
extracted,O
using,O
UniProtKB,S-Repository
 ,O
(,O
http://www.uniprot.org,S-URL
),O
.,O
Visual,O
component,O
–,O
target,O
network,O
was,O
established,O
based,O
on,O
aforementioned,O
data,O
sets,O
through,O
Cytoscape,O
3.7.2,O
(,O
http://www.cytoscape.org/,O
),O
to,O
reflect,O
the,O
complex,O
relationships,O
between,O
active,O
compounds,O
and,O
their,O
potential,O
targets,O
[,O
25,O
],O
.,O
GeneCards,S-Repository
 ,O
database,O
(,O
https://www.genecards.org/,S-URL
),O
and,O
Therapeutic,B-Repository
Target,I-Repository
Database,I-Repository
(TTD,E-Repository
",",O
https://db.idrblab.org/ttd/,S-URL
),O
were,O
used,O
to,O
gather,O
the,O
information,O
on,O
COVID-19,O
-,O
associated,O
target,O
genes,O
[,O
28,O
],O
.,O
GeneCards,S-Repository
 ,O
is,O
a,O
comprehensive,O
database,O
of,O
functions,O
involving,O
proteomics,O
",",O
genomics,O
",",O
and,O
transcriptomics,O
[,O
29,O
],O
.,O
The,O
keywords,O
‘,O
novel,O
coronavirus,O
pneumonia,O
",",O
’,O
‘,O
cough,O
",",O
’,O
and,O
‘,O
fever,O
’,O
were,O
utilized,O
to,O
screen,O
the,O
COVID-19,O
-,O
associated,O
targets,O
.,O
The,O
names,O
of,O
targets,O
were,O
collected,O
from,O
TTD,S-Repository
",",O
which,O
provided,O
information,O
about,O
the,O
therapeutic,O
protein,O
targets,O
",",O
the,O
corresponding,O
ID,O
of,O
each,O
targets,O
and,O
the,O
targeted,O
disease,O
.,O
The,O
common,O
targets,O
of,O
HSBDF,O
and,O
COVID-19,O
were,O
then,O
gathered,O
as,O
the,O
core,O
targets,O
of,O
HSBDF,O
for,O
COVID-19,O
.,O
A,O
total,O
of,O
222,O
active,O
compounds,O
were,O
retrieved,O
in,O
TCMSP,S-Repository
 ,O
database,O
.,O
A,O
total,O
of,O
216,O
possible,O
targets,O
of,O
COVID-19,O
were,O
screened,O
through,O
‘,O
novel,O
coronavirus,O
pneumonia,O
",",O
’,O
‘,O
cough,O
",",O
’,O
and,O
‘,O
fever,O
.,O
’,O
The,O
network,O
contained,O
a,O
total,O
of,O
53,O
nodes,O
",",O
which,O
were,O
the,O
core,O
targets,O
of,O
HSBDF,O
in,O
the,O
treatment,O
of,O
COVID-19,O
.,O
Since,O
both,O
SARS,O
and,O
COVID-19,O
were,O
caused,O
via,O
binding,O
S,O
-,O
protein,O
to,O
ACE2,O
[,O
"37,38",O
],O
",",O
quercetin,O
acted,O
as,O
a,O
competitive,O
antagonist,O
to,O
inhibit,O
infection,O
of,O
SARS,O
-,O
CoV-2,O
.,O
Abstract,O
  ,O
Purpose,O
 ,O
Huashi,O
Baidu,O
formula,O
(,O
HSBDF,O
),O
was,O
developed,O
to,O
treat,O
the,O
patients,O
with,O
severe,O
COVID-19,O
in,O
China,O
.,O
All,O
the,O
components,O
of,O
HSBDF,O
were,O
retrieved,O
from,O
the,O
pharmacology,O
database,O
of,O
TCM,O
system,O
.,O
The,O
genes,O
corresponding,O
to,O
the,O
targets,O
were,O
retrieved,O
using,O
UniProt,S-Repository
 ,O
and,O
GeneCards,S-Repository
 ,O
database,O
.,O
The,O
target,O
protein,O
–,O
protein,O
interaction,O
network,O
was,O
built,O
using,O
STRING,O
database,O
.,O
Conclusion,O
 ,O
Baicalein,O
and,O
quercetin,O
in,O
HSBDF,O
may,O
regulate,O
multiple,O
signaling,O
pathways,O
through,O
ACE2,O
",",O
which,O
might,O
play,O
a,O
therapeutic,O
role,O
on,O
COVID-19,O
.,O
The,O
genome,O
sequences,O
of,O
these,O
viruses,O
were,O
obtained,O
from,O
the,O
RefSeq,S-Repository
 ,O
database,O
(,O
ftp://ftp.ncbi.nlm.nih.gov/genomes/refseq/viral/,S-URL
),O
and,O
RNA,O
fragments,O
of,O
260,O
base,O
in,O
length,O
were,O
generated,O
based,O
on,O
these,O
viral,O
genomic,O
sequences,O
.,O
Since,O
mRNAs,O
incorporating,O
modified,O
nucleosides,O
such,O
as,O
pseudouridine,O
and,O
methylcytidine,O
may,O
make,O
these,O
RNAs,O
less,O
immunogenic,O
[,O
7,O
],O
",",O
pseudouridine,O
instead,O
of,O
uridine,O
and,O
methylcytidine,O
instead,O
of,O
cytidine,O
were,O
used,O
as,O
substrates,O
for,O
IVT,O
.,O
We,O
also,O
added,O
an,O
anti,O
-,O
reverse,O
cap,O
analog,O
(,O
ARCA,O
),O
into,O
the,O
substrate,O
mix,O
to,O
act,O
as,O
a,O
modified,O
nucleoside,O
for,O
incorporation,O
as,O
the,O
5′,O
cap,O
of,O
the,O
IVT,O
mRNA,O
",",O
to,O
avoid,O
inhibition,O
of,O
translation,O
[,O
8,O
],O
.,O
To,O
examine,O
whether,O
the,O
identified,O
RNA,O
stabilizing,O
regions,O
are,O
evolutionarily,O
conserved,O
",",O
we,O
compared,O
the,O
genomes,O
of,O
37,O
viruses,O
belonging,O
to,O
the,O
Coronaviridae,O
family,O
(,O
Table,O
 ,O
S6,O
),O
",",O
including,O
human,O
and,O
bat,O
coronaviruses,O
from,O
the,O
RefSeq,S-Repository
 ,O
database,O
(,O
ftp://ftp.ncbi.nlm.nih.gov/genomes/refseq/viral/,S-URL
),O
and,O
SARS,O
-,O
CoV-2,O
from,O
the,O
NCBI,B-Repository
Nucleotide,E-Repository
 ,O
database,O
(,O
https://www.ncbi.nlm.nih.gov/nuccore/MN908947,S-URL
),O
.,O
The,O
genomic,O
sequences,O
of,O
26,O
different,O
viral,O
genomes,O
across,O
all,O
groups,O
of,O
the,O
Baltimore,O
classification,O
[,O
"6,13",O
],O
(,O
Table,O
 ,O
S1,O
),O
were,O
acquired,O
from,O
the,O
RefSeq,S-Repository
 ,O
database,O
(,O
ftp://ftp.ncbi.nlm.nih.gov/genomes/refseq/viral/,S-URL
),O
.,O
Genome,O
sequences,O
of,O
viruses,O
from,O
the,O
Coronaviridae,O
family,O
were,O
obtained,O
from,O
the,O
RefSeq,S-Repository
 ,O
database,O
(,O
ftp://ftp.ncbi.nlm.nih.gov/genomes/refseq/viral/,S-URL
),O
.,O
The,O
genome,O
sequence,O
of,O
SARS,O
-,O
CoV-2,O
was,O
obtained,O
from,O
the,O
NCBI,B-Repository
Nucleotide,E-Repository
 ,O
database,O
(,O
https://www.ncbi.nlm.nih.gov/nuccore/MN908947,S-URL
),O
.,O
The,O
genomic,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
sampled,O
from,O
human,O
hosts,O
were,O
downloaded,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
[,O
18,O
],O
.,O
Only,O
genome,O
sequences,O
that,O
had,O
no,O
‘,O
N,O
’,O
nucleotides,O
and,O
were,O
incorporated,O
into,O
the,O
Nextstrain,S-Repository
 ,O
website,O
(,O
https://nextstrain.org/ncov/global,S-URL
;,O
last,O
access,O
:,O
2020/0,O
),O
were,O
selected,O
",",O
resulting,O
in,O
"1,116",O
SARS,O
-,O
CoV-2,O
genomes,O
(,O
Table,O
 ,O
S2,O
),O
.,O
Comparative,O
genomic,O
analysis,O
revealed,O
that,O
these,O
RNA,O
sequences,O
and,O
their,O
predicted,O
secondary,O
structures,O
are,O
highly,O
conserved,O
between,O
SARS,O
-,O
CoV,O
and,O
the,O
novel,O
coronavirus,O
",",O
SARS,O
-,O
CoV-2,O
",",O
which,O
is,O
responsible,O
for,O
the,O
global,O
outbreak,O
of,O
the,O
coronavirus,O
-,O
associated,O
disease,O
that,O
emerged,O
in,O
December,O
2019,O
(,O
COVID-19,O
),O
.,O
Abstract,O
  ,O
Background,O
 ,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
a,O
global,O
public,O
health,O
problem,O
that,O
has,O
already,O
caused,O
more,O
than,O
"662,000",O
deaths,O
worldwide,O
.,O
Although,O
the,O
clinical,O
manifestations,O
of,O
COVID-19,O
are,O
dominated,O
by,O
respiratory,O
symptoms,O
",",O
some,O
patients,O
present,O
other,O
severe,O
damage,O
such,O
as,O
cardiovascular,O
",",O
renal,O
and,O
liver,O
injury,O
or,O
/,O
and,O
multiple,O
organ,O
failure,O
",",O
suggesting,O
a,O
spread,O
of,O
the,O
SARS,O
-,O
CoV-2,O
in,O
blood,O
.,O
We,O
herein,O
intended,O
to,O
use,O
the,O
droplet,O
-,O
based,O
digital,O
PCR,O
technology,O
to,O
obtain,O
sensitive,O
detection,O
and,O
precise,O
quantification,O
of,O
plasma,O
SARS,O
-,O
CoV-2,O
viral,O
load,O
(,O
SARS,O
-,O
CoV-2,O
RNAaemia,O
),O
in,O
hospitalized,O
COVID-19,O
patients,O
.,O
Methods,O
 ,O
Fifty,O
-,O
eight,O
consecutive,O
COVID-19,O
patients,O
with,O
pneumonia,O
8,O
to,O
12,O
days,O
after,O
onset,O
of,O
symptoms,O
and,O
12,O
healthy,O
controls,O
were,O
analyzed,O
.,O
Conclusion,O
 ,O
SARS,O
-,O
CoV-2,O
RNAaemia,O
measured,O
by,O
droplet,O
-,O
based,O
digital,O
PCR,O
constitutes,O
a,O
promising,O
prognosis,O
biomarker,O
in,O
COVID-19,O
patients,O
Current,O
report,O
conducted,O
careful,O
examination,O
of,O
the,O
sequences,O
of,O
2019,O
-,O
nCoV,O
",",O
other,O
CoV,O
viruses,O
and,O
HIV-1,O
as,O
well,O
as,O
GenBank,S-Repository
 ,O
database,O
.,O
Blast,O
against,O
viral,O
sequence,O
database,O
also,O
showed,O
these,O
insertion,O
sequences,O
widely,O
exist,O
in,O
all,O
kinds,O
of,O
viruses,O
from,O
bacteriophage,O
",",O
influenza,O
",",O
to,O
giant,O
eukaryotic,O
viruses,O
(,O
Table,O
1,O
),O
.,O
More,O
hits,O
were,O
found,O
for,O
coronaviruses,O
and,O
a,O
few,O
also,O
hit,O
on,O
HIV-1,O
sequences,O
than,O
the,O
search,O
against,O
the,O
entire,O
database,O
(,O
Table,O
1,O
),O
.,O
In,O
February,O
2020,O
",",O
the,O
WHO,O
designated,O
2019,O
-,O
nCoV,O
–,O
caused,O
pneumonia,O
‘,O
COVID-19,O
.,O
’,O
For,O
Bayesian,O
analysis,O
",",O
777,O
total,O
2019,O
-,O
nCoV,O
gene,O
sequences,O
as,O
of,O
29,O
February,O
2020,O
were,O
downloaded,O
from,O
GISAID,S-Dataset
 ,O
[,O
11,O
],O
.,O
The,O
outbreak,O
of,O
the,O
COVID-19,O
pandemia,O
in,O
2019/2020,O
has,O
stimulated,O
research,O
on,O
clinical,O
laboratory,O
findings,O
in,O
this,O
condition,O
",",O
as,O
evidenced,O
by,O
two,O
recent,O
papers,O
in,O
this,O
journal,O
[,O
1,O
],O
",",O
[,O
2,O
],O
.,O
As,O
this,O
D,O
/,O
I,O
polymorphism,O
shows,O
an,O
important,O
geographical,O
variation,O
[,O
7,O
],O
",",O
we,O
postulated,O
that,O
the,O
variability,O
in,O
D,O
/,O
I,O
genotype,O
distribution,O
might,O
partly,O
explain,O
the,O
variable,O
prevalence,O
of,O
the,O
COVID-19,O
infection,O
amongst,O
continental,O
European,O
countries,O
.,O
Therefore,O
",",O
we,O
compared,O
the,O
D,O
-,O
allele,O
frequency,O
of,O
the,O
ACE1,O
gene,O
as,O
obtained,O
in,O
25,O
different,O
European,O
countries,O
with,O
the,O
prevalence,O
and,O
mortality,O
of,O
COVID-19,O
",",O
as,O
calculated,O
on,O
March,O
20,O
",",O
2020,O
by,O
Johns,B-Creator
Hopkins,E-Creator
 ,O
[,O
8,O
],O
.,O
The,O
log,O
transformed,O
prevalence,O
of,O
COVID-19,O
infections,O
inversely,O
correlates,O
with,O
the,O
ACE,O
D,O
allele,O
frequency,O
:,O
log,O
(,O
prevalence,O
;,O
number,O
of,O
cases/106,O
inhabitants,O
),O
 ,O
=,O
 ,O
6.358–0.079,O
(,O
D,O
-,O
allele,O
frequency,O
",",O
%,O
),O
",",O
r2,O
 ,O
=,O
 ,O
0.378,O
;,O
p,O
 ,O
=,O
 ,O
0.001,O
.,O
Similarly,O
",",O
a,O
significant,O
correlation,O
could,O
be,O
noted,O
between,O
COVID-19,O
caused,O
mortality,O
(,O
Spearman,O
r,O
 ,O
=,O
 ,O
−0.510,O
",",O
p,O
 ,O
=,O
 ,O
0.01,O
),O
and,O
the,O
prevalence,O
of,O
the,O
ACE1,O
D,O
-,O
allele,O
.,O
These,O
data,O
suggest,O
that,O
ACE1,O
D,O
/,O
I,O
polymorphism,O
may,O
be,O
regarded,O
as,O
a,O
confounder,O
in,O
the,O
spread,O
of,O
COVID-19,O
and,O
the,O
outcome,O
of,O
the,O
infection,O
in,O
various,O
European,O
populations,O
.,O
We,O
appreciate,O
the,O
constructive,O
comments,O
from,O
Kesici,O
et,O
al,O
.,O
(,O
1,O
),O
and,O
Zeng,O
et,O
al,O
.,O
(,O
2,O
),O
",",O
which,O
mainly,O
focus,O
on,O
the,O
key,O
points,O
about,O
the,O
optimal,O
procedure,O
of,O
convalescent,O
plasma,O
(,O
CP,O
),O
transfusion,O
in,O
severe,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
therapy,O
and,O
about,O
how,O
to,O
improve,O
the,O
effectiveness,O
.,O
Indeed,O
",",O
the,O
adverse,O
effect,O
was,O
minor,O
",",O
whereas,O
a,O
quickly,O
improved,O
outcome,O
of,O
10,O
severe,O
COVID-19,O
patients,O
was,O
observed,O
.,O
Second,O
",",O
the,O
objective,O
for,O
CP,O
transfusion,O
in,O
severe,O
COVID-19,O
therapy,O
is,O
based,O
on,O
an,O
in,O
-,O
depth,O
understanding,O
of,O
disease,O
mechanisms,O
.,O
Particularly,O
",",O
in,O
severe,O
or,O
critical,O
COVID-19,O
cases,O
",",O
lung,O
alveolar,O
macrophages,O
or,O
epithelial,O
cells,O
could,O
produce,O
various,O
proinflammatory,O
cytokines,O
and,O
chemokines,O
",",O
which,O
recruit,O
monocytes,O
and,O
neutrophils,O
to,O
the,O
infection,O
site,O
to,O
clear,O
the,O
virus,O
particles,O
and,O
infected,O
cells,O
",",O
resulting,O
in,O
uncontrolled,O
inflammation,O
.,O
Thus,O
",",O
monitoring,O
the,O
dynamic,O
changes,O
of,O
interleukin-6,O
level,O
",",O
which,O
was,O
significantly,O
elevated,O
in,O
COVID-19,O
",",O
may,O
help,O
to,O
determine,O
the,O
optimal,O
treatment,O
time,O
",",O
generally,O
within,O
2,O
wk,O
.,O
The,O
median,O
duration,O
of,O
hospitalization,O
for,O
COVID-19,O
patients,O
was,O
12.0,O
d,O
(,O
10,O
),O
.,O
In,O
our,O
study,O
",",O
all,O
of,O
the,O
donors,O
were,O
recovered,O
from,O
the,O
common,O
type,O
of,O
COVID-19,O
.,O
COVID-19,O
is,O
spreading,O
rapidly,O
throughout,O
the,O
world,O
;,O
approximately,O
all,O
developed,O
and,O
developing,O
countries,O
and,O
nations,O
(,O
Amirhossein,O
Takian,O
and,O
Kazempour,O
-,O
Ardebili,O
",",O
2020,O
;,O
Holshue,O
et,O
al,O
.,O
",",O
2020,O
;,O
Sohrabi,O
et,O
al,O
.,O
",",O
2020,O
;,O
van,O
Doremalen,O
et,O
al,O
.,O
",",O
2020a,O
),O
.,O
In,O
Iran,O
",",O
the,O
first,O
official,O
announcement,O
of,O
death,O
due,O
to,O
COVID-19,O
was,O
reported,O
by,O
the,O
Ministry,O
of,O
Health,O
and,O
Medical,O
Education,O
on,O
February,O
19,O
",",O
2020,O
(,O
Amirhossein,O
Takian,O
and,O
Kazempour,O
-,O
Ardebili,O
",",O
2020,O
),O
.,O
On,O
March,O
31,O
",",O
2020,O
",",O
Iran,O
with,O
"44,605",O
COVID-19,O
cases,O
and,O
2898,O
its,O
deaths,O
was,O
the,O
7th,O
and,O
6th,O
highest,O
ranking,O
",",O
among,O
203,O
countries,O
and,O
territories,O
throughout,O
the,O
world,O
which,O
have,O
experienced,O
COVID-19,O
outbreak,O
(,O
https://www.worldometers.info/coronavirus/#countries,S-URL
),O
.,O
Given,O
the,O
rapid,O
spread,O
of,O
COVID-19,O
globally,O
",",O
investigations,O
are,O
under,O
way,O
to,O
better,O
understand,O
the,O
potential,O
of,O
airborne,O
transmission,O
mode,O
of,O
the,O
virus,O
as,O
well,O
as,O
the,O
clinical,O
characteristics,O
and,O
severity,O
of,O
the,O
disease,O
(,O
Ghinai,O
et,O
al,O
.,O
",",O
2020,O
;,O
Guan,O
et,O
al,O
.,O
",",O
2020,O
;,O
Holshue,O
et,O
al,O
.,O
",",O
2020,O
;,O
Liu,O
et,O
al,O
.,O
",",O
2020,O
;,O
van,O
Doremalen,O
et,O
al,O
.,O
",",O
2020a,O
),O
.,O
To,O
better,O
manage,O
the,O
risks,O
of,O
COVID-19,O
",",O
particularly,O
for,O
health,O
-,O
care,O
workers,O
(,O
Cheung,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
it,O
is,O
extremely,O
crucial,O
to,O
address,O
the,O
importance,O
of,O
airborne,O
transmission,O
as,O
one,O
of,O
the,O
most,O
important,O
challenge,O
/,O
question,O
of,O
international,O
COVID-19,O
outbreak,O
.,O
We,O
conducted,O
the,O
present,O
study,O
on,O
March,O
17,O
",",O
2020,O
in,O
hospital,O
wards,O
with,O
confirmed,O
COVID-19,O
at,O
Imam,O
Khomeini,O
Hospital,O
Complex,O
in,O
Tehran,O
",",O
Iran,O
.,O
On,O
March,O
31,O
",",O
2020,O
",",O
Tehran,O
province,O
with,O
the,O
highest,O
confirmed,O
COVID-19,O
cases,O
ranked,O
the,O
first,O
place,O
among,O
all,O
provinces,O
in,O
Iran,O
.,O
As,O
a,O
highly,O
efficient,O
approach,O
to,O
sample,O
the,O
airborne,O
viruses,O
",",O
the,O
impinger,O
technique,O
was,O
used,O
in,O
order,O
to,O
collect,O
the,O
air,O
sample,O
of,O
patient,O
rooms,O
with,O
confirmed,O
COVID-19,O
(,O
Dart,O
and,O
Thornburg,O
",",O
2008,O
;,O
Verreault,O
et,O
al,O
.,O
",",O
2008,O
),O
.,O
Table,O
1,O
reveals,O
the,O
specifications,O
of,O
all,O
collected,O
samples,O
of,O
SARS,O
-,O
CoV-2,O
in,O
the,O
air,O
of,O
hospital,O
wards,O
",",O
and,O
Table,O
2,O
provides,O
additional,O
information,O
on,O
environmental,O
status,O
of,O
patient,O
rooms,O
with,O
confirmed,O
COVID-19,O
.,O
As,O
shown,O
in,O
Table,O
1,O
",",O
there,O
were,O
forty,O
-,O
four,O
patients,O
confirmed,O
with,O
COVID-19,O
that,O
were,O
receiving,O
oxygen,O
mask,O
(,O
n,O
 ,O
=,O
 ,O
22,O
),O
and,O
intubation,O
(,O
n,O
 ,O
=,O
 ,O
22,O
),O
treatments,O
.,O
It,O
was,O
reported,O
that,O
COVID-19,O
patients,O
are,O
afflicted,O
with,O
the,O
dry,O
and,O
short,O
cough,O
(,O
Ghinai,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
As,O
we,O
had,O
limited,O
access,O
to,O
the,O
wards,O
",",O
the,O
number,O
of,O
collected,O
samples,O
might,O
not,O
be,O
generalized,O
to,O
the,O
all,O
wards,O
of,O
hospital,O
with,O
confirmed,O
COVID-19,O
patients,O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
emerged,O
in,O
Wuhan,O
city,O
",",O
China,O
",",O
in,O
late,O
2019,O
and,O
has,O
rapidly,O
spread,O
throughout,O
the,O
world,O
.,O
Until,O
now,O
",",O
there,O
has,O
been,O
no,O
evidence,O
for,O
detection,O
of,O
airborne,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
and,O
this,O
may,O
have,O
implication,O
for,O
the,O
potential,O
spread,O
of,O
the,O
COVID-19,O
.,O
We,O
investigated,O
the,O
air,O
of,O
patient,O
rooms,O
with,O
confirmed,O
COVID-19,O
in,O
the,O
largest,O
hospital,O
in,O
Iran,O
",",O
on,O
March,O
17,O
",",O
2020,O
.,O
Fortunately,O
",",O
in,O
this,O
study,O
all,O
air,O
samples,O
which,O
were,O
collected,O
2,O
to,O
5,O
 ,O
m,O
from,O
the,O
patients,O
',O
beds,O
with,O
confirmed,O
COVID-19,O
were,O
negative,O
.,O
We,O
checked,O
the,O
linked,O
original,O
reports,O
from,O
the,O
WHO,O
MERS,O
-,O
CoV,O
disease,O
outbreak,O
news,O
[,O
20,O
],O
and,O
the,O
Saudi,O
MoH,O
[,O
21,O
],O
for,O
each,O
human,O
case,O
listed,O
on,O
FluTrackers,O
[,O
19,O
],O
and,O
extracted,O
data,O
on,O
disease,O
risk,O
factors,O
",",O
including,O
date,O
of,O
notification,O
",",O
date,O
of,O
symptoms,O
onset,O
",",O
date,O
of,O
hospitalization,O
",",O
laboratory,O
confirmation,O
date,O
",",O
complications,O
",",O
death,O
and,O
type,O
of,O
case,O
based,O
on,O
the,O
specified,O
contact,O
history,O
(,O
hospital,O
outbreak,O
-,O
associated,O
case,O
and,O
sporadic,O
case,O
:,O
camel,O
-,O
linked,O
",",O
sheep,O
-,O
linked,O
",",O
community,O
-,O
linked,O
",",O
unknown,O
exposure,O
),O
to,O
enhance,O
the,O
dataset,O
.,O
We,O
included,O
the,O
remaining,O
120,O
complete,O
genome,O
sequences,O
in,O
our,O
dataset,O
.,O
Each,O
sequence,O
contained,O
the,O
basic,O
information,O
of,O
accession,O
number,O
",",O
date,O
of,O
sample,O
collection,O
and,O
location,O
(,O
city,O
),O
.,O
We,O
classified,O
all,O
the,O
criteria,O
into,O
three,O
groups,O
(,O
Figure,O
S1,O
):,O
Based,O
on,O
the,O
available,O
information,O
in,O
the,O
two,O
datasets,O
",",O
we,O
matched,O
each,O
sequence,O
with,O
the,O
human,O
case,O
.,O
Three,O
levels,O
of,O
likelihood,O
of,O
matching,O
were,O
defined,O
(,O
Tables,O
S2,O
and,O
S3,O
):,O
Using,O
Geneious,O
v.11.0.4,O
[,O
22,O
],O
",",O
we,O
annotated,O
all,O
the,O
complete,O
genome,O
sequences,O
with,O
accession,O
numbers,O
.,O
The,O
majority,O
of,O
sequences,O
(,O
n,O
=,O
103,O
",",O
86,O
%,O
),O
were,O
matched,O
to,O
individuals,O
in,O
the,O
MERS,O
-,O
CoV,O
human,O
cases,O
epidemiological,O
dataset,O
(,O
Tables,O
S1,O
–,O
S3,O
),O
",",O
including,O
40,O
(,O
33,O
%,O
),O
unique,O
matched,O
isolates,O
and,O
63,O
(,O
53,O
%,O
),O
likely,O
matched,O
isolates,O
.,O
In,O
this,O
study,O
",",O
we,O
linked,O
and,O
used,O
enhanced,O
surveillance,O
datasets,O
for,O
phylogeographic,O
analysis,O
.,O
We,O
enhanced,O
the,O
dataset,O
and,O
identified,O
12,O
MERS,O
-,O
CoV,O
isolates,O
from,O
the,O
Al,O
Ahsa,O
hospital,O
outbreak,O
for,O
phylogenetic,O
analysis,O
to,O
minimize,O
the,O
bias,O
caused,O
by,O
the,O
small,O
size,O
of,O
the,O
sequence,O
data,O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
caused,O
by,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
virus,O
is,O
having,O
a,O
global,O
impact,O
with,O
latest,O
WHO,S-Creator
 ,O
data,O
indicating,O
"21,294,845",O
cases,O
and,O
"761,779",O
deaths,O
(,O
WHO,S-Creator
 ,O
COVID-19,O
Situation,O
Report,O
209,O
),O
.,O
The,O
novel,O
coronavirus,O
SARS,O
-,O
CoV-2,O
",",O
the,O
infective,O
agent,O
causing,O
COVID-19,O
",",O
is,O
having,O
a,O
global,O
impact,O
both,O
in,O
terms,O
of,O
human,O
disease,O
as,O
well,O
as,O
socially,O
and,O
economically,O
.,O
At,O
the,O
time,O
of,O
writing,O
of,O
this,O
article,O
",",O
the,O
world,O
was,O
battling,O
the,O
unprecedented,O
coronavirus,O
pandemic,O
disease,O
",",O
the,O
so,O
-,O
called,O
COVID-19,O
.,O
A,O
well,O
-,O
known,O
antimalarial,O
drug,O
chloroquine,O
",",O
its,O
derivative,O
hydroxychloroquine,O
and,O
other,O
antivirals,O
which,O
are,O
known,O
to,O
inhibit,O
viral,O
entry,O
into,O
host,O
cells,O
by,O
increasing,O
endosomal,O
pH,O
have,O
been,O
introduced,O
in,O
an,O
attempt,O
to,O
treat,O
COVID-19,O
[,O
10,O
],O
.,O
There,O
are,O
currently,O
197,O
clinical,O
trials,O
assessing,O
the,O
role,O
of,O
antimalarials,O
alone,O
or,O
in,O
combination,O
with,O
other,O
agents,O
against,O
COVID-19,O
infection,O
[,O
12,O
],O
",",O
[,O
13,O
],O
.,O
These,O
poor,O
results,O
highlight,O
the,O
need,O
to,O
test,O
for,O
G6PD,O
deficiency,O
prior,O
to,O
enrolment,O
in,O
clinical,O
trials,O
evaluating,O
antimalarials,O
and,O
other,O
oxidizing,O
drugs,O
in,O
COVID-19,O
.,O
The,O
first,O
half,O
of,O
the,O
year,O
2020,O
has,O
been,O
in,O
the,O
midst,O
of,O
the,O
first,O
wave,O
of,O
COVID-19,O
pandemic,O
.,O
While,O
P,O
-,O
BEST,O
incorporates,O
a,O
specific,O
Reed,O
-,O
Solomon,O
error,O
-,O
correcting,O
code,O
scheme,O
for,O
pooling,O
",",O
we,O
ran,O
simulations,O
around,O
this,O
band,O
with,O
similar,O
aspects,O
(,O
i.e.,O
each,O
sample,O
contributes,O
to,O
exactly,O
6,O
pools,O
in,O
384,O
-,O
well,O
plate,O
setting,O
),O
to,O
observe,O
the,O
efficiency,O
gain,O
rates,O
around,O
perfect,O
recovery,O
operating,O
points,O
.,O
Conducting,O
an,O
effective,O
test,O
",",O
trace,O
&,O
isolate,O
solution,O
might,O
be,O
the,O
key,O
for,O
containing,O
SARS,O
-,O
CoV-2,O
and,O
an,O
elemental,O
part,O
of,O
fighting,O
against,O
the,O
current,O
COVID-19,O
pandemic,O
.,O
Currently,O
proposed,O
COVID-19,O
group,O
testing,O
schemes,O
offer,O
a,O
gain,O
up,O
to,O
no,O
more,O
than,O
10X,O
and,O
25X,O
scale,O
-,O
up,O
for,O
medium,O
(,O
0.5%-10,O
%,O
),O
and,O
low,O
(,O
<,O
0.5,O
%,O
),O
prevalence,O
respectively,O
[,O
10–12,O
",",O
16,O
],O
.,O
Although,O
the,O
current,O
popular,O
approach,O
of,O
COVID-19,O
testing,O
is,O
RT,O
-,O
qPCR,O
based,O
molecular,O
tests,O
",",O
clearly,O
group,O
testing,O
is,O
not,O
limited,O
to,O
PCR,O
based,O
molecular,O
techniques,O
.,O
On,O
the,O
contrary,O
",",O
we,O
know,O
that,O
COVID-19,O
sampling,O
is,O
mainly,O
conducted,O
on,O
populations,O
with,O
social,O
contacts,O
",",O
violating,O
the,O
independence,O
assumptions,O
.,O
The,O
capacity,O
of,O
the,O
current,O
molecular,O
testing,O
convention,O
does,O
not,O
allow,O
high,O
-,O
throughput,O
and,O
community,O
level,O
scans,O
of,O
COVID-19,O
infections,O
.,O
Currently,O
proposed,O
COVID-19,O
group,O
testing,O
schemes,O
offer,O
a,O
gain,O
up,O
to,O
15X-20X,O
scale,O
-,O
up,O
.,O
The,O
codes,O
",",O
protocols,O
",",O
and,O
datasets,O
used,O
during,O
the,O
current,O
study,O
are,O
available,O
from,O
the,O
corresponding,O
author,O
on,O
reasonable,O
request,O
.,O
Currently,O
",",O
a,O
total,O
of,O
14,O
full‐length,O
sequences,O
of,O
the,O
2019‐nCoV,O
were,O
released,O
to,O
GISAID,S-Dataset
 ,O
and,O
GeneBank,S-Repository
.,O
The,O
newly,O
sequenced,O
Beta‐coronavirus,O
(,O
MN908947,S-AccessionNumber
),O
genome,O
was,O
downloaded,O
from,O
the,O
GenBank,S-Repository
 ,O
database,O
.,O
We,O
divided,O
our,O
data,O
set,O
into,O
four,O
clades,O
",",O
the,O
newly,O
discovered,O
2019‐nCoV,O
sequence,O
was,O
grouped,O
as,O
the,O
query,O
sequence,O
.,O
Interestingly,O
",",O
no,O
similar,O
sequence,O
was,O
found,O
with,O
known,O
sequence,O
in,O
the,O
database,O
",",O
suggesting,O
that,O
a,O
putative,O
recombination,O
parent,O
virus,O
was,O
still,O
unknown,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
outbreak,O
has,O
led,O
to,O
the,O
reorganization,O
of,O
national,O
health,O
systems,O
in,O
many,O
specialties,O
including,O
medical,O
oncology,O
.,O
The,O
host,O
immune,O
system,O
is,O
crucial,O
in,O
determining,O
the,O
clinical,O
course,O
of,O
COVID‐19,O
.,O
The,O
severity,O
of,O
COVID‐19,O
is,O
caused,O
not,O
only,O
by,O
direct,O
viral,O
damage,O
",",O
but,O
also,O
by,O
an,O
impaired,O
immune,O
host,O
reaction,O
",",O
sometimes,O
resulting,O
in,O
an,O
extremely,O
strong,O
inflammatory,O
response,O
leading,O
to,O
airways,O
damage,O
and,O
life‐threatening,O
acute,O
respiratory,O
distress,O
syndrome,O
.,O
This,O
interaction,O
may,O
worsen,O
the,O
hyperinflammation,O
with,O
CRS,O
observed,O
in,O
severe,O
cases,O
of,O
COVID‐19,O
",",O
but,O
the,O
antagonism,O
of,O
checkpoint,O
axis,O
like,O
PD‐1,O
/,O
PD‐L1,O
could,O
also,O
potentially,O
participate,O
in,O
accelerating,O
the,O
resolution,O
of,O
viral,O
infection,O
.,O
",",O
  ,O
Beyond,O
this,O
complexity,O
",",O
SARS‐CoV‐2,O
infection,O
in,O
patients,O
with,O
cancer,O
poses,O
also,O
issues,O
related,O
to,O
the,O
differential,O
diagnosis,O
between,O
cancer‐related,O
symptoms,O
or,O
immune‐related,O
adverse,O
events,O
(,O
irAEs,O
),O
and,O
COVID‐19,O
manifestations,O
.,O
The,O
survey,O
(,O
Appendix,O
S1,O
),O
was,O
composed,O
of,O
four,O
sections,O
:,O
(,O
a,O
),O
demographic,O
",",O
training,O
and,O
employment,O
details,O
of,O
respondents,O
(,O
Q1‐8,O
),O
;,O
(,O
b,O
),O
perception,O
of,O
the,O
risk,O
related,O
to,O
SARS‐CoV‐2,O
infection,O
in,O
patients,O
with,O
cancer,O
treated,O
with,O
ICIs,O
(,O
Q9‐11,O
),O
;,O
(,O
c,O
),O
attitudes,O
towards,O
the,O
administration,O
of,O
ICIs,O
and,O
management,O
of,O
toxicities,O
during,O
COVID‐19,O
outbreak,O
(,O
Q12‐16,O
),O
;,O
and,O
(,O
d,O
),O
specific,O
questions,O
focused,O
on,O
attitudes,O
towards,O
the,O
prescription,O
of,O
ICIs,O
for,O
the,O
treatment,O
of,O
different,O
cancer,O
types,O
during,O
COVID‐19,O
outbreak,O
(,O
Q17‐22,O
),O
.,O
Figure,O
 ,O
2,O
depicts,O
whether,O
responding,O
physicians,O
have,O
modified,O
their,O
attitudes,O
in,O
the,O
choice,O
of,O
the,O
ICI,O
to,O
administer,O
and,O
its,O
schedule,O
during,O
COVID‐19,O
outbreak,O
(,O
notably,O
",",O
more,O
than,O
one,O
answer,O
could,O
be,O
selected,O
for,O
this,O
question,O
),O
.,O
Two,O
clinical,O
situations,O
were,O
explored,O
to,O
assess,O
the,O
issues,O
related,O
to,O
the,O
differential,O
diagnosis,O
between,O
irAEs,O
and,O
COVID‐19,O
manifestations,O
in,O
cancer,O
patients,O
treated,O
with,O
ICIs,O
:,O
(,O
a,O
),O
how,O
to,O
manage,O
a,O
patient,O
with,O
onset,O
of,O
dyspnoea,O
and,O
cough,O
(,O
Figure,O
 ,O
4A,O
),O
;,O
(,O
b,O
),O
how,O
to,O
manage,O
a,O
patient,O
whit,O
onset,O
of,O
diarrhoea,O
(,O
Figure,O
 ,O
4B,O
),O
.,O
Moreover,O
",",O
besides,O
the,O
overlapping,O
between,O
cancer‐related,O
signs,O
/,O
symptoms,O
or,O
side,O
effects,O
of,O
oncological,O
treatments,O
(,O
including,O
irAEs,O
),O
and,O
COVID‐19,O
manifestations,O
",",O
additional,O
issues,O
could,O
emerge,O
from,O
the,O
differential,O
diagnosis,O
between,O
radiological,O
findings,O
of,O
lung,O
involvement,O
from,O
SARS‐CoV‐2,O
and,O
pneumonitis,O
induced,O
by,O
ICIs,O
.,O
",",O
This,O
uncertainty,O
is,O
likely,O
due,O
to,O
the,O
lack,O
of,O
univocal,O
evidence,O
on,O
this,O
regard,O
.,O
",",O
 ,O
",",O
 ,O
",",O
  ,O
Furthermore,O
",",O
47.1,O
%,O
of,O
respondents,O
supported,O
the,O
hypothesis,O
of,O
a,O
synergism,O
between,O
the,O
mechanism,O
of,O
action,O
of,O
ICIs,O
and,O
the,O
pathogenesis,O
of,O
SARS‐CoV‐2,O
infections,O
",",O
thus,O
being,O
worried,O
about,O
the,O
potential,O
higher,O
risks,O
of,O
COVID‐19‐related,O
complications,O
in,O
this,O
patient,O
population,O
.,O
Nevertheless,O
",",O
it,O
is,O
comforting,O
that,O
97.1,O
%,O
of,O
respondents,O
would,O
not,O
deny,O
ICIs,O
as,O
a,O
treatment,O
option,O
at,O
the,O
time,O
of,O
COVID‐19,O
outbreak,O
only,O
based,O
on,O
the,O
possible,O
risks,O
of,O
infection,O
by,O
SARS‐CoV‐2,O
",",O
considering,O
that,O
so,O
far,O
a,O
clear,O
evidence,O
of,O
a,O
detrimental,O
effect,O
of,O
their,O
administration,O
still,O
lacks,O
.,O
The,O
European,O
Society,O
for,O
Medical,O
Oncology,O
(,O
ESMO,O
),O
has,O
created,O
dedicated,O
recommendations,O
for,O
the,O
management,O
of,O
various,O
aspects,O
of,O
oncological,O
care,O
",",O
in,O
order,O
to,O
mitigate,O
the,O
negative,O
impact,O
of,O
COVID‐19,O
 ,O
outbreak,O
on,O
patients,O
with,O
cancer,O
.,O
",",O
  ,O
Reducing,O
the,O
number,O
of,O
hospital,O
visits,O
while,O
maintaining,O
treatment,O
effect,O
is,O
a,O
reasonable,O
safety,O
measure,O
that,O
should,O
be,O
taken,O
into,O
account,O
during,O
COVID‐19,O
outbreak,O
.,O
The,O
overlapping,O
between,O
clinical,O
manifestations,O
of,O
irAEs,O
and,O
COVID‐19,O
",",O
and,O
the,O
consequent,O
management,O
",",O
is,O
an,O
additional,O
concern,O
.,O
While,O
immune,O
related,O
pneumonitis,O
is,O
not,O
so,O
frequent,O
in,O
patients,O
with,O
cancer,O
treated,O
with,O
ICIs,O
(,O
1%‐5,O
%,O
with,O
anti‐CTLA‐4,O
or,O
anti,O
PD‐1,O
/,O
PD‐L1,O
as,O
monotherapy,O
",",O
5%‐10,O
%,O
with,O
combination,O
strategies,O
),O
",",O
",",O
  ,O
it,O
enters,O
in,O
the,O
differential,O
diagnosis,O
list,O
at,O
the,O
time,O
of,O
COVID‐19,O
outbreak,O
for,O
almost,O
all,O
respondents,O
.,O
On,O
the,O
contrary,O
",",O
diarrhoea,O
is,O
one,O
of,O
the,O
most,O
frequent,O
irAE,O
",",O
 ,O
and,O
despite,O
its,O
overall,O
rate,O
is,O
10.4,O
%,O
in,O
patients,O
with,O
COVID‐19,O
in,O
a,O
pooled,O
analysis,O
",",O
only,O
28.8,O
%,O
of,O
respondents,O
reported,O
to,O
manage,O
a,O
patient,O
with,O
colitis,O
as,O
a,O
SARS‐CoV‐2‐infected,O
patient,O
until,O
otherwise,O
proven,O
",",O
potentially,O
leading,O
to,O
a,O
risk,O
of,O
contagion,O
in,O
the,O
case,O
of,O
underlying,O
infection,O
by,O
SARS‐CoV‐2,O
.,O
",",O
  ,O
Having,O
dedicated,O
facilities,O
where,O
cancer,O
patients,O
could,O
be,O
managed,O
also,O
in,O
the,O
case,O
of,O
suspected,O
SARS‐CoV‐2,O
infection,O
should,O
be,O
considered,O
of,O
high,O
priority,O
in,O
order,O
to,O
continue,O
providing,O
the,O
needed,O
care,O
in,O
the,O
safest,O
possible,O
environment,O
.,O
Notably,O
",",O
its,O
use,O
has,O
also,O
been,O
associated,O
with,O
a,O
reduction,O
in,O
the,O
risk,O
of,O
death,O
in,O
patients,O
with,O
COVID‐19‐related,O
pneumonia,O
.,O
The,O
results,O
of,O
our,O
survey,O
do,O
not,O
demonstrate,O
a,O
significant,O
change,O
in,O
the,O
attitudes,O
of,O
Italian,O
physicians,O
towards,O
the,O
prescription,O
of,O
ICIs,O
during,O
COVID‐19,O
outbreak,O
.,O
These,O
data,O
",",O
probably,O
driven,O
by,O
the,O
higher,O
risk,O
of,O
COVID‐19,O
severe,O
events,O
in,O
the,O
elderly,O
population,O
",",O
deserve,O
a,O
reflection,O
considering,O
the,O
significant,O
benefit,O
associated,O
with,O
ICIs,O
in,O
this,O
setting,O
.,O
",",O
Abstract,O
  ,O
Background,O
 ,O
During,O
COVID‐19,O
outbreak,O
",",O
oncological,O
care,O
has,O
been,O
reorganized,O
.,O
Patients,O
with,O
cancer,O
have,O
been,O
reported,O
to,O
experience,O
a,O
more,O
severe,O
COVID‐19,O
syndrome,O
;,O
moreover,O
",",O
there,O
are,O
concerns,O
of,O
a,O
potential,O
interference,O
between,O
immune,O
checkpoint,O
inhibitors,O
(,O
ICIs,O
),O
and,O
SARS‐CoV‐2,O
pathogenesis,O
.,O
During,O
COVID‐19,O
outbreak,O
",",O
to,O
reduce,O
hospital,O
visits,O
",",O
55.8,O
%,O
and,O
30.8,O
%,O
opted,O
for,O
the,O
highest,O
labelled,O
dose,O
of,O
each,O
ICI,O
and/or,O
",",O
among,O
different,O
ICIs,O
for,O
the,O
same,O
indication,O
",",O
for,O
the,O
one,O
with,O
the,O
longer,O
interval,O
between,O
cycles,O
",",O
respectively,O
.,O
These,O
results,O
highlight,O
the,O
uncertainties,O
around,O
the,O
perception,O
of,O
a,O
potential,O
interference,O
between,O
ICIs,O
and,O
COVID‐19,O
",",O
supporting,O
the,O
need,O
of,O
focused,O
studies,O
on,O
this,O
topic,O
.,O
Mutation,O
accumulated,O
in,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
genomes,O
during,O
its,O
pandemic,O
spread,O
can,O
cause,O
unpredictable,O
effects,O
on,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
and,O
further,O
complicate,O
epidemic,O
control,O
efforts,O
(,O
1,O
),O
.,O
We,O
collected,O
95,O
SARS,O
-,O
CoV-2,O
samples,O
from,O
the,O
Sichuan,O
Province,O
of,O
China,O
for,O
amplification,O
-,O
free,O
whole,O
-,O
genome,O
sequencing,O
and,O
acquired,O
13,O
whole,O
-,O
genome,O
sequences,O
",",O
which,O
were,O
analyzed,O
for,O
sequence,O
variation,O
and,O
evolution,O
together,O
with,O
199,O
SARS,O
-,O
CoV-2,O
genomes,O
publicly,O
released,O
in,O
the,O
GISAID,B-Dataset
EpiFlu,E-Dataset
 ,O
database,O
(,O
https://www.gisaid.org/,S-URL
),O
(,O
2,O
),O
and,O
7,O
genomes,O
downloaded,O
from,O
the,O
National,B-Repository
Genomics,I-Repository
Data,I-Repository
Center,I-Repository
(NGDC),E-Repository
 ,O
database,O
(,O
https://bigd.big.ac.cn/ncov,S-URL
),O
.,O
To,O
investigate,O
if,O
MERS,O
-,O
CoV,O
can,O
persistently,O
infect,O
cells,O
from,O
an,O
insectivorous,O
bat,O
",",O
we,O
infected,O
big,O
brown,O
bat,O
(,O
Eptesicus,O
fuscus,O
),O
kidney,O
cells,O
(,O
Efk,O
),O
at,O
a,O
low,O
multiplicity,O
of,O
infection,O
(,O
MOI,O
;,O
0.01,O
TCID50,O
/,O
cell,O
),O
(,O
Fig,O
.,O
 ,O
1a,O
),O
.,O
On,O
re,O
-,O
infecting,O
persistently,O
infected,O
bat,O
cells,O
with,O
W,O
 ,O
+,O
 ,O
virus,O
(,O
MOI,O
 ,O
=,O
 ,O
1,O
TCID50,O
/,O
cell,O
),O
",",O
we,O
did,O
not,O
observe,O
an,O
increase,O
in,O
upE,O
or,O
ORF5,O
RNA,O
levels,O
in,O
the,O
superinfected,O
cells,O
",",O
suggesting,O
a,O
lack,O
of,O
replication,O
of,O
W+,O
and,O
ΔORF5,O
virus,O
at,O
24,O
and,O
48,O
hpi,O
(,O
Fig,O
.,O
 ,O
5a,O
",",O
b,O
),O
.,O
Graphs,O
were,O
plotted,O
using,O
GraphPad,O
prism,O
version,O
7,O
.,O
Dicer,O
-,O
ready,O
siRNA,O
(,O
DsiRNA,O
),O
specific,O
to,O
big,O
brown,O
bat,O
and,O
human,O
IRF3,O
was,O
designed,O
and,O
obtained,O
through,O
Integrated,O
DNA,O
Technologies,O
(,O
IDT,O
),O
.,O
Scrambled,O
non,O
-,O
specific,O
DsiRNA,O
(,O
NC,O
DsiRNA,O
;,O
IDT,O
),O
was,O
used,O
as,O
a,O
negative,O
control,O
.,O
Amino,O
acid,O
sequence,O
from,O
CoVs,O
were,O
retrieved,O
from,O
NCBI,S-Repository
’s,O
database,O
(,O
accession,O
numbers,O
in,O
supplementary,O
Fig,O
 ,O
S4d,O
),O
",",O
and,O
multiple,O
sequence,O
alignment,O
was,O
performed,O
using,O
MacVector,O
software,O
.,O
The,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
has,O
led,O
to,O
substantial,O
morbidity,O
and,O
mortality,O
globally,O
",",O
but,O
initial,O
reports,O
suggest,O
historically,O
disadvantaged,O
populations,O
may,O
be,O
most,O
afflicted,O
.,O
Recently,O
",",O
COVID-19,O
testing,O
results,O
for,O
a,O
subset,O
of,O
participants,O
in,O
England,O
were,O
made,O
available,O
[,O
4,O
],O
.,O
Individuals,O
were,O
excluded,O
from,O
this,O
analysis,O
if,O
they,O
had,O
enrolled,O
outside,O
England,O
",",O
died,O
prior,O
to,O
2019,O
",",O
or,O
had,O
an,O
outpatient,O
test,O
positive,O
for,O
COVID-19,O
",",O
in,O
whom,O
the,O
clinical,O
trajectory,O
was,O
uncertain,O
.,O
Additional,O
details,O
are,O
provided,O
in,O
the,O
Additional,O
file,O
1,O
.,O
COVID-19,O
hospitalization,O
was,O
noted,O
in,O
32,O
of,O
7714,O
(,O
0.4,O
%,O
),O
To,O
understand,O
the,O
relationship,O
between,O
socioeconomic,O
status,O
and,O
COVID-19,O
hospitalization,O
",",O
individuals,O
were,O
stratified,O
at,O
enrollment,O
into,O
deciles,O
of,O
the,O
Townsend,O
Deprivation,O
Index,O
",",O
a,O
previously,O
validated,O
composite,O
metric,O
based,O
on,O
employment,O
status,O
",",O
car,O
or,O
home,O
ownership,O
",",O
and,O
household,O
crowding,O
[,O
5,O
],O
.,O
Participants,O
with,O
greater,O
Townsend,O
Deprivation,O
Indices,O
were,O
at,O
substantially,O
higher,O
risk,O
of,O
COVID-19,O
hospitalization,O
",",O
with,O
a,O
similar,O
pattern,O
observed,O
based,O
on,O
self,O
-,O
reported,O
household,O
income,O
(,O
Fig,O
.,O
1b,O
",",O
c,O
),O
.,O
The,O
relationship,O
between,O
race,O
and,O
COVID-19,O
hospitalization,O
was,O
modestly,O
attenuated,O
in,O
a,O
logistic,O
regression,O
model,O
that,O
additionally,O
adjusted,O
for,O
Townsend,O
Deprivation,O
Index,O
",",O
household,O
income,O
",",O
hypertension,O
",",O
diabetes,O
",",O
heart,O
failure,O
",",O
ischemic,O
stroke,O
",",O
dementia,O
",",O
chronic,O
obstructive,O
pulmonary,O
disease,O
",",O
prior,O
pneumonia,O
",",O
dementia,O
",",O
chronic,O
kidney,O
disease,O
",",O
smoking,O
status,O
",",O
statin,O
use,O
",",O
and,O
body,O
mass,O
index,O
--,O
odds,O
ratios,O
for,O
Black,O
and,O
Asian,O
participants,O
of,O
2.4,O
(,O
95%CI,O
1.5–3.7,O
),O
and,O
1.8,O
(,O
95%CI,O
1.1–2.9,O
),O
as,O
compared,O
to,O
White,O
participants,O
respectively,O
.,O
Within,O
a,O
large,O
population,O
of,O
participants,O
in,O
a,O
national,O
biobank,O
",",O
striking,O
gradients,O
in,O
risk,O
of,O
hospitalization,O
for,O
COVID-19,O
were,O
noted,O
according,O
to,O
race,O
and,O
a,O
metric,O
of,O
socioeconomic,O
deprivation,O
.,O
With,O
respect,O
to,O
potential,O
biologic,O
factors,O
",",O
ongoing,O
efforts,O
seek,O
to,O
determine,O
whether,O
genetics,O
--,O
known,O
to,O
both,O
vary,O
substantially,O
across,O
racial,O
groups,O
and,O
contribute,O
to,O
pre,O
-,O
existing,O
comorbidities,O
--,O
plays,O
an,O
important,O
role,O
in,O
COVID-19,O
disease,O
severity,O
.,O
Preliminary,O
reports,O
suggest,O
that,O
the,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID−,O
 ,O
19,O
),O
pandemic,O
has,O
led,O
to,O
disproportionate,O
morbidity,O
and,O
mortality,O
among,O
historically,O
disadvantaged,O
populations,O
.,O
We,O
investigate,O
the,O
racial,O
and,O
socioeconomic,O
associations,O
of,O
COVID−,O
 ,O
19,O
hospitalization,O
among,O
"418,794",O
participants,O
of,O
the,O
UK,B-Repository
Biobank,E-Repository
",",O
of,O
whom,O
549,O
(,O
0.13,O
%,O
),O
had,O
been,O
hospitalized,O
.,O
We,O
further,O
observed,O
a,O
striking,O
gradient,O
in,O
COVID−,O
 ,O
19,O
hospitalization,O
rates,O
according,O
to,O
the,O
Townsend,O
Deprivation,O
Index,O
−,O
a,O
composite,O
measure,O
of,O
socioeconomic,O
deprivation,O
−,O
and,O
household,O
income,O
.,O
According,O
to,O
WHO,S-Creator
 ,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
situation,O
report,O
of,O
17,O
February,O
2020,O
",",O
"71,429",O
cases,O
have,O
been,O
documented,O
globally,O
[,O
2,O
],O
.,O
The,O
outbreak,O
of,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
causing,O
novel,O
coronavirus,O
-,O
infected,O
pneumonia,O
(,O
NCIP,O
),O
",",O
has,O
affected,O
the,O
lives,O
of,O
"71,429",O
people,O
globally,O
.,O
Clinical,O
presentations,O
of,O
COVID-19,O
are,O
highly,O
variable,O
",",O
and,O
while,O
the,O
majority,O
of,O
patients,O
experiences,O
mild,O
to,O
moderate,O
symptoms,O
",",O
10%–20,O
%,O
of,O
patients,O
develop,O
pneumonia,O
and,O
severe,O
disease,O
(,O
Huang,O
et,O
 ,O
al,O
.,O
",",O
2020a,O
;,O
Wang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Zhou,O
et,O
 ,O
al,O
.,O
",",O
2020a,O
),O
.,O
This,O
kinetic,O
may,O
suggest,O
a,O
role,O
for,O
secondary,O
immune,O
responses,O
in,O
the,O
development,O
of,O
severe,O
COVID-19,O
(,O
Ong,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
However,O
",",O
the,O
exact,O
mechanisms,O
that,O
govern,O
the,O
pathophysiology,O
of,O
the,O
different,O
disease,O
courses,O
of,O
COVID-19,O
remain,O
ill,O
-,O
defined,O
.,O
Single,O
-,O
cell,O
studies,O
of,O
bronchoalveolar,O
lavage,O
samples,O
have,O
suggested,O
a,O
complex,O
dysregulation,O
of,O
the,O
pulmonary,O
immune,O
response,O
in,O
severe,O
COVID-19,O
(,O
Chua,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Liao,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Overall,O
",",O
systemic,O
inflammation,O
is,O
linked,O
to,O
an,O
unfavorable,O
clinical,O
course,O
of,O
disease,O
and,O
the,O
development,O
of,O
severe,O
COVID-19,O
(,O
Giamarellos,O
-,O
Bourboulis,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Lucas,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Ong,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Patients,O
with,O
severe,O
COVID-19,O
have,O
high,O
systemic,O
levels,O
of,O
inflammatory,O
cytokines,O
",",O
particularly,O
interleukin,O
(,O
IL)-6,O
and,O
IL-1β,O
A,O
number,O
of,O
studies,O
and,O
regular,O
clinical,O
observations,O
indicate,O
an,O
increase,O
of,O
neutrophils,O
and,O
a,O
decrease,O
of,O
non,O
-,O
classical,O
(,O
CD14loCD16hi,O
),O
monocytes,O
in,O
severe,O
COVID-19,O
(,O
Hadjadj,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Merad,O
and,O
Martin,O
",",O
2020,O
;,O
Sanchez,O
-,O
Cerrillo,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Profound,O
immune,O
dysregulation,O
is,O
commonly,O
observed,O
in,O
severe,O
infections,O
and,O
sepsis,O
",",O
characterized,O
by,O
a,O
progression,O
from,O
hyperinflammatory,O
states,O
to,O
immunosuppression,O
(,O
Remy,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Ritchie,O
and,O
Singanayagam,O
",",O
2020,O
),O
",",O
and,O
similar,O
mechanisms,O
have,O
been,O
proposed,O
for,O
severe,O
COVID-19,O
(,O
Giamarellos,O
-,O
Bourboulis,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Yet,O
",",O
comprehensive,O
insights,O
into,O
the,O
immunopathology,O
of,O
severe,O
COVID-19,O
are,O
still,O
missing,O
.,O
Mitigation,O
of,O
immunodysregulation,O
is,O
therefore,O
viewed,O
as,O
a,O
major,O
therapeutic,O
avenue,O
for,O
the,O
treatment,O
and,O
prevention,O
of,O
severe,O
COVID-19,O
(,O
Dimopoulos,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Jamilloux,O
et,O
 ,O
al,O
.,O
In,O
support,O
of,O
this,O
view,O
",",O
a,O
recent,O
multicenter,O
study,O
reported,O
that,O
dexamethasone,O
treatment,O
significantly,O
reduced,O
mortality,O
in,O
hospitalized,O
patients,O
with,O
COVID-19,O
",",O
particularly,O
in,O
patients,O
on,O
mechanical,O
ventilation,O
(,O
Horby,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Previous,O
studies,O
of,O
peripheral,O
blood,O
mononuclear,O
cell,O
(,O
PBMC,O
),O
transcriptomes,O
in,O
a,O
small,O
number,O
of,O
patients,O
with,O
COVID-19,O
revealed,O
changes,O
in,O
several,O
cellular,O
compartments,O
",",O
including,O
monocytes,O
",",O
natural,O
killer,O
(,O
NK,O
),O
cells,O
",",O
dendritic,O
cells,O
(,O
DCs,O
),O
",",O
and,O
T,O
 ,O
cells,O
(,O
Lee,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Wilk,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
heterogeneity,O
of,O
clinical,O
manifestations,O
and,O
the,O
complexity,O
of,O
immune,O
responses,O
to,O
COVID-19,O
highlight,O
the,O
need,O
for,O
detailed,O
 ,O
analyses,O
using,O
high,O
-,O
resolution,O
techniques,O
and,O
well,O
-,O
characterized,O
clinical,O
cohorts,O
.,O
We,O
hypothesized,O
that,O
distinct,O
responses,O
",",O
particularly,O
within,O
the,O
innate,O
immune,O
system,O
",",O
underlie,O
the,O
different,O
clinical,O
trajectories,O
of,O
COVID-19,O
patients,O
(,O
Chua,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Kuri,O
-,O
Cervantes,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Mathew,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
McKechnie,O
and,O
Blish,O
",",O
2020,O
),O
.,O
Here,O
",",O
we,O
used,O
single,O
-,O
cell,O
transcriptomics,O
and,O
single,O
-,O
cell,O
proteomics,O
to,O
analyze,O
immune,O
responses,O
in,O
blood,O
samples,O
in,O
two,O
independent,O
cohorts,O
of,O
COVID-19,O
patients,O
.,O
In,O
order,O
to,O
probe,O
the,O
divergent,O
immune,O
responses,O
in,O
mild,O
versus,O
severe,O
COVID-19,O
",",O
we,O
analyzed,O
blood,O
samples,O
collected,O
from,O
independent,O
patient,O
cohorts,O
at,O
two,O
university,O
medical,O
centers,O
in,O
Germany,O
.,O
We,O
analyzed,O
a,O
total,O
of,O
24,O
million,O
cells,O
by,O
their,O
protein,O
markers,O
and,O
>,O
"328,000",O
cells,O
by,O
scRNA,O
-,O
seq,O
in,O
242,O
samples,O
from,O
53,O
COVID-19,O
patients,O
and,O
56,O
controls,O
",",O
including,O
8,O
patients,O
with,O
FLI,O
(,O
Figures,O
1,O
A,O
",",O
1B,O
",",O
and,O
S1,O
A,O
;,O
Table,O
S1,O
),O
.,O
(,O
A,O
),O
Pipeline,O
for,O
control,O
and,O
COVID-19,O
blood,O
samples,O
of,O
the,O
two,O
cohorts,O
(,O
see,O
also,O
Table,O
S1,O
),O
.,O
Cells,O
are,O
colored,O
according,O
to,O
donor,O
origin,O
(,O
blue,O
",",O
age,O
-,O
matched,O
controls,O
;,O
gray,O
",",O
FLI,O
;,O
yellow,O
",",O
mild,O
COVID-19,O
;,O
red,O
",",O
severe,O
COVID-19,O
),O
and,O
major,O
lineage,O
subtypes,O
.,O
(,O
D,O
),O
Box,O
and,O
whisker,O
(,O
10–90,O
percentile,O
),O
plots,O
of,O
major,O
cell,O
lineage,O
composition,O
in,O
whole,O
blood,O
from,O
FLI,O
(,O
n,O
 ,O
=,O
8),O
",",O
COVID-19,O
patients,O
with,O
mild,O
(,O
n,O
 ,O
=,O
8),O
or,O
severe,O
disease,O
(,O
n,O
 ,O
=,O
9,O
),O
",",O
age,O
-,O
matched,O
controls,O
measured,O
by,O
mass,O
cytometry,O
(,O
ctrl,O
CyTOF,O
",",O
n,O
 ,O
=,O
9,O
),O
or,O
by,O
flow,O
cytometry,O
(,O
ctrl,O
flow,O
",",O
n,O
 ,O
=,O
19,O
),O
(,O
Kverneland,O
et,O
 ,O
al,O
.,O
",",O
2016,O
),O
.,O
We,O
first,O
characterized,O
alterations,O
of,O
the,O
major,O
leukocyte,O
lineages,O
by,O
mass,O
cytometry,O
on,O
whole,O
blood,O
samples,O
from,O
20,O
COVID-19,O
patients,O
collected,O
between,O
day,O
4,O
and,O
day,O
29,O
after,O
symptom,O
onset,O
and,O
compared,O
them,O
to,O
10,O
age-,O
and,O
gender,O
-,O
matched,O
controls,O
and,O
8,O
FLI,O
patients,O
.,O
Uniform,O
manifold,O
approximation,O
and,O
projection,O
(,O
UMAP,O
),O
analysis,O
revealed,O
distinct,O
clustering,O
of,O
samples,O
from,O
COVID-19,O
patients,O
",",O
FLI,O
",",O
and,O
healthy,O
controls,O
",",O
with,O
marked,O
changes,O
of,O
the,O
monocyte,O
and,O
granulocyte,O
compartment,O
(,O
Figure,O
 ,O
1C,O
),O
.,O
Leukocyte,O
lineages,O
were,O
compared,O
in,O
the,O
earliest,O
available,O
samples,O
in,O
COVID-19,O
patients,O
(,O
days,O
4–13,O
),O
",",O
FLI,O
",",O
and,O
controls,O
(,O
Figure,O
 ,O
1D,O
;,O
Table,O
S1,O
),O
.,O
Cell,O
counts,O
of,O
the,O
published,O
cohort,O
could,O
therefore,O
be,O
used,O
as,O
a,O
reference,O
to,O
report,O
absolute,O
cell,O
counts,O
for,O
leukocyte,O
lineages,O
in,O
COVID-19,O
samples,O
.,O
In,O
line,O
with,O
recent,O
reports,O
(,O
Barnes,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Xia,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
",",O
we,O
observed,O
elevated,O
leukocytes,O
and,O
increased,O
proportions,O
of,O
neutrophils,O
in,O
patients,O
with,O
severe,O
COVID-19,O
(,O
Figure,O
 ,O
1D,O
),O
",",O
whereas,O
only,O
proportional,O
increases,O
in,O
neutrophils,O
were,O
evident,O
in,O
FLI,O
and,O
mild,O
COVID-19,O
patients,O
(,O
Figure,O
 ,O
1D,O
),O
.,O
Total,O
lymphocytes,O
and,O
T,O
 ,O
cells,O
were,O
strongly,O
reduced,O
in,O
all,O
COVID-19,O
and,O
FLI,O
patients,O
",",O
whereas,O
non,O
-,O
classical,O
monocytes,O
were,O
specifically,O
depleted,O
in,O
COVID-19,O
(,O
Figure,O
 ,O
1D,O
),O
.,O
Increased,O
neutrophils,O
in,O
severe,O
COVID-19,O
and,O
loss,O
of,O
non,O
-,O
classical,O
monocytes,O
in,O
both,O
mild,O
and,O
severe,O
disease,O
were,O
validated,O
in,O
cohort,O
2,O
by,O
MCFC,O
(,O
Figure,O
 ,O
S1C,O
;,O
Tables,O
S1,O
and,O
S3,O
),O
.,O
Given,O
the,O
dramatic,O
changes,O
in,O
various,O
immune,O
cell,O
populations,O
(,O
Figures,O
1C,O
and,O
1D,O
),O
",",O
we,O
next,O
assessed,O
their,O
composition,O
and,O
activation,O
state,O
by,O
droplet,O
-,O
based,O
scRNA,O
-,O
seq,O
in,O
27,O
samples,O
from,O
18,O
COVID-19,O
patients,O
(,O
8,O
mild,O
and,O
10,O
severe,O
",",O
cohort,O
1,O
",",O
Table,O
S1,O
),O
collected,O
between,O
day,O
3,O
and,O
day,O
20,O
after,O
symptom,O
onset,O
.,O
A,O
total,O
of,O
"48,266",O
single,O
-,O
cell,O
transcriptomes,O
of,O
PBMCs,O
were,O
analyzed,O
together,O
with,O
"50,783",O
PBMCs,O
from,O
publicly,O
available,O
control,O
datasets,O
(,O
21,O
control,O
donors,O
",",O
Table,O
S1,O
),O
.,O
A,O
distinct,O
subset,O
of,O
CD14,O
 ,O
monocytes,O
(,O
cluster,O
1,O
),O
(,O
Figure,O
 ,O
2A,O
),O
marked,O
by,O
high,O
expression,O
of,O
HLA,O
-,O
DRA,O
",",O
HLA,O
-,O
DRB1,O
",",O
and,O
co,O
-,O
stimulatory,O
molecule,O
CD83,O
(,O
Figure,O
 ,O
S2D,O
),O
",",O
the,O
engagement,O
of,O
which,O
has,O
been,O
linked,O
to,O
prolonged,O
expansion,O
of,O
antigen,O
-,O
specific,O
T,O
 ,O
cells,O
(,O
Hirano,O
et,O
 ,O
al,O
.,O
",",O
2006,O
),O
",",O
was,O
selectively,O
detected,O
in,O
mild,O
COVID-19,O
(,O
Figure,O
 ,O
2C,O
),O
.,O
However,O
",",O
upon,O
closer,O
analysis,O
",",O
this,O
cluster,O
was,O
found,O
to,O
originate,O
from,O
a,O
single,O
donor,O
with,O
mild,O
COVID-19,O
(,O
Figures,O
2A–2C,O
and,O
S2D,O
),O
.,O
In,O
patients,O
with,O
severe,O
COVID-19,O
",",O
monocytes,O
showed,O
low,O
expression,O
of,O
HLA,O
-,O
DR,O
and,O
high,O
expression,O
of,O
alarmins,O
S100A8/9/12,O
(,O
cluster,O
3,O
",",O
Figures,O
2A–2C,O
and,O
S2D,O
),O
.,O
The,O
most,O
prominent,O
change,O
in,O
severe,O
COVID-19,O
was,O
the,O
appearance,O
of,O
two,O
distinct,O
cell,O
populations,O
(,O
cluster,O
5,O
+,O
6,O
),O
",",O
absent,O
in,O
PBMCs,O
of,O
patients,O
with,O
mild,O
COVID-19,O
and,O
control,O
donors,O
(,O
Figure,O
 ,O
2A,O
),O
.,O
(,O
D,O
),O
UMAP,O
visualization,O
of,O
scRNA,O
-,O
seq,O
profiles,O
(,O
BD,O
Rhapsody,O
",",O
cohort,O
2,O
),O
of,O
"139,848",O
PBMCs,O
(,O
50,O
samples,O
of,O
8,O
mild,O
",",O
9,O
severe,O
COVID-19,O
;,O
14,O
samples,O
of,O
13,O
controls,O
;,O
different,O
time,O
points,O
),O
",",O
coloring,O
as,O
in,O
(,O
A,O
),O
(,O
see,O
also,O
Figure,O
 ,O
S2A,O
and,O
Table,O
S4,O
),O
.,O
In,O
the,O
second,O
cohort,O
",",O
PBMCs,O
from,O
17,O
COVID-19,O
patients,O
(,O
8,O
mild,O
",",O
9,O
severe,O
",",O
Table,O
S1,O
),O
",",O
sampled,O
between,O
2,O
and,O
25,O
 ,O
days,O
after,O
symptom,O
onset,O
",",O
and,O
13,O
controls,O
",",O
were,O
collected,O
for,O
scRNA,O
-,O
seq,O
on,O
a,O
microwell,O
-,O
based,O
platform,O
(,O
BD,O
Rhapsody,O
),O
.,O
The,O
monocyte,O
compartment,O
is,O
particularly,O
affected,O
by,O
COVID-19,O
",",O
indicated,O
by,O
a,O
loss,O
of,O
CD14loCD16hi,O
non,O
-,O
classical,O
monocytes,O
(,O
Figures,O
1C,O
and,O
1D,O
),O
.,O
We,O
further,O
explored,O
the,O
phenotypic,O
alterations,O
of,O
the,O
monocyte,O
compartment,O
using,O
mass,O
cytometry,O
(,O
Table,O
S2,O
",",O
panel,O
1,O
),O
on,O
whole,O
blood,O
samples,O
from,O
COVID-19,O
patients,O
with,O
a,O
mild,O
or,O
severe,O
disease,O
(,O
n,O
 ,O
=,O
8,O
+,O
9,O
),O
",",O
patients,O
with,O
FLI,O
(,O
n,O
 ,O
=,O
8),O
",",O
and,O
age-,O
and,O
gender,O
-,O
matched,O
controls,O
(,O
n,O
 ,O
=,O
9,O
",",O
all,O
collected,O
within,O
cohort,O
1,O
",",O
Table,O
S1,O
),O
.,O
Cells,O
are,O
colored,O
according,O
to,O
main,O
cell,O
clusters,O
(,O
1,O
to,O
12,O
",",O
colors,O
as,O
in,O
A,O
),O
as,O
defined,O
in,O
the,O
table,O
",",O
donor,O
origin,O
(,O
blue,O
",",O
controls,O
;,O
gray,O
",",O
FLI,O
;,O
yellow,O
",",O
mild,O
COVID-19,O
;,O
red,O
",",O
severe,O
COVID-19,O
),O
and,O
expression,O
intensity,O
of,O
HLA,O
-,O
DR,O
",",O
CD11c,O
",",O
CD226,O
",",O
and,O
CD69,O
.,O
Monocytes,O
from,O
COVID-19,O
patients,O
separated,O
from,O
those,O
of,O
FLI,O
patients,O
and,O
controls,O
(,O
Figure,O
 ,O
3B,O
),O
",",O
mainly,O
based,O
on,O
elevated,O
CD226,O
and,O
CD69,O
expression,O
in,O
COVID-19,O
.,O
Monocytes,O
in,O
mild,O
and,O
severe,O
COVID-19,O
clustered,O
separately,O
",",O
and,O
monocytes,O
from,O
mild,O
COVID-19,O
clustered,O
closer,O
to,O
monocytes,O
in,O
FLI,O
.,O
FLI,O
patients,O
and,O
mild,O
COVID-19,O
contained,O
higher,O
proportions,O
of,O
HLA,O
-,O
DRhiCD11chi,O
cells,O
(,O
clusters,O
3,O
and,O
11,O
),O
",",O
and,O
total,O
HLA,O
-,O
DRhiCD11chi,O
monocytes,O
were,O
higher,O
compared,O
to,O
controls,O
and,O
severe,O
COVID-19,O
",",O
reflecting,O
blunted,O
monocyte,O
activation,O
in,O
severe,O
COVID-19,O
",",O
reminiscent,O
of,O
observations,O
in,O
sepsis,O
(,O
Janols,O
et,O
 ,O
al,O
.,O
",",O
2014,O
),O
(,O
Figures,O
3A,O
",",O
3C,O
",",O
and,O
3D,O
),O
.,O
Increased,O
levels,O
of,O
activated,O
HLA,O
-,O
DRhiCD11chi,O
monocytes,O
in,O
mild,O
COVID-19,O
patients,O
were,O
confirmed,O
by,O
MCFC,O
in,O
cohort,O
2,O
(,O
Figure,O
 ,O
3E,O
),O
.,O
In,O
severe,O
COVID-19,O
",",O
we,O
detected,O
increased,O
expression,O
of,O
CD226,O
and,O
CD69,O
(,O
cluster,O
10,O
),O
and/or,O
decreased,O
expression,O
of,O
HLA,O
-,O
DR,O
",",O
and,O
total,O
CD226+CD69,O
+,O
monocytes,O
were,O
elevated,O
compared,O
to,O
controls,O
.,O
Thus,O
",",O
an,O
alternative,O
activation,O
pattern,O
of,O
classical,O
monocytes,O
appeared,O
to,O
be,O
COVID-19,O
-,O
specific,O
and,O
was,O
associated,O
with,O
severe,O
disease,O
.,O
Together,O
",",O
this,O
activation,O
pattern,O
may,O
contribute,O
to,O
the,O
reduction,O
of,O
circulating,O
monocytes,O
in,O
COVID-19,O
.,O
Next,O
",",O
we,O
dissected,O
COVID-19,O
-,O
associated,O
phenotypic,O
alterations,O
of,O
monocytes,O
by,O
scRNA,O
-,O
seq,O
.,O
Marker,O
genes,O
of,O
the,O
monocyte,O
clusters,O
derived,O
from,O
Figure,O
 ,O
2A,O
showed,O
that,O
mild,O
COVID-19,O
associated,O
clusters,O
1,O
and,O
2,O
were,O
characterized,O
by,O
an,O
ISG,O
-,O
driven,O
transcriptional,O
program,O
(,O
Figure,O
 ,O
S3,O
A,O
),O
",",O
and,O
gene,O
ontology,O
enrichment,O
analysis,O
(,O
GOEA,O
),O
assigned,O
these,O
clusters,O
to,O
“,O
type,O
I,O
interferon,O
signaling,O
pathway,O
”,O
(,O
Figure,O
 ,O
S3B,O
),O
.,O
S100A,O
),O
was,O
strongly,O
associated,O
with,O
severe,O
COVID-19,O
(,O
Figures,O
2B,O
",",O
S2D,O
",",O
and,O
S3A,O
),O
.,O
For,O
further,O
in,O
-,O
depth,O
analysis,O
",",O
we,O
subclustered,O
the,O
monocyte,O
compartment,O
of,O
the,O
PBMC,O
dataset,O
of,O
cohort,O
2,O
(,O
Figures,O
2D,O
and,O
S3C,O
;,O
Table,O
S1,O
),O
resulting,O
in,O
7,O
subclusters,O
(,O
Figure,O
 ,O
4,O
A,O
),O
.,O
We,O
identified,O
two,O
major,O
clusters,O
(,O
0,O
and,O
2,O
),O
and,O
a,O
smaller,O
cluster,O
(,O
6,O
),O
with,O
low,O
HLA,O
-,O
DR,O
expression,O
",",O
which,O
were,O
associated,O
with,O
severe,O
COVID-19,O
(,O
Figures,O
4B,O
",",O
S3D,O
",",O
and,O
S3E,O
),O
.,O
Moreover,O
",",O
blood,O
monocytes,O
isolated,O
from,O
COVID-19,O
patients,O
showed,O
a,O
blunted,O
cytokine,O
response,O
to,O
LPS,O
stimulation,O
",",O
particularly,O
monocytes,O
from,O
patients,O
with,O
severe,O
COVID-19,O
(,O
Figure,O
 ,O
4D,O
),O
.,O
Accordingly,O
",",O
HLA,O
-,O
DR,O
 ,O
monocyte,O
clusters,O
(,O
0,O
",",O
2,O
",",O
and,O
6,O
),O
were,O
detected,O
almost,O
exclusively,O
in,O
severe,O
COVID-19,O
(,O
Figure,O
 ,O
4E,O
),O
.,O
CD83,O
 ,O
monocytes,O
(,O
cluster,O
1,O
),O
were,O
found,O
in,O
all,O
cases,O
of,O
mild,O
COVID-19,O
",",O
even,O
at,O
late,O
time,O
points,O
(,O
Figures,O
4E,O
and,O
4F,O
),O
.,O
Expression,O
levels,O
were,O
highest,O
at,O
early,O
time,O
points,O
and,O
consistently,O
decreased,O
over,O
time,O
",",O
clearly,O
indicating,O
that,O
the,O
IFN,O
response,O
in,O
COVID-19,O
is,O
inversely,O
linked,O
to,O
disease,O
severity,O
and,O
time,O
(,O
Figures,O
S3F,O
and,O
S3,O
G,O
),O
.,O
In,O
contrast,O
",",O
decreased,O
expression,O
of,O
HLA,O
-,O
DRA,O
and,O
HLA,O
-,O
DRB1,O
in,O
severe,O
COVID-19,O
is,O
evident,O
early,O
on,O
and,O
sustained,O
over,O
time,O
.,O
Transcriptional,O
Differences,O
of,O
Monocytes,O
from,O
Mild,O
and,O
Severe,O
COVID-19,O
",",O
Related,O
to,O
Figure,O
 ,O
4,O
A,O
",",O
Dot,O
plot,O
of,O
the,O
top,O
10,O
marker,O
genes,O
sorted,O
by,O
average,O
log,O
fold,O
change,O
of,O
the,O
clusters,O
within,O
the,O
monocyte,O
space,O
of,O
cohort,O
1,O
(,O
related,O
to,O
Figure,O
 ,O
2,O
",",O
Table,O
S4,O
),O
.,O
(,O
A,O
),O
UMAP,O
visualization,O
of,O
monocytes,O
(,O
"43,772",O
cells,O
;,O
from,O
Figure,O
 ,O
2C,O
",",O
cohort,O
2,O
),O
;,O
46,O
samples,O
from,O
controls,O
(,O
n,O
 ,O
=,O
6,O
),O
and,O
COVID-19,O
(,O
mild,O
",",O
n,O
 ,O
=,O
7,O
;,O
severe,O
",",O
n,O
 ,O
=,O
8),O
.,O
Three,O
main,O
clusters,O
defining,O
monocytes,O
in,O
COVID-19,O
(,O
HLA,O
-,O
DRCD163,O
",",O
HLA,O
-,O
DRS100A,O
",",O
and,O
HLA,O
-,O
DRCD83,O
monocytes,O
),O
indicated,O
by,O
dashed,O
areas,O
.,O
Transcription,O
factor,O
prediction,O
indicated,O
a,O
STAT,O
signaling,O
-,O
driven,O
gene,O
expression,O
program,O
in,O
monocytes,O
in,O
COVID-19,O
(,O
Figure,O
 ,O
4H,O
),O
",",O
with,O
additional,O
regulation,O
by,O
CEBPD,O
and,O
CEBPE,O
",",O
 ,O
which,O
have,O
been,O
implicated,O
in,O
gene,O
expression,O
programs,O
of,O
sepsis,O
-,O
associated,O
monocytes,O
(,O
Reyes,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
PBMCs,O
derived,O
from,O
blood,O
samples,O
of,O
patients,O
with,O
severe,O
COVID-19,O
contained,O
two,O
distinct,O
clusters,O
of,O
LDNs,O
(,O
Figures,O
2A,O
",",O
clusters,O
5,O
and,O
6,O
",",O
and,O
2D,O
",",O
clusters,O
5,O
and,O
6,O
),O
.,O
(,O
A,O
),O
UMAP,O
representation,O
and,O
clustering,O
of,O
low,O
-,O
density,O
neutrophils,O
(,O
LDNs,O
",",O
"3,154",O
cells,O
),O
in,O
PBMCs,O
(,O
cohort,O
1,O
",",O
clusters,O
5/6,O
",",O
Figure,O
 ,O
2A,O
),O
from,O
21,O
samples,O
(,O
6,O
mild,O
",",O
10,O
 ,O
severe,O
COVID-19,O
),O
.,O
NETs,O
have,O
recently,O
been,O
implicated,O
in,O
the,O
pathogenesis,O
of,O
COVID-19,O
(,O
Barnes,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Zuo,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Finally,O
",",O
known,O
inhibitors,O
of,O
T,O
 ,O
cell,O
activation,O
",",O
namely,O
CD274,O
(,O
PD,O
-,O
L1,O
),O
and,O
Arginase,O
1,O
(,O
ARG1,O
),O
(,O
Bronte,O
et,O
 ,O
al,O
.,O
",",O
2003,O
;,O
Li,O
et,O
 ,O
al,O
.,O
",",O
2018,O
),O
were,O
highly,O
expressed,O
in,O
neutrophils,O
in,O
COVID-19,O
patients,O
(,O
Figure,O
 ,O
5E,O
),O
.,O
ARG1,O
 ,O
cells,O
were,O
mainly,O
immature,O
neutrophils,O
(,O
clusters,O
3–6,O
),O
and,O
did,O
not,O
overlap,O
with,O
CD274,O
(,O
PD,O
-,O
L1,O
),O
expressing,O
cells,O
",",O
indicating,O
different,O
populations,O
of,O
dysfunctional,O
and,O
potentially,O
suppressive,O
neutrophils,O
in,O
severe,O
COVID-19,O
.,O
Alterations,O
of,O
the,O
neutrophil,O
compartment,O
were,O
further,O
interrogated,O
by,O
mass,O
cytometry,O
of,O
whole,O
blood,O
samples,O
of,O
COVID-19,O
patients,O
(,O
n,O
 ,O
=,O
8,O
mild,O
 ,O
+,O
9,O
severe,O
",",O
cohort,O
1,O
),O
",",O
FLI,O
patients,O
(,O
n,O
 ,O
=,O
8),O
",",O
and,O
age-,O
and,O
gender,O
-,O
matched,O
controls,O
(,O
n,O
 ,O
=,O
9,O
),O
(,O
Table,O
S1,O
),O
",",O
using,O
a,O
panel,O
designed,O
to,O
detect,O
myeloid,O
cell,O
maturation,O
and,O
activation,O
states,O
as,O
well,O
as,O
markers,O
of,O
immunosuppression,O
or,O
dysfunction,O
(,O
Table,O
S2,O
),O
.,O
Donor,O
origin,O
(,O
blue,O
",",O
controls,O
;,O
gray,O
",",O
FLI,O
;,O
yellow,O
",",O
mild,O
COVID-19,O
;,O
red,O
",",O
severe,O
COVID-19,O
),O
.,O
Neutrophils,O
from,O
COVID-19,O
patients,O
clearly,O
separated,O
from,O
those,O
of,O
controls,O
and,O
also,O
FLI,O
patients,O
in,O
UMAP,O
analysis,O
(,O
Figure,O
 ,O
6B,O
),O
",",O
and,O
neutrophils,O
in,O
patients,O
with,O
severe,O
COVID-19,O
were,O
distinct,O
from,O
those,O
of,O
patients,O
with,O
mild,O
disease,O
(,O
Figure,O
 ,O
6B,O
),O
.,O
Neutrophils,O
from,O
COVID-19,O
",",O
particularly,O
from,O
patients,O
with,O
severe,O
disease,O
",",O
primarily,O
occupied,O
immature,O
pre-,O
and,O
pro,O
-,O
neutrophil,O
-,O
like,O
clusters,O
.,O
In,O
contrast,O
",",O
severe,O
COVID-19,O
is,O
associated,O
with,O
the,O
appearance,O
of,O
immature,O
pre-,O
and,O
pro,O
-,O
neutrophils,O
(,O
Figures,O
6D,O
and,O
6E,O
),O
.,O
Interestingly,O
",",O
immature,O
cell,O
clusters,O
in,O
severe,O
COVID-19,O
showed,O
signs,O
of,O
recent,O
activation,O
like,O
upregulation,O
of,O
CD64,O
(,O
Mortaz,O
et,O
 ,O
al,O
.,O
",",O
2018,O
),O
",",O
RANK,O
",",O
and,O
RANKL,O
(,O
Riegel,O
et,O
 ,O
al,O
.,O
",",O
2012,O
),O
",",O
as,O
well,O
as,O
reduced,O
CD62L,O
expression,O
(,O
Mortaz,O
et,O
 ,O
al,O
.,O
",",O
2018,O
),O
.,O
In,O
addition,O
to,O
loss,O
of,O
CD62L,O
",",O
immature,O
and,O
mature,O
neutrophils,O
from,O
severe,O
COVID-19,O
showed,O
elevated,O
PD,O
-,O
L1,O
expression,O
compared,O
to,O
control,O
samples,O
(,O
Figure,O
 ,O
6E,O
),O
.,O
In,O
both,O
cohorts,O
",",O
we,O
observed,O
a,O
tendency,O
toward,O
(,O
cohort,O
1,O
),O
or,O
significantly,O
higher,O
(,O
cohort,O
2,O
),O
proportions,O
of,O
granulocytes,O
in,O
severe,O
versus,O
mild,O
COVID-19,O
patients,O
",",O
both,O
at,O
early,O
and,O
late,O
time,O
points,O
(,O
Figure,O
 ,O
S5,O
A,O
),O
.,O
We,O
observed,O
a,O
persistent,O
release,O
of,O
immature,O
neutrophils,O
(,O
e.g.,O
",",O
cluster,O
6,O
),O
in,O
severe,O
COVID-19,O
(,O
Figure,O
 ,O
S5B,O
),O
showing,O
high,O
expression,O
of,O
CD64,O
and,O
PD,O
-,O
L1,O
",",O
but,O
downregulation,O
of,O
CD62L,O
as,O
a,O
sign,O
of,O
activation,O
",",O
dysfunction,O
",",O
and,O
immunosuppression,O
(,O
Figure,O
 ,O
S5C,O
),O
.,O
In,O
addition,O
",",O
severe,O
COVID-19,O
patients,O
show,O
further,O
increased,O
frequencies,O
of,O
mature,O
",",O
partially,O
activated,O
neutrophils,O
(,O
cluster,O
3,O
),O
at,O
later,O
time,O
periods,O
(,O
Figure,O
 ,O
S5B,O
),O
.,O
Thus,O
",",O
the,O
neutrophil,O
compartment,O
of,O
severe,O
COVID-19,O
patients,O
is,O
characterized,O
by,O
a,O
combination,O
of,O
persistent,O
signs,O
of,O
inflammation,O
and,O
immunosuppression,O
",",O
which,O
is,O
reminiscent,O
of,O
long,O
-,O
term,O
post,O
-,O
traumatic,O
complications,O
(,O
Hesselink,O
et,O
 ,O
al,O
.,O
",",O
2019,O
),O
.,O
Non,O
-,O
classical,O
monocytes,O
started,O
to,O
recover,O
in,O
COVID-19,O
patients,O
during,O
the,O
later,O
stages,O
of,O
the,O
disease,O
(,O
Figure,O
 ,O
S5A,O
),O
.,O
HLA,O
-,O
DRhiCD11chi,O
monocyte,O
cell,O
clusters,O
also,O
declined,O
at,O
later,O
time,O
points,O
in,O
mild,O
COVID-19,O
(,O
Figures,O
S5D,O
–,O
S5F,O
),O
",",O
which,O
correlates,O
well,O
with,O
the,O
longitudinal,O
changes,O
of,O
IFI6,O
and,O
ISG15,O
as,O
well,O
as,O
HLA,O
-,O
DRA,O
and,O
HLA,O
-,O
DRB1,O
expression,O
profiles,O
(,O
Figures,O
4,O
G,O
and,O
S3F,O
),O
.,O
In,O
contrast,O
",",O
overall,O
proportions,O
of,O
HLA,O
-,O
DRhiCD11chi,O
monocytes,O
in,O
severe,O
COVID-19,O
remained,O
low,O
throughout,O
the,O
course,O
of,O
the,O
disease,O
.,O
Proportions,O
of,O
CD10hi,O
macrophage,O
-,O
like,O
cluster,O
10,O
and,O
CD226+CD69,O
+,O
monocytes,O
were,O
generally,O
higher,O
at,O
later,O
stages,O
in,O
severe,O
COVID-19,O
",",O
which,O
resembled,O
the,O
kinetics,O
of,O
HLA,O
-,O
DR,O
This,O
indicates,O
a,O
prolonged,O
alternative,O
activation,O
of,O
monocytes,O
in,O
severe,O
COVID-19,O
(,O
Figure,O
 ,O
S5E,O
),O
.,O
Whole,O
blood,O
CyTOF,O
analysis,O
(,O
cohort,O
1,O
),O
clearly,O
indicated,O
very,O
distinct,O
phenotypic,O
alterations,O
of,O
the,O
neutrophil,O
compartment,O
in,O
mild,O
and,O
severe,O
forms,O
of,O
COVID-19,O
.,O
Overview,O
of,O
scRNA,O
-,O
Seq,O
Dataset,O
from,O
Cohort,O
2,O
and,O
Additional,O
Characterization,O
of,O
Neutrophils,O
",",O
Related,O
to,O
Figure,O
 ,O
7,O
(,O
A,O
),O
UMAP,O
of,O
35,O
fresh,O
blood,O
samples,O
from,O
cohort,O
2,O
(,O
"122,954",O
cells,O
",",O
PBMCs,O
",",O
and,O
whole,O
blood,O
):,O
controls,O
(,O
n,O
 ,O
=,O
17,O
),O
",",O
mild,O
COVID-19,O
(,O
early,O
",",O
n,O
 ,O
=,O
3,O
;,O
late,O
",",O
n,O
 ,O
=,O
3,O
),O
and,O
severe,O
COVID-19,O
(,O
early,O
",",O
n,O
 ,O
=,O
3,O
",",O
late,O
 ,O
=,O
9,O
),O
.,O
(,O
B,O
),O
UMAP,O
visualization,O
of,O
neutrophils,O
(,O
"58,383",O
cells,O
;,O
34,O
whole,O
blood,O
samples,O
",",O
cohort,O
2,O
):,O
controls,O
(,O
n,O
 ,O
=,O
16,O
),O
",",O
mild,O
COVID-19,O
(,O
early,O
",",O
n,O
 ,O
=,O
3,O
;,O
late,O
",",O
n,O
 ,O
=,O
3,O
),O
",",O
and,O
severe,O
COVID-19,O
(,O
early,O
",",O
n,O
 ,O
=,O
3,O
;,O
late,O
",",O
n,O
 ,O
=,O
9,O
),O
.,O
Seven,O
of,O
the,O
nine,O
neutrophil,O
clusters,O
identified,O
in,O
whole,O
blood,O
in,O
cohort,O
2,O
could,O
also,O
be,O
mapped,O
to,O
the,O
fresh,O
PBMC,O
transcriptomes,O
in,O
cohort,O
1,O
(,O
Figure,O
 ,O
S6F,O
),O
",",O
indicating,O
that,O
scRNA,O
-,O
seq,O
of,O
fresh,O
PBMC,O
in,O
COVID-19,O
patients,O
reveals,O
relevant,O
parts,O
of,O
the,O
neutrophil,O
space,O
.,O
Heatmap,O
and,O
UMAP,O
visualization,O
of,O
the,O
cell,O
type,O
distribution,O
identified,O
pro-,O
and,O
pre,O
-,O
neutrophils,O
mainly,O
at,O
late,O
time,O
points,O
in,O
severe,O
COVID-19,O
(,O
Figures,O
7F,O
and,O
7,O
G,O
),O
.,O
Furthermore,O
",",O
mature,O
neutrophils,O
with,O
a,O
high,O
IFN,O
-,O
signature,O
(,O
cluster,O
1,O
),O
were,O
associated,O
with,O
severe,O
COVID-19,O
(,O
Figures,O
7E,O
and,O
S6,O
G,O
),O
.,O
This,O
cluster,O
was,O
also,O
enriched,O
for,O
markers,O
identified,O
by,O
CyTOF,O
as,O
differentially,O
expressed,O
in,O
patients,O
with,O
severe,O
COVID-19,O
(,O
Figure,O
 ,O
6,O
),O
",",O
such,O
as,O
elevated,O
expression,O
of,O
CD274,O
(,O
PD,O
-,O
L1,O
),O
and,O
FCGR1A,O
(,O
CD64,O
),O
(,O
Figure,O
 ,O
7H,O
),O
.,O
Cluster,O
2,O
was,O
also,O
enriched,O
for,O
cells,O
from,O
COVID-19,O
patients,O
",",O
mainly,O
from,O
severe,O
but,O
also,O
mild,O
cases,O
(,O
Figures,O
7F,O
and,O
7,O
G,O
),O
.,O
Gene,O
signatures,O
from,O
granulocytic,O
MDSC,O
(,O
Bayik,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
and,O
CD274(PD,O
-,O
L1)+,O
neutrophils,O
after,O
LPS,O
exposure,O
(,O
de,O
Kleijn,O
et,O
 ,O
al,O
.,O
",",O
2013,O
),O
",",O
both,O
shown,O
to,O
be,O
immunosuppressive,O
",",O
were,O
enriched,O
in,O
clusters,O
1,O
",",O
2,O
",",O
and,O
6,O
",",O
which,O
mainly,O
harbor,O
cells,O
from,O
severe,O
COVID-19,O
.,O
This,O
indicates,O
a,O
suppressive,O
functionality,O
of,O
these,O
cells,O
in,O
severe,O
COVID-19,O
(,O
Figure,O
 ,O
7I,O
),O
.,O
Predictions,O
of,O
transcription,O
factor,O
(,O
TF)-based,O
regulation,O
of,O
the,O
cluster,O
-,O
specific,O
gene,O
signatures,O
separated,O
mature,O
neutrophils,O
from,O
patients,O
with,O
severe,O
COVID-19,O
(,O
cluster,O
1,O
),O
and,O
control,O
patients,O
(,O
cluster,O
0,O
),O
(,O
Figure,O
 ,O
7J,O
),O
.,O
Particularly,O
CD274,O
(,O
PD-1L,O
),O
was,O
enriched,O
in,O
cluster,O
1,O
compared,O
to,O
cluster,O
2,O
",",O
supporting,O
the,O
potential,O
of,O
neutrophils,O
to,O
progress,O
toward,O
a,O
suppressive,O
phenotype,O
in,O
severe,O
COVID-19,O
(,O
Figure,O
 ,O
S6J,O
),O
.,O
Finally,O
",",O
we,O
studied,O
whether,O
the,O
persistent,O
emergence,O
of,O
immature,O
",",O
potentially,O
dysfunctional,O
neutrophils,O
in,O
severe,O
COVID-19,O
patients,O
can,O
be,O
captured,O
under,O
routine,O
diagnostic,O
conditions,O
.,O
Therefore,O
",",O
samples,O
of,O
32,O
COVID-19,O
patients,O
(,O
Table,O
S1,O
",",O
cohort,O
1,O
),O
were,O
characterized,O
by,O
routine,O
hematology,O
analyses,O
using,O
a,O
clinical,O
flow,O
cytometry,O
system,O
(,O
Sysmex,O
analyzer,O
),O
.,O
Indeed,O
",",O
the,O
assumption,O
of,O
rescue,O
myelopoiesis,O
in,O
severe,O
COVID-19,O
was,O
supported,O
by,O
significantly,O
higher,O
counts,O
in,O
the,O
population,O
of,O
immature,O
granulocytes,O
(,O
IG,O
",",O
representing,O
promyelocytes,O
",",O
myelocytes,O
",",O
and,O
metamyelocytes,O
),O
in,O
this,O
patient,O
group,O
(,O
Figure,O
 ,O
7,O
K,O
),O
.,O
As,O
compared,O
to,O
patients,O
with,O
mild,O
course,O
",",O
severely,O
ill,O
patients,O
displayed,O
increases,O
in,O
width,O
of,O
dispersion,O
of,O
activity,O
and,O
cell,O
volume,O
as,O
surrogates,O
for,O
increased,O
cellular,O
heterogeneity,O
",",O
immaturity,O
",",O
and,O
dysregulation,O
in,O
severe,O
COVID-19,O
(,O
Figure,O
 ,O
7,O
K,O
),O
",",O
resembling,O
previously,O
described,O
alterations,O
in,O
sepsis,O
patients,O
(,O
Stiel,O
et,O
 ,O
al,O
.,O
",",O
2016,O
),O
.,O
Furthermore,O
",",O
neutrophils,O
of,O
severe,O
COVID-19,O
patients,O
were,O
partially,O
dysfunctional,O
",",O
because,O
their,O
oxidative,O
burst,O
upon,O
stimulation,O
with,O
standardized,O
stimuli,O
(,O
E.,O
 ,O
coli,O
or,O
PMA,O
),O
was,O
strongly,O
impaired,O
in,O
comparison,O
to,O
control,O
and,O
mild,O
COVID-19,O
neutrophils,O
",",O
whereas,O
phagocytic,O
activity,O
was,O
preserved,O
(,O
Figure,O
 ,O
7L,O
;,O
Table,O
S1,O
),O
.,O
SARS,O
-,O
CoV-2,O
infection,O
generally,O
causes,O
mild,O
disease,O
in,O
the,O
majority,O
of,O
individuals,O
",",O
however,O
",",O
∼10%–20,O
%,O
of,O
COVID-19,O
patients,O
progress,O
to,O
severe,O
disease,O
with,O
pneumonia,O
and,O
respiratory,O
failure,O
.,O
Dysregulated,O
immune,O
responses,O
have,O
been,O
described,O
in,O
patients,O
with,O
severe,O
COVID-19,O
(,O
Chua,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Giamarellos,O
-,O
Bourboulis,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Lucas,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Merad,O
and,O
Martin,O
",",O
2020,O
;,O
Messner,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Wei,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Zhou,O
et,O
 ,O
al,O
.,O
",",O
2020b,O
),O
.,O
Hence,O
",",O
detailed,O
knowledge,O
of,O
the,O
cellular,O
and,O
molecular,O
processes,O
that,O
drive,O
progression,O
from,O
mild,O
disease,O
to,O
potentially,O
fatal,O
courses,O
of,O
COVID-19,O
is,O
urgently,O
needed,O
to,O
identify,O
predictive,O
biomarkers,O
and,O
therapeutic,O
targets,O
.,O
Here,O
",",O
we,O
employed,O
four,O
complementary,O
technologies,O
at,O
single,O
-,O
cell,O
resolution,O
to,O
assess,O
alterations,O
in,O
the,O
systemic,O
immune,O
response,O
in,O
mild,O
or,O
severe,O
courses,O
of,O
COVID-19,O
.,O
Combining,O
single,O
-,O
cell,O
transcriptomics,O
with,O
single,O
-,O
cell,O
proteomics,O
",",O
using,O
different,O
technological,O
platforms,O
in,O
two,O
independent,O
patient,O
cohorts,O
",",O
provided,O
a,O
detailed,O
view,O
of,O
the,O
systemic,O
immune,O
responses,O
in,O
COVID-19,O
and,O
allowed,O
for,O
cross,O
-,O
validation,O
and,O
in,O
-,O
depth,O
interrogation,O
of,O
key,O
findings,O
.,O
This,O
multipronged,O
approach,O
revealed,O
drastic,O
changes,O
within,O
the,O
myeloid,O
cell,O
compartment,O
during,O
COVID-19,O
",",O
particularly,O
in,O
patients,O
with,O
a,O
severe,O
course,O
of,O
disease,O
.,O
CD83,O
 ,O
monocytes,O
with,O
a,O
strong,O
antiviral,O
IFN,O
-,O
signature,O
was,O
a,O
hallmark,O
of,O
mild,O
COVID-19,O
",",O
which,O
receded,O
during,O
the,O
natural,O
course,O
of,O
disease,O
.,O
In,O
contrast,O
",",O
HLA,O
-,O
DRlo,O
dysfunctional,O
monocytes,O
along,O
with,O
clear,O
evidence,O
of,O
emergency,O
myelopoiesis,O
with,O
release,O
of,O
immature,O
neutrophils,O
including,O
pro-,O
and,O
pre,O
-,O
neutrophils,O
into,O
the,O
circulation,O
marked,O
severe,O
COVID-19,O
.,O
Furthermore,O
",",O
we,O
identified,O
neutrophils,O
in,O
severe,O
COVID-19,O
with,O
transcriptional,O
programs,O
reminiscent,O
of,O
dysfunction,O
and,O
immunosuppression,O
not,O
observed,O
in,O
controls,O
or,O
patients,O
with,O
mild,O
COVID-19,O
.,O
Previous,O
immunophenotyping,O
studies,O
have,O
reported,O
an,O
increase,O
of,O
inflammatory,O
monocytes,O
with,O
a,O
strong,O
IFN,O
-,O
response,O
in,O
COVID-19,O
(,O
Liao,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Merad,O
and,O
Martin,O
",",O
2020,O
;,O
Zhou,O
et,O
 ,O
al,O
.,O
",",O
2020b,O
),O
.,O
Mononuclear,O
phagocytes,O
and,O
neutrophils,O
appear,O
to,O
dominate,O
inflammatory,O
infiltrates,O
in,O
the,O
lungs,O
",",O
and,O
resident,O
alveolar,O
macrophages,O
are,O
replaced,O
by,O
inflammatory,O
monocyte,O
-,O
derived,O
macrophages,O
in,O
patients,O
with,O
severe,O
COVID-19,O
(,O
Chua,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Liao,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Here,O
",",O
we,O
report,O
substantial,O
time-,O
and,O
disease,O
severity,O
-,O
dependent,O
alterations,O
of,O
the,O
monocyte,O
compartment,O
in,O
COVID-19,O
.,O
Marked,O
depletion,O
of,O
CD14loCD16hi,O
non,O
-,O
classical,O
monocytes,O
observed,O
in,O
all,O
COVID-19,O
patients,O
",",O
but,O
not,O
in,O
patients,O
with,O
SARS,O
-,O
CoV-2,O
negative,O
FLI,O
(,O
Figure,O
 ,O
1D,O
),O
",",O
is,O
in,O
line,O
with,O
previous,O
reports,O
on,O
COVID-19,O
",",O
and,O
other,O
severe,O
viral,O
infections,O
(,O
Lüdtke,O
et,O
 ,O
al,O
.,O
",",O
2016,O
;,O
Naranjo,O
-,O
Gómez,O
et,O
 ,O
al,O
.,O
",",O
2019,O
),O
.,O
CD83,O
),O
monocytes,O
in,O
mild,O
COVID-19,O
.,O
This,O
was,O
similar,O
in,O
patients,O
presenting,O
with,O
common,O
cold,O
or,O
FLI,O
",",O
but,O
absent,O
in,O
severe,O
COVID-19,O
(,O
Figures,O
3,O
and,O
4,O
),O
.,O
In,O
contrast,O
",",O
in,O
severe,O
COVID-19,O
",",O
monocytes,O
showed,O
low,O
expression,O
of,O
HLA,O
-,O
DR,O
",",O
and,O
high,O
levels,O
of,O
MAFB,O
",",O
PLBD1,O
",",O
and,O
CD163,O
",",O
all,O
of,O
which,O
are,O
associated,O
with,O
anti,O
-,O
inflammatory,O
macrophage,O
functions,O
(,O
Bronte,O
et,O
 ,O
al,O
.,O
",",O
2016,O
;,O
Cuevas,O
et,O
 ,O
al,O
.,O
",",O
2017,O
;,O
Fischer,O
-,O
Riepe,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
MacParland,O
et,O
 ,O
al,O
.,O
",",O
2018,O
),O
.,O
In,O
fact,O
",",O
we,O
observed,O
that,O
inflammatory,O
cytokine,O
production,O
",",O
including,O
IL-1β,O
release,O
",",O
was,O
impaired,O
in,O
monocytes,O
from,O
patients,O
with,O
severe,O
COVID-19,O
(,O
Figure,O
 ,O
4,O
),O
.,O
LDN,O
in,O
PBMC,O
fractions,O
in,O
severe,O
COVID-19,O
contained,O
immature,O
neutrophils,O
",",O
including,O
pro-,O
and,O
pre,O
-,O
neutrophils,O
",",O
which,O
was,O
not,O
observed,O
in,O
mild,O
cases,O
(,O
Figure,O
 ,O
5,O
),O
.,O
Emergence,O
of,O
pro,O
-,O
neutrophils,O
in,O
severe,O
COVID-19,O
was,O
also,O
detected,O
by,O
single,O
-,O
cell,O
proteomics,O
on,O
whole,O
blood,O
samples,O
.,O
Neutrophils,O
from,O
patients,O
with,O
severe,O
COVID-19,O
showed,O
an,O
impaired,O
oxidative,O
burst,O
response,O
",",O
while,O
their,O
phagocytic,O
capacity,O
was,O
preserved,O
(,O
Figure,O
 ,O
7,O
),O
.,O
Single,O
-,O
cell,O
transcriptomics,O
of,O
whole,O
blood,O
samples,O
revealed,O
mature,O
activated,O
neutrophils,O
in,O
both,O
mild,O
and,O
severe,O
COVID-19,O
(,O
Figure,O
 ,O
7B,O
",",O
cluster,O
2,O
),O
",",O
however,O
",",O
expression,O
of,O
CD274,O
(,O
PD,O
-,O
L1,O
),O
was,O
only,O
found,O
in,O
severe,O
COVID-19,O
(,O
cluster,O
1,O
),O
",",O
and,O
it,O
increased,O
in,O
later,O
stages,O
of,O
the,O
disease,O
.,O
Expression,O
of,O
PD,O
-,O
L1,O
on,O
neutrophils,O
has,O
been,O
associated,O
with,O
T,O
 ,O
cell,O
suppression,O
(,O
Bowers,O
et,O
 ,O
al,O
.,O
",",O
2014,O
;,O
Castell,O
et,O
 ,O
al,O
.,O
",",O
2019,O
;,O
de,O
Kleijn,O
et,O
 ,O
al,O
.,O
",",O
2013,O
;,O
Langereis,O
et,O
 ,O
al,O
.,O
",",O
2017,O
),O
",",O
suggesting,O
that,O
neutrophils,O
in,O
severe,O
COVID-19,O
might,O
exert,O
suppressive,O
functions,O
.,O
Furthermore,O
",",O
the,O
expression,O
of,O
CD177,O
on,O
mature,O
activated,O
neutrophils,O
and,O
the,O
identification,O
of,O
genes,O
associated,O
with,O
anti,O
-,O
inflammatory,O
functions,O
(,O
CD274,O
and,O
ZC3H12A,O
),O
suggest,O
a,O
model,O
in,O
which,O
neutrophils,O
emerging,O
prematurely,O
from,O
the,O
bone,O
marrow,O
are,O
programmed,O
toward,O
an,O
anti,O
-,O
inflammatory,O
or,O
even,O
suppressive,O
phenotype,O
in,O
severe,O
COVID-19,O
.,O
The,O
transcriptional,O
programs,O
induced,O
in,O
immature,O
neutrophils,O
",",O
including,O
pro-,O
and,O
pre,O
-,O
neutrophils,O
",",O
as,O
well,O
as,O
in,O
COVID-19,O
-,O
associated,O
mature,O
neutrophil,O
clusters,O
",",O
align,O
with,O
other,O
observations,O
in,O
severe,O
COVID-19,O
patients,O
",",O
including,O
increased,O
NET,O
formation,O
(,O
Barnes,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Zuo,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
",",O
coagulation,O
(,O
Klok,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Pfeiler,O
et,O
 ,O
al,O
.,O
",",O
2014,O
),O
",",O
and,O
immunothrombosis,O
(,O
Stiel,O
et,O
 ,O
al,O
.,O
",",O
2018,O
;,O
Xu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
contrast,O
",",O
these,O
transcriptional,O
programs,O
were,O
not,O
observed,O
in,O
patients,O
with,O
mild,O
COVID-19,O
or,O
in,O
SARS,O
-,O
CoV-2,O
negative,O
controls,O
",",O
even,O
though,O
the,O
latter,O
exhibited,O
a,O
range,O
of,O
comorbidities,O
(,O
e.g.,O
",",O
COPD,O
",",O
type,O
II,O
diabetes,O
),O
.,O
The,O
pathophysiological,O
consequences,O
of,O
the,O
dysfunctional,O
phenotype,O
of,O
myeloid,O
cells,O
in,O
severe,O
COVID-19,O
remain,O
unclear,O
at,O
this,O
stage,O
.,O
While,O
our,O
dual,O
cohort,O
study,O
design,O
provided,O
robust,O
and,O
reproducible,O
results,O
concerning,O
the,O
alterations,O
within,O
the,O
myeloid,O
compartment,O
in,O
COVID-19,O
",",O
it,O
is,O
too,O
early,O
to,O
speculate,O
on,O
the,O
underlying,O
mechanisms,O
driving,O
this,O
response,O
",",O
such,O
as,O
genetics,O
",",O
lifestyle,O
",",O
comorbidities,O
",",O
environmental,O
factors,O
",",O
or,O
initial,O
viral,O
load,O
(,O
Ellinghaus,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Indeed,O
",",O
in,O
future,O
studies,O
it,O
will,O
be,O
interesting,O
to,O
dissect,O
whether,O
the,O
myeloid,O
subsets,O
in,O
COVID-19,O
are,O
anti,O
-,O
inflammatory,O
or,O
even,O
capable,O
of,O
suppressing,O
other,O
immune,O
cells,O
",",O
and,O
which,O
pathways,O
might,O
be,O
mainly,O
involved,O
.,O
Samples,O
from,O
patients,O
with,O
COVID-19,O
were,O
collected,O
within,O
two,O
cohort,O
studies,O
(,O
Kurth,B-Creator
"et al.,",I-Creator
2020,E-Creator
),O
designed,O
to,O
allow,O
deep,O
molecular,O
and,O
immunological,O
transcriptomic,O
and,O
proteomic,O
profiling,O
of,O
COVID-19,O
in,O
blood,O
.,O
This,O
study,O
was,O
designed,O
to,O
describe,O
immunological,O
deviations,O
in,O
COVID-19,O
patients,O
without,O
intention,O
of,O
the,O
development,O
of,O
new,O
treatments,O
or,O
new,O
diagnostics,O
",",O
and,O
therefore,O
sample,O
size,O
estimation,O
was,O
not,O
included,O
in,O
the,O
original,O
study,O
design,O
.,O
This,O
study,O
includes,O
a,O
subset,O
of,O
patients,O
enrolled,O
between,O
March,O
2,O
and,O
July,O
02,O
2020,O
in,O
the,O
Pa,O
-,O
COVID-19,O
study,O
",",O
a,O
prospective,O
observational,O
cohort,O
study,O
assessing,O
pathophysiology,O
and,O
clinical,O
characteristics,O
of,O
patients,O
with,O
COVID-19,O
at,O
Charité,O
Universitätsmedizin,O
Berlin,O
(,O
Kurth,B-Creator
"et al.,",I-Creator
2020,E-Creator
),O
.,O
The,O
patient,O
population,O
included,O
in,O
all,O
analyses,O
of,O
cohort,O
1,O
consists,O
of,O
10,O
control,O
donors,O
(,O
samples,O
collected,O
in,O
2019,O
before,O
SARS,O
-,O
CoV2,O
outbreak,O
),O
",",O
8,O
patients,O
presenting,O
with,O
flu,O
-,O
like,O
illness,O
but,O
tested,O
SARS,O
-,O
CoV-2,O
-,O
negative,O
",",O
25,O
mild,O
and,O
29,O
severe,O
COVID-19,O
patients,O
(,O
Figures,O
1A,O
and,O
1B,O
;,O
Table,O
S1,O
),O
.,O
All,O
COVID-19,O
patients,O
were,O
tested,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
nasopharyngeal,O
swabs,O
and,O
allocated,O
to,O
mild,O
(,O
WHO,O
2,O
-,O
4,O
),O
or,O
severe,O
(,O
5,O
-,O
7,O
),O
disease,O
according,O
to,O
the,O
WHO,O
clinical,O
ordinal,O
scale,O
.,O
We,O
also,O
included,O
publicly,O
 ,O
available,O
single,O
-,O
cell,O
transcriptome,O
data,O
derived,O
from,O
22,O
control,O
samples,O
into,O
the,O
analysis,O
;,O
3,O
samples,O
were,O
derived,O
from,O
10x,B-Repository
Genomics,E-Repository
",",O
San,O
Francisco,O
",",O
CA,O
94111,O
",",O
USA,O
(,O
5k_pbmc_v3,O
:,O
https://support.10xgenomics.com/single-cell-gene-expression/datasets/3.0.2/5k_pbmc_v3,S-URL
",",O
pbmc_10k_v3,O
:,O
https://support.10xgenomics.com/single-cell-gene-expression/datasets/3.0.0/pbmc_10k_v3,S-URL
",",O
pbmc_1k_v3,O
:,O
https://support.10xgenomics.com/single-cell-gene-expression/datasets/3.0.0/pbmc_1k_v3,S-URL
),O
",",O
19,O
samples,O
derived,O
from,O
Reyes,O
et,O
 ,O
al,O
.,O
(,O
2020,O
),O
.,O
After,O
providing,O
written,O
informed,O
consent,O
",",O
19,O
control,O
donors,O
and,O
22,O
COVID-19,O
patients,O
(,O
Figures,O
1A,O
and,O
1B,O
;,O
Table,O
S1,O
),O
were,O
included,O
in,O
the,O
study,O
.,O
COVID-19,O
patients,O
who,O
tested,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
nasopharyngeal,O
swabs,O
were,O
recruited,O
at,O
the,O
Medical,O
Clinic,O
I,O
of,O
the,O
University,O
Hospital,O
Bonn,O
between,O
March,O
30,O
and,O
June,O
17,O
",",O
2020,O
and,O
allocated,O
to,O
mild,O
(,O
WHO,O
2,O
-,O
4,O
),O
or,O
severe,O
(,O
5,O
-,O
7,O
),O
disease,O
according,O
to,O
the,O
WHO,O
clinical,O
ordinal,O
scale,O
.,O
These,O
individuals,O
were,O
either,O
tested,O
negative,O
for,O
SARS,O
-,O
CoV-2,O
",",O
serologically,O
negative,O
or,O
had,O
no,O
indication,O
for,O
acute,O
COVID-19,O
disease,O
based,O
on,O
clinical,O
or,O
laboratory,O
parameters,O
.,O
1ml,O
of,O
fresh,O
blood,O
from,O
control,O
or,O
COVID-19,O
donors,O
was,O
treated,O
with,O
10ml,O
of,O
RBC,O
lysis,O
buffer,O
(,O
Biolegend,O
),O
.,O
Whitney,O
test,O
was,O
used,O
to,O
report,O
differences,O
in,O
IG,O
count,O
",",O
whereas,O
mixed,O
-,O
effect,O
-,O
analysis,O
and,O
Sidak,O
’s,O
multiple,O
comparison,O
test,O
was,O
applied,O
to,O
report,O
statistical,O
differences,O
of,O
NE,O
-,O
WX,O
",",O
NE,O
-,O
WY,O
and,O
NE,O
-,O
WZ,O
between,O
mild,O
and,O
severe,O
COVID-19,O
patients,O
.,O
Subsequently,O
",",O
the,O
scRNA,O
-,O
seq,O
data,O
from,O
cohort,O
1,O
was,O
integrated,O
with,O
publicly,O
available,O
10x,O
scRNaseq,O
data,O
of,O
healthy,O
controls,O
using,O
the,O
‘,O
harmony,O
’,O
algorithm,O
(,O
Korsunsky,O
et,O
 ,O
al,O
.,O
",",O
2019,O
),O
based,O
on,O
the,O
first,O
20,O
principal,O
components,O
to,O
correct,O
for,O
technical,O
differences,O
in,O
the,O
gene,O
expression,O
counts,O
of,O
the,O
different,O
data,O
sources,O
(,O
Control,O
samples,O
from,O
Reyes,B-Creator
et al.,I-Creator
(2020),E-Creator
",",O
10x,O
v3.1,O
PBMC,O
benchmarking,O
data,O
from,O
healthy,O
controls,O
and,O
10x,O
v3.1,O
scRNA,O
-,O
seq,O
data,O
from,O
cohort,O
1,O
),O
.,O
Cluster,O
marker,O
genes,O
were,O
identified,O
by,O
applying,O
the,O
DE,O
tests,O
for,O
upregulated,O
genes,O
between,O
cells,O
in,O
one,O
cluster,O
to,O
all,O
other,O
clusters,O
in,O
the,O
dataset,O
.,O
To,O
compare,O
shifts,O
in,O
the,O
monocyte,O
and,O
neutrophil,O
populations,O
in,O
the,O
PBMC,O
compartment,O
of,O
COVID-19,O
patients,O
",",O
the,O
percentages,O
of,O
the,O
cellular,O
subsets,O
-,O
as,O
identified,O
by,O
clustering,O
and,O
cluster,O
annotation,O
explained,O
above,O
for,O
the,O
two,O
independent,O
scRNA,O
-,O
seq,O
datasets,O
(,O
cohort,O
1,O
and,O
cohort,O
2,O
),O
-,O
of,O
the,O
total,O
number,O
of,O
PBMC,O
in,O
each,O
dataset,O
were,O
quantified,O
per,O
sample,O
and,O
visualized,O
together,O
in,O
boxplots,O
.,O
The,O
monocyte,O
space,O
was,O
investigated,O
by,O
subsetting,O
the,O
PBMC,O
dataset,O
to,O
those,O
clusters,O
identified,O
as,O
monocytes,O
(,O
cluster,O
0,O
-,O
4,O
),O
",",O
removing,O
cells,O
with,O
strong,O
multi,O
-,O
lineage,O
marker,O
expressions,O
",",O
and,O
repeating,O
the,O
variable,O
gene,O
selection,O
(,O
top,O
"2,000",O
variable,O
genes,O
),O
",",O
regression,O
for,O
the,O
number,O
of,O
UMIs,O
and,O
scaling,O
as,O
described,O
above,O
.,O
Subsequently,O
",",O
the,O
dataset,O
was,O
subsetted,O
for,O
whole,O
blood,O
samples,O
after,O
erythrocyte,O
lysis,O
and,O
clusters,O
identified,O
as,O
neutrophils,O
and,O
immature,O
neutrophils,O
",",O
and,O
re,O
-,O
scaled,O
and,O
regressed,O
.,O
Gene,O
set,O
enrichment,O
was,O
performed,O
on,O
gene,O
sets,O
from,O
the,O
Kyoto,B-Repository
Encyclopedia,I-Repository
of,I-Repository
Genes,I-Repository
and,I-Repository
Genomes,I-Repository
(KEGG),E-Repository
 ,O
database,O
(,O
"Kanehisa,",B-Creator
2019,E-Creator
),O
",",O
Hallmark,O
gene,O
sets,O
(,O
Liberzon,B-Creator
"et al.,",I-Creator
2015,E-Creator
),O
and,O
Gene,B-Repository
Ontology,I-Repository
(GO),E-Repository
 ,O
(,O
Ashburner,B-Creator
"et al.,",I-Creator
2000,E-Creator
;,O
Carbon,B-Creator
"et al.,",I-Creator
2019,E-Creator
),O
using,O
the,O
R,O
package,O
/,O
ClusterProfiler,O
v.3.10.1,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
a,O
mild,O
to,O
moderate,O
respiratory,O
tract,O
infection,O
",",O
however,O
",",O
a,O
subset,O
of,O
patients,O
progress,O
to,O
severe,O
disease,O
and,O
respiratory,O
failure,O
.,O
The,O
mechanism,O
of,O
protective,O
immunity,O
in,O
mild,O
forms,O
and,O
the,O
pathogenesis,O
of,O
severe,O
COVID-19,O
associated,O
with,O
increased,O
neutrophil,O
counts,O
and,O
dysregulated,O
immune,O
responses,O
remain,O
unclear,O
.,O
In,O
a,O
dual,O
-,O
center,O
",",O
two,O
-,O
cohort,O
study,O
",",O
we,O
combined,O
single,O
-,O
cell,O
RNA,O
-,O
sequencing,O
and,O
single,O
-,O
cell,O
proteomics,O
of,O
whole,O
-,O
blood,O
and,O
peripheral,O
-,O
blood,O
mononuclear,O
cells,O
to,O
determine,O
changes,O
in,O
immune,O
cell,O
composition,O
and,O
activation,O
in,O
mild,O
versus,O
severe,O
COVID-19,O
(,O
242,O
samples,O
from,O
109,O
individuals,O
),O
over,O
time,O
.,O
HLA,O
-,O
DR,O
hi,O
CD11c,O
hi,O
inflammatory,O
monocytes,O
with,O
an,O
interferon,O
-,O
stimulated,O
gene,O
signature,O
were,O
elevated,O
in,O
mild,O
COVID-19,O
.,O
Severe,O
COVID-19,O
was,O
marked,O
by,O
occurrence,O
of,O
neutrophil,O
precursors,O
",",O
as,O
evidence,O
of,O
emergency,O
myelopoiesis,O
",",O
dysfunctional,O
mature,O
neutrophils,O
",",O
and,O
HLA,O
-,O
DR,O
lo,O
monocytes,O
.,O
Our,O
study,O
provides,O
detailed,O
insights,O
into,O
the,O
systemic,O
immune,O
response,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
reveals,O
profound,O
alterations,O
in,O
the,O
myeloid,O
cell,O
compartment,O
associated,O
with,O
severe,O
COVID-19,O
.,O
Graphical,O
Abstract,O
     ,O
Analysis,O
of,O
patients,O
with,O
mild,O
and,O
severe,O
COVID-19,O
reveals,O
the,O
presence,O
of,O
dysfunctional,O
neutrophils,O
in,O
the,O
latter,O
that,O
is,O
linked,O
to,O
emergency,O
myelopoiesis,O
.,O
The,O
disease,O
was,O
recognized,O
to,O
be,O
caused,O
by,O
a,O
novel,O
coronavirus,O
(,O
SARS,O
-,O
CoV-2,O
),O
and,O
termed,O
coronavirus,O
disease-19,O
(,O
COVID-19,O
),O
.,O
The,O
symptoms,O
of,O
COVID-19,O
range,O
from,O
fever,O
",",O
dry,O
cough,O
",",O
fatigue,O
",",O
congestion,O
",",O
sore,O
throat,O
",",O
and,O
diarrhea,O
to,O
severe,O
interstitial,O
bilateral,O
pneumonia,O
with,O
a,O
ground,O
-,O
glass,O
image,O
at,O
the,O
CT,O
scan,O
.,O
All,O
these,O
data,O
were,O
inserted,O
in,O
a,O
section,O
of,O
the,O
established,O
and,O
certified,O
Biobank,S-Repository
 ,O
and,O
Registry,B-Repository
of,I-Repository
the,I-Repository
Medical,I-Repository
Genetics,I-Repository
Unit,I-Repository
of,I-Repository
the,I-Repository
Hospital,E-Repository
 ,O
dedicated,O
to,O
COVID-19,O
.,O
The,O
cohort,O
of,O
COVID-19,O
patients,O
consists,O
of,O
131,O
individuals,O
out,O
of,O
whom,O
34,O
females,O
and,O
97,O
males,O
belonging,O
to,O
the,O
GEN,O
-,O
COVID,O
MULTICENTER,O
STUDY,O
(,O
[,O
16,O
],O
",",O
Late,O
Breaking,O
Abstract,O
ESHG,O
2020.2,O
Virtual,O
Conference,O
“,O
WES,O
profiling,O
of,O
COVID-19,O
”,O
),O
.,O
The,O
genome,O
aggregation,O
database,O
gnomAD,S-Repository
 ,O
(,O
https://gnomad.broadinstitute.org/,S-URL
),O
was,O
used,O
to,O
assess,O
allele,O
frequency,O
for,O
each,O
variant,O
among,O
different,O
populations,O
.,O
(,O
PDB,S-Repository
 ,O
ID,O
code,O
1R42,S-AccessionNumber
),O
[,O
24,O
],O
.,O
MD,O
simulations,O
were,O
performed,O
using,O
a,O
high,O
parallel,O
computing,O
infrastructure,O
(,O
HPCS,O
),O
with,O
660,O
cpu,O
within,O
21,O
different,O
nodes,O
",",O
190,O
T,O
of,O
RAM,O
",",O
30,O
T,O
hard,O
disk,O
partition,O
size,O
",",O
and,O
six,O
NVIDIA,O
TESLA,O
gpu,O
with,O
CUDA,O
support,O
.,O
The,O
c.2158A,O
>,O
G,O
p.(Asn720Asp,O
),O
substitution,O
was,O
estimated,O
to,O
have,O
a,O
frequency,O
of,O
0.011,O
(,O
103/9689,O
alleles,O
),O
",",O
which,O
is,O
in,O
line,O
with,O
the,O
frequency,O
of,O
the,O
variant,O
reported,O
in,O
the,O
gnomAD,S-Repository
 ,O
database,O
(,O
0.016,O
),O
",",O
and,O
is,O
lower,O
than,O
the,O
frequency,O
reported,O
in,O
gnomAD,S-Repository
 ,O
for,O
the,O
European,O
non,O
-,O
Finnish,O
population,O
(,O
0.025,O
",",O
2195/87966,O
analyzed,O
alleles,O
),O
.,O
In,O
addition,O
to,O
these,O
variants,O
",",O
28,O
rare,O
missense,O
variants,O
were,O
identified,O
",",O
out,O
of,O
which,O
ten,O
had,O
not,O
previously,O
been,O
reported,O
in,O
GnomAD,S-Repository
 ,O
database,O
and,O
nine,O
truncating,O
variants,O
that,O
had,O
not,O
been,O
reported,O
in,O
gnomAD,S-Repository
 ,O
database,O
(,O
Table,O
 ,O
1,O
and,O
Supplementary,O
Table,O
 ,O
1,O
),O
.,O
In,O
order,O
to,O
shed,O
light,O
on,O
the,O
role,O
of,O
ACE2,O
variants,O
on,O
interindividual,O
variability,O
and,O
susceptibility,O
to,O
COVID-19,O
in,O
Italian,O
population,O
we,O
performed,O
WES,O
analysis,O
on,O
a,O
cohort,O
of,O
131,O
patients,O
and,O
258,O
controls,O
who,O
agreed,O
in,O
participating,O
to,O
the,O
study,O
(,O
see,O
“,O
Materials,O
and,O
methods,O
”,O
),O
.,O
A,O
silent,O
variant,O
the,O
c.2247G,O
>,O
A,O
p.,O
V749V,O
",",O
was,O
also,O
detected,O
in,O
26,O
control,O
individuals,O
(,O
allele,O
frequency,O
0.069,O
),O
compared,O
with,O
five,O
COVID-19,O
patients,O
(,O
allele,O
frequency,O
0.030,O
),O
.,O
Italy,O
has,O
been,O
the,O
first,O
European,O
country,O
that,O
experienced,O
the,O
COVID-19,O
outbreak,O
with,O
a,O
rapid,O
increase,O
in,O
the,O
positive,O
cases,O
in,O
a,O
very,O
short,O
-,O
time,O
period,O
and,O
a,O
morbidity,O
and,O
lethality,O
(,O
~10,O
%,O
),O
definitely,O
higher,O
in,O
comparison,O
with,O
Asian,O
countries,O
",",O
such,O
as,O
China,O
(,O
4,O
%,O
),O
and,O
South,O
Korea,O
(,O
1.2,O
%,O
),O
[,O
32,O
],O
.,O
WES,O
data,O
generated,O
from,O
a,O
wide,O
cohort,O
of,O
COVID-19,O
Italian,O
patients,O
revealed,O
a,O
statistically,O
significant,O
(,O
P,O
 ,O
<,O
 ,O
"0,029",O
),O
higher,O
allelic,O
heterogeneity,O
for,O
ACE2,O
in,O
controls,O
compared,O
with,O
patients,O
with,O
a,O
higher,O
chance,O
to,O
find,O
at,O
least,O
one,O
ACE2,O
variant,O
in,O
the,O
cohort,O
of,O
controls,O
compared,O
with,O
the,O
cohort,O
of,O
patients,O
.,O
A,O
human,O
-,O
to,O
-,O
human,O
transmission,O
was,O
assumed,O
and,O
a,O
previously,O
unrecognized,O
entity,O
",",O
termed,O
coronavirus,O
disease-19,O
(,O
COVID-19,O
),O
due,O
to,O
a,O
novel,O
coronavirus,O
(,O
SARS,O
-,O
CoV-2,O
),O
was,O
described,O
.,O
These,O
findings,O
suggest,O
that,O
a,O
predisposing,O
genetic,O
background,O
may,O
contribute,O
to,O
the,O
observed,O
interindividual,O
clinical,O
variability,O
associated,O
with,O
COVID-19,O
",",O
allowing,O
an,O
evidence,O
-,O
based,O
risk,O
assessment,O
leading,O
to,O
personalized,O
preventive,O
measures,O
and,O
therapeutic,O
options,O
.,O
Therapeutic,O
efficacy,O
and,O
safety,O
of,O
supplementing,O
ACE2,O
and,O
Ang,O
(,O
1‐7,O
),O
with,O
this,O
existing,O
product,O
in,O
non‐critically,O
ill,O
COVID‐19,O
patients,O
in,O
the,O
hospital,O
and,O
at,O
home,O
is,O
in,O
progress,O
.,O
By,O
employing,O
an,O
integrated,O
Phase,O
1,O
and,O
Phase,O
2,O
clinical,O
trial,O
design,O
",",O
this,O
clinical,O
trial,O
addresses,O
an,O
urgent,O
unmet,O
medical,O
need,O
to,O
treat,O
the,O
growing,O
population,O
of,O
COVID‐19,O
patients,O
and,O
protect,O
them,O
from,O
lung,O
and,O
extra‐pulmonary,O
tissue,O
injury,O
.,O
In,O
the,O
late,O
winter,O
of,O
2019,O
",",O
emergence,O
of,O
the,O
SARS,O
-,O
CoV-2,O
virus,O
led,O
to,O
the,O
COVID-19,O
pandemic,O
",",O
manifesting,O
in,O
a,O
serious,O
illness,O
affecting,O
over,O
a,O
million,O
people,O
around,O
the,O
world,O
",",O
including,O
the,O
United,O
States,O
",",O
during,O
the,O
spring,O
of,O
2020,O
[,O
1,O
],O
.,O
Not,O
only,O
is,O
there,O
the,O
likelihood,O
of,O
increased,O
morbidity,O
and,O
mortality,O
if,O
these,O
individuals,O
become,O
infected,O
with,O
the,O
virus,O
",",O
but,O
the,O
social,O
and,O
economic,O
consequences,O
of,O
COVID-19,O
may,O
significantly,O
impact,O
their,O
access,O
to,O
critical,O
healthcare,O
resources,O
.,O
Each,O
has,O
specific,O
considerations,O
that,O
may,O
be,O
impacted,O
by,O
aspects,O
of,O
the,O
COVID-19,O
pandemic,O
.,O
Older,O
adults,O
and,O
people,O
of,O
all,O
ages,O
who,O
have,O
serious,O
underlying,O
medical,O
conditions,O
are,O
at,O
higher,O
risk,O
for,O
severe,O
illness,O
from,O
COVID-19,O
[,O
19,O
],O
.,O
Inflammation,O
in,O
COVID-19,O
infection,O
results,O
in,O
a,O
decrease,O
of,O
helper,O
",",O
suppressor,O
and,O
regulatory,O
T,O
cells,O
and,O
of,O
gamma,O
interferon,O
.,O
The,O
variability,O
in,O
effects,O
of,O
COVID-19,O
infection,O
rates,O
coupled,O
with,O
the,O
variability,O
in,O
baseline,O
GD,O
disease,O
burden,O
will,O
likely,O
complicate,O
addressing,O
the,O
extent,O
of,O
the,O
vulnerability,O
to,O
infection,O
in,O
this,O
population,O
.,O
Initial,O
symptoms,O
of,O
COVID-19,O
include,O
fever,O
",",O
malaise,O
",",O
cough,O
",",O
impairment,O
of,O
sense,O
of,O
smell,O
and/or,O
taste,O
and,O
gastrointestinal,O
disturbance,O
.,O
The,O
pulmonary,O
involvement,O
prevalent,O
in,O
this,O
group,O
may,O
worsen,O
with,O
COVID-19,O
disease,O
.,O
This,O
“,O
inflammatory,O
storm,O
”,O
",",O
observed,O
in,O
very,O
ill,O
patients,O
with,O
COVID-19,O
",",O
results,O
from,O
excessive,O
and,O
prolonged,O
activation,O
of,O
proinflammatory,O
stimuli,O
.,O
[,O
"23,59",O
],O
This,O
inflammatory,O
syndrome,O
may,O
occur,O
days,O
to,O
weeks,O
after,O
acute,O
COVID-19,O
illness,O
",",O
with,O
some,O
patients,O
developing,O
cardiogenic,O
or,O
vasogenic,O
shock,O
requiring,O
intensive,O
care,O
for,O
multiple,O
organ,O
dysfunction,O
.,O
The,O
response,O
of,O
patients,O
with,O
Gaucher,O
disease,O
to,O
COVID-19,O
and/or,O
its,O
pharmacological,O
interventions,O
:,O
Subsequently,O
",",O
five,O
additional,O
2019,O
-,O
nCoV,O
sequences,O
were,O
deposited,O
on,O
the,O
GSAID,S-Dataset
 ,O
database,O
on,O
11th,O
January,O
from,O
institutes,O
across,O
China,O
(,O
Chinese,O
CDC,O
",",O
Wuhan,O
Institute,O
of,O
Virology,O
and,O
Chinese,O
Academy,O
of,O
Medical,O
Sciences,O
&,O
Peking,O
Union,O
Medical,O
College,O
),O
and,O
allowed,O
researchers,O
around,O
the,O
world,O
to,O
begin,O
analyzing,O
the,O
new,O
CoV,O
[,O
5,O
],O
.,O
The,O
sequences,O
of,O
these,O
exported,O
cases,O
and,O
several,O
additional,O
2019,O
-,O
nCoV,O
isolated,O
in,O
China,O
have,O
also,O
been,O
deposited,O
on,O
the,O
GSAID,S-Dataset
 ,O
database,O
[,O
5,O
],O
.,O
COVID-19,O
has,O
infected,O
over,O
20,O
million,O
people,O
and,O
has,O
killed,O
more,O
than,O
"737,000",O
people,O
by,O
mid,O
August,O
2020,O
.,O
There,O
are,O
currently,O
no,O
promising,O
antiviral,O
drugs,O
or,O
vaccines,O
to,O
combat,O
COVID-19,O
.,O
Developing,O
functional,O
computational,O
models,O
and,O
networks,O
to,O
predict,O
potential,O
SARS,O
-,O
CoV,O
-miRNA,O
/,O
lncRNA,O
association,O
may,O
benefit,O
not,O
only,O
the,O
understanding,O
of,O
COVID-19,O
mechanism,O
at,O
the,O
noncoding,O
RNA,O
level,O
",",O
but,O
also,O
the,O
detection,O
of,O
disease,O
biomarkers,O
for,O
disease,O
diagnosis,O
",",O
treatment,O
",",O
prognosis,O
",",O
and,O
prevention,O
.,O
Since,O
it,O
is,O
also,O
important,O
to,O
consider,O
the,O
virus,O
-,O
host,O
protein,O
-,O
protein,O
interaction,O
in,O
order,O
to,O
understand,O
its,O
pathogenesis,O
during,O
infection,O
[,O
"7,8",O
],O
;,O
we,O
used,O
Viruses-,B-Dataset
STRING,E-Dataset
",",O
a,O
protein,O
–,O
protein,O
interaction,O
database,O
specifically,O
designed,O
to,O
analyze,O
the,O
virus,O
-,O
host,O
interactions,O
[,O
9,O
],O
.,O
Furthermore,O
",",O
we,O
used,O
the,O
miRWalk2.0,O
database,O
to,O
generate,O
a,O
network,O
for,O
a,O
comprehensive,O
overview,O
of,O
miRNA,O
-,O
lncRNA,O
interactions,O
using,O
experimentally,O
verified,O
data,O
[,O
11,O
],O
.,O
To,O
generate,O
an,O
interactome,O
network,O
of,O
Human,O
SARS,O
coronavirus,O
(,O
SARS,O
-,O
CoV,O
),O
with,O
human,O
proteins,O
",",O
we,O
used,O
the,O
STRING,S-Repository
 ,O
database,O
http://viruses.string-db.org/,S-URL
 ,O
(,O
version,O
10.5,O
),O
[,O
9,O
],O
.,O
In,O
order,O
to,O
disclose,O
the,O
most,O
possible,O
miRNAs,O
regulating,O
the,O
selected,O
mRNAs,O
",",O
the,O
MiRTarBase,S-Repository
 ,O
(,O
http://miRTarBase.cuhk.edu.cn/,S-URL
),O
",",O
one,O
of,O
the,O
most,O
important,O
experimentally,O
validated,O
miRNA,O
-,O
target,O
interactions,O
(,O
MTIs,O
),O
databases,O
",",O
was,O
employed,O
.,O
Further,O
",",O
miRNA,O
-,O
lncRNA,O
interactions,O
were,O
determined,O
using,O
the,O
miRWalk2.0,S-Repository
 ,O
database,O
(,O
http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/,S-URL
),O
",",O
a,O
database,O
on,O
predicted,O
and,O
published,O
noncoding,O
RNAs,O
;,O
and,O
seed,O
length,O
(,O
SL,O
),O
≥,O
13,O
were,O
selected,O
as,O
the,O
most,O
significant,O
interactions,O
[,O
11,O
],O
.,O
Human,O
SARS,O
coronavirus,O
(,O
SARS,O
-,O
CoV,O
),O
and,O
the,O
Homo,O
sapiens,O
interaction,O
network,O
was,O
downloaded,O
as,O
a,O
vector,O
image,O
from,O
the,O
viruses,B-Dataset
STRING,E-Dataset
 ,O
dataset,O
.,O
Therefore,O
",",O
we,O
aimed,O
to,O
follow,O
a,O
comprehensive,O
bioinformatics,O
approach,O
to,O
dissect,O
the,O
strongest,O
possible,O
changes,O
in,O
the,O
noncoding,O
RNA,O
network,O
in,O
response,O
to,O
the,O
viral,O
infection,O
in,O
humans,O
using,O
the,O
available,O
online,O
databases,O
.,O
STRING,S-Repository
 ,O
online,O
database,O
as,O
a,O
powerful,O
platform,O
to,O
explore,O
the,O
most,O
significant,O
protein,O
-,O
protein,O
interactions,O
between,O
SARS,O
-,O
CoV,O
viral,O
particles,O
and,O
host,O
proteome,O
.,O
Thus,O
",",O
it,O
is,O
of,O
utmost,O
important,O
priority,O
to,O
develop,O
novel,O
therapies,O
for,O
COVID-19,O
.,O
COVID‐19,O
pandemic,O
is,O
now,O
rapidly,O
spreading,O
worldwide,O
",",O
notably,O
in,O
Europe,O
and,O
North,O
America,O
where,O
obesity,O
is,O
highly,O
prevalent,O
(,O
10,O
),O
.,O
All,O
patients,O
were,O
diagnosed,O
with,O
COVID‐19,O
pneumonia,O
according,O
to,O
World,O
Health,O
Organization,O
interim,O
guidance,O
(,O
11,O
),O
",",O
with,O
SARS,O
symptoms,O
characterized,O
by,O
dyspnea,O
",",O
increased,O
respiratory,O
frequency,O
",",O
decreased,O
blood,O
oxygen,O
saturation,O
",",O
and,O
need,O
for,O
oxygen,O
support,O
therapy,O
for,O
at,O
least,O
6,O
L,O
/,O
min,O
.,O
The,O
COVID‐19,O
pandemic,O
is,O
rapidly,O
spreading,O
worldwide,O
",",O
notably,O
in,O
Europe,O
and,O
North,O
America,O
where,O
obesity,O
is,O
highly,O
prevalent,O
.,O
As,O
of,O
28,O
January,O
2020,O
",",O
33,O
genomes,O
of,O
2019‐nCoV,O
obtained,O
from,O
humans,O
have,O
been,O
released,O
on,O
GISAID,S-Dataset
 ,O
(,O
http://gisaid.org/,S-URL
),O
.,O
The,O
final,O
dataset,O
(,O
“,O
dataset_32,O
”,O
),O
included,O
32,O
genomes,O
of,O
2019‐nCoV,O
from,O
China,O
(,O
n,O
 ,O
=,O
 ,O
25,O
),O
",",O
Thailand,O
(,O
n,O
 ,O
=,O
 ,O
2,O
),O
",",O
and,O
USA,O
(,O
n,O
 ,O
=,O
 ,O
5,O
),O
",",O
with,O
sampling,O
dates,O
between,O
24,O
December,O
2019,O
and,O
23,O
January,O
2020,O
.,O
For,O
this,O
dataset,O
",",O
the,O
2019‐nCoV,O
genomes,O
were,O
aligned,O
using,O
MAFFT,O
v7.222,O
 ,O
and,O
then,O
manually,O
curated,O
using,O
BioEdit,O
v7.2.5,O
.,O
In,O
addition,O
",",O
we,O
subsampled,O
three,O
other,O
datasets,O
",",O
that,O
is,O
",",O
“,O
dataset_14,O
”,O
collected,O
between,O
24,O
December,O
2019,O
and,O
1,O
January,O
2020,O
",",O
comprising,O
14,O
genomes,O
from,O
Wuhan,O
",",O
Hubei,O
Province,O
",",O
China,O
;,O
“,O
dataset_24,O
”,O
collected,O
between,O
24,O
December,O
2019,O
and,O
18,O
January,O
2020,O
",",O
comprising,O
24,O
genomes,O
from,O
China,O
and,O
Thailand,O
;,O
and,O
“,O
dataset_30,O
”,O
collected,O
between,O
24,O
December,O
2019,O
and,O
23,O
January,O
2020,O
",",O
comprising,O
30,O
genomes,O
from,O
China,O
",",O
Thailand,O
",",O
and,O
USA,O
.,O
To,O
assess,O
the,O
recombination,O
for,O
the,O
full,O
dataset,O
(,O
ie,O
",",O
“,O
dataset_32,O
”,O
),O
",",O
we,O
employed,O
the,O
pairwise,O
homoplasy,O
index,O
(,O
PHI,O
),O
test,O
to,O
measure,O
the,O
similarity,O
between,O
closely,O
linked,O
sites,O
using,O
SplitsTree,O
v4.15.1,O
.,O
The,O
best‐fit,O
nucleotide,O
substitution,O
model,O
for,O
“,O
dataset_32,O
”,O
was,O
identified,O
according,O
to,O
the,O
Akaike,O
information,O
criterion,O
(,O
AIC,O
),O
",",O
small‐sample,O
corrected,O
AIC,O
(,O
AICc,O
),O
",",O
Bayesian,O
information,O
criterion,O
(,O
BIC,O
),O
",",O
and,O
performance‐based,O
decision,O
theory,O
(,O
DT,O
),O
method,O
with,O
3,O
(,O
24,O
candidate,O
models,O
),O
or,O
11,O
(,O
88,O
candidate,O
models,O
),O
substitution,O
schemes,O
in,O
jModelTest,O
v2.1.10,O
.,O
To,O
evaluate,O
the,O
phylogenetic,O
signals,O
of,O
the,O
datasets,O
",",O
we,O
performed,O
likelihood‐mapping,O
analysis,O
 ,O
using,O
TREE‐PUZZLE,O
v5.3,O
",",O
 ,O
with,O
35,O
 ,O
000,O
to,O
80,O
 ,O
000,O
randomly,O
chosen,O
quartets,O
for,O
the,O
four,O
datasets,O
.,O
For,O
each,O
dataset,O
",",O
we,O
employed,O
HKY,O
",",O
as,O
well,O
as,O
a,O
constant,O
size,O
coalescent,O
tree,O
prior,O
and,O
strict,O
molecular,O
clock,O
model,O
to,O
estimate,O
the,O
time,O
to,O
a,O
most,O
recent,O
common,O
ancestor,O
(,O
TMRCA,O
),O
.,O
We,O
then,O
used,O
two,O
schemes,O
to,O
set,O
the,O
time,O
scale,O
prior,O
for,O
each,O
dataset,O
",",O
that,O
is,O
",",O
constrained,O
evolutionary,O
rate,O
method,O
with,O
a,O
lognormal,O
prior,O
(,O
mean,O
 ,O
=,O
 ,O
1.0,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
;,O
95,O
%,O
Bayesian,O
credible,O
interval,O
(,O
BCI,O
):,O
1.854,O
 ,O
×,O
 ,O
10−4‐4,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
),O
placed,O
on,O
the,O
evolutionary,O
rate,O
parameter,O
based,O
on,O
previous,O
studies,O
",",O
 ,O
",",O
  ,O
and,O
the,O
tip‐dating,O
method,O
",",O
for,O
which,O
the,O
evolutionary,O
rate,O
for,O
each,O
dataset,O
was,O
also,O
estimated,O
.,O
The,O
HIV,O
TRAnsmission,O
Cluster,O
Engine,O
(,O
http://www.hivtrace.org,O
),O
 ,O
was,O
employed,O
to,O
infer,O
transmission,O
network,O
clusters,O
for,O
the,O
full,O
dataset,O
(,O
ie,O
",",O
“,O
dataset_32,O
”,O
),O
.,O
For,O
“,O
dataset_32,O
”,O
",",O
the,O
HKY,O
model,O
provided,O
the,O
best,O
fit,O
across,O
the,O
four,O
different,O
methods,O
(,O
ie,O
",",O
AIC,O
",",O
AICc,O
",",O
BIC,O
",",O
and,O
DT,O
),O
and,O
two,O
different,O
substitution,O
schemes,O
(,O
ie,O
",",O
24,O
and,O
88,O
candidate,O
models,O
),O
",",O
and,O
was,O
thus,O
used,O
in,O
subsequent,O
likelihood‐mapping,O
and,O
phylogenetic,O
analyses,O
for,O
the,O
four,O
datasets,O
.,O
The,O
PHI,O
test,O
of,O
“,O
dataset_32,O
”,O
did,O
not,O
find,O
statistically,O
significant,O
evidence,O
for,O
recombination,O
(,O
P,O
 ,O
=,O
 ,O
1.0,O
),O
.,O
Likelihood‐mapping,O
analysis,O
of,O
“,O
dataset_14,O
”,O
revealed,O
that,O
100,O
%,O
of,O
the,O
quartets,O
were,O
distributed,O
in,O
the,O
center,O
of,O
the,O
triangle,O
",",O
indicating,O
a,O
strong,O
star‐like,O
topology,O
signal,O
reflecting,O
a,O
novel,O
virus,O
",",O
which,O
may,O
be,O
due,O
to,O
exponential,O
epidemic,O
spread,O
(,O
Figure,O
 ,O
1A,O
),O
.,O
Likewise,O
",",O
91.9,O
%,O
",",O
81.8,O
%,O
",",O
and,O
74.7,O
%,O
of,O
the,O
quartets,O
from,O
“,O
dataset_24,O
",",O
”,O
“,O
dataset_30,O
",",O
”,O
and,O
“,O
dataset_32,O
",",O
”,O
respectively,O
",",O
were,O
distributed,O
in,O
the,O
center,O
of,O
the,O
triangle,O
",",O
indicating,O
relatively,O
more,O
phylogenetic,O
signals,O
as,O
additional,O
sequences,O
were,O
analyzed,O
over,O
time,O
(,O
Figure,O
 ,O
1B‐D,O
),O
.,O
ML,O
phylogenetic,O
analysis,O
of,O
the,O
four,O
datasets,O
also,O
showed,O
star‐like,O
topologies,O
",",O
in,O
accordance,O
with,O
the,O
likelihood‐mapping,O
results,O
(,O
Figure,O
 ,O
2,O
),O
.,O
Root‐to‐tip,O
regression,O
analyses,O
between,O
genetic,O
divergence,O
and,O
sampling,O
date,O
using,O
the,O
best‐fitting,O
root,O
showed,O
that,O
“,O
dataset_14,O
”,O
had,O
a,O
relatively,O
strong,O
positive,O
temporal,O
signal,O
(,O
R,O
2,O
 ,O
=,O
 ,O
.2967,O
;,O
correlation,O
coefficient,O
 ,O
=,O
 ,O
.5446,O
),O
(,O
Figure,O
 ,O
3A,O
),O
.,O
In,O
contrast,O
",",O
“,O
dataset_24,O
”,O
had,O
a,O
minor,O
negative,O
temporal,O
signal,O
(,O
R,O
2,O
 ,O
=,O
 ,O
4.4428,O
 ,O
×,O
 ,O
10−2,O
;,O
correlation,O
coefficient,O
 ,O
=,O
 ,O
−.2108,O
),O
(,O
Figure,O
 ,O
3B,O
),O
;,O
whereas,O
",",O
“,O
dataset_30,O
”,O
and,O
“,O
dataset_32,O
”,O
both,O
had,O
minor,O
positive,O
temporal,O
signals,O
(,O
R,O
2,O
 ,O
=,O
 ,O
1.2155,O
 ,O
×,O
 ,O
10−2,O
;,O
correlation,O
coefficient,O
 ,O
=,O
 ,O
.1102,O
and,O
R,O
2,O
 ,O
=,O
 ,O
1.1506,O
 ,O
×,O
 ,O
10−2,O
;,O
correlation,O
coefficient,O
 ,O
=,O
 ,O
.1073,O
),O
(,O
Figure,O
 ,O
3C,O
",",O
D,O
),O
.,O
On,O
the,O
basis,O
of,O
Bayesian,O
time‐scaled,O
phylogenetic,O
analysis,O
using,O
the,O
constrained,O
evolutionary,O
rate,O
method,O
with,O
a,O
lognormal,O
prior,O
(,O
mean,O
 ,O
=,O
 ,O
1.0,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
;,O
95,O
%,O
BCI,O
:,O
1.854,O
 ,O
×,O
 ,O
10−4‐4,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
),O
placed,O
on,O
the,O
evolutionary,O
rate,O
parameter,O
",",O
we,O
estimated,O
the,O
TMRCA,O
dates,O
for,O
2019‐nCoV,O
from,O
the,O
four,O
datasets,O
",",O
that,O
is,O
",",O
1,O
November,O
2019,O
(,O
95,O
%,O
BCI,O
:,O
21,O
July,O
2019,O
and,O
29,O
December,O
2019,O
),O
",",O
10,O
November,O
2019,O
(,O
95,O
%,O
BCI,O
:,O
16,O
July,O
2019,O
and,O
16,O
January,O
2020,O
),O
",",O
21,O
October,O
2019,O
(,O
95,O
%,O
BCI,O
:,O
20,O
May,O
2019,O
and,O
19,O
January,O
2020,O
),O
",",O
and,O
15,O
October,O
2019,O
(,O
95,O
%,O
BCI,O
:,O
2,O
May,O
2019,O
and,O
17,O
January,O
2020,O
),O
for,O
“,O
dataset_14,O
",",O
”,O
“,O
dataset_24,O
",",O
”,O
“,O
dataset_30,O
",",O
”,O
and,O
“,O
dataset_32,O
",",O
”,O
respectively,O
(,O
Table,O
 ,O
1,O
),O
.,O
Furthermore,O
",",O
based,O
on,O
Bayesian,O
time‐scaled,O
phylogenetic,O
analysis,O
using,O
the,O
tip‐dating,O
method,O
",",O
we,O
also,O
estimated,O
the,O
TMRCA,O
dates,O
and,O
evolutionary,O
rates,O
from,O
“,O
dataset_30,O
”,O
and,O
“,O
dataset_32,O
",",O
”,O
with,O
resulting,O
showing,O
6,O
December,O
2019,O
(,O
95,O
%,O
BCI,O
:,O
16,O
November,O
2019,O
and,O
22,O
December,O
2019,O
),O
and,O
6,O
December,O
2019,O
(,O
95,O
%,O
BCI,O
:,O
16,O
November,O
2019,O
and,O
21,O
December,O
2019,O
),O
",",O
respectively,O
;,O
and,O
1.7926,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
(,O
95,O
%,O
BCI,O
:,O
7.216,O
 ,O
×,O
 ,O
10−4‐3.0558,O
 ,O
×,O
 ,O
10−3,O
),O
and,O
1.8266,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
(,O
95,O
%,O
BCI,O
:,O
7.5813,O
 ,O
×,O
 ,O
10−4‐3.0883,O
 ,O
×,O
 ,O
10−3,O
),O
",",O
respectively,O
(,O
Table,O
 ,O
1,O
),O
.,O
Due,O
to,O
poor,O
convergence,O
in,O
the,O
MCMC,O
chains,O
",",O
we,O
did,O
not,O
obtain,O
the,O
TMRCA,O
date,O
and,O
evolutionary,O
rate,O
from,O
“,O
dataset_14,O
”,O
and,O
“,O
dataset_24,O
.,O
”,O
This,O
allowed,O
us,O
to,O
identify,O
a,O
single,O
large,O
transmission,O
cluster,O
that,O
included,O
30,O
of,O
32,O
(,O
93.75,O
%,O
),O
genomes,O
",",O
thus,O
suggesting,O
low,O
genetic,O
divergence,O
for,O
“,O
dataset_32,O
”,O
(,O
Figure,O
 ,O
6A,O
),O
.,O
This,O
allowed,O
us,O
to,O
identify,O
three,O
transmission,O
clusters,O
that,O
included,O
15,O
of,O
32,O
(,O
46.875,O
%,O
),O
genomes,O
for,O
“,O
dataset_32,O
”,O
(,O
Figure,O
 ,O
6B,O
),O
.,O
On,O
the,O
basis,O
of,O
“,O
dataset_32,O
",",O
”,O
which,O
included,O
32,O
genomes,O
of,O
2019‐nCoV,O
strains,O
sampled,O
from,O
China,O
(,O
Wuhan,O
",",O
n,O
 ,O
=,O
 ,O
14,O
;,O
Shenzhen,O
",",O
n,O
 ,O
=,O
 ,O
6,O
;,O
Zhuhai,O
",",O
n,O
 ,O
=,O
 ,O
2,O
;,O
Hangzhou,O
",",O
n,O
 ,O
=,O
 ,O
2,O
;,O
Taiwan,O
",",O
n,O
 ,O
=,O
 ,O
1,O
),O
",",O
Thailand,O
(,O
n,O
 ,O
=,O
 ,O
2,O
),O
",",O
and,O
USA,O
(,O
n,O
 ,O
=,O
 ,O
5,O
),O
with,O
sampling,O
dates,O
between,O
24,O
December,O
2019,O
and,O
23,O
January,O
2020,O
",",O
and,O
subsampled,O
“,O
dataset_14,O
",",O
”,O
“,O
dataset_24,O
",",O
”,O
and,O
“,O
dataset_30,O
",",O
”,O
which,O
included,O
14,O
",",O
24,O
",",O
and,O
30,O
2019‐nCoV,O
strain,O
genomes,O
",",O
respectively,O
",",O
our,O
likelihood‐mapping,O
analysis,O
confirmed,O
additional,O
tree‐like,O
signals,O
(,O
from,O
0,O
%,O
to,O
8.2,O
%,O
",",O
18.2,O
%,O
",",O
and,O
25.4,O
%,O
),O
over,O
time,O
",",O
thus,O
indicating,O
increasing,O
genetic,O
divergence,O
of,O
2019‐nCoV,O
in,O
human,O
hosts,O
(,O
Figure,O
 ,O
1,O
),O
.,O
Of,O
note,O
",",O
the,O
strong,O
star‐like,O
signal,O
(,O
100,O
%,O
of,O
quartets,O
were,O
distributed,O
in,O
the,O
center,O
of,O
the,O
triangle,O
),O
from,O
“,O
dataset_14,O
”,O
at,O
the,O
beginning,O
of,O
the,O
virus,O
outbreak,O
suggests,O
that,O
2019‐nCoV,O
initially,O
exhibited,O
low,O
genetic,O
divergence,O
",",O
with,O
recent,O
and,O
rapid,O
human‐to‐human,O
transmission,O
.,O
This,O
result,O
is,O
consistent,O
with,O
the,O
ML,O
phylogenetic,O
analyses,O
",",O
which,O
showed,O
polytomy,O
topology,O
from,O
“,O
dataset_14,O
”,O
(,O
Figure,O
 ,O
2A,O
),O
.,O
The,O
genetic,O
divergence,O
from,O
“,O
dataset_32,O
”,O
and,O
“,O
dataset_30,O
”,O
was,O
higher,O
than,O
that,O
for,O
“,O
dataset_14,O
",",O
”,O
but,O
still,O
demonstrated,O
minor,O
temporal,O
signals,O
(,O
Figure,O
 ,O
3,O
),O
.,O
Using,O
the,O
constrained,O
evolutionary,O
rate,O
method,O
",",O
the,O
mean,O
TMRCA,O
dates,O
for,O
2019‐nCoV,O
based,O
on,O
the,O
four,O
datasets,O
ranged,O
from,O
15,O
October,O
to,O
10,O
November,O
2019,O
",",O
when,O
using,O
a,O
lognormal,O
prior,O
(,O
mean,O
 ,O
=,O
 ,O
1.0,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
;,O
95,O
%,O
BCI,O
:,O
1.854,O
 ,O
×,O
 ,O
10−4‐4,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
),O
placed,O
on,O
the,O
evolutionary,O
rate,O
parameter,O
(,O
Table,O
 ,O
1,O
),O
.,O
Using,O
the,O
tip‐dating,O
method,O
",",O
the,O
mean,O
TMRCA,O
date,O
and,O
evolutionary,O
rate,O
for,O
2019‐nCoV,O
based,O
on,O
the,O
“,O
dataset_30,O
”,O
and,O
“,O
dataset_32,O
”,O
ranged,O
from,O
16,O
November,O
to,O
22,O
December,O
2019,O
and,O
from,O
1.7926,O
 ,O
×,O
 ,O
10−3,O
to,O
1.8266,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
",",O
respectively,O
(,O
Table,O
 ,O
1,O
),O
.,O
The,O
X‐ray,O
diffraction,O
experiments,O
were,O
carried,O
out,O
at,O
the,O
Structural,O
Biology,O
Center,O
19‐ID,O
beamline,O
at,O
the,O
Advanced,O
Photon,O
Source,O
",",O
Argonne,O
National,O
Laboratory,O
.,O
The,O
data,O
set,O
was,O
processed,O
and,O
scaled,O
with,O
the,O
HKL3000,O
suite,O
.,O
The,O
atomic,O
coordinates,O
and,O
structure,O
factors,O
have,O
been,O
deposited,O
in,O
the,O
PDB,S-Repository
 ,O
under,O
accession,O
code,O
6VWW,S-AccessionNumber
 ,O
and,O
6W01,S-AccessionNumber
 ,O
for,O
Nsp15,O
/,O
apo,O
and,O
Nsp15,O
/,O
cit,O
",",O
respectively,O
.,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
has,O
caused,O
an,O
outbreak,O
in,O
China,O
and,O
is,O
spreading,O
worldwide,O
[,O
1,O
],O
.,O
As,O
a,O
result,O
",",O
South,O
Korea,O
could,O
swiftly,O
approve,O
its,O
first,O
real,O
-,O
time,O
reverse,O
transcription,O
(,O
RT,O
),O
PCR,O
kit,O
for,O
COVID-19,O
testing,O
on,O
February,O
4,O
",",O
2020,O
[,O
4,O
],O
",",O
following,O
the,O
country,O
’s,O
first,O
reported,O
case,O
of,O
COVID-19,O
on,O
January,O
20,O
",",O
2020,O
[,O
5,O
],O
.,O
This,O
issue,O
of,O
Ann,O
Lab,O
Med,O
presents,O
the,O
guidelines,O
for,O
the,O
laboratory,O
diagnosis,O
of,O
COVID-19,O
",",O
which,O
is,O
followed,O
in,O
clinical,O
laboratories,O
in,O
South,O
Korea,O
[,O
6,O
],O
.,O
As,O
local,O
communities,O
continue,O
to,O
be,O
at,O
risk,O
of,O
the,O
virus,O
spread,O
",",O
on,O
February,O
23,O
2020,O
",",O
South,O
Korea,O
raised,O
its,O
national,O
infectious,O
disease,O
alert,O
to,O
the,O
highest,O
level,O
and,O
further,O
mobilized,O
its,O
resources,O
to,O
prevent,O
the,O
spread,O
of,O
COVID-19,O
[,O
7,O
],O
.,O
A,O
vast,O
number,O
of,O
real,O
-,O
time,O
RT,O
PCR,O
testing,O
is,O
being,O
carried,O
out,O
thanks,O
to,O
the,O
timely,O
implementation,O
of,O
EUA,O
;,O
however,O
",",O
the,O
country,O
’s,O
diagnostic,O
capacity,O
requires,O
further,O
improvement,O
such,O
as,O
addressing,O
the,O
need,O
to,O
shorten,O
the,O
6,O
-,O
hr,O
turnaround,O
time,O
for,O
testing,O
in,O
situations,O
such,O
as,O
the,O
current,O
COVID-19,O
crisis,O
.,O
To,O
reduce,O
the,O
spread,O
of,O
COVID-19,O
",",O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
has,O
opened,O
its,O
Emergency,O
Use,O
Listing,O
procedure,O
for,O
new,O
submissions,O
;,O
as,O
of,O
February,O
12,O
",",O
2020,O
",",O
220,O
IVDs,O
have,O
been,O
listed,O
that,O
will,O
be,O
evaluated,O
for,O
analytical,O
sensitivity,O
.,O
The,O
Xpert,O
Xpress,O
SARS,O
-,O
CoV-2,O
(,O
Cepheid,O
",",O
Sunnyvale,O
",",O
CA,O
),O
and,O
BioFire,O
COVID-19,O
Test,O
(,O
BioFire,O
Diagnostics,O
",",O
Salt,O
Lake,O
City,O
",",O
UT,O
),O
",",O
which,O
can,O
be,O
tested,O
within,O
45,O
minutes,O
",",O
received,O
EUA,O
from,O
the,O
United,O
States,O
FDA,O
as,O
of,O
March,O
23,O
",",O
2020,O
[,O
9,O
],O
.,O
The,O
first,O
case,O
of,O
COVID-19,O
in,O
South,O
America,O
was,O
reported,O
in,O
Brazil,O
on,O
February,O
26,O
",",O
in,O
a,O
61,O
 ,O
years,O
old,O
man,O
traveling,O
from,O
Italy,O
(,O
gob.br,O
",",O
2020,O
),O
.,O
In,O
Colombia,O
",",O
the,O
first,O
case,O
of,O
COVID-19,O
was,O
announced,O
on,O
March,O
6,O
",",O
in,O
a,O
traveler,O
from,O
Italy,O
",",O
after,O
which,O
the,O
number,O
of,O
patients,O
has,O
exceeded,O
"43,000",O
and,O
over,O
1500,O
deaths,O
(,O
INS,O
",",O
2020,O
),O
.,O
Both,O
N,O
and,O
S,O
proteins,O
are,O
highly,O
immunogenic,O
and,O
most,O
commercial,O
COVID-19,O
diagnostic,O
tests,O
(,O
molecular,O
and,O
immunologic,O
),O
target,O
these,O
proteins,O
(,O
Álvarez,O
-,O
Díaz,O
et,O
al,O
.,O
",",O
2020,O
;,O
Lee,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Furthermore,O
",",O
non,O
-,O
synonymous,O
mutations,O
in,O
the,O
S,O
and,O
N,O
proteins,O
have,O
been,O
reported,O
",",O
their,O
implications,O
in,O
the,O
potential,O
emergence,O
of,O
antigenically,O
distinct,O
and/or,O
more,O
virulent,O
strains,O
remain,O
to,O
be,O
studied,O
",",O
although,O
it,O
was,O
reported,O
that,O
mutations,O
in,O
the,O
receptor,O
-,O
binding,O
domain,O
(,O
RBD,O
),O
at,O
the,O
S,O
protein,O
of,O
SARS,O
-,O
CoV,O
related,O
viruses,O
disrupt,O
the,O
antigenic,O
structure,O
and,O
binding,O
activity,O
of,O
RBD,O
to,O
ACE2,O
(,O
Du,O
et,O
al,O
.,O
",",O
2009,O
),O
Similarly,O
",",O
non,O
-,O
synonymous,O
mutations,O
could,O
impact,O
the,O
antibody,O
response,O
and,O
the,O
specificity,O
and,O
sensitivity,O
of,O
serological,O
tests,O
for,O
COVID-19,O
diagnosis,O
is,O
unknown,O
.,O
Reads,O
were,O
mapped,O
to,O
the,O
Wuhan,O
-,O
Hu-1,O
reference,O
genome,O
(,O
NC_045512.2,S-AccessionNumber
),O
using,O
BWA,O
(,O
Li,O
et,O
al,O
.,O
",",O
2020,O
),O
and,O
BBmap,O
(,O
brian,O
-,O
jgi,O
",",O
2020,O
),O
;,O
then,O
",",O
assembled,O
consensus,O
sequences,O
were,O
submitted,O
to,O
GISAID,S-Dataset
.,O
Subsequently,O
",",O
461,O
SARS,O
-,O
CoV-2,O
sequences,O
from,O
South,O
American,O
countries,O
",",O
including,O
Argentina,O
",",O
Brazil,O
",",O
Ecuador,O
",",O
Peru,O
",",O
Uruguay,O
and,O
other,O
sequences,O
from,O
Colombia,O
available,O
on,O
the,O
GISAID,S-Dataset
",",O
NCBI,S-Repository
",",O
and,O
GSA,S-Repository
 ,O
databases,O
were,O
analyzed,O
(,O
Supplementary,O
Table,O
S1,O
",",O
and,O
Supplementary,O
Table,O
S2,O
),O
.,O
The,O
first,O
COVID-19,O
case,O
in,O
Colombia,O
was,O
confirmed,O
on,O
March,O
6,O
",",O
2020,O
",",O
from,O
a,O
traveler,O
who,O
entered,O
the,O
country,O
from,O
Italy,O
on,O
February,O
26,O
",",O
2020,O
(,O
EPI_ISL_418262,S-AccessionNumber
),O
.,O
SARS,O
-,O
CoV-2,O
is,O
a,O
new,O
member,O
of,O
the,O
genus,O
Betacoronavirus,O
",",O
responsible,O
for,O
the,O
COVID-19,O
pandemic,O
.,O
The,O
Nucleocapsid,O
(,O
N,O
),O
and,O
Spike,O
(,O
S,O
),O
are,O
highly,O
immunogenic,O
structural,O
proteins,O
and,O
most,O
commercial,O
COVID-19,O
diagnostic,O
assays,O
target,O
these,O
proteins,O
.,O
We,O
used,O
a,O
large,O
database,O
of,O
HLA,O
allele,O
frequencies,O
in,O
world,O
populations,O
(,O
with,O
alleles,O
defined,O
at,O
the,O
second‐field,O
level,O
of,O
resolution,O
",",O
third,O
and,O
fourth‐field,O
levels,O
being,O
recoded,O
to,O
second‐field,O
),O
including,O
data,O
from,O
both,O
the,O
literature,O
(,O
1992‐2017,O
),O
and,O
reports,O
of,O
the,O
11th,O
to,O
16th,O
International,O
HLA,O
and,O
Immunogenetics,O
Workshops,O
(,O
IHIWs,O
),O
.,O
For,O
each,O
of,O
the,O
different,O
loci,O
(,O
HLA‐A,O
",",O
‐B,O
",",O
‐C,O
",",O
‐DRB1,O
",",O
‐DQA1,O
and,O
‐DQB1,O
),O
",",O
the,O
dataset,O
comprises,O
between,O
158,O
and,O
374,O
typed,O
samples,O
",",O
classified,O
according,O
to,O
the,O
hla‐net.eu,O
guidelines,O
",",O
 ,O
into,O
10,O
sub‐continental,O
regions,O
",",O
that,O
is,O
",",O
Sub‐Saharan,O
Africa,O
(,O
SAF,O
),O
",",O
North,O
Africa,O
(,O
NAF,O
),O
",",O
Europe,O
(,O
EUR,O
),O
",",O
South‐West,O
Asia,O
(,O
SWA,O
),O
",",O
North‐East,O
Asia,O
(,O
NEA,O
),O
",",O
South‐East,O
Asia,O
(,O
SEA,O
),O
",",O
Australia,O
(,O
AUS,O
),O
",",O
Oceania,O
(,O
OCE,O
),O
",",O
North,O
America,O
(,O
NAM,O
),O
and,O
South,O
America,O
(,O
SAM,O
),O
.,O
All,O
HLA‐A,O
",",O
‐B,O
",",O
‐C,O
",",O
and,O
‐DRB1,O
alleles,O
that,O
were,O
observed,O
in,O
at,O
least,O
five,O
populations,O
worldwide,O
(,O
according,O
to,O
our,O
database,O
of,O
allele,O
frequencies,O
),O
",",O
that,O
is,O
92,O
HLA‐A,O
",",O
164,O
HLA‐B,O
",",O
55,O
HLA‐C,O
and,O
94,O
HLA‐DRB1,O
were,O
selected,O
to,O
assess,O
the,O
peptide‐binding,O
affinity,O
of,O
their,O
corresponding,O
proteins,O
HLA‐A,O
",",O
HLA‐B,O
",",O
HLA‐C,O
and,O
HLA‐DR,O
",",O
respectively,O
",",O
the,O
latter,O
representing,O
the,O
HLA‐DRA,O
/,O
DRB1,O
dimer,O
as,O
HLA‐DRA,O
is,O
here,O
considered,O
monomorphic,O
.,O
A,O
single,O
model,O
including,O
binding,O
kind,O
as,O
a,O
third,O
predictor,O
was,O
considered,O
and,O
provided,O
similar,O
results,O
but,O
",",O
because,O
three‐way,O
interactions,O
were,O
necessary,O
to,O
report,O
the,O
model,O
",",O
we,O
preferred,O
splitting,O
the,O
data,O
set,O
according,O
to,O
binding,O
kind,O
to,O
simplify,O
the,O
presentation,O
of,O
results,O
.,O
However,O
",",O
a,O
recent,O
meta,O
-,O
analysis,O
of,O
six,O
clinical,O
studies,O
involving,O
"1,687",O
COVID-19,O
patients,O
provided,O
evidence,O
that,O
individuals,O
with,O
diabetes,O
exhibited,O
a,O
similar,O
prevalence,O
of,O
being,O
infected,O
with,O
SARS,O
-,O
CoV-2,O
as,O
the,O
overall,O
population,O
",",O
but,O
presence,O
of,O
diabetes,O
was,O
a,O
critical,O
comorbidity,O
that,O
increased,O
the,O
risk,O
of,O
a,O
poor,O
outcome,O
(,O
4,O
),O
.,O
Certain,O
racial,O
groups,O
such,O
as,O
African,O
Americans,O
and,O
Native,O
Americans,O
are,O
highly,O
prone,O
to,O
developing,O
diabetes,O
and,O
experience,O
disparities,O
in,O
health,O
care,O
making,O
them,O
particularly,O
vulnerable,O
to,O
COVID-19,O
(,O
5,O
),O
.,O
However,O
",",O
to,O
date,O
there,O
is,O
a,O
paucity,O
of,O
data,O
regarding,O
comorbidities,O
",",O
COVID-19,O
outcomes,O
",",O
and,O
mechanisms,O
that,O
modulate,O
viral,O
pathogenesis,O
.,O
In,O
this,O
Perspective,O
",",O
we,O
bring,O
attention,O
to,O
specific,O
factors,O
that,O
may,O
complicate,O
COVID-19,O
in,O
individuals,O
with,O
diabetes,O
including,O
1,O
),O
the,O
presence,O
of,O
bone,O
marrow,O
changes,O
(,O
myeloidosis,O
),O
that,O
predispose,O
those,O
with,O
diabetes,O
to,O
an,O
excessive,O
proinflammatory,O
response,O
(,O
cytokine,O
storm,O
),O
and,O
contribute,O
to,O
insulin,O
resistance,O
and,O
reduced,O
vascular,O
repair,O
",",O
and,O
worsening,O
function,O
of,O
the,O
heart,O
",",O
kidney,O
",",O
and,O
systemic,O
vasculature,O
as,O
a,O
whole,O
;,O
2,O
),O
increased,O
circulating,O
furin,O
levels,O
that,O
could,O
cleave,O
the,O
spike,O
protein,O
and,O
increase,O
infectivity,O
of,O
SARS,O
-,O
CoV-2,O
;,O
3,O
),O
dysregulated,O
autophagy,O
that,O
may,O
promote,O
replication,O
and/or,O
reduce,O
viral,O
clearance,O
;,O
and,O
4,O
),O
gut,O
dysbiosis,O
that,O
leads,O
to,O
widespread,O
systemic,O
inflammation,O
",",O
increased,O
gut,O
glucose,O
and,O
sodium,O
absorption,O
",",O
and,O
reduced,O
tryptophan,O
and,O
other,O
key,O
amino,O
acid,O
absorption,O
needed,O
for,O
incretin,O
secretion,O
and,O
glucose,O
homeostasis,O
.,O
Central,O
to,O
each,O
of,O
these,O
dysfunctions,O
is,O
the,O
dysregulated,O
RAS,O
",",O
in,O
particular,O
",",O
the,O
global,O
loss,O
of,O
ACE2,O
",",O
which,O
we,O
propose,O
is,O
a,O
unifying,O
mechanism,O
that,O
could,O
lead,O
to,O
the,O
increased,O
risk,O
of,O
morbidity,O
and,O
mortality,O
in,O
individuals,O
with,O
diabetes,O
presenting,O
with,O
COVID-19,O
.,O
Notably,O
",",O
COVID-19,O
patients,O
exhibit,O
increased,O
serum,O
levels,O
of,O
Ang,O
-,O
II,O
(,O
6,O
),O
",",O
which,O
would,O
support,O
less,O
cleavage,O
by,O
ACE2,O
and,O
thus,O
potentially,O
less,O
ACE2,O
activity,O
.,O
Emerging,O
COVID-19,O
gastrointestinal,O
disturbances,O
implicate,O
a,O
central,O
role,O
of,O
intestinal,O
pathophysiology,O
in,O
exacerbation,O
of,O
hyperglycemia,O
and,O
blood,O
pressure,O
in,O
individuals,O
with,O
diabetes,O
infected,O
with,O
SARS,O
-,O
CoV-2,O
.,O
ACE2,O
was,O
discovered,O
in,O
2000,O
(,O
7,O
),O
",",O
just,O
2–3,O
years,O
before,O
the,O
first,O
wave,O
of,O
SARS,O
-,O
CoV,O
coronavirus,O
pandemic,O
",",O
when,O
ACE2,O
was,O
identified,O
as,O
the,O
major,O
SARS,O
-,O
CoV,O
“,O
receptor,O
”,O
on,O
host,O
cells,O
.,O
The,O
structure,O
of,O
the,O
hACE2,O
was,O
replotted,O
from,O
pdb,O
ID,O
:,O
1R42,O
(,O
50,O
),O
.,O
The,O
structure,O
of,O
the,O
hACE2,O
bound,O
to,O
SARS,O
-,O
CoV-2,O
receptor,O
binding,O
domain,O
(,O
RBD,O
),O
was,O
replotted,O
from,O
pdb,S-Repository
 ,O
ID,O
:,O
6M0J,S-AccessionNumber
 ,O
(,O
19,O
),O
.,O
High,O
hACE2,O
expression,O
in,O
the,O
nasal,O
epithelium,O
is,O
consistent,O
with,O
clinical,O
observations,O
that,O
symptomatic,O
individuals,O
with,O
COVID-19,O
present,O
with,O
a,O
higher,O
viral,O
load,O
in,O
the,O
nasal,O
cavity,O
compared,O
with,O
the,O
throat,O
(,O
10,O
),O
and,O
that,O
some,O
COVID-19,O
patients,O
complain,O
of,O
inability,O
to,O
smell,O
(,O
13,O
),O
.,O
The,O
hACE2,O
-,O
expressing,O
nasal,O
epithelium,O
may,O
provide,O
an,O
“,O
intermediate,O
site,O
”,O
for,O
viral,O
replication,O
before,O
its,O
invasion,O
of,O
the,O
lungs,O
to,O
cause,O
symptomatic,O
COVID-19,O
and,O
may,O
serve,O
as,O
a,O
sanctuary,O
niche,O
for,O
SARS,O
-,O
CoV-2,O
survival,O
without,O
spreading,O
to,O
the,O
lungs,O
in,O
human,O
subjects,O
",",O
thus,O
perhaps,O
permitting,O
asymptomatic,O
human,O
-,O
to,O
-,O
human,O
transmission,O
.,O
The,O
structure,O
of,O
the,O
homotrimeric,O
SARS,O
-,O
CoV-2,O
spike,O
protein,O
complex,O
was,O
replotted,O
from,O
pdb,S-Repository
 ,O
ID,O
:,O
6VYB,S-AccessionNumber
 ,O
(,O
15,O
),O
.,O
As,O
COVID-19,O
progresses,O
",",O
SARS,O
-,O
CoV-2,O
may,O
also,O
involve,O
the,O
lytic,O
release,O
pathway,O
for,O
newly,O
produced,O
viral,O
particles,O
",",O
bypassing,O
the,O
budding,O
process,O
utilizing,O
the,O
furin,O
-,O
containing,O
Golgi,O
compartments,O
(,O
Fig,O
.,O
4,O
),O
.,O
At,O
this,O
stage,O
of,O
COVID-19,O
",",O
extracellular,O
furin,O
may,O
be,O
utilized,O
to,O
complete,O
the,O
cleavage,O
of,O
spike,O
protein,O
’s,O
furin,O
cleavage,O
sites,O
",",O
facilitating,O
the,O
virus,O
spread,O
in,O
the,O
infected,O
host,O
.,O
Additionally,O
",",O
nonstructural,O
protein,O
6,O
(,O
nsp6,O
),O
of,O
SARS,O
-,O
CoV-2,O
can,O
generate,O
autophagosomes,O
",",O
and,O
an,O
associated,O
mutation,O
in,O
nsp6,O
is,O
identified,O
in,O
COVID-19,O
patients,O
(,O
"4,24",O
),O
.,O
Given,O
the,O
strong,O
association,O
between,O
the,O
RAS,O
and,O
autophagy,O
",",O
both,O
may,O
serve,O
as,O
therapeutic,O
targets,O
to,O
ablate,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
replication,O
",",O
and,O
this,O
may,O
further,O
explain,O
the,O
possible,O
beneficial,O
effects,O
of,O
ACE,O
inhibitors,O
/,O
ATR,O
blockers,O
in,O
the,O
treatment,O
of,O
COVID-19,O
",",O
discussed,O
further,O
below,O
.,O
Several,O
mechanisms,O
may,O
contribute,O
to,O
increased,O
severity,O
of,O
COVID-19,O
progression,O
in,O
subjects,O
with,O
diabetes,O
.,O
Diabetes,O
-,O
associated,O
bone,O
marrow,O
dysfunction,O
and,O
loss,O
of,O
vascular,O
reparative,O
cells,O
",",O
such,O
as,O
CACs,O
",",O
may,O
contribute,O
to,O
vascular,O
dysfunction,O
in,O
COVID-19,O
patients,O
that,O
can,O
be,O
manifested,O
as,O
cardiac,O
disease,O
including,O
arrhythmias,O
",",O
viral,O
myocarditis,O
",",O
heart,O
failure,O
",",O
and,O
cardiac,O
arrest,O
(,O
34–36,O
),O
.,O
In,O
COVID-19,O
patients,O
",",O
the,O
prevalence,O
of,O
kidney,O
disease,O
on,O
admission,O
and,O
the,O
development,O
of,O
acute,O
kidney,O
injury,O
during,O
hospitalization,O
is,O
high,O
and,O
associated,O
with,O
in,O
-,O
hospital,O
mortality,O
(,O
37,O
),O
.,O
The,O
loss,O
of,O
ACE2,O
via,O
ADAM17,O
proteolytic,O
cleavage,O
",",O
which,O
is,O
strongly,O
activated,O
in,O
COVID-19,O
patients,O
",",O
will,O
likely,O
promote,O
further,O
injury,O
to,O
the,O
cardiovascular,O
system,O
and,O
kidneys,O
in,O
patients,O
with,O
diabetes,O
(,O
"7,38",O
),O
.,O
While,O
the,O
lung,O
is,O
not,O
considered,O
a,O
target,O
tissue,O
for,O
diabetic,O
complications,O
",",O
COVID-19,O
patients,O
with,O
diabetes,O
experience,O
worse,O
pulmonary,O
disease,O
than,O
those,O
without,O
diabetes,O
.,O
ARDS,O
triggers,O
multiple,O
pulmonary,O
diseases,O
and,O
is,O
observed,O
in,O
COVID-19,O
patients,O
.,O
The,O
recent,O
demonstration,O
of,O
SARS,O
-,O
CoV-2,O
actively,O
infecting,O
human,O
enterocytes,O
and,O
the,O
mounting,O
gastrointestinal,O
symptomology,O
implicate,O
gastrointestinal,O
tract,O
pathophysiology,O
in,O
COVID-19,O
infection,O
(,O
"12,39",O
),O
.,O
Data,O
coordinates,O
were,O
obtained,O
from,O
pdb,S-Repository
 ,O
ID,O
:,O
6M17,S-AccessionNumber
 ,O
(,O
18,O
),O
.,O
In,O
the,O
patient,O
with,O
diabetes,O
infected,O
with,O
COVID-19,O
",",O
developing,O
pneumonia,O
can,O
be,O
devastating,O
",",O
as,O
preexisting,O
systemic,O
inflammation,O
can,O
rapidly,O
lead,O
to,O
multiple,O
organ,O
failure,O
.,O
Inflammatory,O
cytokine,O
storm,O
is,O
a,O
notable,O
cause,O
of,O
death,O
in,O
critically,O
ill,O
COVID-19,O
patients,O
and,O
may,O
be,O
driven,O
as,O
much,O
by,O
gut,O
-,O
induced,O
inflammation,O
as,O
lung,O
injury,O
.,O
These,O
results,O
provide,O
proof,O
of,O
concept,O
for,O
feasibility,O
of,O
using,O
engineered,O
probiotic,O
species,O
as,O
a,O
live,O
vector,O
for,O
delivery,O
of,O
decoy,O
hACE2,O
for,O
possible,O
treatment,O
of,O
enteric,O
COVID-19,O
infection,O
.,O
Collectively,O
",",O
these,O
results,O
show,O
that,O
DIZE,O
downregulates,O
proinflammatory,O
cytokine,O
production,O
by,O
many,O
distinct,O
cell,O
types,O
and,O
suggest,O
that,O
this,O
drug,O
may,O
provide,O
benefit,O
to,O
COVID-19,O
patients,O
by,O
reducing,O
pulmonary,O
inflammation,O
and,O
fibrosis,O
",",O
gut,O
inflammation,O
",",O
and,O
cytokine,O
storm,O
.,O
Individuals,O
with,O
diabetes,O
suffering,O
from,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
exhibit,O
increased,O
morbidity,O
and,O
mortality,O
compared,O
with,O
individuals,O
without,O
diabetes,O
.,O
We,O
put,O
forth,O
the,O
hypothesis,O
that,O
during,O
this,O
process,O
",",O
reduced,O
ACE2,O
could,O
result,O
in,O
clinical,O
deterioration,O
in,O
COVID-19,O
patients,O
with,O
diabetes,O
via,O
aggravating,O
Ang,O
-,O
II,O
–,O
dependent,O
pathways,O
and,O
partly,O
driving,O
not,O
only,O
lung,O
but,O
also,O
bone,O
marrow,O
and,O
gastrointestinal,O
pathology,O
.,O
A,O
global,O
pandemic,O
of,O
the,O
coronavirus,O
disease,O
COVID-19,O
",",O
a,O
severe,O
respiratory,O
illness,O
caused,O
by,O
a,O
novel,O
virus,O
from,O
the,O
family,O
Coronaviridae,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
has,O
infected,O
millions,O
and,O
caused,O
hundreds,O
of,O
thousands,O
of,O
deaths,O
(,O
World,O
Health,O
Organization,O
2020a,O
),O
.,O
COVID-19,O
manifestation,O
in,O
patients,O
can,O
range,O
from,O
a,O
lack,O
of,O
symptoms,O
to,O
severe,O
pneumonia,O
and,O
death,O
(,O
Huang,O
),O
.,O
Despite,O
these,O
measures,O
",",O
the,O
number,O
of,O
confirmed,O
COVID-19,O
cases,O
has,O
continued,O
to,O
rise,O
(,O
World,O
Health,O
Organization,O
2020a,O
),O
",",O
highlighting,O
the,O
need,O
for,O
an,O
effective,O
vaccine,O
and,O
antiviral,O
agents,O
.,O
Synthesized,O
viral,O
coding,O
sequences,O
were,O
incorporated,O
into,O
Gateway,O
Entry,O
plasmids,O
:,O
either,O
pDONR207,O
(,O
Invitrogen,O
Cat,O
#,O
12213013,O
),O
or,O
pDONR223,O
(,O
Rual,O
),O
.,O
These,O
clones,O
were,O
made,O
by,O
either,O
PCR,O
-,O
amplifying,O
the,O
whole,O
plasmid,O
with,O
primers,O
that,O
eliminated,O
the,O
stop,O
codon,O
",",O
or,O
by,O
amplifying,O
CDS,O
regions,O
from,O
the,O
first,O
collection,O
",",O
using,O
downstream,O
primers,O
with,O
complementary,O
regions,O
that,O
were,O
internal,O
to,O
each,O
stop,O
codon,O
",",O
and,O
which,O
simultaneously,O
incorporated,O
the,O
flanking,O
sequences,O
necessary,O
for,O
incorporation,O
into,O
a,O
Gateway,O
Entry,O
plasmid,O
[,O
pDONR207,O
",",O
pDONR221,O
(,O
Invitrogen,O
Cat,O
#,O
12536017,O
),O
or,O
pDONR223,O
],O
.,O
The,O
world,O
is,O
facing,O
a,O
global,O
pandemic,O
of,O
COVID-19,O
caused,O
by,O
the,O
SARS,O
-,O
CoV-2,O
coronavirus,O
.,O
Since,O
its,O
emergence,O
",",O
the,O
2019,O
strain,O
of,O
coronavirus,O
(,O
hereafter,O
COVID-19,O
),O
has,O
been,O
a,O
rising,O
international,O
cause,O
of,O
morbidity,O
and,O
mortality,O
.,O
This,O
global,O
devastation,O
is,O
partly,O
explained,O
by,O
the,O
nature,O
of,O
viral,O
transmission,O
;,O
the,O
median,O
incubation,O
time,O
from,O
COVID-19,O
infection,O
to,O
the,O
appearance,O
of,O
symptomatic,O
dyspnea,O
ranges,O
from,O
four,O
to,O
seven,O
days,O
",",O
creating,O
a,O
large,O
window,O
of,O
time,O
for,O
transmission,O
during,O
which,O
patients,O
have,O
few,O
symptoms,O
(,O
Guan,O
et,O
al,O
.,O
",",O
2020,O
;,O
Huang,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Almost,O
all,O
COVID-19,O
patients,O
who,O
develop,O
ARDS,O
require,O
mechanical,O
ventilation,O
;,O
these,O
patients,O
tend,O
to,O
remain,O
ventilator,O
dependent,O
for,O
10–14,O
d,O
",",O
and,O
most,O
ventilated,O
patients,O
ultimately,O
succumb,O
to,O
the,O
disease,O
(,O
Bhatraju,O
et,O
al,O
.,O
",",O
2020,O
;,O
Wu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
There,O
is,O
a,O
compelling,O
case,O
for,O
innate,O
immune,O
hyperactivity,O
in,O
driving,O
the,O
acute,O
lung,O
injury,O
that,O
defines,O
severe,O
COVID-19,O
infections,O
.,O
Both,O
DAMPs,O
and,O
PAMPs,O
are,O
likely,O
generated,O
during,O
initial,O
infection,O
and,O
lysis,O
of,O
pneumocytes,O
by,O
COVID-19,O
.,O
Significant,O
evidence,O
indicates,O
that,O
a,O
dysregulated,O
innate,O
immune,O
response,O
contributes,O
to,O
the,O
clinical,O
presentation,O
of,O
patients,O
with,O
severe,O
COVID-19,O
infections,O
.,O
COVID-19,O
–,O
infected,O
patients,O
harbor,O
an,O
expanded,O
population,O
of,O
circulating,O
monocytes,O
that,O
secrete,O
both,O
IL-6,O
and,O
IL-1β,O
(,O
Wen,O
et,O
al,O
.,O
",",O
2020,O
Preprint,O
;,O
Zhang,O
et,O
al,O
.,O
",",O
2020,O
Preprint,O
),O
;,O
as,O
a,O
result,O
",",O
patients,O
with,O
COVID-19,O
have,O
elevated,O
levels,O
of,O
serum,O
IL-6,O
",",O
as,O
well,O
as,O
lactate,O
dehydrogenase,O
levels,O
",",O
compared,O
with,O
healthy,O
controls,O
(,O
Chen,O
et,O
al,O
.,O
",",O
2020a,O
),O
.,O
These,O
elevations,O
in,O
innate,O
immune,O
cytokines,O
have,O
led,O
to,O
the,O
hypothesis,O
that,O
an,O
innate,O
immune,O
-,O
mediated,O
“,O
cytokine,O
storm,O
",",O
”,O
similar,O
to,O
the,O
cytokine,O
release,O
syndrome,O
(,O
CRS,O
),O
observed,O
in,O
patients,O
receiving,O
treatment,O
with,O
chimeric,O
antigen,O
receptor,O
–,O
transduced,O
T,O
cells,O
(,O
CAR,O
-,O
T,O
),O
",",O
is,O
primarily,O
responsible,O
for,O
the,O
toxicity,O
and,O
end,O
-,O
organ,O
damage,O
mediated,O
by,O
COVID-19,O
infections,O
(,O
Grupp,O
et,O
al,O
.,O
",",O
2013,O
;,O
Mehta,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
A,O
role,O
for,O
cytokine,O
-,O
driven,O
neutrophil,O
mobilization,O
in,O
COVID,O
-,O
associated,O
lung,O
toxicity,O
may,O
explain,O
why,O
neutrophilia,O
",",O
despite,O
the,O
absence,O
of,O
secondary,O
bacterial,O
infections,O
",",O
is,O
associated,O
with,O
mortality,O
(,O
Lagunas,O
-,O
Rangel,O
",",O
2020,O
),O
",",O
and,O
why,O
administration,O
of,O
monoclonal,O
antibodies,O
targeting,O
IL-6,O
has,O
shown,O
initial,O
clinical,O
promise,O
(,O
Gritti,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
However,O
",",O
caution,O
is,O
warranted,O
before,O
invoking,O
IL-6,O
–,O
mediated,O
CRS,O
as,O
the,O
sole,O
pathological,O
driver,O
in,O
severe,O
COVID-19,O
infections,O
.,O
First,O
",",O
COVID-19,O
patients,O
lacks,O
most,O
of,O
the,O
hallmarks,O
of,O
CRS,O
",",O
including,O
hypotension,O
",",O
capillary,O
leak,O
syndrome,O
",",O
and,O
neurotoxicity,O
(,O
Hay,O
et,O
al,O
.,O
",",O
2017,O
),O
.,O
Second,O
",",O
the,O
clinical,O
course,O
of,O
CRS,O
is,O
far,O
more,O
acute,O
than,O
that,O
seen,O
in,O
COVID-19,O
infections,O
",",O
with,O
fever,O
occurring,O
within,O
2,O
d,O
and,O
neurotoxicity,O
within,O
5,O
d,O
(,O
Neelapu,O
et,O
al,O
.,O
",",O
2018,O
),O
.,O
Accordingly,O
",",O
serum,O
IL-6,O
levels,O
are,O
far,O
lower,O
in,O
COVID-19,O
infections,O
than,O
in,O
CRS,O
",",O
with,O
peak,O
levels,O
typically,O
less,O
than,O
100,O
pg,O
/,O
ml,O
in,O
COVID-19,O
",",O
compared,O
with,O
"1,000–10,000",O
pg,O
/,O
ml,O
in,O
CRS,O
(,O
Chen,O
et,O
al,O
.,O
",",O
2020a,O
;,O
Maude,O
et,O
al,O
.,O
",",O
2014,O
),O
.,O
Third,O
",",O
deaths,O
in,O
COVID-19,O
–,O
infected,O
patients,O
appear,O
to,O
be,O
due,O
to,O
primary,O
respiratory,O
failure,O
",",O
rather,O
than,O
from,O
distributive,O
shock,O
or,O
status,O
epilepticus,O
",",O
as,O
was,O
predominantly,O
seen,O
in,O
CRS,O
-,O
associated,O
deaths,O
(,O
Lee,O
et,O
al,O
.,O
",",O
2014,O
),O
.,O
Perhaps,O
most,O
importantly,O
",",O
the,O
clinical,O
results,O
of,O
therapeutic,O
blockade,O
of,O
circulating,O
IL-6,O
with,O
tocilizumab,O
or,O
siltuximab,O
are,O
thus,O
far,O
mixed,O
;,O
one,O
clinical,O
trial,O
showed,O
evidence,O
of,O
improvement,O
in,O
33,O
%,O
of,O
patients,O
",",O
at,O
least,O
suggesting,O
that,O
in,O
many,O
cases,O
",",O
a,O
hyperinflammatory,O
response,O
is,O
not,O
primarily,O
responsible,O
for,O
COVID-19,O
–,O
associated,O
morbidity,O
and,O
mortality,O
(,O
Gritti,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
the,O
case,O
of,O
viral,O
infections,O
such,O
as,O
COVID-19,O
",",O
however,O
",",O
macrophage,O
activation,O
is,O
occurring,O
as,O
a,O
primary,O
response,O
to,O
viral,O
infection,O
(,O
Tate,O
et,O
al,O
.,O
",",O
2016,O
),O
.,O
It,O
is,O
also,O
worth,O
noting,O
that,O
while,O
many,O
arms,O
of,O
the,O
innate,O
immune,O
response,O
are,O
potently,O
activated,O
by,O
COVID-19,O
",",O
the,O
type,O
I,O
and,O
type,O
III,O
interferon,O
response,O
appears,O
to,O
be,O
muted,O
in,O
response,O
to,O
COVID-19,O
infection,O
(,O
Blanco,O
-,O
Melo,O
et,O
al,O
.,O
",",O
2020,O
Preprint,O
),O
",",O
suggesting,O
that,O
some,O
aspects,O
of,O
the,O
innate,O
immune,O
response,O
to,O
COVID-19,O
might,O
actually,O
benefit,O
from,O
careful,O
amplification,O
(,O
Kotenko,O
et,O
al,O
.,O
",",O
2003,O
),O
.,O
Regardless,O
of,O
whether,O
innate,O
immune,O
-,O
mediated,O
toxic,O
inflammation,O
contributes,O
to,O
COVID-19,O
–,O
related,O
morbidity,O
and,O
mortality,O
",",O
it,O
is,O
clear,O
that,O
viral,O
dissemination,O
is,O
a,O
key,O
driver,O
of,O
severe,O
disease,O
.,O
The,O
rare,O
histopathologic,O
specimens,O
obtained,O
either,O
postmortem,O
or,O
via,O
liver,O
or,O
kidney,O
biopsy,O
in,O
COVID-19,O
–,O
infected,O
patients,O
have,O
almost,O
universally,O
revealed,O
the,O
presence,O
of,O
inclusion,O
bodies,O
",",O
consistent,O
with,O
viral,O
persistence,O
(,O
Chen,O
et,O
al,O
.,O
",",O
2020,O
Preprint,O
;,O
Diao,O
et,O
al,O
.,O
",",O
2020,O
Preprint,O
;,O
Yao,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
What,O
is,O
permitting,O
viral,O
dissemination,O
in,O
patients,O
who,O
succumb,O
to,O
COVID-19,O
infections,O
?,O
Is,O
the,O
clinical,O
toxicity,O
observed,O
during,O
COVID-19,O
infection,O
a,O
product,O
of,O
adaptive,O
immune,O
hyperactivity,O
or,O
suppression,O
?,O
The,O
clinical,O
presentation,O
of,O
COVID-19,O
infection,O
is,O
more,O
consistent,O
with,O
a,O
subacute,O
rather,O
than,O
an,O
acute,O
viral,O
illness,O
.,O
Compared,O
with,O
H1N1,O
influenza,O
infections,O
",",O
in,O
which,O
the,O
median,O
incubation,O
time,O
was,O
2,O
d,O
and,O
the,O
majority,O
of,O
intensive,O
care,O
unit,O
admissions,O
occurred,O
within,O
24–48,O
h,O
of,O
admission,O
(,O
Bautista,O
et,O
al,O
.,O
",",O
2010,O
),O
",",O
COVID-19,O
–,O
infected,O
patients,O
present,O
to,O
the,O
hospital,O
with,O
a,O
median,O
incubation,O
time,O
of,O
5–7,O
d,O
and,O
are,O
typically,O
hospitalized,O
for,O
an,O
additional,O
3–4,O
d,O
before,O
requiring,O
intensive,O
care,O
unit,O
admission,O
and/or,O
mechanical,O
ventilation,O
(,O
Huang,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
This,O
subacute,O
pattern,O
of,O
progression,O
raises,O
the,O
possibility,O
that,O
immunosuppression,O
",",O
due,O
both,O
to,O
T,O
cell,O
depletion,O
and,O
exhaustion,O
",",O
contributes,O
to,O
COVID-19,O
viral,O
persistence,O
and,O
mortality,O
.,O
Lymphopenia,O
is,O
the,O
most,O
consistent,O
laboratory,O
abnormality,O
in,O
COVID-19,O
–,O
infected,O
patients,O
.,O
Notably,O
",",O
progressive,O
lymphodepletion,O
is,O
observed,O
in,O
patients,O
who,O
clinically,O
deteriorate,O
during,O
COVID-19,O
infection,O
",",O
whereas,O
recovery,O
of,O
lymphocyte,O
counts,O
tends,O
to,O
directly,O
precede,O
clinical,O
recovery,O
(,O
Chen,O
et,O
al,O
.,O
",",O
2020,O
Preprint,O
),O
.,O
Similar,O
to,O
T,O
cells,O
from,O
both,O
mice,O
and,O
humans,O
with,O
chronic,O
viral,O
infections,O
(,O
Day,O
et,O
al,O
.,O
",",O
2006,O
;,O
Fisicaro,O
et,O
al,O
.,O
",",O
2017,O
;,O
Wherry,O
et,O
al,O
.,O
",",O
2007,O
),O
",",O
both,O
lung,O
-,O
resident,O
and,O
circulating,O
T,O
cells,O
from,O
COVID-19,O
patients,O
potently,O
up,O
-,O
regulate,O
markers,O
of,O
T,O
cell,O
exhaustion,O
",",O
including,O
PD-1,O
and,O
Tim-3,O
(,O
Diao,O
et,O
al,O
.,O
",",O
2020,O
Preprint,O
),O
.,O
T,O
cells,O
from,O
severe,O
COVID-19,O
patients,O
exhibit,O
transcriptional,O
hallmarks,O
of,O
terminal,O
T,O
cell,O
exhaustion,O
including,O
expression,O
of,O
CCL4,O
and,O
GZMB,O
;,O
notably,O
",",O
the,O
most,O
expanded,O
T,O
cell,O
population,O
in,O
the,O
bronchoalveolar,O
lavage,O
of,O
severe,O
COVID-19,O
patients,O
is,O
marked,O
by,O
expression,O
of,O
MKI67,O
and,O
TYMS,O
",",O
genes,O
that,O
are,O
specifically,O
up,O
-,O
regulated,O
in,O
terminally,O
exhausted,O
CD8,O
+,O
Conversely,O
",",O
single,O
-,O
cell,O
sequencing,O
of,O
peripheral,O
blood,O
mononuclear,O
cells,O
of,O
patients,O
recovering,O
from,O
COVID-19,O
infection,O
shows,O
signs,O
of,O
clonal,O
expansion,O
",",O
T,O
cell,O
activation,O
",",O
and,O
T,O
cell,O
memory,O
formation,O
",",O
consistent,O
with,O
an,O
effective,O
adaptive,O
immune,O
response,O
(,O
Wen,O
et,O
al,O
.,O
",",O
2020,O
Preprint,O
),O
.,O
T,O
cells,O
to,O
inflammation,O
and,O
lung,O
pathology,O
;,O
indeed,O
",",O
it,O
is,O
worth,O
noting,O
that,O
many,O
markers,O
of,O
T,O
cell,O
exhaustion,O
are,O
also,O
up,O
-,O
regulated,O
in,O
effector,O
T,O
cells,O
",",O
and,O
lung,O
-,O
infiltrating,O
T,O
cells,O
from,O
more,O
mild,O
COVID,O
infections,O
significantly,O
up,O
-,O
regulated,O
genes,O
related,O
to,O
T,O
cell,O
activation,O
.,O
A,O
role,O
for,O
the,O
adaptive,O
immune,O
system,O
in,O
suppressing,O
COVID-19,O
viral,O
dissemination,O
may,O
explain,O
the,O
association,O
of,O
COVID-19,O
disease,O
severity,O
with,O
age,O
.,O
A,O
smaller,O
",",O
more,O
restricted,O
T,O
cell,O
repertoire,O
is,O
likely,O
more,O
prone,O
to,O
antigen,O
-,O
mediated,O
exhaustion,O
during,O
chronic,O
viral,O
infections,O
;,O
conversely,O
",",O
the,O
relatively,O
diverse,O
and,O
expanded,O
pool,O
of,O
naive,O
T,O
cells,O
may,O
explain,O
the,O
relatively,O
diminished,O
severity,O
of,O
COVID-19,O
infections,O
in,O
children,O
(,O
Xu,O
et,O
al,O
.,O
",",O
2020b,O
),O
.,O
In,O
stark,O
contrast,O
to,O
COVID-19,O
",",O
H1N1,O
occurred,O
frequently,O
and,O
caused,O
significant,O
morbidity,O
in,O
children,O
;,O
of,O
note,O
",",O
H1N1,O
infection,O
caused,O
lymphopenia,O
in,O
the,O
majority,O
of,O
pediatric,O
patients,O
(,O
Rhim,O
et,O
al,O
.,O
",",O
2011,O
),O
.,O
Therapeutically,O
",",O
high,O
-,O
dose,O
glucocorticoids,O
are,O
the,O
only,O
strategy,O
used,O
thus,O
far,O
to,O
modulate,O
the,O
adaptive,O
immune,O
system,O
of,O
COVID-19,O
patients,O
.,O
One,O
commonly,O
used,O
therapeutic,O
strategy,O
in,O
severe,O
viral,O
infections,O
",",O
but,O
not,O
yet,O
in,O
COVID-19,O
–,O
infected,O
patients,O
",",O
is,O
the,O
use,O
of,O
antioxidants,O
such,O
as,O
N,O
-,O
acetylcysteine,O
(,O
N,O
-,O
Ac,O
),O
.,O
Is,O
there,O
a,O
way,O
to,O
therapeutically,O
balance,O
immune,O
toxicity,O
and,O
immunosuppression,O
to,O
improve,O
outcomes,O
in,O
COVID-19,O
–,O
infected,O
patients,O
?,O
To,O
answer,O
to,O
this,O
question,O
",",O
we,O
require,O
a,O
deeper,O
understanding,O
of,O
both,O
innate,O
and,O
adaptive,O
immune,O
evolution,O
over,O
the,O
course,O
of,O
COVID-19,O
illness,O
.,O
To,O
this,O
end,O
",",O
there,O
is,O
a,O
need,O
to,O
obtain,O
serial,O
peripheral,O
blood,O
",",O
and,O
",",O
when,O
technically,O
feasible,O
and,O
clinically,O
appropriate,O
",",O
bronchoalveolar,O
lavage,O
samples,O
over,O
the,O
course,O
of,O
COVID-19,O
infection,O
and,O
clearance,O
.,O
The,O
answer,O
to,O
this,O
question,O
will,O
have,O
key,O
implications,O
for,O
the,O
appropriate,O
design,O
of,O
clinical,O
trials,O
aimed,O
as,O
modulating,O
the,O
anti,O
-,O
COVID,O
immune,O
response,O
.,O
Longitudinal,O
assessment,O
of,O
anti,O
-,O
COVID,O
immune,O
responses,O
is,O
particularly,O
important,O
in,O
the,O
setting,O
of,O
therapeutic,O
interventions,O
",",O
both,O
antiviral,O
and,O
immune,O
-,O
targeted,O
.,O
For,O
example,O
",",O
patients,O
who,O
respond,O
to,O
IL-6,O
blockade,O
have,O
a,O
parallel,O
improvement,O
in,O
lymphocyte,O
counts,O
(,O
Xu,O
et,O
al,O
.,O
",",O
2020a,O
Preprint,O
),O
",",O
suggesting,O
that,O
in,O
some,O
cases,O
",",O
COVID-19,O
–,O
associated,O
lymphopenia,O
may,O
be,O
a,O
product,O
of,O
bystander,O
inflammation,O
(,O
Stelekati,O
et,O
al,O
.,O
",",O
2014,O
),O
.,O
Longitudinal,O
sampling,O
of,O
COVID-19,O
–,O
infected,O
patients,O
with,O
either,O
inherent,O
or,O
iatrogenic,O
disruption,O
of,O
host,O
immunity,O
may,O
help,O
identify,O
specific,O
regulators,O
of,O
the,O
anti,O
-,O
COVID,O
immune,O
response,O
(,O
Box,O
2,O
),O
.,O
Second,O
",",O
patients,O
with,O
solid,O
organ,O
transplants,O
require,O
ongoing,O
T,O
cell,O
immunosuppression,O
",",O
offering,O
an,O
opportunity,O
to,O
explore,O
the,O
contribution,O
of,O
the,O
T,O
cell,O
–,O
dependent,O
immune,O
response,O
to,O
COVID-19,O
.,O
In,O
either,O
early,O
or,O
late,O
disease,O
",",O
an,O
effective,O
humoral,O
response,O
is,O
a,O
key,O
contributor,O
to,O
viral,O
clearance,O
;,O
here,O
",",O
we,O
draw,O
particular,O
attention,O
to,O
the,O
promise,O
of,O
treating,O
infected,O
patients,O
with,O
serum,O
from,O
convalescent,O
patients,O
that,O
is,O
rich,O
in,O
immunoglobulins,O
targeting,O
COVID-19,O
(,O
Duan,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
4,O
.,O
This,O
Perspective,O
explores,O
the,O
contributions,O
of,O
the,O
innate,O
and,O
adaptive,O
immune,O
systems,O
to,O
both,O
viral,O
control,O
as,O
well,O
as,O
toxicity,O
during,O
COVID-19,O
infections,O
and,O
offers,O
suggestions,O
to,O
both,O
understand,O
and,O
therapeutically,O
modulate,O
anti,O
-,O
COVID,O
immunity,O
.,O
Compared,O
with,O
recent,O
viral,O
outbreaks,O
",",O
COVID-19,O
infection,O
has,O
a,O
relatively,O
high,O
mortality,O
rate,O
",",O
the,O
reasons,O
for,O
which,O
are,O
not,O
entirely,O
clear,O
.,O
Furthermore,O
",",O
treatment,O
options,O
for,O
COVID-19,O
infection,O
are,O
currently,O
limited,O
.,O
In,O
this,O
Perspective,O
",",O
we,O
explore,O
the,O
contributions,O
of,O
the,O
innate,O
and,O
adaptive,O
immune,O
systems,O
to,O
both,O
viral,O
control,O
as,O
well,O
as,O
toxicity,O
during,O
COVID-19,O
infections,O
and,O
offer,O
suggestions,O
to,O
both,O
understand,O
and,O
therapeutically,O
modulate,O
anti,O
-,O
COVID,O
immunity,O
.,O
The,O
recent,O
emergence,O
of,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus-2,O
(,O
SARS,O
-,O
CoV-2,O
),O
has,O
created,O
a,O
public,O
health,O
emergency,O
across,O
the,O
globe,O
[,O
1–3,O
],O
.,O
The,O
SARS,O
-,O
CoV-2,O
virus,O
was,O
isolated,O
from,O
a,O
nasopharyngeal,O
sample,O
of,O
a,O
patient,O
in,O
Sweden,O
and,O
the,O
isolated,O
virus,O
was,O
confirmed,O
as,O
SARS,O
-,O
CoV-2,O
by,O
sequencing,O
(,O
Genbank,S-Repository
 ,O
accession,O
number,O
MT093571,S-AccessionNumber
),O
.,O
The,O
raw,O
files,O
were,O
imported,O
to,O
Proteome,O
Discoverer,O
v2.4,O
(,O
Thermo,O
Scientific,O
),O
and,O
searched,O
against,O
the,O
Homo,O
sapiens,O
SwissProt,O
(,O
2020_01,O
release,O
with,O
"20,595",O
entries,O
),O
and,O
the,O
pre,O
-,O
leased,O
SARS,O
-,O
CoV-2,O
UniProt,S-Repository
 ,O
(,O
completed,O
with,O
14,O
SARS,O
-,O
CoV-2,O
sequences,O
of,O
COVID-19,O
UniProtKB,O
release,O
2020_04_06,O
),O
protein,O
databases,O
with,O
Mascot,O
v,O
2.5.1,O
search,O
engine,O
(,O
MatrixScience,O
Ltd.,O
",",O
UK,O
),O
.,O
The,O
pathway,O
“,O
Antiviral,O
mechanism,O
by,O
IFN,O
-,O
stimulated,O
genes,O
”,O
and,O
two,O
other,O
events,O
it,O
participates,O
were,O
selected,O
from,O
Reactome,S-Repository
 ,O
database,O
.,O
To,O
further,O
capture,O
the,O
patterns,O
of,O
expression,O
changes,O
in,O
response,O
to,O
the,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
we,O
performed,O
a,O
weighted,O
co,O
-,O
expression,O
network,O
analysis,O
on,O
both,O
transcriptomic,O
and,O
proteomic,O
datasets,O
using,O
all,O
genes,O
and,O
proteins,O
detected,O
",",O
their,O
functional,O
assignments,O
",",O
and,O
the,O
top,O
genes,O
(,O
Figure,O
2(a,O
),O
),O
and,O
proteins,O
(,O
Figure,O
2(b,O
),O
),O
in,O
key,O
network,O
elements,O
.,O
To,O
repurpose,O
antiviral,O
drugs,O
targeting,O
host,O
-,O
viral,O
interactions,O
is,O
an,O
attractive,O
strategy,O
to,O
find,O
drugs,O
that,O
might,O
work,O
against,O
COVID-19,O
.,O
Our,O
data,O
indicate,O
a,O
role,O
of,O
Akt,O
/,O
mTOR,O
/,O
HIF-1,O
in,O
the,O
cellular,O
response,O
to,O
the,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
suggesting,O
that,O
drugs,O
blocking,O
this,O
pathway,O
could,O
possibly,O
be,O
repurposed,O
for,O
COVID-19,O
patients,O
.,O
The,O
activation,O
of,O
Akt,O
/,O
mTOR,O
signaling,O
during,O
SARS,O
-,O
CoV-2,O
infection,O
could,O
be,O
to,O
sustain,O
protein,O
synthesis,O
by,O
increased,O
accession,O
to,O
translation,O
components,O
and,O
by,O
overcoming,O
infection,O
-,O
associated,O
stress,O
by,O
blocking,O
autophagy,O
and,O
apoptosis,O
[,O
31,O
],O
.,O
In,O
COVID-19,O
patients,O
the,O
severity,O
of,O
the,O
disease,O
is,O
associated,O
with,O
a,O
cytokine,O
storm,O
with,O
markedly,O
increased,O
expression,O
of,O
interleukin,O
6,O
(,O
IL-6,O
),O
in,O
the,O
serum,O
of,O
severe,O
cases,O
[,O
42,O
],O
.,O
Whether,O
the,O
currently,O
proposed,O
drugs,O
targeting,O
the,O
Akt,O
/,O
mTOR,O
pathway,O
can,O
be,O
indeed,O
repurposed,O
for,O
COVID-19,O
therapies,O
now,O
needs,O
to,O
be,O
tested,O
carefully,O
in,O
in,O
vitro,O
SARS,O
-,O
CoV-2,O
infection,O
models,O
and,O
in,O
in,O
vivo,O
COVID-19,O
disease,O
models,O
as,O
improper,O
regulation,O
may,O
pose,O
a,O
detrimental,O
effect,O
.,O
The,O
ongoing,O
phase,O
I,O
(,O
SirCo-1,O
",",O
NCT04371640,S-AccessionNumber
),O
",",O
phase,O
II,O
(,O
The,O
SCOPE,O
trials,O
",",O
NCT04341675,S-AccessionNumber
),O
and,O
phase,O
III,O
(,O
NCT04409327,S-AccessionNumber
),O
trials,O
that,O
target,O
mTOR,O
in,O
the,O
severe,O
COVID-19,O
patients,O
will,O
provide,O
more,O
information,O
.,O
Further,O
investigations,O
are,O
required,O
to,O
better,O
understand,O
the,O
molecular,O
sequelae,O
in,O
order,O
to,O
guide,O
potential,O
therapy,O
in,O
the,O
management,O
of,O
severe,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
patients,O
.,O
Further,O
extensive,O
global,O
transmission,O
led,O
to,O
the,O
WHO,O
declaring,O
COVID-19,O
as,O
a,O
pandemic,O
on,O
March,O
11,O
2020,O
.,O
There,O
are,O
thousands,O
of,O
global,O
SARS,O
-,O
CoV-2,O
whole,O
-,O
genome,O
sequences,O
available,O
on,O
the,O
rapid,O
data,O
sharing,O
service,O
hosted,O
by,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID,E-Dataset
;,O
https://www.epicov.org,S-URL
),O
The,O
extraordinary,O
availability,O
of,O
genomic,O
data,O
during,O
the,O
COVID-19,O
pandemic,O
has,O
been,O
made,O
possible,O
thanks,O
to,O
a,O
tremendous,O
effort,O
by,O
hundreds,O
of,O
researchers,O
globally,O
depositing,O
SARS,O
-,O
CoV-2,O
assemblies,O
(,O
Table,O
S1,O
),O
and,O
the,O
proliferation,O
of,O
close,O
to,O
real,O
time,O
data,O
visualisation,O
and,O
analysis,O
tools,O
including,O
NextStrain,S-Repository
 ,O
(,O
https://nextstrain.org,S-URL
),O
and,O
CoV,O
-,O
GLUE,O
(,O
http://cov-glue.cvr.gla.ac.uk,O
),O
.,O
A,O
variant,O
calling,O
pipeline,O
(,O
available,O
at,O
https://github.com/DamienFr/CoV-homoplasy,O
),O
was,O
used,O
to,O
obtain,O
high,O
-,O
confidence,O
alignments,O
for,O
the,O
348,O
(,O
out,O
of,O
889,O
as,O
of,O
April,O
19,O
2020,O
),O
SRA,S-Dataset
 ,O
genomic,O
datasets,O
both,O
meeting,O
our,O
quality,O
criterions,O
and,O
matching,O
GISAID,S-Dataset
 ,O
assemblies,O
.,O
The,O
topology,O
of,O
the,O
Maximum,O
Likelihood,O
phylogeny,O
of,O
these,O
348,O
samples,O
was,O
compared,O
to,O
that,O
of,O
the,O
corresponding,O
samples,O
from,O
the,O
GISAID,S-Dataset
 ,O
genome,O
assemblies,O
using,O
a,O
Mantel,O
test,O
and,O
the,O
Phytools,O
R,O
package,O
(,O
Revell,O
",",O
2012,O
),O
(,O
Figs,O
.,O
S8,O
-,O
S9,O
",",O
see,O
Supplementary,O
text,O
),O
.,O
The,O
7666,O
SARS,O
-,O
CoV-2,O
genomes,O
offer,O
an,O
excellent,O
geographical,O
and,O
temporal,O
coverage,O
of,O
the,O
COVID-19,O
pandemic,O
(,O
Fig,O
.,O
1a,O
-,O
b,O
),O
.,O
Using,O
TreeDater,O
(,O
Volz,O
and,O
Frost,O
",",O
2017,O
),O
",",O
we,O
observe,O
an,O
estimated,O
tMRCA,O
",",O
which,O
corresponds,O
to,O
the,O
start,O
of,O
the,O
COVID-19,O
epidemic,O
",",O
of,O
6,O
October,O
2019–11,O
December,O
2019,O
(,O
95,O
%,O
CIs,O
),O
(,O
Fig,O
.,O
S4,O
),O
.,O
These,O
dates,O
for,O
the,O
start,O
of,O
the,O
epidemic,O
are,O
in,O
broad,O
agreement,O
with,O
previous,O
estimates,O
performed,O
on,O
smaller,O
subsets,O
of,O
the,O
COVID-19,O
genomic,O
data,O
using,O
various,O
computational,O
methods,O
(,O
Table,O
1,O
),O
",",O
though,O
they,O
should,O
still,O
be,O
taken,O
with,O
some,O
caution,O
.,O
Indeed,O
",",O
the,O
sheer,O
size,O
of,O
the,O
dataset,O
precludes,O
the,O
use,O
of,O
some,O
of,O
the,O
more,O
sophisticated,O
inference,O
methods,O
available,O
.,O
The,O
SARS,O
-,O
CoV-2,O
global,O
population,O
has,O
accumulated,O
only,O
moderate,O
genetic,O
diversity,O
at,O
this,O
stage,O
of,O
the,O
COVID-19,O
pandemic,O
with,O
an,O
average,O
pairwise,O
difference,O
of,O
9.6,O
SNPs,O
between,O
any,O
two,O
genomes,O
",",O
providing,O
further,O
support,O
for,O
a,O
relatively,O
recent,O
common,O
ancestor,O
.,O
Indeed,O
",",O
the,O
earliest,O
available,O
strains,O
were,O
collected,O
in,O
Asia,O
",",O
where,O
the,O
COVID-19,O
pandemic,O
started,O
",",O
followed,O
by,O
extensive,O
genome,O
sequencing,O
efforts,O
first,O
in,O
Europe,O
and,O
then,O
in,O
the,O
USA,O
.,O
The,O
SARS,O
-,O
CoV-2,O
genomic,O
diversity,O
found,O
in,O
most,O
countries,O
(,O
with,O
sufficient,O
sequences,O
),O
essentially,O
recapitulates,O
the,O
global,O
diversity,O
of,O
COVID-19,O
from,O
the,O
7666,O
-,O
genome,O
dataset,O
.,O
This,O
is,O
also,O
to,O
an,O
extent,O
the,O
case,O
for,O
Italy,O
(,O
Fig,O
.,O
S2b,O
),O
",",O
which,O
was,O
an,O
early,O
focus,O
of,O
the,O
COVID-19,O
pandemic,O
.,O
However,O
",",O
this,O
global,O
dataset,O
includes,O
only,O
35,O
SARS,O
-,O
CoV-2,O
genomes,O
from,O
Italy,O
",",O
so,O
some,O
of,O
the,O
genetic,O
diversity,O
of,O
SARS,O
-,O
CoV-2,O
strains,O
in,O
circulation,O
likely,O
remains,O
unsampled,O
.,O
The,O
genomic,O
diversity,O
of,O
the,O
global,O
SARS,O
-,O
CoV-2,O
population,O
being,O
recapitulated,O
in,O
multiple,O
countries,O
points,O
to,O
extensive,O
worldwide,O
transmission,O
of,O
COVID-19,O
",",O
likely,O
from,O
extremely,O
early,O
on,O
in,O
the,O
pandemic,O
.,O
The,O
strongest,O
hit,O
in,O
terms,O
of,O
the,O
inferred,O
minimum,O
number,O
of,O
changes,O
required,O
(,O
Fig,O
.,O
3b,O
-,O
c,O
),O
at,O
Orf1ab,O
(,O
"11,083",O
",",O
Codon,O
3606,O
),O
falls,O
over,O
a,O
region,O
encoding,O
the,O
non,O
-,O
structural,O
protein,O
",",O
Nsp6,O
",",O
and,O
is,O
also,O
observed,O
in,O
our,O
analyses,O
of,O
the,O
SRA,S-Dataset
 ,O
dataset,O
(,O
Table,O
S7,O
),O
.,O
Over,O
the,O
last,O
century,O
alone,O
",",O
several,O
global,O
epidemics,O
have,O
claimed,O
millions,O
of,O
lives,O
",",O
including,O
the,O
1957/58,O
influenza,O
A,O
(,O
H2N2,O
),O
pandemic,O
",",O
the,O
sixth,O
(,O
1899–1923,O
),O
and,O
seventh,O
‘,O
El,O
Tor,O
’,O
cholera,O
pandemic,O
(,O
1961–1975,O
),O
",",O
as,O
well,O
as,O
the,O
HIV,O
/,O
AIDS,O
pandemic,O
(,O
1981,O
-,O
today,O
),O
.,O
COVID-19,O
acts,O
as,O
an,O
unwelcome,O
reminder,O
of,O
the,O
major,O
threat,O
that,O
infectious,O
diseases,O
represent,O
in,O
terms,O
of,O
deaths,O
and,O
disruption,O
.,O
The,O
genetic,O
data,O
available,O
at,O
the,O
time,O
looks,O
staggeringly,O
small,O
in,O
comparison,O
to,O
the,O
amount,O
that,O
has,O
already,O
been,O
generated,O
for,O
SARS,O
-,O
CoV-2,O
during,O
the,O
early,O
stages,O
of,O
the,O
COVID-19,O
pandemic,O
.,O
For,O
example,O
",",O
analyses,O
by,O
multiple,O
independent,O
groups,O
place,O
the,O
start,O
of,O
the,O
COVID-19,O
pandemic,O
towards,O
the,O
end,O
of,O
2019,O
(,O
Table,O
1,O
),O
.,O
This,O
site,O
passed,O
our,O
stringent,O
filtering,O
cirteria,O
and,O
was,O
also,O
present,O
in,O
our,O
analysis,O
of,O
the,O
SRA,S-Dataset
 ,O
dataset,O
(,O
Table,O
S7,O
),O
.,O
The,O
virus,O
has,O
since,O
spread,O
globally,O
",",O
resulting,O
in,O
the,O
currently,O
ongoing,O
COVID-19,O
pandemic,O
.,O
We,O
curated,O
a,O
dataset,O
of,O
7666,O
public,O
genome,O
assemblies,O
and,O
analysed,O
the,O
emergence,O
of,O
genomic,O
diversity,O
over,O
time,O
.,O
Highlights,O
    ,O
•,O
 ,O
Phylogenetic,O
estimates,O
support,O
that,O
the,O
COVID-2,O
pandemic,O
started,O
sometimes,O
around,O
6,O
October,O
2019,O
–,O
11,O
December,O
2019,O
.,O
   ,O
•,O
Severe,O
lung,O
inflammation,O
and,O
tissue,O
damage,O
are,O
hallmarks,O
of,O
COVID-19,O
",",O
significantly,O
contributing,O
to,O
mortality,O
from,O
this,O
infection,O
(,O
Mehta,O
et,O
al,O
.,O
",",O
2020,O
),O
;,O
thus,O
",",O
enhancement,O
of,O
inflammation,O
and,O
cytokine,O
storm,O
must,O
be,O
avoided,O
.,O
The,O
absence,O
of,O
pro,O
-,O
inflammatory,O
effects,O
in,O
the,O
lungs,O
(,O
Davidson,O
et,O
al,O
.,O
",",O
2016,O
;,O
Forero,O
et,O
al,O
.,O
",",O
2019,O
;,O
Galani,O
et,O
al,O
.,O
",",O
2017,O
),O
is,O
one,O
of,O
the,O
most,O
important,O
arguments,O
for,O
the,O
specific,O
advantage,O
of,O
IFN,O
-,O
λ,O
over,O
type,O
I,O
IFNs,O
as,O
a,O
treatment,O
option,O
for,O
COVID-19,O
.,O
However,O
",",O
it,O
is,O
very,O
important,O
to,O
establish,O
if,O
immune,O
cells,O
are,O
responsive,O
to,O
IFN,O
-,O
λ,O
in,O
COVID-19,O
",",O
as,O
their,O
activation,O
exacerbates,O
inflammation,O
.,O
In,O
addition,O
",",O
bacterial,O
superinfections,O
can,O
be,O
associated,O
with,O
severe,O
cases,O
of,O
COVID-19,O
(,O
Zhang,O
et,O
al,O
.,O
",",O
2020,O
Preprint,O
),O
",",O
although,O
this,O
varies,O
between,O
clinical,O
studies,O
.,O
Although,O
mouse,O
models,O
do,O
not,O
fully,O
recapitulate,O
human,O
diseases,O
with,O
respect,O
to,O
IFN,O
-,O
λ,O
activities,O
",",O
animal,O
studies,O
give,O
a,O
mandate,O
to,O
carefully,O
evaluate,O
the,O
use,O
of,O
IFN,O
-,O
λ,O
as,O
a,O
therapeutic,O
agent,O
against,O
COVID-19,O
.,O
The,O
Viewpoint,O
discusses,O
the,O
benefits,O
and,O
potential,O
limitations,O
of,O
using,O
interferon,O
lambda,O
(,O
IFN,O
-,O
λ,O
",",O
a,O
type,O
III,O
interferon,O
),O
to,O
prevent,O
",",O
limit,O
",",O
and,O
treat,O
COVID-19,O
.,O
With,O
the,O
first,O
reports,O
on,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
which,O
is,O
caused,O
by,O
the,O
novel,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
the,O
scientific,O
community,O
working,O
in,O
the,O
field,O
of,O
type,O
III,O
IFNs,O
(,O
IFN,O
-,O
λ,O
),O
realized,O
that,O
this,O
class,O
of,O
IFNs,O
could,O
play,O
an,O
important,O
role,O
in,O
this,O
and,O
other,O
emerging,O
viral,O
infections,O
.,O
At,O
the,O
time,O
of,O
writing,O
",",O
the,O
outbreak,O
of,O
the,O
highly,O
infectious,O
novel,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
has,O
swept,O
across,O
all,O
five,O
continents,O
",",O
with,O
>,O
4,O
million,O
confirmed,O
cases,O
globally,O
(,O
9,O
May,O
2020,O
),O
.,O
Patients,O
felt,O
to,O
be,O
at,O
risk,O
can,O
then,O
be,O
identified,O
early,O
and,O
appropriate,O
referral,O
either,O
to,O
a,O
dedicated,O
area,O
for,O
further,O
assessment,O
or,O
to,O
an,O
acute,O
care,O
/,O
COVID‐19,O
assessment,O
centre,O
can,O
be,O
facilitated,O
.,O
Patients,O
and,O
their,O
caregivers,O
should,O
be,O
reminded,O
of,O
the,O
signs,O
and,O
symptoms,O
of,O
COVID‐19,O
",",O
as,O
well,O
as,O
the,O
importance,O
of,O
hand,O
hygiene,O
and,O
other,O
infection,O
control,O
measures,O
.,O
Minimising,O
immunosuppressive,O
therapy,O
",",O
wherever,O
possible,O
",",O
has,O
become,O
a,O
key,O
strategy,O
in,O
the,O
face,O
of,O
COVID‐19,O
.,O
For,O
those,O
patients,O
in,O
whom,O
proceeding,O
with,O
ASCT,O
has,O
been,O
deemed,O
absolutely,O
necessary,O
",",O
increased,O
vigilance,O
will,O
be,O
required,O
in,O
the,O
short‐,O
and,O
longer‐term,O
",",O
given,O
the,O
increased,O
susceptibility,O
to,O
viral,O
infection,O
that,O
will,O
persist,O
beyond,O
the,O
initial,O
post‐transplant,O
period,O
.,O
",",O
 ,O
",",O
  ,O
Until,O
herd,O
immunity,O
is,O
established,O
",",O
the,O
threat,O
of,O
COVID‐19,O
infection,O
for,O
this,O
at‐risk,O
population,O
will,O
very,O
likely,O
persist,O
beyond,O
the,O
immediate,O
crisis,O
and,O
may,O
change,O
our,O
recommendations,O
for,O
surveillance,O
and,O
prevention,O
in,O
the,O
post‐transplant,O
period,O
indefinitely,O
.,O
The,O
very,O
real,O
risk,O
of,O
hospitalisation,O
posed,O
by,O
COVID‐19,O
has,O
increasingly,O
motivated,O
both,O
patients,O
and,O
treating,O
physicians,O
to,O
actively,O
engage,O
in,O
conversations,O
regarding,O
advance,O
directives,O
",",O
goals,O
of,O
care,O
and,O
end‐of‐life,O
planning,O
",",O
and,O
to,O
document,O
these,O
clearly,O
.,O
",",O
Despite,O
the,O
fact,O
that,O
at,O
the,O
time,O
of,O
writing,O
there,O
are,O
>,O
3000,O
published,O
articles,O
on,O
COVID‐19,O
",",O
the,O
data,O
on,O
the,O
true,O
risk,O
posed,O
by,O
this,O
virus,O
to,O
patients,O
with,O
myeloma,O
remain,O
immature,O
.,O
However,O
",",O
there,O
are,O
early,O
suggestions,O
that,O
certain,O
agents,O
used,O
in,O
the,O
treatment,O
of,O
myeloma,O
could,O
be,O
useful,O
against,O
COVID‐19,O
",",O
including,O
selinexor,O
and,O
ixazomib,O
.,O
",",O
 ,O
",",O
  ,O
Angiotensin‐converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
is,O
a,O
co‐receptor,O
for,O
COVID‐19,O
",",O
but,O
it,O
remains,O
unclear,O
whether,O
angiotensin‐converting,O
enzyme,O
inhibitors,O
or,O
receptor,O
blockers,O
",",O
which,O
are,O
commonly,O
co‐prescribed,O
for,O
patients,O
with,O
myeloma,O
",",O
could,O
either,O
aggravate,O
or,O
ameliorate,O
the,O
disease,O
.,O
",",O
 ,O
",",O
One,O
myeloma,O
physician,O
has,O
suggested,O
things,O
will,O
now,O
be,O
considered,O
in,O
terms,O
of,O
whether,O
they,O
were,O
‘,O
BC,O
’,O
(,O
Before,O
COVID‐19,O
),O
or,O
‘,O
AC,O
’,O
(,O
After,O
COVID‐19,O
),O
.,O
A,O
global,O
recession,O
in,O
the,O
wake,O
of,O
COVID‐19,O
seems,O
undeniable,O
and,O
will,O
undoubtedly,O
have,O
a,O
significant,O
impact,O
on,O
healthcare,O
spending,O
regardless,O
of,O
the,O
underlying,O
revenue,O
source,O
and,O
infrastructure,O
.,O
At,O
the,O
time,O
of,O
writing,O
",",O
estimates,O
suggest,O
that,O
in,O
the,O
USA,O
alone,O
",",O
unemployment,O
resulting,O
from,O
the,O
COVID‐19,O
pandemic,O
could,O
reach,O
levels,O
of,O
to,O
52·8,O
 ,O
million,O
",",O
more,O
than,O
three‐times,O
worse,O
than,O
the,O
peak,O
of,O
the,O
Great,O
Recession,O
.,O
Immediate,O
focus,O
is,O
minimising,O
risk,O
of,O
contracting,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
and,O
the,O
sequelae,O
of,O
infection,O
.,O
Healthcare,O
delivery,O
post‐COVID‐19,O
will,O
not,O
return,O
to,O
how,O
it,O
was,O
",",O
and,O
now,O
is,O
the,O
time,O
to,O
invest,O
in,O
novel,O
strategies,O
to,O
deliver,O
the,O
best,O
possible,O
outcomes,O
for,O
patients,O
.,O
The,O
recent,O
pandemic,O
of,O
COVID‐19,O
is,O
yet,O
another,O
manifestation,O
of,O
the,O
might,O
of,O
natural,O
selection,O
.,O
The,O
recent,O
outbreak,O
of,O
COVID‐19,O
",",O
now,O
categorized,O
as,O
a,O
pandemic,O
",",O
is,O
by,O
all,O
means,O
considerably,O
widespread,O
compared,O
with,O
earlier,O
coronavirus,O
outbreaks,O
.,O
The,O
findings,O
provide,O
interesting,O
insights,O
into,O
the,O
potential,O
relationship,O
between,O
natural,O
genetic,O
variants,O
in,O
human,O
ACE2,O
and,O
susceptibility,O
and/or,O
resistance,O
against,O
COVID‐19,O
infection,O
.,O
The,O
present,O
investigation,O
highlights,O
candidate,O
alleles,O
of,O
ACE2,O
that,O
may,O
lead,O
to,O
the,O
variation,O
in,O
the,O
susceptibility,O
and/or,O
resistance,O
against,O
COVID‐19,O
.,O
Finally,O
",",O
clinical,O
manifestations,O
and,O
recovery,O
rate,O
of,O
COVID‐19,O
varies,O
significantly,O
between,O
different,O
age,O
groups,O
",",O
nationalities,O
",",O
and,O
race,O
.,O
",",O
 ,O
",",O
It,O
is,O
possible,O
that,O
in,O
some,O
individuals,O
",",O
if,O
not,O
all,O
",",O
the,O
positive,O
prognosis,O
of,O
the,O
COVID‐19,O
may,O
be,O
due,O
to,O
the,O
existence,O
of,O
ACE2,O
variants,O
like,O
rs73635825,O
(,O
S19P,O
),O
and,O
rs143936283,O
(,O
E329,O
G,O
),O
.,O
Therefore,O
",",O
the,O
findings,O
of,O
this,O
investigation,O
provide,O
clues,O
to,O
screen,O
frequencies,O
of,O
the,O
candidate,O
alleles,O
in,O
different,O
populations,O
to,O
predict,O
the,O
prognosis,O
of,O
COVID‐19,O
.,O
The,O
recent,O
pandemic,O
of,O
COVID‐19,O
",",O
caused,O
by,O
SARS‐CoV‐2,O
",",O
is,O
unarguably,O
the,O
most,O
fearsome,O
compared,O
with,O
the,O
earlier,O
outbreaks,O
caused,O
by,O
other,O
coronaviruses,O
",",O
SARS‐CoV,O
and,O
MERS‐CoV.,O
The,O
findings,O
provide,O
direction,O
to,O
the,O
targeted,O
allele,O
screening,O
in,O
COVID‐19,O
patients,O
",",O
which,O
could,O
further,O
be,O
used,O
in,O
predicting,O
the,O
prognosis,O
of,O
the,O
disease,O
and,O
allocation,O
of,O
the,O
health,O
resources,O
.,O
The,O
first,O
week,O
in,O
the,O
pre‐COVID‐19,O
era,O
was,O
randomly,O
selected,O
",",O
while,O
the,O
second,O
was,O
chosen,O
during,O
the,O
actual,O
COVID‐19,O
emergency,O
.,O
The,O
week,O
between,O
21,O
October,O
2019,O
and,O
26,O
October,O
2019,O
was,O
identified,O
as,O
the,O
pre‐COVID‐19,O
(,O
no,O
closure,O
of,O
the,O
outpatients,O
',O
surgeries,O
available,O
in,O
our,O
Unit,O
for,O
holidays,O
or,O
meetings,O
),O
.,O
The,O
days,O
between,O
12,O
March,O
2020,O
and,O
18,O
March,O
2020,O
characterized,O
the,O
weekly,O
activity,O
of,O
our,O
emergency,O
service,O
during,O
the,O
COVID‐19,O
era,O
(,O
days,O
in,O
the,O
run‐up,O
to,O
the,O
Government,O
decree‐law,O
),O
.,O
In,O
the,O
pre‐COVID‐19,O
era,O
",",O
106,O
patients,O
accessed,O
our,O
emergency,O
outpatients,O
',O
room,O
",",O
whereas,O
just,O
20,O
cases,O
were,O
examined,O
after,O
the,O
emergency,O
decree‐law,O
.,O
The,O
number,O
of,O
unjustified,O
accesses,O
was,O
60,O
in,O
pre‐COVID,O
era,O
",",O
and,O
46,O
patients,O
showed,O
‘,O
true,O
’,O
emergencies,O
.,O
The,O
misuse,O
of,O
the,O
emergency,O
consultation,O
facility,O
is,O
a,O
bad,O
habit,O
and,O
it,O
has,O
been,O
estimated,O
that,O
at,O
least,O
half,O
of,O
the,O
patients,O
do,O
not,O
have,O
a,O
‘,O
true,O
’,O
emergency,O
(,O
range,O
49–82,O
%,O
),O
",",O
",",O
 ,O
",",O
 ,O
",",O
 ,O
",",O
 ,O
",",O
  ,O
which,O
is,O
confirmed,O
by,O
our,O
study,O
(,O
60,O
vs.,O
five,O
unjustified,O
accesses,O
",",O
before,O
/,O
after,O
the,O
COVID‐19,O
pandemic,O
),O
.,O
Patients,O
suffering,O
from,O
acute,O
myocardial,O
infarction,O
will,O
refer,O
to,O
the,O
ES,O
even,O
in,O
the,O
COVID‐19,O
era,O
",",O
and,O
the,O
same,O
will,O
occur,O
in,O
the,O
case,O
of,O
dermatological,O
emergencies,O
.,O
A,O
possible,O
bias,O
in,O
our,O
research,O
may,O
be,O
due,O
to,O
the,O
panic,O
related,O
to,O
the,O
COVID‐19,O
disease,O
",",O
which,O
can,O
explain,O
the,O
drop,O
in,O
the,O
number,O
of,O
consultations,O
(,O
106,O
vs.,O
19,O
",",O
for,O
an,O
81,O
%,O
reduction,O
),O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
has,O
affected,O
most,O
countries,O
in,O
the,O
world,O
.,O
Severe,O
acute,O
respiratory,O
syndrome,O
-,O
related,O
coronavirus,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
COVID-19,O
clinically,O
presents,O
the,O
symptoms,O
with,O
fever,O
and,O
mild,O
respiratory,O
illness,O
",",O
with,O
~20,O
%,O
of,O
cases,O
requiring,O
hospital,O
intervention,O
",",O
of,O
which,O
5,O
%,O
require,O
intensive,O
support,O
(,O
Wu,O
and,O
Mc,O
Googan,O
",",O
2020,O
;,O
Huang,O
et,O
al,O
.,O
",",O
2020,O
;,O
Zhou,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
For,O
validation,O
of,O
differential,O
expression,O
of,O
SARS,O
-,O
CoV-2,O
genes,O
",",O
total,O
RNA,O
was,O
extracted,O
from,O
70,O
COVID-19,O
infected,O
patients,O
using,O
Exgene,O
™,O
Viral,O
DNA,O
/,O
RNA,O
(,O
GeneAll,O
",",O
Korea,O
),O
following,O
the,O
manufacturer,O
's,O
instructions,O
.,O
All,O
SARS,O
-,O
CoV-2,O
whole,O
genome,O
sequences,O
obtained,O
from,O
human,O
hosts,O
with,O
geographical,O
annotations,O
were,O
obtained,O
from,O
NCBI,S-Repository
 ,O
and,O
Global,B-Dataset
initiative,I-Dataset
on,I-Dataset
sharing,I-Dataset
all,I-Dataset
influenza,I-Dataset
data,I-Dataset
(GISAID),E-Dataset
.,O
The,O
average,O
fold,O
coverage,O
of,O
viral,O
reads,O
was,O
sufficient,O
to,O
detect,O
low,O
-,O
abundance,O
microbial,O
species,O
genome,O
from,O
metagenomic,O
datasets,O
",",O
implying,O
the,O
reliability,O
of,O
the,O
assembled,O
draft,O
viral,O
genome,O
for,O
SNP,O
determination,O
and,O
further,O
analyses,O
(,O
Albertsen,O
et,O
al,O
.,O
",",O
2013,O
),O
.,O
The,O
viral,O
RdRP,O
is,O
up,O
regulated,O
during,O
the,O
evolution,O
of,O
RNA,O
viruses,O
",",O
since,O
RdRP,O
is,O
the,O
central,O
enzyme,O
during,O
this,O
process,O
and,O
has,O
the,O
optimal,O
combination,O
of,O
RNA,O
synthesis,O
efficiency,O
and,O
nucleotide,O
incorporation,O
fidelity,O
(,O
Holland,O
et,O
al,O
.,O
",",O
1982,O
;,O
Snijder,O
et,O
al,O
.,O
",",O
2016,O
),O
.,O
Since,O
the,O
branching,O
order,O
of,O
the,O
NJ,O
tree,O
shows,O
location,O
of,O
virus,O
linkage,O
",",O
in,O
principle,O
the,O
NJ,O
tree,O
provides,O
the,O
details,O
that,O
COVID-19,O
spread,O
from,O
one,O
place,O
to,O
another,O
.,O
The,O
findings,O
presented,O
did,O
not,O
support,O
the,O
hypothesis,O
",",O
indicating,O
that,O
the,O
COVID-19,O
may,O
have,O
begun,O
to,O
spread,O
to,O
several,O
regions,O
in,O
the,O
world,O
before,O
its,O
outbreak,O
in,O
Wuhan,O
.,O
A,O
novel,O
coronavirus,O
related,O
to,O
severe,O
acute,O
respiratory,O
syndrome,O
virus,O
",",O
(,O
SARS,O
-,O
CoV-2,O
),O
is,O
the,O
causal,O
agent,O
of,O
the,O
COVID-19,O
pandemic,O
.,O
Four,O
throat,O
swab,O
samples,O
from,O
COVID-19,O
infected,O
patients,O
were,O
pooled,O
",",O
with,O
RNA,O
-,O
Seq,O
read,O
retrieved,O
from,O
SRA,B-Repository
NCBI,E-Repository
 ,O
to,O
detect,O
21,O
SNPs,O
and,O
a,O
replacement,O
across,O
the,O
SARS,O
-,O
CoV-2,O
genomic,O
population,O
.,O
Aging,O
leads,O
to,O
numerous,O
physiological,O
changes,O
",",O
including,O
the,O
deterioration,O
of,O
the,O
immune,O
system,O
",",O
rendering,O
the,O
elderly,O
more,O
susceptible,O
to,O
infections,O
",",O
such,O
as,O
the,O
COVID-19,O
pandemic,O
",",O
and,O
poor,O
responses,O
to,O
vaccines,O
(,O
Ciabattini,O
et,O
al,O
.,O
",",O
2018,O
;,O
Alpert,O
et,O
al,O
.,O
",",O
2019,O
;,O
Onder,O
et,O
al,O
.,O
",",O
2020,O
;,O
Verity,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
We,O
also,O
enrolled,O
young,O
and,O
aged,O
COVID-19,O
patients,O
in,O
the,O
incipient,O
stage,O
and,O
recovery,O
stage,O
to,O
explore,O
how,O
age,O
influenced,O
the,O
capacity,O
for,O
recovery,O
and,O
prognosis,O
of,O
COVID-19,O
infection,O
and,O
to,O
better,O
understand,O
the,O
influence,O
of,O
immune,O
dysregulation,O
in,O
aging,O
and,O
infection,O
.,O
Most,O
impressively,O
",",O
COVID-19,O
caused,O
similar,O
immune,O
cell,O
landscape,O
changes,O
to,O
that,O
of,O
aging,O
and,O
further,O
increased,O
aging,O
-,O
induced,O
immune,O
cell,O
polarization,O
and,O
upregulation,O
of,O
inflammatory,O
genes,O
.,O
To,O
generate,O
a,O
comprehensive,O
immune,O
cell,O
atlas,O
reflecting,O
cellular,O
and,O
systemic,O
adaptations,O
resulting,O
from,O
age,O
and/or,O
COVID-19,O
infection,O
",",O
we,O
integrated,O
scRNA,O
-,O
seq,O
",",O
CyTOF,O
",",O
scATAC,O
-,O
seq,O
and,O
scTCR,O
/,O
BCR,O
-,O
seq,O
of,O
single,O
-,O
cell,O
PBMC,O
suspensions,O
collected,O
from,O
3,O
separate,O
cohorts,O
(,O
Fig,O
.,O
 ,O
1A,O
",",O
1B,O
",",O
and,O
Table,O
S1A,O
–,O
G,O
),O
.,O
In,O
cohort-1,O
",",O
comprising,O
young,O
healthy,O
adults,O
(,O
YA,O
),O
(,O
20–45,O
years,O
old,O
),O
and,O
aged,O
healthy,O
adults,O
(,O
AA,O
),O
(,O
≥60,O
years,O
old,O
),O
",",O
we,O
combined,O
CyTOF,O
(,O
n,O
=,O
10,O
),O
and,O
scATAC,O
-,O
seq,O
(,O
n,O
=,O
10,O
),O
with,O
scRNA,O
-,O
seq,O
(,O
n,O
=,O
16,O
),O
and,O
scTCR,O
/,O
BCR,O
-,O
seq,O
(,O
n,O
=,O
16,O
),O
;,O
in,O
cohort-2,O
",",O
comprising,O
young,O
healthy,O
(,O
YH,O
),O
individuals,O
(,O
30–45,O
years,O
old,O
),O
",",O
aged,O
healthy,O
(,O
AH,O
),O
individuals,O
(,O
≥60,O
years,O
old,O
),O
",",O
young,O
COVID-19,O
onset,O
patients,O
(,O
YCO,O
),O
(,O
30–50,O
years,O
old,O
),O
and,O
aged,O
COVID-19,O
onset,O
patients,O
(,O
ACO,O
),O
(,O
≥70,O
years,O
old,O
),O
",",O
we,O
performed,O
CyTOF,O
analysis,O
(,O
n,O
=,O
8),O
;,O
and,O
in,O
cohort-3,O
",",O
comprising,O
YH,O
individuals,O
",",O
AH,O
individuals,O
",",O
young,O
recovered,O
COVID-19,O
patients,O
(,O
YCR,O
),O
(,O
30–50,O
years,O
old,O
),O
and,O
aged,O
recovered,O
COVID-19,O
patients,O
(,O
ACR,O
),O
(,O
≥70,O
years,O
old,O
),O
",",O
we,O
performed,O
scRNA,O
-,O
seq,O
(,O
n,O
=,O
22,O
),O
(,O
Fig,O
.,O
 ,O
1B,O
),O
.,O
In,O
cohort-2,O
",",O
we,O
measured,O
single,O
-,O
cell,O
protein,O
expression,O
using,O
a,O
26,O
-,O
marker,O
CyTOF,O
panel,O
to,O
discover,O
early,O
cellular,O
changes,O
in,O
incipient,O
COVID-19,O
patients,O
and,O
how,O
those,O
changes,O
were,O
affected,O
by,O
age,O
.,O
Finally,O
",",O
in,O
cohort-3,O
",",O
we,O
compared,O
cellular,O
differences,O
between,O
young,O
and,O
aged,O
recovered,O
COVID-19,O
patients,O
by,O
scRNA,O
-,O
seq,O
analysis,O
(,O
Fig,O
.,O
 ,O
1B,O
),O
.,O
To,O
depict,O
how,O
the,O
immune,O
landscape,O
changes,O
with,O
aging,O
and,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
we,O
enrolled,O
young,O
(,O
YCO,O
",",O
n,O
=,O
2,O
),O
and,O
aged,O
(,O
ACO,O
",",O
n,O
=,O
2,O
),O
patients,O
with,O
incipient,O
COVID-19,O
(,O
to,O
assess,O
the,O
acute,O
inflammatory,O
state,O
),O
in,O
cohort-2,O
and,O
young,O
(,O
YCR,O
",",O
n,O
=,O
2,O
),O
and,O
aged,O
(,O
ACR,O
",",O
n,O
=,O
2,O
),O
patients,O
who,O
had,O
recovered,O
from,O
COVID-19,O
(,O
to,O
assess,O
the,O
recovered,O
state,O
),O
in,O
cohort-3,O
.,O
We,O
first,O
compared,O
the,O
peripheral,O
immune,O
cell,O
composition,O
between,O
COVID-19,O
patients,O
(,O
at,O
the,O
onset,O
stage,O
",",O
CO,O
),O
and,O
their,O
age,O
-,O
matched,O
healthy,O
controls,O
(,O
HC,O
),O
.,O
Importantly,O
",",O
the,O
aging,O
-,O
associated,O
increase,O
in,O
MCs,O
and,O
decrease,O
in,O
TCs,O
were,O
amplified,O
by,O
COVID-19,O
in,O
aged,O
patients,O
compared,O
with,O
healthy,O
aged,O
controls,O
(,O
Fig,O
.,O
 ,O
6I,O
),O
.,O
Notably,O
",",O
we,O
found,O
a,O
higher,O
ratio,O
of,O
MCs,O
",",O
especially,O
inflammatory,O
MCs,O
",",O
and,O
a,O
lower,O
percentage,O
of,O
TCs,O
in,O
aged,O
COVID-19,O
patients,O
than,O
young,O
COVID-19,O
patients,O
(,O
Figs,O
.,O
 ,O
6O,O
and,O
S12N,O
),O
.,O
The,O
patients,O
in,O
cohort-2,O
were,O
diagnosed,O
with,O
severe,O
COVID-19,O
and,O
presented,O
with,O
similar,O
clinical,O
symptoms,O
and,O
CT,O
findings,O
.,O
Aged,O
COVID-19,O
patients,O
had,O
more,O
MCs,O
and,O
fewer,O
TCs,O
than,O
young,O
patients,O
",",O
thus,O
lowering,O
the,O
threshold,O
of,O
developing,O
hyperinflammatory,O
states,O
that,O
may,O
trigger,O
cytokine,O
storms,O
and,O
lymphopenia,O
.,O
To,O
determine,O
how,O
an,O
increased,O
MCs,O
population,O
and,O
decreased,O
TCs,O
population,O
at,O
the,O
onset,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
contribute,O
to,O
faster,O
disease,O
progression,O
in,O
the,O
elderly,O
at,O
the,O
cellular,O
and,O
molecular,O
levels,O
",",O
we,O
used,O
scRNA,O
-,O
seq,O
to,O
investigate,O
the,O
association,O
between,O
aging,O
and,O
COVID-19,O
.,O
Specifically,O
",",O
we,O
analyzed,O
DEGs,O
to,O
explore,O
whether,O
differentially,O
expressed,O
SARS,O
-,O
CoV-2,O
-,O
related,O
genes,O
in,O
aged,O
patients,O
could,O
explain,O
the,O
impact,O
that,O
aging,O
had,O
on,O
the,O
susceptibility,O
and,O
recovery,O
of,O
COVID-19,O
patients,O
in,O
cohort-3,O
(,O
Figs,O
.,O
S13A,O
–,O
C,O
and,O
S14A,O
),O
.,O
Anti,O
-,O
CD147,O
antibody,O
has,O
been,O
tested,O
to,O
treat,O
COVID-19,O
patients,O
with,O
promising,O
effects,O
(,O
Bian,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Altered,O
expression,O
of,O
these,O
molecules,O
in,O
circulating,O
immune,O
cells,O
",",O
especially,O
in,O
CD4,O
Naive,O
",",O
with,O
age,O
might,O
contribute,O
to,O
increased,O
susceptibility,O
and,O
severity,O
of,O
COVID-19,O
in,O
the,O
elderly,O
.,O
Our,O
data,O
demonstrated,O
that,O
the,O
inflammatory,O
response,O
was,O
sustained,O
in,O
the,O
blood,O
environment,O
of,O
COVID-19,O
patients,O
recovering,O
from,O
SARS,O
-,O
CoV-2,O
infection,O
(,O
Wen,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
the,O
recovery,O
stage,O
",",O
the,O
aging,O
-,O
associated,O
increase,O
in,O
MCs,O
and,O
decrease,O
in,O
TCs,O
were,O
amplified,O
by,O
COVID-19,O
in,O
aged,O
covered,O
patients,O
compared,O
with,O
healthy,O
aged,O
controls,O
.,O
The,O
results,O
showed,O
that,O
COVID-19,O
amplifies,O
aging,O
-,O
induced,O
upregulation,O
of,O
inflammatory,O
genes,O
and,O
senescence,O
hallmark,O
genes,O
(,O
CDKN,O
family,O
),O
(,O
López,O
-,O
Otín,O
et,O
al,O
.,O
",",O
2013,O
),O
.,O
These,O
findings,O
indicate,O
that,O
aged,O
people,O
have,O
a,O
slower,O
recovery,O
from,O
COVID-19,O
than,O
young,O
people,O
.,O
Here,O
",",O
we,O
depicted,O
such,O
an,O
atlas,O
from,O
PBMCs,O
harvested,O
from,O
healthy,O
young,O
and,O
old,O
research,O
subjects,O
and,O
young,O
and,O
old,O
patients,O
with,O
COVID-19,O
.,O
Our,O
data,O
suggest,O
that,O
increased,O
numbers,O
of,O
MCs,O
may,O
contribute,O
to,O
cytokine,O
storms,O
in,O
coronavirus,O
infection,O
",",O
as,O
indicated,O
by,O
increased,O
numbers,O
of,O
MCs,O
during,O
aging,O
and,O
further,O
increases,O
in,O
COVID-19,O
",",O
whereas,O
TCs,O
that,O
are,O
critical,O
for,O
virus,O
clearance,O
(,O
Hickman,O
et,O
al,O
.,O
",",O
2015,O
;,O
Herzig,O
et,O
al,O
.,O
",",O
2019,O
),O
were,O
decreased,O
during,O
aging,O
and,O
further,O
reduced,O
in,O
COVID-19,O
.,O
In,O
addition,O
",",O
the,O
polarization,O
from,O
naive,O
to,O
effector,O
cells,O
was,O
further,O
enhanced,O
by,O
SARS,O
-,O
CoV-2,O
infection,O
in,O
COVID-19,O
.,O
Inflammatory,O
genes,O
such,O
as,O
IL1B,O
",",O
TNF,O
",",O
and,O
CXCL8,O
were,O
also,O
increased,O
during,O
aging,O
and,O
were,O
further,O
upregulated,O
in,O
COVID-19,O
.,O
Collectively,O
",",O
these,O
findings,O
reveal,O
that,O
aging,O
reprograms,O
the,O
landscape,O
of,O
human,O
immune,O
cells,O
toward,O
polarized,O
and,O
inflammatory,O
states,O
and,O
thus,O
increases,O
the,O
susceptibility,O
of,O
COVID-19,O
in,O
the,O
elderly,O
.,O
In,O
turn,O
",",O
COVID-19,O
causes,O
more,O
“,O
aging,O
”,O
of,O
polarization,O
and,O
inflammatory,O
states,O
in,O
immune,O
cells,O
.,O
Furthermore,O
",",O
we,O
reveal,O
novel,O
aging,O
-,O
related,O
genes,O
and,O
adaptive,O
immune,O
dysregulation,O
",",O
thus,O
defining,O
the,O
potential,O
contributions,O
of,O
aging,O
-,O
related,O
immune,O
cell,O
disorganization,O
to,O
the,O
high,O
severity,O
rate,O
of,O
aged,O
COVID-19,O
patients,O
(,O
Fig,O
.,O
 ,O
8),O
.,O
Here,O
",",O
we,O
combined,O
scRNA,O
-,O
seq,O
",",O
mass,O
cytometry,O
and,O
scATAC,O
-,O
seq,O
to,O
compare,O
immune,O
cell,O
types,O
in,O
peripheral,O
blood,O
collected,O
from,O
young,O
and,O
old,O
subjects,O
and,O
patients,O
with,O
COVID-19,O
.,O
Notably,O
",",O
COVID-19,O
promoted,O
age,O
-,O
induced,O
immune,O
cell,O
polarization,O
and,O
gene,O
expression,O
related,O
to,O
inflammation,O
and,O
cellular,O
senescence,O
.,O
Therefore,O
",",O
these,O
findings,O
suggest,O
that,O
a,O
dysregulated,O
immune,O
system,O
and,O
increased,O
gene,O
expression,O
associated,O
with,O
SARS,O
-,O
CoV-2,O
susceptibility,O
may,O
at,O
least,O
partially,O
account,O
for,O
COVID-19,O
vulnerability,O
in,O
the,O
elderly,O
.,O
The,O
novel,O
coronavirus,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS‐CoV‐2,O
),O
",",O
is,O
associated,O
with,O
the,O
current,O
pandemic,O
outbreak,O
of,O
COVID‐19,O
.,O
MERS,O
betacoronavirus,O
was,O
used,O
as,O
a,O
control,O
data,O
set,O
as,O
it,O
is,O
well‐studied,O
in,O
both,O
hosts,O
(,O
human,O
and,O
camel,O
),O
",",O
and,O
as,O
their,O
close,O
genetic,O
relationship,O
is,O
well‐characterized,O
.,O
For,O
the,O
next,O
experiment,O
",",O
based,O
on,O
the,O
alignment,O
and,O
comparison,O
of,O
the,O
structures,O
",",O
MERS,O
has,O
been,O
set,O
as,O
a,O
control,O
data,O
set,O
",",O
due,O
to,O
the,O
well‐characterized,O
close,O
relationship,O
between,O
human‐,O
and,O
camel‐delivered,O
strains,O
.,O
",",O
Therefore,O
",",O
our,O
results,O
suggest,O
that,O
the,O
human,O
SARS‐CoV‐2,O
",",O
responsible,O
for,O
the,O
current,O
outbreak,O
of,O
COVID‐19,O
",",O
could,O
also,O
come,O
from,O
yak,O
as,O
an,O
intermediate,O
host,O
.,O
During,O
the,O
submission,O
process,O
of,O
this,O
manuscript,O
",",O
the,O
crystal,O
structure,O
of,O
2019,O
-,O
nCoV,O
Mpro,O
was,O
solved,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6LU7,S-AccessionNumber
),O
",",O
of,O
which,O
the,O
lopinavir,O
/,O
ritonavir,O
binding,O
pocket,O
region,O
is,O
nearly,O
identical,O
to,O
our,O
predicted,O
model,O
(,O
Fig,O
.,O
 ,O
S1,O
),O
.,O
Based,O
on,O
these,O
results,O
",",O
we,O
performed,O
virtual,O
docking,O
to,O
screen,O
for,O
commercial,O
medicines,O
in,O
the,O
DrugBank,S-Repository
 ,O
database,O
that,O
could,O
bind,O
to,O
the,O
above,O
mentioned,O
pocket,O
site,O
of,O
2019,O
-,O
nCoV,O
Mpro,O
",",O
and,O
identified,O
10,O
candidate,O
clinical,O
medicines,O
(,O
Table,O
1,O
;,O
Figs,O
.,O
1B,O
and,O
S3,O
),O
.,O
(,O
Coronavirus,O
COVID-19,O
global,O
cases,O
by,O
the,O
centre,O
for,O
systems,O
science,O
and,O
engineering,O
at,O
Johns,O
Hopkins,O
University,O
),O
[,O
2,O
],O
.,O
A,O
total,O
of,O
45,O
confirmed,O
cases,O
of,O
COVID-19,O
diagnosed,O
at,O
Ramon,O
and,O
Cajal,O
University,O
Hospital,O
between,O
March,O
and,O
May,O
2020,O
were,O
included,O
in,O
this,O
pilot,O
study,O
.,O
In,O
this,O
web,O
",",O
frequencies,O
are,O
aggregated,O
by,O
country,O
but,O
reflect,O
the,O
distribution,O
of,O
HLA,O
data,O
available,O
in,O
this,O
Net,O
database,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
this,O
is,O
one,O
of,O
the,O
first,O
works,O
that,O
study,O
the,O
role,O
played,O
by,O
HLA,O
molecules,O
on,O
individual,O
responses,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
in,O
a,O
cohort,O
of,O
patients,O
from,O
Madrid,O
",",O
the,O
Spanish,O
region,O
with,O
the,O
highest,O
incidence,O
of,O
confirmed,O
cases,O
of,O
COVID-19,O
.,O
It,O
has,O
been,O
reported,O
to,O
have,O
a,O
low,O
affinity,O
for,O
the,O
virus,O
[,O
13,O
],O
and,O
to,O
be,O
statistically,O
significantly,O
associated,O
with,O
severe,O
SARS,O
-,O
CoV-1,O
disease,O
and,O
COVID-19,O
progression,O
in,O
studies,O
conducted,O
in,O
various,O
regions,O
of,O
China,O
[,O
"12,27",O
],O
.,O
The,O
ongoing,O
COVID-19,O
pandemic,O
caused,O
by,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
coronavirus-2,O
(,O
SARS,O
-,O
CoV-2,O
),O
infection,O
has,O
affected,O
over,O
6.5,O
million,O
people,O
thus,O
far,O
",",O
resulting,O
in,O
the,O
death,O
of,O
over,O
four,O
hundred,O
thousand,O
individuals,O
worldwide,O
(,O
1,O
),O
.,O
Recently,O
",",O
new,O
loss,O
of,O
the,O
sense,O
of,O
smell,O
",",O
either,O
total,O
(,O
anosmia,O
),O
or,O
partial,O
(,O
hyposmia,O
),O
",",O
has,O
been,O
recognised,O
as,O
a,O
symptom,O
of,O
COVID-19,O
by,O
the,O
World,O
Health,O
Organisation,O
(,O
WHO,O
),O
and,O
the,O
US,O
Centres,O
for,O
Disease,O
Control,O
and,O
Prevention,O
(,O
CDC,O
),O
(,O
www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html,O
),O
.,O
Accordingly,O
",",O
additional,O
research,O
focus,O
has,O
now,O
been,O
placed,O
on,O
exploring,O
anosmia,O
and,O
the,O
involvement,O
of,O
olfactory,O
receptors,O
(,O
ORs,O
),O
in,O
COVID-19,O
(,O
2,O
),O
.,O
Of,O
note,O
",",O
the,O
severity,O
of,O
COVID-19,O
shows,O
a,O
positive,O
association,O
with,O
certain,O
comorbidities,O
which,O
affect,O
these,O
tissues,O
/,O
systems,O
",",O
including,O
asthma,O
",",O
obesity,O
",",O
diabetes,O
and,O
cancer,O
(,O
7,O
),O
.,O
As,O
such,O
",",O
concentrating,O
on,O
non,O
-,O
neuronal,O
(,O
peripheral,O
),O
expression,O
of,O
ORs,O
",",O
here,O
we,O
provide,O
a,O
comprehensive,O
analysis,O
of,O
the,O
expression,O
profile,O
of,O
ORs,O
in,O
peripheral,O
tissues,O
",",O
several,O
of,O
which,O
co,O
-,O
express,O
ACE2,O
",",O
TMPRSS2,O
and,O
CTSL,O
and,O
are,O
correspondingly,O
associated,O
with,O
comorbidities,O
predisposing,O
to,O
severe,O
COVID-19,O
(,O
Fig,O
.,O
1,O
),O
.,O
Given,O
that,O
cancer,O
is,O
concidered,O
as,O
a,O
comorbididity,O
which,O
predisposes,O
to,O
severe,O
COVID-19,O
",",O
we,O
also,O
investigated,O
the,O
pan,O
-,O
cancer,O
expression,O
of,O
ORs,O
",",O
including,O
data,O
regarding,O
methylation,O
and,O
mutational,O
profiles,O
.,O
Using,O
the,O
TCGA,S-Repository
 ,O
datasets,O
for,O
all,O
cancers,O
",",O
only,O
four,O
ORs,O
appeared,O
to,O
be,O
significantly,O
differentially,O
regulated,O
(,O
Fig,O
.,O
4,O
),O
.,O
However,O
",",O
despite,O
the,O
extensive,O
data,O
regarding,O
decreased,O
methylation,O
status,O
within,O
an,O
array,O
of,O
data,O
sets,O
",",O
when,O
compared,O
with,O
GEPIA,O
expression,O
data,O
",",O
changes,O
in,O
methylation,O
status,O
of,O
nine,O
ORs,O
did,O
not,O
significantly,O
correlate,O
with,O
changes,O
in,O
gene,O
expression,O
.,O
Finally,O
",",O
the,O
data,O
from,O
cBioPortal,S-Repository
 ,O
revealed,O
that,O
the,O
highest,O
level,O
of,O
alterations,O
in,O
the,O
data,O
set,O
for,O
these,O
ORs,O
relates,O
to,O
gene,O
amplification,O
or,O
mutation,O
across,O
the,O
cancer,O
panel,O
(,O
Fig,O
.,O
6,O
),O
.,O
The,O
potential,O
involvement,O
of,O
ORs,O
in,O
the,O
loss,O
of,O
smell,O
as,O
one,O
of,O
the,O
COVID-19,O
presenting,O
symptoms,O
has,O
been,O
hypothesized,O
since,O
the,O
first,O
clinical,O
cases,O
of,O
COVID-19,O
patients,O
with,O
anosmia,O
(,O
15,O
),O
.,O
Indeed,O
",",O
given,O
the,O
known,O
expression,O
and,O
involvement,O
of,O
the,O
airway,O
smooth,O
muscle,O
ORs,O
in,O
bronchodilation,O
and,O
airway,O
relaxation,O
(,O
5,O
),O
;,O
such,O
peripheral,O
expression,O
of,O
ORs,O
may,O
have,O
additional,O
implications,O
relating,O
to,O
COVID-19,O
.,O
As,O
such,O
",",O
damage,O
and,O
potential,O
interference,O
with,O
signalling,O
pathways,O
associated,O
with,O
OR,O
functions,O
",",O
as,O
noted,O
for,O
nasal,O
epithelial,O
ORs,O
",",O
may,O
contribute,O
to,O
underlying,O
mechanisms,O
predisposing,O
to,O
adverse,O
COVID-19,O
related,O
clinical,O
outcomes,O
in,O
patients,O
with,O
certain,O
comorbidities,O
(,O
e.g.,O
",",O
asthma,O
or,O
cancer,O
),O
(,O
16,O
),O
.,O
In,O
addition,O
",",O
our,O
findings,O
suggest,O
potential,O
links,O
which,O
should,O
be,O
explored,O
in,O
the,O
context,O
of,O
male,O
preponderance,O
for,O
severe,O
COVID-19,O
",",O
given,O
that,O
a,O
number,O
of,O
ORs,O
were,O
overexpressed,O
in,O
testes,O
.,O
Interestingly,O
",",O
it,O
has,O
been,O
suggested,O
that,O
androgen,O
sensitivity,O
can,O
be,O
a,O
determinant,O
of,O
the,O
severity,O
COVID-19,O
manifests,O
(,O
24,O
),O
.,O
The,O
noted,O
high,O
levels,O
of,O
TMPRSS2,O
and,O
CTSL,O
expression,O
",",O
coupled,O
with,O
the,O
presented,O
data,O
regarding,O
OR,O
expression,O
(,O
e.g.,O
",",O
OR51E2,O
),O
in,O
malignant,O
and,O
healthy,O
tissues,O
suggest,O
additional,O
implications,O
which,O
merit,O
further,O
research,O
;,O
for,O
example,O
",",O
regarding,O
increased,O
expression,O
in,O
the,O
prostate,O
and,O
predisposition,O
to,O
severe,O
COVID-19,O
documented,O
in,O
male,O
patients,O
(,O
"14,25",O
),O
.,O
New,O
loss,O
of,O
smell,O
(,O
anosmia,O
/,O
hyposmia,O
),O
is,O
now,O
recognized,O
as,O
a,O
COVID-19,O
related,O
symptom,O
",",O
which,O
may,O
be,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
damage,O
of,O
the,O
olfactory,O
receptor,O
(,O
OR,O
),O
cells,O
in,O
the,O
nasal,O
neuroepithelium,O
and/or,O
central,O
involvement,O
of,O
the,O
olfactory,O
bulb,O
.,O
Further,O
in,O
vitro,O
and,O
clinical,O
studies,O
are,O
clearly,O
required,O
to,O
elucidate,O
the,O
role,O
of,O
ORs,O
",",O
both,O
at,O
the,O
olfactory,O
level,O
and,O
the,O
periphery,O
",",O
in,O
the,O
context,O
of,O
COVID-19,O
.,O
At,O
the,O
end,O
of,O
December,O
2019,O
",",O
an,O
outbreak,O
of,O
a,O
respiratory,O
disease,O
affecting,O
humans,O
in,O
China,O
was,O
reported,O
.,O
",",O
A,O
few,O
days,O
after,O
the,O
outbreak,O
was,O
announced,O
",",O
the,O
causal,O
agent,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
was,O
identified,O
as,O
severe,O
acute,O
respiratory,O
syndrome,O
-,O
related,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
a,O
novel,O
betacoronavirus,O
.,O
COVID-19,O
affects,O
people,O
of,O
all,O
ages,O
",",O
most,O
of,O
whom,O
will,O
develop,O
mild,O
to,O
moderate,O
symptoms,O
.,O
Most,O
people,O
with,O
COVID-19,O
(,O
84,O
%,O
),O
develop,O
a,O
mild,O
or,O
uncomplicated,O
illness,O
.,O
For,O
COVID-19,O
patients,O
admitted,O
to,O
ICU,O
",",O
the,O
disease,O
can,O
be,O
complicated,O
by,O
acute,O
respiratory,O
disease,O
syndrome,O
(,O
ARDS,O
),O
",",O
sepsis,O
and,O
septic,O
shock,O
",",O
and,O
multi,O
-,O
organ,O
failure,O
.,O
The,O
WHO,O
has,O
published,O
detailed,O
guidelines,O
for,O
clinical,O
management,O
of,O
patients,O
with,O
COVID-19,O
.,O
For,O
mild,O
COVID-19,O
cases,O
",",O
patients,O
can,O
be,O
provided,O
with,O
antipyretics,O
for,O
fever,O
.,O
The,O
management,O
of,O
severe,O
COVID-19,O
cases,O
includes,O
immediate,O
oxygen,O
therapy,O
and,O
monitoring,O
",",O
it,O
may,O
be,O
necessary,O
to,O
proactively,O
prevent,O
complications,O
and,O
secondary,O
infections,O
",",O
treat,O
underlying,O
diseases,O
and,O
provide,O
organ,O
function,O
support,O
.,O
",",O
Treatment,O
of,O
co,O
-,O
infections,O
relies,O
on,O
empirical,O
antimicrobial,O
therapy,O
to,O
treat,O
all,O
likely,O
pathogens,O
causing,O
severe,O
acute,O
respiratory,O
infection,O
(,O
SARI,O
),O
and,O
sepsis,O
(,O
Figure,O
 ,O
1,O
),O
.,O
Patients,O
suspected,O
to,O
have,O
COVID-19,O
should,O
be,O
administered,O
appropriate,O
empirical,O
antimicrobials,O
within,O
1,O
 ,O
h,O
of,O
identification,O
of,O
sepsis,O
.,O
Administration,O
of,O
antimicrobials,O
in,O
different,O
hospital,O
situations,O
during,O
the,O
COVID-19,O
pandemic,O
and,O
the,O
implications,O
for,O
AMR,O
in,O
One,O
Health,O
sectors,O
.,O
There,O
is,O
no,O
current,O
evidence,O
to,O
recommend,O
any,O
specific,O
treatment,O
for,O
patients,O
with,O
confirmed,O
COVID-19,O
.,O
While,O
a,O
variety,O
of,O
antiviral,O
agents,O
",",O
including,O
antiviral,O
peptides,O
(,O
e.g.,O
favipiravir,O
),O
and,O
corticosteroids,O
have,O
been,O
used,O
in,O
COVID-19,O
patients,O
",",O
their,O
role,O
and,O
mode,O
of,O
action,O
has,O
yet,O
to,O
be,O
established,O
.,O
",",O
Dexamethasone,O
",",O
a,O
corticosteroid,O
",",O
has,O
shown,O
benefits,O
in,O
critically,O
ill,O
patients,O
with,O
COVID-19,O
",",O
reducing,O
the,O
mortality,O
by,O
about,O
one,O
-,O
fifth,O
or,O
one,O
-,O
third,O
in,O
patients,O
requiring,O
oxygen,O
or,O
ventilator,O
support,O
",",O
respectively,O
.,O
The,O
antiviral,O
agent,O
remdesivir,O
is,O
the,O
most,O
promising,O
treatment,O
for,O
COVID-19,O
",",O
as,O
it,O
inhibits,O
the,O
activity,O
of,O
the,O
viral,O
RNA,O
-,O
dependent,O
RNA,O
polymerase,O
.,O
",",O
Information,O
on,O
antimicrobial,O
treatments,O
given,O
to,O
patients,O
with,O
SARS,O
-,O
CoV-2,O
infection,O
is,O
scarce,O
.,O
For,O
example,O
",",O
Chen,O
et,O
al,O
.,O
reported,O
that,O
15,O
%,O
of,O
COVID-19,O
patients,O
received,O
antifungal,O
treatment,O
and,O
71,O
%,O
received,O
antibiotic,O
treatment,O
",",O
25,O
%,O
of,O
whom,O
were,O
treated,O
with,O
a,O
single,O
antibiotic,O
and,O
45,O
%,O
with,O
combination,O
therapy,O
.,O
The,O
administration,O
of,O
antibiotics,O
was,O
also,O
reported,O
in,O
a,O
case,O
of,O
a,O
neonate,O
with,O
non,O
-,O
specific,O
symptoms,O
of,O
COVID-19,O
infection,O
;,O
this,O
neonate,O
received,O
fluid,O
therapy,O
",",O
oxygen,O
therapy,O
and,O
antibiotic,O
therapy,O
with,O
vancomycin,O
and,O
amikacin,O
.,O
Other,O
studies,O
did,O
not,O
describe,O
the,O
antimicrobial,O
types,O
used,O
",",O
reporting,O
only,O
the,O
administration,O
of,O
IV,O
antibiotic,O
and,O
antifungal,O
medications,O
in,O
57,O
%,O
and,O
3,O
%,O
of,O
COVID-19,O
patients,O
",",O
respectively,O
",",O
or,O
that,O
all,O
of,O
41,O
patients,O
(,O
100,O
%,O
),O
received,O
antibiotics,O
and,O
93,O
%,O
received,O
antiviral,O
treatments,O
.,O
Other,O
antibiotic,O
therapeutics,O
proposed,O
for,O
the,O
treatment,O
of,O
COVID-19,O
disease,O
are,O
azithromycin,O
",",O
quercetin,O
",",O
rapamycin,O
and,O
doxycycline,O
.,O
However,O
",",O
the,O
combination,O
of,O
hydroxychloroquine,O
(,O
an,O
analogue,O
of,O
chloroquine,O
considered,O
an,O
old,O
antimalarial,O
drug,O
),O
and,O
azithromycin,O
appeared,O
to,O
be,O
even,O
more,O
effective,O
in,O
COVID-19,O
treatment,O
.,O
The,O
COVID-19,O
pandemic,O
has,O
the,O
potential,O
to,O
become,O
a,O
sustained,O
major,O
public,O
health,O
emergency,O
.,O
In,O
the,O
COVID-19,O
pandemic,O
",",O
it,O
is,O
important,O
to,O
warn,O
of,O
the,O
unreported,O
amounts,O
of,O
antibiotics,O
and,O
antifungals,O
that,O
have,O
been,O
administered,O
worldwide,O
in,O
just,O
a,O
few,O
months,O
.,O
Rawson,O
et,O
al,O
.,O
highlighted,O
several,O
factors,O
and,O
potential,O
impacts,O
during,O
the,O
COVID-19,O
pandemic,O
",",O
as,O
well,O
as,O
potential,O
interventions,O
in,O
the,O
AMR,O
area,O
.,O
Regardless,O
of,O
the,O
COVID-19,O
pandemic,O
",",O
AMR,O
could,O
force,O
up,O
to,O
24,O
million,O
people,O
into,O
extreme,O
poverty,O
by,O
2030,O
and,O
drug,O
-,O
resistant,O
diseases,O
could,O
cause,O
10,O
million,O
deaths,O
each,O
year,O
by,O
2050,O
",",O
as,O
described,O
in,O
a,O
United,O
Nations,O
report,O
for,O
urgent,O
action,O
to,O
avert,O
the,O
AMR,O
crisis,O
.,O
",",O
A,O
sustained,O
One,O
Health,O
approach,O
is,O
essential,O
to,O
engage,O
and,O
unite,O
all,O
stakeholders,O
around,O
a,O
shared,O
vision,O
and,O
common,O
goals,O
",",O
since,O
this,O
global,O
crisis,O
includes,O
humans,O
",",O
animals,O
",",O
plants,O
",",O
food,O
and,O
the,O
environment,O
and,O
knows,O
no,O
borders,O
(,O
Figure,O
 ,O
1,O
),O
.,O
Multisectoral,O
and,O
multifaceted,O
actions,O
on,O
AMR,O
are,O
crucial,O
because,O
human,O
medicine,O
",",O
and,O
the,O
food,O
and,O
agricultural,O
sectors,O
use,O
antibiotics,O
daily,O
.,O
",",O
Abstract,O
 ,O
COVID-19,O
is,O
caused,O
by,O
the,O
SARS,O
-,O
CoV-2,O
virus,O
",",O
which,O
has,O
infected,O
more,O
than,O
4,O
million,O
people,O
with,O
278,O
 ,O
892,O
deaths,O
worldwide,O
as,O
of,O
11,O
May,O
2020,O
.,O
This,O
article,O
highlights,O
the,O
administration,O
of,O
antimicrobials,O
in,O
COVID-19,O
patients,O
worldwide,O
",",O
during,O
the,O
2019–20,O
pandemic,O
.,O
Primary,O
sequence,O
of,O
Saudi,O
Arabia,O
isolate,O
MERS,O
-,O
COVS,O
protein,O
was,O
retrieved,O
from,O
NCBI,S-Repository
 ,O
database,O
using,O
accession,O
number,O
ALW82742.1,S-AccessionNumber
 ,O
[,O
18,O
],O
.,O
Experimentally,O
known,O
3D,O
structure,O
of,O
MERS,O
-,O
COV,O
S,O
protein,O
was,O
retrieved,O
by,O
using,O
PDB,S-Repository
 ,O
ID,O
:,O
5X59,S-AccessionNumber
 ,O
from,O
Protein-Data-Bank,S-Repository
 ,O
[,O
19,O
],O
.,O
This,O
method,O
relies,O
on,O
surface,O
accessibility,O
and,O
amino,O
acid,O
statistics,O
in,O
a,O
collected,O
form,O
dataset,O
of,O
discontinuous,O
epitopes,O
found,O
out,O
by,O
X,O
-,O
ray,O
crystallography,O
of,O
antigen,O
/,O
antibody,O
protein,O
buildings,O
.,O
Aller,O
Hunter,O
server,O
compares,O
peptide,O
’s,O
query,O
sequences,O
opposed,O
to,O
the,O
database,O
of,O
previously,O
reported,O
allergens,O
to,O
give,O
significant,O
outcomes,O
.,O
S,O
protein,O
sequences,O
of,O
8,O
distinctive,O
countries,O
were,O
taken,O
from,O
an,O
open,O
access,O
Genbank,S-Repository
 ,O
database,O
[,O
38,O
],O
.,O
All,O
the,O
predicted,O
peptides,O
3D,O
structures,O
were,O
modelled,O
via,O
PEPFOLD,O
server,O
at,O
RPBS,O
MOBYL,O
portal,O
[,O
41,O
],O
",",O
from,O
Protein,B-Repository
databank,E-Repository
 ,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
3VCL,S-AccessionNumber
),O
at,O
a,O
resolution,O
of,O
1.7,O
Å,O
",",O
the,O
3D,O
structure,O
of,O
human,O
HLA,O
-,O
B7,O
allele,O
crystallized,O
was,O
taken,O
[,O
42,O
],O
and,O
utilized,O
for,O
further,O
molecular,O
docking,O
purpose,O
.,O
3D,O
structure,O
of,O
S,O
protein,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
5X59,S-AccessionNumber
),O
[,O
19,O
],O
was,O
used,O
for,O
discontinuous,O
epitopes,O
prediction,O
",",O
90,O
%,O
specificity,O
",",O
−,O
 ,O
3.700,O
threshold,O
and,O
22.000,O
Angstroms,O
propensity,O
score,O
radius,O
.,O
Crystal,O
structure,O
of,O
human,O
HLA,O
-,O
B7,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
3VCL,S-AccessionNumber
),O
protein,O
was,O
previously,O
accessible,O
with,O
co,O
-,O
crystallized,O
peptide,O
in,O
PDB,S-Repository
 ,O
[,O
42,O
],O
.,O
Peptide,O
‘,O
WPRPIDVSK,O
’,O
was,O
docked,O
(,O
dock,O
score,O
-20.4007,O
 ,O
kcal,O
/,O
mol,O
),O
inside,O
the,O
catalytic,O
pocket,O
of,O
receptor,O
protein,O
through,O
4,O
hydrogen,O
bonds,O
with,O
Arg-62,O
",",O
Glu-152,O
",",O
Glu-163,O
and,O
Trp-167,O
(,O
Fig,O
.,O
 ,O
6b,O
),O
.,O
Since,O
the,O
initial,O
outbreak,O
of,O
COVID-19,O
and,O
identification,O
of,O
a,O
novel,O
enveloped,O
RNA,O
betacoronavirus,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
reports,O
suggest,O
the,O
virus,O
might,O
be,O
evolving,O
",",O
albeit,O
at,O
a,O
lower,O
rate,O
than,O
influenza,O
viruses.1,O
",",O
2,O
",",O
3,O
Nevertheless,O
",",O
in,O
light,O
of,O
the,O
rapid,O
and,O
pandemic,O
-,O
scale,O
spread,O
of,O
COVID-19,O
",",O
mutations,O
in,O
SARS,O
-,O
CoV-2,O
raise,O
new,O
diagnostic,O
challenges,O
",",O
including,O
the,O
redesign,O
of,O
the,O
oligonucleotide,O
sequences,O
in,O
use,O
in,O
RT,O
-,O
qPCR,O
assays,O
to,O
circumvent,O
potential,O
primer,O
–,O
sample,O
mismatches,O
.,O
We,O
report,O
an,O
analysis,O
of,O
all,O
high,O
-,O
coverage,O
SARS,O
-,O
CoV-2,O
genome,O
sequences,O
(,O
1825,O
in,O
total,O
),O
deposited,O
in,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
database,O
as,O
of,O
March,O
30,O
",",O
2020,O
.,O
Oligonucleotide,O
optimisation,O
will,O
be,O
facilitated,O
by,O
global,O
sharing,O
of,O
SARS,O
-,O
CoV-2,O
genomes,O
and,O
the,O
frequently,O
updated,O
reports,O
on,O
sequence,O
analysis,O
that,O
are,O
available,O
on,O
the,O
GISAID,S-Dataset
 ,O
website,O
.,O
This,O
particular,O
disease,O
has,O
been,O
named,O
as,O
COVID-19,O
",",O
with,O
common,O
symptoms,O
such,O
as,O
loss,O
of,O
smell,O
",",O
muscle,O
ache,O
",",O
shortness,O
of,O
breath,O
and,O
fever,O
with,O
cough,O
(,O
Aanouz,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Alagaili,O
et,O
 ,O
al,O
.,O
",",O
2014,O
;,O
Bhakkiyalakshmi,O
et,O
 ,O
al,O
.,O
",",O
2016,O
;,O
Bonkowski,O
&,O
Sinclair,O
",",O
2016,O
),O
.,O
COVID-19,O
has,O
the,O
capability,O
to,O
spread,O
human,O
to,O
human,O
through,O
droplet,O
exchange,O
while,O
coughing,O
",",O
talking,O
",",O
and,O
sneezing,O
(,O
Chan,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Experimentally,O
solved,O
3D,O
structures,O
of,O
the,O
proteins,O
non,O
-,O
structural,O
protein,O
15,O
(,O
nsp15,O
),O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6VWW,S-AccessionNumber
),O
and,O
RNA,O
-,O
dependent,O
polymerase,O
(,O
RdRp,O
),O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6YYT,S-AccessionNumber
),O
",",O
human,O
angiotensin,O
receptor,O
(,O
ace2,O
),O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6M1D,S-AccessionNumber
",",O
chain,O
B,O
),O
were,O
used,O
for,O
this,O
study,O
.,O
"100,000",O
compounds,O
),O
was,O
obtained,O
from,O
ZINC,S-Repository
 ,O
database,O
(,O
Sterling,B-Creator
&,I-Creator
"Irwin,",I-Creator
2015,E-Creator
),O
for,O
the,O
best,O
optimal,O
hit,O
against,O
these,O
mentioned,O
targets,O
.,O
The,O
independence,O
of,O
the,O
endonuclease,O
activity,O
marks,O
our,O
third,O
protein,O
target,O
which,O
is,O
RdRp,O
",",O
known,O
as,O
RNA,O
-,O
dependent,O
polymerase,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6M17,S-AccessionNumber
),O
.,O
The,O
protein,O
on,O
the,O
human,O
side,O
(,O
ACE2,O
receptor,O
–,O
PDB,S-Repository
 ,O
ID,O
6M1D,S-AccessionNumber
),O
is,O
the,O
first,O
entry,O
point,O
for,O
the,O
SARS,O
-,O
CoV-2,O
to,O
playing,O
the,O
crucial,O
role,O
for,O
the,O
host,O
cells,O
allowing,O
the,O
entry,O
of,O
the,O
viral,O
genome,O
(,O
Yan,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
ongoing,O
pandemic,O
COVID-19,O
(,O
COrona,O
Virus,O
Immuno,O
Deficiency-2019,O
),O
which,O
is,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
(,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
–,O
CoronaVirus-2,O
),O
has,O
emerged,O
as,O
a,O
pandemic,O
with,O
"400,000",O
plus,O
deaths,O
till,O
date,O
.,O
The,O
expedition,O
for,O
searching,O
a,O
potential,O
drug,O
or,O
vaccine,O
against,O
COVID-19,O
will,O
be,O
of,O
massive,O
potential,O
and,O
favor,O
.,O
Our,O
studies,O
propose,O
Baicalin,O
and,O
Limonin,O
in,O
combination,O
to,O
be,O
studied,O
in,O
 ,O
vitro,O
and,O
in,O
 ,O
vivo,O
against,O
COVID-19,O
.,O
The,O
age,O
of,O
COVID-19,O
cases,O
in,O
urban,O
areas,O
ranged,O
from,O
19,O
to,O
90,O
years,O
",",O
averaging,O
51.89,O
years,O
(,O
51.89,O
±,O
15.79,O
years,O
),O
",",O
whereas,O
the,O
age,O
of,O
COVID-19,O
cases,O
in,O
suburban,O
areas,O
ranged,O
from,O
9,O
to,O
90,O
years,O
",",O
averaging,O
47.89,O
years,O
(,O
47.89,O
±,O
17.12,O
),O
.,O
The,O
distribution,O
of,O
COVID-19,O
cases,O
by,O
age,O
is,O
shown,O
in,O
Table,O
1,O
.,O
Of,O
all,O
of,O
the,O
COVID-19,O
cases,O
in,O
Tianjin,O
",",O
72,O
were,O
male,O
and,O
63,O
were,O
female,O
",",O
accounting,O
for,O
53.33,O
%,O
and,O
46.67,O
%,O
",",O
respectively,O
.,O
The,O
distribution,O
of,O
COVID-19,O
cases,O
by,O
gender,O
is,O
shown,O
in,O
Table,O
1,O
.,O
Of,O
the,O
total,O
COVID-19,O
cases,O
",",O
101,O
(,O
74.81,O
%,O
),O
cases,O
belonged,O
to,O
family,O
or,O
social,O
setting,O
(,O
including,O
workplace,O
and,O
public,O
place,O
),O
clusters,O
.,O
Figure,O
1,O
shows,O
the,O
familial,O
clustering,O
of,O
COVID-19,O
patients,O
.,O
Of,O
the,O
135,O
COVID-19,O
cases,O
in,O
Tianjin,O
",",O
26,O
(,O
29.55,O
%,O
),O
came,O
into,O
contact,O
with,O
the,O
epidemic,O
area,O
before,O
the,O
onset,O
of,O
symptoms,O
",",O
but,O
109,O
(,O
80.74,O
%,O
),O
had,O
no,O
history,O
of,O
contact,O
with,O
the,O
epidemic,O
area,O
before,O
the,O
onset,O
.,O
As,O
of,O
January,O
31,O
",",O
COVID-19,O
cases,O
with,O
no,O
history,O
of,O
sojourning,O
in,O
Hubei,O
began,O
to,O
account,O
for,O
the,O
majority,O
of,O
the,O
new,O
cases,O
.,O
Among,O
urban,O
residents,O
",",O
there,O
were,O
14,O
(,O
31.10,O
%,O
),O
COVID-19,O
cases,O
of,O
people,O
who,O
had,O
visited,O
Hubei,O
Province,O
and,O
31,O
(,O
68.90,O
%,O
),O
COVID-19,O
cases,O
of,O
people,O
who,O
had,O
not,O
.,O
Among,O
suburban,O
residents,O
",",O
there,O
were,O
6,O
(,O
7.14,O
%,O
),O
COVID-19,O
cases,O
of,O
people,O
who,O
had,O
visited,O
Hubei,O
Province,O
and,O
78,O
(,O
92.86,O
%,O
),O
COVID-19,O
cases,O
of,O
people,O
who,O
had,O
not,O
.,O
This,O
study,O
describes,O
the,O
epidemiologic,O
features,O
of,O
an,O
outbreak,O
of,O
the,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
in,O
Tianjin,O
caused,O
by,O
a,O
novel,O
coronavirus,O
and,O
provides,O
the,O
scientific,O
basis,O
for,O
prevention,O
and,O
control,O
measures,O
.,O
Methods,O
:,O
 ,O
Data,O
from,O
COVID-19,O
cases,O
were,O
collected,O
from,O
daily,O
notifications,O
given,O
to,O
the,O
National,B-Creator
Health,I-Creator
Commission,I-Creator
of,I-Creator
the,I-Creator
People’s,I-Creator
Republic,I-Creator
of,I-Creator
China,E-Creator
 ,O
and,O
Tianjin,B-Creator
Health,I-Creator
Committee,E-Creator
.,O
The,O
incidence,O
of,O
COVID-19,O
was,O
8.65/1,O
000,O
000,O
with,O
a,O
2.22,O
%,O
case,O
fatality,O
rate,O
.,O
A,O
familial,O
clustering,O
was,O
the,O
most,O
important,O
characteristic,O
of,O
COVID-19,O
(,O
accounting,O
for,O
74.81,O
%,O
),O
.,O
Conclusions,O
:,O
 ,O
Current,O
information,O
suggests,O
that,O
people,O
are,O
generally,O
susceptible,O
to,O
COVID-19,O
",",O
which,O
has,O
shown,O
a,O
familial,O
clustering,O
in,O
Tianjin,O
.,O
Thanks,O
to,O
next‐generation,O
sequencing,O
approach,O
",",O
a,O
new,O
coronavirus,O
was,O
quickly,O
identified,O
as,O
the,O
causative,O
agent,O
of,O
the,O
new,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
;,O
moreover,O
",",O
due,O
to,O
the,O
rapid,O
global,O
diffusion,O
",",O
WHO,O
declared,O
the,O
pandemic,O
status,O
on,O
11,O
March,O
2020,O
.,O
The,O
COVID‐19,O
related,O
virus,O
was,O
classified,O
as,O
a,O
betacoronavirus,O
and,O
",",O
considering,O
its,O
close,O
correlation,O
to,O
SARS‐CoV,O
",",O
it,O
was,O
renamed,O
SARS‐CoV‐2,O
.,O
Low‐quality,O
reads,O
bases,O
were,O
trimmed,O
out,O
using,O
Trimmomatic,O
software,O
",",O
 ,O
using,O
13,O
different,O
parameter,O
sets,O
(,O
LEADING:3,O
TRAILING:3,O
SLIDINGWINDOW:4:15,O
MINLEN:36,O
",",O
LEADING:3,O
TRAILING:3,O
SLIDINGWINDOW:4:20,O
MINLEN:36,O
",",O
LEADING:3,O
TRAILING:3,O
SLIDINGWINDOW:4:25,O
MINLEN:36,O
",",O
LEADING:3,O
TRAILING:10,O
SLIDINGWINDOW:4:15,O
MINLEN:36,O
",",O
LEADING:3,O
TRAILING:10,O
SLIDINGWINDOW:4:20,O
MINLEN:36,O
",",O
LEADING:3,O
TRAILING:10,O
SLIDINGWINDOW:4:25,O
MINLEN:36,O
",",O
LEADING:3,O
TRAILING:20,O
SLIDINGWINDOW:4:15,O
MINLEN:36,O
",",O
LEADING:3,O
TRAILING:20,O
SLIDINGWINDOW:4:20,O
MINLEN:36,O
",",O
LEADING:3,O
TRAILING:20,O
SLIDINGWINDOW:4:25,O
MINLEN:36,O
",",O
MAXINFO:50:0.3,O
",",O
MAXINFO:50:0.5,O
",",O
MAXINFO:50:0.7,O
",",O
MAXINFO:50:0.9,O
),O
.,O
Then,O
",",O
single‐nucleotide,O
polymorphism,O
(,O
SNP,O
),O
calling,O
was,O
performed,O
following,O
the,O
GATK,O
Best,O
Practice,O
procedure,O
",",O
 ,O
using,O
the,O
Wuhan‐Hu‐1,O
strain,O
genome,O
(,O
accession,O
MN908947.3,S-AccessionNumber
),O
as,O
reference,O
.,O
A,O
dataset,O
of,O
41,O
genome,O
assemblies,O
of,O
SARS‐CoV‐2,O
strains,O
isolated,O
in,O
Italy,O
between,O
20,O
February,O
2020,O
and,O
30,O
March,O
2020,O
was,O
retrieved,O
from,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
database,O
(,O
Table,O
S1,O
),O
.,O
A,O
global,O
dataset,O
including,O
these,O
41,O
GISAID,S-Dataset
 ,O
genome,O
assemblies,O
and,O
the,O
20,O
genome,O
assemblies,O
generated,O
in,O
this,O
study,O
was,O
produced,O
and,O
aligned,O
using,O
MAFFT,O
.,O
The,O
20,O
SARS‐CoV‐2,O
genome,O
assemblies,O
are,O
available,O
on,O
the,O
GISAD,S-Dataset
 ,O
database,O
(,O
Table,O
 ,O
1,O
),O
.,O
Lombardy,O
had,O
the,O
highest,O
prevalence,O
of,O
COVID‐19,O
in,O
Italy,O
",",O
thus,O
being,O
the,O
likely,O
epicenter,O
of,O
country,O
outbreak,O
.,O
A,O
phylogenetic,O
analysis,O
was,O
conducted,O
on,O
20,O
full‐length,O
genomes,O
from,O
patients,O
addressing,O
to,O
several,O
Lombard,O
hospitals,O
(,O
20,O
February,O
to,O
4,O
April,O
2020,O
),O
",",O
aligned,O
with,O
41,O
Italian,O
viral,O
genome,O
assemblies,O
from,O
GISAID,S-Dataset
 ,O
database,O
as,O
of,O
30,O
March,O
2020,O
.,O
These,O
amino‐acid,O
changes,O
appear,O
to,O
coexist,O
",",O
being,O
always,O
found,O
together,O
in,O
the,O
dataset,O
",",O
as,O
well,O
as,O
present,O
almost,O
exclusively,O
in,O
GISAID,S-Dataset
 ,O
20B,O
clade,O
.,O
Thereafter,O
Lombardy,O
has,O
reported,O
the,O
highest,O
prevalence,O
of,O
COVID‐19,O
cases,O
in,O
the,O
country,O
",",O
especially,O
in,O
Milano,O
",",O
Brescia,O
and,O
Bergamo,O
provinces,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
assess,O
the,O
potential,O
presence,O
of,O
different,O
viral,O
clusters,O
belonging,O
to,O
the,O
six,O
main,O
provinces,O
involved,O
in,O
Lombardy,O
COVID‐19,O
cases,O
in,O
order,O
to,O
highlight,O
peculiar,O
province‐dependent,O
viral,O
characteristics,O
.,O
A,O
phylogenetic,O
analysis,O
was,O
conducted,O
on,O
20,O
full,O
length,O
genomes,O
obtained,O
from,O
patients,O
addressing,O
to,O
several,O
Lombard,O
hospitals,O
from,O
February,O
20th,O
to,O
April,O
4th,O
",",O
2020,O
",",O
aligned,O
with,O
41,O
Italian,O
viral,O
genome,O
assemblies,O
available,O
on,O
GISAID,S-Dataset
 ,O
database,O
as,O
of,O
30th,O
March,O
",",O
2020,O
:,O
two,O
main,O
monophyletic,O
clades,O
",",O
containing,O
8,O
and,O
53,O
isolates,O
",",O
respectively,O
",",O
were,O
identified,O
.,O
In,O
addition,O
",",O
upon,O
entering,O
into,O
cells,O
",",O
exogenous,O
RNAs,O
need,O
to,O
escape,O
from,O
endosomal,O
trapping,O
and/or,O
degradation,O
by,O
large,O
classes,O
of,O
intracellular,O
ribonucleases,O
or,O
RNases,O
(,O
e.g.,O
",",O
endonucleases,O
",",O
and,O
5′,O
and,O
3′,O
exonucleases,O
),O
",",O
become,O
incorporated,O
into,O
specific,O
complex,O
",",O
and,O
get,O
access,O
to,O
the,O
targets,O
(,O
Fig,O
.,O
1,O
),O
to,O
exercise,O
pharmacological,O
effects,O
.,O
Although,O
IVT,O
is,O
unable,O
to,O
specifically,O
assemble,O
post,O
-,O
transcriptionally,O
modified,O
or,O
natural,O
nucleosides,O
into,O
an,O
mRNA,O
molecule,O
at,O
particular,O
sites,O
",",O
and,O
the,O
effects,O
of,O
such,O
modifications,O
on,O
the,O
efficiency,O
of,O
intracellular,O
translation,O
remain,O
obscure,O
",",O
systemic,O
incorporation,O
of,O
pseudouridine,O
(,O
Karikó,O
et,O
al,O
.,O
",",O
2008,O
),O
or,O
N1,O
-,O
methyl,O
-,O
pseudouridine,O
(,O
Svitkin,O
et,O
al,O
.,O
",",O
2017,O
),O
into,O
mRNA,O
substances,O
could,O
be,O
achieved,O
by,O
IVT,O
reactions,O
",",O
leading,O
to,O
an,O
improvement,O
of,O
translational,O
capacity,O
and,O
biological,O
stability,O
",",O
as,O
compared,O
with,O
unmodified,O
counterparts,O
.,O
Entrapment,O
of,O
a,O
ligand,O
can,O
stabilize,O
the,O
incorporation,O
of,O
the,O
switching,O
sequence,O
into,O
the,O
aptamer,O
domain,O
",",O
and,O
thus,O
the,O
expression,O
platform,O
is,O
induced,O
to,O
fold,O
into,O
a,O
specific,O
structure,O
to,O
modulate,O
the,O
expression,O
of,O
genes,O
controlling,O
the,O
biosynthesis,O
and,O
transport,O
of,O
metabolites,O
(,O
Serganov,O
and,O
Nudler,O
",",O
2013,O
;,O
Hallberg,O
et,O
al,O
.,O
",",O
2017,O
),O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
a,O
deadly,O
disease,O
induced,O
by,O
the,O
novel,O
coronavirus,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
was,O
first,O
discovered,O
in,O
China,O
",",O
and,O
is,O
accompanied,O
by,O
a,O
high,O
degree,O
of,O
morbidity,O
and,O
mortality,O
[,O
1,O
],O
.,O
Clinical,O
features,O
of,O
COVID-19,O
may,O
include,O
pyrexia,O
",",O
asthenia,O
",",O
dyspnea,O
",",O
as,O
well,O
as,O
acute,O
respiratory,O
distress,O
syndrome,O
",",O
septic,O
shock,O
",",O
and,O
coagulation,O
dysfunction,O
in,O
critically,O
ill,O
patients,O
[,O
3,O
],O
.,O
However,O
",",O
the,O
medical,O
pharmacotherapy,O
to,O
treat,O
COVID-19,O
is,O
still,O
insufficient,O
[,O
7,O
],O
.,O
Accordingly,O
",",O
it,O
is,O
necessary,O
to,O
explore,O
and,O
develop,O
bioactive,O
compounds,O
to,O
treat,O
COVID-19,O
.,O
All,O
these,O
pieces,O
of,O
evidence,O
suggest,O
that,O
vitamin,O
A,O
may,O
be,O
an,O
optional,O
treatment,O
for,O
COVID-19,O
;,O
however,O
",",O
to,O
date,O
there,O
has,O
been,O
no,O
investigation,O
of,O
VA,O
against,O
SARS,O
-,O
CoV-2,O
",",O
especially,O
its,O
pharmacological,O
mechanism,O
.,O
In,O
this,O
report,O
",",O
we,O
aimed,O
to,O
determine,O
and,O
identify,O
the,O
curative,O
effect,O
of,O
VA,O
for,O
treating,O
COVID-19,O
and,O
to,O
utilize,O
a,O
network,O
pharmacology,O
approach,O
to,O
uncover,O
the,O
mechanisms,O
underlying,O
the,O
therapeutic,O
role,O
of,O
VA,O
.,O
We,O
assayed,O
and,O
identified,O
393,O
SARS,O
-,O
CoV-2,O
-,O
associated,O
genes,O
from,O
the,O
Genecard,S-Repository
 ,O
and,O
OMIM,S-Repository
 ,O
datasets,O
.,O
These,O
findings,O
suggest,O
that,O
vitamin,O
A,O
could,O
be,O
a,O
potential,O
treatment,O
for,O
COVID-19,O
.,O
However,O
",",O
there,O
are,O
few,O
existing,O
drug,O
treatments,O
for,O
COVID-19,O
",",O
and,O
some,O
of,O
the,O
immunotherapy,O
treatments,O
and,O
antiviral,O
drugs,O
used,O
in,O
clinical,O
practice,O
have,O
shown,O
limited,O
therapeutic,O
effectiveness,O
[,O
18,O
],O
.,O
VA,O
may,O
exert,O
potent,O
",",O
beneficial,O
pharmacological,O
activity,O
for,O
the,O
treatment,O
of,O
COVID-19,O
via,O
associated,O
cytoprotection,O
",",O
anti,O
-,O
viral,O
and,O
anti,O
-,O
inflammatory,O
effects,O
",",O
and,O
immunoregulation,O
.,O
In,O
further,O
bioinformatics,O
and,O
computational,O
assays,O
",",O
the,O
therapeutic,O
mechanisms,O
of,O
VA,O
for,O
managing,O
COVID-19,O
could,O
be,O
conjunctively,O
actualized,O
through,O
collective,O
regulation,O
of,O
the,O
FoxO,O
signaling,O
pathway,O
",",O
GnRH,O
signaling,O
pathway,O
",",O
PD,O
-,O
L1,O
expression,O
",",O
and,O
PD-1,O
checkpoint,O
pathway,O
.,O
Adjuvant,O
supplementation,O
of,O
VA,O
may,O
enhance,O
the,O
therapeutic,O
efficacy,O
of,O
current,O
clinical,O
anti,O
-,O
viral,O
agents,O
and,O
immunotherapy,O
to,O
treat,O
potentially,O
fatal,O
COVID-19,O
.,O
More,O
importantly,O
",",O
VA,O
may,O
be,O
used,O
clinically,O
for,O
the,O
treatment,O
of,O
COVID-19,O
",",O
as,O
evidenced,O
by,O
the,O
identified,O
biological,O
processes,O
—,O
which,O
indicate,O
pharmacological,O
functions,O
—,O
and,O
the,O
signaling,O
pathways,O
",",O
which,O
suggest,O
therapeutic,O
mechanisms,O
(,O
Figure,O
6,O
),O
.,O
By,O
using,O
online,O
datasets,O
",",O
in,O
particular,O
TCMSP,S-Dataset
",",O
Drugbank,S-Repository
",",O
SuperPred,S-Dataset
",",O
Swiss,B-Dataset
Target,I-Dataset
Prediction,E-Dataset
",",O
ChemMapper,S-Dataset
",",O
and,O
BATMAN,B-Dataset
TCM,E-Dataset
",",O
all,O
target,O
genes,O
activated,O
by,O
VA,O
were,O
obtained,O
.,O
The,O
genes,O
activated,O
by,O
VA,O
were,O
collected,O
for,O
target,O
correction,O
from,O
reviewed,O
(,O
Swiss-Prot,S-Repository
),O
and,O
Uniprot,S-Repository
 ,O
databases,O
.,O
The,O
Genecard,S-Repository
 ,O
and,O
OMIM,S-Repository
 ,O
datasets,O
were,O
employed,O
to,O
harvest,O
SARS,O
-,O
CoV-2,O
genes,O
.,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
causes,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
an,O
epidemic,O
disease,O
characterized,O
by,O
rapid,O
infection,O
and,O
a,O
high,O
death,O
toll,O
.,O
The,O
clinical,O
diagnosis,O
of,O
patients,O
with,O
COVID-19,O
has,O
risen,O
sharply,O
",",O
especially,O
in,O
Western,O
countries,O
.,O
Globally,O
",",O
an,O
effective,O
treatment,O
for,O
COVID-19,O
is,O
still,O
limited,O
.,O
In,O
this,O
study,O
",",O
bioinformatics,O
analysis,O
and,O
computation,O
assays,O
using,O
a,O
network,O
pharmacology,O
method,O
were,O
conducted,O
to,O
explore,O
and,O
uncover,O
the,O
therapeutic,O
targets,O
and,O
mechanisms,O
of,O
VA,O
for,O
treating,O
COVID-19,O
.,O
Furthermore,O
",",O
seven,O
core,O
targets,O
of,O
VA,O
against,O
COVID-19,O
",",O
including,O
MAPK1,O
",",O
IL10,O
",",O
EGFR,O
",",O
ICAM1,O
",",O
MAPK14,O
",",O
CAT,O
",",O
and,O
PRKCB,O
were,O
identified,O
.,O
With,O
this,O
bioinformatics,O
-,O
based,O
report,O
",",O
we,O
reveal,O
",",O
for,O
the,O
first,O
time,O
",",O
the,O
anti,O
-,O
SARS,O
-,O
CoV-2,O
functions,O
and,O
mechanisms,O
of,O
VA,O
and,O
suggest,O
that,O
VA,O
may,O
act,O
as,O
a,O
potent,O
treatment,O
option,O
for,O
COVID-19,O
",",O
a,O
deadly,O
global,O
epidemic,O
.,O
In,O
December,O
2019,O
",",O
the,O
novel,O
coronavirus,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
emerged,O
in,O
the,O
city,O
of,O
Wuhan,O
in,O
Hubei,O
province,O
",",O
People,O
’s,O
Republic,O
of,O
China,O
",",O
as,O
the,O
etiologic,O
agent,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
which,O
has,O
hence,O
spread,O
worldwide,O
causing,O
a,O
global,O
pandemic,O
(,O
1–3,O
),O
.,O
Megahit,O
generated,O
in,O
all,O
cases,O
7,O
contigs,O
with,O
more,O
than,O
"1,000",O
 ,O
bp,O
and,O
100×,O
coverage,O
;,O
all,O
of,O
these,O
assembled,O
contigs,O
were,O
compared,O
(,O
using,O
BLASTn,O
),O
against,O
the,O
entire,O
nonredundant,O
(,O
nr,O
),O
nucleotide,O
and,O
protein,O
databases,O
.,O
The,O
longer,O
sequences,O
were,O
named,O
hCoV-19,O
/,O
Italy,O
/,O
FVG,O
/,O
ICGEB_S1,O
",",O
_,O
S5,O
",",O
_,O
S8,O
",",O
and,O
_,O
S9,O
and,O
were,O
deposited,O
in,O
GISAID,S-Dataset
 ,O
(,O
see,O
below,O
),O
.,O
Phylogenetic,O
trees,O
were,O
inferred,O
using,O
the,O
maximum,O
likelihood,O
method,O
implemented,O
in,O
the,O
MEGAX,O
program,O
using,O
the,O
GISAID,S-Dataset
 ,O
sequences,O
available,O
at,O
03,O
-,O
16,O
-,O
2020,O
(,O
6,O
),O
.,O
Bootstrap,O
support,O
values,O
were,O
calculated,O
from,O
500,O
pseudoreplicate,O
trees,O
of,O
the,O
whole,O
data,O
set,O
(,O
Fig,O
.,O
2,O
),O
.,O
Despite,O
a,O
high,O
burden,O
of,O
COVID-19,O
in,O
Italy,O
",",O
very,O
little,O
information,O
is,O
available,O
to,O
date,O
from,O
full,O
-,O
length,O
high,O
-,O
quality,O
sequences,O
.,O
The,O
first,O
sequences,O
deposited,O
in,O
GISAID,S-Dataset
 ,O
(,O
EPI_ISL_410545,S-AccessionNumber
 ,O
and,O
EPI_ISL_410546,S-AccessionNumber
),O
were,O
collected,O
in,O
Rome,O
from,O
a,O
Chinese,O
tourist,O
from,O
Hubei,O
province,O
who,O
got,O
infected,O
before,O
visiting,O
Italy,O
",",O
and,O
another,O
one,O
(,O
EPI_ISL_412974,S-AccessionNumber
),O
was,O
from,O
a,O
test,O
-,O
positive,O
Italian,O
citizen,O
returning,O
from,O
China,O
.,O
The,O
longer,O
sequences,O
were,O
named,O
hCoV-19,O
/,O
Italy,O
/,O
FVG,O
/,O
ICGEB_S1,O
",",O
_,O
S5,O
",",O
_,O
S8,O
",",O
and,O
_,O
S9,O
and,O
were,O
deposited,O
in,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
with,O
accession,O
numbers,O
EPI_ISL_417418,S-AccessionNumber
",",O
EPI_ISL_417419,S-AccessionNumber
",",O
EPI_ISL_417421,S-AccessionNumber
",",O
and,O
EPI_ISL_417423,S-AccessionNumber
",",O
respectively,O
(,O
9,O
),O
.,O
According,O
to,O
data,O
presented,O
by,O
the,O
COVID-19,O
situation,O
report,O
from,O
World,B-Creator
Health,I-Creator
Organization,I-Creator
(WHO),E-Creator
",",O
as,O
of,O
May,O
15,O
",",O
2020,O
",",O
the,O
virus,O
has,O
infected,O
more,O
than,O
"4,347,935",O
people,O
around,O
the,O
world,O
including,O
a,O
staggering,O
"297,241",O
deaths,O
",",O
with,O
a,O
cumulative,O
mortality,O
rate,O
of,O
>,O
6.8,O
%,O
and,O
exponentially,O
increased,O
in,O
between,O
March,O
and,O
April,O
[,O
2,O
],O
.,O
Despite,O
the,O
instantaneous,O
and,O
monumental,O
research,O
efforts,O
from,O
the,O
scientific,O
community,O
around,O
the,O
globe,O
at,O
present,O
",",O
no,O
effective,O
antiviral,O
treatment,O
or,O
vaccine,O
is,O
available,O
for,O
COVID-19,O
.,O
Recently,O
several,O
repurposing,O
studies,O
on,O
SARS,O
-,O
CoV-2,O
have,O
been,O
performed,O
using,O
clinically,O
approved,O
drugs,O
[,O
20,O
],O
",",O
among,O
which,O
a,O
very,O
new,O
study,O
comes,O
out,O
on,O
a,O
clinical,O
trial,O
of,O
Lopinavir,O
–,O
Ritonavir,O
drug,O
for,O
COVID-19,O
",",O
which,O
was,O
indicated,O
on,O
top,O
of,O
our,O
drug,O
repurposing,O
study,O
[,O
21,O
],O
.,O
To,O
this,O
end,O
",",O
a,O
recently,O
elucidated,O
X,O
-,O
ray,O
crystal,O
structure,O
of,O
SARS,O
-,O
CoV-2,O
Mpro,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6Y2F,S-AccessionNumber
),O
which,O
have,O
been,O
shown,O
with,O
an,O
α,O
-,O
ketoamide,O
as,O
a,O
potent,O
inhibitor,O
in,O
the,O
enzyme,O
’s,O
active,O
site,O
",",O
was,O
chosen,O
and,O
screened,O
for,O
several,O
FDA,O
approved,O
antiviral,O
drugs,O
to,O
simulate,O
the,O
Mpro,O
–,O
α,O
-,O
ketoamide,O
interactions,O
and,O
thereby,O
blocking,O
the,O
active,O
pocket,O
[,O
16,O
],O
.,O
The,O
crystal,O
structure,O
of,O
SARS,O
-,O
CoV-2,O
Mpro,O
in,O
the,O
apo,O
form,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6Y2E,S-AccessionNumber
),O
and,O
α,O
-,O
ketoamide,O
bound,O
form,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6Y2F,S-AccessionNumber
),O
shows,O
that,O
the,O
protein,O
makes,O
a,O
crystallographic,O
dimer,O
composed,O
of,O
two,O
monomers,O
of,O
identical,O
conformations,O
.,O
For,O
analysis,O
",",O
all,O
the,O
closely,O
related,O
and,O
complete,O
reference,O
genome,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
were,O
downloaded,O
from,O
the,O
NCBI,B-Repository
GenBank,E-Repository
 ,O
database,O
.,O
The,O
recently,O
elucidated,O
X,O
-,O
ray,O
crystal,O
structure,O
coordinates,O
of,O
SAR,O
-,O
CoV-2,O
Mpro,O
was,O
downloaded,O
from,O
RCSB,B-Repository
PDB,E-Repository
 ,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6Y2F,S-AccessionNumber
),O
",",O
having,O
1.75,O
 ,O
Å,O
resolution,O
.,O
To,O
further,O
identify,O
the,O
potent,O
inhibitors,O
for,O
SAR,O
-,O
CoV-2,O
Mpro,O
among,O
the,O
FDA,O
approved,O
antiviral,O
drugs,O
",",O
we,O
have,O
downloaded,O
more,O
than,O
75,O
drug,O
compounds,O
from,O
the,O
PubChem,S-Repository
 ,O
chemical,O
database,O
[,O
24,O
],O
.,O
In,O
the,O
present,O
study,O
",",O
the,O
docked,O
complexes,O
of,O
virtually,O
screened,O
top,O
three,O
drugs,O
Lopinavir,O
–,O
Ritonavir,O
",",O
Tipranavir,O
",",O
and,O
Raltegravir,O
with,O
the,O
X,O
-,O
ray,O
crystal,O
structure,O
of,O
SARS,O
-,O
CoV-2,O
Mpro,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6Y2F,S-AccessionNumber
),O
were,O
analyzed,O
through,O
MD,O
simulations,O
.,O
The,O
rapidly,O
spreading,O
disease,O
caused,O
by,O
the,O
novel,O
SARS,O
-,O
CoV-2,O
is,O
now,O
called,O
COVID-19,O
[,O
43,O
],O
.,O
This,O
drug,O
is,O
mainly,O
used,O
for,O
HIV,O
-,O
AIDS,O
to,O
control,O
HIV,O
infection,O
by,O
inhibiting,O
the,O
protease,O
and,O
help,O
to,O
decrease,O
the,O
amount,O
of,O
HIV,O
in,O
the,O
body,O
by,O
promoting,O
the,O
function,O
of,O
the,O
body,O
’s,O
natural,O
immune,O
system,O
to,O
work,O
better,O
[,O
48,O
],O
.,O
This,O
drug,O
could,O
also,O
be,O
used,O
with,O
other,O
combinations,O
like,O
Raltegravir,O
and,O
Lopinavir,O
for,O
the,O
treatment,O
of,O
COVID-19,O
",",O
if,O
found,O
producing,O
desirable,O
inhibitory,O
effect,O
against,O
SARS,O
-,O
CoV-2,O
protease,O
in,O
biochemical,O
activity,O
assay,O
or,O
cell,O
-,O
based,O
assays,O
.,O
This,O
MD,O
simulation,O
analysis,O
shows,O
the,O
promising,O
binding,O
stability,O
of,O
the,O
drug,O
compounds,O
with,O
the,O
binding,O
pocket,O
of,O
CoV-2,O
Mpro,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6Y2F,S-AccessionNumber
),O
.,O
The,O
rapidly,O
enlarging,O
COVID-19,O
pandemic,O
caused,O
by,O
the,O
novel,O
SARS,O
-,O
corona,O
virus-2,O
is,O
a,O
global,O
public,O
health,O
emergency,O
of,O
an,O
unprecedented,O
level,O
.,O
The,O
recently,O
concluded,O
α,O
-,O
ketoamide,O
ligand,O
-,O
bound,O
X,O
-,O
ray,O
crystal,O
structure,O
of,O
SARS,O
-,O
CoV-2,O
M,O
pro,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6Y2F,S-AccessionNumber
),O
from,O
Zhang,O
et,O
al,O
.,O
has,O
revealed,O
the,O
potential,O
inhibitor,O
binding,O
mechanism,O
and,O
the,O
molecular,O
determinants,O
responsible,O
for,O
substrate,O
binding,O
.,O
The,O
AFCD,O
of,O
Hong,O
Kong,O
stated,O
:,O
‘,O
Although,O
there,O
is,O
no,O
evidence,O
yet,O
that,O
pets,O
can,O
transmit,O
the,O
virus,O
to,O
other,O
pets,O
or,O
back,O
to,O
humans,O
",",O
we,O
strongly,O
advise,O
that,O
mammalian,O
pets,O
including,O
dogs,O
and,O
cats,O
from,O
households,O
with,O
persons,O
confirmed,O
as,O
infected,O
with,O
COVID-19,O
or,O
as,O
close,O
contacts,O
of,O
COVID-19,O
infected,O
persons,O
should,O
be,O
put,O
under,O
quarantine,O
in,O
AFCD,O
facilities,O
to,O
safeguard,O
public,O
and,O
animal,O
health,O
.,O
Neither,O
dog,O
showed,O
any,O
signs,O
of,O
being,O
ill,O
with,O
COVID-19,O
.,O
The,O
dog,O
was,O
17,O
years,O
old,O
and,O
had,O
ongoing,O
health,O
issues,O
that,O
were,O
likely,O
responsible,O
for,O
the,O
death,O
of,O
this,O
dog,O
",",O
rather,O
than,O
COVID-19,O
.,O
On,O
March,O
19,O
",",O
the,O
AFCD,O
reported,O
that,O
a,O
third,O
dog,O
",",O
a,O
German,O
Shepherd,O
Dog,O
living,O
with,O
an,O
owner,O
testing,O
positive,O
for,O
COVID-19,O
",",O
had,O
also,O
tested,O
positive,O
.,O
The,O
decision,O
to,O
test,O
will,O
be,O
made,O
collaboratively,O
between,O
local,O
",",O
state,O
",",O
and,O
federal,O
animal,O
and,O
public,O
health,O
officials,O
’,O
",",O
‘,O
After,O
the,O
decision,O
is,O
made,O
to,O
test,O
",",O
state,O
animal,O
health,O
officials,O
will,O
designate,O
a,O
state,O
-,O
appointed,O
veterinarian,O
",",O
USDA,O
-,O
accredited,O
veterinarian,O
",",O
or,O
foreign,O
animal,O
disease,O
diagnostician,O
to,O
collect,O
the,O
sample,O
using,O
appropriate,O
personal,O
protective,O
equipment,O
(,O
PPE,O
),O
and,O
sample,O
collection,O
methods,O
’,O
",",O
‘,O
While,O
we,O
are,O
recommending,O
these,O
as,O
good,O
practices,O
",",O
it,O
is,O
important,O
to,O
remember,O
that,O
",",O
to,O
date,O
",",O
there,O
have,O
not,O
been,O
any,O
reports,O
of,O
pets,O
or,O
other,O
animals,O
becoming,O
ill,O
with,O
SARS,O
-,O
CoV-2,O
",",O
and,O
there,O
is,O
currently,O
no,O
evidence,O
that,O
pets,O
can,O
spread,O
COVID-19,O
to,O
other,O
animals,O
",",O
including,O
people,O
’,O
(,O
8),O
.,O
Further,O
studies,O
are,O
needed,O
to,O
understand,O
if,O
and,O
how,O
different,O
animals,O
could,O
be,O
affected,O
by,O
COVID-19,O
virus,O
.,O
However,O
",",O
because,O
animals,O
and,O
people,O
can,O
sometimes,O
share,O
diseases,O
(,O
known,O
as,O
zoonotic,O
diseases,O
),O
",",O
it,O
is,O
still,O
recommended,O
that,O
people,O
who,O
are,O
sick,O
with,O
COVID-19,O
limit,O
contact,O
with,O
companion,O
and,O
other,O
animals,O
until,O
more,O
information,O
is,O
known,O
about,O
the,O
virus,O
’,O
(,O
9,O
),O
.,O
CDC,O
advise,O
‘,O
You,O
should,O
restrict,O
contact,O
with,O
pets,O
and,O
other,O
animals,O
while,O
you,O
are,O
sick,O
with,O
COVID-19,O
",",O
just,O
like,O
you,O
would,O
around,O
other,O
people,O
.,O
Although,O
there,O
have,O
not,O
been,O
reports,O
of,O
pets,O
or,O
other,O
animals,O
becoming,O
sick,O
with,O
COVID-19,O
",",O
it,O
is,O
still,O
recommended,O
that,O
people,O
sick,O
with,O
COVID-19,O
limit,O
contact,O
with,O
animals,O
until,O
more,O
information,O
is,O
known,O
about,O
the,O
virus,O
.,O
If,O
you,O
are,O
sick,O
with,O
COVID-19,O
",",O
avoid,O
contact,O
with,O
your,O
pet,O
",",O
including,O
petting,O
",",O
snuggling,O
",",O
being,O
kissed,O
or,O
licked,O
",",O
and,O
sharing,O
food,O
.,O
We,O
studied,O
8612,O
genomes,O
obtained,O
from,O
GISAID’s,B-Dataset
EpiCoV™,E-Dataset
 ,O
presenting,O
less,O
than,O
1,O
%,O
non,O
-,O
DNA,O
characters,O
(,O
high,O
coverage,O
only,O
option,O
),O
(,O
Elbe,B-Creator
and,I-Creator
"Buckland-Merrett,",I-Creator
2017,E-Creator
;,O
Shu,B-Creator
and,I-Creator
"McCauley,",I-Creator
2017,E-Creator
),O
.,O
The,O
final,O
",",O
high,O
-,O
quality,O
dataset,O
had,O
"4,333",O
genomes,O
.,O
Shortly,O
",",O
we,O
made,O
an,O
R,O
script,O
that,O
takes,O
a,O
sequence,O
(,O
the,O
query,O
),O
from,O
the,O
dataset,O
",",O
determines,O
which,O
sequences,O
are,O
identical,O
to,O
it,O
",",O
put,O
these,O
together,O
in,O
an,O
identity,O
cluster,O
",",O
and,O
record,O
the,O
size,O
(,O
number,O
of,O
sequences,O
",",O
interpreted,O
as,O
SV,O
abundance,O
),O
of,O
the,O
cluster,O
.,O
The,O
process,O
was,O
repeated,O
until,O
all,O
the,O
sequences,O
in,O
the,O
dataset,O
were,O
processed,O
.,O
Once,O
aligned,O
",",O
our,O
high,O
-,O
quality,O
dataset,O
presented,O
2713,O
polymorphic,O
sites,O
of,O
which,O
885,O
were,O
parsimony,O
informative,O
.,O
The,O
dataset,O
was,O
phylogenetically,O
analyzed,O
with,O
IQTREE,O
(,O
Minh,O
et,O
al,O
.,O
",",O
2020,O
),O
using,O
the,O
GTR,O
 ,O
+,O
The,O
database,O
used,O
in,O
this,O
study,O
is,O
the,O
major,O
SARS,O
-,O
CoV-2,O
sequence,O
repository,O
and,O
can,O
be,O
considered,O
reliable,O
.,O
The,O
given,O
name,O
to,O
the,O
disease,O
associated,O
with,O
the,O
coronavirus,O
was,O
COVID19,O
",",O
while,O
novel,O
CoV,O
was,O
named,O
as,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
COVID19,O
is,O
milder,O
but,O
a,O
highly,O
transmissible,O
infectious,O
disease,O
compared,O
with,O
SARS,O
(,O
severe,O
acute,O
respiratory,O
syndrome,O
),O
and,O
MERS,O
(,O
Middle,O
East,O
respiratory,O
syndrome,O
),O
outbreaks,O
",",O
according,O
to,O
morbidity,O
and,O
mortality,O
rates,O
[,O
2,O
",",O
3,O
],O
.,O
Today,O
",",O
the,O
involvement,O
of,O
the,O
Huanan,O
market,O
with,O
COVID19,O
origin,O
seems,O
controversial,O
[,O
12,O
",",O
13,O
],O
.,O
Maximum,O
likelihood,O
phylogenetic,O
analysis,O
involved,O
87,O
amino,O
acid,O
sequences,O
from,O
CoV,O
S,O
protein,O
obtained,O
from,O
NCBI,B-Repository
Protein,E-Repository
 ,O
database,O
(,O
www.ncbi.nlm.nih.gov/protein/,S-URL
),O
.,O
Malayan,O
pangolin,O
MT084071,S-AccessionNumber
 ,O
sequence,O
was,O
translated,O
from,O
annotated,O
coding,O
region,O
obtained,O
from,O
NCBI,S-Repository
 ,O
Genbank,S-Repository
 ,O
database,O
(,O
www.ncbi.nlm.nih.gov/genbank/,S-URL
),O
.,O
Accession,O
codes,O
were,O
included,O
in,O
each,O
taxon,O
name,O
.,O
There,O
were,O
a,O
total,O
of,O
1494,O
positions,O
in,O
the,O
final,O
dataset,O
.,O
All,O
amino,O
acids,O
sequences,O
were,O
obtained,O
by,O
NCBI,B-Repository
Protein,E-Repository
 ,O
database,O
(,O
www.ncbi.nlm.nih.gov/protein/,S-URL
),O
.,O
All,O
sequences,O
were,O
obtained,O
from,O
NCBI,B-Repository
Protein,E-Repository
 ,O
database,O
(,O
www.ncbi.nlm.nih.gov/protein/,S-URL
),O
.,O
R.,O
sinicus,O
ASM188883v1,O
sequence,O
was,O
translated,O
based,O
on,O
genome,O
assembly,O
obtained,O
from,O
NCBI,B-Repository
Genome,E-Repository
 ,O
database,O
(,O
www.ncbi.nlm.nih.gov/genome/,S-URL
),O
.,O
Accession,O
codes,O
were,O
included,O
in,O
each,O
taxon,O
name,O
.,O
There,O
were,O
a,O
total,O
of,O
829,O
positions,O
in,O
the,O
final,O
dataset,O
An,O
emergence,O
of,O
a,O
novel,O
coronavirus,O
",",O
causative,O
agent,O
of,O
COVID19,O
",",O
named,O
as,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
occurred,O
due,O
to,O
cross,O
-,O
species,O
transmission,O
.,O
All,O
the,O
data,O
obtained,O
from,O
NCBI,B-Repository
Protein,E-Repository
 ,O
and,O
NCBI,S-Repository
 ,O
GenBank,S-Repository
 ,O
databases,O
included,O
in,O
this,O
research,O
study,O
presented,O
accession,O
code,O
/,O
numbers,O
for,O
research,O
or,O
reanalysis,O
.,O
The,O
rapid,O
emergence,O
of,O
COVID-19,O
has,O
sent,O
shockwaves,O
through,O
healthcare,O
systems,O
globally,O
",",O
with,O
cancer,O
patients,O
at,O
increased,O
risk,O
.,O
As,O
a,O
corollary,O
",",O
the,O
pangolin,O
trade,O
has,O
very,O
recently,O
been,O
pinpointed,O
as,O
posing,O
a,O
serious,O
threat,O
to,O
human,O
health,O
",",O
pangolins,O
being,O
potentially,O
involved,O
in,O
the,O
COVID-19,O
pandemic,O
[,O
5,O
",",O
6,O
],O
.,O
We,O
used,O
the,O
Multilocus,O
tagging,O
option,O
in,O
GenAlex,O
to,O
detect,O
identical,O
genotypes,O
in,O
our,O
dataset,O
(,O
sub,O
-,O
option,O
‘,O
Matches,O
’,O
),O
.,O
The,O
20,O
loci,O
were,O
successfully,O
amplified,O
(,O
with,O
100,O
%,O
PCR,O
success,O
rate,O
),O
",",O
with,O
only,O
0.84,O
%,O
missing,O
data,O
in,O
our,O
final,O
multilocus,O
dataset,O
(,O
Table,O
1,O
),O
.,O
Pangolins,O
",",O
or,O
scaly,O
anteaters,O
",",O
have,O
recently,O
been,O
flagshiped,O
as,O
one,O
of,O
the,O
most,O
illegally,O
traded,O
mammals,O
",",O
and,O
as,O
a,O
corollary,O
",",O
as,O
potential,O
intermediate,O
hosts,O
at,O
the,O
origin,O
of,O
the,O
COVID-19,O
pandemic,O
.,O
The,O
novel,O
coronavirus,O
was,O
named,O
2019‐nCoV,O
by,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
on,O
January,O
12,O
",",O
2020,O
",",O
and,O
was,O
later,O
named,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus‐2,O
(,O
SARS‐CoV‐2,O
),O
by,O
the,O
International,O
Classification,O
Committee,O
of,O
Viruses,O
on,O
February,O
11,O
",",O
2020,O
.,O
",",O
  ,O
Now,O
",",O
the,O
associated,O
disease,O
has,O
been,O
named,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
by,O
the,O
WHO,O
.,O
",",O
The,O
transmission,O
mode,O
for,O
COVID‐19,O
has,O
been,O
shown,O
to,O
be,O
human,O
to,O
human,O
.,O
COVID‐19,O
is,O
currently,O
a,O
global,O
pandemic,O
",",O
and,O
over,O
2,O
 ,O
740,O
 ,O
000,O
cases,O
of,O
COVID‐2019,O
and,O
191,O
 ,O
000,O
deaths,O
have,O
been,O
reported,O
globally,O
as,O
of,O
April,O
24,O
",",O
2020,O
.,O
We,O
hypothesized,O
that,O
HLA,O
variation,O
in,O
the,O
population,O
may,O
be,O
associated,O
with,O
the,O
occurrence,O
of,O
COVID‐19,O
",",O
because,O
HLA,O
plays,O
a,O
pivotal,O
role,O
in,O
the,O
immune,O
response,O
to,O
pathogens,O
.,O
Here,O
",",O
we,O
report,O
HLA,O
allele,O
frequencies,O
in,O
Chinese,O
Han,O
individuals,O
with,O
COVID‐19,O
and,O
a,O
comparison,O
between,O
HLA,O
allele,O
distribution,O
in,O
COVID‐19,O
patients,O
and,O
healthy,O
individuals,O
.,O
Eighty‐two,O
Han,O
individuals,O
from,O
Zhejiang,O
with,O
confirmed,O
COVID‐19,O
were,O
tested,O
.,O
All,O
patients,O
had,O
mild,O
or,O
severe,O
COVID‐19,O
",",O
with,O
none,O
in,O
a,O
critical,O
condition,O
.,O
Individuals,O
were,O
recruited,O
for,O
plasma,O
donation,O
after,O
recovery,O
and,O
the,O
plasma,O
was,O
used,O
for,O
treatment,O
of,O
other,O
COVID‐19,O
patients,O
with,O
severe,O
or,O
critical,O
symptoms,O
.,O
The,O
allele,O
distributions,O
of,O
HLA‐A,O
",",O
‐C,O
",",O
‐B,O
",",O
‐DRB1,O
",",O
‐DQB1,O
",",O
and,O
‐DPB1,O
loci,O
were,O
compared,O
between,O
COVID‐19,O
patients,O
and,O
control,O
individuals,O
.,O
The,O
frequencies,O
and,O
ORs,O
of,O
the,O
HLA,O
alleles,O
",",O
with,O
uncorrected,O
significance,O
",",O
for,O
COVID‐19,O
patients,O
are,O
listed,O
in,O
Table,O
1,O
.,O
HLA‐C*07:29,O
",",O
C*08:01,O
G,O
(,O
including,O
C*08:01,O
and,O
C*08:22,O
),O
",",O
B*15:27,O
",",O
B*40:06,O
",",O
DRB1,O
*,O
04:06,O
",",O
and,O
DPB1,O
*,O
36:01,O
frequencies,O
were,O
higher,O
in,O
COVID‐19,O
patients,O
than,O
in,O
the,O
control,O
population,O
",",O
with,O
uncorrected,O
statistical,O
significance,O
(,O
P,O
<,O
 ,O
.05,O
),O
.,O
Meanwhile,O
",",O
the,O
frequencies,O
of,O
the,O
DRB1,O
*,O
12:02,O
and,O
DPB1,O
*,O
04:01,O
alleles,O
were,O
significantly,O
lower,O
in,O
COVID‐19,O
patients,O
(,O
Pc,O
<,O
 ,O
.05,O
),O
",",O
with,O
ORs,O
of,O
0.44,O
and,O
0.40,O
",",O
respectively,O
.,O
In,O
the,O
present,O
study,O
",",O
HLA‐C*07:29,O
was,O
found,O
in,O
one,O
COVID‐19,O
patient,O
",",O
but,O
in,O
no,O
individuals,O
in,O
the,O
control,O
group,O
.,O
Two,O
alleles,O
",",O
B*07:02,O
(,O
1.38,O
%,O
),O
and,O
B*27:04,O
(,O
1.92,O
%,O
),O
",",O
with,O
frequencies,O
greater,O
than,O
1,O
%,O
in,O
the,O
control,O
group,O
",",O
were,O
not,O
found,O
in,O
COVID‐19,O
patients,O
.,O
Therefore,O
",",O
the,O
association,O
of,O
HLA,O
alleles,O
with,O
COVID‐19,O
warrants,O
further,O
research,O
.,O
",",O
In,O
the,O
present,O
study,O
",",O
these,O
SARS‐susceptibility,O
alleles,O
were,O
not,O
found,O
to,O
occur,O
at,O
a,O
significantly,O
different,O
frequency,O
in,O
COVID‐19,O
patients,O
after,O
P‐value,O
correction,O
.,O
We,O
found,O
that,O
B*15:27,O
alleles,O
may,O
be,O
associated,O
with,O
the,O
occurrence,O
of,O
COVID‐19,O
.,O
Prediction,O
of,O
the,O
peptide‐binding,O
groove,O
of,O
these,O
alleles,O
may,O
help,O
to,O
explain,O
their,O
association,O
with,O
COVID‐19,O
.,O
Although,O
the,O
number,O
of,O
samples,O
in,O
the,O
present,O
study,O
was,O
small,O
",",O
these,O
data,O
will,O
still,O
be,O
useful,O
for,O
exploring,O
the,O
influence,O
of,O
HLA,O
gene,O
polymorphisms,O
on,O
susceptibility,O
to,O
COVID‐19,O
and,O
patient,O
outcomes,O
.,O
COVID‐19,O
is,O
a,O
respiratory,O
disease,O
caused,O
by,O
a,O
novel,O
coronavirus,O
and,O
is,O
currently,O
a,O
global,O
pandemic,O
.,O
HLA,O
variation,O
is,O
associated,O
with,O
COVID‐19,O
because,O
HLA,O
plays,O
a,O
pivotal,O
role,O
in,O
the,O
immune,O
response,O
to,O
pathogens,O
.,O
Here,O
",",O
82,O
individuals,O
with,O
COVID‐19,O
were,O
genotyped,O
for,O
HLA‐A,O
",",O
‐B,O
",",O
‐C,O
",",O
‐DRB1,O
",",O
‐DRB3/4/5,O
",",O
‐DQA1,O
",",O
‐DQB1,O
",",O
‐DPA1,O
",",O
and,O
‐DPB1,O
loci,O
using,O
next‐generation,O
sequencing,O
(,O
NGS,O
),O
.,O
Frequencies,O
of,O
the,O
HLA‐C*07:29,O
",",O
C*08:01,O
G,O
",",O
B*15:27,O
",",O
B*40:06,O
",",O
DRB1,O
*,O
04:06,O
",",O
and,O
DPB1,O
*,O
36:01,O
alleles,O
were,O
higher,O
",",O
while,O
the,O
frequencies,O
of,O
the,O
DRB1,O
*,O
12:02,O
and,O
DPB1,O
*,O
04:01,O
alleles,O
were,O
lower,O
in,O
COVID‐19,O
patients,O
than,O
in,O
the,O
control,O
population,O
",",O
with,O
uncorrected,O
statistical,O
significance,O
.,O
These,O
data,O
suggested,O
that,O
some,O
HLA,O
alleles,O
may,O
be,O
associated,O
with,O
the,O
occurrence,O
of,O
COVID‐19,O
.,O
X,O
-,O
ray,O
data,O
were,O
collected,O
on,O
crystals,O
of,O
the,O
PLpro,O
-,O
ISG15,O
complex,O
at,O
100,O
 ,O
K,O
using,O
a,O
Dectris,O
Eiger,O
9,O
M,O
detector,O
(,O
a,O
2,O
°,O
/s,O
spindle,O
rate,O
),O
on,O
beamline,O
21,O
-,O
ID,O
-,O
D,O
at,O
the,O
Life,O
Sciences,O
-,O
Collaborative,O
Access,O
Team,O
(,O
LS,O
-,O
CAT,O
),O
.,O
To,O
determine,O
the,O
initial,O
phases,O
for,O
the,O
PLpro,O
-,O
ISG15,O
complex,O
",",O
the,O
PLpro,O
domain,O
from,O
the,O
bound,O
PLpro,O
-,O
Ub,O
complex,O
(,O
PDB,S-Repository
 ,O
accession,O
code,O
:,O
),O
was,O
used,O
as,O
a,O
search,O
model,O
and,O
the,O
programs,O
Phaser,O
(,O
McCoy,O
et,O
al,O
.,O
",",O
2007,O
),O
and,O
Phenix,O
were,O
used,O
to,O
identify,O
a,O
molecular,O
replacement,O
solution,O
.,O
Free,O
human,O
ISG15,O
(,O
Narasimhan,O
et,O
al,O
.,O
",",O
2005,O
),O
with,O
the,O
PDB,S-Repository
 ,O
accession,O
code,O
of,O
 ,O
was,O
manually,O
positioned,O
into,O
the,O
corresponding,O
residual,O
electron,O
density,O
using,O
the,O
program,O
Coot,O
(,O
Emsley,O
and,O
Cowtan,O
",",O
2004,O
),O
.,O
The,O
wild,O
-,O
type,O
pEVL8,O
-,O
his8,O
-,O
TEVp,O
-,O
MERS,O
-,O
CoV,O
PLpro,O
-,O
ΔUbl2,O
plasmid,O
was,O
used,O
as,O
a,O
template,O
and,O
primers,O
were,O
designed,O
and,O
synthesized,O
using,O
Integrated,O
DNA,O
Technologies,O
(,O
IDT,O
),O
.,O
Three,O
complete,O
X,O
-,O
ray,O
datasets,O
were,O
collected,O
on,O
crystals,O
of,O
the,O
MERS,O
-,O
CoV,O
PLpro,O
-,O
ISG15,O
complex,O
that,O
were,O
grown,O
at,O
three,O
different,O
citrate,O
concentrations,O
(,O
0.2,O
",",O
0.3,O
and,O
0.35,O
 ,O
M,O
),O
.,O
To,O
identify,O
potential,O
residues,O
of,O
MERS,O
-,O
CoV,O
PLpro,O
that,O
dictate,O
substrate,O
specificity,O
for,O
ISG15,O
versus,O
Ub,O
",",O
the,O
MERS,O
-,O
CoV,O
PLpro,O
-,O
ISG15,O
structure,O
was,O
superimposed,O
with,O
the,O
Ub,O
-,O
bound,O
structure,O
(,O
PDB,S-Repository
 ,O
accession,O
code,O
),O
and,O
the,O
result,O
is,O
shown,O
in,O
Fig,O
.,O
3,O
.,O
The,O
outbreak,O
of,O
a,O
novel,O
coronavirus,O
disease,O
(,O
COVID-19,O
",",O
caused,O
by,O
the,O
2019,O
-,O
nCoV,O
infection,O
),O
in,O
December,O
2019,O
is,O
one,O
of,O
the,O
most,O
severe,O
public,O
health,O
emergencies,O
since,O
the,O
founding,O
of,O
People,O
’s,O
Republic,O
of,O
China,O
in,O
1949,O
.,O
Sadly,O
",",O
as,O
of,O
February,O
20,O
",",O
2020,O
",",O
over,O
two,O
thousand,O
COVID-19,O
cases,O
are,O
confirmed,O
among,O
HCP,O
from,O
476,O
hospitals,O
nationwide,O
",",O
with,O
nearly,O
90,O
%,O
of,O
them,O
from,O
Hubei,O
Province,O
.,O
The,O
experience,O
and,O
lessons,O
learned,O
should,O
be,O
a,O
valuable,O
asset,O
for,O
international,O
health,O
community,O
to,O
contain,O
the,O
ongoing,O
COVID-19,O
epidemic,O
around,O
the,O
world,O
.,O
Identifying,O
the,O
first,O
introduction,O
of,O
the,O
virus,O
is,O
of,O
epidemiological,O
interest,O
",",O
for,O
the,O
tracking,O
and,O
mapping,O
of,O
COVID-19,O
spread,O
in,O
a,O
country,O
.,O
In,O
Italy,O
",",O
and,O
elsewhere,O
",",O
there,O
have,O
been,O
speculations,O
to,O
the,O
effect,O
that,O
COVID-19,O
had,O
been,O
silently,O
circulating,O
before,O
the,O
first,O
case,O
was,O
identified,O
.,O
In,O
France,O
",",O
where,O
the,O
COVID-19,O
epidemic,O
was,O
believed,O
to,O
have,O
started,O
in,O
late,O
January,O
2020,O
",",O
a,O
retrospective,O
analysis,O
of,O
a,O
stored,O
respiratory,O
sample,O
from,O
a,O
patient,O
hospitalised,O
in,O
December,O
2019,O
",",O
demonstrated,O
that,O
the,O
patient,O
was,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
",",O
suggesting,O
that,O
",",O
in,O
France,O
",",O
the,O
epidemic,O
started,O
much,O
earlier,O
than,O
previously,O
thought,O
(,O
Deslandes,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
It,O
is,O
known,O
that,O
gastrointestinal,O
symptoms,O
are,O
seen,O
in,O
patients,O
with,O
COVID-19,O
(,O
between,O
16,O
%,O
to,O
33,O
%,O
in,O
most,O
studies,O
),O
",",O
and,O
that,O
approximately,O
50,O
%,O
of,O
patients,O
with,O
COVID-19,O
have,O
detectable,O
virus,O
in,O
their,O
stool,O
(,O
Ouali,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
viral,O
load,O
in,O
the,O
faeces,O
of,O
COVID-19,O
patients,O
was,O
estimated,O
between,O
103,O
and,O
107,O
copies,O
/,O
mL,O
",",O
depending,O
on,O
the,O
infection,O
course,O
(,O
reviewed,O
in,O
Foladori,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Sequences,O
were,O
submitted,O
to,O
NCBI,S-Repository
 ,O
GenBank,S-Repository
 ,O
with,O
the,O
following,O
accession,O
numbers,O
:,O
MT843229,S-AccessionNumber
-,O
MT843240,S-AccessionNumber
.,O
A,O
sustained,O
local,O
transmission,O
has,O
been,O
documented,O
",",O
so,O
that,O
by,O
11th,O
August,O
2020,O
",",O
250.973,O
COVID-19,O
cases,O
were,O
diagnosed,O
",",O
with,O
35.6441,O
deaths,O
(,O
https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-dashboard,S-URL
),O
.,O
As,O
far,O
as,O
we,O
know,O
",",O
COVID-19,O
first,O
affected,O
Lombardy,O
and,O
Veneto,O
and,O
",",O
later,O
on,O
",",O
all,O
the,O
other,O
regions,O
of,O
Italy,O
.,O
A,O
genomic,O
characterisation,O
and,O
phylogenetic,O
analysis,O
performed,O
on,O
complete,O
SARS,O
-,O
CoV-2,O
genomes,O
isolated,O
from,O
patients,O
involved,O
in,O
the,O
first,O
outbreak,O
of,O
COVID-19,O
in,O
Lombardy,O
",",O
suggested,O
that,O
SARS,O
-,O
CoV-2,O
entered,O
Northern,O
Italy,O
weeks,O
before,O
the,O
first,O
reported,O
case,O
of,O
infection,O
(,O
Zehender,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Therefore,O
",",O
after,O
mid,O
-,O
December,O
2019,O
",",O
SARS,O
-,O
CoV-2,O
had,O
already,O
been,O
circulating,O
in,O
major,O
urban,O
centres,O
surrounding,O
the,O
area,O
(,O
Codogno,O
",",O
in,O
the,O
province,O
of,O
Lodi,O
),O
where,O
the,O
first,O
case,O
of,O
COVID-19,O
was,O
reported,O
in,O
February,O
2020,O
.,O
Significantly,O
",",O
all,O
of,O
these,O
regions,O
documented,O
COVID-19,O
cases,O
starting,O
from,O
25th,O
February,O
(,O
Protezione,O
Civile,O
",",O
2020,O
),O
.,O
Considering,O
the,O
incubation,O
period,O
of,O
COVID-19,O
-,O
6.4,O
 ,O
days,O
on,O
average,O
(,O
Wang,O
et,O
al,O
.,O
",",O
2020,O
),O
-,O
as,O
well,O
as,O
evidence,O
showing,O
that,O
viral,O
shedding,O
may,O
occur,O
in,O
asymptomatic,O
patients,O
(,O
Jiang,O
et,O
al,O
.,O
",",O
2020,O
;,O
Park,O
et,O
al,O
.,O
",",O
2020,O
;,O
Tang,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
it,O
is,O
conceivable,O
that,O
the,O
virus,O
was,O
circulating,O
and,O
being,O
released,O
into,O
the,O
sewage,O
in,O
the,O
Paris,O
area,O
roughly,O
at,O
the,O
same,O
time,O
as,O
in,O
northern,O
Italy,O
",",O
as,O
indicated,O
by,O
our,O
positive,O
sewage,O
samples,O
.,O
A,O
Spanish,O
study,O
in,O
the,O
region,O
of,O
Murcia,O
detected,O
SARS,O
-,O
CoV-2,O
RNA,O
in,O
wastewater,O
before,O
the,O
first,O
COVID-19,O
cases,O
were,O
declared,O
by,O
the,O
local,O
authorities,O
in,O
many,O
of,O
the,O
cities,O
where,O
wastewaters,O
have,O
been,O
sampled,O
(,O
Randazzo,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
revealing,O
that,O
members,O
of,O
the,O
community,O
were,O
shedding,O
SARS,O
-,O
CoV-2,O
RNA,O
before,O
the,O
first,O
cases,O
were,O
reported,O
.,O
The,O
hypothesis,O
of,O
SARS,O
-,O
CoV-2,O
circulation,O
before,O
the,O
identification,O
of,O
the,O
first,O
clinical,O
cases,O
is,O
supported,O
by,O
other,O
epidemiological,O
approaches,O
as,O
well,O
:,O
a,O
seroprevalence,O
study,O
",",O
conducted,O
on,O
healthy,O
blood,O
donors,O
in,O
the,O
province,O
of,O
Milan,O
during,O
the,O
COVID-19,O
epidemic,O
showed,O
that,O
",",O
between,O
12,O
and,O
17,O
February,O
2020,O
",",O
2.0,O
%,O
of,O
donors,O
displayed,O
IgG,O
for,O
SARS,O
-,O
CoV-2,O
(,O
Percivalle,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Recently,O
",",O
van,O
Dorp,O
and,O
co,O
-,O
workers,O
analysed,O
the,O
genomic,O
diversity,O
of,O
SARS,O
-,O
CoV-2,O
in,O
the,O
global,O
population,O
since,O
the,O
beginning,O
of,O
the,O
COVID-19,O
pandemic,O
by,O
comparing,O
7666,O
SARS,O
-,O
CoV-2,O
genomes,O
covering,O
a,O
vast,O
geographical,O
area,O
(,O
van,O
Dorp,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
is,O
responsible,O
for,O
the,O
coronavirus,O
disease,O
COVID-19,O
",",O
a,O
public,O
health,O
emergency,O
worldwide,O
",",O
and,O
Italy,O
is,O
among,O
the,O
most,O
severely,O
affected,O
countries,O
.,O
The,O
first,O
autochthonous,O
Italian,O
case,O
of,O
COVID-19,O
was,O
documented,O
on,O
February,O
21,O
",",O
2020,O
.,O
Clinical,O
specimens,O
from,O
a,O
case,O
-,O
patient,O
who,O
had,O
acquired,O
COVID-19,O
during,O
travel,O
to,O
China,O
and,O
who,O
was,O
identified,O
in,O
Washington,O
",",O
USA,O
",",O
were,O
collected,O
as,O
described,O
(,O
),O
.,O
A,O
nearly,O
full,O
-,O
length,O
viral,O
contig,O
obtained,O
in,O
each,O
sample,O
had,O
100,O
%,O
identity,O
to,O
the,O
2019,O
-,O
nCoV,O
/,O
USA,O
-,O
WA1/2020,O
strain,O
(,O
GenBank,S-Repository
 ,O
accession,O
no,O
.,O
A,O
patient,O
was,O
identified,O
with,O
confirmed,O
COVID-19,O
in,O
Washington,O
State,O
on,O
January,O
22,O
",",O
2020,O
.,O
We,O
sequenced,O
viral,O
RNA,O
from,O
SARS,O
-,O
CoV-2,O
passage,O
4,O
stock,O
and,O
confirmed,O
it,O
to,O
have,O
no,O
nucleotide,O
mutations,O
compared,O
with,O
the,O
original,O
reference,O
sequence,O
(,O
GenBank,S-Repository
 ,O
accession,O
no,O
.,O
MN985325,S-AccessionNumber
),O
.,O
Similar,O
to,O
SARS,O
-,O
CoV,O
",",O
SARS,O
-,O
CoV-2,O
replicated,O
rapidly,O
in,O
Vero,O
cells,O
after,O
an,O
initial,O
eclipse,O
phase,O
",",O
achieving,O
105,O
TCID50,O
/,O
mL,O
by,O
24,O
h,O
postinfection,O
and,O
peaking,O
at,O
>,O
106,O
TCID50,O
/,O
mL.,O
Replication,O
in,O
HUH7.0,O
cells,O
also,O
increased,O
quickly,O
after,O
an,O
initial,O
eclipse,O
phase,O
but,O
plateaued,O
by,O
24,O
h,O
postinoculation,O
in,O
the,O
intracellular,O
compartment,O
at,O
2,O
×,O
103,O
TCID50,O
/,O
mL,O
and,O
decreased,O
after,O
66,O
h,O
postinoculation,O
.,O
Major,O
SARS,O
-,O
CoV-2,O
worldwide,O
clades,O
have,O
been,O
proposed,O
by,O
nomenclature,O
systems,O
including,O
Nextstrain,S-Repository
 ,O
[,O
8,O
],O
and,O
the,O
global,B-Dataset
initiative,I-Dataset
on,I-Dataset
sharing,I-Dataset
all,I-Dataset
influenza,I-Dataset
data,I-Dataset
(GISAID,E-Dataset
",",O
https://www.gisaid.org,S-URL
),O
[,O
9,O
],O
.,O
These,O
are,O
based,O
on,O
viral,O
genomes,O
from,O
>,O
"57,000",O
sequences,O
submitted,O
in,O
GISAID,S-Dataset
 ,O
[,O
9,O
],O
.,O
Clade,O
annotations,O
were,O
attained,O
from,O
Nextstrain,S-Repository
 ,O
[,O
8,O
],O
",",O
who,O
identify,O
variants,O
that,O
define,O
clades,O
of,O
interest,O
from,O
sequences,O
submitted,O
to,O
GISAID,S-Dataset
 ,O
by,O
labs,O
worldwide,O
and,O
updates,O
them,O
periodically,O
in,O
clades.tsv,O
(,O
https://github.com/nextstrain/ncov/blob/master/defaults/clades.tsv,S-URL
),O
.,O
These,O
conclusions,O
are,O
further,O
supported,O
by,O
a,O
larger,O
-,O
scale,O
phylogenetic,O
tree,O
including,O
the,O
ICVL,O
workers,O
and,O
family,O
member,O
samples,O
in,O
addition,O
to,O
25,O
randomly,O
chosen,O
Israel,O
-,O
based,O
samples,O
downloaded,O
from,O
GISAID,S-Dataset
",",O
wherein,O
S7,O
is,O
placed,O
with,O
non,O
-,O
ICVL,O
samples,O
with,O
88,O
%,O
confidence,O
(,O
Figure,O
S1,O
),O
.,O
This,O
novel,O
coronavirus,O
has,O
now,O
been,O
named,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
while,O
the,O
disease,O
it,O
causes,O
is,O
known,O
as,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
(,O
2,O
),O
.,O
Cases,O
have,O
now,O
been,O
identified,O
",",O
and,O
deaths,O
due,O
to,O
COVID-19,O
reported,O
",",O
on,O
all,O
6,O
populated,O
continents,O
(,O
3,O
),O
.,O
The,O
Centers,O
for,O
Disease,O
Control,O
and,O
Prevention,O
(,O
CDC,O
),O
confirmed,O
the,O
first,O
case,O
of,O
COVID-19,O
in,O
the,O
United,O
States,O
on,O
21,O
January,O
.,O
No,O
additional,O
cases,O
of,O
COVID-19,O
were,O
identified,O
in,O
Washington,O
State,O
until,O
28,O
February,O
when,O
two,O
new,O
cases,O
were,O
confirmed,O
",",O
one,O
in,O
Snohomish,O
County,O
and,O
one,O
in,O
neighboring,O
King,O
County,O
",",O
where,O
Seattle,O
is,O
located,O
(,O
6,O
",",O
7,O
),O
.,O
Since,O
28,O
February,O
",",O
the,O
number,O
of,O
cases,O
of,O
COVID-19,O
in,O
Washington,O
has,O
steadily,O
increased,O
and,O
currently,O
stands,O
at,O
"2,096",O
(,O
3,O
),O
.,O
For,O
all,O
of,O
the,O
above,O
primer,O
-,O
probe,O
sets,O
",",O
real,O
-,O
time,O
RT,O
-,O
PCR,O
assays,O
were,O
performed,O
using,O
the,O
AgPath,O
-,O
ID,O
One,O
Step,O
RT,O
-,O
PCR,O
kit,O
(,O
Life,O
Technologies,O
),O
.,O
Known,O
cases,O
of,O
COVID-19,O
have,O
now,O
exceeded,O
"375,000",O
worldwide,O
.,O
A,O
major,O
lesson,O
that,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
has,O
already,O
taught,O
the,O
scientific,O
community,O
is,O
that,O
timely,O
international,O
data,O
sharing,O
and,O
collaborative,O
data,O
analysis,O
is,O
absolutely,O
vital,O
to,O
navigate,O
through,O
policy,O
decisions,O
that,O
have,O
life,O
-,O
or,O
-,O
death,O
consequences,O
.,O
Some,O
of,O
the,O
most,O
pressing,O
issues,O
about,O
COVID-19,O
infections,O
require,O
urgent,O
sharing,O
of,O
high,O
-,O
quality,O
data,O
concerning,O
",",O
for,O
example,O
",",O
risk,O
factors,O
that,O
influence,O
infection,O
",",O
prognosis,O
",",O
and,O
predictions,O
of,O
drug,O
response,O
from,O
phenotypic,O
",",O
genotypic,O
",",O
and,O
epigenetic,O
data,O
.,O
To,O
generate,O
or,O
test,O
scientific,O
hypotheses,O
",",O
we,O
need,O
large,O
-,O
scale,O
and,O
well,O
-,O
characterized,O
patient,O
-,O
level,O
datasets,O
to,O
provide,O
sufficient,O
statistical,O
power,O
.,O
Building,O
and,O
sharing,O
massive,O
datasets,O
containing,O
personal,O
health,O
information,O
have,O
numerous,O
legal,O
and,O
ethical,O
implications,O
that,O
hinder,O
new,O
discoveries,O
and,O
prevent,O
the,O
scientific,O
community,O
from,O
assessing,O
their,O
validity,O
.,O
In,O
this,O
respect,O
",",O
the,O
case,O
of,O
2,O
COVID-19,O
related,O
articles,O
published,O
by,O
The,O
Lancet,O
and,O
The,O
New,O
England,O
Journal,O
of,O
Medicine,O
serves,O
as,O
an,O
example,O
.,O
These,O
instances,O
reinforce,O
the,O
need,O
for,O
a,O
robust,O
privacy-,O
and,O
confidentiality,O
-,O
compliant,O
data,O
-,O
processing,O
and,O
sharing,O
system,O
to,O
address,O
these,O
challenges,O
in,O
the,O
era,O
of,O
COVID-19,O
and,O
future,O
pandemics,O
.,O
Numerous,O
data,O
-,O
driven,O
projects,O
have,O
been,O
launched,O
across,O
the,O
globe,O
to,O
combat,O
COVID-19,O
",",O
as,O
summarized,O
below,O
.,O
On,O
the,O
1,O
hand,O
",",O
several,O
data,O
-,O
sharing,O
projects,O
on,O
COVID-19,O
are,O
based,O
on,O
a,O
decentralized,O
approach,O
",",O
employing,O
the,O
computation,O
of,O
local,O
statistics,O
(,O
sometimes,O
obfuscated,O
to,O
hide,O
small,O
numbers,O
),O
that,O
are,O
subsequently,O
shared,O
and,O
aggregated,O
through,O
meta,O
-,O
analysis,O
.,O
On,O
the,O
other,O
hand,O
",",O
other,O
projects,O
aim,O
to,O
centralize,O
patient,O
-,O
level,O
data,O
from,O
COVID-19,O
at,O
a,O
single,O
site,O
and,O
then,O
perform,O
the,O
analysis,O
.,O
With,O
this,O
goal,O
in,O
mind,O
",",O
we,O
have,O
established,O
an,O
international,O
consortium,O
for,O
Secure,O
Collective,O
Research,O
(,O
SCOR,O
),O
to,O
deploy,O
the,O
next,O
-,O
generation,O
distributed,O
infrastructure,O
and,O
tools,O
for,O
secure,O
data,O
sharing,O
",",O
analysis,O
",",O
and,O
mining,O
while,O
respecting,O
patient,O
privacy,O
and,O
maximizing,O
data,O
utility,O
during,O
global,O
disease,O
outbreaks,O
like,O
the,O
current,O
COVID-19,O
pandemic,O
.,O
SCOR,O
is,O
a,O
new,O
initiative,O
that,O
complements,O
existing,O
multicentric,O
data,O
-,O
sharing,O
efforts,O
to,O
face,O
the,O
COVID-19,O
pandemic,O
.,O
COVID-19,O
research,O
moves,O
rapidly,O
with,O
new,O
initiatives,O
announced,O
daily,O
.,O
In,O
Table,O
 ,O
1,O
we,O
summarize,O
the,O
major,O
initiatives,O
we,O
are,O
aware,O
of,O
(,O
as,O
of,O
June,O
2020,O
),O
and,O
compare,O
them,O
to,O
SCOR,O
along,O
the,O
following,O
axes,O
:,O
Comparison,O
of,O
fully,O
automated,O
systems,O
for,O
COVID-19,O
data,O
sharing,O
is,O
reported,O
in,O
Table,O
 ,O
2,O
below,O
.,O
This,O
issue,O
is,O
alleviated,O
when,O
safe,O
settings,O
are,O
used,O
to,O
create,O
large,O
(,O
protected,O
),O
virtual,O
datasets,O
compared,O
to,O
applying,O
data,O
obfuscation,O
to,O
local,O
datasets,O
.,O
By,O
using,O
MedCo,O
",",O
health,O
professionals,O
and,O
scientists,O
can,O
query,O
data,O
scattered,O
among,O
diverse,O
institutions,O
as,O
if,O
it,O
were,O
stored,O
in,O
a,O
single,O
location,O
(,O
virtual,O
collective,O
dataset,O
),O
but,O
without,O
the,O
need,O
of,O
seeing,O
nor,O
moving,O
the,O
data,O
(,O
see,O
Figure,O
2,O
),O
.,O
Existing,O
health,O
informatics,O
systems,O
do,O
not,O
incorporate,O
the,O
latest,O
progress,O
in,O
modern,O
security,O
and,O
federated,O
machine,O
learning,O
algorithms,O
",",O
which,O
are,O
poised,O
to,O
offer,O
solutions,O
.,O
A,O
recent,O
study,O
indicated,O
that,O
SARS,O
-,O
CoV-2,O
was,O
96,O
%,O
identical,O
to,O
a,O
bat,O
coronavirus,O
RaTG13,O
(,O
accession,O
:,O
MN996532,S-AccessionNumber
),O
at,O
the,O
genomic,O
level,O
",",O
suggesting,O
that,O
bat,O
might,O
be,O
a,O
natural,O
host,O
of,O
SARS,O
-,O
CoV-2,O
[,O
7,O
],O
.,O
GISAID,S-Dataset
 ,O
is,O
a,O
platform,O
for,O
sharing,O
genetic,O
data,O
of,O
influenza,O
.,O
Currently,O
",",O
a,O
rapidly,O
increasing,O
number,O
of,O
SARS,O
-,O
CoV-2,O
genomic,O
sequences,O
are,O
being,O
deposited,O
into,O
this,O
database,O
from,O
laboratories,O
around,O
the,O
world,O
[,O
8,O
],O
.,O
A,O
total,O
of,O
343,O
full,O
-,O
length,O
SARS,O
-,O
CoV-2,O
genomes,O
available,O
in,O
the,O
GISAID,S-Dataset
 ,O
platform,O
(,O
https://platform.gisaid.org/,S-URL
),O
as,O
of,O
10,O
March,O
2020,O
with,O
5,O
March,O
2020,O
as,O
cut,O
-,O
off,O
date,O
were,O
downloaded,O
[,O
8,O
],O
.,O
A,O
total,O
of,O
247,O
sequences,O
with,O
high,O
sequence,O
quality,O
as,O
noted,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
were,O
included,O
for,O
further,O
analysis,O
after,O
removing,O
sequences,O
containing,O
little,O
temporal,O
signal,O
and,O
thus,O
are,O
not,O
unsuitable,O
for,O
inference,O
using,O
phylogenetic,O
molecular,O
clock,O
models,O
.,O
Information,O
regarding,O
the,O
date,O
and,O
country,O
of,O
isolation,O
were,O
also,O
retrieved,O
from,O
the,O
GISAID,S-Dataset
 ,O
platform,O
.,O
The,O
annotated,O
reference,O
genome,O
sequence,O
of,O
the,O
SARS,O
-,O
CoV-2,O
isolate,O
Wuhan,O
-,O
Hu-1,O
(,O
accession,O
:,O
NC_045512.2,S-AccessionNumber
),O
was,O
downloaded,O
from,O
the,O
NCBI,B-Repository
GenBank,E-Repository
 ,O
database,O
.,O
A,O
total,O
of,O
22,O
such,O
genome,O
sequences,O
were,O
reported,O
so,O
far,O
",",O
accounting,O
for,O
9,O
%,O
of,O
the,O
247,O
SARS,O
-,O
CoV-2,O
sequences,O
documented,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
as,O
of,O
5,O
March,O
2020,O
.,O
Viruses,O
in,O
SS4,O
were,O
responsible,O
for,O
the,O
explosive,O
increase,O
in,O
incidence,O
of,O
COVID-19,O
in,O
Europe,O
in,O
March,O
(,O
Table,O
4,O
),O
.,O
Upon,O
completion,O
of,O
analysis,O
of,O
SARS,O
-,O
CoV-2,O
sequences,O
available,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
as,O
of,O
5,O
March,O
2020,O
and,O
identification,O
of,O
the,O
four,O
“,O
super,O
-,O
spreader,O
”,O
type,O
strains,O
",",O
we,O
investigated,O
if,O
viral,O
strains,O
of,O
the,O
four,O
super,O
-,O
spreaders,O
were,O
responsible,O
for,O
the,O
vast,O
majority,O
of,O
subsequent,O
infections,O
.,O
We,O
conducted,O
detailed,O
and,O
comprehensive,O
analyses,O
of,O
247,O
high,O
quality,O
SARS,O
-,O
CoV-2,O
sequences,O
deposited,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
during,O
the,O
period,O
December,O
2019,O
to,O
5,O
March,O
2020,O
to,O
provide,O
insight,O
into,O
the,O
evolution,O
and,O
transmission,O
of,O
this,O
novel,O
virus,O
(,O
Figure,O
3,O
),O
.,O
This,O
second,O
dataset,O
showed,O
that,O
viruses,O
of,O
SS4,O
have,O
since,O
been,O
transmitted,O
to,O
other,O
parts,O
of,O
world,O
including,O
Africa,O
",",O
Asia,O
",",O
North,O
America,O
and,O
Oceania,O
.,O
To,O
trace,O
the,O
evolution,O
route,O
and,O
probe,O
the,O
transmission,O
dynamics,O
of,O
this,O
virus,O
",",O
we,O
performed,O
phylodynamic,O
analysis,O
of,O
247,O
high,O
quality,O
genomic,O
sequences,O
available,O
in,O
the,O
GISAID,S-Dataset
 ,O
platform,O
as,O
of,O
5,O
March,O
2020,O
.,O
The,O
virus,O
was,O
soon,O
identified,O
as,O
novel,O
CoV,O
2019,O
(,O
2019,O
-,O
nCoV,O
),O
",",O
more,O
recently,O
designated,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
while,O
the,O
associated,O
disease,O
is,O
referred,O
to,O
as,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
As,O
of,O
15,O
June,O
2020,O
",",O
there,O
were,O
almost,O
8,O
million,O
confirmed,O
COVID-19,O
cases,O
and,O
"431,541",O
deaths,O
globally,O
(,O
2,O
),O
.,O
(,O
A,O
),O
Schematic,O
diagram,O
of,O
the,O
genomes,O
of,O
SARS,O
-,O
CoV-2,O
isolates,O
Wuhan,O
-,O
Hu-1,O
(,O
GenBank,S-Repository
 ,O
accession,O
no,O
.,O
MN908947,S-AccessionNumber
),O
and,O
human,O
CoV-19,O
/,O
Singapore/12/2020,O
(,O
hCoV-19,O
/,O
Singapore/12/2020,O
),O
Δ382,O
(,O
GISAID,S-Dataset
:,O
EPI_ISL_414378,S-AccessionNumber
),O
.,O
To,O
investigate,O
the,O
possible,O
origin,O
and,O
evolutionary,O
relationships,O
of,O
these,O
Δ382,O
viruses,O
",",O
a,O
maximum,O
likelihood,O
(,O
ML,O
),O
phylogeny,O
of,O
SARS,O
-,O
CoV-2,O
full,O
genomes,O
was,O
inferred,O
from,O
serially,O
sampled,O
data,O
sets,O
.,O
We,O
then,O
tested,O
residual,O
diagnostic,O
samples,O
from,O
COVID-19,O
patients,O
in,O
Singapore,O
for,O
the,O
presence,O
of,O
Δ382,O
viruses,O
to,O
understand,O
the,O
epidemiological,O
fitness,O
of,O
Δ382,O
viruses,O
.,O
Full,O
complete,O
genomes,O
of,O
SARS,O
-,O
CoV-2,O
wild,O
-,O
type,O
and,O
Δ382,O
viruses,O
generated,O
in,O
Singapore,O
were,O
deposited,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
(,O
see,O
Table,O
 ,O
S1,O
in,O
the,O
supplemental,O
material,O
),O
.,O
All,O
available,O
genomes,O
of,O
SARS,O
-,O
CoV-2,O
with,O
associated,O
virus,O
sampling,O
dates,O
were,O
downloaded,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
.,O
To,O
reduce,O
bias,O
from,O
locations,O
with,O
higher,O
virus,O
sampling,O
and,O
genome,O
availability,O
",",O
data,O
sets,O
were,O
subsampled,O
randomly,O
based,O
on,O
geographical,O
location,O
and,O
collection,O
month,O
using,O
in,O
-,O
house,O
scripts,O
.,O
To,O
reconstruct,O
a,O
time,O
-,O
scaled,O
phylogeny,O
",",O
we,O
analyzed,O
serially,O
sampled,O
data,O
sets,O
of,O
419,O
complete,O
genomes,O
(,O
Table,O
 ,O
S5,O
),O
using,O
an,O
uncorrelated,O
lognormal,O
relaxed,O
-,O
clock,O
(,O
UCLN,O
),O
model,O
with,O
an,O
exponential,O
growth,O
coalescent,O
prior,O
and,O
the,O
HKY85+Γ,O
substitution,O
model,O
in,O
BEAST,O
program,O
v1.10.4,O
(,O
29,O
),O
to,O
simultaneously,O
estimate,O
phylogenies,O
",",O
divergence,O
times,O
",",O
and,O
rates,O
of,O
nucleotide,O
substitution,O
.,O
The,O
strict,O
and,O
UCLN,O
models,O
were,O
recently,O
tested,O
by,O
Duchene,O
et,O
al,O
.,O
(,O
30,O
),O
",",O
who,O
showed,O
that,O
the,O
UCLN,O
model,O
is,O
preferred,O
over,O
a,O
strict,O
clock,O
for,O
analyzing,O
large,O
(,O
>,O
122,O
),O
SARS,O
-,O
CoV-2,O
genome,O
data,O
sets,O
.,O
Cells,O
were,O
washed,O
with,O
phosphate,O
-,O
buffered,O
saline,O
(,O
PBS,O
),O
",",O
and,O
SARS,O
-,O
CoV-2,O
viral,O
antigens,O
were,O
detected,O
using,O
a,O
COVID-19,O
convalescent,O
human,O
serum,O
at,O
a,O
1:400,O
dilution,O
in,O
PBS,O
for,O
30,O
 ,O
min,O
at,O
37,O
°,O
C,O
.,O
Supernatant,O
was,O
harvested,O
daily,O
for,O
6,O
days,O
following,O
infection,O
and,O
50,O
%,O
tissue,O
culture,O
infective,O
doses,O
(,O
TCID50,O
),O
titers,O
were,O
determined,O
.,O
Sequences,O
generated,O
in,O
this,O
study,O
have,O
been,O
deposited,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
(,O
see,O
Table,O
 ,O
S1,O
for,O
accession,O
numbers,O
),O
.,O
SARS,O
-,O
CoV-2,O
",",O
first,O
isolated,O
in,O
Wuhan,O
",",O
China,O
",",O
in,O
December,O
2019,O
[,O
1,O
],O
is,O
a,O
new,O
coronavirus,O
responsible,O
for,O
the,O
severe,O
pulmonary,O
/,O
systemic,O
disease,O
called,O
COVID-19,O
.,O
Here,O
",",O
the,O
first,O
COVID-19,O
patient,O
was,O
diagnosed,O
by,O
the,O
Virology,O
Laboratory,O
of,O
Ancona,O
University,O
Hospital,O
on,O
the,O
25,O
February,O
2020,O
.,O
Several,O
research,O
centres,O
started,O
sequencing,O
programs,O
on,O
different,O
platforms,O
and,O
some,O
results,O
are,O
already,O
available,O
[,O
"2,4,5,6",O
],O
in,O
databases,O
such,O
as,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID,E-Dataset
",",O
https://www.gisaid.org/,S-URL
),O
or,O
GenBank,S-Repository
 ,O
(,O
https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/,S-URL
),O
",",O
which,O
will,O
continue,O
to,O
accumulate,O
sequencing,O
data,O
from,O
around,O
the,O
world,O
.,O
Reads,O
were,O
aligned,O
with,O
the,O
Wuhan,O
-,O
Hu-1,O
NCBI,S-Repository
 ,O
Reference,O
Genome,O
(,O
Accession,O
number,O
:,O
MN908947.3,S-AccessionNumber
),O
on,O
the,O
Torrent,O
Suite,O
v.,O
5.10.1,O
.,O
The,O
following,O
plugins,O
were,O
used,O
:,O
Coverage,O
Analysis,O
(,O
v5.10.0.3,O
),O
",",O
Variant,O
Caller,O
(,O
v.5.10.1.19,O
),O
both,O
with,O
“,O
Generic,O
-,O
S5,O
/,O
S5XL,O
(,O
510/520/530,O
),O
-,O
Somatic,O
-,O
Low,O
Stringency,O
”,O
and,O
“,O
Generic,O
-,O
S5,O
/,O
S5XL,O
(,O
510/520/530)-Germ,O
Line,O
-,O
Low,O
Stringency,O
”,O
default,O
parameters,O
and,O
COVID19AnnotateSnpEff,O
(,O
v.1.0.0,O
),O
",",O
a,O
plugin,O
specifically,O
developed,O
for,O
Sars,O
-,O
Cov-2,O
that,O
can,O
predict,O
the,O
effect,O
of,O
a,O
base,O
substitution,O
.,O
In,O
December,O
2019,O
",",O
the,O
first,O
cases,O
of,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
were,O
reported,O
in,O
Wuhan,O
",",O
China,O
",",O
a,O
megacity,O
with,O
a,O
population,O
of,O
approximately,O
11,O
million,O
people,O
.,O
However,O
",",O
despite,O
these,O
efforts,O
",",O
COVID-19,O
spread,O
to,O
many,O
countries,O
across,O
the,O
world,O
",",O
reaching,O
pandemic,O
levels,O
",",O
and,O
continues,O
to,O
be,O
a,O
serious,O
public,O
health,O
concern,O
due,O
to,O
its,O
high,O
mortality,O
rate,O
.,O
With,O
internet,O
search,O
as,O
an,O
important,O
source,O
of,O
epidemiologic,O
information,O
on,O
COVID-19,O
[,O
4,O
],O
",",O
we,O
performed,O
a,O
combined,O
analysis,O
of,O
the,O
infection,O
rates,O
of,O
these,O
population,O
samples,O
using,O
publicly,O
available,O
data,O
(,O
Table,O
1,O
),O
",",O
instead,O
of,O
a,O
simple,O
pooled,O
calculation,O
",",O
considering,O
potential,O
differences,O
in,O
lifestyles,O
and,O
pathogen,O
exposure,O
across,O
different,O
populations,O
.,O
The,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
pandemic,O
began,O
in,O
Wuhan,O
",",O
China,O
",",O
in,O
December,O
2019,O
.,O
One,O
major,O
hitch,O
in,O
developing,O
a,O
COVID-19,O
vaccine,O
is,O
that,O
no,O
medically,O
proven,O
predecessor,O
exists,O
for,O
any,O
type,O
of,O
human,O
coronavirus,O
.,O
While,O
influenza,O
",",O
like,O
COVID-19,O
",",O
causes,O
morbidity,O
among,O
all,O
ages,O
",",O
those,O
most,O
vulnerable,O
to,O
its,O
serious,O
complications,O
",",O
such,O
as,O
pneumonia,O
",",O
are,O
the,O
elderly,O
[,O
17,O
",",O
18,O
],O
.,O
The,O
mechanisms,O
of,O
the,O
‘,O
cytokine,O
storm,O
’,O
and,O
how,O
they,O
contribute,O
to,O
fatalities,O
reported,O
for,O
COVID-19,O
are,O
still,O
 ,O
under,O
investigation,O
.,O
In,O
a,O
study,O
of,O
41,O
patients,O
hospitalized,O
with,O
COVID-19,O
",",O
high,O
levels,O
of,O
pro,O
-,O
inflammatory,O
cytokines,O
were,O
found,O
",",O
including,O
IL-2,O
",",O
IL-7,O
",",O
G,O
-,O
CSF,O
",",O
IP-10,O
",",O
MCP-1,O
",",O
MIP-1A,O
",",O
and,O
TNF,O
-,O
α,O
",",O
in,O
the,O
most,O
severe,O
cases,O
[,O
119,O
],O
.,O
The,O
fight,O
against,O
COVID-19,O
will,O
be,O
difficult,O
and,O
lengthy,O
.,O
During,O
the,O
current,O
COVID-19,O
pandemic,O
",",O
the,O
global,O
ratio,O
between,O
the,O
dead,O
and,O
the,O
survivors,O
is,O
approximately,O
1,O
to,O
10,O
",",O
which,O
has,O
put,O
humanity,O
on,O
high,O
alert,O
and,O
provided,O
strong,O
motivation,O
for,O
the,O
intensive,O
search,O
for,O
vaccines,O
and,O
drugs,O
.,O
The,O
experience,O
accumulated,O
dealing,O
with,O
the,O
biology,O
of,O
zoonotic,O
RNA,O
viruses,O
suggests,O
that,O
the,O
fight,O
against,O
COVID-19,O
will,O
be,O
difficult,O
and,O
lengthy,O
.,O
Unfortunately,O
",",O
RNA,O
viruses,O
constantly,O
sweep,O
their,O
tracks,O
and,O
perhaps,O
one,O
of,O
the,O
most,O
promising,O
solutions,O
in,O
the,O
fight,O
against,O
the,O
COVID-19,O
pandemic,O
is,O
the,O
creation,O
of,O
',O
universal,O
',O
vaccines,O
based,O
on,O
conservative,O
SARS,O
-,O
CoV-2,O
genome,O
sequences,O
(,O
antigen,O
-,O
presenting,O
),O
and,O
unmethylated,O
CpG,O
dinucleotides,O
(,O
adjuvant,O
),O
in,O
the,O
composition,O
of,O
the,O
phosphorothioate,O
backbone,O
of,O
single,O
-,O
stranded,O
DNA,O
oligonucleotides,O
(,O
ODN,O
),O
",",O
which,O
can,O
be,O
effective,O
for,O
long,O
periods,O
of,O
use,O
.,O
Di,O
Giambenedetto,O
et,O
al,O
.,O
 ,O
described,O
their,O
experience,O
with,O
intravenous,O
tocilizumab,O
(,O
TCZ,O
),O
in,O
treating,O
severe,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
.,O
Results,O
of,O
this,O
case,O
series,O
appear,O
to,O
support,O
efficacy,O
and,O
tolerability,O
of,O
TCZ,O
given,O
subcutaneously,O
in,O
patients,O
with,O
COVID‐19,O
",",O
at,O
least,O
in,O
those,O
with,O
pneumonia,O
not,O
requiring,O
mechanical,O
ventilation,O
.,O
Particularly,O
",",O
it,O
has,O
to,O
be,O
seen,O
whether,O
SC,O
TCZ,O
at,O
single,O
dose,O
in,O
early,O
stages,O
of,O
COVID‐19,O
is,O
equally,O
effective,O
to,O
intravenous,O
TCZ,O
given,O
at,O
standard,O
doses,O
.,O
In,O
particular,O
",",O
since,O
SC,O
TCZ,O
was,O
not,O
administered,O
further,O
for,O
rapid,O
improvement,O
of,O
patient,O
conditions,O
",",O
this,O
suggest,O
the,O
possibility,O
of,O
reducing,O
the,O
dosage,O
of,O
TCZ,O
",",O
at,O
least,O
in,O
patients,O
with,O
less,O
severe,O
COVID‐19,O
.,O
We,O
then,O
aligned,O
our,O
complete,O
genome,O
sequences,O
with,O
other,O
related,O
coronavirus,O
sequences,O
archived,O
from,O
GenBank,S-Repository
/,O
GISAID,S-Dataset
 ,O
using,O
Mafft,O
software,O
version,O
7.452,O
.,O
This,O
was,O
later,O
attributed,O
to,O
a,O
novel,O
coronavirus,O
(,O
the,O
COVID-19,O
virus,O
),O
",",O
and,O
represents,O
the,O
third,O
major,O
zoonotic,O
human,O
coronavirus,O
of,O
this,O
century,O
[,O
31,O
],O
:,O
On,O
February,O
28,O
",",O
2020,O
",",O
the,O
World,O
Health,O
Organization,O
set,O
the,O
COVID-19,O
risk,O
assessment,O
for,O
regional,O
and,O
global,O
levels,O
to,O
“,O
Very,O
High,O
”,O
[,O
32,O
],O
.,O
From,O
analyses,O
employing,O
whole,O
genome,O
to,O
viral,O
protein,O
-,O
based,O
comparisons,O
",",O
the,O
COVID-19,O
virus,O
is,O
thought,O
to,O
belong,O
to,O
lineage,O
B,O
(,O
Sarbecovirus,O
),O
of,O
Betacoronavirus,O
.,O
From,O
phylogenetic,O
analysis,O
of,O
the,O
RdRp,O
protein,O
",",O
spike,O
proteins,O
",",O
and,O
full,O
genomes,O
of,O
the,O
COVID-19,O
virus,O
and,O
other,O
coronaviruses,O
",",O
it,O
was,O
found,O
that,O
the,O
COVID-19,O
virus,O
is,O
most,O
closely,O
related,O
to,O
two,O
bat,O
SARS,O
-,O
like,O
coronaviruses,O
",",O
bat,O
-,O
SL,O
-,O
CoVZXC21,O
and,O
bat,O
-,O
SL,O
-,O
CoVZC45,O
",",O
found,O
in,O
Chinese,O
horseshoe,O
bats,O
Rhinolophus,O
sinicus,O
[,O
12,O
",",O
33–37,O
],O
.,O
Along,O
with,O
the,O
phylogenetic,O
data,O
",",O
the,O
genome,O
organization,O
of,O
the,O
COVID-19,O
virus,O
was,O
found,O
to,O
be,O
typical,O
of,O
lineage,O
B,O
(,O
Sarbecovirus,O
),O
Betacoronaviruses,O
[,O
33,O
],O
.,O
From,O
phylogenetic,O
analysis,O
of,O
full,O
genome,O
alignment,O
and,O
similarity,O
plots,O
",",O
it,O
was,O
found,O
that,O
the,O
COVID-19,O
virus,O
has,O
the,O
highest,O
similarity,O
to,O
the,O
bat,O
coronavirus,O
RaTG13,O
[,O
38,O
],O
.,O
Within,O
the,O
COVID-19,O
virus,O
sequences,O
",",O
over,O
99,O
%,O
sequence,O
similarity,O
and,O
a,O
lack,O
of,O
diversity,O
within,O
these,O
strains,O
suggest,O
a,O
common,O
lineage,O
and,O
source,O
",",O
with,O
support,O
for,O
recent,O
emergence,O
of,O
the,O
human,O
strain,O
[,O
12,O
",",O
31,O
],O
.,O
There,O
is,O
ongoing,O
debate,O
whether,O
the,O
COVID-19,O
virus,O
arose,O
following,O
recombination,O
with,O
previously,O
identified,O
bat,O
and,O
unknown,O
coronaviruses,O
[,O
39,O
],O
or,O
arose,O
independently,O
as,O
a,O
new,O
lineage,O
to,O
infect,O
humans,O
[,O
38,O
],O
.,O
In,O
combination,O
with,O
the,O
identification,O
that,O
the,O
angiotensin,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
protein,O
is,O
a,O
receptor,O
for,O
COVID-19,O
virus,O
",",O
as,O
it,O
is,O
for,O
SARS,O
and,O
other,O
Sarbecovirus,O
strains,O
",",O
the,O
hypothesis,O
that,O
the,O
COVID-19,O
virus,O
originated,O
from,O
bats,O
is,O
deemed,O
very,O
likely,O
[,O
12,O
",",O
33,O
",",O
35,O
",",O
38,O
",",O
40–44,O
],O
.,O
In,O
this,O
study,O
",",O
we,O
use,O
MLDSP,O
[,O
50,O
],O
and,O
MLDSP,O
-,O
GUI,O
[,O
51,O
],O
with,O
CGR,O
as,O
a,O
numerical,O
representation,O
of,O
DNA,O
sequences,O
to,O
assess,O
the,O
classification,O
of,O
the,O
COVID-19,O
virus,O
from,O
the,O
perspective,O
of,O
machine,O
learning,O
-,O
based,O
alignment,O
-,O
free,O
whole,O
genome,O
comparison,O
of,O
genomic,O
signatures,O
.,O
Using,O
MLDSP,O
and,O
MLDSP,O
-,O
GUI,O
",",O
we,O
confirm,O
that,O
the,O
COVID-19,O
virus,O
belongs,O
to,O
the,O
Betacoronavirus,O
",",O
while,O
its,O
genomic,O
similarity,O
to,O
the,O
sub,O
-,O
genus,O
Sarbecovirus,O
supports,O
a,O
possible,O
bat,O
origin,O
.,O
The,O
Wuhan,O
seafood,O
market,O
pneumonia,O
virus,O
(,O
COVID-19,O
virus,O
/,O
SARS,O
-,O
CoV-2,O
),O
isolate,O
Wuhan,O
-,O
Hu-1,O
complete,O
reference,O
genome,O
of,O
29903,O
bp,O
was,O
downloaded,O
from,O
the,O
National,B-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,I-Repository
(NCBI),E-Repository
 ,O
database,O
on,O
January,O
23,O
",",O
2020,O
.,O
All,O
of,O
the,O
available,O
28,O
sequences,O
of,O
COVID-19,O
virus,O
and,O
the,O
bat,O
Betacoronavirus,O
RaTG13,O
from,O
the,O
GISAID,S-Dataset
 ,O
platform,O
",",O
and,O
two,O
additional,O
sequences,O
(,O
bat,O
-,O
SL,O
-,O
CoVZC45,O
",",O
and,O
bat,O
-,O
SL,O
-,O
CoVZXC21,O
),O
from,O
the,O
NCBI,S-Repository
",",O
were,O
downloaded,O
on,O
January,O
27,O
",",O
2019,O
.,O
Accession,O
numbers,O
for,O
all,O
the,O
sequences,O
used,O
in,O
this,O
study,O
can,O
be,O
found,O
in,O
S1,O
File,O
of,O
S2,O
and,O
S3,O
Tables,O
.,O
The,O
trained,O
machine,O
learning,O
models,O
are,O
then,O
used,O
to,O
test,O
the,O
COVID-19,O
virus,O
sequences,O
.,O
To,O
determine,O
whether,O
there,O
is,O
a,O
correlation,O
between,O
k,O
-,O
mer,O
frequencies,O
in,O
COVID-19,O
virus,O
genomes,O
and,O
specific,O
taxonomic,O
groups,O
",",O
a,O
Spearman,O
’s,O
rank,O
correlation,O
coefficient,O
test,O
is,O
conducted,O
for,O
k,O
=,O
1,O
to,O
k,O
=,O
7,O
.,O
Table,O
1,O
provides,O
the,O
details,O
of,O
three,O
datasets,O
Test-1,O
",",O
Test-2,O
",",O
Test-3a,O
and,O
Test-3b,O
used,O
for,O
analyses,O
with,O
MLDSP,O
-,O
GUI,O
.,O
Each,O
dataset,O
’s,O
composition,O
(,O
clusters,O
with,O
number,O
of,O
sequences,O
),O
",",O
the,O
respective,O
sequence,O
length,O
statistics,O
",",O
and,O
results,O
of,O
MLDSP,O
-,O
GUI,O
after,O
applying,O
10,O
-,O
fold,O
cross,O
-,O
validation,O
as,O
classification,O
accuracy,O
scores,O
are,O
shown,O
.,O
As,O
shown,O
in,O
Table,O
1,O
",",O
for,O
the,O
first,O
test,O
(,O
Test-1,O
),O
",",O
we,O
organized,O
the,O
dataset,O
of,O
sequences,O
into,O
12,O
clusters,O
(,O
11,O
families,O
",",O
and,O
Riboviria,O
realm,O
),O
.,O
After,O
filtering,O
out,O
the,O
sequences,O
",",O
our,O
pre,O
-,O
processed,O
dataset,O
is,O
left,O
with,O
3273,O
sequences,O
organized,O
into,O
12,O
clusters,O
(,O
Adenoviridae,O
",",O
Anelloviridae,O
",",O
Caudovirales,O
",",O
Geminiviridae,O
",",O
Genomoviridae,O
",",O
Microviridae,O
",",O
Ortervirales,O
",",O
Papillomaviridae,O
",",O
Parvoviridae,O
",",O
Polydnaviridae,O
",",O
Polyomaviridae,O
",",O
and,O
Riboviria,O
),O
.,O
All,O
six,O
classification,O
models,O
trained,O
on,O
3273,O
sequences,O
were,O
used,O
to,O
classify,O
(,O
predict,O
the,O
labels,O
of,O
),O
the,O
29,O
COVID-19,O
virus,O
sequences,O
.,O
Test-1,O
classified,O
the,O
COVID-19,O
virus,O
as,O
belonging,O
to,O
the,O
realm,O
Riboviria,O
.,O
The,O
second,O
test,O
(,O
Test-2,O
),O
is,O
designed,O
to,O
classify,O
the,O
COVID-19,O
virus,O
among,O
the,O
families,O
of,O
the,O
Riboviria,O
realm,O
.,O
We,O
completed,O
the,O
dataset,O
pre,O
-,O
processing,O
using,O
the,O
same,O
rules,O
as,O
in,O
Test-1,O
and,O
obtained,O
a,O
dataset,O
of,O
2779,O
sequences,O
placed,O
into,O
the,O
12,O
families,O
(,O
Betaflexiviridae,O
",",O
Bromoviridae,O
",",O
Caliciviridae,O
",",O
Coronaviridae,O
",",O
Flaviviridae,O
",",O
Peribunyaviridae,O
",",O
Phenuiviridae,O
",",O
Picornaviridae,O
",",O
Potyviridae,O
",",O
Reoviridae,O
",",O
Rhabdoviridae,O
",",O
and,O
Secoviridae,O
),O
",",O
see,O
Table,O
1,O
.,O
MLDSP,O
-,O
GUI,O
with,O
CGR,O
at,O
k,O
=,O
7,O
as,O
the,O
numerical,O
representation,O
was,O
used,O
for,O
the,O
classification,O
of,O
the,O
dataset,O
in,O
Test-2,O
.,O
All,O
six,O
classification,O
models,O
trained,O
on,O
2779,O
sequences,O
were,O
used,O
to,O
classify,O
(,O
predict,O
the,O
label,O
of,O
),O
the,O
29,O
COVID-19,O
virus,O
sequences,O
.,O
Test-2,O
correctly,O
predicted,O
the,O
family,O
of,O
the,O
COVID-19,O
virus,O
sequences,O
as,O
Coronaviridae,O
.,O
The,O
third,O
test,O
(,O
Test-3a,O
),O
is,O
designed,O
to,O
classify,O
the,O
COVID-19,O
virus,O
sequences,O
at,O
the,O
genus,O
level,O
.,O
MLDSP,O
-,O
GUI,O
with,O
CGR,O
at,O
k,O
=,O
7,O
as,O
the,O
numerical,O
representation,O
was,O
used,O
for,O
the,O
classification,O
of,O
the,O
dataset,O
in,O
Test-3a,O
.,O
All,O
six,O
classification,O
models,O
trained,O
on,O
208,O
sequences,O
were,O
used,O
to,O
classify,O
(,O
predict,O
the,O
label,O
of,O
),O
the,O
29,O
COVID-19,O
virus,O
sequences,O
.,O
All,O
six,O
classification,O
models,O
trained,O
on,O
60,O
sequences,O
were,O
used,O
to,O
classify,O
the,O
29,O
COVID-19,O
virus,O
sequences,O
.,O
Given,O
confirmation,O
that,O
the,O
COVID-19,O
virus,O
belongs,O
to,O
the,O
Betacoronavirus,O
genus,O
",",O
there,O
now,O
is,O
a,O
question,O
of,O
its,O
origin,O
and,O
relation,O
to,O
the,O
other,O
viruses,O
of,O
the,O
same,O
genus,O
.,O
To,O
examine,O
this,O
question,O
",",O
we,O
preprocessed,O
our,O
dataset,O
from,O
our,O
third,O
test,O
to,O
keep,O
the,O
sub,O
-,O
clusters,O
of,O
the,O
Betacoronavirus,O
with,O
at,O
least,O
10,O
sequences,O
(,O
Test-4,O
),O
.,O
All,O
six,O
classifiers,O
trained,O
on,O
124,O
sequences,O
predicted,O
the,O
label,O
as,O
Sarbecovirus,O
",",O
when,O
used,O
to,O
predict,O
the,O
labels,O
of,O
29,O
COVID-19,O
virus,O
sequences,O
.,O
For,O
Test-5,O
",",O
we,O
added,O
the,O
COVID-19,O
virus,O
with,O
29,O
sequences,O
as,O
the,O
fifth,O
cluster,O
",",O
see,O
Table,O
3,O
.,O
In,O
the,O
MoDMap3D,O
plot,O
from,O
Test-5,O
",",O
COVID-19,O
virus,O
sequences,O
are,O
placed,O
in,O
a,O
single,O
distinct,O
cluster,O
",",O
see,O
Fig,O
2(b,O
),O
.,O
As,O
visually,O
suggested,O
by,O
the,O
MoDMap3D,O
(,O
Fig,O
2(b,O
),O
),O
",",O
the,O
average,O
inter,O
-,O
cluster,O
distances,O
confirm,O
that,O
the,O
COVID-19,O
virus,O
sequences,O
are,O
closest,O
to,O
the,O
Sarbecovirus,O
(,O
average,O
distance,O
0.0556,O
),O
",",O
followed,O
by,O
Merbecovirus,O
(,O
0.0746,O
),O
",",O
Embecovirus,O
(,O
0.0914,O
),O
",",O
and,O
Nobecovirus,O
(,O
0.0916,O
),O
.,O
The,O
three,O
closest,O
sequences,O
based,O
on,O
the,O
average,O
distances,O
from,O
all,O
COVID-19,O
virus,O
sequences,O
are,O
RaTG13,O
(,O
0.0203,O
),O
",",O
bat,O
-,O
SL,O
-,O
CoVZC45,O
(,O
0.0418,O
),O
",",O
and,O
bat,O
-,O
SL,O
-,O
CoVZXC21,O
(,O
0.0428,O
),O
.,O
For,O
Test-6,O
",",O
we,O
classified,O
Sarbecovirus,O
(,O
47,O
sequences,O
),O
and,O
COVID-19,O
virus,O
(,O
29,O
sequences,O
),O
clusters,O
and,O
achieved,O
separation,O
of,O
the,O
two,O
clusters,O
visually,O
apparent,O
in,O
the,O
MoDMap3D,O
",",O
see,O
Fig,O
2(c,O
),O
.,O
We,O
generated,O
phylogenetic,O
trees,O
(,O
UPGMA,O
and,O
neighbor,O
-,O
joining,O
),O
based,O
on,O
all,O
pairwise,O
distances,O
for,O
the,O
dataset,O
in,O
Test-6,O
that,O
show,O
the,O
separation,O
of,O
the,O
two,O
clusters,O
and,O
relationships,O
within,O
the,O
clusters,O
(,O
Figs,O
3,O
and,O
4,O
),O
.,O
As,O
observed,O
in,O
Test-5,O
",",O
the,O
phylogenetic,O
trees,O
show,O
that,O
the,O
COVID-19,O
virus,O
sequences,O
are,O
closer,O
to,O
the,O
Betacoronavirus,O
RaTG13,O
sequence,O
collected,O
from,O
a,O
bat,O
host,O
.,O
The,O
CGR,O
plots,O
visually,O
suggest,O
and,O
the,O
pairwise,O
distances,O
confirm,O
that,O
the,O
genomic,O
signature,O
of,O
the,O
COVID-19,O
virus,O
Wuhan,O
-,O
Hu-1,O
(,O
Fig,O
5(a,O
),O
),O
is,O
closer,O
to,O
the,O
genomic,O
signature,O
of,O
the,O
BetaCov,O
-,O
RaTG13,O
(,O
Fig,O
5(b,O
),O
;,O
distance,O
:,O
0.0204,O
),O
",",O
followed,O
by,O
the,O
genomic,O
signatures,O
of,O
bat,O
-,O
SL,O
-,O
CoVZC45,O
(,O
Fig,O
5(c,O
),O
;,O
distance,O
:,O
0.0417,O
),O
",",O
bat,O
-,O
SL,O
-,O
CoVZXC21(Fig,O
5(d,O
),O
;,O
distance,O
:,O
0.0428,O
),O
",",O
Alphacoronavirus,O
/,O
DQ811787,S-AccessionNumber
 ,O
PRCV,O
ISU-1,O
(,O
Fig,O
5(e,O
),O
;,O
distance,O
:,O
0.0672,O
),O
",",O
Gammacoronavirus,O
/,O
Infectious,O
bronchitis,O
virus,O
NGA,O
/A116E7/2006/,O
FN430415,S-AccessionNumber
 ,O
(,O
Fig,O
5(f,O
),O
;,O
distance,O
:,O
0.0791,O
),O
",",O
and,O
Deltacoronavirus,O
/,O
PDCoV,O
/,O
USA,O
/,O
Illinois121,O
/2014/,O
KJ481931,S-AccessionNumber
 ,O
(,O
Fig,O
5(g,O
),O
;,O
distance,O
:,O
0.0851,O
),O
.,O
The,O
first,O
test,O
in,O
Fig,O
6,O
shows,O
COVID-19,O
virus,O
being,O
compared,O
to,O
the,O
four,O
genera,O
;,O
Alphacoronavirus,O
",",O
Betacoronavirus,O
",",O
Gammacoronavirus,O
and,O
Deltacoronavirus,O
.,O
The,O
COVID-19,O
virus,O
showed,O
the,O
highest,O
k,O
-,O
mer,O
frequency,O
correlation,O
to,O
Betacoronavirus,O
at,O
k,O
=,O
7,O
(,O
Table,O
4,O
),O
",",O
which,O
is,O
consistent,O
with,O
the,O
MLDSP,O
results,O
in,O
Test-3,O
(,O
Table,O
2,O
),O
.,O
The,O
COVID-19,O
virus,O
was,O
then,O
compared,O
to,O
all,O
sub,O
-,O
genera,O
within,O
the,O
Betacoronavirus,O
genus,O
:,O
Embecovirus,O
",",O
Merbecovirus,O
",",O
Nobecovirs,O
and,O
Sarbecovirus,O
seen,O
in,O
Fig,O
7,O
.,O
These,O
tests,O
confirm,O
the,O
findings,O
in,O
MLDSP,O
and,O
are,O
consistent,O
with,O
the,O
COVID-19,O
virus,O
as,O
part,O
of,O
the,O
sub,O
-,O
genus,O
Sarbecovirus,O
.,O
The,O
strongest,O
correlation,O
value,O
was,O
found,O
between,O
Betacoronavirus,O
and,O
Sarbecovirus,O
when,O
using,O
the,O
data,O
sets,O
from,O
Test,O
3a,O
from,O
Table,O
2,O
and,O
Test,O
4,O
from,O
Table,O
3,O
",",O
respectively,O
.,O
Prior,O
work,O
elucidating,O
the,O
evolutionary,O
history,O
of,O
the,O
COVID-19,O
virus,O
had,O
suggested,O
an,O
origin,O
from,O
bats,O
prior,O
to,O
zoonotic,O
transmission,O
[,O
12,O
",",O
33,O
",",O
35,O
",",O
38,O
",",O
41,O
",",O
62,O
],O
.,O
Most,O
early,O
cases,O
of,O
individuals,O
infected,O
with,O
the,O
COVID-19,O
virus,O
had,O
contact,O
with,O
the,O
Huanan,O
South,O
China,O
Seafood,O
Market,O
[,O
26–31,O
],O
.,O
Still,O
",",O
the,O
early,O
COVID-19,O
virus,O
genomes,O
that,O
have,O
been,O
sequenced,O
and,O
uploaded,O
are,O
over,O
99,O
%,O
similar,O
",",O
suggesting,O
these,O
infections,O
result,O
from,O
a,O
recent,O
cross,O
-,O
species,O
event,O
[,O
12,O
",",O
31,O
",",O
40,O
],O
.,O
These,O
prior,O
analyses,O
relied,O
upon,O
alignment,O
-,O
based,O
methods,O
to,O
identify,O
relationships,O
between,O
the,O
COVID-19,O
virus,O
and,O
other,O
coronaviruses,O
with,O
nucleotide,O
and,O
amino,O
acid,O
sequence,O
similarities,O
.,O
When,O
analyzing,O
the,O
conserved,O
replicase,O
domains,O
of,O
ORF1ab,O
for,O
coronavirus,O
species,O
classification,O
",",O
nearly,O
94,O
%,O
of,O
amino,O
acid,O
residues,O
were,O
identical,O
to,O
SARS,O
-,O
CoV,O
",",O
yet,O
overall,O
genome,O
similarity,O
was,O
only,O
around,O
70,O
%,O
",",O
confirming,O
that,O
the,O
COVID-19,O
virus,O
was,O
genetically,O
different,O
[,O
64,O
],O
.,O
Within,O
the,O
RdRp,O
region,O
",",O
it,O
was,O
found,O
that,O
another,O
bat,O
coronavirus,O
",",O
RaTG13,O
",",O
was,O
the,O
closest,O
relative,O
to,O
the,O
COVID-19,O
virus,O
and,O
formed,O
a,O
distinct,O
lineage,O
from,O
other,O
bat,O
SARS,O
-,O
like,O
coronaviruses,O
[,O
38,O
",",O
40,O
],O
.,O
Other,O
groups,O
found,O
that,O
two,O
bat,O
SARS,O
-,O
like,O
coronaviruses,O
",",O
bat,O
-,O
SL,O
-,O
CoVZC45,O
and,O
bat,O
-,O
SL,O
-,O
CoVZXC21,O
",",O
were,O
also,O
closely,O
related,O
to,O
the,O
COVID-19,O
virus,O
[,O
12,O
",",O
33–37,O
],O
.,O
There,O
is,O
a,O
consensus,O
that,O
these,O
three,O
bat,O
viruses,O
are,O
most,O
similar,O
to,O
the,O
COVID-19,O
virus,O
",",O
however,O
",",O
whether,O
or,O
not,O
the,O
COVID-19,O
virus,O
arose,O
from,O
a,O
recombination,O
event,O
is,O
still,O
unknown,O
[,O
38–40,O
],O
.,O
Regardless,O
of,O
the,O
stance,O
on,O
recombination,O
",",O
current,O
consensus,O
holds,O
that,O
the,O
hypothesis,O
of,O
the,O
COVID-19,O
virus,O
originating,O
from,O
bats,O
is,O
highly,O
likely,O
.,O
Whether,O
or,O
not,O
the,O
COVID-19,O
virus,O
was,O
transmitted,O
directly,O
from,O
bats,O
",",O
or,O
from,O
intermediary,O
hosts,O
",",O
is,O
still,O
unknown,O
",",O
and,O
will,O
require,O
identification,O
of,O
the,O
COVID-19,O
virus,O
in,O
species,O
other,O
than,O
humans,O
",",O
notably,O
from,O
the,O
wet,O
market,O
and,O
surrounding,O
area,O
it,O
is,O
thought,O
to,O
have,O
originated,O
from,O
[,O
30,O
],O
.,O
Snakes,O
had,O
been,O
proposed,O
as,O
an,O
intermediary,O
host,O
for,O
the,O
COVID-19,O
virus,O
based,O
on,O
relative,O
synonymous,O
codon,O
usage,O
bias,O
studies,O
between,O
viruses,O
and,O
their,O
hosts,O
[,O
39,O
],O
",",O
however,O
",",O
this,O
claim,O
has,O
been,O
disputed,O
[,O
79,O
],O
.,O
China,O
CDC,O
released,O
information,O
about,O
environmental,O
sampling,O
in,O
the,O
market,O
and,O
indicated,O
that,O
33,O
of,O
585,O
samples,O
had,O
evidence,O
of,O
the,O
COVID-19,O
virus,O
",",O
with,O
31,O
of,O
these,O
positive,O
samples,O
taken,O
from,O
the,O
location,O
where,O
wildlife,O
booths,O
were,O
concentrated,O
",",O
suggesting,O
possible,O
wildlife,O
origin,O
[,O
80,O
",",O
81,O
],O
.,O
Viral,O
outbreaks,O
like,O
COVID-19,O
demand,O
timely,O
analysis,O
of,O
genomic,O
sequences,O
to,O
guide,O
the,O
research,O
in,O
the,O
right,O
direction,O
.,O
The,O
main,O
advantage,O
alignment,O
-,O
free,O
methodology,O
offers,O
is,O
the,O
ability,O
to,O
analyze,O
large,O
datasets,O
rapidly,O
.,O
In,O
this,O
study,O
we,O
confirm,O
the,O
taxonomy,O
of,O
the,O
COVID-19,O
virus,O
and,O
",",O
more,O
generally,O
",",O
propose,O
a,O
method,O
to,O
efficiently,O
analyze,O
and,O
classify,O
a,O
novel,O
unclassified,O
DNA,O
sequence,O
against,O
the,O
background,O
of,O
a,O
large,O
dataset,O
.,O
We,O
namely,O
use,O
a,O
“,O
decision,O
tree,O
”,O
approach,O
(,O
paralleling,O
taxonomic,O
ranks,O
),O
",",O
and,O
start,O
with,O
the,O
highest,O
taxonomic,O
level,O
",",O
train,O
the,O
classification,O
models,O
on,O
the,O
available,O
complete,O
genomes,O
",",O
test,O
the,O
novel,O
unknown,O
sequences,O
to,O
predict,O
the,O
label,O
among,O
the,O
labels,O
of,O
the,O
training,O
dataset,O
",",O
move,O
to,O
the,O
next,O
taxonomic,O
level,O
",",O
and,O
repeat,O
the,O
whole,O
process,O
down,O
to,O
the,O
lowest,O
taxonomic,O
label,O
.,O
The,O
objective,O
is,O
to,O
train,O
the,O
classification,O
models,O
with,O
the,O
known,O
viral,O
genomes,O
and,O
then,O
predict,O
the,O
labels,O
of,O
the,O
COVID-19,O
virus,O
sequences,O
.,O
The,O
trained,O
models,O
are,O
then,O
used,O
to,O
predict,O
the,O
labels,O
of,O
29,O
COVID-19,O
virus,O
sequences,O
.,O
As,O
expected,O
",",O
all,O
classification,O
models,O
correctly,O
predict,O
that,O
the,O
COVID-19,O
virus,O
sequences,O
belong,O
to,O
the,O
Riboviria,O
realm,O
",",O
see,O
Table,O
2,O
.,O
When,O
the,O
COVID-19,O
virus,O
sequences,O
are,O
tested,O
using,O
the,O
models,O
trained,O
on,O
Test-2,O
",",O
all,O
of,O
the,O
models,O
correctly,O
predict,O
the,O
COVID-19,O
virus,O
sequences,O
as,O
Coronaviridae,O
(,O
Table,O
2,O
),O
.,O
All,O
trained,O
classification,O
models,O
correctly,O
predict,O
the,O
COVID-19,O
virus,O
as,O
Betacoronavirus,O
",",O
see,O
Table,O
2,O
.,O
MLDSP,O
-,O
GUI,O
obtains,O
100,O
%,O
classification,O
accuracy,O
for,O
this,O
additional,O
test,O
and,O
still,O
predicts,O
all,O
of,O
the,O
COVID-19,O
virus,O
sequences,O
as,O
Betacoronavirus,O
.,O
These,O
tests,O
confirm,O
that,O
the,O
COVID-19,O
virus,O
sequences,O
are,O
from,O
the,O
genus,O
Betacoronavirus,O
.,O
All,O
of,O
the,O
classification,O
models,O
trained,O
on,O
the,O
dataset,O
in,O
Test-4,O
predicted,O
the,O
label,O
of,O
all,O
29,O
COVID-19,O
virus,O
sequences,O
as,O
Sarbecovirus,O
.,O
This,O
suggests,O
substantial,O
similarity,O
between,O
the,O
COVID-19,O
virus,O
and,O
the,O
Sarbecovirus,O
sequences,O
.,O
Test-5,O
and,O
Test-6,O
(,O
see,O
Table,O
3,O
),O
are,O
designed,O
to,O
verify,O
that,O
the,O
COVID-19,O
virus,O
sequences,O
can,O
be,O
differentiated,O
from,O
the,O
known,O
species,O
in,O
the,O
Betacoronavirus,O
genus,O
.,O
This,O
shows,O
that,O
although,O
the,O
COVID-19,O
virus,O
and,O
Sarbecovirus,O
are,O
closer,O
on,O
the,O
basis,O
of,O
genomic,O
similarity,O
(,O
Test-4,O
),O
",",O
they,O
are,O
still,O
distinguishable,O
from,O
known,O
species,O
.,O
Therefore,O
",",O
these,O
results,O
suggest,O
that,O
the,O
COVID-19,O
virus,O
may,O
represent,O
a,O
genetically,O
distinct,O
species,O
of,O
Sarbecovirus,O
.,O
All,O
the,O
COVID-19,O
virus,O
sequences,O
are,O
visually,O
seen,O
in,O
MoDMap3D,O
generated,O
from,O
Test-5,O
(,O
see,O
Fig,O
2(b,O
),O
),O
as,O
a,O
closely,O
packed,O
cluster,O
and,O
it,O
supports,O
a,O
fact,O
that,O
there,O
is,O
99,O
%,O
similarity,O
among,O
these,O
sequences,O
[,O
12,O
",",O
31,O
],O
.,O
The,O
MoDMap3D,O
generated,O
from,O
the,O
Test-5,O
(,O
Fig,O
2(b,O
),O
),O
visually,O
suggests,O
and,O
the,O
average,O
distances,O
from,O
COVID-19,O
virus,O
sequences,O
to,O
all,O
other,O
sequences,O
confirm,O
that,O
the,O
COVID-19,O
virus,O
sequences,O
are,O
most,O
proximal,O
to,O
the,O
RaTG13,O
(,O
distance,O
:,O
0.0203,O
),O
",",O
followed,O
by,O
the,O
bat,O
-,O
SL,O
-,O
CoVZC45,O
(,O
0.0418,O
),O
",",O
and,O
bat,O
-,O
SL,O
-,O
CoVZX21,O
(,O
0.0428,O
),O
.,O
The,O
phylogenetic,O
trees,O
placed,O
the,O
RaTG13,O
sequence,O
closest,O
to,O
the,O
COVID-19,O
virus,O
sequences,O
",",O
followed,O
by,O
the,O
bat,O
-,O
SL,O
-,O
CoVZC45,O
and,O
bat,O
-,O
SL,O
-,O
CoVZX21,O
sequences,O
.,O
We,O
further,O
confirm,O
our,O
results,O
regarding,O
the,O
closeness,O
of,O
the,O
COVID-19,O
virus,O
with,O
the,O
sequences,O
from,O
the,O
Betacoronavirus,O
genus,O
(,O
especially,O
sub,O
-,O
genus,O
Sarbecovirus,O
),O
by,O
a,O
quantitative,O
analysis,O
based,O
on,O
the,O
Spearman,O
’s,O
rank,O
correlation,O
coefficient,O
tests,O
.,O
The,O
COVID-19,O
virus,O
was,O
compared,O
to,O
all,O
genera,O
under,O
the,O
Coronaviridae,O
family,O
and,O
the,O
k,O
-,O
mer,O
frequencies,O
showed,O
the,O
strongest,O
correlation,O
to,O
the,O
genus,O
Betacoronavirus,O
",",O
and,O
more,O
specifically,O
Sarbecovirus,O
.,O
The,O
Spearman,O
’s,O
rank,O
tests,O
corroborate,O
that,O
the,O
COVID-19,O
virus,O
is,O
part,O
of,O
the,O
Sarbecovirus,O
sub,O
-,O
genus,O
",",O
as,O
shown,O
by,O
CGR,O
and,O
MLDSP,O
.,O
Attributes,O
of,O
the,O
COVID-19,O
virus,O
genomic,O
signature,O
are,O
consistent,O
with,O
previously,O
reported,O
mechanisms,O
of,O
innate,O
immunity,O
operating,O
in,O
bats,O
as,O
a,O
host,O
reservoir,O
for,O
coronaviruses,O
.,O
The,O
Spearman,O
’s,O
rank,O
correlation,O
data,O
and,O
the,O
patterns,O
observed,O
in,O
the,O
CGR,O
images,O
from,O
Fig,O
5,O
",",O
of,O
the,O
coronavirus,O
genomes,O
",",O
including,O
the,O
COVID-19,O
virus,O
identify,O
patterns,O
such,O
as,O
CG,O
underepresentation,O
",",O
also,O
present,O
in,O
vertebrate,O
and,O
",",O
importantly,O
",",O
bat,O
host,O
genomes,O
.,O
Due,O
to,O
the,O
high,O
amino,O
acid,O
similarities,O
between,O
the,O
COVID-19,O
virus,O
and,O
SARS,O
-,O
CoV,O
main,O
protease,O
essential,O
for,O
viral,O
replication,O
and,O
processing,O
",",O
anticoronaviral,O
drugs,O
targeting,O
this,O
protein,O
and,O
other,O
potential,O
drugs,O
have,O
been,O
identified,O
using,O
virtual,O
docking,O
to,O
the,O
protease,O
for,O
treatment,O
of,O
COVID-19,O
[,O
29,O
",",O
43,O
",",O
44,O
",",O
92–95,O
],O
.,O
The,O
human,O
ACE2,O
receptor,O
has,O
also,O
been,O
identified,O
as,O
the,O
potential,O
receptor,O
for,O
the,O
COVID-19,O
virus,O
and,O
represents,O
a,O
potential,O
target,O
for,O
treatment,O
[,O
41,O
",",O
42,O
],O
.,O
MLDSP,O
-,O
GUI,O
took,O
just,O
10.55,O
seconds,O
to,O
compute,O
a,O
pairwise,O
distance,O
matrix,O
(,O
including,O
reading,O
sequences,O
",",O
computing,O
magnitude,O
spectra,O
using,O
DFT,O
",",O
and,O
calculating,O
the,O
distance,O
matrix,O
using,O
PCC,O
combined,O
),O
for,O
the,O
Test-1,O
(,O
largest,O
dataset,O
used,O
in,O
this,O
study,O
with,O
3273,O
complete,O
genomes,O
),O
.,O
All,O
of,O
the,O
tests,O
combined,O
(,O
Test-1,O
to,O
Test-6,O
),O
are,O
doable,O
in,O
under,O
10,O
minutes,O
including,O
the,O
computationally,O
heavy,O
10,O
-,O
fold,O
cross,O
-,O
validation,O
",",O
and,O
testing,O
of,O
the,O
29,O
COVID-19,O
virus,O
sequences,O
.,O
The,O
2019,O
novel,O
coronavirus,O
(,O
renamed,O
SARS,O
-,O
CoV-2,O
",",O
and,O
generally,O
referred,O
to,O
as,O
the,O
COVID-19,O
virus,O
),O
has,O
spread,O
to,O
184,O
countries,O
with,O
over,O
1.5,O
million,O
confirmed,O
cases,O
.,O
This,O
paper,O
identifies,O
an,O
intrinsic,O
COVID-19,O
virus,O
genomic,O
signature,O
and,O
uses,O
it,O
together,O
with,O
a,O
machine,O
learning,O
-,O
based,O
alignment,O
-,O
free,O
approach,O
for,O
an,O
ultra,O
-,O
fast,O
",",O
scalable,O
",",O
and,O
highly,O
accurate,O
classification,O
of,O
whole,O
COVID-19,O
virus,O
genomes,O
.,O
These,O
tools,O
are,O
used,O
to,O
analyze,O
a,O
large,O
dataset,O
of,O
over,O
5000,O
unique,O
viral,O
genomic,O
sequences,O
",",O
totalling,O
61.8,O
million,O
bp,O
",",O
including,O
the,O
29,O
COVID-19,O
virus,O
sequences,O
available,O
on,O
January,O
27,O
",",O
2020,O
.,O
Our,O
results,O
support,O
a,O
hypothesis,O
of,O
a,O
bat,O
origin,O
and,O
classify,O
the,O
COVID-19,O
virus,O
as,O
Sarbecovirus,O
",",O
within,O
Betacoronavirus,O
.,O
Our,O
method,O
achieves,O
100,O
%,O
accurate,O
classification,O
of,O
the,O
COVID-19,O
virus,O
sequences,O
",",O
and,O
discovers,O
the,O
most,O
relevant,O
relationships,O
among,O
over,O
5000,O
viral,O
genomes,O
within,O
a,O
few,O
minutes,O
",",O
ab,O
initio,O
",",O
using,O
raw,O
DNA,O
sequence,O
data,O
alone,O
",",O
and,O
without,O
any,O
specialized,O
biological,O
knowledge,O
",",O
training,O
",",O
gene,O
or,O
genome,O
annotations,O
.,O
We,O
also,O
examined,O
how,O
many,O
seropositive,O
children,O
had,O
received,O
RT,O
-,O
PCR,O
viral,O
tests,O
for,O
COVID-19,O
.,O
Over,O
a,O
third,O
of,O
children,O
in,O
our,O
study,O
had,O
received,O
at,O
least,O
one,O
viral,O
test,O
(,O
Table,O
 ,O
1,O
;,O
note,O
that,O
administration,O
of,O
a,O
viral,O
test,O
does,O
not,O
imply,O
that,O
a,O
child,O
was,O
suspected,O
of,O
having,O
COVID-19,O
",",O
since,O
tests,O
were,O
routinely,O
administered,O
before,O
hospital,O
admission,O
or,O
procedures,O
such,O
as,O
surgery,O
),O
.,O
A,O
detailed,O
chart,O
review,O
revealed,O
that,O
only,O
the,O
two,O
seropositive,O
children,O
with,O
a,O
RT,O
-,O
PCR,O
-,O
confirmed,O
viral,O
infection,O
had,O
documented,O
COVID-19,O
symptoms,O
(,O
Supplementary,O
Table,O
 ,O
1,O
),O
.,O
Additional,O
RT,O
-,O
PCR,O
-,O
confirmed,O
COVID-19,O
pediatric,O
cases,O
were,O
actively,O
recruited,O
to,O
enroll,O
in,O
another,O
approved,O
study,O
at,O
Seattle,O
Children,O
’s,O
Hospital,O
during,O
this,O
study,O
period,O
.,O
Children,O
are,O
strikingly,O
underrepresented,O
in,O
COVID-19,O
case,O
counts,O
.,O
Most,O
seropositive,O
children,O
(,O
6/8,O
),O
were,O
not,O
suspected,O
of,O
having,O
had,O
COVID-19,O
.,O
COVID-19,O
disease,O
is,O
less,O
common,O
in,O
children,O
than,O
adults,O
",",O
but,O
the,O
extent,O
to,O
which,O
SARS,O
-,O
CoV-2,O
infections,O
are,O
missed,O
through,O
symptom,O
-,O
driven,O
testing,O
is,O
not,O
well,O
understood,O
.,O
In,O
this,O
study,O
",",O
the,O
authors,O
show,O
that,O
approximately,O
1,O
%,O
of,O
children,O
seeking,O
care,O
for,O
reasons,O
other,O
than,O
COVID-19,O
at,O
a,O
Seattle,O
hospital,O
in,O
March,O
/,O
April,O
2020,O
were,O
seropositive,O
for,O
SARS,O
-,O
CoV-2,O
.,O
Full,O
raw,O
data,O
for,O
all,O
serological,O
assays,O
",",O
as,O
well,O
as,O
much,O
demographic,O
and,O
viral,O
-,O
testing,O
data,O
that,O
can,O
be,O
provided,O
without,O
compromising,O
sample,O
and,O
patient,O
de,O
-,O
identification,O
",",O
are,O
available,O
in,O
Supplementary,O
Data,O
files,O
 ,O
1–4,O
.,O
Emerging,O
viral,O
infections,O
represent,O
a,O
threat,O
to,O
global,O
health,O
",",O
and,O
the,O
recent,O
outbreak,O
of,O
novel,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
",",O
novel,O
coronavirus,O
",",O
2019,O
-,O
nCoV,O
),O
exemplifies,O
the,O
risks,O
(,O
",",O
),O
.,O
To,O
assess,O
whether,O
RNA,O
editing,O
could,O
be,O
involved,O
in,O
human,O
host,O
responses,O
to,O
SARS,O
-,O
CoV-2,O
infections,O
",",O
we,O
started,O
from,O
publicly,O
available,O
RNA,O
sequencing,O
datasets,O
from,O
bronchoalveolar,O
lavage,O
fluids,O
(,O
BALF,O
),O
obtained,O
from,O
patients,O
diagnosed,O
with,O
COVID-19,O
.,O
The,O
low,O
editing,O
frequencies,O
we,O
observe,O
resembles,O
the,O
editing,O
present,O
on,O
human,O
transcripts,O
containing,O
Alu,O
sequences,O
",",O
which,O
were,O
found,O
in,O
a,O
limited,O
number,O
in,O
those,O
early,O
datasets,O
.,O
There,O
is,O
no,O
evidence,O
of,O
a,O
sequence,O
context,O
preference,O
if,O
we,O
use,O
a,O
larger,O
dataset,O
such,O
as,O
REDIportal,S-Dataset
 ,O
(,O
),O
",",O
which,O
includes,O
>,O
1.5,O
M,O
sites,O
in,O
Alu,O
repeats,O
(,O
fig,O
.,O
S3,O
),O
.,O
A,O
comparison,O
of,O
the,O
SNV,O
datasets,O
from,O
the,O
transcriptomic,O
and,O
genomic,O
analyses,O
reveals,O
a,O
different,O
weight,O
of,O
A,O
-,O
to,O
-,O
I,O
and,O
C,O
-,O
to,O
-,O
U,O
changes,O
(,O
Figs,O
.,O
2B,O
and,O
4A,O
),O
",",O
with,O
an,O
underrepresentation,O
of,O
A,O
-,O
to,O
-,O
I,O
in,O
the,O
viral,O
genomes,O
.,O
We,O
used,O
REDItools,O
2,O
(,O
",",O
),O
and,O
JACUSA,O
(,O
),O
to,O
call,O
the,O
SNVs,O
using,O
the,O
following,O
command,O
line,O
:,O
Bcftools,O
(,O
),O
has,O
been,O
used,O
to,O
calculate,O
total,O
allelic,O
depths,O
on,O
the,O
forward,O
and,O
reverse,O
strand,O
(,O
ADF,O
and,O
ADR,O
),O
for,O
AS_StrandOddsRatio,O
calculation,O
",",O
with,O
the,O
following,O
command,O
line,O
:,O
Logo,O
alignments,O
were,O
calculated,O
using,O
ggseqlogo,O
",",O
using,O
either,O
the,O
pooled,O
dataset,O
or,O
the,O
dataset,O
of,O
recurring,O
SNVs,O
.,O
SARS,O
-,O
CoV-2,O
genomic,O
sequences,O
were,O
downloaded,O
from,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
and,O
aligned,O
with,O
MUSCLE,O
(,O
),O
.,O
The,O
COVID-19,O
outbreak,O
has,O
become,O
a,O
global,O
health,O
risk,O
",",O
and,O
understanding,O
the,O
response,O
of,O
the,O
host,O
to,O
the,O
SARS,O
-,O
CoV-2,O
virus,O
will,O
help,O
to,O
combat,O
the,O
disease,O
.,O
This,O
report,O
describes,O
the,O
epidemiological,O
and,O
clinical,O
features,O
of,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
among,O
three,O
members,O
of,O
a,O
family,O
following,O
SARS,O
-,O
CoV-2,O
infection,O
.,O
The,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
outbreak,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
was,O
first,O
reported,O
in,O
Wuhan,O
",",O
China,O
",",O
in,O
late,O
2019,O
and,O
has,O
affected,O
more,O
than,O
1,O
 ,O
270,O
 ,O
000,O
people,O
worldwide,O
.,O
Our,O
observations,O
suggest,O
the,O
importance,O
of,O
preventing,O
family,O
transmission,O
and,O
the,O
efficacy,O
of,O
current,O
integrated,O
treatment,O
for,O
mild,O
/,O
moderate,O
pneumonia,O
in,O
COVID-19,O
cases,O
.,O
To,O
identify,O
all,O
relevant,O
variants,O
of,O
ACE2,O
",",O
we,O
performed,O
a,O
search,O
in,O
multiple,O
databases,O
and,O
created,O
workflow,O
for,O
assembling,O
the,O
variants,O
in,O
complex,O
with,O
the,O
SARS,O
-,O
CoV-2,O
RBD,O
(,O
Fig,O
.,O
 ,O
1,O
),O
.,O
XXXX,O
stands,O
for,O
the,O
PDB,S-Repository
 ,O
ID,O
from,O
which,O
the,O
model,O
was,O
extracted,O
",",O
R1,O
is,O
the,O
one,O
-,O
letter,O
residue,O
code,O
of,O
the,O
native,O
residue,O
of,O
the,O
ACE2,O
receptor,O
",",O
NUM,O
is,O
the,O
residue,O
number,O
according,O
to,O
the,O
Uniprot,S-Repository
 ,O
sequence,O
of,O
human,O
ACE2,O
receptor,O
and,O
R2,O
is,O
the,O
one,O
-,O
letter,O
residue,O
code,O
of,O
the,O
variant,O
to,O
which,O
the,O
residue,O
R1,O
was,O
changed,O
.,O
Variants,O
in,O
the,O
3,O
datasets,O
are,O
distinct,O
",",O
showing,O
minor,O
overlap,O
in,O
terms,O
of,O
amino,O
acid,O
substitution,O
(,O
Fig,O
.,O
 ,O
2a,O
),O
.,O
The,O
computational,O
alanine,O
scanning,O
shows,O
a,O
minor,O
overlap,O
with,O
reported,O
mutagenesis,O
studies,O
",",O
where,O
only,O
13,O
%,O
of,O
the,O
total,O
mutations,O
can,O
be,O
found,O
in,O
both,O
datasets,O
.,O
The,O
experimental,O
Procko,S-Dataset
 ,O
dataset,O
(PROCKO),S-Dataset
.,O
Interestingly,O
",",O
overlap,O
of,O
those,O
data,O
with,O
the,O
3,O
datasets,O
described,O
above,O
is,O
minor,O
(,O
78,O
common,O
out,O
of,O
242,O
mutations,O
),O
(,O
Fig,O
.,O
 ,O
4,O
),O
.,O
Due,O
to,O
the,O
higher,O
risk,O
of,O
severe,O
COVID-19,O
symptoms,O
manifesting,O
in,O
cancer,O
patients,O
",",O
we,O
have,O
specifically,O
focused,O
on,O
retrieving,O
genetic,O
variants,O
of,O
ACE2,O
available,O
in,O
COSMIC,O
v91,O
(,O
Fig,O
.,O
 ,O
4,O
),O
.,O
ACE2,O
mutations,O
from,O
COVID-19,O
patients,O
included,O
in,O
LOVD,O
3.0,O
(,O
Fig,O
.,O
 ,O
4,O
),O
.,O
LOVD,O
3.0,O
reports,O
additional,O
variants,O
for,O
the,O
ACE2,O
receptor,O
and,O
includes,O
the,O
N720D,O
mutation,O
which,O
has,O
been,O
identified,O
as,O
a,O
variant,O
in,O
COVID-19,O
patients,O
in,O
the,O
Italian,O
population,O
.,O
N720D,O
is,O
found,O
in,O
genomic,O
data,O
(,O
gnomAD,S-Repository
),O
",",O
cancer,O
(,O
COSMIC,S-Repository
 ,O
v91,O
),O
and,O
COVID-19,O
patients,O
(,O
LOVD,S-Repository
 ,O
3.0,O
),O
.,O
Another,O
ACE2,O
protein,O
variation,O
identified,O
in,O
COVID-19,O
patients,O
is,O
the,O
K26R,O
",",O
which,O
is,O
also,O
included,O
in,O
the,O
gnomAD,S-Repository
 ,O
data,O
",",O
but,O
not,O
in,O
cancer,O
patients,O
.,O
Our,O
dataset,O
includes,O
140,O
variants,O
of,O
human,O
ACE2,O
representing,O
missense,O
mutations,O
found,O
in,O
genome,O
-,O
wide,O
studies,O
",",O
39,O
mutants,O
with,O
reported,O
effects,O
on,O
the,O
recognition,O
of,O
the,O
RBD,O
",",O
and,O
63,O
predictions,O
after,O
computational,O
alanine,O
scanning,O
mutagenesis,O
of,O
ACE2,O
-,O
RBD,O
interface,O
residues,O
.,O
This,O
dataset,O
will,O
help,O
accelerate,O
the,O
design,O
of,O
therapeutics,O
against,O
SARS,O
-,O
CoV-2,O
",",O
as,O
well,O
as,O
contribute,O
to,O
prevention,O
of,O
possible,O
future,O
coronaviruses,O
outbreaks,O
.,O
From,O
Bangladesh,O
",",O
the,O
very,O
first,O
complete,O
genome,O
of,O
SARS‐CoV‐2,O
(,O
hCoV‐19,O
/,O
Bangladesh,O
/,O
CHRF_nCOV19_0001/2020,O
under,O
GISAID,S-Dataset
 ,O
Accession,O
no,O
:,O
EPI/ISL/437912,S-AccessionNumber
),O
was,O
published,O
by,O
the,O
Child,O
Health,O
Research,O
Foundation,O
(,O
CHRF,O
),O
on,O
12,O
May,O
2020,O
.,O
First,O
",",O
Bangladesh,O
reported,O
the,O
first,O
case,O
of,O
COVID‐19,O
on,O
8,O
March,O
2020,O
having,O
a,O
travel,O
history,O
from,O
Italy,O
.,O
Secondly,O
",",O
the,O
sequence,O
is,O
showing,O
99.99,O
%,O
identity,O
to,O
the,O
strains,O
of,O
European,O
",",O
Arabian,O
",",O
and,O
Asian,O
countries,O
(,O
Table,O
 ,O
1,O
listing,O
the,O
representative,O
countries,O
with,O
the,O
strain,O
ID,O
),O
considering,O
a,O
good,O
number,O
of,O
the,O
aligned,O
sequences,O
of,O
the,O
NCBI,S-Repository
 ,O
and,O
GISAID,S-Dataset
 ,O
databases,O
.,O
As,O
Nextstrain,S-Repository
 ,O
or,O
GISAID,S-Dataset
 ,O
deals,O
with,O
a,O
large,O
number,O
of,O
data,O
set,O
(,O
"25,246",O
as,O
of,O
14th,O
April,O
2020,O
),O
and,O
generates,O
an,O
updated,O
picture,O
of,O
the,O
evolutionary,O
timeframe,O
using,O
the,O
maximum,O
clade,O
credibility,O
(,O
MCC,O
),O
tree,O
",",O
at,O
this,O
stage,O
",",O
these,O
results,O
can,O
be,O
considered,O
more,O
reliable,O
.,O
We,O
have,O
found,O
",",O
considering,O
this,O
literature,O
and,O
online,O
resources,O
",",O
that,O
the,O
Bangladeshi,O
strain,O
fell,O
within,O
the,O
clade,O
A2a,O
containing,O
a,O
mutation,O
at,O
the,O
614th,O
position,O
of,O
the,O
spike,O
protein,O
changing,O
amino,O
acid,O
aspartate,O
to,O
glycine,O
(,O
synonymous,O
to,O
G,O
clade,O
according,O
to,O
GISAID,S-Dataset
 ,O
phylogenetic,O
tree,O
),O
and,O
another,O
mutation,O
at,O
the,O
323rd,O
position,O
of,O
NSP12,O
(,O
proline,O
to,O
leucine,O
),O
.,O
",",O
It,O
was,O
also,O
claimed,O
in,O
the,O
report,O
of,O
Ayub,O
 ,O
as,O
of,O
9th,O
April,O
2020,O
that,O
the,O
predominant,O
presence,O
of,O
SARS‐CoV‐2a,O
substrain,O
in,O
a,O
particular,O
city,O
or,O
country,O
",",O
such,O
as,O
United,O
Kingdom,O
(,O
26,O
%,O
),O
",",O
Belgium,O
(,O
31,O
%,O
),O
",",O
Netherland,O
(,O
50,O
%,O
),O
",",O
Portugal,O
(,O
60,O
%,O
),O
",",O
can,O
be,O
a,O
cause,O
of,O
reduced,O
cases,O
of,O
COVID‐19,O
.,O
Among,O
them,O
",",O
mutation,O
E261D,O
(,O
glutamic,O
acid,O
to,O
aspartic,O
acid,O
),O
in,O
the,O
NSP13,O
protein,O
(,O
RNA,O
helicase,O
and/or,O
5′,O
triphosphatase,O
activity,O
),O
was,O
found,O
only,O
in,O
one,O
Austrian,O
strain,O
(,O
hCoV‐19,O
/,O
Austria,O
/,O
CeMM0004/2020,O
),O
collected,O
on,O
3rd,O
March,O
2020,O
.,O
",",O
  ,O
Remarkably,O
",",O
another,O
mutation,O
(,O
I120F,O
:,O
isoleucine,O
to,O
phenylalanine,O
),O
in,O
the,O
NSP2,O
(,O
predicted,O
role,O
in,O
viral,O
pathogenicity,O
),O
 ,O
is,O
not,O
found,O
in,O
any,O
other,O
sequences,O
available,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
.,O
This,O
may,O
be,O
explained,O
by,O
the,O
fact,O
of,O
the,O
return,O
of,O
a,O
lot,O
of,O
immigrants,O
to,O
Bangladesh,O
from,O
other,O
countries,O
",",O
some,O
of,O
which,O
were,O
declared,O
as,O
the,O
COVID‐19,O
epicenters,O
.,O
The,O
COVID-19,O
pandemic,O
is,O
the,O
first,O
pandemic,O
where,O
WGS,O
capacity,O
has,O
been,O
widely,O
available,O
to,O
the,O
public,O
health,O
sector,O
from,O
the,O
beginning,O
.,O
Since,O
the,O
first,O
genomes,O
were,O
published,O
in,O
January,O
2020,O
[,O
1,O
-,O
4,O
],O
",",O
the,O
number,O
of,O
available,O
sequences,O
has,O
rapidly,O
increased,O
to,O
more,O
than,O
"63,000",O
complete,O
genome,O
sequences,O
available,O
in,O
GISAID,S-Dataset
 ,O
as,O
at,O
10,O
July,O
[,O
5,O
],O
.,O
The,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
European,O
Region,O
has,O
been,O
an,O
active,O
contributor,O
",",O
with,O
around,O
"39,000",O
complete,O
genome,O
sequences,O
from,O
35,O
countries,O
published,O
in,O
GISAID,S-Dataset
",",O
with,O
a,O
median,O
time,O
of,O
40,O
days,O
from,O
sample,O
collection,O
to,O
publication,O
according,O
to,O
the,O
GISAID,S-Dataset
 ,O
collection,O
and,O
submission,O
dates,O
.,O
Several,O
nomenclatures,O
have,O
been,O
introduced,O
for,O
SARS,O
-,O
CoV-2,O
(,O
strains,O
in,O
GISAID,S-Dataset
 ,O
use,O
the,O
name,O
hCoV-19,O
),O
",",O
including,O
by,O
Nextstrain,S-Repository
 ,O
[,O
6,O
],O
",",O
GISAID,S-Dataset
 ,O
[,O
7,O
],O
and,O
Rambaut,B-Creator
et,I-Creator
al.,E-Creator
 ,O
(,O
cov-lineages.org,S-URL
),O
[,O
8,O
-,O
10,O
],O
.,O
While,O
Nextstrain,S-Repository
 ,O
and,O
GISAID,S-Dataset
 ,O
clade,O
nomenclatures,O
aim,O
at,O
providing,O
a,O
broad,O
-,O
brush,O
categorisation,O
of,O
globally,O
circulating,O
diversity,O
",",O
the,O
lineages,O
(,O
cov-lineages.org,S-URL
),O
are,O
meant,O
to,O
correspond,O
to,O
outbreaks,O
.,O
The,O
tree,O
is,O
shaded,O
to,O
correspond,O
to,O
the,O
major,O
lineages,O
and,O
all,O
Nextstrain,S-Repository
 ,O
and,O
GISAID,S-Dataset
 ,O
clades,O
.,O
Between,O
Nextstrain,S-Repository
 ,O
clades,O
20A,O
and,O
20C,O
and,O
GISAID,S-Dataset
 ,O
clades,O
G,O
and,O
GH,O
",",O
there,O
are,O
differences,O
in,O
the,O
position,O
where,O
clades,O
are,O
divided,O
(,O
shown,O
as,O
grey,O
in,O
the,O
main,O
tree,O
and,O
lineage,O
columns,O
",",O
and,O
grey,O
stripes,O
in,O
the,O
Nextstrain,S-Repository
 ,O
and,O
GISAID,S-Dataset
 ,O
column,O
),O
.,O
Here,O
",",O
the,O
grey,O
is,O
shown,O
as,O
stripes,O
in,O
the,O
Nextstrain,S-Repository
 ,O
and,O
GISAID,S-Dataset
 ,O
clade,O
columns,O
to,O
reflect,O
how,O
they,O
are,O
categorised,O
by,O
each,O
methodology,O
.,O
The,O
sequence,O
data,O
available,O
from,O
GISAID,S-Dataset
 ,O
were,O
curated,O
using,O
the,O
Pangolin,O
data,O
preparation,O
pipeline,O
[,O
8,O
],O
.,O
There,O
was,O
an,O
initial,O
period,O
in,O
January,O
2020,O
when,O
the,O
19A,O
/,O
L,O
/,O
V,O
/,O
O,O
clades,O
(,O
Nextstrain,S-Repository
/,O
GISAID,S-Dataset
 ,O
nomenclatures,O
),O
were,O
more,O
prevalent,O
in,O
total,O
than,O
the,O
20A,O
/,O
G,O
clades,O
",",O
However,O
",",O
this,O
could,O
partially,O
be,O
an,O
effect,O
of,O
small,O
numbers,O
of,O
sequenced,O
viral,O
genomes,O
in,O
Europe,O
early,O
in,O
the,O
pandemic,O
as,O
well,O
as,O
the,O
widespread,O
sampling,O
strategy,O
focusing,O
on,O
cases,O
with,O
travel,O
history,O
to,O
East,O
Asia,O
.,O
The,O
Nextstrain,S-Repository
 ,O
20C,O
clade,O
peaked,O
at,O
ca,O
20,O
%,O
of,O
the,O
sequences,O
in,O
early,O
April,O
2020,O
and,O
has,O
since,O
then,O
slowly,O
declined,O
and,O
almost,O
disappeared,O
",",O
while,O
the,O
GISAID,S-Dataset
 ,O
GH,O
clade,O
peaked,O
at,O
ca,O
30,O
%,O
in,O
May,O
2020,O
and,O
has,O
rapidly,O
declined,O
since,O
then,O
.,O
From,O
top,O
to,O
bottom,O
:,O
Nextstrain,S-Repository
",",O
GISAID,S-Dataset
 ,O
and,O
cov-lineages.org,S-URL
.,O
Shaded,O
areas,O
:,O
interquartile,O
ranges,O
obtained,O
by,O
bootstrap,O
resampling,O
the,O
dataset,O
by,O
country,O
.,O
The,O
geographical,O
distribution,O
of,O
Nextstrain,S-Repository
 ,O
and,O
GISAID,S-Dataset
 ,O
clades,O
shows,O
that,O
in,O
general,O
",",O
clade,O
19B,O
/,O
S,O
has,O
been,O
very,O
rare,O
",",O
except,O
in,O
Spain,O
and,O
Kazakhstan,O
",",O
and,O
frequencies,O
of,O
the,O
other,O
clades,O
were,O
varied,O
for,O
most,O
countries,O
in,O
the,O
WHO,O
European,O
Region,O
(,O
Figure,O
3,O
),O
.,O
The,O
grey,O
areas,O
represent,O
sequences,O
called,O
differently,O
by,O
the,O
GISAID,S-Dataset
 ,O
and,O
Nextstrain,S-Repository
 ,O
methodologies,O
",",O
and,O
correspond,O
to,O
the,O
grey,O
-,O
shaded,O
partition,O
of,O
the,O
tree,O
in,O
Figure,O
1,O
.,O
The,O
proportion,O
of,O
clades,O
found,O
in,O
each,O
country,O
was,O
calculated,O
using,O
all,O
available,O
full,O
-,O
length,O
",",O
high,O
-,O
quality,O
(,O
>,O
 ,O
"27,000",O
bases,O
",",O
 ,O
<,O
 ,O
"3,000",O
undetermined,O
bases,O
),O
sequences,O
available,O
on,O
GISAID,S-Dataset
.,O
Clade,O
membership,O
for,O
each,O
sequence,O
was,O
determined,O
by,O
given,O
GISAID,S-Dataset
 ,O
annotation,O
or,O
via,O
the,O
Nextstrain,S-Repository
 ,O
clades,O
script,O
",",O
and,O
proportions,O
were,O
calculated,O
for,O
all,O
sequences,O
from,O
a,O
given,O
country,O
.,O
The,O
first,O
three,O
also,O
depend,O
to,O
a,O
large,O
degree,O
on,O
data,O
completeness,O
",",O
which,O
is,O
a,O
limitation,O
in,O
the,O
currently,O
available,O
dataset,O
where,O
the,O
number,O
of,O
sequences,O
per,O
country,O
ranges,O
from,O
four,O
to,O
"28,000",O
.,O
SARS,O
-,O
CoV-2,O
",",O
which,O
causes,O
the,O
disease,O
known,O
as,O
COVID-19,O
",",O
was,O
first,O
reported,O
in,O
late,O
2019,O
(,O
Coronaviridae,O
Study,O
Group,O
of,O
the,O
International,O
Committee,O
on,O
Taxonomy,O
of,O
V.,O
",",O
2020,O
",",O
Lu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Paules,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
COVID-19,O
is,O
characterized,O
by,O
pneumonia,O
",",O
fever,O
",",O
cough,O
",",O
and,O
occasional,O
diarrhea,O
(,O
Guan,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Holshue,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Huang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
",",O
and,O
SARS,O
-,O
CoV-2,O
RNA,O
has,O
been,O
reliably,O
detected,O
in,O
nasopharyngeal,O
swabs,O
",",O
sputum,O
",",O
and,O
stool,O
samples,O
(,O
Wang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Wölfel,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Zou,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Early,O
models,O
of,O
COVID-19,O
transmission,O
dynamics,O
estimate,O
one,O
infectious,O
individual,O
infects,O
slightly,O
over,O
two,O
individuals,O
;,O
travel,O
restrictions,O
reduce,O
that,O
spread,O
to,O
one,O
individual,O
",",O
although,O
these,O
figures,O
might,O
evolve,O
as,O
more,O
accurate,O
epidemiological,O
data,O
become,O
available,O
(,O
Kucharski,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Here,O
",",O
using,O
published,O
and,O
unpublished,O
datasets,O
(,O
all,O
from,O
non,O
-,O
SARS,O
-,O
CoV-2,O
-,O
infected,O
samples,O
),O
",",O
we,O
analyze,O
human,O
",",O
NHP,O
",",O
and,O
mouse,O
tissues,O
that,O
have,O
been,O
clinically,O
identified,O
to,O
harbor,O
virus,O
in,O
patients,O
exhibiting,O
COVID-19,O
symptoms,O
.,O
Here,O
",",O
we,O
focus,O
our,O
analysis,O
and,O
discussion,O
on,O
the,O
specific,O
subsets,O
where,O
ACE2,O
and,O
TMPRSS2,O
are,O
enriched,O
and,O
on,O
relative,O
comparisons,O
within,O
each,O
dataset,O
",",O
rather,O
than,O
between,O
datasets,O
or,O
equivalence,O
to,O
absolute,O
numbers,O
of,O
total,O
cells,O
.,O
Human,O
influenza,O
infection,O
also,O
induces,O
broader,O
expression,O
of,O
ACE2,O
in,O
upper,O
airway,O
epithelial,O
cells,O
and,O
is,O
corroborated,O
by,O
publicly,O
available,O
databases,O
.,O
The,O
dynamic,O
",",O
species,O
-,O
specific,O
and,O
multifaceted,O
role,O
of,O
IFN,O
raises,O
implications,O
for,O
pre,O
-,O
clinical,O
COVID-19,O
disease,O
modeling,O
.,O
To,O
investigate,O
which,O
cells,O
within,O
human,O
and,O
NHP,O
tissues,O
represent,O
likely,O
SARS,O
-,O
CoV-2,O
targets,O
",",O
we,O
analyzed,O
new,O
and,O
existing,O
scRNA,O
-,O
seq,O
datasets,O
to,O
assess,O
which,O
cell,O
types,O
express,O
ACE2,O
",",O
alone,O
or,O
with,O
TMPRSS2,O
.,O
In,O
a,O
previously,O
unpublished,O
dataset,O
consisting,O
of,O
NHP,O
(,O
Macaca,O
mulatta,O
),O
lung,O
tissue,O
collected,O
after,O
necropsy,O
of,O
healthy,O
adult,O
animals,O
and,O
analyzed,O
by,O
using,O
Seq,O
-,O
Well,O
v1,O
(,O
Gierahn,B-Creator
"et al.,",I-Creator
2017,E-Creator
),O
",",O
we,O
recovered,O
at,O
least,O
17,O
distinct,O
major,O
cell,O
types,O
",",O
including,O
various,O
lymphoid,O
",",O
myeloid,O
",",O
and,O
stromal,O
populations,O
(,O
Figures,O
1A–1C,O
;,O
Table,O
S1,O
;,O
STAR,O
Methods,O
),O
.,O
To,O
assess,O
whether,O
the,O
findings,O
from,O
NHP,O
lung,O
cells,O
were,O
similarly,O
present,O
in,O
humans,O
",",O
we,O
analyzed,O
a,O
previously,O
unpublished,O
scRNA,O
-,O
seq,O
dataset,O
derived,O
from,O
surgical,O
resections,O
of,O
fibrotic,O
lung,O
tissue,O
collected,O
with,O
Seq,O
-,O
Well,O
S3,O
(,O
Hughes,B-Creator
"et al.,",I-Creator
2019,E-Creator
),O
.,O
Of,O
note,O
",",O
we,O
also,O
observed,O
TRIM28,O
co,O
-,O
expressed,O
with,O
ACE2,O
and,O
TMPRSS2,O
among,O
type,O
II,O
pneumocytes,O
in,O
this,O
dataset,O
(,O
FDR,O
-,O
adjusted,O
p,O
 ,O
=,O
2.34E−9,O
),O
",",O
which,O
might,O
play,O
a,O
role,O
in,O
potentiating,O
an,O
IFN,O
response,O
in,O
lung,O
epithelial,O
cells,O
(,O
Krischuns,O
et,O
 ,O
al,O
.,O
",",O
2018,O
),O
.,O
Next,O
",",O
using,O
a,O
previously,O
unpublished,O
scRNA,O
-,O
seq,O
dataset,O
consisting,O
of,O
granuloma,O
and,O
adjacent,O
",",O
uninvolved,O
lung,O
samples,O
from,O
Mtb,O
-,O
infected,O
NHPs,O
(,O
Macaca,O
fascicularis,O
),O
collected,O
with,O
Seq,O
-,O
Well,O
S3,O
",",O
we,O
identified,O
subsets,O
of,O
epithelial,O
cells,O
expressing,O
ACE2,O
and,O
TMPRSS2,O
(,O
Figure,O
 ,O
S1,O
;,O
Table,O
S3,O
;,O
STAR,O
Methods,O
),O
.,O
Next,O
",",O
we,O
examined,O
several,O
other,O
tissues,O
for,O
ACE2,O
-,O
expressing,O
cells,O
on,O
the,O
basis,O
of,O
the,O
location,O
of,O
hallmark,O
symptoms,O
of,O
COVID-19,O
",",O
focusing,O
on,O
the,O
gastrointestinal,O
tract,O
due,O
to,O
reports,O
of,O
clinical,O
symptoms,O
and,O
viral,O
shedding,O
(,O
Xiao,B-Creator
"et al.,",I-Creator
2020,E-Creator
),O
.,O
Shown,O
on,O
the,O
right,O
is,O
a,O
tSNE,O
plot,O
of,O
"13,689",O
epithelial,O
cells,O
selected,O
from,O
original,O
dataset,O
generated,O
by,O
10x,O
3′,O
v2,O
(,O
see,O
Figure,O
S2,O
),O
",",O
colored,O
by,O
cellular,O
subsets,O
.,O
(,O
E,O
),O
.,O
In,O
an,O
additional,O
dataset,O
consisting,O
of,O
endoscopic,O
biopsies,O
from,O
the,O
terminal,O
ileum,O
of,O
a,O
human,O
pediatric,O
cohort,O
(,O
n,O
 ,O
=,O
13,O
donors,O
",",O
ranging,O
in,O
age,O
from,O
10,O
to,O
18,O
years,O
old,O
),O
",",O
collected,O
with,O
10X,O
3′,O
v2,O
",",O
we,O
confirmed,O
a,O
large,O
abundance,O
of,O
ACE2,O
+,O
cells,O
with,O
selective,O
expression,O
within,O
absorptive,O
enterocytes,O
(,O
29.7,O
%,O
ACE2,O
+,O
",",O
FDR,O
-,O
adjusted,O
p,O
 ,O
=,O
2.46E−100,O
),O
(,O
Figures,O
3D,O
and,O
3E,O
;,O
Table,O
S5,O
;,O
STAR,O
Methods,O
),O
.,O
To,O
identify,O
potential,O
viral,O
target,O
cells,O
in,O
nasal,O
and,O
sinus,O
tissue,O
",",O
two,O
regions,O
that,O
are,O
frequently,O
primary,O
sites,O
of,O
exposure,O
for,O
coronaviruses,O
",",O
we,O
analyzed,O
existing,O
scRNA,O
-,O
seq,O
datasets,O
from,O
the,O
human,O
upper,O
airway,O
(,O
inferior,O
turbinate,O
and,O
ethmoid,O
sinus,O
mucosa,O
),O
across,O
a,O
spectrum,O
of,O
healthy,O
donors,O
and,O
individuals,O
with,O
allergic,O
inflammation,O
due,O
to,O
chronic,O
rhinosinusitis,O
(,O
CRS,O
),O
collected,O
with,O
Seq,O
-,O
Well,O
v1,O
(,O
Figure,O
 ,O
4A,O
;,O
STAR,O
Methods,O
),O
(,O
Ordovas-Montanes,B-Creator
"et al.,",I-Creator
2018,E-Creator
),O
.,O
We,O
next,O
utilized,O
IFN,O
-,O
inducible,O
gene,O
sets,O
of,O
relevance,O
to,O
human,O
airway,O
epithelial,O
cells,O
",",O
which,O
we,O
derived,O
from,O
a,O
prior,O
study,O
by,O
performing,O
differential,O
expression,O
on,O
a,O
published,O
dataset,O
where,O
air,O
-,O
liquid,O
interface,O
cultures,O
from,O
primary,O
human,O
nasal,O
epithelial,O
cells,O
were,O
treated,O
with,O
IFN,O
-,O
αA,O
/,O
D,O
",",O
IFN,O
-,O
β1a,O
",",O
IFN,O
-,O
γ,O
",",O
IL-4,O
",",O
or,O
IL-13,O
(,O
Giovannini-Chami,B-Creator
"et al.,",I-Creator
2012,E-Creator
",",O
Ordovas-Montanes,B-Creator
"et al.,",I-Creator
2018,E-Creator
),O
.,O
Next,O
",",O
using,O
a,O
publicly,O
available,O
resource,O
(,O
interferome.org,S-URL
),O
that,O
hosts,O
genomic,O
and,O
transcriptomic,O
data,O
from,O
cells,O
or,O
tissues,O
treated,O
with,O
IFN,O
",",O
we,O
queried,O
ACE2,O
expression,O
within,O
human,O
and,O
mouse,O
cells,O
",",O
searching,O
for,O
datasets,O
with,O
a,O
log2,O
-,O
fold,O
-,O
change,O
of,O
>,O
1,O
or,O
 ,O
<,O
−1,O
compared,O
with,O
untreated,O
samples,O
",",O
including,O
all,O
IFN,O
types,O
(,O
Rusinova,O
et,O
 ,O
al,O
.,O
",",O
2013,O
),O
.,O
We,O
recovered,O
21,O
datasets,O
spanning,O
8,O
distinct,O
primary,O
tissues,O
or,O
cell,O
lines,O
with,O
non,O
-,O
trivial,O
changes,O
in,O
ACE2,O
expression,O
after,O
both,O
type,O
I,O
and,O
type,O
II,O
IFN,O
treatment,O
(,O
Figure,O
 ,O
S4A,O
),O
.,O
Immune,O
cell,O
types,O
",",O
such,O
as,O
CD4,O
T,O
 ,O
cells,O
and,O
macrophages,O
",",O
were,O
noticeably,O
absent,O
from,O
datasets,O
with,O
a,O
significant,O
change,O
in,O
ACE2,O
expression,O
after,O
IFN,O
stimulation,O
or,O
were,O
even,O
found,O
to,O
downregulate,O
ACE2,O
(,O
e.g.,O
",",O
primary,O
CD4,O
T,O
 ,O
cells,O
 ,O
+,O
type,O
I,O
IFN,O
),O
(,O
Figure,O
 ,O
S4A,O
",",O
and,O
in,O
our,O
analysis,O
of,O
scRNA,O
-,O
seq,O
peripheral,O
blood,O
mononuclear,O
cell,O
data,O
from,O
Butler,O
et,O
 ,O
al,O
.,O
",",O
(,O
2018,O
),O
;,O
data,O
not,O
shown,O
),O
.,O
Generated,O
from,O
TRANSFAC,S-Repository
 ,O
data,O
using,O
the,O
interferome.org,S-URL
 ,O
database,O
(,O
Matys,B-Creator
"et al.,",I-Creator
2003,E-Creator
",",O
Rusinova,B-Creator
"et al.,",I-Creator
2013,E-Creator
),O
.,O
Furthermore,O
",",O
using,O
both,O
Transcription,B-Repository
Factor,I-Repository
database,I-Repository
(TRANSFAC),E-Repository
 ,O
data,O
hosted,O
by,O
the,O
interferome,S-Dataset
 ,O
database,O
",",O
as,O
well,O
as,O
chromatin,O
immunoprecipitation,O
sequencing,O
(,O
ChIP,O
-,O
seq,O
),O
data,O
(,O
provided,O
by,O
the,O
ENCODE,B-Repository
Factorbook,E-Repository
 ,O
repository,O
),O
",",O
we,O
found,O
evidence,O
for,O
STAT1,O
",",O
STAT3,O
",",O
IRF8,O
",",O
and,O
IRF1,O
binding,O
sites,O
within,O
−1500–500,O
 ,O
bp,O
of,O
the,O
transcription,O
start,O
site,O
of,O
ACE2,O
(,O
all,O
in,O
human,O
studies,O
",",O
Figure,O
 ,O
S4B,O
),O
(,O
Gerstein,O
et,O
 ,O
al,O
.,O
",",O
2012,O
",",O
Matys,O
et,O
 ,O
al,O
.,O
",",O
2003,O
",",O
Wang,O
et,O
 ,O
al,O
.,O
",",O
2012,O
",",O
Wang,O
et,O
 ,O
al,O
.,O
",",O
2013,O
),O
.,O
We,O
collected,O
from,O
both,O
tissue,O
sites,O
because,O
of,O
early,O
reports,O
of,O
anosmia,O
in,O
COVID-19,O
(,O
Lechien,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
We,O
re,O
-,O
analyzed,O
a,O
publicly,O
available,O
dataset,O
of,O
RNA,O
-,O
seq,O
from,O
human,O
lung,O
explants,O
isolated,O
after,O
surgical,O
resections,O
that,O
were,O
infected,O
with,O
influenza,O
A,O
virus,O
ex,O
 ,O
vivo,O
for,O
24,O
h.,O
To,O
review,O
the,O
data,O
presented,O
:,O
(,O
1,O
),O
we,O
found,O
that,O
expression,O
of,O
the,O
cellular,O
entry,O
receptor,O
for,O
SARS,O
-,O
CoV-2,O
",",O
ACE2,O
",",O
is,O
primarily,O
restricted,O
to,O
type,O
II,O
pneumocytes,O
in,O
the,O
lung,O
",",O
absorptive,O
enterocytes,O
within,O
the,O
gut,O
",",O
and,O
goblet,O
secretory,O
cells,O
of,O
the,O
nasal,O
mucosa,O
;,O
(,O
2,O
),O
ACE2,O
and,O
TMPRSS2,O
co,O
-,O
expression,O
in,O
respiratory,O
tissues,O
is,O
consistently,O
found,O
only,O
among,O
a,O
rare,O
subset,O
of,O
epithelial,O
cells,O
;,O
(,O
3,O
),O
we,O
observed,O
similarities,O
in,O
the,O
cellular,O
identities,O
and,O
frequencies,O
of,O
putative,O
SARS,O
-,O
CoV-2,O
target,O
cells,O
across,O
human,O
and,O
NHP,O
cohorts,O
;,O
(,O
4,O
),O
we,O
observe,O
increased,O
expression,O
of,O
ACE2,O
during,O
SHIV,O
and,O
TB,O
infection,O
of,O
NHPs,O
",",O
and,O
HIV,O
/,O
TB,O
co,O
-,O
infection,O
and,O
influenza,O
infection,O
of,O
humans,O
compared,O
with,O
that,O
in,O
matched,O
controls,O
but,O
caution,O
that,O
none,O
of,O
the,O
datasets,O
presented,O
here,O
were,O
designed,O
to,O
answer,O
this,O
specific,O
query,O
.,O
We,O
also,O
present,O
datasets,O
separately,O
",",O
given,O
that,O
each,O
study,O
differed,O
in,O
its,O
methods,O
of,O
tissue,O
processing,O
and,O
collection,O
",",O
which,O
can,O
influence,O
the,O
frequency,O
of,O
recovered,O
cell,O
subsets,O
(,O
STAR,O
Methods,O
),O
.,O
We,O
provide,O
Table,O
S9,O
as,O
a,O
summary,O
of,O
ACE2,O
+,O
and,O
ACE2+TMPRSS2,O
+,O
cells,O
across,O
various,O
datasets,O
.,O
This,O
is,O
based,O
on,O
several,O
lines,O
of,O
evidence,O
:,O
(,O
1,O
),O
we,O
identified,O
a,O
human,O
goblet,O
secretory,O
cell,O
subset,O
in,O
upper,O
airway,O
nasal,O
epithelium,O
enriched,O
for,O
ACE2,O
expression,O
to,O
have,O
the,O
highest,O
IFN,O
-,O
α,O
-,O
induced,O
gene,O
signature,O
;,O
(,O
2,O
),O
we,O
found,O
that,O
IFN,O
-,O
α,O
",",O
and,O
to,O
a,O
lesser,O
extent,O
IFN,O
-,O
β,O
or,O
IFN,O
-,O
γ,O
",",O
induced,O
ACE2,O
expression,O
in,O
a,O
published,O
dataset,O
of,O
air,O
-,O
liquid,O
interface,O
cultures,O
derived,O
from,O
human,O
nasal,O
epithelial,O
cells,O
(,O
Giovannini,O
-,O
Chami,O
et,O
 ,O
al,O
.,O
",",O
2012,O
",",O
Ordovas,O
-,O
Montanes,O
et,O
 ,O
al,O
.,O
",",O
2018,O
),O
;,O
(,O
3,O
),O
we,O
extended,O
our,O
search,O
through,O
the,O
Interferome,S-Dataset
 ,O
database,O
(,O
Rusinova,B-Creator
"et al.,",I-Creator
2013,E-Creator
),O
and,O
found,O
that,O
",",O
in,O
epithelial,O
barrier,O
tissues,O
",",O
type,O
I,O
IFNs,O
upregulate,O
ACE2,O
in,O
multiple,O
studies,O
",",O
especially,O
in,O
primary,O
bronchial,O
cells,O
and,O
keratinocytes,O
(,O
Rusinova,O
et,O
 ,O
al,O
.,O
",",O
2013,O
),O
;,O
(,O
4,O
),O
we,O
found,O
two,O
STAT1,O
binding,O
sites,O
in,O
the,O
promoter,O
of,O
ACE2,O
;,O
(,O
5,O
),O
in,O
our,O
unpublished,O
atlas,O
of,O
SHIV,O
-,O
infected,O
macaques,O
",",O
known,O
to,O
have,O
elevated,O
amounts,O
of,O
chronic,O
IFN,O
signaling,O
",",O
we,O
found,O
ACE2,O
upregulation,O
in,O
absorptive,O
enterocytes,O
;,O
(,O
6,O
),O
we,O
directly,O
provided,O
evidence,O
for,O
IFN,O
-,O
α,O
",",O
and,O
to,O
some,O
extent,O
IFN,O
-,O
γ,O
",",O
inducing,O
ACE2,O
expression,O
in,O
primary,O
human,O
upper,O
airway,O
basal,O
cells,O
;,O
and,O
(,O
7,O
),O
influenza,O
infection,O
in,O
humans,O
",",O
a,O
known,O
inducer,O
of,O
the,O
IFN,O
pathway,O
",",O
leads,O
to,O
increased,O
ACE2,O
expression,O
in,O
goblet,O
secretory,O
cells,O
of,O
the,O
nasal,O
epithelium,O
(,O
Cao,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Altogether,O
",",O
our,O
own,O
and,O
publicly,O
available,O
data,O
highlight,O
that,O
ACE2,O
might,O
have,O
been,O
missed,O
as,O
a,O
canonical,O
ISG,O
because,O
of,O
its,O
notable,O
absence,O
in,O
peripheral,O
blood,O
mononuclear,O
cell,O
datasets,O
and,O
in,O
lung,O
-,O
derived,O
transformed,O
cell,O
lines,O
such,O
as,O
the,O
A549,O
cell,O
line,O
(,O
Butler,O
et,O
 ,O
al,O
.,O
",",O
2018,O
",",O
Letko,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Rusinova,O
et,O
 ,O
al,O
.,O
",",O
2013,O
),O
.,O
Importantly,O
",",O
other,O
groups,O
have,O
independently,O
analyzed,O
publicly,O
available,O
datasets,O
",",O
some,O
referenced,O
in,O
our,O
work,O
",",O
and,O
observed,O
ACE2,O
’s,O
behavior,O
as,O
an,O
ISG,O
(,O
Wang,O
and,O
Cheng,O
",",O
2020,O
),O
.,O
Whether,O
IFNs,O
upregulate,O
ACE2,O
in,O
putative,O
target,O
cell,O
subsets,O
in,O
 ,O
vivo,O
will,O
be,O
of,O
significant,O
interest,O
to,O
define,O
in,O
future,O
work,O
once,O
current,O
COVID-19,O
-,O
related,O
restrictions,O
on,O
basic,O
scientific,O
inquiry,O
are,O
lifted,O
(,O
Qian,O
et,O
 ,O
al,O
.,O
",",O
2013,O
),O
.,O
For,O
example,O
",",O
examining,O
the,O
efficacy,O
of,O
recombinant,O
human,O
ACE2,O
to,O
act,O
as,O
a,O
decoy,O
receptor,O
or,O
the,O
effect,O
of,O
“,O
ACE,O
inhibitors,O
”,O
in,O
patients,O
with,O
",",O
or,O
at,O
risk,O
for,O
",",O
COVID-19,O
will,O
require,O
careful,O
experimentation,O
in,O
appropriate,O
models,O
together,O
with,O
well,O
-,O
controlled,O
clinical,O
trials,O
(,O
Hofmann,O
et,O
 ,O
al,O
.,O
",",O
2004,O
",",O
Monteil,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Vaduganathan,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Furthermore,O
",",O
another,O
study,O
appeared,O
on,O
medRxiv,O
profiling,O
bronchoalveolar,O
lavage,O
fluid,O
from,O
3,O
severe,O
and,O
3,O
mild,O
COVID-19,O
patients,O
",",O
though,O
they,O
were,O
unable,O
to,O
profile,O
sufficient,O
numbers,O
of,O
epithelial,O
cells,O
(,O
Liao,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Our,O
study,O
highlights,O
the,O
power,O
of,O
scRNA,O
-,O
seq,O
datasets,O
",",O
both,O
existing,O
and,O
novel,O
",",O
to,O
derive,O
hypotheses,O
relevant,O
to,O
human,O
disease,O
that,O
might,O
differ,O
from,O
paradigms,O
established,O
by,O
using,O
cell,O
lines,O
.,O
In,O
Table,O
S9,O
",",O
we,O
provide,O
a,O
guide,O
to,O
all,O
datasets,O
analyzed,O
in,O
this,O
paper,O
as,O
well,O
as,O
links,O
to,O
each,O
individual,O
dataset,O
for,O
download,O
with,O
the,O
main,O
landing,O
page,O
here,O
:,O
https://singlecell.broadinstitute.org/single_cell?scpbr=the-alexandria-project,S-URL
.,O
Downloadable,O
datasets,O
include,O
both,O
raw,O
and,O
normalized,O
cell,O
x,O
gene,O
matrices,O
",",O
as,O
well,O
as,O
relevant,O
metadata,O
.,O
These,O
datasets,O
are,O
additionally,O
available,O
here,O
to,O
facilitate,O
downloading,O
:,O
https://drive.google.com/drive/folders/1bxCIqNeZ7wLuVOT16gphwj98_cc9KhrV?usp=sharing,S-URL
.,O
We,O
have,O
also,O
posted,O
these,O
cell,O
x,O
gene,O
matrices,O
to,O
Chan,O
Zuckerberg,O
Initiative,O
cellxgene,O
(,O
https://chanzuckerberg.github.io/cellxgene/posts/cellxgene_cziscience_com,O
),O
and,O
the,O
Broad,O
Institute,O
Single,O
Cell,O
COVID-19,O
portal,O
(,O
https://singlecell.broadinstitute.org/single_cell/covid19,O
),O
as,O
leading,O
community,O
efforts,O
.,O
FASTQ,O
files,O
and,O
cell,O
x,O
gene,O
matrices,O
for,O
NHP,O
and,O
murine,O
datasets,O
",",O
and,O
cell,O
x,O
gene,O
matrices,O
for,O
human,O
datasets,O
",",O
are,O
available,O
at,O
GEO,S-Repository
:,O
GSE148829,S-AccessionNumber
.,O
Full,O
information,O
related,O
to,O
subject,O
age,O
/,O
developmental,O
stage,O
and,O
sex,O
found,O
in,O
metadata,O
associated,O
with,O
provided,O
raw,O
datasets,O
.,O
Full,O
information,O
related,O
to,O
subject,O
age,O
/,O
developmental,O
stage,O
and,O
sex,O
found,O
in,O
metadata,O
associated,O
with,O
provided,O
raw,O
datasets,O
.,O
Expression,O
data,O
for,O
epithelial,O
cells,O
and,O
enterocytes,O
included,O
in,O
this,O
dataset,O
can,O
be,O
visualized,O
and,O
downloaded,O
here,O
:,O
https://singlecell.broadinstitute.org/single_cell/study/SCP807?scpbr=the-alexandria-project#study-summary,S-URL
.,O
Sub,O
-,O
clusters,O
(,O
i.e.,O
",",O
clusters,O
within,O
broad,O
cell,O
type,O
classifications,O
),O
were,O
annotated,O
by,O
cross,O
-,O
referencing,O
cluster,O
-,O
defining,O
genes,O
with,O
curated,O
gene,O
lists,O
and,O
online,O
databases,O
SaVanT,O
(,O
http://newpathways.mcdb.ucla.edu/savant-dev/,O
),O
and,O
GSEA/MsigDB,S-Dataset
 ,O
(,O
https://www.gsea-msigdb.org/gsea/msigdb/index.jsp,S-URL
),O
.,O
Expression,O
data,O
for,O
epithelial,O
cells,O
included,O
in,O
this,O
dataset,O
can,O
be,O
visualized,O
and,O
downloaded,O
here,O
:,O
https://singlecell.broadinstitute.org/single_cell/study/SCP814?scpbr=the-alexandria-project#study-summary,S-URL
.,O
Expression,O
data,O
for,O
epithelial,O
cells,O
included,O
in,O
this,O
dataset,O
can,O
be,O
visualized,O
and,O
downloaded,O
here,O
:,O
Libraries,O
corresponding,O
to,O
4,O
mice,O
",",O
with,O
2,O
Seq,O
-,O
Well,O
arrays,O
per,O
mouse,O
were,O
sequenced,O
using,O
Illumina,O
NextSeq,O
as,O
described,O
(,O
Gierahn,O
et,O
 ,O
al,O
.,O
",",O
2017,O
",",O
Hughes,O
et,O
 ,O
al,O
.,O
",",O
2019,O
),O
.,O
This,O
dataset,O
can,O
be,O
visualized,O
and,O
downloaded,O
here,O
:,O
Libraries,O
corresponding,O
to,O
14,O
mice,O
were,O
aligned,O
to,O
a,O
custom,O
reference,O
genome,O
encompassing,O
both,O
murine,O
(,O
mm10,O
),O
and,O
herpes,O
virus,O
genes,O
:,O
84,O
known,O
genes,O
from,O
MHV68,O
were,O
retrieved,O
from,O
NCBI,S-Repository
 ,O
(,O
NCBI,S-Repository
:,O
txid33708,S-AccessionNumber
),O
and,O
added,O
to,O
the,O
mm10,O
mouse,O
genome,O
.,O
Type,O
I,O
Pneumocytes,O
were,O
excluded,O
from,O
this,O
analysis,O
based,O
on,O
uniformly,O
negative,O
expression,O
of,O
Ace2,O
",",O
resulting,O
in,O
a,O
final,O
dataset,O
subset,O
of,O
"5,558",O
cells,O
.,O
There,O
is,O
pressing,O
urgency,O
to,O
understand,O
the,O
pathogenesis,O
of,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
clade,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
which,O
causes,O
the,O
disease,O
COVID-19,O
.,O
Here,O
",",O
we,O
leverage,O
human,O
",",O
non,O
-,O
human,O
primate,O
",",O
and,O
mouse,O
single,O
-,O
cell,O
RNA,O
-,O
sequencing,O
(,O
scRNA,O
-,O
seq,O
),O
datasets,O
across,O
health,O
and,O
disease,O
to,O
uncover,O
putative,O
targets,O
of,O
SARS,O
-,O
CoV-2,O
among,O
tissue,O
-,O
resident,O
cell,O
subsets,O
.,O
Graphical,O
Abstract,O
     ,O
Highlights,O
    ,O
•,O
 ,O
Meta,O
-,O
analysis,O
of,O
human,O
",",O
non,O
-,O
human,O
primate,O
",",O
and,O
mouse,O
single,O
-,O
cell,O
RNA,O
-,O
seq,O
datasets,O
for,O
putative,O
SARS,O
-,O
CoV-2,O
targets,O
   ,O
•,O
Type,O
II,O
pneumocytes,O
",",O
nasal,O
secretory,O
cells,O
",",O
and,O
absorptive,O
enterocytes,O
are,O
ACE2,O
+,O
TMPRSS2,O
+,O
   ,O
•,O
 ,O
Interferon,O
and,O
influenza,O
increase,O
ACE2,O
in,O
human,O
nasal,O
epithelia,O
and,O
lung,O
tissue,O
   ,O
•,O
 ,O
Mouse,O
Ace2,O
is,O
not,O
upregulated,O
by,O
interferon,O
",",O
raising,O
implications,O
for,O
disease,O
modeling,O
     ,O
Analysis,O
of,O
single,O
-,O
cell,O
RNA,O
-,O
seq,O
datasets,O
from,O
human,O
",",O
non,O
-,O
human,O
primate,O
",",O
and,O
mouse,O
barrier,O
tissues,O
identifies,O
putative,O
cellular,O
targets,O
of,O
SARS,O
-,O
CoV-2,O
on,O
the,O
basis,O
of,O
ACE2,O
and,O
TMPRSS2,O
expression,O
.,O
Of,O
note,O
",",O
the,O
recent,O
outbreak,O
of,O
Corona,O
virus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
",",O
a,O
cluster,O
of,O
pneumonia,O
in,O
humans,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
",",O
turned,O
into,O
a,O
public,O
health,O
emergency,O
of,O
international,O
concern,O
(,O
Sun,O
et,O
 ,O
al,O
.,O
2020,O
),O
.,O
Although,O
our,O
discrete,O
phylogeographic,O
inference,O
results,O
currently,O
do,O
not,O
implicate,O
geographic,O
distance,O
or,O
hog,O
population,O
sizes,O
in,O
farms,O
as,O
drivers,O
of,O
spatial,O
spread,O
",",O
more,O
comprehensive,O
sampling,O
and,O
incorporating,O
additional,O
predictors,O
at,O
different,O
levels,O
(,O
county,O
",",O
prefecture,O
",",O
or,O
province,O
),O
may,O
elucidate,O
important,O
spatial,O
dynamics,O
in,O
the,O
future,O
.,O
The,O
continuous,O
phylogeographic,O
reconstruction,O
that,O
incorporates,O
a,O
directional,O
tendency,O
suggests,O
a,O
southern,O
origin,O
for,O
PDCoV,O
spread,O
in,O
China,O
.,O
A,O
total,O
of,O
119,O
genome,O
sequences,O
and,O
220,O
S,O
gene,O
sequences,O
were,O
used,O
",",O
along,O
with,O
21,O
newly,O
sequenced,O
genomes,O
(,O
GenBank,S-Repository
 ,O
accession,O
numbers,O
in,O
supplementary,O
table,O
S2,O
",",O
Supplementary,O
Material,O
online,O
),O
and,O
29,O
newly,O
sequenced,O
S,O
gene,O
(,O
GenBank,S-Repository
 ,O
accession,O
numbers,O
:,O
MN058045,S-AccessionNumber
–,O
MN058073,S-AccessionNumber
),O
sequences,O
",",O
respectively,O
.,O
We,O
first,O
assessed,O
temporal,O
signal,O
in,O
our,O
data,O
sets,O
using,O
TempEst,O
(,O
Rambaut,O
et,O
 ,O
al,O
.,O
2016,O
),O
and,O
continued,O
to,O
assess,O
the,O
best,O
fitting,O
model,O
through,O
marginal,O
likelihood,O
estimation,O
using,O
path,O
-,O
sampling,O
and,O
stepping,O
-,O
stone,O
estimation,O
approaches,O
.,O
Since,O
its,O
emergence,O
from,O
Wuhan,O
",",O
China,O
",",O
in,O
late,O
2019,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
the,O
virus,O
responsible,O
for,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
has,O
already,O
claimed,O
the,O
lives,O
of,O
more,O
than,O
"70,000",O
individuals,O
worldwide,O
.,O
",",O
With,O
the,O
number,O
of,O
COVID-19,O
cases,O
and,O
deaths,O
increasing,O
with,O
each,O
passing,O
day,O
",",O
there,O
is,O
perhaps,O
no,O
more,O
pressing,O
need,O
in,O
medicine,O
than,O
to,O
identify,O
safe,O
and,O
efficacious,O
therapies,O
to,O
prevent,O
SARS,O
-,O
CoV-2,O
infections,O
as,O
well,O
as,O
to,O
attenuate,O
 ,O
the,O
severity,O
of,O
the,O
resulting,O
COVID-19,O
illness,O
.,O
Although,O
there,O
are,O
no,O
proven,O
US,O
Food,O
and,O
Drug,O
Administration,O
(,O
FDA)–approved,O
drugs,O
to,O
prevent,O
or,O
treat,O
COVID-19,O
",",O
a,O
number,O
of,O
promising,O
novel,O
(,O
eg,O
",",O
remdesivir,O
),O
and,O
repurposed,O
(,O
eg,O
",",O
hydroxychloroquine,O
",",O
potentially,O
together,O
with,O
azithromycin,O
),O
pharmacological,O
agents,O
",",O
 ,O
reported,O
to,O
inhibit,O
the,O
growth,O
of,O
SARS,O
-,O
CoV-2,O
in,O
 ,O
vitro,O
",",O
",",O
 ,O
are,O
being,O
evaluated,O
in,O
randomized,O
clinical,O
trials,O
.,O
In,O
light,O
of,O
(,O
1,O
),O
the,O
need,O
for,O
this,O
practice,O
to,O
continue,O
in,O
the,O
absence,O
of,O
viable,O
",",O
evidence,O
-,O
based,O
therapies,O
and,O
(,O
2,O
),O
the,O
proclivity,O
of,O
many,O
promising,O
COVID-19,O
pharmacotherapies,O
—,O
specifically,O
antimalarial,O
agents,O
such,O
as,O
hydroxychloroquine,O
—,O
to,O
prolong,O
the,O
QTc,O
",",O
thereby,O
increasing,O
the,O
risk,O
of,O
drug,O
-,O
induced,O
torsades,O
de,O
pointes,O
(,O
DI,O
-,O
TdP,O
),O
and,O
drug,O
induced,O
-,O
sudden,O
cardiac,O
death,O
(,O
DI,O
-,O
SCD,O
),O
",",O
this,O
document,O
was,O
assembled,O
to,O
help,O
health,O
care,O
professionals,O
safely,O
use,O
these,O
medications,O
and,O
minimize,O
concomitant,O
risks,O
.,O
",",O
Based,O
on,O
this,O
in,O
 ,O
vitro,O
data,O
",",O
it,O
has,O
been,O
hypothesized,O
that,O
hydroxychloroquine,O
",",O
more,O
so,O
than,O
chloroquine,O
",",O
may,O
have,O
therapeutic,O
efficacy,O
in,O
the,O
COVID-19,O
pandemic,O
by,O
(,O
1,O
),O
preventing,O
SARS,O
-,O
CoV-2,O
infection,O
by,O
inhibiting,O
angiotensin,O
-,O
converting,O
enzyme,O
2,O
–,O
mediated,O
viral,O
entry,O
(,O
ie,O
",",O
preinfection,O
prophylaxis,O
),O
and,O
(,O
2,O
),O
attenuating,O
the,O
postviral,O
cytokine,O
storm,O
observed,O
in,O
severe,O
COVID-19,O
cases,O
via,O
a,O
multitude,O
of,O
immunomodulatory,O
mechanisms,O
(,O
ie,O
",",O
treatment,O
of,O
active,O
infection,O
/,O
postviral,O
sequelae,O
),O
.,O
Promising,O
in,O
 ,O
vitro,O
data,O
",",O
 ,O
as,O
well,O
as,O
anecdotal,O
in,O
 ,O
vivo,O
evidence,O
of,O
therapeutic,O
benefit,O
have,O
led,O
many,O
institutions,O
",",O
including,O
Mayo,O
Clinic,O
",",O
to,O
consider,O
the,O
use,O
of,O
hydroxychloroquine,O
as,O
a,O
first,O
-,O
line,O
COVID-19,O
pharmacotherapy,O
for,O
the,O
time,O
being,O
and,O
spurred,O
an,O
array,O
of,O
clinical,O
trials,O
designed,O
to,O
assess,O
the,O
efficacy,O
of,O
repurposed,O
hydroxychloroquine,O
in,O
both,O
the,O
prevention,O
and,O
treatment,O
of,O
COVID-19,O
.,O
Torsadogenic,O
Potential,O
and,O
Postmarketing,O
Adverse,O
Events,O
Associated,O
With,O
Possible,O
COVID-19,O
Repurposed,O
Pharmacotherapiesa,O
Although,O
some,O
might,O
argue,O
that,O
DI,O
-,O
SCDs,O
in,O
the,O
setting,O
of,O
widespread,O
chloroquine,O
/,O
hydroxychloroquine,O
use,O
represents,O
acceptable,O
“,O
friendly,O
fire,O
”,O
in,O
the,O
war,O
on,O
SARS,O
-,O
CoV-2,O
/,O
COVID-19,O
",",O
we,O
believe,O
that,O
with,O
the,O
institution,O
of,O
a,O
few,O
simple,O
and,O
safe,O
precautions,O
",",O
the,O
risk,O
of,O
DI,O
-,O
TdP,O
and,O
DI,O
-,O
SCD,O
can,O
be,O
mitigated,O
.,O
Although,O
the,O
percentage,O
of,O
individuals,O
at,O
risk,O
is,O
small,O
",",O
given,O
the,O
pandemic,O
nature,O
of,O
COVID-19,O
",",O
in,O
absolute,O
terms,O
the,O
number,O
of,O
individuals,O
potentially,O
at,O
risk,O
for,O
lethal,O
adverse,O
drug,O
effects,O
is,O
large,O
(,O
at,O
least,O
"10,000",O
individuals,O
of,O
the,O
>,O
"1,000,000",O
COVID-19,O
–,O
positive,O
patients,O
worldwide,O
are,O
expected,O
to,O
be,O
at,O
increased,O
risk,O
for,O
DI,O
-,O
TdP,O
/,O
DI,O
-,O
SCD,O
if,O
treated,O
with,O
these,O
medications,O
),O
.,O
Unfortunately,O
",",O
in,O
the,O
context,O
of,O
the,O
COVID-19,O
pandemic,O
",",O
acquisition,O
of,O
the,O
patient,O
’s,O
QTc,O
by,O
the,O
12,O
-,O
lead,O
ECG,O
",",O
which,O
requires,O
additional,O
personnel,O
exposure,O
(,O
ie,O
",",O
ECG,O
technician,O
),O
",",O
and,O
a,O
necessity,O
for,O
serial,O
ECGs,O
",",O
which,O
requires,O
exposure,O
of,O
complex,O
equipment,O
(,O
multiple,O
ECG,O
wires,O
),O
",",O
could,O
further,O
strain,O
the,O
already,O
limited,O
supply,O
of,O
personal,O
protective,O
equipment,O
(,O
PPE,O
),O
in,O
many,O
countries,O
.,O
To,O
this,O
end,O
",",O
AliveCor,O
",",O
Inc,O
",",O
just,O
received,O
emergency,O
clearance,O
from,O
the,O
FDA,O
for,O
use,O
of,O
the,O
KardiaMobile,O
6L,O
device,O
(,O
FDA,O
-,O
approved,O
for,O
atrial,O
fibrillation,O
detection,O
),O
for,O
QTc,O
monitoring,O
of,O
patients,O
with,O
COVID-19,O
treated,O
with,O
QT,O
-,O
prolonging,O
medications,O
such,O
as,O
chloroquine,O
/,O
hydroxychloroquine,O
(,O
March,O
20,O
",",O
2020,O
",",O
1:15,O
PM,O
CST,O
),O
.,O
For,O
patients,O
with,O
COVID-19,O
about,O
to,O
be,O
treated,O
with,O
medications,O
with,O
the,O
increased,O
potential,O
for,O
DI,O
-,O
TdP,O
/,O
DI,O
-,O
SCD,O
(,O
Figure,O
 ,O
1,O
),O
",",O
baseline,O
QTc,O
status,O
should,O
be,O
obtained,O
either,O
by,O
a,O
traditional,O
12,O
-,O
lead,O
ECG,O
or,O
perhaps,O
preferably,O
with,O
the,O
use,O
of,O
a,O
smartphone,O
-,O
enabled,O
mobile,O
QTc,O
meter,O
using,O
the,O
simple,O
infection,O
control,O
measures,O
outlined,O
in,O
Figure,O
 ,O
2,O
to,O
limit,O
personnel,O
exposures,O
and,O
conserve,O
critical,O
PPE,O
.,O
For,O
patients,O
with,O
QTc,O
values,O
less,O
than,O
the,O
99th,O
percentile,O
for,O
age,O
/,O
sex,O
(,O
ie,O
",",O
460,O
ms,O
in,O
prepubertal,O
males,O
/,O
females,O
",",O
470,O
ms,O
in,O
postpubertal,O
males,O
",",O
and,O
480,O
ms,O
in,O
postpubertal,O
females,O
[,O
Figure,O
 ,O
1,O
“,O
green,O
light,O
”,O
status,O
],O
),O
",",O
the,O
risk,O
of,O
DI,O
-,O
TdP,O
/,O
DI,O
-,O
LQTS,O
is,O
low,O
",",O
and,O
chloroquine,O
/,O
hydroxychloroquine,O
(,O
or,O
other,O
QTc,O
-,O
prolonging,O
COVID-19,O
pharmacotherapies,O
),O
should,O
be,O
initiated,O
without,O
delay,O
as,O
outlined,O
in,O
the,O
QTc,O
monitoring,O
algorithm,O
.,O
Remember,O
",",O
whether,O
by,O
12,O
-,O
lead,O
ECG,O
",",O
telemetry,O
",",O
or,O
smartphone,O
-,O
enabled,O
acquisition,O
of,O
the,O
ECG,O
",",O
if,O
the,O
noted,O
QT,O
interval,O
is,O
less,O
than,O
one,O
-,O
half,O
the,O
preceding,O
RR,O
interval,O
",",O
then,O
the,O
calculated,O
QTc,O
will,O
always,O
be,O
less,O
than,O
460,O
ms,O
and,O
the,O
patient,O
can,O
be,O
“,O
green,O
light,O
go,O
”,O
for,O
COVID-19,O
treatments,O
that,O
may,O
have,O
QTc,O
-,O
prolonging,O
potential,O
.,O
For,O
example,O
",",O
in,O
younger,O
patients,O
with,O
COVID-19,O
(,O
ie,O
",",O
<,O
40,O
years,O
),O
who,O
have,O
only,O
mild,O
symptoms,O
and,O
a,O
QTc,O
of,O
500,O
ms,O
or,O
greater,O
",",O
it,O
may,O
be,O
reasonable,O
to,O
avoid,O
treatment,O
altogether,O
because,O
the,O
arrhythmia,O
risk,O
may,O
outweigh,O
the,O
risk,O
of,O
developing,O
COVID-19,O
–,O
related,O
acute,O
respiratory,O
distress,O
syndrome,O
.,O
However,O
",",O
in,O
patients,O
with,O
a,O
QTc,O
of,O
500,O
ms,O
or,O
greater,O
presenting,O
with,O
progressively,O
worsening,O
respiratory,O
symptoms,O
or,O
at,O
greater,O
risk,O
(,O
eg,O
",",O
>,O
65,O
years,O
of,O
age,O
",",O
immunosuppressed,O
",",O
and/or,O
high,O
-,O
risk,O
comorbid,O
conditions,O
),O
for,O
respiratory,O
complications,O
",",O
the,O
potential,O
benefit,O
of,O
QTc,O
-,O
prolonging,O
COVID-19,O
pharmacotherapies,O
may,O
exceed,O
the,O
arrhythmia,O
risk,O
.,O
Therefore,O
",",O
the,O
ultimate,O
goal,O
of,O
QTc,O
surveillance,O
in,O
the,O
COVID-19,O
pandemic,O
should,O
 ,O
be,O
to,O
identify,O
those,O
who,O
can,O
not,O
receive,O
these,O
medications,O
but,O
to,O
identify,O
those,O
with,O
compromised,O
or,O
reduced,O
“,O
repolarization,O
reserve,O
”,O
in,O
whom,O
increased,O
QTc,O
countermeasures,O
can,O
and,O
should,O
be,O
taken,O
to,O
mitigate,O
the,O
risk,O
of,O
drug,O
-,O
related,O
death,O
from,O
DI,O
-,O
TdP,O
/,O
DI,O
-,O
SCD,O
.,O
The,O
timing,O
of,O
on,O
-,O
therapy,O
QTc,O
surveillance,O
will,O
be,O
dictated,O
not,O
only,O
by,O
the,O
pharmacokinetics,O
of,O
the,O
COVID-19,O
therapies,O
used,O
but,O
also,O
by,O
the,O
practical,O
logistics,O
of,O
an,O
institution,O
’s,O
method,O
of,O
QTc,O
monitoring,O
.,O
As,O
the,O
coronavirus,O
disease,O
19,O
(,O
COVID-19,O
),O
global,O
pandemic,O
rages,O
across,O
the,O
globe,O
",",O
the,O
race,O
to,O
prevent,O
and,O
treat,O
this,O
deadly,O
disease,O
has,O
led,O
to,O
the,O
“,O
off,O
-,O
label,O
”,O
repurposing,O
of,O
drugs,O
such,O
as,O
hydroxychloroquine,O
and,O
lopinavir,O
/,O
ritonavir,O
",",O
which,O
have,O
the,O
potential,O
for,O
unwanted,O
QT,O
-,O
interval,O
prolongation,O
and,O
a,O
risk,O
of,O
drug,O
-,O
induced,O
sudden,O
cardiac,O
death,O
.,O
With,O
the,O
possibility,O
that,O
a,O
considerable,O
proportion,O
of,O
the,O
world,O
’s,O
population,O
soon,O
could,O
receive,O
COVID-19,O
pharmacotherapies,O
with,O
torsadogenic,O
potential,O
for,O
therapy,O
or,O
postexposure,O
prophylaxis,O
",",O
this,O
document,O
serves,O
to,O
help,O
health,O
care,O
professionals,O
mitigate,O
the,O
risk,O
of,O
drug,O
-,O
induced,O
ventricular,O
arrhythmias,O
while,O
minimizing,O
risk,O
of,O
COVID-19,O
exposure,O
to,O
personnel,O
and,O
conserving,O
the,O
limited,O
supply,O
of,O
personal,O
protective,O
equipment,O
.,O
As,O
of,O
May,O
13,O
",",O
2020,O
",",O
more,O
than,O
4·1,O
million,O
confirmed,O
cases,O
of,O
COVID-19,O
have,O
been,O
reported,O
with,O
more,O
than,O
280,O
 ,O
000,O
attributable,O
deaths,O
worldwide,O
.,O
The,O
clinical,O
situation,O
in,O
both,O
parents,O
also,O
deteriorated,O
during,O
the,O
primary,O
case,O
's,O
stay,O
in,O
Germany,O
and,O
both,O
were,O
laboratory,O
-,O
confirmed,O
with,O
COVID-19,O
later,O
.,O
After,O
Spanish,O
authorities,O
were,O
informed,O
",",O
patient,O
12,O
was,O
isolated,O
in,O
hospital,O
on,O
Jan,O
30,O
and,O
diagnosed,O
with,O
COVID-19,O
.,O
In,O
December,O
",",O
2019,O
",",O
the,O
newly,O
identified,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
emerged,O
in,O
Wuhan,O
",",O
China,O
",",O
causing,O
COVID-19,O
",",O
a,O
respiratory,O
disease,O
presenting,O
with,O
fever,O
",",O
cough,O
",",O
and,O
often,O
pneumonia,O
.,O
Case,O
interviews,O
were,O
done,O
to,O
describe,O
timing,O
of,O
onset,O
and,O
nature,O
of,O
symptoms,O
and,O
to,O
identify,O
and,O
classify,O
contacts,O
as,O
high,O
risk,O
(,O
had,O
cumulative,O
face,O
-,O
to,O
-,O
face,O
contact,O
with,O
a,O
confirmed,O
case,O
for,O
≥15,O
min,O
",",O
direct,O
contact,O
with,O
secretions,O
or,O
body,O
fluids,O
of,O
a,O
patient,O
with,O
confirmed,O
COVID-19,O
",",O
or,O
",",O
in,O
the,O
case,O
of,O
health,O
-,O
care,O
workers,O
",",O
had,O
worked,O
within,O
2,O
m,O
of,O
a,O
patient,O
with,O
confirmed,O
COVID-19,O
without,O
personal,O
protective,O
equipment,O
),O
or,O
low,O
risk,O
(,O
all,O
other,O
contacts,O
),O
.,O
These,O
results,O
suggest,O
that,O
although,O
the,O
outbreak,O
was,O
controlled,O
",",O
successful,O
long,O
-,O
term,O
and,O
global,O
containment,O
of,O
COVID-19,O
could,O
be,O
difficult,O
to,O
achieve,O
.,O
Emerging,O
epidemiological,O
studies,O
have,O
brought,O
the,O
attentions,O
towards,O
liver,O
injury,O
and,O
liver,O
impairment,O
as,O
a,O
potential,O
outcome,O
of,O
COVID19,O
infection,O
.,O
Similarly,O
",",O
in,O
COVID-19,O
",",O
more,O
than,O
half,O
of,O
patients,O
developed,O
abnormal,O
levels,O
of,O
alanine,O
aminotransferase,O
and,O
aspartate,O
aminotransferase,O
(,O
AST,O
),O
(,O
Zhang,O
et,O
al,O
.,O
2020,O
),O
.,O
Moreover,O
",",O
higher,O
liver,O
dysfunction,O
was,O
observed,O
with,O
more,O
severe,O
presentations,O
of,O
COVID-19,O
and,O
more,O
admission,O
to,O
intensive,O
care,O
units,O
(,O
Guan,O
et,O
al,O
.,O
2020,O
;,O
Huang,O
et,O
al,O
.,O
2020,O
),O
.,O
In,O
the,O
COVID-19,O
",",O
the,O
resulting,O
hepatic,O
dysfunction,O
is,O
accompanied,O
by,O
abnormal,O
coagulation,O
and,O
fibrinolytic,O
pathways,O
leading,O
to,O
worse,O
outcomes,O
(,O
Tang,O
et,O
al,O
.,O
2020,O
;,O
Thachil,O
et,O
al,O
.,O
2020,O
),O
.,O
Liver,O
impairment,O
during,O
COVID-19,O
infection,O
could,O
be,O
due,O
to,O
several,O
factors,O
including,O
the,O
direct,O
infection,O
of,O
liver,O
cells,O
with,O
SARS,O
-,O
CoV-2,O
(,O
Wang,O
et,O
al,O
.,O
2020,O
;,O
Zhao,O
et,O
al,O
.,O
2020,O
),O
",",O
cytokine,O
storm,O
and,O
inflammation,O
",",O
and,O
drug,O
-,O
induced,O
toxicity,O
.,O
Understanding,O
that,O
may,O
reflect,O
how,O
such,O
medications,O
may,O
affect,O
the,O
level,O
of,O
infectivity,O
and,O
permissibility,O
of,O
the,O
liver,O
following,O
COVID-19,O
infection,O
(,O
Boeckmans,O
et,O
al,O
.,O
2020,O
),O
.,O
Not,O
all,O
medications,O
present,O
in,O
Fig,O
.,O
 ,O
1b,O
were,O
available,O
in,O
this,O
dataset,O
.,O
Within,O
the,O
analgesics,O
",",O
acetaminophen,O
revealed,O
a,O
dose,O
-,O
dependent,O
reduction,O
in,O
expression,O
level,O
of,O
ACE2,O
",",O
while,O
the,O
effect,O
of,O
non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
drugs,O
(,O
NSAIDs,O
),O
ranged,O
between,O
no,O
expression,O
change,O
with,O
ibuprofen,O
and,O
meloxicam,O
and,O
mixed,O
effect,O
of,O
decreased,O
ACE2,O
and,O
increased,O
TMPRSS2,O
expressions,O
with,O
diclofenac,O
",",O
naproxen,O
",",O
and,O
nimesulide,O
(,O
Fig,O
.,O
 ,O
1b,O
;,O
Supplementary,O
Table,O
1,O
),O
.,O
Our,O
results,O
are,O
based,O
on,O
public,O
gene,O
expression,O
datasets,O
and,O
thus,O
they,O
may,O
or,O
may,O
not,O
reflect,O
changes,O
in,O
protein,O
expression,O
.,O
Although,O
the,O
increased,O
risk,O
of,O
developing,O
severe,O
COVID-19,O
infections,O
should,O
not,O
be,O
correlated,O
solely,O
with,O
the,O
use,O
of,O
medications,O
",",O
data,O
presented,O
here,O
suggest,O
that,O
we,O
should,O
be,O
vigilant,O
about,O
the,O
potential,O
medication,O
effects,O
.,O
Publicly,O
available,O
gene,O
expression,O
datasets,O
available,O
via,O
Toxicogenomics,B-Dataset
Project-Genomics,I-Dataset
Assisted,I-Dataset
Toxicity,I-Dataset
Evaluation,I-Dataset
System,I-Dataset
(Open,I-Dataset
TG-GATEs),E-Dataset
 ,O
(,O
Igarashi,B-Creator
et,I-Creator
al.,I-Creator
2015,E-Creator
),O
",",O
National,B-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,E-Repository
 ,O
Gene,B-Repository
Expression,I-Repository
Omnibus,E-Repository
 ,O
(,O
NCIB,S-Repository
 ,O
GEO,S-Repository
",",O
https://www.ncbi.nlm.nih.gov/geo,S-URL
),O
and,O
the,O
European,B-Repository
Bioinformatics,I-Repository
Institute,I-Repository
(EMBL-EBI,E-Repository
",",O
https://www.ebi.ac.uk,S-URL
),O
were,O
used,O
.,O
Medication,O
treatments,O
were,O
extracted,O
from,O
TG-GATEs,S-Repository
 ,O
database,O
using,O
the,O
high,O
and,O
middle,O
concentrations,O
.,O
The,O
data,O
for,O
chloroquine,O
derivative,O
medication,O
were,O
extracted,O
from,O
the,O
GSE30351,S-AccessionNumber
 ,O
dataset,O
.,O
The,O
rat,O
in,O
-,O
invitro,O
treatments,O
were,O
obtained,O
from,O
DrugMatrix,S-Repository
 ,O
toxicogenomic,O
database,O
(,O
GSE57805,S-AccessionNumber
),O
.,O
Emerging,O
epidemiological,O
studies,O
brought,O
the,O
attentions,O
towards,O
liver,O
injury,O
and,O
impairment,O
as,O
a,O
potential,O
outcome,O
of,O
COVID19,O
.,O
Understanding,O
that,O
may,O
reflect,O
how,O
such,O
medications,O
may,O
affect,O
the,O
level,O
of,O
infectivity,O
and,O
permissibility,O
of,O
the,O
liver,O
following,O
COVID-19,O
.,O
Using,O
transcriptomic,O
datasets,O
",",O
Toxicogenomic,B-Dataset
Project-Genomics,I-Dataset
Assisted,I-Dataset
Toxicity,I-Dataset
Evaluation,I-Dataset
System,I-Dataset
(Open,I-Dataset
TG-GATEs),E-Dataset
 ,O
and,O
GSE30351,S-AccessionNumber
",",O
we,O
have,O
tested,O
the,O
ability,O
of,O
ninety,O
common,O
medications,O
to,O
regulate,O
COVID-19,O
receptors,O
expression,O
in,O
human,O
primary,O
hepatocytes,O
.,O
To,O
confirm,O
the,O
observed,O
effects,O
on,O
primary,O
human,O
hepatocytes,O
",",O
rat,O
hepatocyte,O
treatments,O
data,O
was,O
obtained,O
from,O
DrugMatrix,S-Repository
 ,O
toxicogenomic,O
database,O
(,O
GSE57805,S-AccessionNumber
),O
",",O
which,O
showed,O
a,O
similar,O
ACE2,O
and,O
TMPRSS2,O
expression,O
pattern,O
.,O
More,O
research,O
is,O
needed,O
to,O
determine,O
the,O
effect,O
of,O
different,O
medications,O
on,O
COVID-19,O
receptors,O
.,O
Since,O
its,O
emergence,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
which,O
causes,O
COVID-19,O
",",O
has,O
become,O
a,O
global,O
health,O
threat,O
.,O
As,O
of,O
July,O
22,O
",",O
2020,O
",",O
more,O
than,O
15,O
million,O
cases,O
of,O
COVID-19,O
have,O
been,O
documented,O
worldwide,O
",",O
with,O
nearly,O
618,O
 ,O
000,O
deaths,O
.,O
Guidelines,O
from,O
the,O
UK,O
and,O
the,O
USA,O
recommend,O
mask,O
use,O
for,O
health,O
-,O
care,O
workers,O
caring,O
for,O
people,O
with,O
COVID-19.9,O
",",O
10,O
However,O
",",O
global,O
shortages,O
of,O
masks,O
",",O
respirators,O
",",O
face,O
shields,O
",",O
and,O
gowns,O
",",O
caused,O
by,O
surging,O
demand,O
and,O
supply,O
chain,O
disruptions,O
",",O
have,O
led,O
to,O
efforts,O
to,O
conserve,O
PPE,O
through,O
extended,O
use,O
or,O
reuse,O
",",O
and,O
disinfection,O
protocols,O
have,O
been,O
developed,O
",",O
for,O
which,O
scientific,O
consensus,O
on,O
best,O
practice,O
is,O
scarce,O
.,O
11,O
",",O
12,O
",",O
13,O
Although,O
addressing,O
the,O
needs,O
of,O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
during,O
the,O
COVID-19,O
pandemic,O
is,O
a,O
high,O
"priority,6",O
",",O
14,O
data,O
to,O
inform,O
such,O
efforts,O
are,O
scarce,O
",",O
and,O
particularly,O
so,O
among,O
Black,O
",",O
Asian,O
",",O
and,O
minority,O
ethnic,O
communities,O
.,O
Thus,O
",",O
we,O
did,O
a,O
prospective,O
population,O
-,O
based,O
study,O
using,O
data,O
from,O
a,O
smartphone,O
-,O
based,O
application,O
(,O
app,O
),O
to,O
investigate,O
the,O
risk,O
of,O
testing,O
positive,O
for,O
COVID-19,O
",",O
the,O
risk,O
of,O
developing,O
symptoms,O
associated,O
with,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
or,O
both,O
",",O
among,O
individuals,O
in,O
the,O
UK,O
and,O
the,O
USA,O
.,O
We,O
did,O
a,O
prospective,O
",",O
observational,O
cohort,O
study,O
using,O
the,O
COVID,O
Symptom,O
Study,O
app,O
.,O
Our,O
study,O
was,O
approved,O
by,O
the,O
Partners,O
Human,O
Research,O
Committee,O
(,O
protocol,O
2020P000909,O
),O
and,O
King,O
's,O
College,O
London,O
ethics,O
committee,O
(,O
REMAS,O
ID,O
18210,O
",",O
LRS-19/20,O
-,O
18210,O
),O
.,O
Information,O
obtained,O
through,O
the,O
COVID,O
Symptom,O
Study,O
app,O
has,O
been,O
described,O
in,O
detail,O
.,O
Briefly,O
",",O
on,O
first,O
use,O
",",O
participants,O
were,O
asked,O
to,O
provide,O
demographic,O
factors,O
and,O
were,O
questioned,O
separately,O
about,O
a,O
series,O
of,O
COVID-19,O
risk,O
factors,O
(,O
appendix,O
pp,O
4–8,O
),O
.,O
Participants,O
were,O
also,O
asked,O
if,O
they,O
had,O
been,O
tested,O
for,O
COVID-19,O
and,O
the,O
results,O
(,O
none,O
",",O
negative,O
",",O
pending,O
",",O
or,O
positive,O
),O
.,O
Our,O
primary,O
outcome,O
was,O
a,O
report,O
of,O
a,O
positive,O
COVID-19,O
test,O
.,O
Follow,O
-,O
up,O
started,O
when,O
participants,O
first,O
reported,O
on,O
the,O
COVID,O
Symptom,O
Study,O
app,O
and,O
continued,O
until,O
a,O
report,O
of,O
a,O
positive,O
COVID-19,O
test,O
or,O
the,O
time,O
of,O
last,O
data,O
entry,O
",",O
whichever,O
occurred,O
first,O
.,O
We,O
used,O
standard,O
calculations,O
to,O
determine,O
the,O
minimum,O
detectable,O
hazard,O
ratio,O
(,O
HR,O
),O
for,O
our,O
primary,O
categorical,O
exposure,O
(,O
health,O
-,O
care,O
worker,O
status,O
),O
and,O
risk,O
of,O
reporting,O
a,O
positive,O
COVID-19,O
test,O
with,O
80,O
%,O
power,O
.,O
Because,O
our,O
primary,O
outcome,O
(,O
positive,O
COVID-19,O
test,O
),O
required,O
a,O
participant,O
to,O
receive,O
a,O
test,O
",",O
we,O
did,O
several,O
prespecified,O
secondary,O
analyses,O
.,O
First,O
",",O
we,O
tested,O
a,O
symptom,O
-,O
based,O
classifier,O
predictive,O
of,O
positive,O
COVID-19,O
testing,O
.,O
Briefly,O
",",O
using,O
logistic,O
regression,O
and,O
symptoms,O
preceding,O
testing,O
",",O
we,O
have,O
previously,O
described,O
that,O
loss,O
of,O
smell,O
or,O
taste,O
",",O
fatigue,O
",",O
persistent,O
cough,O
",",O
and,O
loss,O
of,O
appetite,O
predicted,O
COVID-19,O
positivity,O
with,O
high,O
specificity,O
(,O
appendix,O
p,O
2,O
),O
.,O
To,O
assess,O
factors,O
associated,O
with,O
PPE,O
adequacy,O
",",O
work,O
in,O
especially,O
high,O
-,O
risk,O
clinical,O
settings,O
",",O
or,O
greater,O
exposure,O
to,O
patients,O
with,O
COVID-19,O
(,O
including,O
a,O
post,O
-,O
hoc,O
analysis,O
of,O
race,O
and,O
ethnicity,O
),O
",",O
we,O
used,O
multivariable,O
logistic,O
regression,O
models,O
to,O
estimate,O
adjusted,O
odds,O
ratios,O
(,O
ORs,O
),O
and,O
95,O
%,O
CIs,O
.,O
Between,O
March,O
24,O
and,O
April,O
23,O
",",O
2020,O
",",O
we,O
enrolled,O
2,O
 ,O
810,O
 ,O
103,O
consecutive,O
users,O
of,O
the,O
COVID,O
Symptom,O
Study,O
app,O
to,O
our,O
study,O
.,O
The,O
prevalence,O
of,O
COVID-19,O
was,O
2747,O
cases,O
per,O
100,O
 ,O
000,O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
compared,O
with,O
242,O
cases,O
per,O
100,O
 ,O
000,O
people,O
in,O
the,O
general,O
community,O
(,O
figure,O
),O
.,O
After,O
excluding,O
670,O
 ,O
298,O
participants,O
with,O
less,O
than,O
24,O
h,O
of,O
follow,O
-,O
up,O
and,O
4615,O
individuals,O
who,O
reported,O
a,O
positive,O
COVID-19,O
test,O
at,O
baseline,O
",",O
we,O
included,O
2,O
 ,O
135,O
 ,O
190,O
participants,O
in,O
our,O
prospective,O
inception,O
cohort,O
",",O
of,O
whom,O
99,O
 ,O
795,O
(,O
4·7,O
%,O
),O
identified,O
as,O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
(,O
appendix,O
p,O
14,O
),O
.,O
Based,O
on,O
this,O
cohort,O
",",O
we,O
had,O
80,O
%,O
power,O
to,O
detect,O
a,O
minimum,O
HR,O
of,O
1·16,O
for,O
risk,O
of,O
reporting,O
a,O
positive,O
COVID-19,O
test,O
between,O
health,O
-,O
care,O
workers,O
and,O
the,O
general,O
community,O
.,O
We,O
recorded,O
5545,O
incident,O
reports,O
of,O
positive,O
COVID-19,O
testing,O
over,O
34,O
 ,O
435,O
 ,O
272,O
person,O
-,O
days,O
.,O
In,O
a,O
prespecified,O
secondary,O
analysis,O
",",O
a,O
validated,O
model,O
was,O
used,O
based,O
on,O
a,O
combination,O
of,O
symptoms,O
predictive,O
of,O
COVID-19,O
infection,O
.,O
Compared,O
with,O
the,O
general,O
community,O
",",O
health,O
-,O
care,O
workers,O
initially,O
free,O
of,O
symptoms,O
had,O
an,O
increased,O
risk,O
of,O
predicted,O
COVID-19,O
(,O
adjusted,O
HR,O
2·05,O
",",O
95,O
%,O
CI,O
1·99–2·10,O
),O
",",O
which,O
was,O
higher,O
in,O
the,O
UK,O
(,O
2·09,O
",",O
2·02–2·15,O
),O
than,O
in,O
the,O
USA,O
(,O
1·31,O
",",O
1·14–1·51,O
;,O
pdifference<0·0001,O
),O
.,O
In,O
a,O
post,O
-,O
hoc,O
analysis,O
",",O
compared,O
with,O
individuals,O
in,O
the,O
general,O
community,O
from,O
a,O
non,O
-,O
Hispanic,O
white,O
ethnic,O
background,O
",",O
the,O
risk,O
for,O
a,O
positive,O
COVID-19,O
test,O
was,O
increased,O
for,O
individuals,O
from,O
Black,O
",",O
Asian,O
",",O
and,O
minority,O
ethnic,O
backgrounds,O
in,O
the,O
general,O
community,O
(,O
adjusted,O
HR,O
2·51,O
",",O
95,O
%,O
CI,O
2·18–2·89,O
),O
",",O
for,O
Black,O
",",O
Asian,O
",",O
and,O
minority,O
ethnic,O
health,O
-,O
care,O
workers,O
(,O
21·88,O
",",O
17·78–26·94,O
),O
",",O
and,O
for,O
non,O
-,O
Hispanic,O
white,O
health,O
-,O
care,O
workers,O
(,O
12·58,O
",",O
11·42–13·86,O
;,O
table,O
2,O
),O
.,O
In,O
post,O
-,O
hoc,O
analyses,O
",",O
the,O
association,O
of,O
race,O
and,O
health,O
-,O
care,O
worker,O
status,O
with,O
risk,O
of,O
COVID-19,O
was,O
assessed,O
.,O
Black,O
",",O
Asian,O
",",O
and,O
minority,O
ethnic,O
health,O
-,O
care,O
workers,O
had,O
an,O
increased,O
risk,O
of,O
COVID-19,O
(,O
adjusted,O
HR,O
1·81,O
",",O
95,O
%,O
CI,O
1·45–2·24,O
),O
compared,O
with,O
non,O
-,O
Hispanic,O
white,O
health,O
-,O
care,O
workers,O
.,O
Among,O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
",",O
availability,O
and,O
use,O
of,O
PPE,O
",",O
COVID-19,O
patient,O
exposures,O
",",O
and,O
subsequent,O
risk,O
for,O
testing,O
positive,O
were,O
assessed,O
in,O
prespecified,O
analyses,O
.,O
Compared,O
with,O
health,O
-,O
care,O
workers,O
who,O
reported,O
adequate,O
PPE,O
",",O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
reporting,O
PPE,O
reuse,O
had,O
an,O
increased,O
risk,O
of,O
a,O
positive,O
COVID-19,O
test,O
(,O
adjusted,O
HR,O
1·46,O
",",O
95,O
%,O
CI,O
1·21–1·76,O
),O
",",O
with,O
inadequate,O
PPE,O
associated,O
with,O
a,O
comparable,O
increase,O
in,O
risk,O
after,O
multivariable,O
adjustment,O
(,O
1·31,O
",",O
1·10–1·56,O
;,O
table,O
3,O
),O
.,O
In,O
a,O
prespecified,O
secondary,O
analysis,O
",",O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
with,O
inadequate,O
PPE,O
caring,O
for,O
patients,O
with,O
documented,O
COVID-19,O
had,O
an,O
increased,O
risk,O
for,O
COVID-19,O
after,O
multivariable,O
adjustment,O
(,O
adjusted,O
HR,O
5·91,O
",",O
95,O
%,O
CI,O
4·53–7·71,O
),O
compared,O
with,O
those,O
with,O
adequate,O
PPE,O
not,O
caring,O
for,O
patients,O
with,O
suspected,O
or,O
documented,O
COVID-19,O
(,O
table,O
3,O
),O
.,O
Risk,O
for,O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
reusing,O
PPE,O
and,O
exposed,O
to,O
patients,O
with,O
documented,O
COVID-19,O
was,O
also,O
increased,O
(,O
adjusted,O
HR,O
5·06,O
",",O
95,O
%,O
CI,O
3·90–6·57,O
),O
.,O
Notably,O
",",O
even,O
among,O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
reporting,O
adequate,O
PPE,O
",",O
the,O
risk,O
for,O
COVID-19,O
was,O
increased,O
for,O
those,O
caring,O
for,O
patients,O
with,O
suspected,O
COVID-19,O
(,O
adjusted,O
HR,O
2·39,O
",",O
95,O
%,O
CI,O
1·90–3·00,O
),O
and,O
for,O
those,O
caring,O
for,O
patients,O
with,O
documented,O
COVID-19,O
(,O
4·83,O
",",O
3·99–5·85,O
),O
",",O
compared,O
with,O
health,O
-,O
care,O
workers,O
who,O
did,O
not,O
care,O
for,O
either,O
group,O
(,O
table,O
3,O
),O
.,O
In,O
a,O
post,O
-,O
hoc,O
analysis,O
",",O
differences,O
were,O
noted,O
in,O
PPE,O
adequacy,O
according,O
to,O
race,O
and,O
ethnicity,O
",",O
with,O
non,O
-,O
white,O
health,O
-,O
care,O
workers,O
more,O
frequently,O
reporting,O
reuse,O
of,O
or,O
inadequate,O
access,O
to,O
PPE,O
",",O
even,O
after,O
adjusting,O
for,O
exposure,O
to,O
patients,O
with,O
COVID-19,O
(,O
adjusted,O
OR,O
1·49,O
",",O
95,O
%,O
CI,O
1·36–1·63,O
;,O
table,O
4,O
),O
.,O
In,O
a,O
prespecified,O
secondary,O
analysis,O
",",O
risk,O
of,O
COVID-19,O
by,O
practice,O
location,O
was,O
assessed,O
.,O
In,O
a,O
post,O
-,O
hoc,O
analysis,O
",",O
compared,O
with,O
non,O
-,O
Hispanic,O
white,O
health,O
-,O
care,O
workers,O
",",O
Black,O
",",O
Asian,O
",",O
and,O
minority,O
ethnic,O
health,O
-,O
care,O
workers,O
were,O
more,O
likely,O
to,O
work,O
in,O
higher,O
risk,O
clinical,O
settings,O
",",O
including,O
inpatient,O
hospital,O
or,O
nursing,O
homes,O
(,O
adjusted,O
OR,O
1·13,O
",",O
95,O
%,O
CI,O
1·03–1·23,O
),O
and,O
to,O
care,O
for,O
patients,O
with,O
suspected,O
or,O
documented,O
COVID-19,O
(,O
1·20,O
",",O
1·09–1·30,O
),O
.,O
Our,O
findings,O
could,O
help,O
provide,O
greater,O
context,O
for,O
previous,O
cross,O
-,O
sectional,O
reports,O
from,O
public,O
health,O
authorities,O
suggesting,O
10–20,O
%,O
of,O
SARS,O
-,O
CoV-2,O
infections,O
occur,O
among,O
health,O
-,O
care,O
workers.6,O
",",O
7,O
Our,O
results,O
offer,O
individual,O
-,O
level,O
data,O
additionally,O
accounting,O
for,O
workplace,O
risk,O
factors,O
that,O
complement,O
these,O
limited,O
reports,O
by,O
providing,O
a,O
more,O
precise,O
assessment,O
of,O
the,O
magnitude,O
of,O
increased,O
risk,O
among,O
health,O
-,O
care,O
workers,O
during,O
the,O
initial,O
phases,O
of,O
the,O
COVID-19,O
pandemic,O
.,O
Taken,O
in,O
the,O
context,O
of,O
the,O
requirement,O
for,O
testing,O
to,O
establish,O
a,O
COVID-19,O
diagnosis,O
",",O
our,O
range,O
of,O
results,O
based,O
on,O
either,O
reporting,O
a,O
positive,O
test,O
for,O
COVID-19,O
or,O
symptoms,O
predictive,O
of,O
COVID-19,O
offer,O
several,O
complementary,O
estimates,O
for,O
risk,O
among,O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
.,O
We,O
also,O
provide,O
evidence,O
that,O
sufficient,O
availability,O
of,O
PPE,O
",",O
quality,O
of,O
PPE,O
",",O
or,O
both,O
reduce,O
the,O
risk,O
of,O
COVID-19,O
",",O
but,O
reuse,O
of,O
PPE,O
or,O
inadequate,O
PPE,O
might,O
confer,O
comparably,O
increased,O
risk,O
",",O
which,O
is,O
compatible,O
with,O
findings,O
from,O
one,O
of,O
the,O
first,O
studies,O
to,O
specifically,O
investigate,O
PPE,O
reuse,O
.,O
However,O
",",O
even,O
with,O
adequate,O
PPE,O
",",O
health,O
-,O
care,O
workers,O
who,O
cared,O
for,O
patients,O
with,O
COVID-19,O
remained,O
at,O
increased,O
risk,O
",",O
highlighting,O
the,O
importance,O
of,O
not,O
only,O
ensuring,O
PPE,O
quality,O
and,O
availability,O
but,O
also,O
other,O
aspects,O
of,O
appropriate,O
use,O
",",O
including,O
correct,O
application,O
and,O
removal,O
of,O
PPE,O
and,O
clinical,O
situation,O
(,O
practice,O
location,O
),O
.,O
Furthermore,O
",",O
health,O
-,O
care,O
workers,O
were,O
at,O
greater,O
risk,O
of,O
developing,O
symptoms,O
predictive,O
of,O
eventual,O
COVID-19,O
",",O
which,O
does,O
not,O
reflect,O
access,O
to,O
testing,O
.,O
Second,O
",",O
we,O
obtained,O
information,O
from,O
participants,O
who,O
did,O
not,O
have,O
a,O
positive,O
COVID-19,O
test,O
",",O
which,O
offered,O
an,O
opportunity,O
to,O
prospectively,O
assess,O
risk,O
factors,O
with,O
minimal,O
recall,O
bias,O
.,O
Finally,O
",",O
we,O
gathered,O
information,O
on,O
a,O
wide,O
range,O
of,O
known,O
or,O
suspected,O
risk,O
factors,O
for,O
COVID-19,O
generally,O
not,O
available,O
in,O
existing,O
registries,O
or,O
population,O
-,O
scale,O
surveillance,O
efforts,O
.,O
Our,O
primary,O
outcome,O
was,O
based,O
on,O
the,O
report,O
of,O
a,O
positive,O
COVID-19,O
test,O
.,O
Background,O
 ,O
Data,O
for,O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
and,O
risk,O
of,O
COVID-19,O
are,O
limited,O
.,O
We,O
sought,O
to,O
assess,O
risk,O
of,O
COVID-19,O
among,O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
compared,O
with,O
the,O
general,O
community,O
and,O
the,O
effect,O
of,O
personal,O
protective,O
equipment,O
(,O
PPE,O
),O
on,O
risk,O
.,O
We,O
did,O
a,O
prospective,O
",",O
observational,O
cohort,O
study,O
in,O
the,O
UK,O
and,O
the,O
USA,O
of,O
the,O
general,O
community,O
",",O
including,O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
",",O
using,O
self,O
-,O
reported,O
data,O
from,O
the,O
COVID,O
Symptom,O
Study,O
smartphone,O
application,O
(,O
app,O
),O
from,O
March,O
24,O
(,O
UK,O
),O
and,O
March,O
29,O
(,O
USA,O
),O
to,O
April,O
23,O
",",O
2020,O
.,O
Participants,O
were,O
voluntary,O
users,O
of,O
the,O
app,O
and,O
at,O
first,O
use,O
provided,O
information,O
on,O
demographic,O
factors,O
(,O
including,O
age,O
",",O
sex,O
",",O
race,O
or,O
ethnic,O
background,O
",",O
height,O
and,O
weight,O
",",O
and,O
occupation,O
),O
and,O
medical,O
history,O
",",O
and,O
subsequently,O
reported,O
any,O
COVID-19,O
symptoms,O
.,O
We,O
used,O
Cox,O
proportional,O
hazards,O
modelling,O
to,O
estimate,O
multivariate,O
-,O
adjusted,O
hazard,O
ratios,O
(,O
HRs,O
),O
of,O
our,O
primary,O
outcome,O
",",O
which,O
was,O
a,O
positive,O
COVID-19,O
test,O
.,O
The,O
COVID,O
Symptom,O
Study,O
app,O
is,O
registered,O
with,O
ClinicalTrials.gov,O
",",O
NCT04331509,S-AccessionNumber
 ,O
.,O
Findings,O
 ,O
Among,O
2,O
 ,O
035,O
 ,O
395,O
community,O
individuals,O
and,O
99,O
 ,O
795,O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
",",O
we,O
recorded,O
5545,O
incident,O
reports,O
of,O
a,O
positive,O
COVID-19,O
test,O
over,O
34,O
 ,O
435,O
 ,O
272,O
person,O
-,O
days,O
.,O
Compared,O
with,O
the,O
general,O
community,O
",",O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
were,O
at,O
increased,O
risk,O
for,O
reporting,O
a,O
positive,O
COVID-19,O
test,O
(,O
adjusted,O
HR,O
11·61,O
",",O
95,O
%,O
CI,O
10·93–12·33,O
),O
.,O
To,O
account,O
for,O
differences,O
in,O
testing,O
frequency,O
between,O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
and,O
the,O
general,O
community,O
and,O
possible,O
selection,O
bias,O
",",O
an,O
inverse,O
probability,O
-,O
weighted,O
model,O
was,O
used,O
to,O
adjust,O
for,O
the,O
likelihood,O
of,O
receiving,O
a,O
COVID-19,O
test,O
(,O
adjusted,O
HR,O
3·40,O
",",O
95,O
%,O
CI,O
3·37–3·43,O
),O
.,O
In,O
the,O
UK,O
and,O
the,O
USA,O
",",O
risk,O
of,O
reporting,O
a,O
positive,O
test,O
for,O
COVID-19,O
was,O
increased,O
among,O
front,O
-,O
line,O
health,O
-,O
care,O
workers,O
.,O
Health,O
-,O
care,O
systems,O
should,O
ensure,O
adequate,O
availability,O
of,O
PPE,O
and,O
develop,O
additional,O
strategies,O
to,O
protect,O
health,O
-,O
care,O
workers,O
from,O
COVID-19,O
",",O
particularly,O
those,O
from,O
Black,O
",",O
Asian,O
",",O
and,O
minority,O
ethnic,O
backgrounds,O
.,O
COVID-19,O
is,O
the,O
respiratory,O
illness,O
caused,O
by,O
the,O
SARS,O
-,O
CoV-2,O
virus,O
that,O
is,O
currently,O
affecting,O
millions,O
of,O
people,O
worldwide,O
and,O
putting,O
extraordinary,O
pressure,O
on,O
public,O
health,O
systems,O
everywhere,O
.,O
This,O
process,O
is,O
vital,O
for,O
the,O
entry,O
of,O
SARS,O
-,O
CoV-2,O
into,O
human,O
host,O
cells,O
",",O
and,O
thus,O
it,O
plays,O
an,O
integral,O
role,O
in,O
COVID-19,O
infection,O
and,O
disease,O
progression,O
.,O
COVID-19,O
also,O
has,O
a,O
strong,O
immunological,O
component,O
",",O
where,O
poor,O
outcomes,O
have,O
recently,O
been,O
associated,O
with,O
cytokine,O
storms,O
and,O
a,O
hyperinflammatory,O
immune,O
system,O
[,O
6,O
],O
.,O
Case,O
studies,O
of,O
COVID-19,O
patients,O
show,O
that,O
previous,O
and,O
current,O
smokers,O
experience,O
more,O
severe,O
infections,O
than,O
non,O
-,O
severe,O
infections,O
[,O
7,O
],O
.,O
Since,O
ACE2,O
is,O
also,O
an,O
immunomodulator,O
",",O
its,O
dysregulation,O
could,O
be,O
essential,O
for,O
COVID-19,O
outcomes,O
.,O
Cigarette,O
smoke,O
has,O
been,O
associated,O
with,O
an,O
increased,O
susceptibility,O
to,O
COVID-19,O
[,O
15,O
],O
",",O
although,O
the,O
mechanism,O
for,O
this,O
is,O
unclear,O
.,O
This,O
paper,O
aims,O
to,O
investigate,O
the,O
expression,O
of,O
TMPRSS2,O
",",O
ACE2,O
",",O
and,O
related,O
genes,O
in,O
smokers,O
and,O
determine,O
if,O
the,O
link,O
between,O
smoking,O
and,O
these,O
genes,O
could,O
help,O
explain,O
smokers,O
’,O
apparent,O
increased,O
vulnerability,O
to,O
COVID-19,O
.,O
TMPRSS2,O
expression,O
was,O
correlated,O
to,O
the,O
enrichment,O
of,O
ARRB2,O
",",O
CDK6,O
",",O
ID2,O
",",O
and,O
EP300,O
",",O
as,O
shown,O
in,O
Figure,O
4B.,O
Of,O
the,O
core,O
enriched,O
genes,O
with,O
the,O
most,O
interactions,O
with,O
other,O
core,O
enriched,O
genes,O
in,O
androgen,O
pathways,O
",",O
ARRB2,O
",",O
CDK6,O
",",O
and,O
ID2,O
were,O
all,O
upregulated,O
in,O
smokers,O
.,O
The,O
COVID-19,O
pandemic,O
is,O
marked,O
by,O
a,O
wide,O
range,O
of,O
clinical,O
disease,O
courses,O
",",O
ranging,O
from,O
asymptomatic,O
to,O
deadly,O
.,O
There,O
have,O
been,O
many,O
studies,O
seeking,O
to,O
explore,O
the,O
correlations,O
between,O
COVID-19,O
clinical,O
outcomes,O
and,O
various,O
clinical,O
variables,O
",",O
including,O
age,O
",",O
sex,O
",",O
race,O
",",O
underlying,O
medical,O
problems,O
",",O
and,O
social,O
habits,O
.,O
In,O
particular,O
",",O
the,O
relationship,O
between,O
smoking,O
and,O
COVID-19,O
outcome,O
is,O
controversial,O
",",O
with,O
multiple,O
conflicting,O
reports,O
in,O
the,O
current,O
literature,O
.,O
These,O
data,O
provide,O
a,O
potential,O
model,O
for,O
the,O
increased,O
susceptibility,O
of,O
smoking,O
patients,O
to,O
COVID-19,O
and,O
encourage,O
further,O
exploration,O
into,O
the,O
androgen,O
and,O
tobacco,O
upregulation,O
of,O
ACE2,O
to,O
understand,O
the,O
potential,O
clinical,O
ramifications,O
.,O
For,O
instance,O
",",O
as,O
different,O
countries,O
review,O
and,O
test,O
archived,O
specimens,O
from,O
cases,O
of,O
severe,O
pneumonia,O
or,O
influenza,O
-,O
like,O
illness,O
for,O
SARS,O
-,O
CoV-2,O
",",O
it,O
is,O
expected,O
that,O
additional,O
cases,O
may,O
be,O
identified,O
",",O
such,O
as,O
in,O
France,O
where,O
a,O
patient,O
without,O
travel,O
history,O
to,O
China,O
was,O
identified,O
to,O
have,O
COVID-19,O
in,O
late,O
December,O
concurrent,O
with,O
the,O
initial,O
reported,O
cases,O
from,O
Wuhan,O
.,O
The,O
trimeric,O
and,O
monomeric,O
structures,O
of,O
the,O
Spike,O
protein,O
were,O
generated,O
using,O
Illustrate,O
(,O
https://ccsb.scripps.edu/illustrate/,O
),O
by,O
rendering,O
a,O
protein,O
structure,O
from,O
the,O
Protein,B-Repository
Data,I-Repository
Bank,E-Repository
 ,O
with,O
ID,O
6vsb,S-AccessionNumber
 ,O
(,O
https://www.rcsb.org/structure/6vsb,S-URL
),O
.,O
The,O
COVID-19,O
pandemic,O
",",O
caused,O
by,O
the,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
was,O
declared,O
on,O
March,O
11,O
",",O
2020,O
by,O
the,O
World,O
Health,O
Organization,O
.,O
As,O
of,O
the,O
31st,O
of,O
May,O
",",O
2020,O
",",O
there,O
have,O
been,O
more,O
than,O
6,O
million,O
COVID-19,O
cases,O
diagnosed,O
worldwide,O
and,O
over,O
"370,000",O
deaths,O
",",O
according,O
to,O
Johns,O
Hopkins,O
.,O
The,O
genomic,O
sequence,O
of,O
SARS,O
-,O
CoV-2,O
isolated,O
from,O
the,O
bronchoalveolar,O
lavage,O
fluid,O
of,O
a,O
patient,O
from,O
Wuhan,O
",",O
China,O
showed,O
a,O
length,O
of,O
"29,903",O
nucleotides,O
[,O
GenBank,S-Repository
 ,O
accession,O
number,O
NC_045512,S-AccessionNumber
],O
BepiPred,O
1.0,O
Linear,O
Epitope,O
Prediction,O
module,O
incorporated,O
in,O
Immune,B-Repository
Epitope,I-Repository
Database,I-Repository
(IEDB),E-Repository
 ,O
was,O
used,O
to,O
predict,O
potential,O
epitopes,O
within,O
the,O
S,O
protein,O
(,O
Haste,O
Andersen,O
et,O
al,O
.,O
",",O
2006,O
;,O
Larsen,O
et,O
al,O
.,O
",",O
2006,O
;,O
Ponomarenko,O
and,O
Bourne,O
",",O
2007,O
;,O
Vita,O
et,O
al,O
.,O
",",O
2019,O
),O
.,O
The,O
S,O
glycoprotein,O
sequence,O
is,O
1273,O
amino,O
acids,O
long,O
",",O
except,O
for,O
that,O
of,O
the,O
virus,O
isolated,O
from,O
Kerala,O
(,O
India,O
),O
",",O
which,O
is,O
a,O
1272,O
amino,O
acid,O
long,O
S,O
glycoprotein,O
(,O
GenBank,S-Repository
 ,O
accession,O
number,O
MT012098,S-AccessionNumber
),O
.,O
The,O
potential,O
epitope,O
regions,O
were,O
predicted,O
using,O
the,O
sequence,O
of,O
the,O
S,O
protein,O
of,O
SARS,O
-,O
CoV-2,O
that,O
showed,O
the,O
least,O
variability,O
(,O
GenBank,S-Repository
 ,O
accession,O
number,O
NC_045512,S-AccessionNumber
),O
.,O
Also,O
",",O
identified,O
T,O
-,O
cell,O
epitopes,O
might,O
be,O
considered,O
for,O
incorporation,O
in,O
vaccine,O
designs,O
.,O
Does,O
remdesivir,O
provide,O
a,O
benefit,O
on,O
clinical,O
status,O
for,O
patients,O
hospitalized,O
with,O
moderate,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pneumonia,O
?,O
In,O
this,O
randomized,O
",",O
open,O
-,O
label,O
",",O
phase,O
3,O
trial,O
that,O
included,O
584,O
patients,O
with,O
moderate,O
COVID-19,O
",",O
the,O
day,O
11,O
clinical,O
status,O
distribution,O
measured,O
on,O
a,O
7,O
-,O
point,O
ordinal,O
scale,O
was,O
significantly,O
better,O
for,O
those,O
randomized,O
to,O
a,O
5,O
-,O
day,O
course,O
of,O
remdesivir,O
(,O
median,O
length,O
of,O
treatment,O
",",O
5,O
days,O
),O
compared,O
with,O
those,O
randomized,O
to,O
standard,O
care,O
.,O
Meaning,O
 ,O
Hospitalized,O
patients,O
with,O
moderate,O
COVID-19,O
randomized,O
to,O
a,O
5,O
-,O
day,O
course,O
of,O
remdesivir,O
had,O
a,O
statistically,O
significantly,O
better,O
clinical,O
status,O
compared,O
with,O
those,O
randomized,O
to,O
standard,O
care,O
at,O
11,O
days,O
after,O
initiation,O
of,O
treatment,O
",",O
but,O
the,O
difference,O
was,O
of,O
uncertain,O
clinical,O
importance,O
.,O
Importance,O
 ,O
Remdesivir,O
demonstrated,O
clinical,O
benefit,O
in,O
a,O
placebo,O
-,O
controlled,O
trial,O
in,O
patients,O
with,O
severe,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
but,O
its,O
effect,O
in,O
patients,O
with,O
moderate,O
disease,O
is,O
unknown,O
.,O
Design,O
",",O
Setting,O
",",O
and,O
Participants,O
 ,O
Randomized,O
",",O
open,O
-,O
label,O
trial,O
of,O
hospitalized,O
patients,O
with,O
confirmed,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
infection,O
and,O
moderate,O
COVID-19,O
pneumonia,O
(,O
pulmonary,O
infiltrates,O
and,O
room,O
-,O
air,O
oxygen,O
saturation,O
>,O
94,O
%,O
),O
enrolled,O
from,O
March,O
15,O
through,O
April,O
18,O
",",O
2020,O
",",O
at,O
105,O
hospitals,O
in,O
the,O
United,O
States,O
",",O
Europe,O
",",O
and,O
Asia,O
.,O
Conclusions,O
and,O
Relevance,O
 ,O
Among,O
patients,O
with,O
moderate,O
COVID-19,O
",",O
those,O
randomized,O
to,O
a,O
10,O
-,O
day,O
course,O
of,O
remdesivir,O
did,O
not,O
have,O
a,O
statistically,O
significant,O
difference,O
in,O
clinical,O
status,O
compared,O
with,O
standard,O
care,O
at,O
11,O
days,O
after,O
initiation,O
of,O
treatment,O
.,O
As,O
of,O
26,O
March,O
2020,O
",",O
72,O
genes,O
of,O
SARS‐CoV‐2,O
strains,O
obtained,O
from,O
humans,O
have,O
been,O
collected,O
on,O
GISAID,S-Dataset
 ,O
(,O
http://gisaid.org/,S-URL
),O
.,O
To,O
eliminate,O
the,O
recombination,O
in,O
the,O
dataset,O
",",O
we,O
used,O
splitstreev4.15.1,O
.,O
According,O
to,O
the,O
Bayesian,O
information,O
criterion,O
(,O
BIC,O
),O
method,O
implemented,O
in,O
the,O
jModelTest,O
v2.1.10,O
software,O
",",O
",",O
  ,O
the,O
most,O
suitable,O
nucleotide,O
substitution,O
model,O
for,O
this,O
genomic,O
data,O
set,O
is,O
HKY,O
 ,O
+,O
To,O
set,O
the,O
time,O
scale,O
prior,O
for,O
the,O
dataset,O
",",O
we,O
used,O
a,O
constrained,O
evolution,O
rate,O
with,O
a,O
Log‐normal,O
prior,O
averaged,O
at,O
10−3,O
by,O
substitution,O
per,O
site,O
per,O
year,O
.,O
For,O
the,O
SARS‐CoV‐2,O
genomic,O
dataset,O
from,O
the,O
three,O
geographic,O
locations,O
(,O
Shanghai,O
",",O
Italy,O
",",O
and,O
Spain,O
),O
the,O
most,O
suitable,O
model,O
was,O
HKY,O
 ,O
+,O
 ,O
4,O
according,O
to,O
the,O
BIC,O
method,O
.,O
Phylogenetic,O
analyzes,O
of,O
the,O
SARS‐CoV‐2,O
dataset,O
",",O
using,O
the,O
Bayesian,O
multi‐type,O
birth‐death,O
model,O
and,O
molecular,O
clock,O
calibration,O
",",O
showed,O
an,O
estimate,O
of,O
the,O
rate,O
of,O
evolution,O
of,O
whole,O
genome,O
sequences,O
SARS‐CoV‐2,O
at,O
2.11,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
(,O
95,O
%,O
highest,O
posterior,O
density,O
[,O
HPD,O
],O
:,O
1.56,O
 ,O
×,O
 ,O
10−3,O
to,O
3.89,O
 ,O
×,O
 ,O
10−3,O
),O
.,O
To,O
do,O
this,O
",",O
we,O
reported,O
the,O
phylodynamic,O
and,O
phylogeographic,O
results,O
",",O
proposing,O
the,O
implementation,O
of,O
molecular,O
modeling,O
based,O
on,O
the,O
multi‐type,O
birth‐death,O
model,O
implemented,O
in,O
Beast2,O
",",O
using,O
heterochromatic,O
genomic,O
data,O
retrieved,O
from,O
the,O
GISAID,S-Dataset
 ,O
repository,O
.,O
A,O
tree,O
of,O
maximum,O
credibility,O
was,O
constructed,O
using,O
the,O
72,O
entire,O
genome,O
sequences,O
of,O
this,O
virus,O
",",O
from,O
the,O
three,O
countries,O
(,O
China,O
",",O
Italy,O
",",O
and,O
Spain,O
),O
available,O
as,O
of,O
26,O
March,O
2020,O
on,O
the,O
GISAID,S-Dataset
 ,O
reference,O
frame,O
.,O
As,O
of,O
June,O
18,O
",",O
2020,O
",",O
over,O
8.4,O
million,O
cases,O
and,O
"450,000",O
deaths,O
resulting,O
from,O
infection,O
by,O
a,O
novel,O
SARS,O
coronavirus,O
",",O
SARS,O
-,O
CoV-2,O
(,O
also,O
termed,O
Coronavirus,O
Disease,O
2019,O
or,O
COVID-19,O
),O
",",O
have,O
now,O
been,O
confirmed,O
worldwide,O
;,O
furthermore,O
",",O
there,O
have,O
been,O
more,O
than,O
2.2,O
million,O
confirmed,O
cases,O
and,O
over,O
"110,000",O
deaths,O
due,O
to,O
the,O
COVID-19,O
pandemic,O
in,O
the,O
USA,O
alone,O
[,O
2,O
],O
.,O
Morbidity,O
and,O
mortality,O
due,O
to,O
COVID-19,O
rise,O
dramatically,O
with,O
age,O
and,O
co,O
-,O
existing,O
health,O
conditions,O
",",O
including,O
cancer,O
and,O
cardiovascular,O
diseases,O
",",O
and,O
while,O
most,O
infected,O
individuals,O
recover,O
",",O
even,O
very,O
young,O
and,O
otherwise,O
healthy,O
patients,O
may,O
unpredictably,O
succumb,O
to,O
this,O
disease,O
[,O
3,O
],O
.,O
These,O
observations,O
beg,O
the,O
question,O
of,O
how,O
much,O
of,O
the,O
variation,O
in,O
COVID-19,O
disease,O
severity,O
may,O
be,O
explained,O
by,O
genetic,O
susceptibility,O
.,O
Development,O
of,O
new,O
preventive,O
and/or,O
therapeutic,O
strategies,O
for,O
COVID-19,O
will,O
be,O
greatly,O
facilitated,O
by,O
systematic,O
identification,O
of,O
host,O
genetic,O
pathways,O
and,O
DNA,O
polymorphisms,O
(,O
variants,O
),O
which,O
modulate,O
the,O
risk,O
of,O
infection,O
and,O
severe,O
illness,O
",",O
including,O
the,O
overexuberant,O
immune,O
response,O
to,O
the,O
virus,O
that,O
often,O
portends,O
a,O
poor,O
outcome,O
.,O
Not,O
only,O
has,O
the,O
COVID-19,O
pandemic,O
had,O
huge,O
health,O
and,O
economic,O
impacts,O
in,O
188,O
countries,O
/,O
regions,O
across,O
the,O
world,O
",",O
but,O
the,O
disease,O
has,O
also,O
struck,O
in,O
different,O
racial,O
/,O
ethnic,O
subpopulations,O
.,O
Clinical,O
studies,O
have,O
reported,O
that,O
incidence,O
and,O
mortality,O
rates,O
are,O
significantly,O
different,O
between,O
male,O
and,O
female,O
COVID-19,O
patients,O
",",O
and,O
the,O
disease,O
is,O
associated,O
with,O
pre,O
-,O
existing,O
conditions,O
",",O
such,O
as,O
cancer,O
and,O
cardiovascular,O
disorders,O
",",O
in,O
particular,O
individuals,O
with,O
hypertension,O
receiving,O
anti,O
-,O
hypertensive,O
medications,O
[,O
8,O
],O
.,O
Therefore,O
",",O
a,O
systematic,O
investigation,O
of,O
the,O
functional,O
polymorphisms,O
in,O
ACE2,O
and,O
TMPRSS2,O
among,O
different,O
populations,O
could,O
pave,O
the,O
way,O
for,O
precision,O
medicine,O
and,O
personalized,O
treatment,O
strategies,O
for,O
COVID-19,O
.,O
Here,O
",",O
we,O
investigated,O
genetic,O
susceptibility,O
to,O
COVID-19,O
by,O
examining,O
DNA,O
polymorphisms,O
in,O
ACE2,O
(,O
OMIM,O
300335,O
),O
and,O
TMPRSS2,O
(,O
OMIM,O
602060,O
),O
genes,O
.,O
We,O
assembled,O
a,O
total,O
of,O
437,O
non,O
-,O
synonymous,O
single,O
-,O
nucleotide,O
variants,O
(,O
SNVs,O
),O
in,O
the,O
protein,O
-,O
coding,O
regions,O
of,O
ACE2,O
and,O
TMPRSS2,O
(,O
Fig,O
.,O
 ,O
1a,O
),O
from,O
three,O
databases,O
:,O
(,O
i,O
),O
Genome,B-Repository
Aggregation,I-Repository
Database,I-Repository
(gnomAD,E-Repository
 ,O
v3,O
:,O
gnomad.broadinstitute.org,S-URL
",",O
covering,O
9,O
geographical,O
areas,O
),O
",",O
(,O
ii,O
),O
Exome,B-Repository
Sequencing,I-Repository
Project,I-Repository
(ESP,E-Repository
:,O
evs.gs.washington.edu/EVS/,S-URL
),O
",",O
and,O
(,O
iii,O
),O
1000,B-Repository
Genomes,I-Repository
Project,I-Repository
(1KGP,E-Repository
",",O
www.internationalgenome.org,S-URL
),O
.,O
We,O
further,O
inspected,O
the,O
expression,O
quantitative,O
trait,O
loci,O
(,O
eQTL,O
),O
for,O
ACE2,O
using,O
the,O
GTEx,S-Dataset
 ,O
[,O
13,O
],O
and,O
QTLbase,S-Repository
 ,O
[,O
14,O
],O
databases,O
.,O
We,O
found,O
6,O
germline,O
deleterious,O
variants,O
(,O
p.,O
Val160Met,O
",",O
p.,O
Gly181Arg,O
",",O
p.,O
Arg240Cys,O
",",O
p.,O
Gly259Ser,O
",",O
p.,O
Pro335Leu,O
",",O
and,O
p.,O
Gly432Ala,O
),O
in,O
the,O
TMPRSS2,O
coding,O
region,O
",",O
which,O
are,O
also,O
identified,O
as,O
somatic,O
mutations,O
occurring,O
in,O
different,O
cancer,O
types,O
from,O
TCGA,S-Repository
 ,O
and,O
COSMIC,S-Repository
 ,O
databases,O
(,O
https://cancer.sanger.ac.uk/cosmic,S-URL
),O
.,O
We,O
further,O
evaluated,O
the,O
eQTL,O
profile,O
of,O
TMPRSS2,O
using,O
the,O
GTEx,S-Dataset
 ,O
[,O
13,O
],O
and,O
QTLbase,S-Repository
 ,O
databases,O
[,O
14,O
],O
as,O
well,O
.,O
We,O
found,O
two,O
eQTLs,O
associated,O
with,O
TMPRSS2,O
non,O
-,O
synonymous,O
SNPs,O
(,O
rs12329760,O
(,O
encoding,O
p.,O
Val160Met,O
),O
",",O
p,O
 ,O
=,O
 ,O
4.54,O
 ,O
×,O
 ,O
10−5,O
;,O
rs75603675,O
",",O
p,O
 ,O
=,O
 ,O
0.009,O
),O
in,O
the,O
kidney,O
and,O
bone,O
",",O
respectively,O
",",O
using,O
the,O
QTLbase,S-Repository
 ,O
database,O
[,O
14,O
],O
",",O
while,O
there,O
are,O
no,O
known,O
eQTLs,O
associated,O
with,O
TMPRSS2,O
non,O
-,O
synonymous,O
SNPs,O
from,O
GTEx,S-Dataset
 ,O
[,O
13,O
],O
.,O
These,O
unique,O
but,O
prevalent,O
polymorphisms,O
in,O
TMPRSS2,O
offer,O
potential,O
explanations,O
for,O
differential,O
genetic,O
susceptibility,O
to,O
COVID-19,O
as,O
well,O
as,O
for,O
risk,O
factors,O
",",O
including,O
those,O
with,O
cancer,O
and,O
the,O
high,O
-,O
risk,O
group,O
of,O
male,O
patients,O
.,O
Because,O
TMPRSS2,O
is,O
located,O
on,O
21q22.3,O
",",O
we,O
could,O
speculate,O
that,O
individuals,O
with,O
Down,O
syndrome,O
would,O
be,O
at,O
high,O
risk,O
for,O
COVID-19,O
infection,O
.,O
In,O
addition,O
",",O
oncogenic,O
roles,O
of,O
TMPRSS2,O
may,O
be,O
linked,O
to,O
poor,O
outcomes,O
with,O
COVID-19,O
as,O
well,O
[,O
16,O
],O
",",O
which,O
should,O
be,O
studied,O
in,O
the,O
future,O
.,O
This,O
observation,O
suggests,O
that,O
developmental,O
regulation,O
of,O
TMPRSS2,O
may,O
link,O
the,O
relative,O
protection,O
of,O
infants,O
and,O
children,O
from,O
COVID-19,O
.,O
There,O
are,O
currently,O
no,O
approved,O
effective,O
medications,O
against,O
COVID-19,O
.,O
Several,O
national,O
and,O
international,O
research,O
groups,O
are,O
working,O
on,O
the,O
development,O
of,O
vaccines,O
to,O
prevent,O
COVID-19,O
",",O
but,O
effective,O
vaccines,O
not,O
likely,O
to,O
be,O
available,O
for,O
many,O
months,O
.,O
Several,O
potentially,O
repurposable,O
drugs,O
(,O
Fig,O
.,O
 ,O
2c,O
),O
",",O
including,O
melatonin,O
[,O
19,O
],O
",",O
hydroxychloroquine,O
",",O
and,O
chloroquine,O
",",O
are,O
under,O
investigation,O
for,O
treatment,O
of,O
COVID-19,O
[,O
20,O
],O
.,O
However,O
",",O
further,O
pharmacogenomic,O
studies,O
that,O
integrate,O
drug,O
response,O
and,O
genetic,O
data,O
from,O
patients,O
with,O
COVID-19,O
are,O
urgently,O
needed,O
.,O
Current,O
analysis,O
examined,O
massive,O
genomic,O
data,O
from,O
general,O
population,O
",",O
not,O
COVID-19,O
patient,O
-,O
specific,O
populations,O
.,O
All,O
genetic,O
associations,O
identified,O
in,O
current,O
study,O
are,O
urgently,O
needed,O
to,O
be,O
tested,O
in,O
COVID-19,O
patients,O
in,O
the,O
near,O
future,O
.,O
We,O
anticipate,O
that,O
large,O
-,O
scale,O
genome,O
-,O
wide,O
association,O
studies,O
(,O
GWAS,O
),O
are,O
urgently,O
needed,O
to,O
identify,O
likely,O
causal,O
host,O
genetic,O
risk,O
factors,O
for,O
severe,O
COVID-19,O
outcomes,O
using,O
genetic,O
data,O
from,O
patients,O
with,O
COVID-19,O
;,O
such,O
knowledge,O
will,O
improve,O
risk,O
stratification,O
of,O
individuals,O
exposed,O
to,O
or,O
testing,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
and,O
allow,O
for,O
precision,O
medicine,O
interventions,O
for,O
COVID-19,O
.,O
A,O
COVID-19,O
host,O
genetics,O
initiative,O
is,O
already,O
underway,O
to,O
bring,O
together,O
the,O
human,O
genetics,O
research,O
community,O
to,O
generate,O
",",O
share,O
",",O
and,O
analyze,O
data,O
in,O
a,O
search,O
for,O
the,O
genetic,O
determinants,O
of,O
COVID-19,O
susceptibility,O
",",O
severity,O
",",O
and,O
outcomes,O
[,O
27,O
],O
.,O
The,O
first,O
COVID-19,O
GWAS,O
identified,O
the,O
3p21.31,O
gene,O
cluster,O
(,O
including,O
SLC6A20,O
",",O
LZTFL1,O
",",O
CCR9,O
",",O
FYCO1,O
",",O
CXCR6,O
",",O
and,O
XCR1,O
),O
as,O
a,O
genetic,O
susceptibility,O
locus,O
in,O
severe,O
patients,O
with,O
COVID-19,O
and,O
respiratory,O
failure,O
[,O
28,O
],O
.,O
Yet,O
",",O
our,O
study,O
aims,O
to,O
look,O
for,O
SNPs,O
associated,O
with,O
disease,O
severity,O
of,O
COVID-19,O
",",O
but,O
not,O
disease,O
susceptibility,O
.,O
In,O
summary,O
",",O
systematic,O
identification,O
of,O
the,O
genetic,O
determinants,O
of,O
COVID-19,O
susceptibility,O
",",O
severity,O
",",O
and,O
clinical,O
outcome,O
",",O
including,O
both,O
virus,O
and,O
host,O
factors,O
(,O
e.g.,O
",",O
ACE2,O
and,O
TMPRSS2,O
polymorphisms,O
),O
",",O
could,O
guide,O
personalized,O
treatment,O
in,O
the,O
emerging,O
COVID-19,O
pandemic,O
and,O
even,O
explain,O
current,O
epidemiologic,O
observations,O
(,O
i.e.,O
",",O
males,O
",",O
elderly,O
at,O
high,O
risk,O
",",O
and,O
clinical,O
comorbidities,O
),O
and,O
natural,O
history,O
.,O
Background,O
 ,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
",",O
caused,O
by,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
has,O
now,O
been,O
confirmed,O
worldwide,O
.,O
Yet,O
",",O
COVID-19,O
is,O
strangely,O
and,O
tragically,O
selective,O
.,O
Morbidity,O
and,O
mortality,O
due,O
to,O
COVID19,O
rise,O
dramatically,O
with,O
age,O
and,O
co,O
-,O
existing,O
health,O
conditions,O
",",O
including,O
cancer,O
and,O
cardiovascular,O
diseases,O
.,O
In,O
this,O
study,O
",",O
we,O
investigated,O
genetic,O
susceptibility,O
to,O
COVID-19,O
by,O
examining,O
DNA,O
polymorphisms,O
in,O
ACE2,O
and,O
TMPRSS2,O
(,O
two,O
key,O
host,O
factors,O
of,O
SARS,O
-,O
CoV-2,O
),O
from,O
~,O
 ,O
"81,000",O
human,O
genomes,O
.,O
Unique,O
but,O
prevalent,O
polymorphisms,O
(,O
including,O
p.,O
Val160Met,O
(,O
rs12329760,O
),O
",",O
an,O
expression,O
quantitative,O
trait,O
locus,O
(,O
eQTL,O
),O
),O
in,O
TMPRSS2,O
",",O
offer,O
potential,O
explanations,O
for,O
differential,O
genetic,O
susceptibility,O
to,O
COVID-19,O
as,O
well,O
as,O
for,O
risk,O
factors,O
",",O
including,O
those,O
with,O
cancer,O
and,O
the,O
high,O
-,O
risk,O
group,O
of,O
male,O
patients,O
.,O
We,O
further,O
discussed,O
that,O
polymorphisms,O
in,O
ACE2,O
or,O
TMPRSS2,O
could,O
guide,O
effective,O
treatments,O
(,O
i.e.,O
",",O
hydroxychloroquine,O
and,O
camostat,O
),O
for,O
COVID-19,O
.,O
This,O
study,O
suggested,O
that,O
ACE2,O
or,O
TMPRSS2,O
DNA,O
polymorphisms,O
were,O
likely,O
associated,O
with,O
genetic,O
susceptibility,O
of,O
COVID-19,O
",",O
which,O
calls,O
for,O
a,O
human,O
genetics,O
initiative,O
for,O
fighting,O
the,O
COVID-19,O
pandemic,O
.,O
All,O
population,O
genetic,O
data,O
used,O
in,O
this,O
study,O
are,O
free,O
and,O
available,O
at,O
three,O
databases,O
:,O
(,O
i,O
),O
Genome,B-Repository
Aggregation,I-Repository
Database,I-Repository
(gnomAD,E-Repository
 ,O
v3,O
:,O
gnomad.broadinstitute.org,S-URL
",",O
covering,O
9,O
geographical,O
areas,O
),O
",",O
(,O
ii,O
),O
Exome,B-Repository
Sequencing,I-Repository
Project,I-Repository
(ESP,E-Repository
:,O
evs.gs.washington.edu/EVS/,S-URL
),O
",",O
and,O
(,O
iii,O
),O
1000,B-Repository
Genomes,I-Repository
Project,I-Repository
(1KGP,E-Repository
",",O
www.internationalgenome.org,S-URL
),O
.,O
With,O
respect,O
to,O
the,O
origin,O
of,O
this,O
COVID-19,O
pandemic,O
",",O
of,O
further,O
interest,O
is,O
the,O
fact,O
that,O
the,O
S,O
protein,O
has,O
a,O
specific,O
FCS,O
that,O
is,O
absent,O
in,O
coronaviruses,O
of,O
the,O
same,O
clade,O
as,O
SARS,O
-,O
CoV-2,O
[,O
"8,[14",O
],O
",",O
[,O
15,O
],O
",",O
[,O
16,O
],O
],O
.,O
In,O
the,O
midst,O
of,O
this,O
COVID-19,O
pandemic,O
",",O
FCS,O
is,O
reportedly,O
linked,O
to,O
a,O
natural,O
-,O
selection,O
",",O
instead,O
of,O
purposeful,O
-,O
manipulation,O
",",O
−based,O
hypothesis,O
of,O
the,O
origin,O
of,O
this,O
COVID-19,O
outbreak,O
[,O
"9,[17",O
],O
",",O
[,O
18,O
],O
",",O
[,O
19,O
],O
",",O
[,O
20,O
],O
",",O
[,O
21,O
],O
],O
.,O
Regardless,O
of,O
this,O
COVID-19,O
-,O
origin,O
hypothesis,O
[,O
9,O
],O
",",O
to,O
date,O
(,O
Thu,O
Jun,O
25,O
09:39:392020,O
),O
",",O
it,O
still,O
remains,O
not,O
clear,O
what,O
the,O
actual,O
structural,O
consequence,O
is,O
of,O
the,O
polybasic,O
FCS,O
's,O
insertion,O
into,O
the,O
S,O
protein,O
of,O
SARS,O
-,O
CoV-2,O
.,O
In,O
fact,O
",",O
however,O
",",O
the,O
structural,O
search,O
led,O
to,O
a,O
Cryo,O
-,O
EM,O
structure,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6VSB,S-AccessionNumber
),O
with,O
a,O
range,O
of,O
EUTs,O
[,O
24,O
],O
",",O
representing,O
the,O
three,O
-,O
dimensional,O
structure,O
of,O
the,O
prefusion,O
2019,O
-,O
nCoV,O
spike,O
glycoprotein,O
with,O
a,O
single,O
receptor,O
-,O
binding,O
domain,O
up,O
[,O
1,O
],O
.,O
From,O
an,O
amino,O
acid,O
sequence,O
alignment,O
(,O
Fig,O
.,O
1.2,O
in,O
supplementary,O
file,O
supplement.pdf,O
),O
",",O
it,O
is,O
obvious,O
that,O
those,O
EUTs,O
are,O
widely,O
scattered,O
throughout,O
the,O
homotrimeric,O
structure,O
(,O
PDB,S-Repository
 ,O
ID,O
6VSB,S-AccessionNumber
),O
[,O
1,O
],O
.,O
Yet,O
",",O
with,O
another,O
amino,O
acid,O
sequence,O
alignment,O
(,O
Fig,O
.,O
1.1,O
in,O
supplementary,O
file,O
supplement.pdf,O
),O
",",O
it,O
was,O
revealed,O
that,O
the,O
sequence,O
similarity,O
between,O
the,O
Cryo,O
-,O
EM,O
structure,O
(,O
PDB,S-Repository
 ,O
ID,O
6VSB,S-AccessionNumber
),O
and,O
QHD43416.1,S-AccessionNumber
 ,O
is,O
as,O
high,O
as,O
99.26,O
%,O
",",O
making,O
PDB,S-Repository
 ,O
ID,O
6VSB,S-AccessionNumber
 ,O
rather,O
suitable,O
to,O
be,O
used,O
as,O
a,O
structural,O
template,O
for,O
the,O
subsequent,O
homology,O
structural,O
modelling,O
of,O
the,O
S,O
protein,O
of,O
the,O
SARS,O
-,O
CoV-2,O
.,O
Therefore,O
",",O
the,O
Cryo,O
-,O
EM,O
PDB,S-Repository
 ,O
ID,O
6VSB,S-AccessionNumber
 ,O
structure,O
was,O
used,O
as,O
the,O
template,O
by,O
the,O
SwissModel,O
[,O
23,O
],O
homology,O
modelling,O
server,O
to,O
build,O
a,O
structural,O
model,O
with,O
as,O
less,O
EUTs,O
[,O
24,O
],O
as,O
possible,O
of,O
the,O
S,O
protein,O
of,O
SARS,O
-,O
CoV-2,O
.,O
With,O
SwissModel,O
[,O
23,O
],O
and,O
UCSF,O
Chimera,O
[,O
25,O
],O
",",O
a,O
homology,O
homotrimeric,O
structural,O
model,O
(,O
supplementary,O
file,O
model.pdb,O
),O
of,O
the,O
spike,O
protein,O
of,O
SARS,O
-,O
CoV-2,O
was,O
built,O
with,O
only,O
two,O
EUTs,O
(,O
Fig,O
.,O
1.3,O
in,O
supplementary,O
file,O
supplement.pdf,O
),O
[,O
24,O
],O
",",O
one,O
at,O
its,O
N,O
-,O
terminal,O
and,O
another,O
at,O
its,O
C,O
-,O
terminal,O
",",O
as,O
compared,O
(,O
Fig,O
.,O
1.2,O
in,O
supplementary,O
file,O
supplement.pdf,O
),O
with,O
the,O
widely,O
scattered,O
EUTs,O
[,O
24,O
],O
inside,O
its,O
Cryo,O
-,O
EM,O
structural,O
template,O
PDB,S-Repository
 ,O
ID,O
6VSB,S-AccessionNumber
 ,O
[,O
1,O
],O
.,O
In,O
this,O
figure,O
",",O
the,O
three,O
(,O
A,O
",",O
B,O
and,O
C,O
),O
chains,O
of,O
the,O
spike,O
protein,O
of,O
SARS,O
-,O
CoV-2,O
is,O
shown,O
as,O
green,O
",",O
cyan,O
and,O
purple,O
cartoons,O
",",O
the,O
residue,O
naming,O
scheme,O
is,O
Chain,O
ID,O
",",O
residue,O
name,O
",",O
residue,O
number,O
",",O
the,O
four,O
salt,O
bridges,O
are,O
shown,O
here,O
with,O
four,O
dotted,O
yellow,O
lines,O
",",O
with,O
the,O
lengths,O
of,O
the,O
four,O
inter,O
-,O
chain,O
salt,O
bridges,O
being,O
2.6,O
",",O
2.6,O
",",O
3.3,O
and,O
3.5,O
 ,O
Å,O
",",O
respectively,O
.,O
Incorporating,O
currently,O
available,O
structural,O
data,O
(,O
as,O
of,O
Thu,O
Jun,O
25,O
09:39:402020,O
),O
of,O
the,O
S,O
protein,O
[,O
22,O
],O
",",O
and,O
in,O
the,O
hope,O
of,O
pushing,O
a,O
little,O
bit,O
forward,O
the,O
boundary,O
of,O
our,O
scientific,O
knowledge,O
on,O
COVID-19,O
",",O
this,O
short,O
article,O
presents,O
a,O
comprehensive,O
structural,O
characterization,O
of,O
the,O
FCS,O
inserted,O
into,O
the,O
S,O
protein,O
of,O
SARS,O
-,O
CoV-2,O
",",O
and,O
puts,O
forward,O
a,O
set,O
of,O
structural,O
analysis,O
as,O
below,O
",",O
the,O
polybasic,O
FCS,O
is,O
spatially,O
located,O
at,O
a,O
random,O
coil,O
loop,O
region,O
",",O
mostly,O
distantly,O
solvent,O
-,O
exposed,O
(,O
Fig,O
.,O
1,O
",",O
instead,O
of,O
deeply,O
buried,O
),O
",",O
with,O
no,O
structural,O
proximity,O
to,O
the,O
other,O
part,O
of,O
the,O
S,O
protein,O
of,O
SARS,O
-,O
CoV-2,O
.,O
the,O
S1,O
and,O
S2,O
subunits,O
of,O
the,O
S,O
protein,O
will,O
still,O
be,O
strongly,O
bonded,O
together,O
",",O
at,O
least,O
electrostatically,O
[,O
31,O
],O
from,O
a,O
structural,O
and,O
biophysical,O
point,O
of,O
view,O
",",O
even,O
if,O
the,O
FCS,O
is,O
actually,O
cleaved,O
by,O
furin,O
protease,O
.,O
Nevertheless,O
",",O
in,O
the,O
midst,O
of,O
this,O
COVID-19,O
pandemic,O
[,O
32,O
],O
with,O
more,O
than,O
5.5,O
million,O
(,O
as,O
of,O
Thu,O
Jun,O
25,O
09:39:402020,O
),O
confirmed,O
cases,O
globally,O
",",O
this,O
short,O
article,O
puts,O
forward,O
a,O
set,O
of,O
analysis,O
that,O
the,O
net,O
structural,O
consequence,O
of,O
FCS,O
here,O
is,O
the,O
insertion,O
of,O
a,O
furin,O
cleavage,O
site,O
into,O
the,O
S,O
protein,O
of,O
SARS,O
-,O
CoV-2,O
",",O
and,O
is,O
thus,O
of,O
only,O
limited,O
structural,O
biophysical,O
relevance,O
here,O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
",",O
and,O
our,O
knowledge,O
about,O
the,O
virus,O
",",O
has,O
exponentially,O
grown,O
since,O
media,O
reports,O
of,O
a,O
cluster,O
of,O
acute,O
respiratory,O
infections,O
in,O
Wuhan,O
",",O
Hubei,O
Province,O
",",O
China,O
",",O
were,O
first,O
reported,O
in,O
December,O
2019,O
[,O
1,O
],O
.,O
The,O
demanding,O
pace,O
and,O
large,O
volume,O
of,O
COVID-19,O
science,O
generated,O
in,O
the,O
last,O
3,O
months,O
",",O
however,O
",",O
has,O
made,O
timely,O
scientific,O
communication,O
through,O
the,O
conventional,O
route,O
of,O
published,O
biomedical,O
journals,O
at,O
best,O
challenging,O
",",O
and,O
at,O
worst,O
obsolete,O
.,O
We,O
propose,O
that,O
Twitter,O
has,O
played,O
a,O
fundamental,O
—,O
but,O
often,O
precarious,O
—,O
role,O
in,O
permitting,O
real,O
-,O
time,O
global,O
communication,O
between,O
scientists,O
during,O
the,O
COVID-19,O
epidemic,O
",",O
on,O
a,O
scale,O
not,O
seen,O
before,O
.,O
This,O
discussion,O
also,O
serves,O
as,O
a,O
succinct,O
primer,O
on,O
some,O
of,O
the,O
pivotal,O
epidemiological,O
analyses,O
(,O
and,O
their,O
communication,O
),O
during,O
the,O
early,O
phases,O
of,O
the,O
COVID-19,O
outbreak,O
",",O
as,O
seen,O
through,O
the,O
lens,O
of,O
a,O
Twitter,O
feed,O
.,O
Similarly,O
",",O
concerns,O
of,O
malignant,O
misinformation,O
about,O
COVID-19,O
deliberately,O
spread,O
through,O
this,O
medium,O
are,O
beyond,O
the,O
scope,O
of,O
this,O
commentary,O
[,O
8,O
],O
.,O
As,O
with,O
other,O
outbreaks,O
",",O
early,O
estimation,O
of,O
epidemic,O
parameters,O
during,O
the,O
first,O
month,O
of,O
the,O
COVID-19,O
epidemic,O
has,O
been,O
critical,O
to,O
predict,O
the,O
epidemic,O
trajectory,O
and,O
inform,O
decision,O
making,O
.,O
Indeed,O
",",O
such,O
open,O
-,O
source,O
line,O
-,O
list,O
data,O
remain,O
more,O
comprehensive,O
than,O
what,O
is,O
currently,O
published,O
by,O
some,O
other,O
countries,O
now,O
experiencing,O
major,O
COVID-19,O
epidemics,O
.,O
Accurate,O
approximation,O
and,O
interpretation,O
of,O
the,O
COVID-19,O
case,O
-,O
fatality,O
ratio,O
(,O
CFR,O
),O
has,O
been,O
critical,O
for,O
resource,O
planning,O
and,O
risk,O
messaging,O
.,O
These,O
discussion,O
points,O
were,O
vital,O
to,O
frame,O
any,O
early,O
comparisons,O
of,O
COVID-19,O
morbidity,O
and,O
mortality,O
with,O
that,O
of,O
seasonal,O
or,O
pandemic,O
influenza,O
[,O
33–35,O
],O
.,O
It,O
is,O
important,O
to,O
acknowledge,O
",",O
however,O
",",O
the,O
continued,O
importance,O
of,O
rigorously,O
peer,O
-,O
reviewed,O
journal,O
publications,O
of,O
COVID-19,O
clinical,O
and,O
epidemiological,O
characteristics,O
",",O
especially,O
when,O
accompanied,O
by,O
expert,O
editorials,O
",",O
and,O
particularly,O
given,O
the,O
exponential,O
rise,O
of,O
preprint,O
publications,O
",",O
which,O
may,O
vary,O
in,O
quality,O
[,O
36,O
],O
.,O
Twitter,O
has,O
and,O
continues,O
to,O
serve,O
as,O
a,O
valuable,O
medium,O
to,O
discuss,O
the,O
caveats,O
and,O
future,O
directions,O
in,O
applying,O
infectious,O
disease,O
models,O
in,O
COVID-19,O
decision,O
making,O
[,O
41–44,O
],O
.,O
Still,O
",",O
Twitter,O
remains,O
the,O
double,O
-,O
edged,O
sword,O
of,O
rapid,O
scientific,O
communication,O
during,O
the,O
ongoing,O
COVID-19,O
pandemic,O
.,O
The,O
human,O
and,O
social,O
toll,O
of,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
has,O
already,O
spurred,O
several,O
major,O
public,O
health,O
“,O
lessons,O
learned,O
",",O
”,O
and,O
the,O
theme,O
of,O
effective,O
and,O
responsible,O
scientific,O
communication,O
is,O
among,O
them,O
.,O
We,O
propose,O
that,O
Twitter,O
has,O
played,O
a,O
fundamental,O
—,O
but,O
often,O
precarious,O
—,O
role,O
in,O
permitting,O
real,O
-,O
time,O
global,O
communication,O
between,O
scientists,O
during,O
the,O
COVID-19,O
epidemic,O
",",O
on,O
a,O
scale,O
not,O
seen,O
before,O
.,O
This,O
discussion,O
also,O
serves,O
as,O
a,O
succinct,O
primer,O
on,O
some,O
of,O
the,O
pivotal,O
epidemiological,O
analyses,O
(,O
and,O
their,O
communication,O
),O
during,O
the,O
early,O
phases,O
of,O
the,O
COVID-19,O
outbreak,O
",",O
as,O
seen,O
through,O
the,O
lens,O
of,O
a,O
Twitter,O
feed,O
.,O
Twitter,O
remains,O
the,O
double,O
-,O
edged,O
sword,O
of,O
rapid,O
scientific,O
communication,O
during,O
the,O
ongoing,O
COVID-19,O
pandemic,O
.,O
As,O
of,O
19,O
January,O
2020,O
",",O
13,O
genome,O
sequences,O
of,O
2019‐nCoV,O
have,O
been,O
released,O
on,O
GISAID,S-Dataset
 ,O
(,O
http://gisaid.org/,S-URL
),O
and,O
one,O
strain,O
(,O
virus,O
name,O
:,O
BetaCoV,O
/,O
Wuhan‐Hu‐1/2019,O
;,O
accession,O
ID,O
:,O
EPI_ISL_402125,S-AccessionNumber
),O
has,O
been,O
released,O
on,O
GenBank,S-Repository
 ,O
(,O
https://www.ncbi.nlm.nih.gov/nuccore/MN908947,S-URL
),O
by,O
the,O
Shanghai,B-Creator
Public,I-Creator
Health,I-Creator
Clinical,I-Creator
Center,I-Creator
&,I-Creator
School,I-Creator
of,I-Creator
Public,I-Creator
Health,E-Creator
",",O
Fudan,O
University,O
",",O
Shanghai,O
",",O
China,O
.,O
In,O
this,O
study,O
",",O
we,O
used,O
the,O
latest,O
version,O
(,O
MN908947.3,S-AccessionNumber
),O
",",O
and,O
therefore,O
the,O
genome,O
sequence,O
of,O
strain,O
BetaCoV,O
/,O
Wuhan‐Hu‐1/2019,O
from,O
GISAID,S-Dataset
 ,O
(,O
EPI_ISL_402125,S-AccessionNumber
),O
was,O
excluded,O
.,O
The,O
final,O
dataset,O
included,O
12,O
genome,O
sequences,O
of,O
2019‐nCoV,O
with,O
known,O
sampling,O
date,O
and,O
city,O
(,O
10,O
from,O
individuals,O
in,O
Wuhan,O
",",O
Hubei,O
Province,O
",",O
China,O
",",O
with,O
samples,O
collected,O
between,O
24,O
and,O
30,O
December,O
2019,O
",",O
and,O
two,O
from,O
Chinese,O
individuals,O
in,O
Bangkok,O
",",O
Thailand,O
",",O
who,O
had,O
recently,O
traveled,O
from,O
Wuhan,O
",",O
with,O
samples,O
collected,O
between,O
8,O
and,O
13,O
January,O
2020,O
),O
(,O
Table,O
S1,O
),O
.,O
For,O
this,O
dataset,O
",",O
the,O
2019‐nCoV,O
genome,O
sequences,O
were,O
aligned,O
using,O
MAFFT,O
v7.222,O
 ,O
and,O
then,O
manually,O
curated,O
using,O
BioEdit,O
v7.2.5,O
.,O
To,O
study,O
the,O
amount,O
of,O
evolutionary,O
information,O
contained,O
in,O
the,O
dataset,O
",",O
likelihood‐mapping,O
analysis,O
 ,O
was,O
performed,O
using,O
TREE‐PUZZLE,O
v5.3,O
",",O
 ,O
with,O
30,O
 ,O
000,O
randomly,O
chosen,O
quartets,O
for,O
the,O
entire,O
tree,O
.,O
As,O
no,O
temporal,O
signal,O
was,O
present,O
in,O
the,O
dataset,O
",",O
we,O
employed,O
HKY+G,O
",",O
as,O
well,O
as,O
a,O
constant,O
size,O
coalescent,O
tree,O
prior,O
and,O
strict,O
molecular,O
clock,O
model,O
assuming,O
an,O
evolutionary,O
rate,O
of,O
4.59,O
 ,O
×,O
 ,O
10−4,O
substitutions,O
per,O
site,O
per,O
year,O
to,O
estimate,O
the,O
time,O
to,O
most,O
recent,O
common,O
ancestor,O
(,O
TMRCA,O
),O
for,O
this,O
dataset,O
based,O
on,O
previous,O
genetic,O
analysis,O
.,O
To,O
perform,O
ancestral,O
reconstruction,O
of,O
the,O
unobserved,O
sampling,O
locations,O
(,O
k,O
 ,O
=,O
 ,O
2,O
),O
",",O
discrete,O
phylogeographic,O
analyses,O
 ,O
were,O
performed,O
using,O
the,O
empirical,O
tree,O
distributions,O
generated,O
for,O
our,O
2019‐nCoV,O
dataset,O
.,O
Bayesian,O
analysis,O
was,O
run,O
using,O
BEAST,O
v1.8.4,O
 ,O
and,O
BEAGLE,O
library,O
v2.1.2,O
 ,O
for,O
an,O
MCMC,O
chain,O
of,O
100,O
million,O
iterations,O
",",O
with,O
10,O
 ,O
000,O
samples,O
of,O
all,O
parameters,O
and,O
10,O
 ,O
000,O
trees,O
for,O
our,O
dataset,O
.,O
For,O
this,O
dataset,O
",",O
our,O
likelihood‐mapping,O
analysis,O
revealed,O
a,O
strong,O
star‐like,O
topology,O
signal,O
(,O
Figure,O
 ,O
1,O
),O
",",O
indicating,O
very,O
limited,O
genetic,O
diversity,O
for,O
2019‐nCoV,O
as,O
of,O
now,O
.,O
We,O
also,O
used,O
an,O
assumed,O
evolutionary,O
rate,O
range,O
(,O
95,O
%,O
Bayesian,O
credible,O
interval,O
:,O
1.178,O
 ,O
×,O
 ,O
10−4,O
to,O
3,O
 ,O
×,O
 ,O
10−3,O
substitutions,O
per,O
site,O
per,O
year,O
),O
for,O
this,O
dataset,O
based,O
on,O
previous,O
studies,O
",",O
",",O
 ,O
",",O
  ,O
and,O
estimated,O
that,O
the,O
TMRCA,O
for,O
2019‐nCoV,O
was,O
3,O
September,O
2019,O
(,O
95,O
%,O
Bayesian,O
credible,O
interval,O
:,O
25,O
March,O
2019,O
and,O
20,O
December,O
2019,O
),O
.,O
The,O
outbreak,O
of,O
SARS,O
-,O
CoV-2,O
(,O
the,O
cause,O
of,O
the,O
disease,O
known,O
as,O
COVID-19,O
),O
was,O
first,O
reported,O
in,O
Wuhan,O
city,O
(,O
Hubei,O
province,O
),O
",",O
China,O
",",O
in,O
December,O
2019,O
",",O
and,O
swept,O
across,O
the,O
nation,O
and,O
then,O
around,O
the,O
world,O
within,O
2,O
months,O
",",O
leading,O
to,O
its,O
declaration,O
as,O
a,O
pandemic,O
by,O
the,O
World,O
Health,O
Organisation,O
(,O
WHO,O
),O
on,O
11,O
March,O
2020,O
.,O
As,O
of,O
20,O
May,O
2020,O
",",O
the,O
worldwide,O
COVID-19,O
death,O
toll,O
has,O
reached,O
318,O
789,O
",",O
and,O
nearly,O
5,O
million,O
confirmed,O
cases,O
have,O
been,O
reported,O
across,O
all,O
continents,O
[,O
1,O
],O
.,O
Several,O
studies,O
using,O
mathematical,O
modeling,O
of,O
COVID-19,O
and,O
other,O
coronavirus,O
transmission,O
have,O
suggested,O
that,O
measures,O
such,O
as,O
social,O
distancing,O
and,O
city,O
lockdown,O
may,O
be,O
effective,O
methods,O
of,O
disease,O
control,O
[,O
"5,6",O
],O
",",O
but,O
these,O
seldom,O
assess,O
individual,O
transmission,O
chains,O
.,O
This,O
is,O
seen,O
in,O
the,O
SARS,O
-,O
CoV-2,O
dataset,O
used,O
by,O
Lu,B-Creator
et,I-Creator
al.,E-Creator
 ,O
[,O
7,O
],O
",",O
which,O
has,O
relatively,O
few,O
genomes,O
from,O
outside,O
Guangdong,O
province,O
(,O
e.g.,O
",",O
only,O
32,O
genomes,O
from,O
Hubei,O
province,O
",",O
which,O
had,O
>,O
60000,O
cases,O
at,O
the,O
time,O
),O
.,O
Notably,O
",",O
the,O
SARS,O
-,O
CoV-2,O
genome,O
dataset,O
publicly,O
available,O
at,O
time,O
of,O
writing,O
remains,O
highly,O
uneven,O
across,O
different,O
countries,O
.,O
For,O
instance,O
",",O
the,O
GISAID,B-Dataset
(Global,I-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,E-Dataset
;,O
https://www.gisaid.org,S-URL
),O
database,O
had,O
only,O
five,O
full,O
genome,O
sequences,O
from,O
Iran,O
where,O
>,O
120000,O
cases,O
have,O
been,O
reported,O
;,O
by,O
contrast,O
",",O
it,O
has,O
~1300,O
genomes,O
from,O
~7000,O
cases,O
reported,O
in,O
Australia,O
.,O
The,O
transmission,O
and,O
progression,O
of,O
this,O
disease,O
(,O
COVID-19,O
),O
imply,O
that,O
a,O
great,O
number,O
of,O
infected,O
individuals,O
will,O
need,O
hospitalization,O
and,O
possibly,O
admission,O
to,O
intensive,O
care,O
units,O
[,O
2,O
",",O
3,O
],O
.,O
On,O
May,O
11,O
",",O
over,O
"168,000",O
individuals,O
in,O
Brazil,O
had,O
a,O
confirmed,O
COVID-19,O
infection,O
and,O
around,O
"11,500",O
had,O
died,O
from,O
the,O
disease,O
.,O
The,O
management,O
of,O
early,O
breast,O
cancer,O
(,O
EBC,O
),O
",",O
a,O
disease,O
with,O
well,O
-,O
established,O
treatment,O
protocols,O
[,O
6–8,O
],O
",",O
also,O
had,O
to,O
be,O
adjusted,O
in,O
order,O
to,O
free,O
up,O
hospital,O
beds,O
and,O
vital,O
hospital,O
supplies,O
for,O
individuals,O
infected,O
by,O
COVID-19,O
.,O
This,O
online,O
survey,O
aimed,O
to,O
evaluate,O
how,O
Brazilian,O
breast,O
specialists,O
have,O
managed,O
EBC,O
(,O
stage,O
I,O
/,O
II,O
and,O
clinically,O
negative,O
axilla,O
),O
following,O
publication,O
of,O
emergency,O
treatment,O
protocols,O
[,O
12–14,O
",",O
23,O
",",O
24,O
],O
",",O
at,O
the,O
beginning,O
and,O
during,O
the,O
COVID-19,O
pandemic,O
",",O
according,O
to,O
EBC,O
subtypes,O
[,O
26,O
],O
and,O
oncoplastic,O
surgery,O
.,O
The,O
results,O
were,O
stratified,O
by,O
degree,O
of,O
priority,O
in,O
accordance,O
with,O
the,O
COVID-19,O
Pandemic,O
Breast,O
Cancer,O
Consortium,O
:,O
Priority,O
A,O
patients,O
have,O
a,O
condition,O
that,O
is,O
immediately,O
life,O
threatening,O
and,O
for,O
whom,O
a,O
delay,O
would,O
alter,O
prognosis,O
",",O
while,O
Priority,O
B,O
patients,O
are,O
those,O
who,O
do,O
not,O
have,O
an,O
immediately,O
life,O
threatening,O
condition,O
",",O
but,O
for,O
whom,O
treatment,O
should,O
not,O
be,O
delayed,O
until,O
the,O
end,O
of,O
the,O
pandemic,O
",",O
and,O
Priority,O
C,O
patients,O
are,O
those,O
for,O
whom,O
treatment,O
could,O
be,O
deferred,O
[,O
13,O
],O
.,O
However,O
",",O
there,O
is,O
no,O
statistically,O
significant,O
difference,O
when,O
the,O
southeastern,O
and,O
northeastern,O
regions,O
",",O
those,O
most,O
affected,O
by,O
COVID-19,O
in,O
Brazil,O
",",O
are,O
evaluated,O
together,O
(,O
p,O
 ,O
=,O
 ,O
0.746,O
),O
(,O
Table,O
1,O
),O
.,O
Overall,O
",",O
498,O
respondents,O
(,O
99,O
%,O
),O
lived,O
/,O
worked,O
in,O
a,O
city,O
/,O
town,O
with,O
confirmed,O
cases,O
of,O
COVID-19,O
and,O
258,O
(,O
51.3,O
%,O
),O
reported,O
that,O
there,O
were,O
COVID,O
-,O
free,O
medical,O
establishments,O
in,O
their,O
cities,O
.,O
Being,O
board,O
-,O
certified,O
",",O
having,O
COVID,O
-,O
free,O
hospitals,O
available,O
and,O
working,O
in,O
an,O
academic,O
institute,O
associated,O
with,O
cancer,O
treatment,O
had,O
no,O
significant,O
effect,O
either,O
at,O
the,O
beginning,O
or,O
during,O
the,O
pandemic,O
(,O
Table,O
2,O
),O
.,O
The,O
availability,O
of,O
hospital,O
supplies,O
and,O
beds,O
is,O
greater,O
in,O
the,O
southeast,O
of,O
the,O
country,O
where,O
the,O
concentration,O
of,O
COVID-19,O
cases,O
is,O
greater,O
.,O
In,O
agreement,O
with,O
the,O
SBM,S-Repository
 ,O
database,O
",",O
most,O
respondents,O
live,O
in,O
state,O
capitals,O
or,O
in,O
cities,O
with,O
more,O
than,O
"500,000",O
inhabitants,O
",",O
which,O
are,O
also,O
those,O
most,O
affected,O
by,O
COVID-19,O
[,O
34,O
],O
.,O
The,O
onset,O
of,O
the,O
COVID-19,O
epidemic,O
in,O
Brazil,O
occurred,O
relatively,O
late,O
compared,O
to,O
Europe,O
and,O
North,O
America,O
.,O
The,O
demographic,O
characteristics,O
most,O
associated,O
with,O
a,O
change,O
in,O
management,O
at,O
the,O
beginning,O
of,O
the,O
pandemic,O
were,O
living,O
in,O
the,O
southeast,O
of,O
the,O
country,O
and,O
in,O
a,O
state,O
capital,O
city,O
",",O
coinciding,O
with,O
the,O
areas,O
in,O
which,O
the,O
incidence,O
of,O
COVID-19,O
infection,O
was,O
greatest,O
",",O
with,O
an,O
increasing,O
demand,O
for,O
hospital,O
beds,O
and,O
the,O
implementation,O
of,O
restrictive,O
measures,O
by,O
the,O
government,O
.,O
On,O
the,O
other,O
hand,O
",",O
during,O
the,O
pandemic,O
",",O
various,O
state,O
capital,O
cities,O
made,O
an,O
effort,O
to,O
reserve,O
COVID,O
-,O
free,O
hospitals,O
or,O
wards,O
so,O
as,O
to,O
guarantee,O
the,O
admission,O
of,O
elective,O
patients,O
",",O
particularly,O
cancer,O
patients,O
.,O
According,O
to,O
the,O
advice,O
provided,O
in,O
the,O
Ontario,O
Health,O
Pandemic,O
Planning,O
Clinical,O
Guideline,O
for,O
Patients,O
with,O
Cancer,O
[,O
37,O
],O
",",O
cases,O
of,O
luminal,O
tumors,O
were,O
classified,O
as,O
Priority,O
B,O
",",O
while,O
the,O
COVID-19,O
Pandemic,O
Breast,O
Cancer,O
Consortium,O
stratified,O
such,O
tumors,O
as,O
Priority,O
B3,O
(,O
T2,O
or,O
N1,O
),O
or,O
C1,O
(,O
T1N0,O
),O
[,O
13,O
],O
.,O
Indeed,O
",",O
67,O
%,O
of,O
respondents,O
considered,O
that,O
chemotherapy,O
increases,O
the,O
risk,O
of,O
developing,O
COVID-19,O
-,O
related,O
complications,O
.,O
The,O
COVID-19,O
pandemic,O
has,O
impacted,O
early,O
breast,O
cancer,O
(,O
EBC,O
),O
treatment,O
worldwide,O
.,O
The,O
rapid,O
spread,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
across,O
the,O
globe,O
has,O
led,O
to,O
an,O
outbreak,O
of,O
life,O
-,O
threatening,O
respiratory,O
disease,O
",",O
termed,O
COVID-19,O
(,O
Zhou,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Zhu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
While,O
adults,O
have,O
suffered,O
the,O
highest,O
rates,O
of,O
morbidity,O
and,O
mortality,O
of,O
COVID-19,O
",",O
children,O
were,O
thought,O
to,O
be,O
spared,O
(,O
Dong,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Ludvigsson,O
",",O
2020,O
),O
.,O
The,O
concentration,O
of,O
this,O
disease,O
to,O
regions,O
of,O
high,O
local,O
SARS,O
-,O
CoV-2,O
transmission,O
but,O
",",O
with,O
an,O
onset,O
weeks,O
after,O
the,O
peak,O
COVID-19,O
caseload,O
",",O
suggests,O
MIS,O
-,O
C,O
is,O
a,O
secondary,O
consequence,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
.,O
To,O
estimate,O
the,O
average,O
time,O
between,O
initial,O
infection,O
and,O
MIS,O
-,O
C,O
onset,O
",",O
we,O
determined,O
the,O
temporal,O
delay,O
between,O
peak,O
COVID-19,O
and,O
MIS,O
-,O
C,O
admissions,O
at,O
our,O
institution,O
.,O
We,O
performed,O
high,O
-,O
dimensional,O
cytokine,O
profiling,O
of,O
92,O
analytes,O
using,O
the,O
Olink,O
platform,O
to,O
define,O
the,O
secreted,O
immune,O
response,O
in,O
MIS,O
-,O
C,O
patient,O
plasma,O
and,O
compared,O
it,O
with,O
plasma,O
from,O
age,O
-,O
matched,O
healthy,O
controls,O
",",O
a,O
pediatric,O
patient,O
treated,O
with,O
IVIG,O
with,O
an,O
unrelated,O
infection,O
(,O
urinary,O
tract,O
infection,O
[,O
UTI,O
],O
),O
",",O
and,O
cases,O
of,O
active,O
pediatric,O
and,O
young,O
adult,O
COVID-19,O
infection,O
that,O
did,O
not,O
develop,O
MIS,O
-,O
C.,O
As,O
otherwise,O
healthy,O
children,O
rarely,O
experience,O
clinically,O
apparent,O
COVID-19,O
infections,O
",",O
we,O
used,O
samples,O
from,O
children,O
with,O
immunocompromising,O
comorbidities,O
(,O
Pediatric,O
COVID,O
1,O
and,O
3–6,O
",",O
details,O
in,O
Table,O
S2,O
),O
and,O
one,O
otherwise,O
-,O
healthy,O
child,O
(,O
Pediatric,O
COVID,O
2,O
),O
who,O
did,O
experience,O
acute,O
COVID-19,O
infection,O
.,O
While,O
some,O
of,O
these,O
MIS,O
-,O
C,O
cytokine,O
signatures,O
resembled,O
that,O
of,O
acute,O
or,O
convalescent,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
a,O
unique,O
MIS,O
-,O
C,O
cytokine,O
profile,O
could,O
be,O
distinguished,O
from,O
that,O
of,O
COVID-19,O
.,O
To,O
more,O
finely,O
characterize,O
the,O
cytokine,O
profile,O
differences,O
between,O
MIS,O
-,O
C,O
patients,O
and,O
pediatric,O
COVID-19,O
patients,O
",",O
we,O
conducted,O
PCA,O
analysis,O
restricted,O
to,O
pediatric,O
patients,O
(,O
Figure,O
 ,O
S3,O
A,O
),O
.,O
PC1,O
loading,O
analysis,O
identified,O
components,O
that,O
separated,O
the,O
healthy,O
pediatric,O
controls,O
from,O
all,O
disease,O
patients,O
",",O
while,O
PC2,O
resolved,O
the,O
profiles,O
of,O
pediatric,O
COVID-19,O
and,O
MIS,O
-,O
C,O
(,O
Figure,O
 ,O
2H,O
),O
.,O
Elevations,O
in,O
unique,O
chemokines,O
(,O
CXCL5,O
",",O
CXCL11,O
",",O
CXCL1,O
",",O
and,O
CXCL6,O
),O
and,O
cytokines,O
(,O
including,O
IL-17A,O
",",O
CD40,O
",",O
and,O
IL-6,O
),O
appear,O
to,O
distinguish,O
MIS,O
-,O
C,O
patients,O
from,O
pediatric,O
COVID-19,O
patients,O
(,O
Figure,O
 ,O
S3B,O
),O
.,O
High,O
-,O
Throughput,O
Cytokine,O
Analysis,O
of,O
Pediatric,O
Patient,O
Samples,O
",",O
Related,O
to,O
Figure,O
 ,O
2,O
Next,O
",",O
we,O
performed,O
CyTOF,O
(,O
Cytometry,O
by,O
Time,O
-,O
Of,O
-,O
Flight)-based,O
immunophenotyping,O
on,O
nine,O
MIS,O
-,O
C,O
patients,O
",",O
five,O
age,O
-,O
matched,O
healthy,O
controls,O
",",O
and,O
seven,O
young,O
adults,O
with,O
acute,O
COVID-19,O
infection,O
.,O
These,O
findings,O
suggest,O
that,O
no,O
active,O
peripheral,O
B,O
or,O
T,O
expansion,O
was,O
underway,O
at,O
the,O
time,O
of,O
sampling,O
and,O
distinguish,O
MIS,O
-,O
C,O
from,O
acute,O
COVID-19,O
for,O
which,O
an,O
active,O
bias,O
toward,O
effector,O
populations,O
was,O
readily,O
observed,O
(,O
Figures,O
3C,O
and,O
3D,O
),O
.,O
Among,O
innate,O
cells,O
",",O
CD56lo,O
NK,O
cells,O
were,O
also,O
decreased,O
in,O
MIS,O
-,O
C,O
but,O
not,O
in,O
acute,O
COVID-19,O
peripheral,O
blood,O
(,O
Figure,O
 ,O
3E,O
),O
",",O
while,O
non,O
-,O
classical,O
monocytes,O
and,O
pDCs,O
(,O
plasmacytoid,O
DC,O
),O
frequencies,O
were,O
lower,O
in,O
both,O
groups,O
(,O
Figure,O
 ,O
3F,O
),O
.,O
This,O
antibody,O
response,O
demonstrated,O
typical,O
IgG,O
class,O
switching,O
",",O
absence,O
of,O
circulating,O
IgM,O
but,O
elevated,O
IgA,O
",",O
and,O
effective,O
virus,O
neutralization,O
",",O
resembling,O
",",O
but,O
not,O
identical,O
to,O
",",O
serologies,O
from,O
convalescent,O
COVID-19,O
adults,O
.,O
Clinical,O
criteria,O
detailed,O
in,O
Table,O
S1,O
were,O
used,O
to,O
recruit,O
and,O
classify,O
samples,O
as,O
MIS,O
-,O
C,O
or,O
pediatric,O
COVID,O
.,O
Demographic,O
and,O
clinical,O
data,O
of,O
recruited,O
MIS,O
-,O
C,O
patients,O
and,O
pediatric,O
COVID,O
patients,O
are,O
detailed,O
in,O
Tables,O
1,O
and,O
S2,O
.,O
Samples,O
related,O
to,O
young,O
adults,O
were,O
obtained,O
from,O
the,O
Mount,O
Sinai,O
Health,O
System,O
’s,O
COVID-19,O
Biobank,O
.,O
Under,O
the,O
age,O
of,O
35,O
",",O
found,O
to,O
be,O
SARS,O
-,O
COV-2,O
positive,O
by,O
PCR,O
test,O
and,O
classified,O
with,O
severe,O
/,O
moderate,O
COVID-19,O
.,O
Diluted,O
plasma,O
was,O
then,O
incubated,O
in,O
a,O
1:1,O
volumetric,O
ratio,O
with,O
SARS,O
-,O
CoV-2,O
virus,O
(,O
USA,O
-,O
WA1/2020,O
;,O
GenBank,S-Repository
:,O
MT020880,S-AccessionNumber
),O
at,O
a,O
concentration,O
of,O
100,O
TCID50,O
(,O
50,O
%,O
tissue,O
culture,O
infectious,O
dose,O
),O
in,O
1,O
 ,O
×,O
MEM,O
for,O
1,O
 ,O
h,O
at,O
room,O
temperature,O
.,O
Serology,O
assays,O
assessing,O
plasma,O
reactivity,O
against,O
SARS,O
-,O
CoV-2,O
spike,O
protein,O
were,O
perfomed,O
on,O
samples,O
from,O
healthy,O
patients,O
(,O
pediatric,O
:,O
N,O
 ,O
=,O
4,O
",",O
adults,O
:,O
N,O
 ,O
=,O
7,O
),O
",",O
patients,O
hospitalized,O
for,O
active,O
COVID-19,O
(,O
pediatric,O
:,O
N,O
 ,O
=,O
1,O
",",O
young,O
adult,O
:,O
N,O
 ,O
=,O
4,O
;,O
adult,O
:,O
N,O
 ,O
=,O
3,O
),O
",",O
convalescent,O
COVID-19,O
patients,O
(,O
young,O
adult,O
:,O
N,O
 ,O
=,O
2,O
",",O
adult,O
:,O
N,O
 ,O
=,O
6,O
),O
",",O
active,O
MIS,O
-,O
C,O
patients,O
(,O
N,O
 ,O
=,O
9,O
),O
and,O
convalescent,O
(,O
recovered,O
),O
MIS,O
-,O
C,O
patients,O
(,O
N,O
 ,O
=,O
2,O
;,O
MIS,O
-,O
C,O
4,O
and,O
MIS,O
-,O
C,O
7,O
),O
.,O
Samples,O
for,O
mass,O
cytometry,O
analyses,O
were,O
performed,O
on,O
samples,O
from,O
age,O
-,O
matched,O
healthy,O
controls,O
(,O
n,O
 ,O
=,O
5,O
),O
",",O
acute,O
COVID,O
infection,O
in,O
young,O
adults,O
(,O
n,O
 ,O
=,O
7,O
),O
and,O
MIS,O
-,O
C,O
patients,O
(,O
n,O
 ,O
=,O
9,O
),O
.,O
There,O
is,O
obvious,O
interest,O
in,O
gaining,O
insights,O
into,O
the,O
epidemiology,O
and,O
evolution,O
of,O
the,O
virus,O
that,O
has,O
recently,O
emerged,O
in,O
humans,O
as,O
the,O
cause,O
of,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
.,O
This,O
is,O
particularly,O
true,O
for,O
the,O
work,O
of,O
Forster,O
et,O
al,O
.,O
",",O
since,O
their,O
findings,O
are,O
based,O
on,O
a,O
nonrepresentative,O
dataset,O
of,O
160,O
genomes,O
",",O
with,O
no,O
significant,O
correlation,O
between,O
prevalence,O
of,O
confirmed,O
cases,O
and,O
number,O
of,O
sequenced,O
strains,O
per,O
country,O
(,O
7,O
",",O
8),O
.,O
The,O
essential,O
role,O
of,O
representative,O
sampling,O
is,O
well,O
documented,O
in,O
the,O
literature,O
(,O
9,O
),O
",",O
but,O
was,O
not,O
acknowledged,O
by,O
the,O
authors,O
",",O
who,O
",",O
instead,O
",",O
claim,O
that,O
their,O
“,O
network,O
faithfully,O
traces,O
routes,O
of,O
infections,O
for,O
documented,O
[,O
COVID-19,O
],O
cases,O
",",O
”,O
without,O
taking,O
into,O
consideration,O
missing,O
viral,O
diversity,O
",",O
or,O
evaluating,O
multiple,O
transmission,O
hypotheses,O
that,O
would,O
be,O
consistent,O
with,O
sequence,O
data,O
",",O
or,O
even,O
providing,O
any,O
support,O
on,O
the,O
robustness,O
of,O
the,O
branching,O
pattern,O
in,O
their,O
network,O
.,O
Vero,O
cells,O
were,O
inoculated,O
with,O
equivalent,O
virus,O
titres,O
",",O
and,O
supernatants,O
were,O
collected,O
every,O
12,O
h,O
for,O
120,O
h,O
and,O
titrated,O
by,O
TCID50,O
.,O
Peak,O
titre,O
of,O
full,O
-,O
length,O
viruses,O
ranged,O
from,O
105,O
to,O
106,O
TCID50,O
ml−1,O
",",O
whereas,O
deletion,O
mutants,O
ranged,O
from,O
5×104−1×105,O
TCID50,O
ml−1,O
(,O
Fig,O
.,O
2a,O
),O
",",O
suggesting,O
that,O
these,O
deletions,O
may,O
confer,O
some,O
growth,O
inhibition,O
",",O
but,O
not,O
abrogate,O
it,O
.,O
Hu,O
/,O
Riyadh_KSA_2959_2015,O
cell,O
-,O
associated,O
titre,O
peaked,O
at,O
5×106,O
TCID50,O
ml−1,O
with,O
supernatant,O
peaking,O
at,O
5×104,O
TCID50,O
ml−1,O
.,O
Similarly,O
",",O
Hu,O
/,O
Riyadh_KSA-4050_2015,O
cell,O
-,O
associated,O
titre,O
peaked,O
at,O
1×106,O
TCID50,O
ml−1,O
with,O
supernatant,O
peaking,O
at,O
5×104,O
TCID50,O
ml−1,O
.,O
The,O
COVID-19,O
pandemic,O
caused,O
by,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
virus,O
is,O
of,O
particular,O
concern,O
for,O
people,O
with,O
rheumatic,O
disease,O
or,O
those,O
who,O
are,O
immunosuppressed,O
.,O
In,O
general,O
",",O
immunosuppression,O
and,O
the,O
presence,O
of,O
comorbidities,O
are,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
serious,O
infection,O
in,O
people,O
with,O
rheumatic,O
diseases1,O
therefore,O
",",O
people,O
with,O
rheumatic,O
disease,O
may,O
be,O
at,O
higher,O
risk,O
for,O
a,O
more,O
severe,O
course,O
with,O
COVID-19,O
",",O
including,O
hospitalisation,O
",",O
complications,O
and,O
death,O
.,O
Importantly,O
",",O
some,O
medications,O
used,O
to,O
treat,O
rheumatic,O
diseases,O
",",O
such,O
as,O
hydroxychloroquine,O
and,O
interleukin-6,O
(,O
IL-6,O
),O
inhibitors,O
",",O
are,O
being,O
studied,O
for,O
the,O
prevention,O
and/or,O
treatment,O
of,O
COVID-19,O
and,O
its,O
complications,O
including,O
cytokine,O
-,O
storm,O
.,O
At,O
present,O
",",O
the,O
implications,O
of,O
COVID-19,O
for,O
people,O
living,O
with,O
rheumatic,O
diseases,O
remain,O
poorly,O
understood,O
.,O
To,O
address,O
this,O
knowledge,O
gap,O
",",O
a,O
global,O
network,O
of,O
rheumatologists,O
",",O
scientists,O
and,O
patients,O
developed,O
a,O
physician,O
-,O
reported,O
case,O
registry,O
of,O
people,O
with,O
rheumatic,O
diseases,O
diagnosed,O
with,O
COVID-19.5,O
6,O
This,O
report,O
aims,O
to,O
(,O
1,O
),O
describe,O
the,O
demographic,O
and,O
clinical,O
characteristics,O
of,O
the,O
first,O
600,O
patients,O
submitted,O
to,O
the,O
COVID-19,B-Repository
Global,I-Repository
Rheumatology,I-Repository
Alliance,I-Repository
(C19-GRA),E-Repository
 ,O
physician,O
registry,O
and,O
(,O
2,O
),O
identify,O
factors,O
associated,O
with,O
hospitalisation,O
for,O
COVID-19,O
in,O
this,O
population,O
.,O
5–7,O
Briefly,O
",",O
C19-GRA,S-Repository
 ,O
data,O
regarding,O
individuals,O
with,O
rheumatic,O
diseases,O
diagnosed,O
with,O
COVID-19,O
are,O
captured,O
from,O
rheumatology,O
physicians,O
via,O
two,O
parallel,O
international,O
data,O
entry,O
portals,O
for,O
regulatory,O
reasons,O
:,O
one,O
limited,O
to,O
European,O
countries,O
(,O
eular.org/eular_covid19_database.cfm,S-URL
;,O
hosted,O
by,O
The,O
University,O
of,O
Manchester,O
",",O
UK,O
),O
and,O
a,O
second,O
for,O
all,O
other,O
sites,O
(,O
rheum-covid.org/provider-global/,S-URL
;,O
hosted,O
by,O
the,O
University,O
of,O
California,O
",",O
San,O
Francisco,O
",",O
California,O
",",O
USA,O
),O
.,O
COVID-19,O
diagnoses,O
were,O
predominately,O
made,O
through,O
PCR,O
testing,O
(,O
437,O
",",O
73,O
%,O
),O
",",O
followed,O
by,O
laboratory,O
assay,O
of,O
unknown,O
type,O
(,O
58,O
",",O
10,O
%,O
),O
",",O
CT,O
scan,O
(,O
42,O
",",O
7,O
%,O
),O
or,O
other,O
(,O
31,O
",",O
5,O
%,O
),O
(,O
individuals,O
could,O
be,O
tested,O
using,O
more,O
than,O
one,O
method,O
),O
.,O
The,O
median,O
number,O
of,O
days,O
from,O
COVID-19,O
symptom,O
onset,O
to,O
resolution,O
or,O
death,O
was,O
13,O
(,O
IQR,O
:,O
8–17,O
),O
.,O
NSAID,O
use,O
was,O
reported,O
less,O
frequently,O
among,O
hospitalised,O
patients,O
than,O
non,O
-,O
hospitalised,O
patients,O
(,O
16,O
%,O
vs,O
25,O
%,O
",",O
p=0.02,O
),O
",",O
while,O
there,O
was,O
a,O
higher,O
proportion,O
of,O
patients,O
receiving,O
high,O
doses,O
of,O
glucocorticoids,O
among,O
those,O
who,O
were,O
hospitalised,O
than,O
not,O
hospitalised,O
(,O
16,O
%,O
vs,O
7,O
%,O
for,O
doses,O
≥10,O
 ,O
mg,O
/,O
day,O
",",O
p=0.01,O
),O
.,O
Treatment,O
with,O
b,O
/,O
tsDMARD,O
monotherapy,O
just,O
prior,O
to,O
COVID-19,O
diagnosis,O
was,O
significantly,O
associated,O
with,O
a,O
lower,O
odds,O
of,O
hospitalisation,O
compared,O
with,O
no,O
DMARD,O
therapy,O
(,O
OR=0.46,O
",",O
95,O
%,O
 ,O
CI,O
0.22,O
to,O
0.93,O
;,O
p=0.03,O
),O
.,O
We,O
found,O
no,O
significant,O
association,O
between,O
antimalarial,O
therapy,O
and,O
hospitalisation,O
(,O
OR=0.94,O
",",O
95,O
%,O
 ,O
CI,O
0.57,O
to,O
1.57,O
;,O
p=0.82,O
),O
after,O
adjusting,O
for,O
sex,O
",",O
age,O
over,O
65,O
years,O
",",O
rheumatic,O
disease,O
",",O
smoking,O
status,O
",",O
comorbidities,O
",",O
other,O
csDMARD,O
monotherapy,O
",",O
b,O
/,O
tsDMARD,O
monotherapy,O
",",O
csDMARD,O
-,O
b,O
/,O
tsDMARD,O
combination,O
therapy,O
(,O
excluding,O
antimalarials,O
),O
",",O
NSAID,O
use,O
and,O
glucocorticoid,O
dose,O
.,O
A,O
significant,O
inverse,O
association,O
between,O
any,O
anti,O
-,O
TNF,O
therapy,O
and,O
hospitalisation,O
was,O
found,O
(,O
OR=0.40,O
",",O
95,O
%,O
 ,O
CI,O
0.19,O
to,O
0.81,O
;,O
p=0.01,O
),O
",",O
after,O
controlling,O
for,O
sex,O
",",O
age,O
over,O
65,O
years,O
",",O
rheumatic,O
disease,O
",",O
smoking,O
",",O
comorbidities,O
",",O
csDMARD,O
monotherapy,O
",",O
other,O
b,O
/,O
tsDMARD,O
monotherapy,O
",",O
csDMARD,O
-,O
b,O
/,O
tsDMARD,O
combination,O
therapy,O
(,O
excluding,O
anti,O
-,O
TNF,O
),O
",",O
NSAID,O
use,O
and,O
glucocorticoid,O
dose,O
.,O
Prior,O
to,O
this,O
report,O
",",O
there,O
had,O
been,O
several,O
small,O
case,O
series,O
of,O
COVID-19,O
in,O
patients,O
with,O
rheumatic,O
disease,O
reported,O
from,O
Europe,O
.,O
With,O
few,O
"exceptions,12",O
13,O
prior,O
large,O
descriptive,O
studies,O
of,O
patients,O
with,O
COVID-19,O
from,O
China,O
",",O
Europe,O
and,O
the,O
USA,O
have,O
not,O
included,O
rheumatic,O
disease,O
in,O
their,O
baseline,O
comorbidities,O
.,O
These,O
studies,O
have,O
not,O
allowed,O
for,O
further,O
inference,O
on,O
the,O
characteristics,O
of,O
patients,O
with,O
rheumatic,O
disease,O
and,O
their,O
associations,O
with,O
COVID-19,O
severity,O
.,O
In,O
accordance,O
with,O
previous,O
studies,O
of,O
COVID-19,O
in,O
different,O
populations,O
",",O
we,O
found,O
that,O
patients,O
with,O
comorbidities,O
such,O
as,O
hypertension,O
",",O
cardiovascular,O
disease,O
and,O
diabetes,O
had,O
higher,O
odds,O
of,O
hospitalisation,O
.,O
The,O
use,O
of,O
hydroxychloroquine,O
for,O
the,O
treatment,O
of,O
COVID-19,O
",",O
which,O
was,O
based,O
on,O
in,O
vitro,O
studies,O
",",O
has,O
had,O
mixed,O
results,O
.,O
23,O
24,O
Two,O
randomised,O
controlled,O
trials,O
of,O
hydroxychloroquine,O
had,O
conflicting,O
findings.25,O
26,O
A,O
phase,O
IIb,O
randomised,O
controlled,O
trial,O
comparing,O
two,O
doses,O
of,O
chloroquine,O
among,O
patients,O
hospitalised,O
with,O
COVID-19,O
with,O
historical,O
controls,O
from,O
Wuhan,O
detected,O
a,O
negative,O
safety,O
signal,O
—,O
QTc,O
prolongation,O
—,O
but,O
no,O
clinical,O
benefit,O
.,O
We,O
also,O
did,O
not,O
detect,O
a,O
significant,O
association,O
between,O
NSAID,O
use,O
and,O
hospitalisation,O
in,O
adjusted,O
analyses,O
.,O
Although,O
no,O
prior,O
data,O
in,O
patients,O
with,O
COVID-19,O
have,O
supported,O
a,O
deleterious,O
effect,O
of,O
NSAIDs,O
on,O
clinical,O
outcomes,O
",",O
early,O
reports,O
cautioned,O
against,O
the,O
use,O
of,O
NSAIDs,O
suggesting,O
harm,O
when,O
used,O
during,O
the,O
clinical,O
course,O
of,O
COVID-19.30,O
These,O
observations,O
",",O
while,O
anecdotal,O
",",O
may,O
also,O
relate,O
to,O
confounding,O
by,O
indication,O
",",O
since,O
NSAIDs,O
are,O
also,O
often,O
sold,O
over,O
-,O
the,O
-,O
counter,O
and,O
may,O
not,O
be,O
documented,O
in,O
hospital,O
records,O
with,O
the,O
same,O
accuracy,O
as,O
prescription,O
medications,O
",",O
leading,O
to,O
a,O
reporting,O
bias,O
.,O
Although,O
we,O
caution,O
against,O
causal,O
inference,O
regarding,O
drug,O
effects,O
given,O
significant,O
potential,O
for,O
residual,O
confounding,O
in,O
our,O
study,O
",",O
we,O
also,O
note,O
that,O
there,O
is,O
biological,O
plausibility,O
for,O
the,O
potential,O
benefit,O
of,O
biologic,O
medications,O
in,O
treating,O
COVID-19,O
",",O
as,O
evidenced,O
by,O
those,O
with,O
more,O
severe,O
disease,O
having,O
higher,O
levels,O
of,O
cytokines,O
",",O
including,O
IL-6,O
and,O
TNF.31,O
32,O
The,O
use,O
of,O
IL-6,O
inhibitors,O
is,O
being,O
investigated,O
for,O
COVID-19,O
",",O
particularly,O
in,O
cases,O
complicated,O
by,O
aberrant,O
inflammatory,O
responses,O
or,O
‘,O
cytokine,O
storm,O
’,O
.,O
33,O
34,O
Anti,O
-,O
TNFs,O
have,O
also,O
been,O
suggested,O
as,O
a,O
potential,O
therapy,O
in,O
COVID-19,O
",",O
but,O
this,O
has,O
been,O
based,O
solely,O
on,O
preclinical,O
data.35,O
Randomised,O
",",O
placebo,O
-,O
controlled,O
trials,O
are,O
needed,O
to,O
clarify,O
potential,O
benefits,O
or,O
harms,O
of,O
biologic,O
therapies,O
in,O
treating,O
COVID-19,O
.,O
Strengths,O
of,O
our,O
study,O
include,O
the,O
first,O
large,O
analysis,O
of,O
patients,O
with,O
rheumatic,O
diseases,O
and,O
COVID-19,O
.,O
The,O
registry,O
collects,O
information,O
on,O
specific,O
rheumatic,O
disease,O
diagnoses,O
",",O
which,O
to,O
date,O
have,O
not,O
been,O
captured,O
in,O
large,O
",",O
published,O
case,O
series,O
of,O
COVID-19.15,O
This,O
series,O
of,O
cases,O
demonstrates,O
that,O
the,O
majority,O
of,O
patients,O
with,O
rheumatic,O
diseases,O
captured,O
in,O
our,O
registry,O
recover,O
from,O
COVID-19,O
.,O
Results,O
support,O
the,O
guidance,O
issued,O
by,O
the,O
American,O
College,O
of,O
Rheumatology,O
and,O
the,O
European,O
League,O
Against,O
Rheumatism,O
",",O
which,O
suggest,O
continuing,O
rheumatic,O
medications,O
in,O
the,O
absence,O
of,O
COVID-19,O
infection,O
or,O
SARS,O
-,O
CoV-2,O
exposure.36,O
37,O
Objectives,O
 ,O
COVID-19,O
outcomes,O
in,O
people,O
with,O
rheumatic,O
diseases,O
remain,O
poorly,O
understood,O
.,O
The,O
aim,O
was,O
to,O
examine,O
demographic,O
and,O
clinical,O
factors,O
associated,O
with,O
COVID-19,O
hospitalisation,O
status,O
in,O
people,O
with,O
rheumatic,O
disease,O
.,O
Methods,O
 ,O
Case,O
series,O
of,O
individuals,O
with,O
rheumatic,O
disease,O
and,O
COVID-19,O
from,O
the,O
COVID-19,B-Repository
Global,I-Repository
Rheumatology,I-Repository
Alliance,E-Repository
 ,O
registry,O
:,O
24,O
March,O
2020,O
to,O
20,O
April,O
2020,O
.,O
Non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
drug,O
(,O
NSAID,O
),O
use,O
was,O
not,O
associated,O
with,O
hospitalisation,O
status,O
(,O
OR,O
0.64,O
",",O
95,O
%,O
 ,O
CI,O
0.39,O
to,O
1.06,O
),O
.,O
Neither,O
exposure,O
to,O
DMARDs,O
nor,O
NSAIDs,O
were,O
associated,O
with,O
increased,O
odds,O
of,O
hospitalisation,O
.,O
Thecoronavirus,O
disease-19,O
(,O
COVID-19,O
),O
caused,O
by,O
SARS,O
-,O
CoV-2,O
infection,O
can,O
lead,O
to,O
a,O
series,O
of,O
clinical,O
settings,O
from,O
non,O
-,O
symptomatic,O
viral,O
carriers,O
/,O
spreaders,O
to,O
severe,O
illness,O
characterized,O
by,O
acute,O
respiratory,O
distress,O
syndrome,O
(,O
ARDS,O
),O
.,O
1,O
",",O
2,O
",",O
3,O
A,O
sizable,O
part,O
of,O
patients,O
with,O
COVID-19,O
have,O
mild,O
/,O
moderate,O
clinical,O
symptoms,O
at,O
the,O
early,O
stage,O
of,O
infection,O
",",O
but,O
the,O
disease,O
progression,O
may,O
become,O
quite,O
rapid,O
in,O
the,O
later,O
stage,O
with,O
ARDS,O
as,O
the,O
common,O
manifestation,O
and,O
followed,O
by,O
critical,O
multiple,O
organ,O
failure,O
",",O
causing,O
a,O
high,O
mortality,O
rate,O
of,O
7,O
-,O
10,O
%,O
in,O
the,O
elderly,O
population,O
with,O
non,O
-,O
communicable,O
chronic,O
disease,O
(,O
NCD,O
),O
.,O
[,O
"1,2,4",O
],O
The,O
pathological,O
evidences,O
in,O
the,O
lung,O
of,O
fatal,O
cases,O
are,O
fundamental,O
for,O
the,O
mechanistic,O
understanding,O
and,O
treatment,O
of,O
severe,O
patients,O
with,O
COVID-19,O
.,O
In,O
this,O
study,O
",",O
we,O
investigated,O
the,O
critical,O
pathological,O
changes,O
in,O
the,O
lung,O
of,O
severe,O
COVID-19,O
patients,O
.,O
We,O
hope,O
this,O
work,O
may,O
contribute,O
in,O
a,O
significant,O
way,O
to,O
the,O
understanding,O
of,O
the,O
mechanisms,O
underlying,O
the,O
phenotype,O
of,O
severe,O
cases,O
in,O
COVID-19,O
and,O
appropriate,O
development,O
of,O
treatment,O
strategies,O
.,O
The,O
two,O
deceased,O
COVID-19,O
patients,O
",",O
with,O
the,O
diagnosis,O
confirmed,O
by,O
reverse,O
transcriptase,O
-,O
polymerase,O
chain,O
reaction,O
(,O
RT,O
-,O
PCR,O
),O
for,O
SARS,O
-,O
CoV-2,O
",",O
were,O
a,O
53,O
years,O
old,O
female,O
(,O
Patient,O
No,O
1,O
),O
and,O
a,O
62,O
years,O
old,O
male,O
(,O
Patient,O
No,O
2,O
),O
(,O
Table,O
1,O
),O
.,O
The,O
pathological,O
investigations,O
of,O
severe,O
patients,O
are,O
pivotal,O
for,O
the,O
understanding,O
of,O
pathogenesis,O
of,O
COVID-19,O
and,O
assessment,O
of,O
clinical,O
treatments,O
.,O
Special,O
attention,O
was,O
given,O
to,O
the,O
abnormalities,O
in,O
lungs,O
",",O
which,O
are,O
the,O
main,O
damaged,O
organ,O
in,O
severe,O
COVID-19,O
patients,O
.,O
It,O
is,O
one,O
of,O
common,O
manifestations,O
in,O
the,O
diffuse,O
alveolar,O
damage,O
(,O
DAD,O
),O
that,O
existed,O
in,O
acute,O
respiratory,O
distress,O
syndrome,O
(,O
ARDS,O
),O
not,O
only,O
in,O
COVID19,O
but,O
also,O
in,O
SARS,O
and,O
MERS,O
.,O
9,O
",",O
10,O
",",O
11,O
",",O
12,O
",",O
13,O
Though,O
the,O
endothelial,O
injury,O
and,O
thrombosis,O
were,O
not,O
common,O
in,O
our,O
cases,O
",",O
resent,O
studied,O
showed,O
the,O
high,O
incidence,O
of,O
thromboembolic,O
events,O
in,O
segmental,O
/,O
subsegmental,O
pulmonary,O
arterial,O
vessels,O
[,O
14,O
],O
",",O
pulmonary,O
embolism,O
and,O
deep,O
venous,O
thrombosis,O
[,O
15,O
],O
",",O
and,O
microvascular,O
thrombosis,O
[,O
16,O
],O
",",O
suggested,O
coagulopathy,O
in,O
severe,O
COVID-19,O
infection,O
patients,O
.,O
However,O
",",O
the,O
pathology,O
of,O
lungs,O
in,O
COVID-19,O
also,O
exhibited,O
unique,O
features,O
as,O
compared,O
to,O
SARS,O
.,O
In,O
COVID-19,O
",",O
we,O
found,O
mucous,O
plugs,O
in,O
all,O
respiratory,O
tracts,O
",",O
terminal,O
bronchioles,O
and,O
pulmonary,O
alveoli,O
",",O
which,O
was,O
not,O
described,O
in,O
SARS,O
.,O
Another,O
unique,O
feature,O
of,O
COVID-19,O
was,O
the,O
excessive,O
mucus,O
secretion,O
with,O
serous,O
and,O
fibrinous,O
exudation,O
",",O
which,O
could,O
aggravate,O
the,O
dysfunction,O
of,O
ventilation,O
.,O
Therefore,O
",",O
the,O
pathogenic,O
mechanisms,O
responsible,O
for,O
the,O
hypoxemia,O
could,O
be,O
somehow,O
different,O
between,O
COVID-19,O
and,O
SARS,O
patients,O
.,O
We,O
assumed,O
these,O
lesions,O
could,O
play,O
a,O
part,O
in,O
the,O
sputum,O
suction,O
failure,O
in,O
very,O
severe,O
COVID-19,O
patients,O
.,O
In,O
addition,O
",",O
the,O
differences,O
between,O
COVID-19,O
and,O
SARS,O
could,O
be,O
found,O
at,O
the,O
level,O
of,O
immune,O
cell,O
involvement,O
.,O
In,O
the,O
case,O
of,O
COVID-19,O
",",O
the,O
viral,O
infection,O
of,O
aggregated,O
alveolar,O
macrophages,O
was,O
obvious,O
from,O
early,O
phase,O
to,O
the,O
late,O
stage,O
",",O
according,O
to,O
our,O
study,O
and,O
the,O
results,O
in,O
recent,O
reports,O
of,O
pulmonary,O
pathology,O
[,O
"17,20",O
],O
.,O
The,O
spectacular,O
infiltration,O
and,O
activation,O
of,O
alveolar,O
macrophages,O
in,O
COVID-19,O
might,O
represent,O
the,O
shift,O
of,O
classically,O
activated,O
phenotype,O
(,O
M1,O
),O
to,O
alternatively,O
activated,O
phenotype,O
(,O
M2,O
),O
of,O
these,O
cells,O
",",O
whereas,O
this,O
shift,O
",",O
particularly,O
in,O
the,O
case,O
of,O
antibody,O
-,O
dependent,O
enhancement,O
(,O
ADE,O
),O
",",O
could,O
contribute,O
to,O
the,O
inflammatory,O
injuries,O
and,O
fibrosis,O
of,O
respiratory,O
tracts,O
.,O
[,O
21,O
],O
Recently,O
",",O
the,O
Tocilizumab,O
therapy,O
was,O
recommended,O
in,O
the,O
Guideline,O
of,O
Diagnosis,O
and,O
Treatment,O
of,O
COVID-19,O
(,O
version,O
7,O
),O
by,O
the,O
National,O
Health,O
Commission,O
in,O
China,O
to,O
control,O
the,O
CRS,O
.,O
While,O
potential,O
benefits,O
of,O
this,O
treatment,O
still,O
require,O
definite,O
evidence,O
",",O
our,O
pathological,O
findings,O
tend,O
to,O
support,O
the,O
clinical,O
practice,O
of,O
the,O
anti,O
-,O
IL-6,O
/,O
IL-6R,O
antibody,O
treatment,O
among,O
severe,O
COVID-19,O
patients,O
in,O
order,O
to,O
inhibit,O
the,O
vicious,O
cycle,O
of,O
alveolar,O
macrophage,O
activation,O
and,O
inflammatory,O
injuries,O
.,O
On,O
the,O
other,O
hand,O
",",O
the,O
use,O
of,O
anti,O
-,O
viral,O
effect,O
of,O
convalescent,O
plasma,O
from,O
recovered,O
patients,O
has,O
been,O
shown,O
to,O
be,O
effective,O
in,O
the,O
treatment,O
of,O
severe,O
cases,O
of,O
COVID-19,O
.,O
[,O
24,O
],O
The,O
novel,O
coronavirus,O
pneumonia,O
COVID-19,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
infection,O
could,O
lead,O
to,O
a,O
serious,O
of,O
clinical,O
symptoms,O
and,O
severe,O
illness,O
",",O
including,O
acute,O
respiratory,O
distress,O
syndrome,O
(,O
ARDS,O
),O
and,O
fatal,O
organ,O
failure,O
.,O
We,O
report,O
the,O
fundamental,O
pathological,O
investigation,O
in,O
the,O
lungs,O
and,O
other,O
organs,O
of,O
fatal,O
cases,O
for,O
the,O
mechanistic,O
understanding,O
of,O
severe,O
COVID-19,O
and,O
the,O
development,O
of,O
specific,O
therapy,O
in,O
these,O
cases,O
.,O
The,O
autopsy,O
and,O
pathological,O
investigations,O
of,O
specimens,O
were,O
performed,O
on,O
bodies,O
of,O
two,O
deceased,O
cases,O
with,O
COVID-19,O
.,O
According,O
to,O
the,O
mean,O
expression,O
of,O
ACE2,O
",",O
the,O
mucosa,O
of,O
oral,O
cavity,O
could,O
express,O
ACE2,O
",",O
and,O
the,O
results,O
were,O
validated,O
by,O
the,O
data,O
of,O
normal,O
tissues,O
from,O
the,O
FANTOM5,B-Dataset
CAGE,E-Dataset
 ,O
dataset,O
(,O
Fig,O
.,O
1b,O
),O
.,O
To,O
investigate,O
the,O
potential,O
route,O
of,O
2019,O
-,O
nCov,O
infection,O
on,O
the,O
mucosa,O
of,O
oral,O
cavity,O
",",O
bulk,O
RNA,O
-,O
seq,O
profiles,O
from,O
two,O
public,O
databases,O
including,O
The,B-Repository
Cancer,I-Repository
Genome,I-Repository
Atlas,I-Repository
(TCGA),E-Repository
 ,O
and,O
Functional,B-Dataset
Annotation,I-Dataset
of,I-Dataset
The,I-Dataset
Mammalian,I-Dataset
Genome,I-Dataset
Cap,I-Dataset
Analysis,I-Dataset
of,I-Dataset
Gene,I-Dataset
Expression,I-Dataset
(FANTOM5,I-Dataset
CAGE),E-Dataset
 ,O
dataset,O
were,O
collected,O
.,O
A,O
case,O
-,O
patient,O
in,O
the,O
Riyadh,O
region,O
who,O
reported,O
no,O
high,O
-,O
risk,O
exposures,O
had,O
a,O
66,O
-,O
nt,O
in,O
-,O
frame,O
deletion,O
in,O
ORF1a,O
(,O
Figure,O
;,O
GenBank,S-Repository
 ,O
accession,O
no,O
.,O
MK462255,S-AccessionNumber
),O
.,O
An,O
accurate,O
grasp,O
of,O
COVID-19,O
situation,O
is,O
considered,O
highly,O
important,O
.,O
The,O
website,O
we,O
launched,O
provides,O
graphs,O
of,O
COVID-19,O
cases,O
and,O
deaths,O
per,O
one,O
million,O
population,O
over,O
time,O
including,O
trajectory,O
analysis,O
",",O
and,O
one,O
can,O
easily,O
grasp,O
the,O
COVID-19,O
trend,O
and,O
adequately,O
compare,O
the,O
situation,O
between,O
countries,O
through,O
this,O
interactive,O
graph,O
system,O
.,O
Importantly,O
",",O
data,O
suggest,O
that,O
the,O
severity,O
and,O
mortality,O
risk,O
of,O
nosocomial,O
transmission,O
may,O
be,O
greater,O
than,O
for,O
community,O
-,O
acquired,O
COVID-19,O
(,O
McMichael,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Protection,O
of,O
HCWs,O
and,O
their,O
families,O
from,O
the,O
acquisition,O
of,O
COVID-19,O
in,O
hospitals,O
is,O
paramount,O
",",O
and,O
underscored,O
by,O
rising,O
numbers,O
of,O
HCW,O
deaths,O
nationally,O
and,O
internationally,O
(,O
Cook,O
et,O
al,O
.,O
",",O
2020,O
;,O
CDC,O
COVID-19,O
Response,O
Team,O
",",O
2020,O
),O
.,O
The,O
clinical,O
presentation,O
of,O
COVID-19,O
can,O
include,O
minimal,O
or,O
no,O
symptoms,O
(,O
WHO,O
",",O
2020a,O
),O
.,O
Asymptomatic,O
or,O
pre,O
-,O
symptomatic,O
transmission,O
is,O
clearly,O
reported,O
and,O
is,O
estimated,O
to,O
account,O
for,O
around,O
half,O
of,O
all,O
cases,O
of,O
COVID-19,O
(,O
He,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Recent,O
modelling,O
has,O
suggested,O
that,O
weekly,O
testing,O
of,O
asymptomatic,O
HCWs,O
could,O
reduce,O
onward,O
transmission,O
by,O
16–23,O
%,O
",",O
on,O
top,O
of,O
isolation,O
based,O
on,O
symptoms,O
",",O
provided,O
results,O
are,O
available,O
within,O
24,O
hr,O
(,O
Imperial,O
College,O
COVID-19,O
Response,O
Team,O
",",O
2020,O
),O
.,O
The,O
need,O
for,O
widespread,O
adoption,O
of,O
an,O
expanded,O
screening,O
programme,O
for,O
asymptomatic,O
",",O
as,O
well,O
as,O
symptomatic,O
HCWs,O
",",O
is,O
apparent,O
(,O
Imperial,O
College,O
COVID-19,O
Response,O
Team,O
",",O
2020,O
;,O
Black,O
et,O
al,O
.,O
",",O
2020,O
;,O
Gandhi,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
21,O
individuals,O
underwent,O
repeat,O
testing,O
for,O
a,O
variety,O
of,O
reasons,O
",",O
including,O
evolving,O
symptoms,O
(,O
n,O
 ,O
=,O
 ,O
3,O
),O
and,O
scoring,O
‘,O
medium,O
’,O
probability,O
on,O
clinical,O
COVID-19,O
criteria,O
(,O
Tables,O
1–2,O
),O
(,O
n,O
 ,O
=,O
 ,O
11,O
),O
.,O
Table,O
3,O
outlines,O
the,O
total,O
number,O
of,O
SARS,O
-,O
CoV-2,O
tests,O
performed,O
in,O
each,O
screening,O
group,O
(,O
HCW,O
asymptomatic,O
",",O
HCW,O
symptomatic,O
",",O
and,O
HCW,O
symptomatic,O
household,O
contact,O
),O
categorised,O
according,O
to,O
the,O
ward,O
with,O
the,O
highest,O
anticipated,O
risk,O
of,O
exposure,O
to,O
COVID-19,O
(,O
‘,O
red,O
’,O
",",O
high,O
;,O
‘,O
amber,O
’,O
",",O
medium,O
;,O
‘,O
green,O
’,O
",",O
low,O
;,O
Tables,O
4–5,O
),O
.,O
Each,O
individual,O
in,O
the,O
HCW,O
asymptomatic,O
screening,O
group,O
was,O
contacted,O
by,O
telephone,O
to,O
establish,O
a,O
clinical,O
history,O
",",O
and,O
COVID-19,O
probability,O
criteria,O
(,O
Table,O
1,O
),O
were,O
retrospectively,O
applied,O
to,O
categorise,O
any,O
symptoms,O
in,O
the,O
month,O
prior,O
to,O
testing,O
(,O
Figure,O
2,O
),O
.,O
Individuals,O
captured,O
by,O
the,O
HCW,O
asymptomatic,O
screening,O
group,O
were,O
generally,O
asymptomatic,O
at,O
the,O
time,O
of,O
screening,O
",",O
however,O
could,O
be,O
divided,O
into,O
three,O
sub,O
-,O
groups,O
:,O
(,O
i,O
),O
HCWs,O
with,O
no,O
symptoms,O
at,O
all,O
",",O
(,O
ii,O
),O
HCWs,O
with,O
(,O
chiefly,O
low,O
-,O
to,O
-,O
medium,O
COVID-19,O
probability,O
),O
symptoms,O
commencing,O
 ,O
≤7,O
days,O
prior,O
to,O
screening,O
and,O
(,O
iii,O
),O
HCWs,O
with,O
(,O
typically,O
high,O
COVID-19,O
probability,O
),O
symptoms,O
commencing,O
 ,O
>,O
7,O
days,O
prior,O
to,O
screening,O
(,O
Figure,O
2,O
),O
.,O
Wards,O
are,O
coloured,O
(,O
‘,O
green,O
’,O
",",O
‘,O
amber,O
’,O
",",O
‘,O
red,O
’,O
),O
according,O
to,O
risk,O
of,O
anticipated,O
exposure,O
to,O
COVID-19,O
(,O
Table,O
4,O
),O
.,O
Ward,O
F,O
is,O
an,O
elderly,O
care,O
ward,O
",",O
designated,O
as,O
a,O
‘,O
green,O
’,O
area,O
with,O
Scenario,O
0,O
PPE,O
(,O
Tables,O
4–5,O
),O
",",O
with,O
a,O
high,O
proportion,O
of,O
COVID-19,O
vulnerable,O
patients,O
due,O
to,O
age,O
and,O
comorbidity,O
.,O
It,O
was,O
subsequently,O
found,O
that,O
two,O
further,O
staff,O
members,O
from,O
ward,O
F,O
had,O
previously,O
been,O
admitted,O
to,O
hospital,O
with,O
severe,O
COVID-19,O
infection,O
.,O
Ward,O
Q,O
is,O
a,O
general,O
medical,O
ward,O
designated,O
as,O
a,O
‘,O
red,O
’,O
clinical,O
area,O
for,O
the,O
care,O
of,O
COVID-19,O
positive,O
patients,O
",",O
with,O
a,O
Scenario,O
1,O
PPE,O
protocol,O
(,O
Tables,O
4–5,O
),O
.,O
The,O
majority,O
of,O
individuals,O
who,O
tested,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
after,O
screening,O
due,O
to,O
the,O
presence,O
of,O
symptoms,O
had,O
high,O
COVID-19,O
probability,O
(,O
Table,O
7,O
),O
.,O
Whilst,O
temporally,O
associated,O
",",O
it,O
can,O
not,O
be,O
assumed,O
that,O
these,O
symptoms,O
necessarily,O
resulted,O
from,O
COVID-19,O
.,O
12/30,O
(,O
40,O
%,O
),O
individuals,O
from,O
the,O
HCW,O
asymptomatic,O
screening,O
group,O
reported,O
symptoms,O
 ,O
>,O
 ,O
7,O
days,O
prior,O
to,O
testing,O
",",O
and,O
the,O
majority,O
experiencing,O
symptoms,O
consistent,O
with,O
a,O
high,O
probability,O
of,O
COVID-19,O
had,O
appropriately,O
self,O
-,O
isolated,O
during,O
that,O
period,O
.,O
Patients,O
with,O
COVID-19,O
can,O
remain,O
SARS,O
-,O
CoV-2,O
PCR,O
positive,O
for,O
a,O
median,O
of,O
20,O
days,O
(,O
IQR,O
17–24,O
),O
after,O
symptom,O
onset,O
(,O
Zhou,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
and,O
the,O
limited,O
data,O
available,O
suggest,O
viable,O
virus,O
is,O
not,O
shed,O
beyond,O
eight,O
days,O
(,O
Wölfel,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
This,O
approach,O
was,O
based,O
on,O
the,O
following,O
:,O
low,O
seasonal,O
incidence,O
of,O
alternative,O
viral,O
causes,O
of,O
high,O
COVID-19,O
probability,O
symptoms,O
in,O
the,O
UK,O
(,O
Public,O
Health,O
England,O
",",O
2018,O
),O
",",O
the,O
high,O
potential,O
for,O
SARS,O
-,O
CoV-2,O
exposure,O
during,O
the,O
pandemic,O
and,O
the,O
potential,O
for,O
prolonged,O
",",O
non,O
-,O
infectious,O
shedding,O
of,O
viral,O
RNA,O
(,O
Zhou,O
et,O
al,O
.,O
",",O
2020,O
;,O
Wölfel,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
More,O
comprehensive,O
data,O
will,O
parametrise,O
workforce,O
depletion,O
and,O
COVID-19,O
transmission,O
models,O
.,O
The,O
incorporation,O
of,O
additional,O
information,O
including,O
staffing,O
levels,O
",",O
absenteeism,O
",",O
and,O
changes,O
in,O
proportions,O
of,O
staff,O
self,O
-,O
isolating,O
before,O
and,O
after,O
the,O
introduction,O
of,O
widespread,O
testing,O
will,O
better,O
inform,O
the,O
impact,O
of,O
screening,O
at,O
a,O
national,O
and,O
international,O
level,O
.,O
Such,O
models,O
will,O
be,O
critical,O
for,O
optimising,O
the,O
impact,O
on,O
occupationally,O
-,O
acquired,O
COVID-19,O
",",O
and,O
reducing,O
the,O
likelihood,O
that,O
hospitals,O
become,O
hubs,O
for,O
sustained,O
COVID-19,O
transmission,O
.,O
The,O
first,O
(,O
HCW,O
symptomatic,O
",",O
and,O
HCW,O
symptomatic,O
household,O
contact,O
screening,O
groups,O
),O
allowed,O
any,O
patient,O
-,O
facing,O
or,O
non,O
-,O
patient,O
-,O
facing,O
hospital,O
employee,O
(,O
HCW,O
),O
to,O
refer,O
themselves,O
or,O
a,O
household,O
contact,O
",",O
including,O
children,O
",",O
should,O
they,O
develop,O
symptoms,O
suggestive,O
of,O
COVID-19,O
.,O
High,O
throughput,O
clinical,O
areas,O
where,O
staff,O
might,O
be,O
exposed,O
to,O
large,O
numbers,O
of,O
suspected,O
COVID-19,O
patients,O
were,O
also,O
prioritised,O
for,O
staff,O
screening,O
.,O
These,O
included,O
the,O
Emergency,O
Department,O
",",O
the,O
COVID-19,O
Assessment,O
Unit,O
",",O
and,O
a,O
number,O
of,O
‘,O
red,O
’,O
inpatient,O
wards,O
.,O
We,O
devised,O
a,O
scoring,O
system,O
to,O
determine,O
the,O
clinical,O
probability,O
of,O
COVID-19,O
based,O
on,O
symptoms,O
from,O
existing,O
literature,O
(,O
Wang,O
et,O
al,O
.,O
",",O
2020,O
;,O
Giacomelli,O
et,O
al,O
.,O
",",O
2020,O
;,O
Table,O
1,O
),O
.,O
Self,O
-,O
isolation,O
and,O
household,O
quarantine,O
advice,O
was,O
determined,O
by,O
estimating,O
the,O
pre,O
-,O
test,O
probability,O
of,O
COVID-19,O
(,O
high,O
",",O
medium,O
or,O
low,O
),O
in,O
those,O
with,O
symptoms,O
",",O
based,O
on,O
the,O
presence,O
or,O
absence,O
of,O
typical,O
features,O
(,O
Tables,O
1–2,O
),O
.,O
Pauci,O
-,O
symptomatic,O
individuals,O
were,O
defined,O
as,O
those,O
with,O
low,O
-,O
probability,O
clinical,O
COVID-19,O
criteria,O
(,O
Table,O
2,O
),O
.,O
Samples,O
were,O
sequenced,O
as,O
part,O
of,O
the,O
COVID-19,O
Genomics,O
UK,O
Consortium,O
",",O
COG,O
-,O
UK,O
),O
",",O
a,O
partnership,O
of,O
NHS,O
organisations,O
",",O
academic,O
institutions,O
",",O
UK,O
public,O
health,O
agencies,O
and,O
the,O
Wellcome,O
Sanger,O
Institute,O
.,O
12/30,O
(,O
40,O
%,O
),O
had,O
experienced,O
symptoms,O
compatible,O
with,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19)>7,O
days,O
prior,O
to,O
testing,O
",",O
most,O
self,O
-,O
isolating,O
",",O
returning,O
well,O
.,O
eLife,O
digest,O
 ,O
Patients,O
admitted,O
to,O
NHS,O
hospitals,O
are,O
now,O
routinely,O
screened,O
for,O
SARS,O
-,O
CoV-2,O
(,O
the,O
virus,O
that,O
causes,O
COVID-19,O
),O
",",O
and,O
isolated,O
from,O
other,O
patients,O
if,O
necessary,O
.,O
Over,O
"1,000",O
staff,O
members,O
at,O
a,O
large,O
UK,O
hospital,O
who,O
felt,O
they,O
were,O
well,O
enough,O
to,O
work,O
",",O
and,O
did,O
not,O
fit,O
the,O
government,O
criteria,O
for,O
COVID-19,O
infection,O
",",O
were,O
tested,O
.,O
On,O
closer,O
questioning,O
",",O
around,O
one,O
in,O
five,O
reported,O
no,O
symptoms,O
",",O
two,O
in,O
five,O
very,O
mild,O
symptoms,O
that,O
they,O
had,O
dismissed,O
as,O
inconsequential,O
",",O
and,O
a,O
further,O
two,O
in,O
five,O
reported,O
COVID-19,O
symptoms,O
that,O
had,O
stopped,O
more,O
than,O
a,O
week,O
previously,O
.,O
In,O
parallel,O
",",O
healthcare,O
workers,O
with,O
symptoms,O
of,O
COVID-19,O
(,O
and,O
their,O
household,O
contacts,O
),O
who,O
were,O
self,O
-,O
isolating,O
were,O
also,O
tested,O
",",O
in,O
order,O
to,O
allow,O
those,O
without,O
the,O
virus,O
to,O
quickly,O
return,O
to,O
work,O
and,O
bolster,O
a,O
stretched,O
workforce,O
.,O
Finally,O
",",O
the,O
rates,O
of,O
infection,O
were,O
examined,O
to,O
probe,O
how,O
the,O
virus,O
could,O
have,O
spread,O
through,O
the,O
hospital,O
and,O
among,O
staff,O
–,O
and,O
in,O
particular,O
",",O
to,O
understand,O
whether,O
rates,O
of,O
infection,O
were,O
greater,O
among,O
staff,O
working,O
in,O
areas,O
devoted,O
to,O
COVID-19,O
patients,O
.,O
Despite,O
wearing,O
appropriate,O
personal,O
protective,O
equipment,O
",",O
healthcare,O
workers,O
in,O
these,O
areas,O
were,O
almost,O
three,O
times,O
more,O
likely,O
to,O
test,O
positive,O
than,O
those,O
working,O
in,O
areas,O
without,O
COVID-19,O
patients,O
.,O
The,O
main,O
phase,O
and,O
that,O
is,O
more,O
pathologically,O
relevant,O
to,O
COVID‐19,O
is,O
",",O
however,O
",",O
the,O
delayed,O
pneumonia,O
which,O
itself,O
could,O
vary,O
depending,O
on,O
the,O
disease,O
severity,O
level,O
(,O
Li,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Inhibiting,O
TMPRSS2,O
could,O
exert,O
a,O
dual,O
effect,O
on,O
COVID‐19,O
",",O
that,O
of,O
limiting,O
viral,O
entry,O
by,O
reducing,O
the,O
cleavage,O
of,O
the,O
spike,O
protein,O
in,O
ACE2,O
receptor,O
mediated,O
viral,O
entry,O
as,O
shown,O
by,O
Hoffmann,O
et,O
al,O
.,O
(,O
2020,O
),O
and,O
that,O
of,O
inhibiting,O
NF‐kB,O
pathway,O
leading,O
to,O
a,O
weaker,O
pro‐inflammatory,O
response,O
with,O
less,O
severe,O
lung,O
pathology,O
as,O
shown,O
by,O
Iwata‐Yoshikawa,O
et,O
al,O
.,O
(,O
2019,O
),O
on,O
SARS,O
and,O
MERS‐CoV,O
",",O
with,O
celastrol,O
likely,O
mediating,O
both,O
mechanisms,O
.,O
Even,O
though,O
application,O
of,O
antiinflammatory,O
agents,O
in,O
COVID‐19,O
may,O
be,O
debatable,O
or,O
one,O
should,O
say,O
highly,O
dependent,O
on,O
the,O
disease,O
stage,O
",",O
a,O
trial,O
of,O
compounds,O
like,O
celastrol,O
with,O
promising,O
effect,O
in,O
a,O
variety,O
of,O
related,O
lung,O
diseases,O
is,O
highly,O
encouraged,O
.,O
Moreover,O
recent,O
studies,O
have,O
shown,O
that,O
smokers,O
have,O
lower,O
risk,O
of,O
contracting,O
COVID-19,O
",",O
and,O
one,O
explanation,O
could,O
be,O
the,O
interference,O
between,O
the,O
nicotine,O
which,O
downregulates,O
the,O
ACE2,O
receptor,O
.,O
As,O
no,O
approved,O
therapeutics,O
exists,O
to,O
treat,O
COVID-19,O
",",O
the,O
disease,O
associated,O
to,O
SARS,O
-,O
Cov-2,O
",",O
there,O
is,O
an,O
urgent,O
need,O
to,O
propose,O
molecules,O
that,O
could,O
quickly,O
enter,O
into,O
clinics,O
.,O
COVID-19,O
",",O
caused,O
by,O
SARS,O
-,O
CoV-2,O
",",O
was,O
first,O
reported,O
in,O
several,O
cases,O
with,O
unexplained,O
pneumonia,O
from,O
Wuhan,O
",",O
China,O
",",O
in,O
late,O
December,O
2019,O
.,O
As,O
of,O
Feb,O
24,O
",",O
2020,O
",",O
a,O
total,O
of,O
"77,262",O
COVID-19,O
cases,O
have,O
been,O
confirmed,O
in,O
mainland,O
China,O
with,O
2595,O
deaths,O
",",O
and,O
2069,O
cases,O
outside,O
China,O
with,O
23,O
deaths,O
(,O
WHO,O
",",O
2020,O
),O
.,O
The,O
nucleocapsid,O
protein,O
gene,O
(,O
N,O
gene,O
),O
of,O
SARS,O
-,O
CoV-2,O
downloaded,O
from,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
was,O
chosen,O
as,O
the,O
target,O
region,O
.,O
Only,O
the,O
extracts,O
from,O
SARS,O
-,O
CoV-2,O
strain,O
and,O
COVID-19,O
patient,O
's,O
samples,O
showed,O
positive,O
reactions,O
.,O
The,O
current,O
outbreak,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
was,O
reported,O
in,O
China,O
firstly,O
.,O
A,O
total,O
of,O
eight,O
variants,O
of,O
hACE2,O
that,O
map,O
to,O
the,O
interaction,O
surface,O
are,O
described,O
in,O
the,O
gnomAD,S-Dataset
 ,O
database,O
(,O
Fig,O
.,O
 ,O
4,O
A,O
),O
.,O
The,O
spread,O
of,O
COVID-19,O
caused,O
by,O
the,O
SARS,O
-,O
CoV-2,O
outbreak,O
has,O
been,O
growing,O
since,O
its,O
first,O
identification,O
in,O
December,O
2019,O
.,O
By,O
calculating,O
the,O
binding,O
energy,O
score,O
between,O
RBD,O
and,O
ACE2,O
",",O
we,O
highlighted,O
the,O
putative,O
jump,O
in,O
the,O
affinity,O
from,O
a,O
progenitor,O
form,O
of,O
SARS,O
-,O
CoV-2,O
to,O
the,O
current,O
virus,O
responsible,O
for,O
COVID-19,O
outbreak,O
.,O
There,O
are,O
no,O
known,O
medicines,O
or,O
vaccines,O
to,O
control,O
the,O
COVID-19,O
pandemic,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
(,O
nCoV,O
),O
.,O
Antiviral,O
peptides,O
are,O
superior,O
to,O
conventional,O
drugs,O
and,O
may,O
also,O
be,O
effective,O
against,O
COVID-19,O
.,O
Second,O
",",O
peptides,O
from,O
five,O
antibacterial,O
peptide,O
databases,O
that,O
block,O
nCoV,O
-,O
RBD,O
are,O
identified,O
;,O
finally,O
",",O
a,O
chimeric,O
peptide,O
design,O
approach,O
is,O
used,O
to,O
design,O
peptides,O
that,O
can,O
bind,O
to,O
key,O
nCoV,O
-,O
RBD,O
residues,O
.,O
We,O
found,O
that,O
:,O
(,O
i,O
),O
three,O
amino,O
acid,O
stretches,O
in,O
hACE2,O
interact,O
with,O
nCoV,O
-,O
RBD,O
;,O
(,O
ii,O
),O
effective,O
peptides,O
must,O
bind,O
to,O
three,O
key,O
positions,O
of,O
nCoV,O
-,O
RBD,O
(,O
Gly485,O
/,O
Phe486,O
/,O
Asn487,O
",",O
Gln493,O
",",O
and,O
Gln498,O
/,O
Thr500,O
/,O
Asn501,O
),O
;,O
(,O
iii,O
),O
Phe486,O
",",O
Gln493,O
",",O
and,O
Asn501,O
are,O
critical,O
residues,O
;,O
(,O
iv,O
),O
AC20,O
and,O
AC23,O
derived,O
from,O
hACE2,O
may,O
block,O
two,O
key,O
critical,O
positions,O
;,O
(,O
iv,O
),O
DBP6,O
identified,O
from,O
databases,O
can,O
block,O
the,O
three,O
sites,O
of,O
the,O
nCoV,O
-,O
RBD,O
and,O
interacts,O
with,O
one,O
critical,O
position,O
",",O
Gln498,O
;,O
(,O
v,O
),O
seven,O
chimeric,O
peptides,O
were,O
considered,O
promising,O
",",O
among,O
which,O
cnCoVP-3,O
",",O
cnCoVP-4,O
",",O
and,O
cnCoVP-7,O
are,O
the,O
top,O
three,O
;,O
and,O
(,O
vi,O
),O
cnCoVP-4,O
meets,O
all,O
the,O
criteria,O
and,O
is,O
the,O
best,O
peptide,O
.,O
Results,O
 ,O
Using,O
RNA,O
extracted,O
from,O
cells,O
infected,O
by,O
SARS,O
coronavirus,O
as,O
a,O
positive,O
control,O
",",O
these,O
assays,O
were,O
shown,O
to,O
have,O
a,O
dynamic,O
range,O
of,O
at,O
least,O
seven,O
orders,O
of,O
magnitude,O
(,O
2x10,O
−4,O
-2000,O
TCID,O
50,O
/reaction,O
),O
.,O
According,O
to,O
the,O
study,O
reporting,O
kidney,O
injury,O
cases,O
",",O
direct,O
effect,O
of,O
virus,O
was,O
suspected,O
(,O
Wang,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
and,O
Academician,O
Nanshan,O
",",O
Zhong,O
",",O
leader,O
of,O
high‐level,O
steering,O
team,O
dealing,O
with,O
outbreak,O
of,O
COVID‐19,O
in,O
China,O
",",O
declared,O
that,O
virus,O
of,O
COVID‐19,O
",",O
SARS‐Cov‐2,O
",",O
was,O
separated,O
from,O
patients,O
’,O
urine,O
sample,O
(,O
Le,O
",",O
Knoedler,O
",",O
&,O
Roberge,O
",",O
2020,O
),O
.,O
In,O
this,O
study,O
",",O
based,O
on,O
public,O
databases,O
",",O
single‐cell,O
RNA,O
sequencing,O
(,O
scRNA‐seq,O
),O
technology,O
was,O
used,O
to,O
obtain,O
evidences,O
of,O
potential,O
route,O
of,O
SARS‐Cov‐2,O
entry,O
and,O
underlying,O
pathogenesis,O
of,O
kidney,O
injury,O
in,O
COVID‐19,O
patients,O
.,O
Significantly,O
top,O
200,O
ACE2,O
co‐expressed,O
genes,O
(,O
p,O
value,O
<,O
0.05,O
),O
were,O
collected,O
for,O
following,O
downstream,O
Gene,O
Ontology,O
(,O
GO,O
),O
as,O
well,O
as,O
Kyoto,O
Encyclopedia,O
of,O
Genes,O
and,O
Genomes,O
(,O
KEGG,O
),O
enrichment,O
analysis,O
(,O
p,O
value,O
<,O
0.05,O
),O
",",O
with,O
the,O
corresponding,O
databases,O
of,O
Carlson,O
M,O
(,O
2019,O
),O
.,O
Although,O
the,O
exact,O
evidence,O
for,O
kidney,O
injury,O
caused,O
by,O
COVID‐19,O
 ,O
has,O
not,O
been,O
estimated,O
",",O
several,O
infected,O
patients,O
’,O
studies,O
revealed,O
the,O
potential,O
risk,O
of,O
kidney,O
vulnerable,O
to,O
be,O
damaged,O
due,O
to,O
SARS‐Cov‐2,O
virus,O
direct,O
effect,O
.,O
Hypothesis,O
of,O
virus,O
direct,O
effect,O
resulting,O
in,O
kidney,O
damage,O
was,O
suspected,O
within,O
the,O
abovementioned,O
case‐studies,O
and,O
",",O
more,O
importantly,O
",",O
based,O
on,O
our,O
study,O
results,O
of,O
scRNA‐seq,O
in,O
human,O
kidney,O
",",O
potential,O
route,O
for,O
COVID‐19,O
leading,O
kidney,O
damage,O
via,O
ACE2,O
was,O
estimated,O
.,O
From,O
our,O
GO,O
&,O
KEGG,O
analysis,O
",",O
RAS,O
was,O
a,O
significant,O
pathway,O
in,O
ACE2,O
co‐expressed,O
gene,O
enrichment,O
",",O
which,O
might,O
indicate,O
one,O
of,O
the,O
potential,O
mechanisms,O
of,O
COVID‐19,O
damage,O
to,O
kidney,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
no,O
specific,O
medication,O
could,O
be,O
used,O
to,O
against,O
COVID‐19,O
but,O
symptomatic,O
treatment,O
would,O
be,O
the,O
predominant,O
strategy,O
.,O
Occurrence,O
of,O
AKI,O
is,O
the,O
most,O
frequent,O
renal‐related,O
complication,O
in,O
COVID‐19,O
patients,O
",",O
which,O
increases,O
the,O
risk,O
factor,O
for,O
mortality,O
.,O
Recombinant,O
ACE2,O
was,O
reported,O
to,O
be,O
effective,O
in,O
slowing,O
the,O
progression,O
of,O
kidney,O
disease,O
by,O
reducing,O
albumin,O
excretion,O
and,O
modulating,O
RAS,O
depressor,O
arm,O
(,O
AT2R,O
",",O
ACE2,O
",",O
Ang,O
1–7,O
),O
by,O
ACE2,O
activator,O
or,O
AT2R,O
agonist,O
might,O
protect,O
the,O
kidney,O
from,O
renal,O
injury,O
(,O
Oudit,O
et,O
al,O
.,O
",",O
2010,O
;,O
Sharma,O
",",O
Malek,O
",",O
Mulay,O
",",O
&,O
Gaikwad,O
",",O
2019,O
),O
",",O
which,O
may,O
provide,O
potential,O
clues,O
for,O
clinicians,O
encountering,O
COVID‐19,O
patients,O
",",O
especially,O
complicated,O
with,O
kidney,O
injury,O
.,O
However,O
",",O
the,O
abovementioned,O
mechanism,O
of,O
kidney,O
injury,O
in,O
COVID‐19,O
infection,O
should,O
be,O
verified,O
in,O
experiment,O
under,O
precise,O
experimental,O
design,O
.,O
Several,O
organs,O
are,O
vulnerable,O
to,O
COVID‐19,O
infection,O
.,O
Acute,O
kidney,O
injury,O
(,O
AKI,O
),O
was,O
reported,O
in,O
parts,O
of,O
case‐studies,O
reporting,O
characteristics,O
of,O
COVID‐19,O
patients,O
.,O
Method,O
 ,O
Single‐cell,O
RNA,O
sequencing,O
(,O
scRNA‐seq,O
),O
technology,O
was,O
used,O
to,O
obtain,O
evidence,O
of,O
potential,O
route,O
and,O
ACE2,O
expressing,O
cell,O
in,O
renal,O
system,O
for,O
underlying,O
pathogenesis,O
of,O
kidney,O
injury,O
caused,O
by,O
COVID‐19,O
.,O
From,O
Gene,O
Ontology,O
(,O
GO,O
),O
&,O
KEGG,O
enrichment,O
analysis,O
",",O
imbalance,O
of,O
ACE2,O
expression,O
",",O
renin‐angiotensin,O
system,O
(,O
RAS,O
),O
activation,O
",",O
and,O
neutrophil‐related,O
processes,O
were,O
the,O
main,O
issue,O
of,O
COVID‐19,O
leading,O
kidney,O
injury,O
.,O
Several,O
organs,O
are,O
vulnerable,O
to,O
potential,O
infection,O
of,O
COVID‐19,O
except,O
lung,O
",",O
such,O
as,O
liver,O
",",O
digestive,O
system,O
",",O
reproductive,O
system,O
and,O
urinary,O
system,O
",",O
and,O
SARS‐CoV‐2,O
was,O
separated,O
from,O
patients,O
’,O
urine,O
.,O
Consequently,O
",",O
we,O
hypothesized,O
that,O
COVID‐19,O
might,O
invade,O
human,O
kidney,O
causing,O
renal,O
injury,O
",",O
and,O
this,O
is,O
the,O
first,O
study,O
investigating,O
the,O
potential,O
route,O
of,O
COVID‐19,O
leading,O
kidney,O
injury,O
.,O
The,O
pandemic,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
that,O
is,O
the,O
cause,O
of,O
the,O
respiratory,O
disease,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
has,O
resulted,O
in,O
tens,O
of,O
thousands,O
of,O
deaths,O
globally,O
since,O
it,O
was,O
first,O
identified,O
in,O
Wuhan,O
",",O
China,O
",",O
at,O
the,O
end,O
of,O
2019,O
(,O
1,O
",",O
2,O
),O
.,O
Clinical,O
manifestations,O
of,O
COVID-19,O
range,O
from,O
mild,O
symptoms,O
to,O
severe,O
illness,O
and,O
even,O
death,O
.,O
Viral,O
RNA,O
is,O
detectable,O
not,O
only,O
from,O
respiratory,O
specimens,O
but,O
also,O
in,O
the,O
urine,O
",",O
serum,O
",",O
and,O
stool,O
using,O
reverse,O
transcription,O
-,O
PCR,O
(,O
RT,O
-,O
PCR,O
),O
",",O
and,O
viral,O
RNA,O
has,O
been,O
detected,O
in,O
COVID-19,O
patients,O
for,O
more,O
than,O
30,O
 ,O
days,O
(,O
8–13,O
),O
.,O
To,O
clarify,O
the,O
correlation,O
between,O
the,O
culturability,O
of,O
the,O
virus,O
from,O
clinical,O
specimens,O
and,O
the,O
RNA,O
copy,O
number,O
",",O
in,O
the,O
present,O
study,O
",",O
we,O
investigated,O
the,O
culturability,O
of,O
a,O
total,O
of,O
60,O
specimens,O
from,O
50,O
laboratory,O
-,O
confirmed,O
COVID-19,O
patients,O
that,O
were,O
collected,O
from,O
25,O
January,O
to,O
the,O
end,O
of,O
March,O
2020,O
in,O
Taiwan,O
.,O
As,O
a,O
reference,O
laboratory,O
of,O
the,O
Taiwan,O
Centers,O
for,O
Disease,O
Control,O
(,O
CDC,O
;,O
https://www.cdc.gov.tw/En/,O
),O
",",O
we,O
have,O
been,O
performing,O
viral,O
diagnosis,O
for,O
suspected,O
COVID-19,O
patients,O
.,O
Specimens,O
of,O
suspected,O
COVID-19,O
cases,O
collected,O
by,O
border,O
control,O
systems,O
and,O
different,O
hospitals,O
around,O
Taipei,O
county,O
are,O
routinely,O
sent,O
to,O
our,O
clinical,O
virology,O
laboratory,O
.,O
SARS,O
-,O
CoV-2,O
cDNA,O
was,O
prepared,O
using,O
RNA,O
extracted,O
from,O
the,O
specimens,O
of,O
the,O
first,O
patient,O
with,O
confirmed,O
COVID-19,O
.,O
Detection,O
of,O
SARS,O
-,O
CoV-2,O
by,O
RT,O
-,O
PCR,O
remains,O
the,O
gold,O
standard,O
test,O
for,O
confirming,O
COVID-19,O
",",O
and,O
two,O
negative,O
tests,O
at,O
least,O
24,O
h,O
apart,O
in,O
a,O
clinically,O
recovered,O
patient,O
are,O
one,O
of,O
the,O
important,O
criteria,O
for,O
hospital,O
discharge,O
as,O
recommended,O
by,O
the,O
World,O
Health,O
Organization,O
(,O
22,O
),O
.,O
A,O
previous,O
study,O
indicated,O
that,O
6,O
log10,O
genome,O
copies,O
/,O
ml,O
sample,O
might,O
be,O
required,O
for,O
virus,O
isolation,O
based,O
on,O
analysis,O
of,O
a,O
series,O
of,O
specimens,O
from,O
patients,O
hospitalized,O
for,O
COVID-19,O
",",O
and,O
no,O
virus,O
could,O
be,O
isolated,O
from,O
specimens,O
collected,O
after,O
day,O
8,O
of,O
illness,O
irrespective,O
of,O
the,O
high,O
viral,O
loads,O
(,O
9,O
),O
.,O
Real,O
-,O
time,O
reverse,O
transcription,O
-,O
PCR,O
(,O
RT,O
-,O
PCR,O
),O
is,O
currently,O
the,O
most,O
sensitive,O
method,O
to,O
detect,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
that,O
causes,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
ABSTRACT,O
 ,O
Real,O
-,O
time,O
reverse,O
transcription,O
-,O
PCR,O
(,O
RT,O
-,O
PCR,O
),O
is,O
currently,O
the,O
most,O
sensitive,O
method,O
to,O
detect,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
that,O
causes,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
Most,O
COVID-19,O
studies,O
have,O
focused,O
on,O
its,O
epidemiological,O
and,O
clinical,O
characteristics,O
(,O
Ghinai,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Guan,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
They,O
usually,O
recover,O
with,O
",",O
or,O
even,O
without,O
",",O
conventional,O
medical,O
treatment,O
and,O
therefore,O
are,O
classified,O
as,O
mild,O
or,O
moderate,O
COVID-19,O
(,O
Thevarajan,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
These,O
molecular,O
changes,O
may,O
shed,O
light,O
on,O
therapy,O
development,O
for,O
COVID-19,O
patients,O
.,O
To,O
test,O
this,O
hypothesis,O
",",O
we,O
applied,O
proteomic,O
(,O
Aebersold,O
and,O
Mann,O
",",O
2016,O
",",O
Li,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
and,O
metabolomic,O
(,O
Hou,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Lee,O
et,O
 ,O
al,O
.,O
",",O
2019,O
),O
technologies,O
to,O
analyze,O
the,O
proteome,O
and,O
metabolome,O
of,O
sera,O
from,O
COVID-19,O
patients,O
and,O
several,O
control,O
groups,O
.,O
We,O
procured,O
a,O
cohort,O
of,O
patients,O
(,O
Zheng,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
containing,O
28,O
severe,O
COVID-19,O
patients,O
.,O
These,O
controls,O
were,O
28,O
healthy,O
subjects,O
",",O
25,O
non,O
-,O
COVID-19,O
patients,O
(,O
negative,O
for,O
the,O
SARS,O
-,O
CoV-2,O
nucleic,O
acid,O
test,O
),O
with,O
similar,O
clinical,O
characteristics,O
as,O
COVID-19,O
patients,O
",",O
and,O
25,O
non,O
-,O
severe,O
COVID-19,O
patients,O
.,O
We,O
analyzed,O
12,O
clinical,O
measurements,O
of,O
the,O
COVID-19,O
and,O
non,O
-,O
COVID-19,O
patients,O
(,O
Figure,O
 ,O
S1,O
),O
",",O
including,O
white,O
blood,O
cell,O
count,O
",",O
lymphocyte,O
count,O
",",O
monocyte,O
count,O
",",O
platelet,O
count,O
",",O
C,O
-,O
reactive,O
protein,O
(,O
CRP,O
),O
",",O
alanine,O
aminotransferase,O
(,O
ALT,O
),O
",",O
aspartate,O
aminotransferase,O
(,O
AST,O
),O
",",O
glutamyltransferase,O
(,O
GGT,O
),O
",",O
total,O
bilirubin,O
(,O
TBIL,O
),O
",",O
direct,O
bilirubin,O
(,O
DBIL,O
),O
",",O
creatinine,O
",",O
and,O
glucose,O
.,O
(,O
A,O
),O
Summary,O
of,O
COVID-19,O
patients,O
",",O
including,O
non,O
-,O
severe,O
(,O
n,O
 ,O
=,O
37,O
),O
and,O
severe,O
(,O
n,O
 ,O
=,O
28,O
),O
patients,O
with,O
more,O
details,O
in,O
Table,O
S1,O
.,O
Twelve,O
Clinical,O
Parameters,O
of,O
COVID-19,O
Patients,O
and,O
Non,O
-,O
COVID-19,O
Patients,O
",",O
Related,O
to,O
Figure,O
 ,O
1,O
We,O
next,O
investigated,O
the,O
possibility,O
of,O
identifying,O
the,O
severe,O
cases,O
from,O
COVID-19,O
patients,O
based,O
on,O
the,O
molecular,O
signatures,O
of,O
proteins,O
and,O
metabolites,O
(,O
Table,O
S3,O
),O
.,O
This,O
model,O
reached,O
an,O
area,O
under,O
curve,O
(,O
AUC,O
),O
of,O
0.957,O
in,O
the,O
training,O
set,O
(,O
Figure,O
 ,O
2C,O
),O
.,O
To,O
further,O
validate,O
this,O
classifier,O
",",O
we,O
developed,O
targeted,O
mass,O
spectrometric,O
assays,O
for,O
the,O
22,O
proteins,O
and,O
7,O
metabolites,O
(,O
Figure,O
 ,O
2A,O
),O
and,O
analyzed,O
these,O
29,O
molecules,O
in,O
a,O
second,O
test,O
cohort,O
containing,O
19,O
COVID-19,O
patients,O
(,O
Figure,O
 ,O
1,O
;,O
Table,O
1,O
;,O
Tables,O
S1,O
and,O
S5,O
),O
.,O
We,O
found,O
that,O
105,O
proteins,O
were,O
differentially,O
expressed,O
in,O
the,O
sera,O
of,O
COVID-19,O
patients,O
but,O
not,O
the,O
non,O
-,O
COVID-19,O
patients,O
(,O
Figures,O
S3,O
and,O
S4,O
),O
.,O
It,O
was,O
found,O
that,O
373,O
metabolites,O
were,O
significantly,O
changed,O
in,O
COVID-19,O
patients,O
(,O
Figure,O
 ,O
S4B,O
),O
",",O
whereas,O
the,O
change,O
of,O
204,O
metabolites,O
was,O
correlated,O
with,O
disease,O
severity,O
as,O
evaluated,O
by,O
mFuzz,O
(,O
Figure,O
 ,O
S5,O
),O
.,O
Differentially,O
Expressed,O
Proteins,O
and,O
Metabolites,O
in,O
Different,O
Patient,O
Groups,O
in,O
the,O
Training,O
Cohort,O
",",O
Related,O
to,O
Figure,O
 ,O
4,O
and,O
5,O
Proteins,O
and,O
Metabolites,O
Regulated,O
in,O
COVID-19,O
Patients,O
but,O
Not,O
in,O
Non,O
-,O
COVID-19,O
Patients,O
",",O
Related,O
to,O
Figure,O
 ,O
4,O
and,O
5,O
Identification,O
of,O
Specific,O
Clusters,O
of,O
Proteins,O
and,O
Metabolites,O
in,O
COVID-19,O
Patients,O
",",O
Related,O
to,O
Figure,O
 ,O
4,O
and,O
5,O
Pathway,O
Analysis,O
of,O
93,O
Differentially,O
Expressed,O
Proteins,O
in,O
COVID-19,O
Patients,O
",",O
Related,O
to,O
Figure,O
 ,O
4,O
and,O
5,O
Our,O
data,O
uncovered,O
dysregulation,O
of,O
multiple,O
apolipoproteins,O
including,O
APOA1,O
",",O
APOA2,O
",",O
APOH,O
",",O
APOL1,O
",",O
APOD,O
",",O
and,O
APOM,O
(,O
Figure,O
 ,O
3A,O
),O
.,O
Decrease,O
of,O
APOA1,O
in,O
serum,O
has,O
been,O
reported,O
during,O
the,O
transition,O
of,O
COVID-19,O
patients,O
from,O
mild,O
to,O
severe,O
illness,O
(,O
Nie,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
APOM,O
in,O
sera,O
of,O
severe,O
patients,O
was,O
downregulated,O
compared,O
with,O
healthy,O
and,O
non,O
-,O
severe,O
COVID-19,O
patients,O
.,O
Accumulation,O
of,O
11,O
steroid,O
hormones,O
in,O
COVID-19,O
patients,O
may,O
contribute,O
to,O
macrophage,O
modulation,O
.,O
Metabolites,O
of,O
kynurenate,O
",",O
kynurenine,O
",",O
and,O
8,O
-,O
methoxykynurenate,O
were,O
enriched,O
in,O
COVID-19,O
patients,O
.,O
Our,O
data,O
showed,O
decreased,O
sphingolipids,O
in,O
both,O
non,O
-,O
severe,O
 ,O
and,O
severe,O
COVID-19,O
patients,O
(,O
Figure,O
 ,O
4,O
A,O
),O
.,O
Our,O
data,O
suggest,O
severe,O
COVID-19,O
patients,O
might,O
benefit,O
from,O
this,O
therapeutic,O
strategy,O
.,O
Choline,O
and,O
its,O
derivatives,O
were,O
downregulated,O
in,O
COVID-19,O
patients,O
(,O
Figure,O
 ,O
4B,O
),O
",",O
particularly,O
in,O
severe,O
cases,O
",",O
while,O
phosphocholine,O
",",O
the,O
intermediate,O
product,O
for,O
producing,O
phosphatidylcholine,O
(,O
PC,O
),O
was,O
upregulated,O
(,O
Figure,O
 ,O
4A,O
),O
.,O
Among,O
the,O
most,O
significantly,O
upregulated,O
proteins,O
in,O
the,O
sera,O
of,O
the,O
severe,O
COVID-19,O
patients,O
are,O
APPs,O
",",O
including,O
serum,O
amyloid,O
A-1,O
(,O
SAA1,O
),O
",",O
serum,O
amyloid,O
A-2,O
(,O
SAA2,O
),O
",",O
serum,O
amyloid,O
A-4,O
(,O
SAA4,O
),O
",",O
CRP,O
",",O
alpha-1,O
-,O
antichymotrypsin,O
(,O
SERPINA3,O
),O
",",O
and,O
serum,O
amyloid,O
P,O
-,O
component,O
(,O
SAP,O
/,O
APCS,O
),O
(,O
Figure,O
 ,O
3B,O
),O
.,O
Although,O
CRP,O
has,O
been,O
associated,O
with,O
COVID-19,O
",",O
the,O
other,O
proteins,O
have,O
not,O
previously,O
been,O
reported,O
in,O
COVID-19,O
(,O
Liang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Low,O
platelet,O
count,O
is,O
also,O
reported,O
to,O
be,O
associated,O
with,O
severe,O
COVID-19,O
and,O
mortality,O
(,O
Lippi,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
a,O
proteomic,O
investigation,O
of,O
sera,O
in,O
SARS,O
patients,O
",",O
decreasing,O
PF4,O
was,O
found,O
to,O
be,O
associated,O
with,O
poor,O
prognosis,O
(,O
Poon,O
et,O
 ,O
al,O
.,O
",",O
2012,O
),O
",",O
which,O
is,O
in,O
consistent,O
with,O
our,O
findings,O
in,O
COVID-19,O
.,O
Serotonin,O
level,O
decreases,O
as,O
the,O
severity,O
of,O
COVID-19,O
increases,O
(,O
Figure,O
 ,O
4B,O
),O
and,O
so,O
does,O
the,O
platelet,O
count,O
(,O
Zheng,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Compared,O
with,O
the,O
healthy,O
group,O
",",O
serotonin,O
in,O
non,O
-,O
severe,O
and,O
severe,O
COVID-19,O
patients,O
decreased,O
by,O
2.07,O
-,O
fold,O
(,O
p,O
 ,O
=,O
1.86e-04,O
),O
and,O
3.31,O
-,O
fold,O
(,O
p,O
 ,O
=,O
9.07e-07,O
),O
",",O
respectively,O
.,O
Compared,O
with,O
the,O
healthy,O
controls,O
",",O
more,O
than,O
100,O
metabolites,O
",",O
amino,O
acids,O
and,O
their,O
derivatives,O
",",O
in,O
the,O
sera,O
of,O
COVID-19,O
patients,O
were,O
significantly,O
decreased,O
",",O
whereas,O
their,O
levels,O
were,O
either,O
unchanged,O
or,O
even,O
increased,O
in,O
the,O
sera,O
of,O
non,O
-,O
COVID-19,O
patients,O
.,O
In,O
addition,O
",",O
some,O
arginine,O
derivatives,O
such,O
as,O
argininate,O
",",O
asymmetric,O
dimethylarginine,O
",",O
symmetric,O
dimethylarginine,O
",",O
homoarginine,O
",",O
and,O
N,O
-,O
acetylarginine,O
were,O
also,O
significantly,O
decreased,O
in,O
the,O
sera,O
of,O
non,O
-,O
severe,O
COVID-19,O
patients,O
.,O
Although,O
COVID-19,O
can,O
be,O
diagnosed,O
effectively,O
by,O
nucleic,O
-,O
acid,O
-,O
based,O
methods,O
at,O
an,O
early,O
stage,O
",",O
it,O
is,O
equally,O
critical,O
to,O
identify,O
severe,O
COVID-19,O
patients,O
before,O
the,O
manifestation,O
of,O
severe,O
symptoms,O
to,O
minimize,O
mortality,O
.,O
We,O
achieved,O
an,O
overall,O
accuracy,O
of,O
93.5,O
%,O
in,O
the,O
training,O
set,O
(,O
C1,O
),O
.,O
In,O
this,O
training,O
set,O
(,O
C1,O
),O
",",O
five,O
severe,O
patients,O
were,O
correctly,O
identified,O
based,O
on,O
the,O
analysis,O
of,O
their,O
serum,O
samples,O
collected,O
1,O
to,O
4,O
 ,O
days,O
before,O
they,O
were,O
clinically,O
diagnosed,O
as,O
severe,O
patients,O
(,O
Figure,O
 ,O
1,O
),O
",",O
suggesting,O
that,O
their,O
serum,O
protein,O
and,O
metabolite,O
signatures,O
at,O
the,O
sampling,O
time,O
may,O
already,O
point,O
to,O
further,O
deterioration,O
into,O
severe,O
state,O
even,O
when,O
severe,O
clinical,O
symptoms,O
have,O
not,O
started,O
to,O
appear,O
yet,O
.,O
The,O
proteins,O
and,O
metabolites,O
used,O
in,O
our,O
classifier,O
(,O
Figure,O
 ,O
2A,O
),O
contain,O
several,O
known,O
biomarkers,O
for,O
viral,O
infections,O
",",O
such,O
as,O
SAA2,O
",",O
SAA1,O
",",O
and,O
CRP,O
",",O
which,O
have,O
already,O
been,O
used,O
empirically,O
to,O
monitor,O
the,O
severity,O
of,O
COVID-19,O
.,O
Our,O
data,O
suggest,O
potential,O
benefits,O
of,O
broader,O
testing,O
of,O
these,O
proteins,O
in,O
newly,O
diagnosed,O
cases,O
to,O
identify,O
which,O
COVID-19,O
patients,O
are,O
likely,O
to,O
progress,O
to,O
severe,O
disease,O
.,O
Our,O
data,O
shed,O
light,O
on,O
the,O
molecular,O
changes,O
reflected,O
in,O
COVID-19,O
sera,O
",",O
which,O
could,O
potentially,O
yield,O
critical,O
diagnostic,O
markers,O
or,O
therapeutic,O
targets,O
for,O
managing,O
severe,O
COVID-19,O
patients,O
(,O
Figure,O
 ,O
5,O
),O
.,O
A,O
recent,O
necropsy,O
report,O
revealed,O
alveolar,O
macrophage,O
infiltration,O
and,O
activation,O
in,O
severe,O
COVID-19,O
patients,O
(,O
Liao,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
",",O
supporting,O
our,O
findings,O
.,O
To,O
date,O
",",O
few,O
other,O
therapies,O
are,O
proven,O
effective,O
for,O
severe,O
COVID-19,O
patients,O
.,O
Corticosteroid,O
treatment,O
was,O
effective,O
in,O
suppressing,O
MERS,O
-,O
CoV,O
and,O
SARS,O
-,O
CoV,O
(,O
Arabi,O
et,O
 ,O
al,O
.,O
",",O
2018,O
),O
but,O
showed,O
negligible,O
effect,O
on,O
COVID-19,O
patients,O
and,O
may,O
even,O
have,O
induced,O
lung,O
injury,O
(,O
Russell,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
molecular,O
changes,O
revealed,O
in,O
this,O
study,O
in,O
the,O
COVID-19,O
sera,O
might,O
be,O
useful,O
for,O
prioritizing,O
therapeutic,O
strategies,O
for,O
the,O
severe,O
patients,O
.,O
Our,O
data,O
suggest,O
that,O
severe,O
COVID-19,O
patients,O
might,O
benefit,O
from,O
suppression,O
of,O
complement,O
system,O
.,O
Our,O
metabolomics,O
results,O
showed,O
that,O
more,O
than,O
100,O
lipids,O
including,O
glycerophospholipid,O
",",O
sphingolipids,O
",",O
and,O
fatty,O
acids,O
were,O
downregulated,O
in,O
COVID-19,O
patient,O
sera,O
",",O
probably,O
because,O
of,O
damage,O
to,O
the,O
liver,O
",",O
which,O
is,O
also,O
reflected,O
in,O
aberrancy,O
in,O
bilirubin,O
and,O
bile,O
acids,O
.,O
Drugs,O
inhibiting,O
lipid,O
synthesis,O
such,O
as,O
statin,O
have,O
been,O
proposed,O
to,O
treat,O
HCV,O
(,O
Heaton,O
and,O
Randall,O
",",O
2011,O
),O
and,O
COVID-19,O
(,O
Fedson,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Our,O
data,O
suggest,O
these,O
potential,O
therapeutics,O
might,O
be,O
helpful,O
in,O
the,O
treatment,O
of,O
severe,O
COVID-19,O
patients,O
.,O
Upon,O
COVID-19,O
outbreak,O
",",O
limited,O
information,O
of,O
this,O
pathogen,O
was,O
available,O
",",O
which,O
restricted,O
the,O
collection,O
of,O
a,O
large,O
number,O
of,O
clinical,O
specimens,O
for,O
this,O
study,O
mainly,O
because,O
of,O
biosafety,O
constraints,O
.,O
Our,O
team,O
procured,O
serum,O
samples,O
from,O
65,O
COVID-19,O
patients,O
who,O
visited,O
Taizhou,O
Hospital,O
from,O
January,O
to,O
March,O
2020,O
.,O
They,O
were,O
diagnosed,O
as,O
COVID-19,O
according,O
to,O
the,O
Chinese,O
Government,O
Diagnosis,O
and,O
Treatment,O
Guideline,O
(,O
Trial,O
5th,O
version,O
),O
(,O
NHCPRC,O
",",O
2020,O
),O
.,O
For,O
diagnosing,O
COVID-19,O
",",O
nucleic,O
acid,O
from,O
sputum,O
or,O
throat,O
swab,O
was,O
extracted,O
using,O
nucleic,O
acid,O
extractor,O
(,O
Shanghai,O
Zhijiang,O
",",O
China,O
",",O
EX3600,O
),O
and,O
virus,O
nucleic,O
acid,O
extraction,O
reagent,O
(,O
Shanghai,O
Zhijiang,O
",",O
China,O
",",O
NO,O
.,O
P20200201,O
),O
was,O
used,O
to,O
extract,O
nucleic,O
acid,O
.,O
According,O
to,O
the,O
abovementioned,O
guideline,O
",",O
COVID-19,O
patients,O
are,O
classified,O
into,O
four,O
subgroups,O
:,O
1,O
),O
Mild,O
:,O
mild,O
symptoms,O
without,O
pneumonia,O
;,O
2,O
),O
Typical,O
:,O
fever,O
or,O
respiratory,O
tract,O
symptoms,O
with,O
pneumonia,O
;,O
3,O
),O
Severe,O
:,O
fulfill,O
any,O
of,O
the,O
three,O
criteria,O
:,O
respiratory,O
distress,O
",",O
respiratory,O
rate,O
≥,O
30,O
times,O
/,O
min,O
;,O
means,O
oxygen,O
saturation,O
≤,O
93,O
%,O
in,O
resting,O
state,O
;,O
arterial,O
blood,O
oxygen,O
partial,O
pressure,O
/,O
oxygen,O
concentration,O
≤,O
300,O
 ,O
mmHg,O
(,O
1,O
 ,O
mmHg,O
 ,O
=,O
0.133,O
 ,O
kPa,O
),O
;,O
4,O
),O
Critical,O
:,O
fulfill,O
any,O
of,O
the,O
three,O
criteria,O
:,O
respiratory,O
failure,O
and,O
require,O
mechanical,O
ventilation,O
;,O
shock,O
incidence,O
;,O
admission,O
to,O
ICU,O
with,O
other,O
organ,O
failure,O
.,O
In,O
this,O
study,O
",",O
we,O
included,O
both,O
severe,O
and,O
non,O
-,O
severe,O
patients,O
",",O
with,O
the,O
latter,O
composed,O
of,O
mild,O
and,O
typical,O
COVID-19,O
patients,O
.,O
We,O
also,O
procured,O
25,O
non,O
-,O
COVID-19,O
patients,O
with,O
similar,O
clinical,O
characteristics,O
including,O
fever,O
and/or,O
cough,O
as,O
COVID-19,O
patients,O
however,O
negative,O
in,O
the,O
nucleic,O
acid,O
test,O
.,O
Based,O
on,O
the,O
Chinese,O
Government,O
Diagnosis,O
and,O
Treatment,O
Guideline,O
(,O
Trial,O
5th,O
version,O
),O
(,O
NHCPRC,O
",",O
2020,O
),O
",",O
patients,O
are,O
defined,O
as,O
suspected,O
COVID-19,O
cases,O
when,O
they,O
meet,O
the,O
following,O
three,O
clinical,O
criteria,O
:,O
1,O
),O
fever,O
or,O
respiratory,O
symptoms,O
",",O
2,O
),O
imaging,O
manifestation,O
of,O
pneumonia,O
",",O
and,O
3,O
),O
optional,O
reduction,O
of,O
white,O
blood,O
cell,O
or,O
lymphocyte,O
count,O
at,O
early,O
stage,O
.,O
The,O
patients,O
only,O
need,O
to,O
meet,O
at,O
least,O
two,O
of,O
the,O
above,O
three,O
criteria,O
if,O
they,O
have,O
been,O
exposed,O
to,O
COVID-19,O
individuals,O
.,O
Most,O
non,O
-,O
COVID-19,O
patients,O
exhibited,O
fever,O
and,O
cough,O
.,O
The,O
samples,O
from,O
this,O
study,O
are,O
from,O
a,O
clinical,O
trial,O
that,O
our,O
team,O
initiated,O
and,O
registered,O
in,O
the,O
Chinese,B-Repository
Clinical,I-Repository
Trial,I-Repository
Registry,E-Repository
 ,O
with,O
an,O
ID,O
of,O
ChiCTR2000031365,S-AccessionNumber
.,O
The,O
resultant,O
mass,O
spectrometric,O
data,O
were,O
analyzed,O
using,O
Proteome,O
Discoverer,O
(,O
Version,O
2.4.1.15,O
",",O
Thermo,O
Fisher,O
Scientific,O
),O
using,O
a,O
protein,O
database,O
composed,O
of,O
the,O
Homo,O
sapiens,O
fasta,O
database,O
downloaded,O
from,O
UniProtKB,O
on,O
07,O
Jan,O
2020,O
",",O
containing,O
20412,O
reviewed,O
protein,O
sequences,O
",",O
and,O
the,O
SARS,O
-,O
CoV-2,O
virus,O
fasta,O
downloaded,O
from,O
NCBI,S-Repository
 ,O
(,O
version,O
NC_045512.2,S-AccessionNumber
),O
.,O
IDA,O
mode,O
(,O
rolling,O
collision,O
energy,O
",",O
 ,O
+2,O
to,O
 ,O
+5,O
charge,O
states,O
with,O
intensity,O
criteria,O
above,O
"2,000,000",O
cps,O
to,O
guarantee,O
all,O
untargeted,O
peptides,O
will,O
not,O
be,O
acquired,O
),O
for,O
time,O
-,O
scheduling,O
was,O
set,O
up,O
for,O
51,O
peptides,O
including,O
10,O
iRT,O
peptides,O
(,O
Escher,O
et,O
 ,O
al,O
.,O
",",O
2012,O
),O
with,O
a,O
mass,O
tolerance,O
of,O
50,O
ppm,O
.,O
Early,O
detection,O
and,O
effective,O
treatment,O
of,O
severe,O
COVID-19,O
patients,O
remain,O
major,O
challenges,O
.,O
Here,O
",",O
we,O
performed,O
proteomic,O
and,O
metabolomic,O
profiling,O
of,O
sera,O
from,O
46,O
COVID-19,O
and,O
53,O
control,O
individuals,O
.,O
Targeted,O
proteomics,O
and,O
metabolomics,O
assays,O
were,O
employed,O
to,O
further,O
validate,O
this,O
molecular,O
classifier,O
in,O
a,O
second,O
test,O
cohort,O
of,O
19,O
COVID-19,O
patients,O
",",O
leading,O
to,O
16,O
correct,O
assignments,O
.,O
We,O
identified,O
molecular,O
changes,O
in,O
the,O
sera,O
of,O
COVID-19,O
patients,O
compared,O
to,O
other,O
groups,O
implicating,O
dysregulation,O
of,O
macrophage,O
",",O
platelet,O
degranulation,O
",",O
complement,O
system,O
pathways,O
",",O
and,O
massive,O
metabolic,O
suppression,O
.,O
This,O
study,O
revealed,O
characteristic,O
protein,O
and,O
metabolite,O
changes,O
in,O
the,O
sera,O
of,O
severe,O
COVID-19,O
patients,O
",",O
which,O
might,O
be,O
used,O
in,O
selection,O
of,O
potential,O
blood,O
biomarkers,O
for,O
severity,O
evaluation,O
.,O
Graphical,O
Abstract,O
     ,O
Proteomic,O
and,O
metabolomic,O
analysis,O
of,O
COVID-19,O
sera,O
identifies,O
differentially,O
expressed,O
factors,O
that,O
correlate,O
with,O
disease,O
severity,O
and,O
highlights,O
dysregulation,O
of,O
multiple,O
immune,O
and,O
metabolic,O
components,O
in,O
clinically,O
severe,O
patients,O
.,O
The,O
outbreak,O
of,O
a,O
novel,O
coronavirus,O
(,O
SARS,O
-,O
CoV-2,O
),O
and,O
the,O
associated,O
disease,O
(,O
COVID-19,O
),O
began,O
in,O
Wuhan,O
",",O
China,O
",",O
near,O
the,O
end,O
of,O
2019,O
.,O
COVID-19,O
continues,O
to,O
pose,O
a,O
severe,O
threat,O
to,O
public,O
health,O
and,O
economic,O
prosperity,O
in,O
China,O
[,O
"1,2",O
],O
.,O
COVID-19,O
was,O
more,O
severe,O
in,O
Wuhan,O
soon,O
after,O
its,O
appearance,O
",",O
with,O
severe,O
/,O
critical,O
and,O
fatality,O
rates,O
of,O
approximately,O
32,O
%,O
and,O
11,O
%,O
",",O
respectively,O
[,O
"8,9",O
],O
.,O
Subsequent,O
data,O
as,O
the,O
disease,O
spread,O
revealed,O
a,O
milder,O
form,O
of,O
COVID-19,O
in,O
Zhejiang,O
province,O
[,O
10,O
],O
and,O
nationwide,O
[,O
11,O
],O
.,O
Furthermore,O
",",O
the,O
observation,O
of,O
a,O
similar,O
viral,O
load,O
in,O
symptomatic,O
and,O
asymptomatic,O
COVID-19,O
patients,O
revealed,O
the,O
capacity,O
of,O
SARS,O
-,O
CoV-2,O
for,O
occult,O
transmission,O
[,O
14,O
],O
.,O
Changes,O
in,O
the,O
epidemiological,O
and,O
clinical,O
features,O
of,O
COVID-19,O
relate,O
to,O
the,O
virologic,O
changes,O
of,O
SARS,O
-,O
CoV-2,O
",",O
in,O
which,O
the,O
spike,O
(,O
S,O
),O
surface,O
envelope,O
protein,O
plays,O
an,O
important,O
role,O
[,O
15,O
],O
.,O
Therefore,O
",",O
it,O
is,O
valuable,O
to,O
focus,O
on,O
the,O
sequence,O
mutation,O
and,O
conformation,O
change,O
in,O
S,O
protein,O
for,O
SARS,O
-,O
CoV-2,O
evolution,O
in,O
an,O
established,O
model,O
with,O
the,O
aim,O
of,O
explaining,O
the,O
related,O
changes,O
in,O
COVID-19,O
.,O
This,O
retrospective,O
study,O
investigating,O
the,O
epidemiological,O
",",O
clinical,O
and,O
virologic,O
features,O
of,O
COVID-19,O
was,O
performed,O
at,O
designated,O
hospitals,O
in,O
Zhejiang,O
province,O
between,O
17,O
January,O
and,O
7,O
February,O
2020,O
.,O
We,O
subsequently,O
calculated,O
the,O
time,O
period,O
of,O
positive,O
COVID-19,O
nucleic,O
acid,O
in,O
our,O
hospital,O
.,O
All,O
patients,O
were,O
diagnosed,O
with,O
COVID-19,O
according,O
to,O
the,O
World,O
Health,O
Organization,O
interim,O
guidance,O
[,O
17,O
],O
and,O
the,O
preliminary,O
data,O
were,O
promptly,O
reported,O
to,O
the,O
authority,O
of,O
Zhejiang,O
province,O
.,O
The,O
subtypes,O
of,O
COVID-19,O
were,O
categorized,O
as,O
mild,O
",",O
severe,O
and,O
critical,O
",",O
as,O
recently,O
described,O
[,O
11,O
],O
.,O
One,O
strain,O
of,O
SARS,O
-,O
CoV-2,O
was,O
successfully,O
isolated,O
from,O
a,O
single,O
sputum,O
sample,O
of,O
a,O
patient,O
with,O
a,O
mild,O
COVID-19,O
case,O
at,O
the,O
time,O
of,O
admission,O
in,O
our,O
hospital,O
.,O
Normalization,O
and,O
principal,O
component,O
analysis,O
(,O
PCA,O
),O
were,O
performed,O
using,O
the,O
R,O
package,O
Seurat,O
[,O
24,O
],O
",",O
with,O
different,O
dataset,O
-,O
based,O
data,O
processing,O
methods,O
.,O
Depending,O
on,O
the,O
expression,O
level,O
of,O
cell,O
markers,O
provided,O
in,O
the,O
original,O
article,O
corresponding,O
to,O
the,O
single,O
-,O
cell,O
RNA,O
(,O
scRNA)-seq,O
datasets,O
",",O
we,O
further,O
estimated,O
which,O
cell,O
types,O
the,O
cell,O
clusters,O
belonged,O
to,O
.,O
The,O
rates,O
of,O
mild,O
",",O
severe,O
and,O
critical,O
types,O
of,O
COVID-19,O
were,O
90.1,O
%,O
",",O
7.74,O
%,O
and,O
2.16,O
%,O
",",O
respectively,O
.,O
He,O
visited,O
outpatient,O
clinics,O
one,O
day,O
after,O
symptom,O
onset,O
and,O
was,O
admitted,O
to,O
the,O
hospital,O
with,O
COVID-19,O
on,O
the,O
same,O
day,O
following,O
the,O
PCR,O
result,O
.,O
Consistent,O
with,O
other,O
COVID-19,O
patients,O
",",O
his,O
symptoms,O
included,O
fever,O
",",O
cough,O
and,O
sputum,O
production,O
",",O
with,O
bilateral,O
pneumonia,O
evident,O
in,O
the,O
CT,O
scan,O
.,O
The,O
patient,O
had,O
mild,O
type,O
COVID-19,O
",",O
with,O
normal,O
results,O
for,O
routine,O
blood,O
parameters,O
and,O
inflammation,O
markers,O
(,O
C,O
-,O
reactive,O
protein,O
and,O
procalcitonin,O
),O
.,O
Among,O
the,O
eight,O
strains,O
collected,O
in,O
Wuhan,O
",",O
Guangdong,O
",",O
and,O
Hangzhou,O
",",O
six,O
were,O
collected,O
at,O
the,O
early,O
stage,O
of,O
COVID-19,O
(,O
26,O
December,O
2019,O
to,O
2,O
January,O
2020,O
),O
.,O
In,O
the,O
scRNA,O
-,O
seq,O
datasets,O
",",O
ACE2,O
",",O
Furin,O
and,O
TMPRSS2,O
showed,O
higher,O
expression,O
levels,O
in,O
the,O
liver,O
and,O
colon,O
than,O
in,O
the,O
lung,O
(,O
Figure,O
7(E,O
),O
),O
.,O
Recently,O
",",O
elevated,O
plasmin,O
was,O
reported,O
in,O
COVID-19,O
with,O
comorbidities,O
such,O
as,O
hypertension,O
",",O
diabetes,O
",",O
et,O
al,O
while,O
plasmin,O
or,O
other,O
proteases,O
may,O
be,O
able,O
to,O
cleave,O
FCS,O
[,O
35,O
],O
.,O
COVID-19,O
rapidly,O
spread,O
throughout,O
China,O
and,O
has,O
causing,O
enormous,O
damage,O
.,O
To,O
provide,O
clarity,O
",",O
we,O
selected,O
a,O
COVID-19,O
patient,O
who,O
experienced,O
a,O
mild,O
disease,O
and,O
isolated,O
the,O
causative,O
virus,O
(,O
ZJ01,O
),O
for,O
comparative,O
analysis,O
.,O
Our,O
hypothesis,O
is,O
consistent,O
with,O
changes,O
in,O
the,O
clinical,O
characteristics,O
of,O
COVID-19,O
from,O
published,O
data,O
and,O
our,O
observations,O
",",O
including,O
detection,O
of,O
virus,O
in,O
faeces,O
[,O
38,O
],O
and,O
conjunctival,O
secretions,O
[,O
39,O
],O
",",O
decreased,O
severity,O
/,O
fatality,O
",",O
increased,O
liver,O
/,O
kidney,O
damage,O
and,O
symptoms,O
of,O
the,O
gastrointestinal,O
tract,O
",",O
increased,O
transmissibility,O
",",O
and,O
prolonged,O
period,O
of,O
nucleic,O
acid,O
positivity,O
.,O
The,O
mutations,O
in,O
the,O
SARS,O
-,O
CoV-2,O
virus,O
genome,O
during,O
COVID-19,O
dissemination,O
are,O
unclear,O
.,O
In,O
788,O
COVID-19,O
patients,O
from,O
Zhejiang,O
province,O
",",O
we,O
observed,O
decreased,O
rate,O
of,O
severe,O
/,O
critical,O
cases,O
compared,O
with,O
patients,O
in,O
Wuhan,O
.,O
For,O
mechanisms,O
exploration,O
",",O
we,O
isolated,O
one,O
strain,O
of,O
SARS,O
-,O
CoV-2,O
(,O
ZJ01,O
),O
from,O
a,O
mild,O
COVID-19,O
patient,O
.,O
The,O
evolutionary,O
pattern,O
of,O
SARS,O
-,O
CoV-2,O
towards,O
FCS,O
formation,O
may,O
result,O
in,O
its,O
clinical,O
symptom,O
becoming,O
closer,O
to,O
HKU-1,O
and,O
OC43,O
caused,O
mild,O
flu,O
-,O
like,O
symptoms,O
",",O
further,O
showing,O
its,O
potential,O
in,O
differentiating,O
into,O
mild,O
COVID-19,O
subtypes,O
.,O
Although,O
limited,O
data,O
are,O
available,O
regarding,O
sepsis,O
induced,O
by,O
COVID-19,O
",",O
pathogenic,O
coronaviruses,O
-,O
induced,O
sepsis,O
is,O
observed,O
with,O
Middle,O
East,O
respiratory,O
syndrome,O
[,O
3,O
],O
.,O
Using,O
the,O
Traditional,B-Repository
Chinese,I-Repository
Medicine,I-Repository
Systems,I-Repository
Pharmacology,I-Repository
(TCMSP),E-Repository
 ,O
[,O
17,O
],O
",",O
Drugbank,S-Repository
 ,O
[,O
18,O
],O
",",O
SuperPred,S-Repository
 ,O
[,O
19,O
],O
and,O
Swiss,B-Repository
Target,I-Repository
Prediction,E-Repository
 ,O
[,O
20,O
],O
databases,O
",",O
well,O
-,O
reported,O
pharmacological,O
targets,O
of,O
VC,O
were,O
obtained,O
.,O
Likewise,O
",",O
the,O
DisGeNET,S-Repository
 ,O
[,O
21,O
],O
",",O
Drugbank,S-Repository
",",O
and,O
Genecard,S-Repository
 ,O
[,O
22,O
],O
databases,O
were,O
used,O
to,O
screen,O
pathological,O
targets,O
of,O
sepsis,O
.,O
Using,O
a,O
STRING,O
database,O
",",O
the,O
mapped,O
target,O
of,O
VC,O
action,O
against,O
sepsis,O
were,O
reassayed,O
to,O
harvest,O
a,O
target,O
-,O
to,O
-,O
target,O
function,O
-,O
related,O
protein,O
network,O
",",O
protein,O
–,O
protein,O
interaction,O
(,O
PPI,O
),O
network,O
",",O
and,O
tsv,O
.,O
data,O
.,O
The,O
inclusion,O
criteria,O
for,O
sepsis,O
screening,O
through,O
DisGeNET,S-Repository
 ,O
database,O
was,O
a,O
gene,O
-,O
disease,O
association,O
score,O
 ,O
>,O
 ,O
0.1,O
and,O
for,O
sepsis,O
screening,O
through,O
GeneCards,S-Repository
 ,O
database,O
was,O
a,O
gene,O
score,O
 ,O
>,O
VC,O
drug,O
targets,O
were,O
screened,O
and,O
identified,O
through,O
both,O
the,O
TCMSP,S-Repository
 ,O
and,O
Swiss,B-Repository
Target,I-Repository
Prediction,E-Repository
 ,O
databases,O
",",O
and,O
161,O
VC,O
targets,O
were,O
identified,O
(,O
after,O
removing,O
duplicates,O
),O
using,O
Uniprot,O
database,O
.,O
Using,O
a,O
minimum,O
required,O
interaction,O
score,O
set,O
to,O
0.700,O
(,O
high,O
confidence,O
),O
",",O
a,O
STRING,O
database,O
was,O
used,O
to,O
collect,O
function,O
-,O
related,O
PPI,O
data,O
from,O
the,O
63,O
targets,O
(,O
Supplementary,O
Table,O
1,O
),O
.,O
Abstract,O
 ,O
Sepsis,O
is,O
a,O
life,O
-,O
threatening,O
complication,O
of,O
pneumonia,O
",",O
including,O
coronavirus,O
disease-2019,O
(,O
COVID-19)-induced,O
pneumonia,O
.,O
To,O
date,O
",",O
11,O
million,O
have,O
been,O
infected,O
with,O
SARS,O
-,O
CoV-2,O
",",O
and,O
0.52,O
million,O
have,O
died,O
from,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
(,O
Organization,O
WH,O
",",O
2020,O
),O
.,O
As,O
Japan,O
continues,O
to,O
battle,O
a,O
second,O
wave,O
of,O
COVID-19,O
epidemic,O
",",O
more,O
than,O
"1,000",O
newly,O
infected,O
patients,O
are,O
being,O
confirmed,O
daily,O
.,O
The,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
has,O
raised,O
a,O
global,O
warning,O
and,O
announced,O
the,O
need,O
for,O
a,O
test,O
system,O
for,O
COVID-19,O
-,O
suspected,O
patients,O
(,O
World,O
Health,O
Organization,O
",",O
2020,O
),O
.,O
The,O
development,O
of,O
a,O
more,O
cost,O
-,O
effective,O
and,O
high,O
-,O
throughput,O
test,O
system,O
will,O
be,O
important,O
for,O
preventing,O
viral,O
spread,O
and,O
monitoring,O
infection,O
levels,O
in,O
COVID-19,O
patients,O
.,O
According,O
to,O
the,O
protocol,O
developed,O
by,O
the,O
National,O
Institute,O
of,O
Infectious,O
Diseases,O
(,O
NIID,O
),O
in,O
Japan,O
(,O
Shirato,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
we,O
performed,O
one,O
-,O
step,O
RT,O
-,O
qPCR,O
to,O
detect,O
SARS,O
-,O
CoV-2,O
(,O
Hirotsu,O
et,O
al,O
.,O
",",O
2020d,O
),O
.,O
The,O
clusters,O
of,O
COVID-19,O
are,O
reported,O
in,O
closed,O
environments,O
",",O
which,O
could,O
contribute,O
to,O
secondary,O
transmission,O
and,O
promote,O
super,O
-,O
spreading,O
events,O
(,O
Nishiura,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
this,O
context,O
",",O
our,O
results,O
showed,O
that,O
the,O
antigen,O
test,O
could,O
be,O
used,O
to,O
identify,O
COVID-19,O
-,O
infected,O
individuals,O
who,O
pose,O
a,O
high,O
risk,O
of,O
transmission,O
.,O
Severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
which,O
causes,O
the,O
disease,O
COVID-19,O
",",O
was,O
initially,O
described,O
near,O
the,O
end,O
of,O
20191,O
2,O
and,O
has,O
caused,O
a,O
global,O
pandemic,O
.,O
3,O
COVID-19,O
is,O
characterized,O
predominately,O
by,O
fever,O
",",O
cough,O
",",O
and,O
pneumonia,O
",",O
with,O
some,O
patients,O
presenting,O
with,O
diarrhea,O
and,O
other,O
symptoms,O
.,O
12,O
Analyses,O
of,O
ACE2,O
protein,O
expression,O
by,O
organ,O
system,O
have,O
suggested,O
high,O
levels,O
in,O
epithelia,O
of,O
the,O
lung,O
and,O
small,O
intestine,O
",",O
consistent,O
with,O
presenting,O
symptoms,O
of,O
patients,O
with,O
COVID-19.13,O
Patients,O
with,O
cancer,O
may,O
be,O
at,O
increased,O
risk,O
for,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
deleterious,O
outcomes,O
to,O
COVID-19,O
disease,O
though,O
reports,O
have,O
varied,O
by,O
geography,O
and,O
cancer,O
histology,O
.,O
In,O
a,O
single,O
hospital,O
study,O
from,O
Wuhan,O
",",O
China,O
",",O
patients,O
with,O
cancer,O
made,O
up,O
1,O
%,O
of,O
the,O
overall,O
prevalence,O
of,O
"COVID-19,19",O
substantially,O
higher,O
than,O
the,O
overall,O
incidence,O
of,O
cancer,O
in,O
the,O
Chinese,O
population,O
at,O
0.29%.20,O
Outcomes,O
to,O
COVID-19,O
appeared,O
to,O
be,O
worse,O
in,O
patients,O
with,O
cancer,O
with,O
increased,O
intensive,O
care,O
unit,O
admission,O
",",O
mechanical,O
ventilation,O
",",O
and,O
mortality,O
",",O
especially,O
those,O
who,O
had,O
recently,O
received,O
chemotherapy,O
or,O
surgery,O
.,O
22,O
Particularly,O
",",O
there,O
has,O
been,O
concern,O
that,O
patients,O
being,O
treated,O
with,O
cancer,O
immunotherapy,O
drugs,O
might,O
be,O
at,O
increased,O
risk,O
given,O
the,O
possible,O
overlapping,O
immune,O
-,O
related,O
toxicities,O
for,O
checkpoint,O
blocking,O
antibodies,O
with,O
the,O
pneumonitis,O
and,O
diarrheal,O
syndromes,O
seen,O
in,O
COVID-19,O
.,O
This,O
remains,O
an,O
area,O
of,O
open,O
investigation,O
with,O
analyses,O
even,O
from,O
the,O
same,O
institution,O
giving,O
conflicting,O
results,O
about,O
the,O
risk,O
of,O
immunotherapy,O
",",O
notably,O
in,O
advanced,O
lung,O
cancer.25,O
26,O
Multiple,O
societies,O
",",O
including,O
the,O
Society,O
for,O
Immunotherapy,O
of,O
Cancer,O
",",O
have,O
issued,O
guidance,O
for,O
cancer,O
care,O
during,O
the,O
pandemic,O
as,O
well,O
as,O
the,O
use,O
of,O
immunomodulatory,O
agents,O
such,O
as,O
anti,O
-,O
IL6.27,O
Several,O
clinical,O
associations,O
have,O
arisen,O
from,O
a,O
smaller,O
series,O
of,O
patients,O
infected,O
with,O
COVID-19,O
.,O
To,O
the,O
authors,O
’,O
knowledge,O
",",O
only,O
two,O
tumor,O
types,O
had,O
diabetes,O
status,O
information,O
(,O
pancreatic,O
adenocarcinoma,O
(,O
PAAD,O
),O
and,O
uterine,O
corpus,O
endometrial,O
carcinoma,O
(,O
UCEC,O
),O
),O
",",O
which,O
was,O
retrieved,O
from,O
clinical,O
XML,O
files,O
on,O
GDC,S-Repository
.,O
Macrophage,O
M1,O
/,O
M2,O
and,O
T,O
cells,O
were,O
included,O
in,O
the,O
model,O
based,O
on,O
emerging,O
evidence,O
suggesting,O
an,O
important,O
role,O
of,O
macrophage,O
and,O
proinflammatory,O
phenotype39,O
in,O
COVID-19,O
disease,O
.,O
Given,O
the,O
purpose,O
of,O
this,O
analysis,O
was,O
to,O
evaluate,O
the,O
relative,O
importance,O
of,O
features,O
rather,O
than,O
training,O
and,O
validating,O
a,O
predictive,O
model,O
",",O
we,O
did,O
not,O
split,O
samples,O
into,O
training,O
and,O
test,O
sets,O
.,O
Given,O
the,O
association,O
between,O
COVID-19,O
disease,O
and,O
various,O
organ,O
-,O
specific,O
symptoms,O
",",O
we,O
investigated,O
the,O
distribution,O
of,O
ACE2,O
and,O
TMPRSS2,O
expression,O
in,O
tumor,O
and,O
normal,O
tissues,O
across,O
34,O
tumor,O
types,O
consisting,O
of,O
15,O
tissue,O
types,O
(,O
online,O
supplementary,O
tables,O
1–3,O
),O
.,O
A,O
full,O
description,O
of,O
each,O
cancer,O
ID,O
is,O
provided,O
in,O
online,O
supplementary,O
table,O
1,O
.,O
LAML,O
",",O
acute,O
myeloid,O
leukemia,O
.,O
Several,O
clinical,O
observations,O
on,O
COVID-19,O
indicated,O
clinical,O
factors,O
such,O
as,O
BMI,O
might,O
be,O
associated,O
with,O
severity,O
.,O
Last,O
",",O
we,O
examined,O
a,O
public,O
scRNAseq,O
cohort,O
from,O
patients,O
with,O
COVID-19,O
infection,O
(,O
https://doi.org/10.5281/zenodo.3747336,S-DOI
),O
and,O
confirmed,O
that,O
ACE2,O
was,O
not,O
expressed,O
in,O
immune,O
cells,O
",",O
and,O
TMPRSS2,O
was,O
present,O
in,O
6,O
out,O
of,O
"140,956",O
cells,O
total,O
by,O
one,O
read,O
count,O
.,O
The,O
mortality,O
of,O
COVID-19,O
disease,O
has,O
been,O
substantially,O
greater,O
than,O
that,O
seen,O
with,O
seasonal,O
influenza,O
and,O
led,O
to,O
the,O
identification,O
of,O
or,O
hypothesis,O
that,O
certain,O
clinical,O
factors,O
may,O
be,O
associated,O
with,O
outcomes,O
.,O
An,O
initial,O
hypothesis,O
when,O
considering,O
the,O
deleterious,O
outcomes,O
for,O
patients,O
with,O
cancer,O
and,O
COVID-19,O
disease,O
was,O
that,O
cancer,O
tissues,O
themselves,O
might,O
have,O
higher,O
expression,O
of,O
viral,O
entry,O
related,O
genes,O
.,O
Observing,O
higher,O
ACE2,O
levels,O
in,O
T,O
cell,O
-,O
inflamed,O
tumors,O
may,O
be,O
relevant,O
to,O
the,O
administration,O
of,O
cancer,O
immunotherapy,O
during,O
the,O
COVID-19,O
pandemic,O
",",O
especially,O
in,O
patients,O
with,O
tumors,O
of,O
the,O
aerodigestive,O
tract,O
such,O
as,O
head,O
and,O
neck,O
",",O
lung,O
",",O
and,O
colorectal,O
/,O
anal,O
tracts,O
.,O
49,O
However,O
",",O
if,O
ACE2,O
and,O
TMPRSS2,O
levels,O
are,O
high,O
",",O
making,O
viral,O
infection,O
potentially,O
more,O
likely,O
",",O
concomitant,O
treatment,O
with,O
checkpoint,O
blockade,O
may,O
potentially,O
change,O
antiviral,O
host,O
response50,O
or,O
possibly,O
obscure,O
rapidly,O
delineation,O
of,O
symptoms,O
such,O
as,O
fatigue,O
",",O
dyspnea,O
",",O
"diarrhea,51",O
and,O
complicate,O
irAE,O
management,O
",",O
especially,O
given,O
emerging,O
evidence,O
that,O
corticosteroids,O
may,O
worsen,O
COVID-19,O
disease,O
.,O
To,O
date,O
",",O
it,O
remains,O
unclear,O
whether,O
immune,O
-,O
checkpoint,O
blockade,O
increases,O
risk,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
or,O
subsequent,O
impact,O
of,O
COVID-19.25,O
26,O
Direct,O
infection,O
or,O
dysregulation,O
of,O
immune,O
cell,O
populations,O
is,O
an,O
additional,O
area,O
of,O
concern,O
in,O
patients,O
with,O
cancer,O
and,O
more,O
broadly,O
in,O
infected,O
patients,O
.,O
COVID-19,O
can,O
manifest,O
with,O
lymphopenia,O
with,O
some,O
autopsy,O
series,O
suggesting,O
lymph,O
node,O
or,O
splenic,O
atrophy,O
.,O
Studies,O
have,O
raised,O
the,O
possibility,O
that,O
SARS,O
-,O
CoV-2,O
infects,O
lymphocytes17,O
or,O
"macrophages,53",O
leading,O
to,O
COVID-19,O
associate,O
findings,O
.,O
In,O
our,O
study,O
",",O
we,O
investigated,O
the,O
expression,O
of,O
ACE2,O
and,O
TMPRSS2,O
across,O
multiple,O
single,O
-,O
cell,O
sequencing,O
databases,O
encompassing,O
nine,O
independent,O
studies,O
.,O
Additionally,O
",",O
multiple,O
other,O
known,O
pathologies,O
associated,O
with,O
sepsis,O
and,O
extreme,O
illness,O
could,O
explain,O
these,O
lymph,O
node,O
and,O
splenic,O
findings,O
",",O
and,O
few,O
patients,O
with,O
COVID-19,O
have,O
been,O
documented,O
to,O
have,O
an,O
extreme,O
viremia,O
consistent,O
with,O
what,O
would,O
be,O
required,O
as,O
a,O
prerequisite,O
to,O
such,O
histologic,O
findings,O
.,O
In,O
our,O
analysis,O
",",O
we,O
found,O
strong,O
correlations,O
of,O
specific,O
bacterial,O
flora,O
and,O
high,O
expression,O
of,O
ACE2,O
in,O
COVID-19,O
related,O
organs,O
",",O
including,O
colorectal,O
and,O
kidney,O
.,O
However,O
",",O
this,O
observation,O
suggests,O
that,O
further,O
investigation,O
of,O
the,O
commensal,O
microbiome,O
in,O
COVID-19,O
and,O
possibly,O
that,O
bacterial,O
antibiosis,O
related,O
to,O
coronavirus,O
infection,O
might,O
be,O
of,O
relevance,O
in,O
the,O
future,O
.,O
Rather,O
we,O
sought,O
to,O
investigate,O
factors,O
correlated,O
with,O
viral,O
cell,O
engagement,O
via,O
ACE2,O
and,O
viral,O
entry,O
via,O
TMPRSS2,O
as,O
possible,O
associative,O
risk,O
factors,O
that,O
might,O
be,O
entertained,O
on,O
a,O
clinical,O
or,O
translational,O
level,O
when,O
considering,O
risk,O
for,O
patients,O
with,O
cancer,O
and,O
otherwise,O
of,O
COVID-19,O
.,O
However,O
",",O
we,O
believe,O
our,O
analysis,O
to,O
be,O
the,O
most,O
comprehensive,O
catalog,O
of,O
ACE2,O
and,O
TMPRSS2,O
correlates,O
to,O
date,O
(,O
34,O
tumor,O
types,O
from,O
15,O
tissue,O
types,O
across,O
10,O
 ,O
038,O
subjects,O
including,O
both,O
tumor,O
samples,O
and,O
matched,O
normal,O
tissues,O
as,O
well,O
as,O
scRNAseq,O
databases,O
consisting,O
of,O
patients,O
with,O
cancer,O
and,O
healthy,O
donors,O
),O
.,O
However,O
",",O
these,O
source,O
data,O
constitute,O
the,O
largest,O
collection,O
of,O
microbiota,O
communities,O
identified,O
from,O
patients,O
with,O
cancer,O
",",O
have,O
previously,O
been,O
used,O
in,O
this,O
manner,O
to,O
build,O
prediction,O
algorithms,O
",",O
and,O
the,O
data,O
were,O
optimized,O
via,O
rigorous,O
methodology,O
to,O
control,O
for,O
noise,O
across,O
the,O
data,O
set.35,O
We,O
also,O
note,O
that,O
we,O
are,O
unable,O
in,O
this,O
analysis,O
to,O
comment,O
on,O
respiratory,O
or,O
fecal,O
samples,O
from,O
patients,O
infected,O
with,O
COVID-19,O
and,O
very,O
much,O
look,O
forward,O
to,O
better,O
understanding,O
the,O
functional,O
mechanisms,O
associated,O
with,O
those,O
commensal,O
and,O
pathogenic,O
microbiota,O
related,O
to,O
COVID-19,O
.,O
Last,O
",",O
our,O
work,O
does,O
not,O
determine,O
a,O
causal,O
role,O
of,O
those,O
correlates,O
in,O
driving,O
response,O
or,O
severity,O
of,O
COVID-19,O
disease,O
and,O
would,O
require,O
further,O
mechanistic,O
studies,O
as,O
well,O
as,O
prospective,O
clinical,O
trials,O
in,O
patients,O
to,O
further,O
develop,O
or,O
investigate,O
interventional,O
approaches,O
.,O
Background,O
 ,O
Pandemic,O
COVID-19,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
infection,O
is,O
facilitated,O
by,O
the,O
ACE2,O
receptor,O
and,O
protease,O
TMPRSS2,O
.,O
Modestly,O
sized,O
case,O
series,O
have,O
described,O
clinical,O
factors,O
associated,O
with,O
COVID-19,O
",",O
while,O
ACE2,O
and,O
TMPRSS2,O
expression,O
analyses,O
have,O
been,O
described,O
in,O
some,O
cell,O
types,O
.,O
Patients,O
with,O
cancer,O
may,O
have,O
worse,O
outcomes,O
to,O
COVID-19,O
.,O
We,O
performed,O
an,O
integrated,O
study,O
of,O
ACE2,O
and,O
TMPRSS2,O
gene,O
expression,O
across,O
and,O
within,O
organ,O
systems,O
",",O
by,O
normal,O
versus,O
tumor,O
",",O
across,O
several,O
existing,O
databases,O
(,O
The,B-Repository
Cancer,I-Repository
Genome,I-Repository
"Atlas,",E-Repository
 ,O
Census,B-Repository
of,I-Repository
Immune,I-Repository
Single,I-Repository
Cell,I-Repository
Expression,I-Repository
Atlas,E-Repository
",",O
The,B-Repository
Human,I-Repository
Cell,I-Repository
Landscape,E-Repository
",",O
and,O
more,O
),O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
a,O
respiratory,O
illness,O
caused,O
by,O
a,O
novel,O
coronavirus,O
",",O
was,O
first,O
identified,O
in,O
the,O
Hubei,O
province,O
of,O
China,O
in,O
December,O
2019,O
and,O
has,O
now,O
spread,O
worldwide,O
.,O
The,O
etiologic,O
agent,O
of,O
COVID-19,O
is,O
a,O
β,O
-,O
coronavirus,O
called,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
[,O
1,O
],O
that,O
is,O
closely,O
related,O
to,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
(,O
SARS,O
-,O
CoV,O
),O
",",O
the,O
virus,O
that,O
caused,O
the,O
much,O
more,O
limited,O
SARS,O
outbreak,O
of,O
2002–2003,O
",",O
and,O
to,O
Middle,O
East,O
respiratory,O
syndrome,O
coronavirus,O
(,O
MERS,O
-,O
CoV,O
),O
",",O
the,O
etiologic,O
agent,O
for,O
MERS,O
.,O
The,O
case,O
fatality,O
rate,O
for,O
COVID-19,O
is,O
considerably,O
lower,O
than,O
that,O
reported,O
for,O
SARS,O
(,O
17,O
%,O
),O
or,O
MERS,O
(,O
40,O
%,O
),O
[,O
2,O
],O
;,O
however,O
",",O
SARS,O
-,O
CoV-2,O
spread,O
much,O
more,O
rapidly,O
",",O
quickly,O
causing,O
many,O
more,O
total,O
deaths,O
than,O
infection,O
with,O
both,O
previous,O
coronaviruses,O
combined,O
.,O
Currently,O
",",O
there,O
are,O
no,O
effective,O
treatments,O
for,O
COVID-19,O
and,O
our,O
understanding,O
of,O
the,O
immunological,O
response,O
to,O
SARS,O
-,O
CoV-2,O
is,O
limited,O
.,O
The,O
nucleocapsid,O
N,O
-,O
terminal,O
residues,O
(,O
N,O
-,O
NTD,O
),O
interact,O
with,O
genomic,O
RNA,O
of,O
SARS,O
-,O
CoV-2,O
and,O
incorporate,O
it,O
into,O
progeny,O
particles,O
(,O
Tang,O
et,O
al,O
.,O
This,O
study,O
will,O
provide,O
a,O
better,O
understanding,O
of,O
rapid,O
drug,O
designing,O
to,O
control,O
the,O
global,O
epidemic,O
of,O
SARS,O
-,O
CoV-2,O
.,O
PDB,S-Repository
 ,O
is,O
a,O
database,O
of,O
biomolecule,O
structure,O
",",O
providing,O
crystal,O
structure,O
for,O
proteomics,O
and,O
in,O
silico,O
studies,O
.,O
The,O
crystal,O
structure,O
of,O
nucleocapsid,O
N,O
-,O
terminal,O
domain,O
(,O
N,O
-,O
NTD,O
),O
was,O
retrieved,O
from,O
Protein,B-Repository
Data,I-Repository
Bank,E-Repository
 ,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6yi3,S-AccessionNumber
),O
.,O
Crystal,O
structure,O
of,O
N,O
-,O
NTD,O
(,O
PDB,S-Repository
 ,O
ID,O
6M3M,S-AccessionNumber
),O
and,O
dsRNA,O
(,O
PDB,S-Repository
 ,O
structure,O
2LK2,S-AccessionNumber
),O
",",O
a,O
21,O
-,O
base,O
pair,O
-,O
long,O
dsRNA(Liu,O
et,O
al,O
.,O
Considering,O
the,O
consensus,O
sequences,O
",",O
two,O
non,O
-,O
synonymous,O
changes,O
with,O
respect,O
to,O
the,O
Wuhan,O
-,O
Hu-1,O
NCBI,S-Repository
 ,O
Reference,O
Genome,O
(,O
Accession,O
number,O
:,O
MN908947.3,S-AccessionNumber
),O
[,O
2,O
],O
were,O
observed,O
in,O
the,O
sequence,O
from,O
the,O
clinical,O
sample,O
from,O
patient,O
1,O
:,O
G11083,O
T,O
",",O
leading,O
to,O
L3606F,O
change,O
in,O
Orf1a,O
",",O
and,O
G26144,O
T,O
",",O
leading,O
to,O
G251V,O
change,O
in,O
Orf3a,O
.,O
For,O
the,O
phylogenetic,O
analysis,O
",",O
87,O
full,O
-,O
genome,O
SARS,O
-,O
CoV-2,O
sequences,O
were,O
retrieved,O
from,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
",",O
along,O
with,O
WH-01_MN908947.3,S-AccessionNumber
 ,O
from,O
GenBank,S-Repository
.,O
All,O
the,O
genomes,O
carrying,O
this,O
mutation,O
are,O
included,O
in,O
a,O
significant,O
phylogenetic,O
cluster,O
(,O
bootstrap,O
87,O
%,O
),O
",",O
suggesting,O
a,O
common,O
origin,O
(,O
Fig,O
.,O
 ,O
1,O
),O
;,O
in,O
fact,O
",",O
the,O
G251V,O
substitution,O
in,O
Orf3a,O
has,O
recently,O
been,O
defined,O
as,O
the,O
marker,O
variant,O
of,O
the,O
‘,O
V,O
’,O
clade,O
(,O
GISAID,S-Dataset
),O
.,O
Likewise,O
",",O
in,O
December,O
of,O
2019,O
",",O
a,O
novel,O
coronavirus,O
",",O
SARS,O
-,O
CoV-2,O
",",O
causing,O
the,O
Coronavirus,O
Infection,O
Disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
",",O
represents,O
the,O
third,O
coronavirus,O
to,O
jump,O
the,O
species,O
barrier,O
to,O
cause,O
severe,O
fatal,O
disease,O
in,O
humans,O
",",O
leading,O
to,O
an,O
unprecedented,O
devastating,O
global,O
pandemic,O
that,O
has,O
left,O
the,O
world,O
paralyzed,O
.,O
The,O
receptor,O
binding,O
domain,O
(,O
RBD,O
),O
of,O
the,O
spike,O
protein,O
of,O
SARS,O
-,O
CoV-2,O
(,O
residues,O
319–529,O
),O
(,O
GenBank,S-Repository
:,O
MN975262.1,S-AccessionNumber
),O
",",O
of,O
SARS,O
-,O
CoV-1,O
(,O
residues,O
306–515,O
),O
(,O
Urbani,O
strain,O
;,O
AAP13441.1,S-AccessionNumber
),O
",",O
and,O
of,O
CoV,O
-,O
HKU1,O
(,O
residues,O
310–677,O
),O
(,O
Accession,O
#,O
:,O
AY597011,S-AccessionNumber
),O
were,O
cloned,O
into,O
a,O
pVRC,O
vector,O
with,O
a,O
C,O
-,O
terminal,O
SBP,O
-,O
tag,O
and,O
expressed,O
in,O
HEK293F,O
cells,O
and,O
purified,O
as,O
previously,O
published,O
Bajic,O
et,O
al,O
.,O
",",O
2019,O
.,O
To,O
confirm,O
that,O
RBD,O
-,O
specific,O
responses,O
can,O
differentiate,O
individuals,O
that,O
have,O
been,O
previously,O
exposed,O
to,O
SARS,O
-,O
CoV-2,O
from,O
those,O
that,O
have,O
not,O
been,O
exposed,O
",",O
RBD,O
-,O
specific,O
IgM,O
",",O
IgG,O
",",O
and,O
IgA,O
responses,O
were,O
probed,O
in,O
a,O
group,O
of,O
convalescent,O
(,O
individuals,O
who,O
were,O
previously,O
diagnosed,O
with,O
COVID-19,O
and,O
later,O
recovered,O
",",O
as,O
confirmed,O
by,O
two,O
negative,O
RNA,O
tests,O
),O
and,O
negative,O
community,O
controls,O
.,O
Critical,O
to,O
managing,O
the,O
spread,O
of,O
COVID-19,O
is,O
the,O
ability,O
to,O
diagnose,O
infection,O
and,O
define,O
the,O
acquired,O
immune,O
response,O
across,O
the,O
population,O
.,O
In,O
the,O
early,O
phase,O
of,O
the,O
epidemic,O
",",O
COVID‐19,O
was,O
not,O
widely,O
distributed,O
in,O
children,O
.,O
Later,O
on,O
",",O
1391,O
children,O
from,O
Wuhan,O
who,O
had,O
contact,O
with,O
COVID‐19,O
patients,O
were,O
screened,O
.,O
A,O
similar,O
situation,O
was,O
observed,O
in,O
Italy,O
which,O
is,O
",",O
after,O
China,O
",",O
the,O
second,O
hotspot,O
of,O
the,O
COVID‐19,O
pandemic,O
.,O
One,O
special,O
problem,O
should,O
still,O
be,O
mentioned,O
in,O
this,O
context,O
:,O
in,O
Italy,O
",",O
paediatric,O
hospitalization,O
decreased,O
substantially,O
during,O
the,O
COVID‐19,O
epidemic,O
.,O
An,O
increased,O
number,O
of,O
deaths,O
occurred,O
in,O
Italy,O
due,O
to,O
delayed,O
arrival,O
of,O
children,O
in,O
hospitals,O
",",O
while,O
no,O
child,O
died,O
from,O
COVID‐19,O
in,O
Italy,O
(,O
Lazzerini,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
statistics,O
for,O
the,O
COVID‐19,O
epidemic,O
have,O
shown,O
that,O
the,O
older,O
population,O
has,O
suffered,O
the,O
greatest,O
loss,O
of,O
life,O
",",O
and,O
that,O
nursing,O
homes,O
have,O
been,O
hotspots,O
for,O
transmission,O
.,O
At,O
the,O
end,O
of,O
February,O
2020,O
",",O
a,O
cluster,O
of,O
167,O
epidemiologically,O
linked,O
COVID‐19,O
cases,O
were,O
reported,O
in,O
several,O
long‐term,O
care,O
facilities,O
in,O
Washington,O
state,O
.,O
One,O
in,O
10,O
of,O
>,O
1300,O
accredited,O
nursing,O
facilities,O
reported,O
COVID‐19,O
cases,O
.,O
A,O
cluster,O
of,O
COVID‐19,O
cases,O
in,O
Munich,O
",",O
Germany,O
was,O
analysed,O
in,O
detail,O
.,O
The,O
dynamics,O
of,O
viral,O
shedding,O
was,O
also,O
evaluated,O
in,O
94,O
Chinese,O
COVID‐19,O
patients,O
who,O
provided,O
414,O
throat,O
swabs,O
.,O
It,O
was,O
deduced,O
from,O
this,O
observation,O
that,O
the,O
infectiousness,O
of,O
COVID‐19,O
patients,O
peaked,O
on,O
",",O
or,O
slightly,O
before,O
",",O
symptom,O
onset,O
and,O
that,O
44,O
%,O
of,O
the,O
secondary,O
infections,O
occurred,O
in,O
the,O
pre‐symptomatic,O
phase,O
of,O
the,O
index,O
patient,O
.,O
Increased,O
personal,O
hygiene,O
and,O
social,O
distancing,O
for,O
everyone,O
are,O
",",O
therefore,O
",",O
key,O
instruments,O
for,O
COVID‐19,O
disease,O
control,O
in,O
the,O
community,O
(,O
He,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
At,O
the,O
height,O
of,O
the,O
UK,O
COVID‐19,O
epidemic,O
asymptomatic,O
health,O
care,O
workers,O
(,O
HCW,O
),O
from,O
London,O
were,O
repeatedly,O
tested,O
for,O
viral,O
RNA,O
over,O
6,O
 ,O
weeks,O
.,O
The,O
infection,O
rate,O
in,O
asymptomatic,O
HCW,O
was,O
7,O
%,O
at,O
the,O
peak,O
of,O
the,O
epidemic,O
",",O
and,O
it,O
decreased,O
to,O
1,O
%,O
with,O
the,O
lessening,O
of,O
the,O
epidemic,O
in,O
the,O
population,O
",",O
suggesting,O
that,O
infection,O
was,O
contracted,O
in,O
the,O
community,O
",",O
and,O
not,O
in,O
the,O
hospital,O
",",O
since,O
HCW,O
remained,O
exposed,O
to,O
COVID‐19,O
patients,O
during,O
work,O
(,O
Treibel,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Viruses,O
from,O
53,O
patients,O
were,O
sequenced,O
and,O
compared,O
with,O
177,O
SARS‐CoV‐2,O
sequences,O
deposited,O
in,O
the,O
database,O
.,O
The,O
first,O
case,O
of,O
COVID‐19,O
in,O
the,O
United,O
States,O
was,O
reported,O
on,O
January,O
19,O
at,O
the,O
northwest,O
coast,O
of,O
Washington,O
State,O
and,O
was,O
imported,O
from,O
China,O
.,O
Epidemiologists,O
investigated,O
the,O
first,O
nine,O
COVID‐19,O
cases,O
on,O
the,O
East,O
coast,O
(,O
Connecticut,O
),O
that,O
were,O
observed,O
in,O
mid‐March,O
with,O
genome,O
sequencing,O
.,O
In,O
Wuhan,O
",",O
105,O
index,O
cases,O
of,O
patients,O
suffering,O
from,O
moderate,O
COVID‐19,O
symptoms,O
(,O
fever,O
",",O
cough,O
",",O
fatigue,O
),O
were,O
investigated,O
for,O
secondary,O
transmission,O
to,O
392,O
household,O
contacts,O
.,O
Adding,O
viral‐specific,O
IgG,O
antibody,O
tests,O
to,O
the,O
toolbox,O
of,O
COVID‐19,O
epidemiology,O
have,O
allowed,O
the,O
connection,O
between,O
three,O
previously,O
separated,O
infections,O
clusters,O
in,O
Singapore,O
.,O
Since,O
most,O
COVID‐19,O
transmission,O
seems,O
to,O
occur,O
through,O
close,O
contact,O
",",O
droplets,O
have,O
been,O
considered,O
to,O
be,O
the,O
more,O
likely,O
vehicles,O
.,O
The,O
environment,O
of,O
three,O
COVID‐19,O
patients,O
from,O
a,O
ventilated,O
hospital,O
infection,O
ward,O
in,O
Singapore,O
was,O
tested,O
for,O
viral,O
RNA,O
presence,O
by,O
RT‐PCR,O
.,O
The,O
control,O
measures,O
that,O
stopped,O
the,O
epidemic,O
locally,O
have,O
included,O
:,O
intense,O
infection,O
surveillance,O
of,O
incoming,O
travellers,O
;,O
isolation,O
of,O
COVID‐19,O
cases,O
in,O
hospitals,O
;,O
contact,O
tracing,O
and,O
quarantine,O
in,O
holiday,O
camps,O
;,O
and,O
school,O
closure,O
but,O
no,O
lock‐down,O
",",O
thus,O
preventing,O
the,O
crisis,O
from,O
having,O
a,O
negative,O
economic,O
impact,O
.,O
Unfortunately,O
",",O
the,O
full,O
effect,O
of,O
school,O
closure,O
is,O
still,O
unknown,O
because,O
the,O
susceptibility,O
of,O
children,O
for,O
COVID‐19,O
and,O
their,O
capacity,O
to,O
transmit,O
the,O
infection,O
has,O
not,O
yet,O
been,O
established,O
(,O
Cowling,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
China,O
has,O
contained,O
the,O
COVID‐19,O
epidemic,O
through,O
a,O
combination,O
of,O
different,O
measures,O
including,O
drastic,O
ones,O
.,O
Based,O
on,O
these,O
data,O
and,O
on,O
a,O
mathematical,O
infection,O
model,O
",",O
the,O
authors,O
concluded,O
that,O
social,O
distancing,O
alone,O
is,O
sufficient,O
to,O
control,O
COVID‐19,O
spread,O
.,O
The,O
definition,O
for,O
a,O
confirmed,O
case,O
of,O
COVID‐19,O
was,O
changed,O
five,O
times,O
in,O
China,O
",",O
which,O
accounts,O
for,O
the,O
increase,O
in,O
knowledge,O
about,O
the,O
epidemic,O
.,O
COVID‐19,O
deaths,O
at,O
care,O
homes,O
were,O
three,O
times,O
as,O
high,O
as,O
COVID‐19,O
deaths,O
in,O
hospitals,O
(,O
Burki,O
",",O
2020,O
),O
.,O
In,O
comparison,O
",",O
the,O
global,O
death,O
toll,O
of,O
COVID‐19,O
is,O
now,O
315′000,O
(,O
status,O
May,O
18,O
),O
.,O
A,O
direct,O
comparison,O
of,O
these,O
two,O
figures,O
is,O
difficult,O
for,O
two,O
reasons,O
:,O
death,O
levels,O
are,O
affected,O
by,O
vaccination,O
campaigns,O
against,O
seasonal,O
influenza,O
and,O
by,O
strict,O
containment,O
measures,O
for,O
COVID‐19,O
.,O
It,O
seems,O
plausible,O
that,O
without,O
any,O
containment,O
measures,O
COVID‐19,O
mortality,O
would,O
surpass,O
greatly,O
the,O
number,O
of,O
deaths,O
from,O
seasonal,O
influenza,O
.,O
The,O
presumption,O
that,O
the,O
COVID‐19,O
mortality,O
is,O
comparable,O
to,O
that,O
of,O
seasonal,O
influenza,O
deaths,O
is,O
fundamentally,O
flawed,O
because,O
it,O
compares,O
numbers,O
which,O
are,O
obtained,O
by,O
different,O
methods,O
.,O
The,O
death,O
rate,O
for,O
COVID‐19,O
",",O
which,O
has,O
just,O
crossed,O
the,O
100,O
 ,O
000,O
figure,O
in,O
the,O
United,O
States,O
",",O
is,O
an,O
actual,O
count,O
of,O
dead,O
patients,O
.,O
Expressed,O
as,O
deaths,O
per,O
peak,O
week,O
",",O
influenza,O
claimed,O
a,O
maximum,O
1616,O
deaths,O
per,O
week,O
",",O
while,O
COVID‐19,O
took,O
about,O
15,O
 ,O
000,O
lives,O
per,O
week,O
at,O
its,O
peak,O
in,O
the,O
United,O
States,O
(,O
Faust,O
and,O
del,O
Rio,O
",",O
2020,O
),O
.,O
Epidemiologists,O
from,O
Harvard,O
University,O
derived,O
projections,O
from,O
model,O
calculations,O
about,O
the,O
future,O
dynamics,O
of,O
the,O
COVID‐19,O
epidemic,O
.,O
In,O
contrast,O
to,O
the,O
case,O
fatality,O
rate,O
(,O
CFR,O
),O
which,O
expresses,O
the,O
number,O
of,O
deaths,O
per,O
clinically,O
ill,O
patients,O
(,O
which,O
varies,O
from,O
1.4,O
%,O
to,O
15,O
%,O
for,O
COVID‐19,O
),O
",",O
IFR,O
is,O
the,O
number,O
of,O
deaths,O
per,O
infected,O
individual,O
.,O
While,O
we,O
know,O
",",O
approximatively,O
",",O
the,O
number,O
of,O
COVID‐19,O
deaths,O
and,O
COVID‐19,O
cases,O
",",O
we,O
do,O
not,O
definitively,O
know,O
the,O
number,O
of,O
infected,O
persons,O
",",O
since,O
this,O
would,O
require,O
large,O
and,O
systematic,O
seroprevalence,O
studies,O
",",O
but,O
which,O
are,O
lacking,O
.,O
Anosmia,O
(,O
loss,O
of,O
smell,O
),O
appeared,O
as,O
a,O
strong,O
predictor,O
of,O
COVID‐19,O
",",O
while,O
fever,O
was,O
not,O
a,O
diagnostic,O
criterion,O
unless,O
combined,O
with,O
other,O
symptoms,O
.,O
Also,O
",",O
long‐term,O
effects,O
of,O
the,O
disease,O
",",O
and,O
the,O
impact,O
of,O
the,O
COVID‐19,O
epidemic,O
on,O
social,O
relations,O
",",O
mental,O
health,O
",",O
and,O
financial,O
outcome,O
can,O
be,O
evaluated,O
with,O
this,O
tool,O
.,O
A,O
preliminary,O
evaluation,O
of,O
a,O
COVID‐19,O
Symptom,O
Tracker,O
smartphone,O
app,O
from,O
UK,O
users,O
showed,O
that,O
the,O
loss,O
of,O
smell,O
was,O
reported,O
by,O
59,O
%,O
of,O
people,O
with,O
respiratory,O
infection,O
who,O
tested,O
positive,O
for,O
SARS‐CoV‐2,O
",",O
compared,O
with,O
18,O
%,O
of,O
respiratory,O
patients,O
who,O
tested,O
negative,O
.,O
Clinical,O
criteria,O
that,O
allow,O
a,O
diagnosis,O
of,O
COVID‐19,O
without,O
a,O
viral,O
RNA,O
test,O
would,O
be,O
welcome,O
for,O
mass,O
screening,O
and,O
telemedicine,O
in,O
an,O
epidemic,O
situation,O
.,O
French,O
physicians,O
have,O
also,O
reported,O
that,O
many,O
COVID‐19,O
patients,O
reported,O
loss,O
of,O
smell,O
and,O
loss,O
of,O
taste,O
",",O
without,O
nasal,O
congestion,O
.,O
When,O
these,O
criteria,O
were,O
combined,O
in,O
a,O
retrospective,O
questionnaire,O
this,O
combination,O
of,O
signs,O
had,O
a,O
sensitivity,O
of,O
42,O
%,O
and,O
a,O
specificity,O
of,O
95,O
%,O
for,O
detecting,O
COVID‐19,O
patients,O
(,O
Bénézit,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
U.S.,O
physicians,O
even,O
suspected,O
that,O
SARS‐CoV‐2,O
might,O
",",O
in,O
addition,O
to,O
the,O
respiratory,O
and,O
alimentary,O
tract,O
",",O
also,O
infect,O
cranial,O
nerves,O
(,O
i.e.,O
being,O
neurotropic,O
),O
",",O
which,O
potentially,O
explains,O
the,O
observation,O
of,O
neurological,O
signs,O
in,O
9,O
%,O
of,O
COVID‐19,O
patients,O
(,O
Chu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
These,O
datasets,O
can,O
not,O
be,O
extrapolated,O
to,O
the,O
population,O
at,O
large,O
.,O
In,O
the,O
United,O
States,O
",",O
the,O
COVID‐19,O
epidemic,O
has,O
taken,O
more,O
lives,O
in,O
1,O
month,O
than,O
over,O
8,O
 ,O
years,O
during,O
the,O
Vietnam,O
War,O
.,O
With,O
more,O
than,O
1.7,O
million,O
cases,O
",",O
and,O
more,O
than,O
100,O
 ,O
000,O
deaths,O
",",O
the,O
‘,O
America,O
first,O
’,O
slogan,O
has,O
become,O
sadly,O
ironic,O
in,O
the,O
context,O
of,O
COVID‐19,O
.,O
The,O
CDC,O
",",O
once,O
a,O
pillar,O
and,O
international,O
reference,O
for,O
combating,O
diseases,O
worldwide,O
",",O
instrumental,O
in,O
eradicating,O
smallpox,O
and,O
coping,O
with,O
AIDS,O
or,O
Ebola,O
",",O
has,O
lost,O
its,O
technical,O
competence,O
and,O
public,O
trust,O
due,O
to,O
contradictory,O
scientific,O
messages,O
and,O
the,O
undermining,O
of,O
trust,O
in,O
scientific,O
evidence,O
by,O
the,O
current,O
U.S.,O
administration,O
.,O
At,O
the,O
end,O
of,O
May,O
",",O
the,O
United,O
Kingdom,O
directly,O
follows,O
the,O
United,O
States,O
in,O
the,O
international,O
mortality,O
ranking,O
list,O
with,O
more,O
than,O
38,O
 ,O
000,O
COVID‐19,O
deaths,O
.,O
The,O
European,O
Centre,O
for,O
Disease,O
Prevention,O
and,O
Control,O
(,O
ECDC,O
),O
",",O
which,O
was,O
established,O
in,O
2004,O
to,O
create,O
a,O
complement,O
to,O
the,O
U.S.,O
CDC,O
",",O
failed,O
to,O
become,O
a,O
hub,O
in,O
Europe,O
of,O
knowledge,O
for,O
COVID‐19,O
and,O
a,O
coordination,O
centre,O
for,O
Europe‐wide,O
epidemic,O
counter‐strategies,O
.,O
Even,O
the,O
city‐state,O
of,O
Singapore,O
",",O
where,O
the,O
early,O
handling,O
of,O
the,O
COVID‐19,O
was,O
lauded,O
as,O
exemplary,O
public,O
health,O
action,O
",",O
had,O
‘,O
blind,O
spots,O
’,O
on,O
their,O
screen,O
in,O
overlooking,O
the,O
miserable,O
living,O
conditions,O
of,O
migrant,O
workers,O
that,O
became,O
hotspots,O
of,O
COVID‐19,O
transmission,O
.,O
It,O
will,O
be,O
important,O
that,O
they,O
also,O
find,O
the,O
money,O
needed,O
for,O
COVID‐19,O
containment,O
among,O
migrant,O
workers,O
",",O
refugees,O
and,O
populations,O
at,O
risk,O
in,O
developing,O
countries,O
.,O
When,O
the,O
leading,O
nation,O
of,O
the,O
western,O
hemisphere,O
leaves,O
now,O
the,O
WHO,O
",",O
this,O
is,O
a,O
disastrous,O
signal,O
for,O
global,O
public,O
health,O
at,O
this,O
crucial,O
moment,O
of,O
the,O
COVID‐19,O
pandemic,O
.,O
In,O
the,O
absence,O
of,O
an,O
efficient,O
drug,O
treatment,O
or,O
a,O
vaccine,O
",",O
the,O
control,O
of,O
the,O
COVID‐19,O
pandemic,O
relies,O
on,O
classic,O
infection,O
control,O
measures,O
.,O
The,O
2019,O
novel,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
is,O
highly,O
infectious,O
1,O
",",O
2,O
",",O
outbreak,O
of,O
which,O
has,O
been,O
announced,O
as,O
a,O
global,O
pandemic,O
by,O
the,O
World,O
Health,O
Organization,O
on,O
11,O
March,O
2020,O
.,O
The,O
pathogen,O
contributed,O
to,O
COVID-19,O
is,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
2(SARS,O
-,O
CoV-2,O
),O
",",O
a,O
sister,O
of,O
SARS,O
-,O
CoV,O
3,O
",",O
4,O
.,O
The,O
RNA,O
binding,O
domain,O
of,O
SARS,O
-,O
CoV-2,O
spike,O
protein,O
binds,O
to,O
ACE2,O
with,O
a,O
20,O
-,O
30,O
-,O
fold,O
higher,O
affinity,O
than,O
SARS,O
-,O
CoV,O
6,O
-,O
9,O
",",O
which,O
may,O
contribute,O
to,O
the,O
rapid,O
transmission,O
of,O
COVID-19,O
.,O
To,O
comprehensively,O
investigate,O
the,O
mRNA,O
expression,O
of,O
ACE2,O
in,O
human,O
tissues,O
",",O
we,O
collected,O
the,O
transcriptome,O
datasets,O
in,O
three,O
public,O
databases,O
",",O
including,O
the,O
Tissue,B-Dataset
Atlas,I-Dataset
of,I-Dataset
Human,I-Dataset
Protein,I-Dataset
Atlas,I-Dataset
(HPA),E-Dataset
",",O
Genotype-Tissue,B-Dataset
Expression,I-Dataset
(GTEx),E-Dataset
",",O
and,O
Functional,B-Dataset
Annotation,I-Dataset
of,I-Dataset
Mammalian,I-Dataset
Genomes,I-Dataset
5,I-Dataset
(FANTOM5),I-Dataset
Cap,I-Dataset
Analysis,I-Dataset
of,I-Dataset
Gene,I-Dataset
Expression,I-Dataset
(CAGE),E-Dataset
 ,O
18,O
-,O
22,O
.,O
Given,O
the,O
minor,O
difference,O
between,O
these,O
three,O
data,O
sets,O
",",O
we,O
analyzed,O
the,O
overlapped,O
tissues,O
among,O
them,O
using,O
a,O
Venn,O
diagram,O
.,O
Indeed,O
",",O
such,O
results,O
were,O
further,O
supported,O
by,O
the,O
transcriptome,O
in,O
other,O
different,O
databases,O
",",O
including,O
Monaco,S-Creator
 ,O
scaled,O
dataset,O
and,O
Schmiedel,S-Creator
 ,O
dataset,O
25,O
",",O
26,O
(,O
.,O
With,O
the,O
global,O
outbreak,O
of,O
COVID-19,O
",",O
the,O
development,O
of,O
the,O
drugs,O
against,O
SARS,O
-,O
CoV-2,O
had,O
become,O
an,O
urgent,O
work,O
.,O
Therefore,O
",",O
the,O
comprehensive,O
investigation,O
of,O
ACE2,O
expression,O
in,O
human,O
tissues,O
has,O
implications,O
for,O
understanding,O
the,O
transmission,O
routes,O
of,O
SARS,O
-,O
CoV-2,O
and,O
the,O
development,O
of,O
anti,O
-,O
COVID-19,O
drugs,O
.,O
However,O
",",O
given,O
the,O
great,O
heterogeneity,O
among,O
humans,O
",",O
the,O
transcriptome,O
and,O
proteomic,O
dataset,O
with,O
a,O
larger,O
number,O
of,O
samples,O
and,O
a,O
wider,O
range,O
of,O
tissues,O
such,O
as,O
blood,O
cells,O
should,O
be,O
collected,O
to,O
analyze,O
.,O
In,O
this,O
study,O
",",O
we,O
made,O
a,O
comprehensive,O
investigation,O
of,O
the,O
mRNA,O
and,O
protein,O
expression,O
of,O
ACE2,O
in,O
human,O
tissues,O
using,O
public,O
transcriptome,O
",",O
proteomic,O
datasets,O
",",O
and,O
antibody,O
-,O
based,O
protein,O
profiles,O
.,O
Despite,O
all,O
these,O
databases,O
utilized,O
in,O
this,O
study,O
based,O
on,O
RNA,O
-,O
seq,O
",",O
there,O
is,O
a,O
minor,O
difference,O
among,O
the,O
transcriptome,O
result,O
obtained,O
from,O
different,O
databases,O
",",O
which,O
may,O
be,O
caused,O
by,O
tissue,O
source,O
",",O
technical,O
artifacts,O
inherent,O
in,O
the,O
respective,O
methodologies,O
",",O
and,O
gene,O
model,O
annotation,O
issues,O
among,O
them,O
.,O
The,O
high,O
expression,O
level,O
of,O
ACE2,O
in,O
the,O
gastrointestinal,O
tract,O
may,O
explain,O
why,O
most,O
of,O
COVID-19,O
patients,O
show,O
gastrointestinal,O
symptoms,O
in,O
the,O
early,O
stage,O
of,O
the,O
infection,O
41,O
.,O
Given,O
there,O
was,O
a,O
divergence,O
toward,O
the,O
potential,O
of,O
intrauterine,O
vertical,O
transmission,O
in,O
women,O
who,O
develop,O
COVID-19,O
pneumonia,O
during,O
pregnancy,O
42,O
-,O
44,O
",",O
we,O
also,O
paid,O
attention,O
to,O
the,O
expression,O
of,O
ACE2,O
in,O
the,O
female,O
reproduction,O
-,O
associated,O
tissues,O
.,O
Of,O
note,O
",",O
all,O
the,O
transcriptome,O
in,O
different,O
database,O
revealed,O
no,O
ACE2,O
mRNA,O
and,O
protein,O
in,O
the,O
common,O
blood,O
cells,O
",",O
including,O
basophil,O
",",O
eosinophil,O
",",O
neutrophil,O
",",O
classical,O
monocytes,O
",",O
non,O
-,O
classical,O
monocyte,O
",",O
Treg,O
",",O
gd,O
-,O
T,O
cell,O
",",O
MAIT,O
T,O
-,O
cell,O
",",O
memory,O
CD4,O
T,O
-,O
cell,O
",",O
naïve,O
CD4,O
T,O
-,O
cell,O
",",O
memory,O
B,O
-,O
cell,O
",",O
naïve,O
B,O
-,O
cell,O
",",O
plasmacytoid,O
DC,O
",",O
myeloid,O
DC,O
",",O
NK,O
cell,O
",",O
and,O
total,O
PBMC,O
",",O
suggesting,O
the,O
potential,O
of,O
resistance,O
of,O
immune,O
cell,O
against,O
SARS,O
-,O
CoV-2,O
.,O
SARS,O
-,O
CoV-2,O
infection,O
also,O
caused,O
a,O
remodeling,O
myeloid,O
in,O
severe,O
COVID-19,O
patients,O
45,O
.,O
Interestingly,O
",",O
a,O
prior,O
study,O
reported,O
that,O
COVID-19,O
susceptibility,O
seems,O
to,O
be,O
related,O
to,O
blood,O
group,O
",",O
whereas,O
whether,O
such,O
results,O
are,O
associated,O
with,O
the,O
level,O
of,O
ACE2,O
remains,O
uncertain,O
46,O
.,O
The,O
way,O
the,O
tissue,O
is,O
fixed,O
or,O
processed,O
can,O
affect,O
the,O
result,O
of,O
IHC,O
or,O
proteomics,O
of,O
these,O
databases,O
.,O
To,O
obtain,O
the,O
comprehensive,O
information,O
regarding,O
the,O
transcriptome,O
of,O
human,O
tissues,O
",",O
we,O
collected,O
the,O
transcriptome,O
from,O
three,O
public,O
databases,O
",",O
including,O
the,O
Human,B-Dataset
Protein,I-Dataset
Atlas,I-Dataset
(HPA),I-Dataset
tissues,I-Dataset
atlas,E-Dataset
",",O
Genotype-Tissue,B-Dataset
Expression,I-Dataset
(GTEx),E-Dataset
 ,O
project,O
",",O
and,O
Functional,B-Dataset
Annotation,I-Dataset
of,I-Dataset
Mammalian,I-Dataset
Genomes,I-Dataset
5,I-Dataset
(FANTOM5),E-Dataset
 ,O
project,O
.,O
All,O
these,O
databases,O
update,O
irregularly,O
and,O
the,O
version,O
of,O
them,O
we,O
analyzed,O
is,O
the,O
latest,O
.,O
HIPED,O
is,O
an,O
integrated,O
proteomics,O
platform,O
residing,O
within,O
GeneCards,O
",",O
which,O
involved,O
69,O
normal,O
anatomical,O
entities,O
(,O
tissues,O
",",O
cells,O
",",O
and,O
fluids,O
),O
from,O
four,O
databases,O
including,O
ProteomicsDB,S-Repository
",",O
MOPED,S-Repository
",",O
PaxDb,S-Repository
",",O
and,O
MaxQB,S-Repository
 ,O
51,O
.,O
The,O
public,O
transcriptome,O
datasets,O
from,O
Schmiedel,B-Creator
B.J.,E-Creator
 ,O
25,O
and,O
Monaco,B-Creator
G.,E-Creator
 ,O
26,O
were,O
also,O
collected,O
to,O
analyze,O
the,O
mRNA,O
expression,O
of,O
ACE2,O
in,O
human,O
common,O
blood,O
cells,O
.,O
Given,O
the,O
heterogeneity,O
among,O
humans,O
",",O
the,O
datasets,O
covering,O
more,O
tissues,O
with,O
a,O
larger,O
size,O
of,O
samples,O
should,O
be,O
analyzed,O
.,O
The,O
bulk,O
RNA,O
-,O
seq,O
profiles,O
from,O
three,O
separate,O
public,O
datasets,O
including,O
HPA,B-Dataset
tissue,I-Dataset
Atlas,E-Dataset
",",O
GTEx,S-Dataset
",",O
and,O
FANTOM5,B-Dataset
CAGE,E-Dataset
 ,O
were,O
also,O
obtained,O
to,O
determine,O
the,O
expression,O
of,O
ACE2,O
in,O
human,O
tissues,O
.,O
The,O
pandemic,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
caused,O
by,O
the,O
2019,O
novel,O
coronavirus,O
(,O
2019,O
-,O
nCoV,O
or,O
SARS,O
-,O
CoV-2,O
),O
infection,O
has,O
become,O
a,O
Public,O
Health,O
Emergency,O
of,O
International,O
Concern,O
(,O
PHEIC,O
),O
with,O
more,O
than,O
6,O
million,O
cases,O
and,O
"376,320",O
deaths,O
as,O
of,O
June,O
2,O
",",O
2020,O
(,O
WHO,O
",",O
2020,O
",",O
https://covid19.who.int,O
),O
.,O
SARS,O
-,O
CoV-2,O
infection,O
causes,O
disorder,O
of,O
natural,O
and,O
adaptive,O
immunity,O
",",O
leading,O
to,O
tissue,O
damage,O
and,O
systemic,O
inflammation,O
",",O
which,O
is,O
the,O
main,O
reason,O
for,O
death,O
of,O
COVID-19,O
patients,O
(,O
Huang,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
To,O
study,O
the,O
gene,O
function,O
of,O
new,O
coronavirus,O
",",O
SARS,O
-,O
CoV-2,O
ORFs,O
of,O
the,O
structural,O
genes,O
(,O
S,O
",",O
E,O
",",O
M,O
",",O
and,O
N,O
),O
and,O
the,O
accessory,O
genes,O
(,O
3a,O
",",O
6,O
",",O
7a,O
",",O
8,O
and,O
10,O
),O
(,O
GenBank,S-Repository
 ,O
ID,O
MN908947.3,S-AccessionNumber
),O
were,O
synthesized,O
by,O
Sangon,O
Biotechnology,O
Co.,O
",",O
Ltd.,O
(,O
Shanghai,O
",",O
China,O
),O
",",O
and,O
then,O
cloned,O
into,O
pCAGGS,O
vector,O
with,O
a,O
tag,O
encoding,O
hemagglutinin,O
(,O
HA,O
),O
at,O
the,O
N,O
-,O
terminus,O
of,O
each,O
protein,O
(,O
Fig,O
.,O
1,O
A,O
),O
.,O
ORF3b,O
is,O
not,O
performed,O
in,O
this,O
study,O
",",O
since,O
the,O
first,O
sequence,O
published,O
in,O
the,O
database,O
did,O
not,O
annotate,O
the,O
ORF3b,O
gene,O
.,O
The,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
is,O
a,O
novel,O
human,O
coronavirus,O
causing,O
the,O
pandemic,O
of,O
severe,O
pneumonia,O
(,O
Coronavirus,O
Disease,O
2019,O
",",O
COVID-19,O
),O
.,O
Innate,O
immune,O
response,O
is,O
critical,O
for,O
the,O
host,O
defense,O
against,O
viral,O
infection,O
and,O
the,O
dysregulation,O
of,O
the,O
host,O
innate,O
immune,O
responses,O
probably,O
aggravates,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
contributing,O
to,O
the,O
high,O
morbidity,O
and,O
lethality,O
of,O
COVID-19,O
.,O
The,O
complete,O
genomes,O
of,O
15,O
2019‐nCoV,O
sequences,O
have,O
been,O
downloaded,O
from,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
and,O
GenBank,S-Repository
 ,O
(,O
http://www.ncbi.nlm.nih.gov/genbank/,S-URL
),O
.,O
A,O
dataset,O
has,O
been,O
built,O
using,O
five,O
highly,O
similar,O
sequences,O
for,O
SARS,O
",",O
two,O
sequences,O
for,O
the,O
Middle,O
East,O
respiratory,O
syndrome,O
(,O
MERS,O
),O
",",O
and,O
five,O
highly,O
similar,O
sequences,O
for,O
bat,O
SARS‐like,O
coronavirus,O
.,O
The,O
percentage,O
of,O
similarity,O
has,O
been,O
identified,O
using,O
a,O
basic,O
local,O
alignment,O
search,O
tool,O
(,O
https://blast.ncbi.nlm.nih.gov/Blast.cgi,O
),O
;,O
eventually,O
duplicated,O
sequences,O
have,O
been,O
excluded,O
from,O
the,O
datasets,O
.,O
The,O
dataset,O
including,O
27,O
sequences,O
has,O
been,O
aligned,O
using,O
multiple,O
sequence,O
alignment,O
online,O
tool,O
 ,O
and,O
manually,O
edited,O
using,O
BioEdit,O
program,O
v7.0.5,O
.,O
The,O
ability,O
to,O
rapidly,O
connect,O
with,O
scientists,O
in,O
spite,O
of,O
institutional,O
shutdowns,O
has,O
",",O
on,O
top,O
of,O
this,O
",",O
facilitated,O
the,O
engagement,O
of,O
researchers,O
in,O
collaborative,O
activities,O
targeted,O
against,O
COVID-19,O
.,O
The,O
European,B-Repository
COVID-19,I-Repository
Data,I-Repository
Portal,E-Repository
 ,O
[,O
6,O
],O
",",O
announced,O
by,O
the,O
European,O
Commission,O
President,O
Ursula,O
von,O
der,O
Leyen,O
on,O
20,O
April,O
2020,O
",",O
for,O
example,O
",",O
is,O
setting,O
out,O
to,O
help,O
scientists,O
coordinate,O
the,O
sharing,O
of,O
research,O
data,O
related,O
to,O
the,O
fight,O
against,O
COVID-19,O
using,O
the,O
European,O
Open,O
Science,O
Cloud,O
.,O
Additional,O
activities,O
include,O
new,O
global,O
efforts,O
that,O
aim,O
to,O
sequence,O
SARS,O
-,O
CoV-2,O
viral,O
genomes,O
along,O
with,O
patient,O
-,O
matched,O
host,O
genomes,O
or,O
to,O
utilize,O
existing,O
cohorts,O
such,O
as,O
the,O
UK,B-Repository
Biobank,E-Repository
 ,O
[,O
7,O
],O
",",O
in,O
order,O
to,O
dissect,O
the,O
role,O
of,O
host,O
genetics,O
in,O
the,O
COVID-19,O
disease,O
course,O
.,O
On,O
top,O
of,O
this,O
",",O
new,O
international,O
platforms,O
such,O
as,O
Crowdfight,B-Dataset
COVID-19,E-Dataset
 ,O
[,O
8,O
],O
or,O
data,B-Dataset
against,I-Dataset
COVID-19,E-Dataset
 ,O
[,O
9,O
],O
aim,O
to,O
empower,O
scientists,O
to,O
work,O
together,O
in,O
fighting,O
SARS,O
-,O
CoV-2,O
",",O
by,O
connecting,O
expertise,O
from,O
different,O
fields,O
with,O
data,O
resources,O
.,O
Another,O
example,O
is,O
a,O
regular,O
workshop,O
series,O
hosted,O
by,O
the,O
European,O
Laboratory,O
of,O
Intelligent,O
Systems,O
(,O
ELLIS,O
),O
",",O
which,O
seeks,O
to,O
connect,O
the,O
expertise,O
of,O
leading,O
researchers,O
in,O
machine,O
learning,O
and,O
artificial,O
intelligence,O
for,O
the,O
fight,O
against,O
COVID-19,O
.,O
Although,O
49,O
%,O
of,O
scientists,O
reported,O
that,O
their,O
research,O
hours,O
have,O
been,O
reduced,O
during,O
the,O
COVID-19,O
outbreak,O
",",O
many,O
indicated,O
that,O
they,O
are,O
using,O
the,O
times,O
of,O
shutdown,O
to,O
devote,O
more,O
time,O
to,O
data,O
analysis,O
(,O
43,O
%,O
),O
",",O
manuscript,O
or,O
thesis,O
writing,O
(,O
45,O
%,O
),O
",",O
or,O
developing,O
grant,O
applications,O
(,O
11,O
%,O
),O
(,O
see,O
Fig,O
.,O
 ,O
1,O
),O
.,O
Indeed,O
",",O
there,O
are,O
early,O
signs,O
that,O
manuscript,O
submissions,O
to,O
scientific,O
journals,O
have,O
already,O
been,O
increasing,O
since,O
COVID-19,O
-,O
related,O
restrictions,O
have,O
emerged,O
[,O
4,O
],O
.,O
And,O
somewhat,O
impressively,O
",",O
over,O
a,O
hundred,O
respondents,O
(,O
102,O
",",O
18,O
%,O
of,O
the,O
total,O
),O
indicated,O
that,O
they,O
shifted,O
the,O
regular,O
scientific,O
activities,O
to,O
be,O
able,O
to,O
directly,O
contribute,O
to,O
research,O
with,O
the,O
aim,O
to,O
combat,O
COVID-19,O
.,O
A,O
recent,O
inquiry,O
circulated,O
among,O
members,O
of,O
the,O
European,O
Molecular,O
Biology,O
Organization,O
(,O
EMBO,O
),O
provides,O
an,O
independent,O
testament,O
of,O
the,O
willingness,O
of,O
life,O
scientists,O
to,O
contribute,O
to,O
fighting,O
COVID-19,O
(,O
https://www.data-against-covid.org,S-URL
),O
.,O
A,O
novel,O
coronavirus,O
SARS‐CoV‐2,O
leading,O
to,O
COVID‐19,O
was,O
identified,O
for,O
the,O
first,O
time,O
in,O
December,O
2019,O
and,O
as,O
of,O
today,O
has,O
infected,O
already,O
more,O
than,O
5.0,O
million,O
and,O
killed,O
more,O
than,O
320,O
000,O
people,O
worldwide,O
(,O
as,O
of,O
20th,O
of,O
May,O
2020,O
),O
.,O
An,O
anti‐CD147,O
antibody,O
that,O
blocks,O
infection,O
with,O
SARS‐CoV‐2,O
in,O
vitro,O
and,O
its,O
humanized,O
drug,O
(,O
meplazumab,O
),O
has,O
been,O
already,O
used,O
in,O
a,O
clinical,O
trial,O
in,O
patients,O
with,O
COVID‐19,O
pneumonia,O
.,O
The,O
percentage,O
of,O
improvement,O
in,O
patients,O
with,O
severe,O
and,O
critical,O
COVID‐19,O
presentations,O
seemed,O
higher,O
in,O
weekly,O
meplazumab,O
treatment,O
compared,O
to,O
patients,O
on,O
the,O
conventional,O
treatment,O
.,O
They,O
can,O
be,O
incorporated,O
to,O
the,O
viral,O
capsid,O
and,O
released,O
",",O
which,O
further,O
enables,O
virus,O
binding,O
to,O
CD147,O
and,O
subsequent,O
infection,O
of,O
CD147‐expressing,O
cells,O
.,O
Since,O
cyclophilins,O
are,O
regulators,O
of,O
NFAT,O
activation,O
",",O
the,O
extracellular,O
binding,O
of,O
the,O
virus,O
through,O
cyclophilin‐CD147,O
complex,O
",",O
as,O
well,O
as,O
intracellular,O
interactions,O
of,O
cyclophilins,O
with,O
the,O
virus,O
proteins,O
might,O
be,O
important,O
in,O
COVID‐19,O
development,O
.,O
We,O
analyzed,O
gene,O
expression,O
of,O
SARS‐CoV‐2,O
receptors,O
and,O
related,O
molecules,O
’,O
(,O
Table,O
 ,O
S1,O
),O
in,O
a,O
broad,O
range,O
of,O
tissues,O
and,O
immune,O
cells,O
from,O
the,O
human,O
RNA‐seq,O
databases,O
generated,O
by,O
our,O
ex,O
vivo,O
and,O
in,O
vitro,O
approaches,O
in,O
the,O
Swiss,B-Repository
Institute,I-Repository
of,I-Repository
Asthma,I-Repository
and,I-Repository
Allergy,I-Repository
Research,I-Repository
(SIAF),E-Repository
",",O
by,O
our,O
collaborators,O
or,O
from,O
the,O
Gene,B-Repository
Expression,I-Repository
Omnibus,E-Repository
 ,O
(,O
http://www.ncbi.nlm.nih.gov/,S-URL
),O
.,O
We,O
further,O
investigated,O
different,O
expression,O
patterns,O
of,O
ACE2‐,O
",",O
CD147‐,O
",",O
and,O
CD26‐related,O
genes,O
in,O
the,O
context,O
of,O
potential,O
COVID‐19,O
risk,O
factors,O
",",O
namely,O
age,O
",",O
gender,O
",",O
smoking,O
status,O
",",O
diagnosis,O
of,O
asthma,O
",",O
chronic,O
obstructive,O
pulmonary,O
disease,O
(,O
COPD,O
),O
",",O
hypertension,O
",",O
obesity,O
",",O
and,O
atopic,O
dermatitis,O
(,O
AD,O
),O
(,O
Table,O
 ,O
S3,O
),O
.,O
Genes,O
of,O
interest,O
were,O
extracted,O
from,O
all,O
datasets,O
.,O
Clinical,O
evidence,O
from,O
COVID‐19,O
patients,O
worldwide,O
clearly,O
demonstrates,O
an,O
association,O
between,O
disease,O
severity,O
and,O
morbidity,O
with,O
age,O
.,O
We,O
analyzed,O
expression,O
of,O
ACE2‐,O
",",O
CD147‐,O
",",O
and,O
CD26‐related,O
genes,O
from,O
different,O
cells,O
and,O
tissues,O
in,O
various,O
comorbidities,O
and,O
risk,O
factors,O
",",O
which,O
have,O
been,O
shown,O
",",O
or,O
are,O
suspected,O
to,O
predispose,O
to,O
SARS‐CoV‐2,O
infection,O
and/or,O
COVID‐19,O
progression,O
.,O
Next,O
",",O
we,O
analyzed,O
the,O
ACE2‐,O
",",O
CD147‐,O
",",O
and,O
CD26‐related,O
gene,O
expression,O
in,O
our,O
controls,O
",",O
asthma,O
and,O
COPD,O
patients,O
according,O
to,O
the,O
additional,O
clinical,O
features,O
",",O
which,O
have,O
been,O
reported,O
as,O
risk,O
factors,O
for,O
COVID‐19,O
",",O
such,O
as,O
hypertension,O
",",O
smoking,O
",",O
gender,O
",",O
and,O
obesity,O
.,O
",",O
In,O
summary,O
",",O
these,O
findings,O
suggest,O
that,O
higher,O
BMI,O
and,O
older,O
age,O
lead,O
to,O
higher,O
expression,O
of,O
CD147‐related,O
genes,O
on,O
immune,O
cells,O
",",O
but,O
not,O
on,O
the,O
barrier,O
cells,O
",",O
which,O
potentially,O
can,O
influence,O
the,O
development,O
and,O
the,O
course,O
of,O
COVID‐19,O
.,O
As,O
we,O
found,O
a,O
high,O
expression,O
of,O
ACE2‐,O
",",O
CD147‐,O
",",O
and,O
CD26‐related,O
genes,O
in,O
the,O
skin,O
biopsies,O
of,O
healthy,O
subjects,O
",",O
and,O
since,O
COVID‐19‐related,O
skin,O
lesions,O
have,O
been,O
recently,O
reported,O
",",O
 ,O
we,O
also,O
analyzed,O
the,O
skin,O
biopsies,O
of,O
healthy,O
subjects,O
and,O
AD,O
patients,O
.,O
COVID‐19,O
pandemic,O
is,O
developing,O
at,O
such,O
a,O
pace,O
that,O
extraordinary,O
actions,O
are,O
being,O
initiated,O
to,O
learn,O
quickly,O
about,O
its,O
biology,O
",",O
transmission,O
",",O
and,O
potential,O
means,O
of,O
prevention,O
and,O
treatment,O
.,O
In,O
this,O
spirit,O
",",O
we,O
first,O
performed,O
an,O
extensive,O
literature,O
and,O
database,O
search,O
and,O
curated,O
a,O
list,O
of,O
proven,O
and,O
potential,O
receptors,O
for,O
SARS‐CoV‐2,O
and,O
interaction,O
partners,O
",",O
whose,O
expression,O
in,O
different,O
tissues,O
and,O
cells,O
might,O
be,O
involved,O
in,O
the,O
course,O
of,O
immunological,O
response,O
in,O
COVID‐19,O
(,O
Figure,O
 ,O
6,O
),O
.,O
While,O
interesting,O
associations,O
were,O
observed,O
to,O
be,O
age‐dependent,O
",",O
these,O
findings,O
must,O
be,O
further,O
explored,O
and,O
repeated,O
due,O
to,O
the,O
possibility,O
of,O
batch‐specific,O
systematic,O
variations,O
in,O
the,O
gene,O
expression,O
values,O
between,O
in‐house,O
and,O
public,O
datasets,O
.,O
Despite,O
our,O
efforts,O
in,O
applying,O
identical,O
data,O
analysis,O
workflow,O
for,O
the,O
datasets,O
produced,O
by,O
our,O
group,O
and,O
those,O
available,O
in,O
public,O
repositories,O
",",O
different,O
sequencing,O
facilities,O
and,O
experiment,O
protocols,O
can,O
lead,O
to,O
altered,O
gene,O
expression,O
values,O
",",O
especially,O
for,O
genes,O
with,O
extreme,O
gene,O
length,O
and,O
G,O
/,O
C,O
content,O
.,O
Finally,O
",",O
we,O
analyzed,O
gene,O
expression,O
in,O
adults,O
with,O
known,O
and,O
potential,O
COVID‐19,O
comorbidities,O
and,O
risk,O
factors,O
such,O
as,O
COPD,O
",",O
asthma,O
",",O
hypertension,O
",",O
obesity,O
",",O
smoking,O
",",O
male,O
gender,O
",",O
and,O
AD,O
.,O
Interestingly,O
",",O
we,O
observed,O
high,O
expression,O
of,O
ACE2,O
and,O
TMPRSS2,O
in,O
bronchial,O
airway,O
epithelium,O
:,O
in,O
HBECs,O
ALI,O
cultures,O
in,O
vitro,O
",",O
as,O
well,O
as,O
in,O
vivo,O
in,O
humans,O
in,O
bronchial,O
biopsies,O
",",O
indicating,O
that,O
they,O
can,O
be,O
as,O
important,O
in,O
initiation,O
and,O
progression,O
of,O
COVID‐19,O
",",O
as,O
recently,O
shown,O
for,O
type,O
II,O
pneumocytes,O
.,O
On,O
the,O
other,O
hand,O
",",O
ACE2,O
and,O
the,O
angiotensin,O
II,O
type,O
2,O
receptor,O
(,O
AT2,O
),O
were,O
reported,O
to,O
protect,O
from,O
severe,O
acute,O
lung,O
injury,O
in,O
mice,O
",",O
 ,O
therefore,O
an,O
importance,O
of,O
ACE2,O
in,O
SARS‐CoV‐2,O
infection,O
and,O
COVID‐19,O
progression,O
should,O
be,O
further,O
explored,O
.,O
Even,O
though,O
initially,O
asthma,O
was,O
not,O
reported,O
to,O
be,O
a,O
significant,O
comorbidity,O
for,O
COVID‐19,O
",",O
more,O
observations,O
from,O
Europe,O
and,O
the,O
US,O
seem,O
to,O
show,O
otherwise,O
.,O
Thus,O
",",O
it,O
is,O
possible,O
that,O
ACE2,O
expression,O
in,O
the,O
airways,O
of,O
allergic,O
patients,O
",",O
even,O
if,O
slightly,O
protective,O
in,O
terms,O
of,O
infection,O
with,O
SARS‐CoV‐2,O
",",O
might,O
also,O
predispose,O
to,O
faster,O
progression,O
of,O
COVID‐19,O
to,O
more,O
severe,O
forms,O
",",O
especially,O
in,O
case,O
of,O
higher,O
TMPRSS2,O
expression,O
.,O
We,O
found,O
that,O
immune,O
cells,O
do,O
not,O
express,O
ACE2,O
",",O
TMPRSS2,O
",",O
or,O
SLC6A19,O
",",O
which,O
has,O
also,O
been,O
observed,O
by,O
others,O
.,O
",",O
  ,O
Importantly,O
though,O
",",O
we,O
found,O
that,O
CD147,O
and,O
its,O
extracellular,O
agonists,O
and,O
transmembrane,O
partners,O
are,O
highly,O
expressed,O
in,O
innate,O
and,O
adaptive,O
immune,O
cells,O
in,O
the,O
lungs,O
and,O
in,O
the,O
periphery,O
",",O
suggesting,O
that,O
they,O
should,O
be,O
further,O
investigated,O
in,O
SARS‐CoV‐2,O
spread,O
and,O
COVID‐19,O
pathology,O
.,O
Obesity,O
is,O
one,O
of,O
the,O
main,O
comorbidities,O
reported,O
in,O
patients,O
with,O
severe,O
COVID‐19,O
",",O
 ,O
and,O
since,O
CD147,O
expression,O
in,O
the,O
whole,O
blood,O
correlates,O
positively,O
with,O
BMI,O
in,O
our,O
cohort,O
",",O
it,O
certainly,O
needs,O
further,O
attention,O
in,O
relation,O
to,O
COVID‐19,O
.,O
Importantly,O
",",O
CD147,O
expression,O
is,O
upregulated,O
by,O
high,O
glucose,O
concentrations,O
",",O
 ,O
which,O
might,O
reflect,O
its,O
correlation,O
with,O
obesity,O
",",O
and,O
potentially,O
also,O
with,O
diabetes,O
",",O
another,O
very,O
important,O
COVID‐19,O
comorbidity,O
.,O
Thus,O
",",O
our,O
results,O
suggest,O
a,O
possible,O
role,O
of,O
CD147,O
and,O
its,O
extracellular,O
and,O
intracellular,O
ligands,O
in,O
COVID‐19,O
pathogenesis,O
via,O
regulation,O
of,O
cell,O
metabolism,O
",",O
motility,O
",",O
and,O
activation,O
",",O
especially,O
in,O
patients,O
with,O
comorbidities,O
.,O
A,O
clinical,O
trial,O
with,O
anti‐CD147,O
in,O
COVID‐19,O
patients,O
seems,O
to,O
confirm,O
its,O
pleiotropic,O
role,O
in,O
SARS‐CoV‐2,O
infection,O
",",O
but,O
it,O
requires,O
further,O
research,O
to,O
investigate,O
the,O
involved,O
mechanisms,O
and,O
molecules,O
.,O
Recent,O
studies,O
reported,O
that,O
many,O
COVID‐19,O
cases,O
developed,O
nonpruritic,O
",",O
erythematous,O
rashes,O
",",O
urticaria,O
",",O
or,O
varicella‐like,O
lesions,O
",",O
",",O
  ,O
but,O
so,O
far,O
it,O
is,O
not,O
known,O
if,O
they,O
are,O
a,O
place,O
of,O
viral,O
replication,O
or,O
just,O
a,O
local,O
reaction,O
to,O
systemic,O
infection,O
.,O
Similarly,O
",",O
not,O
much,O
is,O
yet,O
known,O
about,O
the,O
potential,O
connections,O
between,O
AD,O
and,O
the,O
course,O
of,O
COVID‐19,O
.,O
Abstract,O
  ,O
Background,O
 ,O
Morbidity,O
and,O
mortality,O
from,O
COVID‐19,O
caused,O
by,O
novel,O
coronavirus,O
SARS‐CoV‐2,O
is,O
accelerating,O
worldwide,O
",",O
and,O
novel,O
clinical,O
presentations,O
of,O
COVID‐19,O
are,O
often,O
reported,O
.,O
The,O
aim,O
of,O
our,O
study,O
was,O
to,O
analyze,O
the,O
expression,O
of,O
known,O
and,O
potential,O
SARS‐CoV‐2,O
receptors,O
and,O
related,O
molecules,O
in,O
the,O
extensive,O
collection,O
of,O
primary,O
human,O
cells,O
and,O
tissues,O
from,O
healthy,O
subjects,O
of,O
different,O
age,O
and,O
from,O
patients,O
with,O
risk,O
factors,O
and,O
known,O
comorbidities,O
of,O
COVID‐19,O
.,O
We,O
performed,O
RNA,O
sequencing,O
and,O
explored,O
available,O
RNA‐Seq,O
databases,O
to,O
study,O
gene,O
expression,O
and,O
co‐expression,O
of,O
ACE2,O
",",O
CD147,O
(,O
BSG,O
),O
",",O
and,O
CD26,O
(,O
DPP4,O
),O
and,O
their,O
direct,O
and,O
indirect,O
molecular,O
partners,O
in,O
primary,O
human,O
bronchial,O
epithelial,O
cells,O
",",O
bronchial,O
and,O
skin,O
biopsies,O
",",O
bronchoalveolar,O
lavage,O
fluid,O
",",O
whole,O
blood,O
",",O
peripheral,O
blood,O
mononuclear,O
cells,O
(,O
PBMCs,O
),O
",",O
monocytes,O
",",O
neutrophils,O
",",O
DCs,O
",",O
NK,O
cells,O
",",O
ILC1,O
",",O
ILC2,O
",",O
ILC3,O
",",O
CD4,O
+,O
and,O
CD8,O
+,O
We,O
analyzed,O
the,O
material,O
from,O
healthy,O
children,O
and,O
adults,O
",",O
and,O
from,O
adults,O
in,O
relation,O
to,O
their,O
disease,O
or,O
COVID‐19,O
risk,O
factor,O
status,O
.,O
Altered,O
expression,O
of,O
these,O
receptors,O
related,O
to,O
age,O
",",O
gender,O
",",O
obesity,O
and,O
smoking,O
",",O
as,O
well,O
as,O
with,O
the,O
disease,O
status,O
",",O
might,O
contribute,O
to,O
COVID‐19,O
morbidity,O
and,O
severity,O
patterns,O
.,O
The,O
recognition,O
in,O
2019,O
of,O
the,O
first,O
outbreak,O
in,O
Wuhan,O
",",O
China,O
",",O
of,O
a,O
respiratory,O
disease,O
(,O
COVID‐19,O
),O
associated,O
with,O
a,O
novel,O
coronavirus,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS‐CoV‐2,O
),O
triggered,O
an,O
international,O
response,O
unparalleled,O
in,O
its,O
scale,O
and,O
tempo.1,O
",",O
2,O
",",O
3,O
",",O
4,O
",",O
5,O
",",O
6,O
In,O
particular,O
",",O
the,O
rapid,O
sharing,O
and,O
integration,O
of,O
clinical,O
and,O
epidemiological,O
data,O
has,O
facilitated,O
understanding,O
of,O
the,O
spectrum,O
of,O
clinical,O
disease,O
caused,O
by,O
SARS‐CoV‐2,O
and,O
the,O
extent,O
of,O
its,O
global,O
spread,O
",",O
although,O
there,O
are,O
still,O
many,O
unanswered,O
questions,O
.,O
In,O
China,O
",",O
he,O
had,O
had,O
no,O
contact,O
with,O
live,O
food,O
markets,O
",",O
people,O
known,O
to,O
have,O
COVID‐19,O
",",O
or,O
hospitals,O
.,O
Our,O
sequences,O
are,O
available,O
at,O
GenBank,S-Repository
 ,O
(,O
accession,O
number,O
",",O
MT007544.1,S-AccessionNumber
),O
",",O
and,O
the,O
genome,O
was,O
rapidly,O
uploaded,O
to,O
the,O
Global,B-Dataset
Initiative,I-Dataset
of,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
(GISAID),E-Dataset
 ,O
(,O
accession,O
number,O
",",O
EPI_ISL_406844,S-AccessionNumber
),O
.,O
We,O
have,O
described,O
the,O
first,O
reported,O
case,O
of,O
COVID‐19,O
in,O
Australia,O
",",O
with,O
rapid,O
diagnosis,O
",",O
and,O
isolation,O
",",O
imaging,O
",",O
and,O
sharing,O
of,O
the,O
causative,O
agent,O
",",O
SARS‐CoV‐2,O
.,O
Major,O
outcomes,O
 ,O
Clinical,O
course,O
and,O
laboratory,O
features,O
of,O
the,O
first,O
reported,O
case,O
of,O
COVID,O
‐19,O
(,O
the,O
illness,O
caused,O
by,O
SARS,O
‐CoV‐2,O
),O
in,O
Australia,O
;,O
isolation,O
",",O
whole,O
genome,O
sequencing,O
",",O
imaging,O
",",O
and,O
rapid,O
sharing,O
of,O
virus,O
from,O
the,O
patient,O
.,O
The,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
a,O
novel,O
RNA,O
virus,O
of,O
the,O
Coronaviridae,O
family,O
",",O
caused,O
an,O
outbreak,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
in,O
China,O
in,O
late,O
December,O
2019,O
",",O
and,O
has,O
been,O
rapidly,O
spreading,O
to,O
more,O
than,O
214,O
countries,O
and,O
areas,O
since,O
then,O
[,O
1,O
],O
",",O
[,O
2,O
],O
.,O
COVID-19,O
is,O
the,O
third,O
pandemic,O
caused,O
by,O
coronavirus,O
in,O
the,O
last,O
20,O
 ,O
years,O
;,O
and,O
it,O
has,O
resulted,O
in,O
more,O
than,O
"4,993,470",O
infections,O
and,O
claimed,O
nearly,O
"327,738",O
lives,O
as,O
of,O
May,O
22,O
",",O
2020,O
",",O
exceeding,O
any,O
other,O
epidemic,O
caused,O
by,O
betacoronaviruses,O
in,O
the,O
human,O
history,O
",",O
for,O
example,O
",",O
SARS,O
in,O
2002–2003,O
and,O
the,O
Middle,O
East,O
respiratory,O
syndrome,O
(,O
MERS,O
),O
in,O
2012,O
(,O
https://www.ecdc.europa.eu/en/2019-ncov-background-disease,O
),O
.,O
Among,O
the,O
extensive,O
studies,O
conducted,O
on,O
COVID-19,O
",",O
one,O
essential,O
question,O
is,O
to,O
trace,O
the,O
origin,O
and,O
transmission,O
between,O
humans,O
",",O
shedding,O
light,O
on,O
the,O
molecular,O
mechanism,O
underlying,O
epidemiological,O
and,O
pathological,O
characteristics,O
of,O
the,O
virus,O
.,O
One,O
example,O
of,O
an,O
infection,O
cluster,O
is,O
the,O
COVID-19,O
outbreak,O
in,O
the,O
Diamond,O
Princess,O
cruise,O
[,O
9,O
],O
.,O
The,O
dataset,O
used,O
for,O
this,O
study,O
includes,O
"12,909",O
genomic,O
sequences,O
as,O
of,O
May,O
4,O
",",O
2020,O
",",O
of,O
which,O
487,O
genomes,O
are,O
from,O
China,O
(,O
15,O
provinces,O
and,O
regions,O
),O
and,O
"12,422",O
genomes,O
are,O
from,O
72,O
other,O
countries,O
of,O
the,O
world,O
.,O
Second,O
",",O
from,O
Jan,O
10,O
",",O
2020,O
to,O
Feb,O
29,O
",",O
2020,O
",",O
only,O
11,O
out,O
of,O
the,O
718,O
samples,O
in,O
the,O
public,O
databases,O
",",O
i.e.,O
",",O
2019,B-Repository
Novel,I-Repository
Coronavirus,I-Repository
Resource,I-Repository
(2019nCoVR),E-Repository
 ,O
[,O
14,O
],O
and,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
",",O
were,O
collected,O
from,O
Wuhan,O
.,O
Third,O
",",O
before,O
Dec,O
24,O
",",O
2019,O
",",O
no,O
sequence,O
was,O
collected,O
in,O
the,O
databases,O
during,O
this,O
early,O
stage,O
.,O
Fifteen,O
of,O
the,O
68,O
(,O
22.06,O
%,O
),O
H1,O
haplotypes,O
were,O
collected,O
only,O
from,O
patients,O
near,O
WSM,O
showing,O
severe,O
symptoms,O
of,O
COVID-19,O
in,O
a,O
short,O
time,O
interval,O
(,O
Dec,O
30,O
",",O
2019,O
–,O
Jan,O
7,O
",",O
2020,O
),O
",",O
which,O
was,O
the,O
initial,O
period,O
of,O
COVID-19,O
outbreak,O
.,O
WSM,O
was,O
widely,O
considered,O
as,O
the,O
source,O
of,O
the,O
COVID-19,O
outbreak,O
since,O
it,O
was,O
first,O
identified,O
around,O
late,O
December,O
",",O
2019,O
.,O
However,O
",",O
some,O
studies,O
claimed,O
COVID-19,O
might,O
originate,O
at,O
an,O
earlier,O
time,O
point,O
and,O
outside,O
of,O
WSM,O
(,O
e.g.,O
",",O
[,O
15,O
],O
),O
.,O
The,O
estimated,O
TMRCA,O
and,O
the,O
associated,O
95,O
%,O
CIs,O
are,O
both,O
earlier,O
than,O
the,O
outbreak,O
time,O
of,O
COVID-19,O
in,O
WSM,O
.,O
We,O
observe,O
remarkable,O
changes,O
in,O
the,O
prevalence,O
of,O
L,O
lineage,O
during,O
the,O
COVID-19,O
pandemic,O
(,O
Figure,O
S3A,O
),O
.,O
A,O
total,O
of,O
"12,909",O
SARS,O
-,O
CoV-2,O
genomes,O
available,O
on,O
May,O
4,O
",",O
2020,O
were,O
downloaded,O
from,O
GISAID,S-Dataset
 ,O
(,O
http://www.gisaid.org,S-URL
),O
and,O
National,B-Repository
Genomics,I-Repository
Data,I-Repository
Center,E-Repository
 ,O
(,O
https://bigd.big.ac.cn/ncov/,S-URL
),O
.,O
A,O
novel,O
RNA,O
virus,O
",",O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
is,O
responsible,O
for,O
the,O
ongoing,O
outbreak,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
Population,O
genetic,O
analysis,O
could,O
be,O
useful,O
for,O
investigating,O
the,O
origin,O
and,O
evolutionary,O
dynamics,O
of,O
COVID-19,O
.,O
The,O
results,O
indicate,O
that,O
COVID-19,O
might,O
originate,O
earlier,O
than,O
and,O
outside,O
of,O
Wuhan,O
Seafood,O
Market,O
.,O
A,O
total,O
of,O
65,O
SARS,O
-,O
CoV-2,O
patient,O
isolate,O
sequences,O
were,O
collected,O
from,O
NCBI,S-Repository
 ,O
and,O
GISAID,S-Dataset
 ,O
databases,O
and,O
aligned,O
against,O
SARS,O
-,O
CoV-2,O
reference,O
sequence,O
NC_045512.2,S-AccessionNumber
 ,O
(,O
Table,O
S1,O
),O
.,O
Using,O
databases,O
and,O
published,O
data,O
",",O
we,O
filtered,O
our,O
considered,O
miRNA,O
to,O
those,O
with,O
documented,O
expression,O
in,O
SARS,O
-,O
CoV-2,O
target,O
cells,O
",",O
and,O
additionally,O
focused,O
on,O
miRNAs,O
that,O
have,O
been,O
reported,O
as,O
components,O
of,O
the,O
anti,O
-,O
viral,O
miRNA,O
-,O
mediated,O
defence,O
system,O
.,O
It,O
is,O
well,O
established,O
that,O
patients,O
with,O
cardiovascular,O
disease,O
are,O
overrepresented,O
in,O
symptomatic,O
COVID-19,O
cohorts,O
and,O
have,O
a,O
higher,O
mortality,O
rate,O
[,O
55,O
],O
.,O
Nsp4,O
A9259,O
G,O
is,O
present,O
in,O
a,O
sequence,O
obtained,O
from,O
Vietnam,O
(,O
GISAID,S-Dataset
:,O
EPI_ISL_416429,S-AccessionNumber
),O
.,O
However,O
",",O
further,O
investigations,O
into,O
the,O
interactions,O
of,O
miR-197,O
-,O
5p,O
expression,O
",",O
the,O
C3037U,O
mutation,O
",",O
and,O
COVID-19,O
disease,O
severity,O
in,O
this,O
cardiovascular,O
patients,O
are,O
required,O
.,O
The,O
tree,O
structure,O
was,O
validated,O
by,O
running,O
the,O
analysis,O
on,O
100,O
bootstrapped,O
input,O
datasets,O
.,O
Briefly,O
",",O
this,O
analysis,O
finds,O
the,O
eigenvectors,O
describing,O
the,O
highest,O
variance,O
within,O
a,O
categorical,O
dataset,O
",",O
like,O
ours,O
.,O
Our,O
dataset,O
derived,O
from,O
the,O
MUSCLE,O
MSA,O
of,O
70,O
genomes,O
and,O
generated,O
32,O
 ,O
206,O
positions,O
:,O
the,O
categories,O
in,O
each,O
coordinate,O
could,O
be,O
A,O
(,O
Adenine,O
),O
",",O
C,O
(,O
Cytosine,O
),O
",",O
G,O
(,O
Guanine,O
;,O
T,O
[,O
Thymine,O
],O
",",O
although,O
being,O
an,O
single,O
strand,O
RNA,O
virus,O
",",O
it,O
would,O
be,O
more,O
appropriate,O
to,O
use,O
U,O
[,O
Uracil,O
],O
),O
",",O
N,O
(,O
Nucleotide,O
",",O
uncertain,O
location,O
:,O
very,O
rare,O
in,O
this,O
dataset,O
",",O
and,O
accounting,O
for,O
only,O
nine,O
positions,O
",",O
or,O
0.0004,O
%,O
of,O
all,O
the,O
data,O
),O
.,O
So,O
",",O
we,O
searched,O
for,O
ORF8,O
homologous,O
substrates,O
in,O
the,O
Mammalia,O
NCBI,S-Repository
 ,O
nr,O
protein,O
database,O
",",O
but,O
could,O
not,O
find,O
matches,O
within,O
the,O
E‐value,O
threshold,O
of,O
1,O
.,O
In,O
summary,O
",",O
we,O
found,O
that,O
all,O
data,O
sets,O
",",O
including,O
both,O
the,O
on,O
-,O
going,O
outbreak,O
of,O
SARS,O
-,O
CoV-2,O
in,O
China,O
and,O
the,O
2003,O
SARS,O
-,O
CoV,O
epidemic,O
in,O
China,O
and,O
worldwide,O
",",O
were,O
well,O
fitted,O
to,O
the,O
Boltzmann,O
function,O
(,O
Fig,O
.,O
1,O
and,O
S1,O
),O
.,O
The,O
world,O
is,O
facing,O
a,O
dire,O
situation,O
of,O
global,O
public,O
health,O
emergency,O
due,O
to,O
a,O
viral,O
pandemic,O
of,O
severe,O
febrile,O
pneumonia,O
like,O
respiratory,O
syndrome,O
caused,O
by,O
a,O
novel,O
coronavirus,O
",",O
named,O
SARS,O
-,O
CoV-2,O
",",O
causing,O
the,O
COVID-19,O
disease,O
.,O
Clinical,O
onset,O
of,O
infection,O
in,O
COVID-19,O
is,O
characterized,O
by,O
symptoms,O
as,O
headache,O
",",O
dry,O
cough,O
",",O
and,O
fever,O
;,O
in,O
severe,O
cases,O
multi,O
-,O
organ,O
failure,O
",",O
and,O
even,O
deaths,O
(,O
3,O
),O
.,O
Additionally,O
",",O
neutralizing,O
monoclonal,O
antibody,O
-,O
based,O
therapeutics,O
are,O
also,O
being,O
developed,O
to,O
combat,O
COVID-19,O
crisis,O
(,O
13,O
",",O
14,O
),O
.,O
This,O
study,O
has,O
identified,O
potential,O
anti,O
-,O
SARS,O
-,O
CoV-2,O
agents,O
",",O
which,O
can,O
be,O
directly,O
tested,O
for,O
in,O
vitro,O
and,O
in,O
vivo,O
studies,O
",",O
to,O
combat,O
a,O
global,O
threat,O
of,O
COVID-19,O
.,O
Drug,O
molecules,O
targeting,O
the,O
S,O
-,O
protein,O
has,O
the,O
potential,O
to,O
cure,O
COVID-19,O
infections,O
and,O
to,O
tackle,O
the,O
pandemic,O
.,O
Since,O
the,O
newly,O
published,O
structure,O
of,O
SARS,O
-,O
CoV-2,O
S,O
-,O
protein,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6VSB,S-AccessionNumber
),O
lacks,O
important,O
loop,O
residues,O
of,O
S,O
-,O
RBD,O
domain,O
proposed,O
to,O
be,O
involved,O
in,O
receptor,O
binding,O
",",O
therefore,O
a,O
homology,O
model,O
was,O
generated,O
utilizing,O
it,O
as,O
a,O
template,O
(,O
Figures,O
3A,O
",",O
B,O
),O
.,O
A,O
3D,O
model,O
of,O
S1,O
subunit,O
of,O
SARS,O
-,O
CoV-2,O
S,O
-,O
protein,O
",",O
was,O
predicted,O
using,O
SWISS,O
MODEL,O
(,O
NCBI,S-Repository
 ,O
reference,O
sequence,O
:,O
MN908947.3,S-AccessionNumber
),O
and,O
the,O
pre,O
-,O
fusion,O
structure,O
of,O
SARS,O
-,O
CoV-2,O
spike,O
glycoprotein,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6VSB,S-AccessionNumber
),O
was,O
used,O
as,O
template,O
(,O
Figure,O
3,O
),O
.,O
The,O
predicted,O
homology,O
model,O
for,O
S1,O
subunit,O
of,O
S,O
-,O
protein,O
was,O
submitted,O
in,O
PMDB,S-Repository
 ,O
database,O
(,O
PMDB,S-Repository
 ,O
ID,O
:,O
PM0082972,S-AccessionNumber
),O
",",O
and,O
the,O
HADDOCK,O
tool,O
was,O
used,O
to,O
identify,O
interacting,O
residues,O
between,O
receptor,O
and,O
S,O
-,O
RBD,O
of,O
S,O
-,O
protein,O
(,O
Figure,O
S2,O
),O
.,O
Crystal,O
structure,O
of,O
S,O
-,O
protein,O
of,O
SARS,O
-,O
CoV-2,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6VSB,S-AccessionNumber
),O
",",O
published,O
recently,O
",",O
lacks,O
residues,O
present,O
in,O
the,O
S,O
-,O
RBD,O
region,O
of,O
SARS,O
-,O
CoV-2,O
.,O
Chimeric,O
S,O
-,O
RBD,O
of,O
SARS,O
-,O
CoV-2,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
6VW1,S-AccessionNumber
),O
has,O
been,O
reported,O
",",O
but,O
the,O
structure,O
comprises,O
majorly,O
of,O
SARS,O
-,O
CoV,O
residues,O
and,O
contains,O
only,O
S,O
-,O
RBM,O
of,O
SARS,O
-,O
CoV-2,O
.,O
The,O
datasets,O
presented,O
in,O
this,O
study,O
can,O
be,O
found,O
in,O
online,O
repositories,O
.,O
The,O
names,O
of,O
the,O
repository,O
/,O
repositories,O
and,O
accession,O
number(s,O
),O
can,O
be,O
found,O
in,O
the,O
article,O
/,O
Supplementary,O
Material,O
.,O
The,O
rapidly,O
spreading,O
",",O
highly,O
contagious,O
and,O
pathogenic,O
SARS,O
-,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
associated,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
has,O
been,O
declared,O
as,O
a,O
pandemic,O
by,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
.,O
The,O
repurposing,O
of,O
drugs,O
can,O
provide,O
a,O
rapid,O
and,O
potential,O
cure,O
toward,O
exponentially,O
expanding,O
COVID-19,O
.,O
Timely,O
identification,O
and,O
determination,O
of,O
an,O
effective,O
drug,O
to,O
combat,O
and,O
tranquilize,O
the,O
COVID-19,O
global,O
crisis,O
is,O
the,O
utmost,O
need,O
of,O
hour,O
.,O
(,O
Gorbalenya,O
et,O
al,O
.,O
",",O
2020,O
;,O
Jiang,O
et,O
al,O
.,O
",",O
2020,O
),O
causing,O
human,O
pneumonia,O
(,O
i.e.,O
",",O
COVID-19,O
),O
",",O
was,O
first,O
reported,O
in,O
Wuhan,O
",",O
Hubei,O
",",O
Central,O
China,O
(,O
Wu,O
et,O
al,O
.,O
",",O
2020a,O
;,O
Zhou,O
et,O
al,O
.,O
",",O
2020,O
;,O
Zhu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Since,O
the,O
outbreak,O
of,O
COVID-19,O
was,O
first,O
identified,O
in,O
Wuhan,O
in,O
mid,O
-,O
December,O
2019,O
",",O
the,O
first,O
infected,O
individuals,O
identified,O
in,O
other,O
provinces,O
and,O
regions,O
of,O
China,O
",",O
and,O
other,O
countries,O
",",O
during,O
January,O
2020,O
",",O
have,O
been,O
assumed,O
to,O
have,O
been,O
infected,O
in,O
Wuhan,O
or,O
through,O
contact,O
with,O
people,O
from,O
Wuhan,O
(,O
Chan,O
et,O
al,O
.,O
",",O
2020,O
;,O
Holshue,O
et,O
al,O
.,O
",",O
2020,O
;,O
Phan,O
et,O
al,O
.,O
",",O
2020,O
;,O
Rothe,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
this,O
study,O
",",O
we,O
used,O
93,O
genomes,O
of,O
SARS,O
-,O
CoV-2,O
from,O
the,O
GISAID,S-Dataset
 ,O
EpiFluTM,O
database,O
(,O
Shu,O
&,O
McCauley,O
",",O
2017,O
),O
(,O
access,O
date,O
12,O
February,O
2020,O
),O
to,O
decode,O
the,O
evolution,O
and,O
transmissions,O
of,O
SARS,O
-,O
CoV-2,O
in,O
the,O
first,O
two,O
months,O
of,O
its,O
spread,O
.,O
To,O
decode,O
the,O
evolutionary,O
history,O
of,O
SARS,O
-,O
CoV-2,O
",",O
we,O
retrieved,O
96,O
complete,O
genomes,O
from,O
GISAID,S-Dataset
 ,O
(,O
Supplementary,O
Table,O
S1,O
",",O
access,O
by,O
12,O
February,O
2020,O
),O
(,O
Shu,O
&,O
McCauley,O
",",O
2017,O
),O
.,O
The,O
genome,O
EPI_ISL_402131,S-AccessionNumber
 ,O
(,O
bat,O
-,O
RaTG13,O
-,O
CoV,O
",",O
hereafter,O
),O
from,O
GISAID,S-Dataset
 ,O
was,O
also,O
included,O
as,O
the,O
outgroup,O
",",O
because,O
it,O
is,O
the,O
closest,O
sister,O
betacoronavirus,O
available,O
to,O
SARS,O
-,O
CoV-2,O
(,O
Zhou,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
We,O
carefully,O
used,O
three,O
datasets,O
(,O
i.e.,O
",",O
four,O
core,O
substitution,O
sites,O
",",O
120,O
substitution,O
sites,O
",",O
and,O
1,O
235,O
substitution,O
sites,O
",",O
Supplementary,O
Datasets,O
),O
to,O
evaluate,O
the,O
relationship,O
between,O
bat,O
-,O
RaTG13,O
-,O
CoV,O
and,O
four,O
associated,O
/,O
central,O
haplotypes,O
of,O
SARS,O
-,O
CoV-2,O
(,O
H1,O
",",O
H3,O
",",O
H13,O
",",O
and,O
H38,O
),O
.,O
Three,O
different,O
datasets,O
were,O
used,O
to,O
infer,O
evolutionary,O
networks,O
",",O
which,O
consistently,O
supported,O
H13,O
and,O
H38,O
as,O
the,O
potentially,O
ancestral,O
haplotypes,O
",",O
i.e.,O
",",O
the,O
outgroup,O
bat,O
-,O
RaTG13,O
-,O
CoV,O
could,O
connect,O
to,O
both,O
H13,O
and,O
H38,O
",",O
or,O
H38,O
alone,O
",",O
or,O
through,O
a,O
medium,O
vector,O
mv1,O
(,O
an,O
intermediate,O
host,O
or,O
the,O
first,O
infected,O
humans,O
),O
connected,O
to,O
both,O
H13,O
and,O
H38,O
by,O
single,O
mutations,O
at,O
positions,O
18067,O
(,O
S,O
",",O
synonymous,O
substitution,O
),O
and/or,O
29102,O
(,O
S,O
),O
",",O
referring,O
to,O
the,O
numbering,O
of,O
the,O
alignment,O
length,O
29,O
910,O
bp,O
(,O
Figure,O
5,O
),O
.,O
Five,O
main,O
groups,O
can,O
be,O
recognized,O
in,O
the,O
network,O
using,O
the,O
dataset,O
of,O
120,O
substitution,O
sites,O
(,O
Figure,O
3A,O
),O
.,O
The,O
outbreak,O
of,O
COVID-19,O
started,O
in,O
mid,O
-,O
December,O
2019,O
in,O
Wuhan,O
",",O
China,O
.,O
In,O
this,O
study,O
",",O
we,O
used,O
93,O
complete,O
genomes,O
of,O
SARS,O
-,O
CoV-2,O
from,O
the,O
GISAID,S-Dataset
 ,O
EpiFlu,O
TM,O
database,O
to,O
investigate,O
the,O
evolution,O
and,O
human,O
-,O
to,O
-,O
human,O
transmissions,O
of,O
SARS,O
-,O
CoV-2,O
in,O
the,O
first,O
two,O
months,O
of,O
the,O
outbreak,O
.,O
The,O
dataset,O
of,O
four,O
core,O
substitution,O
sites,O
is,O
the,O
four,O
variable,O
sites,O
shared,O
among,O
bat,O
-,O
RaTG13,O
-,O
CoV,O
and,O
the,O
four,O
central,O
node,O
haplotypes,O
.,O
The,O
dataset,O
of,O
120,O
substitution,O
sites,O
refers,O
to,O
all,O
variable,O
sites,O
of,O
coding,O
regions,O
in,O
SARS,O
-,O
CoV-2,O
haplotypes,O
.,O
The,O
dataset,O
of,O
1235,O
substitution,O
sites,O
refers,O
to,O
all,O
variable,O
sites,O
of,O
coding,O
regions,O
among,O
bat,O
-,O
RaTG13,O
-,O
CoV,O
and,O
SARS,O
-,O
CoV-2,O
haplotypes,O
.,O
SARS,O
-,O
CoV-2,O
is,O
the,O
causative,O
agent,O
of,O
current,O
pandemic,O
of,O
novel,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
which,O
has,O
infected,O
millions,O
of,O
people,O
and,O
is,O
responsible,O
for,O
more,O
than,O
"200,000",O
deaths,O
worldwide,O
in,O
a,O
span,O
of,O
just,O
4,O
 ,O
months,O
.,O
In,O
both,O
cases,O
",",O
the,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
isolate,O
Wuhan,O
-,O
Hu-1,O
as,O
reference,O
genome,O
(,O
Accession,O
NC_045512.2,S-AccessionNumber
),O
was,O
used,O
as,O
the,O
reference,O
sequence,O
.,O
Five,O
individuals,O
had,O
contact,O
with,O
COVID-19,O
patients,O
in,O
particular,O
;,O
both,O
S2,O
and,O
S3,O
had,O
contact,O
with,O
the,O
same,O
patient,O
(,O
table,O
 ,O
1,O
),O
.,O
All,O
the,O
nine,O
sequences,O
have,O
been,O
submitted,O
in,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
database,O
.,O
Phylogenetic,O
tree,O
analysis,O
of,O
the,O
sequences,O
",",O
along,O
with,O
other,O
complete,O
viral,O
genome,O
sequences,O
submitted,O
from,O
India,O
in,O
GISAID,S-Dataset
",",O
revealed,O
that,O
seven,O
of,O
these,O
sequences,O
belonged,O
to,O
the,O
A2a,O
clade,O
while,O
only,O
one,O
sequence,O
belonged,O
to,O
clade,O
B4,O
(,O
figure,O
 ,O
1,O
and,O
table,O
 ,O
1,O
),O
.,O
To,O
understand,O
transmission,O
histories,O
of,O
these,O
nine,O
SARS,O
-,O
CoV-2,O
isolates,O
from,O
West,O
Bengal,O
",",O
we,O
aligned,O
these,O
sequences,O
with,O
more,O
than,O
6000,O
global,O
sequences,O
",",O
including,O
thirty,O
sequences,O
submitted,O
in,O
GISAID,S-Dataset
 ,O
from,O
India,O
(,O
at,O
the,O
time,O
of,O
our,O
analysis,O
),O
to,O
identify,O
specific,O
mutations,O
that,O
occur,O
at,O
the,O
highest,O
level,O
of,O
the,O
tip,O
in,O
a,O
branch,O
leading,O
to,O
the,O
specific,O
subtype,O
.,O
Out,O
of,O
these,O
",",O
two,O
sequences,O
were,O
obtained,O
from,O
individuals,O
with,O
contact,O
history,O
of,O
a,O
COVID-19,O
patient,O
who,O
had,O
travelled,O
from,O
Italy,O
.,O
Interestingly,O
",",O
two,O
out,O
of,O
three,O
sequences,O
harbouring,O
these,O
mutations,O
obtained,O
by,O
us,O
belonged,O
to,O
Kolkata,O
and,O
with,O
contact,O
history,O
with,O
one,O
COVID-19,O
patient,O
who,O
had,O
travelled,O
from,O
London,O
(,O
UK,O
),O
.,O
The,O
third,O
sequence,O
was,O
obtained,O
from,O
a,O
COVID-19,O
patient,O
from,O
Darjeeling,O
",",O
India,O
who,O
had,O
history,O
of,O
travel,O
from,O
Chennai,O
",",O
India,O
.,O
Therefore,O
",",O
we,O
used,O
the,O
TissueAtlas,S-Dataset
 ,O
database,O
to,O
analyse,O
the,O
presence,O
and,O
correlation,O
of,O
these,O
miRNAs,O
in,O
body,O
fluids,O
.,O
When,O
Ser202,O
is,O
phosphorylated,O
which,O
incorporates,O
a,O
large,O
negative,O
group,O
tethered,O
to,O
the,O
sidechain,O
of,O
Ser,O
",",O
as,O
seen,O
in,O
many,O
other,O
substrates,O
of,O
kinases,O
",",O
it,O
is,O
likely,O
that,O
charge,O
neutralization,O
takes,O
place,O
involving,O
positively,O
charged,O
sidechains,O
in,O
the,O
sequential,O
and,O
spatial,O
vicinity,O
.,O
Substantial,O
uncertainties,O
surround,O
the,O
trajectory,O
of,O
the,O
recent,O
epidemic,O
of,O
COVID-19,O
in,O
India,O
.,O
Interestingly,O
",",O
while,O
two,O
out,O
the,O
three,O
sequences,O
harbouring,O
these,O
mutations,O
were,O
from,O
individuals,O
who,O
shared,O
contact,O
history,O
with,O
a,O
COVID-19,O
patient,O
with,O
history,O
of,O
travel,O
from,O
Italy,O
",",O
two,O
out,O
of,O
the,O
three,O
samples,O
from,O
West,O
Bengal,O
shared,O
contact,O
history,O
with,O
the,O
same,O
COVID-19,O
patient,O
with,O
history,O
of,O
travel,O
from,O
UK,O
.,O
This,O
correlates,O
with,O
the,O
fact,O
that,O
these,O
two,O
individuals,O
had,O
also,O
been,O
known,O
to,O
have,O
contact,O
with,O
the,O
same,O
COVID-19,O
patient,O
.,O
Interestingly,O
",",O
both,O
these,O
individuals,O
belonged,O
to,O
the,O
same,O
district,O
of,O
East,O
Medinipur,O
",",O
had,O
history,O
of,O
contact,O
with,O
COVID-19,O
patients,O
and,O
did,O
not,O
exhibit,O
any,O
clinical,O
symptom,O
.,O
Interesting,O
correlation,O
was,O
observed,O
between,O
these,O
mutations,O
and,O
travel,O
or,O
contact,O
history,O
of,O
COVID-19,O
positive,O
cases,O
.,O
Recent,O
correspondence,O
in,O
this,O
Journal,O
has,O
highlighted,O
the,O
current,O
threat,O
posed,O
by,O
recently,O
-,O
emerging,O
corona,O
virus,O
disease,O
2019,O
(,O
COVID-19,O
),O
in,O
the,O
world,O
.,O
The,O
COVID-19,O
is,O
infection,O
caused,O
by,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
and,O
is,O
characterized,O
by,O
fever,O
",",O
dry,O
cough,O
",",O
weak,O
",",O
and,O
so,O
on,O
.,O
Recently,O
",",O
COVID-19,O
epidemic,O
in,O
China,O
has,O
been,O
well,O
controlled,O
",",O
whereas,O
the,O
risk,O
of,O
imported,O
COVID-19,O
cases,O
has,O
increased,O
dramatically,O
.,O
However,O
",",O
limited,O
studies,O
on,O
full,O
-,O
length,O
genome,O
characterization,O
of,O
SARS,O
-,O
CoV-2,O
from,O
COVID-19,O
cases,O
imported,O
from,O
abroad,O
.,O
Eight,O
COVID-19,O
patients,O
imported,O
from,O
overseas,O
were,O
admitted,O
to,O
Yunnan,O
Provincial,O
Infectious,O
Disease,O
Hospital,O
from,O
March,O
15,O
",",O
2020,O
to,O
March,O
26,O
",",O
2020,O
.,O
Two,O
cases,O
YN_Im01,O
and,O
YN_Im03,O
were,O
from,O
Spain,O
to,O
Yunnan,O
",",O
YN_Im02,O
from,O
France,O
",",O
YN_Im04,O
from,O
Cambodia,O
",",O
YN_Im05,O
from,O
Sri,O
Lanka,O
",",O
and,O
YN_Im06,O
-,O
08,O
",",O
a,O
family,O
cluster,O
of,O
COVID-19,O
patients,O
from,O
the,O
United,O
States,O
(,O
Fig,O
.,O
1A,O
),O
.,O
YN_Im06,O
was,O
severe,O
",",O
YN_Im01,O
",",O
YN_Im05,O
",",O
YN_Im07,O
",",O
and,O
YN_Im08,O
were,O
moderate,O
",",O
YN_Im02,O
was,O
mild,O
",",O
and,O
YN_Im03,O
and,O
YN_Im04,O
were,O
asymptomatic,O
according,O
to,O
the,O
latest,O
COVID-19,O
diagnostic,O
criteria,O
(,O
5th,O
edition,O
),O
published,O
by,O
the,O
National,O
Health,O
Commission,O
of,O
China,O
(,O
Fig,O
.,O
1B,O
),O
.,O
So,O
far,O
",",O
three,O
main,O
clades,O
involving,O
G,O
",",O
V,O
",",O
and,O
S,O
have,O
been,O
identified,O
based,O
on,O
marker,O
mutations,O
in,O
the,O
complete,O
SARS,O
-,O
CoV-2,O
genome,O
according,O
to,O
the,O
latest,O
genotyping,O
rules,O
recommended,O
by,O
the,O
GISAID,S-Dataset
 ,O
databas,O
.,O
Further,O
",",O
phylogenetic,O
trees,O
for,O
SARS,O
-,O
CoV-2,O
full,O
-,O
length,O
nucleotide,O
sequences,O
were,O
constructed,O
based,O
on,O
the,O
obtained,O
datasets,O
with,O
the,O
maximum,O
-,O
likelihood,O
method,O
using,O
IQ,O
-,O
tree,O
.,O
Moreover,O
",",O
three,O
novel,O
mutations,O
",",O
including,O
D1962V,O
in,O
nsp3,O
from,O
the,O
strain,O
YN_Im03,O
",",O
L1375F,O
in,O
nsp3,O
and,O
A829,O
T,O
in,O
S,O
protein,O
from,O
the,O
isolate,O
YN_Im04,O
were,O
first,O
identified,O
in,O
this,O
study,O
according,O
to,O
the,O
comparison,O
with,O
"11,231",O
genomic,O
sequences,O
available,O
at,O
GISAID,S-Dataset
 ,O
on,O
4/26/2020.10,O
Given,O
that,O
the,O
three,O
COVID-19,O
patients,O
were,O
diagnosed,O
on,O
the,O
same,O
day,O
and,O
the,O
viruses,O
originated,O
from,O
the,O
same,O
strain,O
",",O
indicated,O
that,O
the,O
strain,O
is,O
replicating,O
and,O
mutating,O
rapidly,O
in,O
different,O
individuals,O
.,O
After,O
being,O
interviewed,O
by,O
quarantine,O
officers,O
",",O
she,O
was,O
transferred,O
to,O
Bamrasnaradura,O
Infectious,O
Disease,O
Institute,O
(,O
BIDI,O
),O
Hospital,O
",",O
Nonthaburi,O
",",O
for,O
isolation,O
and,O
laboratory,O
investigations,O
.,O
Genomic,O
sequencing,O
analysis,O
included,O
Sanger,O
and,O
next,O
generation,O
sequencing,O
were,O
performed,O
by,O
the,O
Emerging,O
Infectious,O
Diseases,O
Health,O
Science,O
Center,O
",",O
the,O
Thai,O
Red,O
Cross,O
Society,O
and,O
the,O
Thai,O
National,O
Institute,O
of,O
Health,O
",",O
Department,O
of,O
Medical,O
Sciences,O
and,O
the,O
sequence,O
shared,O
via,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),I-Dataset
EpiCoV,E-Dataset
 ,O
database,O
(,O
EPI_ISL_403962,S-AccessionNumber
),O
.,O
Subsequent,O
genome,O
sequencing,O
was,O
again,O
compatible,O
with,O
the,O
SARS,O
-,O
CoV-2,O
and,O
shared,O
via,O
the,O
GISAID,B-Dataset
EpiCoV,E-Dataset
 ,O
database,O
(,O
EPI_ISL_403963,S-AccessionNumber
),O
.,O
The,O
genomes,O
of,O
the,O
two,O
separate,O
cases,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
are,O
identical,O
over,O
the,O
full,O
length,O
of,O
close,O
to,O
30,O
kb,O
and,O
are,O
furthermore,O
identical,O
to,O
five,O
other,O
sequences,O
(,O
four,O
from,O
Wuhan,O
and,O
one,O
from,O
Zhejiang,O
),O
;,O
together,O
these,O
sequences,O
form,O
the,O
largest,O
cluster,O
of,O
identical,O
cases,O
within,O
the,O
early,O
outbreak,O
",",O
comprising,O
a,O
core,O
of,O
at,O
least,O
indirectly,O
linked,O
cases,O
(,O
Figure,O
2,O
),O
.,O
According,O
to,O
the,O
cases,O
’,O
history,O
",",O
the,O
two,O
imported,O
COVID-19,O
cases,O
described,O
here,O
are,O
not,O
directly,O
linked,O
",",O
yet,O
their,O
genomes,O
are,O
identical,O
.,O
The,O
missing,O
link,O
to,O
the,O
market,O
",",O
the,O
time,O
of,O
travel,O
and,O
onset,O
of,O
symptoms,O
in,O
the,O
two,O
COVID-19,O
cases,O
together,O
with,O
the,O
incubation,O
period,O
of,O
mean,O
6.4,O
days,O
(,O
range,O
:,O
5.6–7.7,O
),O
[,O
16,O
],O
and,O
the,O
time,O
of,O
closest,O
genome,O
neighbours,O
obtained,O
from,O
sequences,O
in,O
Wuhan,O
",",O
suggest,O
that,O
transmission,O
within,O
Wuhan,O
beyond,O
the,O
Huanan,O
Seafood,O
Market,O
is,O
likely,O
to,O
have,O
occurred,O
in,O
the,O
first,O
week,O
of,O
January,O
or,O
earlier,O
.,O
Therefore,O
",",O
while,O
one,O
can,O
not,O
exclude,O
the,O
possibility,O
that,O
asymptomatic,O
cases,O
in,O
their,O
incubation,O
period,O
would,O
be,O
missed,O
and,O
become,O
infectious,O
later,O
",",O
screening,O
of,O
incoming,O
travellers,O
from,O
an,O
affected,O
area,O
proved,O
successful,O
at,O
least,O
in,O
these,O
two,O
instances,O
",",O
when,O
COVID-19,O
cases,O
were,O
detected,O
",",O
isolated,O
",",O
observed,O
and,O
only,O
discharged,O
once,O
they,O
tested,O
negative,O
for,O
SARS,O
-,O
CoV-2,O
.,O
Rapid,O
response,O
including,O
genome,O
sequencing,O
and,O
sharing,O
via,O
GISAID,S-Dataset
 ,O
[,O
"18,19",O
],O
(,O
https://www.gisaid.org/,S-URL
),O
enabled,O
fast,O
dissemination,O
of,O
results,O
and,O
provided,O
a,O
glimpse,O
of,O
early,O
transmission,O
patterns,O
in,O
this,O
outbreak,O
.,O
We,O
report,O
two,O
cases,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
in,O
travellers,O
from,O
Wuhan,O
",",O
China,O
to,O
Thailand,O
.,O
Probably,O
started,O
in,O
December,O
2019,O
from,O
a,O
zoonotic,O
transmission,O
from,O
traded,O
wild,O
animals,O
in,O
a,O
Wuhan,O
market,O
(,O
Hubei,O
Province,O
",",O
China,O
),O
[,O
"1,2",O
],O
",",O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
quickly,O
reached,O
a,O
planetary,O
dimension,O
forcing,O
billions,O
of,O
people,O
into,O
lockdown,O
",",O
grinding,O
to,O
a,O
halt,O
most,O
of,O
the,O
world,O
economies,O
",",O
and,O
killing,O
in,O
excess,O
of,O
"375,000",O
of,O
the,O
6.1,O
million,O
people,O
known,O
to,O
be,O
infected,O
(,O
as,O
of,O
2,O
June,O
2020,O
),O
.,O
Initially,O
catalogued,O
as,O
a,O
respiratory,O
disease,O
(,O
severe,O
acute,O
respiratory,O
syndrome,O
",",O
SARS,O
),O
",",O
the,O
investigation,O
of,O
severe,O
COVID-19,O
cases,O
progressively,O
revealed,O
their,O
association,O
with,O
a,O
dysfunctional,O
pro,O
-,O
inflammatory,O
response,O
leading,O
to,O
severe,O
lung,O
damages,O
[,O
3,O
],O
",",O
but,O
also,O
cardiovascular,O
complications,O
[,O
4,O
],O
and,O
multi,O
-,O
organ,O
failures,O
[,O
5,O
],O
.,O
The,O
unexpected,O
severity,O
and,O
dimension,O
of,O
the,O
COVID-19,O
pandemic,O
prompted,O
national,O
research,O
organizations,O
to,O
ask,O
their,O
scientists,O
",",O
even,O
without,O
prior,O
knowledge,O
on,O
coronaviruses,O
",",O
to,O
use,O
their,O
expertise,O
to,O
contribute,O
to,O
the,O
solution,O
of,O
this,O
formidable,O
challenge,O
.,O
In,O
this,O
paper,O
",",O
I,O
present,O
a,O
bioinformatic,O
investigation,O
of,O
publicly,O
available,O
sequence,O
data,O
",",O
in,O
an,O
attempt,O
to,O
identify,O
which,O
molecular,O
processes,O
might,O
be,O
responsible,O
of,O
the,O
specific,O
clinical,O
picture,O
of,O
COVID-19,O
.,O
Several,O
coincidental,O
findings,O
examined,O
in,O
the,O
light,O
of,O
the,O
rich,O
pre,O
-,O
existing,O
bibliographical,O
information,O
strongly,O
suggest,O
that,O
virus,O
-,O
induced,O
de,O
-,O
mono,O
-,O
ADP,O
-,O
ribosylation,O
(,O
de,O
-,O
MARylation,O
),O
of,O
STAT1,O
might,O
be,O
one,O
of,O
the,O
key,O
steps,O
leading,O
to,O
the,O
inflammatory,O
cytokine,O
storm,O
seen,O
in,O
the,O
most,O
severe,O
COVID-19,O
cases,O
.,O
Due,O
to,O
the,O
lockdown,O
constraints,O
imposed,O
during,O
the,O
COVID-19,O
epidemic,O
",",O
all,O
the,O
bioinformatics,O
analyses,O
presented,O
in,O
this,O
article,O
were,O
performed,O
on,O
publicly,O
accessible,O
bioinformatic,O
platforms,O
.,O
As,O
previously,O
noticed,O
",",O
the,O
most,O
similar,O
isolate,O
is,O
bat,O
coronavirus,O
RaTG13,O
with,O
96.7,O
%,O
similarity,O
(,O
Accession,O
#,O
QHR63299,S-AccessionNumber
),O
[,O
1,O
],O
",",O
followed,O
by,O
two,O
other,O
bat,O
isolates,O
(,O
#,O
AVP78030,S-AccessionNumber
",",O
#,O
AVP78041,S-AccessionNumber
",",O
93.5,O
%,O
and,O
92.5,O
%,O
identical,O
",",O
respectively,O
),O
[,O
9,O
],O
",",O
and,O
several,O
similar,O
pangolin,O
isolates,O
(,O
e.g.,O
",",O
#,O
QIQ54046,S-AccessionNumber
",",O
85.4,O
%,O
identical,O
),O
(,O
Cao,O
et,O
al,O
.,O
",",O
unpublished,O
),O
.,O
It,O
turns,O
out,O
that,O
this,O
protein,O
plays,O
a,O
significant,O
role,O
in,O
the,O
regulation,O
of,O
the,O
inflammatory,O
response,O
that,O
is,O
out,O
of,O
control,O
in,O
severe,O
cases,O
of,O
COVID-19,O
.,O
By,O
following,O
the,O
natural,O
incentive,O
of,O
all,O
viruses,O
to,O
maximize,O
their,O
infectivity,O
",",O
hereby,O
increasing,O
the,O
density,O
of,O
its,O
receptor,O
",",O
SARS,O
-,O
CoV-2,O
triggers,O
a,O
cytokine,O
storm,O
as,O
an,O
unfortunate,O
side,O
-,O
effect,O
of,O
COVID-19,O
.,O
As,O
more,O
cases,O
of,O
COVID-19,O
are,O
studied,O
and,O
treated,O
worldwide,O
",",O
it,O
had,O
become,O
apparent,O
that,O
the,O
lethal,O
and,O
most,O
severe,O
cases,O
of,O
pneumonia,O
are,O
due,O
to,O
an,O
out,O
-,O
of,O
-,O
control,O
inflammatory,O
response,O
to,O
the,O
SARS,O
-,O
CoV-2,O
virus,O
.,O
A,O
number,O
of,O
convergent,O
findings,O
suggest,O
de,O
-,O
mono,O
-,O
ADP,O
-,O
ribosylation,O
(,O
de,O
-,O
MARylation,O
),O
of,O
STAT1,O
by,O
the,O
SARS,O
-,O
CoV-2,O
nsp3,O
as,O
a,O
putative,O
cause,O
of,O
the,O
cytokine,O
storm,O
observed,O
in,O
the,O
most,O
severe,O
cases,O
of,O
COVID-19,O
.,O
Incorporation,O
of,O
the,O
nitrogen,O
atom,O
in,O
the,O
course,O
of,O
evolution,O
allowed,O
the,O
synthesis,O
of,O
amino,O
acids,O
",",O
as,O
well,O
as,O
nucleic,O
acids,O
.,O
In,O
contrast,O
",",O
SARS,O
-,O
CoV-2,O
was,O
rapidly,O
identified,O
following,O
the,O
onset,O
of,O
the,O
COVID-19,O
epidemic,O
",",O
as,O
viruses,O
appear,O
to,O
be,O
identified,O
only,O
by,O
the,O
infectious,O
diseases,O
that,O
they,O
cause,O
.,O
Viruses,O
",",O
including,O
the,O
SARS,O
-,O
CoV-2,O
virus,O
responsible,O
for,O
the,O
current,O
COVID-19,O
epidemic,O
",",O
are,O
a,O
key,O
to,O
the,O
understanding,O
of,O
life,O
and,O
evolution,O
.,O
Nitrogen,O
incorporation,O
in,O
the,O
primordial,O
cell,O
chemistry,O
allowed,O
synthesis,O
of,O
amino,O
acids,O
and,O
nucleic,O
acids,O
",",O
a,O
prelude,O
to,O
RNA,O
and,O
subsequently,O
DNA,O
.,O
This,O
classification,O
is,O
consistent,O
with,O
estimations,O
on,O
case,O
fatality,O
ratio,O
of,O
MERS,O
",",O
SARS,O
and,O
COVID-19,O
",",O
which,O
is,O
35,O
%,O
",",O
9,O
%,O
and,O
2.4,O
%,O
respectively,O
and,O
with,O
our,O
observations,O
on,O
odds,O
ratio,O
of,O
CG,O
in,O
their,O
ORFS,O
",",O
which,O
is,O
0.56,O
",",O
0.44,O
and,O
0.39,O
respectively,O
(,O
Table,O
S1,O
),O
.,O
The,O
outbreak,O
of,O
COVID-19,O
has,O
brought,O
great,O
threat,O
to,O
human,O
health,O
.,O
The,O
disease,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
",",O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
has,O
affected,O
millions,O
of,O
people,O
",",O
with,O
a,O
death,O
toll,O
amounting,O
to,O
hundreds,O
of,O
thousands,O
worldwide,O
(,O
",",O
),O
.,O
As,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
continues,O
to,O
cause,O
devastation,O
",",O
scientists,O
race,O
to,O
increase,O
their,O
understanding,O
of,O
the,O
disease,O
-,O
causing,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
.,O
The,O
binding,O
pocket,O
on,O
the,O
ribosome,O
may,O
be,O
a,O
target,O
for,O
drugs,O
to,O
treat,O
COVID-19,O
.,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
is,O
the,O
causative,O
agent,O
of,O
the,O
current,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
.,O
A,O
major,O
reason,O
for,O
the,O
failure,O
to,O
know,O
when,O
or,O
where,O
the,O
virus,O
first,O
appeared,O
seems,O
to,O
have,O
been,O
the,O
widespread,O
occurrence,O
of,O
asymptomatic,O
cases,O
of,O
COVID‐19,O
.,O
Importantly,O
",",O
there,O
appear,O
to,O
be,O
observations,O
that,O
suggest,O
that,O
a,O
virus,O
causing,O
severe,O
cases,O
of,O
atypical,O
pneumonia,O
already,O
existed,O
in,O
mid‐December,O
2019,O
in,O
China,O
(,O
Guo,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
possibly,O
even,O
in,O
Italy,O
",",O
in,O
France,O
",",O
and,O
in,O
the,O
United,O
States,O
in,O
January,O
2020,O
not,O
initially,O
ascribed,O
to,O
COVID‐19,O
.,O
It,O
could,O
well,O
be,O
that,O
early,O
ancestors,O
of,O
SARS‐CoV‐2,O
",",O
producing,O
asymptomatic,O
infections,O
had,O
already,O
spread,O
before,O
causing,O
clinical,O
—,O
COVID‐19,O
—,O
disease,O
(,O
Forster,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
Wuhan,O
hospitals,O
",",O
the,O
healthcare,O
personnel,O
observed,O
that,O
the,O
clinical,O
characteristics,O
of,O
COVID‐19,O
patients,O
at,O
the,O
onset,O
of,O
the,O
disease,O
became,O
progressively,O
different,O
",",O
possibly,O
as,O
new,O
coronavirus,O
variants,O
emerged,O
and,O
spread,O
over,O
time,O
and,O
generations,O
.,O
We,O
have,O
tried,O
to,O
summarize,O
here,O
reasons,O
to,O
hope,O
for,O
a,O
positive,O
outcome,O
of,O
the,O
outbreak,O
of,O
COVID‐2,O
",",O
namely,O
via,O
progressive,O
attenuation,O
of,O
the,O
virus,O
(,O
Armengaud,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Thus,O
",",O
besides,O
this,O
optimistic,O
exit,O
from,O
the,O
COVID‐19,O
epidemic,O
",",O
we,O
should,O
be,O
concerned,O
by,O
the,O
high,O
recombination,O
potential,O
of,O
the,O
virus,O
",",O
which,O
may,O
erase,O
the,O
mutations,O
that,O
allowed,O
it,O
to,O
evolve,O
towards,O
attenuation,O
.,O
Monitoring,O
as,O
a,O
function,O
of,O
time,O
the,O
genome,O
sequences,O
in,O
closely,O
related,O
cases,O
is,O
critical,O
to,O
anticipate,O
the,O
future,O
of,O
SARS‐CoV‐2,O
and,O
hence,O
of,O
COVID‐19,O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
has,O
spread,O
globally,O
and,O
caused,O
massive,O
loss,O
of,O
life,O
and,O
economic,O
hardship,O
.,O
Treatment,O
strategies,O
for,O
critically,O
ill,O
COVID-19,O
patients,O
are,O
lacking,O
",",O
with,O
only,O
limited,O
evidence,O
available,O
for,O
a,O
battery,O
of,O
antiviral,O
",",O
antibiotic,O
",",O
and,O
anti,O
-,O
inflammatory,O
agents,O
",",O
and,O
aggressive,O
supportive,O
therapy,O
.,O
There,O
are,O
early,O
anti,O
–,O
COVID-19,O
efficacy,O
data,O
with,O
remdesivir,O
.,O
New,O
therapies,O
are,O
needed,O
to,O
improve,O
outcomes,O
for,O
critically,O
ill,O
COVID-19,O
patients,O
.,O
Several,O
small,O
observational,O
studies,O
published,O
during,O
the,O
COVID-19,O
pandemic,O
suggest,O
convalescent,O
plasma,O
is,O
part,O
of,O
an,O
effective,O
treatment,O
strategy,O
for,O
patients,O
with,O
severe,O
disease.17,O
",",O
18,O
",",O
19,O
",",O
20,O
The,O
first,O
report,O
describing,O
administration,O
of,O
convalescent,O
plasma,O
to,O
five,O
patients,O
early,O
in,O
the,O
COVID-19,O
outbreak,O
in,O
Wuhan,O
was,O
recently,O
published,O
.,O
Symptomatic,O
patients,O
with,O
a,O
high,O
degree,O
of,O
clinical,O
suspicion,O
for,O
COVID-19,O
disease,O
were,O
tested,O
in,O
the,O
Molecular,O
Diagnostics,O
Laboratory,O
at,O
Houston,O
Methodist,O
Hospital,O
using,O
a,O
validated,O
assay,O
applied,O
for,O
under,O
Emergency,O
Use,O
Authorization,O
from,O
the,O
US,O
Food,O
and,O
Drug,O
Administration,O
.,O
Twenty,O
-,O
five,O
patients,O
with,O
severe,O
and/or,O
life,O
-,O
threatening,O
COVID-19,O
disease,O
were,O
enrolled,O
in,O
the,O
study,O
from,O
March,O
28,O
",",O
2020,O
",",O
to,O
April,O
14,O
",",O
2020,O
.,O
A,O
total,O
of,O
nine,O
donors,O
provided,O
plasma,O
that,O
was,O
used,O
to,O
transfuse,O
COVID-19,O
patients,O
;,O
two,O
donors,O
gave,O
plasma,O
on,O
multiple,O
occasions,O
.,O
The,O
observed,O
thrombotic,O
complications,O
are,O
consistent,O
with,O
findings,O
reported,O
for,O
COVID-19,O
patients,O
.,O
The,O
current,O
study,O
was,O
performed,O
to,O
evaluate,O
the,O
safety,O
and,O
potential,O
benefit,O
of,O
transfusing,O
convalescent,O
plasma,O
to,O
patients,O
with,O
severe,O
COVID-19,O
disease,O
.,O
To,O
date,O
",",O
this,O
is,O
the,O
largest,O
cohort,O
assessed,O
for,O
outcomes,O
pertaining,O
to,O
convalescent,O
plasma,O
transfusion,O
for,O
COVID-19,O
.,O
Several,O
case,O
studies,O
investigating,O
the,O
use,O
of,O
convalescent,O
plasma,O
to,O
treat,O
severe,O
COVID-19,O
have,O
recently,O
been,O
"published,17",O
",",O
18,O
",",O
19,O
",",O
20,O
",",O
21,O
and,O
the,O
overall,O
findings,O
presented,O
herein,O
are,O
consistent,O
with,O
these,O
reports,O
.,O
The,O
results,O
from,O
this,O
study,O
support,O
the,O
existing,O
data,O
from,O
the,O
COVID-19,O
literature,O
that,O
point,O
to,O
underlying,O
medical,O
conditions,O
",",O
such,O
as,O
obesity,O
",",O
type,O
2,O
diabetes,O
",",O
and,O
hypertension,O
",",O
playing,O
a,O
large,O
role,O
in,O
patients,O
',O
COVID-19,O
disease,O
course,O
and,O
outcomes.36,O
",",O
37,O
",",O
38,O
Of,O
transfused,O
patients,O
in,O
this,O
study,O
",",O
68,O
%,O
(,O
17/25,O
),O
had,O
a,O
body,O
mass,O
index,O
in,O
the,O
obese,O
category,O
and,O
84,O
%,O
were,O
considered,O
overweight,O
.,O
Despite,O
inconclusive,O
data,O
on,O
ribavirin,O
's,O
efficacy,O
in,O
the,O
treatment,O
of,O
SARS,O
during,O
the,O
2003,O
epidemic,O
",",O
proven,O
safety,O
and,O
ready,O
availability,O
supported,O
its,O
use,O
in,O
the,O
treatment,O
of,O
our,O
COVID-19,O
patients,O
.,O
Tocilizumab,O
was,O
recently,O
shown,O
to,O
reduce,O
mortality,O
in,O
a,O
retrospective,O
analysis,O
of,O
20,O
severe,O
COVID-19,O
patients,O
.,O
The,O
patient,O
outcomes,O
in,O
the,O
current,O
study,O
are,O
similar,O
to,O
those,O
recently,O
published,O
describing,O
treating,O
COVID-19,O
patients,O
with,O
remdesivir,O
on,O
a,O
compassionate,O
-,O
use,O
basis,O
.,O
Initial,O
donors,O
",",O
who,O
donated,O
repeatedly,O
",",O
were,O
blood,O
type,O
O.,O
Because,O
ABO,O
compatibility,O
was,O
a,O
requirement,O
for,O
recipient,O
selection,O
early,O
in,O
the,O
study,O
",",O
many,O
of,O
our,O
early,O
recipients,O
were,O
also,O
type,O
O.,O
Zhao,O
et,O
 ,O
al,O
have,O
reported,O
that,O
of,O
the,O
2173,O
patients,O
analyzed,O
in,O
their,O
study,O
of,O
COVID-19,O
patients,O
in,O
China,O
",",O
most,O
had,O
type,O
A,O
blood,O
.,O
Regardless,O
",",O
our,O
data,O
do,O
not,O
reflect,O
a,O
higher,O
rate,O
of,O
blood,O
type,O
A,O
in,O
COVID-19,O
patients,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
",",O
has,O
spread,O
globally,O
",",O
and,O
no,O
proven,O
treatments,O
are,O
available,O
.,O
Patients,O
(,O
n,O
=,O
 ,O
25,O
),O
with,O
severe,O
and/or,O
life,O
-,O
threatening,O
COVID-19,O
disease,O
were,O
enrolled,O
at,O
the,O
Houston,O
Methodist,O
hospitals,O
from,O
March,O
28,O
",",O
2020,O
",",O
to,O
April,O
14,O
",",O
2020,O
.,O
The,O
data,O
indicate,O
that,O
administration,O
of,O
convalescent,O
plasma,O
is,O
a,O
safe,O
treatment,O
option,O
for,O
those,O
with,O
severe,O
COVID-19,O
disease,O
.,O
"21,789",O
complete,O
SARS,O
-,O
CoV2,O
genomes,O
were,O
downloaded,O
from,O
GISAID,S-Dataset
 ,O
(,O
Shu,B-Creator
and,I-Creator
McCauley,I-Creator
2017,E-Creator
),O
(,O
May,O
28,O
",",O
2020,O
),O
.,O
We,O
observed,O
"8,427",O
SNPs,O
in,O
the,O
current,O
dataset,O
(,O
May,O
28,O
",",O
2020,O
),O
and,O
we,O
defined,O
five,O
major,O
clades,O
which,O
contains,O
15,O
subclades,O
(,O
Fig.1,O
",",O
Fig,O
.,O
S2,O
),O
compared,O
to,O
the,O
prototype,O
(,O
MN908947.3,S-AccessionNumber
),O
.,O
(,O
Rambaut,O
et,O
al,O
.,O
2020,O
),O
and,O
GISAID,S-Dataset
 ,O
(,O
Shu,O
and,O
McCauley,O
2017,O
),O
.,O
We,O
have,O
tested,O
this,O
protocol,O
on,O
24,O
RNA,O
samples,O
from,O
COVID-19,O
patients,O
",",O
and,O
generated,O
the,O
barcode,O
information,O
from,O
the,O
publicly,O
accessible,O
Python,O
script,O
(,O
https://github.com/raeece/sarscov2barcode,O
),O
.,O
(,O
A,O
),O
The,O
structure,O
of,O
the,O
SARS,O
-,O
CoV-2,O
spike,O
trimer,O
in,O
its,O
open,O
conformation,O
(,O
chains,O
are,O
cyan,O
",",O
magenta,O
and,O
grey,O
),O
bound,O
to,O
the,O
human,O
receptor,O
ACE2,O
(,O
black,O
),O
modeled,O
based,O
on,O
PDB,S-Repository
 ,O
accessions,O
6m17,S-AccessionNumber
 ,O
and,O
6vyb,S-AccessionNumber
.,O
In,O
this,O
study,O
",",O
we,O
have,O
defined,O
5,O
major,O
clades,O
(,O
G614,O
",",O
S84,O
",",O
V251,O
",",O
I378,O
and,O
D392,O
),O
of,O
fully,O
-,O
sequenced,O
SARS,O
-,O
CoV-2,O
genomes,O
available,O
until,O
May,O
28,O
",",O
2020,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
.,O
This,O
is,O
due,O
to,O
biases,O
of,O
genome,O
data,O
deposits,O
from,O
the,O
sequencing,O
laboratories,O
based,O
mainly,O
in,O
the,O
Northern,O
hemisphere,O
and,O
new,O
datasets,O
may,O
define,O
new,O
clades,O
or,O
subclades,O
in,O
the,O
near,O
future,O
from,O
other,O
regions,O
",",O
including,O
Africa,O
",",O
the,O
Indian,O
subcontinent,O
and,O
Latin,O
America,O
from,O
where,O
there,O
are,O
comparably,O
few,O
genomes,O
available,O
at,O
present,O
.,O
The,O
U.S.,O
Food,O
and,O
Drug,O
Administration,O
(,O
USFDA,O
),O
has,O
authorised,O
Illumina,O
COVIDSeq,O
test,O
which,O
is,O
intended,O
for,O
the,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
virus,O
RNA,O
for,O
research,O
use,O
(,O
https://www.illumina.com/products/by-type/ivd-products/covidseq.html,O
),O
.,O
According,O
to,O
the,O
COVIDseq,O
instructions,O
",",O
up,O
to,O
384,O
results,O
per,O
lane,O
can,O
be,O
processed,O
on,O
the,O
NovaSeq,O
6000,O
System,O
for,O
whole,O
-,O
genome,O
sequecing,O
.,O
Our,O
methodology,O
is,O
complementary,O
to,O
the,O
COVIDSeq,O
test,O
and,O
aimed,O
at,O
revealing,O
the,O
major,O
clades,O
of,O
the,O
virus,O
in,O
a,O
given,O
sample,O
.,O
A,O
total,O
of,O
"21,789",O
complete,O
genomes,O
were,O
downloaded,O
from,O
GISAID,S-Dataset
 ,O
on,O
May,O
28,O
",",O
2020,O
for,O
analyses,O
.,O
The,O
current,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
has,O
created,O
challenges,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
cancer,O
.,O
These,O
patients,O
are,O
at,O
a,O
high,O
risk,O
of,O
contracting,O
COVID-19,O
because,O
of,O
the,O
following,O
factors,O
:,O
older,O
age,O
(,O
≥65,O
years,O
),O
",",O
medical,O
comorbidities,O
",",O
and,O
Eastern,O
Cooperative,O
Oncology,O
Group,O
status,O
≥2,O
.,O
",",O
Furthermore,O
",",O
the,O
SGO,O
has,O
stated,O
that,O
use,O
of,O
neoadjuvant,O
chemotherapy,O
may,O
be,O
effective,O
in,O
delaying,O
surgery,O
and,O
hospitalization,O
during,O
the,O
COVID-19,O
pandemic,O
.,O
In,O
both,O
cases,O
",",O
the,O
patients,O
underwent,O
3,O
cycles,O
of,O
chemotherapy,O
followed,O
by,O
repeat,O
imaging,O
with,O
plans,O
for,O
possible,O
IDS,O
.,O
Although,O
IDS,O
has,O
been,O
shown,O
to,O
be,O
less,O
morbid,O
than,O
primary,O
cytoreductions,O
",",O
there,O
are,O
still,O
inherent,O
surgical,O
risks,O
.,O
The,O
viral,O
titers,O
of,O
the,O
control,O
mixtures,O
(,O
mixtures,O
containing,O
DMSO,O
),O
were,O
103.25,O
-,O
6.75,O
50,O
%,O
tissue,O
culture,O
infective,O
dose,O
(,O
TCID50)/mL.,O
Solutions,O
with,O
virus,O
and,O
SS,O
-,O
derived,O
components,O
were,O
incubated,O
at,O
25,O
°,O
C,O
for,O
varying,O
periods,O
of,O
time,O
",",O
from,O
10,O
s,O
to,O
48,O
h.,O
The,O
log10,O
TCID50,O
/,O
mL,O
was,O
calculated,O
using,O
the,O
Behrens,O
–,O
Kärber,O
method,O
[,O
20,O
],O
.,O
The,O
concentration,O
of,O
SS,O
-,O
derived,O
samples,O
was,O
250,O
µg,O
/,O
mL,O
in,O
the,O
mixture,O
containing,O
purified,O
IAV,O
(,O
8.25,O
log10,O
TCID50,O
/,O
mL,O
),O
.,O
The,O
concentration,O
of,O
SS,O
-,O
derived,O
samples,O
was,O
250,O
µg,O
/,O
mL,O
in,O
the,O
mixture,O
containing,O
purified,O
IAV,O
(,O
8.25,O
log10,O
TCID50,O
/,O
mL,O
),O
",",O
FCV,O
(,O
7.25,O
log10,O
TCID50,O
/,O
mL,O
),O
",",O
and,O
MNV,O
(,O
7.25,O
log10,O
TCID50,O
/,O
mL,O
),O
.,O
The,O
concentration,O
of,O
Fr,O
1C,O
was,O
250,O
µg,O
/,O
mL,O
in,O
the,O
mixture,O
containing,O
SARS,O
-,O
CoV-2,O
(,O
4.75,O
log10,O
TCID50,O
/,O
mL,O
),O
.,O
Fr,O
1C,O
(,O
250,O
µg,O
/,O
mL,O
),O
or,O
DMSO,O
diluent,O
was,O
added,O
to,O
a,O
PBS,O
containing,O
purified,O
IAV,O
(,O
200,O
µg,O
/,O
mL,O
",",O
5.75,O
log10,O
TCID50,O
/,O
mL,O
),O
.,O
The,O
virucidal,O
activity,O
of,O
Fr,O
1C,O
was,O
the,O
most,O
potent,O
of,O
this,O
set,O
;,O
incubation,O
with,O
Fr,O
1C,O
resulted,O
in,O
>,O
99.98,O
%,O
inactivation,O
of,O
IAV,O
(,O
i.e.,O
",",O
a,O
reduction,O
≥3.83,O
log10,O
TCID50,O
/,O
mL,O
;,O
Table,O
2A,O
),O
.,O
All,O
fractions,O
except,O
Fr,O
1A,O
inactivated,O
FCV,O
within,O
1,O
min,O
;,O
>,O
99.79,O
%,O
of,O
FCV,O
was,O
inactivated,O
within,O
this,O
time,O
frame,O
(,O
reduction,O
≥2.67,O
log10,O
TCID50,O
/,O
mL,O
;,O
Table,O
2B,O
),O
.,O
Overall,O
",",O
MNV,O
inactivation,O
of,O
>,O
98.52,O
%,O
was,O
observed,O
in,O
response,O
to,O
these,O
fractions,O
(,O
reduction,O
≥1.83,O
log10,O
TCID50,O
/,O
mL,O
;,O
Table,O
2C,O
),O
.,O
Compound,O
Nos,O
.,O
2–4,O
(,O
25,O
µg,O
/,O
mL,O
),O
had,O
virucidal,O
activity,O
against,O
both,O
of,O
IAV,O
and,O
FCV,O
at,O
1,O
min,O
",",O
with,O
>,O
93.24,O
%,O
inactivation,O
of,O
IAV,O
and,O
FCV,O
(,O
reduction,O
≥1.17,O
log10,O
TCID50,O
/,O
mL,O
;,O
Table,O
3A,O
",",O
B,O
),O
.,O
We,O
found,O
that,O
the,O
aqueous,O
extract,O
and,O
Fr,O
1B,O
–,O
E,O
(,O
all,O
at,O
25,O
µg,O
/,O
mL,O
),O
had,O
significant,O
virucidal,O
activity,O
against,O
SARS,O
-,O
CoV-2,O
within,O
1,O
min,O
of,O
exposure,O
;,O
>,O
99,O
%,O
of,O
the,O
virus,O
was,O
inactivated,O
by,O
components,O
within,O
these,O
fractions,O
(,O
i.e.,O
",",O
reduction,O
of,O
≥2,O
log10,O
TCID50,O
/,O
mL,O
),O
.,O
We,O
found,O
that,O
>,O
99.53,O
%,O
of,O
the,O
virus,O
was,O
inactivated,O
by,O
Fr,O
1C,O
within,O
10,O
s,O
of,O
exposure,O
(,O
reduction,O
of,O
≥2.33,O
log10,O
TCID50,O
/,O
mL,O
;,O
Table,O
4A,O
),O
.,O
We,O
found,O
that,O
25,O
µg,O
/,O
mL,O
of,O
Fr,O
1C,O
inactivated,O
>,O
99.6,O
%,O
of,O
SARS,O
-,O
CoV-2,O
within,O
10,O
s,O
(,O
reduction,O
of,O
≥2.33,O
log,O
10,O
TCID,O
50,O
/mL,O
),O
.,O
Coronavirus,O
disease‐2019,O
(,O
COVID‐19,O
),O
",",O
which,O
is,O
caused,O
by,O
a,O
novel,O
coronavirus,O
termed,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS‐CoV‐2,O
),O
",",O
is,O
a,O
respiratory,O
disease,O
that,O
officially,O
started,O
in,O
the,O
Chinese,O
city,O
of,O
Wuhan,O
Hubei,O
Province,O
during,O
December,O
2019,O
and,O
has,O
since,O
spread,O
globally,O
as,O
a,O
pandemic,O
.,O
As,O
of,O
13,O
May,O
2020,O
",",O
the,O
total,O
COVID‐19,O
world,O
cases,O
have,O
surpassed,O
four,O
million,O
with,O
more,O
than,O
250,O
 ,O
000,O
deaths,O
.,O
All,O
79,O
COVID‐19,O
whole,O
genome,O
sequences,O
isolated,O
from,O
Italian,O
patients,O
from,O
29,O
January,O
2020,O
to,O
27,O
April,O
2020,O
(,O
53,O
",",O
11,O
",",O
6,O
",",O
6,O
",",O
2,O
",",O
and,O
1,O
isolates,O
from,O
regions,O
Abruzzo,O
",",O
Lazio,O
",",O
Friuli,O
Venezia,O
Giulia,O
",",O
Lombardy,O
",",O
Veneto,O
",",O
and,O
Marche,O
",",O
respectively,O
),O
(,O
Table,O
 ,O
1,O
),O
and,O
48,O
COVID‐19,O
sequences,O
from,O
24,O
December,O
2019,O
to,O
17,O
January,O
2020,O
in,O
China,O
have,O
been,O
downloaded,O
from,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
database,O
.,O
The,O
data,O
set,O
has,O
been,O
aligned,O
using,O
multiple,O
sequence,O
alignment,O
(,O
MAFFT,O
),O
online,O
tool,O
 ,O
and,O
manually,O
edited,O
using,O
Bioedit,O
program,O
v7.0.5,O
.,O
In,O
fact,O
",",O
recent,O
evidence,O
 ,O
strongly,O
suggests,O
that,O
the,O
virus,O
was,O
circulating,O
unrecognized,O
in,O
Lombardy,O
since,O
at,O
least,O
mid‐January,O
",",O
while,O
the,O
first,O
official,O
COVID‐19,O
Italian,O
case,O
was,O
notified,O
in,O
Codogno,O
(,O
Lombardy,O
),O
only,O
the,O
21st,O
of,O
February,O
.,O
For,O
this,O
and,O
the,O
additional,O
reason,O
that,O
many,O
efforts,O
to,O
generate,O
a,O
safe,O
and,O
efficacious,O
COVID‐19,O
vaccine,O
focus,O
upon,O
the,O
spike,O
component,O
",",O
changes,O
in,O
its,O
composition,O
and,O
structure,O
are,O
particularly,O
relevant,O
.,O
Nucleocapsid,O
protein,O
was,O
also,O
proposed,O
to,O
be,O
important,O
in,O
COVID‐19,O
infectivity,O
.,O
This,O
new,O
coronavirus,O
disease,O
(,O
COVID‐19,O
),O
has,O
caused,O
more,O
than,O
3100,O
deaths,O
",",O
mainly,O
in,O
continental,O
China,O
and,O
mostly,O
on,O
elderly,O
people,O
",",O
who,O
are,O
affected,O
by,O
fever,O
and,O
serious,O
respiratory,O
diseases,O
like,O
pneumonia,O
.,O
",",O
 ,O
",",O
SARS‐CoV‐2,O
has,O
a,O
single‐stranded,O
RNA,O
genome,O
and,O
its,O
length,O
is,O
similar,O
to,O
other,O
related,O
coronaviruses,O
",",O
with,O
an,O
extension,O
near,O
29,O
 ,O
890,O
 ,O
bp,O
(,O
GenBank,S-Repository
 ,O
NC_045512.2,S-AccessionNumber
),O
.,O
The,O
most,O
related,O
genomes,O
available,O
in,O
public,O
databases,O
were,O
bat‐SL‐CoVZC45,O
(,O
GenBank,S-Repository
 ,O
MG772933,S-AccessionNumber
),O
with,O
an,O
87.99,O
%,O
sequence,O
identity,O
and,O
bat‐SL‐CoVZXC21,O
(,O
GenBank,S-Repository
 ,O
MG772934,S-AccessionNumber
),O
with,O
an,O
87.23,O
%,O
sequence,O
identity,O
",",O
 ,O
followed,O
by,O
the,O
human,O
viruses,O
SARS‐CoV‐Tor2,O
(,O
GenBank,S-Repository
 ,O
NC_004718,S-AccessionNumber
),O
and,O
MERS‐CoV,O
(,O
GenBank,S-Repository
 ,O
NC_019843,S-AccessionNumber
),O
with,O
a,O
79.0,O
%,O
and,O
51.8,O
%,O
of,O
nucleotide,O
identity,O
",",O
respectively,O
.,O
There,O
are,O
also,O
at,O
least,O
six,O
predicted,O
ORFs,O
as,O
hypothetical,O
proteins,O
with,O
no,O
associated,O
function,O
.,O
",",O
 ,O
",",O
Near,O
286,O
complete,O
genomes,O
of,O
SARS‐CoV‐2,O
and,O
related,O
viruses,O
",",O
has,O
been,O
submitted,O
to,O
the,O
GISAID,S-Dataset
 ,O
database,O
(,O
www.gisaid.org/CoV2020,S-URL
),O
collecting,O
genetic,O
information,O
of,O
the,O
outbreak,O
worldwide,O
.,O
Recently,O
Tang,O
et,O
al,O
 ,O
and,O
GISAD,S-Dataset
 ,O
database,O
in,O
the,O
SARS‐CoV‐2,O
portal,O
defined,O
three,O
subtypes,O
:,O
S,O
",",O
G,O
",",O
and,O
V,O
",",O
according,O
to,O
nucleotide,O
variants,O
that,O
produce,O
amino,O
acid,O
changes,O
.,O
COVID‐19,O
cases,O
in,O
Spain,O
started,O
to,O
be,O
reported,O
since,O
February,O
1st,O
with,O
a,O
very,O
low,O
number,O
of,O
cases,O
for,O
about,O
a,O
month,O
",",O
where,O
the,O
reported,O
cases,O
may,O
be,O
underestimated,O
",",O
and,O
after,O
a,O
month,O
the,O
infected,O
people,O
started,O
to,O
raise,O
over,O
a,O
hundred,O
patients,O
.,O
",",O
In,O
2020,O
",",O
SARS‐CoV‐2,O
",",O
first,O
reported,O
from,O
Hubei,O
province,O
of,O
China,O
in,O
December,O
2019,O
",",O
has,O
become,O
the,O
first,O
coronavirus,O
to,O
cause,O
a,O
pandemic,O
.,O
",",O
  ,O
Most,O
patients,O
with,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
present,O
with,O
respiratory,O
symptoms,O
",",O
while,O
18,O
%,O
exhibit,O
gastrointestinal,O
symptoms,O
.,O
Radiologically,O
",",O
COVID‐19,O
is,O
characterized,O
by,O
multifocal,O
and,O
peripheral,O
ground‐glass,O
opacities,O
",",O
but,O
2.9,O
%,O
of,O
severe,O
cases,O
did,O
not,O
show,O
any,O
abnormalities,O
in,O
their,O
lung,O
computed,O
tomography,O
.,O
",",O
  ,O
Complications,O
include,O
acute,O
respiratory,O
distress,O
syndrome,O
",",O
arrhythmia,O
",",O
secondary,O
bacterial,O
infection,O
",",O
and,O
multiorgan,O
failure,O
.,O
",",O
  ,O
Pathologically,O
",",O
COVID‐19,O
was,O
characterized,O
by,O
diffuse,O
alveolar,O
damage,O
",",O
endothelialitis,O
interstitial,O
lymphocyte,O
infiltrates,O
",",O
and,O
multinucleated,O
syncytial,O
cells,O
in,O
the,O
lung,O
",",O
and,O
microvascular,O
steatosis,O
in,O
the,O
liver,O
.,O
",",O
The,O
importance,O
of,O
diagnostic,O
testing,O
is,O
well,O
demonstrated,O
with,O
COVID‐19,O
.,O
Many,O
groups,O
have,O
shared,O
their,O
in‐house,O
real‐time,O
reverse,O
transcription‐polymerase,O
chain,O
reaction,O
(,O
RT‐PCR,O
),O
protocol,O
with,O
the,O
World,O
Health,O
Organization,O
during,O
the,O
early,O
period,O
of,O
COVID‐19,O
",",O
which,O
have,O
tremendously,O
helped,O
clinical,O
microbiology,O
laboratories,O
around,O
the,O
world,O
in,O
the,O
detection,O
of,O
SARS‐CoV‐2,O
.,O
According,O
to,O
an,O
analysis,O
by,O
GISAID,S-Dataset
",",O
0.02,O
%,O
to,O
0.53,O
%,O
of,O
the,O
genomes,O
contain,O
mutations,O
in,O
the,O
last,O
five,O
nucleotides,O
of,O
the,O
3′,O
ends,O
of,O
the,O
published,O
RT‐PCR,O
primer,O
regions,O
.,O
These,O
specimens,O
included,O
101,O
clinical,O
specimens,O
collected,O
from,O
COVID‐19,O
patients,O
admitted,O
to,O
Queen,O
Mary,O
Hospital,O
",",O
or,O
from,O
COVID‐19,O
patients,O
admitted,O
to,O
Princess,O
Margaret,O
Hospital,O
for,O
whom,O
specimens,O
were,O
sent,O
to,O
Queen,O
Mary,O
Hospital,O
for,O
viral,O
load,O
testing,O
.,O
The,O
consensus,O
sequences,O
of,O
five,O
specimens,O
from,O
four,O
patients,O
(,O
HKU‐902a,O
",",O
HKU‐903a,O
",",O
HKU‐903b,O
",",O
HKU‐907b,O
",",O
and,O
HKU‐908a,O
),O
were,O
previously,O
deposited,O
into,O
NCBI,B-Repository
GenBank,E-Repository
 ,O
(,O
accession,O
number,O
:,O
MT114412,S-AccessionNumber
",",O
MT114414,S-AccessionNumber
",",O
MT114415,S-AccessionNumber
",",O
MT114417,S-AccessionNumber
",",O
MT114418,S-AccessionNumber
),O
.,O
The,O
consensus,O
sequences,O
of,O
HKU‐904a,O
",",O
HKU‐905a,O
",",O
HKU‐911a,O
",",O
HKU‐913a,O
",",O
and,O
HKU‐915a,O
have,O
been,O
deposited,O
into,O
NCBI,B-Repository
GenBank,E-Repository
 ,O
(,O
accession,O
number,O
:,O
MT365028,S-AccessionNumber
‐,O
MT365032,S-AccessionNumber
),O
.,O
Raw,O
reads,O
",",O
after,O
excluding,O
human,O
reads,O
",",O
have,O
been,O
deposited,O
into,O
BioProject,O
(,O
Bioproject,O
ID,O
:,O
PRJNA627286,S-AccessionNumber
),O
.,O
The,O
concentration,O
of,O
the,O
virus,O
culture,O
stock,O
was,O
1.8,O
 ,O
×,O
 ,O
107,O
50,O
%,O
tissue,O
culture,O
infective,O
doses,O
(,O
TCID50)/mL.,O
Triplicates,O
were,O
performed,O
for,O
each,O
dilution,O
in,O
two,O
independent,O
experiments,O
.,O
Nucleotide,O
sequences,O
were,O
downloaded,O
from,O
NCBI,B-Repository
Genbank,E-Repository
 ,O
and,O
GISAID,S-Dataset
 ,O
(,O
Table,O
S2,O
),O
.,O
Specific,O
primers,O
and,O
probes,O
targeting,O
SARS‐CoV‐2,O
were,O
selected,O
by,O
aligning,O
more,O
than,O
7000,O
SARS‐CoV‐2,O
sequences,O
downloaded,O
from,O
GISAID,S-Dataset
 ,O
on,O
22,O
April,O
2020,O
",",O
other,O
human,O
Betacoronaviruses,O
",",O
and,O
a,O
bat,O
SARS‐like,O
coronavirus,O
(,O
Figure,O
 ,O
1,O
),O
.,O
Of,O
these,O
101,O
COVID‐19,O
patients,O
",",O
SARS‐CoV‐2,O
was,O
detected,O
by,O
at,O
least,O
one,O
of,O
nsp1,O
",",O
N,O
or,O
E,O
gene,O
RT‐PCR,O
assays,O
in,O
99,O
patients,O
(,O
98.0,O
%,O
),O
",",O
and,O
85,O
patients,O
(,O
84.2,O
%,O
),O
were,O
detected,O
by,O
all,O
three,O
RT‐PCR,O
assays,O
(,O
Table,O
 ,O
2,O
),O
.,O
Together,O
with,O
the,O
analysis,O
done,O
by,O
GISAID,S-Dataset
",",O
 ,O
which,O
showed,O
higher,O
mutation,O
rate,O
in,O
the,O
published,O
N,O
gene,O
primers,O
/,O
probe,O
region,O
",",O
nsp1,O
can,O
serve,O
as,O
an,O
alternative,O
target,O
for,O
the,O
detection,O
of,O
SARS‐CoV‐2,O
.,O
Shortly,O
after,O
the,O
announcement,O
of,O
SARS‐CoV‐2,O
as,O
the,O
causative,O
pathogen,O
of,O
COVID‐19,O
",",O
Shirato,O
et,O
al,O
 ,O
has,O
reported,O
the,O
use,O
of,O
a,O
conventional,O
nested,O
RT‐PCR,O
targeting,O
nsp1,O
gene,O
",",O
but,O
require,O
Sanger,O
sequencing,O
for,O
confirmation,O
.,O
Abstract,O
 ,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS‐CoV‐2,O
),O
has,O
caused,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
pandemic,O
.,O
Accurate,O
detection,O
of,O
SARS‐CoV‐2,O
using,O
molecular,O
assays,O
is,O
critical,O
for,O
patient,O
management,O
and,O
the,O
control,O
of,O
the,O
COVID‐19,O
pandemic,O
.,O
Using,O
sequence‐independent,O
single‐primer,O
amplification,O
and,O
nanopore,O
whole‐genome,O
sequencing,O
",",O
we,O
have,O
found,O
that,O
the,O
nonstructural,O
protein,O
1,O
(,O
nsp1,O
),O
gene,O
",",O
located,O
at,O
the,O
5′,O
end,O
of,O
the,O
SARS‐CoV‐2,O
genome,O
",",O
was,O
highly,O
expressed,O
in,O
the,O
nasopharyngeal,O
or,O
saliva,O
specimens,O
of,O
9,O
COVID‐19,O
patients,O
of,O
different,O
clinical,O
severity,O
.,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
genus,O
Betacoronavirus,O
",",O
subgenus,O
Sarbecovirus,O
",",O
family,O
Coronaviridae,O
",",O
is,O
a,O
positive,O
-,O
polarity,O
single,O
-,O
stranded,O
RNA,O
virus,O
that,O
probably,O
originated,O
in,O
bats,O
(,O
Andersen,O
et,O
al,O
.,O
",",O
2020,O
",",O
Lu,O
et,O
al,O
.,O
",",O
2020,O
",",O
Gorbalenya,O
et,O
al,O
.,O
",",O
2020,O
),O
and,O
is,O
the,O
causative,O
agent,O
of,O
coronavirus,O
disease,O
of,O
2019,O
(,O
COVID-19,O
),O
(,O
Li,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
dynamics,O
of,O
the,O
COVID-19,O
pandemic,O
have,O
proven,O
to,O
be,O
complex,O
.,O
Many,O
challenges,O
remain,O
pertaining,O
to,O
a,O
better,O
understanding,O
of,O
the,O
epidemiology,O
",",O
pathology,O
",",O
and,O
transmission,O
of,O
COVID-19,O
.,O
For,O
example,O
",",O
the,O
clinical,O
manifestations,O
of,O
COVID-19,O
range,O
from,O
an,O
asymptomatic,O
infection,O
",",O
mild,O
respiratory,O
illness,O
to,O
pneumonia,O
",",O
respiratory,O
failure,O
",",O
multiorgan,O
failure,O
",",O
and,O
death,O
(,O
Guan,O
et,O
al,O
.,O
",",O
2020,O
",",O
Jiang,O
et,O
al,O
.,O
",",O
2020,O
",",O
Zhu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Furthermore,O
",",O
SARS,O
-,O
CoV-2,O
genomic,O
RNA,O
has,O
been,O
detected,O
in,O
airborne,O
material,O
collected,O
by,O
air,O
samplers,O
positioned,O
distal,O
to,O
COVID-19,O
patients,O
(,O
Liu,O
et,O
al,O
.,O
",",O
2020,O
",",O
Guo,O
et,O
al,O
.,O
",",O
2020,O
",",O
Santarpia,O
et,O
al,O
.,O
",",O
2020,O
",",O
Chia,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Because,O
efforts,O
to,O
isolate,O
virus,O
in,O
cell,O
cultures,O
in,O
the,O
aforementioned,O
air,O
sampling,O
studies,O
in,O
hospital,O
wards,O
were,O
not,O
made,O
(,O
Guo,O
et,O
al,O
.,O
",",O
2020,O
",",O
Chia,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
or,O
failed,O
when,O
they,O
were,O
attempted,O
due,O
to,O
overgrowth,O
by,O
faster,O
replicating,O
respiratory,O
viruses,O
(,O
Lednicky,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
and,O
so,O
far,O
only,O
one,O
has,O
provided,O
evidence,O
of,O
virus,O
isolation,O
(,O
Santarpia,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
uncertainties,O
about,O
the,O
role,O
of,O
aerosols,O
in,O
COVID-19,O
transmission,O
remain,O
.,O
Because,O
",",O
we,O
previously,O
collected,O
SARS,O
-,O
CoV-2,O
from,O
the,O
air,O
of,O
a,O
respiratory,O
illness,O
ward,O
within,O
a,O
clinic,O
but,O
were,O
unable,O
to,O
isolate,O
the,O
virus,O
in,O
cell,O
cultures,O
due,O
to,O
out,O
-,O
competition,O
by,O
other,O
respiratory,O
viruses,O
(,O
Lednicky,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
we,O
sought,O
to,O
perform,O
air,O
sampling,O
tests,O
in,O
a,O
hospital,O
room,O
reserved,O
for,O
COVID-19,O
patients,O
",",O
to,O
lessen,O
the,O
probability,O
of,O
collecting,O
other,O
airborne,O
human,O
respiratory,O
viruses,O
.,O
We,O
thus,O
collected,O
aerosols,O
containing,O
SARS,O
-,O
CoV-2,O
in,O
a,O
room,O
housing,O
COVID-19,O
patients,O
using,O
our,O
VIVAS,O
air,O
samplers,O
that,O
collect,O
virus,O
particles,O
without,O
damaging,O
them,O
",",O
thus,O
conserving,O
their,O
viability,O
.,O
Air,O
samples,O
were,O
collected,O
in,O
a,O
room,O
that,O
was,O
part,O
of,O
a,O
designated,O
COVID-19,O
ward,O
(,O
Figure,O
1,O
),O
.,O
Following,O
the,O
removal,O
of,O
host,O
sequences,O
(,O
Chlorocebus,O
sabaeus,O
;,O
GenBank,S-Repository
 ,O
assembly,O
accession,O
number,O
GCA_000409795.2,S-AccessionNumber
),O
using,O
Kraken,O
2,O
(,O
wood,O
et,O
al,O
.,O
",",O
2019,O
),O
",",O
de,O
novo,O
assembly,O
of,O
paired,O
-,O
end,O
reads,O
was,O
performed,O
in,O
SPAdes,O
v3.13.0,O
with,O
default,O
parameters,O
(,O
Bankevich,O
et,O
al,O
.,O
",",O
2012,O
),O
.,O
Whereas,O
the,O
concentration,O
of,O
SARS,O
-,O
CoV-2,O
genome,O
equivalents,O
per,O
liter,O
of,O
air,O
were,O
estimated,O
(,O
Table,O
2,O
),O
",",O
the,O
determination,O
of,O
the,O
specific,O
infectivity,O
(,O
ratio,O
of,O
SARS,O
-,O
CoV-2,O
genome,O
equivalents,O
present,O
for,O
every,O
one,O
able,O
to,O
infect,O
a,O
cell,O
in,O
culture,O
),O
required,O
the,O
performance,O
of,O
a,O
plaque,O
assay,O
or,O
a,O
standard,O
50,O
%,O
endpoint,O
dilution,O
assay,O
(,O
TCID50,O
assay,O
),O
.,O
Plaque,O
assays,O
could,O
not,O
be,O
performed,O
due,O
to,O
a,O
nationwide,O
nonavailability,O
of,O
some,O
critical,O
media,O
components,O
(,O
due,O
to,O
COVID-19,O
pandemic,O
-,O
related,O
temporary,O
lockdown,O
of,O
production,O
facilities,O
),O
",",O
so,O
TCID50,O
assays,O
were,O
performed,O
in,O
Vero,O
E6,O
cells,O
to,O
estimate,O
the,O
percentage,O
of,O
the,O
collected,O
virus,O
particles,O
that,O
were,O
viable,O
.,O
Estimates,O
ranged,O
from,O
2,O
to,O
74,O
TCID50,O
units,O
/,O
L,O
of,O
air,O
(,O
Table,O
4,O
),O
.,O
The,O
nearly,O
complete,O
genome,O
sequence,O
(,O
and,O
the,O
virus,O
isolate,O
),O
was,O
designated,O
SARS,O
-,O
CoV-2,O
/,O
human,O
/,O
UF-19/2020,O
",",O
and,O
this,O
genome,O
sequence,O
has,O
been,O
deposited,O
in,O
GenBank,S-Repository
 ,O
(,O
accession,O
no,O
.,O
MT668716,S-AccessionNumber
),O
and,O
in,O
GISAID,S-Dataset
 ,O
(,O
accession,O
no,O
.,O
EPI_ISL_480349,S-AccessionNumber
),O
.,O
This,O
complete,O
genome,O
sequence,O
of,O
the,O
virus,O
collected,O
by,O
the,O
air,O
samplers,O
(,O
and,O
the,O
virus,O
therein,O
),O
was,O
considered,O
the,O
same,O
isolate,O
and,O
designated,O
SARS,O
-,O
CoV-2,O
/,O
Environment,O
/,O
UF-20/2020,O
",",O
and,O
this,O
genome,O
sequence,O
has,O
been,O
deposited,O
in,O
GenBank,S-Repository
 ,O
(,O
accession,O
no,O
.,O
MT670008,S-AccessionNumber
),O
and,O
in,O
GISAID,S-Dataset
 ,O
(,O
accession,O
no,O
.,O
EPI_ISL_477163,S-AccessionNumber
),O
.,O
The,O
virus,O
’,O
genomic,O
sequence,O
currently,O
falls,O
within,O
GISAID,S-Dataset
 ,O
clade,O
B.1(GH,O
),O
",",O
which,O
is,O
characterized,O
by,O
mutations,O
C241,O
T,O
",",O
C3037,O
T,O
",",O
A23403,O
G,O
",",O
G25563,O
T,O
",",O
S,O
-,O
D614,O
G,O
",",O
and,O
NS3,O
-,O
Q57H,O
relative,O
to,O
reference,O
genome,O
WIV04,O
(,O
GenBank,S-Repository
 ,O
accession,O
no,O
.,O
As,O
reported,O
in,O
air,O
sampling,O
tests,O
performed,O
by,O
others,O
(,O
Liu,O
et,O
al,O
.,O
",",O
2020,O
",",O
Wang,O
et,O
al,O
.,O
",",O
2020,O
",",O
Holshue,O
et,O
al,O
.,O
",",O
2020,O
",",O
Santarpia,O
et,O
al,O
.,O
",",O
2020,O
),O
and,O
in,O
our,O
previous,O
report,O
(,O
Lednicky,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
airborne,O
SARS,O
-,O
CoV-2,O
was,O
present,O
in,O
a,O
location,O
with,O
COVID-19,O
patients,O
.,O
Unlike,O
previous,O
studies,O
",",O
we,O
have,O
demonstrated,O
that,O
the,O
virus,O
in,O
aerosols,O
can,O
be,O
viable,O
",",O
and,O
this,O
suggests,O
that,O
there,O
is,O
an,O
inhalation,O
risk,O
for,O
acquiring,O
COVID-19,O
within,O
the,O
vicinity,O
of,O
people,O
who,O
emit,O
the,O
virus,O
through,O
expirations,O
including,O
coughs,O
",",O
sneezes,O
",",O
and,O
speaking,O
.,O
The,O
amount,O
of,O
airborne,O
virus,O
detected,O
per,O
liter,O
of,O
air,O
was,O
small,O
",",O
and,O
future,O
studies,O
should,O
address,O
(,O
a,O
),O
whether,O
this,O
is,O
typical,O
for,O
COVID-19,O
",",O
(,O
b,O
),O
if,O
this,O
represented,O
virus,O
production,O
relative,O
to,O
the,O
phase,O
of,O
infection,O
in,O
the,O
patient,O
",",O
(,O
c,O
),O
if,O
this,O
was,O
a,O
consequence,O
of,O
active,O
air,O
flow,O
related,O
to,O
air,O
exchanges,O
within,O
the,O
room,O
",",O
(,O
d,O
),O
or,O
if,O
the,O
low,O
number,O
of,O
virus,O
was,O
due,O
to,O
technical,O
difficulties,O
in,O
removing,O
small,O
airborne,O
particles,O
from,O
the,O
air,O
(,O
Pan,O
et,O
al,O
.,O
",",O
2019,O
),O
.,O
Our,O
findings,O
reveal,O
that,O
viable,O
SARS,O
-,O
CoV-2,O
can,O
be,O
present,O
in,O
aerosols,O
generated,O
by,O
a,O
COVID-19,O
patient,O
in,O
a,O
hospital,O
room,O
in,O
the,O
absence,O
of,O
an,O
aerosol,O
-,O
generating,O
procedure,O
",",O
and,O
can,O
thus,O
serve,O
as,O
a,O
source,O
for,O
transmission,O
of,O
the,O
virus,O
in,O
this,O
setting,O
.,O
Moreover,O
",",O
the,O
public,O
health,O
implications,O
are,O
broad,O
",",O
particularly,O
as,O
current,O
best,O
practices,O
for,O
limiting,O
the,O
spread,O
of,O
COVID-19,O
center,O
on,O
social,O
distancing,O
",",O
wearing,O
of,O
face,O
coverings,O
while,O
in,O
proximity,O
to,O
others,O
and,O
hand,O
washing,O
.,O
With,O
the,O
current,O
surge,O
of,O
cases,O
",",O
to,O
help,O
stem,O
the,O
COVID-19,O
pandemic,O
",",O
clear,O
guidance,O
on,O
control,O
measures,O
against,O
SARS,O
-,O
CoV-2,O
aerosols,O
are,O
needed,O
",",O
as,O
recently,O
voiced,O
by,O
other,O
scientists,O
(,O
Morawska,O
and,O
Milton,O
",",O
2020,O
),O
.,O
Air,O
samples,O
collected,O
in,O
the,O
hospital,O
room,O
of,O
two,O
coronavirus,O
disease-2019,O
(,O
COVID-19,O
),O
patients,O
",",O
one,O
ready,O
for,O
discharge,O
and,O
the,O
other,O
newly,O
admitted,O
",",O
were,O
subjected,O
to,O
RT,O
-,O
qPCR,O
and,O
virus,O
culture,O
.,O
Estimates,O
of,O
viable,O
viral,O
concentrations,O
ranged,O
from,O
6,O
to,O
74,O
TCID,O
50,O
units,O
/,O
L,O
of,O
air,O
.,O
Conclusions,O
 ,O
Patients,O
with,O
respiratory,O
manifestations,O
of,O
COVID-19,O
produce,O
aerosols,O
in,O
the,O
absence,O
of,O
aerosol,O
-,O
generating,O
procedures,O
that,O
contain,O
viable,O
SARS,O
-,O
CoV-2,O
",",O
and,O
these,O
aerosols,O
may,O
serve,O
as,O
a,O
source,O
of,O
transmission,O
of,O
the,O
virus,O
.,O
The,O
disease,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
was,O
called,O
“,O
coronavirus,O
disease,O
2019,O
”,O
(,O
COVID-19,O
),O
[,O
7,O
],O
.,O
The,O
complete,O
genomic,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
were,O
obtained,O
from,O
2019,B-Repository
Novel,I-Repository
Coronavirus,I-Repository
Resource,I-Repository
(2019nCoVR),E-Repository
 ,O
[,O
12,O
],O
and,O
two,O
databases,O
",",O
including,O
the,O
National,B-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,I-Repository
(NCBI),E-Repository
 ,O
[,O
13,O
],O
and,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
[,O
14,O
],O
.,O
The,O
differences,O
and,O
similarities,O
of,O
clinical,O
characteristics,O
between,O
COVID-19,O
and,O
SARS,O
were,O
summarized,O
in,O
Table,O
1,O
.,O
The,O
main,O
timeline,O
of,O
SARS,O
and,O
COVID-19,O
epidemic,O
development,O
were,O
shown,O
in,O
Figure,O
1a,O
",",O
b,O
",",O
respectively,O
.,O
In,O
comparison,O
",",O
COVID-19,O
showed,O
similar,O
trends,O
with,O
SARS,O
patients,O
[,O
28,O
],O
.,O
Beijing,O
Centers,O
for,O
Diseases,O
Control,O
and,O
Prevention,O
indicated,O
that,O
the,O
typical,O
case,O
of,O
COVID-19,O
has,O
a,O
progressive,O
aggravation,O
process,O
.,O
COVID-19,O
can,O
be,O
classified,O
into,O
light,O
",",O
normal,O
",",O
severe,O
",",O
and,O
critical,O
types,O
based,O
on,O
the,O
severity,O
of,O
the,O
disease,O
[,O
31,O
],O
:,O
(,O
1,O
),O
Mild,O
cases,O
—,O
the,O
clinical,O
symptoms,O
were,O
mild,O
",",O
and,O
no,O
pneumonia,O
was,O
found,O
on,O
the,O
chest,O
computed,O
tomography,O
(,O
CT,O
),O
;,O
(,O
2,O
),O
normal,O
cases,O
—,O
fever,O
",",O
respiratory,O
symptoms,O
",",O
and,O
patients,O
found,O
to,O
have,O
imaging,O
manifestations,O
of,O
pneumonia,O
;,O
(,O
3,O
),O
severe,O
cases,O
—,O
one,O
of,O
the,O
following,O
three,O
conditions,O
:,O
Respiratory,O
distress,O
",",O
respiratory,O
rate,O
≥,O
30,O
times,O
/,O
min,O
(,O
in,O
resting,O
state,O
",",O
refers,O
to,O
oxygen,O
saturation,O
≤,O
93,O
%,O
),O
",",O
partial,O
arterial,O
oxygen,O
pressure,O
(,O
PaO2)/oxygen,O
absorption,O
concentration,O
(,O
FiO2,O
),O
≤,O
300,O
mmHg,O
(,O
1,O
mmHg,O
=,O
0.133,O
kPa,O
),O
;,O
(,O
4,O
),O
critical,O
cases,O
—,O
one,O
of,O
the,O
following,O
three,O
conditions,O
:,O
Respiratory,O
failure,O
and,O
the,O
need,O
for,O
mechanical,O
ventilation,O
",",O
shock,O
",",O
or,O
the,O
associated,O
failure,O
of,O
other,O
organs,O
requiring,O
the,O
intensive,O
care,O
unit,O
[,O
32,O
],O
.,O
It,O
has,O
been,O
demonstrated,O
that,O
the,O
latency,O
of,O
COVID-19,O
varies,O
from,O
3–7,O
days,O
on,O
average,O
",",O
for,O
up,O
to,O
14,O
days,O
[,O
35,O
],O
.,O
By,O
comparison,O
",",O
we,O
found,O
that,O
the,O
average,O
latency,O
of,O
COVID-19,O
is,O
slightly,O
longer,O
than,O
that,O
of,O
SARS,O
.,O
Li,O
et,O
al,O
.,O
reported,O
that,O
people,O
who,O
have,O
not,O
been,O
exposed,O
to,O
SARS,O
-,O
CoV-2,O
are,O
all,O
susceptible,O
to,O
COVID-19,O
[,O
41,O
],O
.,O
Among,O
the,O
"8,866",O
patients,O
who,O
have,O
been,O
confirmed,O
with,O
COVID-19,O
",",O
nearly,O
half,O
of,O
the,O
patients,O
have,O
been,O
aged,O
50,O
years,O
or,O
older,O
(,O
47.7,O
%,O
),O
[,O
36,O
],O
.,O
However,O
",",O
severe,O
COVID-19,O
cases,O
and,O
deaths,O
have,O
mostly,O
been,O
in,O
the,O
middle,O
-,O
aged,O
adults,O
and,O
the,O
elderly,O
with,O
long,O
smoking,O
histories,O
or,O
other,O
basic,O
diseases,O
",",O
such,O
as,O
heart,O
disease,O
and,O
hypertension,O
[,O
"43,44",O
],O
.,O
At,O
the,O
time,O
that,O
this,O
paper,O
was,O
been,O
submitted,O
",",O
COVID-19,O
patients,O
mortality,O
rate,O
was,O
2.1,O
%,O
[,O
45,O
],O
.,O
According,O
to,O
the,O
latest,O
data,O
on,O
Feb.,O
14th,O
",",O
2020,O
[,O
"55,56",O
],O
",",O
there,O
have,O
been,O
a,O
total,O
of,O
"67,081",O
clinically,O
diagnosed,O
cases,O
of,O
COVID-19,O
in,O
worldwide,O
",",O
with,O
"1,526",O
deaths,O
.,O
As,O
the,O
origin,O
area,O
of,O
COVID-19,O
",",O
Hubei,O
province,O
has,O
been,O
the,O
most,O
severely,O
infected,O
area,O
",",O
with,O
"54,406",O
cumulative,O
diagnosis,O
cases,O
.,O
At,O
present,O
",",O
the,O
COVID-19,O
outbreak,O
has,O
been,O
spread,O
to,O
all,O
parts,O
of,O
China,O
and,O
around,O
the,O
world,O
",",O
including,O
the,O
United,O
States,O
",",O
Thailand,O
",",O
and,O
Japan,O
.,O
The,O
distribution,O
of,O
COVID-2019,O
patients,O
in,O
China,O
(,O
including,O
Hong,O
Kong,O
",",O
Macao,O
and,O
Taiwan,O
),O
and,O
Hubei,O
Province,O
is,O
shown,O
in,O
Figure,O
3,O
.,O
As,O
the,O
number,O
of,O
COVID-19,O
patients,O
in,O
China,O
has,O
been,O
growing,O
rapidly,O
",",O
preventing,O
the,O
spread,O
of,O
SARS,O
-,O
CoV-2,O
is,O
the,O
most,O
important,O
and,O
urgent,O
task,O
[,O
57,O
],O
.,O
The,O
possible,O
pathogens,O
of,O
SARS,O
and,O
COVID-19,O
are,O
both,O
derived,O
from,O
wild,O
animals,O
[,O
63,O
],O
.,O
The,O
early,O
symptoms,O
of,O
SARS,O
and,O
COVID-19,O
are,O
very,O
similar,O
to,O
winter,O
influenza,O
",",O
and,O
the,O
most,O
important,O
way,O
to,O
distinguish,O
flu,O
and,O
pneumonia,O
is,O
to,O
take,O
throat,O
swabs,O
for,O
viral,O
testing,O
[,O
68,O
],O
.,O
Both,O
SARS,O
-,O
CoV,O
and,O
SARS,O
-,O
CoV-2,O
are,O
CoVs,O
;,O
hence,O
",",O
the,O
treatment,O
strategies,O
of,O
SARS,O
could,O
be,O
relevant,O
for,O
COVID-19,O
[,O
74,O
],O
.,O
Now,O
",",O
isolation,O
",",O
antiviral,O
",",O
and,O
symptomatic,O
treatments,O
are,O
still,O
mainly,O
adopted,O
for,O
COVID-19,O
treatment,O
.,O
As,O
effective,O
drugs,O
for,O
SARS,O
",",O
hormones,O
and,O
interferons,O
can,O
also,O
be,O
used,O
to,O
treat,O
COVID-19,O
[,O
74,O
],O
.,O
Lopinavir,O
/,O
ritonavir,O
has,O
also,O
been,O
clinically,O
tested,O
in,O
treatment,O
of,O
COVID-19,O
",",O
and,O
showed,O
wonderfully,O
effective,O
treatment,O
for,O
some,O
patients,O
",",O
but,O
the,O
general,O
clinical,O
effect,O
has,O
not,O
been,O
determined,O
[,O
78,O
],O
.,O
A,O
high,O
-,O
resolution,O
crystal,O
structure,O
of,O
SARS,O
-,O
CoV-2,O
coronavirus,O
3CL,O
hydrolase,O
(,O
Mpro,O
),O
was,O
announced,O
after,O
the,O
outbreak,O
of,O
COVID-19,O
in,O
the,O
world,O
[,O
80,O
],O
",",O
and,O
human,O
coronaviruses,O
(,O
HCoVs,O
),O
have,O
been,O
treated,O
as,O
severe,O
pathogens,O
in,O
respiratory,O
tract,O
infections,O
.,O
Clinical,O
trials,O
of,O
remdesivir,O
for,O
treatment,O
of,O
COVID-19,O
just,O
started,O
on,O
Feb.,O
5th,O
and,O
12th,O
",",O
2020,O
in,O
Wuhan,O
and,O
Beijing,O
",",O
respectively,O
",",O
and,O
the,O
experimental,O
results,O
remain,O
unclear,O
[,O
"85,86",O
],O
.,O
As,O
a,O
large,O
number,O
of,O
people,O
have,O
left,O
Wuhan,O
",",O
the,O
control,O
of,O
the,O
epidemic,O
situation,O
is,O
extremely,O
urgent,O
",",O
and,O
the,O
treatments,O
of,O
COVID-19,O
are,O
imminent,O
.,O
Hence,O
",",O
clinical,O
drugs,O
and,O
therapies,O
for,O
treating,O
SARS,O
may,O
be,O
used,O
as,O
a,O
reference,O
for,O
COVID-19,O
treatment,O
[,O
74,O
],O
.,O
Although,O
more,O
and,O
more,O
studies,O
for,O
SARS,O
-,O
CoV-2,O
have,O
sprung,O
up,O
since,O
the,O
outbreak,O
of,O
this,O
epidemic,O
COVID-19,O
",",O
based,O
on,O
our,O
comparison,O
",",O
we,O
propose,O
some,O
key,O
questions,O
to,O
be,O
clarified,O
in,O
future,O
studies,O
(,O
Table,O
3,O
),O
.,O
In,O
-,O
depth,O
understanding,O
the,O
underlying,O
pathogenic,O
mechanisms,O
of,O
SARS,O
-,O
CoV-2,O
will,O
reveal,O
more,O
targets,O
for,O
better,O
therapy,O
of,O
COVID-19,O
.,O
This,O
virus,O
causes,O
acute,O
lung,O
symptoms,O
",",O
leading,O
to,O
a,O
condition,O
that,O
has,O
been,O
named,O
as,O
“,O
coronavirus,O
disease,O
2019,O
”,O
(,O
COVID-19,O
),O
.,O
To,O
date,O
",",O
Covid-19,O
associated,O
pneumonia,O
accounts,O
(,O
as,O
of,O
14th,O
July,O
2020,O
",",O
source,O
:,O
www.who.int,O
",",O
“,O
COVID-19,O
Situation,O
report,O
-,O
176,O
”,O
),O
almost,O
13,O
Million,O
confirmed,O
cases,O
and,O
more,O
than,O
550′000,O
deaths,O
since,O
its,O
first,O
reported,O
discovery,O
in,O
the,O
Hubei,O
province,O
in,O
China,O
in,O
December,O
2019,O
[,O
1,O
],O
.,O
Reference,O
coronavirus,O
genomes,O
were,O
obtained,O
either,O
from,O
NCBI,B-Repository
GenBank,E-Repository
 ,O
(,O
https://www.ncbi.nlm.nih.gov/genbank/,S-URL
),O
or,O
from,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
databases,O
as,O
suggested,O
from,O
the,O
recent,O
discoveries,O
on,O
the,O
proximal,O
origins,O
of,O
SARS,O
-,O
CoV-2,O
[,O
"2,3",O
],O
(,O
Detailed,O
accession,O
numbers,O
in,O
Supplementary,O
Table,O
 ,O
1,O
),O
.,O
Although,O
little,O
information,O
is,O
available,O
on,O
lung,O
epithelium,O
ageing,O
-,O
dependent,O
mechanisms,O
",",O
we,O
hypothesize,O
that,O
E,O
protein,O
significantly,O
increase,O
this,O
dysfunction,O
",",O
especially,O
in,O
elderly,O
people,O
as,O
evidenced,O
by,O
COVID-19,O
epidemiological,O
data,O
.,O
We,O
compared,O
the,O
genomic,O
sequences,O
of,O
E,O
protein,O
of,O
SARS,O
-,O
CoV-2,O
",",O
SARS,O
-,O
CoV,O
and,O
the,O
closely,O
related,O
genomes,O
of,O
bats,O
and,O
pangolins,O
obtained,O
from,O
the,O
GISAID,S-Dataset
 ,O
and,O
GenBank,S-Repository
 ,O
databases,O
.,O
Large,O
scale,O
testing,O
is,O
essential,O
",",O
but,O
estimates,O
indicate,O
that,O
large,O
numbers,O
of,O
mild,O
",",O
asymptomatic,O
or,O
pre,O
-,O
symptomatic,O
COVID-19,O
cases,O
are,O
not,O
detected,O
by,O
current,O
testing,O
efforts,O
(,O
Kobayashi,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
the,O
U.S.,O
",",O
one,O
estimate,O
suggest,O
that,O
only,O
1.6,O
%,O
of,O
COVID-19,O
cases,O
have,O
been,O
detected,O
(,O
Vollmer,O
",",O
2020,O
),O
",",O
while,O
another,O
study,O
estimates,O
that,O
about,O
17.9,O
%,O
of,O
individuals,O
infected,O
with,O
SARS,O
-,O
CoV-2,O
are,O
asymptomatic,O
at,O
their,O
first,O
positive,O
test,O
and,O
may,O
not,O
develop,O
symptoms,O
for,O
up,O
to,O
two,O
weeks,O
(,O
Mizumoto,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
However,O
",",O
most,O
symptoms,O
associated,O
with,O
COVID-19,O
",",O
such,O
as,O
fever,O
and,O
cough,O
",",O
are,O
non,O
-,O
specific,O
and,O
do,O
not,O
distinguish,O
COVID-19,O
cases,O
from,O
individuals,O
with,O
other,O
respiratory,O
infections,O
(,O
Guan,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Nucleic,O
acid,O
tests,O
employing,O
RT,O
-,O
PCR,O
",",O
are,O
the,O
primary,O
means,O
employed,O
to,O
diagnose,O
COVID-19,O
using,O
respiratory,O
samples,O
(,O
CDC,O
",",O
2020,O
;,O
Udugama,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
A,O
recently,O
deployed,O
isothermal,O
assays,O
for,O
COVID-19,O
that,O
uses,O
the,O
Abbott,O
ID,O
Now,O
system,O
requires,O
less,O
expensive,O
equipment,O
and,O
less,O
training,O
",",O
but,O
also,O
produces,O
less,O
definitive,O
results,O
.,O
Thus,O
",",O
RT,O
-,O
qPCR,O
assays,O
are,O
still,O
the,O
gold,O
-,O
standard,O
for,O
COVID-19,O
diagnosis,O
.,O
Rapid,O
and,O
ultrasensitive,O
COVID-19,O
diagnostic,O
assays,O
that,O
are,O
capable,O
of,O
high,O
-,O
throughput,O
analyses,O
and,O
which,O
do,O
not,O
require,O
a,O
high,O
degree,O
of,O
technical,O
expertise,O
or,O
sophisticated,O
equipment,O
are,O
required,O
to,O
expand,O
COVID-19,O
testing,O
capacity,O
.,O
One,O
recently,O
published,O
report,O
",",O
incorporated,O
RT,O
-,O
LAMP,O
with,O
CRISPR,O
-,O
Cas12a,O
to,O
allow,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
in,O
respiratory,O
swab,O
RNA,O
extracts,O
in,O
a,O
colorimetric,O
lateral,O
flow,O
assay,O
(,O
Broughton,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
COVID-19,O
CRISPR,O
-,O
FDS,O
assay,O
we,O
describe,O
uses,O
a,O
streamlined,O
approach,O
that,O
does,O
not,O
require,O
any,O
special,O
equipment,O
beyond,O
that,O
found,O
in,O
most,O
clinical,O
and,O
research,O
laboratories,O
.,O
COVID-19,O
CRISPR,O
-,O
FDS,O
assays,O
performed,O
with,O
RT,O
-,O
PCR,O
and,O
RT,O
-,O
RPA,O
amplified,O
samples,O
",",O
detected,O
samples,O
spiked,O
with,O
≥2,O
copies,O
of,O
the,O
target,O
RNA,O
sequence,O
",",O
regardless,O
of,O
the,O
method,O
used,O
in,O
the,O
pre,O
-,O
amplification,O
step,O
(,O
Fig,O
.,O
3,O
A,O
and,O
B,O
),O
",",O
in,O
good,O
agreement,O
with,O
our,O
calculated,O
estimate,O
for,O
its,O
LOD,O
.,O
For,O
the,O
analysis,O
of,O
clinical,O
samples,O
",",O
a,O
COVID-19,O
CRISPR,O
-,O
FDS,O
assay,O
result,O
was,O
considered,O
positive,O
if,O
it,O
was,O
equal,O
or,O
greater,O
than,O
a,O
cut,O
-,O
off,O
threshold,O
equal,O
to,O
the,O
mean,O
signal,O
of,O
the,O
negative,O
control,O
samples,O
plus,O
three,O
times,O
its,O
standard,O
deviation,O
(,O
Kim,O
et,O
al,O
.,O
",",O
2016,O
),O
.,O
Although,O
RT,O
-,O
qPCR,O
is,O
the,O
most,O
widely,O
used,O
diagnostic,O
method,O
for,O
COVID-19,O
",",O
its,O
sensitivity,O
has,O
not,O
proven,O
satisfactory,O
",",O
resulting,O
in,O
a,O
relatively,O
high,O
number,O
of,O
false,O
-,O
negative,O
results,O
",",O
so,O
that,O
a,O
substantial,O
number,O
of,O
infected,O
individuals,O
do,O
not,O
receive,O
proper,O
diagnoses,O
and,O
treatment,O
.,O
In,O
a,O
study,O
of,O
more,O
than,O
1000,O
patients,O
",",O
75,O
%,O
of,O
COVID-19,O
suspects,O
had,O
negative,O
RT,O
-,O
qPCR,O
test,O
results,O
but,O
positive,O
chest,O
computerized,O
tomograph,O
results,O
",",O
and,O
48,O
%,O
of,O
these,O
patients,O
were,O
considered,O
highly,O
likely,O
to,O
have,O
had,O
COVID-19,O
",",O
with,O
an,O
additional,O
33,O
%,O
considered,O
probable,O
cases,O
(,O
Ai,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Various,O
isothermal,O
amplification,O
methods,O
",",O
such,O
as,O
RPA,O
and,O
LAMP,O
",",O
have,O
been,O
reported,O
for,O
the,O
detection,O
of,O
COVID-19,O
(,O
Ding,O
et,O
al,O
.,O
",",O
2020,O
;,O
Lucia,O
et,O
al,O
.,O
",",O
2020,O
;,O
Yu,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
but,O
many,O
problems,O
were,O
identified,O
upon,O
detailed,O
analysis,O
of,O
these,O
methods,O
",",O
including,O
low,O
sensitivity,O
and,O
low,O
throughput,O
.,O
We,O
do,O
not,O
see,O
this,O
as,O
a,O
major,O
drawback,O
given,O
the,O
clear,O
need,O
for,O
rapid,O
",",O
sensitive,O
",",O
and,O
robust,O
assays,O
to,O
diagnose,O
COVID-19,O
.,O
CRISPR,O
assay,O
diagnostic,O
results,O
obtained,O
nasal,O
swab,O
samples,O
of,O
individuals,O
with,O
suspected,O
COVID-19,O
cases,O
were,O
comparable,O
to,O
paired,O
results,O
from,O
a,O
CDC,O
-,O
approved,O
quantitative,O
RT,O
-,O
PCR,O
(,O
RT,O
-,O
qPCR,O
),O
assay,O
performed,O
in,O
a,O
state,O
testing,O
lab,O
",",O
and,O
superior,O
to,O
those,O
produced,O
by,O
same,O
assay,O
in,O
a,O
clinical,O
lab,O
",",O
where,O
the,O
RT,O
-,O
qPCR,O
assay,O
exhibited,O
multiple,O
invalid,O
or,O
inconclusive,O
results,O
.,O
Based,O
on,O
these,O
findings,O
",",O
we,O
believe,O
that,O
a,O
CRISPR,O
-,O
based,O
fluorescent,O
application,O
has,O
potential,O
to,O
improve,O
current,O
COVID-19,O
screening,O
efforts,O
.,O
Highlights,O
    ,O
•,O
 ,O
Integrated,O
CRISPR,O
for,O
COVID-19,O
clinical,O
diagnosis,O
.,O
•,O
 ,O
Detection,O
environment,O
friendly,O
and,O
compatible,O
for,O
high,O
throughput,O
COVID-19,O
screening,O
in,O
hospital,O
.,O
•,O
 ,O
Improve,O
diagnosis,O
of,O
individuals,O
with,O
suspected,O
COVID-19,O
infections,O
.,O
A,O
new,O
coronavirus,O
SARS,O
-,O
CoV-2,O
capable,O
to,O
infect,O
humans,O
",",O
emerged,O
in,O
mid,O
-,O
December,O
2019,O
in,O
Wuhan,O
",",O
China,O
",",O
causing,O
the,O
novel,O
disease,O
COVID-19,O
(,O
Wu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
A,O
recent,O
study,O
which,O
analyzed,O
COVID-19,O
symptoms,O
in,O
monozygotic,O
and,O
dizygotic,O
twins,O
",",O
reported,O
that,O
50,O
(,O
95,O
%,O
confidence,O
intervals,O
29–70)%,O
of,O
the,O
variance,O
of,O
‘,O
predicted,O
COVID-19,O
’,O
phenotype,O
is,O
due,O
to,O
genetic,O
factors,O
(,O
Williams,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
It,O
has,O
been,O
shown,O
that,O
plasmin,O
is,O
also,O
capable,O
to,O
cleave,O
furin,O
sites,O
(,O
Zhao,O
et,O
al,O
.,O
",",O
2020,O
),O
and,O
that,O
individuals,O
with,O
elevated,O
plasmin,O
demonstrated,O
higher,O
susceptibility,O
to,O
COVID-19,O
(,O
Ji,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
At,O
the,O
beginning,O
of,O
May,O
2020,O
",",O
in,O
the,O
full,O
swing,O
of,O
COVID-19,O
pandemic,O
",",O
the,O
data,O
on,O
genetic,O
susceptibility,O
or,O
resistance,O
to,O
SARS,O
-,O
CoV-2,O
which,O
would,O
be,O
based,O
on,O
the,O
genotyping,O
of,O
individuals,O
infected,O
by,O
SARS,O
-,O
CoV-2,O
are,O
still,O
lacking,O
.,O
Furthermore,O
",",O
we,O
can,O
learn,O
from,O
clinical,O
experiences,O
of,O
the,O
SARS,O
-,O
CoV-2,O
infection,O
which,O
showed,O
that,O
plasmin,O
and,O
other,O
airway,O
proteases,O
could,O
also,O
be,O
important,O
for,O
patients,O
experiencing,O
more,O
severe,O
form,O
of,O
COVID-19,O
(,O
Ji,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
To,O
systematically,O
examine,O
the,O
coding,O
variants,O
in,O
selected,O
genes,O
and,O
differences,O
in,O
the,O
allele,O
frequency,O
between,O
populations,O
",",O
we,O
performed,O
comparative,O
analysis,O
of,O
22,O
variants,O
found,O
in,O
FURIN,O
",",O
PLG,O
",",O
PRSS1,O
",",O
TMPRSS11a,O
",",O
MBL2,O
and,O
OAS1,O
genes,O
from,O
Serbian,O
population,O
database,O
with,O
different,O
European,O
populations,O
and,O
super,O
-,O
populations,O
extracted,O
from,O
1kGP,S-Repository
 ,O
database,O
(,O
Genomes,B-Creator
Project,I-Creator
et,I-Creator
"al.,",I-Creator
2015,E-Creator
),O
.,O
Having,O
in,O
mind,O
that,O
individuals,O
with,O
elevated,O
plasmin,O
had,O
greater,O
susceptibility,O
to,O
COVID-19,O
and,O
more,O
severe,O
clinical,O
manifestations,O
(,O
Ji,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
rare,O
variants,O
in,O
PLG,O
",",O
such,O
as,O
p.,O
Arg261His,O
and,O
p.,O
Ala494Val,O
may,O
be,O
recognized,O
as,O
potential,O
markers,O
of,O
inter,O
-,O
individual,O
differences,O
in,O
susceptibility,O
to,O
coronavirus,O
.,O
Having,O
in,O
mind,O
the,O
MAF,O
difference,O
between,O
Spanish,O
and,O
East,O
Asian,O
populations,O
",",O
it,O
would,O
be,O
interesting,O
to,O
further,O
investigate,O
whether,O
it,O
also,O
reflects,O
the,O
remarkable,O
differences,O
in,O
susceptibility,O
and,O
morbidity,O
to,O
COVID-19,O
between,O
these,O
populations,O
.,O
While,O
variant,O
p.,O
Gln293Arg,O
was,O
described,O
as,O
a,O
cumulative,O
risk,O
factor,O
for,O
esophageal,O
squamous,O
cell,O
carcinoma,O
(,O
Suo,O
et,O
al,O
.,O
",",O
2019,O
),O
",",O
its,O
effect,O
on,O
the,O
protease,O
activity,O
and,O
COVID-19,O
susceptibility,O
remains,O
to,O
be,O
elucidated,O
.,O
New,O
coronavirus,O
SARS,O
-,O
CoV-2,O
is,O
capable,O
to,O
infect,O
humans,O
and,O
cause,O
a,O
novel,O
disease,O
COVID-19,O
.,O
Aiming,O
to,O
understand,O
a,O
host,O
genetic,O
component,O
of,O
COVID-19,O
",",O
we,O
focused,O
on,O
variants,O
in,O
genes,O
encoding,O
proteases,O
and,O
genes,O
involved,O
in,O
innate,O
immunity,O
that,O
could,O
be,O
important,O
for,O
susceptibility,O
and,O
resistance,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
.,O
This,O
has,O
been,O
made,O
evident,O
by,O
the,O
ongoing,O
pandemic,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
",",O
officially,O
named,O
COVID-19,O
",",O
caused,O
by,O
the,O
betacoronavirus,O
SARS,O
-,O
CoV-2,O
.,O
Most,O
important,O
in,O
the,O
context,O
of,O
the,O
COVID-19,O
pandemic,O
",",O
four,O
betacoronaviruses,O
",",O
SARS,O
-,O
CoV,O
",",O
SARS,O
-,O
CoV-2,O
",",O
MERS,O
-,O
CoV,O
",",O
and,O
SCH,O
1,O
014,O
-,O
CoV,O
",",O
a,O
bat,O
coronavirus,O
",",O
were,O
significantly,O
crippled,O
by,O
TOP3B,O
KO,O
(,O
Fig,O
.,O
2C,O
),O
.,O
As,O
of,O
April,O
30th,O
",",O
2020,O
there,O
were,O
approximately,O
3.1,O
 ,O
M,O
confirmed,O
cases,O
of,O
COVID-19,O
worldwide,O
and,O
more,O
than,O
217.000,O
infection,O
-,O
related,O
deaths,O
.,O
Therefore,O
",",O
in,O
our,O
study,O
",",O
CFR,O
was,O
calculated,O
as,O
the,O
ratio,O
between,O
the,O
death,O
cases,O
due,O
to,O
COVID-19,O
",",O
over,O
the,O
total,O
number,O
of,O
SARS,O
-,O
CoV-2,O
reported,O
cases,O
14,O
 ,O
days,O
before,O
",",O
as,O
previously,O
described,O
[,O
11,O
],O
.,O
Mortality,O
calculations,O
during,O
the,O
epidemics,O
are,O
difficult,O
",",O
mostly,O
due,O
to,O
calculation,O
biases,O
:,O
during,O
the,O
initial,O
period,O
of,O
the,O
epidemic,O
",",O
many,O
patients,O
were,O
diagnosed,O
with,O
COVID-19,O
only,O
after,O
developing,O
critical,O
illness,O
or,O
even,O
at,O
the,O
time,O
of,O
death,O
",",O
whereas,O
asymptomatic,O
or,O
paucisymptomatic,O
patients,O
were,O
untested,O
",",O
leading,O
to,O
an,O
underestimation,O
of,O
the,O
denominator,O
[,O
11,O
],O
.,O
We,O
chose,O
to,O
analyze,O
the,O
Country,O
-,O
specific,O
data,O
relative,O
to,O
the,O
number,O
of,O
COVID-19,O
deaths,O
in,O
April,O
2020,O
",",O
when,O
some,O
of,O
the,O
initial,O
biases,O
were,O
likely,O
attenuated,O
",",O
using,O
the,O
method,O
described,O
[,O
11,O
],O
.,O
However,O
",",O
even,O
if,O
the,O
daily,O
number,O
of,O
death,O
patients,O
divided,O
per,O
age,O
is,O
available,O
for,O
each,O
Country,O
",",O
we,O
could,O
not,O
provide,O
in,O
this,O
study,O
a,O
further,O
normalization,O
of,O
the,O
CFR,O
taking,O
into,O
account,O
patients,O
age,O
",",O
since,O
a,O
similar,O
daily,O
database,O
of,O
infected,O
people,O
divided,O
per,O
age,O
is,O
not,O
publicly,O
available,O
.,O
A,O
database,O
of,O
487,O
genome,O
sequences,O
isolated,O
from,O
patients,O
infected,O
with,O
SARS,O
-,O
CoV-2,O
in,O
Italy,O
",",O
Spain,O
",",O
Germany,O
",",O
France,O
",",O
UK,O
",",O
Sweden,O
and,O
USA,O
has,O
been,O
randomly,O
collected,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
",",O
aligned,O
and,O
compared,O
to,O
the,O
SARS,O
-,O
CoV-2,O
reference,O
genome,O
.,O
The,O
only,O
significant,O
difference,O
is,O
the,O
newly,O
emerged,O
mutation,O
nt24368,O
",",O
that,O
in,O
our,O
database,O
was,O
detected,O
only,O
in,O
the,O
genomes,O
analyzed,O
in,O
Sweden,O
.,O
Background,O
 ,O
Severe,O
acute,O
respiratory,O
syndrome,O
CoV-2,O
(,O
SARS,O
-,O
CoV-2,O
),O
caused,O
the,O
first,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
outbreak,O
in,O
China,O
and,O
has,O
become,O
a,O
public,O
health,O
emergency,O
of,O
international,O
concern,O
.,O
Case,O
fatality,O
rate,O
was,O
calculated,O
as,O
the,O
ratio,O
between,O
the,O
death,O
cases,O
due,O
to,O
COVID-19,O
",",O
over,O
the,O
total,O
number,O
of,O
SARS,O
-,O
CoV-2,O
reported,O
cases,O
14,O
 ,O
days,O
before,O
.,O
We,O
also,O
analyzed,O
487,O
genomic,O
sequences,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
derived,O
from,O
patients,O
infected,O
by,O
SARS,O
-,O
CoV-2,O
from,O
January,O
2020,O
to,O
April,O
2020,O
in,O
Italy,O
",",O
Spain,O
",",O
Germany,O
",",O
France,O
",",O
Sweden,O
",",O
UK,O
and,O
USA,O
.,O
SARS,O
-,O
CoV-2,O
reference,O
genome,O
was,O
obtained,O
from,O
the,O
GenBank,S-Repository
 ,O
database,O
(,O
NC_045512.2,S-AccessionNumber
),O
.,O
We,O
calculated,O
case,O
fatality,O
rates,O
by,O
dividing,O
the,O
death,O
number,O
of,O
a,O
specific,O
day,O
by,O
the,O
number,O
of,O
patients,O
with,O
confirmed,O
COVID-19,O
infection,O
observed,O
14,O
 ,O
days,O
before,O
and,O
normalized,O
by,O
a,O
ρ,O
factor,O
which,O
takes,O
into,O
account,O
the,O
diagnostic,O
PCR,O
testing,O
capability,O
of,O
each,O
Country,O
and,O
the,O
number,O
of,O
positive,O
cases,O
detected,O
.,O
Data,O
available,O
in,O
the,O
GISAID,S-Dataset
 ,O
database,O
and,O
in,O
a,O
public,O
repository,O
that,O
does,O
not,O
issue,O
datasets,O
with,O
DOIs,O
.,O
Chemoinformatics,O
searches,O
from,O
the,O
IUPHAR,O
/,O
BPS,O
Guide,O
to,O
Pharmacology,O
(,O
2020–3,O
-,O
12,O
),O
and,O
the,O
ChEMBL25,O
database,O
on,O
the,O
human,O
interactors,O
yielded,O
16,O
approved,O
drugs,O
",",O
3,O
investigational,O
new,O
drugs,O
(,O
clinical,O
),O
",",O
and,O
18,O
pre,O
-,O
clinical,O
candidates,O
(,O
Supplementary,O
Table,O
4,O
),O
;,O
while,O
target-,O
and,O
pathway,O
-,O
specific,O
literature,O
search,O
revealed,O
13,O
approved,O
drugs,O
",",O
9,O
investigational,O
new,O
drugs,O
(,O
clinical,O
),O
",",O
and,O
10,O
preclinical,O
candidates,O
(,O
Supplementary,O
Table,O
5,O
),O
.,O
Two,O
classes,O
of,O
molecules,O
emerged,O
as,O
effectively,O
reducing,O
viral,O
infectivity,O
:,O
protein,O
biogenesis,O
inhibitors,O
(,O
zotatifin,O
",",O
ternatin-4,O
",",O
and,O
PS3061,O
;,O
Fig,O
.,O
6b,O
",",O
Extended,O
Data,O
Fig,O
.,O
9,O
),O
and,O
ligands,O
of,O
the,O
Sigma1,O
and,O
Sigma2,O
receptors,O
:,O
haloperidol,O
",",O
PB28,O
",",O
PD-144418,O
and,O
hydroxychloroquine,O
",",O
which,O
is,O
undergoing,O
clinical,O
trials,O
in,O
COVID-19,O
patients,O
;,O
we,O
also,O
subsequently,O
found,O
the,O
SigmaR1,O
/,O
R2,O
active,O
drugs,O
clemastine,O
",",O
cloperastine,O
",",O
and,O
progesterone,O
(,O
Fig,O
.,O
6c,O
",",O
Extended,O
Data,O
Fig,O
.,O
9,O
),O
and,O
the,O
clinical,O
molecule,O
siramesine,O
(,O
Extended,O
Data,O
Figure,O
9,O
),O
to,O
be,O
antiviral,O
.,O
TCID50,O
assays,O
on,O
supernatants,O
from,O
infected,O
cells,O
treated,O
with,O
PB28,O
(,O
IC90,O
0.278,O
μM,O
),O
and,O
zotatifin,O
(,O
IC90,O
0.037,O
μM,O
),O
revealed,O
a,O
more,O
potent,O
inhibition,O
than,O
was,O
observed,O
in,O
the,O
NP,O
-,O
staining,O
assay,O
(,O
Fig,O
.,O
6d,O
),O
.,O
A,O
critical,O
question,O
going,O
forward,O
is,O
whether,O
these,O
or,O
related,O
inhibitors,O
of,O
viral,O
protein,O
biogenesis,O
will,O
show,O
therapeutic,O
benefit,O
in,O
COVID-19,O
patients,O
.,O
Plitidepsin,O
is,O
currently,O
under,O
consideration,O
by,O
the,O
Spanish,O
Medicines,O
Agency,O
for,O
a,O
Phase,O
II,O
trial,O
in,O
hospitalized,O
COVID-19,O
patients,O
.,O
By,O
the,O
same,O
standard,O
",",O
we,O
find,O
that,O
the,O
widely,O
used,O
antitussive,O
dextromethorphan,O
harbors,O
proviral,O
activity,O
and,O
therefore,O
its,O
use,O
should,O
merit,O
caution,O
and,O
further,O
study,O
in,O
the,O
context,O
of,O
COVID-19,O
.,O
Therefore,O
",",O
this,O
area,O
of,O
pharmacology,O
has,O
great,O
promise,O
for,O
repurposing,O
and,O
for,O
the,O
optimization,O
of,O
new,O
agents,O
in,O
the,O
fight,O
against,O
COVID-19,O
.,O
To,O
identify,O
drugs,O
and,O
reagents,O
that,O
modulate,O
the,O
332,O
host,O
factors,O
interacting,O
with,O
SARS,O
-,O
CoV-2,O
-,O
HEK293T/17,O
(,O
MiST,O
>,O
=,O
0.70,O
),O
",",O
we,O
used,O
two,O
approaches,O
:,O
1,O
),O
a,O
chemoinformatic,O
analysis,O
of,O
open,O
-,O
source,O
chemical,O
databases,O
and,O
2,O
),O
a,O
target-,O
and,O
pathway,O
-,O
specific,O
literature,O
search,O
",",O
drawing,O
on,O
specialist,O
knowledge,O
within,O
our,O
group,O
.,O
Chemoinformatically,O
",",O
we,O
retrieved,O
"2,472",O
molecules,O
from,O
the,O
IUPHAR,O
/,O
BPS,O
Guide,O
to,O
Pharmacology,O
(,O
2020–3,O
-,O
12,O
),O
(,O
Supplementary,O
Table,O
7,O
),O
that,O
interacted,O
with,O
30,O
human,O
“,O
prey,O
”,O
proteins,O
(,O
38,O
approved,O
",",O
71,O
in,O
clinical,O
trials,O
),O
",",O
and,O
found,O
"10,883",O
molecules,O
(,O
95,O
approved,O
",",O
369,O
in,O
clinical,O
trials,O
),O
from,O
the,O
ChEMBL,S-Repository
25,O
database,O
(,O
Supplementary,O
Table,O
8),O
.,O
For,O
both,O
approaches,O
",",O
molecules,O
were,O
prioritized,O
on,O
their,O
FDA,O
approval,O
status,O
",",O
activity,O
at,O
the,O
target,O
of,O
interest,O
better,O
than,O
1,O
μM,O
",",O
and,O
commercial,O
availability,O
",",O
drawing,O
on,O
the,O
ZINC,S-Repository
 ,O
database,O
.,O
Complete,O
methods,O
can,O
be,O
found,O
here,O
(,O
https://github.com/momeara/BioChemPantry/tree/master/vignette/COVID19,O
),O
.,O
The,O
analysis,O
is,O
based,O
on,O
"2,784",O
sequences,O
obtained,O
from,O
GISAID,S-Dataset
 ,O
on,O
April,O
4,O
",",O
2020,O
.,O
The,O
novel,O
coronavirus,O
SARS,O
-,O
CoV-2,O
",",O
the,O
causative,O
agent,O
of,O
COVID-19,O
respiratory,O
disease,O
",",O
has,O
infected,O
over,O
2.3,O
million,O
people,O
",",O
killed,O
over,O
"160,000",O
",",O
and,O
caused,O
worldwide,O
social,O
and,O
economic,O
disruption,O
1,O
",",O
2,O
.,O
Further,O
studies,O
of,O
these,O
host,O
factor,O
targeting,O
agents,O
",",O
including,O
their,O
combination,O
with,O
drugs,O
that,O
directly,O
target,O
viral,O
enzymes,O
",",O
could,O
lead,O
to,O
a,O
therapeutic,O
regimen,O
to,O
treat,O
COVID-19,O
.,O
The,O
dataset,O
used,O
for,O
phylogenetic,O
analysis,O
included,O
(,O
n,O
 ,O
=,O
 ,O
54,O
),O
genomes,O
sequences,O
from,O
the,O
current,O
2019‐nCoV,O
epidemic,O
plus,O
(,O
n,O
 ,O
=,O
 ,O
2,O
),O
closely,O
related,O
bat,O
strains,O
(,O
SARS‐like,O
CoV,O
),O
retrieved,O
from,O
NCBI,S-Repository
 ,O
(,O
http://www.ncbi.nlm.nih.gov/genbank/,S-URL
),O
and,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
databases,O
.,O
Both,O
SS,O
and,O
PS,O
estimators,O
indicated,O
the,O
uncorrelated,O
relaxed,O
molecular,O
clock,O
(,O
Bayes,O
factor,O
 ,O
=,O
 ,O
4.3,O
),O
as,O
the,O
best‐fitted,O
model,O
to,O
the,O
dataset,O
under,O
analysis,O
.,O
A,O
maximum,O
clade,O
credibility,O
tree,O
has,O
been,O
built,O
using,O
a,O
dataset,O
of,O
54,O
genome,O
sequences,O
of,O
2019‐nCoV,O
plus,O
two,O
closely,O
related,O
bat,O
strains,O
(,O
SARS‐like,O
CoV,O
),O
available,O
in,O
GenBank,S-Repository
.,O
During,O
the,O
cruise,O
",",O
a,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
outbreak,O
occurred,O
among,O
the,O
passengers,O
and,O
crew,O
members,O
",",O
ultimately,O
resulting,O
in,O
712,O
confirmed,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
cases,O
with,O
13,O
deaths,O
[,O
1,O
],O
",",O
the,O
largest,O
disease,O
outbreak,O
involving,O
a,O
cruise,O
ship,O
to,O
date,O
.,O
Investigation,O
into,O
the,O
Diamond,O
Princess,O
outbreak,O
provides,O
further,O
evidence,O
of,O
the,O
case,O
fatality,O
ratio,O
(,O
CFR,O
),O
of,O
COVID-19,O
in,O
isolation,O
.,O
Epidemiological,O
findings,O
on,O
COVID-19,O
are,O
increasingly,O
linked,O
to,O
information,O
from,O
whole,O
-,O
genome,O
sequencing,O
of,O
SARS,O
-,O
CoV-2,O
.,O
The,O
outbreak,O
of,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
caused,O
by,O
a,O
novel,O
(,O
new,O
),O
coronavirus,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
has,O
been,O
characterized,O
as,O
a,O
global,O
pandemic,O
[,O
1–5,O
],O
.,O
COVID-19,O
is,O
rapidly,O
spreading,O
across,O
the,O
world,O
and,O
affecting,O
all,O
populations,O
.,O
Thus,O
",",O
it,O
’s,O
important,O
to,O
systematically,O
characterize,O
and,O
evaluate,O
potentially,O
deleterious,O
variants,O
in,O
ACE2,O
",",O
which,O
may,O
affect,O
SARS,O
-,O
CoV-2,O
recognition,O
and,O
infection,O
",",O
and,O
COVID-19,O
susceptibility,O
and,O
treatment,O
.,O
A,O
recent,O
genome,O
-,O
wide,O
association,O
study,O
(,O
GWAS,O
),O
including,O
835,O
patients,O
with,O
COVID-19,O
and,O
severe,O
disease,O
(,O
defined,O
as,O
respiratory,O
failure,O
),O
and,O
1255,O
control,O
participants,O
from,O
Italy,O
",",O
plus,O
775,O
patients,O
and,O
950,O
control,O
participants,O
from,O
Spain,O
was,O
conducted,O
by,O
the,O
Severe,O
COVID-19,O
GWAS,O
Group,O
[,O
22,O
],O
.,O
They,O
identified,O
multiple,O
genetic,O
variants,O
and,O
genes,O
associated,O
with,O
COVID-19,O
with,O
respiratory,O
failure,O
.,O
Although,O
our,O
study,O
has,O
characterized,O
the,O
putative,O
functional,O
and,O
structurally,O
related,O
variants,O
in,O
ACE2,O
with,O
top,O
allele,O
frequencies,O
in,O
various,O
populations,O
",",O
the,O
lack,O
of,O
phenotypes,O
of,O
COVID-19,O
prevents,O
us,O
from,O
identifying,O
susceptibility,O
variants,O
associated,O
with,O
a,O
phenotype,O
of,O
COVID-19,O
.,O
However,O
",",O
our,O
findings,O
",",O
together,O
with,O
other,O
ACE2,O
genetic,O
studies,O
[,O
17,O
",",O
19,O
],O
",",O
can,O
prioritize,O
the,O
promising,O
variants,O
in,O
ACE2,O
for,O
further,O
fast,O
-,O
track,O
genotyping,O
in,O
blood,O
samples,O
from,O
COVID-19,O
patients,O
",",O
which,O
could,O
provide,O
a,O
great,O
opportunity,O
to,O
identify,O
susceptibility,O
variants,O
in,O
ACE2,O
related,O
to,O
symptoms,O
of,O
COVID-19,O
patients,O
.,O
The,O
outbreak,O
of,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
was,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
through,O
its,O
surface,O
spike,O
glycoprotein,O
(,O
S,O
-,O
protein,O
),O
recognition,O
on,O
the,O
receptor,O
Angiotensin,O
-,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
in,O
humans,O
.,O
These,O
findings,O
provide,O
novel,O
insight,O
into,O
the,O
genetic,O
variation,O
in,O
ACE2,O
which,O
may,O
affect,O
the,O
SARS,O
-,O
CoV-2,O
recognition,O
and,O
infection,O
",",O
and,O
COVID-19,O
susceptibility,O
and,O
treatment,O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
outbreak,O
has,O
become,O
a,O
public,O
health,O
emergency,O
globally.1,O
",",O
2,O
Until,O
26,O
May,O
2020,O
",",O
there,O
were,O
7126,O
confirmed,O
cases,O
reported,O
in,O
Australia,O
(,O
https://coronavirus.jhu.edu/map.html,S-URL
),O
.,O
Panel,O
A,O
:,O
Deletions,O
and,O
mutations,O
in,O
the,O
primary,O
",",O
secondary,O
and,O
tertiary,O
structures,O
of,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
s2,O
m,O
RNA,O
genetic,O
element,O
based,O
on,O
the,O
three‐dimensional,O
crystal,O
structure,O
of,O
the,O
SARS,O
virus,O
.,O
Up,O
to,O
29,O
April,O
",",O
1319,O
sequences,O
of,O
the,O
Australian,O
SARS‐CoV‐2,O
isolates,O
are,O
available,O
in,O
the,O
website,O
of,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
.3,O
The,O
GenBank,S-Repository
 ,O
accession,O
numbers,O
of,O
these,O
viruses,O
are,O
recorded,O
in,O
Table,O
S1,O
.,O
Finally,O
",",O
we,O
compared,O
the,O
pan,O
-,O
CoV,O
assay,O
’s,O
performance,O
to,O
the,O
US,O
Center,O
for,O
Disease,O
Control,O
and,O
Prevention,O
’s,O
2019,O
-,O
nCoV,O
RT,O
-,O
PCR,O
assay,O
[,O
11,O
],O
against,O
a,O
set,O
of,O
clinical,O
specimens,O
from,O
COVID-19,O
patients,O
.,O
As,O
the,O
COVID-19,O
pandemic,O
is,O
currently,O
surging,O
",",O
pathogen,O
discovery,O
of,O
novel,O
CoVs,O
now,O
seems,O
even,O
more,O
important,O
than,O
before,O
.,O
To,O
assess,O
the,O
assay,O
's,O
clinical,O
performance,O
",",O
we,O
tested,O
a,O
large,O
panel,O
of,O
previously,O
studied,O
specimens,O
:,O
192,O
human,O
respiratory,O
specimens,O
from,O
pneumonia,O
patients,O
",",O
5,O
clinical,O
specimens,O
from,O
COVID-19,O
patients,O
",",O
81,O
poultry,O
oral,O
secretion,O
specimens,O
",",O
109,O
pig,O
slurry,O
specimens,O
",",O
and,O
31,O
aerosol,O
samples,O
from,O
a,O
live,O
bird,O
market,O
.,O
We,O
apply,O
genomic,O
alignment,O
analysis,O
to,O
observe,O
SARS,O
-,O
CoV-2,O
sequences,O
from,O
GenBank,S-Repository
 ,O
(,O
http://www.ncbi.nim.nih.gov/genebank,S-URL
/,O
):,O
MN,B-AccessionNumber
908947,E-AccessionNumber
 ,O
(,O
China,O
",",O
C1,O
),O
;,O
MN985325,S-AccessionNumber
 ,O
(,O
United,O
States,O
:,O
WA,O
",",O
UW,O
),O
;,O
MN996527,S-AccessionNumber
 ,O
(,O
China,O
",",O
C2,O
),O
;,O
MT007544,S-AccessionNumber
 ,O
(,O
Australia,O
:,O
Victoria,O
",",O
A1,O
),O
;,O
MT027064,S-AccessionNumber
 ,O
(,O
United,O
States,O
:,O
CA,O
",",O
UC,O
),O
;,O
MT039890,S-AccessionNumber
 ,O
(,O
South,O
Korea,O
",",O
K1,O
),O
;,O
MT066175,S-AccessionNumber
 ,O
(,O
Taiwan,O
",",O
T1,O
),O
;,O
MT066176,S-AccessionNumber
 ,O
(,O
Taiwan,O
",",O
T2,O
),O
;,O
LC528232,S-AccessionNumber
 ,O
(,O
Japan,O
",",O
J1,O
),O
;,O
and,O
LC528233,S-AccessionNumber
 ,O
(,O
Japan,O
",",O
J2,O
),O
and,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,E-Dataset
 ,O
database,O
(,O
https://www.gisaid.org,S-URL
 ,O
),O
.,O
We,O
analyze,O
database,O
by,O
genome,O
alignment,O
search,O
for,O
nonstructural,O
ORFs,O
and,O
structural,O
E,O
",",O
M,O
",",O
N,O
",",O
and,O
S,O
proteins,O
.,O
Because,O
the,O
disease,O
",",O
COVID-19,O
",",O
spread,O
across,O
China,O
and,O
beyond,O
(,O
Phan,O
",",O
2020,O
),O
",",O
WHO,O
was,O
obliged,O
to,O
declare,O
as,O
pandemic,O
on,O
March,O
11,O
and,O
reported,O
a,O
total,O
of,O
confirmed,O
"4,617,176",O
cases,O
and,O
"307,988",O
deaths,O
until,O
May,O
15,O
",",O
22:41,O
GMT,O
(,O
WHO,O
",",O
2020,O
),O
.,O
Therefore,O
",",O
this,O
study,O
was,O
conducted,O
to,O
unfold,O
SARS,O
-,O
CoV-2,O
virus,O
genome,O
to,O
identify,O
regulatory,O
elements,O
such,O
as,O
CpG,O
islands,O
",",O
transcription,O
factors,O
(,O
TFs,O
),O
and,O
their,O
corresponding,O
binding,O
sites,O
(,O
TFBSs,O
),O
involved,O
in,O
the,O
regulation,O
of,O
its,O
gene,O
expression,O
so,O
that,O
it,O
provide,O
baseline,O
information,O
for,O
designing,O
COVID-19,O
disease,O
control,O
strategy,O
and,O
for,O
further,O
detail,O
molecular,O
characterization,O
of,O
SARS,O
-,O
CoV-2,O
virus,O
genome,O
.,O
In,O
this,O
analysis,O
all,O
eleven,O
SARS,O
-,O
CoV-2,O
gene,O
coding,O
sequences,O
",",O
available,O
in,O
NCBI,S-Repository
 ,O
database,O
with,O
the,O
start,O
codon,O
at,O
the,O
beginning,O
of,O
the,O
sequence,O
and,O
only,O
functional,O
genes,O
(,O
protein,O
coding,O
),O
were,O
considered,O
.,O
The,O
output,O
of,O
TOMTOM,O
includes,O
LOGOS,O
representing,O
the,O
alignment,O
of,O
the,O
candidate,O
motif,O
and,O
TF,O
with,O
the,O
p,O
-,O
value,O
and,O
q,O
-,O
value,O
(,O
a,O
measure,O
of,O
false,O
discovery,O
rate,O
),O
of,O
the,O
match,O
",",O
and,O
links,O
back,O
to,O
the,O
parent,O
transcription,O
database,O
for,O
more,O
detailed,O
information,O
about,O
it,O
(,O
Bailey,O
et,O
al,O
.,O
",",O
2006,O
;,O
Bailey,O
et,O
al,O
.,O
",",O
2009,O
),O
.,O
The,O
GOMO,O
output,O
is,O
HTML,O
and,O
shows,O
the,O
GO,O
terms,O
",",O
GO,O
name,O
and,O
Gene,O
ID,O
.,O
Buttons,O
on,O
the,O
GOMO,O
HTML,O
output,O
allow,O
one,O
or,O
all,O
of,O
the,O
Gene,O
ID,O
to,O
be,O
forwarded,O
for,O
further,O
analysis,O
",",O
to,O
ascertain,O
which,O
molecular,O
and,O
biological,O
functions,O
are,O
associated,O
with,O
the,O
candidate,O
motif,O
.,O
MVI,O
was,O
compared,O
to,O
registered,O
motifs,O
in,O
publically,O
available,O
databases,O
such,O
as,O
Prokaryote,O
DNA,O
to,O
see,O
if,O
they,O
are,O
similar,O
to,O
known,O
regulatory,O
motifs,O
for,O
transcription,O
factor,O
using,O
the,O
TOMTOM,O
web,O
application,O
(,O
Reese,O
",",O
2001,O
),O
.,O
The,O
output,O
from,O
TOMTOM,O
also,O
links,O
the,O
parent,O
TF,O
database,O
for,O
more,O
detail,O
information,O
for,O
activation,O
",",O
repression,O
or,O
dual,O
regulatory,O
effects,O
on,O
the,O
matched,O
motif,O
.,O
As,O
a,O
result,O
",",O
MVI,O
matched,O
with,O
10,O
out,O
of,O
84,O
known,O
motifs,O
found,O
in,O
the,O
databases,O
.,O
As,O
we,O
tried,O
to,O
check,O
the,O
role,O
of,O
CRP,O
TFs,O
in,O
UniProt,O
protein,O
database,O
",",O
they,O
can,O
act,O
as,O
an,O
activator,O
",",O
repressor,O
",",O
co,O
-,O
activator,O
or,O
co,O
-,O
repressor,O
in,O
Escherichia,O
coli,O
and,O
Yersinia,O
pestis,O
where,O
similar,O
function,O
was,O
revealed,O
for,O
CcpA,O
transcription,O
factor,O
in,O
Lactococcus,O
lactis,O
and,O
Streptococcus,O
pneumoniae,O
.,O
In,O
UniProt,S-Repository
 ,O
protein,O
database,O
LexA,O
transcription,O
factor,O
is,O
also,O
named,O
as,O
LexA,O
repressor,O
functioning,O
as,O
a,O
repressor,O
of,O
a,O
number,O
of,O
genes,O
in,O
bacteria,O
such,O
as,O
Rhizobium,O
meliloti,O
.,O
But,O
",",O
further,O
investigation,O
about,O
ArcA,O
transcription,O
factor,O
from,O
UniProt,O
protein,O
data,O
base,O
revealed,O
it,O
is,O
a,O
protein,O
with,O
two,O
component,O
signal,O
transduction,O
system,O
controlling,O
aerobic,O
respiration,O
response,O
regulator,O
with,O
gene,O
ontology,O
(,O
molecular,O
function,O
),O
of,O
mainly,O
serving,O
as,O
DNA,O
-,O
binding,O
transcription,O
activator,O
activity,O
in,O
bacteria,O
.,O
SARS,O
-,O
CoV-2,O
is,O
a,O
new,O
virus,O
responsible,O
for,O
an,O
outbreak,O
of,O
respiratory,O
illness,O
known,O
as,O
COVID-19,O
",",O
which,O
has,O
spread,O
to,O
several,O
countries,O
around,O
the,O
world,O
and,O
a,O
global,O
effort,O
is,O
being,O
undertaken,O
to,O
characterize,O
the,O
molecular,O
features,O
and,O
evolutionary,O
origins,O
of,O
this,O
virus,O
.,O
For,O
this,O
purpose,O
",",O
we,O
first,O
computationally,O
surveyed,O
all,O
SARS,O
-,O
CoV-2,O
virus,O
genes,O
with,O
the,O
open,O
reading,O
frames,O
from,O
NCBI,S-Repository
 ,O
database,O
and,O
found,O
eleven,O
sequences,O
to,O
accomplish,O
the,O
mentioned,O
features,O
by,O
using,O
bioinformatics,O
tools,O
.,O
Highlights,O
    ,O
•,O
 ,O
Computationally,O
surveyed,O
all,O
SARS,O
-,O
CoV-2,O
genes,O
with,O
the,O
open,O
reading,O
frames,O
from,O
NCBI,S-Repository
 ,O
database,O
showed,O
eleven,O
gene,O
sequences,O
   ,O
•,O
The,O
risk,O
of,O
morbidity,O
and,O
mortality,O
from,O
COVID-19,O
as,O
a,O
consequence,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
infection,O
is,O
not,O
uniform,O
across,O
the,O
UK,O
population,O
.,O
The,O
evidence,O
to,O
support,O
this,O
claim,O
is,O
scarce,O
and,O
limited,O
to,O
retrospective,O
series,O
arising,O
from,O
China,O
",",O
the,O
epicentre,O
of,O
the,O
COVID-19,O
pandemic,O
",",O
and,O
involving,O
small,O
numbers,O
of,O
patients.2,O
",",O
3,O
",",O
4,O
However,O
",",O
despite,O
these,O
severe,O
limitations,O
",",O
the,O
promulgation,O
of,O
this,O
hypothesis,O
has,O
led,O
to,O
widespread,O
global,O
changes,O
to,O
patterns,O
of,O
prescribing,O
chemotherapy,O
and,O
anticancer,O
treatment,O
.,O
In,O
a,O
global,O
health,O
emergency,O
",",O
oncologists,O
must,O
secure,O
evidence,O
from,O
a,O
large,O
dataset,O
",",O
which,O
can,O
then,O
inform,O
their,O
risk,O
-,O
benefit,O
analyses,O
for,O
individual,O
patients,O
in,O
terms,O
of,O
the,O
use,O
of,O
anticancer,O
treatments.6,O
",",O
7,O
On,O
March,O
18,O
",",O
2020,O
",",O
we,O
launched,O
the,O
UK,B-Dataset
Coronavirus,I-Dataset
Cancer,I-Dataset
Monitoring,I-Dataset
Project,I-Dataset
(UKCCMP),E-Dataset
",",O
with,O
widespread,O
support,O
across,O
our,O
national,O
cancer,O
network,O
.,O
Within,O
5,O
weeks,O
",",O
the,O
UKCCMP,S-Dataset
 ,O
had,O
generated,O
the,O
largest,O
prospective,O
database,O
of,O
COVID-19,O
in,O
patients,O
with,O
cancer,O
that,O
had,O
been,O
generated,O
to,O
date,O
.,O
We,O
aimed,O
to,O
describe,O
the,O
clinical,O
and,O
demographic,O
characteristics,O
and,O
COVID-19,O
outcomes,O
in,O
this,O
cohort,O
of,O
patients,O
with,O
cancer,O
and,O
symptomatic,O
COVID-19,O
",",O
and,O
attempted,O
to,O
assess,O
how,O
the,O
presence,O
of,O
cancer,O
and,O
the,O
receipt,O
of,O
cytotoxic,O
chemotherapy,O
and,O
other,O
anticancer,O
treatments,O
affects,O
the,O
COVID-19,O
disease,O
phenotype,O
.,O
The,O
UKCCMP,S-Dataset
 ,O
database,O
of,O
UK,O
patients,O
COVID-19,O
who,O
have,O
cancer,O
with,O
was,O
launched,O
with,O
the,O
support,O
of,O
the,O
UK,O
oncology,O
professional,O
bodies,O
",",O
including,O
the,O
Association,B-Creator
of,I-Creator
Cancer,I-Creator
Physicians,E-Creator
",",O
the,O
Royal,B-Creator
College,I-Creator
of,I-Creator
Radiologists,E-Creator
",",O
the,O
National,B-Creator
Oncology,I-Creator
Trainees,I-Creator
Research,I-Creator
Collaborative,I-Creator
for,I-Creator
Healthcare,I-Creator
Research,E-Creator
",",O
patient,O
support,O
groups,O
including,O
Macmillan,B-Creator
Cancer,I-Creator
Support,E-Creator
",",O
and,O
charities,O
including,O
Action,B-Creator
Radiotherapy,E-Creator
.,O
The,O
database,O
was,O
designed,O
as,O
a,O
public,O
health,O
surveillance,O
registry,O
to,O
support,O
rapid,O
clinical,O
decision,O
making,O
",",O
in,O
accordance,O
with,O
the,O
UK,O
Policy,O
Framework,O
for,O
Health,O
and,O
Social,O
Care,O
Research,O
",",O
the,O
UK,O
National,O
Research,O
Ethics,O
Service,O
",",O
and,O
the,O
UK,O
Governance,O
Arrangement,O
for,O
Research,O
Ethic,O
Committees,O
.,O
Case,O
reporting,O
was,O
led,O
by,O
a,O
COVID-19,O
emergency,O
response,O
reporting,O
individual,O
(,O
ERRI,O
),O
",",O
supported,O
by,O
a,O
local,O
emergency,O
response,O
reporting,O
group,O
(,O
LERRG,O
),O
at,O
each,O
centre,O
.,O
The,O
data,O
fields,O
were,O
then,O
updated,O
as,O
soon,O
as,O
treatment,O
and,O
outcomes,O
had,O
been,O
identified,O
and,O
also,O
to,O
reflect,O
the,O
worse,O
COVID-19,O
severity,O
categories,O
during,O
hospitalisation,O
.,O
Patient,O
demographics,O
",",O
treatment,O
details,O
",",O
COVID-19,O
disease,O
course,O
",",O
and,O
cancer,O
features,O
were,O
obtained,O
by,O
the,O
direct,O
assessment,O
of,O
the,O
ERRI,O
and,O
LERRG,O
",",O
or,O
through,O
hospital,O
medical,O
records,O
.,O
The,O
COVID-19,O
severity,O
category,O
was,O
determined,O
according,O
to,O
WHO,O
guidelines,O
.,O
This,O
definition,O
included,O
deaths,O
described,O
as,O
related,O
to,O
COVID-19,O
during,O
admission,O
",",O
as,O
well,O
as,O
deaths,O
reported,O
as,O
a,O
consequence,O
of,O
any,O
other,O
cause,O
during,O
admission,O
",",O
such,O
as,O
due,O
to,O
cancer,O
progression,O
or,O
treatment,O
toxicity,O
.,O
55,O
cancer,O
centres,O
had,O
appointed,O
a,O
COVID-19,O
LERRG,O
and,O
formed,O
part,O
of,O
this,O
clinical,O
network,O
of,O
cancer,O
centres,O
.,O
Our,O
patient,O
cohort,O
consisted,O
of,O
the,O
first,O
800,O
patients,O
with,O
active,O
cancer,O
who,O
had,O
documented,O
SARS,O
-,O
CoV-2,O
infection,O
presenting,O
as,O
symptomatic,O
COVID-19,O
disease,O
.,O
The,O
median,O
time,O
from,O
identification,O
of,O
documented,O
COVID-19,O
disease,O
until,O
study,O
endpoints,O
were,O
met,O
(,O
death,O
or,O
discharge,O
from,O
hospital,O
),O
was,O
5,O
days,O
(,O
range,O
0–38,O
),O
.,O
A,O
mild,O
COVID-19,O
severity,O
category,O
was,O
recorded,O
in,O
412,O
(,O
52,O
%,O
),O
patients,O
",",O
with,O
96,O
(,O
12,O
%,O
),O
patients,O
not,O
requiring,O
hospital,O
admission,O
.,O
226,O
(,O
28,O
%,O
),O
patients,O
died,O
",",O
with,O
reports,O
stating,O
that,O
the,O
death,O
was,O
principally,O
attributable,O
to,O
COVID-19,O
in,O
most,O
patients,O
(,O
211,O
[,O
93,O
%,O
],O
),O
.,O
To,O
explore,O
this,O
relationship,O
in,O
greater,O
detail,O
",",O
we,O
did,O
an,O
in,O
-,O
depth,O
analysis,O
of,O
the,O
281,O
patients,O
who,O
had,O
received,O
recent,O
chemotherapy,O
(,O
ie,O
",",O
within,O
4,O
weeks,O
of,O
testing,O
positive,O
for,O
COVID-19,O
;,O
figure,O
3,O
),O
.,O
Therefore,O
",",O
we,O
did,O
a,O
multivariate,O
analysis,O
with,O
adjustment,O
for,O
age,O
",",O
gender,O
",",O
and,O
comorbidities,O
and,O
found,O
that,O
deaths,O
in,O
patients,O
with,O
COVID-19,O
who,O
have,O
cancer,O
who,O
had,O
received,O
recent,O
chemotherapy,O
were,O
still,O
no,O
more,O
likely,O
than,O
in,O
those,O
who,O
had,O
not,O
(,O
table,O
3,O
),O
.,O
Finally,O
",",O
we,O
analysed,O
the,O
use,O
of,O
other,O
forms,O
of,O
anticancer,O
therapies,O
within,O
4,O
weeks,O
of,O
testing,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
presenting,O
with,O
COVID-19,O
.,O
Second,O
",",O
many,O
oncologists,O
are,O
being,O
redeployed,O
to,O
general,O
or,O
acute,O
medicine,O
roles,O
to,O
support,O
the,O
many,O
COVID-19,O
admissions,O
requiring,O
intensive,O
medical,O
support,O
and,O
input,O
.,O
Third,O
",",O
two,O
small,O
studies2,O
",",O
3,O
reporting,O
COVID-19,O
outcomes,O
in,O
patients,O
with,O
cancer,O
have,O
resulted,O
in,O
the,O
community,O
being,O
fearful,O
of,O
giving,O
effective,O
anticancer,O
treatments,O
.,O
These,O
studies,O
concluded,O
that,O
cancer,O
patients,O
are,O
not,O
only,O
more,O
susceptible,O
to,O
contracting,O
the,O
virus,O
compared,O
with,O
the,O
general,O
population,O
",",O
but,O
also,O
at,O
risk,O
of,O
developing,O
more,O
severe,O
sequelae.3,O
",",O
4,O
In,O
the,O
largest,O
cohort,O
of,O
105,O
cancer,O
patients,O
",",O
consisting,O
of,O
only,O
17,O
on,O
chemotherapy,O
",",O
six,O
patients,O
on,O
immunotherapy,O
",",O
and,O
four,O
on,O
targeted,O
therapies,O
",",O
strong,O
recommendations,O
were,O
made,O
about,O
the,O
COVID-19,O
risk,O
from,O
anticancer,O
treatments,O
.,O
To,O
clarify,O
the,O
relationship,O
between,O
cancer,O
",",O
anticancer,O
treatments,O
",",O
and,O
COVID-19,O
",",O
larger,O
-,O
scale,O
datasets,O
are,O
necessary,O
.,O
We,O
described,O
the,O
demographics,O
of,O
patients,O
with,O
COVID-19,O
who,O
have,O
cancer,O
and,O
explored,O
the,O
effect,O
of,O
cytotoxic,O
chemotherapy,O
and,O
other,O
anticancer,O
treatments,O
on,O
the,O
trajectory,O
of,O
COVID-19,O
.,O
We,O
identified,O
that,O
the,O
phenotype,O
of,O
diagnosed,O
COVID-19,O
disease,O
in,O
over,O
half,O
of,O
cancer,O
patients,O
is,O
mild,O
",",O
but,O
death,O
from,O
COVID-19,O
in,O
this,O
cohort,O
was,O
observed,O
in,O
a,O
substantial,O
proportion,O
of,O
patients,O
.,O
Using,O
our,O
dataset,O
",",O
we,O
are,O
unable,O
to,O
answer,O
the,O
question,O
as,O
to,O
whether,O
this,O
finding,O
might,O
arise,O
as,O
a,O
result,O
of,O
advance,O
patient,O
health,O
-,O
care,O
directives,O
",",O
hospital,O
and,O
ITU,O
admission,O
policies,O
",",O
a,O
reluctance,O
of,O
treating,O
physicians,O
to,O
use,O
ITU,O
resources,O
for,O
patients,O
with,O
cancer,O
",",O
or,O
historically,O
fewer,O
ITU,O
beds,O
available,O
in,O
the,O
UK,O
.,O
Our,O
analysis,O
is,O
partly,O
dependent,O
on,O
the,O
UK,O
national,O
COVID-19,O
testing,O
policy,O
",",O
which,O
is,O
less,O
permissive,O
than,O
that,O
of,O
other,O
"nations,18",O
",",O
19,O
and,O
also,O
relies,O
on,O
RT,O
-,O
PCR,O
",",O
which,O
has,O
a,O
well,O
described,O
false,O
-,O
negative,O
result,O
.,O
The,O
project,O
might,O
therefore,O
under,O
-,O
report,O
total,O
COVID-19,O
cases,O
in,O
patients,O
with,O
cancer,O
",",O
particularly,O
those,O
with,O
no,O
or,O
mild,O
symptoms,O
and,O
who,O
do,O
not,O
require,O
treatment,O
at,O
or,O
present,O
to,O
health,O
-,O
care,O
centres,O
.,O
A,O
selection,O
bias,O
might,O
exist,O
",",O
in,O
that,O
those,O
patients,O
who,O
were,O
not,O
on,O
chemotherapy,O
might,O
have,O
stopped,O
chemotherapy,O
because,O
of,O
a,O
poor,O
performance,O
status,O
",",O
thus,O
increasing,O
the,O
risk,O
of,O
death,O
from,O
COVID-19,O
disease,O
",",O
and,O
reducing,O
our,O
ability,O
to,O
assess,O
the,O
real,O
risk,O
of,O
anticancer,O
treatments,O
in,O
a,O
population,O
with,O
a,O
better,O
performance,O
status,O
.,O
Finally,O
",",O
we,O
have,O
not,O
commented,O
on,O
overall,O
incidence,O
of,O
COVID-19,O
positivity,O
among,O
cancer,O
patients,O
because,O
we,O
do,O
not,O
yet,O
have,O
secure,O
numerators,O
and,O
denominators,O
for,O
that,O
calculation,O
.,O
Background,O
 ,O
Individuals,O
with,O
cancer,O
",",O
particularly,O
those,O
who,O
are,O
receiving,O
systemic,O
anticancer,O
treatments,O
",",O
have,O
been,O
postulated,O
to,O
be,O
at,O
increased,O
risk,O
of,O
mortality,O
from,O
COVID-19,O
.,O
We,O
aimed,O
to,O
describe,O
the,O
clinical,O
and,O
demographic,O
characteristics,O
and,O
COVID-19,O
outcomes,O
in,O
patients,O
with,O
cancer,O
.,O
The,O
UKCCMP,S-Dataset
 ,O
is,O
the,O
first,O
COVID-19,O
clinical,O
registry,O
that,O
enables,O
near,O
real,O
-,O
time,O
reports,O
to,O
frontline,O
doctors,O
about,O
the,O
effects,O
of,O
COVID-19,O
on,O
patients,O
with,O
cancer,O
.,O
We,O
excluded,O
patients,O
with,O
a,O
radiological,O
or,O
clinical,O
diagnosis,O
of,O
COVID-19,O
",",O
without,O
a,O
positive,O
RT,O
-,O
PCR,O
test,O
.,O
Findings,O
 ,O
From,O
March,O
18,O
",",O
to,O
April,O
26,O
",",O
2020,O
",",O
we,O
analysed,O
800,O
patients,O
with,O
a,O
diagnosis,O
of,O
cancer,O
and,O
symptomatic,O
COVID-19,O
.,O
412,O
(,O
52,O
%,O
),O
patients,O
had,O
a,O
mild,O
COVID-19,O
disease,O
course,O
.,O
281,O
(,O
35,O
%,O
),O
patients,O
had,O
received,O
cytotoxic,O
chemotherapy,O
within,O
4,O
weeks,O
before,O
testing,O
positive,O
for,O
COVID-19,O
.,O
After,O
adjusting,O
for,O
age,O
",",O
gender,O
",",O
and,O
comorbidities,O
",",O
chemotherapy,O
in,O
the,O
past,O
4,O
weeks,O
had,O
no,O
significant,O
effect,O
on,O
mortality,O
from,O
COVID-19,O
disease,O
",",O
when,O
compared,O
with,O
patients,O
with,O
cancer,O
who,O
had,O
not,O
received,O
recent,O
chemotherapy,O
(,O
1·18,O
[,O
0·81–1·72,O
],O
;,O
p=0·380,O
),O
.,O
Interpretation,O
 ,O
Mortality,O
from,O
COVID-19,O
in,O
cancer,O
patients,O
appears,O
to,O
be,O
principally,O
driven,O
by,O
age,O
",",O
gender,O
",",O
and,O
comorbidities,O
.,O
We,O
are,O
not,O
able,O
to,O
identify,O
evidence,O
that,O
cancer,O
patients,O
on,O
cytotoxic,O
chemotherapy,O
or,O
other,O
anticancer,O
treatment,O
are,O
at,O
an,O
increased,O
risk,O
of,O
mortality,O
from,O
COVID-19,O
disease,O
compared,O
with,O
those,O
not,O
on,O
active,O
treatment,O
.,O
In,O
December,O
2019,O
",",O
reports,O
emerged,O
of,O
a,O
cluster,O
of,O
cases,O
of,O
pneumonia,O
of,O
unknown,O
cause,O
in,O
Wuhan,O
City,O
",",O
China,O
",",O
culminating,O
in,O
the,O
identification,O
of,O
a,O
novel,O
coronavirus,O
on,O
12,O
January,O
2020,O
",",O
denoted,O
as,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
and,O
the,O
associated,O
disease,O
as,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
[,O
1,O
],O
.,O
All,O
COVID-19,O
papers,O
drew,O
heavily,O
or,O
exclusively,O
on,O
data,O
and,O
experience,O
from,O
China,O
.,O
Abbreviations,O
:,O
COVID-19,O
",",O
coronavirus,O
disease,O
2019,O
;,O
HDAS,O
",",O
Healthcare,O
Databases,O
Advanced,O
Search,O
;,O
MERS,O
-,O
CoV,O
",",O
Middle,O
East,O
respiratory,O
syndrome,O
coronavirus,O
;,O
PRISMA,O
",",O
Preferred,O
Reporting,O
Items,O
for,O
Systematic,O
Reviews,O
and,O
Meta,O
-,O
Analyses,O
;,O
SARS,O
-,O
CoV,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
;,O
SARS,O
-,O
CoV-2,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
;,O
WHO,O
",",O
World,O
Health,O
Organization,O
.,O
Children,O
are,O
affected,O
by,O
COVID-19,O
",",O
but,O
extant,O
data,O
(,O
largely,O
case,O
series,O
from,O
China,O
),O
suggest,O
they,O
are,O
less,O
likely,O
to,O
be,O
affected,O
than,O
adults,O
.,O
The,O
Report,O
of,O
the,O
WHO,O
-,O
China,O
Joint,O
Mission,O
on,O
COVID-19,O
[,O
7,O
],O
concludes,O
that,O
“,O
we,O
can,O
not,O
determine,O
the,O
extent,O
of,O
infection,O
among,O
children,O
",",O
what,O
role,O
children,O
play,O
in,O
transmission,O
",",O
whether,O
children,O
are,O
less,O
susceptible,O
or,O
whether,O
they,O
simply,O
present,O
differently,O
.,O
”,O
In,O
an,O
early,O
epidemiological,O
analysis,O
of,O
507,O
COVID-19,O
cases,O
",",O
mainly,O
from,O
China,O
",",O
13,O
(,O
2.6,O
%,O
),O
were,O
younger,O
than,O
15,O
years,O
",",O
and,O
the,O
relative,O
risk,O
of,O
COVID-19,O
in,O
children,O
was,O
less,O
than,O
0.5,O
compared,O
with,O
the,O
population,O
average,O
[,O
10,O
],O
.,O
Symptoms,O
of,O
COVID-19,O
are,O
nonspecific,O
and,O
disease,O
presentation,O
ranges,O
from,O
asymptomatic,O
to,O
severe,O
pneumonia,O
and,O
death,O
[,O
7,O
],O
.,O
Wei,O
et,O
al,O
[,O
9,O
],O
identified,O
all,O
hospitalized,O
infants,O
in,O
China,O
diagnosed,O
with,O
COVID-19,O
infection,O
between,O
8,O
December,O
2019,O
and,O
6,O
February,O
2020,O
.,O
In,O
Singapore,O
",",O
a,O
well,O
6,O
-,O
month,O
-,O
old,O
infant,O
with,O
COVID-19,O
and,O
high,O
viral,O
load,O
was,O
detected,O
as,O
part,O
of,O
a,O
cluster,O
and,O
was,O
also,O
asymptomatic,O
throughout,O
admission,O
[,O
16,O
],O
.,O
Asymptomatic,O
cases,O
are,O
also,O
reported,O
in,O
the,O
English,O
abstract,O
of,O
a,O
Chinese,O
paper,O
",",O
which,O
reports,O
clinical,O
data,O
and,O
CT,O
chest,O
images,O
of,O
15,O
children,O
(,O
aged,O
4–14,O
years,O
old,O
),O
diagnosed,O
with,O
COVID-19,O
in,O
Shenzhen,O
.,O
The,O
Report,O
of,O
the,O
WHO,O
-,O
China,O
Joint,O
Mission,O
on,O
COVID-19,O
stated,O
that,O
2.5,O
%,O
of,O
the,O
cases,O
among,O
those,O
under,O
19,O
years,O
old,O
were,O
severe,O
and,O
0.2,O
%,O
were,O
critical,O
[,O
7,O
],O
.,O
Among,O
the,O
105,O
children,O
admitted,O
to,O
Wuhan,O
’s,O
Children,O
’s,O
Hospital,O
",",O
the,O
sole,O
hospital,O
for,O
treating,O
COVID-19,O
in,O
children,O
in,O
Wuhan,O
",",O
8,O
(,O
7.6,O
%,O
),O
were,O
reported,O
to,O
have,O
severe,O
disease,O
[,O
18,O
],O
.,O
Both,O
parents,O
developed,O
symptomatic,O
COVID-19,O
days,O
after,O
they,O
looked,O
after,O
the,O
sick,O
infant,O
without,O
personal,O
protective,O
measures,O
[,O
12,O
],O
.,O
Nevertheless,O
",",O
we,O
identify,O
that,O
children,O
appear,O
to,O
be,O
less,O
affected,O
by,O
COVID-19,O
than,O
adults,O
by,O
observed,O
rate,O
of,O
infection,O
;,O
while,O
17.8,O
%,O
of,O
the,O
population,O
were,O
aged,O
0–15,O
years,O
old,O
",",O
only,O
2.1,O
%,O
of,O
reported,O
cases,O
in,O
a,O
large,O
case,O
series,O
from,O
China,O
were,O
in,O
the,O
0–19,O
-,O
year,O
age,O
group,O
[,O
23,O
],O
.,O
Reliable,O
evidence,O
about,O
clinical,O
features,O
and,O
outcomes,O
of,O
COVID-19,O
in,O
children,O
is,O
limited,O
to,O
small,O
case,O
series,O
and,O
case,O
reports,O
.,O
We,O
detected,O
only,O
a,O
weak,O
signal,O
that,O
children,O
with,O
comorbidities,O
are,O
at,O
increased,O
risk,O
or,O
are,O
overrepresented,O
among,O
pediatric,O
COVID-19,O
cases,O
.,O
Given,O
that,O
poor,O
COVID-19,O
outcomes,O
have,O
been,O
seen,O
in,O
adults,O
with,O
underlying,O
conditions,O
",",O
a,O
similar,O
issue,O
in,O
children,O
might,O
be,O
anticipated,O
when,O
sufficient,O
data,O
are,O
available,O
.,O
One,O
study,O
attempts,O
to,O
assess,O
the,O
impact,O
of,O
Hong,O
Kong,O
’s,O
public,O
health,O
measures,O
and,O
population,O
behavior,O
change,O
on,O
COVID-19,O
transmission,O
",",O
using,O
routine,O
influenza,O
surveillance,O
data,O
as,O
a,O
proxy,O
",",O
assuming,O
that,O
influenza,O
and,O
COVID-19,O
are,O
likely,O
transmitted,O
in,O
similar,O
ways,O
[,O
25,O
],O
.,O
The,O
authors,O
demonstrate,O
the,O
substantial,O
impact,O
that,O
familiar,O
public,O
health,O
measures,O
(,O
including,O
school,O
closure,O
),O
",",O
social,O
distancing,O
",",O
and,O
behavioral,O
change,O
could,O
have,O
in,O
slowing,O
down,O
COVID-19,O
transmission,O
",",O
although,O
questions,O
remain,O
about,O
whether,O
these,O
measures,O
can,O
avoid,O
fatigue,O
and,O
be,O
sustained,O
in,O
the,O
long,O
term,O
.,O
While,O
the,O
evidence,O
we,O
reviewed,O
related,O
mainly,O
to,O
data,O
from,O
China,O
",",O
as,O
the,O
COVID-19,O
pandemic,O
spreads,O
worldwide,O
data,O
are,O
beginning,O
to,O
emerge,O
from,O
other,O
countries,O
",",O
including,O
Italy,O
[,O
26,O
],O
",",O
South,O
Korea,O
[,O
27,O
],O
",",O
Iceland,O
[,O
28,O
],O
",",O
and,O
the,O
United,O
States,O
[,O
29,O
],O
.,O
Abstract,O
  ,O
Background,O
 ,O
Few,O
pediatric,O
cases,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
have,O
been,O
reported,O
and,O
we,O
know,O
little,O
about,O
the,O
epidemiology,O
in,O
children,O
",",O
although,O
more,O
is,O
known,O
about,O
other,O
coronaviruses,O
.,O
We,O
searched,O
3,O
databases,O
and,O
the,O
COVID-19,O
resource,O
centers,O
of,O
11,O
major,O
journals,O
and,O
publishers,O
.,O
Twenty,O
-,O
four,O
studies,O
relating,O
to,O
COVID-19,O
were,O
included,O
in,O
the,O
review,O
.,O
Children,O
appear,O
to,O
be,O
less,O
affected,O
by,O
COVID-19,O
than,O
adults,O
by,O
observed,O
rate,O
of,O
cases,O
in,O
large,O
epidemiological,O
studies,O
.,O
Conclusions,O
 ,O
Children,O
appear,O
to,O
have,O
a,O
low,O
observed,O
case,O
rate,O
of,O
COVID-19,O
but,O
may,O
have,O
rates,O
similar,O
to,O
adults,O
of,O
infection,O
with,O
SARS,O
-,O
CoV-2,O
.,O
This,O
discrepancy,O
may,O
be,O
because,O
children,O
are,O
asymptomatic,O
or,O
too,O
mildly,O
infected,O
to,O
draw,O
medical,O
attention,O
and,O
be,O
tested,O
and,O
counted,O
in,O
observed,O
cases,O
of,O
COVID-19,O
.,O
Initial,O
reports,O
from,O
China,O
observed,O
low,O
rates,O
of,O
COVID-19,O
in,O
children,O
compared,O
with,O
adults,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
fatalities,O
are,O
rare,O
before,O
adrenarche,O
/,O
puberty,O
(,O
<,O
10,O
 ,O
years,O
of,O
age,O
),O
",",O
and,O
the,O
vulnerability,O
of,O
males,O
to,O
severe,O
disease,O
has,O
been,O
constantly,O
reported,O
over,O
the,O
past,O
months,O
of,O
pandemic,O
.,O
Theoretically,O
",",O
the,O
hyperandrogenic,O
phenotype,O
might,O
correlate,O
with,O
COVID-19,O
increased,O
viral,O
load,O
",",O
increased,O
viral,O
dissemination,O
",",O
and,O
severity,O
of,O
lung,O
involvement,O
(,O
Infographic,O
1,O
),O
.,O
The,O
SARS,O
outbreak,O
of,O
2002–2004,O
",",O
the,O
MERS,O
outbreaks,O
since,O
2012,O
and,O
the,O
current,O
COVID‐19,O
outbreak,O
since,O
2019,O
demonstrate,O
the,O
potential,O
of,O
coronaviruses,O
",",O
especially,O
bat‐derived,O
betacoronaviruses,O
(,O
Zhou,O
et,O
 ,O
al,O
.,O
",",O
 ,O
2020,O
),O
",",O
to,O
cause,O
PHEICs,O
",",O
with,O
COVID‐19,O
having,O
escalated,O
to,O
a,O
global,O
pandemic,O
.,O
For,O
the,O
ongoing,O
COVID‐19,O
outbreak,O
",",O
as,O
illustrated,O
in,O
Figure,O
 ,O
1,O
",",O
applying,O
in,O
silico,O
approaches,O
can,O
rapidly,O
provide,O
answers,O
to,O
questions,O
like,O
:,O
Is,O
the,O
first,O
sequenced,O
SARS‐CoV‐2,O
genome,O
(,O
often,O
called,O
the,O
‘,O
reference,O
genome,O
’,O
in,O
GISAID,S-Dataset
",",O
GenBank,S-Repository
",",O
etc,O
.,O
),O
closest,O
to,O
the,O
original,O
or,O
‘,O
true,O
reference,O
’,O
strain,O
which,O
entered,O
humans,O
(,O
which,O
may,O
not,O
have,O
been,O
sequenced,O
and/or,O
which,O
may,O
still,O
be,O
circulating,O
with,O
minimal,O
mutations,O
),O
?,O
All,O
available,O
viral,O
sequences,O
were,O
downloaded,O
from,O
GISAID,S-Dataset
 ,O
(,O
on,O
05/03/2020,O
",",O
see,O
Appendix,O
 ,O
S3,O
(,O
Elbe,O
",",O
&,O
Buckland‐Merrett,O
",",O
2017,O
),O
),O
",",O
filtering,O
for,O
complete,O
sequences,O
of,O
human,O
origin,O
(,O
187,O
genomes,O
in,O
total,O
),O
.,O
We,O
also,O
included,O
one,O
recently,O
reported,O
viral,O
sequence,O
from,O
the,O
European,B-Repository
Virus,I-Repository
Archive,E-Repository
 ,O
global,O
(,O
Ref‐SKU,O
:,O
026V‐03883,S-AccessionNumber
),O
and,O
the,O
two,O
Australian,O
sequences,O
in,O
the,O
full,O
data,O
set,O
.,O
This,O
data,O
set,O
of,O
181,O
sequences,O
was,O
aligned,O
against,O
each,O
other,O
using,O
Muscle,O
(,O
v3.8.31,O
),O
(,O
Madeira,O
et,O
 ,O
al,O
.,O
",",O
 ,O
2019,O
),O
.,O
The,O
C1,O
cluster,O
mainly,O
represents,O
Wuhan,O
and,O
isolates,O
captured,O
early,O
on,O
;,O
C2,O
and,O
C3,O
contain,O
later,O
isolates,O
",",O
such,O
as,O
Sydney/3,O
",",O
Australia,O
/,O
VIC01,O
and,O
France,O
/,O
IDF0372,O
in,O
C2,O
and,O
Australia,O
/,O
NSW01,O
",",O
Australia,O
/,O
QLD01‐3,O
",",O
Australia,O
/,O
VIC02,O
and,O
USA,O
/,O
WA1,O
in,O
C3,O
.,O
There,O
may,O
also,O
be,O
three,O
additional,O
clusters,O
emerging,O
(,O
C4‐6,O
),O
with,O
C4,O
capturing,O
the,O
suspected,O
community,O
spread,O
from,O
Lombardy,O
(,O
‘,O
Narrative,O
:,O
Genomic,O
analysis,O
of,O
COVID‐19,O
spread,O
’,O
",",O
n.d,O
.,O
),O
",",O
C5,O
regionally,O
mixed,O
(,O
Asia,O
and,O
North,O
Amerika,O
),O
and,O
C6,O
from,O
Australia,O
and,O
Asia,O
",",O
notably,O
Australia,O
/,O
NSW05‐7,O
(,O
see,O
fully,O
annotated,O
tree,O
in,O
Figure,O
S5,O
),O
.,O
Their,O
analysis,O
was,O
only,O
on,O
103,O
GISAID,S-Dataset
 ,O
isolates,O
and,O
includes,O
betacoronaviruses,O
from,O
bats,O
",",O
which,O
roots,O
the,O
tree,O
differently,O
and,O
merges,O
C1,O
and,O
C2,O
.,O
However,O
",",O
this,O
alignment‐free,O
method,O
positions,O
isolates,O
with,O
deletions,O
(,O
viz,O
.,O
Australia,O
/,O
VIC01,O
and,O
Canada,O
/,O
ON‐VIDO‐01,O
),O
further,O
away,O
from,O
Wuhan‐Hu‐1,O
than,O
in,O
the,O
phylogenetic,O
tree,O
",",O
demonstrating,O
the,O
ability,O
of,O
the,O
K‐mer,O
method,O
to,O
represent,O
deletions,O
accurately,O
(,O
see,O
Supplemental,O
Table,O
7,O
),O
.,O
While,O
Nextstrain,S-Repository
 ,O
(,O
',O
Narrative,O
:,O
Genomic,O
analysis,O
of,O
COVID‐19,O
spread,O
',O
",",O
n.d,O
.,O
),O
is,O
a,O
powerful,O
aid,O
in,O
visualizing,O
the,O
available,O
strains,O
in,O
real,O
time,O
",",O
it,O
currently,O
relies,O
on,O
phylogeny,O
only,O
and,O
thus,O
may,O
be,O
hampered,O
in,O
its,O
conclusions,O
.,O
C2,O
is,O
represented,O
by,O
Australia,O
/,O
VIC01,O
and,O
France,O
/,O
IDF0372,O
",",O
and,O
C3,O
is,O
represented,O
by,O
USA,O
/,O
WA1,O
.,O
The,O
central,O
location,O
of,O
Germany,O
/,O
BavPat1,O
and,O
France,O
/,O
IDF0372,O
may,O
reflect,O
a,O
broad,O
representation,O
across,O
multiple,O
clusters,O
",",O
in,O
contrast,O
to,O
Canada,O
/,O
ON‐VIDO‐01,O
and,O
Australia,O
/,O
VIC01,O
",",O
which,O
are,O
located,O
further,O
away,O
from,O
the,O
SARS‐CoV‐2,O
centre,O
marked,O
by,O
the,O
rectangle,O
in,O
Figure,O
 ,O
4b,O
inset,O
.,O
The,O
vertical,O
lines,O
hence,O
cluster,O
isolates,O
with,O
a,O
similar,O
number,O
of,O
‘,O
missing,O
’,O
bases,O
;,O
for,O
example,O
",",O
Australia,O
/,O
VIC01,O
and,O
Canada,O
/,O
ON‐VIDO‐01,O
have,O
10‐bp,O
deletions,O
",",O
while,O
Korea,O
/,O
KCDC05,O
and,O
Australia,O
/,O
Sydney02,O
have,O
a,O
40‐bp,O
shorter,O
sequence,O
and,O
42‐bp,O
deletion,O
",",O
respectively,O
.,O
Furthermore,O
",",O
releasing,O
the,O
full,O
high‐throughput,O
sequencing,O
data,O
sets,O
rather,O
than,O
the,O
consensus,O
sequences,O
would,O
allow,O
a,O
more,O
detailed,O
exploration,O
of,O
the,O
existing,O
quasispecies,O
to,O
further,O
improve,O
isolate,O
selection,O
.,O
We,O
discuss,O
the,O
currently,O
chosen,O
SARS‐CoV‐2,O
strains,O
for,O
international,O
coronavirus,O
disease,O
(,O
COVID‐19,O
),O
models,O
in,O
the,O
context,O
of,O
their,O
phylogeny,O
as,O
well,O
as,O
in,O
a,O
novel,O
alignment‐free,O
bioinformatic,O
approach,O
.,O
The,O
ongoing,O
pandemic,O
of,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
causing,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
has,O
imposed,O
an,O
increasing,O
demand,O
on,O
daily,O
diagnostic,O
screening,O
.,O
Given,O
the,O
high,O
specificity,O
of,O
the,O
RT,O
-,O
qPCR,O
(,O
Alcoba,O
-,O
Florez,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
focus,O
was,O
on,O
evaluating,O
the,O
rate,O
of,O
false,O
negatives,O
(,O
FN,O
),O
and,O
assay,O
sensitivity,O
using,O
the,O
same,O
98,O
COVID-19,O
patient,O
samples,O
.,O
Since,O
all,O
samples,O
were,O
COVID-19,O
positive,O
for,O
at,O
least,O
one,O
solution,O
/,O
viral,O
target,O
",",O
results,O
with,O
threshold,O
cycle,O
(,O
Ct,O
),O
values,O
>,O
40,O
or,O
those,O
that,O
remained,O
undetected,O
during,O
the,O
45,O
cycles,O
of,O
the,O
experiments,O
were,O
considered,O
FN,O
observations,O
(,O
Fig,O
.,O
1,O
",",O
Table,O
1,O
),O
.,O
Attending,O
to,O
individual,O
targets,O
",",O
it,O
was,O
found,O
that,O
the,O
most,O
sensitive,O
solution,O
was,O
the,O
LightMix,O
®,O
Modular,O
SARS,O
-,O
CoV,O
(,O
COVID19,O
),O
(,O
TIB,O
MOLBIOL,O
",",O
Berlin,O
",",O
Germany,O
),O
used,O
in,O
combination,O
with,O
a,O
primer,O
-,O
probe,O
set,O
for,O
the,O
E,O
-,O
gene,O
(,O
97.9,O
%,O
[,O
92.8–99.7,O
],O
),O
(,O
Table,O
1,O
),O
.,O
Finally,O
",",O
because,O
the,O
LightMix,O
®,O
Modular,O
SARS,O
-,O
CoV,O
(,O
COVID19,O
),O
kit,O
with,O
primer,O
-,O
probes,O
for,O
the,O
E,O
-,O
gene,O
showed,O
the,O
highest,O
sensitivity,O
",",O
it,O
was,O
tested,O
on,O
samples,O
that,O
were,O
preheated,O
at,O
70,O
 ,O
°,O
C,O
for,O
10,O
 ,O
minutes,O
in,O
a,O
substitution,O
of,O
the,O
RNA,O
extraction,O
(,O
Alcoba,O
-,O
Florez,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
RT,O
-,O
qPCR,O
for,O
selected,O
target,O
genes,O
of,O
SARS,O
-,O
CoV-2,O
has,O
been,O
key,O
in,O
the,O
global,O
response,O
to,O
the,O
COVID-19,O
pandemic,O
.,O
Given,O
the,O
rapid,O
spread,O
of,O
the,O
virus,O
at,O
this,O
time,O
",",O
it,O
is,O
likely,O
that,O
the,O
RT,O
-,O
qPCR,O
assays,O
will,O
continue,O
to,O
be,O
a,O
central,O
tool,O
for,O
controlling,O
COVID-19,O
.,O
However,O
",",O
as,O
happened,O
in,O
the,O
past,O
due,O
to,O
supply,O
chain,O
issues,O
",",O
policy,O
decisions,O
and,O
laboratory,O
testing,O
capacities,O
(,O
Alcoba,O
-,O
Florez,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
it,O
is,O
predictable,O
that,O
the,O
diagnosis,O
of,O
COVID-19,O
will,O
continue,O
relying,O
on,O
a,O
variety,O
of,O
solutions,O
among,O
laboratories,O
and,O
countries,O
(,O
Vogels,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
These,O
findings,O
will,O
help,O
to,O
assess,O
the,O
impact,O
of,O
the,O
selected,O
solution,O
on,O
FN,O
diagnoses,O
of,O
COVID-19,O
(,O
Ramdas,O
et,O
al,O
.,O
",",O
2020,O
),O
and,O
to,O
choose,O
a,O
solution,O
that,O
minimizes,O
misdiagnoses,O
of,O
an,O
active,O
SARS,O
-,O
CoV-2,O
infection,O
.,O
The,O
ongoing,O
COVID-19,O
pandemic,O
continues,O
to,O
impose,O
demands,O
on,O
diagnostic,O
screening,O
.,O
Six,O
different,O
RT,O
-,O
qPCR,O
alternatives,O
were,O
evaluated,O
for,O
SARS,O
-,O
CoV-2,O
/,O
COVID-19,O
diagnosis,O
based,O
on,O
standard,O
RNA,O
extractions,O
.,O
These,O
results,O
will,O
help,O
to,O
calibrate,O
the,O
impact,O
of,O
false,O
negative,O
diagnoses,O
of,O
COVID-19,O
",",O
and,O
to,O
detect,O
and,O
control,O
new,O
SARS,O
-,O
CoV-2,O
outbreaks,O
and,O
community,O
transmissions,O
.,O
The,O
coding,O
sequences,O
of,O
the,O
N,O
genes,O
along,O
with,O
their,O
accession,O
numbers,O
were,O
obtained,O
from,O
the,O
GenBank,S-Repository
 ,O
database,O
(,O
Supplementary,O
file,O
),O
.,O
COVID-19,O
has,O
launched,O
our,O
community,O
of,O
practice,O
into,O
a,O
new,O
reality,O
of,O
digital,O
care,O
.,O
As,O
highlighted,O
by,O
the,O
COVID-19,O
pandemic,O
",",O
digital,O
solutions,O
are,O
becoming,O
essential,O
for,O
the,O
provision,O
of,O
clinical,O
genetics,O
services,O
.,O
We,O
assume,O
that,O
upon,O
the,O
end,O
of,O
the,O
COVID-19,O
pandemic,O
",",O
the,O
structure,O
of,O
scientific,O
meetings,O
will,O
be,O
re,O
-,O
examined,O
.,O
The,O
recent,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
has,O
caused,O
worldwide,O
disruption,O
which,O
also,O
extends,O
to,O
the,O
arena,O
of,O
scientific,O
meetings,O
around,O
the,O
world,O
.,O
In,O
the,O
current,O
coronavirus,O
outbreak,O
",",O
the,O
global,O
community,O
is,O
mounting,O
a,O
large,O
-,O
scale,O
public,O
health,O
response,O
to,O
understand,O
the,O
pathogen,O
",",O
SARS,O
-,O
CoV-2,O
",",O
and,O
combat,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
Below,O
we,O
briefly,O
outline,O
the,O
response,O
—,O
including,O
actions,O
taken,O
by,O
national,O
Nodes,O
—,O
and,O
note,O
that,O
this,O
strategy,O
directly,O
answers,O
to,O
priority,O
action,O
8,O
(,O
“,O
Access,O
to,O
research,O
infrastructures,O
”,O
),O
and,O
action,O
9,O
(,O
“,O
Research,O
data,O
sharing,O
platform,O
”,O
),O
in,O
the,O
EU,O
action,O
plan,O
for,O
COVID-19,O
[,O
10,O
],O
.,O
ELIXIR,S-Repository
 ,O
provides,O
updated,O
information,O
on,O
services,O
run,O
by,O
ELIXIR,S-Repository
 ,O
Nodes,O
that,O
can,O
be,O
used,O
by,O
researchers,O
working,O
on,O
COVID-19,O
via,O
elixir-europe.org/services/covid-19-resources,S-URL
.,O
National,O
infrastructures,O
provide,O
important,O
focal,O
points,O
for,O
the,O
efforts,O
around,O
COVID-19,O
and,O
many,O
ELIXIR,S-Repository
 ,O
Nodes,O
are,O
tasked,O
with,O
coordinating,O
national,O
data,O
spaces,O
for,O
health,O
",",O
clinical,O
and,O
epidemiological,O
data,O
.,O
National,O
infrastructures,O
also,O
provide,O
the,O
bulk,O
of,O
 ,O
data,O
processing,O
capabilities,O
for,O
the,O
many,O
COVID-19,O
research,O
projects,O
now,O
underway,O
.,O
This,O
federated,O
model,O
provides,O
the,O
coordination,O
across,O
Europe,O
to,O
ensure,O
consistent,O
discovery,O
and,O
access,O
to,O
relevant,O
human,O
genetic,O
datasets,O
for,O
research,O
.,O
As,O
much,O
of,O
the,O
COVID-19,O
host,O
data,O
will,O
come,O
directly,O
from,O
clinical,O
care,O
it,O
will,O
likely,O
be,O
subject,O
to,O
national,O
laws,O
and,O
regulations,O
and,O
therefore,O
",",O
for,O
example,O
",",O
much,O
of,O
the,O
data,O
is,O
unlikely,O
to,O
be,O
consented,O
to,O
leave,O
national,O
jurisdictions,O
.,O
As,O
part,O
of,O
the,O
COVID-19,O
response,O
ELIXIR,S-Repository
 ,O
will,O
accelerate,O
 ,O
implementation,O
of,O
the,O
Federated,B-Repository
European,I-Repository
Genome-phenome,I-Repository
Archive,I-Repository
(FEGA),E-Repository
 ,O
to,O
provide,O
 ,O
the,O
necessary,O
infrastructure,O
and,O
coordination,O
between,O
European,O
national,O
initiatives,O
and,O
ensure,O
rapid,O
sharing,O
of,O
COVID-19,O
host,O
data,O
in,O
full,O
compliance,O
with,O
national,O
regulations,O
(,O
e.g.,O
GDPR,O
),O
.,O
In,O
addition,O
",",O
the,O
rapid,O
response,O
to,O
the,O
COVID-19,O
pandemic,O
provides,O
a,O
blueprint,O
for,O
European,O
data,O
access,O
in,O
projects,O
such,O
as,O
1,B-Repository
Million,I-Repository
European,I-Repository
Genomes,E-Repository
 ,O
[,O
12,O
],O
.,O
The,O
federated,O
EGA,O
nodes,O
forms,O
a,O
set,O
of,O
 ,O
connected,O
European,O
COVID-19,O
Data,O
Spaces,O
",",O
that,O
bring,O
together,O
national,O
health,O
informatics,O
infrastructure,O
[,O
13,O
],O
and,O
European,O
archives,O
such,O
as,O
those,O
at,O
EMBL,O
–,O
EBI,O
[,O
14,O
],O
.,O
This,O
interconnected,O
ecosystem,O
will,O
allow,O
data,O
from,O
ongoing,O
European,O
projects,O
as,O
well,O
as,O
the,O
many,O
re,O
-,O
focussed,O
national,O
research,O
programmes,O
to,O
be,O
widely,O
accessed,O
",",O
reused,O
and,O
linked,O
to,O
global,O
COVID-19,O
initiatives,O
.,O
Public,O
databases,O
are,O
key,O
to,O
ensuring,O
that,O
datasets,O
—,O
from,O
short,O
-,O
read,O
sequence,O
data,O
to,O
protein,O
structures,O
—,O
are,O
stored,O
over,O
the,O
long,O
-,O
term,O
and,O
accessed,O
by,O
scientists,O
in,O
academia,O
and,O
industry,O
.,O
ELIXIR,S-Repository
 ,O
is,O
an,O
open,O
data,O
infrastructure,O
and,O
advocates,O
the,O
open,O
sharing,O
—,O
wherever,O
possible,O
for,O
reasons,O
of,O
personal,O
privacy,O
and,O
public,O
health,O
—,O
of,O
COVID-19,O
data,O
.,O
ELIXIR,S-Repository
’s,O
response,O
aims,O
to,O
ensure,O
that,O
COVID-19,O
data,O
are,O
well,O
annotated,O
and,O
accessible,O
for,O
reuse,O
by,O
the,O
research,O
community,O
and,O
society,O
.,O
EMBL–EBI,S-Repository
 ,O
has,O
a,O
dedicated,O
page,O
to,O
assist,O
deposition,O
and,O
sharing,O
of,O
SARS,O
-,O
CoV-2,O
data,O
into,O
molecular,O
databases,O
.,O
In,O
the,O
first,O
weeks,O
of,O
teh,O
European,O
response,O
ELIXIR,S-Repository
 ,O
has,O
further,O
reached,O
out,O
 ,O
to,O
the,O
data,O
generation,O
underway,O
in,O
the,O
facilities,O
of,O
the,O
ESFRI,O
Research,O
Infrastructures,O
and,O
ensure,O
that,O
data,O
is,O
deposited,O
in,O
existing,O
archives,O
where,O
possible,O
(,O
e.g.,O
EMBL–EBI,S-Repository
 ,O
COVID19,O
Portal,O
",",O
ENA,O
",",O
IDR,O
",",O
Biostudies,O
etc,O
.,O
),O
and,O
 ,O
are,O
made,O
FAIR,O
for,O
the,O
research,O
community,O
at,O
large,O
.,O
National,O
infrastructures,O
—,O
some,O
of,O
which,O
already,O
form,O
part,O
of,O
EOSC,O
—,O
are,O
also,O
providing,O
open,O
-,O
access,O
biocomputing,O
resources,O
with,O
COVID-19,O
workflows,O
and,O
toolkits,O
.,O
Via,O
the,O
EOSC,O
-,O
Life,O
project3,O
we,O
are,O
also,O
investigating,O
if,O
resources,O
can,O
be,O
made,O
available,O
to,O
resource,O
-,O
poor,O
countries,O
in,O
the,O
fight,O
against,O
COVID-19,O
.,O
As,O
projects,O
on,O
COVID-19,O
research,O
studies,O
emerge,O
from,O
many,O
initiatives,O
driven,O
from,O
ELIXIR,S-Repository
 ,O
Nodes,O
",",O
ELIXIR,S-Repository
 ,O
has,O
launched,O
the,O
ELIXIR,S-Repository
 ,O
support,O
for,O
SARS,O
-,O
CoV-2,O
research,O
webpage,O
to,O
display,O
the,O
services,O
that,O
ELIXIR,O
Nodes,O
offer,O
to,O
scientists,O
 ,O
(,O
Fig,O
.,O
1,O
),O
.,O
The,O
webpage,O
focuses,O
on,O
Node,O
services,O
that,O
enable,O
European,O
researchers,O
to,O
carry,O
out,O
research,O
into,O
COVID-19,O
.,O
ELIXIR,S-Repository
",",O
the,O
European,O
research,O
infrastructure,O
for,O
life,O
science,O
data,O
",",O
provides,O
open,O
access,O
to,O
data,O
",",O
tools,O
and,O
workflows,O
in,O
the,O
response,O
to,O
the,O
COVID-19,O
pandemic,O
.,O
1,O
.,O
Connecting,O
national,O
COVID-19,O
data,O
platforms,O
to,O
create,O
federated,O
European,O
COVID-19,O
Data,O
Spaces,O
;,O
2,O
.,O
Fostering,O
good,O
data,O
management,O
to,O
make,O
COVID-19,O
data,O
open,O
",",O
FAIR,O
and,O
reusable,O
over,O
the,O
long,O
term,O
;,O
3,O
.,O
Providing,O
open,O
tools,O
",",O
workflows,O
and,O
computational,O
resources,O
to,O
drive,O
reproducible,O
and,O
collaborative,O
science,O
.,O
Some,O
Nodes,O
have,O
prioritised,O
access,O
to,O
their,O
national,O
cloud,O
and,O
compute,O
facilities,O
for,O
all,O
COVID-19,O
research,O
projects,O
",",O
while,O
others,O
have,O
developed,O
tools,O
to,O
search,O
",",O
access,O
and,O
share,O
all,O
data,O
related,O
to,O
the,O
pandemic,O
in,O
a,O
national,O
healthcare,O
setting,O
.,O
The,O
first,O
coronavirus,O
diasease,O
2019,O
(,O
COVID‐19,O
),O
case,O
in,O
South,O
America,O
was,O
reported,O
on,O
25,O
February,O
2020,O
",",O
in,O
Sao,O
Paulo,O
",",O
Brazil,O
",",O
and,O
since,O
has,O
spread,O
so,O
that,O
as,O
of,O
20,O
March,O
",",O
cases,O
of,O
SARS‐CoV‐2,O
infection,O
have,O
been,O
reported,O
from,O
all,O
Latin,O
American,O
countries,O
.,O
Therefore,O
",",O
genomic,O
epidemiology,O
studies,O
must,O
be,O
in,O
place,O
to,O
understand,O
the,O
dynamics,O
of,O
COVID‐19,O
epidemic,O
.,O
Colombia,O
",",O
the,O
fifth,O
largest,O
country,O
in,O
South,O
America,O
is,O
the,O
fourth,O
country,O
in,O
number,O
of,O
confirmed,O
new,O
COVID‐19,O
cases,O
in,O
the,O
region,O
by,O
30th,O
July,O
2020,O
.,O
Following,O
identification,O
of,O
the,O
first,O
COVID‐19,O
case,O
in,O
Colombia,O
",",O
on,O
6,O
March,O
2020,O
",",O
in,O
a,O
female,O
traveler,O
returning,O
from,O
Milan,O
",",O
Italy,O
",",O
the,O
Colombian,O
government,O
implemented,O
early,O
control,O
measures,O
.,O
Comparative,O
genome,O
analysis,O
of,O
our,O
88,O
cases,O
and,O
three,O
previously,O
reported,O
Colombian,O
cases,O
was,O
carried,O
out,O
relative,O
to,O
publicly,O
available,O
background,O
data,O
from,O
2744,O
cases,O
sampled,O
from,O
the,O
GISAID,B-Dataset
EpiCoV,E-Dataset
 ,O
database,O
to,O
obtain,O
a,O
full,O
representation,O
of,O
global,O
lineage,O
diversity,O
.,O
Consensus,O
viral,O
sequences,O
from,O
each,O
case,O
were,O
also,O
submitted,O
to,O
GISAID,S-Dataset
 ,O
(,O
accessions,O
:,O
EPI_ISL_447734,S-AccessionNumber
‐,O
EPI_ISL_447817,S-AccessionNumber
),O
.,O
Whole,O
genome,O
sequences,O
for,O
the,O
samples,O
included,O
in,O
each,O
dataset,O
were,O
aligned,O
using,O
MAFFT,O
v7.40755,O
 ,O
with,O
FFT‐NS‐2,O
algorithm,O
and,O
default,O
parameter,O
settings,O
.,O
The,O
genome,O
sequence,O
of,O
88,O
samples,O
isolated,O
from,O
patients,O
with,O
COVID‐19,O
from,O
different,O
regions,O
of,O
Colombia,O
allowed,O
identifying,O
11,O
independent,O
lineages,O
",",O
suggesting,O
a,O
massive,O
introduction,O
of,O
the,O
virus,O
in,O
the,O
country,O
(,O
Figure,O
 ,O
1,O
),O
.,O
The,O
novel,O
coronavirus,O
SARS,O
-,O
CoV-2,O
that,O
causes,O
COVID-19,O
and,O
first,O
identified,O
in,O
the,O
Wuhan,O
region,O
of,O
China,O
[,O
1,O
],O
is,O
an,O
enveloped,O
positive,O
sense,O
RNA,O
virus,O
of,O
the,O
family,O
Coronaviridae,O
and,O
genus,O
Betacoronavirus,O
(,O
[,O
2,O
],O
.,O
In,O
view,O
of,O
the,O
potential,O
application,O
of,O
IFITM,O
proteins,O
’,O
induction,O
to,O
target,O
SARS,O
-,O
CoV-2,O
infection,O
that,O
causes,O
COVID-19,O
",",O
this,O
article,O
layout,O
insights,O
into,O
the,O
known,O
antiviral,O
mechanisms,O
and,O
therapeutic,O
agents,O
related,O
to,O
IFITM,O
.,O
Though,O
by,O
14,O
March,O
2020,O
",",O
fewer,O
than,O
500,O
SARS,O
-,O
CoV-2,O
genomes,O
were,O
published,O
on,O
public,O
databases,O
including,O
China,B-Repository
National,I-Repository
GeneBank,I-Repository
DataBase,I-Repository
(CNGBdb),E-Repository
",",O
NCBI,S-Repository
 ,O
GenBank,S-Repository
",",O
and,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
",",O
and,O
much,O
remains,O
unknown,O
about,O
the,O
epidemiology,O
and,O
evolution,O
of,O
the,O
virus,O
.,O
For,O
metatranscriptomic,O
and,O
hybrid,O
capture,O
sequencing,O
data,O
",",O
total,O
reads,O
were,O
first,O
processed,O
using,O
Kraken,O
v0.10.5,O
[,O
20,O
],O
(,O
default,O
parameters,O
),O
with,O
a,O
self,O
-,O
built,O
database,O
of,O
Coronaviridae,O
genomes,O
(,O
including,O
SARS,O
",",O
MERS,O
",",O
and,O
SARS,O
-,O
CoV-2,O
genome,O
sequences,O
downloaded,O
from,O
GISAID,S-Dataset
",",O
NCBI,S-Repository
",",O
and,O
CNGB,S-Repository
),O
to,O
identify,O
Coronaviridae,O
-,O
like,O
reads,O
in,O
a,O
loose,O
manner,O
.,O
Nucleotide,O
positions,O
with,O
sequencing,O
depth,O
<,O
 ,O
100×,O
or,O
<,O
 ,O
5,O
-,O
fold,O
higher,O
than,O
that,O
of,O
negative,O
controls,O
were,O
masked,O
as,O
ambiguous,O
base,O
N.,O
The,O
Coronaviridae,O
-,O
like,O
reads,O
from,O
metatranscriptomic,O
and,O
hybrid,O
capture,O
sequencing,O
data,O
were,O
aligned,O
against,O
the,O
SARS,O
-,O
CoV-2,O
reference,O
genome,O
(,O
GISAID,S-Dataset
 ,O
accession,O
:,O
EPI_ISL_402119,S-AccessionNumber
),O
[,O
27,O
],O
with,O
BWA,O
aln,O
(,O
v0.7.16,O
),O
[,O
28,O
],O
.,O
SARS,O
-,O
CoV-2,O
reads,O
of,O
metatranscriptomic,O
and,O
hybrid,O
capture,O
sequencing,O
data,O
were,O
identified,O
by,O
aligning,O
the,O
Coronaviridae,O
-,O
like,O
reads,O
against,O
the,O
SARS,O
-,O
CoV-2,O
reference,O
genome,O
(,O
GISAID,S-Dataset
 ,O
accession,O
:,O
EPI_ISL_402119,S-AccessionNumber
),O
[,O
27,O
],O
with,O
BWA,O
in,O
a,O
strict,O
manner,O
of,O
coverage,O
≥,O
 ,O
95,O
%,O
and,O
identity,O
≥,O
 ,O
90,O
%,O
.,O
To,O
estimate,O
the,O
minimum,O
data,O
required,O
for,O
genome,O
assembly,O
and,O
genome,O
variation,O
analysis,O
",",O
we,O
applied,O
gradient,O
-,O
based,O
sampling,O
to,O
the,O
SARS,O
-,O
CoV-2,O
genome,O
alignments,O
(,O
referred,O
to,O
BAM,O
files,O
),O
to,O
each,O
dataset,O
using,O
SAMtools,O
(,O
v1.9,O
),O
[,O
29,O
],O
.,O
For,O
metatranscriptomic,O
sequencing,O
of,O
clinical,O
samples,O
",",O
raw,O
sequencing,O
data,O
of,O
a,O
single,O
sequence,O
lane,O
(,O
approximately,O
60–75,O
 ,O
Gb,O
per,O
sample,O
),O
was,O
used,O
to,O
simultaneously,O
assess,O
the,O
RNA,O
expression,O
patterns,O
of,O
human,O
",",O
bacteria,O
",",O
and,O
viruses,O
in,O
clinical,O
samples,O
from,O
COVID-19,O
patients,O
.,O
Next,O
",",O
we,O
applied,O
Kraken,O
2,O
[,O
39,O
],O
(,O
version,O
2.0.8,O
-,O
beta,O
",",O
parameters,O
:,O
--threads,O
24,O
--confidence,O
0,O
),O
to,O
assign,O
microbial,O
taxonomic,O
ranks,O
to,O
non,O
-,O
human,O
RNA,O
reads,O
against,O
the,O
large,O
reference,O
database,O
MiniKraken2,O
(,O
April,O
2019,O
",",O
8,O
 ,O
GB,O
),O
built,O
from,O
the,O
Refseq,S-Repository
 ,O
bacteria,O
",",O
archaea,O
",",O
and,O
viral,O
libraries,O
and,O
the,O
h38,O
human,O
genome,O
.,O
We,O
sampled,O
eight,O
specimens,O
from,O
COVID-19,O
patients,O
in,O
February,O
2020,O
",",O
including,O
throat,O
swab,O
",",O
nasal,O
swab,O
",",O
anal,O
swab,O
",",O
and,O
sputum,O
specimens,O
",",O
and,O
the,O
corresponding,O
cycle,O
threshold,O
(,O
Ct,O
),O
value,O
of,O
SARS,O
-,O
CoV-2,O
qRT,O
-,O
PCR,O
ranges,O
from,O
18,O
to,O
32,O
(,O
Table,O
 ,O
1,O
),O
.,O
To,O
ensure,O
the,O
confidence,O
of,O
the,O
datasets,O
",",O
we,O
included,O
serial,O
dilutions,O
of,O
the,O
cultured,O
isolate,O
and,O
negative,O
controls,O
prepared,O
from,O
nuclease,O
-,O
free,O
water,O
and,O
human,O
nucleic,O
acids,O
since,O
the,O
1st,O
PCR,O
.,O
All,O
samples,O
in,O
~,O
 ,O
400,O
 ,O
bp,O
amplicon,O
-,O
based,O
sequencing,O
exhibited,O
>,O
 ,O
99.5,O
%,O
coverage,O
of,O
1×,O
depth,O
across,O
the,O
SARS,O
-,O
CoV-2,O
genome,O
except,O
for,O
1E+01,O
(,O
95.23,O
%,O
),O
",",O
GZMU0031,O
(,O
73.65,O
%,O
),O
",",O
HNA,O
(,O
6.17,O
%,O
),O
",",O
and,O
water,O
(,O
60.24,O
%,O
),O
and,O
>,O
 ,O
97.00,O
%,O
coverage,O
of,O
100×,O
depth,O
across,O
the,O
SARS,O
-,O
CoV-2,O
genome,O
except,O
for,O
GZMU0030,O
(,O
94.15,O
%,O
),O
",",O
GZMU0042,O
(,O
88.17,O
%,O
),O
",",O
GZMU0014,O
(,O
71.66,O
%,O
),O
",",O
D7,O
(,O
39.49,O
%,O
),O
",",O
GZMU0031,O
(,O
0.00,O
%,O
),O
",",O
HNA,O
(,O
0.00,O
%,O
),O
",",O
and,O
water,O
(,O
0.00,O
%,O
),O
",",O
suggesting,O
the,O
primers,O
were,O
well,O
designed,O
and,O
the,O
positive,O
datasets,O
were,O
reliable,O
(,O
Fig,O
.,O
 ,O
3a,O
),O
.,O
Considering,O
the,O
costs,O
for,O
sequencing,O
",",O
storage,O
",",O
and,O
analysis,O
increase,O
substantially,O
with,O
larger,O
datasets,O
",",O
we,O
tried,O
to,O
estimate,O
how,O
much,O
sequencing,O
data,O
must,O
be,O
produced,O
for,O
each,O
approach,O
in,O
order,O
to,O
achieve,O
10×,O
depth,O
across,O
95,O
%,O
of,O
the,O
SARS,O
-,O
CoV-2,O
genome,O
",",O
and,O
the,O
results,O
can,O
be,O
found,O
in,O
Additional,O
 ,O
file,O
 ,O
2,O
Table,O
 ,O
3,O
.,O
a,O
SNVs,O
detected,O
between,O
clinical,O
samples,O
against,O
a,O
reference,O
genome,O
(,O
GISAID,S-Dataset
 ,O
accession,O
:,O
EPI_ISL_402119,S-AccessionNumber
),O
[,O
27,O
],O
.,O
For,O
serial,O
dilutions,O
of,O
the,O
cultured,O
isolate,O
",",O
the,O
minor,O
allele,O
frequencies,O
detected,O
in,O
capture,O
sequencing,O
datasets,O
were,O
generally,O
approximate,O
to,O
meta,O
sequencing,O
",",O
while,O
most,O
allele,O
frequencies,O
in,O
amplicon,O
sequencing,O
datasets,O
deviated,O
with,O
those,O
in,O
meta,O
sequencing,O
(,O
Fig,O
.,O
 ,O
4c,O
),O
.,O
Background,O
 ,O
COVID-19,O
(,O
coronavirus,O
disease,O
2019,O
),O
has,O
caused,O
a,O
major,O
epidemic,O
worldwide,O
;,O
however,O
",",O
much,O
is,O
yet,O
to,O
be,O
known,O
about,O
the,O
epidemiology,O
and,O
evolution,O
of,O
the,O
virus,O
partly,O
due,O
to,O
the,O
scarcity,O
of,O
full,O
-,O
length,O
SARS,O
-,O
CoV-2,O
(,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
),O
genomes,O
reported,O
.,O
The,O
data,O
that,O
support,O
the,O
findings,O
of,O
this,O
study,O
have,O
been,O
deposited,O
into,O
CNSA,B-Repository
(CNGB,I-Repository
Nucleotide,I-Repository
Sequence,I-Repository
Archive,E-Repository
",",O
https://db.cngb.org/cnsa/,S-URL
),O
of,O
CNGBdb,S-Repository
 ,O
with,O
project,O
IDs,O
CNP0000951,S-AccessionNumber
 ,O
[,O
50,O
],O
and,O
CNP0000955,S-AccessionNumber
 ,O
[,O
51,O
],O
;,O
into,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
",",O
registration,O
required,O
),O
with,O
accession,O
numbers,O
EPI_ISL_414663,S-AccessionNumber
",",O
EPI_ISL_414686,S-AccessionNumber
",",O
EPI_ISL_414687,S-AccessionNumber
",",O
EPI_ISL_414688,S-AccessionNumber
",",O
EPI_ISL_414689,S-AccessionNumber
",",O
EPI_ISL_414690,S-AccessionNumber
",",O
EPI_ISL_414691,S-AccessionNumber
",",O
and,O
EPI_ISL_414692,S-AccessionNumber
 ,O
[,O
52,O
],O
;,O
and,O
into,O
NCBI,S-Repository
 ,O
with,O
accession,O
numbers,O
MT568634,S-AccessionNumber
",",O
MT568635,S-AccessionNumber
",",O
MT568636,S-AccessionNumber
",",O
MT568637,S-AccessionNumber
",",O
MT568638,S-AccessionNumber
",",O
MT568639,S-AccessionNumber
",",O
MT568640,S-AccessionNumber
",",O
MT568641,S-AccessionNumber
 ,O
[,O
53,O
],O
and,O
PRJNA637515,S-AccessionNumber
 ,O
[,O
54,O
],O
.,O
The,O
present,O
outbreak,O
of,O
the,O
coronavirus,O
-,O
associated,O
acute,O
respiratory,O
disease,O
is,O
named,O
coronavirus,O
disease,O
19,O
(,O
COVID-19,O
),O
by,O
WHO,O
.,O
Since,O
the,O
pandemic,O
of,O
COVID-19,O
",",O
more,O
than,O
332,O
",",O
930,O
people,O
from,O
147,O
countries,O
and,O
territories,O
have,O
been,O
confirmed,O
sicked,O
and,O
more,O
than,O
14,O
",",O
510,O
have,O
died,O
from,O
the,O
rapidly,O
-,O
spreading,O
SARS,O
-,O
CoV-2,O
virus,O
as,O
of,O
March,O
23,O
",",O
2020,O
[,O
2,O
],O
.,O
Total,O
558,O
complete,O
genome,O
sequences,O
of,O
the,O
SARS,O
-,O
CoV-2,O
strains,O
from,O
the,O
infected,O
individuals,O
are,O
retrieved,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
[,O
26,O
],O
as,O
of,O
March,O
23,O
",",O
2020,O
.,O
Only,O
the,O
complete,O
genomes,O
of,O
high,O
-,O
coverage,O
and,O
having,O
no,O
stretches,O
of’NNNNN,O
’,O
are,O
included,O
in,O
the,O
dataset,O
.,O
The,O
GISAID,S-Dataset
 ,O
Ids,O
of,O
SARS,O
-,O
CoV-2,O
isolates,O
are,O
listed,O
in,O
the,O
supplementary,O
material,O
.,O
This,O
study,O
retrieved,O
the,O
SNP,O
genotypes,O
of,O
558,O
SARS,O
-,O
CoV-2,O
strains,O
in,O
GISAID,S-Dataset
 ,O
database,O
from,O
the,O
globe,O
.,O
The,O
emerging,O
global,O
infectious,O
COVID-19,O
disease,O
by,O
novel,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
presents,O
critical,O
threats,O
to,O
global,O
public,O
health,O
and,O
the,O
economy,O
since,O
it,O
was,O
identified,O
in,O
late,O
December,O
2019,O
in,O
China,O
.,O
This,O
virus,O
was,O
labeled,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
and,O
defined,O
as,O
the,O
causal,O
agent,O
of,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
[,O
2,O
],O
.,O
On,O
5,O
March,O
2020,O
",",O
the,O
first,O
COVID-19,O
case,O
was,O
reported,O
in,O
KwaZulu,O
-,O
Natal,O
",",O
South,O
Africa,O
",",O
from,O
a,O
traveler,O
from,O
Italy,O
.,O
Reads,O
are,O
then,O
filtered,O
and,O
sorted,O
",",O
on,O
a,O
protein,O
level,O
",",O
into,O
“,O
bins,O
”,O
corresponding,O
to,O
recognized,O
viral,O
species,O
",",O
using,O
DIAMOND,O
[,O
16,O
],O
and,O
the,O
UniRef90,S-Repository
 ,O
database,O
(,O
https://www.uniprot.org/help/uniref,S-URL
),O
.,O
All,O
of,O
the,O
sequences,O
were,O
deposited,O
in,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
(,O
Accession,O
IDs,O
in,O
Table,O
S2,O
),O
.,O
Moreover,O
",",O
"10,959",O
GISAID,S-Dataset
 ,O
reference,O
genomes,O
(,O
all,O
authors,O
acknowledged,O
in,O
Table,O
S3,O
),O
and,O
54,O
whole,O
genomes,O
generated,O
at,O
KwaZulu,O
-,O
Natal,O
Research,O
Innovation,O
and,O
Sequencing,O
Platform,O
(,O
KRISP,O
),O
were,O
aligned,O
in,O
Mafft,O
v7·313,O
(,O
FF,O
-,O
NS-2,O
),O
[,O
19,O
],O
",",O
followed,O
by,O
manual,O
inspection,O
and,O
editing,O
in,O
the,O
Geneious,O
Prime,O
software,O
suite,O
(,O
Biomatters,O
Ltd.,O
",",O
New,O
Zealand,O
),O
.,O
All,O
of,O
the,O
data,O
produced,O
have,O
been,O
deposited,O
in,O
the,O
GISAID,S-Dataset
 ,O
(,O
consensus,O
genomes,O
),O
(,O
Accession,O
IDs,O
in,O
Table,O
S2,O
),O
and,O
at,O
the,O
FASTQ,O
short,O
reads,O
deposited,O
at,O
the,O
Short,B-Repository
Read,I-Repository
Archive,I-Repository
(SRA),E-Repository
 ,O
with,O
accession,O
code,O
PRJNA636748,S-AccessionNumber
.,O
In,O
addition,O
",",O
13,O
samples,O
delivered,O
from,O
the,O
hospital,O
outbreak,O
were,O
sequenced,O
",",O
but,O
the,O
patient,O
or,O
healthcare,O
worker,O
from,O
the,O
sample,O
ID,O
",",O
or,O
the,O
sample,O
ID,O
",",O
has,O
been,O
lost,O
",",O
or,O
the,O
sample,O
itself,O
was,O
lost,O
during,O
transport,O
or,O
in,O
storage,O
",",O
before,O
coming,O
to,O
the,O
laboratories,O
.,O
In,O
total,O
",",O
108,O
COVID-19,O
positive,O
individuals,O
were,O
sequenced,O
in,O
less,O
than,O
three,O
weeks,O
.,O
The,O
COVID-19,O
pandemic,O
has,O
spread,O
very,O
fast,O
around,O
the,O
world,O
.,O
The,O
ongoing,O
COVID-19,O
pandemic,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
has,O
raised,O
worldwide,O
alert,O
.,O
The,O
atomic,O
coordinates,O
of,O
HKU2,O
spike,O
and,O
SADS,O
-,O
CoV,O
spike,O
have,O
been,O
deposited,O
in,O
the,O
Worldwide,B-Repository
Protein,I-Repository
Data,I-Repository
Bank,E-Repository
 ,O
with,O
the,O
accession,O
codes,O
6M15,S-AccessionNumber
 ,O
and,O
6M16,S-AccessionNumber
",",O
respectively,O
;,O
the,O
corresponding,O
maps,O
have,O
been,O
deposited,O
in,O
the,O
Electron,B-Repository
Microscopy,I-Repository
Data,I-Repository
Bank,E-Repository
 ,O
with,O
the,O
accession,O
codes,O
EMD-30037,S-AccessionNumber
 ,O
and,O
EMD-30038,S-AccessionNumber
",",O
respectively,O
.,O
In,O
addition,O
",",O
a,O
combined,O
approach,O
using,O
both,O
HbA1c,O
and,O
FPG,O
measurement,O
was,O
evaluated,O
in,O
the,O
Pregnancy,O
and,O
Infant,O
Development,O
(,O
PRIDE,O
),O
Study,O
cohort,O
(,O
4303,O
women,O
):,O
HbA1c,O
levels,O
≥,O
 ,O
5.7,O
%,O
(,O
39,O
 ,O
mmol,O
/,O
mol,O
),O
and/or,O
FPG,O
levels,O
≥,O
 ,O
92,O
 ,O
mg,O
/,O
dL,O
had,O
a,O
detection,O
rate,O
of,O
51,O
%,O
for,O
HIP,O
",",O
as,O
defined,O
by,O
UK,O
National,O
Institute,O
for,O
Health,O
and,O
Care,O
Excellence,O
(,O
NICE,O
),O
criteria,O
",",O
and,O
a,O
12,O
%,O
rate,O
of,O
false,O
-,O
positive,O
cases,O
.,O
However,O
",",O
in,O
the,O
absence,O
of,O
additional,O
evidence,O
",",O
we,O
recommend,O
that,O
this,O
guidance,O
be,O
followed,O
only,O
for,O
the,O
duration,O
of,O
the,O
COVID-19,O
pandemic,O
",",O
with,O
a,O
return,O
back,O
to,O
the,O
usual,O
French,O
recommended,O
screening,O
procedure,O
when,O
it,O
appears,O
to,O
be,O
safe,O
and,O
feasible,O
to,O
do,O
so,O
.,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
a,O
recent,O
pandemic,O
outbreak,O
",",O
which,O
was,O
first,O
reported,O
in,O
Wuhan,O
(,O
Hubei,O
province,O
),O
",",O
China,O
",",O
causing,O
novel,O
coronavirus,O
pneumonia,O
(,O
COVID-19,O
),O
",",O
resulted,O
in,O
more,O
than,O
"298,000",O
deaths,O
",",O
as,O
on,O
14th,O
May,O
2020,O
.,O
Even,O
though,O
COVID-19,O
presents,O
relatively,O
mild,O
symptoms,O
compared,O
to,O
the,O
recent,O
outbreaks,O
like,O
Ebola,O
or,O
Middle,O
East,O
Respiratory,O
Syndrome,O
(,O
MERS,O
),O
",",O
they,O
are,O
highly,O
transmissible,O
and,O
can,O
lead,O
to,O
severe,O
pneumonia,O
and,O
death,O
(,O
Boopathi,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
DiMaio,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
this,O
study,O
",",O
we,O
have,O
modeled,O
SARS,O
-,O
CoV-2,O
N7,O
-,O
MTase,O
protein,O
structure,O
in,O
order,O
to,O
decipher,O
the,O
molecular,O
architecture,O
of,O
the,O
substrate,O
-,O
binding,O
site,O
and,O
to,O
perform,O
virtual,O
screening,O
and,O
docking,O
analysis,O
to,O
identify,O
an,O
attractive,O
and,O
novel,O
lead,O
compound,O
from,O
TCM@Taiwan,S-Repository
 ,O
database,O
",",O
which,O
can,O
assist,O
researchers,O
in,O
designing,O
a,O
potent,O
antiviral,O
drug,O
against,O
COVID-19,O
by,O
blocking,O
the,O
SARS,O
-,O
CoV-2,O
’s,O
RNA,O
capping,O
mechanism,O
required,O
for,O
evading,O
the,O
host,O
defense,O
.,O
Amino,O
acid,O
flipping,O
is,O
incorporated,O
for,O
side,O
-,O
chains,O
angles,O
of,O
amino,O
acids,O
(,O
Asn,O
",",O
Gln,O
",",O
and,O
His,O
),O
and,O
it,O
may,O
influence,O
the,O
hydrogen,O
bond,O
formation,O
and,O
generate,O
tautomer,O
/,O
ionized,O
states,O
(,O
Sastry,O
et,O
 ,O
al,O
.,O
",",O
2013,O
),O
.,O
For,O
ligand,O
preparation,O
",",O
the,O
substrate,O
of,O
the,O
Guanine,O
-,O
N7,O
methyltransferase,O
namely,O
G3A,O
(,O
Guanosine,O
-,O
P3,O
-,O
"Adenosine-5′,5′-Triphosphate",O
),O
is,O
downloaded,O
from,O
the,O
PubChem,S-Repository
 ,O
(,O
ID,O
:,O
135450590,S-AccessionNumber
),O
and,O
for,O
screening,O
approaches,O
",",O
22122,O
molecules,O
from,O
TCM,B-Repository
Database@Taiwan,E-Repository
 ,O
is,O
used,O
(,O
Ma,B-Creator
"et al.,",I-Creator
2016,E-Creator
;,O
Wang,B-Creator
"et al.,",I-Creator
2018,E-Creator
),O
.,O
In,O
order,O
to,O
identify,O
the,O
appropriate,O
compounds,O
that,O
perfectly,O
fits,O
the,O
substrate,O
-,O
binding,O
site,O
of,O
the,O
G3A,O
",",O
the,O
Glide,O
incorporated,O
virtual,O
screening,O
protocol,O
is,O
used,O
(,O
Grover,O
et,O
 ,O
al,O
.,O
",",O
2012,O
;,O
Kawatkar,O
et,O
 ,O
al,O
.,O
",",O
2009,O
;,O
Muralidharan,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
whole,O
database,O
is,O
initially,O
screened,O
with,O
High,O
Throughput,O
Virtual,O
Screening,O
(,O
HTVS,O
),O
",",O
for,O
identifying,O
appropriate,O
compounds,O
that,O
fit,O
in,O
the,O
substrate,O
-,O
binding,O
site,O
(,O
Lobo,O
-,O
Galo,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Patidar,O
et,O
 ,O
al,O
.,O
",",O
2016,O
),O
.,O
The,O
experimental,O
structure,O
of,O
the,O
Guanine,O
-,O
N7,O
methyltransferase,O
enzyme,O
is,O
unavailable,O
in,O
the,O
PDB,S-Repository
 ,O
and,O
BLASTp,O
results,O
suggest,O
the,O
crystal,O
structure,O
of,O
the,O
SARS,O
-,O
CoV,O
nsp14,O
-,O
nsp10,O
complex,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
5c8s,S-AccessionNumber
),O
as,O
the,O
template,O
for,O
structure,O
modeling,O
.,O
To,O
disturb,O
the,O
G3A,O
binding,O
towards,O
the,O
Asn388,O
",",O
the,O
whole,O
TCM,S-Repository
 ,O
database,O
is,O
searched,O
for,O
a,O
suitable,O
compound,O
using,O
the,O
HTVS,O
method,O
.,O
The,O
XP,O
docking,O
and,O
Prime,O
MM,O
/,O
GBSA,O
provides,O
the,O
TCM,O
57025,O
(,O
5a,O
),O
",",O
TCM,O
3495,O
(,O
5b,O
),O
",",O
TCM,O
20111,O
(,O
5c,O
),O
",",O
TCM,O
31007,O
(,O
5d,O
),O
and,O
TCM,O
5376,O
(,O
5e,O
),O
from,O
the,O
TCM,O
database,O
as,O
the,O
best,O
compounds,O
that,O
can,O
bind,O
with,O
the,O
substrate,O
-,O
binding,O
site,O
of,O
SARS,O
-,O
CoV-2,O
N7,O
-,O
MTase,O
as,O
shown,O
in,O
Figure,O
5(a,O
–,O
e,O
),O
.,O
For,O
tackling,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
",",O
researchers,O
from,O
around,O
the,O
world,O
are,O
swiftly,O
working,O
on,O
designing,O
and,O
identifying,O
inhibitors,O
against,O
all,O
possible,O
viral,O
key,O
protein,O
targets,O
.,O
For,O
an,O
in,O
-,O
depth,O
understanding,O
of,O
these,O
substrate,O
specificities,O
",",O
we,O
tried,O
to,O
screen,O
and,O
identify,O
inhibitors,O
from,O
the,O
Traditional,B-Repository
Chinese,I-Repository
Medicine,I-Repository
(TCM),E-Repository
 ,O
database,O
.,O
We,O
strongly,O
believe,O
the,O
final,O
compounds,O
can,O
become,O
COVID-19,O
therapeutics,O
",",O
with,O
huge,O
international,O
support,O
.,O
Therefore,O
",",O
our,O
study,O
proposes,O
the,O
top,O
hit,O
compounds,O
from,O
the,O
Traditional,B-Repository
Chinese,I-Repository
Medicine,I-Repository
(TCM),E-Repository
 ,O
database,O
using,O
a,O
combination,O
of,O
several,O
computational,O
approaches,O
.,O
The,O
recent,O
outbreak,O
of,O
the,O
novel,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
and,O
the,O
associated,O
need,O
for,O
vital,O
social,O
practices,O
that,O
reduce,O
further,O
spread,O
have,O
disrupted,O
clinical,O
research,O
functions,O
worldwide,O
[,O
1,O
],O
.,O
Ironically,O
",",O
this,O
interruption,O
coincides,O
with,O
an,O
especially,O
critical,O
need,O
for,O
human,O
biospecimen,O
research,O
to,O
better,O
understand,O
the,O
biology,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
and,O
the,O
pathology,O
of,O
COVID-19,O
.,O
Building,O
a,O
COVID-19,O
biorepository,O
is,O
a,O
delicate,O
and,O
complex,O
task,O
that,O
requires,O
maximum,O
biosafety,O
measures,O
and,O
minimum,O
interruption,O
in,O
an,O
overburdened,O
clinical,O
delivery,O
system,O
.,O
We,O
also,O
feature,O
the,O
earliest,O
outcome,O
of,O
this,O
pipeline,O
",",O
which,O
is,O
the,O
recently,O
reported,O
genomic,O
characterization,O
linking,O
the,O
US,O
and,O
European,O
viral,O
strains,O
",",O
a,O
crucial,O
development,O
in,O
our,O
efforts,O
to,O
combat,O
COVID-19,O
[,O
3,O
],O
.,O
The,O
CBRD,O
adheres,O
to,O
all,O
biosafety,O
level-3,O
guidelines,O
for,O
COVID-19,O
collections,O
as,O
outlined,O
by,O
the,O
Center,O
for,O
Disease,O
Control,O
[,O
4,O
],O
.,O
To,O
maximize,O
COVID-19,O
collections,O
",",O
we,O
modified,O
this,O
protocol,O
to,O
prospectively,O
enroll,O
all,O
patients,O
presenting,O
to,O
NYULH,O
with,O
a,O
COVID-19,O
nasopharyngeal,O
diagnostic,O
test,O
performed,O
into,O
Labvantage,O
.,O
The,O
clinical,O
information,O
from,O
enrolled,O
patients,O
is,O
extracted,O
from,O
the,O
electronic,O
medical,O
record,O
and,O
recorded,O
in,O
107,O
discrete,O
demographic,O
",",O
medical,O
",",O
and,O
COVID-19,O
-,O
specific,O
data,O
fields,O
(,O
Additional,O
file,O
1,O
:,O
Appendix,O
S1,O
),O
in,O
a,O
REDCap,S-Repository
 ,O
[,O
5,O
],O
database,O
.,O
The,O
protocol,O
for,O
COVID-19,O
biospecimen,O
collections,O
for,O
research,O
at,O
NYULH,O
minimizes,O
interruptions,O
in,O
the,O
delivery,O
of,O
care,O
",",O
includes,O
vital,O
biosafety,O
measures,O
",",O
and,O
maximizes,O
the,O
research,O
potential,O
for,O
banked,O
COVID-19,O
biospecimens,O
(,O
Fig,O
.,O
 ,O
1,O
),O
.,O
NYULH,O
saw,O
its,O
first,O
confirmed,O
case,O
of,O
COVID-19,O
on,O
March,O
11,O
",",O
2020,O
.,O
In,O
accordance,O
with,O
national,O
and,O
international,O
policies,O
",",O
the,O
IRB,O
approved,O
a,O
waiver,O
of,O
consent,O
to,O
permit,O
COVID-19,O
biospecimen,O
collection,O
on,O
March,O
28,O
",",O
2020,O
.,O
Of,O
the,O
first,O
"11,120",O
patients,O
accrued,O
to,O
the,O
COVID-19,O
database,O
",",O
4267,O
(,O
38.4,O
%,O
),O
tested,O
positive,O
and,O
approximately,O
10,O
%,O
required,O
hospitalization,O
.,O
We,O
therefore,O
suggest,O
establishing,O
a,O
main,O
biorepository,O
with,O
institutional,O
governance,O
for,O
all,O
patients,O
tested,O
for,O
COVID-19,O
.,O
The,O
creation,O
of,O
this,O
resource,O
at,O
NYULH,O
has,O
enriched,O
the,O
community,O
with,O
high,O
-,O
quality,O
patient,O
-,O
linked,O
COVID-19,O
specimens,O
",",O
which,O
has,O
already,O
contributed,O
to,O
novel,O
findings,O
about,O
SARS,O
-,O
CoV-2,O
epidemiology,O
[,O
3,O
],O
.,O
The,O
outbreak,O
of,O
the,O
novel,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
and,O
consequent,O
social,O
distancing,O
practices,O
have,O
disrupted,O
essential,O
clinical,O
research,O
functions,O
worldwide,O
.,O
Ironically,O
",",O
this,O
coincides,O
with,O
an,O
immediate,O
need,O
for,O
research,O
to,O
comprehend,O
the,O
biology,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
and,O
the,O
pathology,O
of,O
COVID-19,O
.,O
However,O
",",O
building,O
a,O
COVID-19,O
biorepository,O
amidst,O
the,O
active,O
pandemic,O
is,O
a,O
complex,O
and,O
delicate,O
task,O
.,O
Using,O
an,O
amended,O
institutional,O
biobanking,O
protocol,O
",",O
these,O
efforts,O
led,O
to,O
accrual,O
of,O
"11,120",O
patients,O
presenting,O
for,O
SARS,O
-,O
CoV-2,O
testing,O
",",O
4267,O
(,O
38.4,O
%,O
),O
of,O
whom,O
tested,O
positive,O
for,O
COVID-19,O
.,O
